PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Lu, JK; Ashwell, KWS; Waite, P				Lu, JK; Ashwell, KWS; Waite, P			Advances in secondary spinal cord injury - Role of apoptosis	SPINE			English	Article						apoptosis; cytokines; excitotoxicity; free radicals; secondary spinal cord injury	TRAUMATIC BRAIN INJURY; WHITE-MATTER PATHOLOGY; D-ASPARTATE RECEPTOR; NITRIC-OXIDE; CONTROLLED TRIAL; CELL-DEATH; NEURONAL APOPTOSIS; DNA FRAGMENTATION; GM-1 GANGLIOSIDE; RAT	The outcome of spinal cord injury depends on the extent of secondary damage produced by a series of cellular and molecular events initiated by the primary trauma. This article reviews the evidence that secondary spinal cord injury involves the apoptotic as well as necrotic death of neurons and glial cells. Also discussed are the major factors that can contribute to cell death, such as glutamatergic excitotoxicity, free radical damage, cytokines, and inflammation. The development of innovative therapeutic strategies to reduce secondary spinal cord injury depends on an increased understanding of secondary injury mechanisms at the molecular and biochemical level. Such therapeutic interventions may include the use bf antiapoptotic drugs, free radical scavengers, and antiinflammatory agents. These could be targeted to block key reactions on cellular and molecular injury cascades, thus reducing secondary tissue damage, minimizing side effects, and improving functional recovery.	Univ New S Wales, Sch Anat, Neural Injury Res Unit, Sydney, NSW 2052, Australia	Waite, P (corresponding author), Univ New S Wales, Sch Anat, Neural Injury Res Unit, Sydney, NSW 2052, Australia.						Agrawal SK, 1996, J NEUROSCI, V16, P545; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Anderson DK, 1991, J NEUROTRAUM, V8, P187, DOI 10.1089/neu.1991.8.187; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DALKARA T, 1994, BRAIN PATHOL, V4, P49; DAWSON TM, 1995, ANN NEUROL, V37, P115, DOI 10.1002/ana.410370122; DAWSON TM, 1994, ANN NY ACAD SCI, V738, P76; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; GEISLER FH, 1993, ANN EMERG MED, V22, P1041, DOI 10.1016/S0196-0644(05)82748-9; GUTH L, 1994, EXP NEUROL, V126, P76, DOI 10.1006/exnr.1994.1043; HALL ED, 1993, RES P ARNMD, V71, P81; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hochman A, 1998, J NEUROCHEM, V71, P741; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Hu S, 1997, NEUROCHEM INT, V30, P427, DOI 10.1016/S0197-0186(96)00078-2; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Jacobs T P, 1987, Cent Nerv Syst Trauma, V4, P95; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Katoh K, 1996, NEUROSCI LETT, V216, P9; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; KEW JNC, 1999, 5 IBRO WORLD C NEUR, V5, P31; Lazarov-Spiegler O, 1998, MOL MED TODAY, V4, P337, DOI 10.1016/S1357-4310(98)01298-2; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lu J, 1999, SPINE, V24, P926, DOI 10.1097/00007632-199905010-00019; Maroney AC, 1998, J NEUROSCI, V18, P104; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; Nishisho T, 1996, NEUROSURGERY, V39, P950, DOI 10.1097/00006123-199611000-00014; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; Rosenberg LJ, 1999, J NEUROSCI, V19, P6122, DOI 10.1523/JNEUROSCI.19-14-06122.1999; Rosenberg LJ, 1999, J NEUROSCI, V19, P464; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; Sullivan PG, 1999, J NEUROSCI, V19, P6248; SVENSSON LG, 1993, J VASC SURG, V17, P357, DOI 10.1016/0741-5214(93)90421-H; Takahashi K, 1999, J COMP NEUROL, V404, P159, DOI 10.1002/(SICI)1096-9861(19990208)404:2<159::AID-CNE2>3.0.CO;2-E; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; Villa PG, 1998, J CELL SCI, V111, P713; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; YANASE M, 1995, J NEUROSURG, V83, P884, DOI 10.3171/jns.1995.83.5.0884; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459	56	174	200	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	JUL 15	2000	25	14					1859	1866		10.1097/00007632-200007150-00022			8	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	334XQ	WOS:000088211900024	10888960				2021-06-18	
J	Salazar, AM; Warden, DL; Schwab, K; Spector, J; Braverman, S; Walter, J; Cole, R; Rosner, MM; Martin, EM; Ecklund, J; Ellenbogen, RG				Salazar, AM; Warden, DL; Schwab, K; Spector, J; Braverman, S; Walter, J; Cole, R; Rosner, MM; Martin, EM; Ecklund, J; Ellenbogen, RG		Defense Vet Head Injury Program DV	Cognitive rehabilitation for traumatic brain injury - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MILITARY MEDICAL SYSTEM; HEAD-INJURY; BENEFIT	Context Traumatic brain injury (TBI) is a principal cause of death and disability in young adults. Rehabilitation for TBI has not received the same level of scientific scrutiny for efficacy and cost-efficiency that is expected in other medical fields. Objective To evaluate the efficacy of inpatient cognitive rehabilitation for patients with TBI. Design and Setting Single-center, parallel-group, randomized trial conducted from January 1992 through February 1997 at a US military medical referral center. Patients One hundred twenty active-duty military personnel who had sustained a moderate-to-severe closed head injury, manifested by a Glasgow Coma Scale score of 13 or less, or posttraumatic amnesia lasting at least 24 hours, or focal cerebral contusion or hemorrhage on computed tomography or magnetic resonance imaging. Interventions Patients were randomly assigned to an intensive, standardized, 8-week, in-hospital cognitive rehabilitation program (n=67) or a limited home rehabilitation program with weekly telephone support from a psychiatric nurse (n=53). Main Outcome Measures Return to gainful employment and fitness for military duty at 1-year follow-up, compared by intervention group. Results At 1-year follow-up, there was no significant difference between patients who had received the intensive in-hospital cognitive rehabilitation program vs the limited home rehabilitation program in return to employment (90% vs 94%, respectively; P=.51; difference, 4% [95% confidence interval {CI}, -5% to 14%]) or fitness for duty (73% vs 66%,respectively; P=.43; difference, 7% [95% CI, -10% to 24%]). There also were no significant differences in cognitive, behavioral, or quality-of-life measures. In a post-hoc subset analysis of patients who were unconscious for more than 1 hour (n=75) following TBI, the in-hospital group had a greater return-to-duty rate (80% vs 58%; P=.05). Conclusions In this study, the overall benefit of in-hospital cognitive rehabilitation for patients with moderate-to-severe TBI was similar to that of home rehabilitation. These findings emphasize the importance of conducting randomized trials to evaluate TBI rehabilitation interventions.	Walter Reed Army Med Ctr, Def & Vet Head Injury Program, Washington, DC 20307 USA; Henry M Jackson Fdn, Def & Vet Head Injury Program, Rockville, MD USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	Salazar, AM (corresponding author), Walter Reed Army Med Ctr, Def & Vet Head Injury Program, Bldg 1,Room B210, Washington, DC 20307 USA.						ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Braverman SE, 1999, BRAIN INJURY, V13, P405; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; CHESNUT R, 1998, EVIDENCE REPORT REHA, P11; Chesnut R, 1999, EVIDENCE REPORT REHA, P1; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; GORAN DA, 1993, BRAIN INJURY, V7, P219, DOI 10.3109/02699059309029674; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; HAGEN C, 1982, COGNITIVE REHABILITA, P131; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; JACKSON H F, 1992, Brain Injury, V6, P109, DOI 10.3109/02699059209029650; LEVIN HS, 1990, ARCH NEUROL-CHICAGO, V47, P223, DOI 10.1001/archneur.1990.00530020131027; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MELAMED S, 1992, Brain Injury, V6, P233, DOI 10.3109/02699059209029665; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Prigatano G., 1989, TRAUMATIC BRAIN INJU, P175; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; RUFF R M, 1990, Brain Injury, V4, P339, DOI 10.3109/02699059009026187; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1993, J HEAD TRAUMA REHAB, V8, P45, DOI DOI 10.1097/00001199-199303000-00006; *US ARM, 1995, STAND MED FITN ARM R, P14; VOLPE BT, 1990, ARCH NEUROL-CHICAGO, V47, P220, DOI 10.1001/archneur.1990.00530020128026; Wehman P, 1989, Brain Inj, V3, P397, DOI 10.3109/02699058909004563	33	174	177	0	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	2000	283	23					3075	3081		10.1001/jama.283.23.3075			7	Medicine, General & Internal	General & Internal Medicine	323PV	WOS:000087574900031	10865301	Bronze			2021-06-18	
J	Feuerstein, GZ; Wang, XK; Barone, FC				Feuerstein, GZ; Wang, XK; Barone, FC			The role of cytokines in the neuropathology of stroke and neurotrauma	NEUROIMMUNOMODULATION			English	Article						interleukin-1 beta; tumor necrosis factor-alpha; brain injury; thromboembolic stroke; closed head injury; leukocytes; gene expression; adhesion molecules; pharmacotherapy	TUMOR-NECROSIS-FACTOR; FOCAL CEREBRAL-ISCHEMIA; INTERLEUKIN-1-BETA MESSENGER-RNA; CENTRAL-NERVOUS-SYSTEM; PROTEIN-KINASE-C; TRANSIENT FOREBRAIN ISCHEMIA; BLOOD-BRAIN-BARRIER; RECEPTOR-TYPE-I; RAT-BRAIN; FACTOR-ALPHA	Accumulating evidence during the last decade has shown that the CNS can mount a well-defined inflammatory reaction to a variety of insults including trauma, ischemia, transplantation, viral infections as well as neurodegeneration. Many aspects of this centrally derived inflammatory response parallel to some extent the nature of such a reaction in the periphery. Through the recent application of molecular genetic techniques including PCR, utilization of cDNA probes in conjuncture with the availability of highly specific antibodies, new concepts are rapidly emerging as to the molecular mechanisms associated with the development of brain injury. In particular, the importance of cytokines, especially TNF alpha and IL-1 beta, is emphasized in the propagation and maintenance of a CNS inflammatory response. This review summarizes evidence in support of a case for ischemia and trauma eliciting an inflammatory condition in the injured brain. The inflammatory condition consists of cells (neutrophils early after the onset of brain injury and subsequently monocyte infiltration) and mediators (cytokines, chemokines and adhesion molecules). It is clear that de novo up-regulation of pro-inflammatory cytokines, chemokines and endothelial-leukocyte adhesion molecules in the brain occurs soon following focal ischemia and trauma and at a time when the tissue injury is evolving. The significance of the inflammatory response and its contribution to brain injury are now becoming better understood. Evidence has emerged in support of the role of cytokines in driving the inflammatory response and that this process is causally related to the degree of brain injury. Evidence reviewed includes: (1) the capacity of specific cytokines to exacerbate brain damage; (2) the capacity of specific cytokine blockade to reduce ischemic brain damage; (3) depletion of circulating neutrophils reduces ischemic brain injury, and (4) antagonists of the endothelial-leukocyte adhesion interactions (e.g, anti-ICAM-1) reduce ischemic brain injury. Targeting the cytokines that drive the brain inflammatory response to injury provides opportunities to intervene with novel therapeutics in stroke and neurotrauma.	SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, King Of Prussia, PA 19406 USA	Barone, FC (corresponding author), SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, 709 Swedeland Rd,POB 1539, King Of Prussia, PA 19406 USA.	Frank_C_Barone@SBPHRD.com					AGUAYO AJ, 1981, J EXP BIOL, V95, P231; Albers GW, 1997, AM J CARDIOL, V80, pD4; ALVAREZ XA, 1994, AGENTS ACTIONS, V41, pC70, DOI 10.1007/BF02007772; BALASINGAM V, 1994, J NEUROSCI, V14, P846; BAN E, 1992, CYTOKINE, V4, P48, DOI 10.1016/1043-4666(92)90036-Q; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barone F C, 1997, Expert Opin Investig Drugs, V6, P501, DOI 10.1517/13543784.6.5.501; BARONE FC, 1992, NEUROSCI BIOBEHAV R, V16, P219, DOI 10.1016/S0149-7634(05)80182-4; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; BARONE FC, 1992, STROKE, V23, P1337, DOI 10.1161/01.STR.23.9.1337; BARONE FC, 1995, MOL CHEM NEUROPATHOL, V24, P13, DOI 10.1007/BF03160109; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BARONE FC, 1998, INFLAMMATORY MED CNS, P325; BEDNAR MM, 1991, STROKE, V22, P44, DOI 10.1161/01.STR.22.1.44; BEERHUIZEN H, 1993, J LEUKOCYTE BIOL, V54, P363; BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BOWES MP, 1993, EXP NEUROL, V119, P215, DOI 10.1006/exnr.1993.1023; BOWES MP, 1995, NEUROLOGY, V45, P815, DOI 10.1212/WNL.45.4.815; BRISTULF J, 1994, EUR CYTOKINE NETW, V5, P319; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; BUTTINI M, 1994, MOL BRAIN RES, V23, P126, DOI 10.1016/0169-328X(94)90218-6; BUTTINI M, 1995, NEUROSCIENCE, V65, P523, DOI 10.1016/0306-4522(94)00525-A; Buttini M, 1996, NEUROSCIENCE, V71, P1, DOI 10.1016/0306-4522(95)00414-9; CHEN H, 1992, NEUROSCI RES COMMUN, V11, P93; CHEN H, 1994, ANN NEUROL, V35, P458, DOI 10.1002/ana.410350414; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; CLARK RK, 1994, BRAIN RES BULL, V35, P387, DOI 10.1016/0361-9230(94)90119-8; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; CLARK WM, 1991, J NEUROSURG, V75, P623, DOI 10.3171/jns.1991.75.4.0623; CUNNINGHAM ET, 1992, J NEUROSCI, V12, P1101; Dawson DA, 1996, NEUROSCI LETT, V218, P41, DOI 10.1016/0304-3940(96)13116-5; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; DERESKI MO, 1992, NEUROSCI RES COMMUN, V11, P179; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1988, FASEB J, V2, P108; DUTKA AJ, 1989, STROKE, V20, P390, DOI 10.1161/01.STR.20.3.390; ENG LF, 1988, BIOCH PATHOLOGY ASTR, P79; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEUERSTEIN GZ, 1998, CEREBROVASC DIS, P507; GARCIA JE, 1992, EXP NEUROL, V118, P309, DOI 10.1016/0014-4886(92)90188-V; Garcia JH, 1997, BRAIN PATHOL, V7, P1151, DOI 10.1111/j.1750-3639.1997.tb00998.x; GARCIA JH, 1974, J NEUROPATH EXP NEUR, V33, P408, DOI 10.1097/00005072-197407000-00007; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GOLDBLUM SE, 1990, AM J PHYSIOL, V258, pL57; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GOROSPE M, 1993, J BIOL CHEM, V268, P6214; GRANGER DN, 1993, CAN J PHYSIOL PHARM, V71, P67, DOI 10.1139/y93-011; GRAU AJ, 1992, STROKE, V23, P33, DOI 10.1161/01.STR.23.1.33; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; HALLENBECK JM, 1990, ARCH NEUROL-CHICAGO, V47, P1245, DOI 10.1001/archneur.1990.00530110107027; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; HALLENBECK JM, 1988, STROKE, V19, P863, DOI 10.1161/01.STR.19.7.863; HART RP, 1993, J NEUROIMMUNOL, V44, P49, DOI 10.1016/0165-5728(93)90267-3; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; Hayward NJ, 1996, EXP NEUROL, V139, P188, DOI 10.1006/exnr.1996.0093; HEINEL LA, 1994, BRAIN RES BULL, V34, P137, DOI 10.1016/0361-9230(94)90010-8; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; HSU CY, 1993, STROKE, V24, pI78; JIANG N, 1994, NEUROSCI RES COMMUN, V15, P85; KASSIS S, 1993, AGENTS ACTIONS, V39, pC64, DOI 10.1007/BF01972722; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; KOBAYASHI E, 1990, BIOCHEM BIOPH RES CO, V172, P993; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; Kogure K, 1996, ACT NEUR S, V66, P40; Koroshetz WJ, 1996, TRENDS PHARMACOL SCI, V17, P227, DOI 10.1016/0165-6147(96)10020-1; LI Y, 1994, STROKE, V25, P849, DOI 10.1161/01.STR.25.4.849; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; LIEBERMAN AP, 1992, J BIOL CHEM, V267, P2123; LINDSAY RM, 1986, ASTROCYTES CELL BIOL, V3, P231; LIU T, 1993, NEUROSCI LETT, V164, P125, DOI 10.1016/0304-3940(93)90873-J; LIU T, 1993, STROKE, V24, P1746, DOI 10.1161/01.STR.24.11.1746; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; MARTIN D, 1995, EXP NEUROL, V131, P221, DOI 10.1016/0014-4886(95)90044-6; MARTIN D, 1994, EXP NEUROL, V130, P362, DOI 10.1006/exnr.1994.1215; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MINAMI M, 1991, BIOCHEM BIOPH RES CO, V176, P593, DOI 10.1016/S0006-291X(05)80225-6; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; MOHLER KM, 1993, J IMMUNOL, V151, P1548; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; NAKANE A, 1992, INFECT IMMUN, V60, P523, DOI 10.1128/IAI.60.2.523-528.1992; Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P229, DOI 10.1097/00004647-199702000-00013; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; NOWAK TS, 1990, STROKE, V21, P107; O'CALLAGHAN J P, 1991, Biomedical and Environmental Sciences, V4, P197; Ohtsuki T, 1996, J CEREBR BLOOD F MET, V16, P1137, DOI 10.1097/00004647-199611000-00007; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; PARE M, 1982, BRAIN RES, V243, P360, DOI 10.1016/0006-8993(82)90261-X; PERRY VH, 1991, INT REV CYTOL, V125, P203, DOI 10.1016/S0074-7696(08)61220-6; PIANI D, 1992, EUR J IMMUNOL, V22, P2429, DOI 10.1002/eji.1830220936; POBER JS, 1990, PHYSIOL REV, V70, P427; POZZILLI C, 1985, STROKE, V16, P251, DOI 10.1161/01.STR.16.2.251; PRABHAKAR U, 1993, EUR CYTOKINE NETW, V4, P31; REIER PJ, 1986, ASTROCYTES, P263; REINISCH N, 1994, NEUROSCI LETT, V166, P165, DOI 10.1016/0304-3940(94)90476-6; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; ROMANIC AM, IN PRESS STROKE; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; Rothwell NJ, 1996, NAT MED, V2, P746, DOI 10.1038/nm0796-746; ROTHWELL NJ, 1991, TRENDS PHARMACOL SCI, V12, P430, DOI 10.1016/0165-6147(91)90623-Z; ROTHWELL NJ, 1993, CEREBROVAS BRAIN MET, V5, P178; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; Ryan M, 1997, PHARMACOTHERAPY, V17, P959; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHMIDSCHONBEIN GW, 1987, FASEB J, V46, P2397; SCHWARTZ M, 1991, BRAIN RES, V545, P334, DOI 10.1016/0006-8993(91)91309-O; SELMAJ K, 1995, J NEUROIMMUNOL, V56, P135, DOI 10.1016/0165-5728(94)00139-F; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SEMMLER J, 1993, INT J IMMUNOPHARMACO, V15, P409, DOI 10.1016/0192-0561(93)90052-Z; SHALABY MR, 1985, J IMMUNOL, V135, P2069; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; SHIGA Y, 1991, NEUROSCI LETT, V125, P110, DOI 10.1016/0304-3940(91)90003-C; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SHOMHI E, 1996, J CEREB BLOOD FLOW M, V16, P378; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SIMS JE, 1994, CLIN IMMUNOL IMMUNOP, V72, P9, DOI 10.1006/clin.1994.1100; SIREN AL, 1992, STROKE, V23, P1643, DOI 10.1161/01.STR.23.11.1643; Smith R A, 1992, Immunol Ser, V56, P131; TAKAO T, 1990, ENDOCRINOLOGY, V127, P3070, DOI 10.1210/endo-127-6-3070; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TCHELINGERIAN JL, 1993, NEURON, V10, P213, DOI 10.1016/0896-6273(93)90312-F; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TSCHAIKOWSKY K, 1994, SHOCK, V1, P401, DOI 10.1097/00024382-199406000-00002; TSUCHIHASHI Y, 1981, ACTA NEUROPATHOL, V53, P213, DOI 10.1007/BF00688024; UEMURA Y, 1991, BRAIN RES, V552, P99, DOI 10.1016/0006-8993(91)90665-I; VASTHARE US, 1990, SURG NEUROL, V33, P261, DOI 10.1016/0090-3019(90)90046-R; Wahlgren NG, 1997, CEREBROVASC DIS, V7, P24, DOI 10.1159/000108249; WANG XJ, IN PRESS J NEUROCHEM; WANG XK, 1995, STROKE, V26, P1665, DOI 10.1161/01.STR.26.9.1665; WANG XK, 1995, BRAIN RES BULL, V36, P607, DOI 10.1016/0361-9230(94)00243-T; WANG XK, 1995, J CEREBR BLOOD F MET, V15, P166, DOI 10.1038/jcbfm.1995.18; WANG XK, 1994, MOL BRAIN RES, V26, P61, DOI 10.1016/0169-328X(94)90074-4; Wang XK, 1998, STROKE, V29, P516, DOI 10.1161/01.STR.29.2.516; WANG XK, 1995, STROKE, V26, P661, DOI 10.1161/01.STR.26.4.661; Wang XK, 1997, STROKE, V28, P155, DOI 10.1161/01.STR.28.1.155; WANG XK, 1994, MOL CHEM NEUROPATHOL, V23, P103, DOI 10.1007/BF02815404; WARREN JS, 1990, CRIT REV CL LAB SCI, V28, P37, DOI 10.3109/10408369009105897; WELSH FA, 1992, J CEREBR BLOOD F MET, V12, P204, DOI 10.1038/jcbfm.1992.30; WILKINSON SE, 1994, TRENDS PHARMACOL SCI, V15, P53, DOI 10.1016/0165-6147(94)90110-4; Wong Mal-Li, 1994, Neuroimmunomodulation, V1, P181, DOI 10.1159/000097159; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YABUUCHI K, 1994, MOL BRAIN RES, V26, P135, DOI 10.1016/0169-328X(94)90084-1; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; YOUNG P, 1993, AGENTS ACTIONS, V39, pC67, DOI 10.1007/BF01972723; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747; ZHANG RL, 1994, J NEUROL SCI, V125, P3, DOI 10.1016/0022-510X(94)90234-8	163	174	181	0	8	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7401	1423-0216		NEUROIMMUNOMODULAT	Neuroimmunomodulation	MAY-AUG	1998	5	3-4					143	159		10.1159/000026331			17	Endocrinology & Metabolism; Immunology; Neurosciences	Endocrinology & Metabolism; Immunology; Neurosciences & Neurology	118EV	WOS:000075826200004	9730680				2021-06-18	
J	Hsieh, JC; StahleBackdahl, M; Hagermark, O; StoneElander, S; Rosenquist, G; Ingvar, M				Hsieh, JC; StahleBackdahl, M; Hagermark, O; StoneElander, S; Rosenquist, G; Ingvar, M			Traumatic nociceptive pain activates the hypothalamus and the periaqueductal gray: A positron emission tomography study	PAIN			English	Article						positron emission tomography; regional cerebral blood flow; hypothalamus; periaqueductal gray; pain; trauma; human brain	POSTERIOR PARIETAL CORTEX; ANTERIOR CINGULATE CORTEX; CEREBRAL BLOOD-FLOW; RHESUS-MONKEY; BRAIN ATLAS; LOCALIZATION; STIMULATION; RESPONSES; ATTENTION; THALAMUS	The study was conducted to investigate which areas of the brain respond to a painful encounter of minor dermal injury (a model of clinical pain) elicited by intracutaneous injection of a minute amount of ethanol. Four healthy volunteers (27-46 years) were subjected to positron emission tomographic (PET) investigation of regional cerebral blood flow (rCBF), using [O-15]butanol as tracer. The ethanol (20 mu l, 70%) and saline (20 mu l, 0.9%) were injected intracutaneously 3 times in a single-blinded, semi-randomised manner for the pain experiment. All the injections were performed, adjacent to each other, at the lateral aspect of the right upper arm. Subjective sensory intensity of pain, unpleasantness and anxiety were rated with separate 100-mm visual analogue scales together with the Spielberger's State Anxiety Inventory (Spielberger et al. 1970) and heart rate. Paired-subtraction (pixel-by-pixel) between ethanol and saline was performed. Traumatic pain significantly caused higher ratings of intensity and affect scales, i.e., pain intensity, unpleasantness and increased sympathetic activity (evidenced by tachycardia). In contrast the anxiety rating remained unchanged. Acute traumatic nociceptive pain prominently activated the hypothalamus and periaqueductal gray (FAG). In addition, activations of the prefrontal cortex (PFC), insular, anterior cingulate cortex (ACC); posterior parietal cortex (PPC), primary motor/somatosensory areas (MI/SI: face, upper arm), supplementary motor area (SMA), and cerebellum were also demonstrated, The central processing of the pain-relevant/anticipatory arousal also engaged the FAG. This study demonstrates the involvement of the human cerebral cortex in perception, arousal, cognitive evaluative processes, and, hence, affective reactions (somatic/autonomic outflow) associated with pain. The pain stimulus of traumatic character may, by its very nature, evoke the central processing to involve both the hypothalamus and the FAG.	KAROLINSKA HOSP, DEPT CLIN NEUROSCI, CLIN NEUROPHYSIOL SECT, KAROLINSKA INST, S-17176 STOCKHOLM, SWEDEN; KAROLINSKA HOSP, KAROLINSKA INST, DEPT DERMATOL, S-17176 STOCKHOLM, SWEDEN; KAROLINSKA HOSP, KAROLINSKA INST, KAROLINSKA PHARM, S-17176 STOCKHOLM, SWEDEN; NATL YANG MING UNIV, VET GEN HOSP, SECT NEUROANESTHESIA, TAIPEI 11217, TAIWAN; NATL YANG MING UNIV, VET GEN HOSP, DEPT ANESTHESIOL, PAIN UNIT, TAIPEI 11217, TAIWAN; NATL YANG MING UNIV, SCH MED, TAIPEI 11217, TAIWAN				Ingvar, Martin/0000-0002-9041-5714			AGGLETON JP, 1993, TRENDS NEUROSCI, V16, P328, DOI 10.1016/0166-2236(93)90110-8; Andersen RA, 1987, HDB PHYSL 1, P483; APKARIAN AV, 1992, NEUROSCI LETT, V140, P141, DOI 10.1016/0304-3940(92)90088-O; ARNTZ A, 1994, PAIN, V56, P307, DOI 10.1016/0304-3959(94)90169-4; BANDLER R, 1994, TRENDS NEUROSCI, V17, P379, DOI 10.1016/0166-2236(94)90047-7; Bentivoglio M, 1993, NEUROBIOLOGY CINGULA, P71; BERGSTROM M, 1981, J COMPUT ASSIST TOMO, V5, P136, DOI 10.1097/00004728-198102000-00027; BOHM C, 1989, EUR J NUCL MED, V15, P687, DOI 10.1007/BF00631757; BOUCKOMS AJ, 1994, TXB PAIN, P1171; Brodmann K., 1909, VERGLEICHENDE LOKALI; BURTON H, 1993, SOMATOSENS MOT RES, V10, P297, DOI 10.3109/08990229309028839; BUSHNELL MC, 1989, EXP BRAIN RES, V78, P415; CANAVERO S, 1993, NEUROSURGERY, V32, P185, DOI 10.1227/00006123-199302000-00006; Casey K. L., 1993, Society for Neuroscience Abstracts, V19, P1074; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802; CAVADA C, 1989, J COMP NEUROL, V287, P393, DOI 10.1002/cne.902870402; CESARO P, 1991, PAIN, V47, P329, DOI 10.1016/0304-3959(91)90224-L; CHUDLER EH, 1995, PAIN, V60, P3, DOI 10.1016/0304-3959(94)00172-B; Coghill R. C., 1993, Society for Neuroscience Abstracts, V19, P1573; COGHILL RC, 1994, J NEUROSCI, V14, P4095; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE; Cousins MJ, 1994, TXB PAIN, P357; CRAIG AD, 1994, NATURE, V372, P770, DOI 10.1038/372770a0; DAVIS KD, 1994, PAIN, V59, P189, DOI 10.1016/0304-3959(94)90071-X; DERBYSHIRE SWG, 1994, J NEUROL NEUROSUR PS, V57, P1166, DOI 10.1136/jnnp.57.10.1166; DERBYSHIRE SWG, 1993, J CEREB BLOOD FLO S1, V13, P5546; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; DIPIERO V, 1994, PAIN, V56, P167, DOI 10.1016/0304-3959(94)90091-4; DIPIERO V, 1991, PAIN, V46, P9, DOI 10.1016/0304-3959(91)90026-T; DONG WK, 1989, BRAIN RES, V484, P314, DOI 10.1016/0006-8993(89)90375-2; DONG WK, 1994, J NEUROPHYSIOL, V72, P542; DREVETS WC, 1995, NATURE, V373, P249, DOI 10.1038/373249a0; Dum R. P., 1993, NEUROBIOLOGY CINGULA, P415, DOI 10.1007/978-1-4899-6704-6_15; DUNCAN GH, 1992, SCIENCE, V255, P215, DOI 10.1126/science.255.5041.215-a; DUNCAN GH, 1989, PAIN, V37, P295, DOI 10.1016/0304-3959(89)90194-2; DUNCAN GH, 1994, SOC NEUR ABSTR, V20, P1672; FOIT A, 1980, ELECTROEN CLIN NEURO, V50, P426, DOI 10.1016/0013-4694(80)90008-5; FRACKOWIAK RSJ, 1994, TRENDS NEUROSCI, V17, P109, DOI 10.1016/0166-2236(94)90119-8; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Gelnar P. A., 1994, Society for Neuroscience Abstracts, V20, P1572; George M S, 1994, Hum Brain Mapp, V1, P194, DOI 10.1002/hbm.460010305; GHATAN PH, 1995, NEUROIMAGE, V2, P112, DOI 10.1006/nimg.1995.1014; GIESLER GJ, 1994, TRENDS NEUROSCI, V17, P244, DOI 10.1016/0166-2236(94)90007-8; GRAEFF FG, 1990, HDB ANXIETY, V3, P307; GREITZ T, 1991, J COMPUT ASSIST TOMO, V15, P26, DOI 10.1097/00004728-199101000-00003; HAXBY JV, 1994, J NEUROSCI, V14, P6336; HEILMAN KM, 1987, HDB PHYSL 1, V5, P461; HODGE CJ, 1990, CRIT REV NEUROBIOL, V5, P363; HOLTE S, 1989, EUR J NUCL MED, V15, P719, DOI 10.1007/BF00631763; HSIEH JC, 1994, J NEUROPHYSIOL, V72, P3004; HSIEH JC, 1995, IN PRESS PAIN; HURTIG RR, 1994, J CEREBR BLOOD F MET, V14, P423, DOI 10.1038/jcbfm.1994.53; Iadarola M. J., 1993, Society for Neuroscience Abstracts, V19, P1074; IADAROLA MJ, 1995, IN PRESS PAIN; INGVAR M, 1994, J CEREBR BLOOD F MET, V14, P628, DOI 10.1038/jcbfm.1994.78; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; KAWASHIMA R, 1995, CEREB CORTEX, V5, P111, DOI 10.1093/cercor/5.2.111; KAWASHIMA R, 1994, J NEUROSCI, V14, P3462; KEW JJM, 1994, J NEUROPHYSIOL, V72, P2517; KUPFERMANN I, 1993, PRINCIPLES NEURAL SC, P735; Lazarus R.S., 1991, EMOTION ADAPTATION; Lazarus RS, 1991, STRESS COPING ANTHOL, P207; LeDoux JE, 1984, HDB COGNITIVE NEUROS, P357; LEVENTHAL H, 1979, J PERS SOC PSYCHOL, V37, P688, DOI 10.1037/0022-3514.37.5.688; Leventhal H., 1979, EMOTIONS PERSONALITY, P261, DOI 10.1007/978-1-4613-2892-6_10; LIBET B, 1973, HDB SENSORY PHYSL, V2, P744; LIM SH, 1994, ELECTROEN CLIN NEURO, V91, P179, DOI 10.1016/0013-4694(94)90068-X; LIOTTI M, 1994, J CLIN NEUROPHYSIOL, V11, P175, DOI 10.1097/00004691-199403000-00003; LUITEN PGM, 1987, PROG NEUROBIOL, V28, P1, DOI 10.1016/0301-0082(87)90004-9; MATHEWS A, 1990, BEHAV RES THER, V28, P455, DOI 10.1016/0005-7967(90)90132-3; MELZACK R, 1968, P423; Mesulam M. M., 1985, CEREB CORTEX, V4, P179, DOI DOI 10.1007/978-1-4757-9619-3_5; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; PAUS T, 1993, J NEUROPHYSIOL, V70, P453; PENFIELD W, 1955, CEREBRAL CORTEX MAN; PORRINO LJ, 1993, NEUROBIOLOGY CINGULA, P445; Posner M.I., 1994, IMAGES MIND; POSNER MI, 1994, P NATL ACAD SCI USA, V91, P7398, DOI 10.1073/pnas.91.16.7398; PRICE DD, 1988, PSYCHOL NEURAL MECHA; ROSEN SD, 1994, LANCET, V344, P147, DOI 10.1016/S0140-6736(94)92755-3; SCHMAHMANN JD, 1990, J COMP NEUROL, V295, P299, DOI 10.1002/cne.902950212; SEITZ RJ, 1992, ACTA NEUROL SCAND, V86, P60, DOI 10.1111/j.1600-0404.1992.tb08055.x; SERGENT J, 1994, TRENDS NEUROSCI, V17, P221, DOI 10.1016/0166-2236(94)90002-7; Spielberger C.D., 1970, STATE TRAIT ANXIETY; STEIN JF, 1989, Q J EXP PHYSIOL CMS, V74, P583, DOI 10.1113/expphysiol.1989.sp003314; Talairach J., 1988, COPLANAR STEREOTAXIC; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; THIERRY AM, 1990, PROG BRAIN RES, V85, P357; TOMAZ C, 1993, BEHAV BRAIN RES, V58, P99, DOI 10.1016/0166-4328(93)90094-7; Vogt BA, 1993, NEUROBIOLOGY CINGULA, P313; WHITE JC, 1969, PAIN NEUROSURGEON; WILLIS WD, 1995, NATURE, V373, P19, DOI 10.1038/373019a0	93	174	175	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	FEB	1996	64	2					303	314		10.1016/0304-3959(95)00129-8			12	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	UJ288	WOS:A1996UJ28800012	8740608				2021-06-18	
J	OMMAYA, AK; HIRSCH, AE				OMMAYA, AK; HIRSCH, AE			TOLERANCES FOR CEREBRAL CONCUSSION FROM HEAD IMPACT AND WHIPLASH IN PRIMATES	JOURNAL OF BIOMECHANICS			English	Article																Ewing C, 1969, 13 STAPP CAR CRASH C, P400; FAAS FH, 1968, J NEUROSURG, V28, P137, DOI 10.3171/jns.1968.28.2.0137; Hirsch A, 1968, 2876 DEP NAV NAV SHI; HOLBOURN AHS, 1943, LANCET, V2, P245; KORNHAUSER M, 1954, J APPL MECH-T ASME, V21, P371; Ommaya A, 1967, 11 P STAPP CAR CRASH, P47; Ommaya A, 1966, 10 P STAPP CAR CRASH, P197; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1969, LANCET, V2, P237; OMMAYA AK, 1969, J NEUROSURG, V30, P25, DOI 10.3171/jns.1969.30.1.0025; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1970, P INT C ACC PATH WAS	12	174	180	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.		1971	4	1					13	&		10.1016/0021-9290(71)90011-X			0	Biophysics; Engineering, Biomedical	Biophysics; Engineering	I6990	WOS:A1971I699000002	5001829				2021-06-18	
J	Crane, PK; Gibbons, LE; Dams-O'Connor, K; Trittschuh, E; Leverenz, JB; Keene, CD; Sonnen, J; Montine, TJ; Bennett, DA; Leurgans, S; Schneider, JA; Larson, EB				Crane, Paul K.; Gibbons, Laura E.; Dams-O'Connor, Kristen; Trittschuh, Emily; Leverenz, James B.; Keene, C. Dirk; Sonnen, Joshua; Montine, Thomas J.; Bennett, David A.; Leurgans, Sue; Schneider, Julie A.; Larson, Eric B.			Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings	JAMA NEUROLOGY			English	Article							ALZHEIMERS-DISEASE; CLINICAL-DIAGNOSIS; DEMENTIA; RISK; PATHOLOGY; IMPAIRMENT; HISTORY	IMPORTANCE The late effects of traumatic brain injury (TBI) are of great interest, but studies characterizing these effects are limited. OBJECTIVE To determine whether TBI with loss of consciousness (LOC) is associated with an increased risk for clinical and neuropathologic findings of Alzheimer disease (AD), Parkinson disease (PD), and other dementias. DESIGN, SETTING, AND PARTICIPANTS This study analyzed data from the Religious Orders Study (ROS), Memory and Aging Project (MAP), and Adult Changes in Thought study (ACT). All ROS and MAP participants and a subset of ACT participants consent to autopsy. Studies performed annual (ROS and MAP) or biennial (ACT) cognitive and clinical testing to identify incident cases of dementia and AD. The 7130 participants included members of a Seattle-area health care delivery system (ACT), priests and nuns living in orders across the United States (ROS), and Chicago-area adults in retirement communities (MAP). Of these, 1589 underwent autopsy. Primary hypothesis was that TBI with LOC would be associated with increased risk for AD and neurofibrillary tangles. Data were accrued from 1994 to April 1, 2014. EXPOSURES Self-reported TBI when the participant was free of dementia, categorized as no more than 1 vs more than 1 hour of LOC. MAIN OUTCOMES AND MEASURES Clinical outcomes included incident all-cause dementia, AD, and PD in all studies and incident mild cognitive impairment and progression of parkinsonian signs in ROS and MAP. Neuropathologic outcomes included neurofibrillary tangles, neuritic plaques, microinfarcts, cystic infarcts, Lewy bodies, and hippocampal sclerosis in all studies. RESULTS Of 7130 participants (2879 [40.4%] men; overall mean [SD] age, 79.9 [6.9] years), 865 reported a history of TBI with LOC. In 45 190 person-years of follow-up, 1537 incident cases of dementia and 117 of PD were identified. No association was found between TBI with LOC and incident dementia (ACT: HR for TBI with LOC <= 1 hour, 1.03; 95% CI, 0.83-1.27; HR for TBI with LOC > 1 hour, 1.18; 95% CI, 0.77-1.78; ROS and MAP: HR for TBI with LOC <= 1 hour, 0.87; 95% CI, 0.58-1.29; HR for TBI with LOC > 1 hour, 0.84; 95% CI, 0.44-1.57) or AD (findings similar to those for dementia). Associations were found for TBI with LOC and incident PD in ACT (HR for TBI with LOC > 1 hour, 3.56; 95% CI, 1.52-8.28) and progression of parkinsonian signs in ROS and MAP (odds ratio [OR] for TBI with LOC <= 1 hour, 1.65; 95% CI, 1.23-2.21; OR for TBI with LOC > 1 hour, 2.23; 95% CI, 1.16-4.29). Traumatic brain injury with LOC was associated with Lewy bodies (any Lewy body in ACT: RR for TBI with LOC > 1 hour, 2.64; 95% CI, 1.40-4.99; Lewy bodies in substantia nigra and/or locus ceruleus in ACT: RR for TBI with LOC > 1 hour, 3.30; 95% CI, 1.71-6.38; Lewy bodies in frontal or temporal cortex in ACT: RR for TBI with LOC > 1 hour, 5.73; 95% CI, 2.18-15.0; ROS and MAP: RR for TBI with LOC <= 1 hour, 1.64; 95% CI, 1.00-2.70; pooled RR for TBI with LOC <= 1 hour, 1.59; 95% CI, 1.06-2.39) and microinfarcts (any cortical microinfarct in ROS and MAP: RR for TBI with LOC > 1 hour, 2.12; 95% CI, 1.12-4.01; pooled RR for TBI with LOC > 1 hour, 1.58; 95% CI, 1.06-2.35). CONCLUSIONS AND RELEVANCE Pooled clinical and neuropathologic data from 3 prospective cohort studies indicate that TBI with LOC is associated with risk for Lewy body accumulation, progression of parkinsonism, and PD, but not dementia, AD, neuritic plaques, or neurofibrillary tangles.	[Crane, Paul K.; Gibbons, Laura E.] Univ Washington, Dept Med, 325 Ninth Ave,Box 359780, Seattle, WA 98104 USA; [Dams-O'Connor, Kristen] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Trittschuh, Emily] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Leverenz, James B.] Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA; [Keene, C. Dirk; Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Sonnen, Joshua] Univ Utah, Dept Pathol, Salt Lake City, UT USA; [Bennett, David A.; Leurgans, Sue] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA; [Schneider, Julie A.] Rush Univ, Med Ctr, Dept Pathol, Chicago, IL 60612 USA; [Larson, Eric B.] Grp Hlth Res Inst, Ctr Hlth Studies, Seattle, WA USA; [Montine, Thomas J.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA	Crane, PK (corresponding author), Univ Washington, Dept Med, 325 Ninth Ave,Box 359780, Seattle, WA 98104 USA.	pcrane@uw.edu	Melief, Erica/M-6436-2019	Leverenz, James/0000-0002-0896-0749	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01 AG006781, U01 NS086625, P50 AG005136, P50 NS062684, K01 HD074651, P30 AG10161, RF1 AG015819, R01 AG17917, R01 AG22018, R01 AG042210, R01 NS78009]; Paul G. Allen Family Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086625, P50NS062684, R01NS078009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010161, R01AG017917, R01AG042210, U01AG006781, RF1AG015819, R01AG022018, P50AG005136] Funding Source: NIH RePORTER	This study was supported by grants U01 AG006781, U01 NS086625, P50 AG005136, P50 NS062684, K01 HD074651, P30 AG10161, RF1 AG015819, R01 AG17917, R01 AG22018, R01 AG042210, and R01 NS78009 from the NIH and a grant from the Paul G. Allen Family Foundation (data collection and analysis).	Abner EL, 2014, DEMENT GERIATR COGN, V37, P294, DOI 10.1159/000355478; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Arvanitakis Z, 2011, ANN NEUROL, V69, P320, DOI 10.1002/ana.22112; Bennett DA, 2002, NEUROLOGY, V59, P198, DOI 10.1212/WNL.59.2.198; Bennett DA, 2006, NEUROEPIDEMIOLOGY, V27, P169, DOI 10.1159/000096129; Bennett DA, 2012, ANN NEUROL, V72, P599, DOI 10.1002/ana.23654; Bennett DA, 2012, CURR ALZHEIMER RES, V9, P646; Bennett DA, 2012, CURR ALZHEIMER RES, V9, P628; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Buchman AS, 2012, ANN NEUROL, V71, P258, DOI 10.1002/ana.22588; Crane PK, 2013, NEW ENGL J MED, V369, P540, DOI 10.1056/NEJMoa1215740; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Institute of Medicine, 2009, LONG TERM CONS TRAUM, V7; Kukull WA, 2002, ARCH NEUROL-CHICAGO, V59, P1737, DOI 10.1001/archneur.59.11.1737; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; Schneider JA, 2009, ANN NEUROL, V66, P200, DOI 10.1002/ana.21706; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sonnen JA, 2010, NEUROLOGY, V75, P1203, DOI 10.1212/WNL.0b013e3181f52db1; Sonnen JA, 2007, ANN NEUROL, V62, P406, DOI 10.1002/ana.21208; Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015; Whiteneck GG, 2016, J HEAD TRAUMA REHAB, V31, pE55, DOI 10.1097/HTR.0000000000000140	30	173	175	1	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	SEP	2016	73	9					1062	1069		10.1001/jamaneurol.2016.1948			8	Clinical Neurology	Neurosciences & Neurology	DX2MV	WOS:000384205200008	27400367	Green Accepted, Bronze	Y	N	2021-06-18	
J	Sorrentino, E; Diedler, J; Kasprowicz, M; Budohoski, KP; Haubrich, C; Smielewski, P; Outtrim, JG; Manktelow, A; Hutchinson, PJ; Pickard, JD; Menon, DK; Czosnyka, M				Sorrentino, E.; Diedler, J.; Kasprowicz, M.; Budohoski, K. P.; Haubrich, C.; Smielewski, P.; Outtrim, J. G.; Manktelow, A.; Hutchinson, P. J.; Pickard, J. D.; Menon, D. K.; Czosnyka, M.			Critical Thresholds for Cerebrovascular Reactivity After Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						ICP; CPP; PRx; TBI; Prognosis; Head injury; Prognostic factors; Thresholds	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURIES; GLASGOW COMA SCALE; INTRACRANIAL HYPERTENSION; CARE	Introduction Pressure-reactivity index (PRx) is a useful tool in brain monitoring of trauma patients, but the question remains about its critical values. Using our TBI database, we identified the thresholds for PRx and other monitored parameters that maximize the statistical difference between death/survival and favorable/unfavorable outcomes. We also investigated how these thresholds depend on clinical factors such as age, gender and initial GCS. Methods A total of 459 patients from our database were eligible. Tables of 2 9 2 format were created grouping patients according to survival/death or favorable/unfavorable outcomes and varying thresholds for PRx, ICP and CPP. Pearson's chi square was calculated, and the thresholds returning the highest score were assumed to have the best discriminative value. The same procedure was repeated after division according to clinical factors. Results In all patients, we found that PRx had different thresholds for survival (0.25) and for favorable outcome (0.05). Thresholds of 70 mmHg for CPP and 22 mmHg for ICP were identified for both survival and favorable outcomes. The ICP threshold for favorable outcome was lower (18 mmHg) in females and patients older than 55 years. In logistic regression models, independent variables associating with mortality and unfavorable outcome were age, GCS, ICP and PRx. Conclusion The prognostic role of PRx is confirmed but with a lower threshold of 0.05 for favorable outcome than for survival (0.25). Results for ICP are in line with current guidelines. However, the lower value in elderly and in females suggests increased vulnerability to intracranial hypertension in these groups.	[Sorrentino, E.; Budohoski, K. P.; Smielewski, P.; Outtrim, J. G.; Manktelow, A.; Hutchinson, P. J.; Pickard, J. D.; Menon, D. K.; Czosnyka, M.] Univ Cambridge, Cambridge, England; [Diedler, J.] Heidelberg Univ, Heidelberg, Germany; [Kasprowicz, M.] Wroclaw Univ Technol, Inst Biomed Engn & Instrumentat, PL-50370 Wroclaw, Poland; [Haubrich, C.] Univ Aachen, Aachen, Germany	Czosnyka, M (corresponding author), Univ Cambridge, Cambridge, England.	mc141@medschl.cam.ac.uk		Kasprowicz, Magdalena/0000-0002-2271-7737; Smielewski, Peter/0000-0001-5096-3938; Outtrim, Joanne/0000-0001-8118-6430	National Institute of Health Research, Biomedical Research Centre, Cambridge University Hospital Foundation TrustNational Institute for Health Research (NIHR); Technology Foresight Challenge Fund [FCA 234/95]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MRC G9439390]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0001354, G1000183B, G9439390, G0001354B, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	The project was supported by the National Institute of Health Research, Biomedical Research Centre, Cambridge University Hospital Foundation Trust - Neurosciences Theme and Senior Investigator Awards (JDP, DKM), Technology Foresight Challenge Fund (Grant FCA 234/95), MRC Programme Grant (MRC G9439390). Clifford and Mary Corbridge Trust (KPB) and Foundation for Polish Science (MK). Many thanks to all colleagues participating in head injury monitoring program in Cambridge, UK in 1991-2009, whose experience, knowledge and clinical material helped us to write this study: Mrs. P. Al-Rawi, Mrs. D. Chattfield, Mrs. C. Turner, Dr. M. Balestreri, Miss. M. Hiler, Dr. SK Piechnik, Dr. LA Steiner, Mr. E. Guazzo, Mr. PC Whetfield, Mr. P. Minhas, Dr. M. Soehle, Mr. R. Kett-White, Dr. E. Schmidt, Mr. I. Timofeev, Mr. A. Helmy. Mr. PJ Kirkpatrick, Dr. B. Matta, Dr. J. Coles, Prof. A. Gupta, nursing and research staff from Neurosciences Critical Care Unit and Wolfson Brain Imaging Centre. Dr. M. Czosnyka is on leave from Warsaw University of Technology, Poland.	[Anonymous], 2007, J NEUROTRAUM, V24, pS1, DOI 10.1089/neu.2007.9997; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA S1, V24, pS54; Castellani G, 2009, NEUROCRIT CARE, V11, P143, DOI 10.1007/s12028-009-9235-7; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2008, ACTA NEUROCHIR SUPPL, V102, P25, DOI 10.1007/978-3-211-85578-2_5; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Smielewski P, 2005, ACT NEUR S, V95, P43; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa Paul, 2003, Neurosurg Focus, V15, pE4; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; Young Jeffrey S, 2003, Neurosurg Focus, V15, pE2	32	173	178	0	8	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2012	16	2					258	266		10.1007/s12028-011-9630-8			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	949ZS	WOS:000304618500009	21964774				2021-06-18	
J	Meares, S; Shores, EA; Taylor, AJ; Batchelor, J; Bryant, RA; Baguley, IJ; Chapman, J; Gurka, J; Marosszeky, JE				Meares, Susanne; Shores, E. Arthur; Taylor, Alan J.; Batchelor, Jennifer; Bryant, Richard A.; Baguley, Ian J.; Chapman, Jennifer; Gurka, Joseph; Marosszeky, Jeno E.			The Prospective Course of Postconcussion Syndrome: The Role of Mild Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						mild traumatic brain injury; concussion; postconcussion syndrome; posttraumatic stress disorder; pain	POSTTRAUMATIC-STRESS-DISORDER; CHRONIC PAIN; HEAD-INJURY; SEX-DIFFERENCES; DIAGNOSTIC-CRITERIA; ACCIDENT SURVIVORS; SYMPTOMS; SCALE; IRAQ; MODERATE	Objective: To investigate whether postconcussion syndrome (PCS) represents long-term sequelae associated with mild traumatic brain injury (mTBI). Methods: Prospective consecutive admissions to a Level 1 trauma hospital were assessed a mean 4.9 days and again 106.2 days post-injury. The final sample comprised 62 mTBI and 58 nonbrain injured trauma controls (TC). Change or lack of change in individual PCS-like symptoms and PCS was examined. Multilevel logistic regression was used to analyze whether mTBI predicts 3-month PCS (Time 2; T2); whether predictors of PCS (within 14 days of injury, Time 1; T1) predict 3-month PCS, and how change in these predictors from T1 to T2 were associated with change in PCS status. Variables included demographic, injury-related, financial incentives, neuropsychological, and psychiatric disorder. Results: MTBI did not predict PCS. PCS was comparable (T1: mTBI: 40.3%, TC: 50.0%; T2: mTBI: 46.8%, TC: 48.3%). At T2, 38.6% were new cases of PCS; between 30.8% and 86.2% reported either a new or more frequent symptom. A pre-injury depressive or anxiety disorder (OR = 2.99, 95% CI [1.38, 6.45]), and acute posttraumatic stress (OR = 1.05, 95% CI [1.00, 1.00]) were early markers of PCS, regardless of mTBI. An interaction between time and posttraumatic stress disorder (PTSD) suggested the relationship between the severity of PTSD symptoms and PCS strengthened over time (OR = 2.66, 95% CI [1.08, 6.55]). Pain was related to PCS. Females were more likely than males to have PCS. Conclusion: The data suggest the phenomenon of PCS in trauma patients does not show an association with mTBI.	[Meares, Susanne; Shores, E. Arthur; Taylor, Alan J.; Batchelor, Jennifer] Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia; [Bryant, Richard A.] Univ New S Wales, Sch Psychol, Sydney, NSW, Australia; [Baguley, Ian J.; Chapman, Jennifer; Gurka, Joseph; Marosszeky, Jeno E.] Westmead Hosp, Dept Rehabil Med, Sydney, NSW, Australia	Shores, EA (corresponding author), Macquarie Univ, Dept Psychol, N Ryde, NSW 2109, Australia.	arthur.shores@mq.edu.au	Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021; Bryant, Richard/AAA-6479-2019	Baguley, Ian J/0000-0001-5650-3705; Bryant, Richard/0000-0002-9607-819X; Shores, Edwin A/0000-0003-1553-5131; Meares, Susanne/0000-0002-3859-9974; Batchelor, Jennifer/0000-0003-4438-4993	Motor Accidents Authority of NSW [04/238]	This article is based on data used by Susanne Meares in her PhD dissertation, and is a longitudinal extension of Meares, S., Shores, E. A., Taylor, A. J., Batchelor, J., Bryant, R. A., Baguley, I. J., Chapman, J., Gurka, J., Dawson, K., Capon, L., & Marosszeky, J. E. (2008). Mild traumatic brain injury does not predict acute postconcussion syndrome. Journal of Neurology, Neurosurgery & Psychiatry, 79, 300-306. We would like to acknowledge the assistance of Dr Valerie Malka and staff from the Department of Trauma, Westmead Hospital in recruitment of patients, and Mss Katie Dawson, Lyn Capon, Samantha Meeth and Dr Sarah Fairjones for their contribution to data collection. This work was supported by a Motor Accidents Authority of NSW grant No. 04/238.	*AM ASS AUT MED, 2001, ABBR INJ SCAL 1990 R; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andrews G, 2001, BRIT J PSYCHIAT, V178, P145, DOI 10.1192/bjp.178.2.145; Asmundson GJG, 2006, COGN BEHAV PRACT, V13, P8, DOI 10.1016/j.cbpra.2005.03.001; Babor TF., 2001, AUDIT ALCOHOL USE DI, V2nd; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P1044; Bryant RA, 2000, PSYCHOL ASSESSMENT, V12, P61, DOI 10.1037/1040-3590.12.1.61; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Carlin JB, 2008, STATA J, V8, P49, DOI 10.1177/1536867X0800800104; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; ERICHSEN JE, 2010, CONCUSSION SPINE NER; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Felmingham K, 2010, J ABNORM PSYCHOL, V119, P241, DOI 10.1037/a0017551; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; *GLOBALRPH, 2004, CLIN ULT REF; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Green P., 1996, WORD MEMORY TEST USE; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Jenewein J, 2009, J TRAUMA STRESS, V22, P540, DOI 10.1002/jts.20453; Jensen M.P., 2001, HDB PAIN ASSESSMENT, P15; Jones C, 2005, J TRAUMA STRESS, V18, P181, DOI 10.1002/jts.20031; Jones DWC, 1919, BRAIN, V42, P171, DOI 10.1093/brain/42.3.171; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; MILLER EN, 1999, CALCAP CALIFORNIA CO; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Norman SB, 2008, PSYCHOL MED, V38, P533, DOI 10.1017/S0033291707001389; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Psychological Corporation, 2001, WECHSL TEST AD READ; Rabe-Hesketh S., 2008, MULTILEVEL LONGITUDI; ROBERTSON E, 1994, CLIN NEUROPSYCHOL, V8, P69; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1982, SYMBOL DIGIT MODALIT; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; Van Damme S, 2010, NEUROSCI BIOBEHAV R, V34, P204, DOI 10.1016/j.neubiorev.2009.01.005; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; WALL PD, 1999, TXB PAIN; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; World Health Organisation, 1993, ICD 10 CLASSIFICATIO	74	173	174	0	35	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2011	25	4					454	465		10.1037/a0022580			12	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	787WQ	WOS:000292407800004	21574719				2021-06-18	
J	Hashmi, JT; Huang, YY; Osmani, BZ; Sharma, SK; Naeser, MA; Hamblin, MR				Hashmi, Javad T.; Huang, Ying-Ying; Osmani, Bushra Z.; Sharma, Sulbha K.; Naeser, Margaret A.; Hamblin, Michael R.			Role of Low-Level Laser Therapy in Neurorehabilitation	PM&R			English	Article								This year marks the 50th anniversary of the discovery of the laser. The development of lasers for medical use, which became known as low-level laser therapy (LLLT) or photobiomodulation, followed in 1967. In recent years, LLLT has become an increasingly mainstream modality, especially in the areas of physical medicine and rehabilitation. At first used mainly for wound healing and pain relief, the medical applications of LLLT have broadened to include diseases such as stroke, myocardial infarction, and degenerative or traumatic brain disorders. This review will cover the mechanisms of LLLT that operate both on a cellular and a tissue level. Mitochondria are thought to be the principal photoreceptors, and increased adenosine triphosphate, reactive oxygen species, intracellular calcium, and release of nitric oxide are the initial events. Activation of transcription factors then leads to expression of many protective, anti-apoptotic, antioxidant, and pro-proliferation gene products. Animal studies and human clinical trials of LLLT for indications with relevance to neurology, such as stroke, traumatic brain injury, degenerative brain disease, spinal cord injury, and peripheral nerve regeneration, will be covered. PM R 2010;2:S292-S305	[Hashmi, Javad T.; Huang, Ying-Ying; Sharma, Sulbha K.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Hashmi, Javad T.; Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02114 USA; [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China; [Osmani, Bushra Z.] Aga Khan Med Coll, Karachi, Pakistan; [Naeser, Margaret A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Naeser, Margaret A.] VA Boston Healthcare Syst, Boston, MA USA	Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Huang, yingying/J-7329-2012; Huang, Ying-ying/G-3153-2011; Hamblin, Michael R/H-2758-2019	Huang, yingying/0000-0002-4038-0277; Huang, Ying-ying/0000-0003-3066-6981; Hamblin, Michael R/0000-0001-6431-4605	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; Center for Integration of Medicine and Innovative Technology [DAMD17-02-2-0006]; CDMRP Program in TBI [W81XWH-09-1-0514]; Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9950-04-1-0079]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	Disclosure: research in the Hamblin laboratory supported by NIH grant R01AI050875, Center for Integration of Medicine and Innovative Technology (DAMD17-02-2-0006), CDMRP Program in TBI (W81XWH-09-1-0514), and Air Force Office of Scientific Research (FA9950-04-1-0079)	Aimbire F, 2006, PHOTOMED LASER SURG, V24, P33, DOI 10.1089/pho.2006.24.33; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Avni D, 2005, PHOTOMED LASER SURG, V23, P273, DOI 10.1089/pho.2005.23.273; Barbosa RI, 2010, LASER MED SCI, V25, P423, DOI 10.1007/s10103-009-0750-8; BARD GREGORY, 1965, ARCH PHYS MED REHABIL, V46, P567; Baxter G. D., 1994, THERAPEUTIC LASERS T, P89; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Carnevalli CMM, 2003, J CLIN LASER MED SUR, V21, P193, DOI 10.1089/104454703768247756; Chen A C-H, 2010, PHOTOMED LASER SURG; Chen ACH, 2009, PROC SPIE, V7165, DOI 10.1117/12.809605; CHENG N, 1982, CLIN ORTHOP RELAT R, P264; Cruanes CJ, 1984, LASER THERAPY TODAY, P95; De Scheerder IK, 2001, LASER SURG MED, V28, P212, DOI 10.1002/lsm.1040; Deadman P, 1998, HOVE E ESSEX ENGLAND, V256, P548; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; FROST E A M, 1976, American Journal of Acupuncture, V4, P45; Gigo-Benato D, 2004, LASER MED SCI, V19, P57, DOI 10.1007/s10103-004-0300-3; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; GRECO M, 1989, BIOCHEM BIOPH RES CO, V163, P1428, DOI 10.1016/0006-291X(89)91138-8; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; KARU T, 1989, Journal of Photochemistry and Photobiology B Biology, V3, P638, DOI 10.1016/1011-1344(89)80088-0; KARU T, 1989, HEALTH PHYS, V56, P691, DOI 10.1097/00004032-198905000-00015; KARU T, 1995, J PHOTOCH PHOTOBIO B, V27, P219, DOI 10.1016/1011-1344(94)07078-3; Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355; KARU TJ, 1984, NUOVO CIMENTO D, V3, P309, DOI 10.1007/BF02457460; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lampl Yair, 2007, Expert Rev Neurother, V7, P961, DOI 10.1586/14737175.7.8.961; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Lapchak PA, 2008, STROKE, V39, P3073, DOI 10.1161/STROKEAHA.108.516393; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Lapchak PA, 2009, BRAIN RES, V1303, P144, DOI 10.1016/j.brainres.2009.09.064; Lewin JS, 1996, J COMPUT ASSIST TOMO, V20, P695, DOI 10.1097/00004728-199609000-00002; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lohr NL, 2009, J MOL CELL CARDIOL, V47, P256, DOI 10.1016/j.yjmcc.2009.03.009; LONGO L, 1986, TERAPIA LASER; MESTER E, 1971, AM J SURG, V122, P532, DOI 10.1016/0002-9610(71)90482-X; MESTER E, 1972, ACTA CHIR HUNG, V13, P315; Mester E, 1967, KISERL ORVOSTUD, V19, P628; Mi XQ, 2004, PHOTOMED LASER SURG, V22, P477, DOI 10.1089/pho.2004.22.477; Mi XQ, 2004, J PHOTOCH PHOTOBIO B, V74, P7, DOI 10.1016/j.jphotobiol.2004.01.003; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; Moges H, 2009, LASER SURG MED, V41, P52, DOI 10.1002/lsm.20732; Moreira MS, 2009, J PHOTOCH PHOTOBIO B, V97, P145, DOI 10.1016/j.jphotobiol.2009.09.002; NAESER MA, 1995, AM J ACUPUNCTURE, V23, P13; NAESER MA, 1994, ACUPUNCTURE ELECTRO, V19, P227, DOI 10.3727/036012994816357231; Naeser MA, 1992, NEUROREHAB NEURAL RE, V6, P163; Naeser MA, 1994, CLIN REHABIL, V8, P127; Naeser MA, 1994, LASER ACUPUNCTURE IN, P40; Naeser MA, 2010, PHOTOMED LA IN PRESS; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron U, 2001, LASER SURG MED, V28, P204, DOI 10.1002/lsm.1039; Oron U, 2001, CIRCULATION, V103, P296; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; PASSARELLA S, 1984, FEBS LETT, V175, P95, DOI 10.1016/0014-5793(84)80577-3; PASTORE D, 1994, BIOCHEM MOL BIOL INT, V34, P817; Petrides M, 1995, ANN NY ACAD SCI, V769, P85, DOI 10.1111/j.1749-6632.1995.tb38133.x; Rochkind S, 1988, Acta Neurochir Suppl (Wien), V43, P91; Rochkind S, 2007, PHOTOMED LASER SURG, V25, P436, DOI 10.1089/pho.2007.2093; Rochkind S, 2007, PHOTOMED LASER SURG, V25, P137, DOI 10.1089/pho.2007.2076; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Shefer G, 2002, J CELL SCI, V115, P1461; Shen JF, 2008, J CEREBR BLOOD F MET, V28, P1460, DOI 10.1038/jcbfm.2008.37; Sompol P, 2006, J MOL NEUROSCI, V29, P279, DOI 10.1385/JMN:29:3:279; Stemer Andrew B, 2010, Curr Cardiol Rep, V12, P29, DOI 10.1007/s11886-009-0071-3; SUNDERLAND A, 1989, J NEUROL NEUROSUR PS, V52, P1267, DOI 10.1136/jnnp.52.11.1267; Swick D, 2002, NEUROPSYCHOLOGIA, V40, P1240, DOI 10.1016/S0028-3932(01)00226-3; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Trimmer PA, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-26; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; WAN S, 1981, PHOTOCHEM PHOTOBIOL, V34, P679, DOI 10.1111/j.1751-1097.1981.tb09424.x; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2010, PROC SPIE, V7552, DOI 10.1117/12.841014; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Yaakobi T, 2001, J APPL PHYSIOL, V90, P2411; Zhang L, 2008, CELL PHYSIOL BIOCHEM, V22, P215, DOI 10.1159/000149799; Zhang RL, 1997, BRAIN RES, V766, P83, DOI 10.1016/S0006-8993(97)00580-5; ZHANG YH, 1994, INFECT IMMUN, V62, P4140, DOI 10.1128/IAI.62.10.4140-4144.1994; Zhang YO, 2003, J INVEST DERMATOL, V120, P849, DOI 10.1046/j.1523-1747.2003.12133.x; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	85	173	184	1	45	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-1482	1934-1563		PM&R	PM&R	DEC	2010	2	12		2			S292	S305		10.1016/j.pmrj.2010.10.013			14	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	V24LT	WOS:000208412600010	21172691	Green Accepted			2021-06-18	
J	David, Y; Cacheaux, LP; Ivens, S; Lapilover, E; Heinemann, U; Kaufer, D; Friedman, A				David, Yaron; Cacheaux, Luisa P.; Ivens, Sebastian; Lapilover, Ezequiel; Heinemann, Uwe; Kaufer, Daniela; Friedman, Alon			Astrocytic Dysfunction in Epileptogenesis: Consequence of Altered Potassium and Glutamate Homeostasis?	JOURNAL OF NEUROSCIENCE			English	Article							BLOOD-BRAIN-BARRIER; TEMPORAL-LOBE EPILEPSY; EXCITATORY SYNAPTIC CURRENTS; CENTRAL-NERVOUS-SYSTEM; RECTIFYING K+ CHANNEL; TIME-COURSE; HIPPOCAMPAL SLICES; GLIAL-CELLS; SPINAL-CORD; ELECTROPHYSIOLOGICAL PROPERTIES	Focal epilepsy often develops following traumatic, ischemic, or infectious brain injury. While the electrical activity of the epileptic brain is well characterized, the mechanisms underlying epileptogenesis are poorly understood. We have recently shown that in the rat neocortex, long-lasting breakdown of the blood-brain barrier (BBB) or direct exposure of the neocortex to serum-derived albumin leads to rapid upregulation of the astrocytic marker GFAP (glial fibrillary acidic protein), followed by delayed (within 4-7 d) development of an epileptic focus. We investigated the role of astrocytes in epileptogenesis in the BBB-breakdown and albumin models of epileptogenesis. We found similar, robust changes in astrocytic gene expression in the neocortex within hours following treatment with deoxycholic acid (BBB breakdown) or albumin. These changes predict reduced clearance capacity for both extracellular glutamate and potassium. Electrophysiological recordings in vitro confirmed the reduced clearance of activity-dependent accumulation of both potassium and glutamate 24 h following exposure to albumin. We used a NEURON model to simulate the consequences of reduced astrocytic uptake of potassium and glutamate on EPSPs. The model predicted that the accumulation of glutamate is associated with frequency-dependent (> 100 Hz) decreased facilitation of EPSPs, while potassium accumulation leads to frequency-dependent (10-50 Hz) and NMDA-dependent synaptic facilitation. In vitro electrophysiological recordings during epileptogenesis confirmed frequency-dependent synaptic facilitation leading to seizure-like activity. Our data indicate a transcription-mediated astrocytic transformation early during epileptogenesis. We suggest that the resulting reduction in the clearance of extracellular potassium underlies frequency-dependent neuronal hyperexcitability and network synchronization.	[Friedman, Alon] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol, IL-84105 Beer Sheva, Israel; [David, Yaron; Friedman, Alon] Ben Gurion Univ Negev, Dept Neurosurg, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel; [Cacheaux, Luisa P.; Kaufer, Daniela] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; [Kaufer, Daniela] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; [Ivens, Sebastian; Lapilover, Ezequiel; Heinemann, Uwe; Friedman, Alon] Charite, Neurocure Res Ctr, Inst Neurophysiol, D-10117 Berlin, Germany	Friedman, A (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol, IL-84105 Beer Sheva, Israel.	alonf@bgu.ac.il			SonderforschungsbereichGerman Research Foundation (DFG) [TR3]; German-Israel Foundation for Scientific Research and DevelopmentGerman-Israeli Foundation for Scientific Research and Development; Israel Science FoundationIsrael Science Foundation [566/07]; United States-Israel Binational Science FoundationUS-Israel Binational Science Foundation; CURE Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS066005] Funding Source: NIH RePORTER	This study was supported by the Sonderforschungsbereich TR3 (A. F., U. H.), the German-Israel Foundation for Scientific Research and Development (A. F.), the Israel Science Foundation (566/07, A. F.), Minerva Stiftung (Y. D.), the United States-Israel Binational Science Foundation (A. F., D. K.), and the CURE Foundation (D. K., A. F.).	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Araque A, 2001, ANNU REV PHYSIOL, V63, P795, DOI 10.1146/annurev.physiol.63.1.795; Arnth-Jensen N, 2002, NAT NEUROSCI, V5, P325, DOI 10.1038/nn825; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BARRES BA, 1990, ANNU REV NEUROSCI, V13, P441, DOI 10.1146/annurev.neuro.13.1.441; Bergles DE, 1998, J NEUROSCI, V18, P7709; Bordey A, 2001, J NEUROPHYSIOL, V85, P1719; Bordey A, 1998, EPILEPSY RES, V32, P286, DOI 10.1016/S0920-1211(98)00059-X; Butt AM, 2006, J CELL MOL MED, V10, P33, DOI 10.1111/j.1582-4934.2006.tb00289.x; Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; Chen KC, 2000, BIOPHYS J, V78, P2776, DOI 10.1016/S0006-3495(00)76822-6; CIANI S, 1978, J MEMBRANE BIOL, V44, P103, DOI 10.1007/BF01976035; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; DEROUICHE A, 1991, BRAIN RES, V552, P346, DOI 10.1016/0006-8993(91)90103-3; Diamond JS, 2005, J NEUROSCI, V25, P2906, DOI 10.1523/JNEUROSCI.5125-04.2005; Diamond JS, 2000, J NEUROPHYSIOL, V83, P2835; Ding S, 2007, J NEUROSCI, V27, P10674, DOI 10.1523/JNEUROSCI.2001-07.2007; Djukic B, 2007, J NEUROSCI, V27, P11354, DOI 10.1523/JNEUROSCI.0723-07.2007; Egelman DM, 1999, BIOPHYS J, V76, P1856, DOI 10.1016/S0006-3495(99)77345-5; Eid T, 2008, EPILEPSIA, V49, P42, DOI 10.1111/j.1528-1167.2008.01492.x; FERTZIGER AP, 1970, EXP NEUROL, V26, P571, DOI 10.1016/0014-4886(70)90150-0; Gabriel S, 1998, NEUROSCI LETT, V242, P9, DOI 10.1016/S0304-3940(98)00012-3; GEURSEN A, 1987, J PHYSIOL-LONDON, V391, P419, DOI 10.1113/jphysiol.1987.sp016746; Gronau I, 2007, INFORM PROCESS LETT, V104, P205, DOI 10.1016/j.ipl.2007.07.002; Heinemann U, 1999, Adv Neurol, V79, P583; HEINEMANN U, 1990, EXP BRAIN RES, V79, P283, DOI 10.1007/BF00608237; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; Hibino H, 2004, J BIOL CHEM, V279, P44065, DOI 10.1074/jbc.M405985200; Hickenbottom SL, 1998, SEMIN NEUROL, V18, P485, DOI 10.1055/s-2008-1040901; Higashi K, 2001, AM J PHYSIOL-CELL PH, V281, pC922; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; Hinterkeuser S, 2000, EUR J NEUROSCI, V12, P2087, DOI 10.1046/j.1460-9568.2000.00104.x; Iserhot C, 2004, BRAIN RES, V1027, P151, DOI 10.1016/j.brainres.2004.08.052; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Jansen LA, 2005, EPILEPSIA, V46, P1871, DOI 10.1111/j.1528-1167.2005.00289.x; Jauch R, 2002, BRAIN RES, V925, P18, DOI 10.1016/S0006-8993(01)03254-1; Kager H, 2000, J NEUROPHYSIOL, V84, P495; Kampa BM, 2004, J PHYSIOL-LONDON, V556, P337, DOI 10.1113/jphysiol.2003.058842; Kaufer D, 2004, NAT NEUROSCI, V7, P947, DOI 10.1038/nn1296; Kivi A, 2000, EUR J NEUROSCI, V12, P2039, DOI 10.1046/j.1460-9568.2000.00103.x; Koller H, 2000, BRAIN RES, V872, P194, DOI 10.1016/S0006-8993(00)02434-3; KUFFLER SW, 1964, J NEUROPHYSIOL, V27, P290; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; LUX HD, 1973, EXP BRAIN RES, V17, P190; Marchi N, 2007, EPILEPSIA, V48, P732, DOI 10.1111/j.1528-1167.2007.00988.x; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; Myme CIO, 2003, J NEUROPHYSIOL, V90, P771, DOI 10.1152/jn.00070.2003; Neuwelt EA, 2004, NEUROSURGERY, V54, P131, DOI 10.1227/01.NEU.0000097715.11966.8E; NEWMAN EA, 1993, J NEUROSCI, V13, P3333; NEWMAN EA, 1984, SCIENCE, V225, P1174, DOI 10.1126/science.6474173; Oliet SHR, 2001, SCIENCE, V292, P923, DOI 10.1126/science.1059162; Otis T, 1996, J NEUROSCI, V16, P7496; Pasler D, 2007, BRAIN RES, V1173, P14, DOI 10.1016/j.brainres.2007.07.013; Pavlovsky L, 2003, EXP NEUROL, V179, P181, DOI 10.1016/S0014-4886(02)00016-X; Proper EA, 2002, BRAIN, V125, P32, DOI 10.1093/brain/awf001; Rebhan M, 1998, BIOINFORMATICS, V14, P656, DOI 10.1093/bioinformatics/14.8.656; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; Saftenku EE, 2005, J THEOR BIOL, V234, P363, DOI 10.1016/j.jtbi.2004.11.036; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P641, DOI 10.1113/jphysiol.1984.sp015088; SARANTIS M, 1993, NEURON, V11, P541, DOI 10.1016/0896-6273(93)90158-N; Savtchenko LP, 2000, BIOPHYS J, V78, P1119, DOI 10.1016/S0006-3495(00)76670-7; Scanziani M, 1997, NATURE, V385, P630, DOI 10.1038/385630a0; Schroder W, 2000, EPILEPSIA, V41, pS181, DOI 10.1111/j.1528-1157.2000.tb01578.x; Schroder W, 1999, GLIA, V28, P166, DOI 10.1002/(SICI)1098-1136(199911)28:2<166::AID-GLIA8>3.3.CO;2-K; Schwarcz R, 2008, EPILEPSIA, V49, P1, DOI 10.1111/j.1528-1167.2008.01487.x; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Shao LR, 2004, J NEUROPHYSIOL, V92, P1366, DOI 10.1152/jn.00131.2004; Somjen GG, 2008, J COMPUT NEUROSCI, V25, P349, DOI 10.1007/s10827-008-0083-9; Sonkusare SK, 2005, PHARMACOL RES, V51, P1, DOI 10.1016/j.phrs.2004.05.005; Su ZZ, 2003, P NATL ACAD SCI USA, V100, P1955, DOI 10.1073/pnas.0136555100; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Takayasu Y, 2004, EUR J NEUROSCI, V19, P1285, DOI 10.1111/j.1460-9568.2004.03224.x; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Tessler S, 1999, NEUROSCIENCE, V88, P1083, DOI 10.1016/S0306-4522(98)00301-7; Tian GF, 2005, NAT MED, V11, P973, DOI 10.1038/nm1277; Tomkins O, 2007, NEUROBIOL DIS, V25, P367, DOI 10.1016/j.nbd.2006.10.006; Tomkins O, 2001, CELL MOL NEUROBIOL, V21, P675, DOI 10.1023/A:1015147920283; Traub RD, 2003, J NEUROPHYSIOL, V89, P909, DOI 10.1152/jn.00573.2002; Turecek R, 2000, J NEUROSCI, V20, P2054; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; Wallraff A, 2006, J NEUROSCI, V26, P5438, DOI 10.1523/JNEUROSCI.0037-06.2006; Wetherington J, 2008, NEURON, V58, P168, DOI 10.1016/j.neuron.2008.04.002; Zhao S, 2005, J COMPUT BIOL, V12, P1047, DOI 10.1089/cmb.2005.12.1047; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	92	173	178	0	9	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	AUG 26	2009	29	34					10588	10599		10.1523/JNEUROSCI.2323-09.2009			12	Neurosciences	Neurosciences & Neurology	487ZJ	WOS:000269317900014	19710312	Bronze, Green Published, Green Accepted			2021-06-18	
J	Hamada, I; Hunter, AC; Szebeni, J; Moghimi, SM				Hamada, I.; Hunter, A. C.; Szebeni, J.; Moghimi, S. M.			Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process	MOLECULAR IMMUNOLOGY			English	Article						Anaphylatoxins; Anaphylaxis; Complement system; Ficolin/MASP-2; Non-ionic surfactants; Poly(ethylene glycol); Pseudoallergy	LIPOSOME-ENCAPSULATED HEMOGLOBIN; HUMAN C4-BINDING PROTEIN; MAST-CELLS; IN-VITRO; MECHANISM; BLOOD; ANAPHYLAXIS; IMMUNOLOGY; HYDRATION; THERAPY	Poly(ethylene glycol) (PEG) is receiving increasing attention as an intravenous therapeutic agent per se in a variety of experimental therapeutics and veterinary settings, such as spinal cord injury and traumatic axonal brain injury. PEG is often perceived to be immunologically safe, but here we demonstrate that near-monodisperse endotoxin-free PEGs, at concentrations relevant to above-mentioned settings, can generate complement activation products in human serum on a time scale of minutes (reflected in significant rises in serum levels of C4d, Bb, C3a-desArg and SC5b-9). With the aid of sera depleted from either C2 or C1q, and devoid of anti-PEG antibodies, we further demonstrate that, depending on PEG concentration and M-wt, generation of complement activation products occur either exclusively through the lectin pathway activation or through both the lectin pathway and increased fluid phase turnover of the alternative pathway. Inhibition of PEG-mediated C4d elevation in C1q-depleted serum by the broad serine protease inhibitor Futhan and anti-MASP-2 antibodies as well as competitive studies with D-mannose and N-acetylglucosamine indicated a likely role for ficolins/MASP-2 in PEG-mediated triggering of the lectin pathway and independent of calcium. PEG-mediated amplification of the alternative pathway is a complex process related to protein partitioning and exclusion effect, but factor H depletion/exclusion seems to play a minor role. Our results are relevant to the proposed potential therapeutic applications of intravenous PEG and warn about possible acute PEG infusion-related reactions in sensitive individuals and animals. PEG-mediated generation of complement activation products further provides a plausible explanation to the previously reported unexplained anaphylaxis or the referred cardiovascular collapse in sensitive animals that have received medicines containing high levels of PEG as solubilizer/carrier. (c) 2008 Elsevier Ltd. All rights reserved.	[Moghimi, S. M.] Univ Copenhagen, Dept Pharmaceut Analyt Chem, Fac Pharmaceut Sci, DK-2100 Copenhagen O, Denmark; [Hamada, I.; Hunter, A. C.] Univ Brighton, Mol Targeting & Polymer Toxicol Grp, Sch Pharm, Brighton, E Sussex, England; [Szebeni, J.] Bay Zoltan Inst Nanotechnol, Dept Nanomed, H-3515 Miskolc, Hungary; [Szebeni, J.] Semmelweis Univ, Sch Med, H-1085 Budapest, Hungary	Moghimi, SM (corresponding author), Univ Copenhagen, Dept Pharmaceut Analyt Chem, Fac Pharmaceut Sci, Univ Pk 2, DK-2100 Copenhagen O, Denmark.	momo@farma.ku.dk	; Hunter, Alan/D-4573-2016	Moghimi, Seyed Moein/0000-0003-0836-926X; Hunter, Alan/0000-0003-1100-7761			Armstrong JK, 2007, CANCER-AM CANCER SOC, V110, P103, DOI 10.1002/cncr.22739; ASAKURA S, 1954, J CHEM PHYS, V22, P1255, DOI 10.1063/1.1740347; BHAT R, 1992, PROTEIN SCI, V1, P1133, DOI 10.1002/pro.5560010907; Borgens RB, 2000, FASEB J, V14, P27; Crupi V, 1996, J MOL STRUCT, V381, P207, DOI 10.1016/0022-2860(96)09308-8; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; FUJITA T, 1978, J EXP MED, V148, P1044, DOI 10.1084/jem.148.4.1044; Hamad I, 2008, MOL IMMUNOL, V45, P3797, DOI 10.1016/j.molimm.2008.05.020; Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033; HATTORI R, 1989, J BIOL CHEM, V264, P9053; INGRAM DA, 1993, J CARDIOVASC PHARM, V22, P456, DOI 10.1097/00005344-199309000-00017; ITO BR, 1993, AM J PHYSIOL, V264, pH1346; Jack DL, 2001, J INFECT DIS, V184, P836, DOI 10.1086/323204; KENT KM, 1990, AM J CARDIOL, V66, P279, DOI 10.1016/0002-9149(90)90836-P; Koob AO, 2006, J NEUROSCI RES, V83, P1558, DOI 10.1002/jnr.20837; Kozielski M, 2006, J MOL LIQ, V128, P105, DOI 10.1016/j.molliq.2005.12.012; Krarup A, 2004, J BIOL CHEM, V279, P47513, DOI 10.1074/jbc.M407161200; Lambris JD, 2008, NAT REV MICROBIOL, V6, P132, DOI 10.1038/nrmicro1824; Laverty PH, 2004, J NEUROTRAUM, V21, P1767, DOI 10.1089/neu.2004.21.1767; LEE RT, 1991, J BIOL CHEM, V266, P4810; MARONE G, 1995, INT ARCH ALLERGY IMM, V107, P72, DOI 10.1159/000236935; Moghimi SM, 2006, FASEB J, V20, P2591, DOI 10.1096/fj.06-6186fje; Moghimi SM, 2004, BBA-MOL BASIS DIS, V1689, P103, DOI 10.1016/j.bbadis.2004.02.005; MOORE FD, 1982, J IMMUNOL, V128, P1302; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; Pfeifer PH, 1999, CLIN CHEM, V45, P1190; POLICE AM, 1985, CRIT CARE MED, V13, P96, DOI 10.1097/00003246-198502000-00008; RICHTER AW, 1983, INT ARCH ALLER A IMM, V70, P124, DOI 10.1159/000233309; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; SZEBENI J, 1994, BIOCHEM BIOPH RES CO, V205, P255, DOI 10.1006/bbrc.1994.2658; Szebeni J, 2006, AM J PHYSIOL-HEART C, V290, pH1050, DOI 10.1152/ajpheart.00622.2005; Szebeni J, 2005, TOXICOLOGY, V216, P106, DOI 10.1016/j.tox.2005.07.023; Szebeni J, 1998, JNCI-J NATL CANCER I, V90, P300, DOI 10.1093/jnci/90.4.300; Szebeni J, 1997, TRANSFUSION, V37, P150, DOI 10.1046/j.1537-2995.1997.37297203517.x; Tardieu A, 2002, ACTA CRYSTALLOGR D, V58, P1549, DOI 10.1107/S0907444902014439; Tasaki K, 1996, J AM CHEM SOC, V118, P8459, DOI 10.1021/ja951005c; TREMPER KK, 1984, CRIT CARE MED, V12, P428, DOI 10.1097/00003246-198405000-00003; VERCELLOTTI GM, 1982, BLOOD, V59, P1299, DOI 10.1182/blood.V59.6.1299.1299; Wallis R, 2002, IMMUNOBIOLOGY, V205, P433, DOI 10.1078/0171-2985-00144; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; YAMAOKA T, 1994, J PHARM SCI, V83, P601, DOI 10.1002/jps.2600830432	43	173	173	3	51	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0161-5890			MOL IMMUNOL	Mol. Immunol.	DEC	2008	46	2					225	232		10.1016/j.molimm.2008.08.276			8	Biochemistry & Molecular Biology; Immunology	Biochemistry & Molecular Biology; Immunology	378BN	WOS:000261296200002	18849076				2021-06-18	
J	Armonda, RA; Bell, RS; Vo, AH; Ling, G; DeGraba, TJ; Crandall, B; Ecklund, J; Campbell, WW				Armonda, Rocco A.; Bell, Randy S.; Vo, Alexander H.; Ling, Geoffrey; DeGraba, Thomas J.; Crandall, Benjamin; Ecklund, James; Campbell, William W.			Wartime traumatic cerebral vasospasm: Recent review of combat casualties	NEUROSURGERY			English	Article						angiography; angioplasty; blast; Iraq; pseudoaneurysm; vasospasm	SEVERE HEAD-INJURY; TRANSCRANIAL DOPPLER ULTRASOUND; BASILAR ARTERY VASOSPASM; BLOOD-FLOW VELOCITY; BRAIN-TISSUE PO(2); SUBARACHNOID HEMORRHAGE; POSTTRAUMATIC VASOSPASM; TIME-COURSE; ULTRASONOGRAPHY; HYPEREMIA	Objective: Blast related neurotrauma is associated with the severest casualties from Operation Iraq Freedom (OIF). A consequences of this is cerebral vasospasm. This study evaluated all inpatient neurosurgical consults related to battle injury from OIF. Methods: Evaluation of all admissions from OIF from April 2003 to October 2005 was performed on patients with neurotrauma and a diagnostic cerebral angiogram. Differences between patients with and without vasospasm and predictors of vasospam were analyzed. Results: Fifty-seven out of 119 nuerosurgical consults were evaluated. Of these, 47.4% had traumatic vasospasm sustained blast trauma. Average spasm duration was 14.3 days, with a range of up to 30 days vasospasm was associated with the presence of pseudoaneurysm (P = 0.05), hemorrhage (P = 0.03), the number of lobes injured (P = 0.012), and mortality (P = 0.029). Those with vasospasm fared worse than those without (p = 0.002). The number of lobes injured and the presence of pseudoaneurysm were significant predictors of vasospasm (P = 0.016 and 0.02, respectively). There was a significant quadratic trend towards nuerological improvement for those recieving aggressive open surgical treatment (P = 0.002). In the vasospam group, angioplasty with microballoon significantly lowered middle cerebrel artery and basilar blood-flow velocities (P = 0.046 and 0.026, respectively). Conclusion: Traumatic vasospasm occurred in a sustantial number of patients with severe neurotrauma, and clinical outcomes were worse for those with this condition. However, aggressive open surgical and endovascular treatment strategies may have improved outcome. This was the first study to analyze the effects of blast-related injury on the cerebral vasculature.	USN, Med Ctr, Dept Neurosurg, Bethesda, MD 20814 USA; Natl Capital Neurosurg Consortium, Washington, DC USA; Univ Texas, Med Branch, Elect Hlth Network, AT&T Ctr TeleHlth, Galveston, TX 77555 USA; USN, Med Ctr, Dept Neurol, Bethesda, MD 20814 USA	Armonda, RA (corresponding author), USN, Med Ctr, Dept Neurosurg, 8901 Wisconsin Ave, Bethesda, MD 20814 USA.	RAArmonda@bethesda.med.navy.mil					Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bakshi A, 1998, NATL MED J INDIA, V11, P220; BYNOE RP, 1991, J VASC SURG, V14, P346, DOI 10.1016/0741-5214(91)90087-B; Cairns CJS, 2003, ANAESTH INTENS CARE, V31, P87, DOI 10.1177/0310057X0303100117; CHAN KH, 1992, SURG NEUROL, V38, P433, DOI 10.1016/0090-3019(92)90111-Y; Chesnut R M, 1995, New Horiz, V3, P581; Chhabra R, 2001, NEUROL INDIA, V49, P138; COMPTON J S, 1990, British Journal of Neurosurgery, V4, P9, DOI 10.3109/02688699009000676; DICKMAN CA, 1991, NEUROSURGERY, V28, P467, DOI 10.1227/00006123-199103000-00026; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Fischer Hanna, AM WAR MILITARY OPER; GOMEZ CR, 1991, SURG NEUROL, V35, P30, DOI 10.1016/0090-3019(91)90198-I; HALBACH VV, 1993, J NEUROSURG, V79, P183, DOI 10.3171/jns.1993.79.2.0183; HAMER J, 1976, NEUROCHIRURGIA, V19, P185; HARDERS AG, 1987, J NEUROSURG, V66, P718, DOI 10.3171/jns.1987.66.5.0718; Hoelper BM, 2003, NEUROSURGERY, V52, P970, DOI 10.1227/01.NEU.0000053033.98317.A3; Kordestani RK, 1997, NEUROSURGERY, V41, P351, DOI 10.1097/00006123-199708000-00003; Lee EJ, 1997, J FORMOS MED ASSOC, V96, P5; LOVERIDGE B, 2005, NEUROCRIT CARE, V2, P241; Manno EM, 1997, CRIT CARE CLIN, V13, P79, DOI 10.1016/S0749-0704(05)70297-9; MARSHALL LF, 1978, J NEUROSURG, V48, P560, DOI 10.3171/jns.1978.48.4.0560; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Mobbs RJ, 2001, NEUROL INDIA, V49, P158; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; POTTER JM, 1947, BR J SURG S1, V1, P260; Romner B, 1996, J NEUROSURG, V85, P90, DOI 10.3171/jns.1996.85.1.0090; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; SEILER RW, 1986, J NEUROSURG, V64, P594, DOI 10.3171/jns.1986.64.4.0594; Soustiel JF, 2004, SURG NEUROL, V62, P201, DOI 10.1016/j.surneu.2003.10.037; Soustiel JF, 2002, ACTA NEUROCHIR, V144, P137, DOI 10.1007/s007010200016; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Takis C, 1997, AM J NEURORADIOL, V18, P1661; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; Vajramani GV, 1999, BRIT J NEUROSURG, V13, P468, DOI 10.1080/02688699908540620; Valadka AB, 2002, ACT NEUR S, V81, P299; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WILKINS RH, 1990, CRIT REV NEUROBIOL, V6, P51; Yamada K, 1998, NEUROSURGERY, V43, P153, DOI 10.1097/00006123-199807000-00101; Zubkov AY, 1999, J NEUROTRAUM, V16, P763, DOI 10.1089/neu.1999.16.763; Zubkov AY, 2000, SURG NEUROL, V53, P260, DOI 10.1016/S0090-3019(99)00187-1; Zubkov ZY, 2000, SURG NEUROL, V53, P126; ZURYNSKI YA, 1995, J NEUROL SCI, V134, P41, DOI 10.1016/0022-510X(95)00178-X; 2001, J TRAUMA S2, V51, pS26	49	173	179	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	DEC	2006	59	6					1215	1225		10.1227/01.NEU.0000249190.46033.94			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	113MR	WOS:000242602500021	17277684				2021-06-18	
J	Bramlett, HM; Dietrich, WD				Bramlett, HM; Dietrich, WD			Quantitative structural changes in white and gray matter 1 year following traumatic brain injury in rats	ACTA NEUROPATHOLOGICA			English	Article						atrophy; fluid percussion injury; histopathology; chronic; rat	CEREBRAL BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; HEAD-INJURY; AXONAL INJURY; COMPUTED-TOMOGRAPHY; NEURONAL APOPTOSIS; CONTUSION INJURY; ATROPHY; RECOVERY; MEMORY	There is evidence for chronic atrophy after human head trauma, which may be associated with long-term functional deficits. However, using established models of traumatic brain injury (TBI) only limited data are available for clarifying the extent of progressive gray and white matter atrophy. In the present study, male Sprague-Dawley rats underwent moderate (2.01-2.21 atm) para-sagittal fluid percussion brain injury (n=7) or sham (n=3) surgery and were killed at I year post TBI. Semiserial sections were obtained through the neuraxis and double stained with hematoxylin and eosin to demarcate gray matter structures and Luxol fast blue for white matter visualization. Both ipsilateral and contralateral volume measurements were obtained for the following structures: cerebral cortex, hippocampus, dentate gyrus, thalamus, lateral ventricle, external capsule, internal capsule, cerebral peduncle and corpus callosum. Quantitative assessment of ipsilateral gray matter structures from TBI rats revealed significant reductions in cerebral cortical area measurements posterior from the trauma epicenter compared to sham animals. Importantly, several white matter tracts exhibited dramatic atrophy. A comparison of TBI and sham groups demonstrated a significant (P<0.05) decrease in the external capsule and cerebral peduncle volumes (P<0.007). In addition, there was a significant volume expansion (533% of control) of the ipsilateral lateral ventricle (P<0.03). These novel data emphasize the need to clarify the pathophysiology of progressive white matter damage after TBI and the development of therapeutic strategies to target white matter pathology.	Univ Miami, Sch Med, Dept Neurol Surg, Neurotrauma Res Ctr, Miami, FL 33101 USA; Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33101 USA	Bramlett, HM (corresponding author), Univ Miami, Sch Med, Dept Neurol Surg, Neurotrauma Res Ctr, POB 016960,Mail R-48, Miami, FL 33101 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291] Funding Source: Medline		Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; BARCLAY L, 1985, BIOL PSYCHIAT, V20, P146, DOI 10.1016/0006-3223(85)90074-5; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Grossman SD, 1999, J NEUROSCI, V19, P5711, DOI 10.1523/JNEUROSCI.19-14-05711.1999; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kurumatani T, 1998, STROKE, V29, P1058, DOI 10.1161/01.STR.29.5.1058; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, P28; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; REIDERGROSWASSE.I, 1992, AM J ROENTGENOL, V160, P147; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Stys PK, 2000, NEUROSCIENTIST, V6, P230, DOI 10.1177/107385840000600405; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TERAYAMA Y, 1993, SURG NEUROL, V39, P177, DOI 10.1016/0090-3019(93)90179-5; TERAYAMA Y, 1991, J CEREBR BLOOD F MET, V11, P852, DOI 10.1038/jcbfm.1991.145; TIMMING R, 1982, ARCH PHYS MED REHAB, V63, P154; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; WISE SP, 1977, J COMP NEUROL, V175, P129, DOI 10.1002/cne.901750202; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZILLES L, 1985, CORTEX RAT STEREOTAX	61	173	180	0	8	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	JUN	2002	103	6					607	614		10.1007/s00401-001-0510-8			8	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	557EE	WOS:000175894500010	12012093				2021-06-18	
J	Carney, N; Chesnut, RM; Maynard, H; Mann, NC; Patterson, P; Helfand, M				Carney, N; Chesnut, RM; Maynard, H; Mann, NC; Patterson, P; Helfand, M			Effect of cognitive rehabilitation on outcomes for persons with traumatic brain injury: A systematic review	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive rehabilitation; evidence based; systematic review	CLOSED-HEAD-INJURY; NEUROPSYCHOLOGICAL REHABILITATION; ATTENTION; EFFICACY; DEFICITS; ADULTS; REMEDIATION; EMPLOYMENT; THERAPY; PROGRAM	We evaluated evidence for the effectiveness of cognitive rehabilitation methods to improve outcomes for persons with traumatic brain injury (TBT). A search of MEDLINE, HealthSTAR, CINAHL, PsycINFO, and the Cochrane Library produced 600 potential references. Thirty-two studies met predetermined inclusion criteria and were abstracted; data from 24 were placed into evidence tables. Two randomized controlled trials and one observational study provided evidence that specific forms of cognitive rehabilitation reduce memory failures and anxiety, and improve self-concept and interpersonal relationships for persons with TBI. The durability and clinical relevance of these findings is not established. Future research utilizing control groups and multivariate analysis must incorporate subject variability and must include standard definitions of the intervention and relevant outcome measures that reflect health and function.	Oregon Hlth & Sci Univ, Dept Emergency Med, Div Med Informat & Outcomes Res, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA	Carney, N (corresponding author), Oregon Hlth & Sci Univ, Dept Emergency Med, Div Med Informat & Outcomes Res, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.						Batchelor J, 1988, J HEAD TRAUMA REHAB, V3, P78, DOI DOI 10.1097/00001199-198809000-00012; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; CHESNUT RM, 1999, 99EOO6 AHCPR; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; Coelho CA, 1996, J SPEECH HEAR RES, V39, pS5, DOI 10.1044/jshr.3905.s5; DEACON D, 1991, J CLIN EXP NEUROPSYC, V13, P639, DOI 10.1080/01688639108401079; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; Goldstein, 1995, ORGANISM HOLISTIC AP; GOLDSTEIN G, 1988, CLIN NEUROPSYCHOL, V2, P251; Gray J. M., 1992, NEUROPSYCHOL REHABIL, V2, P97; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HELFFENSTEIN DA, 1982, INT J CLIN NEUROPSYC, V4, P139; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Kerner M, 1985, COGNIT REHABIL, V11, P26; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MIDDLETON DK, 1991, PERCEPT MOTOR SKILL, V72, P527, DOI 10.2466/PMS.72.2.527-530; MOORESOHLBERG M, 1998, PEER REV EVIDENCE RE; NEISTADT ME, 1992, AM J OCCUP THER, V46, P141, DOI 10.5014/ajot.46.2.141; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RUFF R, 1994, BRAIN INJURY, V8, P3, DOI 10.3109/02699059409150954; RUFF R M, 1990, Brain Injury, V4, P339, DOI 10.3109/02699059009026187; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; Sackett DL., 1997, EVIDENCE BASED MED P; SCHERZER BP, 1986, ARCH PHYS MED REHAB, V67, P366; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; THOMASS BA, 1994, EUR J COMMUN, V9, P25, DOI 10.1177/0267323194009001002; TWUM M, 1994, J CLIN EXP NEUROPSYC, V16, P630, DOI 10.1080/01688639408402674; *US PREV SERV TASK, 1996, GID CLIN PREV SERV; WEHMAN P, 1989, J APPL BEHAV ANAL, V22, P395, DOI 10.1901/jaba.1989.22-395; WEHMAN P, 1989, J HEAD TRAUMA REHAB, V4, P66; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wood R L, 1987, Int Disabil Stud, V9, P149; YLVISAKER M, 1998, PEER REV EVIDENCE RE; 1998, P SUBC TBI REH 4 ANN	45	173	175	1	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1999	14	3					277	307		10.1097/00001199-199906000-00008			31	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	203XY	WOS:000080734500008	10381980				2021-06-18	
J	KNUDSON, MM; LEWIS, FR; CLINTON, A; ATKINSON, K; MEGERMAN, J				KNUDSON, MM; LEWIS, FR; CLINTON, A; ATKINSON, K; MEGERMAN, J			PREVENTION OF VENOUS THROMBOEMBOLISM IN TRAUMA PATIENTS	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	24th Annual Meeting of the Western-Trauma-Association	FEB 27-MAR 04, 1994	CRESTED BUTTE, CO	W TRAUMA ASSOC			DEEP-VEIN THROMBOSIS; EXTERNAL PNEUMATIC COMPRESSION; MAJOR TRAUMA; PULMONARY-EMBOLISM; ULTRASONOGRAPHY; PROPHYLAXIS; INJURIES	Trauma patients are at risk for thromboembolic complications, but effective methods of prophylaxis have not been established for this heterogenous population. In this prospective trial, 400 trauma patients were assigned to one of three groups, depending upon their injuries, and randomized within each group to a treatment mode: Group I: sequential gradient pneumatic leg compression (SCD), low-dose subcutaneous heparin (H), or control (C); Group II: H or C; Group HI: SCD or C. Venous duplex ultrasound examinations were performed on admission and weekly thereafter. Of the 251 patients who completed the study, 15 (6%) developed lower extremity venous thrombosis and two additional patients developed pulmonary embolism (one fatal). Significant risk factors associated with the development of thromboembolism included immobilization > 3 days, age 30 years or older, and the presence of pelvic or lower extremity fractures. In patients with neurotrauma who cannot receive heparin (Group III), the SOD was more effective than control in preventing DVT (p = 0.057). Neither H nor SCD appeared to offer protection for the other groups of trauma patients, but surveillance with ultrasound examinations allowed for prompt recognition and treatment of occult deep vein thrombosis.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA; HENRY FORD HOSP,DETROIT,MI; KENDALL HEALTHCARE PROD CO,MANSFIELD,MA							BRAUNWALD E, 1993, PREVENTION VENOUS TH, pR7; BURCH JM, 1990, J TRAUMA, V30, P1450, DOI 10.1097/00005373-199012000-00003; BURNS GA, 1993, J TRAUMA, V35, P405, DOI 10.1097/00005373-199309000-00012; COMEROTA AJ, 1992, AM J SURG, V164, P265, DOI 10.1016/S0002-9610(05)81083-9; COON WW, 1977, ANN SURG, V186, P149, DOI 10.1097/00000658-197708000-00006; DENNIS JW, 1993, J TRAUMA, V35, P132, DOI 10.1097/00005373-199307000-00021; FRANCIS CW, 1992, JAMA-J AM MED ASSOC, V267, P2911, DOI 10.1001/jama.267.21.2911; FREEARK RJ, 1967, ARCH SURG-CHICAGO, V95, P567; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HILL SL, 1989, AM SURGEON, V55, P543; HOYT DB, 1993, J TRAUMA, V35, P524, DOI 10.1097/00005373-199310000-00005; KNUDSON MM, 1992, J TRAUMA, V32, P2, DOI 10.1097/00005373-199201000-00002; KUDAK KA, 1989, AM J SURG, V158, P515; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; MEREDITH JW, 1993, J TRAUMA, V35, P187, DOI 10.1097/00005373-199308000-00003; MYLLYNEN P, 1985, J TRAUMA, V25, P541, DOI 10.1097/00005373-198506000-00013; OMALLEY KF, 1990, J TRAUMA, V30, P748, DOI 10.1097/00005373-199006000-00018; Paiement G D, 1992, Semin Arthroplasty, V3, P118; ROGERS FB, 1993, J TRAUMA, V35, P637, DOI 10.1097/00005373-199310000-00021; SCHMIDT U, 1992, J TRAUMA, V33, P312, DOI 10.1097/00005373-199208000-00023; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; SHACKFORD SR, 1990, AM J SURG, V159, P365, DOI 10.1016/S0002-9610(05)81272-3; WHITE RH, 1990, J BONE JOINT SURG AM, V72A, P495, DOI 10.2106/00004623-199072040-00004; WINCHELL RJ, IN PRESS J TRAUMA; YELON JA, 1992, J TRAUMA, V33, P532, DOI 10.1097/00005373-199210000-00008; 1993, RESOURCES OPTIMAL CA	26	173	174	0	5	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	1994	37	3					480	487		10.1097/00005373-199409000-00025			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	PG534	WOS:A1994PG53400026	8083913				2021-06-18	
J	YAMAKAMI, I; MCINTOSH, TK				YAMAKAMI, I; MCINTOSH, TK			EFFECTS OF TRAUMATIC BRAIN INJURY ON REGIONAL CEREBRAL BLOOD-FLOW IN RATS AS MEASURED WITH RADIOLABELED MICROSPHERES	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article									UNIV CONNECTICUT, CTR HLTH, DEPT SURG, SURG RES CTR, FARMINGTON, CT 06032 USA; VET ADM MED CTR, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, CTR NEURAL INJURY, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA					NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM 35690] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM035690] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V3; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; BAER RW, 1984, AM J PHYSIOL, V246, pH418; BRANSTON NM, 1974, EXP NEUROL, V45, P195, DOI 10.1016/0014-4886(74)90112-5; BUCKBERG GD, 1971, J APPL PHYSIOL, V31, P598; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EGER EI, 1984, BRIT J ANAESTH, V56, pS71; FLAIM SF, 1978, AM J PHYSIOL, V235, pH587; GADIAN DG, 1986, ABSTR SOC MAGN RESON, V5; Glantz S.A., 1987, PRIMER BIOSTATISTICS; HALL D, 1985, CNS TRAUMA, V2, P75; HANSEN T D, 1987, Anesthesiology (Hagerstown), V67, pA574, DOI 10.1097/00000542-198709001-00574; HEISS WD, 1976, ARCH NEUROL-CHICAGO, V33, P813, DOI 10.1001/archneur.1976.00500120017003; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; HEYMANN MA, 1977, PROG CARDIOVASC DIS, V20, P55, DOI 10.1016/S0033-0620(77)80005-4; HOFFMAN WE, 1981, LIFE SCI, V28, P2167, DOI 10.1016/0024-3205(81)90624-X; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MACPHERSON P, 1973, J NEUROL NEUROSURG P, V36; MALIK AB, 1976, J APPL PHYSIOL, V40, P472; MCCULLOUGH D, 1971, J TRAUM, V11, P422, DOI 10.1097/00005373-197105000-00007; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1988, IN PRESS NEUROSCIENC; MEYER JS, 1970, J NEUROSURG, V32, P304, DOI 10.3171/jns.1970.32.3.0304; MICHENFE.JD, 1974, ANESTHESIOLOGY, V41, P231, DOI 10.1097/00000542-197409000-00004; MONK CR, 1987, ANESTHESIOLOGY, V64, pA577; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; PIERCE EC, 1962, J CLIN INVEST, V41, P1664, DOI 10.1172/JCI104623; RUDOLPH AM, 1967, CIRC RES, V21, P163, DOI 10.1161/01.RES.21.2.163; STANEK KA, 1983, AM J PHYSIOL, V245, pH920; THULBORN KR, 1982, J CEREBR BLOOD F MET, V2, P299, DOI 10.1038/jcbfm.1982.31; TODD MM, 1984, ANESTHESIOLOGY, V60, P276, DOI 10.1097/00000542-198404000-00002; TSUCHIYA M, 1977, AM J PHYSIOL, V233, pH617; TSUCHIYA M, 1978, AM J PHYSIOL, V235, pH357; TUMA RF, 1986, AM J PHYSIOL, V250, pH137; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; WAGNER KR, 1985, J NEUROSURG, V63, P88, DOI 10.3171/jns.1985.63.1.0088	38	173	174	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	1989	9	1					117	124		10.1038/jcbfm.1989.16			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	R9753	WOS:A1989R975300015	2910893	Bronze			2021-06-18	
J	Zhang, XD; Wang, HS; Antaris, AL; Li, LL; Diao, S; Ma, R; Nguyen, A; Hong, GS; Ma, ZR; Wang, J; Zhu, SJ; Castellano, JM; Wyss-Coray, T; Liang, YY; Luo, J; Dai, HJ				Zhang, Xiao-Dong; Wang, Huasen; Antaris, Alexander L.; Li, Lulin; Diao, Shuo; Ma, Rui; Nguyen, Andy; Hong, Guosong; Ma, Zhuoran; Wang, Joy; Zhu, Shoujun; Castellano, Joseph M.; Wyss-Coray, Tony; Liang, Yongye; Luo, Jian; Dai, Hongjie			Traumatic Brain Injury Imaging in the Second Near-Infrared Window with a Molecular Fluorophore	ADVANCED MATERIALS			English	Article							CEREBRAL-BLOOD-FLOW; ACUTE SUBDURAL-HEMATOMA; IN-VIVO; CARBON NANOTUBES; PATHOPHYSIOLOGY; DISRUPTION; RAT; PERFUSION; ISCHEMIA; DAMAGE	Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. A bright, renal-excreted, and biocompatible near-infrared II fluorophore for in vivo imaging of TBI is designed. A transient hypoperfusion in the injured cerebral region, followed by fluorophore leakage, is observed. NIR-II fluorophores can provide noninvasive assessment of TBI.	[Zhang, Xiao-Dong; Antaris, Alexander L.; Diao, Shuo; Hong, Guosong; Ma, Zhuoran; Wang, Joy; Zhu, Shoujun; Dai, Hongjie] Stanford Univ, Dept Chem, Stanford, CA 94305 USA; [Wang, Huasen; Ma, Rui; Liang, Yongye] South Univ Sci & Technol China, Dept Mat Sci & Engn, Shenzhen 518055, Peoples R China; [Castellano, Joseph M.; Wyss-Coray, Tony; Luo, Jian] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Wyss-Coray, Tony] VA Palo Alto Hlth Care Syst, Ctr Tissue Regenerat Repair & Restorat, Palo Alto, CA 94304 USA; [Li, Lulin; Nguyen, Andy; Luo, Jian] VA Palo Alto Hlth Care Syst, Palo Alto Vet Inst Res, Palo Alto, CA 94304 USA; [Zhang, Xiao-Dong] Tianjin Univ, Sch Sci, Dept Phys, Tianjin 300354, Peoples R China	Liang, YY (corresponding author), South Univ Sci & Technol China, Dept Mat Sci & Engn, Shenzhen 518055, Peoples R China.	liangyy@sustc.edu.cn; jianl@stanford.edu; hdai@stanford.edu	Zhang, Xiaodong/M-7731-2019; zhu, shoujun/S-8058-2017; Liang, Yongye/AAH-1981-2020; Luo, Jian/B-8449-2014; Hong, Guosong/A-7551-2013; Wyss-Coray, Tony/AAF-3380-2019; Liang, Yongye/G-6033-2018; Zhang, Xiaodong/F-4665-2015	zhu, shoujun/0000-0002-2412-6121; Liang, Yongye/0000-0002-7416-8792; Luo, Jian/0000-0002-2064-8467; Hong, Guosong/0000-0002-8858-4471; Wyss-Coray, Tony/0000-0001-5893-0831; Liang, Yongye/0000-0002-7416-8792; Zhang, Xiaodong/0000-0002-7212-0138; Castellano, Joseph/0000-0002-8026-6292	Calbrain Program; Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471786]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS092868]; Department of Veterans AffairsUS Department of Veterans Affairs [RX001218]; South University of Science and Technology of China [FRG-SUSTC1501A-62]; Recruitment Program of Global Youth Experts of China; Shenzhen Key Lab [ZDSYS201505291525382]; Shenzhen peacock program [KQTD20140630160825828]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092868] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX001218] Funding Source: NIH RePORTER	H.D., J.L., Y.L., X.Z., and A. A. conceived and designed the experiments. X.Z., A. A., S.D., and J.L. performed the all experiments. L.J., L.L., and A.N., contributed to staining. Y.L., H.W., and R.W. contributed to the design and synthesis of molecules. H.D., J.L., Y.L., X.D., A. A., H.W., S.D., T.W.C, G.H., Z.M., and J.M.C. analyzed the data and wrote the manuscript. All authors discussed the results and commented on the manuscript. X.Z. and H.W. contributed equally to this work. This study was supported by grants from the Calbrain Program to H. D., Natural Science Foundation of China (Grant No. 81471786) to X. Z., from the National Institutes of Health (Grant No. NS092868) to J. L., from the Department of Veterans Affairs (RX001218) to T.W.C. Y.L. acknowledges financial supports from the South University of Science and Technology of China (Grant No. FRG-SUSTC1501A-62), "The Recruitment Program of Global Youth Experts of China", the Shenzhen Key Lab funding (Grant No. ZDSYS201505291525382) and the Shenzhen peacock program (Grant No. KQTD20140630160825828). All animal experiments were performed in compliance with the Guidelines for the Care and Use of Research Animals established by the Stanford University Animal Studies Committee and the Institutional Animal Care and Use Committees (IACUC) of VA Palo Alto Health Care System.	Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; Abulrob A, 2008, MOL IMAGING, V7, P248, DOI 10.2310/7290.2008.00025; Antaris AL, 2016, NAT MATER, V15, P235, DOI [10.1038/NMAT4476, 10.1038/nmat4476]; Bardhan NM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5918; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bigler E.D., 2015, BRAIN NEUROTRAUMA MO; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Chen GC, 2014, ADV FUNCT MATER, V24, P2481, DOI 10.1002/adfm.201303263; Choi HS, 2007, NAT BIOTECHNOL, V25, P1165, DOI 10.1038/nbt1340; Cucullo L, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-40; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; Diao S, 2015, ANGEW CHEM INT EDIT, V54, P14758, DOI 10.1002/anie.201507473; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; Ezan P, 2012, J CEREBR BLOOD F MET, V32, P1457, DOI 10.1038/jcbfm.2012.45; Ghosh D, 2014, P NATL ACAD SCI USA, V111, P13948, DOI 10.1073/pnas.1400821111; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; Heath DL, 2001, J NEUROTRAUM, V18, P465, DOI 10.1089/089771501750171074; Hong G., 2014, NAT COMMUN, V5, P4206, DOI DOI 10.1038/NCOMMS5206; Hong G., 2012, ANGEW CHEM INT EDIT, V51, P9956; Hong GS, 2014, NAT PHOTONICS, V8, P723, DOI [10.1038/NPHOTON.2014.166, 10.1038/nphoton.2014.166]; Hong GS, 2012, NAT MED, V18, P1841, DOI 10.1038/nm.2995; Immonen R, 2010, J CEREBR BLOOD F MET, V30, P1318, DOI 10.1038/jcbfm.2010.15; Klohs J, 2009, J NEUROSCI METH, V180, P126, DOI 10.1016/j.jneumeth.2009.03.002; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Li LL, 2013, CHEM SOC REV, V42, P291, DOI 10.1039/c2cs35257e; Li W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114173; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; Long JA, 2015, J CEREBR BLOOD F MET, V35, P1852, DOI 10.1038/jcbfm.2015.143; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; Mathiisen TM, 2010, GLIA, V58, P1094, DOI 10.1002/glia.20990; Mustafa AG, 2013, NEUROSCIENCES, V18, P222; Naczynski DJ, 2015, NANO LETT, V15, P96, DOI 10.1021/nl504123r; Nakane Y, 2013, CHEM COMMUN, V49, P7584, DOI 10.1039/c3cc44000a; Nielsen S, 1997, J NEUROSCI, V17, P171; Pan CJ, 2013, ANGEW CHEM INT EDIT, V52, P10775, DOI 10.1002/anie.201305728; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Rigg JL, 2011, PM&R, V3, pS380, DOI 10.1016/j.pmrj.2011.08.005; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Sawauchi S, 2004, J NEUROTRAUM, V21, P563, DOI 10.1089/089771504774129892; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Shao AD, 2015, ANGEW CHEM INT EDIT, V54, P7275, DOI 10.1002/anie.201501478; Shen YM, 2007, MAGN RESON IMAGING, V25, P219, DOI 10.1016/j.mri.2006.09.018; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Sugiyasu K, 2010, J AM CHEM SOC, V132, P14754, DOI 10.1021/ja107444m; Sword J, 2013, BRAIN, V136, P1446, DOI 10.1093/brain/awt026; Tao Z., 2013, ANGEW CHEM, V125, P13240, DOI DOI 10.1002/ange.201307346; Thomale UW, 2002, ACTA NEUROCHIR SUPPL, V81, P229; Wang R., 2015, ANGEW CHEM INT ED EN, V126, P12282, DOI [10.1002/ange.201407420, DOI 10.1002/ANGE.201407420]; Welsher K, 2011, P NATL ACAD SCI USA, V108, P8943, DOI 10.1073/pnas.1014501108; Welsher K, 2009, NAT NANOTECHNOL, V4, P773, DOI [10.1038/NNANO.2009.294, 10.1038/nnano.2009.294]; WILLIAMS ATR, 1983, ANALYST, V108, P1067, DOI 10.1039/an9830801067; Wunder A, 2012, EPILEPSIA, V53, P14, DOI 10.1111/j.1528-1167.2012.03698.x; Xu HT, 2007, NAT NEUROSCI, V10, P549, DOI 10.1038/nn1883; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yang FY, 2011, J NUCL MED, V52, P478, DOI 10.2967/jnumed.110.083071; Zhang LZ, 2015, ADV MATER, V27, P6496, DOI 10.1002/adma.201502267	58	172	175	28	409	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	0935-9648	1521-4095		ADV MATER	Adv. Mater.	AUG 24	2016	28	32					6872	+		10.1002/adma.201600706			9	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	DU8RU	WOS:000382482500008	27253071	Green Accepted			2021-06-18	
J	Abdul-Muneer, PM; Schuetz, H; Wang, F; Skotak, M; Jones, J; Gorantla, S; Zimmerman, MC; Chandra, N; Haorah, J				Abdul-Muneer, P. M.; Schuetz, Heather; Wang, Fang; Skotak, Maciej; Jones, Joselyn; Gorantla, Santhi; Zimmerman, Matthew C.; Chandra, Namas; Haorah, James			Induction of oxidative and nitrosative damage leads to cerebrovascular inflammation in an animal model of mild traumatic brain injury induced by primary blast	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Mild traumatic brain injury; Blood-brain barrier; Oxidative stress; Perivascular unit; Neuroinflammation; Primary blast; Free radicals	ACETYL-L-CARNITINE; MECHANISM; PERICYTES; STRESS; HEALTH	We investigate the hypothesis that oxidative damage of the cerebral vascular barrier interface (the blood-brain barrier, BBB) causes the development of mild traumatic brain injury (TBI) during a primary blast-wave spectrum. The underlying biochemical and cellular mechanisms of this vascular layer-structure injury are examined in a novel animal model of shock tube. We first established that low-frequency (123 kPa) single or repeated shock wave causes BBB/brain injury through biochemical activation by an acute mechanical force that occurs 6-24 h after the exposure. This biochemical damage of the cerebral vasculature is initiated by the induction of the free radical-generating enzymes NADPH oxidase 1 and inducible nitric oxide synthase. Induction of these enzymes by shock-wave exposure paralleled the signatures of oxidative and nitrosative damage (4-HNE/3-NT) and reduction of the BBB tight-junction (TJ) proteins occludin, claudin-5, and zonula occluden 1 in the brain microvessels. In parallel with TJ protein disruption, the perivascular unit was significantly diminished by single or repeated shock-wave exposure coinciding with the kinetic profile. Loosening of the vasculature and perivascular unit was mediated by oxidative stress-induced activation of matrix metalloproteinases and fluid channel aquaporin-4, promoting vascular fluid cavitation/edema, enhanced leakiness of the BBB, and progression of neuroinflammation. The BBB leakiness and neuroinflammation were functionally demonstrated in an in vivo model by enhanced permeativity of Evans blue and sodium fluorescein low-molecular-weight tracers and the infiltration of immune cells across the BBB. The detection of brain cell proteins neuron-specific enolase and sloop in the blood samples validated the neuroastroglial injury in shock-wave TBI. Our hypothesis that cerebral vascular injury occurs before the development of neurological disorders in mild TBI was further confirmed by the activation of caspase-3 and cell apoptosis mostly around the perivascular region. Thus, induction of oxidative stress and activation of matrix metalloproteinases by shock wave underlie the mechanisms of cerebral vascular BBB leakage and neuroinflammation. Published by Elsevier Inc.	[Abdul-Muneer, P. M.; Schuetz, Heather; Gorantla, Santhi; Haorah, James] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA; [Jones, Joselyn; Zimmerman, Matthew C.] Univ Nebraska, Med Ctr, Dept Cellular & Integrat Physiol, Omaha, NE 68198 USA; [Wang, Fang; Skotak, Maciej; Chandra, Namas] Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA	Haorah, J (corresponding author), Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, 600 S 42nd St, Omaha, NE 68198 USA.	jhaorah@unmc.edu	Skotak, Maciej/H-4769-2019	Skotak, Maciej/0000-0003-2584-7294; Zimmerman, Matthew/0000-0001-5658-9051; Abdul-Muneer, P. M/0000-0001-8231-4385	NIH/NIAAAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R21 AA020370-01A1, RO1 AA017398]; U.S. Army Research Office project "Army UNL Center of Trauma Mechanics" [W911NF- 08-10483]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA017398, R21AA020370] Funding Source: NIH RePORTER	This work was supported by NIH/NIAAA Grants R21 AA020370-01A1 and RO1 AA017398 to J.H. and by the U.S. Army Research Office project "Army UNL Center of Trauma Mechanics" (Contract W911NF- 08-10483) to N.C.	Alikunju S, 2011, BRAIN BEHAV IMMUN, V25, pS129, DOI 10.1016/j.bbi.2011.01.007; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Chandra N., 2011, U.S. provisional patent application, Patent No. 61542354; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Ganpule S., BIOMECH MOD IN PRESS; Goldstein L. E., 2012, SCI TRANSL MED; Haorah J, 2008, GLIA, V56, P78, DOI 10.1002/glia.20596; Haorah J, 2011, FREE RADICAL BIO MED, V51, P1601, DOI 10.1016/j.freeradbiomed.2011.06.020; Haorah J, 2008, FREE RADICAL BIO MED, V45, P1542, DOI 10.1016/j.freeradbiomed.2008.08.030; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Muneer PMA, 2012, ARTERIOSCL THROM VAS, V32, P1167, DOI 10.1161/ATVBAHA.112.247668; Muneer PMA, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-23; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; Rump TJ, 2010, FREE RADICAL BIO MED, V49, P1494, DOI 10.1016/j.freeradbiomed.2010.08.011; Santiago PN, 2010, PSYCHIAT SERV, V61, P575, DOI 10.1176/ps.2010.61.6.575; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; TEASDALE G, 1974, LANCET, V2, P81; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Wilk JE, 2010, DRUG ALCOHOL DEPEN, V108, P115, DOI 10.1016/j.drugalcdep.2009.12.003; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946	29	172	177	4	48	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	JUL	2013	60						282	291		10.1016/j.freeradbiomed.2013.02.029			10	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	151UU	WOS:000319486500031	23466554	Green Accepted			2021-06-18	
J	Iliff, JJ; Nedergaard, M				Iliff, Jeffrey J.; Nedergaard, Maiken			Is There a Cerebral Lymphatic System?	STROKE			English	Article; Proceedings Paper	28th Princeton Conference	MAY 17-19, 2012	Cincinnati, OH			aquaporin-4; astrocyte; glymphatic; microinfarction; reactive gliosis; traumatic brain injury	BULK FLOW; CEREBROSPINAL-FLUID; EXTRACELLULAR FLUID; BRAIN; AQUAPORIN-4; TRANSPORT; EFFLUX; WATER		[Iliff, Jeffrey J.; Nedergaard, Maiken] Univ Rochester, Med Ctr, Div Glial Dis & Therapeut, Ctr Translat Neuromed,Dept Neurosurg, Rochester, NY 14642 USA	Iliff, JJ (corresponding author), Univ Rochester, Med Ctr, Div Glial Dis & Therapeut, Ctr Translat Neuromed,Dept Neurosurg, Box 645,601 Elmwood Ave, Rochester, NY 14642 USA.	jeffrey_iliff@urmc.rochester.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078167, F32NS073373, R01NS078304, R01NS075177] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS078304, R01 NS078167, R01 NS075177, F32 NS073373] Funding Source: Medline		Abbott NJ, 2004, NEUROCHEM INT, V45, P545, DOI 10.1016/j.neuint.2003.11.006; AUKLAND K, 1993, PHYSIOL REV, V73, P1, DOI 10.1152/physrev.1993.73.1.1; CSERR HF, 1992, BRAIN PATHOL, V2, P269, DOI 10.1111/j.1750-3639.1992.tb00703.x; CSERR HF, 1981, AM J PHYSIOL, V240, pF319; Groothuis DR, 2007, J CEREBR BLOOD F MET, V27, P43, DOI 10.1038/sj.jcbfm.9600315; ICHIMURA T, 1991, BRAIN RES, V545, P103, DOI 10.1016/0006-8993(91)91275-6; Iliff JJ, 2013, J CLIN INVEST, V123, P1299, DOI 10.1172/JCI67677; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Koh L, 2005, FLUIDS BARRIERS CNS, V2, DOI 10.1186/1743-8454-2-6; Mathiisen TM, 2010, GLIA, V58, P1094, DOI 10.1002/glia.20990; Neal CJ, 2007, J NEUROTRAUM, V24, P1609, DOI 10.1089/neu.2007.0301; Nielsen S, 1997, J NEUROSCI, V17, P171; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Praetorius J, 2007, PFLUG ARCH EUR J PHY, V454, P1, DOI 10.1007/s00424-006-0170-6; PULLEN RGL, 1987, AM J PHYSIOL, V253, pF538; Ren Z, 2013, J CEREB BLOOD FLOW M; Rennels M L, 1990, Adv Neurol, V52, P431; RENNELS ML, 1985, BRAIN RES, V326, P47, DOI 10.1016/0006-8993(85)91383-6; SCHMIDSCHONBEIN GW, 1990, PHYSIOL REV, V70, P987; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sykova E, 2008, PHYSIOL REV, V88, P1277, DOI 10.1152/physrev.00027.2007; Verkhratsky A, 2012, ASN NEURO, V4, DOI 10.1042/AN20120010; Wang MH, 2012, J NEUROSCI, V32, P17948, DOI 10.1523/JNEUROSCI.1860-12.2012	24	172	178	0	43	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	JUN	2013	44	6		1			S93	S95		10.1161/STROKEAHA.112.678698			3	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	151KI	WOS:000319459000034	23709744	Green Accepted, Bronze			2021-06-18	
J	Turgeon, AF; Lauzier, F; Simard, JF; Scales, DC; Burns, KEA; Moore, L; Zygun, DA; Bernard, F; Meade, MO; Dung, TC; Ratnapalan, M; Todd, S; Harlock, J; Fergusson, DA				Turgeon, Alexis F.; Lauzier, Francois; Simard, Jean-Francois; Scales, Damon C.; Burns, Karen E. A.; Moore, Lynne; Zygun, David A.; Bernard, Francis; Meade, Maureen O.; Tran Cong Dung; Ratnapalan, Mohana; Todd, Stephanie; Harlock, John; Fergusson, Dean A.		Canadian Critical Care Trials Grp	Mortality associated with withdrawal of life-sustaining therapy for patients with severe traumatic brain injury: a Canadian multicentre cohort study	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							INTENSIVE-CARE-UNIT; SEVERE HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; PROGNOSTIC MODELS; PERFORMANCE; MANAGEMENT; OUTCOMES; SUPPORT; IMPACT; RATES	Background: Severe traumatic brain injury often leads to death from withdrawal of life-sustaining therapy, although prognosis is difficult to determine. Methods: To evaluate variation in mortality following the withdrawal of life-sustaining therapy and hospital mortality in patients with critical illness and severe traumatic brain injury, we conducted a two-year multicentre retrospective cohort study in six Canadian level-one trauma centres. The effect of centre on hospital mortality and withdrawal of life-sustaining therapy was evaluated using multi-variable logistic regression adjusted for baseline patient-level covariates (sex, age, pupillary reactivity and score on the Glasgow coma scale). Results: We randomly selected 720 patients with traumatic brain injury for our study. The overall hospital mortality among these patients was 228/720 (31.7%, 95% confidence interval [CI] 28.4%-35.2%) and ranged from 10.8% to 44.2% across centres (chi(2) test for overall difference, p < 0.001). Most deaths (70.2% [160/228], 95% CI 63.9%-75.7%) were associated with withdrawal of life-sustaining therapy, ranging from 45.0% (18/40) to 86.8% (46/53) (chi(2) test for overall difference, p < 0.001) across centres. Adjusted odd ratios (ORs) for the effect of centre on hospital mortality ranged from 0.61 to 1.55 (p < 0.001). The incidence of withdrawal of life-sustaining therapy varied by centre, with ORs ranging from 0.42 to 2.40 (p = 0.001). About one half of deaths that occurred following the withdrawal of life-sustaining therapies happened within the first three days of care. Interpretation: We observed significant variation in mortality across centres. This may be explained in part by regional variations in physician, family or community approaches to the withdrawal of life-sustaining therapy. Considering the high proportion of early deaths associated with the withdrawal of life sustaining therapy and the limited accuracy of current prognostic indicators, caution should be used regarding early withdrawal of life sustaining therapy following severe traumatic brain injury.	[Turgeon, Alexis F.; Lauzier, Francois; Simard, Jean-Francois; Moore, Lynne; Tran Cong Dung] Univ Quebec, Ctr Rech, Ctr Hosp, Hop Enfants Jesus, Ste Foy, PQ G1V 2M3, Canada; [Turgeon, Alexis F.; Lauzier, Francois] Univ Laval, Div Crit Care Med, Dept Anesthesiol, Quebec City, PQ, Canada; [Lauzier, Francois] Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada; [Moore, Lynne] Univ Laval, Dept Social & Prevent Med, Quebec City, PQ, Canada; [Scales, Damon C.; Burns, Karen E. A.; Ratnapalan, Mohana] Univ Toronto, Dept Crit Care Med, Toronto, ON, Canada; [Zygun, David A.; Todd, Stephanie] Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; [Bernard, Francis] Univ Montreal, Dept Internal Med, Montreal, PQ, Canada; [Meade, Maureen O.] McMaster Univ, Dept Crit Care Med, Hamilton, ON, Canada; [Harlock, John] McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada; [Fergusson, Dean A.] Univ Ottawa, Ottawa Hlth Res Inst, Ctr Transfus & Crit Care Res, Clin Epidemiol Unit, Ottawa, ON, Canada	Turgeon, AF (corresponding author), Univ Quebec, Ctr Rech, Ctr Hosp, Hop Enfants Jesus, Ste Foy, PQ G1V 2M3, Canada.	alexis.turgeon@fmed.ulaval.ca	Lauzier, Francois/B-9237-2015; harlock, JA/AAR-6215-2020	Lauzier, Francois/0000-0002-6530-5513; Ratnapalan, Mohana/0000-0002-6505-6107; Fergusson, Dean/0000-0002-3389-2485	Fondation de l'Hopital de l'Enfant-Jesus; Fonds de recherche Sante Quebec; Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	The work was supported in part by the Fondation de l'Hopital de l'Enfant-Jesus, who had no role in any part of conducting the study or preparing the manuscript. Dr. Turgeon and Dr. Lauzier are recipients of a research career award from the Fonds de recherche Sante Quebec. Dr. Moore is a recipient of a postdoctoral fellowship grant from the Canadian Institutes for Health Research (CIHR). Mohana Ratnapalan has received a stipend as a summer student with Sunnybrook Health Sciences Centre. Dr. Fergusson and Dr. Scales are recipients of New Investigator Awards from the CIHR.	Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; BLACKWELL T, 2010, NATL POST TORON 0914; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; DuBose JJ, 2008, ARCH SURG-CHICAGO, V143, P1213, DOI 10.1001/archsurg.143.12.1213; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Lilford R, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c2016; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mayor SA, 1999, NEUROLOGY, V52, P1602, DOI 10.1212/WNL.52.8.1602; Moore L, 2010, ANN SURG, V251, P952, DOI 10.1097/SLA.0b013e3181d97589; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Naidech AM, 2009, NEUROCRIT CARE, V11, P45, DOI 10.1007/s12028-009-9186-z; Nathens AB, 2008, J TRAUMA, V64, P81, DOI 10.1097/TA.0b013e31815dd4d7; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Plaisier BR, 2002, AM SURGEON, V68, P159; Shafi S, 2009, ARCH SURG-CHICAGO, V144, P64, DOI 10.1001/archsurg.2008.509; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; Thomas JW, 1998, MED CARE RES REV, V55, P371, DOI 10.1177/107755879805500401	25	172	174	0	5	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946	1488-2329		CAN MED ASSOC J	Can. Med. Assoc. J.	OCT 4	2011	183	14					1581	1588		10.1503/cmaj.101786			8	Medicine, General & Internal	General & Internal Medicine	825YN	WOS:000295318300007	21876014	Bronze, Green Published			2021-06-18	
J							Alzheimers Assoc	Alzheimer's Association Report 2011 Alzheimer's disease facts and figures	ALZHEIMERS & DEMENTIA			English	Article						Alzheimer's disease; Dementia; Prevalence; Incidence; Mortality; Caregivers; Family caregiver; Spouse caregiver; Health care costs; Health expenditures; Long-term care costs; Hospice care costs; Medicare spending; Medicaid spending; Early detection; Early diagnosis; Delayed diagnosis	MILD COGNITIVE IMPAIRMENT; NURSING-HOME PLACEMENT; QUALITY STANDARDS SUBCOMMITTEE; TRAUMATIC BRAIN-INJURY; VASCULAR RISK-FACTORS; PRIMARY-CARE; DEMENTIA DIAGNOSIS; METABOLIC SYNDROME; MEDICARE CLAIMS; HEAD-INJURY	Alzheimer's disease (AD) is the sixth leading cause of all deaths in the United States and is the fifth leading cause of death in Americans aged >= 65 years. Although other major causes of death have been on the decrease, deaths because of AD have been rising dramatically. Between 2000 and 2008 (preliminary data), heart disease deaths decreased by 13%, stroke deaths by 20%, and prostate cancer-related deaths by 8%, whereas deaths because of AD increased by 66%. An estimated 5.4 million Americans have AD; approximately 200,000 people aged <65 years with AD comprise the younger-onset AD population. Every 69 seconds, someone in America develops AD; by 2050, the time is expected to accelerate to every 33 seconds. Over the coming decades, the baby boom population is projected to add 10 million people to these numbers. In 2050, the incidence of AD is expected to approach nearly a million people per year, with a total estimated prevalence of 11 to 16 million people. Dramatic increases in the numbers of "oldest-old" (those aged >= 85 years) across all racial and ethnic groups will also significantly affect the numbers of people living with AD. In 2010, nearly 15 million family and other unpaid caregivers provided an estimated 17 billion hours of care to people with AD and other dementias, a contribution valued at more than $202 billion. Medicare payments for services to beneficiaries aged >= 65 years with AD and other dementias are almost 3 times higher than for beneficiaries without these conditions. Total payments in 2011 for health care, long-term care, and hospice services for people aged >= 65years with AD and other dementias are expected to be $183 billion (not including the contributions of unpaid caregivers). This report provides information to increase understanding of the public health effect of AD, including incidence and prevalence, mortality, health expenditures and costs of care, and effect on caregivers and society in general. The report also examines the current state of AD detection and diagnosis, focusing on the benefits of early detection and the factors that present challenges to accurate diagnosis. (C) 2011 The Alzheimer's Association. All rights reserved.								Adams WL, 2005, GERONTOLOGIST, V45, P231, DOI 10.1093/geront/45.2.231; Adelman Ronald D, 2004, Am J Alzheimers Dis Other Demen, V19, P233, DOI 10.1177/153331750401900409; Alagiakrishnan K, 2008, CAN FAM PHYSICIAN, V54, P521; Alzheimer's Association, 2010, ALZH ASS BRING TOG T; Alzheimer's Association, 2006, EARL ONS DEM NAT CHA; Alzheimer's Association, 2009, 1 ALZH ASS; Alzheimer's Association, 2008, VOIC ALZH DIS SUMM R; Alzheimer's Association, 2010, CHANG TRAJ ALZH DIS; Alzheimer's Association, 2009, 2 ALZH ASS; American Association for Long-Term Care Insurance, 2010, 2008 LTCI SOURC BOOK; American Health Care Association, 2004, NURS FAC BEDS DED SP; American Health Care Association, 2009, NURS FAC BEDS DED SP; American Health Care Association, 2010, MED COND MENT STAT C; American Health Care Association, 2010, NURS FAC BEDS DED SP; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; [Anonymous], 2009, 2009 NAT ALL C UNPUB; [Anonymous], 2000, URB I ALZH ASS BAS D; Anstey KJ, 2007, AM J EPIDEMIOL, V166, P367, DOI 10.1093/aje/kwm116; Arrighi HM, 2010, ALZ DIS ASSOC DIS, V24, P90, DOI 10.1097/WAD.0b013e31819fe7d1; Ayalon L, 2004, INT J GERIATR PSYCH, V19, P51, DOI 10.1002/gps.1037; BACHMAN DL, 1993, NEUROLOGY, V43, P515, DOI 10.1212/WNL.43.3_Part_1.515; Barnes LL, 2003, NEUROLOGY, V60, P1777, DOI 10.1212/01.WNL.0000065892.67099.2A; BOHNSTEDT M, 1994, J CLIN EPIDEMIOL, V47, P1381, DOI 10.1016/0895-4356(94)90082-5; Boise L, 1999, GERONTOLOGIST, V39, P457, DOI 10.1093/geront/39.4.457; Boise L, 2004, J GERONTOL A-BIOL, V59, P621, DOI 10.1093/gerona/59.6.M621; Bouldin ED, 2009, CAREGIVING US CAREGI; Bouldin ED, 2007, CAREGIVING US CAREGI; Boustani M, 2003, ANN INTERN MED, V138, P927, DOI 10.7326/0003-4819-138-11-200306030-00015; Boustani M, 2006, INT J GERIATR PSYCH, V21, P556, DOI 10.1002/gps.1524; Bradford A, 2009, ALZ DIS ASSOC DIS, V23, P306, DOI 10.1097/WAD.0b013e3181a6bebc; Brayne C, 2007, JAMA-J AM MED ASSOC, V298; Brookmeyer R, 2002, ARCH NEUROL-CHICAGO, V59, P1764, DOI 10.1001/archneur.59.11.1764; Buhr GT, 2006, GERONTOLOGIST, V46, P52, DOI 10.1093/geront/46.1.52; Caplan C, 2004, OUT OF POCKET SPENDI; Carpenter BD, 2008, J AM GERIATR SOC, V56, P405, DOI 10.1111/j.1532-5415.2007.01600.x; Centers for Disease Control and Prevention and The Merck Company Foundation, 2007, STAT AG HLTH AM 2007; Christakis NA, 2006, NEW ENGL J MED, V354, P719, DOI 10.1056/NEJMsa050196; Clark PC, 2005, J AM GERIATR SOC, V53, P2012, DOI 10.1111/j.1532-5415.2005.53569.x; Connell CM, 2009, J AM GERIATR SOC, V57, P1562, DOI 10.1111/j.1532-5415.2009.02395.x; Corrada MM, 2010, ANN NEUROL, V67, P114, DOI 10.1002/ana.21915; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; De Meyer G, 2010, ARCH NEUROL-CHICAGO, V67, P949, DOI 10.1001/archneurol.2010.179; Dilworth-Anderson P, 2008, ALZHEIMERS DEMENT, V4, P305, DOI 10.1016/j.jalz.2008.03.001; Dubois B, 2010, LANCET NEUROL, V9, P1118, DOI 10.1016/S1474-4422(10)70223-4; Elliott AF, 2010, J AM GERIATR SOC, V58, P30, DOI 10.1111/j.1532-5415.2009.02631.x; Evans DA, 1997, ARCH NEUROL-CHICAGO, V54, P1399, DOI 10.1001/archneur.1997.00550230066019; Evans DA, 2003, ARCH NEUROL-CHICAGO, V60, P185, DOI 10.1001/archneur.60.2.185; Fillenbaum GG, 1998, J CLIN EPIDEMIOL, V51, P587, DOI 10.1016/S0895-4356(98)00024-9; Fitten LJ, 2001, J AM GERIATR SOC, V49, P1301, DOI 10.1046/j.1532-5415.2001.49257.x; Fitzpatrick AL, 2004, J AM GERIATR SOC, V52, P195, DOI 10.1111/j.1532-5415.2004.52058.x; Fong TG, 2010, FERRIS CLIN ADVISOR; Fortinsky RH, 2004, GERONTOLOGIST, V44, P739, DOI 10.1093/geront/44.6.739; Franz CE, 2007, ALZ DIS ASSOC DIS, V21, P241, DOI 10.1097/WAD.0b013e3181461955; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Fredman L, 2010, J GERONTOL A-BIOL, V65, P565, DOI 10.1093/gerona/glq025; Ganguli M, 2005, ARCH NEUROL-CHICAGO, V62, P779, DOI 10.1001/archneur.62.5.779; Ganguli M, 1999, J AM GERIATR SOC, V47, P842, DOI 10.1111/j.1532-5415.1999.tb03842.x; Garity J, 2006, J GERONTOL NURS, V32, P39, DOI 10.3928/00989134-20060601-07; Gaugler JE, 2008, J AM GERIATR SOC, V56, P421, DOI 10.1111/j.1532-5415.2007.01593.x; Gitlin LN, 2010, JAMA-J AM MED ASSOC, V304, P983, DOI 10.1001/jama.2010.1253; Gitlin LN, 2010, J AM GERIATR SOC, V58, P1465, DOI 10.1111/j.1532-5415.2010.02971.x; Green RC, 2002, JAMA-J AM MED ASSOC, V287, P329, DOI 10.1001/jama.287.3.329; Grossberg GT, 2010, PRIMARY CARE COMPANI, V12; Groswasser Z, 2002, BRAIN INJURY, V16, P681, DOI 10.1080/02699050110119835; Gurland BJ, 1999, INT J GERIATR PSYCH, V14, P481, DOI 10.1002/(SICI)1099-1166(199906)14:6<481::AID-GPS959>3.0.CO;2-5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hall CB, 2009, NEUROLOGY, V73, P356, DOI 10.1212/WNL.0b013e3181b04ae3; Hampel H, 2008, ALZHEIMERS DEMENT, V4, P38, DOI 10.1016/j.jalz.2007.08.006; Hanninen T, 2002, ACTA NEUROL SCAND, V106, P148, DOI 10.1034/j.1600-0404.2002.01225.x; HE W, 2005, CURRENT POPULATION R, P23; Hebert LE, 2004, NEUROLOGY, V62, P1645, DOI 10.1212/01.WNL.0000123018.01306.10; Hebert LE, 2001, AM J EPIDEMIOL, V153, P132, DOI 10.1093/aje/153.2.132; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Hebert LE, 2001, ALZ DIS ASSOC DIS, V15, P169, DOI 10.1097/00002093-200110000-00002; Hejl A, 2002, J NEUROL NEUROSUR PS, V73, P390, DOI 10.1136/jnnp.73.4.390; Helzner EP, 2008, NEUROLOGY, V71, P1489, DOI 10.1212/01.wnl.0000334278.11022.42; Hendrie Hugh C, 2006, Alzheimers Dement, V2, P12, DOI 10.1016/j.jalz.2005.11.004; Henry J. Kaiser Family Foundation, 2010, MED FACT SHEET MED G, P1066; Henry J. Kaiser Family Foundation, 2009, MED FACT SHEET PRESC; Henry J. Kaiser Family Foundation, 2010, MED FACT SHEET PRESC, P7044; Hinton L, 2005, J AM GERIATR SOC, V53, P1405, DOI 10.1111/j.1532-5415.2005.53409.x; Hinton L, 2004, ALZ DIS ASSOC DIS, V18, P134, DOI 10.1097/01.wad.0000127444.23312.ff; Hinton L, 2007, J GEN INTERN MED, V22, P1487, DOI 10.1007/s11606-007-0317-y; Hirdes JP, 2004, GERONTOLOGIST, V44, P665, DOI 10.1093/geront/44.5.665; Hooker K, 2002, J GERONTOL B-PSYCHOL, V57, pP453, DOI 10.1093/geronb/57.5.P453; Hyde J, 2007, GERONTOLOGIST, V47, P51, DOI 10.1093/geront/47.Supplement_1.51; Institute for Social Research, 2009, NAT FOOTB LEAG PLAY; Institute of Medicine, 2008, RET AG AM BUILD HLTH; Ives DG, 2009, J AM GERIATR SOC, V57, P133, DOI 10.1111/j.1532-5415.2008.02056.x; Jellinger KA, 2007, J NEUROL SCI, V257, P80, DOI 10.1016/j.jns.2007.01.045; Jellinger KA, 2007, ALZHEIMERS DEMENT, V3, P40, DOI 10.1016/j.jalz.2006.09.002; Johnson R. W., 2006, PROFILE FRAIL OLDER; Kaiser Commission on Medicaid and the Uninsured, 2010, KAIS COMM MED UN MED, P2168; Kaiser Commission on Medicaid and the Uninsured, 2005, KAIS COMM MED UN DIS; Katzman R, 1996, NEUROLOGY, V46, P889; Kaufer DL, 2008, NEUROLOGY CLIN PRACT; KIECOLTGLASER JK, 1995, LANCET, V346, P1194, DOI 10.1016/S0140-6736(95)92899-5; KiecoltGlaser JK, 1996, P NATL ACAD SCI USA, V93, P3043, DOI 10.1073/pnas.93.7.3043; KIECOLTGLASER JK, 1991, PSYCHOSOM MED, V53, P345, DOI 10.1097/00006842-199107000-00001; Kivipelto M, 2005, ARCH NEUROL-CHICAGO, V62, P1556, DOI 10.1001/archneur.62.10.1556; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; Kukull WA, 2002, ARCH NEUROL-CHICAGO, V59, P1737, DOI 10.1001/archneur.59.11.1737; Larson EB, 2004, ANN INTERN MED, V140, P501, DOI 10.7326/0003-4819-140-7-200404060-00008; Lautenschlager NT, 1996, NEUROLOGY, V46, P641, DOI 10.1212/WNL.46.3.641; Lee CC, 2010, J GERONTOL B-PSYCHOL, V65, P185, DOI 10.1093/geronb/gbp131; Lin PJ, 2010, ALZHEIMERS DEMENT, V6, P334, DOI 10.1016/j.jalz.2009.09.001; Lopez OL, 2003, ARCH NEUROL-CHICAGO, V60, P1385, DOI 10.1001/archneur.60.10.1385; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MACERA CA, 1992, J AM GERIATR SOC, V40, P479, DOI 10.1111/j.1532-5415.1992.tb02015.x; Mahoney Diane Feeney, 2003, J Gerontol Nurs, V29, P24; Manly J. J., 2004, CRITICAL PERSPECTIVE; Maslow K, 2006, IMPROVING HOSP CARE; Mausbach BT, 2010, J AM COLL CARDIOL, V55, P2599, DOI 10.1016/j.jacc.2009.11.093; MAYEUX R, 1991, ARCH NEUROL-CHICAGO, V48, P269, DOI 10.1001/archneur.1991.00530150037014; McDowell I, 2007, J CLIN EXP NEUROPSYC, V29, P127, DOI 10.1080/13803390600582420; Met Life Mature Market Institute, 2009, MARK SURV LONG TERM; MetLife Mature Market Institute and LifePlans Inc, 2006, METLIFE STUD ALZH DI; Miech RA, 2002, NEUROLOGY, V58, P209, DOI 10.1212/WNL.58.2.209; Milne A, 2008, INT PSYCHOGERIATR, V20, P911, DOI 10.1017/S1041610208007394; MININO A, 2010, DEATHS PRELIMINARY D; Mitchell G, 2006, GERONTOLOGIST, V46, P483, DOI 10.1093/geront/46.4.483; Mitchell SL, 2005, J AM GERIATR SOC, V53, P299, DOI 10.1111/j.1532-5415.2005.53118.x; Mittelman MS, 2006, NEUROLOGY, V67, P1592, DOI 10.1212/01.wnl.0000242727.81172.91; Mok W, 2004, Am J Alzheimers Dis Other Demen, V19, P161, DOI 10.1177/153331750401900309; Monin JK, 2009, PSYCHOL AGING, V24, P681, DOI 10.1037/a0016355; Morhardt Darby, 2010, Alzheimer Dis Assoc Disord, V24 Suppl, pS42, DOI 10.1097/WAD.0b013e3181f14ad5; *NAT CTR HLTH STAT, 2002, NAT VIT STAT REP, V50; Neuman P, 2007, HEALTH AFFAIR, V26, P1692, DOI 10.1377/hlthaff.26.6.1692; OKEEFFE J, 2006, ADULT DAY SERVICES K; Okonkwo OC, 2008, NEUROLOGY, V71, P1474, DOI 10.1212/01.wnl.0000334301.32358.48; OLICHNEY JM, 1995, J AM GERIATR SOC, V43, P890, DOI 10.1111/j.1532-5415.1995.tb05532.x; Ostbye T, 2008, HEALTH SERV RES, V43, P313, DOI 10.1111/j.1475-6773.2007.00748.x; Partners in Caregiving, 2002, PARTN CAR NAT STUD A; Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474-4422(09)70236-4; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Plassman BL, 2007, NEUROEPIDEMIOLOGY, V29, P125, DOI 10.1159/000109998; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Polidori MC, 2009, J ALZHEIMERS DIS, V17, P921, DOI 10.3233/JAD-2009-1114; Porell F, 2009, CTR MED MED SERVICES; Port CL, 2005, GERONTOLOGIST, V45, P87, DOI 10.1093/geront/45.suppl_1.87; Potter GG, 2009, ALZHEIMERS DEMENT, V5, P445, DOI 10.1016/j.jalz.2009.04.1234; Pressley JC, 2003, J CLIN EPIDEMIOL, V56, P896, DOI 10.1016/S0895-4356(03)00133-1; Raji CA, 2010, HUM BRAIN MAPP, V31, P353, DOI 10.1002/hbm.20870; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Roberts RO, 2008, NEUROEPIDEMIOLOGY, V30, P58, DOI 10.1159/000115751; Rocca WA, 1998, AM J EPIDEMIOL, V148, P51, DOI 10.1093/oxfordjournals.aje.a009560; Roe CM, 2007, NEUROLOGY, V68, P223, DOI 10.1212/01.wnl.0000251303.50459.8a; Rubenstein LZ, 2007, J AM GERIATR SOC, V55, P166, DOI 10.1111/j.1532-5415.2007.01044.x; Rudolph JL, 2010, J AM GERIATR SOC, V58, P1542, DOI 10.1111/j.1532-5415.2010.02924.x; Rusanen M, 2010, ARCH INTERN MED; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Schneider JA, 2007, NEUROLOGY, V69, P2197, DOI 10.1212/01.wnl.0000271090.28148.24; Schneider JA, 2009, ANN NEUROL, V66, P200, DOI 10.1002/ana.21706; Schubert CC, 2008, J GEN INTERN MED, V23, P1736, DOI 10.1007/s11606-008-0711-0; Schulz R, 2004, JAMA-J AM MED ASSOC, V292, P961, DOI 10.1001/jama.292.8.961; Schulz R, 2003, NEW ENGL J MED, V349, P1936, DOI 10.1056/NEJMsa035373; SCHULZ R, 2002, GERONTECHNOLOGY, V2, P15, DOI DOI 10.4017/GT.2002.02.01.003.00; Seshadri S, 1997, NEUROLOGY, V49, P1498, DOI 10.1212/WNL.49.6.1498; Seshadri S, 2006, STROKE, V37, P345, DOI 10.1161/01.STR.0000199613.38911.b2; Shaw WS, 1999, J PSYCHOSOM RES, V46, P215, DOI 10.1016/S0022-3999(98)00084-1; Shriver M, 2010, SHRIVER REPORT WOMAN; SILVERMAN M, 1995, J AM GERIATR SOC, V43, P733, DOI 10.1111/j.1532-5415.1995.tb07041.x; Solomon A, 2009, DEMENT GERIATR COGN, V28, P75, DOI 10.1159/000231980; Sorensen S, 2002, GERONTOLOGIST, V42, P356, DOI 10.1093/geront/42.3.356; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; Stern Y, 2006, ALZ DIS ASSOC DIS, V20, P112, DOI 10.1097/01.wad.0000213815.20177.19; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Taylor DH, 2008, J AM GERIATR SOC, V56, P322, DOI 10.1111/j.1532-5415.2007.01558.x; Teel CS, 2004, AGING MENT HEALTH, V8, P422, DOI 10.1080/13607860410001725018; Triebel KL, 2009, NEUROLOGY, V73, P928, DOI 10.1212/WNL.0b013e3181b87971; Tsivgoulis G, 2009, NEUROLOGY, V73, P589, DOI 10.1212/WNL.0b013e3181b38969; Turner S, 2004, AGE AGEING, V33, P461, DOI 10.1093/ageing/afh140; U.S. Census Bureau, 2010, US POP PROJ NAT POP; U.S. Department of Health and Human Services Centers for Medicare and Medicaid Services, 2009, NURS HOM DAT COMP; Vickrey BG, 2006, ANN INTERN MED, V145, P713, DOI 10.7326/0003-4819-145-10-200611210-00004; Viswanathan A, 2009, NEUROLOGY, V72, P368, DOI 10.1212/01.wnl.0000341271.90478.8e; Vitaliano PP, 2002, PSYCHOSOM MED, V64, P418, DOI 10.1097/00006842-200205000-00006; Vitaliano PP, 2003, PSYCHOL BULL, V129, P946, DOI 10.1037/0033-2909.129.6.946; Voisin T, 2009, DRUG AGING, V26, P135, DOI 10.2165/0002512-200926020-00005; von Kanel R, 2006, J GERONTOL A-BIOL, V61, P963, DOI 10.1093/gerona/61.9.963; Wachterman M, 2008, JAMA-J AM MED ASSOC, V300, P2608, DOI 10.1001/jama.2008.768; Whitmer RA, 2008, NEUROLOGY, V71, P1057, DOI 10.1212/01.wnl.0000306313.89165.ef; Wilson RS, 2011, ALZHEIMERS DEMENT, V7, P74, DOI 10.1016/j.jalz.2010.11.006; Wolff J, 2008, CTR MED MED SERVICES; Wu W, 2008, ANN NEUROL, V64, P698, DOI 10.1002/ana.21557; Xie J, 2008, BMJ-BRIT MED J, V336, P258, DOI 10.1136/bmj.39433.616678.25; Xu J, 2010, DEATHS FINAL DATA 20; Yaffe K, 2002, JAMA-J AM MED ASSOC, V287, P2090, DOI 10.1001/jama.287.16.2090; Yaffe K, 2007, CURR ALZHEIMER RES, V4, P123, DOI 10.2174/156720507780362191; Zhu CW, 2006, J AM GERIATR SOC, V54, P1596, DOI 10.1111/j.1532-5415.2006.00871.x	191	172	176	1	42	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	MAR	2011	7	2					208	244		10.1016/j.jalz.2011.02.004			37	Clinical Neurology	Neurosciences & Neurology	742GX	WOS:000288930400010					2021-06-18	
J	Peskind, ER; Petrie, EC; Cross, DJ; Pagulayan, K; McCraw, K; Hoff, D; Hart, K; Yu, CE; Raskind, MA; Cook, DG; Minoshima, S				Peskind, Elaine R.; Petrie, Eric C.; Cross, Donna J.; Pagulayan, Kathleen; McCraw, Kathleen; Hoff, David; Hart, Kim; Yu, Chang-En; Raskind, Murray A.; Cook, David G.; Minoshima, Satoshi			Cerebrocerebellar hypometabolism associated with repetitive blast exposure mild traumatic brain injury in 12 Iraq war Veterans with persistent post-concussive symptoms	NEUROIMAGE			English	Article						Positron emission tomography; Mild traumatic brain injury; Post-concussive symptoms; Cerebellum; Blast; Veterans; Cognition	CEREBRAL GLUCOSE-METABOLISM; APOLIPOPROTEIN-E; VALIDATION; CEREBELLUM; VALIDITY; PTSD; CARE	Disagreement exists regarding the extent to which persistent post-concussive symptoms (PCS) reported by Iraq combat Veterans with repeated episodes of mild traumatic brain injury (mTBI) from explosive blasts represent structural or functional brain damage or an epiphenomenon of comorbid depression or posttraumatic stress disorder (PTSD). Objective assessment of brain function in this population may clarify the issue. To this end, twelve Iraq war Veterans (32.0 +/- 8.5 [mean +/- standard deviation (SD)] years of age) reporting one or more blast exposures meeting American Congress of Rehabilitation Medicine criteria for mTBI and persistent PCS and 12 cognitively normal community volunteers (53.0 +/- 4.6 years of age) without history of head trauma underwent brain fluorodeoxyglucose positron emission tomography (FDG-PET) and neuropsychological assessments and completed PCS and psychiatric symptom rating scales. Compared to controls, Veterans with mTBI (with or without PTSD) exhibited decreased cerebral metabolic rate of glucose in the cerebellum, vermis, pons, and medial temporal lobe. They also exhibited subtle impairments in verbal fluency, cognitive processing speed, attention, and working memory, similar to those reported in the literature for patients with cerebellar lesions. These FDG-PET imaging findings suggest that regional brain hypometabolism may constitute a neurobiological substrate for chronic PCS in Iraq combat Veterans with repetitive blast-trauma mTBI. Given the potential public health implications of these findings, further investigation of brain function in these Veterans appears warranted. Published by Elsevier Inc.	[Peskind, Elaine R.; Petrie, Eric C.; Pagulayan, Kathleen; McCraw, Kathleen; Hoff, David; Hart, Kim; Raskind, Murray A.] Vet Affairs Puget Sound Hlth Care Syst, NW Network Mental Illness Res Educ & Clin Ctr MIR, Seattle, WA 98108 USA; [Yu, Chang-En; Cook, David G.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98108 USA; [Peskind, Elaine R.; Petrie, Eric C.; Pagulayan, Kathleen; Raskind, Murray A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Cross, Donna J.; Minoshima, Satoshi] Univ Washington, Dept Radiol, Seattle, WA 98195 USA; [Yu, Chang-En; Cook, David G.] Univ Washington, Dept Med, Seattle, WA 98195 USA	Peskind, ER (corresponding author), Vet Affairs Puget Sound Hlth Care Syst, NW Network Mental Illness Res Educ & Clin Ctr MIR, Mail Code S-116-MIRECC,1660 S Columbian Way, Seattle, WA 98108 USA.	peskind@uw.edu	Pagulayan, Kati/AAR-9225-2020	Minoshima, Satoshi/0000-0002-0043-3047; Petrie, Eric/0000-0003-1188-6321; Cross, Donna/0000-0003-1918-2214	Northwest Network Mental Illness, Research, Education, and Clinical Center (MIRECC); Office of Research and Development Medical Research Service, Department of Veterans AffairsUS Department of Veterans Affairs; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P50 AG05136, K08 AG023670, R01 NS045254]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG023670, P50AG005136] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000521, I01RX001612] Funding Source: NIH RePORTER	This material is based upon work supported, in part, by the Northwest Network Mental Illness, Research, Education, and Clinical Center (MIRECC) and Office of Research and Development Medical Research Service, Department of Veterans Affairs; by grants P50 AG05136, K08 AG023670, and R01 NS045254 from the National Institutes of Health; and by a grant from an anonymous foundation.	BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bremner JD, 1997, ARCH GEN PSYCHIAT, V54, P246; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Connors S, 2009, NEW ENGL J MED, V361, P536, DOI 10.1056/NEJMvcm0803922; Doty RL, 1996, LARYNGOSCOPE, V106, P353, DOI 10.1097/00005537-199603000-00021; Eibner C, 2009, NEW ENGL J MED, V361, P537; EMI M, 1988, GENOMICS, V3, P373, DOI 10.1016/0888-7543(88)90130-9; Molina ME, 2010, WORLD J BIOL PSYCHIA, V11, P493, DOI 10.3109/15622970701472094; First MB., 2002, STRUCTURED CLIN INTE; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Gur RC, 2001, NEUROPSYCHOPHARMACOL, V25, P766, DOI 10.1016/S0893-133X(01)00278-0; Hattori N, 2009, J NUCL MED, V50, P1054, DOI 10.2967/jnumed.108.060368; HIXSON JE, 1990, J LIPID RES, V31, P545; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; MARTINEZMARTIN P, 1994, MOVEMENT DISORD, V9, P76, DOI 10.1002/mds.870090112; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Meyers J E, 2000, Appl Neuropsychol, V7, P154, DOI 10.1207/S15324826AN0703_6; MINOSHIMA S, 1994, J NUCL MED, V35, P949; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; Park E, 2007, PROG BRAIN RES, V161, P327, DOI 10.1016/S0079-6123(06)61023-6; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Psychological Corporation, 2001, WECHSL TEST AD READ; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; RUFF RM, 1992, PERCEPT MOTOR SKILL, V75, P1311, DOI 10.2466/PMS.75.8.1311-1319; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Schmahmann JD, 2004, J NEUROPSYCH CLIN N, V16, P367, DOI 10.1176/appi.neuropsych.16.3.367; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sigford B, 2009, NEW ENGL J MED, V361, P536, DOI 10.1056/NEJMc096180; Stoodley CJ, 2009, NEUROIMAGE, V44, P489, DOI 10.1016/j.neuroimage.2008.08.039; Talairach J., 1988, COPLANAR STEREOTAXIC; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; VIANO DC, 2005, NEUROSURGERY, V57, P915; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Wechsler D., 1987, WECHSLER MEMORY SCAL; WECHSLER D, 1986, WAIS R ADM SCORING M; Willis MW, 2002, PSYCHIAT RES-NEUROIM, V114, P23, DOI 10.1016/S0925-4927(01)00126-3; Worsley K.J., 1996, QUANTIFICATION BRAIN, P327	47	172	174	0	33	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN	2011	54			1			S76	S82		10.1016/j.neuroimage.2010.04.008			7	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	813ZF	WOS:000294408600011	20385245	Green Accepted			2021-06-18	
J	Papa, L; Akinyi, L; Liu, MC; Pineda, JA; Tepas, JJ; Oli, MW; Zheng, WR; Robinson, G; Robicsek, SA; Gabrielli, A; Heaton, SC; Hannay, HJ; Demery, JA; Brophy, GM; Layon, J; Robertson, CS; Hayes, RL; Wang, KKW				Papa, Linda; Akinyi, Linnet; Liu, Ming Cheng; Pineda, Jose A.; Tepas, Joseph J., III; Oli, Monika W.; Zheng, Wenrong; Robinson, Gillian; Robicsek, Steven A.; Gabrielli, Andrea; Heaton, Shelley C.; Hannay, H. Julia; Demery, Jason A.; Brophy, Gretchen M.; Layon, Joe; Robertson, Claudia S.; Hayes, Ronald L.; Wang, Kevin K. W.			Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						trauma; brain injury; human; biomarkers; proteomics; diagnostic; neuronal death; cerebrospinal fluid	NEURON-SPECIFIC ENOLASE; SEVERE HEAD-INJURY; ALPHA-II-SPECTRIN; OUTCOME PREDICTION; CEREBROSPINAL-FLUID; CLINICAL-TRIALS; PROTEIN AGGREGATION; ISCHEMIC-STROKE; PRACTICAL SCALE; CARDIAC-ARREST	Objective: Ubiquitin C-terminal hydrolase (UCH-L1), also called neuronal-specific protein gene product (PGP 9.3), is highly abundant in neurons. To assess the reliability of UCH-L1 as a potential biomarker for traumatic brain injury (TBI) this study compared cerebrospinal fluid (CSF) levels of UCH-L1 from adult patients with severe TBI to uninjured controls; and examined the relationship between levels with severity of injury, complications and functional outcome. Design: This study was designed as prospective case control study. Patients: This study enrolled 66 patients, 41 with severe TBI, defined by a Glasgow coma scale (GCS) score of <= 8, who underwent intraventricular intracranial pressure monitoring and 25 controls without TBI requiring CSF drainage for other medical reasons. Setting: Two hospital system level I trauma centers. Measurements and Main Results: Ventricular CSF was sampled from each patient at 6, 12, 24, 48, 72, 96, 120, 144, and 168 hrs following TBI and analyzed for UCH-L1. Injury severity was assessed by the, GCS score, Marshall Classification on computed tomography and a complicated postinjury course. Mortality was assessed at 6 wks and long-term outcome was assessed using the Glasgow outcome score 6 months after injury. TBI patients had significantly elevated CSF levels of UCH-L1 at each time point after injury compared to uninjured controls. Overall mean levels of UCH-L1 in TBI patients was 44.2 ng/mL (+/-7.9) compared with 2.7 ng/mL (+/-0.7) in controls (p < .001). There were significantly higher levels of UCH-L1 in patients with a lower GCS score at 24 hrs, in those with postinjury complications, in those with 6-wk mortality, and in those with a poor 6-month dichotomized Glasgow outcome score. Conclusions: These data suggest that this novel biomarker has the potential to determine injury severity in TBI patients. Further studies are needed to validate these findings in a larger sample. (Crit Care Med 2010; 38:138-144)	[Papa, Linda] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL USA; [Akinyi, Linnet; Liu, Ming Cheng; Oli, Monika W.; Robinson, Gillian] Banyan Biomarkers Inc, Alachua, FL USA; [Pineda, Jose A.] Washington Univ, Dept Pediat & Neurol, St Louis, MO USA; [Tepas, Joseph J., III] Univ Florida, Dept Surg & Pediat, Jacksonville, FL USA; [Zheng, Wenrong] Univ Florida, Ctr Traumat Brain Injury Studies, Gainesville, FL USA; [Robicsek, Steven A.; Gabrielli, Andrea; Layon, Joe] Univ Florida, Dept Anesthesia, Gainesville, FL USA; [Heaton, Shelley C.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; [Hannay, H. Julia] Univ Houston, Dept Psychol, Houston, TX USA; [Demery, Jason A.] VA Hosp, Dept Psychol, Gainesville, FL USA; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Pharm, Richmond, VA USA; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL USA	Papa, L (corresponding author), Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL USA.	lpstat@aol.com	Pineda, Jose/W-2806-2019	Wang, Kevin/0000-0002-9343-6473; Layon, A. Joseph/0000-0002-2226-9516; Hannay, H. Julia/0000-0001-7023-912X; Brophy, Gretchen/0000-0002-4749-2693	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS052831] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052831] Funding Source: NIH RePORTER		*AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P463; [Anonymous], 1999, JAMA, V282, P974; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Campbell CGN, 2004, CAN J NEUROL SCI, V31, P213, DOI 10.1017/S0317167100053853; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; Coleman MP, 2004, CNS NEUROL DISORD-DR, V3, P227, DOI 10.2174/1568007043337436; COOPER E, 1994, INT J BIOL MARKER, P205; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Ge PF, 2007, STROKE, V38, P3230, DOI 10.1161/STROKEAHA.107.487108; Gong B, 2007, DRUG NEWS PERSPECT, V20, P365, DOI 10.1358/dnp.2007.20.6.1138160; HAIMOTO H, 1987, LAB INVEST, V57, P489; Hu BR, 2001, J CEREBR BLOOD F MET, V21, P865, DOI 10.1097/00004647-200107000-00012; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1294, DOI 10.1097/00004647-200009000-00003; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; JENNETT B, 1975, LANCET, V1, P480; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Keller JN, 2000, J CEREBR BLOOD F MET, V20, P1467, DOI 10.1097/00004647-200010000-00008; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Laser H, 2003, J NEUROSCI RES, V74, P906, DOI 10.1002/jnr.10806; Laskowitz D T, 1998, J Stroke Cerebrovasc Dis, V7, P234, DOI 10.1016/S1052-3057(98)80032-3; Lincoln S, 1999, NEUROREPORT, V10, P427, DOI 10.1097/00001756-199902050-00040; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Majetschak M, 2005, CRIT CARE MED, V33, P1589, DOI 10.1097/01.CCM.0000169883.41245.23; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martens P, 1996, ACAD EMERG MED, V3, P126, DOI 10.1111/j.1553-2712.1996.tb03399.x; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Papa Linda, 2008, Expert Opin Med Diagn, V2, P937, DOI 10.1517/17530059.2.8.937; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; ROINE RO, 1989, ARCH NEUROL-CHICAGO, V46, P753, DOI 10.1001/archneur.1989.00520430047015; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saigoh K, 1999, NAT GENET, V23, P47; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000; USUI A, 1989, CLIN CHEM, V35, P1942; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Willis D, 2005, J NEUROSCI, V25, P778, DOI 10.1523/JNEUROSCI.4235-04.2005; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Xiong H, 2000, Sheng Li Ke Xue Jin Zhan, V31, P217; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Ytrebo LM, 2001, SCAND J CLIN LAB INV, V61, P217; 2000, J HEAD TRAUMA REHABI, V15, P750	61	172	183	1	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JAN	2010	38	1					138	144		10.1097/CCM.0b013e3181b788ab			7	Critical Care Medicine	General & Internal Medicine	539AE	WOS:000273224800021	19726976	Green Accepted			2021-06-18	
J	Maudsley, AA; Domenig, C; Govind, V; Darkazanli, A; Studholme, C; Arheart, K; Bloomer, C				Maudsley, A. A.; Domenig, C.; Govind, V.; Darkazanli, A.; Studholme, C.; Arheart, K.; Bloomer, C.			Mapping of Brain Metabolite Distributions by Volumetric Proton MR Spectroscopic Imaging (MRSI)	MAGNETIC RESONANCE IN MEDICINE			English	Article						brain; metabolite distributions; age; proton MR spectroscopic imaging; data processing	MAGNETIC-RESONANCE SPECTROSCOPY; IN-VIVO; ABSOLUTE QUANTITATION; WHITE-MATTER; REPRODUCIBILITY; GENDER; FIELD; GRAY; QUANTIFICATION; REGISTRATION	Distributions of proton MR-detected metabolites have been mapped throughout the brain in a group of normal subjects using a volumetric MR spectroscopic imaging (MRSI) acquisition with an interleaved water reference. Data were processed with intensity and spatial normalization to enable voxel-based analysis methods to be applied across a group of subjects. Results demonstrate significant regional, tissue, and gender-dependent variations of brain metabolite concentrations, and variations of these distributions with normal aging. The greatest alteration of metabolites with age was observed for white-matter choline and creatine. An example of the utility of the normative metabolic reference information is then demonstrated for analysis of data acquired from a subject who suffered a traumatic brain injury. This study demonstrates the ability to obtain proton spectra from a wide region of the brain and to apply fully automated processing methods. The resultant data provide a normative reference for subsequent utilization for studies of brain injury and disease. Magn Reson Med 61: 548-559, 2009. (C) 2008 Wiley-Liss, Inc.	[Maudsley, A. A.; Domenig, C.; Govind, V.; Darkazanli, A.; Bloomer, C.] Univ Miami, Miller Sch Med, Dept Radiol, Miami, FL 33136 USA; [Arheart, K.] Univ Miami, Miller Sch Med, Dept Epidemiol, Miami, FL 33136 USA; [Studholme, C.] Univ Calif San Francisco, Vet Adm Med Ctr, San Francisco, CA USA	Maudsley, AA (corresponding author), Univ Miami, Miller Sch Med, Dept Radiol, 1150 NW 14th St,Suite 713, Miami, FL 33136 USA.	AMaudsley@med.miami.edu		Govind, Varan/0000-0002-1205-5194; Maudsley, Andrew/0000-0001-7653-3063	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EB000822, NS041946, NS055107]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055107, R01NS041946] Funding Source: NIH RePORTER	National Institutes of Health; Grant numbers: EB000822; NS041946; NS055107.	ALGER JR, 1993, J COMPUT ASSIST TOMO, V17, P191, DOI 10.1097/00004728-199303000-00006; Angelie E, 2001, AM J NEURORADIOL, V22, P119; Braun CMJ, 2002, LATERALITY, V7, P97, DOI 10.1080/13576500143000212; Brooks JCW, 2001, CEREB CORTEX, V11, P598, DOI 10.1093/cercor/11.7.598; Chang L, 1996, LIFE SCI, V58, P2049, DOI 10.1016/0024-3205(96)00197-X; Collins DL, 1998, IEEE T MED IMAGING, V17, P463, DOI 10.1109/42.712135; Degaonkar MN, 2005, J MAGN RESON IMAGING, V22, P175, DOI 10.1002/jmri.20353; DEVITO TJ, 2004, P 12 ANN M ISMRM KYO; Durazzo TC, 2007, FRONT BIOSCI-LANDMRK, V12, P4079, DOI 10.2741/2373; Gasparovic C, 2006, MAGN RESON MED, V55, P1219, DOI 10.1002/mrm.20901; GOVINDARAJU V, 2008, P 16 ANN M ISMRM TOR; Harada M, 2001, NEURORADIOLOGY, V43, P448, DOI 10.1007/s002340000513; Helms G, 2000, NMR BIOMED, V13, P398, DOI 10.1002/1099-1492(200011)13:7<398::AID-NBM660>3.0.CO;2-W; Inglese M, 2006, AM J NEURORADIOL, V27, P684; Jacobs MA, 2001, MAGNET RESON MED, V46, P699, DOI 10.1002/mrm.1248; Jung RE, 2005, NEUROIMAGE, V26, P965, DOI 10.1016/j.neuroimage.2005.02.039; Kadota T, 2001, AM J NEURORADIOL, V22, P128; Knight-Scott J, 2003, MAGN RESON IMAGING, V21, P787, DOI 10.1016/S0730-725X(03)00179-6; Komoroski RA, 2004, MAGN RESON IMAGING, V22, P721, DOI 10.1016/j.mri.2003.12.001; Komoroski RA, 1999, MAGN RESON IMAGING, V17, P427, DOI 10.1016/S0730-725X(98)00186-6; KREIS R, 1993, J MAGN RESON SER B, V102, P9, DOI 10.1006/jmrb.1993.1056; Maudsley AA, 2006, NMR BIOMED, V19, P492, DOI 10.1002/nbm.1025; Maudsley AA, 2008, P 16 ANN M ISMRM TOR; McLean MA, 2000, MAGNET RESON MED, V44, P401, DOI 10.1002/1522-2594(200009)44:3<401::AID-MRM10>3.0.CO;2-W; Nagae-Poetscher LM, 2004, J MAGN RESON IMAGING, V19, P27, DOI 10.1002/jmri.10429; Pfefferbaum A, 1999, MAGNET RESON MED, V41, P276, DOI 10.1002/(SICI)1522-2594(199902)41:2<276::AID-MRM10>3.0.CO;2-8; Ratai EM, 2008, J MAGN RESON IMAGING, V27, P1188, DOI 10.1002/jmri.21365; Rooney WD, 2007, MAGN RESON MED, V57, P308, DOI 10.1002/mrm.21122; Rousseau F, 2005, PROC SPIE, V5747, P1213, DOI 10.1117/12.596345; Safriel Y, 2005, AM J NEURORADIOL, V26, P1439; Schirmer T, 2000, NMR BIOMED, V13, P28, DOI 10.1002/(SICI)1099-1492(200002)13:1<28::AID-NBM606>3.0.CO;2-L; Schuff N, 2001, MAGN RESON MED, V45, P899, DOI 10.1002/mrm.1119; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Soher BJ, 1996, MAGNET RESON MED, V35, P356, DOI 10.1002/mrm.1910350313; Studholme C, 1997, MED PHYS, V24, P25, DOI 10.1118/1.598130; Wansapura JP, 1999, JMRI-J MAGN RESON IM, V9, P531, DOI 10.1002/(SICI)1522-2586(199904)9:4<531::AID-JMRI4>3.0.CO;2-L; Wiedermann D, 2001, MAGN RESON IMAGING, V19, P1073, DOI 10.1016/S0730-725X(01)00441-6; Wilkinson ID, 1997, MAGN RESON IMAGING, V15, P243, DOI 10.1016/S0730-725X(96)00334-7; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	39	172	174	0	20	JOHN WILEY & SONS INC	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0740-3194			MAGN RESON MED	Magn. Reson. Med.	MAR	2009	61	3					548	559		10.1002/mrm.21875			12	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	410WF	WOS:000263608300007	19111009	Bronze, Green Accepted			2021-06-18	
J	Catroppa, C; Anderson, VA; Morse, SA; Haritou, F; Rosenfeld, JV				Catroppa, Cathy; Anderson, Vicki A.; Morse, Sue A.; Haritou, Flora; Rosenfeld, Jeffrey V.			Outcome and predictors of functional recovery 5 years following pediatric traumatic brain injury (TBI)	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						behavior; children; functional outcome; traumatic brain injury	CLOSED-HEAD-INJURY; SHORT-TERM; EARLY-CHILDHOOD; CHILDREN; FAMILY; ADOLESCENTS; PERFORMANCE; ATTENTION; BEHAVIOR; ACHIEVEMENT	Objectives The aim was to examine functional outcomes following traumatic brain injury (TBI) during early childhood, to investigate impairments up to 5 years postinjury and identify predictors of outcome. Methods The study compared three groups of children (mild 11, moderate 22, severe 15), aged 2.0-6.11 years at injury, to a healthy control group (n=17). Using a prospective, longitudinal design, adaptive abilities, behavior, and family functioning were investigated acutely, 6, 30 months and 5 years postinjury, with educational progress investigated at 30 months and 5 years postinjury. Results A strong association was suggested between injury severity and outcomes across all domains. Further, 5-year outcomes in adaptive and behavioral domains were best predicted by preinjury levels of child function, and educational performance by injury severity. Conclusion Children who sustain a severe TBI in early childhood are at greatest risk of long-term impairment in day-to-day skills in the long-term postinjury.	[Catroppa, Cathy] Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; [Catroppa, Cathy; Anderson, Vicki A.] Univ Melbourne, Melbourne, Vic 3010, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Clayton, Vic 3800, Australia	Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au	Rosenfeld, Jeffrey V/B-7249-2011				AMACHER AL, 1988, PAEDIAT HEAD INJURIE; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BEGALI V, 1992, TRAUMATIC HEAD INJUR; BERGERGROSS P, 1985, PERCEPT MOTOR SKILL, V61, P254, DOI 10.2466/pms.1985.61.1.254; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CLARK E, 1987, J PSYCHOEDUCATIONAL, V5, P99; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Eslinger PJ, 2000, DEV NEUROPSYCHOL, V18, P297, DOI 10.1207/S1532694203Eslinger; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Lachar D, 1992, PERSONALITY INVENTOR; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Nelson J E, 2002, Pediatr Rehabil, V5, P37, DOI 10.1080/1363849021000007088; NOLLER P, 1992, J ADOLESCENCE, V15, P101, DOI 10.1016/0140-1971(92)90041-3; Noller P, 1988, ICPS FAMILY FU UNPUB; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Savage Ronald C, 2005, Pediatr Rehabil, V8, P92; Slater E. J., 1989, J ADOLESCENT RES, V4, P371; Sparrow S., 1984, VINELAND ADAPTIVE BE; Stuss DT, 2004, BRAIN COGNITION, V55, P69, DOI 10.1016/s0278-2626(03)00271-9; Tabachnick B.G., 2000, USING MULTIVARIATE S, V4th; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; WECHSLER D, 1987, MANUAL PRESCHOOL PRI; Wechsler D., 1991, MANUAL WECHSLER INTE; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	57	172	173	0	16	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693			J PEDIATR PSYCHOL	J. Pediatr. Psychol.	AUG	2008	33	7					707	718		10.1093/jpepsy/jsn006			12	Psychology, Developmental	Psychology	322XR	WOS:000257409100004	18296728	Green Published, Bronze			2021-06-18	
J	Dijkers, MPJM				Dijkers, MPJM			Quality of life of individuals with spinal cord injury: A review of conceptualization, measurement, and research findings	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article; Proceedings Paper	3rd International Congress on Restorationn of Mobility in Spinal Cord Injury Rehabiliation	APR, 2004	Amsterdam, NETHERLANDS			affect; health status; outcome assessment (health care); personal satisfaction; quality-adjusted life years; quality of life; reproducibility of results; review; spinal cord injuries; utility	TRAUMATIC BRAIN-INJURY; GENERAL HEALTH QUESTIONNAIRE; SICKNESS IMPACT PROFILE; CLINICAL-PRACTICE; ENVIRONMENTAL-FACTORS; PARTNER RELATIONSHIPS; RHEUMATOID-ARTHRITIS; STATE EVALUATIONS; PERCEIVED HEALTH; UTILITIES INDEX	Quality of life (QoL) is increasingly becoming a key concept in research and clinical services. However, no agreement exists on what QoL is and how it is to be measured. This paper reviews three different yet linked approaches to QoL conceptualization: QoL as subjective well-being; QoL as achievement; and QoL as utility. People with spinal cord injury (SCI) tend to report fewer feelings of well-being, on average, than nondisabled persons; score lower on physical, mental, and social health and in other domains of life that people consider important to life quality; and have a health state that is preferred much less than that of the average person. Many QoL instruments used in SCI research have not been validated for this group, or have questionable assumptions, and clinical applications of QoL measures still have many problems. Much SCI QoL research tends to be atheoretical.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Dijkers, MPJM (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave Levy Pl,Box 1240, New York, NY 10029 USA.	marcel.dijkers@msnyuhealth.org		Dijkers, Marcel/0000-0002-8362-5596	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133G030026, H133A020501, H133N000027] Funding Source: Medline		Adkins RH, 2004, NEUROREHABILITATION, V19, P3; Allotey P, 2003, SOC SCI MED, V57, P949, DOI 10.1016/S0277-9536(02)00463-X; Anand S, 1997, J HEALTH ECON, V16, P685, DOI 10.1016/S0167-6296(97)00005-2; Andresen EM, 1999, ARCH PHYS MED REHAB, V80, P877, DOI 10.1016/S0003-9993(99)90077-1; Andrews F. M., 1976, SOCIAL INDICATORS WE; Annells M, 2001, INT J NURS STUD, V38, P9, DOI 10.1016/S0020-7489(00)00063-8; Ardelt M, 1997, J GERONTOL B-PSYCHOL, V52, pP15, DOI 10.1093/geronb/52B.1.P15; Arnesen T, 1999, BMJ-BRIT MED J, V319, P1423, DOI 10.1136/bmj.319.7222.1423; ASHBY J, 1994, QUAL LIFE RES, V3, P257, DOI 10.1007/BF00434899; BACH JR, 1994, ARCH PHYS MED REHAB, V75, P626, DOI 10.1016/0003-9993(94)90183-X; Bastian H, 2000, REPROD HEALTH MATTER, V8, P113, DOI 10.1016/S0968-8080(00)90012-0; Beaton DE, 2002, CURR OPIN RHEUMATOL, V14, P109, DOI 10.1097/00002281-200203000-00006; Benony H, 2002, AM J PHYS MED REHAB, V81, P437, DOI 10.1097/00002060-200206000-00008; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Bhavnani Vanita, 2002, Health Expect, V5, P156, DOI 10.1046/j.1369-6513.2002.00177.x; Bradburn N. M., 1965, REPORTS HAPPINESS PI; Brazier J, 1998, J CLIN EPIDEMIOL, V51, P1115, DOI 10.1016/S0895-4356(98)00103-6; Brazier J, 1999, HEALTH ECON, V8, P41, DOI 10.1002/(SICI)1099-1050(199902)8:1<41::AID-HEC395>3.0.CO;2-#; BRICKMAN P, 1978, J PERS SOC PSYCHOL, V36, P917, DOI 10.1037/0022-3514.36.8.917; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; BURCKHARDT CS, 1989, RES NURS HEALTH, V12, P347, DOI 10.1002/nur.4770120604; CALMAN KC, 1984, J MED ETHICS, V10, P124, DOI 10.1136/jme.10.3.124; Catz A, 2001, DISABIL REHABIL, V23, P263; CLAYTON KS, 1994, ARCH PHYS MED REHAB, V75, P633, DOI 10.1016/0003-9993(94)90184-8; Cohen J, 1996, J MED ETHICS, V22, P267, DOI 10.1136/jme.22.5.267; Costa P, 2001, EUR UROL, V39, P107, DOI 10.1159/000052421; COSTA PT, 1980, J PERS SOC PSYCHOL, V38, P668, DOI 10.1037/0022-3514.38.4.668; CREWE NM, 1990, REHABIL PSYCHOL, V35, P205, DOI 10.1037/0090-5550.35.4.205; CRIBB A, 1985, J MED ETHICS, V11, P142, DOI 10.1136/jme.11.3.142; Dazord A, 1995, EUR REV APPL PSYCHOL, V45, P271; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P863, DOI 10.1016/0895-4356(94)90189-9; DECKER SD, 1985, AM J OCCUP THER, V39, P740, DOI 10.5014/ajot.39.11.740; Deconinck H, 2003, SPINAL CORD, V41, P303, DOI 10.1038/sj.sc.3101443; DIENER E, 1984, J PERS SOC PSYCHOL, V47, P1105, DOI 10.1037/0022-3514.47.5.1105; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Diener E., 1993, HDB EMOTIONS, P405; Dijkers M, 1997, SPINAL CORD, V35, P829, DOI 10.1038/sj.sc.3100571; Dijkers M, 1999, AM J PHYS MED REHAB, V78, P286, DOI 10.1097/00002060-199905000-00022; DIJKERS M, 1997, J SPINAL CORD MED, V20, P121; Dijkers Marcel P., 1995, P185; Dijkers Marcel P J M, 2003, J Allied Health, V32, P38; Dijkers MP, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50241; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dijkers MPJM, 2000, ARCH PHYS MED REHAB, V81, pS63, DOI 10.1053/apmr.2000.20627; Dijkers MPJM, 1999, ARCH PHYS MED REHAB, V80, P867, DOI 10.1016/S0003-9993(99)90076-X; Dijkers MPJM, 2002, SPINAL CORD, V40, P351, DOI 10.1038/sj.sc.3101310; Ditto PH, 1996, HEALTH PSYCHOL, V15, P332, DOI 10.1037/0278-6133.15.5.332; Duggan C. H., 1999, CANADIAN J REHABILIT, V12, P179; Duggan CH, 2001, REHABIL PSYCHOL, V46, P3, DOI 10.1037/0090-5550.46.1.3; EMMONS RA, 1986, J PERS SOC PSYCHOL, V51, P1058, DOI 10.1037/0022-3514.51.5.1058; Feeny D, 2002, MED CARE, V40, P113, DOI 10.1097/00005650-200202000-00006; FEENY D, 1995, PHARMACOECONOMICS, V7, P490, DOI 10.2165/00019053-199507060-00004; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P843, DOI 10.7326/0003-4819-99-6-843; FERRANS CE, 1992, RES NURS HEALTH, V15, P29, DOI 10.1002/nur.4770150106; FERRANS CE, 1985, ADV NURS SCI, V8, P15, DOI 10.1097/00012272-198510000-00005; Forchheimer M, 2004, AM J PHYS MED REHAB, V83, P390, DOI 10.1097/01.PHM.0000124441.78275.C9; Fougeyrollas P, 1998, INT J REHABIL RES, V21, P127, DOI 10.1097/00004356-199806000-00002; Frisch M. B., 1992, COMPREHENSIVE CASEBO, P27; Frisch M.B., 1992, PSYCHOL ASSESSMENT, V4, P92, DOI [DOI 10.1037/1040-3590.4.1.92, 10.1037/1040-3590.4.1.92]; Frisch MB, 1998, CLIN PSYCHOL-SCI PR, V5, P19, DOI 10.1111/j.1468-2850.1998.tb00132.x; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; GARDNER BP, 1985, BRIT MED J, V291, P1620, DOI 10.1136/bmj.291.6509.1620; GERHART KA, 1994, ANN EMERG MED, V23, P807, DOI 10.1016/S0196-0644(94)70318-3; Gerritsen DL, 2004, QUAL LIFE RES, V13, P611, DOI 10.1023/B:QURE.0000021314.17605.40; Gilbody SM, 2002, PSYCHOL MED, V32, P1345, DOI 10.1017/S0033291702006001; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; Groessl EJ, 2004, AM J PREV MED, V26, P126, DOI 10.1016/j.amepre.2003.10.007; Grossman HA, 2003, AIDS READ, V13, P595; Grossman Howard A, 2003, AIDS Read, V13, P583; GUTTMANN L, 1973, SPINAL CORD INJURIES, P1; Guyatt GH, 2002, MAYO CLIN PROC, V77, P371, DOI 10.4065/77.4.371; Hallin P, 2000, SPINAL CORD, V38, P509, DOI 10.1038/sj.sc.3101054; Hampton NZ, 2004, DISABIL REHABIL, V26, P203, DOI 10.1080/09638280310001639704; Hampton NZ, 2001, INT J REHABIL RES, V24, P69, DOI 10.1097/00004356-200103000-00010; Hampton NZ, 1999, J APPL REHABIL COUN, V30, P35; Hays RD, 2000, PHARMACOECONOMICS, V18, P419, DOI 10.2165/00019053-200018050-00001; Hays RD, 2002, ARCH PHYS MED REHAB, V83, pS4, DOI 10.1053/apmr.2002.36837; Hickey A, 1999, INDIVIDUAL QUALITY L, P119; Hickey AM, 1996, BRIT MED J, V313, P29, DOI 10.1136/bmj.313.7048.29; Higginson IJ, 2001, BRIT MED J, V322, P1297, DOI 10.1136/bmj.322.7297.1297; HUNT SM, 1980, J EPIDEMIOL COMMUN H, V34, P281, DOI 10.1136/jech.34.4.281; Jacobsen PB, 2002, ONCOLOGY-NY, V16, P133; Johnston MV, 2002, ARCH PHYS MED REHAB, V83, pS26, DOI 10.1053/apmr.2002.37100; KAPLAN RM, 1979, MED CARE, V17, P501, DOI 10.1097/00005650-197905000-00005; KAPLAN RM, 1993, QUAL LIFE RES, V2, P467, DOI 10.1007/BF00422221; KAPLAN RM, 1995, PSYCHOSOM MED, V57, P138, DOI 10.1097/00006842-199503000-00006; KAZIS LE, 1990, J CLIN EPIDEMIOL, V43, P1243, DOI 10.1016/0895-4356(90)90025-K; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kemp BJ, 1999, DISABIL REHABIL, V21, P241; Kennedy P, 2003, BRIT J CLIN PSYCHOL, V42, P41, DOI 10.1348/014466503762842002; Kewman DG, 1998, REHABIL PSYCHOL, V43, P143, DOI 10.1037/0090-5550.43.2.143; Keyes CLM, 2002, J PERS SOC PSYCHOL, V82, P1007, DOI 10.1037//0022-3514.82.6.1007; Knight Sara J, 2002, Clin Prostate Cancer, V1, P105, DOI 10.3816/CGC.2002.n.012; Kopec JA, 2003, J CLIN EPIDEMIOL, V56, P317, DOI 10.1016/S0895-4356(02)00609-1; KRAUSE JS, 1987, REHABIL PSYCHOL, V32, P205; Krause JS, 2000, SPINAL CORD, V38, P77, DOI 10.1038/sj.sc.3100961; KRAUSE JS, 1992, REHABIL PSYCHOL, V37, P61, DOI 10.1037/0090-5550.37.1.61; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; Kreuter M, 2000, SPINAL CORD, V38, P2, DOI 10.1038/sj.sc.3100933; Kreuter M, 1996, ARCH PHYS MED REHAB, V77, P541, DOI 10.1016/S0003-9993(96)90292-0; KUYKEN W, 1995, SOC SCI MED, V41, P1403, DOI 10.1016/0277-9536(95)00112-k; LAWTON MP, 1975, J GERONTOL, V30, P85, DOI 10.1093/geronj/30.1.85; Leplege A, 1997, JAMA-J AM MED ASSOC, V278, P47, DOI 10.1001/jama.278.1.47; Lindblad AK, 2002, ACTA ONCOL, V41, P507; Livneh H, 2003, INT J REHABIL RES, V26, P191, DOI 10.1097/00004356-200309000-00005; LlewellynThomas HA, 1996, MED DECIS MAKING, V16, P262, DOI 10.1177/0272989X9601600311; Lucke KT, 2004, QUAL LIFE RES, V13, P97, DOI 10.1023/B:QURE.0000015284.95515.17; Macduff C, 2000, J ADV NURS, V32, P375, DOI 10.1046/j.1365-2648.2000.01486.x; Mallard AGC, 1997, SOC INDIC RES, V40, P259, DOI 10.1023/A:1006812301761; Manns PJ, 2001, QUAL HEALTH RES, V11, P795, DOI 10.1177/104973201129119541; Marcoen Alfons, 2002, Tijdschr Gerontol Geriatr, V33, P156; MARINO RJ, 2000, INT STANDARDS NEUROL; Marx RG, 1999, J CLIN EPIDEMIOL, V52, P105, DOI 10.1016/S0895-4356(98)00148-6; Maslow A.H., 1987, MOTIVATION PERSONALI, V3rd ed.; May LA, 2002, SPINAL CORD, V40, P341, DOI 10.1038/sj.sc.3101311; May LA, 2001, QUAL LIFE RES, V10, P503, DOI 10.1023/A:1013027520429; MAYNARD FM, 1987, ARCH PHYS MED REHAB, V68, P862; McColl MA, 2000, ARCH PHYS MED REHAB, V81, P817, DOI 10.1053/apmr.2000.5567; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882; Meyers AR, 2000, ARCH PHYS MED REHAB, V81, pS5, DOI 10.1053/apmr.2000.20618; Michalos AC, 2002, SOC INDIC RES, V59, P321, DOI 10.1023/A:1019601213926; Mihaylov SI, 2004, DEV MED CHILD NEUROL, V46, P299; MOR V, 1988, J CLIN EPIDEMIOL, V41, P1055, DOI 10.1016/0895-4356(88)90074-1; Morris J, 1998, QUAL LIFE RES, V7, P85; Muldoon MF, 1998, BMJ-BRIT MED J, V316, P542, DOI 10.1136/bmj.316.7130.542; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P481; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; Nord E, 2003, HEALTH ECON, V12, P873, DOI 10.1002/hec.838; Ormel J, 1997, SOC SCI MED, V45, P1051, DOI 10.1016/S0277-9536(97)00032-4; PALYS TS, 1983, J PERS SOC PSYCHOL, V44, P1221, DOI 10.1037/0022-3514.44.6.1221; Patterson TL, 1996, PSYCHIAT RES, V63, P169, DOI 10.1016/0165-1781(96)02797-7; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Pentland W, 2002, SPINAL CORD, V40, P374, DOI 10.1038/sj.sc.3101295; Phillips VL, 2001, PUBLIC HEALTH REP, V116, P94, DOI 10.1093/phr/116.S1.94; Polsky D, 2001, HEALTH ECON, V10, P27, DOI 10.1002/1099-1050(200101)10:1<27::AID-HEC561>3.0.CO;2-R; Post MWM, 1998, SCAND J REHABIL MED, V30, P23; Post MWM, 1998, ARCH PHYS MED REHAB, V79, P395, DOI 10.1016/S0003-9993(98)90139-3; Post MWM, 2001, CLIN REHABIL, V15, P103, DOI 10.1191/026921501672698006; RAPKIN BD, 1992, PSYCHOL AGING, V7, P138, DOI 10.1037/0882-7974.7.1.138; RAPKIN BD, 2000, ADAPTATION CHANGING, P53, DOI DOI 10.1037/10382-004; Revicki DA, 1997, QUAL LIFE RES, V6, P595, DOI 10.1023/A:1018420418455; Riemsma R P, 2001, Health Technol Assess, V5, P1; Rochette A, 2001, DISABIL REHABIL, V23, P559; Rosenberg M., 1989, SOC ADOLESCENT SELF; ROSSER R, 1993, J ROY SOC MED, V86, P315; Ruggeri M, 2001, BRIT J PSYCHIAT, V178, P268, DOI 10.1192/bjp.178.3.268; Russak SM, 2003, ARTHRIT RHEUM-ARTHR, V49, P574, DOI 10.1002/art.11208; RUTA DA, 1994, MED CARE, V32, P1109, DOI 10.1097/00005650-199411000-00004; Ryff CD, 1998, PSYCHOL INQ, V9, P1, DOI 10.1207/s15327965pli0901_1; SIMS ACP, 1975, PSYCHOL MED, V5, P62, DOI 10.1017/S0033291700007224; SINGER P, 1995, J MED ETHICS, V21, P144, DOI 10.1136/jme.21.3.144; SIOSTEEN A, 1990, PARAPLEGIA, V28, P476, DOI 10.1038/sc.1990.64; SOOPRAMANIEN A, 1995, PARAPLEGIA, V33, P49, DOI 10.1038/sc.1995.12; Sprangers MAG., 2000, ADAPTATION CHANGING; STENSMAN R, 1994, PARAPLEGIA, V32, P416, DOI 10.1038/sc.1994.68; Stiggelbout AM, 2001, J CLIN ONCOL, V19, P220, DOI 10.1200/JCO.2001.19.1.220; Stover SL, 1999, ARCH PHYS MED REHAB, V80, P1365, DOI 10.1016/S0003-9993(99)90246-0; Tate DG, 2002, ARCH PHYS MED REHAB, V83, pS18, DOI 10.1053/apmr.2002.36835; TENNANT C, 1977, MED J AUSTRALIA, V2, P392, DOI 10.5694/j.1326-5377.1977.tb114568.x; Tsevat J, 1998, JAMA-J AM MED ASSOC, V279, P371, DOI 10.1001/jama.279.5.371; Tzonichaki I, 2002, OTJR-OCCUP PARTICI H, V22, P96, DOI 10.1177/153944920202200302; Ubel PA, 2003, QUAL LIFE RES, V12, P599, DOI 10.1023/A:1025119931010; Veenhoven R., 2000, J HAPPINESS STUD, V1, P1, DOI [10.1023/A:1010072010360, DOI 10.1023/A:1010072010360]; Ville I, 2001, SOC SCI MED, V52, P369, DOI 10.1016/S0277-9536(00)00140-4; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wehman P, 2000, AM J PHYS MED REHAB, V79, P161, DOI 10.1097/00002060-200003000-00009; Westgren N, 1998, ARCH PHYS MED REHAB, V79, P1433, DOI 10.1016/S0003-9993(98)90240-4; White CL, 2004, QUAL LIFE RES, V13, P625, DOI 10.1023/B:QURE.0000021312.37592.4f; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, P1793, DOI 10.1016/j.apmr.2004.04.024; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITENECK GG, 1999, CREATION CRAIG HOSP; *WHO, 1949, CONST WORLD HLTH ORG; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wood-Dauphinee S, 2002, RESTOR NEUROL NEUROS, V20, P135; WOODRICH F, 1983, J REHABIL, V49, P26; World Health Organization, 2001, INT CLASS FUNCT DIS; Wyrwich KW, 2004, AM HEART J, V147, P615, DOI 10.1016/j.ahj.2003.10.039; Wyrwich KW, 2000, J EVAL CLIN PRACT, V6, P39, DOI 10.1046/j.1365-2753.2000.00238.x; YERXA EJ, 1986, OCCUP THER J RES, V6, P271, DOI 10.1177/153944928600600502	183	172	180	1	16	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.	MAY-JUN	2005	42	3		1			87	110		10.1682/JRRD.2004.08.0100			24	Rehabilitation	Rehabilitation	974PA	WOS:000232602700010	16195966				2021-06-18	
J	Tierney, RT; Sitler, MR; Swanik, CB; Swanik, KA; Higgins, M; Torg, J				Tierney, RT; Sitler, MR; Swanik, CB; Swanik, KA; Higgins, M; Torg, J			Gender differences in head-neck segment dynamic stabilization during head acceleration	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						head injury; concussion; biomechanics; neuromuscular control; pathomechanics	STIFFNESS; IMPACT; CONCUSSIONS; INJURY; JOINT; TIMES; MEN	TIERNEY, R. T., M. R. SITLER, C. B. SWANIK, K. A. SWANIK, M. HIGGINS, and J. TORG. Gender Differences in Head-Neck Segment Dynamic Stabilization during Head Acceleration. Med. Sci. Sports Exerc., Vol. 37, No. 2, pp. 272-279, 2005. Purpose: Recent epidemiological research has revealed that gender differences exist in concussion incidence but no study has investigated why females may be at greater risk of concussion. Our purpose was to determine whether gender differences existed in head-neck segment kinematic and neuromuscular control variables responses to an external force application with and without neck muscle preactivation. Methods: Forty (20 females and 20 males) physically active volunteers participated in the study. The independent variables were gender, force application (known vs unknown), and force direction (forced flexion vs forced extension). The dependent variables were kinematic and EMG variables, head-neck segment stiffness, and head-neck segment flexor and extensor isometric strength. Statistical analyses consisted of multiple multivariate and univariate analyses of variance, follow-up univariate analyses of variance, and t-tests (P less than or equal to 0.05). Results: Gender differences existed in head-neck segment dynamic stabilization during head angular acceleration. Females exhibited significantly greater head-neck segment peak angular acceleration (50%) and displacement (39%) than males despite initiating muscle activity significantly earlier (SCM only) and using a greater percentage of their maximum head-neck segment muscle activity (79% peak activity and 117% muscle activity area). The head-neck segment angular acceleration differences may be because females exhibited significantly less isometric strength (49%), neck girth (30%), and head mass (43%), resulting in lower levels of head-neck segment stiffness (29%). Conclusion: For our subject demographic, the results revealed gender differences in head-neck segment dynamic stabilization during head acceleration in response to an external force application. Females exhibited significantly greater head-neck segment peak angular acceleration and displacement than males despite initiating muscle activity earlier (SCM only) and using a greater percentage of their maximum head-neck segment muscle activity.	Temple Univ, Dept Kinesiol, Athlet Training Div, Biokinet Res Lab, Philadelphia, PA 19122 USA; Univ Delaware, Dept Hlth & Exercise Sci, Newark, DE USA; Temple Univ Hosp & Med Sch, Dept Orthodont, Philadelphia, PA 19140 USA	Tierney, RT (corresponding author), Temple Univ, Dept Kinesiol, Athlet Training Div, Biokinet Res Lab, 127 Pearson Hall, Philadelphia, PA 19122 USA.	rtierney@temple.edu	Swanik, Charles/C-4377-2014	Swanik, Charles/0000-0001-9701-2005			Barth JT, 2001, J ATHL TRAINING, V36, P253; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Borsa PA, 2002, J ATHL TRAINING, V37, P240; Brault JR, 2000, CLIN BIOMECH, V15, P426, DOI 10.1016/S0268-0033(99)00097-2; BRUNT D, 1990, ARCH PHYS MED REHAB, V71, P473; Chleboun GS, 1997, CLIN BIOMECH, V12, P383, DOI 10.1016/S0268-0033(97)00027-2; COHEN LA, 1961, J NEUROPHYSIOL, V24, P1; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Garces GL, 2002, MED SCI SPORT EXER, V34, P464, DOI 10.1097/00005768-200203000-00013; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; Gorden JA, 2003, J ATHL TRAINING, V38, P209; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Ito Y, 1997, EXP BRAIN RES, V117, P266, DOI 10.1007/s002210050221; KREIGHBAUM E, 1996, BIOMECHANICS QUALITA, P282; Kumar S, 2000, ACCIDENT ANAL PREV, V32, P233, DOI 10.1016/S0001-4575(99)00114-1; Lephart SM, 2000, PROPRIOCEPTION NEURO, P16; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; MCNAIR PJ, 1992, CLIN BIOMECH, V7, P131, DOI 10.1016/0268-0033(92)90027-2; McNair PJ, 2002, CLIN BIOMECH, V17, P536, DOI 10.1016/S0268-0033(02)00062-1; OATIS CA, 1993, PHYS THER, V73, P740, DOI 10.1093/ptj/73.11.740; Pearson K. A. J. G., 2000, PRINCIPLES NEUROSCIE, P713; PLAGENHOEF S, 1983, RES Q EXERCISE SPORT, V54, P169, DOI 10.1080/02701367.1983.10605290; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; REID SE, 1981, AVIAT SPACE ENVIR MD, V52, P78; SCHANTZ P, 1983, ACTA PHYSIOL SCAND, V117, P219, DOI 10.1111/j.1748-1716.1983.tb07200.x; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; STRAUB SJ, 2001, J ATHL TRAINING, V36, pS27; Swanik CB, 1997, J SPORT REHABIL, V6, P182, DOI 10.1123/jsr.6.2.182; Vasavada AN, 1998, SPINE, V23, P412, DOI 10.1097/00007632-199802150-00002; WINTER EM, 1991, EUR J APPL PHYSIOL O, V63, P124, DOI 10.1007/BF00235181; Wittek A, 2000, HUMAN BIOMECHANICS AND INJURY PREVENTION, P71; Wittek A, 2001, IEEE T BIO-MED ENG, V48, P143, DOI 10.1109/10.909635	32	172	173	2	33	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	FEB	2005	37	2					272	279		10.1249/01.MSS.0000152734.47516.AA			8	Sport Sciences	Sport Sciences	896AU	WOS:000226907800015	15692324				2021-06-18	
J	Atwood, LD; Wolf, PA; Heard-Costa, NL; Massaro, JM; Beiser, A; D'Agostino, RB; DeCarli, C				Atwood, LD; Wolf, PA; Heard-Costa, NL; Massaro, JM; Beiser, A; D'Agostino, RB; DeCarli, C			Genetic variation in white matter hyperintensity volume in the Framingham study	STROKE			English	Article						hereditary disease; population genetics; MRI scans	CARDIOVASCULAR-DISEASE; BRAIN MORPHOLOGY; ELDERLY-PEOPLE; RISK-FACTORS; LESIONS; MR; ASSOCIATION; PREVALENCE; METABOLISM; PEDIGREES	Background and Purpose - In a previous study of normal elderly male twins, the heritability of quantitative white matter hyperintensity (WMH) volume has been estimated to be high (0.73). We investigated heritability of WMH in a family-based sample of the Framingham Heart Study for sex differences and the impact of age. Methods - Brain magnetic resonance scans were performed on 2012 individuals in the cohort and offspring of the Framingham study. This report was limited to 1330 stroke-free and dementia-free members ( mean age 61.0 years) of the Framingham offspring. Individuals with a history of multiple sclerosis, stroke, dementia, or other neurological condition including traumatic brain injury were excluded from this analysis. WMH volume and total cranial volume (TCV) were quantified using a previously published algorithm. Because of extreme skewing, measures of WMH were log-transformed before analysis. Variance components methods were used to estimate heritability of WMH after adjusting for sex, age, age(2), and TCV. Results - In the full dataset, WMH heritability was 0.55 ( P < 0.0001). Heritability among women was 0.78 ( P < 0.0001) whereas heritability among men was 0.52 ( P < 0.0003). Heritability varied as average age increased, with a peak of 0.68 ( P < 0.0001) in individuals aged 55 or older. Conclusion - Using a family-based study design comprising generally healthy individuals, this study found high heritability of WMH overall and similar heritability for both men and women. In addition, the heritability of WMH remained high among individuals in whom the prevalence of cerebrovascular brain injury was generally low, suggesting that WMH is also likely to be an excellent genetic marker of brain aging.	Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biostat, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Math & Stat, Boston, MA 02118 USA; Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA; Univ Calif Davis, Ctr Neurosci, Sacramento, CA 95817 USA	Atwood, LD (corresponding author), Boston Univ, Sch Med, Dept Neurol, 715 Albany St,B-609, Boston, MA 02118 USA.	lda@bu.edu	DeCarli, Charles/B-5541-2009	Massaro, Joseph/0000-0002-2682-4812; Beiser, Alexa/0000-0001-8551-7778; Heard-Costa, Nancy/0000-0001-9730-0306; Wolf, Philip/0000-0002-3628-301X	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [N01-HC-25195] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG16495, P30 AG13846] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS17950, R01 NS017950] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [N01HC025195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS017950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846, R01AG016495] Funding Source: NIH RePORTER		Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844; AMOS CI, 1994, AM J HUM GENET, V54, P535; Bakker SLM, 1999, NEUROLOGY, V52, P578, DOI 10.1212/WNL.52.3.578; BRAFFMAN BH, 1988, AM J ROENTGENOL, V151, P551, DOI 10.2214/ajr.151.3.551; Carmelli D, 1998, STROKE, V29, P1177, DOI 10.1161/01.STR.29.6.1177; Cupples L., 1988, FRAMINGHAM HEART STU; de Leeuw FE, 2001, J NEUROL NEUROSUR PS, V70, P9, DOI 10.1136/jnnp.70.1.9; de Leeuw FE, 2000, J NEUROL, V247, P291, DOI 10.1007/s004150050586; DECARLI C, 1995, NEUROLOGY, V45, P2077, DOI 10.1212/WNL.45.11.2077; DeCarli C, 1999, STROKE, V30, P529, DOI 10.1161/01.STR.30.3.529; DECARLI C, 1992, J COMPUT ASSIST TOMO, V16, P274, DOI 10.1097/00004728-199203000-00018; DECARLI C, 1993, NEUROLOGY S2, V43, pA403; FAZEKAS F, 1993, NEUROLOGY, V43, P1683, DOI 10.1212/WNL.43.9.1683; GRAFTON ST, 1991, ARCH NEUROL-CHICAGO, V48, P293, DOI 10.1001/archneur.1991.00530150061019; Hatazawa J, 1997, STROKE, V28, P1944, DOI 10.1161/01.STR.28.10.1944; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; Liao DP, 1997, NEUROEPIDEMIOLOGY, V16, P149, DOI 10.1159/000368814; Longstreth WT, 1996, STROKE, V27, P1274, DOI 10.1161/01.STR.27.8.1274; MANOLIO TA, 1993, CIRCULATION, V88, P2163, DOI 10.1161/01.CIR.88.5.2163; MARSHALL DW, 1988, ARCH NEUROL-CHICAGO, V45, P33, DOI 10.1001/archneur.1988.00520250039016; Murphy DGM, 1996, ARCH GEN PSYCHIAT, V53, P585; Reed T, 2000, NEUROEPIDEMIOLOGY, V19, P76, DOI 10.1159/000026242; Swan GE, 1998, NEUROLOGY, V51, P986, DOI 10.1212/WNL.51.4.986; Swan GE, 2000, NEUROLOGY, V54, P2108, DOI 10.1212/WNL.54.11.2108; Yue NC, 1997, RADIOLOGY, V202, P33, DOI 10.1148/radiology.202.1.8988189	25	172	175	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	JUL	2004	35	7					1609	1613		10.1161/01.STR.0000129643.77045.10			5	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	832HE	WOS:000222257300017	15143299	Bronze			2021-06-18	
J	Albanese, J; Leone, M; Alliez, JR; Kaya, JM; Antonini, F; Alliez, B; Martin, C				Albanese, J; Leone, M; Alliez, JR; Kaya, JM; Antonini, F; Alliez, B; Martin, C			Decompressive craniectomy for severe traumatic brain injury: Evaluation of the effects at one year	CRITICAL CARE MEDICINE			English	Article						head trauma; brain edema; intracranial pressure; intensive care unit; pupillary reactivity	CEREBRAL EDEMA; HEAD-INJURY; SURGERY	Objective: To assess the effect on outcome (1 yr) of decompressive craniectomy performed within or after the first 24 hrs posttrauma in severely head-injured trauma patients with intractable cerebral hypertension. Design: Retrospective cohort study. Settings: Intensive care unit of a university hospital. Patients. Among 816 patients with severe head trauma (Glasgow Coma Scale less than or equal to8), 40 underwent decompressive craniectomy. After data collection, patients were divided into two groups: early and late decompressive craniectomy. An early decompressive craniectomy was performed within the first 24 hrs in patients according to the following criteria: a Glasgow Coma Scale score <6 and the existence of clinical signs of cerebral herniation (absence of pupillary reflexes), correlated with abnormalities in computed tomography scan including hematoma, appearance of diffuse or unilateral brain swelling, and/or cerebral herniation. The intracranial pressure in these patients was not measured before the decompressive craniectomy was performed. A late decompressive craniectomy (>24 hrs) was performed according to following criteria: an intractable intracranial hypertension with intracranial pressure >35 mm Hg, a unilateral or bilateral absence of pupillary reflexes, and the same abnormalities in computed tomography scan as previously described. Intervention: Twenty-seven patients with signs of cerebral herniation required the procedure at the time of initial evacuation of a mass lesion. In 13 patients, decompressive craniectomy was performed because of elevated intracranial pressure refractory to medical treatment consisting of cerebrospinal fluid derivation, deep sedation, osmotherapy, hyperventilation, and nesdonal or propofol. Measurements and Main Results: Five patients (19%) in whom an early decompressive craniectomy was performed had good recoveries (social rehabilitation), eight patients (30%) remained in a persistent vegetative state or with a severe disability, and 14 died (52%). On the other hand, the performance of late decompressive craniectomy in case of medical treatment failure was followed by social rehabilitation in five patients (38%) and death in three patients (23%). A persistent vegetative state or a severe disability was observed in five patients (38%). Meningitis or cerebral abscess occurred in six patients after decompressive craniectomy and were easily cured by antibiotic treatment. Conclusions. In 40 patients with intractable intracranial hypertension and at very high risk of brain death, decompressive craniectomy allowed 25% of patients to attain social rehabilitation at 1 yr.	Marseilles Sch Med, Marseilles Univ Hosp Syst, Dept Intens Care, Marseille, France; Marseilles Sch Med, Marseilles Univ Hosp Syst, Ctr Trauma, Marseille, France; Marseilles Sch Med, Marseilles Univ Hosp Syst, Dept Neurosurg, Marseille, France	Leone, M (corresponding author), Hop Nord Marseille, Dept Anesthesie Reanimat, Bd P Dramard, F-13915 Marseille 20, France.	marc.leone@ap-hm.fr	Leone, Marc/P-4835-2016	Leone, Marc/0000-0002-3097-758X			Albanese J, 2001, YB INTENSIVE CARE EM, P353; Cooper P R, 1976, Surg Neurol, V5, P25; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; Forgacs P, 2001, CLIN INFECT DIS, V32, P179, DOI 10.1086/318471; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Guerra WKW, 1999, INTENS CARE MED, V25, P1327; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; MAAS AIR, 1996, YB INTENSIVE CARE EM, P707; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; Meier U, 2000, ACTA NEUROCHIR SUPPL, V76, P475; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; SHIGEMORI M, 1980, ACTA NEUROCHIR, V54, P61, DOI 10.1007/BF01401944; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P463; Valadka AB, 2001, NEUROSURGERY, V48, P17, DOI 10.1097/00006123-200101000-00004	17	172	185	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	2003	31	10					2535	2538		10.1097/01.CCM.0000089927.67396.F3			4	Critical Care Medicine	General & Internal Medicine	733LZ	WOS:000186003100018	14530763				2021-06-18	
J	Cummins, RA; Lau, ALD				Cummins, RA; Lau, ALD			Community integration or community exposure? A review and discussion in relation to people with an intellectual disability	JOURNAL OF APPLIED RESEARCH IN INTELLECTUAL DISABILITIES			English	Article						community integration; intellectual disability; quality of life; subjective well-being	TRAUMATIC BRAIN INJURY; QUALITY-OF-LIFE; MENTALLY-RETARDED ADULTS; SOCIAL-ROLE VALORIZATION; DEVELOPMENTAL-DISABILITIES; LEARNING-DISABILITIES; HANDICAPPED ADULTS; SELF-ESTEEM; HIGH-SCHOOL; WELL	Background This paper reviews the issue of integration as it applies to people with an intellectual disability. A compelling finding is the almost exclusive orientation of the literature to physical integration within the general community of non-disabled people. Moreover, it seems to be generally assumed that the more frequently people experience such integration the better their lives will be. Methods We question the validity of this assumption on several grounds. It is social, not physical integration, that has a reliable positive influence on well-being. This is an important conclusion as some disabled people find effective social integration with the general community extremely difficult to achieve. Because of this, the consequences of an overly enthusiastic program of integration for such people has more potential to be more stressful than beneficial. Results We further argue that, as integration is being pursued to benefit the individual, the essential goal of service provision should be to achieve a sense of community connectedness, rather than being concerned with physical integration within the general community. Conclusion It is proposed that such connectedness is more likely to be achieved within the community of people with an intellectual disability.	Deakin Univ, Sch Psychol, Melbourne, Vic 3125, Australia; Hong Kong Polytech Univ, Dept Rehabil Studies, Hong Kong, Hong Kong, Peoples R China	Cummins, RA (corresponding author), Deakin Univ, Sch Psychol, 221 Burwood Highway, Melbourne, Vic 3125, Australia.			Cummins, Robert/0000-0001-9014-7193			ANDERSON DJ, 1992, J DEV DISABILITIES, V1, P16; Aubry T, 1996, Can J Commun Ment Health, V15, P5; Baker PA, 2000, J APPL RES INTELLECT, V13, P169, DOI 10.1046/j.1468-3148.2000.00015.x; BIRENBAUM A, 1977, AM J MENT DEFIC, V83, P323; Brewer P, 1994, BRIT J OCCUPATIONAL, V57, P467; BROWN M, 1980, REHABILITATION CLIEN; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; CAMPBELL AC, 1968, BRIT J PREV SOC MED, V22, P165; CHESELDINE SE, 1981, J MENT DEFIC RES, V25, P49; CLEGG JA, 1991, AM J MENT RETARD, V95, P663; Colantonio A, 2000, BRAIN COGNITION, V44, P19; COLE DA, 1991, J SPEC EDUC, V25, P340, DOI 10.1177/002246699102500306; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; COX DR, 1989, WELFARE PRACTICE MUL; CRAPPS JM, 1989, RES DEV DISABIL, V10, P153, DOI 10.1016/0891-4222(89)90004-8; Crisp R, 1996, AUST PSYCHOL, V31, P133, DOI 10.1080/00050069608260193; Cummins R. A., 1997, COMPREHENSIVE QUALIT, P1; Cummins RA, 2001, J INTELLECT DEV DIS, V26, P83, DOI 10.1080/13668250020032787; Cummins RA, 2001, MENT RETARD DEV D R, V7, P99, DOI 10.1002/mrdd.1014; CUMMINS RA, 1995, SOC INDIC RES, V35, P179, DOI 10.1007/BF01079026; CUMMINS RA, 2003, IN PRESS SOCIAL INDI; Cummins RA., 2002, J HAPPINESS STUD, V3, P37, DOI [10.1023/A:1015678915305, DOI 10.1023/A:1015678915305]; Cutts S, 2001, J INTELLECT DEV DIS, V26, P127, DOI 10.1080/13668250020054440; de Kock U., 1988, MENT HANDICAP RES, V1, P127; Dewees M, 1996, PSYCHIATR SERV, V47, P1088; EMERSON EB, 1985, AM J MENT DEF, V90, P277; Emerson E, 2000, J INTELLECT DEV DIS, V25, P263, DOI 10.1080/13668250020019575; FELCE D, 1991, RES DEV DISABIL, V12, P315, DOI 10.1016/0891-4222(91)90015-K; FELCE D, 1992, RES DEV DISABIL, V13, P27, DOI 10.1016/0891-4222(92)90038-8; FELCE D, 1988, IRISH J PSYCHOL, V9, P346, DOI 10.1080/03033910.1988.10557725; FELCE D, 1986, APPL RES MENT RETARD, V7, P393, DOI 10.1016/S0270-3092(86)80013-3; FELCE D, 1985, BEHAV RES THER, V23, P337, DOI 10.1016/0005-7967(85)90012-9; FELCE D, 1989, STAFFED HOUSING ADUL; FELCE D, 1996, DEINSTITUTIONALIZATI; FIRTH GH, 1980, ED TRAINING MENTALLY, V15, P199; Fleming J, 1999, BRAIN INJURY, V13, P417; FLYNN M, 1987, REASSESSING COMMUNIT; GOLDBERG EM, 1982, EFFECTIVENESS SOCIAL; GOTTLIEB J, 1975, J SPEC EDUC, V9, P307, DOI 10.1177/002246697500900309; GOW L, 1988, EXCEPT CHILDREN, V35, P5, DOI DOI 10.1080/0156655880350102; Heckman TG, 1998, PSYCHOL HEALTH, V13, P859, DOI 10.1080/08870449808407436; Heller T, 1998, AM J MENT RETARD, V103, P236, DOI 10.1352/0895-8017(1998)103<0236:IOAATO>2.0.CO;2; HENDRIX E, 1981, MENT RETARD, V19, P295; INGE KJ, 1988, EDUC TRAIN MENT RET, V23, P97; JONES E, 1997, OPPORTUNITY PROMOTIO; Jordan A., 2001, INT J DISABIL DEV ED, V48, P33, DOI DOI 10.1080/10349120120036297; KEBBON L, 1982, NORMALIZATION SWEDEN; KEITH K. D, 1990, QUALITY LIFE PERSPEC, P93; KENNEDY C, 1989, J SOC ISSUES, V45, P65, DOI 10.1111/j.1540-4560.1989.tb01555.x; Knox M, 2000, J APPL RES INTELLECT, V13, P17, DOI 10.1046/j.1468-3148.2000.00001.x; Krajewski J, 2000, MENT RETARD, V38, P154, DOI 10.1352/0047-6765(2000)038<0154:AOHSST>2.0.CO;2; LAKIN KC, 1981, DEINSTITUTIONALIZATI, P213; LANDESMAN S, 1986, MENT RETARD, V24, P141; LANDESMANDWYER S, 1981, AM J MENT DEF, V86, P223; Lunsky Y, 2001, J INTELL DISABIL RES, V45, P106, DOI 10.1046/j.1365-2788.2001.00334.x; MALIN NA, 1982, BRIT J MENT SUBNORM, V28, P29, DOI 10.1179/bjms.1982.004; MANKOWSKI E, 1995, ADV SOCIAL COGNITION, V8; Margalit M, 1998, J LEARN DISABIL, V31, P173, DOI 10.1177/002221949803100207; Markowitz FE, 1998, J HEALTH SOC BEHAV, V39, P335, DOI 10.2307/2676342; Marquis R, 2000, DISABIL SOC, V15, P411, DOI 10.1080/713661967; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; MCCONKEY R, 1981, INT J REHABIL RES, V4, P493, DOI 10.1097/00004356-198112000-00002; MCDEVITT SC, 1978, MENT RETARD, V161, P22; MCGAUGHEY MJ, 1995, MENT RETARD, V33, P170; Meyer B, 2001, J PSYCHOPATHOL BEHAV, V23, P265, DOI 10.1023/A:1012731520781; Minnes P, 2002, J APPL RES INTELLECT, V15, P377, DOI 10.1046/j.1468-3148.2002.00134.x; Myers F, 1998, DISABIL SOC, V13, P389, DOI 10.1080/09687599826704; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; OKUN MA, 1984, INT J AGING HUM DEV, V19, P111, DOI 10.2190/QGJN-0N81-5957-HAQD; ORELOVE RP, 1982, ED TRAINING MENTALLY, V17, P325; Raynes N., 1994, COST QUALITY COMMUNI; RAYNES NV, 1987, HOMES MENTALLY HANDI; RHOADES C, 1977, MENT RETARD, V15, P24; Robertson J, 2001, MENT RETARD, V39, P201, DOI 10.1352/0047-6765(2001)039<0201:SNOPWM>2.0.CO;2; ROMER D, 1983, APPL RES MENT RETARD, V4, P303, DOI 10.1016/0270-3092(83)90031-0; ROOK KS, 1984, J PERS SOC PSYCHOL, V46, P1097, DOI 10.1037/0022-3514.46.5.1097; Rowles GD, 1996, J APPL GERONTOL, V15, P188, DOI 10.1177/073346489601500204; SALZBERG CL, 1981, MENT RETARD, V19, P127; Sarason S. B., 1977, PSYCHOL SENSE COMMUN; SAXBY H, 1986, BRIT J MENT SUBNORM, V32, P69, DOI 10.1179/bjms.1986.010; SCHALOCK RL, 1993, AM J MENT RETARD, V98, P400; SCHALOCK RL, 1986, AM J MENT DEF, V90, P669; SHERKAT DE, 1992, SOC INDIC RES, V26, P259, DOI 10.1007/BF00286562; SINNOTTOSWALD M, 1991, EDUC TRAIN MENT RET, V26, P388; Smalley KA, 1997, EDUC TRAIN MENT RET, V32, P42; SMITH CL, 1991, SOC INDIC RES, V24, P367, DOI 10.1007/BF00383735; THRONE JM, 1979, MENT RETARD, V17, P171; Todd S., 1988, DISABILITY HANDICAP, V3, P239; WILLER B, 1981, AM J MENT DEF, V86, P252; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WOLFENSBERGER W, 1995, MENT RETARD, V33, P163; Wolfensberger W, 2000, MENT RETARD, V38, P105, DOI 10.1352/0047-6765(2000)038<0105:ABOOSR>2.0.CO;2; WOLFENSBERGER W, 1970, AM J PSYCHIAT, V127, P291, DOI 10.1176/ajp.127.3.291; Wolfensberger W., 1972, PRINCIPLE NORMALIZAT; Wolfensberger W., 1992, BRIEF INTRO SOCIAL R, V2nd rev. ed	95	172	173	0	34	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2322			J APPL RES INTELLECT	J. Appl. Res. Intellect. Disabil.	JUN	2003	16	2					145	157		10.1046/j.1468-3148.2003.00157.x			13	Psychology, Educational; Rehabilitation	Psychology; Rehabilitation	679XT	WOS:000182947800006					2021-06-18	
J	Dillingham, TR; Pezzin, LE; MacKenzie, EJ; Burgess, AR				Dillingham, TR; Pezzin, LE; MacKenzie, EJ; Burgess, AR			Use and satisfaction with prosthetic devices among persons with trauma-related amputations - A long-term outcome study	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						amputation; prosthesis; amputee; outcome	LOWER-LIMB AMPUTATION; TRANSFEMORAL AMPUTATION; REHABILITATION; AMPUTEES; PHANTOM; INJURY; PEOPLE; KNEE; LIFE	Objective: To document and examine the use, satisfaction, and problems with prosthetic devices among persons who suffered a trauma-related lower limb amputation. Design: Abstracted medical records and follow-up interview data were collected for a retrospective cohort of persons with a lower limb trauma-related amputation who received their acute care at the University of Maryland R. Adams Cowley Shock Trauma Center, Baltimore, MD, between 1984 and 1994. Patients with spinal cord injury, traumatic brain injury, or only toe amputations were excluded. Results: There were 146 patients identified. Of those, 9% died during the acute admission and 3.5% died after discharge. Seventy-eight amputees were available for interview (68% response rate). The majority of those interviewed were male (87%), and two-thirds had undergone amputation before age 40 yr. Nearly 95% had a prosthesis and wore it an average of 80 hr (SD = 33) per week. Despite high use, only 43% reported being satisfied with the comfort of their prosthesis. About one-quarter of all users reported problems with wounds, skin irritation, or pain. Traumatic amputees used an average of four prostheses since injury, about one new prosthesis every 2 yr. Statistical analyses revealed that males reported higher prosthetic use (P < 0.01). Higher Injury Severity Score negatively impacted on prosthetic use (P < 0.01). Phantom pain negatively influenced reported satisfaction with the prosthesis (P <less than> 0.03) Conclusions: Although almost all persons living with trauma-related amputations use prosthetic devices, the majority are not satisfied with prosthetic comfort. Phantom pain and residual limb skin problems are also common afflictions in this population.	Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA; Univ Maryland, Sch Med, Ctr Shock Trauma, Baltimore, MD 21201 USA	Dillingham, TR (corresponding author), 10352 Waverly Woods Dr, Ellicott City, MD 21042 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR302486] Funding Source: Medline		*ASS ADV AUT MED, 1990, ABBR INJ SCAL; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BEEKMAN CE, 1987, PHYS THER, V67, P1510, DOI 10.1093/ptj/67.10.1510; Burger H, 1997, PROSTHET ORTHOT INT, V21, P35; Burger H, 1997, DISABIL REHABIL, V19, P272, DOI 10.3109/09638289709166538; DELUCCIA N, 1992, PROSTHET ORTHOT INT, V16, P124; Gauthier-Gagnon C, 1999, ARCH PHYS MED REHAB, V80, P706, DOI 10.1016/S0003-9993(99)90177-6; Gauthier-Gagnon C, 1998, J PROSTHET ORTHOT, V10, P99; HELM P, 1986, ACTA ORTHOP SCAND, V57, P154, DOI 10.3109/17453678609000891; Hoaglund F T, 1983, J Rehabil R D, V20, P57; Legro MW, 1998, ARCH PHYS MED REHAB, V79, P931, DOI 10.1016/S0003-9993(98)90090-9; MALONE JM, 1979, ANN SURG, V189, P798, DOI 10.1097/00000658-197906000-00018; MILLSTEIN S, 1985, PROSTHET ORTHOT INT, V9, P69; MOORE TJ, 1989, CLIN ORTHOP RELAT R, P219, DOI 10.1097/00003086-198901000-00032; NIELSEN CC, 1989, J PROSTHET ONCOL, V4, P242; NIELSEN CC, 1990, J PROSTHET ORTHOT, P125; Pezzin LE, 2000, ARCH PHYS MED REHAB, V81, P292, DOI 10.1053/apmr.2000.0810292; RYBARCZYK BD, 1992, ARCH PHYS MED REHAB, V73, P1169; SHEIKH K, 1985, J SOC OCCUP MED, V35, P114; SHERMAN RA, 1985, PAIN, V21, P91, DOI 10.1016/0304-3959(85)90080-6; SHERMAN RA, 1984, PAIN, V18, P83, DOI 10.1016/0304-3959(84)90128-3; SMITH DG, 1995, J TRAUMA, V38, P44, DOI 10.1097/00005373-199501000-00013; Smith DG, 1999, CLIN ORTHOP RELAT R, P29; VAIDA G, 1991, PHYS MED REHABIL CLI, P325	24	172	178	0	35	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	AUG	2001	80	8					563	571		10.1097/00002060-200108000-00003			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	454BR	WOS:000169953000003	11475475				2021-06-18	
J	Springer, JE; Azbill, RD; Nottingham, SA; Kennedy, SE				Springer, JE; Azbill, RD; Nottingham, SA; Kennedy, SE			Calcineurin-mediated BAD dephosphorylation activates the caspase-3 apoptotic cascade in traumatic spinal cord injury	JOURNAL OF NEUROSCIENCE			English	Article						calcineurin; caspase-3; FK506; glutamate receptors; NMDA; Bcl-xL; BAD translocation	EXCITATORY AMINO-ACIDS; CYTOCHROME-C; BRAIN INJURY; CELL-DEATH; MITOCHONDRIAL-FUNCTION; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; CYCLOSPORINE-A; PROTEIN; KINASE	We report here that activation of the caspase-3 apoptotic cascade in spinal cord injury is regulated, in part, by calcineurin-mediated BAD dephosphorylation. BAD, a proapoptotic member of the bcl-2 gene family, is rapidly dephosphorylated after injury, dissociates from 14-3-3 in the cytosol, and translocates to the mitochondria of neurons where it binds to Bcl-x(L). Pretreatment of animals with FK506, a potent inhibitor of calcineurin activity, or MK801, an NMDA glutamate receptor antagonist, blocked BAD dephosphorylation and abolished activation of the caspase-3 apoptotic cascade. These findings extend previous in vitro observations and are the first to implicate the involvement of glutamate-mediated calcineurin activation and BAD dephosphorylation as upstream, premitochondrial signaling events leading to caspase-3 activation in traumatic spinal cord injury.	Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Ctr Spinal Cord & Brain Injury Res, Lexington, KY 40536 USA	Springer, JE (corresponding author), Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Ctr Spinal Cord & Brain Injury Res, 800 Rose St, Lexington, KY 40536 USA.	jspring@pop.uky.edu		Azbill, David/0000-0001-7989-1771	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040015] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40015, R01 NS040015] Funding Source: Medline		Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Bochelen D, 1999, J PHARMACOL EXP THER, V288, P653; Butcher SP, 1997, J NEUROSCI, V17, P6939; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Clark RSB, 1999, FASEB J, V13, P813; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAWSON TM, 1994, NEUROSCIENCE, V62, P569, DOI 10.1016/0306-4522(94)90389-1; DEL PL, 1997, SCIENCE, V278, P687; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farooque M, 1996, J NEUROTRAUM, V13, P537, DOI 10.1089/neu.1996.13.537; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; Ide T, 1996, NEUROSCI LETT, V204, P157, DOI 10.1016/0304-3940(96)12352-1; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; Liu XZ, 1997, J NEUROSCI, V17, P5395; Ma JY, 1998, BRIT J PHARMACOL, V124, P756, DOI 10.1038/sj.bjp.0701871; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; Namura S, 1998, J NEUROSCI, V18, P3659; Nicotera P, 1997, Adv Neurol, V72, P95; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; Pari G, 2000, NEUROREPORT, V11, P9, DOI 10.1097/00001756-200001170-00003; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pizzi M, 2000, NEUROPHARMACOLOGY, V39, P903, DOI 10.1016/S0028-3908(99)00257-9; Regan RF, 1996, NEUROSCI LETT, V213, P9, DOI 10.1016/0304-3940(96)12823-8; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; SEWELL TJ, 1994, J BIOL CHEM, V269, P21094; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; URCA G, 1990, BRAIN RES, V529, P7, DOI 10.1016/0006-8993(90)90805-L; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; WIEDERRECHT G, 1993, ANN NY ACAD SCI, V696, P9, DOI 10.1111/j.1749-6632.1993.tb17137.x; Wood AM, 1998, J NEUROCHEM, V70, P677; Xu DG, 1997, J COMP NEUROL, V382, P247; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhang C, 1999, J NEUROCHEM, V73, P1650, DOI 10.1046/j.1471-4159.1999.0731650.x; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	51	172	182	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	OCT 1	2000	20	19					7246	7251					6	Neurosciences	Neurosciences & Neurology	358BY	WOS:000089538400018	11007881				2021-06-18	
J	Pezzin, LE; Dillingham, TR; MacKenzie, EJ				Pezzin, LE; Dillingham, TR; MacKenzie, EJ			Rehabilitation and the long-term outcomes of persons with trauma-related amputations	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						rehabilitation; outcomes; trauma; amputations	AMPUTEE; RETURN	Objective: To examine the long-term outcomes of persons undergoing trauma-related amputations, and to explore factors affecting their physical, social, and mental health and the role of inpatient rehabilitation in improving such outcomes. Design: Abstracted medical records and interview data sought for a retrospective cohort of persons who had undergone a lower-limb trauma-related amputation. Participants: Patients identified with a principal or secondary diagnosis of a trauma-related amputation to the lower extremity at the University of Maryland Shock Trauma Center between 1984 and 1994. Patients with spinal cord injury or traumatic brain injury were excluded. Results: Of 146 patients who had trauma-related amputations to the lower limb at the University of Maryland Shock Trauma Center during the study period, nearly 9% died during the acute admission and 3.5% died after discharge. About 87% of all trauma-related amputations involved males, and roughly three quarters involved white persons. About 80% of all amputations occurred before age 40. The health profile of traumatic amputee subjects interviewed in the study (n = 78, 68% response rate) was systematically lower than that of the general US population for all SF-36 scores. The differences in profiles were largest among SF-36 scales sensitive to differences in physical health status, particularly physical functioning, role limitations due to physical health, and bodily pain. About one fourth of persons with a trauma-related amputation reported ongoing severe problems with the residual limb, including phantom pain, wounds, and sores. The number of inpatient rehabilitation nights significantly improved the ability of patients with amputation to function in their physical roles, increased vitality, and reduced bodily pain. Inpatient rehabilitation was also significantly correlated with improved vocational outcomes, Conclusions: These findings suggest a substantial effect of inpatient rehabilitation in improving long-term outcomes of persons with trauma-related amputations.	Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD 21218 USA	Pezzin, LE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Emergency Med, 1830 E Monument St,Suite 6-100, Baltimore, MD 21205 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR302486] Funding Source: Medline		CURLEY MD, 1982, MIL MED, V147, P572; Dillingham TR, 1998, ARCH PHYS MED REHAB, V79, P279, DOI 10.1016/S0003-9993(98)90007-7; EBSKOV LB, 1994, J TRAUMA, V36, P778; GLATTLY HAROLD W., 1964, SOUTHERN MED J, V57, P1373; Greene W., 1993, ECONOMETRIC ANAL; KAY HW, 1975, ORTHOTICS PROSTHET, V29, P3; KEGEL B, 1993, ARCH PHYS MED REHAB, V72, P350; KISHBAUGH D, 1995, MIL MED, V160, P82; Lee T., 1985, THEORY PRACTICE ECON; Melchiorre PJ, 1996, AM J PHYS MED REHAB, V75, P9, DOI 10.1097/00002060-199601000-00004; MILLSTEIN S, 1985, PROSTHET ORTHOT INT, V9, P69; PIERCE RO, 1993, ORTHOPEDICS, V16, P793; POHJOLAINEN T, 1988, PROSTHET ORTHOT INT, V12, P9; SHEIKH K, 1985, J SOC OCCUP MED, V35, P114; SMITH DG, 1995, J TRAUMA, V38, P44, DOI 10.1097/00005373-199501000-00013; Staas WE, 1988, REHABILITATION MED P, P635; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WARE JE, 1994, SP 36 PHYSICAL MENTA; WARE JE, 1994, SF 36 HLTH SURVEY MA; WHITE J, 1988, REHABILITATION MED P, P585	20	172	179	0	15	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2000	81	3					292	300		10.1053/apmr.2000.0810292			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	289NQ	WOS:000085629200011	10724073				2021-06-18	
J	Pike, BR; Zhao, XR; Newcomb, JK; Posmantur, RM; Wang, KKW; Hayes, RL				Pike, BR; Zhao, XR; Newcomb, JK; Posmantur, RM; Wang, KKW; Hayes, RL			Regional calpain and caspase-3 proteolysis of alpha-spectrin after traumatic brain injury	NEUROREPORT			English	Article						apoptosis; cell death; CNS; CPP32; cytoskeleton; fodrin; ischemia; necrosis; neuron	SPINAL-CORD INJURY; POLY(ADP-RIBOSE) POLYMERASE; NEURONAL APOPTOSIS; RAT; ACTIVATION; DEGRADATION; BREAKDOWN; ISCHEMIA; PROTEIN; CONTRIBUTES	ACTIVITY Of calpains and caspase-3 inferred from proteolysis of the cytoskeletal protein cx-spectrin into signature spectrin breakdown products (SBDPs) was used to provide the first systematic and simultaneous comparison of changes in activity of these two families of cysteine proteases after traumatic brain injury (TBI) in rats. Distinct regional and temporal patterns of calpain/caspase-3 processing of alpha-spectrin were observed in brain regions ipsilateral to the site of injury after TBI, including large increases of 145 kDa calpain-mediated SBDP in cortex (up to 30-fold), and enduring increases (up to 2 weeks) of 145 kDa SBDP in hippocampus and thalamus. By contrast, 120kDa caspase-3-mediated SBDP was absent in cortex and showed up to a 2-fold increase in hippocampus and striatum at early (hours) after TBI. Future studies will clarify the pathological significance of large regional differences in activation of calpain and caspase-3 proteases after TBI. NeuroReport 9: 2437-2442 (C) 1998 Rapid Science Ltd.	Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Vivian L Smith Ctr, Houston, TX 77030 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Neurosci Therapeut, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48105 USA	Hayes, RL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Vivian L Smith Ctr, 6431 Fannin St,Suite 7-154, Houston, TX 77030 USA.			Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS010584, R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32-NS10584, R01-NS21458] Funding Source: Medline		Adamec E, 1998, MOL BRAIN RES, V54, P35, DOI 10.1016/S0169-328X(97)00304-5; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Faddis BT, 1997, J NEUROSCI, V17, P951; HONG SC, 1994, BRAIN RES, V661, P43, DOI 10.1016/0006-8993(94)91178-9; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NATH R, IN PRESS J NEUROCHEM; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NITATORI T, 1995, J NEUROSCI, V15, P1001; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, IN PRESS J BIOL CHEM; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YOKOTA M, 1995, STROKE, V26, P1901, DOI 10.1161/01.STR.26.10.1901	26	172	173	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	AUG 3	1998	9	11					2437	2442		10.1097/00001756-199808030-00002			6	Neurosciences	Neurosciences & Neurology	110YE	WOS:000075408500003	9721910				2021-06-18	
J	CHRISTMAN, CW; GRADY, MS; WALKER, SA; HOLLOWAY, KL; POVLISHOCK, JT				CHRISTMAN, CW; GRADY, MS; WALKER, SA; HOLLOWAY, KL; POVLISHOCK, JT			ULTRASTRUCTURAL STUDIES OF DIFFUSE AXONAL INJURY IN HUMANS	JOURNAL OF NEUROTRAUMA			English	Article							SEVERE HEAD TRAUMA; NEUROFILAMENT SUBUNITS; BRAIN-DAMAGE; PATHOGENESIS; ASSAULT; CALIBER	Diffuse axonal injury (DAI) is observed commonly in traumatically brain injured humans. However, traditional histologic methods have proven of limited use in identifying reactive axonal change early (<12 h) in the posttraumatic course. Recently, we have reported, in both humans and animals, that antibodies targeting neurofilament subunits are useful in the light microscopic recognition of early reactive change. In the present study, we extend our previous efforts in humans by analyzing the progression of traumatic brain injury (TBI)-induced axonal change at the ultrastructural level. This effort was initiated to follow the subcellular progression of reactive axonal change in humans and to determine whether this progression parallels that described in animals. Two commercially prepared antibodies were used to recognize reactive axonal change in patients surviving from 6 to 88 h. The NR4 antibody was used to target the light neurofilament subunit (NF-L), and the SMI32 antibody was used to target the heavy neurofilament subunit (NF-H). Plastic-embedded tissue sections were screened for evidence of reactive axonal change, and once identified, this reactive change was analyzed at the ultrastructural lever. At 6 h survival, focally enlarged, immunoreactive axons with axolemmal infolding or disordered neurofilaments were seen within fields of axons exhibiting no apparent abnormality. By 12 h, some axons exhibited continued neurofilamentous misalignment, pronounced immunoreactivity, vacuolization, and, occasionally, disconnection. At later stages, specifically 30 and 60 h survival, further accumulation of neurofilaments and organelles had led to the further expansion of the axis cylinder, and clearly disconnected reactive swellings were recognized. These contained a dense core of disordered immunoreactive neurofilaments partially encompassed by a cap of less densely aggregated organelles. At 88 h, the reactive axons were larger and elongated, consistent with the continued delivery of organelles by axoplasmic transport. At the later time points, considerable heterogeneity was observed, with focally enlarged disconnected axons being observed in relation to axons showing less advanced reactive change. Our findings suggest that neurofilamentous disruption is a pivotal event in axonal injury.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,RICHMOND,VA 23298; UNIV WASHINGTON,DEPT NEUROSURG,SEATTLE,WA 98195; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROL SURG,RICHMOND,VA 23298				Holloway, Kathryn/0000-0003-3777-0060	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193, K08NS001371] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS01371, NS20193] Funding Source: Medline		Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; ANGELIDES KJ, 1989, J CELL BIOL, V108, P1495, DOI 10.1083/jcb.108.4.1495; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; CROOKS DA, 1992, MED SCI LAW, V32, P109, DOI 10.1177/106002809203200204; FRIEDE RL, 1970, ANAT REC, V167, P379, DOI 10.1002/ar.1091670402; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Graham D I, 1983, Acta Neurochir Suppl (Wien), V32, P65; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; IMAJO T, 1987, AM J FOREN MED PATH, V8, P217, DOI 10.1097/00000433-198708030-00004; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARKER JR, 1990, ANN CLIN LAB SCI, V20, P220; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 1985, CENTRAL NERVOUS SYST, P443; SAHUQUILLO J, 1989, ACTA NEUROCHIR, V101, P149, DOI 10.1007/BF01410531; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; SCHLAEPFER WW, 1985, J NEUROCHEM, V44, P502, DOI 10.1111/j.1471-4159.1985.tb05442.x; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Tomlinson B, 1970, J CLIN PATHOL S4, V23, P154; VALADKA AB, 1994, UNPUB J NEUROTRAUMA; VANEZIS P, 1987, FORENSIC SCI INT, V35, P1, DOI 10.1016/0379-0738(87)90018-1; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	37	172	176	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	1994	11	2					173	186		10.1089/neu.1994.11.173			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	NR684	WOS:A1994NR68400004	7523685				2021-06-18	
J	Blennow, K; Brody, DL; Kochanek, PM; Levin, H; McKee, A; Ribbers, GM; Yaffe, K; Zetterberg, H				Blennow, Kaj; Brody, David L.; Kochanek, Patrick M.; Levin, Harvey; McKee, Ann; Ribbers, Gerard M.; Yaffe, Kristine; Zetterberg, Henrik			Traumatic brain injuries	NATURE REVIEWS DISEASE PRIMERS			English	Article							SPECTRIN BREAKDOWN PRODUCTS; AMYLOID PRECURSOR PROTEIN; NEURON-SPECIFIC ENOLASE; DIFFUSE AXONAL INJURY; QUALITY-OF-LIFE; INTRAAXONAL NEUROFILAMENT COMPACTION; FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; ALPHA-II-SPECTRIN; CEREBROSPINAL-FLUID	Traumatic brain injuries (TBIs) are clinically grouped by severity: mild, moderate and severe. Mild TBI (the least severe form) is synonymous with concussion and is typically caused by blunt non-penetrating head trauma. The trauma causes stretching and tearing of axons, which leads to diffuse axonal injury - the best-studied pathogenetic mechanism of this disorder. However, mild TBI is defined on clinical grounds and no well-validated imaging or fluid biomarkers to determine the presence of neuronal damage in patients with mild TBI is available. Most patients with mild TBI will recover quickly, but others report persistent symptoms, called post-concussive syndrome, the underlying pathophysiology of which is largely unknown. Repeated concussive and subconcussive head injuries have been linked to the neurodegenerative condition chronic traumatic encephalopathy (CTE), which has been reported post-mortem in contact sports athletes and soldiers exposed to blasts. Insights from severe injuries and CTE plausibly shed light on the underlying cellular and molecular processes involved in mild TBI. MRI techniques and blood tests for axonal proteins to identify and grade axonal injury, in addition to PET for tau pathology, show promise as tools to explore CTE pathophysiology in longitudinal clinical studies, and might be developed into diagnostic tools for CTE. Given that CTE is attributed to repeated head trauma, prevention might be possible through rule changes by sports organizations and legislators.	[Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Sahlgrenska Acad, SE-43180 Molndal, Sweden; [Blennow, Kaj; Zetterberg, Henrik] Sahlgrens Univ Hosp, Clin Neurochem Lab, Gothenburg, Sweden; [Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Ctr Resuscitat Res, Pittsburgh, PA USA; [Levin, Harvey] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Levin, Harvey] Michael E DeBakey VA Med Ctr, Houston, TX USA; [McKee, Ann] VA Boston Healthcare Syst, Dept Vet Affairs, Boston, MA USA; [McKee, Ann] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [McKee, Ann] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [Ribbers, Gerard M.] Erasmus Univ, Med Ctr, Dept Rehabil Med, Rotterdam, Netherlands; [Ribbers, Gerard M.] Rijndam Rehabil Ctr, Rotterdam, Netherlands; [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Yaffe, Kristine] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA; [Zetterberg, Henrik] UCL, Inst Neurol, London, England	Blennow, K (corresponding author), Univ Gothenburg, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Sahlgrenska Acad, SE-43180 Molndal, Sweden.	kaj.blennow@neuro.gu.se	Ribbers, Gerard M/C-1454-2014; Ribbers, Gerard/N-3623-2019	Ribbers, Gerard M/0000-0002-6114-349X; 	US Department of DefenseUnited States Department of Defense [WH81XWH-14-2-0018]; US National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS086714-01]; US Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Affairs Biorepository [CSP 501]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1U01NS086659-01]; US National Institute of Ageing Boston University Alzheimer disease Disease Center [P30AG13846, 0572063345-5]; Department of DefenseUnited States Department of Defense [W81XWH-13-2-0064, WXWH-13-2-0095, VA I01 RX 002170]; National Operating Committee on Standards for Athletic Equipment; Concussion Legacy Foundation; Andlinger Foundation; World Wrestling Entertainment; National Football League	K.B. holds the Torsten Soderberg Professorship in Medicine at the Royal Swedish Academy of Sciences. P.M.K. is supported by the US Department of Defense (grant WH81XWH-14-2-0018). H.L. is supported by the US National Institute of Neurological Disorders and Stroke (grant R21 NS086714-01). A.M. is supported by the US Department of Veterans Affairs, the Veterans Affairs Biorepository (program CSP 501), the National Institute of Neurological Disorders and Stroke (grant 1U01NS086659-01), the US National Institute of Ageing Boston University Alzheimer disease Disease Center (grant P30AG13846; supplement 0572063345-5), the Department of Defense (W81XWH-13-2-0064, CENC award WXWH-13-2-0095 and VA I01 RX 002170) and the National Operating Committee on Standards for Athletic Equipment and the Concussion Legacy Foundation. This work was also supported by unrestricted gifts from the Andlinger Foundation, the World Wrestling Entertainment and the National Football League.	Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Andelic N, 2015, J NEUROL, V262, P523, DOI 10.1007/s00415-014-7595-1; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; ATHA J, 1985, BRIT MED J, V291, P1756, DOI 10.1136/bmj.291.6511.1756; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bennett RE, 2015, J NEUROSCI METH, V245, P25, DOI 10.1016/j.jneumeth.2015.02.005; Bennett RE, 2013, J NEUROPATH EXP NEUR, V72, P396, DOI 10.1097/NEN.0b013e31828e24ab; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Blennow K, 2011, ACTA NEUROL SCAND, V123, P245, DOI 10.1111/j.1600-0404.2010.01408.x; Blennow K, 2015, TRENDS PHARMACOL SCI, V36, P297, DOI 10.1016/j.tips.2015.03.002; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Blennow K, 2010, NAT REV NEUROL, V6, P131, DOI 10.1038/nrneurol.2010.4; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Brody David L, 2015, Handb Clin Neurol, V127, P267, DOI 10.1016/B978-0-444-52892-6.00017-9; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, NONF INJ DAT; Chauny JM, 2016, J EMERG MED, V51, P519, DOI 10.1016/j.jemermed.2016.05.045; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Clavaguera F, 2010, M S-MED SCI, V26, P121, DOI 10.1051/medsci/2010262121; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Critchley M, 1949, PUNCH DRUNK SYNDROME; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Davidson J, 2015, NEUROSCIENTIST, V21, P424, DOI 10.1177/1073858414543150; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; DiTommaso C, 2014, HEADACHE, V54, P511, DOI 10.1111/head.12254; Eisenmenger LB, 2016, SEMIN NUCL MED, V46, P57, DOI 10.1053/j.semnuclmed.2015.09.003; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gandy S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-37; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Grauwmeijer E, 2014, ARCH PHYS MED REHAB, V95, P1268, DOI 10.1016/j.apmr.2014.02.002; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HAIMOTO H, 1987, LAB INVEST, V57, P489; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hannon MJ, 2013, J CLIN ENDOCR METAB, V98, P3229, DOI 10.1210/jc.2013-1555; Hasan KM, 2014, J NEUROTRAUM, V31, P466, DOI [10.1089/NEU.2013.3085, 10.1089/neu.2013.3085]; Helmick KM, 2015, BRAIN IMAGING BEHAV, V9, P358, DOI 10.1007/s11682-015-9399-z; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huang YD, 2004, J MOL NEUROSCI, V23, P189, DOI 10.1385/JMN:23:3:189; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Irimia A, 2015, NEUROPSYCH DIS TREAT, V11, DOI 10.2147/NDT.S79174; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kelly DF, 2014, J NEUROTRAUM, V31, P1161, DOI 10.1089/neu.2013.3212; Kim J, 2014, MOL CELLS, V37, P767, DOI 10.14348/molcells.2014.0248; King AI, 2000, ANNU REV BIOMED ENG, V2, P55, DOI 10.1146/annurev.bioeng.2.1.55; Klose M, 2015, J CLIN MED, V4, P1480, DOI 10.3390/jcm4071480; Klose M, 2014, J CLIN ENDOCR METAB, V99, P101, DOI 10.1210/jc.2013-2397; Klunk WE, 2011, NEUROBIOL AGING, V32, pS20, DOI 10.1016/j.neurobiolaging.2011.09.006; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Krahulik D, 2010, J NEUROSURG, V113, P581, DOI 10.3171/2009.10.JNS09930; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar RG, 2015, BRAIN BEHAV IMMUN, V45, P253, DOI 10.1016/j.bbi.2014.12.021; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Liao GP, 2015, PEDIATR CRIT CARE ME, V16, P245, DOI 10.1097/PCC.0000000000000324; Ljungqvist J., 2016, J NEUROTRAUMA; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Magnoni S, 2015, BRAIN, V138, P2263, DOI 10.1093/brain/awv152; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Marklund N, 2014, J NEUROTRAUM, V31, P42, DOI 10.1089/neu.2013.2964; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Maudsley AA, 2015, J NEUROTRAUM, V32, P1056, DOI 10.1089/neu.2014.3505; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mez J, 2016, JAMA NEUROL, V73, P353, DOI 10.1001/jamaneurol.2015.3998; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Montenigro P. H., 2016, J NEUROTRAUMA; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Neselius S, 2015, KNEE SURG SPORT TR A, V23, P2536, DOI 10.1007/s00167-014-3066-6; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Okamura N, 2016, AGEING RES REV, V30, P107, DOI 10.1016/j.arr.2015.12.010; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Oliver JM, 2016, J NEUROTRAUM, V33, P1784, DOI 10.1089/neu.2015.4295; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Olsson B, 2011, PROG NEUROBIOL, V95, P520, DOI 10.1016/j.pneurobio.2011.04.006; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Presson N, 2015, BRAIN IMAGING BEHAV, V9, P484, DOI 10.1007/s11682-015-9386-4; Raby CA, 1998, J NEUROCHEM, V71, P2505; Ramont L, 2005, CLIN CHEM LAB MED, V43, P1215, DOI 10.1515/CCLM.2005.210; Randall J, 2013, RESUSCITATION, V84, P351, DOI 10.1016/j.resuscitation.2012.07.027; Reams N, 2016, JAMA NEUROL, V73, P743, DOI 10.1001/jamaneurol.2015.5015; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Ryu J, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0153-3; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Scholl M, 2014, PET CLIN, V9, P371, DOI 10.1016/j.cpet.2014.07.005; Schwetye KE, 2010, NEUROBIOL DIS, V40, P555, DOI 10.1016/j.nbd.2010.06.018; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sharp David J, 2015, Pract Neurol, V15, P172, DOI 10.1136/practneurol-2015-001087; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Smith C, 2013, NEUROPATH APPL NEURO, V39, P35, DOI 10.1111/nan.12006; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2015, J CLIN MED, V4, P847, DOI 10.3390/jcm4050847; Tanriverdi F, 2015, NEUROPSYCH DIS TREAT, V11, P1835, DOI 10.2147/NDT.S65814; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Theadom A, 2016, BRIT J GEN PRACT, V66, pE16, DOI 10.3399/bjgp16X683161; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Titus DJ, 2015, EXP NEUROL, V263, P254, DOI 10.1016/j.expneurol.2014.10.020; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Unden L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0533-y; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van Huijzen, 2008, HUMAN CENTRAL NERVOU; Verghese PB, 2011, LANCET NEUROL, V10, P241, DOI 10.1016/S1474-4422(10)70325-2; Villemagne VL, 2015, LANCET NEUROL, V14, P114, DOI 10.1016/S1474-4422(14)70252-2; Walcott BP, 2012, NEUROTHERAPEUTICS, V9, P65, DOI 10.1007/s13311-011-0087-4; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Wang XJ, 2014, NMR BIOMED, V27, P843, DOI 10.1002/nbm.3129; Weiner MW, 2015, ALZHEIMERS DEMENT, V11, P865, DOI 10.1016/j.jalz.2015.04.005; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; West TA, 2014, J NEUROTRAUM, V31, P159, DOI 10.1089/neu.2013.3031; Whiteneck GG, 2016, J HEAD TRAUMA REHAB, V31, pE43, DOI 10.1097/HTR.0000000000000141; Wielenga-Boiten JE, 2015, J HEAD TRAUMA REHAB, V30, P424, DOI 10.1097/HTR.0000000000000128; Wilkinson Charles W, 2012, Front Neurol, V3, P11, DOI 10.3389/fneur.2012.00011; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Willemse-Van Son AHP, 2009, J REHABIL MED, V41, P521, DOI 10.2340/16501977-0377; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Young LA, 2015, SEMIN NEUROL, V35, P5, DOI 10.1055/s-0035-1544242; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zeng S, 2014, GENET TEST MOL BIOMA, V18, P202, DOI 10.1089/gtmb.2013.0421; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt163; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	221	171	177	2	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2056-676X			NAT REV DIS PRIMERS	Nat. Rev. Dis. Primers	NOV 17	2016	2								16084	10.1038/nrdp.2016.84			19	Medicine, General & Internal	General & Internal Medicine	EQ2AE	WOS:000397869900001	27853132		Y	N	2021-06-18	
J	McKee, AC; Robinson, ME				McKee, Ann C.; Robinson, Meghan E.			Military-related traumatic brain injury and neurodegeneration	ALZHEIMERS & DEMENTIA			English	Article						Chronic traumatic encephalopathy; Veterans; Neurodegeneration; Traumatic brain injury; Tauopathy; TDP-43; Alzheimer's disease	POSTTRAUMATIC-STRESS-DISORDER; FOOTBALL-LEAGUE PLAYER; HEAD-INJURY; ALZHEIMERS-DISEASE; WHITE-MATTER; CEREBRAL VASOSPASM; EXPLOSIVE BLAST; AXONAL INJURY; WAR VETERANS; ENCEPHALOPATHY	Mild traumatic brain injury (mTBI) includes concussion, subconcussion, and most exposures to explosive blast from improvised explosive devices. mTBI is the most common traumatic brain injury affecting military personnel; however, it is the most difficult to diagnose and the least well understood. It is also recognized that some mTBIs have persistent, and sometimes progressive, long-term debilitating effects. Increasing evidence suggests that a single traumatic brain injury can produce long-term gray and white matter atrophy, precipitate or accelerate age-related neurodegeneration, and increase the risk of developing Alzheimer's disease, Parkinson's disease, and motor neuron disease. In addition, repetitive mTBIs can provoke the development of a tauopathy, chronic traumatic encephalopathy. We found early changes of chronic traumatic encephalopathy in four young veterans of the Iraq and Afghanistan conflict who were exposed to explosive blast and in another young veteran who was repetitively concussed. Four of the five veterans with early-stage chronic traumatic encephalopathy were also diagnosed with posttraumatic stress disorder. Advanced chronic traumatic encephalopathy has been found in veterans who experienced repetitive neurotrauma while in service and in others who were accomplished athletes. Clinically, chronic traumatic encephalopathy is associated with behavioral changes, executive dysfunction, memory loss, and cognitive impairments that begin insidiously and progress slowly over decades. Pathologically, chronic traumatic encephalopathy produces atrophy of the frontal and temporal lobes, thalamus, and hypothalamus; septal abnormalities; and abnormal deposits of hyperphosphorylated tau as neurofibrillary tangles and disordered neurites throughout the brain. The incidence and prevalence of chronic traumatic encephalopathy and the genetic risk factors critical to its development are currently unknown. Chronic traumatic encephalopathy has clinical and pathological features that overlap with postconcussion syndrome and posttraumatic stress disorder, suggesting that the three disorders might share some biological underpinnings. (C) 2014 Published by Elsevier Inc. on behalf of The Alzheimer's Association.	[McKee, Ann C.; Robinson, Meghan E.] VA Boston Healthcare Syst, Boston, MA 02114 USA; [McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [McKee, Ann C.] Boston Univ, Sch Med, Alzheimer Dis Ctr, Boston, MA 02118 USA	McKee, AC (corresponding author), VA Boston Healthcare Syst, Boston, MA 02114 USA.	amckee@bu.edu	Meijer, Anna/K-5118-2016		Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Affairs Biorepository [CSP 501]; Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [UO1NS086659-01]; National Institute of Aging Boston University Alzheimer's Disease Center [P30AG13846, 0572063345-5]; Sports Legacy Institute; National Operating Committee on Standards for Athletic Equipment; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000991] Funding Source: NIH RePORTER	The authors gratefully acknowledge the use of resources and facilities at the Boston VA Healthcare System (Boston, MA) and Edith Nourse Rogers Memorial Veterans Hospital (Bedford, MA), as well as all of the individuals whose participation and contributions made this work possible. This work was supported by the Department of Veterans Affairs; Veterans Affairs Biorepository (CSP 501); the Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B6796-C); the National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering UO1NS086659-01), National Institute of Aging Boston University Alzheimer's Disease Center [P30AG13846; supplement 0572063345-5]; the Sports Legacy Institute; and the National Operating Committee on Standards for Athletic Equipment. This work was also supported by unrestricted gifts from the National Football League, the Andlinger Foundation, and the WWE.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Critchley M, 1949, PUNCH DRUNK SYNDROME; Defense and Veterans Brain Injury Center, SPORTS CONC VS MIL C; Duckworth Josh L, 2013, Pathophysiology, V20, P23, DOI 10.1016/j.pathophys.2012.03.001; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; ERB DE, 1991, EXP BRAIN RES, V83, P253; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Knudsen SK, 2003, NEUROSCI RES, V46, P377, DOI 10.1016/S0168-0102(03)00101-9; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Mott FW, 1916, LANCET, V1, P441; Mott FW, 1916, LANCET, V1, P331; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Omalu BI, 2006, NEUROSURGERY, V59, P1086; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Schmidt S, 2010, J NEUROL SCI, V291, P22, DOI 10.1016/j.jns.2010.01.011; Schofield PW, 1997, NEUROLOGY, V49, P30, DOI 10.1212/WNL.49.1.30; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Strickland D, 1996, ACTA NEUROL SCAND, V94, P45, DOI 10.1111/j.1600-0404.1996.tb00038.x; Taber KH, 2014, J HEAD TRAUMA REHABI; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Winterstein CE, 1937, LANCET, V230, P719; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006	75	171	172	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	JUN	2014	10	3		1			S242	S253		10.1016/j.jalz.2014.04.003			12	Clinical Neurology	Neurosciences & Neurology	CP8GM	WOS:000360130700018	24924675	Green Accepted, Other Gold			2021-06-18	
J	Tran, HT; LaFerla, FM; Holtzman, DM; Brody, DL				Tran, Hien T.; LaFerla, Frank M.; Holtzman, David M.; Brody, David L.			Controlled Cortical Impact Traumatic Brain Injury in 3xTg-AD Mice Causes Acute Intra-Axonal Amyloid-beta Accumulation and Independently Accelerates the Development of Tau Abnormalities	JOURNAL OF NEUROSCIENCE			English	Article							DIFFUSE AXONAL INJURY; TRANSGENIC MOUSE MODEL; LONG-TERM ACCUMULATION; REPETITIVE HEAD-INJURY; PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; A-BETA; NEUROFILAMENT COMPACTION; NEUROFIBRILLARY TANGLES; MONOCLONAL-ANTIBODIES	Alzheimer's disease (AD) is a neurodegenerative disorder characterized pathologically by progressive neuronal loss, extracellular plaques containing the amyloid-beta (A beta) peptides, and neurofibrillary tangles composed of hyperphosphorylated tau proteins. A beta is thought to act upstream of tau, affecting its phosphorylation and therefore aggregation state. One of the major risk factors for AD is traumatic brain injury (TBI). Acute intra-axonal A beta and diffuse extracellular plaques occur in similar to 30% of human subjects after severe TBI. Intra-axonal accumulations of tau but not tangle-like pathologies have also been found in these patients. Whether and how these acute accumulations contribute to subsequent AD development is not known, and the interaction between A beta and tau in the setting of TBI has not been investigated. Here, we report that controlled cortical impact TBI in 3xTg-AD mice resulted in intra-axonal A beta accumulations and increased phospho-tau immunoreactivity at 24 h and up to 7 d after TBI. Given these findings, we investigated the relationship between A beta and tau pathologies after trauma in this model by systemic treatment of Compound E to inhibit gamma-secretase activity, a proteolytic process required for A beta production. Compound E treatment successfully blocked posttraumatic A beta accumulation in these injured mice at both time points. However, tau pathology was not affected. Our data support a causal role for TBI in acceleration of AD-related pathologies and suggest that TBI may independently affect A beta and tau abnormalities. Future studies will be required to assess the behavioral and long-term neurodegenerative consequences of these pathologies.	[Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Holtzman, David M.] Washington Univ, Dept Dev Biol & Anat, St Louis, MO 63110 USA; [Holtzman, David M.; Brody, David L.] Washington Univ, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA; [LaFerla, Frank M.] Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA	Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,Campus Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS065069, K08 NS049237, AG13956, P30 NS057105]; Burroughs Wellcome Career Award in the Biomedical SciencesBurroughs Wellcome Fund; Thrasher Research Fund; Cure Alzheimer's Fund; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS057105, R01NS065069, K08NS049237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R37AG013956, R01AG013956, R01AG021982] Funding Source: NIH RePORTER	This work was supported by NIH Grants R01 NS065069 (D.L.B.), K08 NS049237 (D.L.B.), and AG13956 (D.M.H.); a Burroughs Wellcome Career Award in the Biomedical Sciences (D.L.B.); the Thrasher Research Fund (D.L.B.); the Cure Alzheimer's Fund (D.M.H.); and NIH Neuroscience Blueprint Core Grant P30 NS057105 to Washington University. We thank Drs. J. R. Cirrito, J. S. Kim, and C. L. Mac Donald and T. J. Esparza for methodological assistance; R. H. Baloh, R. Bennett, J. R. Cirrito, T. J. Esparza, C. L. Mac Donald, and T. Malone for critical review of this manuscript; and Peter Davies and Eli Lilly and Co. for monoclonal antibodies.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; ADAMS JH, 1984, LANCET, V2, P1420; ADAMS JH, 1982, INJURY, V13, P444, DOI 10.1016/0020-1383(82)90105-X; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Baki L, 2004, EMBO J, V23, P2586, DOI 10.1038/sj.emboj.7600251; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Cirrito JR, 2003, J NEUROSCI, V23, P8844; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; CORSELLIS JAN, 1959, J MENT SCI, V105, P714; Czirr E, 2007, J BIOL CHEM, V282, P24504, DOI 10.1074/jbc.M700618200; Dewachter I, 2008, NEUROBIOL AGING, V29, P639, DOI 10.1016/j.neurobiolaging.2006.11.019; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Grimwood S, 2005, NEUROPHARMACOLOGY, V48, P1002, DOI 10.1016/j.neuropharm.2005.01.016; Hurtado DE, 2010, AM J PATHOL, V177, P1977, DOI 10.2353/ajpath.2010.100346; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kang JE, 2007, P NATL ACAD SCI USA, V104, P10673, DOI 10.1073/pnas.0700148104; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Mastrangelo MA, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-81; Mattson MP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3114pe10; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MERCKEN M, 1992, ACTA NEUROPATHOL, V84, P265, DOI 10.1007/BF00227819; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mouton PR, 2002, J MICROSC-OXFORD, V206, P54, DOI 10.1046/j.1365-2818.2002.01006.x; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003; Oddo S, 2006, AM J PATHOL, V168, P184, DOI 10.2353/ajpath.2006.050593; Olson R E, 2001, Curr Opin Drug Discov Devel, V4, P390; Perez M, 2005, NEUROSCIENCE, V130, P339, DOI 10.1016/j.neuroscience.2004.09.029; Planel E, 2004, J NEUROSCI, V24, P2401, DOI 10.1523/JNEUROSCI.5561-03.2004; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Seiffert D, 2000, MOL BRAIN RES, V84, P115, DOI 10.1016/S0169-328X(00)00230-8; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003; Thinakaran G, 2004, PHARMACOL RES, V50, P411, DOI 10.1016/j.phrs.2003.12.026; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Witter M. P., 2004, RAT NERVOUS SYSTEM, P635, DOI [10.1016/B978-012547638-6/50022-5, DOI 10.1016/B978-012547638-6/50022-5]; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yan P, 2009, J NEUROSCI, V29, P10706, DOI 10.1523/JNEUROSCI.2637-09.2009; Yang T, 2008, MOL BRAIN, V1, DOI 10.1186/1756-6606-1-15; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	81	171	177	0	17	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 29	2011	31	26					9513	9525		10.1523/JNEUROSCI.0858-11.2011			13	Neurosciences	Neurosciences & Neurology	784WP	WOS:000292189500009	21715616	Green Accepted, Bronze, Green Published			2021-06-18	
J	Readnower, RD; Chavko, M; Adeeb, S; Conroy, MD; Pauly, JR; McCarron, RM; Sullivan, PG				Readnower, Ryan D.; Chavko, Mikulas; Adeeb, Saleena; Conroy, Michael D.; Pauly, James R.; McCarron, Richard M.; Sullivan, Patrick G.			Increase in Blood-Brain Barrier Permeability, Oxidative Stress, and Activated Microglia in a Rat Model of Blast-Induced Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; oxidative stress; inflammation; blood-brain barrier; PK11195	BENZODIAZEPINE BINDING-SITES; PERIPHERAL BENZODIAZEPINE; EXERCISE PERFORMANCE; INDUCED NEUROTRAUMA; NEURONAL DEATH; LUNG INJURY; MOUSE MODEL; HEAD-INJURY; TIME-COURSE; EXPOSURE	Traumatic brain injury (TBI) as a consequence of exposure to blast is increasingly prevalent in military populations, with the underlying pathophysiological mechanisms mostly unknown. In the present study, we utilized an air-driven shock tube to investigate the effects of blast exposure (120 kPa) on rat brains. Immediately following exposure to blast, neurological function was reduced. BBB permeability was measured using IgG antibody and evaluating its immunoreactivity in the brain. At 3 and 24 hr postexposure, there was a transient significant increase in IgG staining in the cortex. At 3 days postexposure, IgG immunoreactivity returned to control levels. Quantitative immunostaining was employed to determine the temporal course of brain oxidative stress following exposure to blast. Levels of 4-hydroxynonenal (4-HNE) and 3-nitrotyrosine (3-NT) were significantly increased at 3 hr postexposure and returned to control levels at 24 hr postexposure. The response of microglia to blast exposure was determined by autoradiographic localization of H-3-PK11195 binding. At 5 days postexposure, increased binding was observed in the contralateral and ipsilateral dentate gyrus. These regions also displayed increased binding at 10 days postexposure; in addition to these regions there was increased binding in the contralateral ventral hippocampus and substantia nigra at this time point. By using antibodies against CD11b/c, microglia morphology characteristic of activated microglia was observed in the hippocampus and substantia nigra of animals exposed to blast. These results indicate that BBB breakdown, oxidative stress, and microglia activation likely play a role in the neuropathology associated with TBI as a result of blast exposure. (C) 2010 Wiley-Liss, Inc.	[Readnower, Ryan D.; Conroy, Michael D.; Pauly, James R.; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA; [Chavko, Mikulas; Adeeb, Saleena; McCarron, Richard M.] USN, Med Res Ctr, Silver Spring, MD USA	Sullivan, PG (corresponding author), 741 S Limestone,BBSRB 475, Lexington, KY 40536 USA.	patsull@email.uky.edu			Office of Naval Research Work UnitOffice of Naval Research [601153N.04508.5180.A0805]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32 DA022738]; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	Contract grant sponsor: Office of Naval Research Work Unit 601153N.04508.5180.A0805; Contract grant sponsor: National Institutes of Health; Contract grant number: 5T32 DA022738.	Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Banati RB, 1997, J NEUROCYTOL, V26, P77, DOI 10.1023/A:1018567510105; Bauman RA, 1997, TOXICOLOGY, V121, P65, DOI 10.1016/S0300-483X(97)03656-1; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; BENAVIDES J, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P39; BENAVIDES J, 2001, CURR PROTOC NEUROSCI, pCH7; Bisler S, 2002, J CHEM NEUROANAT, V23, P187, DOI 10.1016/S0891-0618(01)00155-7; BOGO V, 1971, EFFECTS AIRBLAST DIS, V2659, P1; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; BUTLER TR, 2009, NEUROSCIENC IN PRESS; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Denny-Brown D, 1940, J PHYSIOL-LONDON, V99, P153, DOI 10.1113/jphysiol.1940.sp003887; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUBOIS A, 1988, BRAIN RES, V445, P77, DOI 10.1016/0006-8993(88)91076-1; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; ENTERS EK, 1992, BRAIN RES, V576, P271; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; GIULIAN D, 1995, J NEUROSCI, V15, P7712; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; Gorbunov NV, 2004, CRIT CARE MED, V32, P1028, DOI 10.1097/01.CCM.0000120051.79520.B6; GOTTI B, 1990, BRAIN RES, V522, P290, DOI 10.1016/0006-8993(90)91473-T; GROOM GN, 1995, J NUCL MED, V36, P2207; Grossman R, 2003, NEUROIMAGE, V20, P1971, DOI 10.1016/j.neuroimage.2003.06.003; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hawes JJ, 2005, J NEUROCHEM, V93, P1168, DOI 10.1111/j.1471-4159.2005.03105.x; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HSATINGS TG, 2009, J BIOENERG IN PRESS; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mundie TG, 2000, J TRAUMA, V48, P1115, DOI 10.1097/00005373-200006000-00019; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; RIESKE E, 1989, BRAIN RES, V492, P1, DOI 10.1016/0006-8993(89)90883-4; SALJO A, 2009, J NEUROTRAU IN PRESS; Scarf AM, 2009, J MED CHEM, V52, P581, DOI 10.1021/jm8011678; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029	61	171	174	1	29	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC	2010	88	16					3530	3539		10.1002/jnr.22510			10	Neurosciences	Neurosciences & Neurology	679WJ	WOS:000284191200011	20882564	Green Accepted			2021-06-18	
J	Cabraja, M; Klein, M; Lehmann, TN				Cabraja, Mario; Klein, Martin; Lehmann, Thomas-Nikolas			Long-term results following titanium cranioplasty of large skull defects	NEUROSURGICAL FOCUS			English	Article						craniectomy; decompressive surgery; calvarial reconstruction	ENGINEERED BONE-GRAFTS; TRAUMATIC BRAIN-INJURY; COMPUTER-AIDED-DESIGN; HYDROXYAPATITE CEMENT; DECOMPRESSIVE CRANIECTOMY; CRANIOFACIAL SURGERY; CALVARIAL DEFECTS; TECHNICAL NOTE; CASE SERIES; BLOOD-FLOW	Object. Decompressive craniectomy is an established procedure to lower intracranial pressure. Therefore, cranioplasty remains a necessity in neurosurgery as well. If the patient's own bone flap is not available, the surgeon can choose between various alloplast grafts. A review of the literature proves that 4-13.8% of polymethylmethacrylate plates and 2.6-10% of hydroxyapatite-based implants require replacement. In this retrospective study of large skull defects, the authors compared computer-assisted design/computer-assisted modeled (CAD/CAM) titanium implants for cranioplasty with other frequently used materials described in literature. Methods. Twenty-six patients underwent cranioplasty with CAD/CAM titanium implants (mean diameter 112 mm). With the aid of visual analog scales, the patients' pain and cosmesis were evaluated 6-12 years (mean 8.1 years) after insertion of the implants. Results. None of the implants had to be removed. Of all patients, 68% declared their outcomes as excellent, 24% as good, 0.8% as fair, and 0% as poor. There was no resulting pain in 84% of the patients, and 88% were satisfied with the cosmetic result, noting > 75 mm on the visual analog scale of cosmesis. All patients would have chosen cranioplasty again, stating an improvement in their quality of life by the calvarial reconstruction. Nevertheless, follow-up images obtained in 4 patients undergoing removal of meningiomas was only suboptimal. Conclusions. With the aid of CAD technology, all currently used alloplastic materials are suited even for large skull defect cranioplasty. Analysis of the authors' data and the literature shows that cranioplasty with CAD/CAM titanium implants provides the lowest rate of complications, reasonable costs, and acceptable postoperative imaging. Polymethylmethacrylate is suited for primary cranioplasty or for long-term follow-up imaging of tumors. Titanium implants seem to be the material of choice for secondary cranioplasty of large skull defects resulting from decompressive craniectomy after trauma or infarction. Expensive HA-based ceramics show no obvious advantage over titanium or PMMA. (DOI: 10.3171/2009.3.FOCUS091)	[Cabraja, Mario; Lehmann, Thomas-Nikolas] Charite Univ Med Berlin, Dept Neurosurg, D-13353 Berlin, Germany; [Klein, Martin] Charite Univ Med Berlin, Dept Maxillofacial Surg Clin Navigat & Robot, D-13353 Berlin, Germany	Cabraja, M (corresponding author), Charite Univ Med Berlin, Dept Neurosurg, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	mario.cabraja@charite.de					Auguste KI, 2006, J NEUROSURG, V105, P640, DOI 10.3171/jns.2006.105.4.640; BLAKE GB, 1990, BRIT J PLAST SURG, V43, P528, DOI 10.1016/0007-1226(90)90115-G; BRANTIGAN JW, 1993, SPINE, V18, P2106, DOI 10.1097/00007632-199310001-00030; Bruce JN, 2003, J NEUROSURG, V98, P1203, DOI 10.3171/jns.2003.98.6.1203; CHANDLER CL, 1994, BRIT J NEUROSURG, V8, P409, DOI 10.3109/02688699408995107; Costantino PD, 2000, OTOLARYNG HEAD NECK, V123, P409, DOI 10.1067/mhn.2000.107679; D'Urso PS, 1998, BRIT J PLAST SURG, V51, P522, DOI 10.1016/S0007-1226(98)90026-1; Dean D, 2003, J CRANIOFAC SURG, V14, P819, DOI 10.1097/00001665-200311000-00002; Durham SR, 2003, NEUROSURGERY, V52, P842, DOI 10.1227/01.NEU.0000054220.01290.8E; Eppley BL, 2003, J CRANIOFAC SURG, V14, P209, DOI 10.1097/00001665-200303000-00014; Eufinger H, 1998, PLAST RECONSTR SURG, V102, P300, DOI 10.1097/00006534-199808000-00002; Feinberg SE, 2001, CELLS TISSUES ORGANS, V169, P309, DOI 10.1159/000047896; Friedman C D, 2000, Arch Facial Plast Surg, V2, P124, DOI 10.1001/archfaci.2.2.124; GLADSTONE HB, 1995, OTOLARYNG CLIN N AM, V28, P381; Gosain AK, 1999, J CRANIOFAC SURG, V10, P404, DOI 10.1097/00001665-199909000-00006; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Green D, 2002, BONE, V30, P810, DOI 10.1016/S8756-3282(02)00727-5; Hieu L C, 2002, Technol Health Care, V10, P413; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; Jho DH, 2007, J NEUROSURG, V107, P440, DOI 10.3171/JNS-07/08/0440; Joffe J, 1999, BRIT J NEUROSURG, V13, P576, DOI 10.1080/02688699943088; JOFFE JM, 1992, BRIT J NEUROSURG, V6, P343, DOI 10.3109/02688699209023793; Kamyszek T, 2001, Mund Kiefer Gesichtschir, V5, P233, DOI 10.1007/s100060100317; Kriegel RJ, 2007, ZBL NEUROCHIR, V68, P182, DOI 10.1055/s-2007-985857; MAAS CS, 1990, ARCH OTOLARYNGOL, V116, P551; Marchac D, 2008, J PLAST RECONSTR AES, V61, P744, DOI 10.1016/j.bjps.2007.10.055; Matic D, 2002, PLAST RECONSTR SURG, V110, P1, DOI 10.1097/00006534-200207000-00001; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Oreffo ROC, 1999, BONE, V25, p5S, DOI 10.1016/S8756-3282(99)00124-6; Park HK, 2001, NEUROL RES, V23, P267, DOI 10.1179/016164101101198424; PARK J, 2008, J NEUROSURG; Poetker DM, 2004, OTOL NEUROTOL, V25, P604, DOI 10.1097/00129492-200407000-00031; Pomrink GJ, 2003, BIOMATERIALS, V24, P1023, DOI 10.1016/S0142-9612(02)00443-X; Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516; Rohner D, 2002, Mund Kiefer Gesichtschir, V6, P162; Sanus GZ, 2008, J CRANIOFAC SURG, V19, P88, DOI 10.1097/scs.0b013e31815c93fe; Saringer W, 2002, ACTA NEUROCHIR, V144, P1193, DOI 10.1007/s00701-002-0995-5; Schantz JT, 2003, TISSUE ENG, V9, pS113, DOI 10.1089/10763270360697021; Schantz JT, 2003, TISSUE ENG, V9, pS127, DOI 10.1089/10763270360697030; Scolozzi P, 2007, J CRANIOFAC SURG, V18, P224, DOI 10.1097/01.scs.0000249359.56417.7e; VANGOOL AV, 1985, J MAXILLOFAC SURG, V13, P2, DOI 10.1016/S0301-0503(85)80005-9; Verheggen R, 2001, ACTA NEUROCHIR, V143, P919, DOI 10.1007/s007010170022; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Yoshida K, 1996, J NEUROL NEUROSUR PS, V61, P166, DOI 10.1136/jnnp.61.2.166	46	171	180	1	27	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	JUN	2009	26	6							E10	10.3171/2009.3.FOCUS091			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	451WK	WOS:000266501400010	19485714	Bronze			2021-06-18	
J	Yeates, KO; Taylor, HG; Rusin, J; Bangert, B; Dietrich, A; Nuss, K; Wright, M; Nagin, DS; Jones, BL				Yeates, Keith Owen; Taylor, H. Gerry; Rusin, Jerome; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn; Wright, Martha; Nagin, Daniel S.; Jones, Bobby L.			Longitudinal Trajectories of Postconcussive Symptoms in Children With Mild Traumatic Brain Injuries and Their Relationship to Acute Clinical Status	PEDIATRICS			English	Article						mild traumatic brain injury; postconcussive symptoms; clinical predictors	POST-CONCUSSION SYNDROME; MINOR HEAD-INJURIES; TOMOGRAPHY; SEVERITY; SEQUELAE	OBJECTIVE. We examined whether mild traumatic brain injuries in children and adolescents, especially when associated with acute clinical features reflecting more severe injury, result in different postinjury trajectories of postconcussive symptoms compared with mild orthopedic injuries. PARTICIPANTS AND METHODS. Participants in this prospective and longitudinal cohort study were 8- to 15-year-old children, 186 with mild traumatic brain injuries and 99 with mild orthopedic injuries, who were recruited from consecutive admissions to emergency departments in 2 large children's hospitals. Parents rated current postconcussive symptoms within 3 weeks of injury and at 1, 3, and 12 months after injury. At the initial assessment, parents also provided retrospective ratings of preinjury symptoms, and children with mild traumatic brain injuries received MRI of the brain. Clinical features examined as predictors of postconcussive symptoms included loss of consciousness, Glasgow Coma Scale score below 15, other injuries, acute symptoms of concussion, and intracranial abnormalities on the MRI. RESULTS. Finite mixture modeling identified 4 longitudinal trajectories of postconcussive symptoms (ie, no postconcussive symptoms, moderate persistent postconcussive symptoms, high acute/resolved postconcussive symptoms, high acute/persistent postconcussive symptoms). The mild traumatic brain injuries and orthopedic injuries groups demonstrated a different distribution of trajectories. Children with mild traumatic brain injuries were more likely than those with orthopedic injuries to demonstrate high acute/resolved and high acute/persistent trajectories relative to the no postconcussive symptoms group. The 2 trajectories with high acute levels of postconcussive symptoms were especially likely among children with mild traumatic brain injuries whose acute clinical presentation reflected more severe injury. CONCLUSIONS. Mild traumatic brain injuries, particularly those that are more severe, are more likely than orthopedic injuries to result in transient or persistent increases in postconcussive symptoms in the first year after injury. Additional research is needed to elucidate the range of factors, both injury related and non-injury related, that place some children with mild traumatic brain injuries at risk for postconcussive symptoms. Pediatrics 2009; 123:735-743	[Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, Columbus, OH 43220 USA; [Yeates, Keith Owen; Dietrich, Ann; Nuss, Kathryn] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry; Wright, Martha] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Wright, Martha] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43220 USA; [Dietrich, Ann; Nuss, Kathryn] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43220 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Nagin, Daniel S.; Jones, Bobby L.] Carnegie Mellon Univ, Heinz Coll, Pittsburgh, PA 15213 USA	Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, 700 Childrens Dr, Columbus, OH 43220 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892; Nuss, Kathryn/0000-0003-2185-7364	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD44099, HD39834]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039834, K02HD044099] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health grants HD44099 and HD39834 (to Dr Yeates).	Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Dunning J, 2004, ARCH DIS CHILD, V89, P653, DOI 10.1136/adc.2003.027722; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; Falk AC, 2006, ACTA PAEDIATR, V95, P1533, DOI 10.1080/08035250600731957; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Giza CC, 2001, J ATHL TRAINING, V36, P228; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; KRAUS JF, 2000, TRAUMATIC HEAD INJUR, P22; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Nacajauskaite O, 2006, BRAIN DEV-JPN, V28, P507, DOI 10.1016/j.braindev.2006.02.010; Nagin D., 2005, GROUP BASED MODELING; Nagin DS, 1999, PSYCHOL METHODS, V4, P139, DOI 10.1037/1082-989X.4.2.139; POLISSAR NL, 1994, BRAIN INJURY, V8, P249, DOI 10.3109/02699059409150977; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; STEVENS G, 1985, SOC SCI RES, V14, P142, DOI 10.1016/0049-089X(85)90008-0; TEASDALE G, 1974, LANCET, V2, P81; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	47	171	171	0	20	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAR	2009	123	3					735	743		10.1542/peds.2008-1056			9	Pediatrics	Pediatrics	413XH	WOS:000263825500001	19254996	Green Accepted			2021-06-18	
J	Lipton, ML; Gellella, E; Lo, C; Gold, T; Ardekani, BA; Shifteh, K; Bello, JA; Branch, CA				Lipton, Michael L.; Gellella, Erik; Lo, Calvin; Gold, Tamar; Ardekani, Babak A.; Shifteh, Keivan; Bello, Jacqueline A.; Branch, Craig A.			Multifocal White Matter Ultrastructural Abnormalities in Mild Traumatic Brain Injury with Cognitive Disability: A Voxel-Wise Analysis of Diffusion Tensor Imaging	JOURNAL OF NEUROTRAUMA			English	Article						cognitive impairment; diffusion tensor imaging; magnetic resonance imaging; mild traumatic brain injury	BLUNT-HEAD TRAUMA; AXONAL INJURY; WEIGHTED MR; REGISTRATION; ALGORITHMS; INTEGRITY	The purpose of the present study is to identify otherwise occult white matter abnormalities in patients suffering persistent cognitive impairment due to mild traumatic brain injury (TBI). The study had Institutional Review Board (IRB) approval, included informed consent and complied with the U. S. Health Insurance Portability and Accountability Act (HIPAA) of 1996. We retrospectively analyzed diffusion tensor MRI (DTI) of 17 patients (nine women, eight men; age range 26-70 years) who had cognitive impairment due to mild TBI that occurred 8 months to 3 years prior to imaging. Comparison was made to 10 healthy controls. Fractional anisotropy (FA) and mean diffusivity (MD) images derived from DTI (1.5 T; 25 directions; b=1000) were compared using whole brain histogram and voxel-wise analyses. Histograms of white matter FA show an overall shift toward lower FA in patients. Areas of significantly decreased FA (p<0.005) were found in the subject group in corpus callosum, subcortical white matter, and internal capsules bilaterally. Co-located elevation of mean diffusivity (MD) was found in the patients within each region. Similar, though less extensive, findings were demonstrated in each individual patient. Multiple foci of low white matter FA and high MD are present in cognitively impaired mild TBI patients, with a distribution that conforms to that of diffuse axonal injury. Evaluation of single subjects also reveals foci of low FA, suggesting that DTI may ultimately be useful for clinical evaluation of individual patients.	[Lipton, Michael L.] Montefiore Med Ctr, Dept Radiol, Bronx, NY 10467 USA; [Lipton, Michael L.; Gellella, Erik; Lo, Calvin; Gold, Tamar; Shifteh, Keivan; Bello, Jacqueline A.; Branch, Craig A.] Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10467 USA; [Lipton, Michael L.] Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Bronx, NY 10467 USA; [Branch, Craig A.] Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10467 USA; [Lipton, Michael L.; Ardekani, Babak A.; Branch, Craig A.] Nathan S Kline Inst Psychiat Res, Ctr Adv Brain Imaging, Orangeburg, NY 10962 USA	Lipton, ML (corresponding author), Montefiore Med Ctr, Dept Radiol, 111 E 210th St, Bronx, NY 10467 USA.	mlipton@aecom.yu.edu					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Ardekani BA, 2005, J NEUROSCI METH, V142, P67, DOI 10.1016/j.jneumeth.2004.07.014; Ardekani BA, 2001, MAGN RESON IMAGING, V19, P959, DOI 10.1016/S0730-725X(01)00418-0; ARDEKANI BA, 1995, J COMPUT ASSIST TOMO, V19, P615, DOI 10.1097/00004728-199507000-00022; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; CDC, 2003, REP C MILD TRAUM BRA; COBBS LE, 2006, AM J NEURORADIOL, V27, P879; GAMLOOA AM, 2006, NEUROREHABILITATION, V21, P327; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1994, RADIOLOGY, V191, P1; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lim KO, 2006, AM J PSYCHIAT, V163, P2008, DOI 10.1176/appi.ajp.163.11.2008; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; LO C, 2006, P AM SOC NEUR SAN DI; McArthur DL, 2004, BRAIN PATHOL, V14, P185, DOI 10.1111/j.1750-3639.2004.tb00052.x; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Nakahara M, 2001, ACTA RADIOL, V42, P365, DOI 10.1034/j.1600-0455.2001.420404.x; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Tisserand DJ, 2006, BRAIN COGNITION, V60, P216; Weight DG, 1998, PSYCHIAT CLIN N AM, V21, P609, DOI 10.1016/S0193-953X(05)70026-5; Wieshmann UC, 1999, LANCET, V353, P1242, DOI 10.1016/S0140-6736(99)00248-2	37	171	171	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2008	25	11					1335	1342		10.1089/neu.2008.0547			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	384BP	WOS:000261718900005	19061376				2021-06-18	
J	Lee, H; Wintermark, M; Gean, AD; Ghajar, J; Manley, GT; Mukherjee, P				Lee, Hana; Wintermark, Max; Gean, Alisa D.; Ghajar, Jamshid; Manley, Geoffrey T.; Mukherjee, Pratik			Focal Lesions in Acute Mild Traumatic Brain Injury and Neurocognitive Outcome: CT versus 3T MRI	JOURNAL OF NEUROTRAUMA			English	Article						computerized tomography; high-field magnetic resonance imaging; mild traumatic brain injury; neurocognitive outcome; traumatic axonal injury	DIFFUSE AXONAL INJURY; HEAD-INJURY; SEQUELAE	Mild traumatic brain injury (mTBI) is associated with long-term cognitive deficits. This study compared the detection rate of acute post-traumatic focal lesions on computed tomography (CT) and 3T (Tesla) magnetic resonance (MR) imaging with neurocognitive outcomes. Adults (n = 36; age range, 19-52 years) with a single episode of mTBI (Glasgow Coma Scale 13-15, as well as loss of consciousness and post-traumatic amnesia) were prospectively enrolled and had CT within 24 h of injury and 3T MR within 2 weeks of injury. The CT and MR scans were reviewed by two neuroradiologists who were blinded to clinical information. Twenty-eight of these mTBI subjects and 18 matched healthy volunteers also underwent serial neurocognitive testing. Of the 36 mTBI cases, intraparenchymal lesions were detected in 18 CT and 27 acute MR exams, consisting of hemorrhagic traumatic axonal injury (TAI) (eight CT, 17 MR), non-hemorrhagic TAI (zero CT, four MR), and cerebral contusions ( 13 CT, 21 MR). Mild TBI patients had significantly worse performance on working memory tasks than matched controls at the acute time point (< 2 weeks), and at 1 month and at 1 year post-injury; yet there was no significant correlation of imaging findings with working memory impairment. In conclusion, 3T MR detected parenchymal lesions in 75% of this mTBI cohort with loss of consciousness and post-traumatic amnesia, a much higher rate than CT. However, the CT and 3T MR imaging findings did not account for cognitive impairment, suggesting that newer imaging techniques such as diffusion tensor imaging are needed to provide biomarkers for neurocognitive and functional outcome in mTBI.	[Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; [Lee, Hana; Wintermark, Max; Gean, Alisa D.; Manley, Geoffrey T.; Mukherjee, Pratik] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Ghajar, Jamshid] Weill Cornell Med Coll, New York, NY USA; [Ghajar, Jamshid] Brain Trauma Fdn, New York, NY USA	Mukherjee, P (corresponding author), Univ Calif San Francisco, Dept Radiol, 505 Parnassus Ave,L-358, San Francisco, CA 94143 USA.	pratik@radiology.ucsf.edu	Mukherjee, Pratik/A-5446-2008	Wintermark, Max/0000-0002-6726-3951; Mukherjee, Pratik/0000-0001-7473-7409	James S. McDonnell Foundation; UCSF Academic Senate; UCSF Brain and Spinal Injury Center	This research was supported by a collaborative grant from the James S. McDonnell Foundation to the Brain Trauma Foundation for the Cognitive and Neurobiological Research Consortium (CNRC) in Traumatic Brain Injury, and by the UCSF Academic Senate and UCSF Brain and Spinal Injury Center.	ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Centers for Disease Control, 2001, TRAUM BRAIN INJ US R; Delis D, 2000, CALIFORNIA VERBAL LE; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; Tellier A, 1999, BRAIN INJURY, V13, P463; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	24	171	181	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2008	25	9					1049	1056		10.1089/neu.2008.0566			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	360JX	WOS:000260054900001	18707244				2021-06-18	
J	Bye, N; Habgood, MD; Callaway, JK; Malakooti, N; Potter, A; Kossmann, T; Morganti-Kossmann, MC				Bye, Nicole; Habgood, Mark D.; Callaway, Jennifer K.; Malakooti, Nakisa; Potter, Ann; Kossmann, Thomas; Morganti-Kossmann, M. Cristina			Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration	EXPERIMENTAL NEUROLOGY			English	Article						apoptosis; cytokines; inflammation; microglia; minocycline; traumatic brain injury	CLOSED-HEAD INJURY; INTERLEUKIN-1 RECEPTOR ANTAGONIST; FOCAL CEREBRAL-ISCHEMIA; PROINFLAMMATORY CYTOKINE EXPRESSION; IMPROVES FUNCTIONAL RECOVERY; CYTOCHROME-C RELEASE; SPINAL-CORD-INJURY; MOUSE MODEL; TNF-ALPHA; DEATH	Cerebral inflammation and apoptotic cell death are two processes implicated in the progressive tissue damage that occurs following traumatic brain injury (TBI), and strategies to inhibit one or both of these pathways are being investigated as potential therapies for TBI patients. The tetracycline derivative minocycline was therapeutically effective in various models of central nervous system injury and disease, via mechanisms involving suppression of inflammation and apoptosis. We therefore investigated the effect of minocycline in TBI using a closed head injury model. Following TBI, mice were treated with minocycline or vehicle, and the effect on neurological outcome, lesion volume, inflammation and apoptosis was evaluated for up to 7 days. Our results show that while minocycline decreases lesion volume and improves neurological outcome at I day post-trauma, this response is not maintained at 4 days. The early beneficial effect is likely not due to anti-apoptotic mechanisms, as the density of apoptotic cells is not affected at either time-point. However, protection by minocycline is associated with a selective anti-inflammatory response, in that microglial activation and interleukin-1 beta expression are reduced, while neutrophil infiltration and expression of multiple cytokines are not affected. These findings demonstrate that further studies on minocycline in TBI are necessary in order to consider it as a novel therapy for brain-injured patients. Crown Copyright (c) 2006 Published by Elsevier Inc. All rights reserved.	Monash Univ, Alfred Hosp Dept Med, Natl Trauma Res Inst, Clayton, Vic 3168, Australia; Monash Univ, Alfred Hosp Dept Med, Dept Trauma Surg, Clayton, Vic 3168, Australia; Monash Univ, Dept Med, Clayton, Vic 3168, Australia; Monash Univ, Dept Surg, Clayton, Vic 3168, Australia; Univ Melbourne, Dept Pharmacol, Parkville, Vic 3052, Australia	Morganti-Kossmann, MC (corresponding author), Monash Univ, Alfred Hosp Dept Med, Natl Trauma Res Inst, Clayton, Vic 3168, Australia.	cristina.morganti-kossmann@med.monash.edu.au	Malakooti, Nakisa/V-4775-2019	Malakooti, Nakisa/0000-0002-8638-8848; Morganti-Kossmann, Cristina/0000-0002-0807-2063			Arvin KL, 2002, ANN NEUROL, V52, P54, DOI 10.1002/ana.10242; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Boutin H, 2001, J NEUROSCI, V21, P5528; BOUTIN H, 2001, J NEUROSCI, V21, pA1; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Diguet E, 2004, EUR J NEUROSCI, V19, P3266, DOI 10.1111/j.0953-816X.2004.03372.x; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Fan LW, 2005, J NEUROSCI RES, V82, P71, DOI 10.1002/jnr.20623; Fox C, 2005, J CEREBR BLOOD F MET, V25, P1138, DOI 10.1038/sj.jcbfm.9600121; GARCIA JH, 1995, AM J PATHOL, V147, P1477; He Y, 2001, BRAIN RES, V909, P187, DOI 10.1016/S0006-8993(01)02681-6; Hua R, 2006, BRAIN RES, V1090, P172, DOI 10.1016/j.brainres.2006.03.072; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559; Lawrence CB, 1998, EUR J NEUROSCI, V10, P1188, DOI 10.1046/j.1460-9568.1998.00136.x; Ledeboer A, 2005, PAIN, V115, P71, DOI 10.1016/j.pain.2005.02.009; Lee SM, 2004, J NEUROCHEM, V91, P568, DOI 10.1111/j.1471-4159.2004.02780.x; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; LODDICK SA, 2002, IMMUN INFLAMM DIS, P90; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Morimoto N, 2005, BRAIN RES, V1044, P8, DOI 10.1016/j.brainres.2005.02.062; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rancan M, 2004, J CEREBR BLOOD F MET, V24, P1110, DOI 10.1097/01.WCB.0000133470.91843.72; Schallert T, 2000, PHARMACOLOGY OF CEREBRAL ISCHEMIA 2000, P329; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Smith DL, 2003, ANN NEUROL, V54, P186, DOI 10.1002/ana.10614; Sriram K, 2006, J NEUROCHEM, V96, P706, DOI 10.1111/j.1471-4159.2005.03566.x; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Szymanska A, 2006, EXP NEUROL, V197, P189, DOI 10.1016/j.expneurol.2005.09.011; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Wang CX, 2003, BRAIN RES, V963, P327, DOI 10.1016/S0006-8993(02)04045-3; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Xu L, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-7; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	54	171	172	0	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2007	204	1					220	233		10.1016/j.expneurol.2006.10.013			14	Neurosciences	Neurosciences & Neurology	148PC	WOS:000245086100022	17188268				2021-06-18	
J	Maas, AIR; Steyerberg, EW; Butcher, I; Dammers, R; Lu, J; Marmarou, A; Mushkudiani, NA; McHugh, GS; Murray, GD				Maas, Andrew I. R.; Steyerberg, Ewout W.; Butcher, Isabella; Dammers, Ruben; Lu, Juan; Marmarou, Anthony; Mushkudiani, Nino A.; McHugh, Gillian S.; Murray, Gordon D.			Prognostic value of computerized tomography scan characteristics in traumatic brain injury: Results from the IMPACT study	JOURNAL OF NEUROTRAUMA			English	Article						cisterns; computerized tomography; CT classification; outcome; prognosis; shift; traumatic brain injury; traumatic subarachnoid hemorrhage	SEVERE HEAD-INJURY; GLASGOW COMA SCALE; SUBARACHNOID HEMORRHAGE; OUTCOME PREDICTION; DATA-BANK; CLASSIFICATION; MANAGEMENT; MORTALITY; ADMISSION; SCORE	Computerized tomography (CT) scanning provides an objective assessment of the structural damage to the brain following traumatic brain injury (TBI). We aimed to describe and quantify the relationship between CT characteristics and 6-month outcome, assessed by the Glasgow Outcome Scale (GOS). Individual patient data from the IMPACT database were available on CT classification (N = 5209), status of basal cisterns (N = 3861), shift (N = 4698), traumatic subarachnoid hemorrhage (tSAH) (N = 7407), and intracranial lesions (N = 7613). We used binary logistic and proportional odds regression for prognostic analyses. The CT classification was strongly related to outcome, with worst outcome for patients with diffuse injuries in CT class III (swelling; OR 2.50; CI 2.09-3.0) or CT class IV (shift; OR 3.03; CI 2.12-4.35). The prognosis in patients with mass lesions was better for patients with an epidural hematoma (OR 0.64; CI 0.56-0.72) and poorer for an acute subdural hematoma (OR 2.14; CI 1.87-2.45). Partial obliteration of the basal cisterns (OR 2.45; CI 1.88-3.20), tSAH (OR 2.64; CI 2.42-2.89), or midline shift (1-5 mm-OR 1.36; CI 1.09-1.68); > 5 mm-OR 2.20; CI 1.64-2.96) were strongly related to poorer outcome. Discrepancies were found between the scoring of basal cisterns/shift and the CT classification, indicating observer variation. These were less marked in studies that had used a central review process. Multivariable analysis indicated that individual CT characteristics added substantially to the prognostic value of the CT classification alone. We conclude that both the CT classification and individual CT characteristics are important predictors of outcome in TBI. For clinical trials, a central review process is advocated to minimize observer variability in CT assessment.	Erasmus MC, Dept Neurosurg, NL-3000 CA Rotterdam, Netherlands; Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands; Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland; Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, Richmond, VA USA	Maas, AIR (corresponding author), Erasmus MC, Dept Neurosurg, POB 2040, NL-3000 CA Rotterdam, Netherlands.	airmaas@erasmusmc.nl	Dammers, Ruben/AAL-8391-2021; Maas, Andrew IR/C-5584-2013; Dammers, Ruben/AAD-9095-2021; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Dammers, Ruben/0000-0001-7033-0644; Lu, Juan/0000-0002-5389-7603; Murray, Gordon/0000-0001-9866-4734; Steyerberg, Ewout/0000-0002-7787-0122	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-042691] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER		Azian AA, 2001, ACTA NEUROCHIR, V143, P711, DOI 10.1007/s007010170051; Bahloul M, 2004, J TRAUMA, V57, P255, DOI 10.1097/01.TA.0000083004.35231.1E; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001; Caroli M, 2001, SURG NEUROL, V56, P82, DOI 10.1016/S0090-3019(01)00540-7; Chesnut R M, 2000, Clin Neurosurg, V46, P185; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P643, DOI 10.3109/02688699308995093; GAETANI P, 1995, J NEUROL NEUROSUR PS, V59, P635, DOI 10.1136/jnnp.59.6.635; Greene KA, 1996, J TRAUMA, V41, P964, DOI 10.1097/00005373-199612000-00004; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Kakarieka A, 1995, Neurologia, V10, P159; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; LIU HM, 1995, J TRAUMA, V38, P330, DOI 10.1097/00005373-199503000-00003; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Moskopp D, 1995, NEUROSURG REV, V18, P253, DOI 10.1007/BF00383876; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Nissen JJ, 1999, J NEUROL NEUROSUR PS, V67, P796, DOI 10.1136/jnnp.67.6.796; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; Pillai SV, 2003, NEUROL INDIA, V51, P345; QUATTROCCHI KB, 1991, SURG NEUROL, V35, P183, DOI 10.1016/0090-3019(91)90069-L; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; SELLADURAI BM, 1992, BRIT J NEUROSURG, V6, P549, DOI 10.3109/02688699209002372; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	39	171	178	1	9	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2007	24	2					303	314		10.1089/neu.2006.0033			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	150AL	WOS:000245187900010	17375995				2021-06-18	
J	Reeves, TM; Phillips, LL; Povlishock, JT				Reeves, TM; Phillips, LL; Povlishock, JT			Myelinated and unmyelinated axons of the corpus callosum differ in vulnerability and functional recovery following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						traumatic axonal injury; brain injury; compound action potentials; corpus callosum; axonal excitability; recovery of function	CYTOSKELETAL CHANGES; SODIUM-CHANNELS; NERVE-FIBERS; RAT; EXCITABILITY; DEAFFERENTATION; ACCELERATION; TETRODOTOXIN; PRIMATE; CALCIUM	Traumatic axonal injury (TAI), a corm-non feature of traumatic brain injury, is associated with postinjury morbidity and mortality. However, TAI is not uniformly expressed in all axonal populations, with fiber caliber and anatomical location influencing specific TAI pathology. To study differential axonal vulnerability to brain injury, axonal excitability and integrity were assessed in the corpus callosurn following fluid percussion injury in the rat. In brain slice electrophysiological recordings, compound action potentials (CAPs) were evoked in the corpus callosum, and injury effects were quantified separately for CAP waveform components generated by myelinated axons (N-2 wave) and by unmyelinated axons (N-2 wave). Ultrastructural analyses were also conducted of TAI-induced morphological changes in these axonal populations. The two populations of axons differed in response to brain injury, and in their functional recovery, during the first week postinjury. Amplitudes of N-1 and N-2 were significantly depressed at 3 h, 1 day, and 3 days survival. N-1 amplitudes exhibited a recovery to control levels by 7 days postinjury. In contrast, N-2 amplitudes were persistently suppressed through 7 days postinjury. Strength-duration properties of evoked CAPs further differentiated the effects of injury in these axonal populations, with N-2 exhibiting an elevated strength-duration time constant postinjury. Ultrastructural observations revealed degeneration of myelinated axons consistent with diffuse injury sequelae, as well as previously undocumented pathology within the unmyelinated fiber population. Collectively, these findings demonstrate differential vulnerabilities of axons to brain injury and suggest that damage to unmyelinated fibers may play a significant role in morbidity associated with brain injury. (c) 2005 Elsevier Inc. All rights reserved.	Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Reeves, TM (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Med Coll Virginia Campus,1217 E Marshall St,Room, Richmond, VA 23298 USA.	tmreeves@vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193, R01 NS020193] Funding Source: Medline		Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; BANIK NL, 1987, NEUROCHEM PATHOL, V7, P57, DOI 10.1007/BF02834292; BOSTOCK H, 1983, J PHYSIOL-LONDON, V341, P41, DOI 10.1113/jphysiol.1983.sp014791; Bostock H, 1997, J PHYSIOL-LONDON, V498, P277, DOI 10.1113/jphysiol.1997.sp021857; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Burke D, 2000, BRAIN, V123, P992, DOI 10.1093/brain/123.5.992; Burke D, 1998, BRAIN, V121, P1975, DOI 10.1093/brain/121.10.1975; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Fitzpatrick MO, 1998, J NEUROL NEUROSUR PS, V64, P285, DOI 10.1136/jnnp.64.3.285; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRAHAM DI, 1988, PROG CLIN BIOL RES, V234, P159; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; LAMANTIA AS, 1990, J COMP NEUROL, V291, P520, DOI 10.1002/cne.902910404; MAXWELL WL, 1988, ACTA NEUROPATHOL, V76, P395, DOI 10.1007/BF00686977; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mogyoros I, 1998, BRAIN, V121, P851, DOI 10.1093/brain/121.5.851; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Povlishock J T, 2000, Clin Neurosurg, V46, P113; Povlishock John T., 1995, P504; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; PRESTON RJ, 1983, EXP NEUROL, V79, P808, DOI 10.1016/0014-4886(83)90044-4; Reeves TM, 2003, J NEUROSCI, V23, P10182; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STURROCK RR, 1980, NEUROPATH APPL NEURO, V6, P415, DOI 10.1111/j.1365-2990.1980.tb00219.x; SWADLOW HA, 1980, ARCH NEUROL-CHICAGO, V37, P114, DOI 10.1001/archneur.1980.00500510072016; SWADLOW HA, 1976, EXP NEUROL, V53, P125; Swanson TH, 1998, BRAIN RES, V784, P188, DOI 10.1016/S0006-8993(97)01323-1; WAXMAN SG, 1976, EXP NEUROL, V53, P115, DOI 10.1016/0014-4886(76)90287-9; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Xiao ZC, 1999, J BIOL CHEM, V274, P26511, DOI 10.1074/jbc.274.37.26511	40	171	172	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	NOV	2005	196	1					126	137		10.1016/j.expneurol.2005.07.014			12	Neurosciences	Neurosciences & Neurology	976SG	WOS:000232753000015	16109409				2021-06-18	
J	Keenan, HT; Runyan, DK; Marshall, SW; Nocera, MA; Merten, DF				Keenan, HT; Runyan, DK; Marshall, SW; Nocera, MA; Merten, DF			A population-based comparison of clinical and outcome characteristics of young children with serious inflicted and noninflicted traumatic brain injury	PEDIATRICS			English	Article						child abuse; traumatic brain injury; shaken baby syndrome	SHAKEN BABY SYNDROME; INTENSIVE-CARE-UNIT; HEAD-INJURY; PRACTICAL SCALE; RISK; SEVERITY; SHAKING; DAMAGE; COMA	Objective. Diagnosing inflicted traumatic brain injury (TBI) in young children is difficult in practice. Comparisons of children with inflicted and noninflicted TBI may help to identify markers of inflicted TBI. The objective of this study was to compare inflicted and noninflicted TBI in terms of presenting complaints, clinical features, and hospital outcomes. Methods. The presenting complaint, clinical finding, hospital course, and outcome of all children who were aged 2 years or younger in North Carolina and were admitted to a pediatric intensive care unit or died with a TBI in 2000 and 2001 were reviewed. Clinical presentation and injury types were compared between children with inflicted and noninflicted TBI. Risk ratios were used to compare clinical and outcome characteristics between the 2 groups. Among survivors, multivariate binomial regression was used to examine the adjusted risk of a poor outcome dependent on injury type. Results. A total of 80 (52.6%) children had inflicted and 72 (47.3%) children had noninflicted TBI. Children with noninflicted TBI ( not in a motor vehicle crash) were more likely to present to the emergency department asymptomatic (44.8% vs 8.3%) and to have a specific history of trauma than children with inflicted TBI. Retinal hemorrhage, metaphyseal fracture, rib fracture, and subdural hemorrhage were more commonly found in children with inflicted compared with noninflicted TBI. Skeletal survey and ophthalmologic examination combined would have missed 8 (10.0%) inflicted TBI cases. Conclusions. Manner of presentation and injury types are helpful in distinguishing inflicted TBI. Clinicians should not rule out inflicted TBI on the basis of skeletal survey and ophthalmoscopy alone but should proceed to computed tomography and/or magnetic resonance imaging.	Univ N Carolina, Sch Med, Dept Social Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Orthoped, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Radiol, Chapel Hill, NC 27599 USA	Keenan, HT (corresponding author), Univ N Carolina, Sch Med, Dept Social Med, Wing D,CB 7240, Chapel Hill, NC 27599 USA.	hkeenan@med.unc.edu	Runyan, Desmond/S-3974-2016	Runyan, Desmond/0000-0001-5571-9029; Marshall, Stephen/0000-0002-2664-9233	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD041040] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD041040, K23 HD041040-03, K23 HD041040-01A2] Funding Source: Medline; ODCDC CDC HHS [R49/CCR402444] Funding Source: Medline		Alexander RC, 2001, CHILD ABUSE MED DIAG, P47; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; CAFFEY J, 1974, PEDIATRICS, V54, P396; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Fiser DH, 2000, CRIT CARE MED, V28, P1173, DOI 10.1097/00003246-200004000-00043; Gilliland MGF, 1996, J FORENSIC SCI, V41, P114; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; JENNETT B, 1975, LANCET, V1, P480; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; King WJ, 2003, CAN MED ASSOC J, V168, P155; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Skov T, 1998, INT J EPIDEMIOL, V27, P91, DOI 10.1093/ije/27.1.91; STIER DM, 1993, PEDIATRICS, V91, P642; TEASDALE G, 1974, LANCET, V2, P81; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	23	171	173	0	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	SEP	2004	114	3					633	639		10.1542/peds.2003-1020-L			7	Pediatrics	Pediatrics	851AU	WOS:000223657600009	15342832	Green Accepted			2021-06-18	
J	Mosenthal, AC; Livingston, DH; Lavery, RF; Knudson, MM; Lee, S; Morabito, D; Manley, GT; Nathens, A; Jurkovich, G; Hoyt, DB; Coimbra, R				Mosenthal, AC; Livingston, DH; Lavery, RF; Knudson, MM; Lee, S; Morabito, D; Manley, GT; Nathens, A; Jurkovich, G; Hoyt, DB; Coimbra, R			The effect of age on functional outcome in mild traumatic brain injury: 6-month report of a prospective multicenter trial	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	33rd Annual Meeting of the Western-Trauma-Association	FEB 23-28, 2003	SNOWBIRD, UT	Western Trauma Assoc		traumatic brain injury; elderly; functional outcome; mortality	HEAD-INJURY; INPATIENT REHABILITATION; INDEPENDENCE MEASURE; MORTALITY; SEVERITY; EPIDEMIOLOGY; WORSE	Objective: Elderly patients (aged 60 years and older) have been demonstrated to have an increased mortality after isolated traumatic brain injury (TBI); however, the prognosis of those patients surviving their hospitalization is unknown. We hypothesized that surviving elderly patients would also have decreased functional outcome, and this study examined the functional outcome of patients with isolated TBI at discharge and at 6 months posthospitalization. Methods: This was a multicenter prospective study of all patients with isolated moderate to severe TBI defined as Head Abbreviated Injury Scale score of 3 with an Abbreviated Injury Scale score in any other body area of 1. Patients surviving to discharge gave their consent and were enrolled. Data collected included demographics, Glasgow Coma Scale (GCS) score at admission, and neurosurgical interventions. Outcome data included discharge disposition and Glasgow Outcome Scale score and modified Functional Independence Measure (FIM) score at discharge and at 6 months. Results: Two hundred thirty-five patients were enrolled, with 44 (19%) aged greater than or equal to 65 years. Mechanisms of injury were falls (34%), assaults (28%), motor vehicle collisions (14%), pedestrian (11%), and other (12 %). Falls were more common in the older patients and assaults in the younger group. The mean admitting GCS score was 12.8 (95% confidence interval [CI], 12.4-13.3), with older patients having a higher mean GCS score, 14.1 (95% CI, 13.6-14.6) versus 12.5 (95% CI, 12.0-13.1; p = 0.03). There were no differences in the percentage of patients admitted to the intensive care unit or requiring neurosurgical intervention between younger and older patients. Because there were few elderly patients with low GCS scores who survived to discharge, outcome measures focused on those patients with GCS scores of 13 to 15. A greater percentage of elderly were discharged to rehabilitation (28% vs. 16 %, p = 0.08). The mean discharge FIM score was 10.4 (95% CI, 9.8-11.0) for the elderly versus 11.4 (95% CI, 11.1-11.7) for the young (p = 0.001), with 68 % elderly and 89% young discharged with total independent scores of 11 to 12. At 6 months, the difference narrowed, but the mean FIM score was still greater for the young group, 11.7 (95% CI, 11.6-11.9) versus 11.0 (95% CI, 10.6-11.4; p < 0.001). Conclusion: Functional outcome after isolated mild TBI as measured by the Glasgow Outcome Scale and modified FIM is generally good to excellent for both elderly and younger patients. Older patients required more inpatient rehabilitation and lagged behind their younger counterparts but continued to recover and improve after discharge. Although there were statistically significant differences in the FIM score at both discharge and 6 months, the clinical importance of these small differences in the mean FIM score to the patient's quality of life is less clear. Measurable improvement in functional status during the first 6 months after injury is observed in both groups. Aggressive management and care of older patients with TBI is warranted, and efforts should be made to decrease inpatient mortality. Continued follow-up is ongoing to determine whether these outcomes persist at 12 months.	Univ Med & Dent New Jersey, Univ Hosp,Med Sch, New Jersey Trauma Ctr, Dept Surg, Newark, NJ 07103 USA; Univ Calif San Francisco, San Francisco Gen Med Ctr, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Injure Prevent & Res Inst, Seattle, WA 98195 USA	Mosenthal, AC (corresponding author), Univ Med & Dent New Jersey, Univ Hosp,Med Sch, New Jersey Trauma Ctr, Dept Surg, 150 Bergen St,Mezzanine N, Newark, NJ 07103 USA.	mosentac@umdnj.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851			*AG HLTH CAR POL R, 1998, REH TRAUM BRAIN INJ; American College of Surgeons Committee on Trauma Prehospital Trauma Care, 1998, RES OPT CAR INJ PAT, P13; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Butcher JL, 1996, J TRAUMA, V41, P4, DOI 10.1097/00005373-199607000-00002; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Huang ME, 2000, AM J PHYS MED REHAB, V79, P327, DOI 10.1097/00002060-200007000-00003; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; O'Dell MW, 1998, ARCH PHYS MED REHAB, V79, P1530, DOI 10.1016/S0003-9993(98)90414-2; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; SAYWELL RM, 1989, J AM GERIATR SOC, V37, P625, DOI 10.1111/j.1532-5415.1989.tb01253.x; Segal ME, 1996, AM J PHYS MED REHAB, V75, P208, DOI 10.1097/00002060-199605000-00013; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; VANAALST JA, 1991, J TRAUMA, V31, P1096; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	27	171	173	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2004	56	5					1042	1048		10.1097/01.TA.0000127767.83267.33			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	824RH	WOS:000221703200027	15179244				2021-06-18	
J	MARION, DW; CARLIER, PM				MARION, DW; CARLIER, PM			PROBLEMS WITH INITIAL GLASGOW COMA SCALE ASSESSMENT CAUSED BY PREHOSPITAL TREATMENT OF PATIENTS WITH HEAD-INJURIES - RESULTS OF A NATIONAL SURVEY	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							PROGNOSIS; MORTALITY	The rapid treatment of patients with a severe head injury often includes prehospital intubation and sedation, but such measures compromise the ability to obtain an accurate Glasgow Coma Scale (GCS) score in the emergency department (ED). Major head injury centers in the United States were surveyed to determine how they currently obtain initial GCS scores when these or other complicating circumstances exist. A two-page questionnaire was distributed to seven members of the trauma team at 17 major neurotrauma centers in which they were asked who usually determines the initial GCS scores, where they are assessed, and when. Respondents were also asked how they assign scores for patients who received medications or were intubated before arrival at their hospital and how they score patients who are hypotensive, hypoxic, or have severe periorbital swelling. Most centers assess the initial GCS scores in their ED within 1 hour after the discovery of the patient by prehospital personnel. Most neurosurgeons said that hypotension and hypoxia are stabilized before the initial GCS scores are assessed and that intubated patients receive a non-numerical designation. But the majority of non-neurosurgical ED personnel said that they determine the initial GCS scores immediately after arrival of the patients in their department, regardless of hypoxia or hypotension. There also were significant discrepancies between attending neurosurgeons and their residents with regard to who actually assesses the GCS scores and how the scores are determined for patients who have received neuromuscular paralysis or sedation or who have severe periorbital swelling. In addition, 20% of attending neurosurgeons and 24% of non-neurosurgical ED personnel reported using the worst, rather than the best, GCS sum score when motor or eye-opening abilities are asymmetrical. This survey revealed important inter-center and intra-center differences of opinion regarding how the initial GCS scores are obtained. Such differences make it difficult to interpret the results of head injury studies that use the initial GCS scores to describe injury severity. The results of this survey emphasize the need for nationally recognized policies for determining the initial GCS scores that account for contemporary prehospital management of patients with severe head injuries.	UNIV PITTSBURGH, SCH MED, DEPT NEUROL SURG, BRAIN TRAUMA RES CTR, PITTSBURGH, PA 15261 USA			Marion, Donald/AAR-5749-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NINDS 1P20NS30318-01] Funding Source: Medline		BOUZARTH WF, 1978, J TRAUMA, V18, P571, DOI 10.1097/00005373-197808000-00003; BRAAKMAN R, 1977, CLIN NEUROL NEUROSUR, V80, P104; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; Fielding K, 1990, Aust J Adv Nurs, V7, P13; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; IVAN LP, 1973, NEUROLOGY, V23, P650, DOI 10.1212/WNL.23.6.650; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; Knight R L, 1986, Crit Care Nurse, V6, P65; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; SALCMAN M, 1981, NEUROSURGERY, V8, P15; Stalhammar D, 1986, Acta Neurochir Suppl (Wien), V36, P91; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; TITTERINGTON DM, 1981, J ROY STAT SOC A STA, V144, P145, DOI 10.2307/2981918; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WINKLER J V, 1984, Journal of Emergency Medicine, V2, P1, DOI 10.1016/0736-4679(84)90038-6	23	171	175	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	1994	36	1					89	95		10.1097/00005373-199401000-00014			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	MU062	WOS:A1994MU06200014	8295256				2021-06-18	
J	Singh, V; Roth, S; Llovera, G; Sadler, R; Garzetti, D; Stecher, B; Dichgans, M; Liesz, A				Singh, Vikramjeet; Roth, Stefan; Llovera, Gemma; Sadler, Rebecca; Garzetti, Debora; Stecher, Baerbel; Dichgans, Martin; Liesz, Arthur			Microbiota Dysbiosis Controls the Neuroinflammatory Response after Stroke	JOURNAL OF NEUROSCIENCE			English	Article						inflammation; microbiota; stroke; T cells	REGULATORY T-CELLS; IMMUNE MODULATOR FINGOLIMOD; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; GUT MICROBIOTA; ISCHEMIC-STROKE; MECHANISMS; AXIS; INFILTRATION; LYMPHOCYTES	Acute brain ischemia induces a local neuroinflammatory reaction and alters peripheral immune homeostasis at the same time. Recent evidence has suggested a key role of the gut microbiota in autoimmune diseases by modulating immune homeostasis. Therefore, we investigated the mechanistic link among acute brain ischemia, microbiota alterations, and the immune response after brain injury. Using two distinct models of acute middle cerebral artery occlusion, we show by next-generation sequencing that large stroke lesions cause gut microbiota dysbiosis, which in turn affects stroke outcome via immune-mediated mechanisms. Reduced species diversity and bacterial overgrowth of bacteroidetes were identified as hallmarks of poststroke dysbiosis, which was associated with intestinal barrier dysfunction and reduced intestinal motility as determined by in vivo intestinal bolus tracking. Recolonizing germ-free mice with dysbiotic poststroke microbiota exacerbates lesion volume and functional deficits after experimental stroke compared with the recolonization with a normal control microbiota. In addition, recolonization of mice with a dysbiotic microbiome induces a proinflammatory T-cell polarization in the intestinal immune compartment and in the ischemic brain. Using in vivo cell-tracking studies, we demonstrate the migration of intestinal lymphocytes to the ischemic brain. Therapeutic transplantation of fecal microbiota normalizes brain lesion-induced dysbiosis and improves stroke outcome. These results support a novel mechanism in which the gut microbiome is a target of stroke-induced systemic alterations and an effector with substantial impact on stroke outcome.	[Singh, Vikramjeet; Roth, Stefan; Llovera, Gemma; Sadler, Rebecca; Dichgans, Martin; Liesz, Arthur] Klinikum Univ Munchen, Inst Stroke & Dementia Res, D-81377 Munich, Germany; [Singh, Vikramjeet; Roth, Stefan; Llovera, Gemma; Sadler, Rebecca; Dichgans, Martin; Liesz, Arthur] Munich Cluster Syst Neurol SyNergy, D-80336 Munich, Germany; [Garzetti, Debora; Stecher, Baerbel] Klinikum Univ Munchen, Max Von Pettenkofer Inst, D-80336 Munich, Germany; [Garzetti, Debora; Stecher, Baerbel] German Ctr Infect Res DZIF, Partner Site Munich, D-80336 Munich, Germany	Liesz, A (corresponding author), Inst Stroke & Dementia Res, Feodor Lynen Str 17, D-81377 Munich, Germany.	Arthur.Liesz@med.uni-muenchen.de	Stecher, Barbel/B-9940-2019; Stecher, Barbel/A-2911-2015	Stecher, Barbel/0000-0002-7445-5193; Singh, Vikramjeet/0000-0002-7361-8317; Llovera, Gemma/0000-0002-7509-7500	Excellence Cluster of the German Research Foundation "Munich Cluster for Systems Neurology (SyNergy)";  [SPP1656];  [STE 1971/4-1]	This work was supported by the Excellence Cluster of the German Research Foundation "Munich Cluster for Systems Neurology (SyNergy)" to A.L. and by the SPP1656 " Intestinal Microbiota" (STE 1971/4-1) to B.S. All DNA sequences used for microbial community analyses have been deposited in MG-RAST (http://metagenomics.anl.gov/) under accession number 9778. We thank Kerstin Hofmann for providing technical assistance, Rainer Malik (Institute for Stroke and Dementia Research, Munich, Germany) for advice regarding the sequencing analysis, Sandrine Brugiroux (Max-von-Pettenkofer Institute, Munich, Germany) for technical advice regarding fluorescence in situ hybridization, and Kathleen McCoy (University of Bern, Switzerland) for providing GF mice.	Appel SH, 2009, J CLIN INVEST, V119, P13, DOI 10.1172/JCI38096; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Bain CC, 2014, IMMUNOL REV, V260, P102, DOI 10.1111/imr.12192; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; Benakis C, 2016, NAT MED; Berer K, 2011, NATURE, V479, P538, DOI 10.1038/nature10554; Carabotti M, 2015, ANN GASTROENTEROL, V28, P203; Chamorro A, 2007, J NEUROL SCI, V252, P29, DOI 10.1016/j.jns.2006.10.001; Chamorro A, 2012, NAT REV NEUROL, V8, P401, DOI 10.1038/nrneurol.2012.98; Claesson MJ, 2012, NATURE, V488, P178, DOI 10.1038/nature11319; Collins SM, 2012, NAT REV MICROBIOL, V10, P735, DOI 10.1038/nrmicro2876; Cryan JF, 2012, NAT REV NEUROSCI, V13, P701, DOI 10.1038/nrn3346; El Aidy S, 2012, MUCOSAL IMMUNOL, V5, P567, DOI 10.1038/mi.2012.32; Engler Tania M N de M, 2014, Open Nurs J, V8, P43, DOI 10.2174/1874434601408010043; Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030; Fu Y, 2014, P NATL ACAD SCI USA, V111, P18315, DOI 10.1073/pnas.1416166111; Gelderblom M, 2012, BLOOD, V120, P3793, DOI 10.1182/blood-2012-02-412726; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Hofmann U, 2015, CIRC RES, V116, P354, DOI 10.1161/CIRCRESAHA.116.304072; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Houlden A, 2016, BRAIN BEHAV IN PRESS; Huang YF, 2007, CELL IMMUNOL, V248, P4, DOI 10.1016/j.cellimm.2007.03.009; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; JANDER S, 1995, J CEREBR BLOOD F MET, V15, P42, DOI 10.1038/jcbfm.1995.5; Karlsson FH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2266; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kleinschnitz C, 2010, BLOOD, V115, P3835, DOI 10.1182/blood-2009-10-249078; Lee YK, 2011, P NATL ACAD SCI USA, V108, P4615, DOI 10.1073/pnas.1000082107; Liesz A, 2015, J NEUROSCI, V35, P583, DOI 10.1523/JNEUROSCI.2439-14.2015; Liesz A, 2013, J NEUROSCI, V33, P17350, DOI 10.1523/JNEUROSCI.4901-12.2013; Liesz A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074839; Liesz A, 2013, J NEUROIMMUNOL, V257, P46, DOI 10.1016/j.jneuroim.2013.01.013; Liesz A, 2011, BRAIN, V134, P704, DOI 10.1093/brain/awr008; Liesz A, 2009, STROKE, V40, P2849, DOI 10.1161/STROKEAHA.109.549618; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Llovera G, 2014, JOVE-J VIS EXP, DOI 10.3791/51729; Lucin KM, 2009, NEURON, V64, P110, DOI 10.1016/j.neuron.2009.08.039; Magrone T, 2013, IMMUN AGEING, V10, DOI 10.1186/1742-4933-10-31; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Meyer F, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-386; Mracsko E, 2014, BRAIN BEHAV IMMUN, V41, P200, DOI 10.1016/j.bbi.2014.05.015; Neumann J, 2015, ACTA NEUROPATHOL, V129, P259, DOI 10.1007/s00401-014-1355-2; Offner H, 2006, J IMMUNOL, V176, P6523, DOI 10.4049/jimmunol.176.11.6523; Olsen AB, 2013, NEUROGASTROENT MOTIL, V25, DOI 10.1111/nmo.12121; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; SCHROETER M, 1994, J NEUROIMMUNOL, V55, P195, DOI 10.1016/0165-5728(94)90010-8; Schwartz M, 2014, NEUROSCIENTIST, V20, P343, DOI 10.1177/1073858413516799; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749; Shichita T, 2009, NAT MED, V15, P946, DOI 10.1038/nm.1999; Singh V, 2016, ANTIOXID REDOX SIGN, V24, P635, DOI 10.1089/ars.2015.6397; Swidsinski A, 2012, INTEST RES, V10, P332, DOI 10.5217/ir.2012.10.4.332; Vilz TO, 2012, JOVE-J VIS EXP, DOI 10.3791/4086; Vogelgesang A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008718; Yilmaz G, 2006, CIRCULATION, V113, P2105, DOI 10.1161/CIRCULATIONAHA.105.593046; Yin J, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002699; Zhou W, 2013, BRAIN PATHOL, V23, P34, DOI 10.1111/j.1750-3639.2012.00614.x; Zhu ZL, 2015, CIRCULATION, V132, P1104, DOI 10.1161/CIRCULATIONAHA.115.016371	61	170	195	2	57	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 13	2016	36	28					7428	7440		10.1523/JNEUROSCI.1114-16.2016			13	Neurosciences	Neurosciences & Neurology	DS1ST	WOS:000380380500010	27413153	Bronze, Green Published	Y	N	2021-06-18	
J	Tang-Schomer, MD; Johnson, VE; Baas, PW; Stewart, W; Smith, DH				Tang-Schomer, Min D.; Johnson, Victoria E.; Baas, Peter W.; Stewart, William; Smith, Douglas H.			Partial interruption of axonal transport due to microtubule breakage accounts for the formation of periodic varicosities after traumatic axonal injury	EXPERIMENTAL NEUROLOGY			English	Article						Diffuse axonal injury; DAI; Traumatic brain injury; TBI; Axons; Microtubules; Axon varicosities; Axonal transport; Amyloid precursor protein; Axonal stretch	AMYLOID PRECURSOR PROTEIN; DYNAMIC STRETCH INJURY; HEAD-INJURY; BRAIN-INJURY; BETA-APP; UNMYELINATED AXONS; SODIUM-CHANNELS; TETRODOTOXIN; DEGENERATION; ELONGATION	Due to their viscoelastic nature, white matter axons are susceptible to damage by high strain rates produced during traumatic brain injury (TBI). Indeed, diffuse axonal injury (DAI) is one of the most common features of TBI, characterized by the hallmark pathological profiles of axonal bulbs at disconnected terminal ends of axons and periodic swellings along axons, known as "varicosities." Although transport interruption underlies axonal bulb formation, it is unclear how varicosities arise, with multiple sites accumulating transported materials along one axon. Recently, axonal microtubules have been found to physically break during dynamic stretch injury of cortical axons in vitro. Here, the same in vitro model was used in parallel with histopathological analyses of human brains acquired acutely following TBI to examine the potential role of mechanical microtubule damage in varicosity formation post-trauma. Transmission electron microscopy (TEM) following in vitro stretch injury revealed periodic breaks of individual microtubules along axons that regionally corresponded with undulations in axon morphology. However, typically less than a third of microtubules were broken in any region of an axon. Within hours, these sites of microtubule breaks evolved into periodic swellings. This suggests axonal transport may be halted along one broken microtubule, yet can proceed through the same region via other intact microtubules. Similar axonal undulations and varicosities were observed following TBI in humans, suggesting primary microtubule failure may also be a feature of DAI. These data indicate a novel mechanism of mechanical microtubule damage leading to partial transport interruption and varicosity formation in traumatic axonal injury. (C) 2011 Elsevier Inc. All rights reserved.	[Tang-Schomer, Min D.; Johnson, Victoria E.; Smith, Douglas H.] Univ Penn, Penns Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Tang-Schomer, Min D.; Johnson, Victoria E.; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Baas, Peter W.] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA; [Stewart, William] Univ Glasgow, Div Clin Neurosci, Glasgow, Lanark, Scotland; [Stewart, William] So Gen Hosp, Inst Neurol Sci, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland	Smith, DH (corresponding author), Univ Penn, Penns Ctr Brain Injury & Repair, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	Tang-Schomer, Min/AAD-9501-2020; Tang-Schomer, Min/C-1967-2013	Tang-Schomer, Min/0000-0001-7585-3890; 	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS056202, NS038104, NS048949]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048949, P01NS056202, R01NS038104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R03AG038911] Funding Source: NIH RePORTER	We thank Kevin Browne of the Dept. Neurosurgery and Center for Brain Injury and Repair, University of Pennsylvania for his technical assistance; Ray Meade from the Biomedical Imaging Core at University of Pennsylvania for EM assistance, and Janice E. Stewart, Dept. Neuropathology, Southern General Hospital, Glasgow, UK for her assistance with immunohistochemical procedures for human studies. This work is supported by the National Institute of Health grants: NS056202, NS038104, NS048949 (all DHS).	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; DENNERLL TJ, 1989, J CELL BIOL, V109, P3073, DOI 10.1083/jcb.109.6.3073; Faul M.D., 2010, TRAUMATIC BRAIN INJU; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Hammarlund M, 2007, J CELL BIOL, V176, P269, DOI 10.1083/jcb.200611117; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Lambri M, 2001, CLIN NEUROPATHOL, V20, P263; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; RAND CW, 1946, ARCH NEURO PSYCHIATR, V55, P79, DOI 10.1001/archneurpsyc.1946.02300130003001; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Reichard RR, 2003, J NEUROTRAUM, V20, P347, DOI 10.1089/089771503765172309; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Staal JA, 2011, J NEUROTRAUM, V28, P841, DOI 10.1089/neu.2010.1658; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tang MD, 2003, J AM CHEM SOC, V125, P12988, DOI 10.1021/ja037677h; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yu WQ, 2005, J NEUROSCI, V25, P5573, DOI 10.1523/JNEUROSCI.0834-05.2005; YU WQ, 1994, J NEUROSCI, V14, P2818; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	32	170	172	0	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	2012	233	1					364	372		10.1016/j.expneurol.2011.10.030			9	Neurosciences	Neurosciences & Neurology	890CY	WOS:000300123900041	22079153	Green Accepted			2021-06-18	
J	Elder, GA; Cristian, A				Elder, Gregory A.; Cristian, Adrian			Blast-Related Mild Traumatic Brain Injury: Mechanisms of Injury and Impact on Clinical Care	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						animal models; blast overpressure wave; blast-related brain injury; improvised explosive device; mild traumatic brain injury; Operation Enduring Freedom; Operation Iraqi Freedom; pathophysiology; postconcussion syndrome; posttraumatic stress disorder; shell shock	POSTTRAUMATIC-STRESS-DISORDER; INDUCED NEUROTRAUMA; SHELL SHOCK; RAT-BRAIN; EXPOSURE; IRAQ; WAVE	Mild traumatic brain injury has been called the signature injury of the wars in Iraq and Afghanistan. In both theaters of operation, traumatic brain injury has been a significant cause of mortality and morbidity, with blast-related injury the most common cause. Improvised explosive devices have been the major cause of blast injuries. It is estimated that 10% to 20% of veterans returning from these operations have suffered a traumatic brain injury, and there is concern that blast-related injury may produce adverse long-term health affects and affect the resilience and in-theater performance of troops. Blast-related injury occurs through several mechanisms related to the nature of the blast overpressure wave itself as well as secondary and tertiary injuries. Animal studies clearly show that blast overpressure waves are transmitted to the brain and can cause changes that neuropathologically are most similar to diffuse axonal injury. One striking feature of the mild traumatic brain injury cases being seen in veterans of the wars in Iraq and Afghanistan is the high association of mild traumatic brain injury with posttraumatic stress disorder. The overlap in symptoms between the disorders has made distinguishing them clinically challenging. The high rates of mild trumatic brain injury and posttraumatic stress disorder in the current operations are of significant concern for the long-term health of Us veterans with associated economic implications. Mt Sinai J Med 76.111-118, 2009 (C) 2009 Mount Sinai School of Medicine	[Elder, Gregory A.; Cristian, Adrian] Vet Affairs Med Ctr, James J Peters Dept, Rehabil Med Serv, Bronx, NY USA	Elder, GA (corresponding author), Vet Affairs Med Ctr, James J Peters Dept, Rehabil Med Serv, Bronx, NY USA.	gregory.elder@va.gov					ALVAREZ L, 2008, NY TIMES        0826; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 1996, J TRAUMA, V40, pS148, DOI 10.1097/00005373-199603001-00032; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Gennarelli T. A., 2005, TXB TRAUMATIC BRAIN, P27; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; O'Hanlon Michael E., IRAQ INDEX TRACKING; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T, 2008, INVISIBLE WOUNDS WAR; *VA POL, VA POL SYST CAR HOM; Warden DL, 2005, J NEUROTRAUM, V22, P1178; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071	26	170	173	3	33	JOHN WILEY & SONS INC	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0027-2507			MT SINAI J MED	Mt. Sinai J. Med.	MAR-APR	2009	76	2					111	118		10.1002/msj.20098			8	Medicine, General & Internal	General & Internal Medicine	427OE	WOS:000264787800004	19306373				2021-06-18	
J	Viano, DC; Casson, IR; Pellman, EJ				Viano, David C.; Casson, Ira R.; Pellman, Elliot J.			Concussion in professional football: Biomechanics of the struck player - Part 14	NEUROSURGERY			English	Article						biomechanics; concussion; football; impact tolerances; neck injury; sport injury prevention	HIGH-SCHOOL; AMERICAN FOOTBALL; GAME IMPACTS; BRAIN-INJURY; RECOVERY; PERFORMANCE	OBJECTIVE: Impacts Causing concussion in professional football were simulated in laboratory tests to determine collision mechanics. This study focuses on the biomechanics of concussion in the struck player. METHODS: Twenty-five helmet impacts were reconstructed using Hybrid III dummies. Head impact velocity, direction, and helmet kinematics-matched game video. Translational and rotational accelerations were measured in both players' heads; 6-axis upper neck responses were measured in all striking and five struck players. Head kinematics and biomechanics were determined for concussed players. Head displacement, rotation, and neck loads were determined because finite element analysis showed maximum strains occurring in the midbrain after the high impact forces. A model was developed of the helmet impact to study the influence of neck strength and other parameters on head responses. RESULTS: The impact response of the concussed player's head includes peak accelerations of 94 +/- 28 g and 6432 +/- 1813 r/s(2), and velocity changes of 7.2 +/- 1.8 m/s and 34.8 +/- 15.2 r/s. Near the end of impact (10 ms), head movement is only 20.2 +/- 6.8 mm and 6.9 +/- 2.5 degrees. After impact, there is rapid head displacement involving a fourfold increase to 87.6 +/- 21.2 mm and 29.9 +/- 9.5 degrees with neck tension and bending at 20 ms. Impacts to the front of the helmet, the source of the majority of National Football League concussions, cause rotation primarily around the z axis (superior-inferior axis) because the force is forward of the neck centerline. This twists the head to the right or left an average of 17.6 +/- 12.7 degrees, causing a moment of 17.7 +/- 3.3 Nm and neck tension of 1704 +/- 432 N at 20 ms. The head injury criterion correlates with concussion risk and is proportional to Delta V-4/d(1.5) for half-sine acceleration. Stronger necks reduce head acceleration, AV, and displacement. Even relatively small reductions in AV have a large effect on head injury criterion that may reduce concussion risks because changes in AV change head injury criterion through the 4th power. CONCLUSION: This study addresses head responses causing concussion in National Football League players. Although efforts are underway to reduce impact acceleration through helmet padding, further study is needed of head kinematics after impact and their contribution to concussion, including rapid head displacement, z-axis rotation, and neck tension up to the time of maximum strain in the midbrain. Neck strength influences head AV and head injury criterion and may help explain different concussion risks in professional and youth athletes, women, and children.	ProBiomech LLC, Bloomfield Hills, MI 48304 USA; Long Isl Jewish Med Ctr, Dept Neurol, New Hyde Pk, NY 11042 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; ProHlth Care Associates LLP, Lake Success, NY USA	Viano, DC (corresponding author), ProBiomech LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net					BACKAITIS SH, 1994, HYBRID, V3; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; CHOU CC, 1974, ANAL STUDIES HEAD IN; Denny-Brown D, 1941, BRAIN, V64, P1, DOI 10.1093/brain/64.1.1; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gurdjian E S, 1964, Clin Neurosurg, V12, P112; GURDJIAN E S, 1964, J Trauma, V4, P309; GURDJIAN ES, 1975, IMPACT HEAD INJURY M, P181; Hilker Christopher E, 2002, Stapp Car Crash J, V46, P417; HODGSON VR, 1980, REDUCING SERIOUS INJ, V7; HODGSON VR, 1985, UTILITY HEAD INJURY; HODGSON VR, 1972, 16 STAPP CAR CRASH C; IRWIN AL, 1997, 41 STAPP CAR CRASH C; Ivarsson J, 2000, J BIOMECH, V33, P181, DOI 10.1016/S0021-9290(99)00144-X; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mertz H. J, 1996, HEAD INJURY RISK ASS; Mertz Harold J, 2003, Stapp Car Crash J, V47, P155; MERTZ HJ, 1989, 890756 SAE; MERTZ HJ, 2001, STAPP CAR CRASH J, V45; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; MYERS BS, 1989, 33 STAPP CAR CRASH C; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; NEWMAN JA, 1993, BIOMECHANICS HUMAN T, P292; NEWMAN JA, 1975, 19 STAPP CAR CRASH C; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; UNTERHARNSCHEIDT F, 1970, TEX REP BIOL MED, V28, P421; Viano David C, 2003, Traffic Inj Prev, V4, P214, DOI 10.1080/15389580309877; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; WISMANS J, 1996, 30 STAPP CAR CRASH C; ZHANG L., 2001, RECENT ADV BRAIN INJ	42	170	170	0	378	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2007	61	2					313	327		10.1227/01.NEU.0000279969.02685.D0			15	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	197AN	WOS:000248525400022	17762744				2021-06-18	
J	Jiang, JY; Xu, W; Li, WP; Xu, WH; Zhang, J; Bao, YH; Ying, YH; Luo, QZ				Jiang, JY; Xu, W; Li, WP; Xu, WH; Zhang, J; Bao, YH; Ying, YH; Luo, QZ			Efficacy of standard trauma craniectomy for refractory intracranial hypertension with severe traumatic brain injury: A multicenter, prospective, randomized controlled study	JOURNAL OF NEUROTRAUMA			English	Article						limited craniectomy; outcome; refractory intracranial hypertension; severe traumatic brain injury; standard trauma craniectomy	DECOMPRESSION; TUMORS	To compare the effect of standard trauma craniectomy (STC) versus limited craniectomy (LC) on the outcome of severe traumatic brain injury (TBI) with refractory intracranial hypertension, we conducted a study at five medical centers of 486 patients with severe TBI (Glasgow Coma Scale score <= 8) and refractory intracranial hypertension. In all 486 cases, refractory intracranial hypertension, caused by unilateral massive frontotemporoparietal contusion, intracerebral/subdural hematoma, and brain edema, was confirmed on a CT scan. The patients were randomly divided into two groups, one of which underwent STC (n = 241) with a unilateral frontotemporoparietal bone flap (12 x 15 cm), and the second of which underwent LC (n = 245) with a routine temporoparietal bone flap (6 x 8 cm). At 6-month follow-up, 96 patients (39.8%) in the STC group had a favorable outcome on the basis of the Glasgow Outcome Scale, including 62 patients who had a good recovery and 34 who showed moderate deficits. Another 145 patients (60.2%) in the STC group had an unfavorable outcome, including 73 with severe deficits, nine with persistent vegetative status, and 63 who died. By comparison, only 70 patients (28.6%) in the LC group had a favorable outcome, including 41 who had a good recovery and 29 who had moderate deficits. Another 175 patients (71.4%) in the LC group had an unfavorable outcome, including 82 with severe deficits, seven with persistent vegetative status, and 86 who died (p < 0.05). In addition to these findings, the incidence of delayed intracranial hematoma, incisional hernia, and CSF fistula was lower in the STC group than in the LC group (p < 0.05), although the incidence of acute encephalomyelocele, traumatic seizure, and intracranial infection was not significantly different in the two groups (p > 0.05). The results of the study indicate that STC significantly improves outcome in severe TBI with refractory intracranial hypertension resulting from unilateral frontotemporoparietal contusion with or without intracerebral or subdural hematoma. This suggests that STC, rather than LC, be recommended for such patients.	Shanghai Med Univ 2, Renji Hosp, Dept Neurosurg, Shanghai 200001, Peoples R China; Second Affiliated Hosp, Kunming Med Coll, Dept Neurosurg, Kunming, Peoples R China; Shenzheng Second Peoples Hosp, Dept Neurosurg, Shenzheng, Peoples R China; Yixing Peoples Hosp, Dept Neurosurg, Yixing, Peoples R China; Longgang Hosp, Dept Neurosurg, Longgang, Peoples R China	Jiang, JY (corresponding author), Shanghai Med Univ 2, Renji Hosp, Dept Neurosurg, Shanghai 200001, Peoples R China.	Jiangjyb@online.sh.cn					Alexander E, 1987, Br J Neurosurg, V1, P427, DOI 10.3109/02688698708999632; American Association of Neurological Surgeons, 1996, J NEUROTRAUM, V13, P639; BECKER DP, 1990, NEUROLOGICAL SURG, P2017; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Cushing H, 1905, SURG GYNECOL OBSTET, V1, P297; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KERR FWL, 1968, MAYO CLIN PROC, V43, P852; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Shigemori M, 1979, Acta Neurochir Suppl (Wien), V28, P195; Spiller WG, 1906, J AMER MED ASSOC, V47, P679; TEASDALE G, 1974, LANCET, V2, P81; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; YAMAURA A, 1979, Neurologia Medico-Chirurgica, V19, P717, DOI 10.2176/nmc.19.717	17	170	186	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2005	22	6					623	628		10.1089/neu.2005.22.623			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	936EN	WOS:000229838400002	15941372				2021-06-18	
J	Kesler, SR; Adams, HF; Blasey, CM; Bigler, ED				Kesler, SR; Adams, HF; Blasey, CM; Bigler, ED			Premorbid intellectual functioning, education, and brain size in traumatic brain injury: An investigation of the cognitive reserve hypothesis	APPLIED NEUROPSYCHOLOGY			English	Article						cognitive reserve; intracranial brain volume; pre- and post-injury IQ; static MRI	CLOSED-HEAD-INJURY; FRAGILE-X-SYNDROME; ALZHEIMERS-DISEASE; IQ; VOLUME; INTELLIGENCE; MR; SCHIZOPHRENIA; PREDICTORS; MORPHOLOGY	Cognitive reserve theories have been postulated in an attempt to explain individual differences in functional outcome following cerebral insult or disease. These theories suggest that higher education and psychometric intelligence may preserve functional capacity regardless of injury or disease severity. This study investigated cognitive reserve in 25 participants with traumatic brain injury (TBI) using high-resolution magnetic resonance imaging (MRI) analyses. We examined the relationships between total intracranial volume (TICV), ventricle-to-brain ratio (VBR), education level, and standardized testing obtained prior to injury with post-injury cognitive outcome. Participants with lower post-injury IQ scores had significantly lower TICV values, irrespective of injury severity, and experienced significantly greater change in IQ from pre- to post-injury. TICV and education correctly predicted participants' post-injury IQ category (greater than or equal to 90 or < 90). However premorbid standardized testing (PST) scores did not predict cognitive outcome. The results of this study suggest that larger premorbid brain volume and higher education level may decrease vulnerability to cognitive deficits following TBI, consistent with the notion of a cognitive reserve.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, State Psychiat Neuroimaging Lab, Palo Alto, CA 94304 USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.	erin_bigler@byu.edu					Alexander GE, 1997, AM J PSYCHIAT, V154, P165; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; ANDREASEN NC, 1993, AM J PSYCHIAT, V150, P130; Axelrod BN, 1999, J CLIN EXP NEUROPSYC, V21, P368, DOI 10.1076/jcen.21.3.368.916; Bassell GJ, 2000, EUR J NEUROSCI, V12, P2; Bassett R, 2000, POWER ENG J, V14, P3; BEMIS SE, 1968, J APPL PSYCHOL, V52, P240, DOI 10.1037/h0025733; Bennett G.K., 1990, DIFFERENTIAL APTITUD; Bigio EH, 2002, NEUROPATH APPL NEURO, V28, P218, DOI 10.1046/j.1365-2990.2002.00385.x; Bigler E D, 1999, Appl Neuropsychol, V6, P217, DOI 10.1207/s15324826an0604_4; Bigler ED, 1995, DEV NEUROPSYCHOL, V11, P377, DOI 10.1080/87565649509540628; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2001, ARCH NEUROL-CHICAGO, V58, P831, DOI 10.1001/archneur.58.5.831; BIGLER ED, 2002, UNPUB INTRACRANIAL V; BIGLER ED, 2002, IN PRESS J INT NEURO; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Castellanos FX, 2002, JAMA-J AM MED ASSOC, V288, P1740, DOI 10.1001/jama.288.14.1740; Churchill JD, 2002, DEV PSYCHOBIOL, V40, P323, DOI 10.1002/dev.10036; Coffey CE, 1999, NEUROLOGY, V53, P189, DOI 10.1212/WNL.53.1.189; Cohen CI, 2000, NEUROLOGY, V54, P1207, DOI 10.1212/WNL.54.5.1207; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COLLINS LF, 2000, COMP VALIDITY NART N; Crawford JR, 2001, BRIT J CLIN PSYCHOL, V40, P97, DOI 10.1348/014466501163517; Cummings JL, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.1_Suppl_1.S2; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Drachman DA, 2002, NEUROLOGY, V59, P156, DOI 10.1212/WNL.59.2.156; Dunai FA, 2001, MIL MED, V166, P422; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gao BL, 2000, J NEUROPSYCH CLIN N, V12, P385, DOI 10.1176/appi.neuropsych.12.3.385; Graves AB, 2001, NEUROLOGY, V57, P1453, DOI 10.1212/WNL.57.8.1453; Grove WM, 2001, PSYCHOL ASSESSMENT, V13, P396, DOI 10.1037/1040-3590.13.3.396; Irwin SA, 2001, AM J MED GENET, V98, P161, DOI 10.1002/1096-8628(20010115)98:2<161::AID-AJMG1025>3.0.CO;2-B; Kastner JW, 2001, PERCEPT MOTOR SKILL, V92, P381, DOI 10.2466/PMS.92.2.381-390; Keenan JP, 2001, NEUROIMAGE, V14, P1402, DOI 10.1006/nimg.2001.0925; Kesler SR, 2000, BRAIN INJURY, V14, P851; Kraiuhin C, 1996, BRAIN INJURY, V10, P677, DOI 10.1080/026990596124098; Lee CU, 2002, ARCH GEN PSYCHIAT, V59, P775, DOI 10.1001/archpsyc.59.9.775; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; MacLullich AMJ, 2002, NEUROLOGY, V59, P169, DOI 10.1212/WNL.59.2.169; Mayes S D, 1989, Brain Inj, V3, P301, DOI 10.3109/02699058909029643; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; Meadows AB, 2002, MIL MED, V167, P140; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mori E, 1997, AM J PSYCHIAT, V154, P18, DOI 10.1176/ajp.154.1.18; MURPHY KR, 1988, PSYCHOLOGICAL TESTIN; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Reiss AL, 1996, BRAIN, V119, P1763, DOI 10.1093/brain/119.5.1763; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Seidman LJ, 2002, ARCH GEN PSYCHIAT, V59, P839, DOI 10.1001/archpsyc.59.9.839; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stern RA, 1996, ARCH NEUROL-CHICAGO, V53, P148, DOI 10.1001/archneur.1996.00550020052015; STERN Y, 1992, ANN NEUROL, V32, P371, DOI 10.1002/ana.410320311; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; TEASDALE G, 1974, LANCET, V2, P81; THORNDIKE RL, 1986, STANFORDBINET INTELL; Tisserand DJ, 2001, NEUROLOGY, V56, P969, DOI 10.1212/WNL.56.7.969; Tofil S, 1996, BRAIN INJURY, V10, P901, DOI 10.1080/026990596123873; Veiel HOF, 2001, PSYCHOL ASSESSMENT, V13, P356, DOI 10.1037/1040-3590.13.3.356; VERON PA, 2000, HDB INTELLIGENCE, P245; Watt KJ, 1999, J NEUROL NEUROSUR PS, V66, P474, DOI 10.1136/jnnp.66.4.474; Wechsler, 1981, WAIS R MANUAL; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; WILLIAMS R, 1967, J MED TECHNOL, V33, P142; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	69	170	172	1	19	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2003	10	3					153	162		10.1207/S15324826AN1003_04			10	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	780NL	WOS:000189387500004	12890641				2021-06-18	
J	Bayir, H; Kagan, VE; Tyurina, YY; Tyurin, V; Ruppel, RA; Adelson, PD; Graham, SH; Janesko, K; Clark, RSB; Kochanek, PM				Bayir, H; Kagan, VE; Tyurina, YY; Tyurin, V; Ruppel, RA; Adelson, PD; Graham, SH; Janesko, K; Clark, RSB; Kochanek, PM			Assessment of antioxidant reserves and oxidative stress in cerebrospinal fluid after severe traumatic brain injury in infants and children	PEDIATRIC RESEARCH			English	Article; Proceedings Paper	Annual Meeting of the Pediatric-Academic-Societies	APR 28-MAY 13, 2001	Baltimore, MD	Pediat Acad Soc			ENTRAPPED SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; ASCORBIC-ACID; HEAD-INJURY; HYDROGEN-PEROXIDE; FREE-RADICALS; EXPRESSION; OXIDANTS; MODERATE	Studies in experimental traumatic brain injury (TBI) support a key role for oxidative stress. The degree of oxidative injury in clinical TBI, however, remains to be defined. We assessed antioxidant defenses and oxidative stress in pediatric TBI by applying a comprehensive battery of assays to cerebrospinal fluid samples. Using a protocol approved by our institutional review board, 87 cerebrospinal fluid samples from I I infants and children with severe TBI (Glasgow Coma Scale score less than or equal to 8) and 8 controls were studied, Cerebrospinal fluid was drained as standard care after TBI. CSF was assessed on d 1, 2. and 5-7 after ventricular drain placement. Biochemical markers of oxidative stress included F-2-isoprostane and protein sulfhydryl (detected by ELISA and fluorescence assay, respectively). Antioxidant defenses were measured by determination of total antioxidant reserve (via chemiluminescence assay), and ascorbate (via HPLC) and glutathione (via fluorescence assay) concentrations. Free radical production (ascorbate radical) was assessed by electron paramagnetic resonance spectroscopy. F-2-isoprostane was markedly increased versus control. maximal on d 1 (93.8 +/- 30.8 pg/mL versus 7.6 +/- 5.1 pg/mL, p < 0.05). Total antioxidant reserve was reduced versus control. Reduction was maximal on d 5-7 (81.8 +/- 3.7 muM versus 178.9 +/- 2.2 muM, p < 0.05). Ascorbate was remarkably reduced (53.8 +/- 8 muM versus 163.8 +/- 21 AM on d 1, p < 0.05). Ascorbate depletion was likely associated with its free radical oxidation, as evidenced by electron paramagnetic resonance spectroscopy. Glutathione levels increased on d 1, then decreased versus control (0.19 +/- 0.05 muM versus 1.2 +/- 0.16 muM, p < 0.05). This is the first comprehensive study of antioxidant reserve and oxidative injury in clinical TBI. Progressive compromise of antioxidant defenses and evidence of free radical-mediated lipid peroxidation are noted. These markers could be used to monitor antioxidant strategies in clinical trials.	Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Environm & Occupat Hlth & Pharmacol, Pittsburgh, PA 15261 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.	kochanekpm@anes.upmc.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Tyurina, Yulia/0000-0003-0287-2091; Tyurin, Vladimir/0000-0002-3474-1697	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318] Funding Source: NIH RePORTER		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AMSTAD PA, 1992, CANCER RES, V52, P3952; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BRAU RH, 1984, NEUROSURGERY, V14, P142, DOI 10.1227/00006123-198402000-00004; BUETTNER GR, 1993, FREE RADICAL BIO MED, V14, P49, DOI 10.1016/0891-5849(93)90508-R; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Clark RSB, 1999, FASEB J, V13, P813; COBBS CS, 1995, CANCER RES, V55, P727; DELBIGIO MR, 1989, NEUROSURGERY, V25, P416, DOI 10.1227/00006123-198909000-00016; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; Greco A, 1999, NEUROLOGY, V53, P1876, DOI 10.1212/WNL.53.8.1876; Hall E D, 1987, Acta Anaesthesiol Belg, V38, P421; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hall ED, 1997, J PHARMACOL EXP THER, V281, P895; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hensley K, 2000, FREE RADICAL BIO MED, V28, P1456, DOI 10.1016/S0891-5849(00)00252-5; IKEDA Y, 1990, NEUROSURGERY, V27, P1; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; KARIBE H, 1994, BRAIN RES, V649, P12, DOI 10.1016/0006-8993(94)91043-X; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; KONTOS CD, 1992, AM J PHYSIOL, V263, pH1234; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1993, STROKE, V24, P427, DOI 10.1161/01.STR.24.3.427; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Langmuir ME, 1996, FLUORESCENCE MICROSCOPY AND FLUORESCENT PROBES, P229; Lonnrot K, 1996, FREE RADICAL BIO MED, V21, P211, DOI 10.1016/0891-5849(95)02207-4; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1995, J NEUROTRAUM, V12, P929, DOI 10.1089/neu.1995.12.929; MEISTER A, 1992, BIOCHEM PHARMACOL, V44, P1905, DOI 10.1016/0006-2952(92)90091-V; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; REBEC GV, 1994, PROG NEUROBIOL, V43, P537, DOI 10.1016/0301-0082(94)90052-3; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; SEN S, 1993, NEUROSCI LETT, V162, P117, DOI 10.1016/0304-3940(93)90574-5; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SPECTOR R, 1984, FED PROC, V43, P196; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; TYURINA YY, 1995, TOXICOL APPL PHARM, V131, P277, DOI 10.1006/taap.1995.1070; Van Hove JLK, 1998, J INHERIT METAB DIS, V21, P799, DOI 10.1023/A:1005462400552; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Wahlgren NG, 1997, INT REV NEUROBIOL, V40, P337; WATSON BD, 1993, PROG BRAIN RES, V96, P69; Wei EP, 1996, AM J PHYSIOL-HEART C, V271, pH1262; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1; Yao YH, 1996, BIOCHEMISTRY-US, V35, P2767, DOI 10.1021/bi951712i; YOUNG W, 1988, STROKE, V19, P1013, DOI 10.1161/01.STR.19.8.1013; ZUCCARELLO M, 1989, J NEUROSURG, V71, P98, DOI 10.3171/jns.1989.71.1.0098	52	170	171	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998	1530-0447		PEDIATR RES	Pediatr. Res.	MAY	2002	51	5					571	578		10.1203/00006450-200205000-00005			8	Pediatrics	Pediatrics	544QM	WOS:000175171600005	11978879	Bronze			2021-06-18	
J	Frantseva, MV; Kokarovtseva, L; Naus, CG; Carlen, PL; MacFabe, D; Velazquez, JLP				Frantseva, MV; Kokarovtseva, L; Naus, CG; Carlen, PL; MacFabe, D; Velazquez, JLP			Specific gap junctions enhance the neuronal vulnerability to brain traumatic injury	JOURNAL OF NEUROSCIENCE			English	Article						trauma; gap junctions; antisense; electrophysiology; organotypic slices; cx43 knock-out	MICE LACKING CONNEXIN43; DIFFERENTIAL EXPRESSION; NERVE INJURY; INTERCELLULAR COMMUNICATION; HIPPOCAMPAL SLICE; PYRAMIDAL NEURONS; INFARCT VOLUME; RAT; DAMAGE; HOMEOSTASIS	Traumatic brain injury results in neuronal loss and associated neurological deficits. Although most research on the factors leading to trauma-induced damage focuses on synaptic or ionic mechanisms, the possible role of direct intercellular communication via gap junctions has remained unexplored. Gap junctions connect directly the cytoplasms of coupled cells; hence, they offer a way to propagate stress signals from cell to cell. We investigated the contribution of gap junctional communication (GJC) to cell death using an in vitro trauma model. The impact injury, induced by a weight dropped on the distal CA1 area of organotypic hippocampal slices, results in glutamate-dependent cell loss. The gap junctional blockers carbenoxolone and octanol decreased significantly post-traumatic cell death, measured by propidium iodide staining over a 72 hr period after the impact. Dye coupling in the pyramidal layers was enhanced immediately after the injury and decreased over the following 24 hr. To determine whether specific connexins were involved in the spread of trauma-induced cell death, we used organotypic slices from connexin43 (Cx43) knock-out mice, as well as acute knock-outs by incubation with antisense oligodeoxynucleotides. Simultaneous knockdown of two neuronal connexins resulted in significant neuroprotection. Slices from the null-mutant Cx43 mice, as well as the acute Cx43 knockdown, also showed decreased cell death after the impact. The gap junctional blockers alleviated the trauma-induced impairment of synaptic function as measured by electrophysiological field potential recordings. These results indicate that GJC enhances the cellular vulnerability to traumatic injury. Hence, specific gap junctions could be a novel target to reduce injury and secondary damage to the brain and maximize recovery from trauma.	Hosp Sick Children, Dept Neurol, Toronto, ON M5G 1X8, Canada; Dept Med Neurol, Toronto, ON M5T 2S8, Canada; Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada; Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada	Velazquez, JLP (corresponding author), Hosp Sick Children, Dept Neurol, 555 Univ Ave,Room 6535 Hill Wing, Toronto, ON M5G 1X8, Canada.	jlpv@sickkids.ca		Carlen, Peter/0000-0002-3339-8102			Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Bani-Yaghoub M, 1999, DEV GENET, V24, P69, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<69::AID-DVG8>3.0.CO;2-M; Beardslee MA, 2000, CIRC RES, V87, P656, DOI 10.1161/01.RES.87.8.656; Blanc EM, 1998, J NEUROCHEM, V70, P958; BRICOLO AP, 1990, HDB CLIN NEUROLOGY, P181; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Castejon OJ, 1998, BRAIN INJURY, V12, P409, DOI 10.1080/026990598122539; Chandross KJ, 1996, MOL CELL NEUROSCI, V7, P501, DOI 10.1006/mcne.1996.0036; Chandross KJ, 1998, GLIA, V24, P21, DOI 10.1002/(SICI)1098-1136(199809)24:1<21::AID-GLIA3>3.0.CO;2-3; Chang QA, 2000, J NEUROSCI, V20, P674, DOI 10.1523/JNEUROSCI.20-02-00674.2000; CHURCH J, 1991, J NEUROSCI, V11, P3289; Condorelli DF, 1998, EUR J NEUROSCI, V10, P1202, DOI 10.1046/j.1460-9568.1998.00163.x; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Cotrina ML, 1998, J NEUROSCI, V18, P2520; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; DANGELO CM, 1973, J NEUROSURG, V2, P791; DAVIDSON JS, 1988, J PHARMACOL EXP THER, V246, P1104; DERMIETZEL R, 1989, P NATL ACAD SCI USA, V86, P10148, DOI 10.1073/pnas.86.24.10148; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Frantseva MV, 1999, J NEUROSCI METH, V89, P25, DOI 10.1016/S0165-0270(99)00030-8; GarciaDorado D, 1997, CIRCULATION, V96, P3579; Goldberg GS, 1996, EXP CELL RES, V222, P48, DOI 10.1006/excr.1996.0006; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Huang XL, 1999, NAHRUNG, V43, P79, DOI [10.1002/(SICI)1521-3803(19990301)43:2&lt;79::AID-FOOD79&gt;3.0.CO;2-8, 10.1002/(SICI)1521-3803(19990301)43:2<79::AID-FOOD79>3.3.CO;2-#]; Iwata F, 1998, AM J PHYSIOL-GASTR L, V275, pG883; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; Joshi I, 2001, J NEUROPHYSIOL, V85, P414; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Li WEI, 1998, EUR J NEUROSCI, V10, P2444, DOI 10.1046/j.1460-9568.1998.00253.x; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Nadarajah B, 1997, J NEUROSCI, V17, P3096; Nagaoka T, 1999, J HISTOCHEM CYTOCHEM, V47, P937, DOI 10.1177/002215549904700711; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Obeidat AS, 1998, EUR J NEUROSCI, V10, P3451, DOI 10.1046/j.1460-9568.1998.00358.x; PEREZVELAZQUEZ JL, 1994, J NEUROSCI, V14, P4308; Rawanduzy A, 1997, J NEUROSURG, V87, P916, DOI 10.3171/jns.1997.87.6.0916; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; ROHLMANN A, 1994, NEUROREPORT, V5, P409, DOI 10.1097/00001756-199401120-00009; Rorig B, 1996, J PHYSIOL-LONDON, V490, P31; Ross FM, 2000, NEUROSCIENCE, V100, P789, DOI 10.1016/S0306-4522(00)00346-8; Rozental R, 2001, METH MOL B, V154, P447; Rozental R, 2000, BRAIN RES REV, V32, P189, DOI 10.1016/S0165-0173(99)00097-1; Ruiz-Meana M, 1999, CIRC RES, V85, P280, DOI 10.1161/01.RES.85.3.280; Saito R, 1997, J CEREBR BLOOD F MET, V17, P857, DOI 10.1097/00004647-199708000-00004; Scemes E, 1998, GLIA, V24, P74, DOI 10.1002/(SICI)1098-1136(199809)24:1<74::AID-GLIA8>3.0.CO;2-0; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SIUSHANSIAN R, 2002, IN PRESS J COMP NEUR; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; SPRAY DC, 1996, GAP JUNCTIONS NERVOU, P1; Stein CA, 1998, ANTISENSE NUCLEIC A, V8, P129, DOI 10.1089/oli.1.1998.8.129; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Teubner B, 2001, J NEUROSCI, V21, P1117; Trosko JE, 1998, TOXICOL LETT, V103, P71, DOI 10.1016/S0378-4274(98)00288-4; Velazquez JLP, 1997, J NEUROSCI, V17, P9085; Velazquez JLP, 1996, DEV BRAIN RES, V97, P293; WADE MH, 1986, SCIENCE, V232, P525, DOI 10.1126/science.3961495; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; YUSTE R, 1995, NEURON, V14, P7, DOI 10.1016/0896-6273(95)90236-8	61	170	181	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	FEB 1	2002	22	3					644	653		10.1523/JNEUROSCI.22-03-00644.2002			10	Neurosciences	Neurosciences & Neurology	518HB	WOS:000173660800014	11826094	Green Published, Other Gold			2021-06-18	
J	Ponsford, J; Willmott, C; Rothwell, A; Cameron, P; Ayton, G; Nelms, R; Curran, C; Ng, KT				Ponsford, J; Willmott, C; Rothwell, A; Cameron, P; Ayton, G; Nelms, R; Curran, C; Ng, KT			Cognitive and behavioral outcome following mild traumatic head injury in children	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mild pediatric head injury; mild pediatric traumatic brain injury; outcome	BRAIN INJURY; NEUROPSYCHOLOGICAL SEQUELAE; SEVERITY; RECOVERY; AMNESIA; COHORT; STRESS; SCALE	Objectives: To investigate outcome in children with mild traumatic head injury (THI) at 1 week and 3 months postinjury and to identify factors associated with persisting problems. Design: Postconcussional symptomatology, behavior ratings, and neuropsychological test performance mere examined at 1 week and 3 months postinjury. Setting: Participants were recruited from successive presentations to emergency departments of two major hospitals. Participants: 130 Children with mild THI were compared with 96 children having other minor injuries as controls. Results: Children with mild THI experienced headaches, dizziness, and fatigue but exhibited no cognitive impairments, relative to controls, at 1 week postinjury. By 3 months, symptoms had resolved. However, 17% of children showed significant ongoing problems. They were more likely to have a history of previous head injury, learning difficulties, neurological or psychiatric problems, or family stressors. Conclusions: Persisting problems following mild head injury in children are more common in those with previous head injury, preexisting learning difficulties, or neurological, psychiatric, or family problems. These "at-risk" children should be identified in the emergency department and monitored.	Monash Univ, Bethesda Hosp, Melbourne, Vic 3004, Australia; Bethesda Hosp, Richmond, Vic, Australia; Julia Farr Serv S Australia, Howe Rehabil Serv, Melbourne, Vic, Australia; Royal Melbourne Hosp, Melbourne, Vic, Australia; Western Hosp, Emergency Dept, Richmond, Vic, Australia	Ponsford, J (corresponding author), Monash Univ, Bethesda Hosp, Melbourne, Vic 3004, Australia.		Willmott, Catherine/AAA-5105-2019	Willmott, Catherine/0000-0001-8517-9035; Cameron, Peter/0000-0002-1443-557X			Achenbach TM, 1983, MANUAL CHILD BEHAV C; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR; BERROL S, 1992, PHYSICAL MED REHABIL, V6, P1; Bijur P., 1995, TRAUMATIC HEAD INJUR; BIJUR PE, 1990, PEDIATRICS, V86, P337; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dunn L., 1981, PEABODY PICTURE VOCA; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JOHNSON DA, 1988, J CHILD PSYCHOL PSYC, V29, P199, DOI 10.1111/j.1469-7610.1988.tb00704.x; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Levin HS, 1989, MILD HEAD INJURY; MAROSSZEKY NEV, 1993, CLIN NEUROPSYCHOL, V7, P85, DOI 10.1080/13854049308401890; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; ROWE KJ, 1993, ASSESSING EXTERNALIS; RUTTER M, 1983, DEV NEUROPSYCHIAT; Sheslow D., 1990, WIDE RANGE ASSESSMEN; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Sparrow S., 1984, VINELAND ADAPTIVE BE; Tabachnick BG, 2013, USING MULTIVARIATE S; TAYLOR HG, 1987, J PEDIATR PSYCHOL, V12, P394; Wechsler D., 1991, WECHSLER INTELLIGENC; WILLMOTT C, 1996, INT PERSPECTIVES TRA, P305	37	170	171	0	13	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1999	14	4					360	372		10.1097/00001199-199908000-00005			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	224LW	WOS:000081901400006	10407209				2021-06-18	
J	JAKOB, RP; MINIACI, A; ANSON, PS; JABERG, H; OSTERWALDER, A; GANZ, R				JAKOB, RP; MINIACI, A; ANSON, PS; JABERG, H; OSTERWALDER, A; GANZ, R			4-PART VALGUS IMPACTED FRACTURES OF THE PROXIMAL HUMERUS	JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME			English	Article								There is a specific type of displaced four-part fracture of the proximal humerus which consists of valgus impaction of the head fragment; this deserves special consideration because the rate of avascular necrosis is lower than that of other displaced four-part fractures. Using either closed reduction or limited open reduction and minimal internal fixation, 74% satisfactory results can be achieved in this injury.		JAKOB, RP (corresponding author), UNIV BERN,INSELSPITAL,DEPT ORTHOPAED SURG,CH-3010 BERN,SWITZERLAND.						DEANQUIN CE, 1982, SHOULDER SURG, P207; DUPARC J, 1976, REV CHIR ORTHOP, V62, P91; JAKOB RP, 1981, HELV CHIR ACTA, V48, P595; Jakob RP, 1984, SURG SHOULDER, P330; LEE CK, 1981, J TRAUMA, V21, P788, DOI 10.1097/00005373-198109000-00006; LEYSHON RL, 1984, ACTA ORTHOP SCAND, V55, P48, DOI 10.3109/17453678408992310; MILLS HJ, 1985, J TRAUMA, V25, P801, DOI 10.1097/00005373-198508000-00013; Muller ME, 1990, COMPREHENSIVE CLASSI; NEER CS, 1970, J BONE JOINT SURG AM, VA 52, P1077, DOI 10.2106/00004623-197052060-00001; NEER CS, 1970, J BONE JOINT SURG AM, VA 52, P1090, DOI 10.2106/00004623-197052060-00002; STABLEFORTH PG, 1984, J BONE JOINT SURG BR, V66, P104; STURZENEGGER M, 1982, ARCH ORTHOP TRAUM SU, V100, P249, DOI 10.1007/BF00381665; TANNER MW, 1983, CLIN ORTHOP RELAT R, V179, P116	13	170	185	0	3	BRITISH EDITORIAL SOC BONE JOINT SURGERY	LONDON	22 BUCKINGHAM STREET, LONDON, ENGLAND WC2N 6ET	0301-620X			J BONE JOINT SURG BR	J. Bone Joint Surg.-Br. Vol.	MAR	1991	73	2					295	298					4	Orthopedics; Surgery	Orthopedics; Surgery	FD093	WOS:A1991FD09300026	2005159				2021-06-18	
J	Metzler-Baddeley, C; O'Sullivan, MJ; Bells, S; Pasternak, O; Jones, DK				Metzler-Baddeley, Claudia; O'Sullivan, Michael J.; Bells, Sonya; Pasternak, Ofer; Jones, Derek K.			How and how not to correct for CSF-contamination in diffusion MRI	NEUROIMAGE			English	Article						Diffusion MRI; Partial volume effects; Atrophy; Fornix; Ageing	TRAUMATIC BRAIN-INJURY; SPHERICAL DECONVOLUTION; MULTIPLE-SCLEROSIS; FIBER TRACKING; TENSOR MRI; TRACTOGRAPHY; ORIENTATION; DISEASE; MICROSTRUCTURE; SCHIZOPHRENIA	Diffusion MRI is used extensively to investigate changes in white matter microstructure related to brain development and pathology. Ageing, however, is also associated with significant white and grey matter loss which in turn can lead to cerebrospinal fluid (CSF) based partial volume artefacts in diffusion MRI metrics. This is especially problematic in regions prone to CSF contamination, such as the fornix and the genu of corpus callosum, structures that pass through or close to the ventricles respectively. The aim of this study was to model the effects of CSF contamination on diffusion MRI metrics, and to evaluate different post-acquisition strategies to correct for CSF-contamination: Controlling for whole brain volume and correcting on a voxel-wise basis using the Free Water Elimination (FWE) approach. Using the fornix as an exemplar of a structure prone to CSF-contamination, corrections were applied to tract-specific and voxel-based [tract based spatial statistics (TBSS)] analyses of empirical DT-MRI data from 39 older adults (53-93 years of age). In addition to significant age-related decreases in whole brain volume and fornix tissue volume fraction, age was also associated with a reduction in mean fractional anisotropy and increase in diffusivity metrics in the fornix. The experimental data agreed with the simulations in that diffusivity metrics (mean diffusivity, axial and radial diffusivity) were more prone to partial volume CSF-contamination errors than fractional anisotropy. After FWE-based voxel-by-voxel partial volume corrections, the significant positive correlations between age and diffusivity metrics, in particular with axial diffusivity, disappeared whereas the correlation with anisotropy remained. In contrast, correcting for whole brain volume had little effect in removing these spurious correlations. Our study highlights the importance of correcting for CSF-contamination partial volume effects in the structures of interest on a voxel-by-voxel basis prior to drawing inferences about underlying changes in white matter structures and have implications for the interpretation of many recent diffusion MRI results in ageing and disease. (C) 2011 Elsevier Inc. All rights reserved.	[Metzler-Baddeley, Claudia; O'Sullivan, Michael J.; Bells, Sonya; Jones, Derek K.] Cardiff Univ, Sch Psychol, Cardiff Univ Brain Res Imaging Ctr CUBRIC, Cardiff, S Glam, Wales; [Metzler-Baddeley, Claudia; O'Sullivan, Michael J.; Bells, Sonya; Jones, Derek K.] Cardiff Univ, Neurosci & Mental Hlth Res Inst, Cardiff, S Glam, Wales; [O'Sullivan, Michael J.] Kings Coll London, Dept Clin Neurosci, Inst Psychiat, London WC2R 2LS, England; [Pasternak, Ofer] Harvard Univ, Sch Med, Dept Psychiat, Psychiat Neuroimaging Lab,Brigham & Womens Hosp, Boston, MA 02115 USA	Metzler-Baddeley, C (corresponding author), Cardiff Univ, Sch Psychol, Cardiff Univ Brain Res Imaging Ctr CUBRIC, Pk Pl, Cardiff, S Glam, Wales.	Metzler-BaddeleyC@cardiff.ac.uk	Jones, Derek K/D-1460-2009; Metzler-Baddeley, Claudia/A-1595-2010; Metzler-Baddeley, Claudia/ABG-2313-2020; O'Sullivan, Michael/A-1796-2010	Metzler-Baddeley, Claudia/0000-0002-8646-1144; O'Sullivan, Michael/0000-0002-2869-4580; Jones, Derek K/0000-0003-4409-8049; Bells, Sonya/0000-0001-8688-1571	Medical Research Council, UKUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0801418B, G0701912] Funding Source: researchfish	This work was supported by the Medical Research Council, UK.	Aggleton JP, 2000, BRAIN, V123, P800, DOI 10.1093/brain/123.4.800; Agosta F, 2011, RADIOLOGY, V258, P853, DOI 10.1148/radiol.10101284; Alexander AL, 2001, MAGN RESON MED, V45, P770, DOI 10.1002/mrm.1105; Allen JS, 2005, NEUROBIOL AGING, V26, P1245, DOI 10.1016/j.neurobiolaging.2005.05.023; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Caroli A, 2009, EXPERT REV MED DEVIC, V6, P569, DOI 10.1586/ERD.09.35; Catani M, 2002, NEUROIMAGE, V17, P77, DOI 10.1006/nimg.2002.1136; Chou MC, 2005, AM J NEURORADIOL, V26, P591; Concha L, 2005, AM J NEURORADIOL, V26, P2267; Fjell AM, 2008, NEUROIMAGE, V42, P1654, DOI 10.1016/j.neuroimage.2008.06.005; Ikram MA, 2008, NEUROBIOL AGING, V29, P882, DOI 10.1016/j.neurobiolaging.2006.12.012; Inglese M, 2010, NMR BIOMED, V23, P865, DOI 10.1002/nbm.1515; Jones DK, 2010, NMR BIOMED, V23, P803, DOI 10.1002/nbm.1543; Jones DK, 1999, MAGN RESON MED, V42, P37, DOI 10.1002/(SICI)1522-2594(199907)42:1<37::AID-MRM7>3.0.CO;2-O; Jones DK, 2005, AM J GERIAT PSYCHIAT, V13, P1092, DOI 10.1176/appi.ajgp.13.12.1092; Jones DK, 2005, MAGNET RESON MED, V53, P1462, DOI 10.1002/mrm.20484; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; JONES DK, 2005, P ISMRM 13 ANN M MIA, P225; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Konrad K, 2010, HUM BRAIN MAPP, V31, P904, DOI 10.1002/hbm.21058; Koo BB, 2009, NEUROIMAGE, V44, P136, DOI 10.1016/j.neuroimage.2008.07.064; Kubicki M, 2007, J PSYCHIATR RES, V41, P15, DOI 10.1016/j.jpsychires.2005.05.005; Lee JE, 2009, NEUROIMAGE, V44, P870, DOI 10.1016/j.neuroimage.2008.09.041; Leemans A., 2009, 17 ANN M INT SOC MAG; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lodygensky GA, 2010, J ANAT, V217, P418, DOI 10.1111/j.1469-7580.2010.01280.x; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Metzler-Baddeley C, 2011, J NEUROSCI, V31, P13236, DOI 10.1523/JNEUROSCI.2317-11.2011; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; O'Sullivan M, 2005, NEUROLOGY, V65, P1584, DOI 10.1212/01.wnl.0000184480.07394.fb; O'Sullivan M, 2008, NEUROIMAGE, V43, P312, DOI 10.1016/j.neuroimage.2008.07.049; Oakes TR, 2007, NEUROIMAGE, V34, P500, DOI 10.1016/j.neuroimage.2006.10.007; Pajevic S, 1999, MAGNET RESON MED, V42, P526, DOI 10.1002/(SICI)1522-2594(199909)42:3<526::AID-MRM15>3.0.CO;2-J; Papadakis NG, 2002, MAGNET RESON MED, V48, P394, DOI 10.1002/mrm.10204; Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055; Patel B, 2011, INT J STROKE, V6, P47, DOI 10.1111/j.1747-4949.2010.00552.x; Pfefferbaum A, 2003, MAGNET RESON MED, V49, P953, DOI 10.1002/mrm.10452; PIERPAOLI C, 2003, P INT SOC MAGN RESON, V11, P70; Pierpaoli C, 2004, P 12 ANN M ISMRM KYO, P1215; Rashid W, 2004, MULT SCLER J, V10, P9, DOI 10.1191/1352458504ms985oa; Seppi K, 2010, NEUROIMAG CLIN N AM, V20, P29, DOI 10.1016/j.nic.2009.08.016; SKATE S, 2001, MAGN RESON IMAGING, V19, P1125; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; *SPSS INC, 2008, SPSS 16 0; Sullivan EV, 2010, DEV NEUROPSYCHOL, V35, P233, DOI 10.1080/87565641003689556; Takao H, 2011, NEUROIMAGE, V57, P958, DOI 10.1016/j.neuroimage.2011.05.019; Tournier JD, 2008, NEUROIMAGE, V42, P617, DOI 10.1016/j.neuroimage.2008.05.002; Tournier JD, 2007, NEUROIMAGE, V35, P1459, DOI 10.1016/j.neuroimage.2007.02.016; Tournier JD, 2004, NEUROIMAGE, V23, P1176, DOI 10.1016/j.neuroimage.2004.07.037; Vos SB, 2011, NEUROIMAGE, V55, P1566, DOI 10.1016/j.neuroimage.2011.01.048; Westerhausen R, 2011, NEUROIMAGE, V56, P874, DOI 10.1016/j.neuroimage.2011.03.013; Wild EJ, 2009, MOVEMENT DISORD, V24, pS691, DOI 10.1002/mds.22500	58	169	170	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119			NEUROIMAGE	Neuroimage	JAN 16	2012	59	2					1394	1403		10.1016/j.neuroimage.2011.08.043			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	864AY	WOS:000298210600058	21924365				2021-06-18	
J	Ponsford, J; Cameron, P; Fitzgerald, M; Grant, M; Mikocka-Walus, A				Ponsford, Jennie; Cameron, Peter; Fitzgerald, Mark; Grant, Michele; Mikocka-Walus, Antonina			Long-Term Outcomes after Uncomplicated Mild Traumatic Brain Injury: A Comparison with Trauma Controls	JOURNAL OF NEUROTRAUMA			English	Article						mild traumatic brain injury outcomes	WESTMEAD PTA SCALE; CONCUSSION SYMPTOMS; HOSPITAL ANXIETY; VALIDITY; DEPRESSION; CHECKLIST; ATTENTION; INTERVIEW; RECOVERY; IMPACT	The question as to whether mild traumatic brain injury (mTBI) results in persisting sequelae over and above those experienced by individuals sustaining general trauma remains controversial. This prospective study aimed to document outcomes 1 week and 3 months post-injury following mTBI assessed in the emergency department (ED) of a major adult trauma center. One hundred and twenty-three patients presenting with uncomplicated mTBI and 100 matched trauma controls completed measures of post-concussive symptoms and cognitive performance (Immediate Post-Concussion Assessment and Cognitive Testing battery; ImPACT) and pre-injury health-related quality of life (SF-36) in the ED. These measures together with measures of psychiatric status (the Mini-International Neuropsychiatric Interview [MINI]) pre- and post-injury, the Hospital Anxiety and Depression Scale, Visual Analogue Scale for Pain, Functional Assessment Questionnaire, and PTSD Checklist-Specific, were re-administered at follow-up. Participants with mTBI showed significantly more severe post-concussive symptoms in the ED and at 1 week post-injury. They performed more poorly than controls on the Visual Memory subtest of the ImPACT at 1 week and 3 months post-injury. Both the mTBI and control groups recovered well physically, and most were employed 3 months post-injury. There were no significant group differences in psychiatric function. However, the group with mild TBI was more likely to report ongoing memory and concentration problems in daily activities. Further investigation of factors associated with these ongoing problems is warranted.	[Ponsford, Jennie] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia; [Ponsford, Jennie; Grant, Michele; Mikocka-Walus, Antonina] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Cameron, Peter; Fitzgerald, Mark] Alfred Hosp, Melbourne, Vic, Australia; [Ponsford, Jennie; Cameron, Peter; Fitzgerald, Mark; Grant, Michele; Mikocka-Walus, Antonina] Natl Trauma Res Inst, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	Mikocka-Walus, Antonina/R-2363-2017; Mikocka-Walus, Antonina/B-4160-2010	Cameron, Peter/0000-0002-1443-557X; Fitzgerald, Mark/0000-0003-0183-7761; Mikocka-Walus, Antonina/0000-0003-4864-3956	Victorian Neurotrauma Initiative	This research was funded by a grant from the Victorian Neurotrauma Initiative. The authors also gratefully acknowledge the assistance of staff in the Alfred Hospital Emergency and Trauma Care Department.	Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kraus J. F., 1999, REHABILITATION ADULT, P3; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Shores EA, 2008, J NEUROL NEUROSUR PS, V79, P1100, DOI 10.1136/jnnp.2007.132571; SNAITH RP, 1986, BRIT MED J, V292, P344, DOI 10.1136/bmj.292.6516.344; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; Zhang L, 2006, AM J NEURORADIOL, V27, P2000	41	169	172	0	37	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					937	946		10.1089/neu.2010.1516			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600008	21410321				2021-06-18	
J	Cheyne, JA; Solman, GJF; Carriere, JSA; Smilek, D				Cheyne, J. Allan; Solman, Grayden J. F.; Carriere, Jonathan S. A.; Smilek, Daniel			Anatomy of an error: A bidirectional state model of task engagement/disengagement and attention-related errors	COGNITION			English	Article						Mind-wandering; Attention; Attentional engagement; Attentional disengagement; SART; Inattention; Attentional error; Action slips; Sustained attention	DEFICIT-HYPERACTIVITY-DISORDER; ANTERIOR CINGULATE CORTEX; TRAUMATIC BRAIN-INJURY; SUSTAINED ATTENTION; RESPONSE VARIABILITY; PREFRONTAL CORTEX; COGNITIVE CONTROL; INDIVIDUAL-DIFFERENCES; EVERYDAY ATTENTION; UNRELATED THOUGHT	We present arguments and evidence for a three-state attentional model of task engagement/disengagement. The model postulates three states of mind-wandering: occurrent task inattention, generic task inattention, and response disengagement. We hypothesize that all three states are both causes and consequences of task performance outcomes and apply across a variety of experimental and real-world tasks. We apply this model to the analysis of a widely used GO/NOGO task, the Sustained Attention to Response Task (SART). We identify three performance characteristics of the SART that map onto the three states of the model: RT variability, anticipations, and omissions. Predictions based on the model are tested, and largely corroborated, via regression and lag-sequential analyses of both successful and unsuccessful withholding on NOGO trials as well as self-reported mind-wandering and everyday cognitive errors. The results revealed theoretically consistent temporal associations among the state indicators and between these and SART errors as well as with self-report measures. Lag analysis was consistent with the hypotheses that temporal transitions among states are often extremely abrupt and that the association between mind-wandering and performance is bidirectional. The bidirectional effects suggest that errors constitute important occasions for reactive mind-wandering. The model also enables concrete phenomenological, behavioral, and physiological predictions for future research. (C) 2009 Elsevier B.V. All rights reserved.	[Cheyne, J. Allan; Solman, Grayden J. F.; Carriere, Jonathan S. A.; Smilek, Daniel] Univ Waterloo, Dept Psychol, Waterloo, ON N2L 3G1, Canada	Smilek, D (corresponding author), Univ Waterloo, Dept Psychol, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.	dsmilek@uwaterloo.ca		Solman, Grayden/0000-0001-9026-3143			ANTROBUS JS, 1968, BRIT J PSYCHOL, V59, P423, DOI 10.1111/j.2044-8295.1968.tb01157.x; Bellgrove MA, 2005, NEUROPSYCHOLOGIA, V43, P1847, DOI 10.1016/j.neuropsychologia.2005.03.011; Bellgrove MA, 2004, NEUROPSYCHOLOGIA, V42, P1910, DOI 10.1016/j.neuropsychologia.2004.05.007; Bellgrove MA, 2006, CORTEX, V42, P838, DOI 10.1016/S0010-9452(08)70426-X; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; BRAND M, 1984, INTENDING ACTING; Bratman Michael., 1987, INTENTION PLANS PRAC; Braver TS, 2003, NEURON, V39, P713, DOI 10.1016/S0896-6273(03)00466-5; Braver TS, 2001, CEREB CORTEX, V11, P825, DOI 10.1093/cercor/11.9.825; Burgund ED, 2003, NEUROIMAGE, V19, P29, DOI 10.1016/S1053-8119(03)00061-2; Carriere JSA, 2008, CONSCIOUS COGN, V17, P835, DOI 10.1016/j.concog.2007.04.008; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Castellanos FX, 2005, BIOL PSYCHIAT, V57, P1416, DOI 10.1016/j.biopsych.2004.12.005; Cheyne JA, 2006, CONSCIOUS COGN, V15, P578, DOI 10.1016/j.concog.2005.11.009; Cohen JD, 2000, NAT NEUROSCI, V3, P421, DOI 10.1038/74783; Dockree PM, 2007, EUR J NEUROSCI, V25, P900, DOI 10.1111/j.1460-9568.2007.05324.x; Dockree PM, 2005, NEUROIMAGE, V27, P587, DOI 10.1016/j.neuroimage.2005.05.044; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Donaldson DI, 2001, NEUROIMAGE, V13, P129, DOI 10.1006/nimg.2000.0664; DOUSE T, 1900, MIND N S, V9, P85; Falkenstein M, 1990, PSYCHOPHYSIOLOGICAL; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; Fassbender C, 2006, J PSYCHOPHYSIOL, V20, P286, DOI 10.1027/0269-8803.20.4.286; Garavan H, 2006, BRAIN RES, V1105, P130, DOI 10.1016/j.brainres.2006.03.029; GIAMBRA LM, 1995, CONSCIOUS COGN, V4, P1, DOI 10.1006/ccog.1995.1001; Gilden DL, 2007, PSYCHOL SCI, V18, P796, DOI 10.1111/j.1467-9280.2007.01982.x; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hervey AS, 2006, CHILD NEUROPSYCHOL, V12, P125, DOI 10.1080/09297040500499081; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Hester R, 2004, CEREB CORTEX, V14, P986, DOI 10.1093/cercor/bhh059; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P2234, DOI 10.1016/j.neuropsychologia.2007.02.019; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P630, DOI 10.1016/j.neuropsychologia.2006.03.034; Kane MJ, 2007, PSYCHOL SCI, V18, P614, DOI 10.1111/j.1467-9280.2007.01948.x; Kaufman JN, 2003, J NEUROSCI, V23, P7839; Klein C, 2006, BIOL PSYCHIAT, V60, P1088, DOI 10.1016/j.biopsych.2006.04.003; Kvavilashvili L, 2004, COGNITIVE PSYCHOL, V48, P47, DOI 10.1016/S0010-0285(03)00115-4; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Mackworth NH, 1948, Q J EXP PSYCHOL, V1, P6, DOI 10.1080/17470214808416738; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T, 2001, J CHILD PSYCHOL PSYC, V42, P1065, DOI 10.1111/1469-7610.00806; Manly T, 2004, NEUROPSYCHOL REHABIL, V14, P89, DOI 10.1080/09602010343000110; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P1, DOI 10.1016/S0028-3932(01)00086-0; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; Mele A., 1992, SPRINGS ACTION; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Mitchell JP, 2007, PSYCHOL SCI, V18, P292, DOI 10.1111/j.1467-9280.2007.01891.x; Mullins C, 2005, J AM ACAD CHILD PSY, V44, P169, DOI 10.1097/00004583-200502000-00009; NORMAN DA, 1981, PSYCHOL REV, V88, P1, DOI 10.1037/0033-295X.88.1.1; O'Connell RG, 2007, EUR J NEUROSCI, V25, P2571, DOI 10.1111/j.1460-9568.2007.05477.x; O'Connell RG, 2004, NEUROREPORT, V15, P2535, DOI 10.1097/00001756-200411150-00021; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Pacherie E, 2008, COGNITION, V107, P179, DOI 10.1016/j.cognition.2007.09.003; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; RASMUSSEN J, 1980, CHANGES WORKING LIFE; REASON J, 1984, BRIT J CLIN PSYCHOL, V23, P121, DOI 10.1111/j.2044-8260.1984.tb00635.x; Reason J., 1990, HUMAN ERROR; Reason J. T., 1984, VARIETIES ATTENTION; REASON JT, 1982, ABSENT MINDED PSYCHO; REASON JT, 1979, ASPECTS CONSCIOUSNES, V1; REASON JT, 1998, INT J COGNITIVE TECH, V3, P24; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; SARASON IG, 1986, J PERS SOC PSYCHOL, V51, P215, DOI 10.1037/0022-3514.51.1.215; Schooler JW, 2002, TRENDS COGN SCI, V6, P339, DOI 10.1016/S1364-6613(02)01949-6; Schooler JW, 2005, THINKING SEEING VISU; Searle J, 1983, INTENTIONALITY; Singer J. L., 1966, DAYDREAMING; SINGER JL, 1978, STREAM CONSCIOUSNESS; Smallwood J, 2006, CONSCIOUS COGN, V15, P218, DOI 10.1016/j.concog.2005.03.003; Smallwood J, 2004, CONSCIOUS COGN, V13, P789, DOI 10.1016/j.concog.2004.07.004; Smallwood J, 2004, CONSCIOUS COGN, V13, P657, DOI 10.1016/j.concog.2004.06.003; Smallwood J, 2003, CONSCIOUS COGN, V12, P169, DOI 10.1016/S1053-8100(02)00003-X; Smallwood J., 2002, IMAGINATION COGNITIO, V22, P13, DOI [10.2190/TBML-N8JN-W5YB-4L9R, DOI 10.2190/TBML-N8JN-W5YB-4L9R]; Smallwood JM, 2003, CONSCIOUS COGN, V12, P452, DOI 10.1016/S1053-8100(03)00018-7; Smallwood J, 2008, BRAIN COGNITION, V66, P50, DOI 10.1016/j.bandc.2007.05.004; Smallwood J, 2007, COGNITION EMOTION, V21, P816, DOI 10.1080/02699930600911531; Smallwood J, 2007, PSYCHON B REV, V14, P527, DOI 10.3758/BF03194102; Smallwood J, 2006, PSYCHOL BULL, V132, P946, DOI 10.1037/0033-2909.132.6.946; Sonuga-Barke EJS, 2007, NEUROSCI BIOBEHAV R, V31, P977, DOI 10.1016/j.neubiorev.2007.02.005; Stemmer B, 2004, NEUROPSYCHOLOGIA, V42, P118, DOI 10.1016/S0028-3932(03)00121-0; TEASDALE JD, 1995, BEHAV RES THER, V33, P25, DOI 10.1016/0005-7967(94)E0011-7; TEASDALE JD, 1993, EUR J COGN PSYCHOL, V5, P417, DOI 10.1080/09541449308520128; Velanova K, 2003, J NEUROSCI, V23, P8460; VINCENTE K, 2004, HUMAN FACTOR; Visscher KM, 2003, NEUROIMAGE, V19, P1694, DOI 10.1016/S1053-8119(03)00178-2; WEGNER DM, 1997, SCI APPROACHES CONSC; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012	87	169	171	4	35	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0010-0277	1873-7838		COGNITION	Cognition	APR	2009	111	1					98	113		10.1016/j.cognition.2008.12.009			16	Psychology, Experimental	Psychology	426HZ	WOS:000264699900007	19215913				2021-06-18	
J	Boone, KB				Boone, Kyle Brauer			The Need For Continuous and Comprehensive Sampling of Effort/Response Bias During Neuropsychological Examinations	CLINICAL NEUROPSYCHOLOGIST			English	Article						Effort; Response bias; Malingering; Neuropsychological scores	TRAUMATIC BRAIN-INJURY; RECOGNITION TRIAL; PERFORMANCE; SENSITIVITY; SCORES; PAIN; SPECIFICITY; UTILITY; MMPI-2; ISSUES	While most neuropsychologists are now administering measures of response bias in neuropsychological evaluations, it is still likely that detection of non-credible test performance is inadequate due to faulty assumptions regarding poor effort, namely that it remains constant across a battery of tests. Four cases are described that illustrate the variability in negative response bias that occurs during neuropsychological evaluations; if effort had not been periodically sampled with heterogeneous types of effort indicators during these examinations, the suspect performance would not have been detected. These examples argue for both continuous and comprehensive sampling of effort, specifically that negative response bias be routinely monitored throughout neuropsychological evaluations, and that effort indicators involving differing cognitive abilities be employed to assess for feigning of selective deficits.	[Boone, Kyle Brauer] Alliant Univ, Ctr Forens Studies, Los Angeles, CA USA; [Boone, Kyle Brauer] Los Angeles Biomed Inst, Los Angeles, CA USA	Boone, KB (corresponding author), Alliant Univ, Ctr Forens Studies, Los Angeles Campus, Los Angeles, CA USA.	kboone@labiomed.org					Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 2003, J CLIN EXP NEUROPSYC, V25, P420, DOI 10.1076/jcen.25.3.420.13806; Boone, 2007, ASSESSMENT FEIGNED C; Boone K., 2002, DOT COUNTING TEST; Boone K. B., 2002, B TEST; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; CARROLL LJ, 2004, J REHABILITATION MED, V37, P61; DEAN AD, CLIN NEUROP IN PRESS; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gavett BE, 2005, APPL NEUROPSYCHOL, V12, P1, DOI 10.1207/s15324826an1201_1; GOLDBERG HB, 2007, ASSESSMENT FEIGNED C; GREIFFENSTEIN MF, 2007, ASSESSMENT FEIGNED C; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; Iverson GL, 2007, CLIN NEUROPSYCHOL, V21, P532, DOI 10.1080/13854040600611392; King JH, 2002, CLIN NEUROPSYCHOL, V16, P506, DOI 10.1076/clin.16.4.506.13912; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; LARRABEE GL, 2004, 32 ANN M INT NEUR SO; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; Nitch S, 2006, CLIN NEUROPSYCHOL, V20, P873, DOI 10.1080/13854040590967603; O'Bryant SE, 2008, APPL NEUROPSYCHOL, V15, P113, DOI 10.1080/09084280802083921; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Rosenfeld B, 2000, ARCH CLIN NEUROPSYCH, V15, P349, DOI 10.1016/S0887-6177(99)00025-6; Salazar X. F., 2007, ASSESSMENT FEIGNED C; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; VICTOR T, 2007, ANN INT NEUR SOC M; VICTOR TL, CLIN NEUROP IN PRESS; ZIEGLER EA, 2008, ANN AM AC CLIN NEUR	49	169	169	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	4					729	741	PII 904732228	10.1080/13854040802427803			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	442VQ	WOS:000265869100116	18949583				2021-06-18	
J	De Beaumont, L; Lassonde, M; Leclerc, S; Theoret, H				De Beaumont, Louis; Lassonde, Maryse; Leclerc, Suzanne; Theoret, Hugo			Long-term and cumulative effects of sports concussion on motor cortex inhibition	NEUROSURGERY			English	Article						cortical silent period; intracortical inhibition; gamma-aminobutyric acid-B interneuron receptors; sports concussions; transcranial magnetic stimulation	TRANSCRANIAL MAGNETIC STIMULATION; TRAUMATIC BRAIN-INJURY; SILENT PERIOD; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; MECHANISMS; SEVERITY	OBJECTIVE: Using transcranial magnetic stimulation paradigms, this study investigated motor cortex integrity as a function of an athlete's prior history of concussions. PATIENTS AND METHODS: Motor cortex excitatory and inhibitory mechanisms were studied in athletes using four different transcranial magnetic stimulation protocols, namely 1) resting motor threshold, 2) intracortical inhibition and intracortical facilitation in a paired-pulse paradigm, 3) excitability of the corticospinal system using an input-output curve, and 4) intracortical inhibition in a cortical silent-period paradigm. Motor-evoked potentials were recorded from the first dorsal interosseous muscle of the right hand. RESULTS: Cortical silent-period duration in athletes who have experienced multiple concussions was prolonged when compared to that of normal control participants. Linear regression suggested that concussion severity was the main factor explaining motor cortex dysfunction. Moreover, when we retested the athletes, the cortical silent period was more prolonged in those who sustained another concussion after baseline testing had occurred. CONCLUSION: Findings from this study indicate that sports-related concussions result in long-term motor system dysfunctions that seem to be attributable to subclinical intracortical inhibitory system abnormalities. This study also shows that sustaining subsequent concussions exacerbates this deficit, and thus provides additional support for the contention that the adverse effects of sports-related concussions on intracortical inhibitory systems are cumulative.	Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, Montreal, PQ H3C 3J7, Canada; St Justine Hosp, Res Ctr, Montreal, PQ, Canada; Univ Montreal, Clin Med Sport, Montreal, PQ H3C 3J7, Canada	De Beaumont, L (corresponding author), Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	louis.de.beaumont@umontreal.ca		Theoret, Hugo/0000-0002-7458-8797			Abbruzzese G, 2002, J CLIN NEUROPHYSIOL, V19, P307, DOI 10.1097/00004691-200208000-00005; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT., 1989, MILD HEAD INJURY, P257; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Garvey MA, 2001, CLIN NEUROPHYSIOL, V112, P1451, DOI 10.1016/S1388-2457(01)00581-8; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; INGHILLERI M, 1993, J PHYSIOL-LONDON, V466, P521; Kelly J, 1997, JAMA-J AM MED ASSOC, V277, P1190; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Liepert J, 1997, J NEURAL TRANSM, V104, P1207, DOI 10.1007/BF01294721; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; PRIORI A, 1994, BRAIN, V117, P317, DOI 10.1093/brain/117.2.317; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Terao Y, 2002, J CLIN NEUROPHYSIOL, V19, P322, DOI 10.1097/00004691-200208000-00006; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306; Ziemann U, 1998, ELECTROMYOGR MOTOR C, V109, P321, DOI 10.1016/S0924-980X(98)00023-X; ZIEMANN U, 1993, NEUROSCI LETT, V156, P167, DOI 10.1016/0304-3940(93)90464-V	32	169	169	2	37	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2007	61	2					329	336		10.1227/01.NEU.0000280000.03578.B6			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	197AN	WOS:000248525400024	17762745				2021-06-18	
J	Urdzikova, L; Jendelova, P; Glogarova, K; Burian, M; Hajek, M; Sykova, E				Urdzikova, Lucia; Jendelova, Pavla; Glogarova, Katerina; Burian, Martin; Hajek, Milan; Sykova, Eva			Transplantation of bone marrow stem cells as well as mobilization by granulocyte-colony stimulating factor promotes recovery after spinal cord injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						G-CSF; lesion; marrow cells; mesenchymal stem cells; MRI; nanoparticles; repair	MAGNETIC-RESONANCE TRACKING; TRAUMATIC BRAIN-INJURY; IN-VIVO TRACKING; STROMAL CELLS; FUNCTIONAL RECOVERY; PROGENITOR CELLS; BLOOD-FLOW; ADULT-RAT; CULTURES; NANOPARTICLES	Emerging clinical studies of treating brain and spinal cord injury (SCI) with autologous adult stem cells led us to compare the effect of an intravenous injection of mesenchymal stem cells (MSCs), an injection of a freshly prepared mononuclear fraction of bone marrow cells (BMCs) or bone marrow cell mobilization induced by granulocyte colony stimulating factor (G-CSF) in rats with a balloon-induced spinal cord compression lesion. MSCs were isolated from rat bone marrow by their adherence to plastic, labeled with iron-oxide nanoparticles and expanded in vitro. Seven days after injury, rats received an intravenous injection of MSCs or BMCs or a subcutaneous injection of GCSF (from day 7 to 11 post-injury). Functional status was assessed weekly for 5 weeks after SCI, using the Basso-Beattie-Bresnehan (BBB) locomotor rating score and the plantar test. Animals with SCI treated with MSCs, BMCs, or G-CSF had higher BBB scores and better recovery of hind limb sensitivity than controls injected with saline. Morphometric measurements showed an increase in the spared white matter. MR images of the spinal cords were taken ex vivo 5 weeks after SCI using a Bruker 4.7-T spectrometer. The lesions populated by grafted MSCs appeared as dark hypointense areas. Histology confirmed a large number of iron-containing and PKH 26-positive cells in the lesion site. We conclude that treatment with three different bone marrow cell populations had a positive effect on behavioral outcome and histopathological assessment after SCI, which was most pronounced after MSC injection.	Acad Sci Czech Republ, Inst Expt Med, Prague 14220 4, Czech Republic; Charles Univ, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; Charles Univ, Fac Med 2, Dept Neurosci, Prague, Czech Republic; Inst Clin & Expt Med, Dept Radiol, MR Unit, Prague, Czech Republic	Sykova, E (corresponding author), Acad Sci Czech Republ, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.	sykova@biomed.cas.cz	Jendelova, Pavla/H-2516-2014; Sykova, Eva/H-2659-2014	Jendelova, Pavla/0000-0002-4644-9212; Machova Urdzikova, Lucia/0000-0001-7622-5837			Akiyama Y, 2002, GLIA, V39, P229, DOI 10.1002/glia.10102; ASHTON BA, 1980, CLIN ORTHOP RELAT R, P294; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Brock J. H., 1989, IRON IMMUNITY CANCER, P35; Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141; Bulte JWM, 2002, J CEREBR BLOOD F MET, V22, P899, DOI 10.1097/00004647-200208000-00001; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503, DOI 10.1097/00004647-200205000-00001; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Dame C, 2003, DEV BRAIN RES, V143, P217, DOI 10.1016/S0165-3806(03)00134-2; DEMETRI GD, 1991, BLOOD, V78, P2791; EAVES CJ, 1991, BLOOD, V78, P110; Eglitis MA, 1999, NEUROREPORT, V10, P1289, DOI 10.1097/00001756-199904260-00025; FEHLINGS MG, 1989, J NEUROSURG, V71, P403, DOI 10.3171/jns.1989.71.3.0403; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fukumoto Y, 1997, BRIT J HAEMATOL, V97, P666, DOI 10.1046/j.1365-2141.1997.842724.x; Heard SO, 1998, CRIT CARE MED, V26, P748, DOI 10.1097/00003246-199804000-00027; HOEHN M, 2002, P NATL ACAD SCI USA, V100, P1073; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Inoue M, 2003, GLIA, V44, P111, DOI 10.1002/glia.10285; Jacobs T P, 1987, Cent Nerv Syst Trauma, V4, P95; Jendelova P, 2003, MAGNET RESON MED, V50, P767, DOI 10.1002/mrm.10585; Jendelova P, 2004, J NEUROSCI RES, V76, P232, DOI 10.1002/jnr.20041; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; KOBRINE AI, 1975, J NEUROSURG, V42, P144, DOI 10.3171/jns.1975.42.2.0144; Lee IH, 2004, EXP NEUROL, V187, P509, DOI 10.1016/j.expneurol.2004.02.007; Lewin M, 2000, NAT BIOTECHNOL, V18, P410; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097-4652(199807)176:1<57::AID-JCP7>3.0.CO;2-7; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; MURPHY SP, 2004, 343348 GCSF; Park HC, 2005, TISSUE ENG, V11, P913, DOI 10.1089/ten.2005.11.913; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Rice A, 1992, J Hematother, V1, P19, DOI 10.1089/scd.1.1992.1.19; RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022; Sasaki M, 2001, GLIA, V35, P26, DOI 10.1002/glia.1067; Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17; Shyu WC, 2004, CIRCULATION, V110, P1847, DOI 10.1161/01.CIR.0000142616.07367.66; Sykova E, 2005, ANN NY ACAD SCI, V1049, P146, DOI 10.1196/annals.1334.014; SYKOVA E, 2005, 8195 SOC NEUR; SYKOVA E, 2006, IN PRESS CELL MOL NE; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; Vanicky I, 2001, J NEUROTRAUM, V18, P1399, DOI 10.1089/08977150152725687; Wang DZ, 2001, RARE METAL MAT ENG, V30, P1; WEAVER CH, 1993, BLOOD, V82, P1981; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C	52	169	193	0	22	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2006	23	9					1379	1391		10.1089/neu.2006.23.1379			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	085LP	WOS:000240605900009	16958589				2021-06-18	
J	Nakayama, N; Okumura, A; Shinoda, J; Yasokawa, YT; Miwa, K; Yoshimura, SI; Iwama, T				Nakayama, N.; Okumura, A.; Shinoda, J.; Yasokawa, Y-T; Miwa, K.; Yoshimura, S-I; Iwama, T.			Evidence for white matter disruption in traumatic brain injury without macroscopic lesions	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							DIFFUSE AXONAL INJURY; CLOSED HEAD-INJURY; MR; FORNIX; ANTERIOR; VISUALIZATION; TRACTOGRAPHY; EXPERIENCE; ATROPHY; HUMANS	Background: Non-missile traumatic brain injury (nmTBI) without macroscopically detectable lesions often results in cognitive impairments that negatively affect daily life. Aim: To identify abnormal white matter projections in patients with nmTBI with cognitive impairments using diffusion tensor magnetic resonance imaging (DTI). Methods: DTI scans of healthy controls were compared with those of 23 patients with nmTBI who manifested cognitive impairments but no obvious neuroradiological lesions. DTI was comprised of fractional anisotropy analysis, which included voxel-based analysis and confirmatory study using regions of interest (ROI) techniques, and magnetic resonance tractography of the corpus callosum and fornix. Results: A decline in fractional anisotropy around the genu, stem and splenium of the corpus callosum was shown by voxel-based analysis. Fractional anisotropy values of the genu (0.47), stem (0.48), and splenium of the corpus callosum (0.52), and the column of the fornix (0.51) were lower in patients with nmTBI than in healthy controls (0.58, 0.61, 0.62 and 0.61, respectively) according to the confirmatory study of ROIs. The white matter architecture in the corpus callosum and fornix of patients with nmTBI were seen to be coarser than in the controls in the individual magnetic resonance tractography. Conclusions: Disruption of the corpus callosum and fornix in patients with nmTBI without macroscopically detectable lesions is shown. DTI is sensitive enough to detect abnormal neural fibres related to cognitive dysfunction after nmTBI.	Kizawa Mem Hosp, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, Minokamo City, Gifu, Japan; Gifu Univ, Dept Neurosurg, Grad Sch Med, Gifu, Japan	Nakayama, N (corresponding author), 630 Shimokobi, Minokamo City, Gifu 5050034, Japan.	doctor.1@jasmine.ocn.ne.jp					Abe O, 2004, NMR BIOMED, V17, P411, DOI 10.1002/nbm.907; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ellis CM, 1999, NEUROLOGY, V53, P1051, DOI 10.1212/WNL.53.5.1051; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GARCIABENGOCHEA F, 1987, SURG NEUROL, V27, P361, DOI 10.1016/0090-3019(87)90012-7; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Head D, 2004, CEREB CORTEX, V14, P410, DOI 10.1093/cercor/bhh003; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Konishi J, 2005, NEUROLOGY, V64, P108, DOI 10.1212/01.WNL.0000148477.65273.0C; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1992, J NEUROTRAUM, V9, P359; Masutani Y, 2003, EUR J RADIOL, V46, P53, DOI 10.1016/S0720-048X(02)00328-5; Mori S, 2000, ANN NEUROL, V47, P412, DOI 10.1002/1531-8249(200003)47:3<412::AID-ANA28>3.3.CO;2-8; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; O'Sullivan M, 2001, NEUROLOGY, V57, P632, DOI 10.1212/WNL.57.4.632; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tuch DS, 2002, MAGNET RESON MED, V48, P577, DOI 10.1002/mrm.10268; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y; Witwer BP, 2002, J NEUROSURG, V97, P568, DOI 10.3171/jns.2002.97.3.0568	28	169	177	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	2006	77	7							850	10.1136/jnnp.2005.077875			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	054ZL	WOS:000238417900012	16574734	Green Published			2021-06-18	
J	Babikian, T; Boone, KB; Lu, P; Arnold, G				Babikian, T; Boone, KB; Lu, P; Arnold, G			Sensitivity and specificity of various digit span scores in the detection of suspect effort	CLINICAL NEUROPSYCHOLOGIST			English	Article							MALINGERED NEUROCOGNITIVE DYSFUNCTION; TRAUMATIC BRAIN INJURY; NEUROPSYCHOLOGICAL TESTS; PERFORMANCE PATTERNS; ALZHEIMERS-DISEASE; CROSS-VALIDATION; RELIABLE DIGITS; HEAD-INJURY; MEMORY; POPULATION	Digit Span Age-Corrected Scaled Score (ACSS) and Reliable Digit Span (RDS) have been suggested as effective in assessing credibility. The purpose of this study was to confirm the efficacy of suggested cutoffs for ACSS and RDS and to explore the utility of other Digit Span variables in a large sample (N = 66) of "real-world >= suspect effort patients versus clinic patients with no motive to feign (N = 56) and controls (N = 32). With specificity at >= 90%, sensitivity of ACSS increased from 32% to 42% when a <= 5 cutoff was used instead of the recommended <= 4. The RDS recommended cutoff of <= 7 resulted in a sensitivity of 62% but with an unacceptably high false positive rate (23%); dropping the cutoff to <= 6 raised the specificity to 93% but sensitivity fell to 45%. Cutoffs for other Digit Span scores did not exceed 45% sensitivity with the exception of 50% sensitivity (11% false positive rate) for average time per digit for all attempted items > 1.0 second. A criterion of ACSS <= 5 or RDS <= 6 was associated with 51% sensitivity (91% specificity) while RDS <= 6 or longest string with at least one item correct <= 4 was associated with 54% sensitivity (88% specificity). While only moderately sensitive, Digit Span scores, including new time variables, may have a unique and effective role in the detection of suspect effort.	Harbor UCLA Med Ctr, Dept Psychiat, ABPP, Torrance, CA 90509 USA; Loma Linda Univ, Dept Psychol, Loma Linda, CA 92350 USA; Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA	Boone, KB (corresponding author), Harbor UCLA Med Ctr, Dept Psychiat, ABPP, Box 495,1000 W Carson St,F-9, Torrance, CA 90509 USA.	kboone@rei.edu					Backman L, 2001, BRAIN, V124, P96, DOI 10.1093/brain/124.1.96; BERNARD LC, 1993, J CLIN PSYCHOL, V49, P45, DOI 10.1002/1097-4679(199301)49:1<45::AID-JCLP2270490107>3.0.CO;2-7; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2000, ARCH CLIN NEUROPSYCH, V15, P227, DOI 10.1016/S0887-6177(99)00014-1; Calderon J, 2001, J NEUROL NEUROSUR PS, V70, P157, DOI 10.1136/jnnp.70.2.157; CARLESIMO GA, 1994, ACTA NEUROL SCAND, V89, P132; Duncan SA, 2002, ASSESSMENT, V9, P56, DOI 10.1177/1073191102009001007; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 1996, ARCH CLIN NEUROPSYCH, V11, P283, DOI 10.1016/0887-6177(95)00038-0; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Kraemer H.C., 1992, EVALUATING MED TESTS; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers J E, 2001, Appl Neuropsychol, V8, P234, DOI 10.1207/S15324826AN0804_6; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; STERNE DM, 1969, J CLIN PSYCHOL, V25, P173, DOI 10.1002/1097-4679(196904)25:2<173::AID-JCLP2270250216>3.0.CO;2-9; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740	32	169	169	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB	2006	20	1					145	159		10.1080/13854040590947362			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	999OL	WOS:000234399000009	16393925				2021-06-18	
J	Noraberg, J; Poulsen, FR; Blaabjerg, M; Kristensen, BW; Bonde, C; Montero, M; Meyer, M; Gramsbergen, JB; Zimmer, J				Noraberg, Jens; Poulsen, Frantz Rom; Blaabjerg, Morten; Kristensen, Bjarne Winther; Bonde, Christian; Montero, Maria; Meyer, Morten; Gramsbergen, Jan Bert; Zimmer, Jens			Organotypic Hippocampal Slice Cultures for Studies of Brain Damage, Neuroprotection and Neurorepair	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Neurodegeneration; stroke; cerebral ischemia; epilepsia; seizures; Alzheimer's disease (AD); traumatic brain injury (TBI); in vitro models; oxygen-glucose deprivation (OGD); beta-amyloid (Abeta); propidium iodide (PI); CA1; fascia dentata; axonal sprouting; neurogenesis		Slices of developing brain tissue can be grown for several weeks as socalled organotypic slice cultures. Here we summarize and review studies using hippocampal slice cultures to investigate mechanisms and treatment strategies for the neurodegenerative disorders like stroke (cerebral ischemia), Alzheimer's disease (AD) and epilepsia. Studies of non-excitotoxic neurotoxic compounds and the experimental use of slice cultures in studies of HIV neurotoxicity, traumatic brain injury (TBI) and neurogenesis are included. For cerebral ischemia, experimental models with oxygen-glucose deprivation (OGD) and exposure to glutamate receptor agonists (excitotoxins) are reviewed. For epilepsia, focus is on induction of seizures with effects on neuronal loss, axonal sprouting and neurogenesis. For Alzheimer's disease, the review centers on the use of beta-amyloid (Abeta) in different models, while the section on repair is focused on neurogenesis and cell migration. The culturing techniques, set-up of models, and analytical tools, including markers for neurodegeneration, like the fluorescent dye propidium iodide (PI), are reviewed and discussed. Comparisons are made between hippocampal slice cultures and other in vitro models using dispersed cell cultures, experimental in vivo models, and in some instances, clinical trials. New techniques including slice culturing of hippocampal tissue from transgenic mice as well as more mature brain tissue, and slice cultures coupled to microelectrode arrays (MEAs), on-line biosensor monitoring, and time-lapse fluorescence microscopy are also presented.	[Noraberg, Jens; Poulsen, Frantz Rom; Blaabjerg, Morten; Kristensen, Bjarne Winther; Bonde, Christian; Montero, Maria; Meyer, Morten; Gramsbergen, Jan Bert; Zimmer, Jens] Univ Southern Denmark, Inst Med Biol, Anat & Neurobiol, Odense, Denmark	Noraberg, J (corresponding author), Univ Southern Denmark, Anat & Neurobiol, Winslowparken 21, DK-5000 Odense C, Denmark.	jnoraberg@health.sdu.dk	Kristensen, Bjarne Winther/AAX-5491-2020; Kristensen, Bjarne Winther/A-6690-2012	Kristensen, Bjarne Winther/0000-0002-6352-0826; Blaabjerg, Morten/0000-0001-6007-1861; Poulsen, Frantz Rom/0000-0001-5715-6901	Danish MRCDanish Medical Research Council; NeuroScreen ApS; EU-FP5 grant [QLK3-CT-2001-00407]	Randi Godskesen, Inge Holst, Dorte Bramsen and Dorte Lyholmer are gratefully acknowledged for their technical assistance. This work was supported by the Danish MRC, NeuroScreen ApS and the EU-FP5 grant (QLK3-CT-2001-00407).	AbdelHamid KM, 1997, J NEUROSCI, V17, P3538; ABE K, 1995, STROKE, V26, P1478, DOI 10.1161/01.STR.26.8.1478; Aberg MAI, 2000, J NEUROSCI, V20, P2896; Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Adamchik Y, 2000, NEUROSCIENCE, V99, P731, DOI 10.1016/S0306-4522(00)00229-3; Adembri C, 2004, J NEUROTRAUM, V21, P1103, DOI 10.1089/0897715041651079; AggounZouaoui D, 1996, NEUROREPORT, V7, P433, DOI 10.1097/00001756-199601310-00014; ALLEN YS, 1995, CLIN EXP PHARMACOL P, V22, P370, DOI 10.1111/j.1440-1681.1995.tb02021.x; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Anderson CM, 2001, J NEUROCHEM, V79, P1207; Arnett ALH, 2004, BRAIN RES, V1028, P59, DOI 10.1016/j.brainres.2004.08.064; Arsenijevic Y, 1998, J NEUROSCI, V18, P2118; BAHR BA, 1995, J NEUROSCI RES, V42, P294, DOI 10.1002/jnr.490420303; BAHR BA, 1994, EXP NEUROL, V129, P81, DOI 10.1006/exnr.1994.1149; Bahr BA, 1995, HIPPOCAMPUS, V5, P425, DOI 10.1002/hipo.450050505; Baird TA, 2003, STROKE, V34, P2208, DOI 10.1161/01.STR.0000085087.41330.FF; Barth A, 2005, EXP BRAIN RES, V161, P351, DOI 10.1007/s00221-004-2079-7; Barth A, 1996, EXP NEUROL, V141, P330, DOI 10.1006/exnr.1996.0168; Barth A, 1996, NEUROREPORT, V7, P1461, DOI 10.1097/00001756-199606170-00003; Baskys A, 2005, J NEUROL SCI, V229, P201, DOI 10.1016/j.jns.2004.11.028; Baskys A, 2002, DRUG DEVELOP RES, V56, P393, DOI 10.1002/ddr.10091; Baskys A, 2001, BRAIN RES, V907, P188, DOI 10.1016/S0006-8993(01)02517-3; Bauer M, 2001, NEUROSCI LETT, V308, P169, DOI 10.1016/S0304-3940(01)01999-1; Bausch SB, 2000, J NEUROPHYSIOL, V84, P2918; Bausch SB, 2004, J NEUROPHYSIOL, V92, P3582, DOI 10.1152/jn.01028.2003; Behl C, 1997, EUR J NEUROSCI, V9, P912, DOI 10.1111/j.1460-9568.1997.tb01442.x; Behl C, 1997, MOL PHARMACOL, V51, P535; Behnisch T, 2004, BRAIN RES, V1012, P187, DOI 10.1016/j.brainres.2004.03.037; Bell KA, 2004, J NEUROCHEM, V91, P349, DOI 10.1111/j.1471-4159.2004.02722.x; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; Belmadani A, 2003, J NEUROVIROL, V9, P45, DOI 10.1080/13550280390173409; Belmadani A, 2004, NEUROREPORT, V15, P2093, DOI 10.1097/00001756-200409150-00019; Bendel O, 2004, BRAIN RES, V1025, P35, DOI 10.1016/j.brainres.2004.07.089; Benediktsson AM, 2005, J NEUROSCI METH, V141, P41, DOI 10.1016/j.jneumeth.2004.05.013; Benninger F, 2003, J NEUROSCI, V23, P7075, DOI 10.1523/JNEUROSCI.23-18-07075.2003; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bernabeu R, 2000, J CEREBR BLOOD F MET, V20, P1669, DOI 10.1097/00004647-200012000-00006; Bernard A, 1999, EUR J NEUROSCI, V11, P604, DOI 10.1046/j.1460-9568.1999.00479.x; Bickler PE, 2003, ANESTH ANALG, V97, P564, DOI 10.1213/01.ANE.0000068880.82739.7B; Bijak M, 1999, NEUROSCI LETT, V268, P115, DOI 10.1016/S0304-3940(99)00381-X; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Blaabjerg M, 2003, EXP NEUROL, V183, P573, DOI 10.1016/S0014-4886(03)00204-8; Blaabjerg M, 2001, BRAIN RES, V898, P91, DOI 10.1016/S0006-8993(01)02148-5; BLACK MA, 1995, J NEUROCHEM, V65, P2170; Bonde C, 2003, NEUROCHEM INT, V43, P381, DOI 10.1016/S0197-0186(03)00025-1; Bonde C, 2003, NEUROCHEM INT, V43, P371, DOI 10.1016/S0197-0186(03)00024-X; Bonde C, 2002, NEUROSCI LETT, V327, P49, DOI 10.1016/S0304-3940(02)00382-8; Bonde C, 2000, NEUROREPORT, V11, P4069, DOI 10.1097/00001756-200012180-00032; Bonde C, 2005, NEUROSCIENCE; Bouilleret V, 1999, NEUROSCIENCE, V89, P717, DOI 10.1016/S0306-4522(98)00401-1; Brana C, 1999, J NEUROSCI METH, V90, P7, DOI 10.1016/S0165-0270(99)00045-X; Brana C, 1999, EUR J NEUROSCI, V11, P2375, DOI 10.1046/j.1460-9568.1999.00653.x; Brana C, 1999, AIDS, V13, P1443, DOI 10.1097/00002030-199908200-00002; Breder J, 2000, NEUROPHARMACOLOGY, V39, P1779, DOI 10.1016/S0028-3908(00)00027-7; Bruce AJ, 1996, P NATL ACAD SCI USA, V93, P2312, DOI 10.1073/pnas.93.6.2312; BRUCE AJ, 1995, EXP NEUROL, V132, P209, DOI 10.1016/0014-4886(95)90026-8; Budziszewska B, 1998, EUR NEUROPSYCHOPHARM, V8, P7, DOI 10.1016/S0924-977X(97)00037-0; CAMERON HA, 1995, J NEUROSCI, V15, P4687; Capogna M, 1999, EUR J NEUROSCI, V11, P433, DOI 10.1046/j.1460-9568.1999.00450.x; Carpenedo R, 2002, J NEUROCHEM, V82, P1465, DOI 10.1046/j.1471-4159.2002.01090.x; Cater HL, 2003, J NEUROCHEM, V87, P1381, DOI 10.1046/j.1471-4159.2003.02100.x; Cater HL, 2001, J PHYSIOL-LONDON, V531, P459, DOI 10.1111/j.1469-7793.2001.0459i.x; Cavaliere F, 2003, NEUROSCIENCE, V120, P85, DOI 10.1016/S0306-4522(03)00228-8; Ceccatelli S, 1997, NEUROREPORT, V8, P3779, DOI 10.1097/00001756-199712010-00025; CHANG LW, 1983, NEUROBEH TOXICOL TER, V5, P443; Cho SG, 2004, NEUROCHEM INT, V45, P117, DOI 10.1016/j.neuint.2003.11.012; Choi D, 1998, MT SINAI J MED, V65, P133; CHOI DW, 1987, J NEUROSCI, V7, P357; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Cimarosti H, 2001, NEUROSCI LETT, V315, P33, DOI 10.1016/S0304-3940(01)02310-2; Clapp-Lilly KL, 2001, NEUROREPORT, V12, P1277, DOI 10.1097/00001756-200105080-00044; Collins MA, 2000, NEUROREPORT, V11, P1219, DOI 10.1097/00001756-200004270-00015; Collins MA, 1998, FASEB J, V12, P221; COLTMAN BW, 1995, J COMP NEUROL, V362, P209, DOI 10.1002/cne.903620205; CONDORELLI DF, 1992, MOL PHARMACOL, V41, P660; Cozzi A, 2002, NEUROPHARMACOLOGY, V43, P119, DOI 10.1016/S0028-3908(02)00080-1; CRAIN SM, 1976, NEUROPHYSIOLOGICAL S; Cronberg T, 2004, STROKE, V35, P753, DOI 10.1161/01.STR.0000117576.09512.32; CURTIS DR, 1974, ERG PHYSIOL BIOL CH, V69, P97; Dago L, 2002, J NEUROCHEM, V81, P17, DOI 10.1046/j.1471-4159.2002.00803.x; Dailey ME, 1996, J NEUROSCI, V16, P2983; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Davoli MA, 2002, J NEUROSCI METH, V115, P55, DOI 10.1016/S0165-0270(01)00531-3; Dawson VL, 1996, J NEUROSCI, V16, P2479; Debonnel G, 1990, Can Dis Wkly Rep, V16 Suppl 1E, P59; Dehghani F, 2003, EUR J NEUROSCI, V18, P1061, DOI 10.1046/j.1460-9568.2003.02821.x; DIEMER NH, 1992, ACTA NEUROL SCAND, V86, P45, DOI 10.1111/j.1600-0404.1992.tb08052.x; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Drakew A, 1996, NEUROSCIENCE, V70, P31, DOI 10.1016/0306-4522(95)00379-W; Duff K, 2002, J MOL NEUROSCI, V19, P317, DOI 10.1385/JMN:19:3:317; Duman RS, 2001, J PHARMACOL EXP THER, V299, P401; Egert U, 1998, BRAIN RES PROTOC, V2, P229, DOI 10.1016/S1385-299X(98)00013-0; Ehrengruber MU, 1999, P NATL ACAD SCI USA, V96, P7041, DOI 10.1073/pnas.96.12.7041; Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597; Ekdahl CT, 2002, EUR J NEUROSCI, V16, P1463, DOI 10.1046/j.1460-9568.2002.02202.x; Eliason DA, 2002, DEV BRAIN RES, V137, P75, DOI 10.1016/S0165-3806(02)00413-3; Elliott-Hunt CR, 2004, P NATL ACAD SCI USA, V101, P5105, DOI 10.1073/pnas.0304823101; Emilien G, 2000, ARCH NEUROL-CHICAGO, V57, P176, DOI 10.1001/archneur.57.2.176; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fan R, 2004, EXP NEUROL, V185, P241, DOI 10.1016/j.expneurol.2003.09.023; Feiner JR, 2005, ANESTH ANALG, V100, P215, DOI 10.1213/01.ANE.0000142129.17005.73; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Finley M, 2004, BRAIN RES, V1001, P125, DOI 10.1016/j.brainres.2003.12.009; FISHER RS, 1989, BRAIN RES REV, V14, P245, DOI 10.1016/0165-0173(89)90003-9; FRANDSEN A, 1989, J NEUROCHEM, V53, P297, DOI 10.1111/j.1471-4159.1989.tb07327.x; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Frantseva MV, 2000, EUR J NEUROSCI, V12, P1431, DOI 10.1046/j.1460-9568.2000.00016.x; Frantseva MV, 1999, J NEUROSCI METH, V89, P25, DOI 10.1016/S0165-0270(99)00030-8; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Gagliardi RJ, 2000, ARQ NEURO-PSIQUIAT, V58, P583, DOI 10.1590/S0004-282X2000000300030; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; GAHWILER BH, 1988, TRENDS NEUROSCI, V11, P484, DOI 10.1016/0166-2236(88)90007-0; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; Gimsa U, 2000, BRAIN PATHOL, V10, P365; Giovannelli L, 1998, NEUROSCIENCE, V87, P349, DOI 10.1016/S0306-4522(98)00169-9; GLOVELI T, 1995, DEV BRAIN RES, V87, P145, DOI 10.1016/0165-3806(95)00069-P; GOLDBERG MP, 1987, J PHARMACOL EXP THER, V243, P784; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Gould E, 1999, NEUROPSYCHOPHARMACOL, V21, pS46, DOI 10.1038/sj.npp.1395369; Gould E, 1999, BIOL PSYCHIAT, V46, P1472, DOI 10.1016/S0006-3223(99)00247-4; Gramsbergen JB, 2003, J NEUROCHEM, V85, P399, DOI 10.1046/j.1471-4159.2003.01673.x; Gutierrez R, 1999, BRAIN RES, V815, P294, DOI 10.1016/S0006-8993(98)01102-0; Gutierrez R, 1999, BRAIN RES, V815, P304, DOI 10.1016/S0006-8993(98)01101-9; HARRIGAN MR, 1995, NEUROBIOL AGING, V16, P779, DOI 10.1016/0197-4580(95)00095-V; Harris-White ME, 1998, J NEUROSCI, V18, P10366; Hassen GW, 2004, BRAIN RES PROTOC, V13, P135, DOI 10.1016/j.brainresprot.2004.03.004; HATFIELD RH, 1992, EUR J PHARMACOL, V216, P1, DOI 10.1016/0014-2999(92)90201-E; Heinemann U, 2002, PROG BRAIN RES, V135, P197; Heinemann U, 2002, EPILEPSIA, V43, P168, DOI 10.1046/j.1528-1157.43.s.5.15.x; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; Hirt L, 2004, STROKE, V35, P1738, DOI 10.1161/01.STR.0000131480.03994.b1; Hofmann F, 2004, BRAIN RES, V1017, P184, DOI 10.1016/j.brainres.2004.05.044; Holopainen IE, 2004, NEUROCHEM INT, V45, P1, DOI 10.1016/j.neuint.2004.01.005; HUMPEL C, 1993, NEUROSCIENCE, V53, P909, DOI 10.1016/0306-4522(93)90476-V; Hunter AJ, 1997, INT REV NEUROBIOL, V40, P95; HUNTER AJ, 1995, TRENDS PHARMACOL SCI, V16, P123, DOI 10.1016/S0165-6147(00)88999-3; Ikegaya Y, 2002, NEUROSCIENCE, V113, P253, DOI 10.1016/S0306-4522(02)00217-8; Ikegaya Y, 2002, EUR J NEUROSCI, V15, P1859, DOI 10.1046/j.1460-9568.2002.02035.x; Ikegaya Y, 1998, BIOL PHARM BULL, V21, P231; INSEL TR, 1990, NEUROSCIENCE, V35, P31, DOI 10.1016/0306-4522(90)90117-M; IVERSEN LL, 1995, BIOCHEM J, V311, P1; Jacobs BL, 2000, MOL PSYCHIATR, V5, P262, DOI 10.1038/sj.mp.4000712; Jahnsen H, 1999, METHODS, V18, P160, DOI 10.1006/meth.1999.0769; Jakobsen B, 2002, AMINO ACIDS, V23, P37, DOI 10.1007/s00726-001-0107-5; Jankowsky JL, 1999, EXP NEUROL, V159, P333, DOI 10.1006/exnr.1999.7137; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; JOHANSEN FF, 1993, MOL CHEM NEUROPATHOL, V18, P161, DOI 10.1007/BF03160030; JOHANSEN FF, 1986, BRAIN RES, V377, P344, DOI 10.1016/0006-8993(86)90878-4; JONAS P, 1995, NEURON, V15, P987, DOI 10.1016/0896-6273(95)90087-X; Jourquin J, 2003, EUR J NEUROSCI, V18, P1507, DOI 10.1046/j.1460-9568.2003.02876.x; Kalda A, 1999, NEUROSCIENCE, V92, P7, DOI 10.1016/S0306-4522(98)00726-X; Kamada M, 2004, EUR J NEUROSCI, V20, P2499, DOI 10.1111/j.1460-9568.2004.03721.x; Katoh-Semba R, 1999, NEUROSCI RES, V35, P19, DOI 10.1016/S0168-0102(99)00059-0; Keynes RG, 2004, EUR J NEUROSCI, V19, P1163, DOI 10.1111/j.1460-9568.2004.03217.x; Kim HJ, 2002, FASEB J, V16, P118, DOI 10.1096/fj.01-0987fje; Kim JA, 2002, NEUROPHARMACOLOGY, V42, P1109, DOI 10.1016/S0028-3908(02)00052-7; Kirino T, 2000, NEUROPATHOLOGY, V20, pS95; Kobayashi NR, 2000, EUR J NEUROSCI, V12, P110; Kobayashi T, 1998, EUR J PHARMACOL, V363, P1, DOI 10.1016/S0014-2999(98)00774-2; Koeneman BA, 2004, J NEUROSCI METH, V137, P257, DOI 10.1016/j.jneumeth.2004.02.033; KOH J, 1991, BRAIN RES, V548, P318, DOI 10.1016/0006-8993(91)91140-V; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Koob GF, 2002, ALCOHOL CLIN EXP RES, V26, P586, DOI 10.1097/00000374-200204000-00021; Kovacs R, 1999, NEUROREPORT, V10, P207, DOI 10.1097/00001756-199902050-00002; Kovacs R, 2000, NEUROREPORT, V11, P2107, DOI 10.1097/00001756-200007140-00010; Krassioukov AV, 2002, BRAIN RES PROTOC, V10, P60, DOI 10.1016/S1385-299X(02)00180-0; Krathwohl MD, 2004, STEM CELLS, V22, P109, DOI 10.1634/stemcells.22-1-109; Kristensen BW, 2003, BRAIN RES, V973, P303, DOI 10.1016/S0006-8993(03)02550-2; Kristensen BW, 2003, BRAIN RES, V964, P264, DOI 10.1016/S0006-8993(02)04080-5; Kristensen BW, 2001, BRAIN RES, V917, P21, DOI 10.1016/S0006-8993(01)02900-6; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Kunkler PE, 1997, J CEREBR BLOOD F MET, V17, P26, DOI 10.1097/00004647-199701000-00005; Laake JH, 1999, BRAIN RES PROTOC, V4, P173, DOI 10.1016/S1385-299X(99)00021-5; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LAURBERG S, 1981, J COMP NEUROL, V200, P433, DOI 10.1002/cne.902000310; Lauterborn JC, 2000, J NEUROSCI, V20, P8, DOI 10.1523/JNEUROSCI.20-01-00008.2000; Lawrence EJ, 2005, RESUSCITATION, V64, P383, DOI 10.1016/j.resuscitation.2004.07.016; Lemaire V, 2000, P NATL ACAD SCI USA, V97, P11032, DOI 10.1073/pnas.97.20.11032; Leutgeb JK, 2003, J NEUROSCI METH, V130, P19, DOI 10.1016/S0165-0270(03)00228-0; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Li Z, 2004, BRAIN RES, V1021, P8, DOI 10.1016/j.brainres.2004.05.115; Liang L, 2004, FEBS LETT, V566, P261, DOI 10.1016/j.febslet.2004.04.047; Lipton P, 1999, PHYSIOL REV, V79, P1431; Liu JL, 1998, J NEUROSCI, V18, P7768; Liu RL, 2003, J NEUROCHEM, V85, P492, DOI 10.1046/j.1471-4159.2003.01708.x; Locht LJ, 2002, J NEUROSCI METH, V115, P77, DOI 10.1016/S0165-0270(02)00004-3; London JA, 1996, P NATL ACAD SCI USA, V93, P4147, DOI 10.1073/pnas.93.9.4147; LYSKO PG, 1994, STROKE, V25, P2476, DOI 10.1161/01.STR.25.12.2476; Mackay KB, 2003, J CEREBR BLOOD F MET, V23, P1160, DOI 10.1097/01.WCB.0000087091.01171.AE; Malinak C, 1996, BIOL NEONATE, V69, P257; MALOUF AT, 1992, NEUROBIOL AGING, V13, P543, DOI 10.1016/0197-4580(92)90054-2; MARKSTEINER J, 1990, NEUROSCI LETT, V112, P143, DOI 10.1016/0304-3940(90)90193-D; Matyja E, 2000, FOLIA NEUROPATHOL, V38, P47; McCabe BK, 2001, J NEUROSCI, V21, P2094, DOI 10.1523/JNEUROSCI.21-06-02094.2001; MCDONALD JW, 1993, J NEUROSCI, V13, P4445; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; McKinney RA, 1999, NAT NEUROSCI, V2, P44, DOI 10.1038/4548; McManus T, 2004, J NEUROCHEM, V91, P327, DOI 10.1111/j.1471-4159.2004.02711.x; Mei JM, 1996, MOL CHEM NEUROPATHOL, V27, P155, DOI 10.1007/BF02815091; Meli E, 2003, TOXICOL LETT, V139, P153, DOI 10.1016/S0378-4274(02)00429-0; Meli E, 2002, PHARMACOL BIOCHEM BE, V73, P439, DOI 10.1016/S0091-3057(02)00834-1; Meyer M, 2000, EXP NEUROL, V164, P82, DOI 10.1006/exnr.2000.7419; MICHAELS RL, 1990, J NEUROSCI, V10, P283; MILLER LP, 1990, NEUROSCIENCE, V35, P45, DOI 10.1016/0306-4522(90)90118-N; Mitrasinovic OM, 2001, J BIOL CHEM, V276, P30142, DOI 10.1074/jbc.M104265200; Mizuhashi S, 2000, NEUROSCI RES, V38, P35, DOI 10.1016/S0168-0102(00)00137-1; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; MONAGHAN DT, 1983, NATURE, V306, P176, DOI 10.1038/306176a0; MONCADA C, 1992, NEUROREPORT, V3, P530; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Moroni F, 2002, NEUROPHARMACOLOGY, V42, P741, DOI 10.1016/S0028-3908(02)00033-3; Moroni F, 2001, CELL DEATH DIFFER, V8, P921, DOI 10.1038/sj.cdd.4400884; Moroni F, 1999, ADV EXP MED BIOL, V467, P199; Morrison B, 2002, BRIT J PHARMACOL, V137, P1255, DOI 10.1038/sj.bjp.0704986; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Moskowitz SI, 2001, BRAIN RES, V913, P207, DOI 10.1016/S0006-8993(01)02756-1; MULLER D, 1994, NEUROSCIENCE, V61, P441, DOI 10.1016/0306-4522(94)90424-3; MULLER M, 1993, PFLUG ARCH EUR J PHY, V422, P418, DOI 10.1007/BF00374304; MULLER M, 1993, P NATL ACAD SCI USA, V90, P257, DOI 10.1073/pnas.90.1.257; MULLER M, 1994, HIPPOCAMPUS, V4, P204, DOI 10.1002/hipo.450040211; Munirathinam S, 2004, J NEUROSCI RES, V77, P739, DOI 10.1002/jnr.20209; Murphy RC, 2001, MOL THER, V3, P113, DOI 10.1006/mthe.2000.0235; Nacher J, 2001, EUR J NEUROSCI, V13, P512, DOI 10.1046/j.0953-816x.2000.01424.x; NADLER JV, 1980, BRAIN RES, V191, P387, DOI 10.1016/0006-8993(80)91289-5; NADLER JV, 1980, J COMP NEUROL, V192, P333, DOI 10.1002/cne.901920209; Naganska E, 2001, FOLIA NEUROPATHOL, V39, P129; Nagao T, 1996, NEUROSCIENCE, V72, P399, DOI 10.1016/0306-4522(95)00534-X; Nagerl UV, 2004, NEURON, V44, P759, DOI 10.1016/j.neuron.2004.11.016; Naidu A, 2002, BRAIN RES, V958, P100, DOI 10.1016/S0006-8993(02)03480-7; Nam Y, 2004, IEEE T BIO-MED ENG, V51, P158, DOI 10.1109/TBME.2003.820336; NEWELL DW, 1995, J NEUROSCI, V15, P7702; NEWELL DW, 1990, NEUROSCI LETT, V116, P325, DOI 10.1016/0304-3940(90)90095-Q; NEWELL DW, 1993, NEUROTOXICOLOGY, V14, P375; NEWELL DW, 1995, BRAIN RES, V675, P38, DOI 10.1016/0006-8993(95)00039-S; Noer H, 2002, EXP NEUROL, V176, P237, DOI 10.1006/exnr.2002.7934; Noraberg J, 1998, BRAIN RES, V783, P305, DOI 10.1016/S0006-8993(97)01358-9; Noraberg J, 2004, ATLA-ALTERN LAB ANIM, V32, P329, DOI 10.1177/026119290403200403; Noraberg J, 1999, BRAIN RES PROTOC, V3, P278, DOI 10.1016/S1385-299X(98)00050-6; Noraberg J., 1997, Society for Neuroscience Abstracts, V23, P1935; Noraberg J, 1998, NEUROREPORT, V9, P3177, DOI 10.1097/00001756-199810050-00010; Noraberg J, 2002, RESTORATIVE NEUROLOG, V20, P272; O'Kusky JR, 2000, J NEUROSCI, V20, P8435, DOI 10.1523/JNEUROSCI.20-22-08435.2000; Oliva AA, 2000, J NEUROSCI, V20, P3354, DOI 10.1523/JNEUROSCI.20-09-03354.2000; Oliva AA, 2002, J NEUROSCI, V22, P8052; Olsson T, 2004, EUR J NEUROSCI, V20, P1197, DOI 10.1111/j.1460-9568.2004.03564.x; Olsson T, 2003, BRAIN RES, V982, P260, DOI 10.1016/S0006-8993(03)03014-2; ONeill MJ, 1997, EUR J PHARMACOL, V332, P121, DOI 10.1016/S0014-2999(97)01074-1; Pancetti F, 2004, NEUROTOXICOLOGY, V25, P817, DOI 10.1016/j.neuro.2004.01.008; Parent JM, 1997, J NEUROSCI, V17, P3727; Parent JM, 2002, J NEUROSCI, V22, P3174, DOI 10.1523/JNEUROSCI.22-08-03174.2002; Parent JM, 1998, NEUROSCI LETT, V247, P9, DOI 10.1016/S0304-3940(98)00269-9; Pellegrini-Giampietro DE, 1999, NEUROPHARMACOLOGY, V38, P1607, DOI 10.1016/S0028-3908(99)00097-0; PICO RM, 1994, EPILEPSY RES, V19, P27, DOI 10.1016/0920-1211(94)90085-X; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; Pomper JK, 2004, EPILEPSY RES, V59, P61, DOI 10.1016/j.eplepsyres.2004.03.002; Poulsen FR, 2004, NEUROSCIENCE, V126, P665, DOI 10.1016/j.neuroscience.2004.04.008; Poulsen FR, 2002, BRAIN RES, V950, P103, DOI 10.1016/S0006-8993(02)03009-3; Prendergast MA, 2000, ALCOHOL CLIN EXP RES, V24, P1583, DOI 10.1097/00000374-200010000-00017; Prendergast MA, 2004, NEUROSCIENCE, V124, P869, DOI 10.1016/j.neuroscience.2003.12.013; Prendergast MA, 2002, BRAIN RES, V954, P300, DOI 10.1016/S0006-8993(02)03360-7; Pringle AK, 1996, NEUROSCI LETT, V211, P203, DOI 10.1016/0304-3940(96)12745-2; Pringle AK, 2003, EUR J NEUROSCI, V18, P117, DOI 10.1046/j.1460-9568.2003.02734.x; Pringle AK, 2003, N-S ARCH PHARMACOL, V368, P216, DOI 10.1007/s00210-003-0778-4; Pringle AK, 1997, BRAIN RES, V755, P36, DOI 10.1016/S0006-8993(97)00089-9; Pringle AK, 2001, NEUROSCI LETT, V305, P29, DOI 10.1016/S0304-3940(01)01795-5; Pringle AK, 1996, STROKE, V27, P2124, DOI 10.1161/01.STR.27.11.2124; Radojevic V, 2004, EXP NEUROL, V188, P11, DOI 10.1016/j.expneurol.2004.03.015; Raineteau O, 2004, MOL CELL NEUROSCI, V26, P241, DOI 10.1016/j.mcn.2004.01.003; Ray AM, 2000, BRAIN RES, V867, P62, DOI 10.1016/S0006-8993(00)02230-7; Rekling JC, 2003, NEUROSCI LETT, V335, P167, DOI 10.1016/S0304-3940(02)01193-X; RIMVALL K, 1987, ACTA NEUROPATHOL, V74, P183, DOI 10.1007/BF00692850; Roelandse M, 2003, NEUROSCIENCE, V121, P39, DOI 10.1016/S0306-4522(03)00405-6; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; Routbort MJ, 1999, NEUROSCIENCE, V94, P755, DOI 10.1016/S0306-4522(99)00358-9; Runden E, 1998, J NEUROSCI, V18, P7296; Rytter A, 2003, J CEREBR BLOOD F MET, V23, P23, DOI 10.1097/01.WCB.0000034361.37277.1B; SACAAN AI, 1992, NEUROSCI LETT, V139, P77, DOI 10.1016/0304-3940(92)90862-2; Sakaguchi T, 1999, NEUROSCIENCE, V92, P677, DOI 10.1016/S0306-4522(99)00023-8; SAKAGUCHI T, 1994, NEUROSCI RES, V20, P157, DOI 10.1016/0168-0102(94)90033-7; Samoilova M, 2003, J NEUROCHEM, V86, P687, DOI 10.1046/j.1471-4159.2003.01893.x; Sanderson KL, 1997, BRAIN RES, V744, P7, DOI 10.1016/S0006-8993(96)01060-8; Savas A, 2001, NEUROL RES, V23, P669, DOI 10.1179/016164101101199018; Scharfman HE, 2001, NEUROSCIENCE, V104, P741, DOI 10.1016/S0306-4522(01)00132-4; Schermer C, 2002, NEUROSCI LETT, V328, P180, DOI 10.1016/S0304-3940(02)00496-2; Self RL, 2004, BRAIN RES, V995, P39, DOI 10.1016/j.brainres.2003.09.052; Sheldon RA, 2001, NEUROSCI LETT, V304, P165, DOI 10.1016/S0304-3940(01)01788-8; Shimono K, 2002, J NEUROSCI METH, V120, P193, DOI 10.1016/S0165-0270(02)00202-9; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; SNOW AD, 1993, HIPPOCAMPUS, V3, P257; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Spahr-Schopfer I, 2000, ANESTHESIOLOGY, V92, P1408, DOI 10.1097/00000542-200005000-00032; Stein TD, 2004, J NEUROSCI, V24, P7707, DOI 10.1523/JNEUROSCI.2211-04.2004; Stoppini L, 1997, NEUROSCIENCE, V80, P1127, DOI 10.1016/S0306-4522(97)00132-2; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Stoppini L, 1997, J NEUROSCI METH, V72, P23, DOI 10.1016/S0165-0270(96)00151-3; STRAIN SM, 1991, NEUROSCIENCE, V44, P343, DOI 10.1016/0306-4522(91)90059-W; STRASSER U, 1995, J NEUROSCI METH, V57, P177, DOI 10.1016/0165-0270(94)00147-9; STRASSER U, 1995, BRAIN RES, V687, P167, DOI 10.1016/0006-8993(95)00519-V; Sveen ML, 2004, NEUROSCI LETT, V362, P6, DOI 10.1016/j.neulet.2004.01.051; Taguchi M, 2003, BIOORG MED CHEM LETT, V13, P3681, DOI 10.1016/j.bmcl.2003.08.020; Tanapat P, 1998, INT J DEV NEUROSCI, V16, P235, DOI 10.1016/S0736-5748(98)00029-X; Teschemacher AG, 2005, ADV DRUG DELIVER REV, V57, P79, DOI 10.1016/j.addr.2004.05.004; Teter B, 1999, J NEUROCHEM, V73, P2613, DOI 10.1046/j.1471-4159.1999.0732613.x; Teter B, 1999, NEUROSCIENCE, V91, P1009, DOI 10.1016/S0306-4522(98)00630-7; Thomas AM, 2005, NEUROSCIENCE, V131, P303, DOI 10.1016/j.neuroscience.2004.11.002; Thomas MP, 1998, ALCOHOL CLIN EXP RES, V22, P51, DOI 10.1097/00000374-199802000-00006; Thomas MP, 2000, NEUROPHARMACOLOGY, V39, P218, DOI 10.1016/S0028-3908(99)00107-0; THOMPSON SM, 1993, BRAIN PATHOL, V3, P413, DOI 10.1111/j.1750-3639.1993.tb00769.x; Thompson SM, 1996, J COMP NEUROL, V372, P515; TONDER N, 1994, EPILEPSIA, V35, P1299, DOI 10.1111/j.1528-1157.1994.tb01802.x; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; van Bergen A, 2003, BRAIN RES BRAIN RES, V11, P133; van Leuven F, 2000, PROG NEUROBIOL, V61, P305, DOI 10.1016/S0301-0082(99)00055-6; Velazquez JLP, 1997, J NEUROSCI, V17, P9085; Velazquez JLP, 2003, J NEUROTRAUM, V20, P633, DOI 10.1089/089771503322144554; VERONESI B, 1991, TOXICOL APPL PHARM, V108, P428, DOI 10.1016/0041-008X(91)90089-W; Verwer RWH, 2002, FASEB J, V16, P54, DOI 10.1096/fj.01-0504com; Vincent VAM, 2002, J NEUROCHEM, V82, P1388, DOI 10.1046/j.1471-4159.2002.01087.x; Vincent VAM, 2002, NEUROBIOL AGING, V23, P349, DOI 10.1016/S0197-4580(01)00338-4; Viswanath V, 2000, P NATL ACAD SCI USA, V97, P2270, DOI 10.1073/pnas.030365297; Vornov JJ, 1998, EXP NEUROL, V149, P109, DOI 10.1006/exnr.1997.6673; VORNOV JJ, 1994, STROKE, V25, P457, DOI 10.1161/01.STR.25.2.457; VORNOV JJ, 1995, EXP NEUROL, V133, P7, DOI 10.1006/exnr.1995.1002; VORNOV JJ, 1991, EXP NEUROL, V114, P11, DOI 10.1016/0014-4886(91)90079-R; Vornov JJ, 1998, CURR OPIN NEUROL, V11, P39, DOI 10.1097/00019052-199802000-00007; WAHL P, 1989, J NEUROCHEM, V53, P1316, DOI 10.1111/j.1471-4159.1989.tb07430.x; Walsh K, 2005, NEUROBIOL DIS, V18, P2, DOI 10.1016/j.nbd.2004.09.002; Wang XM, 2004, NEUROPHARMACOLOGY, V47, P1008, DOI 10.1016/j.neuropharm.2004.07.036; Wilde GJC, 1997, J NEUROCHEM, V69, P883; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; Wolf SA, 2001, GLIA, V36, P414, DOI 10.1002/glia.1127; Xiang ZM, 2000, J NEUROSCI METH, V98, P145, DOI 10.1016/S0165-0270(00)00197-7; Xiang ZM, 2004, EXP NEUROL, V186, P70, DOI 10.1016/j.expneurol.2003.10.015; XIE YX, 1994, BRAIN RES, V652, P216, DOI 10.1016/0006-8993(94)90230-5; Xu GP, 2002, BRAIN RES, V952, P153, DOI 10.1016/S0006-8993(02)02988-8; Xu KX, 1999, GLIA, V25, P390, DOI 10.1002/(SICI)1098-1136(19990215)25:4<390::AID-GLIA8>3.0.CO;2-7; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Yoshinaga H, 2003, CAN J PHYSIOL PHARM, V81, P683, DOI 10.1139/Y03-060; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhong C, 2003, NEUROSCI LETT, V342, P93, DOI 10.1016/S0304-3940(03)00255-6; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684; ZIMMER J, 1987, J COMP NEUROL, V264, P1, DOI 10.1002/cne.902640102; ZIMMER J, 1984, J COMP NEUROL, V228, P432, DOI 10.1002/cne.902280310; ZIMMER J, 1973, BRAIN RES, V64, P293, DOI 10.1016/0006-8993(73)90185-6	350	169	178	0	20	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2005	4	4					435	452		10.2174/1568007054546108			18	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	VI5XH	WOS:000497842800010	16101559				2021-06-18	
J	McDowell, S; Whyte, J; D'Esposito, M				McDowell, S; Whyte, J; D'Esposito, M			Differential effect of a dopaminergic agonist on prefrontal function in traumatic brain injury patients	BRAIN			English	Article						dopamine; executive function; frontal lobes; traumatic brain injury; working memory	POSITRON EMISSION TOMOGRAPHY; SPATIAL WORKING-MEMORY; FRONTAL-LOBE DAMAGE; CARD SORTING TEST; PARKINSONS-DISEASE; COGNITIVE PERFORMANCE; RECEPTOR MECHANISMS; RHESUS-MONKEY; HEAD-INJURY; CORTEX	We examined the effects of low-dose bromocriptine, a D-2 dopamine receptor agonist, on processes thought to be subserved by the prefrontal cortex, including working memory and executive function, in individuals,vith traumatic brain injury. A group of 24 subjects was tested using a double-blind, placebo-controlled crossover trial, counterbalanced for order. Bromocriptine was found to improve performance on some tasks thought to be subserved by prefrontal function, but not others. Specifically, there was improvement in performance on clinical measures of executive function and in dual-task performance, but not measures that tap the ability to maintain information in working memory without significant executive demands. Also, on control tasks not thought to be dependent on the prefrontal cortex, no improvement on bromocriptine was noted. These results demonstrate a selective effect of bromocriptine on cognitive processes which involve executive control, and provide a foundation for potential therapies for patients with prefrontal damage causing dysexecutive syndromes.	Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19104 USA; Temple Univ, Sch Med, Moss Rehabil Res Inst, Philadelphia, PA 19122 USA; Temple Univ, Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19122 USA	D'Esposito, M (corresponding author), Univ Penn, Med Ctr, Dept Neurol, 3400 Spruce St, Philadelphia, PA 19104 USA.	despo@mail.med.upenn.edu		Whyte, John/0000-0002-4381-1474	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001762] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD01097, HD07425] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS01762] Funding Source: Medline		ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; AKRITAS MG, 1991, J AM STAT ASSOC, V86, P457, DOI 10.2307/2290594; ARNSTEN AFT, 1995, J NEUROSCI, V15, P3429; ARNSTEN AFT, 1994, PSYCHOPHARMACOLOGY, V116, P143, DOI 10.1007/BF02245056; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BENCH CJ, 1993, NEUROPSYCHOLOGIA, V31, P907, DOI 10.1016/0028-3932(93)90147-R; BERMAN KF, 1995, NEUROPSYCHOLOGIA, V33, P1027, DOI 10.1016/0028-3932(95)00035-2; BOWEN FP, 1975, NEUROLOGY, V25, P701, DOI 10.1212/WNL.25.8.701; BROWN RM, 1979, BRAIN RES, V168, P133, DOI 10.1016/0006-8993(79)90132-X; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; CAMPS M, 1989, NEUROSCIENCE, V28, P275, DOI 10.1016/0306-4522(89)90179-6; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; COOPER JA, 1992, BRAIN, V115, P1701, DOI 10.1093/brain/115.6.1701; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; DEKEYSER J, 1990, ANN NEUROL, V27, P157, DOI 10.1002/ana.410270210; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; DESPOSITO M, 1998, IN PRESS COG BRAIN R; DESPOSITO M, 1998, IN PRESS BRAIN COGNI; DIVAC I, 1967, J COMP PHYSIOL PSYCH, V63, P184, DOI 10.1037/h0024348; DURSO R, 1982, NEUROLOGY, V32, P674, DOI 10.1212/WNL.32.6.674; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FUNAHASHI S, 1993, J NEUROSCI, V13, P1479; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; GODWINAUSTEN RB, 1977, J NEUROL NEUROSUR PS, V40, P479, DOI 10.1136/jnnp.40.5.479; GOETZ CG, 1992, NEUROL CLIN, V10, P527; GOLDMANRAKIC PS, 1990, J NEUROSCI, V10, P2125; HARTMAN A, 1992, CLIN REHABIL, V6, P133; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Kimberg DY, 1997, NEUROREPORT, V8, P3581, DOI 10.1097/00001756-199711100-00032; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; KOCH GG, 1972, BIOMETRICS, V28, P577, DOI 10.2307/2556170; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; LAL S, 1989, BRAIN, V3, P319; LANGE KW, 1992, PSYCHOPHARMACOLOGY, V107, P394, DOI 10.1007/BF02245167; Lange KW, 1995, J NEURAL TRANSM-SUPP, P423; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LUCIANA M, 1992, J COGNITIVE NEUROSCI, V4, P58, DOI 10.1162/jocn.1992.4.1.58; Luciana M, 1997, J COGNITIVE NEUROSCI, V9, P330, DOI 10.1162/jocn.1997.9.3.330; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Muller U, 1998, J NEUROSCI, V18, P2720; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Owen AM, 1996, CEREB CORTEX, V6, P31, DOI 10.1093/cercor/6.1.31; Owen AM, 1997, NEUROPSYCHOLOGIA, V35, P519, DOI 10.1016/S0028-3932(96)00101-7; Petrides Michael, 1994, Current Opinion in Neurobiology, V4, P207, DOI 10.1016/0959-4388(94)90074-4; Postle BR, 1997, NEUROPSYCHOLOGY, V11, P171, DOI 10.1037/0894-4105.11.2.171; RINNE JO, 1990, BRAIN RES, V508, P349, DOI 10.1016/0006-8993(90)90423-9; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TAYLOR AE, 1986, BRAIN, V109, P279, DOI 10.1093/brain/109.2.279; VANWOERKOM TCAM, 1982, EUR NEUROL, V21, P227, DOI 10.1159/000115485; VENDRELL P, 1995, NEUROPSYCHOLOGIA, V33, P341, DOI 10.1016/0028-3932(94)00116-7; VERIN M, 1993, NEUROPSYCHOLOGIA, V31, P1379, DOI 10.1016/0028-3932(93)90105-9; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0; WONG DF, 1984, SCIENCE, V226, P1393, DOI 10.1126/science.6334363; Zarahn E., 1996, Society for Neuroscience Abstracts, V22, P968	61	169	173	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUN	1998	121		6				1155	1164		10.1093/brain/121.6.1155			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	ZW163	WOS:000074381800012	9648550	Bronze			2021-06-18	
J	Bell, MJ; Kochanek, PM; Doughty, LA; Carcillo, JA; Adelson, PD; Clark, RSB; Wisniewski, SR; Whalen, MJ; DeKosky, ST				Bell, MJ; Kochanek, PM; Doughty, LA; Carcillo, JA; Adelson, PD; Clark, RSB; Wisniewski, SR; Whalen, MJ; DeKosky, ST			Interleukin-6 and interleukin-10 in cerebrospinal fluid after severe traumatic brain injury in children	JOURNAL OF NEUROTRAUMA			English	Article						interleukin-6; interleukin-10; children; cerebrospinal fluid; trauma	CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; CYTOKINE PRODUCTION; MENINGITIS; INFECTIONS; BACTERIAL; DISEASES; COMPLEX	Cytokines may play an important role in the pathophysiology of traumatic brain injury (TBI) in children. Interleukin-6 (IL-6) is a proinflammatory cyotkine that plays a role in regenerative processes within the central nervous system (CNS), whereas interleukin-10 (IL-PO) is an antiinflammatory cytokine. Both have been measured in serum and cerebrospinal fluid (CSF) as an index of the degree of inflammation in diseases, including sepsis and meningitis. We hypothesized that both IL-6 and IL-10 would be increased in the CSF of children after severe TBI. Fifteen children who sustained severe TBI (Glascow Coma Score [GCS] less than or equal to 7) were studied. Standard neurointensive care was provided. Ventricular CSF collected the first 3 days after TBI was analyzed for IL-6 and IL-10 concentrations by ELISA. Controls were 20 children who were evaluated for meningitis with diagnostic lumbar puncture subsequently found to have no CSF pleocytosis and negative cultures. IL-6 was increased in children after TBI versus controls on all days studied (day 1, 3158.2 +/- 621.8 pg/ml; day 2, 1111.6 +/- 337.0 pg/ml; day 3, 826.7 +/- 193.5 pg/ml vs. 20.6 +/- 5.8 pg/ml, p < 0.0001, Mann-Whitney Rank Sum). IL-10 was increased in children after TBI vs controls on all days studied (day 1, 47.2 +/- 12.9 pg/ml; day 2, 21.0 +/- 6.7 pg/ml; day 3, 15.5 +/- 5.9 pg/ml vs. 8.9 +/- 7.5 pg/ml, p < 0.01). Increased IL-10 concentrations were independently associated with age < 4 years and mortality (p = 0.004 and 0.04, respectively, multivariate linear model). This study demonstrates that IL-6 is increased after TBI in children to levels similar to those reported in adults and is the first to show that IL-10 is increased in CSF of humans after TBI. These data suggest that there may be an age-dependent production of IL-10 after TBI in children.	UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,PITTSBURGH,PA 15260; UNIV PITTSBURGH,ALZHEIMERS DIS RES CTR,PITTSBURGH,PA; UNIV PITTSBURGH,DEPT ANESTHESIOL & CRIT CARE MED,PITTSBURGH,PA; UNIV PITTSBURGH,DEPT PEDIAT,PITTSBURGH,PA 15260; UNIV PITTSBURGH,DEPT NEUROL SURG,PITTSBURGH,PA 15260; UNIV PITTSBURGH,DEPT EPIDEMIOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,DEPT PSYCHIAT,PITTSBURGH,PA			Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758; Wisniewski, Stephen/0000-0002-3877-9860	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2P50NS30318-04A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER		CHAVANET P, 1992, J INFECT DIS, V166, P428, DOI 10.1093/infdis/166.2.428; Cuhna FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155; DOUGHTY LA, 1996, CRIT CARE MED, V24, P137; DULKERIAN SJ, 1995, J PEDIATR-US, V126, P872, DOI 10.1016/S0022-3476(95)70199-0; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; FREI K, 1993, J EXP MED, V178, P1255, DOI 10.1084/jem.178.4.1255; GALLO P, 1994, J NEUROL SCI, V126, P49, DOI 10.1016/0022-510X(94)90093-0; GIJBELS K, 1990, EUR J IMMUNOL, V20, P233, DOI 10.1002/eji.1830200134; KIKUCHI T, 1995, NEUROL RES, V17, P106, DOI 10.1080/01616412.1995.11740296; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KOSSMAN T, 1995, P 5 WIGG BERN C VIEN; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; LAVERDA AM, 1994, ACTA PAEDIATR, V83, P1038, DOI 10.1111/j.1651-2227.1994.tb12979.x; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; MAIMONE D, 1991, J NEUROIMMUNOL, V32, P67, DOI 10.1016/0165-5728(91)90073-G; MALEFYT RD, 1991, J EXP MED, V174, P915; MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562; MATSUZONO Y, 1995, ACTA PAEDIATR, V84, P879, DOI 10.1111/j.1651-2227.1995.tb13784.x; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PERRELLA O, 1992, J NEUROL, V239, P387; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; SHENG WS, 1995, CLIN DIAGN LAB IMMUN, V2, P604, DOI 10.1128/CDLI.2.5.604-608.1995; TARKOWSKI E, 1995, STROKE, V26, P1393, DOI 10.1161/01.STR.26.8.1393; TORRE D, 1992, SCAND J INFECT DIS, V24, P787, DOI 10.3109/00365549209062465; TSAI CY, 1994, SCAND J RHEUMATOL, V23, P57, DOI 10.3109/03009749409103028; VANFURTH AM, 1995, CLIN INFECT DIS, V21, P220, DOI 10.1093/clinids/21.1.220; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; ZHAI Q, 1996, NEUROSCIENCE, V22, P5	29	169	172	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	1997	14	7					451	457		10.1089/neu.1997.14.451			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	XP778	WOS:A1997XP77800003	9257663				2021-06-18	
J	Stein, DM; Boswell, S; Sliker, CW; Lui, FY; Scalea, TM				Stein, Deborah M.; Boswell, Sharon; Sliker, Clint W.; Lui, Felix Y.; Scalea, Thomas M.			Blunt Cerebrovascular Injuries: Does Treatment Always Matter?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Carotid artery injury; Vertebral artery injury; Blunt cerebrovascular injury; Diagnosis; Treatment; Infarction	COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CAROTID-ARTERY INJURIES; VASCULAR NECK INJURIES; ENDOVASCULAR THERAPY; EARLY-DIAGNOSIS; SCREENING-TEST; DISSECTION; ACCURACY; IMPROVES; OUTCOMES	Background: Blunt cerebrovascular injuries (BCVI) have become an increasingly recognized entity. Stroke as a result of these injuries can have devastating consequences. Optimal screening criteria, diagnostic imaging, and therapy for BCVIs have not been elucidated. Our institution began to apply liberal screening criteria using a whole-body scanning protocol with multidetector computed tomographic (WB-MDCT) scans to diagnose these injuries. The purpose of this study is to describe a single institution's large experience in patients with BCVI in an effort to provide insight into the diagnosis and management of these injuries. Methods: All patients with a BCVI admitted to the R Adams Cowley Shock Trauma Center during a 30-month period were included in this study. Choice of diagnostic evaluation and treatment regimens were at the discretion of the treating attending physician. Review of medical records and all relevant radiographic studies were retrospectively performed for the purposes of this study. Results: During the study period, there were 12,667 patients admitted to the R Adams Cowley Shock Trauma Center. There were 147 patients identified with 200 carotid or vertebral artery injuries. The incidence of BVCI was 1.2%. Mortality was 13%. Anatomic injury risk factors for BCVI (major facial fractures, skull base fractures, cervical spine fractures or spinal cord injury, or traumatic brain injury) were found in only 78%. Major thoracic injury was found in 63% of patients with carotid artery injuries and cervical spine fractures or spinal cord injury was found in 74% of patients with vertebral artery injuries. The initial screening test employed was a WB-MDCT in 96% of patients of which 84% detected a BCVI Treatments included endovascular therapy (22%), antiplatelet medications (36%), anticoagulation (10%), and combination therapy with antiplatelet agents and anticoagulation (18%). Thirty percent received no therapy, primarily due to contraindications from concomitant injuries. There were 18 (12%) patients who had a stroke. Of these patients, 8 (44%) had evidence of infarction at admission, 6 were diagnosed within 72 hours, and 4 were diagnosed after 1 week. Stroke-related mortality was 50%, whereas clinical follow-up after hospital discharge demonstrated only one patient with disability as a result of infarction. Of 10 patients who did not have stroke at admission, 3 were fully treated, 5 had specific contrain-dications to therapy, and 2 had no or false-negative imaging before infarction. Stroke rates for untreated patients were 25.8% and patients treated with any therapy had a stroke rate of 3.9% (p = 0.0003). Radiographic follow-up >1 month after injury demonstrated improvement in over 50% of patients. Conclusions: BCVIs are not infrequent after blunt trauma. These injuries occur even in the absence of classically described risk factors. Liberal screening with WB-MDCT incorporates detection of these injuries into the initial diagnostic evaluation. Stroke occurs in a substantial number of patients and carries a very high mortality. However, nearly one third of patients with BCVI are not candidates for therapy. Treatment does reduce the risk of infarction in patients with BCVI, but strokes, when they occur, are not preventable.	[Stein, Deborah M.] Univ Maryland, Med Ctr, Div Crit Care, R Adams Cowley Shock Trauma Ctr,Program Trauma, Baltimore, MD 21201 USA	Stein, DM (corresponding author), Univ Maryland, Med Ctr, Div Crit Care, R Adams Cowley Shock Trauma Ctr,Program Trauma, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu		Stein, Deborah/0000-0003-3683-3963			Beletsky V, 2003, STROKE, V34, P2856, DOI 10.1161/01.STR.0000098649.39767.BC; Berne JD, 2004, J TRAUMA, V57, P11, DOI 10.1097/01.TA.0000135499.70048.C7; Berne JD, 2001, J AM COLL SURGEONS, V192, P314, DOI 10.1016/S1072-7515(01)00772-4; Berne JD, 2006, J TRAUMA, V60, P1204, DOI 10.1097/01.ta.0000220435.55791.ce; Biffl WL, 2006, J TRAUMA, V60, P745, DOI 10.1097/01.ta.0000204034.94034.c4; Biffl WL, 2002, ANN SURG, V235, P699, DOI 10.1097/00000658-200205000-00012; Biffl WL, 2002, J TRAUMA, V53, P850, DOI 10.1097/00005373-200211000-00008; Biffl WL, 2001, WORLD J SURG, V25, P1036, DOI 10.1007/s00268-001-0056-x; Biffl WL, 1998, ANN SURG, V228, P462, DOI 10.1097/00000658-199810000-00003; Biffl WL, 2001, J TRAUMA, V50, P969, DOI 10.1097/00005373-200105000-00039; Biffl WL, 2000, ANN SURG, V231, P672, DOI 10.1097/00000658-200005000-00007; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Biffl WL, 1999, AM J SURG, V178, P517, DOI 10.1016/S0002-9610(99)00245-7; Bub LD, 2005, J TRAUMA, V59, P691, DOI 10.1097/01.ta.0000177698.23357.77; Bush RL, 2001, J ENDOVASC THER, V8, P53, DOI 10.1583/1545-1550(2001)008<0053:ESPACE>2.0.CO;2; Carrillo EH, 1999, J TRAUMA, V46, P1120, DOI 10.1097/00005373-199906000-00030; Chen JY, 2006, EMERG RADIOL, V12, P192, DOI 10.1007/s10140-006-0471-2; Citron Steven J, 2003, J Vasc Interv Radiol, V14, pS257; COGBILL TH, 1994, J TRAUMA, V37, P473, DOI 10.1097/00005373-199409000-00024; Coldwell DM, 2000, J TRAUMA, V48, P470, DOI 10.1097/00005373-200003000-00016; Cothren CC, 2005, AM J SURG, V190, P845, DOI 10.1016/j.amsurg.2005.08.007; Cothren CC, 2005, ARCH SURG-CHICAGO, V140, P480, DOI 10.1001/archsurg.140.5.480; Cothren CC, 2004, ARCH SURG-CHICAGO, V139, P540, DOI 10.1001/archsurg.139.5.540; Cothren CC, 2003, J TRAUMA, V55, P811, DOI 10.1097/01.TA.0000092700.92587.32; DAVIS JW, 1990, J TRAUMA, V30, P1514, DOI 10.1097/00005373-199012000-00013; Diaz-Daza O, 2003, CARDIOVASC INTER RAD, V26, P213, DOI 10.1007/s00270-002-2619-0; Eastman AL, 2006, J TRAUMA, V60, P925, DOI 10.1097/01.ta.0000197479.28714.62; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; Gomez CR, 1999, CRIT CARE CLIN, V15, P789, DOI 10.1016/S0749-0704(05)70088-9; HIGASHIDA RT, 1989, AM J ROENTGENOL, V153, P577, DOI 10.2214/ajr.153.3.577; Hughes KM, 2000, AM SURGEON, V66, P1023; Kraus RR, 1999, AM J SURG, V178, P190, DOI 10.1016/S0002-9610(99)00157-9; Lyrer P, 2003, COCHRANE DATABASE SY; Martin MJ, 2005, J TRAUMA, V59, P860, DOI 10.1097/01.ta.0000187964.47703.e9; Mayberry JC, 2004, ARCH SURG-CHICAGO, V139, P609, DOI 10.1001/archsurg.139.6.609; McKevitt EC, 2002, J TRAUMA, V53, P472, DOI 10.1097/00005373-200209000-00013; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Miller PR, 2001, J TRAUMA, V51, P279, DOI 10.1097/00005373-200108000-00009; Mutze S, 2005, RADIOLOGY, V237, P884, DOI 10.1148/radiol.2373042189; Parikh AA, 1997, J AM COLL SURGEONS, V185, P80, DOI 10.1016/S1072-7515(01)00886-9; Rogers FB, 1999, J TRAUMA, V46, P380, DOI 10.1097/00005373-199903000-00005; Schneidereit NP, 2006, J TRAUMA, V60, P209, DOI 10.1097/01.ta.0000195651.60080.2c; Simionato F, 1999, NEURORADIOLOGY, V41, P543, DOI 10.1007/s002340050801; Stuhlfaut JW, 2005, AM J ROENTGENOL, V185, P1063, DOI 10.2214/AJR.04.1217; Utter GH, 2006, J AM COLL SURGEONS, V203, P838, DOI 10.1016/j.jamcollsurg.2006.08.003; Veras LM, 2000, SPINE, V25, P1171, DOI 10.1097/00007632-200005010-00019; Wahl WL, 2002, J TRAUMA, V52, P896, DOI 10.1097/00005373-200205000-00012	47	168	171	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2009	66	1					132	143		10.1097/TA.0b013e318142d146			12	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	395SJ	WOS:000262543500017	19131816				2021-06-18	
J	Goldman, SM; Tanner, CM; Oakes, D; Bhudhikanok, GS; Gupta, AR; Langston, JW				Goldman, Samuel M.; Tanner, Caroline M.; Oakes, David; Bhudhikanok, Grace S.; Gupta, A-Rijali; Langston, J. William			Head injury and Parkinson's disease risk in twins	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; ENVIRONMENTAL-INFLUENCES; INFLAMMATORY RESPONSE; ALPHA-SYNUCLEIN; TAU; NEURODEGENERATION; IMMUNOREACTIVITY; ACCUMULATION; ASSOCIATION; EXPRESSION	Objective: Head injury is an inconsistently reported risk factor for Parkinson's disease (PD). Many related variables might confound this association, such as differences in childhood and adolescent lifestyles or genetically determined risk-taking behaviors. Twin studies circumvent some of these problems, because twins are genetically and environmentally much more similar than typical cases and control subjects. Methods: We conducted a case-control study in 93 twin pairs discordant for PD ascertained from the National Academy of Sciences/National Research Council World War II Veteran Twins Cohort. Results: A prior head injury with amnesia or loss of consciousness was associated with an increased risk for PD (odds ratio, 3.8; 95% confidence interval, 1.3-11; p = 0.014). Truncating observations 10 years before PD onset enhanced the association. Though less precise, the association was somewhat stronger in monozygotic than in dizygotic pairs. Risk increased further with a subsequent head injury (p trend = 0.022) and with head injuries requiring hospitalization. Duration of unconsciousness was not associated. In a subanalysis of 18 pairs concordant for PD, the twin with younger onset PD was more likely to have sustained a head injury, although numbers were small. Interpretation: Our results suggest that mild-to-moderate closed head injury may increase PD risk decades later.	Parkinsons Inst, Sunnyvale, CA 94089 USA; Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14627 USA	Goldman, SM (corresponding author), Parkinsons Inst, 1170 Morse Ave, Sunnyvale, CA 94089 USA.	sgoldman@thepi.org	Goldman, Samuel/A-2225-2014	Goldman, Samuel/0000-0002-3039-9927	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U10 NS31321, R01 NS40467] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040467, U10NS031321] Funding Source: NIH RePORTER		Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Beal MF, 2003, ANN NY ACAD SCI, V991, P120; Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81; BHARUCHA NE, 1986, NEUROLOGY, V36, P284, DOI 10.1212/WNL.36.2.284; Bouchard TJ, 2003, J NEUROBIOL, V54, P4, DOI 10.1002/neu.10160; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; CEDERLOEF R, 1961, ACTA GENET STAT MED, V11, P338; Chen HL, 2003, ARCH NEUROL-CHICAGO, V60, P1059, DOI 10.1001/archneur.60.8.1059; COCCARO EF, 1993, PSYCHIAT RES, V48, P229, DOI 10.1016/0165-1781(93)90074-Q; DeMichele G, 1996, MOVEMENT DISORD, V11, P17, DOI 10.1002/mds.870110105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78; Eriksen JL, 2005, ARCH NEUROL-CHICAGO, V62, P353, DOI 10.1001/archneur.62.3.353; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Frantseva M, 2002, PROG BRAIN RES, V137, P171; GALLO JJ, 1995, PSYCHOL MED, V25, P1211, DOI 10.1017/S0033291700033183; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Giasson BI, 2003, SCIENCE, V300, P636, DOI 10.1126/science.1082324; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; HAMMOND HA, 1994, AM J HUM GENET, V55, P175; Irving EA, 1996, NEUROSCI LETT, V213, P189; JABLON S, 1967, AM J HUM GENET, V19, P133; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liu PK, 2002, ANN NY ACAD SCI, V962, P226, DOI 10.1111/j.1749-6632.2002.tb04071.x; Maher NE, 2002, NEUROLOGY, V58, P79, DOI 10.1212/WNL.58.1.79; Maries E, 2003, NAT REV NEUROSCI, V4, P727, DOI 10.1038/nrn1199; MARTYN CN, 1995, J NEUROL SCI, V132, P201, DOI 10.1016/0022-510X(95)00148-U; McCann SJ, 1998, NEUROEPIDEMIOLOGY, V17, P310, DOI 10.1159/000026185; McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005; McGue M, 1998, ANNU REV NEUROSCI, V21, P1, DOI 10.1146/annurev.neuro.21.1.1; Meredith GE, 2004, PARKINSONISM RELAT D, V10, P191, DOI 10.1016/j.parkreldis.2004.01.001; MORANO A, 1994, ACTA NEUROL SCAND, V89, P164; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; Ross George W., 2003, Neurology, V60, pA416; Schapira AHV, 1998, ANN NEUROL, V44, pS89, DOI 10.1002/ana.410440714; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Seidler A, 1996, NEUROLOGY, V46, P1275, DOI 10.1212/WNL.46.5.1275; SEMCHUK KM, 1993, NEUROLOGY, V43, P1173, DOI 10.1212/WNL.43.6.1173; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Smith GA, 2004, CLIN PEDIATR, V43, P335, DOI 10.1177/000992280404300404; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.3.CO;2-R; TORGERSEN S, 1979, ACTA GENET MED GEMEL, V28, P225, DOI 10.1017/S0001566000009077; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Werneck ALD, 1999, ARQ NEURO-PSIQUIAT, V57, P347, DOI 10.1590/S0004-282X1999000300001; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554	52	168	169	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JUL	2006	60	1					65	72		10.1002/ana.20882			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	060TW	WOS:000238825500012	16718702				2021-06-18	
J	Whyte, J; Hart, T; Vaccaro, M; Grieb-Neff, P; Risser, A; Polansky, M; Coslett, HB				Whyte, J; Hart, T; Vaccaro, M; Grieb-Neff, P; Risser, A; Polansky, M; Coslett, HB			Effects of methylphenidate on attention deficits after traumatic brain injury - A multidimensional randomized controlled trial	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						traumatic brain injury; methylphenidate; attention deficits	CLOSED-HEAD-INJURY; DOUBLE-BLIND; REHABILITATION; CHILDREN; ADULTS; PERFORMANCE; DISORDERS; FAILURES; PLACEBO; TASK	Objective: To evaluate the effects of methylphenidate on a variety of aspects of attention, ranging from laboratory-based impairment measures to caregiver ratings and work productivity, in individuals after traumatic brain injury. Design: A total of 34 adults with moderate to severe traumatic brain injury and attention complaints in the postacute phase of recovery were enrolled in a 6-wk, double-blind, placebo-controlled, repeated crossover study of methylphenidate, administered in a dose of 0.3 mg/kg/dose, twice a day. A wide range of attentional measures was gathered weekly, including computerized and paper-and-pencil tests of attention, videotaped records of individual work in a distracting environment, real-time observational scoring of attentiveness in a classroom environment, and caregiver and clinician rating scales of attentiveness. Participants also attempted to guess their drug condition each week. Data from the first ten participants were used for pilot purposes, to develop attentional factors for composite scoring, and to identify attentional dimensions suggestive of a treatment effect for independent replication. The remaining 24 participants results were used to confirm potential treatment effects seen in the pilot sample, using Wilcoxon's signed-ranks test on composite factor scores and individual variables. Results: A total of 54 dependent variables were reduced to 13 composite factors and 13 remaining individual variables. Of the 13 attentional factors, five showed suggestive treatment effects in the pilot sample. Of these, three showed statistically significant treatment effects in the replication sample: speed of information processing (effect sizes, -0.06 to 0.48; P < 0.001), attentiveness during individual work tasks (effect sizes, 0.15-0.62; P = 0.01), and caregiver ratings of attention (effect sizes, 0.44-0.50; P = 0.01). Of the individual variables, four showed suggestive treatment effects in the pilot sample, but only one showed significant treatment effects in the replication sample: reaction time before errors in the Sustained Attention to Response Task (effect size, 0.20; P = 0.03). No treatment-related improvement was seen in divided attention, sustained attention, or susceptibility to distraction. None of the variables showed suggestive or definite negative treatment effects. Effect sizes for those performance measures positively affected by methylphenidate were in the small to medium range and included both impairment and activity level measures. Improvements in processing speed did not seem to come at the expense of accuracy. Conclusions: Methylphenidate, at 0.3 mg/kg/dose, given twice a day to individuals with attentional complaints after traumatic brain injury, seems to have clinically significant positive effects on speed of processing, caregiver ratings of attention, and some aspects of on-task behavior in naturalistic tasks. Further research is needed to identify the optimal dose and to extend these findings to less carefully selected individuals.	Albert Einstein Healthcare Network, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; Drexel Univ, Dept Biostat, Philadelphia, PA 19104 USA; Univ Texas, Dept Sympton Res, Houston, TX USA; Thomas Jefferson Univ, Dept Rehabil Med, Philadelphia, PA 19107 USA	Whyte, J (corresponding author), Albert Einstein Healthcare Network, Moss Rehabil Res Inst, 1200 W Tabor Rd,Suite 213, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD39621] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS39163] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039163] Funding Source: NIH RePORTER		Alban JP, 2004, AM J PHYS MED REHAB, V83, P131, DOI 10.1097/01.phm.0000112308.68586.1d; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Bedard AC, 2002, J CHILD ADOL PSYCHOP, V12, P301, DOI 10.1089/104454602762599844; BIRMAHER B, 1989, J AM ACAD CHILD PSY, V28, P768, DOI 10.1097/00004583-198909000-00020; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Capruso D. X., 2000, HEAD INJURY, P525; CARLSON CL, 1991, J CHILD PSYCHOL PSYC, V32, P463, DOI 10.1111/j.1469-7610.1991.tb00324.x; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Conners C K, 2002, J Atten Disord, V6 Suppl 1, pS17; COONS HW, 1981, ELECTROEN CLIN NEURO, V51, P373, DOI 10.1016/0013-4694(81)90101-2; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; Francisco GE, 1996, AM J PHYS MED REHAB, V75, P63, DOI 10.1097/00002060-199601000-00016; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; HOFFMAN BB, 2001, PHARM BASIS THERAPEU; KRAUS J, 1994, NEUROPSYCHIATRY TRAU; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Pliszka SR, 1998, PEDIATR CLIN N AM, V45, P1085, DOI 10.1016/S0031-3955(05)70063-8; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; PORTNEY LG, 1993, APPL PRACTICE APPEND, P651; Posner M. I., 1986, CHRONOMETRIC EXPLORA; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REID MK, 1984, J ABNORM CHILD PSYCH, V12, P169, DOI 10.1007/BF00913468; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Scheres A, 2003, J ABNORM CHILD PSYCH, V31, P105, DOI 10.1023/A:1021729501230; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; SPENCER T, 1995, ARCH GEN PSYCHIAT, V52, P434; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; VANZOMEREH EH, 1994, CLIN NEUROPSYCHOLOGY; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Whyte J, 1998, REHABILITATION MED P, P1191; Whyte J, 1997, ASSESSING MED REHABI, P43; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007	48	168	171	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUN	2004	83	6					401	420		10.1097/01.PHM.0000128789.75375.D3			20	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	822QB	WOS:000221553600001	15166683				2021-06-18	
J	Basford, JR; Chou, LS; Kaufman, KR; Brey, RH; Walker, A; Malec, JF; Moessner, AM; Brown, AW				Basford, JR; Chou, LS; Kaufman, KR; Brey, RH; Walker, A; Malec, JF; Moessner, AM; Brown, AW			An assessment of gait and balance deficits after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						balance; brain injuries; gait; rehabilitation; vestibular function tests	CENTER-OF-MASS; PERSISTENT POSTCONCUSSION SYNDROME; DIFFUSE AXONAL INJURY; CLOSED-HEAD INJURY; POSITIONAL VERTIGO; POSTURAL STABILITY; OLDER-PEOPLE; MILD HEAD; SWAY; POSTUROGRAPHY	Objective: To assess the sensations of instability that many patients report after traumatic brain injury (TBI). Design: A controlled study. Setting: A motion analysis and vestibular and balance laboratory. Participants: Twenty subjects, 10 with TBI and complaints of instability, and 10 without TBI. Interventions: Balance and gait analysis. Main Outcome Measures: Dizziness Handicap Inventory (DHI), caloric irrigation, optokinetic testing, Dix-Hallpike Test, posturography, and center of mass (COM) movement. Results: Subjects were well matched in terms of age, height, weight, and gender. DHI scores of those with and without TBI differed significantly (32.2+/-23.0 vs 0.2+/-0.63, P<.001). Caloric and optokinetic circularvection testing were abnormal only in subjects with TBI (8/10 and 4/10, respectively). Benign paroxysmal positioning vertigo was present in only 3 subjects with TBI, and this either resolved spontaneously (n=1) or was successfully treated (n=2). Composite posturography scores of those with and without TBI differed significantly (69.6&PLUSMN;35.8 vs 79.5&PLUSMN;40.5, P=.02). Gait parameters also differed significantly between the groups (P=.05), with the subjects with TBI having lower anterior and posterior and higher medial and lateral COM displacements and velocities. Conclusion: Patients' complaints of instability after TBI may have objective correlates and may be rectifiable. Balance and gait testing in these patients is warranted.	Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Otorhinolaryngol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mot Anal Lab, Dept Orthoped Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Sect Neuropsychol & Rehabil Psychol, Rochester, MN 55905 USA; Univ Oregon, Dept Exercise & Movement Sci, Eugene, OR 97403 USA	Basford, JR (corresponding author), Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, 200 SW 2nd St, Rochester, MN 55905 USA.			Kaufman, Kenton/0000-0002-7311-3781; Brown, Allen W./0000-0001-7228-3351			Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; BAIRD RJ, 2000, THESIS B YOUNG U PRO; BALOH R, 1996, DISORDERS VESTIBULAR, P126; BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; Bradshaw DRS, 2001, J BIOMECH, V34, P85, DOI 10.1016/S0021-9290(00)00135-4; CARHART R, 1959, J SPEECH HEAR DISORD, V24, P330, DOI 10.1044/jshd.2404.330; Chou LS, 2001, GAIT POSTURE, V13, P17, DOI 10.1016/S0966-6362(00)00087-4; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DEMPSTER WT, 1967, AM J ANAT, V120, P33, DOI 10.1002/aja.1001200104; DIX R, 1952, ANN OTO RHINOL LARYN, V6, P987; Eng J.J., 1993, GAIT POSTURE, V1, P141, DOI 10.1016/0966-6362(93)90055-6; EPLEY JM, 1992, OTOLARYNG HEAD NECK, V107, P399, DOI 10.1177/019459989210700310; Evans MK, 1999, OTOLARYNG HEAD NECK, V120, P164, DOI 10.1016/S0194-5998(99)70401-8; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Growney E, 1997, GAIT POSTURE, V6, P147, DOI 10.1016/S0966-6362(97)01114-4; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; JACOBSON GP, 1993, HDB BALANCE FUNCTION, P195; JIAN YC, 1993, GAIT POSTURE, V1, P9, DOI DOI 10.1016/0966-6362(93)90038-3; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kaya BK, 1998, J GERONTOL A-BIOL, V53, pM126, DOI 10.1093/gerona/53A.2.M126; Kerber KA, 1998, NEUROLOGY, V51, P574, DOI 10.1212/WNL.51.2.574; Krebs DE, 1998, ARCH PHYS MED REHAB, V79, P1489, DOI 10.1016/S0003-9993(98)90408-7; Lahat E, 1996, PEDIATR NEUROL, V15, P299, DOI 10.1016/S0887-8994(96)00221-4; Lahbabi M., 1997, Revue de Stomatologie et de Chirurgie Maxillo-Faciale, V98, P295; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LINDSAY JT, 1998, J NEUROTRAUM, V15, P573; Malec JF, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P15; MALEC JF, 1996, NEUROLOGY TRAUMA, P231; Mariak Z, 1997, Eur J Ophthalmol, V7, P68; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mrazik M, 2000, BRAIN INJURY, V14, P921, DOI 10.1080/026990500445736; Muthu P, 2001, EMERG MED J, V18, P310, DOI 10.1136/emj.18.4.310; *NEUR INT, 1991, EQ SYST DAT INT MAN; NEWTON RA, 1995, BRAIN INJURY, V9, P445, DOI 10.3109/02699059509008204; O'Neill DE, 1998, AM J OTOL, V19, P797; Pai YC, 1997, J BIOMECH, V30, P347, DOI 10.1016/S0021-9290(96)00165-0; Pickett W, 2001, CAN MED ASSOC J, V165, P288; RUBIN AM, 1995, AM J OTOL, V16, P216; Sosin DM, 1996, BRAIN INJURY, V10, P47; TINETTI ME, 1988, NEW ENGL J MED, V319, P1071; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Whitman GT, 2001, NEUROLOGY, V57, P990, DOI 10.1212/WNL.57.6.990; Winter DA., 1991, BIOMECHANICS MOTOR C; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7; Zatsiorsky V. M., 1985, BIOMECHANICS B, P233	50	168	170	1	23	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2003	84	3					343	349		10.1053/apmr.2003.50034			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	653KL	WOS:000181434300005	12638101				2021-06-18	
J	Erlanger, D; Kaushik, T; Cantu, R; Barth, JT; Broshek, DK; Freeman, JR; Webbe, FM				Erlanger, D; Kaushik, T; Cantu, R; Barth, JT; Broshek, DK; Freeman, JR; Webbe, FM			Symptom-based assessment of the severity of a concussion	JOURNAL OF NEUROSURGERY			English	Article						brain concussion; athletic injury; sports neuropsychology; computerized cognitive testing	MILD HEAD-INJURY; BRAIN-INJURY; SAFE RETURN; FOOTBALL; COLLEGIATE; PERFORMANCE; PATHOPHYSIOLOGY; CONSCIOUSNESS	Object. Current grading systems of concussion and return-to-play guidelines have little empirical support. The authors therefore examined the relationships of the characteristics and symptoms of concussion and the history of concussion to three indicators of concussion severity-number of immediate symptoms, number of symptoms at the initial follow-up examination, and duration of symptoms-to establish an empirical basis for grading concussions. Methods. Forty-seven athletes who sustained concussions were administered alternate forms of an Internet-based neurocognitive test until their performances were within normal limits relative to baseline levels. Assessments of observer-reported and self-reported symptoms at the sideline of the playing field on the day of injury, and at follow-up examinations were also obtained as part of a comprehensive concussion management protocol. Although loss of consciousness (LOC) was a useful indicator of the initial severity of the injury, it did not correlate with other indices of concussion severity, including duration of symptoms. Athletes reporting memory problems at follow-up examinations had significantly more symptoms in general, longer durations of those symptoms, and significant decreases in scores on neurocognitive tests administered approximately 48 hours postinjury. This decline of scores on neurocognitive testing was significantly associated with an increased duration of symptoms. A history of concussion was unrelated to the number and duration of symptoms. Conclusions. This paper represents the first documentation of empirically derived indicators of the clinical course of postconcussion symptom resolution. Self-reported memory problems apparent 24 hours postconcussion were robust indicators of the severity of sports-related concussion and should be a primary consideration in determining an athlete's readiness to return to competition. A decline on neurocognitive testing was the only objective measure significantly related to the duration of symptoms. Neither a brief LOC nor a history of concussion was a useful predictor of the duration of postconcussion symptoms.	Columbia Univ, Dept Neurosci & Educ, New York, NY USA; HeadMinder Inc, New York, NY USA; Albert Einstein Coll Med, Dept Psychiat, Bronx, NY 10467 USA; Emerson Hosp, Dept Surg, Concord, MA USA; Univ Virginia, Dept Psychiat Med, Charlottesville, VA USA; Florida Inst Technol, Dept Psychol, Melbourne, FL 32901 USA	Erlanger, D (corresponding author), 3 E 65th St,Suite 5B, New York, NY 10021 USA.	david@headminder.com	Webbe, Frank/A-8074-2009	Webbe, Frank/0000-0002-4370-5698			ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; Barth JT., 1989, MILD HEAD INJURY, P257; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; ECHEMENDIA RJ, IN PRESS SPORTS NEUR; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; ERLANGER DM, 2002, HEADMINDER CONCUSSIO; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harmon KG, 1999, AM FAM PHYSICIAN, V60, P887; Hayes RL, 1989, MILD HEAD INJURY, P54; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 2001, J ATHL TRAINING, V36, P249; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Macciocchi SN, 1999, ARCH CLIN NEUROPSYCH, V14, P781; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M., 2000, STANDARDIZED ASSESSM; Mrazik M, 1999, ARCH CLIN NEUROPSYCH, V14, P781; WEBBE FM, IN PRESS APPL NEUROP; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44	31	168	170	0	25	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2003	98	3					477	484		10.3171/jns.2003.98.3.0477			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	653WW	WOS:000181460900005	12650417				2021-06-18	
J	Joshi, M; Fehlings, MG				Joshi, M; Fehlings, MG			Development and characterization of a novel, graded model of clip compressive spinal cord injury in the mouse: Part 1. Clip design, behavioral outcomes, and histopathology	JOURNAL OF NEUROTRAUMA			English	Article						histopathology; in vivo model; knockout mouse; locomotion assessment; neurotrauma; pathophysiology	DELAYED WALLERIAN DEGENERATION; SCANNING ELECTRON-MICROSCOPY; FIBRILLARY ACIDIC PROTEIN; VASCULAR CORROSION CASTS; MUTATION WLD(S); 3-DIMENSIONAL ANALYSIS; NEUROLOGICAL FUNCTION; GENETIC INFLUENCES; CELLULAR REACTIONS; EVOKED-POTENTIALS	In order to take advantage of various genetically manipulated mice available to study the pathophysiology of spinal cord injury (SCI), we adapted an extradural clip compression injury model to the mouse (FEJOTA(TM) mouse clip). The dimensions of the modified aneurysm clip blades were customized for application to the mouse spinal cord. Three clips with different springs were made to produce differing magnitudes of closing force (3, 8, and 24 g). The clips were calibrated regularly to ensure that the closing force remained constant. The surgical procedure involved a laminectomy at T3 and T4, followed by extradural application of the clip at this level for 1 min to produce SCI. Three injury severities (3, 8, and 24 g), sham (passage of dissector extradurally at T3-4), and transection control groups were examined (n = 12/group). Quantitative behavioural assessments using the Basso, Beattie, and Bresnahan (BBB; H > 46; df = 4; p < 0.001; Kruskal-Wallis one-way ANOVA) and inclined plane (IP; F = 123; df = 4; p < 0.000 1; two-way repeated measures ANOVA) tests showed a significant graded increase in neurological deficits with increasing severity of injury. By day 14, the motor recovery of the mice plateaued. Qualitative examination of the injury site morphology indicated that microcystic cavitation, degenerating axons, and robust astrogliosis were characteristic of the murine response to clip compressive SCI. Morphometric analyses of H&E/Luxol Fast Blue stained sections at every 50 mum from the injury epicenter indicated that with greater injury severity there was a progressive decrease in residual tissue (F = 220, df = 3; p < 0.0001; two-way ANOVA). In addition, statistically significant differences were found in the amount of residual tissue at the injury epicenter between all of the injury severities (p < 0.05, SNK test). This novel, graded compressive model of SCI will facilitate future studies of the pathological mechanisms of SCI using transgenic and knockout murine systems.	Univ Toronto, Toronto Western Hosp, Dept Surg, Div Neurosurg, Toronto, ON M5T 2S8, Canada	Fehlings, MG (corresponding author), Univ Toronto, Univ Hlth Network, Dept Surg, 399 Bathurst St,Suite 2-417, Toronto, ON M5T 2S8, Canada.	michael.fehlings@uhn.on.ca		Fehlings, Michael/0000-0002-5722-6364			Agrawal SK, 1997, J NEUROTRAUM, V14, P81, DOI 10.1089/neu.1997.14.81; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bjugn R, 1997, EXP NEUROL, V148, P179, DOI 10.1006/exnr.1997.6610; BLIGHT AR, 1993, ADV NEUROL, V59, P91; BRESNAHAN JC, 1976, J NEUROL SCI, V28, P521, DOI 10.1016/0022-510X(76)90122-2; Bunge R P, 1997, Adv Neurol, V72, P305; DOLAN EJ, 1980, J NEUROSURG, V53, P749, DOI 10.3171/jns.1980.53.6.0749; DOLAN EJ, 1979, J NEUROSURG, V51, P229, DOI 10.3171/jns.1979.51.2.0229; Farooque M, 2000, ACTA NEUROPATHOL, V100, P13, DOI 10.1007/s004010051187; Farooque M, 1999, NEUROREPORT, V10, P131, DOI 10.1097/00001756-199901180-00024; Fehlings MG, 1997, J NEUROSCI METH, V71, P215, DOI 10.1016/S0165-0270(96)00147-1; Fehlings MG, 1996, BRAIN RES, V736, P135, DOI 10.1016/0006-8993(96)00667-1; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; FEHLINGS MG, 1989, ELECTROEN CLIN NEURO, V74, P241, DOI 10.1016/0168-5597(89)90055-5; FEHLINGS MG, 1987, EXP NEUROL, V95, P548; Fujiki M, 1996, J COMP NEUROL, V371, P469; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; Jakeman LB, 2000, J NEUROTRAUM, V17, P299, DOI 10.1089/neu.2000.17.299; KOYANAGI I, 1993, NEUROSURGERY, V32, P260, DOI 10.1227/00006123-199302000-00015; KOYANAGI I, 1993, NEUROSURGERY, V33, P277; KOYANAGI I, 1993, NEUROSURGERY, V33, P285, DOI 10.1227/00006123-199308000-00016; Kuhn PL, 1998, J NEUROTRAUM, V15, P125, DOI 10.1089/neu.1998.15.125; Lang-Lazdunski L, 2000, STROKE, V31, P208, DOI 10.1161/01.STR.31.1.208; LAVEY RS, 1994, INT J RADIAT ONCOL, V30, P609, DOI 10.1016/0360-3016(92)90947-G; Little JW, 1999, ARCH PHYS MED REHAB, V80, P587, DOI 10.1016/S0003-9993(99)90204-6; LO YC, 1993, INT J RADIAT ONCOL, V27, P309, DOI 10.1016/0360-3016(93)90242-N; LO YC, 1992, INT J RADIAT ONCOL, V22, P57, DOI 10.1016/0360-3016(92)90982-N; MA M, 1999, SOC NEUR; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Nashmi R, 2000, EUR J NEUROSCI, V12, P491, DOI 10.1046/j.1460-9568.2000.00926.x; Nashmi R, 1997, J NEUROTRAUM, V14, P151, DOI 10.1089/neu.1997.14.151; Pan WH, 1999, J NEUROSCI, V19, P3649; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; Schwartz G, 2001, J NEUROSURG, V94, P245, DOI 10.3171/spi.2001.94.2.0245; Steward O, 1999, EXP NEUROL, V157, P19, DOI 10.1006/exnr.1999.7040; Tator CH, 1998, NEUROSURGERY, V42, P696, DOI 10.1097/00006123-199804000-00007; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1992, J NEUROTRAUM, V9, P139, DOI 10.1089/neu.1992.9.139; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Wamil AW, 1998, P NATL ACAD SCI USA, V95, P13188, DOI 10.1073/pnas.95.22.13188; Wang X, 1997, EXP NEUROL, V148, P568, DOI 10.1006/exnr.1997.6702; Zhang ZY, 1996, J COMP NEUROL, V371, P485; Zhang ZY, 1998, EXP NEUROL, V149, P221, DOI 10.1006/exnr.1997.6717	50	168	179	1	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2002	19	2					175	190		10.1089/08977150252806947			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	526ER	WOS:000174117100001	11893021				2021-06-18	
J	Kane, MJ; Angoa-Perez, M; Briggs, DI; Viano, DC; Kreipke, CW; Kuhn, DM				Kane, Michael J.; Angoa-Perez, Mariana; Briggs, Denise I.; Viano, David C.; Kreipke, Christian W.; Kuhn, Donald M.			A mouse model of human repetitive mild traumatic brain injury	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Traumatic brain injury; Mild; Repetitive; Concussive; Head acceleration; Tauopathy	CLOSED-HEAD INJURY; METHAMPHETAMINE-INDUCED NEUROTOXICITY; PROFESSIONAL FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; COGNITIVE IMPAIRMENT; MICROGLIAL ACTIVATION; RECURRENT CONCUSSION; ANIMAL-MODELS; MICE; BIOMECHANICS	A novel method for the study of repetitive mild traumatic brain injury (rmTBI) that models the most common form of head injury in humans is presented. Existing animal models of TBI impart focal, severe damage unlike that seen in repeated and mild concussive injuries, and few are configured for repetitive application. Our model is a modification of the Marmarou weight drop method and allows repeated head impacts to lightly anesthetized mice. A key facet of this method is the delivery of an impact to the cranium of an unrestrained subject allowing rapid acceleration of the free-moving head and torso, an essential characteristic known to be important for concussive injury in humans, and a factor that is missing from existing animal models of TBI. Our method does not require scalp incision, emplacement of protective skull helmets or surgery and the procedure can be completed in 1-2 min. Mice spontaneously recover the righting reflex and show no evidence of seizures, paralysis or impaired behavior. Skull fractures and intracranial bleeding are very rare. Minor deficits in motor coordination and locomotor hyperactivity recover over time. Histological analyses reveal mild astrocytic reactivity (increased expression of GFAP) and increased phospho-tau but a lack of blood-brain-barrier disruption, edema and microglial activation. This new animal model is simple and cost-effective and will facilitate characterization of the neurobiological and behavioral consequences of rmTBI. It is also ideal for high throughput screening of potential new therapies for mild concussive injuries as experienced by athletes and military personnel. Published by Elsevier B.V.	[Kane, Michael J.; Angoa-Perez, Mariana; Briggs, Denise I.; Kreipke, Christian W.; Kuhn, Donald M.] John D Dingell VA Med Ctr, Res & Dev Serv, Detroit, MI 48201 USA; [Kane, Michael J.; Angoa-Perez, Mariana; Briggs, Denise I.; Kuhn, Donald M.] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; [Viano, David C.] ProBiomechanics LLC, Bloomfield Hills, MI 48304 USA; [Viano, David C.] Wayne State Univ, Sch Engn, Dept Biomed Engn, Detroit, MI 48201 USA; [Kreipke, Christian W.] Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA	Kuhn, DM (corresponding author), John D Dingell VA Med Ctr, Res & Dev Serv, 4646 John R, Detroit, MI 48201 USA.	donald.kuhn@wayne.edu		Briggs, Denise/0000-0002-4824-3947	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Department of Veteran's AffairsUS Department of Veterans Affairs; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA010756, R01DA017327] Funding Source: NIH RePORTER	This research was supported by grants from the NIH and the Department of Veteran's Affairs. We thank the carpentry shop at the John D. Dingell VA Medical Center for its expert assistance in fashioning the brass weights used in these studies.	Angoa-Perez M, 2010, NEUROTOXICOLOGY, V31, P738, DOI 10.1016/j.neuro.2010.06.007; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen AJW, 2010, NEURON, V66, P11, DOI 10.1016/j.neuron.2010.04.004; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Finnie JW, 2001, AUST VET J, V79, P628, DOI 10.1111/j.1751-0813.2001.tb10785.x; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Goodman MD, 2011, J SURG RES, V165, P30, DOI 10.1016/j.jss.2010.05.055; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Kawai N, 2001, BRAIN RES, V895, P50, DOI 10.1016/S0006-8993(01)02026-1; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Konrad KN, 2000, BRAIN INJURY, V14, P859; Kreipke CW, 2006, MICROVASC RES, V71, P197, DOI 10.1016/j.mvr.2006.02.002; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Masada T, 2001, J CEREBR BLOOD F MET, V21, P22, DOI 10.1097/00004647-200101000-00004; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Planel E, 2007, J NEUROSCI, V27, P3090, DOI 10.1523/JNEUROSCI.4854-06.2007; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thomas DM, 2008, J NEUROCHEM, V106, P696, DOI 10.1111/j.1471-4159.2008.05421.x; Thomas DM, 2008, J NEUROCHEM, V105, P605, DOI 10.1111/j.1471-4159.2007.05155.x; Thomas DM, 2009, J NEUROCHEM, V109, P1745, DOI 10.1111/j.1471-4159.2009.06094.x; Thomas DM, 2004, J PHARMACOL EXP THER, V311, P1, DOI 10.1124/jpet.104.070961; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	68	167	168	0	52	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	JAN 15	2012	203	1					41	49		10.1016/j.jneumeth.2011.09.003			9	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	859SM	WOS:000297896100005	21930157	Green Accepted			2021-06-18	
J	Belanger, HG; Spiegel, E; Vanderploeg, RD				Belanger, Heather G.; Spiegel, Eric; Vanderploeg, Rodney D.			Neuropsychological performance following a history of multiple self-reported concussions: A meta-analysis	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Brain concussion; Multiple concussions; Head injury; Minor; Neuropsychological; Traumatic brain injury; Cognition	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; HEAD-INJURY; RELIABILITY; IMPAIRMENT; RECOVERY; OUTCOMES; SPORT	Debate continues about the long-term neuropsychological impact of multiple mild traumatic brain injuries (MTBI). A meta-analysis of the relevant literature was conducted to determine the impact of having a history of more than one self-reported MTBI (versus just One MTBI) across seven cognitive domains, as well as symptom complaints. The analysis was based on 8 studies, all conducted with athletes. involving 614 cases Of multiple MTBI and 926 control cases of a single MTBI The overall effect of multiple MTBI on neuropsychological functioning was minimal and not significant (d = 0.06). However. follow-up analyses revealed that Multiple self-reported MTBI was associated with poorer performance on measures of delayed memory and executive functioning. The implications and limitations of these findings are discussed. (JINS, 2010, 16 262-267.)	[Belanger, Heather G.; Spiegel, Eric; Vanderploeg, Rodney D.] James A Haley VA, Dept Mental Hlth & Behav Sci, Tampa, FL USA; [Belanger, Heather G.; Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL USA; [Belanger, Heather G.; Vanderploeg, Rodney D.] Def & Vet Brain Injury Ctr, Tampa, FL USA	Belanger, HG (corresponding author), James A Haley Vet Hosp, Mental Hlth & Behav Sci 116B,13000 Bruce B Downs, Tampa, FL 33612 USA.	heather.belanger@va.gov			Department of Veterans Affairs, Veterans Health Administration (VHA)US Department of Veterans Affairs; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; James A. Haley Veterans' HospitalUS Department of Veterans Affairs	The research reported here was Supported by the Department of Veterans Affairs, Veterans Health Administration (VHA). Further support was provided by the Defense and Veterans Brain Injury Center and the James A. Haley Veterans' Hospital. The views expressed herein are those of the authors and do not necessarily reflect the views of the Department of Veterans Affairs. There are no conflicts of interest.	Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; Baddeley A.D., 1992, SPEED CAPACITY LANGU; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benton A., 1976, MULTILINGUAL APHASIA; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; BORG J, 2004, J REHABIL MED S, V43, P61; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CDC, 2003, REP C MILD TRAUM BRA; *CDC, 2007, NAT CTR INJ PREV CON; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; DELIA LF, 1989, COLOUR TRIALS 1 2; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; DREW RH, 1986, J CLIN PSYCHOL, V42, P520, DOI 10.1002/1097-4679(198605)42:3<520::AID-JCLP2270420319>3.0.CO;2-6; Erlanger DM, 1999, CONCUSSION RESOLUTIO; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halstead WC, 1985, HALSTEAD REITAN NEUR; Hunter JE, 1990, METHODS METAANALYSIS; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson G, 2007, CLIN J SPORT MED, V17, P31; *LAF INSTR CO, INSTR GROOV PEGB; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Randolph C, 1998, REPEATABLE BATTERY A; SCHMIDT FL, 2003, HDB PSYCHOL, V2, P533; Smith A., 1973, SYMBOL DIGIT MODALIT; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; THURMAN DJ, 2001, HEAD TRAUMA BASIC PR; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wechsler D, 1997, WAIS 3 ADM SCORING M	54	167	168	0	54	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2010	16	2					262	267		10.1017/S1355617709991287			6	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	562DZ	WOS:000275030900006	20003581				2021-06-18	
J	Koenig, MA; Bryan, M; Lewin, JL; Mirski, MA; Geocadin, RG; Stevens, RD				Koenig, M. A.; Bryan, M.; Lewin, J. L., III; Mirski, M. A.; Geocadin, R. G.; Stevens, R. D.			Reversal of transtentorial herniation with hypertonic saline	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC INTRACRANIAL HYPERTENSION; CEREBRAL EDEMA; MASS LESIONS; PRESSURE; MANNITOL; HEMORRHAGE; DOGS; INFUSION; DEXTRAN	Objective: To evaluate the role of 23.4% saline in the management of transtentorial herniation (TTH) in patients with supratentorial lesions. Methods: Consecutive patients with clinically defined TTH treated with 23.4% saline (30 to 60 mL) were included in a retrospective cohort. Factors associated with successful reversal of TTH were determined. Results: Seventy-six TTH events occurred in 68 patients admitted with intracerebral hemorrhage (n = 29), subarachnoid hemorrhage (n = 16), stroke (n = 8), brain tumor (n = 8), subdural hematoma (n = 5), epidural hematoma (n = 1), and meningitis (n = 1). In addition to 23.4% saline, TTH management included hyperventilation (70% of events), mannitol (57%), propofol (62%), pentobarbital (15%), ventriculostomy drainage (27%), and decompressive hemicraniectomy (18%). Reversal of TTH occurred in 57/76 events (75%). Intracranial pressure decreased from 23 +/- 16 mm Hg at the time of TTH to 14 +/- 10 mm Hg at 1 hour (p = 0.002), and 11 +/- 12 mm Hg at 24 hours (p = 0.001) among 22 patients with intracranial pressure monitors. Reversal of TTH was predicted by a >= 5 mmol/L rise in serum sodium concentration (p = 0.001) or an absolute serum sodium of >= 145 mmol/L (p = 0.007) 1 hour after 23.4% saline. Adverse effects included transient hypotension in 13 events (17%); no evidence of central pontine myelinolysis was detected on post-herniation MRI (n = 18). Twenty-two patients (32%) survived to discharge, with severe disability in 17 and mild to moderate disability in 5. Conclusion: Treatment with 23.4% saline was associated with rapid reversal of transtentorial herniation (TTH) and reduced intracranial pressure, and had few adverse effects. Outcomes of TTH were poor, but medical reversal may extend the window for adjunctive treatments.	[Koenig, M. A.; Mirski, M. A.; Geocadin, R. G.; Stevens, R. D.] Johns Hopkins Univ, Div Neurosci Crit Care, Sch Med, Dept Neurol, Baltimore, MD 21287 USA; [Koenig, M. A.; Mirski, M. A.; Geocadin, R. G.; Stevens, R. D.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21287 USA; [Koenig, M. A.; Lewin, J. L., III; Mirski, M. A.; Geocadin, R. G.; Stevens, R. D.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care Med, Baltimore, MD 21287 USA; [Lewin, J. L., III] Johns Hopkins Univ, Sch Med, Dept Pharm, Baltimore, MD 21287 USA	Stevens, RD (corresponding author), Johns Hopkins Univ, Div Neurosci Crit Care, Sch Med, Dept Neurol, 600 N Wolfe St,Meyer 8-140, Baltimore, MD 21287 USA.	rstevens@jhmi.edu		, Mersine/0000-0002-3259-7628			Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; Bereczki D, 2000, STROKE, V31, P2719, DOI 10.1161/01.STR.31.11.2719; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; Bhardwaj Anish, 2004, Curr Opin Crit Care, V10, P126, DOI 10.1097/00075198-200404000-00009; COTE CJ, 1979, ANESTHESIOLOGY, V50, P30, DOI 10.1097/00000542-197901000-00007; Huang SJ, 2006, SURG NEUROL, V65, P539, DOI 10.1016/j.surneu.2005.11.019; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; KIEN ND, 1991, ANESTH ANALG, V73, P597; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Meyer A, 1920, ARCH NEURO PSYCHIATR, V4, P387, DOI 10.1001/archneurpsyc.1920.02180220036003; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Qureshi AI, 2002, J NEUROSURG ANESTH, V14, P22, DOI 10.1097/00008506-200201000-00005; Qureshi AI, 2000, CRIT CARE MED, V28, P1556, DOI 10.1097/00003246-200005000-00049; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; Sahuquillo J, 1999, J NEUROSURG, V90, P16, DOI 10.3171/jns.1999.90.1.0016; Saltarini M, 2002, Eur J Emerg Med, V9, P262, DOI 10.1097/00063110-200209000-00011; Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877; SILVA MR, 1990, CRIT CARE MED, V18, P203, DOI 10.1097/00003246-199002000-00015; Skoglund TS, 2005, ACTA ANAESTH SCAND, V49, P337, DOI 10.1111/j.1399-6576.2005.00624.x; Suarez JI, 1999, J NEUROSURG ANESTH, V11, P178, DOI 10.1097/00008506-199907000-00004; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P521, DOI [10.1089/neu.2000.17.521, DOI 10.1089/NEU.2000.17.521]; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; WEAVER DD, 1982, J NEUROSURG, V56, P660, DOI 10.3171/jns.1982.56.5.0660; Weed LH, 1919, AM J PHYSIOL, V48, P531; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; ZERVAS NT, 1972, NEW ENGL J MED, V286, P1075, DOI 10.1056/NEJM197205182862003	30	167	170	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAR 25	2008	70	13					1023	1029		10.1212/01.wnl.0000304042.05557.60			7	Clinical Neurology	Neurosciences & Neurology	278OZ	WOS:000254297500008	18272864				2021-06-18	
J	Sayer, NA; Chiros, CE; Sigford, B; Scott, S; Clothier, B; Pickett, T; Lew, HL				Sayer, Nina A.; Chiros, Christine E.; Sigford, Barbara; Scott, Steven; Clothier, Barbara; Pickett, Treven; Lew, Henry L.			Characteristics and rehabilitation outcomes among patients with blast and other injuries sustained during the global war on terror	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; length of stay; outcome assessment (health care); rehabilitation	TRAUMATIC BRAIN-INJURY; DISABILITY; PREDICTION; IRAQ; CARE; VIOLENCE	Objective: To describe characteristics and rehabilitation outcomes among patients who received inpatient rehabilitation for blast and other injuries sustained in Iraq and Afghanistan during the Global War on Terror. Design: Observational study based on chart review and Department of Veterans Affairs (VA) administrative data. Setting: The 4 VA polytrauma rehabilitation centers (PRCs). Participants: Service members (N= 188) admitted to a PRC during the first 4 years of the Global War on Terror for injuries sustained during Operation Iraqi Freedom or Operation Enduring Freedom. Intervention: Multidisciplinary comprehensive rehabilitation program. Main Outcomes Measures: Cognitive and motor FIM instrument gain scores and length of stay (LOS). Results: Most war-injured patients had traumatic brain injury, injuries to several other body systems and organs, and associated pain. Fifty-six percent had blast-related injuries, and the pattern of injuries was unique among those with injuries secondary to blasts. Soft fissue, eye, oral and maxillofacial, otologic, penetrating brain injuries, symptoms of post-traumatic stress disorder, and auditory impairments were more common in blast-injured patients than in those with war injuries of other etiologies. The mechanism of the injury did not predict functional outcomes. LOS was variable, particularly for those with blast injuries. Patients with low levels of independence at admissions made the most progress but remained more dependent at discharge compared with other PRC patients. The rate of gain was slower in this low-functioning group. Conclusions: Blasts produce a unique constellation of injuries but do not make a unique contribution to functional gain scores. Findings underscore the need for assessment and treatment of pain and mental health problems among patients with polytrauma and blast-related injuries. Patients with polytrauma have lifelong needs, and future research should examine needs over time after community re-entry.	[Sayer, Nina A.; Chiros, Christine E.; Clothier, Barbara] Vet Adm Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55417 USA; [Sayer, Nina A.; Sigford, Barbara] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Sayer, Nina A.] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA; [Scott, Steven] James A Haley Vet Adm Med Ctr, Tampa, FL 33612 USA; [Scott, Steven] Univ S Florida, Coll Med, Tampa, FL USA; [Pickett, Treven; Lew, Henry L.] Def & Vet Brain Injury Ctr, Richmond, VA USA; [Pickett, Treven] McGuire VA Med Ctr, Richmond, VA USA; [Pickett, Treven] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, VA USA; [Lew, Henry L.] VA Med Ctr, Palo Alto, CA USA; [Lew, Henry L.] Stanford Univ, Sch Med, Stanford, CA 94305 USA	Sayer, NA (corresponding author), Vet Adm Med Ctr, Ctr Chron Dis Outcomes Res 152 2E, 1 Vet Dr, Minneapolis, MN 55417 USA.	nina.sayer@med.va.gov	Sayer, Nina/E-3249-2016				[Anonymous], US CAS STAT; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; *CDCP DEP HHS, 2005, EXPL BLAST INJ PRIM; Coupland RM, 1999, BRIT MED J, V319, P407, DOI 10.1136/bmj.319.7207.407; *DAT MAN SERV, 1987, GUID US UN DAT SET M; *DEP VET AFF, 2005, VHA HDB DEP VET AFF; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Druss BG, 2000, AM J PSYCHIAT, V157, P1485, DOI 10.1176/appi.ajp.157.9.1485; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gerhart KA, 2003, J TRAUMA, V55, P1045, DOI 10.1097/01.TA.0000044353.69681.96; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Mazaux JM, 2001, J REHABIL MED, V33, P99; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Okie S, 2006, NEW ENGL J MED, V355, P2609, DOI 10.1056/NEJMp068235; Peake JB, 2005, NEW ENGL J MED, V352, P219, DOI 10.1056/NEJMp048312; PERLIN JB, 2005, ACTING SECRETARY HLT; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; STINEMAN MG, 1993, ARCH PHYS MED REHAB, V74, P787, DOI 10.1016/0003-9993(93)90001-Q; Warden DL, 2005, J NEUROTRAUM, V22, P1178; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; *WHO, ICF CHECKLIST VERS 2	34	167	167	0	20	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2008	89	1					163	170		10.1016/j.apmr.2007.05.025			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	249LB	WOS:000252228600028	18164349				2021-06-18	
J	Dick, R; Putukian, M; Agel, J; Evans, TA; Marshall, SW				Dick, Randall; Putukian, Margot; Agel, Julie; Evans, Todd A.; Marshall, Stephen W.			Descriptive epidemiology of collegiate women's soccer injuries: National Collegiate Athletic Association injury surveillance system, 1988-1989 through 2002-2003	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; injury prevention; knee injuries; ankle injuries; concussions	CRUCIATE LIGAMENT INJURIES; ANKLE SPRAINS; RISK-FACTORS; TRAINING-PROGRAM; POSTURAL CONTROL; ELITE FOOTBALL; INDOOR SOCCER; KNEE INJURY; PLAYERS; PREVENTION	Objective: To review 15 years of National Collegiate Athletic Association (NCAA) injury surveillance data for women's soccer and identify potential areas for injury prevention initiatives. Background. The number of NCAA schools sponsoring women's soccer has grown tremendously, from 271 in 19881989 to 879 schools in 2002-2003. During that time, the NCAA Injury Surveillance System has collected game and practice injury data for women's soccer across all 3 NCAA divisions. Main Results: The rate of injury was more than 3 times higher in games than in practices (16.44 versus 5.23 injuries per 1000 athlete-exposures, rate ratio = 3.2, 95% confidence interval = 3.1, 3.4, P <.01), and preseason practices had an injury rate that was more than 3 times greater than the rate for in-season practices (9.52 versus 2.91 injuries per 1000 athlete-exposures, rate ratio = 3.3, 95% confidence interval = 3.1, 3.5, P <.01). Approximately 70% of all game and practice injuries affected the lower extremities. Ankle ligament sprains (18.3%), knee internal derangements (15.9%), concussions (8.6%), and leg contusions (8.3%) accounted for a substantial portion of game injuries. Upper leg muscle-tendon strains (21.3%), ankle ligament sprains (15.3%), knee internal derangements (7.7%), and pelvis and hip muscle strains (7.6%) represented most of the practice injuries. Injuries were categorized as attributable to player contact, "other contact" (eg, contact with the ball, ground, or other object), or no contact. Player-to-player contact accounted for more than half of all game injuries (approximately 54%) but less than 20% of all practice injuries. The majority of practice injuries involved noncontact injury mechanisms. Knee internal derangements, ankle ligament sprains, and concussions were the leading game injuries that resulted in 10 or more days of time lost as a result of injury. Recommendations: Ankle ligament sprains, knee internal derangements, and concussions are common injuries in women's soccer. Research efforts have focused on knee injuries and concussions in soccer, and further epidemiologic data are needed to determine if preventive strategies will help to alter the incidence of these injuries. Furthermore, the specific nature of the player contact leading to concussions and lower extremity injuries should be investigated. Preventive efforts should continue to focus on reducing knee injuries, ankle injuries, and concussions in women collegiate soccer players. Key Words: athletic injuries, injury prevention,	Princeton Univ, McCosh Hlth Ctr, Princeton, NJ 08544 USA; Natl Collegiate Athlet Assoc, Indianapolis, IN USA; Univ Minnesota, Minneapolis, MN 55455 USA; Univ No Iowa, Cedar Falls, IA 50614 USA; Univ N Carolina, Chapel Hill, NC 27515 USA	Putukian, M (corresponding author), Princeton Univ, McCosh Hlth Ctr, Princeton, NJ 08544 USA.	putukian@princeton.edu		Marshall, Stephen/0000-0002-2664-9233			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Andersen TE, 2004, AM J SPORT MED, V32, p62S, DOI 10.1177/0363546503261412; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Caraffa A, 1996, Knee Surg Sports Traumatol Arthrosc, V4, P19, DOI 10.1007/BF01565992; Dick R, 2007, J ATHL TRAINING, V42, P173; Dvorak J, 2000, AM J SPORT MED, V28, pS69; EKSTRAND J, 1983, AM J SPORT MED, V11, P63, DOI 10.1177/036354658301100203; EKSTRAND J, 1984, INT J SPORTS MED S, V5, P140; Elias SR, 2001, MED SCI SPORT EXER, V33, P359, DOI 10.1097/00005768-200103000-00004; Emery CA, 2005, AM J SPORT MED, V33, P1882, DOI 10.1177/0363546505279576; Fauno P, 2006, INT J SPORTS MED, V27, P75, DOI 10.1055/s-2005-837485; Fuller CW, 2004, AM J SPORT MED, V32, p17S, DOI 10.1177/0363546503261249; Fuller CW, 2004, AM J SPORT MED, V32, p43S, DOI 10.1177/0363546503261248; FULLER CW, 2005, BR J SPORTS MED S1, V39, P3; Griffin LY, 2006, AM J SPORT MED, V34, P1512, DOI 10.1177/0363546506286866; Hagglund M, 2006, BRIT J SPORT MED, V40, P767, DOI 10.1136/bjsm.2006.026609; Hewett TE, 1999, AM J SPORT MED, V27, P699, DOI 10.1177/03635465990270060301; Hewett TE, 2006, AM J SPORT MED, V34, P490, DOI 10.1177/0363546505282619; Hewett TE, 2006, AM J SPORT MED, V34, P299, DOI 10.1177/0363546505284183; Hewett TE, 2005, AM J SPORT MED, V33, P492, DOI 10.1177/0363546504269591; Le Gall F, 2006, AM J SPORT MED, V34, P928, DOI 10.1177/0363546505283271; LINDENFELD TN, 1994, AM J SPORT MED, V22, P364, DOI 10.1177/036354659402200312; Mandelbaum BR, 2005, AM J SPORT MED, V33, P1003, DOI 10.1177/0363546504272261; McGuine TA, 2006, AM J SPORT MED, V34, P1103, DOI 10.1177/0363546505284191; Murphy DF, 2003, BRIT J SPORT MED, V37, P13, DOI 10.1136/bjsm.37.1.13; Myklebust G, 2003, CLIN J SPORT MED, V13, P71, DOI 10.1097/00042752-200303000-00002; *NAT COLL ATHL ASS, 2006, 1981 82 2004 05 NCAA; Petersen J, 2005, BRIT J SPORT MED, V39, P319, DOI 10.1136/bjsm.2005.018549; Peterson L, 2000, AM J SPORT MED, V28, pS51; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Putukian M, 1996, AM J SPORT MED, V24, P317, DOI 10.1177/036354659602400312; Rahnama N, 2002, BRIT J SPORT MED, V36, P354, DOI 10.1136/bjsm.36.5.354; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Soderman K, 2001, SCAND J MED SCI SPOR, V11, P299, DOI 10.1034/j.1600-0838.2001.110508.x; STRAUMENAESHEIM TM, 2005, BR J SPORTS MED S1, V39, P70; SURVE I, 1994, AM J SPORT MED, V22, P601, DOI 10.1177/036354659402200506; Walden M, 2006, BRIT J SPORT MED, V40, P158, DOI 10.1136/bjsm.2005.021055; Woods C, 2003, BRIT J SPORT MED, V37, P233, DOI 10.1136/bjsm.37.3.233	39	167	168	0	20	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	APR-JUN	2007	42	2					278	285					8	Sport Sciences	Sport Sciences	180RC	WOS:000247382300015	17710177				2021-06-18	
J	McDonald, BC; Flashman, LA; Saykin, AJ				McDonald, BC; Flashman, LA; Saykin, AJ			Executive dysfunction following traumatic brain injury: Neural substrates and treatment strategies	NEUROREHABILITATION			English	Article						executive functions; traumatic brain injury; TBI; assessment; treatment	CLOSED HEAD-INJURY; COGNITIVE REHABILITATION; COMPUTED-TOMOGRAPHY; FRONTAL-LOBE; MILD; SPECT; MRI; NEUROGENESIS; PERFORMANCE; INDIVIDUALS	Executive dysfunction is among the most common and disabling aspects of cognitive impairment following traumatic brain injury (TBI), and may include deficits in reasoning, planning, concept formation, mental flexibility, aspects of attention and awareness, and purposeful behavior. These impairments are generally attributed to frontal systems dysfunction, due either to direct insult to the frontal lobes or to disruption of their connections to other brain regions. Evaluation of executive deficits typically includes neuropsychological assessment, though adjunctive interviews can be critical in detecting subtle dysexecutive symptoms that may not be apparent on standardized testing. Rehabilitation programs emphasizing cognitive-behavioral approaches to the retraining of planning and problem-solving skills can be effective in ameliorating identified executive deficits. In addition, pharmacological approaches may be useful in addressing aspects of executive dysfunction. This review summarizes the nature of executive deficits following TBI, their neuroanatomical substrates, selected assessment and treatment strategies, and recent research findings and trends.	Dartmouth Coll Sch Med, Dept Psychiat, Hanover, NH USA; Dartmouth Coll Sch Med, Dept Radiol, Hanover, NH USA; Dartmouth Coll Sch Med, Dept Comp Sci, Hanover, NH USA; New Hampshire Hosp, Concord, NH USA	McDonald, BC (corresponding author), Dartmouth Hitchcock Med Ctr, Neuropsychol Program, Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Brenna.C.McDonald@dartmouth.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40472-01] Funding Source: Medline		Anderson K., 1998, SEMIN CLIN NEUROPSYC, V3, P232; BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; CAMPBELL JJ, 1994, J NEUROPSYCH CLIN N, V6, P411; Challman TD, 2000, MAYO CLIN PROC, V75, P711; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; Cimino C.R., 1994, CLIN GUIDE NEUROPSYC, P69; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; FOXX RM, 1989, BEHAV THER, V20, P61, DOI 10.1016/S0005-7894(89)80118-2; Fuster J, 1989, PREFRONTAL CORTEX; FUSTER JM, 1989, PREFRONTAL CORTEX AN; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gioia G.A., 2000, BEHAV RATING INVENTO; GLENN MB, 1989, AM J PHYS MED REHAB, V68, P221, DOI 10.1097/00002060-198910000-00004; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GORDON WA, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P175; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; Gutentag SS, 1998, ASSESSMENT, V5, P263, DOI 10.1177/107319119800500306; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kolb B., 1996, FUNDAMENTALS HUMAN N; Leon-Carrion J, 1998, INT J NEUROSCI, V94, P75, DOI 10.3109/00207459808986440; Levin H. S., 1991, FRONTAL LOBE FUNCTIO; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Luria, 1973, WORKING BRAIN INTRO; Luria A. R., 1966, HIGHER CORTICAL FUNC; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V5, P213, DOI DOI 10.1037/0894-4105.5.3.213; Masdeu J C, 1994, J Neuroimaging, V4, P177; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Mazmanian Paul E., 1993, Brain Injury, V7, P319, DOI 10.3109/02699059309034958; MCALLISTER TW, 1985, J CLIN PSYCHIAT, V46, P393; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Morse P, 1992, CLIN SYNDROMES ADULT, P85; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Nybo T, 1999, BRAIN INJURY, V13, P759; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Raskin SA, 1996, NEUROPSYCHOLOGY, V10, P416, DOI 10.1037/0894-4105.10.3.416; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; RASKIN SA, 2000, NEUROPSYCHOLOGICAL M; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUSSELL EW, 1994, CLIN GUIDE NEUROPSYC, P211; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Teng CJ, 2001, BRAIN INJURY, V15, P463, DOI 10.1080/02699050010005931; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; VARNEY N, 1991, NEUROPSYCHOLOGY, V5, P223; Whelan F J, 2000, Ann Clin Psychiatry, V12, P131; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200	62	167	170	0	24	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2002	17	4					333	344					12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	636GA	WOS:000180445200007	12547981				2021-06-18	
J	McCrea, M				McCrea, M			Standardized mental status testing on the sideline after sport-related concussion	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; neuropsychological tests	MILD HEAD-INJURY; FOOTBALL PLAYERS; COLLEGIATE; RECOVERY	Objective: The effects of concussion on mental status are often difficult to assess on routine clinical examination. I investigated the efficacy of standardized mental status testing on the sport sideline to detect abnormalities that result from concussion and provide an objective measure of postinjury cognitive recovery. Design and Setting: All subjects underwent a standardized preseason baseline mental status evaluation. Standardized testing of injured and uninjured control subjects was repeated on the sideline immediately after concussion and 48 hours after injury. Subjects: Sixty-three high school and collegiate football players with concussion and 55 uninjured control subjects were studied. Measurements: The Standardized Assessment of Concussion (SAC) was administered to evaluate neurocognitive functioning and neurologic status. Results: Immediately after concussion, injured subjects performed significantly below preinjury baseline and below uninjured controls on the SAC. Measurable deficits in orientation, concentration, and memory were evident immediately after concussion. A decline in SAC score at time of injury was 95% sensitive and 76% specific in accurately classifying injured and uninjured subjects on the sideline. Injured subjects demonstrated significant improvements in SAC score 48 hours after injury. Conclusions: Standardized mental status testing can be a valuable tool to assist the sports medicine clinician in detecting the immediate effects of concussion on mental status, tracking resolution of immediate postconcussive mental status abnormalities, and making more informed decisions on return to play after injury.	Waukesha Mem Hosp, Neuropsychol Serv, Waukesha, WI 53188 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA	McCrea, M (corresponding author), Waukesha Mem Hosp, Neuropsychol Serv, 721 Amer Ave,Suite 501, Waukesha, WI 53188 USA.						Barth JT., 1989, MILD HEAD INJURY, P257; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Huck SW, 1996, READING STAT RES; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; KUTNER KC, 1998, NATL ACAD NEUROPSYCH, V5, P19; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 1996, STANDARDIZED ASSESSM; McCrea M., 2000, STANDARDIZED ASSESSM; Pottinger LS, 1999, ARCH CLIN NEUROPSYCH, V14, P39, DOI 10.1093/arclin/14.1.39a; Riemann BL, 2000, J ATHL TRAINING, V35, P19; RIEMANN BL, 1999, J SPORT REHABIL, V8, P1; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; *SPSS INC, 1999, SPSS ADV MOD 10 0	25	167	171	2	23	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					274	279					6	Sport Sciences	Sport Sciences	557NC	WOS:000175913800010					2021-06-18	
J	Ingebrigtsen, T; Romner, B; Kock-Jensen, C				Ingebrigtsen, T; Romner, B; Kock-Jensen, C			Scandinavian guidelines for initial management of minimal, mild, and moderate head injuries	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; management; guidelines; computed tomography; costs	TRAUMATIC INTRACRANIAL HEMATOMA; COMPUTED-TOMOGRAPHY; OBSERVATION WARD; BRAIN INJURY; RISK; EMERGENCY; NORWAY; CLASSIFICATION; COMPLICATIONS; MORTALITY	Background: The Scandinavian Neurotrauma Committee was initiated by the Scandinavian Neurosurgical Society to develop evidence-based guidelines for improved care of neurotrauma patients. Methods: A MEDLINE search identified 475 papers dealing with the management of minimal, mild, and moderate head injuries. Forty-two studies presenting class II evidence on the initial management of such injuries were reviewed and management guidelines were developed. Results: Implementation of the Head Injury Severity Scale is advocated. Patients with minimal injuries (no loss of consciousness, Glasgow Coma Scale score of 15) can be safely discharged, Routine early computed tomographic scan is recommended in cases with mild injuries (history of loss of consciousness, Glasgow Coma Scale score = 14-15) and patients with normal scans may be discharged, Computed tomographic scan and admission is mandatory in moderate injuries (Glasgow Coma Scale score = 13), All patients harboring additional risk factors should be scanned and admitted. A flow-chart for clinical decision making and a Head Injury Instruction card is introduced. Conclusions: The Scandinavian Neurotrauma Committee suggests guidelines that should be safe and cost-effective for the initial management of minimal, mild, and moderate head injuries.		Ingebrigtsen, T (corresponding author), Univ Tromso Hosp, Dept Neurosurg, N-9038 Tromso, Norway.	nevktoi@rito.no		Ingebrigtsen, Tor/0000-0001-5966-9786			*AM MED ASS OFF QU, 1990, ATTR GUID DEV PRACT; Arienta C, 1997, SURG NEUROL, V48, P213, DOI 10.1016/S0090-3019(97)00019-0; Bartlett J, 1998, BRIT J NEUROSURG, V12, P349, DOI 10.1080/02688699844871; Bellner J, 1999, ACTA NEUROL SCAND, V100, P355; BOROVICH B, 1985, J NEUROSURG, V63, P30, DOI 10.3171/jns.1985.63.1.0030; BROWN SR, 1994, J ACCID EMERG MED, V11, P144; Cook L S, 1994, Acad Emerg Med, V1, P227; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; Duus BR, 1997, ACTA NEUROCHIR, V139, P743, DOI 10.1007/BF01420047; DUUS BR, 1994, ANN EMERG MED, V23, P1279, DOI 10.1016/S0196-0644(94)70352-3; EDNA TH, 1984, SCAND J SOC MED, V12, P7, DOI 10.1177/140349488401200103; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Ingebrigtsen T, 1997, ACTA NEUROL SCAND, V95, P51, DOI 10.1111/j.1600-0404.1997.tb00068.x; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; LEE ST, 1995, ACTA NEUROCHIR, V135, P136, DOI 10.1007/BF02187757; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; MACLAREN RE, 1993, BRIT J SURG, V80, P215, DOI 10.1002/bjs.1800800230; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; Murshid WR, 1998, ACTA NEUROCHIR, V140, P56, DOI 10.1007/s007010050058; NARAYAN RK, 1995, J NEUROTRAUM, V12, P907, DOI 10.1089/neu.1995.12.907; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Parsley J, 1997, J ACCID EMERG MED, V14, P238; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; SERVADEI F, 1988, SURG NEUROL, V30, P364, DOI 10.1016/0090-3019(88)90199-1; SERVADEI F, 1995, ACTA NEUROCHIR, V133, P50, DOI 10.1007/BF01404947; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SHANON A, 1994, PEDIATR EMERG CARE, V10, P322, DOI 10.1097/00006565-199412000-00004; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; Stein SC, 1996, NEUROSURG QUART, V6, P108, DOI 10.1097/00013414-199606000-00004; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Study Group on Head Injury of the Italian Society for Neurosurgery, 1996, J NEUROSURG SCI, V40, P11; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; Volans AP, 1998, J ACCID EMERG MED, V15, P159; VOSS M, 1995, BRIT MED J, V311, P1395, DOI 10.1136/bmj.311.7017.1395; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; WARREN D, 1989, Pediatric Emergency Care, V5, P83, DOI 10.1097/00006565-198906000-00003	48	167	170	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2000	48	4					760	766		10.1097/00005373-200004000-00029			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	304TH	WOS:000086499900040	10780615				2021-06-18	
J	Asikainen, I; Kaste, M; Sarna, S				Asikainen, I; Kaste, M; Sarna, S			Early and late posttraumatic seizures in traumatic brain injury rehabilitation patients: Brain injury factors causing late seizures and influence of seizures on long-term outcome	EPILEPSIA			English	Article						posttraumatic seizures; rehabilitation; outcome	PENETRATING HEAD-INJURY; FINNISH PATIENTS 5; PROGNOSTIC FACTORS; EPILEPSY; POPULATION; PROGRAM	Purpose: To demonstrate risk factors involved in the origin of late posttraumatic seizures (LPTSs) in civilian traumatic brain injury (TBI) rehabilitation patients and the occurrence of LPTSs in this population, as well as the time of the first late seizures, and influence of these seizures on functional and occupational long-term outcome. Methods: A consecutive sample of 490 patients (age range, 0.8-71 years) with TBI, and with postinjury problems in their education and employment, were followed up for greater than or equal to 5 years from the time of injury in a rehabilitation and reemployment program. The study was carried out at the outpatient neurologic clinic of the Kauniala Hospital, which specializes in brain injuries in Finland and works in close cooperation with the Department of Clinical Neurosciences at the Helsinki University Central Hospital. Main outcome measures were functional outcome, as measured on the Glasgow Outcome Scale (GOS), and the capacity for employment at the end of follow-up. Outcomes were studied separately among patients with late seizures and for the nonseizure group. Results: Children age 7 years or younger at time of injury more often had early posttraumatic seizures (EPTSs), than did adolescents or adults. The time elapsed between brain injury and the first late seizure also was longer in older age groups. EPTSs and depressed skull fracture had a statistically significant relation to the Origin of LPTSs. Permanent posttraumatic neurologic deficit, linear skull fracture, and permanent local brain lesion documented on a computed tomography (CT) scan appeared clinically important as risk factors, Late seizures did worsen the functional outcome but had no significant influence on reemployment at the end of follow-up. Conclusions: Young children are more prone to early seizures, and adolescents and adults, to late seizures. The main risk factors for LPTSs are early seizures and depressed skull fracture. Severity of brain injury. as measured by a low GCS score, prolonged unconsciousness, and posttraumatic amnesia (PTA) without local brain lesion, should not be considered risk factor for LPTSs. Thorough follow-up of patients with TBI with seizures and adequate antiepileptic therapy may help attain rehabilitation goals and reemployment.	Kauniala Hosp, Dept Neurol, Kauniainen 02700, Finland; Univ Helsinki, Dept Clin Neurosci, Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland	Asikainen, I (corresponding author), Kauniala Hosp, Dept Neurol, Kylpylantie 19, Kauniainen 02700, Finland.			Kaste, Markku/0000-0001-6557-6412; Sarna, Seppo/0000-0003-3458-1627			ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; CORKIN S, 1984, ARCH NEUROL-CHICAGO, V41, P975, DOI 10.1001/archneur.1984.04050200081022; da Silva A M, 1992, Acta Neurochir Suppl (Wien), V55, P56; DALESSANDRO R, 1988, ARCH NEUROL-CHICAGO, V45, P42, DOI 10.1001/archneur.1988.00520250048019; DASILVA AM, 1990, ACT NEUR S, V50, P48; De Santis A, 1992, Acta Neurochir Suppl (Wien), V55, P64; Elvidge A, 1939, T AM NEUROL ASSOC, V65, P125; JABBARI B, 1986, ELECTROEN CLIN NEURO, V64, P285, DOI 10.1016/0013-4694(86)90151-3; Jennet B, 1975, EPILEPSY NONMISSILE; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1974, J NEUROSURG, V41, P208, DOI 10.3171/jns.1974.41.2.0208; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jennett B, 1975, EPILEPSY NONMISSILE; LEVITON A, 1981, EPIDEMIOL REV, V3, P67, DOI 10.1093/oxfordjournals.epirev.a036240; PAMPIGLIONE G, 1975, OUTCOME SEVERE DAMAG, P263; SALAZAR A M, 1985, Neurology, V35, P230; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALAZAR AM, 1987, ADV EPILEPSY, V16, P753; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; Temkin N R, 1991, Neurosurg Clin N Am, V2, P425; WALKER AE, 1961, FOLLOW UP STUDY HEAD; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; WEISS GH, 1972, J NEUROSURG, V37, P164, DOI 10.3171/jns.1972.37.2.0164	28	167	175	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0013-9580			EPILEPSIA	Epilepsia	MAY	1999	40	5					584	589		10.1111/j.1528-1157.1999.tb05560.x			6	Clinical Neurology	Neurosciences & Neurology	191ZW	WOS:000080053800007	10386527				2021-06-18	
J	Mazaux, JM; Masson, F; Levin, HS; Alaoui, P; Maurette, P; Barat, M				Mazaux, JM; Masson, F; Levin, HS; Alaoui, P; Maurette, P; Barat, M			Long-term neuropsychological outcome and loss of social autonomy after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	1st World Congress of Traumatic Brain Injury	MAY 05-07, 1995	COPENHAGEN, DENMARK				HEAD-INJURY; FOLLOW-UP	Objective: To assess which social activities were still impaired 5 years after a traumatic brain injury (TBI) in adults, and which neuropsychological impairments were associated with this loss of social autonomy. Design: Cross-sectional study of 79 patients selected from the follow-up cohort of an epidemiologic survey of 2,116 TBI patients. Setting: The present study was of ambulatory patients seen at hospital or at their homes. The inception cohort was from the trauma center of a university hospital and from a general hospital that is representative of level II trauma centers in Aquitaine, France. Patients: Seventy-nine patients selected from a representative sample of 407 patients who were included in the 5-year follow-up study of the initial cohort (convenience sample). Main Outcome Measures: Glasgow Outcome Scale (GOS) and loss of social autonomy as assessed by the European Brain Injury Society's European Head Injury Evaluation Chart; assessment of neurobehavioral impairments by means of the Neurobehavioral Rating Scale-Revised. Results: Up to 16 patients suffered disability for at least one social skill because of cognitive/behavioral reasons. Seven needed full-time supervision. Performing administrative tasks and financial management, writing letters and calculating, driving, planning the week, and using public transport were the most impaired social abilities. Loss of social autonomy was mainly observed in severely injured patients. Univariate analysis showed that mental fatigability, motor slowing, memory difficulties, and disorders of executive function were associated with low scores on the GOS, unemployment, and difficulties in shopping, using public transport, and performing financial management and administrative tasks. Conclusion: Persistent impairments of executive functions and speed of psychomotor processing are major factors associated with loss of social autonomy and inability to return to work long after TBI in adults. Improving these impairments in concrete social situations represents a major challenge for cognitive rehabilitation. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	CHU BORDEAUX, HOP PELLEGRIN, DEPT EMERGENCY CARE, BORDEAUX, FRANCE; BAYLOR COLL MED, HOUSTON, TX 77030 USA	Mazaux, JM (corresponding author), CHU BORDEAUX, HOP PELLEGRIN, SERV REEDUCAT NEUROL, DEPT REHABIL, BORDEAUX, FRANCE.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; BARAT M, 1986, REEDUCATION READAPTA; Burgess P. W., 1990, COGNITIVE REHABILITA, P183; DAWSON D, 1993, BRAIN INJURY, V7, P339; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DODWELL D, 1988, J NEUROL NEUROSUR PS, V51, P833, DOI 10.1136/jnnp.51.6.833; JENNETT B, 1975, LANCET, V1, P480; LEVIN H S, 1990, Annales de Readaptation et de Medecine Physique, V33, P35; Levin H. S., 1991, FRONTAL LOBE FUNCTIO; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MAZAUX JM, 1989, INTEGRATING THEORY P, P337; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P29; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Stuss D.T., 1986, FRONTAL LOBES; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; TRUELLE JL, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P69; TRUELLE JL, 1994, INST RES BN, P281; VANIER M, 1997, J INT NEUROPSYCH SOC, V3, P29; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Von Cramon DY, 1992, NEUROPSYCHOL REHABIL, P203	27	167	172	0	16	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1997	78	12					1316	1320		10.1016/S0003-9993(97)90303-8			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	YK894	WOS:A1997YK89400006	9421984				2021-06-18	
J	MICHAUD, LJ; RIVARA, FP; GRADY, MS; REAY, DT				MICHAUD, LJ; RIVARA, FP; GRADY, MS; REAY, DT			PREDICTORS OF SURVIVAL AND SEVERITY OF DISABILITY AFTER SEVERE BRAIN INJURY IN CHILDREN	NEUROSURGERY			English	Article						BRAIN INJURIES; HEAD INJURIES; PEDIATRICS; PROGNOSIS; TRAUMA	SEVERE HEAD-INJURY; COMA; SCALE; MANAGEMENT; EXPERIENCE; TOMOGRAPHY; CHILDHOOD; PROGNOSIS; INFANCY; LESION	SEVENTY-FIVE CHILDREN, 16 years of age or younger, consecutively admitted to a level I trauma center over a 2-year period with severe nonpenetrating traumatic brain injuries were studied to assess factors predictive of survival and level of disability. The mortality rate was 33%; 31% had good recovery, 12% had moderate disability, 19% had severe disability, and 5% remained in a vegetative state. Factors were analyzed separately for potential effects on survival and, with fatalities excluded, for potential effects on the level of disability in survivors. Clinical status in the field and emergency room, although highly associated with survival, was less predictive of the level of disability in survivors. Glasgow Coma Scale scores 72 hours after injury, especially the motor component, were significantly better predictors of quality of survival. The severity of the brain injury and the presence and severity of extracranial injuries were strongly related both to survival and quality of survival. Chest injuries, in particular, were associated with increased mortality and morbidity, as was level of oxygenation; these factors were highly correlated. Factors most significantly predictive of survival were severity of total injuries as assessed with the Injury Severity Score and pupillary responses in the emergency room; factors most predictive of disability were Glasgow Coma Scale motor responses 72 hours after injury and level of oxygenation in the emergency room. These findings of differential predictive factors for outcomes of survival versus quality of survival have implications relevant both to clinical care and to research involving severely brain-injured children.	UNIV WASHINGTON,SEATTLE,WA 98195; HARBORVIEW INJURY PREVENT & RES CTR,SEATTLE,WA					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001371] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 01371] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR002570-03] Funding Source: Medline		BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Breslow N, 1980, STATISTICAL METHODS, V32; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BUTTERWORTH JF, 1981, NEUROSURGERY, V9, P242, DOI 10.1227/00006123-198109000-00004; Comninos S C, 1979, Acta Neurochir Suppl (Wien), V28, P144; DHELLEMMES P, 1985, J NEUROSURG, V62, P861, DOI 10.3171/jns.1985.62.6.0861; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GUTIERREZ FA, 1975, CHILD BRAIN, V1, P269; Gutierrez FA, 1981, CONCEPTS PEDIAT NEUR, P188; Humphreys RP, 1983, CONCEPTS PEDIATRIC N, V3, P191; JAGGER J, 1983, LANCET, V2, P97; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; KRAUS JF, 1987, PEDIATRICS, V79, P501; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOKKEBERG AR, 1984, J NEUROSURG, V61, P254, DOI 10.3171/jns.1984.61.2.0254; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MAYER T, 1982, CLIN PEDIATR, V21, P391, DOI 10.1177/000992288202100701; MAZZA C, 1982, ACTA NEUROCHIR, V65, P67, DOI 10.1007/BF01405443; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NORUSIS MJ, 1986, SPSS PC PLUS IBM PC; PFENNINGER J, 1983, INTENS CARE MED, V9, P13, DOI 10.1007/BF01693699; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P161; TEASDALE G, 1974, LANCET, V2, P81; WALKER ML, 1985, CONCEPTS PEDIATR NEU, V6, P84; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687; ZUCCARELLO M, 1985, CHILD NERV SYST, V1, P158, DOI 10.1007/BF00735731; 1987, EPIDEMIOLOGICAL GRAP; 1980, ABBREVIATED INJURY S	44	167	171	1	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	AUG	1992	31	2					254	264		10.1227/00006123-199208000-00010			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	JJ520	WOS:A1992JJ52000010	1513431				2021-06-18	
J	Heinrich, C; Bergami, M; Gascon, S; Lepier, A; Vigano, F; Dimou, L; Sutor, B; Berninger, B; Gotz, M				Heinrich, Christophe; Bergami, Matteo; Gascon, Sergio; Lepier, Alexandra; Vigano, Francesca; Dimou, Leda; Sutor, Bernd; Berninger, Benedikt; Goetz, Magdalena			Sox2-Mediated Conversion of NG2 Glia into Induced Neurons in the Injured Adult Cerebral Cortex	STEM CELL REPORTS			English	Article							NEURAL STEM-CELLS; OLIGODENDROCYTE PRECURSOR CELLS; IN-VIVO; GABAERGIC INTERNEURONS; FUNCTIONAL-NEURONS; HUMAN FIBROBLASTS; REACTIVE GLIOSIS; BRAIN; PROGENITORS; HIPPOCAMPUS	The adult cerebral cortex lacks the capacity to replace degenerated neurons following traumatic injury. Conversion of nonneuronal cells into induced neurons has been proposed as an innovative strategy toward brain repair. Here, we show that retrovirus-mediated expression of the transcription factors Sox2 and Ascl1, but strikingly also Sox2 alone, can induce the conversion of genetically fate-mapped NG2 glia into induced doublecortin (DCX)(+) neurons in the adult mouse cerebral cortex following stab wound injury in vivo. In contrast, lentiviral expression of Sox2 in the unlesioned cortex failed to convert oligodendroglial and astroglial cells into DCX+ cells. Neurons induced following injury mature morphologically and some acquire NeuN while losing DCX. Patch-clamp recording of slices containing Sox2- and/or Ascl1-transduced cells revealed that a substantial fraction of these cells receive synaptic inputs from neurons neighboring the injury site. Thus, NG2 glia represent a potential target for reprogramming strategies toward cortical repair.	[Heinrich, Christophe; Bergami, Matteo; Gascon, Sergio; Lepier, Alexandra; Vigano, Francesca; Dimou, Leda; Sutor, Bernd; Berninger, Benedikt; Goetz, Magdalena] Univ Munich, Inst Physiol, D-80336 Munich, Germany; [Heinrich, Christophe] Univ Grenoble Alpes, Grenoble Inst Neurosci, INSERM U836, F-38000 Grenoble, France; [Gascon, Sergio; Dimou, Leda; Goetz, Magdalena] Natl Res Ctr Environm & Hlth, Inst Stem Cell Res, D-85764 Neuherberg, Germany; [Berninger, Benedikt] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Physiol Chem, D-55128 Mainz, Germany; [Berninger, Benedikt] Johannes Gutenberg Univ Mainz, Focus Program Translat Neurosci, D-55131 Mainz, Germany; [Goetz, Magdalena] Munich Cluster Syst Neurol SyNergy, D-80336 Munich, Germany	Gotz, M (corresponding author), Univ Munich, Inst Physiol, D-80336 Munich, Germany.	berningb@uni-mainz.de; magdalena.goetz@helmholtz-muenchen.de	Dimou, Leda/E-7968-2012; Bergami, Matteo/AAI-9972-2020; Berninger, Benedikt/H-4098-2019; HEINRICH, Christophe/N-9069-2019; HEINRICH, Christophe/K-1300-2017	Berninger, Benedikt/0000-0003-2652-2782; HEINRICH, Christophe/0000-0003-1266-718X; HEINRICH, Christophe/0000-0003-1266-718X; Gascon, Sergio/0000-0001-8756-7082	DFGGerman Research Foundation (DFG)European Commission [SPP1356, BE 4182/2-2, GO 640/9-2, GO640/6-1, GO640/7-1, GO640/8-1]; BMBFFederal Ministry of Education & Research (BMBF) [01GN1009A, 01GN0976]; Bavarian State Ministry of Sciences, Research and the Arts (ForNeuroCell); Belgian Science Policy OfficeBelgian Federal Science Policy Office [P7/20]; BMBFFederal Ministry of Education & Research (BMBF); LMU Research fellowship program; Collaborative Research Center 870 - DFGGerman Research Foundation (DFG)	We thank Dr. M. Wernig (Stanford University) for the Sox2 sequence and Dr. C. Lie (Erlangen University) for the Sox2 viral vector. We are grateful to Dr. G. Masserdotti and Dr. M. Karow for help with the viral vector cloning and production. We are grateful to G. Jaeger for excellent technical assistance and to I. Muhlhahn and D. Franzen for virus production. We thank A. von Streitberg for oral gavaging of the animals with tamoxifen. This work was supported by grants from the SPP1356 (BE 4182/2-2 and GO 640/9-2) of the DFG, the BMBF (01GN1009A and 01GN0976), the Bavarian State Ministry of Sciences, Research and the Arts (ForNeuroCell) to B.B. and M.G., the Belgian Science Policy Office (P7/20 Wibrain) to B.B., and BMBF and DFG grants (GO640/6-1, 7-1, and 8-1) to M.G. We are indebted to the Collaborative Research Center 870 funded by the DFG for financing the viral vector facility. M.B. was funded by the LMU Research fellowship program.	Arlotta P, 2014, CURR OPIN NEUROBIOL, V27, P208, DOI 10.1016/j.conb.2014.04.007; Bardehle S, 2013, NAT NEUROSCI, V16, P580, DOI 10.1038/nn.3371; Bergami M, 2012, DEV NEUROBIOL, V72, P1016, DOI 10.1002/dneu.22025; Bergles DE, 2000, NATURE, V405, P187, DOI 10.1038/35012083; Berninger B, 2007, J NEUROSCI, V27, P8654, DOI 10.1523/JNEUROSCI.1615-07.2007; Beyer WR, 2002, J VIROL, V76, P1488, DOI 10.1128/JVI.76.3.1488-1495.2002; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Colin A, 2009, GLIA, V57, P667, DOI 10.1002/glia.20795; Dimou L, 2008, J NEUROSCI, V28, P10434, DOI 10.1523/JNEUROSCI.2831-08.2008; Dimou L, 2014, PHYSIOL REV, V94, P709, DOI 10.1152/physrev.00036.2013; Gage FH, 2013, NEURON, V80, P588, DOI 10.1016/j.neuron.2013.10.037; Ge WP, 2009, P NATL ACAD SCI USA, V106, P328, DOI 10.1073/pnas.0811353106; Giorgetti A, 2012, P NATL ACAD SCI USA, V109, P12556, DOI 10.1073/pnas.1209523109; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Grande A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3373; Guo ZY, 2014, CELL STEM CELL, V14, P188, DOI 10.1016/j.stem.2013.12.001; Heinrich C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000373; Heins N, 2002, NAT NEUROSCI, V5, P308, DOI 10.1038/nn828; Hughes EG, 2013, NAT NEUROSCI, V16, P668, DOI 10.1038/nn.3390; Karow M, 2012, CELL STEM CELL, V11, P471, DOI 10.1016/j.stem.2012.07.007; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kondo T, 2004, GENE DEV, V18, P2963, DOI 10.1101/gad.309404; Kronenberg G, 2010, STROKE, V41, P2944, DOI 10.1161/STROKEAHA.110.583039; Ladewig J, 2012, NAT METHODS, V9, P575, DOI [10.1038/NMETH.1972, 10.1038/nmeth.1972]; Lin SC, 2004, NAT NEUROSCI, V7, P24, DOI 10.1038/nn1162; Motori E, 2013, CELL METAB, V18, P844, DOI 10.1016/j.cmet.2013.11.005; Ninkovic J, 2013, CELL STEM CELL, V13, P403, DOI 10.1016/j.stem.2013.07.002; Niu WZ, 2013, NAT CELL BIOL, V15, P1164, DOI 10.1038/ncb2843; Ohira K, 2010, NAT NEUROSCI, V13, P173, DOI 10.1038/nn.2473; Oliva AA, 2000, J NEUROSCI, V20, P3354, DOI 10.1523/JNEUROSCI.20-09-03354.2000; Pevny LH, 2010, INT J BIOCHEM CELL B, V42, P421, DOI 10.1016/j.biocel.2009.08.018; Ring KL, 2012, CELL STEM CELL, V11, P100, DOI 10.1016/j.stem.2012.05.018; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Simon C, 2012, GENESIS, V50, P506, DOI 10.1002/dvg.22003; Sirko S, 2013, CELL STEM CELL, V12, P426, DOI 10.1016/j.stem.2013.01.019; Su ZD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4338; Torper O, 2013, P NATL ACAD SCI USA, V110, P7038, DOI 10.1073/pnas.1303829110; Vierbuchen T, 2010, NATURE, V463, P1035, DOI 10.1038/nature08797	39	166	169	0	30	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	2213-6711			STEM CELL REP	Stem Cell Rep.	DEC 9	2014	3	6					1000	1014		10.1016/j.stemcr.2014.10.007			15	Cell & Tissue Engineering; Cell Biology	Cell Biology	AW3BC	WOS:000346159300008	25458895	DOAJ Gold, Green Published			2021-06-18	
J	Brown, NJ; Mannix, RC; O'Brien, MJ; Gostine, D; Collins, MW; Meehan, WP				Brown, Naomi J.; Mannix, Rebekah C.; O'Brien, Michael J.; Gostine, David; Collins, Michael W.; Meehan, William P., III			Effect of Cognitive Activity Level on Duration of Post-Concussion Symptoms	PEDIATRICS			English	Article						concussion; post-concussion syndrome; sports medicine; mild; traumatic brain injury	CEREBRAL-BLOOD-FLOW; TRAUMATIC BRAIN-INJURY; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; SPORT HELD; ZURICH; RATS	OBJECTIVE: To determine the effect of cognitive activity level on duration of post-concussion symptoms. METHODS: We conducted a prospective cohort study of patients who presented to a Sports Concussion Clinic within 3 weeks of injury between October 2009 and July 2011. At each visit, patients completed a scale that recorded their average level of cognitive activity since the previous visit. The product of cognitive activity level and days between visits ( cognitive activity-days) was calculated and divided into quartiles. Kaplan-Meier Product Limit method was used to generate curves of symptom duration based on cognitive activity level. To adjust for other possible predictors of concussion recovery, we constructed a Cox proportional hazard model with cognitive activity-days as the main predictor. RESULTS: Of the 335 patients included in the study, 62% were male, 19% reported a loss of consciousness, and 37% reported experiencing amnesia at the time of injury. The mean age of participants was 15 years ( range, 8-23) and the mean number of previous concussions was 0.76; 39% of athletes had sustained a previous concussion. The mean Post-Concussion Symptom Scale score at the initial visit was 30 ( SD, 26). The overall mean duration of symptoms was 43 days ( SD, 53). Of all variables assessed, only total symptom burden at initial visit and cognitive activity level were independently associated with duration of symptoms. CONCLUSIONS: Increased cognitive activity is associated with longer recovery from concussion. This study supports the use of cognitive rest and adds to the current consensus opinion. Pediatrics 2014; 133: e299e304	[Brown, Naomi J.] Childrens Hosp Philadelphia, Div Sports Med, Philadelphia, PA 19104 USA; [Mannix, Rebekah C.; Meehan, William P., III] Childrens Hosp Boston, Div Emergency Med, Boston, MA USA; [Mannix, Rebekah C.; O'Brien, Michael J.; Meehan, William P., III] Childrens Hosp Boston, Brain Injury Ctr, Boston, MA USA; [O'Brien, Michael J.; Gostine, David; Meehan, William P., III] Childrens Hosp Boston, Sports Concuss Clin, Div Sports Med, Boston, MA USA; [O'Brien, Michael J.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA 02453 USA; [Collins, Michael W.] Univ Pittsburgh, Med Ctr, Sports Concuss Program, Pittsburgh, PA USA	Meehan, WP (corresponding author), Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100, Waltham, MA 02453 USA.	william.meehan@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020; Meijer, Anna/K-5118-2016		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A1]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128, P30HD018655] Funding Source: NIH RePORTER	Funded by NIH grant T32 HD040128-06A1 to Dr Meehan. Funded by the National Institutes of Health (NIH).	[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Grady MF, 2012, PEDIATR ANN, V41, P377, DOI 10.3928/00904481-20120827-12; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Holbourn AHS, 1943, LANCET, V2, P438; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	24	166	166	1	41	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2014	133	2					E299	E304		10.1542/peds.2013-2125			6	Pediatrics	Pediatrics	AD7AR	WOS:000333413600021	24394679	Green Published			2021-06-18	
J	Al-Jamal, KT; Gherardini, L; Bardi, G; Nunes, A; Guo, C; Bussy, C; Herrero, MA; Bianco, A; Prato, M; Kostarelos, K; Pizzorusso, T				Al-Jamal, Khuloud T.; Gherardini, Lisa; Bardi, Giuseppe; Nunes, Antonio; Guo, Chang; Bussy, Cyrill; Herrero, M. Antonia; Bianco, Alberto; Prato, Maurizio; Kostarelos, Kostas; Pizzorusso, Tommaso			Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						nanomedicine; neurodegenerative; neuroprotection; neurosciences; gene therapy	SMALL INTERFERING RNA; CASPASE ACTIVATION; PLASMID DNA; DELIVERY; GENE; INJURY; INTERNALIZATION; INHIBITION; NEURONS; STROKE	Stroke is the second cause of death worldwide with ischemic stroke accounting for 80% of all stroke insults. Caspase-3 activation contributes to brain tissue loss and downstream biochemical events that lead to programmed cell death after traumatic brain injury. Alleviation of symptoms following ischemic neuronal injury can be potentially achieved by either genetic disruption or pharmacological inhibition of caspases. Here, we studied whether silencing of Caspase-3 using carbon nanotube-mediated in vivo RNA interference (RNAi) could offer a therapeutic opportunity against stroke. Effective delivery of siRNA directly to the CNS has been shown to normalize phenotypes in animal models of several neurological diseases. It is shown here that peri-lesional stereotactic administration of a Caspase-3 siRNA (siCas 3) delivered by functionalized carbon nanotubes (f-CNT) reduced neurodegeneration and promoted functional preservation before and after focal ischemic damage of the rodent motor cortex using an endothelin-1 induced stroke model. These observations illustrate the opportunity offered by carbon nanotube-mediated siRNA delivery and gene silencing of neuronal tissue applicable to a variety of different neuropathological conditions where intervention at well localized brain foci may offer therapeutic and functional benefits.	[Al-Jamal, Khuloud T.; Nunes, Antonio; Guo, Chang; Bussy, Cyrill; Kostarelos, Kostas] Univ London, Sch Pharm, Ctr Drug Delivery Res, Nanomed Lab, London WC1N 1AX, England; [Gherardini, Lisa; Bardi, Giuseppe; Pizzorusso, Tommaso] Consiglio Nazl Ric Neurosci Inst, I-56100 Pisa, Italy; [Herrero, M. Antonia] Univ Castilla La Mancha, Fac Quim IRICA, Dept Quim Organ, E-13071 Ciudad Real, Spain; [Bianco, Alberto] CNRS, Inst Biol Mol & Cellulaire, UPR Immunol & Chim Therapeut 9021, F-67000 Strasbourg, France; [Prato, Maurizio] Univ Trieste, Dept Pharmaceut Sci, Ctr Excellence Nanostruct Mat, I-34127 Trieste, Italy; [Pizzorusso, Tommaso] Univ Florence, Area San Salvi, Dept Psychol, I-50135 Florence, Italy; [Al-Jamal, Khuloud T.] Kings Coll London, Inst Pharmaceut Sci, London SE1 9NH, England	Kostarelos, K (corresponding author), Univ London, Sch Pharm, Ctr Drug Delivery Res, Nanomed Lab, 29-39 Brunswick Sq, London WC1N 1AX, England.	kostas.kostarelos@pharmacy.ac.uk; tommaso@in.cnr.it	Guo, Chang/AAL-7693-2021; Herrero, Maria Antonia/ABC-3466-2020; Bussy, Cyrill/C-7190-2008; herrero, Maria Antonia/I-4245-2014; Bardi, Giuseppe/K-7057-2019; Prato, Maurizio/G-7067-2012; Bardi, Giuseppe/B-6452-2013; Kostarelos, Kostas/AAP-6879-2021; Pizzorusso, Tommaso/D-1399-2013	Guo, Chang/0000-0002-9662-1885; Herrero, Maria Antonia/0000-0002-8860-9325; Bussy, Cyrill/0000-0001-8870-443X; herrero, Maria Antonia/0000-0002-8860-9325; Bardi, Giuseppe/0000-0001-9662-3007; Prato, Maurizio/0000-0002-8869-8612; Bardi, Giuseppe/0000-0001-9662-3007; Kostarelos, Kostas/0000-0002-2224-6672; gherardini, lisa/0000-0002-7003-4295; Pizzorusso, Tommaso/0000-0001-5614-0668; AL-JAMAL, KHULOUD/0000-0001-5165-2699	European CommissionEuropean CommissionEuropean Commission Joint Research Centre; United Kingdom EPSRCUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC); Regione ToscanaRegione Toscana; Engineering and Physical Sciences Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/G061998/1] Funding Source: researchfish	This work was supported by the following grants: European Commission FP6 NINIVE (to K. K. and T. P.), FP7 ANTICARB (to K. K., M. P., and A. B.), FP7 PLASTICISE (to T. P.), and the United Kingdom EPSRC "Nanotechnology Grand Challenges: Healthcare" (to K. K. and K.T.A.-J.), EXTRAPLAST IIT (to T. P.), the CANESTRO project of the Regione Toscana (to T. P.). A. B. wishes to thank the Centre National de la Recherche Scientifique (CNRS).	Al-Jamal KT, 2010, FASEB J, V24, P4354, DOI 10.1096/fj.09-141036; Herrero MA, 2009, J AM CHEM SOC, V131, P9843, DOI 10.1021/ja903316z; Bardi G, 2009, NANOMED-NANOTECHNOL, V5, P96, DOI 10.1016/j.nano.2008.06.008; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cai D, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/34/345102; Chen CH, 2009, NEUROBIOL DIS, V33, P509, DOI 10.1016/j.nbd.2008.12.010; Chu Y, 2007, CURR HYPERTENS REP, V9, P19, DOI 10.1007/s11906-007-0005-7; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Dorn G, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh044; Gao LZ, 2006, CHEMBIOCHEM, V7, P239, DOI 10.1002/cbic.200500227; Gaudilliere B, 2002, J BIOL CHEM, V277, P46442, DOI 10.1074/jbc.M206653200; Georgakilas V, 2002, CHEM COMMUN, P3050, DOI 10.1039/b209843a; Georgakilas V, 2002, J AM CHEM SOC, V124, P14318, DOI 10.1021/ja0260869; Gilmour G, 2004, BEHAV BRAIN RES, V150, P171, DOI 10.1016/j.bbr.2003.07.006; Kam NWS, 2005, J AM CHEM SOC, V127, P12492, DOI 10.1021/ja053962k; Karatas H, 2009, J NEUROSCI, V29, P13761, DOI 10.1523/JNEUROSCI.4246-09.2009; Kateb B, 2007, NEUROIMAGE, V37, pS9, DOI 10.1016/j.neuroimage.2007.03.078; Kostarelos K, 2009, NAT NANOTECHNOL, V4, P627, DOI 10.1038/nnano.2009.241; Kostarelos K, 2007, NAT NANOTECHNOL, V2, P108, DOI 10.1038/nnano.2006.209; Krichevsky AM, 2002, P NATL ACAD SCI USA, V99, P11926, DOI 10.1073/pnas.182272699; Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901; Kumar P, 2006, PLOS MED, V3, P505, DOI 10.1371/journal.pmed.0030096; Lacerda L, 2007, NANO TODAY, V2, P38, DOI 10.1016/S1748-0132(07)70172-X; Lacerda L, 2007, ADV MATER, V19, P1480, DOI 10.1002/adma.200601412; Lee HJ, 2011, NAT NANOTECHNOL, V6, P120, DOI 10.1038/nnano.2010.281; Liu Y, 2005, ANGEW CHEM INT EDIT, V44, P4782, DOI 10.1002/anie.200500042; Matsumoto K, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/11/115101; Namura S, 1998, J NEUROSCI, V18, P3659; Pantarotto D, 2004, ANGEW CHEM INT EDIT, V43, P5242, DOI 10.1002/anie.200460437; Pantarotto D, 2004, CHEM COMMUN, P16, DOI 10.1039/b311254c; Pardridge WM, 2007, ADV DRUG DELIVER REV, V59, P141, DOI 10.1016/j.addr.2007.03.008; Podesta JE, 2009, SMALL, V5, P1176, DOI 10.1002/smll.200801572; Rabuffetti M, 2000, J NEUROSCI, V20, P4398, DOI 10.1523/JNEUROSCI.20-12-04398.2000; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Singh R, 2005, J AM CHEM SOC, V127, P4388, DOI 10.1021/ja0441561; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Thakker DR, 2005, MOL PSYCHIATR, V10, P782, DOI 10.1038/sj.mp.4001687; Torocsik B, 2002, J NEUROSCI, V22, P8971; Wang YL, 2005, NEUROSCI RES, V53, P241, DOI 10.1016/j.neures.2005.06.021; Zhang LY, 2010, METHODS MOL BIOL, V625, P55, DOI 10.1007/978-1-60761-579-8_6; Zhang ZH, 2006, CLIN CANCER RES, V12, P4933, DOI 10.1158/1078-0432.CCR-05-2831	41	166	171	0	71	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JUL 5	2011	108	27					10952	10957		10.1073/pnas.1100930108			6	Multidisciplinary Sciences	Science & Technology - Other Topics	787LC	WOS:000292376700013	21690348	Green Published, Bronze			2021-06-18	
J	Nakamura, T; Hillary, FG; Biswal, BB				Nakamura, Toru; Hillary, Frank G.; Biswal, Bharat B.			Resting Network Plasticity Following Brain Injury	PLOS ONE			English	Article							SMALL-WORLD NETWORKS; WORKING-MEMORY; FUNCTIONAL CONNECTIVITY; NEURONAL AVALANCHES; FMRI; REORGANIZATION; ARCHITECTURE; PERFORMANCE; ACTIVATION; CORTEX	The purpose of this study was to examine neural network properties at separate time-points during recovery from traumatic brain injury (TBI) using graph theory. Whole-brain analyses of the topological properties of the fMRI signal were conducted in 6 participants at 3 months and 6 months following severe TBI. Results revealed alterations of network properties including a change in the degree distribution, reduced overall strength in connectivity, and increased "small-worldness'' from 3 months to 6 months post injury. The findings here indicate that, during recovery from injury, the strength but not the number of network connections diminishes, so that over the course of recovery, the network begins to approximate what is observed in healthy adults. These are the first data examining functional connectivity in a disrupted neural system during recovery.	[Nakamura, Toru; Biswal, Bharat B.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Radiol, Newark, NJ 07103 USA; [Hillary, Frank G.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA	Nakamura, T (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Radiol, 185 S Orange Ave, Newark, NJ 07103 USA.	fhillary@psu.edu; bbiswal@yahoo.com	nakamura, Toru/A-4535-2010; Hillary, Frank/AAN-8622-2021	nakamura, toru/0000-0002-5340-6333	US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01NS049176]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG032088] Funding Source: NIH RePORTER	The current work is supported by US National Institutes of Health grant 5R01NS049176 to B. B. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Amaral LAN, 2000, P NATL ACAD SCI USA, V97, P11149, DOI 10.1073/pnas.200327197; Baba K, 2004, AUST NZ J STAT, V46, P657, DOI 10.1111/j.1467-842X.2004.00360.x; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Barrat A, 2004, P NATL ACAD SCI USA, V101, P3747, DOI 10.1073/pnas.0400087101; Beggs JM, 2004, J NEUROSCI, V24, P5216, DOI 10.1523/JNEUROSCI.0540-04.2004; Beggs JM, 2003, J NEUROSCI, V23, P11167; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Biswal BB, 1997, NMR BIOMED, V10, P165, DOI 10.1002/(SICI)1099-1492(199706/08)10:4/5<165::AID-NBM454>3.0.CO;2-7; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Chialvo DR, 2004, PHYSICA A, V340, P756, DOI 10.1016/j.physa.2004.05.064; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Eguiluz VM, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.018102; Fair DA, 2007, NEUROIMAGE, V35, P396, DOI 10.1016/j.neuroimage.2006.11.051; FITZPATRICK NM, 2008, 36 ANN M INT NEUR SO; Fox MD, 2006, NAT NEUROSCI, V9, P23, DOI 10.1038/nn1616; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Friston Karl J., 1994, Human Brain Mapping, V2, P56, DOI 10.1002/hbm.460020107; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hillary FG, 2007, CLIN NEUROPSYCHOL, V21, P58, DOI 10.1080/13854040601064542; HILLARY FG, BRAIN IMAGI IN PRESS; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2006, HUM BRAIN MAPP, V27, P837, DOI 10.1002/hbm.20226; Humphries MD, 2006, P ROY SOC B-BIOL SCI, V273, P503, DOI 10.1098/rspb.2005.3354; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Latora V, 2003, EUR PHYS J B, V32, P249, DOI 10.1140/epjb/e2003-00095-5; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Liu Y, 2008, BRAIN, V131, P945, DOI 10.1093/brain/awn018; Marchiori M, 2000, PHYSICA A, V285, P539, DOI 10.1016/S0378-4371(00)00311-3; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; Micheloyannis S, 2006, SCHIZOPHR RES, V87, P60, DOI 10.1016/j.schres.2006.06.028; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Onnela JP, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.065103; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Price CJ, 2006, J MAGN RESON IMAGING, V23, P816, DOI 10.1002/jmri.20580; Price CJ, 1999, HUM BRAIN MAPP, V8, P102, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<102::AID-HBM6>3.0.CO;2-J; Price CJ, 2002, NEUROCASE, V8, P345, DOI 10.1076/neur.8.4.345.16186; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; Rypma B, 2002, J COGNITIVE NEUROSCI, V14, P721, DOI 10.1162/08989290260138627; Rypma B, 1999, NEUROIMAGE, V9, P216, DOI 10.1006/nimg.1998.0404; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Stam CJ, 2007, CEREB CORTEX, V17, P92, DOI 10.1093/cercor/bhj127; Stanley HE., 1971, INTRO PHASE TRANSITI; TEASDALE G, 1974, LANCET, V2, P81; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Wang L, 2006, NEUROIMAGE, V31, P496, DOI 10.1016/j.neuroimage.2005.12.033; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918	58	166	170	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2009	4	12							e8220	10.1371/journal.pone.0008220			9	Multidisciplinary Sciences	Science & Technology - Other Topics	533NI	WOS:000272830300009	20011533	DOAJ Gold, Green Published			2021-06-18	
J	Koenigs, M; Huey, ED; Raymont, V; Cheon, B; Solomon, J; Wassermann, EM; Grafman, J				Koenigs, Michael; Huey, Edward D.; Raymont, Vanessa; Cheon, Bobby; Solomon, Jeffrey; Wassermann, Eric M.; Grafman, Jordan			Focal brain damage protects against post-traumatic stress disorder in combat veterans	NATURE NEUROSCIENCE			English	Article							MEDIAL PREFRONTAL CORTEX; TRANSCRANIAL MAGNETIC STIMULATION; DOUBLE-BLIND; AMYGDALA; VIETNAM; ACTIVATION; PTSD	Post-traumatic stress disorder ( PTSD) is an often debilitating mental illness that is characterized by recurrent distressing memories of traumatic events. PTSD is associated with hypoactivity in the ventromedial prefrontal cortex ( vmPFC), hyperactivity in the amygdala and reduced volume in the hippocampus, but it is unknown whether these neuroimaging findings reflect the underlying cause or a secondary effect of the disorder. To investigate the causal contribution of specific brain areas to PTSD symptoms, we studied a unique sample of Vietnam War veterans who suffered brain injury and emotionally traumatic events. We found a substantially reduced occurrence of PTSD among those individuals with damage to one of two regions of the brain: the vmPFC and an anterior temporal area that included the amygdala. These results suggest that the vmPFC and amygdala are critically involved in the pathogenesis of PTSD.	[Koenigs, Michael; Huey, Edward D.; Raymont, Vanessa; Wassermann, Eric M.; Grafman, Jordan] Natl Inst Neurol Disorders & Stroke, Cognit Neurosci Sect, US Natl Inst Hlth, Bethesda, MD 20892 USA; [Raymont, Vanessa; Cheon, Bobby] Natl Naval Med Ctr, Henry M Jackson Fdn, Vietnam Head Injury Study, Bethesda, MD 20889 USA; [Solomon, Jeffrey] Med Numer, Germantown, MD 20876 USA	Grafman, J (corresponding author), Natl Inst Neurol Disorders & Stroke, Cognit Neurosci Sect, US Natl Inst Hlth, 10 Ctr Dr,MSC 1440, Bethesda, MD 20892 USA.	grafmanj@ninds.nih.gov	Wassermann, Eric M./AAC-9064-2020	Wassermann, Eric M./0000-0003-0628-0210; Grafman, Jordan H./0000-0001-8645-4457; Cheon, Bobby/0000-0001-6815-619X; Koenigs, Michael/0000-0002-5799-4881	Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [Z01 NS002792-19, Z01 NS003024-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS002792, ZIANS003024, ZIANS002977] Funding Source: NIH RePORTER		Aggleton J.P., 2000, AMYGDALA FUNCTIONAL; AGGLETON JP, 1980, BRAIN RES, V190, P347, DOI 10.1016/0006-8993(80)90279-6; Alonso J, 2004, ACTA PSYCHIAT SCAND, V109, P38; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; AYUSOMATEOS JL, 2002, GLOBAL BURDEN POST T; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bremner JD, 1999, AM J PSYCHIAT, V156, P1787; Bremner JD, 1999, BIOL PSYCHIAT, V45, P806, DOI 10.1016/S0006-3223(98)00297-2; Cohen H, 2004, AM J PSYCHIAT, V161, P515, DOI 10.1176/appi.ajp.161.3.515; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Coryell MW, 2007, BIOL PSYCHIAT, V62, P1140, DOI 10.1016/j.biopsych.2007.05.008; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Driessen M, 2004, BIOL PSYCHIAT, V55, P603, DOI 10.1016/j.biopsych.2003.08.018; Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213; First MB., 2002, STRUCTURED CLIN INTE; Fitzgerald PB, 2003, ARCH GEN PSYCHIAT, V60, P1002, DOI 10.1001/archpsyc.60.9.1002; Greenberg BD, 2006, NEUROPSYCHOPHARMACOL, V31, P2384, DOI 10.1038/sj.npp.1301165; Hendler T, 2003, NEUROIMAGE, V19, P587, DOI 10.1016/S1053-8119(03)00141-1; Henry TR, 2002, NEUROLOGY, V59, pS3, DOI 10.1212/WNL.59.6_suppl_4.S3; Herskovits EH, 2002, RADIOLOGY, V224, P345, DOI 10.1148/radiol.2242011439; Liberzon I, 1999, BIOL PSYCHIAT, V45, P817, DOI 10.1016/S0006-3223(98)00246-7; Likhtik E, 2005, J NEUROSCI, V25, P7429, DOI 10.1523/JNEUROSCI.2314-05.2005; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; Quirk GJ, 2003, J NEUROSCI, V23, P8800, DOI 10.1523/jneurosci.23-25-08800.2003; Quirk GJ, 2006, CURR OPIN NEUROBIOL, V16, P723, DOI 10.1016/j.conb.2006.07.004; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rauch SL, 2003, NEUROREPORT, V14, P913, DOI 10.1097/01.wnr.0000071767.24455.10; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Stefanacci L, 2002, J COMP NEUROL, V451, P301, DOI 10.1002/cne.10339; Talairach J., 1988, COPLANAR STEREOTAXIC; Tranel D, 2005, BRAIN, V128, P2872, DOI 10.1093/brain/awh643; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wassermann EM, 2005, TRENDS COGN SCI, V9, P503, DOI 10.1016/j.tics.2005.09.001; Wood JN, 2003, NAT REV NEUROSCI, V4, P139, DOI 10.1038/nrn1033	38	166	174	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	FEB	2008	11	2					232	237		10.1038/nn2032			6	Neurosciences	Neurosciences & Neurology	256FC	WOS:000252712100018	18157125	Green Accepted			2021-06-18	
J	Cavanaugh, JT; Guskiewicz, KM; Giuliani, C; Marshall, S; Mercer, V; Stergiou, N				Cavanaugh, JT; Guskiewicz, KM; Giuliani, C; Marshall, S; Mercer, V; Stergiou, N			Detecting altered postural control after cerebral concussion in athletes with normal postural stability	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							MILD HEAD-INJURY; COLLEGIATE FOOTBALL PLAYERS; NCAA CONCUSSION; TIME-SERIES; REGULARITY; COMPLEXITY; SPORTS; DYNAMICS; ENTROPY	Objective: To determine if approximate entropy (ApEn), a regularity statistic from non-linear dynamics, could detect changes in postural control during quiet standing in athletes with normal postural stability after cerebral concussion. Methods: The study was a retrospective, case series analysis of centre of pressure ( COP) data collected during the Sensory Organization Test ( SOT) from NCAA Division I ( USA) athletes prior to and within 48 h after injury. Subjects were 21 male and six female athletes from a variety of sports who sustained a cerebral concussion between 1997 and 2003. After injury, athletes displayed normal postural stability equivalent to preseason levels. For comparison, COP data also were collected from 15 male and 15 female healthy non-athletes on two occasions. ApEn values were calculated for COP anterior-posterior (AP) and medial-lateral (ML) time series. Results: Compared to healthy subjects, COP oscillations among athletes generally became more regular ( lower ApEn value) after injury despite the absence of postural instability. For AP time series, declines in ApEn values were much larger in SOT conditions 1 and 2 ( approximately three times as large as the standard error of the mean) than for all other conditions. For ML time series, ApEn values declined after injury in all sensory conditions (F-1,F-55 = 6.36, p = 0.02). Conclusions: Athletes who demonstrated normal postural stability after concussion nonetheless displayed subtle changes in postural control. Changes in ApEn may have represented a clinically abnormal finding. ApEn analysis of COP oscillations may be a valuable supplement to existing concussion assessment protocols for athletes.	Duke Univ, Med Ctr, Durham, NC 27710 USA; Univ N Carolina, Chapel Hill, NC USA; Univ Nebraska, Omaha, NE 68182 USA	Cavanaugh, JT (corresponding author), Duke Univ, Med Ctr, Durham, NC 27710 USA.	jimcavanaugh@nc.rr.com	Mercer, Vicki/AAN-6669-2021	Marshall, Stephen/0000-0002-2664-9233; Guskiewicz, Kevin/0000-0002-8682-2130; Cavanaugh, James/0000-0001-7132-6313			Bodfish JW, 2001, AM J MENT RETARD, V106, P123, DOI 10.1352/0895-8017(2001)106<0123:SAMCDI>2.0.CO;2; Cavanaugh JT, 2004, GAIT POSTURE S1, V20, pS55; CAVANAUGH JT, 2004, GAIT POSTURE S1, V20, pS54; CAVANAUGH JT, 2003, P ANN M AM SOC BIOM; COLLINS JJ, 1993, EXP BRAIN RES, V95, P308, DOI 10.1007/BF00229788; DICK R, 2003, NATL COLL ATHLETIC A; GOLDIE PA, 1989, ARCH PHYS MED REHAB, V70, P510; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2002, ORTHOP PHYS THER CLI, V11, P143; Harbourne RT, 2003, DEV PSYCHOBIOL, V42, P368, DOI 10.1002/dev.10110; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kurz M., 2004, INNOVATIVE ANALYSES, P93; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; *NEUROCOM INT INC, 1991, EQ SYST DAT INT MAN; Newell K., 1998, APPL NONLINEAR DYNAM, P80; PINCUS SM, 1994, AM J PHYSIOL, V266, pH1643, DOI 10.1152/ajpheart.1994.266.4.H1643; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; PINCUS SM, 1991, J CLIN MONITOR, V7, P335, DOI 10.1007/BF01619355; Pincus Steven M., 1995, QUANT NEUROENDOCRINO, V28, P336; Portney L., 2015, FDN CLIN RES APPL PR, V3rd ed.; Powell JW, 2001, J ATHL TRAINING, V36, P307; RICCIO GE, 1993, VARIABILITY AND MOTOR CONTROL, P317; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Sabatini AM, 2000, MED BIOL ENG COMPUT, V38, P617, DOI 10.1007/BF02344866; Salenius S, 2003, CURR OPIN NEUROBIOL, V13, P678, DOI 10.1016/j.conb.2003.10.008; Schiff Steven J., 1994, Integrative Physiological and Behavioral Science, V29, P246, DOI 10.1007/BF02691329; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Stergiou N, 2004, INNOVATIVE ANAL HUMA, P63; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; Theiler J, 1996, ELECTROEN CLIN NEURO, V98, P213, DOI 10.1016/0013-4694(95)00240-5; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003	35	166	166	0	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	NOV	2005	39	11					805	811		10.1136/bjsm.2004.015909			7	Sport Sciences	Sport Sciences	976HJ	WOS:000232723600010	16244188	Green Published, Bronze			2021-06-18	
J	Lesne, S; Ali, C; Gabriel, C; Croci, N; MacKenzie, ET; Glabe, CG; Plotkine, M; Marchand-Verrecchia, C; Vivien, D; Buisson, A				Lesne, S; Ali, C; Gabriel, C; Croci, N; MacKenzie, ET; Glabe, CG; Plotkine, M; Marchand-Verrecchia, C; Vivien, D; Buisson, A			NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production	JOURNAL OF NEUROSCIENCE			English	Article						amyloid; APP; secretase; glutamate receptors; calmodulin; neurons	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; HEAD-INJURY; CEREBRAL-ISCHEMIA; RISK-FACTOR; EXPRESSION; CALCIUM; APP; DEPOSITION	Acute brain injuries have been identified as a risk factor for developing Alzheimer's disease (AD). Because glutamate plays a pivotal role in these pathologies, we studied the influence of glutamate receptor activation on amyloid-beta (A beta) production in primary cultures of cortical neurons. We found that sublethal NMDA receptor activation increased the production and secretion of A beta. This effect was preceded by an increased expression of neuronal Kunitz protease inhibitory domain (KPI) containing amyloid-beta precursor protein (KPI-APP) followed by a shift from beta-secretase to beta-secretase-mediated APP processing. This shift is a result of the inhibition of the beta-secretase candidate tumor necrosis factor-alpha converting enzyme ( TACE) when associated with neuronal KPI-APPs. This KPI-APP/TACE interaction was also present in AD brains. Thus, our findings reveal a cellular mechanism linking NMDA receptor activation to neuronal A beta secretion. These results suggest that even mild deregulation of the glutamatergic neurotransmission may increase A beta production and represent a causal risk factor for developing AD.	Univ Caen, UMR 6185, Ctr Cyceron, CNRS, F-14074 Caen, France; Univ Caen, Equipe Inst Natl Sante & Rech Med Avenir tPA Work, F-14074 Caen, France; Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Paris 05, Fac Sci Pharmaceut & Biol, Pharmacol Lab, EA2510, F-75006 Paris, France	Buisson, A (corresponding author), Univ Caen, UMR 6185, Ctr Cyceron, CNRS, Blvd H Becquerel,BP5229, F-14074 Caen, France.	buisson@cyceron.fr	buisson, alain/AAI-8218-2020; MARCHAND-LEROUX, Catherine/L-7453-2017; Mackenzie, Eric Thomson/L-1938-2015	buisson, alain/0000-0002-4281-7911; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; MacKenzie, Eric T/0000-0003-1057-7033; Lesne, Sylvain/0000-0001-9411-1868; VIVIEN, DENIS/0000-0002-7636-2185; Ali, Carine/0000-0001-8007-7910			ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; BEHROUZ N, 1989, LAB INVEST, V61, P576; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bussiere T, 2002, NEUROSCIENCE, V112, P75, DOI 10.1016/S0306-4522(02)00056-8; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Cotman CW, 1996, NEUROBIOL AGING, V17, P723; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; Ho LB, 1996, J BIOL CHEM, V271, P30929, DOI 10.1074/jbc.271.48.30929; Hsiao K, 1998, EXP GERONTOL, V33, P883, DOI 10.1016/S0531-5565(98)00045-X; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Husi H, 2000, NAT NEUROSCI, V3, P661; Husi H, 2001, TRENDS NEUROSCI, V24, P259, DOI 10.1016/S0166-2236(00)01792-6; Kim HS, 1998, NEUROREPORT, V9, P533; LEBLANC AC, 1991, FEBS LETT, V292, P171, DOI 10.1016/0014-5793(91)80861-V; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Moir RD, 1998, J BIOL CHEM, V273, P5013, DOI 10.1074/jbc.273.9.5013; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nagy Z, 1997, J NEUROPATH EXP NEUR, V56, P165, DOI 10.1097/00005072-199702000-00007; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Popa-Wagner A, 1998, STROKE, V29, P2196, DOI 10.1161/01.STR.29.10.2196; REFOLO LM, 1989, BIOCHEM BIOPH RES CO, V164, P664, DOI 10.1016/0006-291X(89)91511-8; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROSE K, 1993, IN VITRO BIOL METHOD, P46; ROSES AD, 1995, NAT MED, V1, P603, DOI 10.1038/nm0795-603; SAIDO TC, 1994, J BIOL CHEM, V269, P15253; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; Sergeant N, 2002, J NEUROCHEM, V81, P663, DOI 10.1046/j.1471-4159.2002.00901.x; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Willoughby DA, 1995, J MOL NEUROSCI, V6, P257, DOI 10.1007/BF02736785; Xie JY, 2001, NATURE, V410, P936, DOI 10.1038/35073593	56	166	173	0	17	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	OCT 12	2005	25	41					9367	9377		10.1523/JNEUROSCI.0849-05.2005			11	Neurosciences	Neurosciences & Neurology	973TU	WOS:000232546300006	16221839	Green Published, Bronze			2021-06-18	
J	Romner, B; Ingebrigtsen, T; Kongstad, F; Borgesen, SE				Romner, B; Ingebrigtsen, T; Kongstad, F; Borgesen, SE			Traumatic brain damage: Serum S-100 protein measurements related to neuroradiological findings	JOURNAL OF NEUROTRAUMA			English	Article						computed tomography; head injury; magnetic resonance imaging; management; S-100 protein	MINOR HEAD-INJURY; MAGNETIC-RESONANCE; COMPUTED-TOMOGRAPHY; MILD; MANAGEMENT; CLASSIFICATION; S100-BETA; SURGERY; MARKER	This study was designed to investigate the correlation between 5-100 protein serum measurements and neuroradiological findings in patients with head injury. We studied 278 patients with minor, moderate, and severe head injuries and 110 controls with no history of neurological disease. The study recruited patients from three Scandinavian neurotrauma centers, Serum levels of 5-100 protein were measured at admittance, and computed tomographic scans of the brain were obtained within 24 h postinjury in all patients. In a subgroup of 45 patients with minor head injuries, magnetic resonance imaging was also performed, Increased serum level of S-100 protein was detected in 108 (39%) patients, and CT scan demonstrated intracranial pathology in 25 (9%) (brain contusion n = 13, subdural hematoma n = 6, epidural hematoma n = 2, traumatic subarachnoid hemorrhage IE = 2, and brain edema II = 2), The proportion of patients with detectable serum level was significantly (p < 0.01) higher among those with intracranial pathology (92%) compared to those without (34%), The negative predictive value of an undetectable 5-100 serum level was 0.99. Undetectable serum level of 5-100 protein predicts normal intracranial findings on CT scan, Determination of 5-100 protein in serum may be used to select patients for CT scanning.	Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden; Univ Tromso Hosp, Dept Neurosurg, N-9012 Tromso, Norway; Rigshosp, Dept Neurosurg, DK-2100 Copenhagen, Denmark	Romner, B (corresponding author), Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden.			Ingebrigtsen, Tor/0000-0001-5966-9786			Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; GANDY SE, 1984, ANN NEUROL, V16, P254, DOI 10.1002/ana.410160217; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; HAIMOTO H, 1987, LAB INVEST, V57, P489; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; JENKINS A, 1986, LANCET, V2, P445; JENSEN R, 1985, J NEUROCHEM, V45, P700, DOI 10.1111/j.1471-4159.1985.tb04048.x; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; *MILD TRAUM BRAIN, 1993, J HEAD TRAUMA REHAB, V8, P83; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Nygaard O, 1997, CLIN CHEM, V43, P541; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Stein SC, 1996, NEUROSURG QUART, V6, P108, DOI 10.1097/00013414-199606000-00004; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; USUI A, 1989, CLIN CHEM, V35, P1942; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	24	166	176	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2000	17	8					641	647		10.1089/089771500415391			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	347WF	WOS:000088951600002	10972241				2021-06-18	
J	Buki, A; Okonkwo, DO; Povlishock, JT				Buki, A; Okonkwo, DO; Povlishock, JT			Postinjury cyclosporin A administration limits axonal damage and disconnection in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; calpain; cylosporin A; mitochondrial permeability transition; trauma	CALPAIN-I; NEUROFILAMENT SUBUNITS; AXOLEMMAL PERMEABILITY; HEAD-INJURY; RATS; ISCHEMIA; SPECTRIN; NEURONS; MODEL; ACCELERATION	Recent observations concerning presumed calcium-induced mitochondrial damage and focal intraaxonal proteolysis in the pathogenesis of traumatic axonal injury (TAI) have opened new perspectives for therapeutic intervention. Studies from our laboratory demonstrated that cyclosporin A (CsA), a potent inhibitor of Ca2+-induced mitochondrial damage, administered 30 min prior to traumatic brain injury preserved mitochondrial integrity in those axonal foci destined to undergo delayed disconnection. We attributed this neuroprotection to the inhibition by CsA of mitochondrial permeability transition (MPT). Additional experiments proved that CsA pretreatment also significantly reduced calcium-induced, calpain-mediated spectrin proteolysis (CMSP) and neurofilament compaction (NFC), pivotal events in the pathogenesis of axonal failure and disconnection. Given these provocative findings the goal of the current study was to evaluate the potential of CsA to inhibit calcium-induced axonal damage in a more clinically relevant postinjury treatment paradigm. To this end, cyclosporin A was administered intrathecally to Sprague Dawley rats 30 min following impact acceleration traumatic brain injury. The first group of animals were sacrificed 120 min postinjury and the density of CMSP and NFC immunoreactive damaged axonal segments of CsA-treated and vehicle-treated injured animals were quantitatively analyzed. A second group of CsA- versus vehicle-treated rats was sacrificed at 24 h postinjury to compare the density of damaged axons displaying beta amyloid precursor protein (APP) immunoreactivity, a signature protein of axonal perturbation and disconnection. Postinjury CsA administration resulted in a significant decrease (>60%) in CMSP/NFC immunoreactivity in corticospinal tracts and medial longitudinal fasciculi. A similar decrease was detected in the density of APP inmunoreactive damaged axons, indicating an attenuation of axonal disconnection at 24 h postinjury in CsA-treated animals. These results once again suggest that the maintenance of the functional integrity of the mitochondria can prevent TAI, presumably via the preservation of the local energy homeostasis of the axon. Moreover and perhaps more importantly, these studies also demonstrate the efficacy of CsA administration when given in the early posttraumatic period. Collectively, our findings suggest that a therapeutic window exists for the use of drugs targeting mitochondria and energy regulation in traumatic brain injury.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Univ Med Sch Pecs, Dept Neurosurg, Pecs, Hungary	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA.	jpovlish@hsc.vcu.edu	Buki, Andras/B-1960-2010		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER		Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Friberg H, 1998, J NEUROSCI, V18, P5151; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; GAMBERUCCI A, 1994, J BIOL CHEM, V269, P23597; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; LEE VMY, 1987, J NEUROSCI, V7, P3474; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Sabatini DM, 1997, MOL NEUROBIOL, V15, P223, DOI 10.1007/BF02740635; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; ZAGON IS, 1986, J NEUROSCI, V6, P2977; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	36	166	170	1	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1999	16	6					511	521		10.1089/neu.1999.16.511			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	206LD	WOS:000080879800007	10391367				2021-06-18	
J	Xu, J; Fan, GS; Chen, SW; Wu, YJ; Xu, XM; Hsu, CY				Xu, J; Fan, GS; Chen, SW; Wu, YJ; Xu, XM; Hsu, CY			Methylprednisolone inhibition of TNF-alpha expression and NF-kappa B activation after spinal cord injury in rats	MOLECULAR BRAIN RESEARCH			English	Article						cytokine; gene expression; inflammation; secondary injury; transcription factor	CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; DELAYED WALLERIAN DEGENERATION; FOCAL CEREBRAL-ISCHEMIA; TRANSCRIPTION FACTOR; GENETIC INFLUENCES; CELLULAR REACTIONS; ENDOTHELIAL-CELLS; TRAUMATIC INJURY; VASCULAR INJURY	Post-traumatic inflammatory reaction has been implicated in the secondary injury after SCI. TNF-alpha is a key inflammatory mediator, which plays a pathogenetic role in cell death in inflammatory disorders and traumatic brain injury. TNF-alpha exerts its effector actions, at least partially, through the activation of a pro-inflammatory transcription factor, NF-kB, which in turn upregulates such genes as iNOS, cytokines, adhesive molecules, and others. Consistent with a post-traumatic inflammatory reaction after SCI, we noted an increase in TNF-alpha expression by Western blotting (4.5-fold increase at 1 day after SCI, P < 0.01) and immunohistochemistry in a rat SCI model. Post-traumatic TNF-alpha expression was accompanied by an increase in NF-kB binding activity in nuclear proteins isolated from the injured cord (3.9-fold increase, P < 0.01). MP is the only drug proven effective in improving neurological function in patients with acute SCI. The mechanism of action of MP is not fully understood, but is thought to be related to its antioxidant effects. MP is also a potent anti-inflammatory agent, which has been recently shown to inhibit NF-kB binding activity. MP (30 mg/kg, i.v.) given immediately after SCI reduced TNF-alpha expression by 55% (P < 0.01) and NF-kB binding activity. These findings suggest that post-traumatic inflammatory activity that is mediated by the TNF-alpha-NF-kB cascade can be suppressed by MP. (C) 1998 Elsevier Science B.V. All rights reserved.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63104 USA	Hsu, CY (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	hsuc@neuro.wustl.edu		Xu, Xiao-ming/0000-0002-7229-0081; Hsu, Chung Y./0000-0002-5632-2733	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS37230] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037230] Funding Source: NIH RePORTER		AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; ANDERSON DK, 1988, J NEUROSURG, V69, P562, DOI 10.3171/jns.1988.69.4.0562; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; BALENTINE JD, 1978, LAB INVEST, V39, P236; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BLIGHT AR, 1995, BRAIN, V118, P735, DOI 10.1093/brain/118.3.735; BLIGHT AR, 1992, J NEUROTRAUMA, V9, P83; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUGHLER JM, 1982, J NEUROSURG, V56, P838, DOI 10.3171/jns.1982.56.6.0838; Buttini M, 1996, NEUROSCIENCE, V71, P1, DOI 10.1016/0306-4522(95)00414-9; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Chen AQ, 1996, EXP NEUROL, V138, P261, DOI 10.1006/exnr.1996.0065; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; DEMEDIUK P, 1985, P NATL ACAD SCI USA, V82, P7071, DOI 10.1073/pnas.82.20.7071; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Fujiki M, 1996, J COMP NEUROL, V371, P469; GHODOSH LA, 1989, CURRENT PROTOCOLS MO; GRELL M, 1994, J IMMUNOL, V153, P1963; GRIFFITHS IR, 1978, ACTA NEUROPATHOL, V41, P33, DOI 10.1007/BF00689554; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HALL ED, 1982, SURG NEUROL, V18, P320, DOI 10.1016/0090-3019(82)90140-9; Hamada Y, 1996, J NEUROCHEM, V66, P1525; HILL GE, 1995, J THORAC CARDIOV SUR, V110, P1658, DOI 10.1016/S0022-5223(95)70027-7; HOLETS VR, 1987, BRAIN RES, V408, P141, DOI 10.1016/0006-8993(87)90366-0; HSU C Y, 1990, Journal of Neurotrauma, V7, P115, DOI 10.1089/neu.1990.7.115; HSU CY, 1985, J NEUROL SCI, V70, P275, DOI 10.1016/0022-510X(85)90169-8; HSU CY, 1986, J NEUROL SCI, V74, P289, DOI 10.1016/0022-510X(86)90114-0; HSU CY, 1988, J NEUROL SCI, V83, P55, DOI 10.1016/0022-510X(88)90019-6; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; Hsu CY, 1996, NEUROTRAUMA, P1433; Ikeda K, 1997, THROMB HAEMOSTASIS, V77, P394; KIBERD BA, 1994, J LAB CLIN MED, V124, P496; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Lippert U, 1996, SKIN PHARMACOL, V9, P93; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Liu XZ, 1997, J NEUROSCI, V17, P5395; MEANS ED, 1981, J NEUROSURG, V55, P200, DOI 10.3171/jns.1981.55.2.0200; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Rothwell NJ, 1996, PHARMACOL THERAPEUT, V69, P85, DOI 10.1016/0163-7258(95)02033-0; SALMINEN A, 1995, BIOCHEM BIOPH RES CO, V212, P939, DOI 10.1006/bbrc.1995.2060; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; WAGNER FC, 1981, J NEUROSURG, V54, P802, DOI 10.3171/jns.1981.54.6.0802; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Xu J, 1997, BIOCHEM BIOPH RES CO, V235, P394, DOI 10.1006/bbrc.1997.6800; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x; XU J, 1992, J NEUROTRAUM, V9, P245, DOI 10.1089/neu.1992.9.245; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667; Zhang ZY, 1996, J COMP NEUROL, V371, P485	57	166	181	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	AUG 31	1998	59	2					135	142		10.1016/S0169-328X(98)00142-9			8	Neurosciences	Neurosciences & Neurology	123LF	WOS:000076126100002	9729336				2021-06-18	
J	Qureshi, AI; Suarez, JI; Bhardwaj, A; Mirski, M; Schnitzer, MS; Hanley, DF; Ulatowski, JA				Qureshi, AI; Suarez, JI; Bhardwaj, A; Mirski, M; Schnitzer, MS; Hanley, DF; Ulatowski, JA			Use of hypertonic (3%)saline/acetate infusion in the treatment of cerebral edema: Effect on intracranial pressure and lateral displacement of the brain	CRITICAL CARE MEDICINE			English	Article						hypertonic saline; intracranial pressure; cerebral edema; head trauma; intracerebral hemorrhage; cerebral infarction; sodium; osmolality; Glasgow Coma Scale; computed tomography; Glasgow Outcome Scale	CLOSED-HEAD-INJURY; HIGH-DOSE MANNITOL; HEMORRHAGIC-SHOCK; WATER-CONTENT; BARRIER PERMEABILITY; BLOOD-FLOW; SALINE; RESUSCITATION; HYPERTENSION; OSMOLALITY	Objective: To determine the effect of continuous hypertonic (3%) saline/acetate infusion on intracranial pressure (ICP) and lateral displacement of the brain in patients with cerebral edema. Design: Retrospective chart review. Settings: Neurocritical care unit of a university hospital. Patients: Twenty seven consecutive patients with cerebral edema (30 episodes), including patients with head trauma (n = 8), postoperative edema (n = 5), nontraumatic intracranial hemorrhage (n = 8), and cerebral infarction (n = 6). Intervention: Intravenous infusion of 3% saline/acetate to in crease serum sodium concentrations to 145 to 155 mmol/L. Measurements and Main Results: A reduction in mean ICP within the first 12 hrs correlating with an increase in the serum sodium concentration was observed in patients with head trauma (r(2) = .91, p = .03), and postoperative edema (r(2) = .82, p = .06), but not in patients with nontraumatic intracranial hemorrhage or cerebral infarction. In patients with head trauma, the beneficial effect of hypertonic saline on ICP was short-lasting, and after 72 hrs of infusion, four patients required intravenous pentobarbital due to poor ICP control. Among the 21 patients who had a repeat computed tomographic scan within 72 hrs of initiating hypertonic sa line, lateral displacement of the brain was reduced in patients with head trauma (2.8 +/- 1.4 to 1.1 +/- 0.9 [SEM]) and in patients with postoperative edema (3.1 +/- 1.6 to 1.1 +/- 0.7). This effect was not observed in patients with nontraumatic intracranial bleeding or cerebral infarction. The treatment was terminated in three patients due to the development of pulmonary edema, and was terminated in another three patients due to development of diabetes insipidus. Conclusions: Hypertonic saline administration as a 3% infusion appears to be a promising therapy for cerebral edema in patients with head trauma or postoperative edema. Further studies are required to determine the optimal duration of benefit and the specific patient population that is most likely to benefit from this treatment.	Johns Hopkins Med Inst, Div Neurosci Crit Care, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Neurosurg, Baltimore, MD 21205 USA	Qureshi, AI (corresponding author), Johns Hopkins Med Inst, Div Neurosci Crit Care, Baltimore, MD 21205 USA.			Qureshi, Adnan/0000-0003-4962-540X			Archer D, 1996, J NEUROSURG ANESTH, V8, P174; Bullock R, 1995, New Horiz, V3, P448; DAUTERMANN C, 1992, ADV EXP MED BIOL, V317, P731; DEAN AG, 1995, EPI INFO VERSION 6 W; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; GARCIASOLA R, 1991, ACTA NEUROCHIR, V109, P114, DOI 10.1007/BF01403005; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; HANSEN TD, 1994, NEUROSURGERY, V34, P505, DOI 10.1227/00006123-199403000-00017; HARTMANN A, 1990, ACT NEUR S, V51, P168; HARTWELL RC, 1993, NEUROSURGERY, V32, P444, DOI 10.1227/00006123-199303000-00017; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KIRBY RR, 1990, POCKET COMPANION CRI, P28; KOFKE WA, 1993, J NEUROSURG ANESTH, V5, P1; KOHAN DE, 1989, MANUAL MED THERAPEUT, P52; KUROIWA T, 1985, ACTA NEUROPATHOL, V68, P122, DOI 10.1007/BF00688633; MANNINEN PH, 1987, CAN J ANAESTH, V34, P442, DOI 10.1007/BF03014345; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; OBRIEN MD, 1974, ARCH NEUROL-CHICAGO, V30, P461, DOI 10.1001/archneur.1974.00490360037008; OKEN DE, 1994, RENAL FAILURE, V16, P147, DOI 10.3109/08860229409044856; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; ROPPER AH, 1986, NEW ENGL J MED, V314, P953, DOI 10.1056/NEJM198604103141504; Schell RM, 1996, J NEUROSURG ANESTH, V8, P178, DOI 10.1097/00008506-199604000-00022; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; TORNHEIM PA, 1981, J NEUROSURG, V55, P407, DOI 10.3171/jns.1981.55.3.0407; VONBERENBERG P, 1994, ACTA NEUROCHIR, P531; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011; ZORNOW MH, 1990, ACT NEUR S, V51, P324; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	34	166	174	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	1998	26	3					440	446		10.1097/00003246-199803000-00011			7	Critical Care Medicine	General & Internal Medicine	ZA628	WOS:000072384100011	9504569				2021-06-18	
J	Dietrich, WD; Alonso, O; Halley, M; Busto, R				Dietrich, WD; Alonso, O; Halley, M; Busto, R			Delayed posttraumatic brain hyperthermia worsens outcome after fluid percussion brain injury: A light and electron microscopic study in rats	NEUROSURGERY			English	Article						blood-brain barrier; brain trauma; diffuse axonal injury; hyperthermia	DIFFUSE AXONAL INJURY; CNS WHITE MATTER; CEREBRAL-ARTERY OCCLUSION; ISCHEMIC NEURONAL INJURY; SEVERE HEAD-INJURY; MODERATE HYPOTHERMIA; VASCULAR-PERMEABILITY; NEUROFILAMENT SUBUNITS; FOREBRAIN ISCHEMIA; TEMPERATURE	THE MORPHOLOGICAL CONSEQUENCES of delayed posttraumatic brain hyperthermia (39 degrees C) after fluid percussion brain injury were assessed in rats. Sprague-Dawley rats anesthetized with 4% halothane and maintained on a 70:30 mixture of nitrous oxide:oxygen and 0.5% halothane underwent moderate (1.5-2.0 atm) traumatic brain injury with the injury screw positioned parasagittally over the right parieto-occipital cortex. At 24 hours after traumatic brain injury, the rats were reanesthetized and randomized into two groups in which either a 3-hour period of brain normothermia (36.5 degrees C, n = 18) or hyperthermia (39 degrees C, n = 18) was maintained. Sham-operated controls (n = 10) underwent all surgical and temperature-monitoring procedures. After the 3-hour monitoring period, the rats were allowed to survive for 3 days for light microscopic analysis or were injected with the protein tracer horseradish peroxidase and were perfusion-fixed 15 minutes later for light and electron microscopic analysis. At 4 days after traumatic brain injury, delayed posttraumatic hyperthermia (n = 12) significantly increased mortality (47%) and contusion volume (1.7 +/- 0.69 mm(3), mean a standard error of the mean), compared to normothermia (n = 12) (18% mortality and 0.13 +/- 0.21 mm(3) contusion volume) (P < 0.01, analysis of variance). At 15 minutes after the 3-hour hyperthermic period, the area of hemorrhage and horseradish peroxidase extravasation overlying the lateral external capsule was significantly increased (2.52 +/- 0.71 mm(2), mean a standard error of the mean, versus 0.43 +/- 0.16 mm(2)) (P < 0.01), compared to normothermic rats. Examination of toluidine blue-stained plastic sections demonstrated a higher frequency of abnormally swollen myelinated axons per high microscopic field with hyperthermia. For example, numbers of swollen axons within the sixth layer of the right somatosensory cortex, corpus callosum, and internal capsule were 7.3 +/- 1.3, 4.2 +/- 1.4, and 3.0 +/- 1.2 axons (mean +/- standard error of the mean) with normothermia, respectively, compared with 24.7 +/- 12.1, 33.1 +/- 4.2, and 27.3 +/- 3.1 axons with hyperthermia respectively (P < 0.01). An ultrastructural examination of the swollen axons demonstrated a severely thinned myelin sheath containing axoplasm devoid of cytoskeletal components. These experimental results indicate that posttraumatic brain hyperthermia might increase morbidity and mortality in patients with head injury by aggravating axonal and microvascular damage.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101; UNIV MIAMI,SCH MED,NEUROTRAUMA CLIN RES CTR,MIAMI,FL 33101	Dietrich, WD (corresponding author), UNIV MIAMI,SCH MED,DEPT NEUROL D4 5,MIAMI,FL 33101, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27127, NS 30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027127, P50NS030291] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; CHEN H, 1991, NEUROLOGY, V41, P1133, DOI 10.1212/WNL.41.7.1133; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CORTEZ SC, 1989, BRAIN RES, V482, P272; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; DIETRICH WD, 1995, J CEREB BLOOD FLO S1, V15, pS718; DIETRICH WD, IN PRESS CELLULAR MO; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Graham D I, 1983, Acta Neurochir Suppl (Wien), V32, P65; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; HAYASHI N, 1993, ADV NEUROTRAUMA RES, V5, P61; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; LUTZ HA, 1982, HEAD INJURY BASIC CL, P221; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK J T, 1989, Society for Neuroscience Abstracts, V15, P1113; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1992, ROLE OF NEUROTRANSMITTERS IN BRAIN INJURY, P265; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; RANSOM BR, 1992, CAN J PHYSIOL PHARM, V70, pS181, DOI 10.1139/y92-261; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; ROUSSEAUX P, 1980, SURG NEUROL, V14, P459; RUSSELL JM, 1974, J GEN PHYSIOL, V63, P144, DOI 10.1085/jgp.63.2.144; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; STERNAU L, 1991, J CEREB BLOOD FLO S2, V11, pS123; STYS PK, 1992, J CEREBR BLOOD F MET, V12, P977, DOI 10.1038/jcbfm.1992.135; STYS PK, 1991, ANN NEUROL, V30, P375, DOI 10.1002/ana.410300309; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; WAXMAN SG, 1991, TRENDS NEUROSCI, V14, P461, DOI 10.1016/0166-2236(91)90046-W; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Young W, 1988, J Neurotrauma, V5, P219, DOI 10.1089/neu.1988.5.219; ZILLES KJL, 1985, CORTEX BRAIN STEREOT	64	166	174	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	MAR	1996	38	3					533	541		10.1097/00006123-199603000-00023			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	TW572	WOS:A1996TW57200051	8837806				2021-06-18	
J	MADDOCKS, DL; DICKER, GD; SALING, MM				MADDOCKS, DL; DICKER, GD; SALING, MM			THE ASSESSMENT OF ORIENTATION FOLLOWING CONCUSSION IN ATHLETES	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						CONCLUSION; ORIENTATION		The purpose of this study was to investigate the sensitivity of orientation and recent memory questions in the diagnosis of concussion. In a prospective study over 7 consecutive years (1985-1991), all players at a professional Australian Rules Football club who sustained a concussive injury (n = 28) were administered a set of questions evaluating orientation and recent memory. Concussion was diagnosed independently on the basis of loss or disturbance of consciousness and clinical symptoms. A control group of age-matched nonconcussed players was administered the same set of questions. The results showed that items evaluating recently acquired information were more sensitive in the assessment of concussion than standard orientation items. The relative sensitivity of orientation questions must be considered when they are used in the clinical diagnosis of concussion in sport.	MONASH UNIV,DEPT COMMUNITY MED,CLAYTON,VIC 3168,AUSTRALIA	MADDOCKS, DL (corresponding author), UNIV MELBOURNE,FAC MED,DEPT BEHAV SCI,PARKVILLE,VIC 3052,AUSTRALIA.							0	166	168	0	25	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JAN	1995	5	1					32	35		10.1097/00042752-199501000-00006			4	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	QF930	WOS:A1995QF93000006	7614078				2021-06-18	
J	Marchi, N; Bazarian, JJ; Puvenna, V; Janigro, M; Ghosh, C; Zhong, JH; Zhu, T; Blackman, E; Stewart, D; Ellis, J; Butler, R; Janigro, D				Marchi, Nicola; Bazarian, Jeffrey J.; Puvenna, Vikram; Janigro, Mattia; Ghosh, Chaitali; Zhong, Jianhui; Zhu, Tong; Blackman, Eric; Stewart, Desiree; Ellis, Jasmina; Butler, Robert; Janigro, Damir			Consequences of Repeated Blood-Brain Barrier Disruption in Football Players	PLOS ONE			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; NEUROLOGICAL DISORDERS; PROFESSIONAL FOOTBALL; IMPACT BIOMECHANICS; ALZHEIMERS-DISEASE; SERUM S100-BETA; AUTOANTIBODIES; CONCUSSION	The acknowledgement of risks for traumatic brain injury in American football players has prompted studies for sideline concussion diagnosis and testing for neurological deficits. While concussions are recognized etiological factors for a spectrum of neurological sequelae, the consequences of sub-concussive events are unclear. We tested the hypothesis that blood-brain barrier disruption (BBBD) and the accompanying surge of the astrocytic protein S100B in blood may cause an immune response associated with production of auto-antibodies. We also wished to determine whether these events result in disrupted white matter on diffusion tensor imaging (DT) scans. Players from three college football teams were enrolled (total of 67 volunteers). None of the players experienced a concussion. Blood samples were collected before and after games (n = 57); the number of head hits in all players was monitored by movie review and post-game interviews. S100B serum levels and auto-antibodies against S100B were measured and correlated by direct and reverse immunoassays (n = 15 players; 5 games). A subset of players underwent DTI scans pre- and post-season and after a 6-month interval (n = 10). Cognitive and functional assessments were also performed. After a game, transient BBB damage measured by serum S100B was detected only in players experiencing the greatest number of sub-concussive head hits. Elevated levels of auto-antibodies against S100B were elevated only after repeated sub-concussive events characterized by BBBD. Serum levels of S100B auto-antibodies also predicted persistence of MRI-DTI abnormalities which in turn correlated with cognitive changes. Even in the absence of concussion, football players may experience repeated BBBD and serum surges of the potential autoantigen S100B. The correlation of serum S100B, auto-antibodies and DTI changes support a link between repeated BBBD and future risk for cognitive changes.	[Marchi, Nicola; Puvenna, Vikram; Ghosh, Chaitali; Stewart, Desiree; Ellis, Jasmina; Janigro, Damir] Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA; [Puvenna, Vikram; Ghosh, Chaitali; Janigro, Damir] Cleveland Clin, Lerner Coll Med, Dept Neurosurg, Cleveland, OH 44106 USA; [Puvenna, Vikram; Ghosh, Chaitali; Janigro, Damir] Cleveland Clin, Lerner Coll Med, Dept Cell & Mol Med, Cleveland, OH 44106 USA; [Janigro, Mattia; Janigro, Damir] Flocel Inc, Cleveland, OH USA; [Ellis, Jasmina] Baldwin Wallace Coll, Berea, OH USA; [Butler, Robert] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Bazarian, Jeffrey J.; Zhong, Jianhui; Zhu, Tong; Blackman, Eric] Univ Rochester, Med Ctr, Rochester, NY 14642 USA	Janigro, D (corresponding author), Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.	janigrd@ccf.org	Zhong, Jianhui/AAE-6061-2020; Zhu, Tong/A-9402-2011; Marchi, Nicola/J-8607-2016	Blackman, Eric/0000-0002-9405-8435; Janigro, Damir/0000-0003-2165-5826; Marchi, Nicola/0000-0001-9124-0226; Ghosh, Chaitali/0000-0003-4078-0278	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21HD057256]; Flocel, Inc; National Football League-Charities Grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD057256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078307] Funding Source: NIH RePORTER	Support was received from: NINDS R21HD057256; Salary for MJ supported by Flocel, Inc; National Football League-Charities Grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ankeny DP, 2010, TRENDS IMMUNOL, V31, P332, DOI 10.1016/j.it.2010.06.006; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Ben Abdesselam O, 2003, CLIN CHEM, V49, P836, DOI 10.1373/49.5.836; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; D'Andrea MR, 2001, HISTOPATHOLOGY, V38, P120, DOI 10.1046/j.1365-2559.2001.01082.x; Engelhardt B, 2005, TRENDS IMMUNOL, V26, P485, DOI 10.1016/j.it.2005.07.004; Fazio V, 2004, ANN THORAC SURG, V78, P46, DOI 10.1016/j.athoracsur.2003.11.042; Gruden MA, 2007, J NEUROIMMUNOL, V186, P181, DOI 10.1016/j.jneuroim.2007.03.023; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Janigro D, 2012, EPILEPSIA, V53, P26, DOI 10.1111/j.1528-1167.2012.03472.x; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Levin EC, 2010, BRAIN RES, V1345, P221, DOI 10.1016/j.brainres.2010.05.038; Maetzler W, 2011, J ALZHEIMERS DIS, V26, P171, DOI 10.3233/JAD-2011-110221; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Marchi N, 2007, EPILEPSIA, V48, P732, DOI 10.1111/j.1528-1167.2007.00988.x; Marchi N, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-34; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Neuwelt EA, 2011, NAT REV NEUROSCI, V12, P169, DOI 10.1038/nrn2995; Ocwieja KE, 2012, ANN BIOMED ENG, V40, P90, DOI 10.1007/s10439-011-0401-7; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Pardini J, 2011, YOUMANS NEUROLOGICAL, P3380; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Poletaev AB, 2000, AUTOIMMUNITY, V32, P33, DOI 10.3109/08916930008995985; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Sorokina EG, 2010, ZH NEVROL PSIKHIATR, V110, P30; Steiner J, 2010, PSYCHONEUROENDOCRINO, V35, P321, DOI 10.1016/j.psyneuen.2009.07.012; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Storace D, 2010, ARCH NEUROL-CHICAGO, V67, P867, DOI 10.1001/archneurol.2010.137; Taira BR, 2012, ANN EMERG MED, V60, P236, DOI 10.1016/j.annemergmed.2012.04.004; Teasdale TW, 2003, J NEUROL NEUROSUR PS, V74, P933, DOI 10.1136/jnnp.74.7.933; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; Tomkins O, 2007, NEUROBIOL DIS, V25, P367, DOI 10.1016/j.nbd.2006.10.006; Vincent A, 2006, NEURON, V52, P123, DOI 10.1016/j.neuron.2006.09.024; Vincent A, 2011, LANCET NEUROL, V10, P759, DOI 10.1016/S1474-4422(11)70096-5; Vogelbaum MA, 2005, CANCER-AM CANCER SOC, V104, P817, DOI 10.1002/cncr.21220; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	47	165	168	0	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2013	8	3							e56805	10.1371/journal.pone.0056805			11	Multidisciplinary Sciences	Science & Technology - Other Topics	117EP	WOS:000316936100009	23483891	DOAJ Gold, Green Published			2021-06-18	
J	Holland, SK; Vannest, J; Mecoli, M; Jacola, LM; Tillema, JM; Karunanayaka, PR; Schmithorst, VJ; Yuan, W; Plante, E; Byars, AW				Holland, Scott K.; Vannest, Jennifer; Mecoli, Marc; Jacola, Lisa M.; Tillema, Jan-Mendelt; Karunanayaka, Prasanna R.; Schmithorst, Vincent J.; Yuan, Weiliong; Plante, Elena; Byars, Anna W.			Functional MRI of language lateralization during development in children	INTERNATIONAL JOURNAL OF AUDIOLOGY			English	Article						language development; fMRI pediatric speech; perinatal stroke; traumatic brain injury; epilepsy; verb generation; brain development; child language	TEMPORAL-LOBE EPILEPSY; ANTERIOR SPEECH REGION; BRAIN ACTIVATION; SENTENCE COMPREHENSION; INTRACTABLE EPILEPSY; FMRI DATA; DOMINANCE; CORTEX; ORGANIZATION; INFANTS	Changes in the distribution of language function in the brain have been documented from infancy through adulthood. Even macroscopic measures of language lateralization reflect a dynamic process of language development. In this review, we summarize a series of functional MRI studies of language skills in children ages of five to 18 years,both typically-developing children and children with brain injuries or neurological disorders that occur at different developmental stages with different degrees of severity. These studies used a battery of fMRI-compatible language tasks designed to tap sentential and lexical language skills that develop early and later in childhood.	Cincinnati Childrens Res Fdn, Dept Radiol, Cincinnati, OH 45229 USA; Univ Cincinnati, Cincinnati Childrens Res Fdn, Pediat Neuroimaging Res Consortium, Cincinnati, OH 45221 USA; Univ Arizona, Dept Speech Language & Hearing Sci, Tucson, AZ USA	Holland, SK (corresponding author), Cincinnati Childrens Res Fdn, Dept Radiol, ML 5031,3333 Burnet Ave, Cincinnati, OH 45229 USA.	Scott.Holland@cchmc.org	Jacola, Lisa/N-5649-2018	Jacola, Lisa/0000-0003-2698-5816; Holland, Scott/0000-0003-3719-0875	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD038578, R01 HD038578-06A1, R01 HD038578-07, R01 HD038578-05, R01 HD038578-04, R01 HD038578-08, R01-HD044279, R01-HD38578, R01 HD038578-01, R01 HD038578-03, R01 HD038578-02, R43 HD044279] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH073764, R01-MH073764] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23-NS01467] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R43HD044279, R01HD038578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER		Adcock JE, 2003, NEUROIMAGE, V18, P423, DOI 10.1016/S1053-8119(02)00013-7; Ahmad Z, 2003, NEUROLOGY, V60, P1598, DOI 10.1212/01.WNL.0000059865.32155.86; ALBANESE E, 1989, ARCH NEUROL-CHICAGO, V46, P307, DOI 10.1001/archneur.1989.00520390073019; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Balsamo LM, 2002, ARCH NEUROL-CHICAGO, V59, P1168, DOI 10.1001/archneur.59.7.1168; Benson RR, 1999, NEUROLOGY, V52, P798, DOI 10.1212/WNL.52.4.798; Billingsley RL, 2001, BRAIN, V124, P1218, DOI 10.1093/brain/124.6.1218; Binder JR, 2006, NEUROIMAGE, V33, P739, DOI 10.1016/j.neuroimage.2006.06.053; Binder JR, 1997, CLIN NEUROSCI, V4, P87; BLONDER LX, 1991, BRAIN, V114, P1115, DOI 10.1093/brain/114.3.1115; Blumenfeld HK, 2006, BRAIN LANG, V99, P226, DOI 10.1016/j.bandl.2005.07.004; Booth JR, 2004, J COGNITIVE NEUROSCI, V16, P1234, DOI 10.1162/0898929041920496; Booth JR, 2000, DEV NEUROPSYCHOL, V18, P139, DOI 10.1207/S15326942DN1802_1; Braver TS, 2001, CEREB CORTEX, V11, P825, DOI 10.1093/cercor/11.9.825; Brazdil M, 2005, EUR J NEUROL, V12, P268, DOI 10.1111/j.1468-1331.2004.01127.x; BRIDGES A, 1980, J CHILD LANG, V7, P89, DOI 10.1017/S0305000900007042; Brizzolara D, 2002, NEUROPSYCHOLOGIA, V40, P620, DOI 10.1016/S0028-3932(01)00158-0; Byars AW, 2002, J CHILD NEUROL, V17, P885, DOI 10.1177/08830738020170122201; Carrow-Woolfolk E., 1995, ORAL WRITTEN LANGUAG, V1; CHI JG, 1977, ARCH NEUROL-CHICAGO, V34, P346, DOI 10.1001/archneur.1977.00500180040008; Choi Y, 2003, J PSYCHOLINGUIST RES, V32, P197, DOI 10.1023/A:1022400424874; Chou TL, 2006, NEUROIMAGE, V29, P1141, DOI 10.1016/j.neuroimage.2005.09.064; Dehaene-Lambertz G, 2002, SCIENCE, V298, P2013, DOI 10.1126/science.1077066; Desmond JE, 1995, BRAIN, V118, P1411, DOI 10.1093/brain/118.6.1411; EMERSON HF, 1979, J CHILD LANG, V6, P279, DOI 10.1017/S0305000900002300; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FALZI G, 1982, ARCH NEUROL-CHICAGO, V39, P239, DOI 10.1001/archneur.1982.00510160045009; Fenson L., 1993, MACARTHUR COMMUNICAT; Friederici AD, 2003, CEREB CORTEX, V13, P170, DOI 10.1093/cercor/13.2.170; Gaillard WD, 2002, NEUROLOGY, V59, P256, DOI 10.1212/WNL.59.2.256; GERKEN L, 1994, COGNITION, V51, P237, DOI 10.1016/0010-0277(94)90055-8; Hertz-Pannier L, 2000, J RADIOL, V81, P717; HertzPannier L, 1997, NEUROLOGY, V48, P1003, DOI 10.1212/WNL.48.4.1003; Holland SK, 2001, NEUROIMAGE, V14, P837, DOI 10.1006/nimg.2001.0875; Jacola LM, 2006, NEUROPEDIATRICS, V37, P46, DOI 10.1055/s-2006-923934; Janszky J, 2003, BRAIN, V126, P2043, DOI 10.1093/brain/awg193; Jusczyk P. W., 1997, DISCOVERY SPOKEN LAN; KARUNANAYAKA PR, 2007, IN PRESS NEURO REHAB; Karunanayaka PR, 2007, NEUROIMAGE, V34, P349, DOI 10.1016/j.neuroimage.2006.08.028; Kuhl PK, 2006, DEVELOPMENTAL SCI, V9, pF13, DOI 10.1111/j.1467-7687.2006.00468.x; Kuperberg GR, 2000, J COGNITIVE NEUROSCI, V12, P321, DOI 10.1162/089892900562138; Levitsky W, 1968, Trans Am Neurol Assoc, V93, P232; Liegeois F, 2002, NEUROIMAGE, V17, P1861, DOI 10.1006/nimg.2002.1327; MANDEL DR, 1994, COGNITION, V53, P155, DOI 10.1016/0010-0277(94)90069-8; Mandel DR, 1996, COGNITIVE DEV, V11, P181, DOI 10.1016/S0885-2014(96)90002-7; METZNER R, 1999, P ISMRM, V7, P775; Morse S, 1999, Pediatr Rehabil, V3, P139; MULLER RA, 1998, ARCH NEUROL-CHICAGO, P55; Muzik O, 2000, NEUROIMAGE, V12, P538, DOI 10.1006/nimg.2000.0651; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Papanicolaou AC, 2001, J CHILD NEUROL, V16, P241; Pena M, 2003, P NATL ACAD SCI USA, V100, P11702, DOI 10.1073/pnas.1934290100; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; Plante E, 2006, BRAIN LANG, V97, P332, DOI 10.1016/j.bandl.2005.12.004; Price CJ, 2000, J ANAT, V197, P335, DOI 10.1046/j.1469-7580.2000.19730335.x; PUGH K, 2006, DEVELOPMENTAL SCI, V9, P451; Pugh K, 2006, DEVELOPMENTAL SCI, V9, P448, DOI 10.1111/j.1467-7687.2006.00528.x; Ravizza SM, 2004, NEUROIMAGE, V22, P562, DOI 10.1016/j.neuroimage.2004.01.039; Saltzman J, 2002, BRAIN COGNITION, V48, P517, DOI 10.1006/brcg.2001.1409; Schapiro MB, 2004, NEUROREPORT, V15, P2575, DOI 10.1097/00001756-200412030-00003; Schmithorst V.J., 2000, CCHIPS CINCINNATI CH; Schmithorst VJ, 2006, NEUROIMAGE, V31, P1366, DOI 10.1016/j.neuroimage.2006.01.010; Schmithorst VJ, 2001, IEEE T MED IMAGING, V20, P535, DOI 10.1109/42.929619; Schmithorst VJ, 2005, NEUROIMAGE, V25, P444, DOI 10.1016/j.neuroimage.2004.12.006; SCHMITHORST VJ, 2005, NEUROIMAGE; SCHMITHORST VJ, 2006, IN PRESS HUM BRAIN M; Scott SK, 2000, BRAIN, V123, P2400, DOI 10.1093/brain/123.12.2400; Springer JA, 1999, BRAIN, V122, P2033, DOI 10.1093/brain/122.11.2033; Staudt M, 2002, BRAIN, V125, P2222, DOI 10.1093/brain/awf227; Staudt M, 2001, NEUROLOGY, V57, P122, DOI 10.1212/WNL.57.1.122; Szaflarski JP, 2006, ANN NEUROL, V59, P796, DOI 10.1002/ana.20817; Szaflarski JP, 2006, HUM BRAIN MAPP, V27, P202, DOI 10.1002/hbm.20177; Talairach J., 1988, COPLANAR STEREOTAXIC; Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848; Thickbroom GW, 1999, EXP BRAIN RES, V126, P431, DOI 10.1007/s002210050749; Thivard L, 2005, NEUROIMAGE, V24, P841, DOI 10.1016/j.neuroimage.2004.10.001; TILLEMA JM, 2007, IN PRESS BRAIN LANG; WADA JA, 1975, ARCH NEUROL-CHICAGO, V32, P239, DOI 10.1001/archneur.1975.00490460055007; Wexler BE, 1997, MAGN RESON IMAGING, V15, P385, DOI 10.1016/S0730-725X(96)00232-9; Wilke M, 2003, AM J NEURORADIOL, V24, P42; Wilke M, 2002, HUM BRAIN MAPP, V17, P48, DOI 10.1002/hbm.10053; Wilke M, 2006, NEUROIMAGE, V32, P400, DOI 10.1016/j.neuroimage.2006.03.012; Wood AG, 2004, NEUROLOGY, V63, P1035, DOI 10.1212/01.WNL.0000140707.61952.CA; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933; Worthington C, 1997, STEREOT FUNCT NEUROS, V69, P197, DOI 10.1159/000099874; Xiong JH, 1998, HUM BRAIN MAPP, V6, P42, DOI 10.1002/(SICI)1097-0193(1998)6:1<42::AID-HBM4>3.0.CO;2-L; Xiong JH, 1995, HUM BRAIN MAPP, V3, P287, DOI 10.1002/hbm.460030404; Yuan WH, 2006, PEDIATRICS, V118, P971, DOI 10.1542/peds.2006-0467; Yuan WH, 2006, EPILEPSIA, V47, P593, DOI 10.1111/j.1528-1167.2006.00474.x	89	165	168	0	27	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1499-2027	1708-8186		INT J AUDIOL	Int. J. Audiol.	SEP	2007	46	9					533	551		10.1080/14992020701448994			19	Audiology & Speech-Language Pathology; Otorhinolaryngology	Audiology & Speech-Language Pathology; Otorhinolaryngology	222EF	WOS:000250278200008	17828669	Green Accepted			2021-06-18	
J	Flik, K; Lyman, S; Marx, RG				Flik, K; Lyman, S; Marx, RG			American collegiate men's ice hockey - An analysis of injuries	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						ice hockey; athlete exposures; injuries; concussions	CHECKING; PLAYERS; FINLAND; CANADA; HEAD	Background: Reported rates and types of ice hockey injuries have been variable. Ice hockey combines tremendous speeds with aggressive physical play and therefore has great inherent potential for injury. Purpose: To identify rates and determinants of injury in American men's collegiate ice hockey. Study Design: Prospective cohort study. Methods: Data were collected from 8 teams in a Division I athletic conference for 1 season using an injury reporting form specific for ice hockey. Results: There were a total of 113 injuries in 23 096 athlete exposures. Sixty-five percent of injuries occurred during games, although games accounted for only 23% of all exposures. The overall injury rate was 4.9 per 1000 athlete exposures (13.8 per 1000 game athlete exposures and 2.2 per 1000 practice athlete exposures). Collision with an opponent (32.8%) or the boards (18.6%) caused more than half of all injuries. Concussion (18.6%) was the most common injury, followed by knee medial collateral ligament sprains, acromioclavicular joint injuries, and ankle sprains. Conclusions: The risk of injury in men's collegiate ice hockey is much greater during games than during practices. Concussions are a main cause for time lost and remain an area of major concern.	Hosp Special Surg, Foster Ctr Clin Outcome Res, Sports Med & Shoulder Serv, New York, NY 10021 USA	Marx, RG (corresponding author), Hosp Special Surg, Foster Ctr Clin Outcome Res, Sports Med & Shoulder Serv, 535 E 70th St, New York, NY 10021 USA.	marxr@hss.edu					BIASCA N, 1995, UNFALLCHIRURG, V98, P283; BJORKENHEIM JM, 1993, ACTA ORTHOP SCAND, V64, P459; DALY PJ, 1990, SPORTS MED, V10, P122, DOI 10.2165/00007256-199010020-00005; Ferrara MS, 1999, CLIN J SPORT MED, V9, P30; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Groger A, 2001, SPORTVERLETZ SPORTSC, V15, P82, DOI 10.1055/s-2001-19047; Jorgensen U, 1986, Br J Sports Med, V20, P7; LAPRADE RF, 1995, AM J SPORT MED, V23, P773, DOI 10.1177/036354659502300624; LORENTZON R, 1988, AM J SPORT MED, V16, P392, DOI 10.1177/036354658801600415; Molsa J, 2000, AM J SPORT MED, V28, P322; Molsa J, 1997, AM J SPORT MED, V25, P495, DOI 10.1177/036354659702500412; Pashby T, 2001, CLIN J SPORT MED, V11, P211, DOI 10.1097/00042752-200110000-00001; PATTERSSON M, 1993, BRIT J SPORT MED, V27, P251, DOI 10.1136/bjsm.27.4.251; SIM FH, 1987, AM J SPORT MED, V15, P30, DOI 10.1177/036354658701500105; Smith AM, 1997, AM J SPORT MED, V25, P500, DOI 10.1177/036354659702500413; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Sutherland G W, 1976, Am J Sports Med, V4, P264, DOI 10.1177/036354657600400605; Tator CH, 2000, CAN MED ASSOC J, V162, P787; Tegner Y, 1991, Br J Sports Med, V25, P87; VINGER PF, 1976, ARCH OPHTHALMOL-CHIC, V94, P74; Watson RC, 1996, CLIN J SPORT MED, V6, P108, DOI 10.1097/00042752-199604000-00008	22	165	166	0	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2005	33	2					183	187		10.1177/0363546504267349			5	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	890HF	WOS:000226501600002	15701603				2021-06-18	
J	Bellander, BM; Cantais, E; Enblad, P; Hutchinson, P; Nordstrom, CH; Robertson, C; Sahuquillo, J; Smith, M; Stocchetti, N; Ungerstedt, U; Unterberg, A; Olsen, NV				Bellander, BM; Cantais, E; Enblad, P; Hutchinson, P; Nordstrom, CH; Robertson, C; Sahuquillo, J; Smith, M; Stocchetti, N; Ungerstedt, U; Unterberg, A; Olsen, NV			Consensus meeting on microdialysis in neurointensive care	INTENSIVE CARE MEDICINE			English	Article						microdialysis; traumatic brain injury; subarachnoid hemorrhage	INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; BEDSIDE MICRODIALYSIS; BRAIN; GUIDELINES	Background: Microdialysis is used in many European neurointensive care units to monitor brain chemistry in patients suffering subarachnoid hemorrhage (SAH) or traumatic brain injury (TBI). Discussion: We present a consensus agreement achieved at a meeting in Stockholm by a group of experienced users of microdialysis in neurointensive care, defining the use of microdialysis, placement of catheters, unreliable values, chemical markers, and clinical use in SAH and in TBI. Conclusions: As microdialysis is maturing into a clinically useful technique for early detection of cerebral ischemia and secondary brain damage, there is a need to following such definition regarding when and how to use microdialysis after SAH and TBI.	Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; Karolinska Hosp & Inst, Dept Clin Neurosci, Neurosurg Sect, Stockholm, Sweden; Mil Teaching Hosp, Serv Reanimat, Toulon, France; Uppsala Univ, Dept Neurosci, Neurosurg Sect, Uppsala, Sweden; Addenbrookes Hosp, Acad Dept Neurosurg, Cambridge, England; Univ Lund Hosp, Dept Clin Neurosci, S-22185 Lund, Sweden; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Vall Hebron Univ Hosp, Dept Neurosurg, Barcelona, Spain; Natl Hosp Neurol & Neurosurg, Dept Neuroanaesthesia, London WC1N 3BG, England; Osped Maggiore, Policlin IRCCS, Dept Anaesthesia & Intens Care, Milan, Italy; Univ Klinikum Heidelberg, Neurochirurg Klin & Poliklin, Heidelberg, Germany; Univ Copenhagen Hosp, Dept Neuroanaesthesia, DK-2100 Copenhagen, Denmark	Ungerstedt, U (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Nanna Svartz Vag 2, S-17177 Stockholm, Sweden.	urban.ungerstedt@fyfa.ki.se	Stocchetti, Nino/O-7444-2017; Smith, Martin/B-2616-2009; Sahuquillo, Juan/B-3577-2008	Stocchetti, Nino/0000-0003-3250-6834; Sahuquillo, Juan/0000-0003-0713-5875; Olsen, Niels Vidiendal/0000-0001-7724-3981	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G9439390] Funding Source: Medline		Chesnut R M, 1995, New Horiz, V3, P366; Hillered L, 1999, ACT NEUR S, V75, P3; Hutchinson P, 2002, ACT NEUR S, V81, P341; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Siesj_o B K, 1978, BRAIN ENERGY METABOL; Stahl N, 2003, ACTA NEUROL SCAND, V108, P211, DOI 10.1034/j.1600-0404.2003.00095.x; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; UNGERSTEDT U, 1974, B SCHWEIZ AKAD MED, V30, P44; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740	16	165	168	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	DEC	2004	30	12					2166	2169		10.1007/s00134-004-2461-8			4	Critical Care Medicine	General & Internal Medicine	882ZG	WOS:000225978300004	15549254				2021-06-18	
J	Hofman, PAM; Stapert, SZ; van Kroonenburgh, MJPG; Jolles, J; de Kruijk, J; Wilmink, JT				Hofman, PAM; Stapert, SZ; van Kroonenburgh, MJPG; Jolles, J; de Kruijk, J; Wilmink, JT			MR imaging, single-photon emission CT, and neurocognitive performance after mild traumatic brain injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							CLOSED-HEAD-INJURY; CEREBRAL BLOOD-FLOW; TECHNETIUM-99M-HMPAO SPECT; POSTCONCUSSION SYNDROME; COMPUTED-TOMOGRAPHY; AGE; DIFFUSION; SYMPTOMS; SEQUELAE; HEALTH	BACKGROUND AND PURPOSE: Mild traumatic brain injury (mTBI) (Glasgow Coma Scale = 14-15) is a common neurologic disorder and a common cause of neurocognitive deficits in the young population. Most patients recover fully from mTBI, but 15% to 29% of patients have persistent neurocognitive problems. Although a partially organic origin is considered likely, little brain imaging evidence exists for this assumption. The aims of the present study were to establish the prevalence of posttraumatic lesions in mTBI patients on MR images and to assess the relation between these imaging findings and posttraumatic symptoms, Secondly, we explored the value of early posttraumatic single-photon emission CT (SPECT) for the evaluation of mTBI, METHODS: Twenty-one consecutive patients were included in the study. Patients underwent MR examination, technetium-99m hexamethylpropylene amine oxime SPECT, and neurocognitive assessment within 5 days after injury. Neurocognitive follow-up was conducted 2 and 6 months after injury, and MR imaging was repeated after 6 months. Lesion size and brain atrophy were measured on the MR studies. RESULTS: Twelve (57%) of 21 patients had abnormal MR findings, and 11 (61%) of 18 had abnormal SPECT findings. Patients with abnormal MR or SPECT findings had brain atrophy at follow-up. The mean neurocognitive performance of all subjects was within normal range. There was no difference in neurocognitive performance between patients with normal and abnormal MR findings, Patients with abnormal MR findings only showed significantly slower reaction times during a reaction-time task. Seven patients had persistent neurocognitive complaints and one patient met the criteria for a postconcussional syndrome, CONCLUSION: Brain lesions are common after mTBI; up to 77% of patients may have abnormal findings either on MR images or SPECT scans, and these lesions may lead to brain atrophy, The association between hypoperfusion seen on acute SPECT and brain atrophy after 6 months suggests the possibility of (secondary) ischemic brain damage. There is only a weak correlation between neuroimaging findings and neurocognitive outcome.	Univ Hosp Maastricht, Dept Radiol, NL-6202 AZ Maastricht, Netherlands; Univ Hosp Maastricht, Dept Nucl Med, NL-6202 AZ Maastricht, Netherlands; Univ Hosp Maastricht, Dept Neurol, NL-6202 AZ Maastricht, Netherlands; Maastricht Univ, Dept Neurocognit, Maastricht, Netherlands; Maastricht Univ, Dept Neuropsychol & Psychiat, Maastricht, Netherlands; Maastricht Univ, Inst Brain & Behav, Maastricht, Netherlands	Hofman, PAM (corresponding author), Univ Hosp Maastricht, Dept Radiol, POB 5800, NL-6202 AZ Maastricht, Netherlands.						ARVIGO F, 1985, SURG NEUROL, V24, P211, DOI 10.1016/0090-3019(85)90187-9; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; FRANCES CA, 1994, DIAGNOSTIC STAT MANU; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Gean A, 1994, IMAGING HEAD TRAUMA; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Hofman PAM, 1999, MAGN RESON MED, V42, P803, DOI 10.1002/(SICI)1522-2594(199910)42:4<803::AID-MRM24>3.3.CO;2-6; HOUX P, 1991, COGNITIVE AGING HLTH; Houx P. J., 1994, VULNERABLE BRAIN ENV, P25; HOUX PJ, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P353; HOUX PJ, 1993, PERCEPT MOTOR SKILL, V76, P195, DOI 10.2466/pms.1993.76.1.195; ICHISE M, 1994, J NUCL MED, V35, P217; Jacobs A, 1996, J NUCL MED, V37, P1605; Jenkins LW, 1999, BRAIN RES, V817, P132, DOI 10.1016/S0006-8993(98)01237-2; Jolles J, 1995, MAASTRICHT AGING STU; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KRAUS JF, 1989, MILD HEAD INJURY, P8; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Masdeu J C, 1994, J Neuroimaging, V4, P177; MATSUDA H, 1992, EUR J NUCL MED, V19, P195; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; REISS AL, 1999, BRAINIMAGE 3 1; ROPER SN, 1991, J NUCL MED, V32, P1684; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; TEASDALE G, 1974, LANCET, V2, P81; vanBoxtel MPJ, 1996, EXP AGING RES, V22, P363, DOI 10.1080/03610739608254017; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILSON J T L, 1990, Brain Injury, V4, P349; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007	51	165	172	0	9	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	MAR	2001	22	3					441	449					9	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	409VC	WOS:000167405500005	11237964				2021-06-18	
J	D'Ambrosio, R; Maris, DO; Grady, MS; Winn, HR; Janigro, D				D'Ambrosio, R; Maris, DO; Grady, MS; Winn, HR; Janigro, D			Impaired K+ homeostasis and altered electrophysiological properties of post-traumatic hippocampal glia	JOURNAL OF NEUROSCIENCE			English	Article						glial neuronal interactions; ion homeostasis; patch clamp; potassium selective microelectrodes; epilepsy; traumatic brain injury	HYPERPOLARIZATION-ACTIVATED CURRENT; BRAIN INJURY; REACTIVE GLIOSIS; PYRAMIDAL CELLS; HEAD TRAUMA; WHOLE-CELL; RAT; POTASSIUM; ASTROCYTES; SEIZURES	Traumatic brain injury (TBI) can be associated with memory impairment, cognitive deficits, or seizures, all of which can reflect altered hippocampal function. Whereas previous studies have focused on the involvement of neuronal loss in posttraumatic hippocampus, there has been relatively little understanding of changes in ionic homeostasis, failure of which can result in neuronal hyperexcitability and abnormal synchronization. Because glia play a crucial role in the homeostasis of the brain microenvironment, we investigated the effects of TBI on rat hippocampal glia. Using a fluid percussion injury (FPI) model and patch-clamp recordings from hippocampal slices, we have found impaired glial physiology 2 d after FPI. Electrophysiologically, we observed reduction in transient outward and inward K+ currents. To assess the functional consequences of these glial changes, field potentials and extracellular K+ activity were recorded in area CA3 during antidromic stimulation. An abnormal extracellular K+ accumulation was observed in the posttraumatic hippocampal slices, accompanied by the appearance of CA3 afterdischarges. After pharmacological blockade of excitatory synapses and of K+ inward currents, uninjured slices showed the same altered K+ accumulation in the absence of abnormal neuronal activity. We suggest that TBI causes loss of K+ conductance in hippocampal glia that results in the failure of glial K+ homeostasis, which in turn promotes abnormal neuronal function. These findings provide a new potential mechanistic link between traumatic brain injury and subsequent development of disorders such as memory loss, cognitive decline, seizures, and epilepsy.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA	Janigro, D (corresponding author), Cleveland Clin Fdn NB20, 9500 Euclid Ave,Desk S80, Cleveland, OH 44195 USA.			Janigro, Damir/0000-0003-2165-5826	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL051614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS018895] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL051614] Funding Source: Medline; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ES 07033, P30 ES007033] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS018895, NS 18895, NS 51614] Funding Source: Medline		Ammann D., 1986, ION SELECTIVE MICROE; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BALLANYI K, 1987, J PHYSIOL-LONDON, V382, P159, DOI 10.1113/jphysiol.1987.sp016361; Bordey A, 1998, EPILEPSY RES, V32, P286, DOI 10.1016/S0920-1211(98)00059-X; Bordey A, 1997, J NEUROPHYSIOL, V78, P461; BOSMITH RE, 1993, BRIT J PHARMACOL, V110, P343, DOI 10.1111/j.1476-5381.1993.tb13815.x; BURNARD DM, 1990, BRAIN RES, V510, P43, DOI 10.1016/0006-8993(90)90725-Q; Chvatal A, 1997, J NEUROSCI RES, V49, P98, DOI 10.1002/(SICI)1097-4547(19970701)49:1<98::AID-JNR11>3.0.CO;2-0; CHVATAL A, 1998, SOC NEUR ABSTR, V24; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; D'Ambrosio R, 1998, J NEUROSCI, V18, P4425; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EISENMAN G, 1967, GLASS ELECTRODES HYD; FELDBERG W, 1957, J PHYSIOL-LONDON, V139, P408, DOI 10.1113/jphysiol.1957.sp005901; Francke M, 1997, GLIA, V20, P210, DOI 10.1002/(SICI)1098-1136(199707)20:3<210::AID-GLIA5>3.0.CO;2-B; Gasparini S, 1997, PFLUG ARCH EUR J PHY, V435, P99, DOI 10.1007/s004240050488; Gasparini S, 1996, NATO ADV SCI I A-LIF, V289, P63; GLOTZNER FL, 1973, BRAIN RES, V55, P159; GRADY MS, 1996, J NEUROSURG, V13, P599; HAGLUND MM, 1990, J NEUROPHYSIOL, V63, P225; HALLIWELL JV, 1982, BRAIN RES, V250, P71, DOI 10.1016/0006-8993(82)90954-4; Hetherington PA, 1997, BEHAV NEUROSCI, V111, P20, DOI 10.1037/0735-7044.111.1.20; HILLE B, 1993, IONIC CHANNELS EXCIT; Janigro D, 1997, J NEUROSCI, V17, P2813; JENNETT B, 1973, SCOT MED J, V18, P8, DOI 10.1177/003693307301800103; JENSEN MS, 1994, J NEUROPHYSIOL, V71, P831; KRAUS JF, 1987, HEAD INJURY, P1; LEWIS DV, 1977, EPILEPSIA, V18, P499, DOI 10.1111/j.1528-1157.1977.tb04997.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MACCAFERRI G, 1993, J NEUROPHYSIOL, V69, P2129; MacCallum RC, 1996, PSYCHOL METHODS, V1, P130, DOI 10.1037/1082-989X.1.2.130; MacFarlane SN, 1997, J NEUROSCI, V17, P7316; McKhann GM, 1997, J NEUROSCI, V17, P6850; MELTZER SJ, 1899, AM J PHYSIOL, V3, P9; Mi HY, 1996, J NEUROSCI, V16, P2421; NEWMAN EA, 1984, NATURE, V309, P155, DOI 10.1038/309155a0; Newman Eric A., 1995, P717; NICOLSKY BP, 1937, ZH FIZ KHIM, V10, P495; ORKAND RK, 1966, J NEUROPHYSIOL, V29, P788; PEDLEY TA, 1976, EXP NEUROL, V50, P346, DOI 10.1016/0014-4886(76)90010-8; POLLEN D A, 1970, Science (Washington D C), V167, P1252, DOI 10.1126/science.167.3922.1252; RANSOM CB, 1995, J NEUROPHYSIOL, V73, P333; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Schwartzkroin Philip A., 1993, P83; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NRHM, 1996, NEUROLOGICAL SURG, P1834; THOMPSON RF, 1991, NEUROPSYCHOLOGIA, V29, P571, DOI 10.1016/0028-3932(91)90011-V; TRAYNELIS SF, 1988, J NEUROPHYSIOL, V59, P259; Wheal HV, 1998, TRENDS NEUROSCI, V21, P167, DOI 10.1016/S0166-2236(97)01182-X; ZUCKERMANN EC, 1968, EXP NEUROL, V20, P87, DOI 10.1016/0014-4886(68)90126-X	52	165	168	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 15	1999	19	18					8152	8162					11	Neurosciences	Neurosciences & Neurology	235KB	WOS:000082539900047	10479715				2021-06-18	
J	Taylor, HG; Yeates, KO; Wade, SL; Drotar, D; Klein, SK; Stancin, T				Taylor, HG; Yeates, KO; Wade, SL; Drotar, D; Klein, SK; Stancin, T			Influences on first-year recovery from traumatic brain injury in children	NEUROPSYCHOLOGY			English	Article							FAMILY ASSESSMENT DEVICE; PEDIATRIC HEAD-INJURY; PSYCHIATRIC SEQUELAE; ACADEMIC-PERFORMANCE; FOLLOW-UP; VALIDITY; SEVERITY; RELIABILITY; ADOLESCENTS; BEHAVIOR	This study examined recovery over the first year following traumatic brain injury (TBI) in children 6-12 years of age. Forty-two children with severe TBI and 52 with moderate TBI were compared to 58 children with orthopedic injuries. The children and their families were evaluated at a baseline assessment and at 6- and 12-month follow-ups. Findings documented cognitive, achievement, and behavioral sequelae of TBI, with only limited evidence for recovery over the first year postinjury. Outcomes were predicted by preinjury factors, TBI severity, and measures of the postinjury family environment. Some of the sequelae of severe TBI were more marked in the context of higher compared with lower levels of family burden or dysfunction. The findings confirm the need to consider environmental contributions to outcomes of TBI in children.	Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Columbus Childrens Hosp, Columbus, OH USA; Univ Cincinnati, Dept Phys Med & Rehabil, Cincinnati, OH 45221 USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Case Western Reserve Univ, Metrohlth Med Ctr, Cleveland, OH USA	Taylor, HG (corresponding author), Rainbow Babies & Childrens Hosp, Dept Pediat, 11100 Euclid Ave, Cleveland, OH 44106 USA.	hgt2@po.cwru.edu	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Achenbach T.M., 1991, MANUAL TEACHERS REPO; Aiken L.S., 1991, MULTIPLE REGRESSION; ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; BEERY KE, 1989, REVISED ADM SCORING; BENDERSKY M, 1994, DEV PSYCHOL, V30, P184; Bishop DS, 1988, J HEAD TRAUMA REHAB, V3, P16; BRESLAU N, 1995, EPIDEMIOL REV, V17, P96, DOI 10.1093/oxfordjournals.epirev.a036191; BRESLAU N, 1990, ARCH GEN PSYCHIAT, V47, P15; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Brown L., 1990, TEST NONVERBAL INTEL; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHADWICK O, 1985, DEV MED CHILD NEUROL, V27, P69; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P339, DOI 10.1080/01688639408402644; DELIS DC, 1986, CALIFORNIA VERBAL LE; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; DEPOMPEI R, 1989, TOP LANG DISORD, V9, P78, DOI 10.1097/00011363-198903000-00008; DEROGATIS LR, 1982, BRIEF SYMPTOM INVENT, V1; DiSimoni F., 1978, TOKEN TEST CHILDREN; Drotar D, 1997, J PEDIATR PSYCHOL, V22, P149; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FARMER JE, 1996, J INT NEUROPSYCH SOC, V2, P38; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fletcher J M, 1991, Brain Inj, V5, P337, DOI 10.3109/02699059109008106; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; FRANCIS DJ, 1994, NEUROPSYCHOL REV, V4, P199, DOI 10.1007/BF01874892; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KNIGHTS RM, 1980, REVISED SMOOTHED NOR; KOLB B, 1989, AM PSYCHOL, V44, P1203, DOI 10.1037/0003-066X.44.9.1203; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; LEZAK M, 1987, J CLIN EXPT NEUROPSY, V10, P111; LINDGREN S, 1984, PEDIAT ASSESSMENT CO; LYTTON H, 1990, DEV PSYCHOL, V26, P683, DOI 10.1037/0012-1649.26.5.683; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MOOS R, 1988, LIFE STRESSORS SOCIA; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; ROURKE BP, 1977, J ABNORM CHILD PSYCH, V5, P9, DOI 10.1007/BF00915756; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; RUTTER M, 1985, J CHILD PSYCHOL PSYC, V26, P349, DOI 10.1111/j.1469-7610.1985.tb01938.x; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; Sattler J. M., 1992, ASSESSMENT CHILDREN; Semel E., 1987, CELFR CLIN EVALUATIO; Sparrow S., 1984, VINELAND ADAPTIVE BE; Spreen O., 1991, COMPENDIUM NEUROPSYC; STEIN D, 1987, CLIN NEUROPSYCHOLOGY, P13; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; STICE E, 1995, DEV PSYCHOL, V31, P322, DOI 10.1037/0012-1649.31.2.322; Taylor HG, 1998, CHILD NEUROPSYCHOL, V4, P21, DOI 10.1076/chin.4.1.21.3188; TAYLOR HG, 1993, J CLIN CHILD PSYCHOL, V22, P196, DOI 10.1207/s15374424jccp2202_6; TAYLOR HG, 1995, TRAUMATIC HEAD INJUR, P88; TAYLOR HG, 1992, CLIN NEUROPSYCHOL, V6, P259; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V3, P1; TEASDALE G, 1974, LANCET, V2, P81; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; WAALAND P, 1991, NEUROPSYCHOL REHABIL, V1, P19; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Walker H. M., 1988, WALKERMCCONNELL SCAL; WECHSLER D, 1991, WISCIII WECHSLER INT; WOODCOCK RW, 1989, WOODCOCKJOHNSON TEST; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; YEATES KO, 1994, CLIN NEUROPSYCHOL, V8, P91, DOI 10.1080/13854049408401546; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763	86	165	165	0	11	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JAN	1999	13	1					76	89		10.1037/0894-4105.13.1.76			14	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	162HA	WOS:000078338800010	10067779				2021-06-18	
J	Wada, K; Chatzipanteli, K; Kraydieh, S; Busto, R; Dietrich, WD				Wada, K; Chatzipanteli, K; Kraydieh, S; Busto, R; Dietrich, WD			Inducible nitric oxide synthase expression after traumatic brain injury and neuroprotection with aminoguanidine treatment in rats	NEUROSURGERY			English	Article						aminoguanidine; fluid-percussion brain injury; inducible nitric oxide synthase; nitric oxide; nitric oxide inhibitor; rat	FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; SMOOTH-MUSCLE CELLS; L-ARGININE; HEAD-INJURY; ENDOTHELIAL-CELLS; ARTERY OCCLUSION; RELAXING FACTOR; GLIAL-CELLS; INDUCTION	OBJECTIVE: We investigated the time course of inducible nitric oxide synthase (iNOS) enzymatic activity and immunocytochemical localization of iNOS expression after traumatic brain injury (TBI), as well as the possible role of iNOS in the pathogenesis of TBI. METHODS: Male Sprague-Dawley rats were anesthetized and underwent moderate parasagittal fluid-percussion brain injury. Rats were decapitated 5 minutes, 6 hours, 1 day, 3 days, 7 days, or 14 days later, and iNOS enzymatic activities were measured (n = 6-8). To determine whether nitric oxide produced by iNOS contributed to the histopathological consequences of TBI, inhibition of iNOS activity using aminoguanidine (intraperitoneal injections of 100 mg/kg aminoguanidine [n = 9] or vehicle [n = 8], twice each day) was conducted for 3 days. RESULTS: Significantly elevated iNOS activity was detected at 3 days (276.8 +/- 72.3% of contralateral value, means +/- standard errors; P < 0.05), and the most robust increase occurred 7 days after TBI (608.0 +/- 127.0%, P < 0.01) in the injured parietal cerebral cortex. Immunostaining for iNOS and glial fibrillary acidic protein, at 3 and 7 days after TBI, revealed that the major cellular sources of iNOS expression were cortical Layer 1 astrocytes and macrophages within the subarachnoid space. Administration of aminoguanidine did not reduce contusion volume significantly; however, treatment reduced total cortical necrotic neuron counts (1367.6 +/- 210.3; P < 0.01, compared with vehicle, 2808.5 +/- 325.1). CONCLUSION: These data indicate that iNOS is expressed after moderate parasagittal fluid-percussion brain injury, in a time-dependent manner, and that inhibition of iNOS synthesis improves histopathological outcomes. Thus, inhibition of iNOS activation may represent a potential therapeutic strategy for the treatment of TBI.	Univ Miami, Sch Med, Dept Neurol D45, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Sch Med, Neurotrauma Res Ctr, Miami, FL 33136 USA; Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 359, Japan	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Dept Neurol D45, POB 016960, Miami, FL 33101 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1996, CELL PHYSL, V40, pC1424; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bonmann E, 1997, NEUROSCI LETT, V230, P109, DOI 10.1016/S0304-3940(97)00485-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DAWSON DA, 1992, NEUROSCI LETT, V142, P151, DOI 10.1016/0304-3940(92)90361-A; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ESTEVEZ AG, 1995, J NEUROCHEM, V65, P1543; FLEMING I, 1991, EUR J PHARMACOL, V200, P375, DOI 10.1016/0014-2999(91)90602-M; GALEA E, 1994, J NEUROSCI RES, V37, P406, DOI 10.1002/jnr.490370313; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Iadecola C, 1996, STROKE, V27, P1373, DOI 10.1161/01.STR.27.8.1373; Iadecola C, 1995, AM J PHYSIOL, V268, P286; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; Kong LY, 1996, BRAIN RES, V729, P102, DOI 10.1016/0006-8993(96)00417-9; Luth HJ, 1997, NEUROREPORT, V8, P2321; Merrill JE, 1997, J NEUROSCI RES, V48, P372, DOI 10.1002/(SICI)1097-4547(19970515)48:4<372::AID-JNR9>3.3.CO;2-5; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; MOORE IE, 1987, NEUROPATH APPL NEURO, V13, P219, DOI 10.1111/j.1365-2990.1987.tb00185.x; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829; Moskowitz MA, 1996, ADV NEUROL, V71, P365; NAGAFUJI T, 1992, NEUROSCI LETT, V147, P159, DOI 10.1016/0304-3940(92)90584-T; NATHAN C, 1992, FASEB J, V6, P3051; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PAAKKARI I, 1995, ANN MED, V27, P369, DOI 10.3109/07853899509002590; PALMER RMJ, 1992, BRIT J PHARMACOL, V105, P11, DOI 10.1111/j.1476-5381.1992.tb14202.x; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RAVICHANDRAN LV, 1995, AM J PHYSIOL-HEART C, V268, pH2216; RENGASAMY A, 1993, MOL PHARMACOL, V44, P124; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SIMMONS ML, 1993, EUR J NEUROSCI, V5, P825, DOI 10.1111/j.1460-9568.1993.tb00934.x; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; SUZUKI S, 1995, J NEUROSURG, V83, P862, DOI 10.3171/jns.1995.83.5.0862; Szabo C, 1995, Adv Pharmacol, V34, P113; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; WALLACE MN, 1994, NEUROSCIENCE, V59, P905, DOI 10.1016/0306-4522(94)90294-1; XIA Q, 1994, J LEUKOCYTE BIOL, V56, P576; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Yakovlev A., 1994, Society for Neuroscience Abstracts, V20, P423; YOSHIDA T, 1995, NEUROSCI LETT, V194, P214, DOI 10.1016/0304-3940(95)11752-I; Young W, 1988, J Neurotrauma, V5, P219, DOI 10.1089/neu.1988.5.219; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; ZILLES L, 1985, CORTEX BRAIN STEREOT	72	165	170	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0148-396X			NEUROSURGERY	Neurosurgery	DEC	1998	43	6					1427	1436		10.1097/00006123-199812000-00096			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	141LP	WOS:000077145700086	9848857				2021-06-18	
J	Colicos, MA; Dixon, CE; Dash, PK				Colicos, MA; Dixon, CE; Dash, PK			Delayed, selective neuronal death following experimental cortical impact injury in rats: Possible role in memory deficits	BRAIN RESEARCH			English	Article						cortical impact; cell death; hippocampus; spatial memory	TRAUMATIC BRAIN INJURY; TRANSIENT FOREBRAIN ISCHEMIA; FLUID-PERCUSSION MODEL; HEAD-INJURY; DAMAGE; NECROSIS; LESIONS; HIPPOCAMPUS; MONKEYS; GERBIL	Clinical and experimental studies show that loss of neurons in the hippocampus and/or the entorhinal cortex can impede formation and storage of spatial memory. Using a controlled cortical impact model of traumatic brain injury (TBI) in rats, we have examined the temporal and spatial pattern of neuronal death using silver impregnation and cresyl violet staining. Dystrophic neurons can be detected in the dentate gyrus, and the CAI and CA3 subfields of the hippocampus for up to 2 weeks following injury. These dystrophic cells appeared shrunken and possessed features of apoptosis. Areas containing the dystrophic cells suffer substantial cell loss as demonstrated by thinning of the neuronal layers. Dystrophic cells are also found in the amygdala, entorhinal and piriform cortices, thalamic and hypothalamic regions, and surrounding the contusion site. The loss of these cells may contribute to the memory deficits observed following TBI.	UNIV TEXAS,HLTH SCI CTR,DEPT ANAT & NEUROBIOL,HOUSTON,TX 77225; UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77225					NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH49962] Funding Source: Medline		AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; AUER RN, 1988, ANN NEUROL, V24, P699, DOI 10.1002/ana.410240602; BABB L, 1991, ADV NEUROL, V44, P949; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; CRAIN BJ, 1988, NEUROSCIENCE, V27, P387; DASH PK, 1995, J NEUROSCI, V15, P2030; DECKWERTH TL, 1993, ANN NY ACAD SCI, V679, P121, DOI 10.1111/j.1749-6632.1993.tb18293.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, 1996, IN PRESS J NEUROTRAU; GALLYAS F, 1980, STAIN TECHNOL, V55, P299, DOI 10.3109/10520298009067258; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P386, DOI 10.1007/BF00713530; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GRUENTHAL M, 1986, EXP NEUROL, V93, P621, DOI 10.1016/0014-4886(86)90181-0; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; LEVIN HS, 1992, J NEUROTRAUM, pS359; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; MEUNIER M, 1993, J NEUROSCI, V13, P5418; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NEVANDER G, 1985, ANN NEUROL, V18, P281, DOI 10.1002/ana.410180303; OLNEY JW, 1983, BRAIN RES BULL, V10, P699, DOI 10.1016/0361-9230(83)90038-2; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; SLOVITER RS, 1993, J COMP NEUROL, V330, P337, DOI 10.1002/cne.903300305; SLOVITER RS, 1993, J COMP NEUROL, V330, P624; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SUZUKI WA, 1993, J NEUROSCI, V13, P2430; WARNER MA, 1991, J CEREBR BLOOD F MET, V11, P600, DOI 10.1038/jcbfm.1991.110	38	165	170	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 11	1996	739	1-2					111	119		10.1016/S0006-8993(96)00819-0			9	Neurosciences	Neurosciences & Neurology	VV253	WOS:A1996VV25300014	8955931				2021-06-18	
J	Metz, C; Holzschuh, M; Bein, T; Woertgen, C; Frey, A; Frey, I; Taeger, K; Brawanski, A				Metz, C; Holzschuh, M; Bein, T; Woertgen, C; Frey, A; Frey, I; Taeger, K; Brawanski, A			Moderate hypothermia in patients with severe head injury: Cerebral and extracerebral effects	JOURNAL OF NEUROSURGERY			English	Article						moderate hypothermia; head injury; secondary brain injury; intracranial pressure; cerebral ischemia; side effect	VENOUS OXYGEN-SATURATION; SEVERE BRAIN INJURY; BLOOD-FLOW; MILD HYPOTHERMIA; METABOLIC-RATE; ISCHEMIA; COAGULOPATHY; TEMPERATURE; PRESSURE; LACTATE	Cerebral and extracerebral effects of moderate hypothermia (core temperature 32.5 degrees C-33.0 degrees C) were prospectively studied in 10 patients with severe closed head injury (Glasgow Coma Scale score < 7) in the intensive care unit of a university hospital. Hypothermia was induced by cooling the patient's body surface with water-circulating blankets. Before cooling, a conventional intracranial pressure (ICP) reduction therapy was applied, which remained unchanged throughout the study. Cerebral blood flow (CBF), cerebral metabolic rates for oxygen (CMRO(2)) and lactate (CMRL), and ICP were simultaneously measured prior to inducing hypothermia, after obtaining hypothermia. after 24 hours of hypothermia, and after rewarming. With respect to extracerebral effects, supplemental investigations were conducted 24 and 72 hours after rewarming. The median delay between injury and induction of hypothermia was 16 hours. Hypothermia reduced CMRO(2) by 45% (p < 0.01), whereas CBF did not change significantly. Before cooling, six patients had elevated CMRL indicating cerebral ischemia. Cooling normalized CMRL in all patients (p < 0.01). The intracranial hypertension present prior to cooling declined markedly during hypothermia (p < 0.01) without significant rebound effects after rewarming. Cardiac index decreased by 18% after hypothermia was reached (p < 0.05), recovered at 24 hours of hypothermia, and surpassed baseline values after rewarming. Platelet counts dropped continuously up to 24 hours after rewarming (p < 0.01). Plasma coagulation tests did not show significant worsening. Creatinine clearance decreased during cooling (p < 0.01) and recovered by 24 hours after rewarming. Twenty-four hours after cooling had begun, eight patients had elevated serum lipase activity (p < 0.01) and four of them acquired pancreatitis. Rewarming normalized both pancreatic alterations. Seven patients made a good recovery; one survived severely disabled; and two patients died. Moderate hypothermia is effective in preventing secondary brain damage while reducing cerebral ischemia. However, there are potentially hazardous side effects that require additional monitoring.	UNIV REGENSBURG HOSP,DEPT ANESTHESIA,REGENSBURG,GERMANY; UNIV REGENSBURG HOSP,DEPT NEUROSURG,REGENSBURG,GERMANY							BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOELHOUWER RU, 1987, CRIT CARE MED, V15, P310, DOI 10.1097/00003246-198704000-00006; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CARDELL M, 1991, J NEUROCHEM, V57, P1814, DOI 10.1111/j.1471-4159.1991.tb06387.x; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHIOLERO RL, 1989, CRIT CARE MED, V17, P328, DOI 10.1097/00003246-198904000-00006; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CRONE C, 1970, Acta Physiologica Scandinavica, V80, p47A, DOI 10.1111/j.1748-1716.1970.tb04870.x; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DUGUID H, 1961, LANCET, V2, P1213; FERRARA A, 1990, AM J SURG, V160, P515, DOI 10.1016/S0002-9610(05)81018-9; FOULIS AK, 1982, J CLIN PATHOL, V35, P1244, DOI 10.1136/jcp.35.11.1244; Foulkes MA, 1991, J NEUROSURG S, V75, P8, DOI 10.3171/sup.1991.75.1s.00s8; FRERICHS KU, 1990, STROKE, V21, P614, DOI 10.1161/01.STR.21.4.614; Gibbs EL, 1942, J BIOL CHEM, V144, P325; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GUBLER KD, 1994, J TRAUMA, V36, P847, DOI 10.1097/00005373-199406000-00015; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HEISTAD DD, 1972, J CLIN INVEST, V51, P1469, DOI 10.1172/JCI106943; HERVEY GR, 1973, P ROY SOC MED, V66, P1053, DOI 10.1177/003591577306601034; HIRANO T, 1992, BRIT J SURG, V79, P803, DOI 10.1002/bjs.1800790832; HOOTON TM, 1981, AM J MED, V70, P960, DOI 10.1016/0002-9343(81)90562-3; INAO S, 1989, J NEUROSURG, V69, P736; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENNETT B, 1975, LANCET, V1, P480; JEWITT D, 1974, LANCET, V2, P363; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; LUCE JM, 1986, CHEST, V89, P864, DOI 10.1378/chest.89.6.864; LUNA GK, 1987, J TRAUMA, V27, P1014, DOI 10.1097/00005373-198709000-00010; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; MACLEAN D, 1973, BMJ-BRIT MED J, V4, P757, DOI 10.1136/bmj.4.5895.757; MARBACH EP, 1967, CLIN CHEM, V13, P314; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Marshall SB, 1991, J NEUROSURG S, V75, P14; MCNICOL NW, 1964, BRIT MED J, V1, P19; MEYER DM, 1990, J SURG RES, V48, P61, DOI 10.1016/0022-4804(90)90147-T; MICHENFELDER JD, 1968, ANESTHESIOLOGY, V29, P1107, DOI 10.1097/00000542-196811000-00005; MICHENFELDER JD, 1992, J CEREBR BLOOD F MET, V12, P877, DOI 10.1038/jcbfm.1992.120; MORALES P, 1957, ANN SURG, V145, P488, DOI 10.1097/00000658-195704000-00005; NEMOTO EM, 1993, J NEUROSURG ANESTH, V5, P290; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OLDENDORF WH, 1971, EUR NEUROL, V6, P49, DOI 10.1159/000114465; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; PATT A, 1988, SURG CLIN N AM, V68, P775; RAMSAY MAE, 1989, BRIT MED J, V298, P656; Rappaport Z H, 1981, Prog Neurol Surg, V10, P1, DOI 10.1159/000384765; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; RUPP SM, 1986, ANESTHESIA, P1995; SEGAR WE, 1956, AM J PHYSIOL, V185, P528; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; STEEN PA, 1980, ANESTHESIOLOGY, V52, P224, DOI 10.1097/00000542-198003000-00007; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; TEASDALE G, 1974, LANCET, V2, P81; TODD MM, 1992, ANESTHESIOLOGY, V76, P161; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; ZIMMER R, 1975, AM J PHYSIOL, V229, P432	65	165	183	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	1996	85	4					533	541		10.3171/jns.1996.85.4.0533			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	VJ247	WOS:A1996VJ24700001	8814152				2021-06-18	
J	WOODRING, JH; LEE, C				WOODRING, JH; LEE, C			LIMITATIONS OF CERVICAL RADIOGRAPHY IN THE EVALUATION OF ACUTE CERVICAL TRAUMA	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							RADIOLOGIC EVALUATION; SPINE	We retrospectively reviewed the medical records and cervical films, computed tomographic (CT) scans, and tomographic studies of 216 consecutive patients with cervical injuries. A trauma series of roentgenograms-a cross-table lateral (CTL), a supine anteroposterior, and an open-mouth odontoid view-was performed in 100%; CT scanning was performed in 100%; and tomography was done in 9% of cases. We determined what percentage of the patients were asymptomatic initially in the emergency department; the total numbers of fractures, subluxations, and dislocations of the cervical spine in these patients; and what percentage of the cervical injuries were not detected with the plain films. Of the 216 patients in the series, 188 (87%) had known signs or symptoms of cervical injury; however, 28 (13%) of the patients were initially asymptomatic with no neurologic deficit. Of these 28, 17 were intoxicated or had mild closed head injuries; however, in 11 (5%) there was no clinical clue to their cervical injury other than a known injury mechanism. Prospectively, 67% of the fractures and 45% of the subluxations and dislocations were not detected by the CTL films, and 32% of the patients, over half of whom had unstable cervical injuries, were falsely identified as having normal spines. Prospectively, the trauma series improved the sensitivity of plain films for detecting cervical injuries but still did not detect 61% of the fractures and 36% of the subluxations and dislocations, and falsely identified 23% of the patients, half of whom had unstable cervical injuries. as having normal cervical spines. We conclude that cervical roentgenography cannot be relied upon either to definitively determine the true extent and severity of cervical injuries in trauma victims or to exclude cervical injuries in these patients. In trauma victims for whom the plain films are positive for injury and in those in whom the plain films are negative for injury but there is a high clinical suspicion of cervical injury, CT scanning should be liberally employed for a more definitive evaluation of the cervical spine.		WOODRING, JH (corresponding author), UNIV KENTUCKY,MED CTR,DEPT DIAGNOST RADIOL,800 ROSE ST,LEXINGTON,KY 40536, USA.						ACHESON MB, 1987, AM J ROENTGENOL, V148, P1179, DOI 10.2214/ajr.148.6.1179; BOROCK EC, 1991, J TRAUMA, V31, P1001, DOI 10.1097/00005373-199107000-00021; MAULL KI, 1977, SOUTHERN MED J, V70, P477, DOI 10.1097/00007611-197704000-00033; MCKEE TR, 1990, J TRAUMA, V30, P623, DOI 10.1097/00005373-199005000-00018; MILLER DL, 1991, AM J ROENTGENOL, V156, P638, DOI 10.2214/ajr.156.3.1899772; MIRVIS SE, 1989, RADIOLOGY, V170, P831, DOI 10.1148/radiology.170.3.2492671; ROBERGE RJ, 1988, J TRAUMA, V28, P784, DOI 10.1097/00005373-198806000-00010; ROSS SE, 1987, J TRAUMA, V27, P1055, DOI 10.1097/00005373-198709000-00017; SHAFFER MA, 1981, ANN EMERG MED, V10, P508, DOI 10.1016/S0196-0644(81)80004-2; VANDEMARK RM, 1990, AM J ROENTGENOL, V155, P465, DOI 10.2214/ajr.155.3.2117342; WHITE A A, 1976, Spine, V1, P15, DOI 10.1097/00007632-197603000-00003; 1989, ADV TRAUMA LIFE SUPP	12	165	165	0	5	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	1993	34	1					32	39		10.1097/00005373-199301000-00006			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	KP908	WOS:A1993KP90800006	8437193				2021-06-18	
J	Zhou, YX; Milham, MP; Lui, YW; Miles, L; Reaume, J; Sodickson, DK; Grossman, RI; Ge, YL				Zhou, Yongxia; Milham, Michael P.; Lui, Yvonne W.; Miles, Laura; Reaume, Joseph; Sodickson, Daniel K.; Grossman, Robert I.; Ge, Yulin			Default-Mode Network Disruption in Mild Traumatic Brain Injury	RADIOLOGY			English	Article							INDEPENDENT COMPONENT ANALYSIS; STATE FUNCTIONAL CONNECTIVITY; STRUCTURAL CONNECTIVITY; RESTING BRAIN; UNITED-STATES; CONSCIOUSNESS; DYSFUNCTION; IMPAIRMENT; DISORDERS; ATTENTION	Purpose: To investigate the integrity of the default-mode network (DMN) by using independent component analysis (ICA) methods in patients shortly after mild traumatic brain injury (MTBI) and healthy control subjects, and to correlate DMN connectivity changes with neurocognitive tests and clinical symptoms. Materials and Methods: This study was approved by the institutional review board and complied with HIPAA regulations. Twenty-three patients with MTBI who had posttraumatic symptoms shortly after injury (<2 months) and 18 age-matched healthy control subjects were included in this study. Resting-state functional magnetic resonance imaging was performed at 3 T to characterize the DMN by using ICA methods, including a single-participant ICA on the basis of a comprehensive template from core seeds in the posterior cingulate cortex (PCC) and medial prefrontal cortex (MPFC) nodes. ICA z images of DMN components were compared between the two groups and correlated with neurocognitive tests and clinical performance in patients by using Pearson and Spearman rank correlation. Results: When compared with the control subjects, there was significantly reduced connectivity in the PCC and parietal regions and increased frontal connectivity around the MPFC in patients with MTBI (P < .01). These frontoposterior opposing changes within the DMN were significantly correlated (r = -0.44, P = .03). The reduced posterior connectivity correlated positively with neurocognitive dysfunction (eg, cognitive flexibility), while the increased frontal connectivity correlated negatively with posttraumatic symptoms (ie, depression, anxiety, fatigue, and postconcussion syndrome). Conclusion: These results showed abnormal DMN connectivity patterns in patients with MTBI, which may provide insight into how neuronal communication and information integration are disrupted among DMN key structures after mild head injury. (C) RSNA, 2012	[Zhou, Yongxia; Lui, Yvonne W.; Miles, Laura; Reaume, Joseph; Sodickson, Daniel K.; Grossman, Robert I.; Ge, Yulin] NYU, Sch Med, Dept Radiol, Ctr Biomed Imaging, New York, NY 10016 USA; [Milham, Michael P.] NYU, Ctr Child Study, Phyllis Green & Randolph Cowen Inst Pediat Neuros, New York, NY 10016 USA	Ge, YL (corresponding author), NYU, Sch Med, Dept Radiol, Ctr Biomed Imaging, 660 1st Ave,4th Floor, New York, NY 10016 USA.	yulin.ge@nyumc.org	Milham, Michael P/K-9501-2014; Ge, Yulin/L-7052-2019; Lang, Steven/AAE-8102-2021; Ge, Yulin/D-9060-2019; Milham, Michael P./Y-3160-2019	Lang, Steven/0000-0003-1669-9146; Ge, Yulin/0000-0002-2320-6031; Zhou, Yongxia (Sharon)/0000-0002-4931-2318; Sodickson, Daniel/0000-0002-2436-4664	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS039135, NS039135-08S1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039135] Funding Source: NIH RePORTER	This research was supported by the National Institutes of Health (grants R01 NS039135 and NS039135-08S1).	American Psychiatric Association, 2010, DIAGN STAT MAN MENT; Andrews-Hanna JR, 2010, NEURON, V65, P550, DOI 10.1016/j.neuron.2010.02.005; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Beckmann CF, 2005, NEUROIMAGE, V25, P294, DOI 10.1016/j.neuroimage.2004.10.043; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; Bennett CM, 2009, SOC COGN AFFECT NEUR, V4, P417, DOI 10.1093/scan/nsp053; Boly M, 2008, ANN NY ACAD SCI, V1129, P119, DOI 10.1196/annals.1417.015; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cauda F, 2009, J NEUROL NEUROSUR PS, V80, P429, DOI 10.1136/jnnp.2007.142349; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cordes D, 2001, AM J NEURORADIOL, V22, P1326; Daniels JK, 2010, J PSYCHIATR NEUROSCI, V35, P258, DOI 10.1503/jpn.090010; De Luca M, 2006, NEUROIMAGE, V29, P1359, DOI 10.1016/j.neuroimage.2005.08.035; Delis DC, 2000, CALIFORNIA VERBAL LE; DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius MD, 2007, BIOL PSYCHIAT, V62, P429, DOI 10.1016/j.biopsych.2006.09.020; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johnson MK, 2006, SOC COGN AFFECT NEUR, V1, P56, DOI 10.1093/scan/nsl004; Jones DT, 2011, NEUROLOGY, V77, P1524, DOI 10.1212/WNL.0b013e318233b33d; Kelly RE, 2010, INT J BIOMED IMAGING, V2010, DOI 10.1155/2010/868976; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lee TW, 1999, NEURAL COMPUT, V11, P417, DOI 10.1162/089976699300016719; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lux WE, 2007, J REHABIL RES DEV, V44, P951, DOI 10.1682/JRRD.2007.01.0009; Ma LS, 2007, MAGN RESON IMAGING, V25, P47, DOI 10.1016/j.mri.2006.09.032; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Meyers J., 1995, REY COMPLEX FIGURE T; Petchprapai Nutthita, 2007, J Neurosci Nurs, V39, P260; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Reitan R., 1992, TRIAL MAKING TEST MA; Rocca MA, 2010, NEUROLOGY, V74, P1252, DOI 10.1212/WNL.0b013e3181d9ed91; Rombouts SARB, 1997, AM J NEURORADIOL, V18, P1317; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shulman GL, 1997, HUM BRAIN MAPP, V5, P317, DOI 10.1002/(SICI)1097-0193(1997)5:4<317::AID-HBM19>3.0.CO;2-A; Silver JM., 2011, TXB TRAUMATIC BRAIN, V2nd ed.; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smith A., 1973, SYMBOL DIGIT MODALIT; Sosin DM, 1996, BRAIN INJURY, V10, P47; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Uddin LQ, 2009, HUM BRAIN MAPP, V30, P625, DOI 10.1002/hbm.20531; van de Ven VG, 2004, HUM BRAIN MAPP, V22, P165, DOI 10.1002/hbm.20022; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Vialatte FB, 2008, BIOL CYBERN, V98, P295, DOI 10.1007/s00422-008-0210-8; Wechsler D, 1985, WECHSLER ADULT INTEL; World Health Organization, 2007, INT CLASS DIS REL HL; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Zhang DY, 2010, NAT REV NEUROL, V6, P15, DOI 10.1038/nrneurol.2009.198; Zhang ZQ, 2010, BRAIN RES, V1323, P152, DOI 10.1016/j.brainres.2010.01.042; Zhao XH, 2007, EUR J RADIOL, V63, P373, DOI 10.1016/j.ejrad.2007.02.006; Zuo XN, 2010, NEUROIMAGE, V49, P2163, DOI 10.1016/j.neuroimage.2009.10.080	69	164	172	0	20	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	DEC	2012	265	3					882	892		10.1148/radiol.12120748			11	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	041SA	WOS:000311420300026	23175546	Green Published, Bronze			2021-06-18	
J	Galetta, KM; Barrett, J; Allen, M; Madda, F; Delicata, D; Tennant, AT; Branas, CC; Maguire, MG; Messner, LV; Devick, S; Galetta, SL; Balcer, LJ				Galetta, K. M.; Barrett, J.; Allen, M.; Madda, F.; Delicata, D.; Tennant, A. T.; Branas, C. C.; Maguire, M. G.; Messner, L. V.; Devick, S.; Galetta, S. L.; Balcer, L. J.			The King-Devick test as a determinant of head trauma and concussion in boxers and MMA fighters	NEUROLOGY			English	Article							NATIONAL FOOTBALL LEAGUE; BRAIN-INJURY; ATHLETIC CONCUSSION; PLAY; ENCEPHALOPATHY; RELIABILITY; IMPAIRMENT; MANAGEMENT; RETURN; RISK	Objective: Sports-related concussion has received increasing attention as a cause of short-and long-term neurologic symptoms among athletes. The King-Devick (K-D) test is based on measurement of the speed of rapid number naming (reading aloud single-digit numbers from 3 test cards), and captures impairment of eye movements, attention, language, and other correlates of suboptimal brain function. We investigated the K-D test as a potential rapid sideline screening for concussion in a cohort of boxers and mixed martial arts fighters. Methods: The K-D test was administered prefight and postfight. The Military Acute Concussion Evaluation (MACE) was administered as a more comprehensive but longer test for concussion. Differences in postfight K-D scores and changes in scores from prefight to postfight were compared for athletes with head trauma during the fight vs those without. Results: Postfight K-D scores (n = 39 participants) were significantly higher (worse) for those with head trauma during the match (59.1 +/- 7.4 vs 41.0 +/- 6.7 seconds, p < 0.0001, Wilcoxon rank sum test). Those with loss of consciousness showed the greatest worsening from prefight to postfight. Worse postfight K-D scores (r(s) = -0.79, p = 0.0001) and greater worsening of scores (r(s) = 0.90, p < 0.0001) correlated well with postfight MACE scores. Worsening of K-D scores by >= 5 seconds was a distinguishing characteristic noted only among participants with head trauma. High levels of test-retest reliability were observed (intraclass correlation coefficient 0.97 [95% confidence interval 0.90-1.0]). Conclusions: The K-D test is an accurate and reliable method for identifying athletes with head trauma, and is a strong candidate rapid sideline screening test for concussion. Neurology (R) 2011; 76:1456-1462	[Galetta, K. M.; Barrett, J.; Galetta, S. L.; Balcer, L. J.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Maguire, M. G.; Galetta, S. L.; Balcer, L. J.] Univ Penn, Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA; [Maguire, M. G.] Univ Penn, Sch Med, Dept Biostat, Philadelphia, PA 19104 USA; [Branas, C. C.; Balcer, L. J.] Univ Penn, Sch Med, Dept Epidemiol, Philadelphia, PA 19104 USA; [Allen, M.; Messner, L. V.] Illinois Coll Optometry, Chicago, IL USA; [Devick, S.] King Devick Test LLC, Downers Grove, IL USA; [Tennant, A. T.] Nefilim Associates LLC, Swampscott, MA USA; [Madda, F.] Univ Illinois, Dept Surg, Med Ctr, Chicago, IL 60680 USA; [Delicata, D.] Good Samaritan Hosp, Downers Grove, IL USA	Balcer, LJ (corresponding author), Univ Penn, Sch Med, Dept Neurol, 3 E Gates Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.	lbalcer@mail.med.upenn.edu			Inspire Pharmaceuticals; Pfizer Inc.Pfizer; NIH/NEIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI); National MS SocietyNational Multiple Sclerosis Society	K. M. Galetta, J. Barrett, Dr. Allen, Dr. Madda, Dr. Delicato, Dr. Tennant, and Dr. Branas report no disclosures. Dr. Maguire serves on the editorial boards of Ophthalmology, Cornea, and Current Opinion in Ophthalmology; and receives research support from Inspire Pharmaceuticals, Pfizer Inc., and the NIH/NEI. Dr. Messner reports no disclosures. Dr. Devick is an employee of and holds stock in King-Devick Test, LLC; and has a patent pending re: The King-Devick Test. Dr. Galetta serves on the editorial boards of Neurology (R) and the Journal of Neuro-ophthalmology; has received speaker honoraria from Biogen Idec and Teva Pharmaceutical Industries Ltd.; has served as a consultant for Biogen Idec, Medtronic, Inc., and Teva Pharmaceutical Industries Ltd.: and serves on the speakers' bureau for Biogen Idec. Dr. Balcer serves on a scientific advisory board for Biogen Idec; has received speaker honoraria from Biogen Idec and Bayer Schering Pharma; and receives research support from the NIH/NEI and the National MS Society.	Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cantu RC, 2007, NEUROSURGERY, V60, P963, DOI 10.1227/01.NEU.0000255430.62291.7B; Cantu RC, 2007, NEW ENGL J MED, V356, P1787; Cantu RC, 2009, CURR SPORT MED REP, V8, P6, DOI 10.1249/JSR.0b013e31819677db; Casson IR, 2009, PHYS MED REH CLIN N, V20, P195, DOI 10.1016/j.pmr.2008.10.006; Casson IR, 2009, ARCH NEUROL-CHICAGO, V66, P419, DOI 10.1001/archneurol.2008.592; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; DOOREN JC, 2010, WALL STREET J    AUG; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Gregory Sean, 2010, Time, V175, P36; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; HINE C, 2010, CHICAGO TRIBUNE AUG; Hunt T, 2010, CLIN SPORT MED, V29, P5, DOI 10.1016/j.csm.2009.09.002; Lovell M, 2009, CLIN SPORT MED, V28, P95, DOI 10.1016/j.csm.2008.08.008; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Mayers L, 2008, ARCH NEUROL-CHICAGO, V65, P1158, DOI 10.1001/archneur.65.9.1158; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Miller G, 2009, SCIENCE, V325, P670, DOI 10.1126/science.325_670; OMALU BI, 2009, J FORENSIC NURS, V6, P40; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; ORTIZ J, 2010, US TODAY         AUG; Reddy CC, 2009, CURR SPORT MED REP, V8, P10, DOI 10.1249/JSR.0b013e31819539ca; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; SAMSON K, 2010, NEUROLOGY TODAY, V10, P1; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Vagnozzi R, BRAIN; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vastag B, 2002, JAMA-J AM MED ASSOC, V287, P437, DOI 10.1001/jama.287.4.437; Wennberg RA, 2008, CAN J NEUROL SCI, V35, P647, DOI 10.1017/S031716710000946X; Zazryn TR, 2009, CLIN J SPORT MED, V19, P20, DOI 10.1097/JSM.0b013e31818f1582	40	164	167	3	49	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	APR	2011	76	17					1456	1462		10.1212/WNL.0b013e31821184c9			7	Clinical Neurology	Neurosciences & Neurology	754VB	WOS:000289884700008	21288984	Green Published			2021-06-18	
J	Redell, JB; Moore, AN; Ward, NH; Hergenroeder, GW; Dash, PK				Redell, John B.; Moore, Anthony N.; Ward, Norman H., III; Hergenroeder, Georgene W.; Dash, Pramod K.			Human Traumatic Brain Injury Alters Plasma microRNA Levels	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; microRNA; mild traumatic brain injury; plasma; traumatic brain injury	INTERCELLULAR TRANSFER; CIRCULATING MICRORNAS; BIOMARKERS; SERUM; IDENTIFICATION; DIAGNOSIS; PROTEINS; EXPRESSION; EXOSOMES; PTEN	Circulating microRNAs (miRNAs) present in the serum/plasma are characteristically altered in many pathological conditions, and have been employed as diagnostic markers for specific diseases. We examined if plasma miRNA levels are altered in patients with traumatic brain injury (TBI) relative to matched healthy volunteers, and explored their potential for use as diagnostic TBI biomarkers. The plasma miRNA profiles from severe TBI patients (Glasgow Coma Scale [GCS] score <= 8) and age-, gender-, and race-matched healthy volunteers were compared by microarray analysis. Of the 108 miRNAs identified in healthy volunteer plasma, 52 were altered after severe TBI, including 33 with decreased and 19 with increased relative abundance. An additional 8 miRNAs were detected only in the TBI plasma. We used quantitative RT-PCR to determine if plasma miRNAs could identify TBI patients within the first 24 h post-injury. Receiver operating characteristic curve analysis indicated that miR-16, miR-92a, and miR-765 were good markers of severe TBI (0.89, 0.82, and 0.86 AUC values, respectively). Multiple logistic regression analysis revealed that combining these miRNAs markedly increased diagnostic accuracy (100% specificity and 100% sensitivity), compared to either healthy volunteers or orthopedic injury patients. In mild TBI patients (GCS score > 12), miR-765 levels were unchanged, while the plasma levels of miR-92a and miR-16 were significantly increased within the first 24 h of injury compared to healthy volunteers, and had AUC values of 0.78 and 0.82, respectively. Our results demonstrate that circulating miRNA levels are altered after TBI, providing a rich new source of potential molecular biomarkers. Plasma-derived miRNA biomarkers, used in combination with established clinical practices such as imaging, neurocognitive, and motor examinations, have the potential to improve TBI patient classification and possibly management.	[Dash, Pramod K.] Univ Texas MD Anderson Canc Ctr, Univ Texas Med Sch, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Ward, Norman H., III; Hergenroeder, Georgene W.; Dash, Pramod K.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77225 USA; [Hergenroeder, Georgene W.] Univ Texas MD Anderson Canc Ctr, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas MD Anderson Canc Ctr, Univ Texas Med Sch, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002; Hergenroeder, Georgene/0000-0002-6170-2191	TIRR Foundation; Gillson Longenbaugh Foundation; American Heart AssociationAmerican Heart Association [09BGIA2260018]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS078596] Funding Source: NIH RePORTER	This research was supported by grants from Mission Connect-Project of the TIRR Foundation (to P.K.D.), the Gillson Longenbaugh Foundation (to P.K.D.), and the American Heart Association (09BGIA2260018 to J.B.R.).	Agarwal S, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S1-S29; Ai J, 2010, BIOCHEM BIOPH RES CO, V391, P73, DOI 10.1016/j.bbrc.2009.11.005; Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Al-Nedawi K, 2009, CELL CYCLE, V8, P2014, DOI 10.4161/cc.8.13.8988; Avnit-Sagi T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005033; Bartels CL, 2009, CLIN CHEM, V55, P623, DOI 10.1373/clinchem.2008.112805; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chang N, 2007, TRENDS NEUROSCI, V30, P581, DOI 10.1016/j.tins.2007.08.006; Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Cogswell JP, 2008, J ALZHEIMERS DIS, V14, P27, DOI 10.3233/jad-2008-14103; Cordes KR, 2009, CIRC RES, V104, P724, DOI 10.1161/CIRCRESAHA.108.192872; Cortez MA, 2009, EXPERT OPIN BIOL TH, V9, P703, DOI [10.1517/14712590902932889 , 10.1517/14712590902932889]; Dash PK, 2010, J NEUROSCI RES, V88, P1719, DOI 10.1002/jnr.22336; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; De Smaele E, 2010, BRAIN RES, V1338, P100, DOI 10.1016/j.brainres.2010.03.103; Doebele C, 2010, BLOOD, V115, P4944, DOI 10.1182/blood-2010-01-264812; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gilad S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003148; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Kaddar T, 2009, BIOL CELL, V101, P511, DOI 10.1042/BC20080213; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI 10.1373/clinchem.2009.131797; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li SC, 2010, GENOMICS, V96, P1, DOI 10.1016/j.ygeno.2010.03.009; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Linsley PS, 2007, MOL CELL BIOL, V27, P2240, DOI 10.1128/MCB.02005-06; Lodes MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006229; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mathivanan S, 2009, PROTEOMICS, V9, P4997, DOI 10.1002/pmic.200900351; Michael A, 2010, ORAL DIS, V16, P34, DOI 10.1111/j.1601-0825.2009.01604.x; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Posmantur RM, 1998, NEUROCHEM RES, V23, P1265, DOI 10.1023/A:1020792132629; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Rogelj B, 2004, REV NEUROSCIENCE, V15, P185; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Siman R, 2009, J NEUROTRAUM, V26, pA61; Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI 10.1586/EPR.09.17; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Tanaka M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005532; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wang GK, 2010, EUR HEART J, V31, P659, DOI 10.1093/eurheartj/ehq013; Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yuan A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004722; Zernecke A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000610; Zhang QG, 2007, FEBS LETT, V581, P495, DOI 10.1016/j.febslet.2006.12.055	60	164	172	0	88	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2147	2156		10.1089/neu.2010.1481			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400004	20883153	Green Published			2021-06-18	
J	Miles, L; Grossman, RI; Johnson, G; Babb, JS; Diller, L; Inglese, M				Miles, Laura; Grossman, Robert I.; Johnson, Glyn; Babb, James S.; Diller, Leonard; Inglese, Matilde			Short-term DTI predictors of cognitive dysfunction in mild traumatic brain injury	BRAIN INJURY			English	Article						brain injury; diffuse axonal injury; neuroimaging; neuropsychological	DIFFUSE AXONAL INJURY; HEAD-INJURY; MAGNETIC-RESONANCE; SEVERITY; DAMAGE; REHABILITATION; SPECTROSCOPY; ATROPHY; IMAGES; LONG	Primary objective: To explore whether baseline diffusion tensor imaging (DTI) metrics are predictive of cognitive functioning 6 months post-injury in patients with mild traumatic brain injury (MTBI). Research design: Seventeen patients with MTBI and 29 sex- and age-matched healthy controls were studied. Methods and procedures: Participants underwent an MRI protocol including DTI, at an average of 4.0 (range: 1-10) days post-injury. Mean diffusivity (MD) and fractional anisotropy (FA) were measured in the following white matter (WM) regions: centra semiovale, the genu and the splenium of the corpus callosum and the posterior limb of the internal capsule. Participants underwent neuropsychological (NP) testing at baseline and at 6-month follow-up. Least squares regression analysis was used to evaluate the association of MD and FA with each NP test score at baseline and follow-up. Main outcomes and results: Compared to controls, average MD was significantly higher (p = 0.02) and average FA significantly lower (p = 0.0001) in MTBI patients. At the follow-up, there was a trend toward a significant association between baseline MD and response speed (r = -0.53, p = 0.087) and a positive correlation between baseline FA and Prioritization form B (r = 0.72, p = 0.003). Conclusions: DTI may provide short-term non-invasive predictive markers of cognitive functioning in patients with MTBI.	[Miles, Laura; Grossman, Robert I.; Johnson, Glyn; Babb, James S.; Inglese, Matilde] NYU, Dept Radiol, Sch Med, New York, NY 10016 USA; [Diller, Leonard] Rusk Inst Rehabil Med, Dept Psychol, New York, NY USA	Inglese, M (corresponding author), NYU, Dept Radiol, Sch Med, 650 1st Ave,6th Floor, New York, NY 10016 USA.	matilde.inglese@med.nyu.edu	Inglese, Matilde/AAH-3189-2020	Inglese, Matilde/0000-0002-9610-0297; Diller, Leonard/0000-0001-7295-7846; Babb, James/0000-0003-1798-1186; Johnson, Glyn/0000-0001-6826-5054	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00096] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS051623, R01 NS39135] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051623, R01NS039135] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BENYISHAY Y, 1980, NEW YORK U MED CTR R, V61; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; DIKEMAN S, 1986, J NEUROL NEUROSUR PS, V49, P1227; DILLER L, 1993, ADV STROKE REHABILIT, P162; DOWNEY J, 1922, DOWNEY GROUP WILL TE; DOWNEY J, 1923, WILL TEMPERANT TESTI; Erlanger DM, 2002, J HEAD TRAUMA REHAB, V17, P458, DOI 10.1097/00001199-200210000-00007; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; FRENCHMAN KA, 1995, J CLIN EXPT NEUROPSY, V27, P224; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; HUGENHOLTZ H, 1988, NEUROSURGERY, V23, P682; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; LEBIHAN D, 1992, AM J ROENTGENOL, V159, P591, DOI 10.2214/ajr.159.3.1503032; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Rath JF, 2004, ARCH CLIN NEUROPSYCH, V19, P613, DOI 10.1016/j.acn.2003.08.006; RATOK J, 1992, NEROPSYCHOLOGY, V6, P395; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Spreen O., 1977, NEUROSENSORY CTR COM; Stewart DP, 1996, ACAD EMERG MED, V3, P21, DOI 10.1111/j.1553-2712.1996.tb03297.x; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468	47	164	165	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	2					115	122		10.1080/02699050801888816			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	258DW	WOS:000252849600002	18240040				2021-06-18	
J	Guo, QM; Sayeed, I; Baronne, LM; Hoffman, SW; Guennoun, R; Stein, DG				Guo, QM; Sayeed, I; Baronne, LM; Hoffman, SW; Guennoun, R; Stein, DG			Progesterone administration modulates AQP4 expression and edema after traumatic brain injury in male rats	EXPERIMENTAL NEUROLOGY			English	Article						progesterone; traumatic brain injury; aquaporin-4; GFAP; cerebral edema	CEREBRAL-ARTERY OCCLUSION; CORTICAL IMPACT INJURY; AQUAPORIN WATER CHANNELS; INFLAMMATORY RESPONSE; PREFRONTAL CORTEX; MEMBRANE DOMAINS; CONTUSION INJURY; SPINAL-CORD; CELL-DEATH; TRANSPORT	This study investigates whether progesterone administration regulates AQP4 and GFAP expression in rats with bilateral contusion injuries of the medial frontal cortex. Male rats were given 0 or 16 mg/kg injections of progesterone at 1, 6, 24, and 48 h post-injury. Brains were extracted at 24 h or 72 h post-injury and assayed for cerebral edema and AQP4 and GFAP expression using Western blot analysis. Progesterone treatments reduced brain water content significantly in the brain-injured groups. There was no significant change in AQP4 expression 24 It after progesterone treatment compared to lesion + vehicle animals. However, progesterone significantly reduced AQP4 expression at 72 h post-injury in the tissue bounded by the lateral ventricles and the peri-contusion areas compared to lesion+ vehicle rats, but increased AQP4 expression in the tissue surrounding the third ventricle. Also progesterone effects on GFAP expression varied according to brain region. Our results can be taken to show that the expression of AQP4 protein after TBI is time-dependent, region-specific, and possibly implicated in the formation and resolution of TBI-induced cerebral edema. (C) 2005 Elsevier Inc. All rights reserved.	Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; INSERM, U488, F-94276 Le Kremlin Bicetre, France	Stein, DG (corresponding author), Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA.	dstci04@emory.edu	Stein, Donald/AAJ-5139-2020; Guennoun, Rachida/F-2420-2011	Guennoun, Rachida/0000-0002-9219-7300	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040825, R01NS038664] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS40825, 1R01NS38664] Funding Source: Medline		Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Amiry-Moghaddam M, 2004, FASEB J, V18, P542, DOI 10.1096/fj.03-0869fje; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Beaumont A, 2002, ACT NEUR S, V81, P217; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Eid T, 2005, P NATL ACAD SCI USA, V102, P1193, DOI 10.1073/pnas.0409308102; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Griesdale DEG, 2004, SURG NEUROL, V61, P418, DOI 10.1016/j.surneu.2003.10.047; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hill AE, 2004, J MEMBRANE BIOL, V197, P1, DOI 10.1007/s00232-003-0639-6; Hoffman SW, 2003, J NEUROTRAUM, V20, P859, DOI 10.1089/089771503322385791; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Nagelhus EA, 2004, NEUROSCIENCE, V129, P905, DOI 10.1016/j.neuroscience.2004.08.053; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Nico B, 2001, J CELL SCI, V114, P1297; Nielsen S, 1997, J NEUROSCI, V17, P171; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; PAULSON OB, 1987, SCIENCE, V237, P896, DOI 10.1126/science.3616619; Pellerin L, 2004, NEUROSCIENTIST, V10, P53, DOI 10.1177/1073858403260159; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Saadoun S, 2003, J CLIN PATHOL, V56, P972, DOI 10.1136/jcp.56.12.972; Simard M, 2004, NEUROSCIENCE, V129, P877, DOI 10.1016/j.neuroscience.2004.09.053; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Stroop R, 1998, ACT NEUR S, V71, P303; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Tomas-Camardiel M, 2004, J NEUROCHEM, V91, P891, DOI 10.1111/j.1471-4159.2004.02759.x; Unterberg AW, 1997, ACT NEUR S, V70, P106; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Venero JL, 2004, CURR PHARM DESIGN, V10, P2153, DOI 10.2174/1381612043384150; Verkman AS, 2000, EXP PHYSIOL, V85, p233S, DOI 10.1111/j.1469-445X.2000.tb00028.x; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	53	164	186	1	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2006	198	2					469	478		10.1016/j.expneurol.2005.12.013			10	Neurosciences	Neurosciences & Neurology	033RJ	WOS:000236866400019	16445913				2021-06-18	
J	Prigatano, GP				Prigatano, GP			Disturbances of self-awareness and rehabilitation of patients with traumatic brain injury - A 20-year perspective	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	32nd Annual Meeting of the International-Neuropsychological-Society	FEB 04-07, 2004	Baltimore, MD	Int Neuropsychol Soc		anosognosia; impaired self-awareness; review; traumatic brain injury	CLOSED-HEAD-INJURY; COMPETENCE RATING-SCALE; IMPAIRED AWARENESS; BEHAVIORAL LIMITATIONS; COGNITIVE DEFICITS; ALZHEIMERS-DISEASE; ANOSOGNOSIA; UNAWARENESS; ADULTS; CONSCIOUSNESS	Over the last 20 years, numerous papers that are relevant to understanding the problem of impaired self-awareness after moderately severe to severe traumatic brain injury have appeared. This article reviews many of these papers and summarizes salient findings relevant to rehabilitation and future research.	St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ 85013 USA; Med Ctr, Phoenix, AZ 85013 USA	Prigatano, GP (corresponding author), St Josephs Hosp, Barrow Neurol Inst, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	gprigat@chw.edu					ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Barco P.P., 1991, COGNITIVE REHABILITA, P129; Bieman-Copland S, 2000, BRAIN COGNITION, V44, P1; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; Borgaro SR, 2002, J HEAD TRAUMA REHAB, V17, P526, DOI 10.1097/00001199-200212000-00004; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Chittum WR, 1996, BRAIN INJURY, V10, P763; Cotrell V, 1999, ALZ DIS ASSOC DIS, V13, P151, DOI 10.1097/00002093-199907000-00007; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; DEBETTIGNIES BH, 1990, J CLIN EXP NEUROPSYC, V12, P355, DOI 10.1080/01688639008400980; Derouesne C, 1999, INT J GERIATR PSYCH, V14, P1019, DOI 10.1002/(SICI)1099-1166(199912)14:12<1019::AID-GPS61>3.0.CO;2-F; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Flashman L. A., 1998, SEMINARS CLIN NEUROP, V3, P201; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Freud S., 1924, GEN INTRO PSYCHOANAL; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; Gasquoine PG, 1994, J HEAD TRAUMA REHAB, V9, P16, DOI DOI 10.1097/00001199-199412000-00004; GENTRY LR, 2002, MAGNETIC RESONANCE I, V2, P1059; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; HART T, IN PRESS ARCH PHYS M; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; HOUSE A, 1988, J NEUROL NEUROSUR PS, V51, P112, DOI 10.1136/jnnp.51.1.112; Jehkonen M, 2000, ACTA NEUROL SCAND, V102, P378, DOI 10.1034/j.1600-0404.2000.102006378.x; Jennett B, 1981, MANAGEMENT HEAD INJU; Johnson SC, 2002, BRAIN, V125, P1808, DOI 10.1093/brain/awf181; Klonoff PS, 1989, J HEAD TRAUMA REHAB, V4, P37; LABAW WL, 1969, PSYCHIATR, V32, P174, DOI 10.1080/00332747.1969.11023582; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Lamar M, 2002, J NEUROPSYCH CLIN N, V14, P430, DOI 10.1176/appi.neuropsych.14.4.430; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; Malec JF, 2002, ARCH PHYS MED REHAB, V83, P1759, DOI 10.1053/apmr.2002.36072; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Pedersen PM, 1996, J NEUROL REHABIL, V10, P243; PRIGATANO G, 2003, OXFORD HDB CLIN NEUR, P387; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1997, CLIN NEUROPSYCHOL, V11, P1; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 2003, NEUROPSYCHOL REHABIL, V13, P13, DOI 10.1080/09602010244000282; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; PRIGATANO GP, IN PRESS J HEAD TRAU; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Prigatano GP, 1996, BLACKWELL DICT NEURO, P80; Prigozhin L, 1996, FREE BOUNDARY PROBLE, V10, P2; RAMACHANDRAN VS, 1994, INT REV NEUROBIOL, V37, P291; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; Rebmann MJ, 1995, REHABIL PSYCHOL, V40, P279, DOI 10.1037/0090-5550.40.4.279; Schacter DL., 1991, AWARENESS DEFICIT BR, P17; Seltzer B, 1997, GERONTOLOGIST, V37, P20, DOI 10.1093/geront/37.1.20; Seltzer B, 2001, NEUROPSY NEUROPSY BE, V14, P122; Seltzer B, 1995, J CLIN GEROPSYCHOL, V1, P79; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SHERER M, IN PRESS J HEAD TRAU; SHERER M, IN PRESS REHABILITAT; SHERER M, 1997, J INT NEUROPSYCH SOC, V3, P75; Small M, 1996, EUR NEUROL, V36, P353, DOI 10.1159/000117293; STARKSTEIN SE, 1992, STROKE, V23, P1446, DOI 10.1161/01.STR.23.10.1446; STARKSTEIN SE, 1993, NEUROPSY NEUROPSY BE, V6, P43; STONE SP, 1993, AGE AGEING, V22, P46, DOI 10.1093/ageing/22.1.46; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y; Vuilleumier P, 2001, BRAIN, V124, P1077, DOI 10.1093/brain/124.6.1077; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO; YOUNGJOHN JR, 1989, REHABIL PSYCHOL, V34, P217, DOI 10.1037//0090-5550.34.3.217; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	83	164	164	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2005	20	1					19	29		10.1097/00001199-200501000-00004			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	894AT	WOS:000226762900003	15668568				2021-06-18	
J	Covassin, T; Swanik, CB; Sachs, ML				Covassin, T; Swanik, CB; Sachs, ML			Sex differences and the incidence of concussions among collegiate athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injury; concussion rates; athletic injury	SOCCER PLAYERS	Objective: To compare sex differences regarding the incidence of concussions among collegiate athletes during the 1997-1998, 1998-1999, and 1999-2000 seasons. Design and Setting: A cohort study of collegiate athletes using the National Collegiate Athletic Association (NCAA) Injury Surveillance System; certified athletic trainers recorded data during the 1997-2000 academic years. Subjects: Collegiate athletes participating in men's and women's soccer, lacrosse, basketball, softball, baseball, and gymnastics. Measurements: Certified athletic trainers from participating NCAA institutions recorded weekly injury and athlete-exposure data from the first day of preseason practice to the final post-season game. Injury rates and incidence density ratios were computed. Incidence density ratio is an estimate of the relative risk based on injury rates per 1000 athlete-exposures. Results: Of 14 591 reported injuries, 5.9% were classified as concussions. During the 3-year study, female athletes sustained 167 (3.6%) concussions during practices and 304 (9.5%) concussions during games, compared with male athletes, who sustained 148 (5.2%) concussions during practices and 254 (6.4%) concussions during games. Chi-square analysis revealed significant differences between male and female soccer players (chi(1)(2) = 12.99, P = .05) and basketball players (chi(1)(2) = 5.14, P = .05). Conclusions: Female athletes sustained a higher percentage of concussions during games than male athletes. Of all the sports, women's soccer and men's lacrosse were found to have the highest injury rate of concussions. Incidence density ratio was greatest for male and female soccer players.	Shippensburg Univ, Shippensburg, PA 17257 USA; Temple Univ, Philadelphia, PA 19122 USA	Covassin, T (corresponding author), Shippensburg Univ, Shippensburg, PA 17257 USA.		Swanik, Charles/C-4377-2014	Swanik, Charles/0000-0001-9701-2005			Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Brown J., 2001, LACROSSE MAGAZIN MAY, P26; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P10; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; GRONWALL D, 1975, LANCET, V2, P995; Kelly JP, 1997, NEUROLOGY, V48, P581; KELLY JP, 1995, CURRENT THERAPY SPOR, V4, P21; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; *NAT ATHL TRAIN AS, P MILD BRAIN INJ SUM; *NAT COL ATHL ASS, 2000, NCAA INJ SURV SYST A; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Starkey C, 2000, J ATHL TRAINING, V35, P161	14	164	166	0	27	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2003	38	3					238	244					7	Sport Sciences	Sport Sciences	732CJ	WOS:000185923000012	14608434				2021-06-18	
J	Coles, JP; Minhas, PS; Fryer, TD; Smielewski, P; Aigbirihio, F; Donovan, T; Downey, SPMJ; Williams, G; Chatfield, D; Matthews, JC; Gupta, AK; Carpenter, TA; Clark, JC; Pickard, JD; Menon, DK				Coles, JP; Minhas, PS; Fryer, TD; Smielewski, P; Aigbirihio, F; Donovan, T; Downey, SPMJ; Williams, G; Chatfield, D; Matthews, JC; Gupta, AK; Carpenter, TA; Clark, JC; Pickard, JD; Menon, DK			Effect of hyperventilation on cerebral blood flow in traumatic head injury: Clinical relevance and monitoring correlates	CRITICAL CARE MEDICINE			English	Article						head injury; positron emission tomography; cerebral blood flow; ischemia; cerebral oxygenation; hyperventilation	ACUTE BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; MAGNETIC-RESONANCE; OXYGEN-CONSUMPTION; METABOLIC-RATE; JUGULAR BULB; ACUTE ANEMIA; ISCHEMIA; THRESHOLDS; SATURATION	Objective: To investigate the effect of hyperventilation on cerebral blood flow in traumatic brain injury. Design: A prospective interventional study. Setting. A specialist neurocritical care unit. Patients. Fourteen healthy volunteers and 33 patients within 7 days of closed head injury. Interventions: All subjects underwent positron emission tomography imaging of cerebral blood flow. In patients, Paco(2) was reduced from 36 +/- 1 to 29 +/- 1 torr (4.8 +/- 0.1 to 3.9 +/- 0.1 kPa) and measurements repeated. Jugular venous saturation (Sjvo(2)) and arteriovenous oxygen content differences (AVDO(2)) were monitored in 25 patients and values related to positron emission tomography variables. Measurements and Main Results. The volumes of critically hypoperfused and hyperperfused brain (HypoBV and HyperBV, in milliliters) were calculated based on thresholds of 10 and 55 mL(.)100g(-1.)min(-1), respectively. Whereas baseline HypoBV was significantly higher in patients (p < .05), baseline HyperBV was similar to values in healthy volunteers. Hyperventilation resulted in increases in cerebral perfusion pressure (p < .0001) and reductions in intracranial pressure (p < .001), whereas Sjvo(2) (>50%) and AVDO(2) (<9 mL/mL) did not exceed global ischemic thresholds. However, despite these beneficial effects, hyperventilation shifted the cerebral blood flow distribution curve toward the hypoperfused range, with a decrease in global cerebral blood flow (31 +/- 1 to 23 +/- 1 mL(.)100g(-1.)min(-1); p < .0001) and an increase in HypoBV (22 [1-141] to 51 [2-428] mL; p < .0001). Hyperventilation-induced increases in HypoBV were apparently nonlinear, with a threshold value between 34 and 38 torr (4.5-5 kPa). Conclusions: Hyperventilation increases the volume of severely hypoperfused tissue within the injured brain, despite improvements in cerebral perfusion pressure and intracranial pressure. Significant hyperperfusion is uncommon, even at a time when conventional clinical management includes a role for modest hyperventilation. These reductions in regional cerebral perfusion are not associated with ischemia, as defined by global monitors of oxygenation, but may represent regions of potentially ischemic brain tissue.	Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England	Coles, JP (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Box 93, Cambridge CB2 2QQ, England.	jpc44@wbic.cam.ac.uk	Donovan, Tim/AAF-3563-2019; Matthews, Julian C/M-9116-2015	Matthews, Julian C/0000-0002-7472-658X; Donovan, Tim/0000-0003-4112-861X; Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Baron JC, 1999, CEREBROVASC DIS, V9, P193, DOI 10.1159/000015955; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P513; CRUZ J, 1994, CRIT CARE MED, V22, P1465, DOI 10.1097/00003246-199409000-00018; CRUZ J, 1993, CRIT CARE MED, V21, P1218, DOI 10.1097/00003246-199308000-00024; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; Gibbs EL, 1942, J BIOL CHEM, V144, P325; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; KETY SS, 1946, J CLIN INVEST, V25, P107, DOI 10.1172/JCI101680; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; MADDEN JA, 1993, PHARMACOL THERAPEUT, V59, P229, DOI 10.1016/0163-7258(93)90045-F; Marchal G, 1999, BRAIN, V122, P2387, DOI 10.1093/brain/122.12.2387; MARCHAL G, 1992, ARCH NEUROL-CHICAGO, V49, P1013, DOI 10.1001/archneur.1992.00530340029014; MARCOUX FW, 1982, STROKE, V13, P339, DOI 10.1161/01.STR.13.3.339; Marion D W, 1995, New Horiz, V3, P439; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Metz C, 1998, J CEREBR BLOOD F MET, V18, P332, DOI 10.1097/00004647-199803000-00012; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; POWERS WJ, 1992, NEUROL CLIN, V10, P31; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; Robertson C S, 1995, New Horiz, V3, P410; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; Schierhout G, 2000, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD000566, 10.1002/14651858. CD000566]; SEIFERT H, 1995, BRIT J RADIOL, V68, P301, DOI 10.1259/0007-1285-68-807-301; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Staroselskaya IA, 2001, ARCH NEUROL-CHICAGO, V58, P1069, DOI 10.1001/archneur.58.7.1069; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; Studholme C, 1996, Med Image Anal, V1, P163, DOI 10.1016/S1361-8415(96)80011-9; Studholme C, 1997, MED PHYS, V24, P25, DOI 10.1118/1.598130; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; YONAS H, 1989, NEUROSURGERY, V24, P368, DOI 10.1227/00006123-198903000-00010; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6	46	164	166	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2002	30	9					1950	1959		10.1097/00003246-200209000-00002			10	Critical Care Medicine	General & Internal Medicine	599XC	WOS:000178359600002	12352026				2021-06-18	
J	Bethea, JR; Dietrich, WD				Bethea, JR; Dietrich, WD			Targeting the host inflammatory response in traumatic spinal cord injury	CURRENT OPINION IN NEUROLOGY			English	Article							TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; BLOOD-BRAIN-BARRIER; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; KAPPA-B ACTIVATION; GROWTH-FACTOR-BETA; MODERATE HYPOTHERMIA; FACTOR-ALPHA; PROTECT NEURONS	Both acute and chronic inflammatory processes have been shown to influence outcome in experimental models of spinal cord injury. Although early inflammatory responses may participate in secondary injury processes, more delayed inflammatory events may be reparative. Therapeutic strategies that target these events are currently based on experimental findings that have clarified the cellular and molecular processes involved in the inflammatory response to injury, An increasing body of literature supports the hypothesis that acute inflammatory events are attenuated by therapeutic hypothermia and other anti-inflammatory strategies, whereas immune neuroprotection and axonal regeneration can be achieved by transfer of activated T cells or by treatment with therapeutic vaccines. These data are summarized in the present review.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Lois Pope LIFE Ctr,Dept Neurol Surg, Miami, FL 33136 USA	Bethea, JR (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, Lois Pope LIFE Ctr,Dept Neurol Surg, 1095 NW 14th Terrace,R-48, Miami, FL 33136 USA.		Calabrese, Massimiliano/I-6195-2012				Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; Bandtlow CE, 2000, GLIA, V29, P175, DOI 10.1002/(SICI)1098-1136(20000115)29:2<175::AID-GLIA11>3.0.CO;2-F; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; BARNA BP, 1994, J NEUROIMMUNOL, V50, P101, DOI 10.1016/0165-5728(94)90220-8; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; BECKMAN JS, 1996, CELL PHYSL, V40, pC1424; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1; Benzing T, 1999, NAT MED, V5, P913, DOI 10.1038/11354; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bethea JR, 1998, J NEUROSCI, V18, P3251; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; Brodie C, 1996, FEBS LETT, V394, P117, DOI 10.1016/0014-5793(96)00911-8; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; CHATZIPANTELI K, 2002, IN PRESS J NEUROTRAU; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Clark RAF., 1996, MOL CELLULAR BIOL WO; CRISI GM, 1995, EUR J IMMUNOL, V25, P3035, DOI 10.1002/eji.1830251108; CUNHA FG, 1992, BIOCHEM BIOPH RES CO, V183, P1155; David S, 1998, MENT RETARD DEV D R, V4, P171, DOI 10.1002/(SICI)1098-2779(1998)4:3<171::AID-MRDD4>3.0.CO;2-R; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; Dietrich WD, 2000, BRAIN HYPOTHERMIA: PATHOLOGY, PHARMACOLOGY, AND TREATMENT OF SEVERE BRAIN INJURY, P39; DUSART I, 1994, EUR J NEUROSCI, V7, P12; Felberg RA, 2001, CIRCULATION, V104, P1799, DOI 10.1161/hc4001.097037; FREI K, 1994, J IMMUNOL, V152, P2720; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; Ghirnikar RS, 1996, J NEUROSCI RES, V46, P727; Grilli M, 2000, EUR J NEUROSCI, V12, P2265, DOI 10.1046/j.1460-9568.2000.00090.x; HALLENBECK JM, 1996, ADV NEUROL, V71, P282; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hara H, 1997, J CEREBR BLOOD F MET, V17, P515, DOI 10.1097/00004647-199705000-00005; Hauben E, 2001, J CLIN INVEST, V108, P591, DOI 10.1172/JCI12837; HAUSMANN ON, 2002, IN PRESS EUR J NEURO; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Ho A, 1997, EXP NEUROL, V148, P348, DOI 10.1006/exnr.1997.6659; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286; Ishikawa M, 1999, STROKE, V30, P1679, DOI 10.1161/01.STR.30.8.1679; Issazadeh S, 1996, J NEUROIMMUNOL, V69, P103; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; Kim GM, 2001, J NEUROSCI, V21, P6617; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Koedel U, 1996, J IMMUNOL, V157, P5185; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Ousman SS, 2001, J NEUROSCI, V21, P4649, DOI 10.1523/JNEUROSCI.21-13-04649.2001; Pan WH, 1999, J NEUROSCI, V19, P3649; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; Plunkett JA, 2001, EXP NEUROL, V168, P144, DOI 10.1006/exnr.2000.7604; POPOVICH PG, 1997, J COMP NEUROL, V377, P433; Romano MF, 1996, J IMMUNOL, V156, P2119; ROTT O, 1994, EUR J IMMUNOL, V24, P1434, DOI 10.1002/eji.1830240629; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Sutcliffe IT, 2001, J CEREBR BLOOD F MET, V21, P1310, DOI 10.1097/00004647-200111000-00007; TAGA K, 1994, J CLIN INVEST, V94, P251, DOI 10.1172/JCI117315; Taoka Y, 1998, J NEUROSCI, V18, P1393; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; TUREEN J, 1995, J CLIN INVEST, V95, P1086, DOI 10.1172/JCI117755; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yu CG, 2001, NEUROSURGERY, V49, P152, DOI 10.1097/00006123-200107000-00023; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355	74	164	172	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1350-7540			CURR OPIN NEUROL	Curr. Opin. Neurol.	JUN	2002	15	3					355	360		10.1097/00019052-200206000-00021			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	560GT	WOS:000176074900021	12045737				2021-06-18	
J	Bergsneider, M; Hovda, DA; Lee, SM; Kelly, DF; McArthur, DL; Vespa, PM; Lee, JH; Huang, SC; Martin, NA; Phelps, ME; Becker, DP				Bergsneider, M; Hovda, DA; Lee, SM; Kelly, DF; McArthur, DL; Vespa, PM; Lee, JH; Huang, SC; Martin, NA; Phelps, ME; Becker, DP			Dissociation of cerebral glucose metabolism and level of consciousness during the period of metabolic depression following human traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						coma; hematoma; positron emission tomography	POSITRON EMISSION TOMOGRAPHY; BLOOD-FLOW; RAT-BRAIN; HYPERMETABOLISM; ISCHEMIA; COMA; HYPERGLYCOLYSIS; ACCUMULATION; CONSUMPTION; ANESTHESIA	Utilizing [F-18]fluorodeoxyglucose positron emission tomography (FDG-PET), we studied the correlation between CMRglc and the level of consciousness within the first month following human traumatic brain injury. Forty-three FDG-PET scans obtained on 42 mild to severely head-injured patients were quantitatively analyzed for the determination of regional cerebral metabolic rate of glucose (CMRglc). Reduction of cerebral glucose utilization, defined as a CMRglc of less than or equal to 4.9 mg/100 g/min, was present regionally in 88% of the studies. The prevalence of global cortical CMRglc reduction was higher in severely head-injured patients (86% versus 67% mild-moderate), although the absolute magnitude was similar across the injury severity spectrum (mean CMRglc 3.9 +/- 0.6 mg/100 g/min). The level of consciousness, as measured by the Glasgow Coma Scale, correlated poorly with the global cortical CMRglc value (r = 0.08; p = 0.63). With regards to severity of head injury, this correlation was worst for the severely injured (r = -0.11; p = 0.58) and better for the mildly injured patients (r = 0.50; p = 0.07). In most cases, intraparenchymal hemorrhagic lesions were associated with either focal CMRglc reduction or elevation. It is concluded that the etiologies of CMRglc reduction are likely multifactorial given the complex nature of traumatic brain injury and that the reduction of CMRglc represents a fundamental pathobiologic state following head injury that is not tightly coupled to level of consciousness.	Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90095 USA; Harbor UCLA Med Ctr, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA	Bergsneider, M (corresponding author), Univ Calif Los Angeles, Div Neurosurg, Box 957039, Los Angeles, CA 90095 USA.	mbergsneider@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Martin, Neil/0000-0002-6565-4131	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308] Funding Source: Medline		Alkire MT, 1997, ANESTHESIOLOGY, V86, P549, DOI 10.1097/00000542-199703000-00006; ALKIRE MT, 1995, ANESTHESIOLOGY, V82, P393, DOI 10.1097/00000542-199502000-00010; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BERGSNEIDER M, 1995, J CEREB BLOOD FLO S1, V15, pS26; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRODERSEN P, 1974, J NEUROL NEUROSUR PS, V37, P384, DOI 10.1136/jnnp.37.4.384; Brown JIM, 1998, NEUROSURGERY, V42, P1057, DOI 10.1097/00006123-199805000-00060; CHUGANI HT, 1993, PEDIATR NEUROL, V9, P10, DOI 10.1016/0887-8994(93)90003-U; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; Cruz J, 1997, J NEUROSURG, V87, P803; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Hasselbalch SG, 1998, J CEREBR BLOOD F MET, V18, P154, DOI 10.1097/00004647-199802000-00005; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; Hovda DA, 1998, DEV BRAIN RES, V110, P39, DOI 10.1016/S0165-3806(98)00092-3; HOVDA DA, 1996, NEUROTRAUMA, P1459; HUANG SC, 1980, AM J PHYSIOL, V238, pE69; INOUE M, 1991, J CEREBR BLOOD F MET, V11, P242, DOI 10.1038/jcbfm.1991.56; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KOBAYASHI M, 1977, J NEUROCHEM, V29, P53, DOI 10.1111/j.1471-4159.1977.tb03923.x; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; PAPPIUS HM, 1988, METAB BRAIN DIS, V3, P303, DOI 10.1007/BF00999542; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; Queen SA, 1997, BRAIN RES, V777, P42, DOI 10.1016/S0006-8993(97)00717-8; Rappaport Z H, 1981, Prog Neurol Surg, V10, P1, DOI 10.1159/000384765; ROBERTSON CS, 1988, J TRAUMA, V28, P1523, DOI 10.1097/00005373-198811000-00002; Samii A, 1999, J NEUROTRAUM, V16, P879, DOI 10.1089/neu.1999.16.879; SHAH KR, 1983, NEUROSCI LETT, V40, P287, DOI 10.1016/0304-3940(83)90053-8; SHALIT MN, 1972, NEUROLOGY, V22, P155, DOI 10.1212/WNL.22.2.155; SHIRAISHI K, 1989, J CEREBR BLOOD F MET, V9, P765, DOI 10.1038/jcbfm.1989.110; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; TEASDALE G, 1974, LANCET, V2, P81; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	46	164	167	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2000	17	5					389	401		10.1089/neu.2000.17.389			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	316BB	WOS:000087146500002	10833058				2021-06-18	
J	Sohlberg, MM; McLaughlin, KA; Pavese, A; Heidrich, A; Posner, MI				Sohlberg, MM; McLaughlin, KA; Pavese, A; Heidrich, A; Posner, MI			Evaluation of attention process training and brain injury education in persons with acquired brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; PERFORMANCE; DEFICITS; PASAT; PET; COGNITION; VALIDITY; SYSTEM; MEMORY	Fourteen patients with stable acquired brain injuries exhibiting attention and working memory deficits were given 10 weeks of attention process training (APT) and 10 weeks of brain injury education in a cross-over design. Structured interviews and neuropsychological tests were used prior to rehabilitation and after both treatments to determine the influence of the interventions on tasks of daily life and performance on attentional networks involving vigilance, orienting, and executive function. The overall results showed that most patients made improvements. Some of these gains were due to practice from repetitive administration of the tests. In addition, the type of intervention also influenced the results. The brain injury education seemed to be most effective in improving self-reports of psychosocial function. APT influenced self-reports of cognitive function and had a stronger influence on performance of executive attention tasks than was found with the brain injury education therapy. Vigilance and orienting networks showed little specific improvement due to therapy. However, vigilance level influenced the improvement with therapy on some tests of executive attention. We consider the implications of these results for future studies of the locus of attentional improvement and for the design of improved interventions.	Univ Oregon, Eugene, OR 97403 USA; Cornell Univ Med Coll, Sackler Inst Human Brain Funct, New York, NY USA	Sohlberg, MM (corresponding author), 5251 Univ Oregon, Eugene, OR 97403 USA.	mckay@oregon.uoregon.edu					Awh E, 1995, ANN NY ACAD SCI, V769, P97, DOI 10.1111/j.1749-6632.1995.tb38134.x; Ben-Yishay Y., 1987, NEUROPSYCHOLOGICAL R; Benton A, 1989, MULTILINGUAL APHASIA; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; BURG JS, 1995, BRAIN INJURY, V9, P395, DOI 10.3109/02699059509005779; Cabeza R, 1997, J COGNITIVE NEUROSCI, V9, P1, DOI 10.1162/jocn.1997.9.1.1; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE; CORBETTA M, 1993, J NEUROSCI, V13, P1202; Crawford JR, 1998, NEUROPSYCHOL REHABIL, V8, P255, DOI 10.1080/713755575; DEARY IJ, 1991, PERS INDIV DIFFER, V12, P983, DOI 10.1016/0191-8869(91)90027-9; DEARY IJ, 1994, BIOL PSYCHOL, V38, P1, DOI 10.1016/0301-0511(94)90046-9; DIENER D, 1988, MEM COGNITION, V16, P367, DOI 10.3758/BF03197048; DIGIROLAMO GJ, UNPUB SIMILAR TIME C; DILLER L, 1974, REHABILITATION MONOG, V50; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; EGAN V, 1988, PERS INDIV DIFFER, V9, P179, DOI 10.1016/0191-8869(88)90046-3; GORDON M, 1988, Journal of Clinical Psychology, V44, P682, DOI 10.1002/1097-4679(198809)44:5<682::AID-JCLP2270440504>3.0.CO;2-E; GORDON M, 1986, J CHILDREN CONT SOC, V19, P53; Gray J. M., 1992, NEUROPSYCHOL REHABIL, V2, P97; GRONWALL D, 1981, NEUROPSYCHOLOGY, V5, P253; GRONWALL D, 1987, NEUROBEHAVIORAL RECO; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HAYDEN S, 1978, DICHOTIC LISTENING T; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; Kazdin A. E., 1982, SINGLE CASE RES DESI; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; Lucyshyn JM, 1997, J CONSULT CLIN PSYCH, V65, P241, DOI 10.1037/0022-006X.65.2.241; Malec JF., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; Mateer C.A., 1990, COGNITIVE REHABILITA; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; Mateer CA, 1988, NEUROPSYCHOLOGICAL S, P202; Mega MS, 1998, NEUROLOGY, V50, P145, DOI 10.1212/WNL.50.1.145; NEIMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811; NISSEN M, 1986, J HEAD TRAUMA REHAB, V1, P13; O'Neill R.E., 1990, FUNCTIONAL ANAL PROB; OBRZUT JE, 1983, J EXP CHILD PSYCHOL, V35, P46, DOI 10.1016/0022-0965(83)90069-3; OSGOOD G, 1990, 909 U OR I COGN DEC; PAVESE A, 1999, UNPUB PATHOLOGIES AT; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; Posner M.I., 1994, IMAGES MIND; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; Reitan RM., 1985, HALSTEAD REITAN NEUR; RICHARDSON ED, 1994, CLIN NEUROPSYCHOL, V8, P416, DOI 10.1080/13854049408402044; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; Ruff RM, 1997, BRAIN LANG, V57, P394, DOI 10.1006/brln.1997.1755; RUSSELL EW, 1992, J CLIN PSYCHOL, V48, P530, DOI 10.1002/1097-4679(199207)48:4<530::AID-JCLP2270480415>3.0.CO;2-B; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Sherman EMS, 1997, CLIN NEUROPSYCHOL, V11, P34, DOI 10.1080/13854049708407027; SimmonsMackie NN, 1996, DISABIL REHABIL, V18, P540, DOI 10.3109/09638289609166315; SIVAK M, 1984, INT J REHABIL RES, V7, P389, DOI 10.1097/00004356-198412000-00002; Sohlberg M. M, 1989, COGNITIVE REHABILITA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; SOHLBERG MM, 1994, ATTENTION PROCESS TR, V2; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; STURM W, 1993, DEV ASSESSMENT REHAB; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wood R L, 1987, Int Disabil Stud, V9, P149	72	164	168	1	38	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2000	22	5					656	676		10.1076/1380-3395(200010)22:5;1-9;FT656			21	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	370ZD	WOS:000165152400012	11094401				2021-06-18	
J	Bramlett, HM; Dietrich, WD; Green, EJ; Busto, R				Bramlett, HM; Dietrich, WD; Green, EJ; Busto, R			Chronic histopathological consequences of fluid-percussion brain injury in rats: Effects of post-traumatic hypothermia	ACTA NEUROPATHOLOGICA			English	Article						traumatic brain injury; hypothermia; fluid percussion; rat; contusion	MODERATE HYPOTHERMIA; CEREBRAL-ISCHEMIA; HEAD-INJURY; VENTRICULAR DILATION; BARRIER DISRUPTION; PROTECTION; DAMAGE; VULNERABILITY; ATROPHY; MODEL	Early outcome measures of experimental traumatic brain injury (TBI) are useful for characterizing the traumatic severity as well as for clarifying the pathomechanisms underlying patterns of neuronal vulnerability. However, it is increasingly apparent that acute outcome measures may not always be accurate predictors of chronic outcome, particularly when assessing the efficacy of potential therapeutic regimens. This study examined the chronic histopathological outcome in rats 8 weeks following fluid-percussive TBI coupled with moderate posttraumatic brain hypothermia, a protocol that provides acute neuronal protection. Animals received a moderate parasagittal percussive head injury (2.01-2.38 atm) or sham procedure followed immediately by 3 h of brain hypothermia (30 degrees C) or normothermia (37 degrees C). Eight weeks following TBI, serial tissue sections were stained with hematoxylin and eosin or immunostained for glial fibrillary acidic protein. Tissue damage, gliosis and immunoreactive astrocytes were observed in the ipsilateral thalamus, hippocampus, and in the neocortex lateral to the injury site. Within the thalamus, focal necrosis was restricted to selective thalamic nuclei. Significant hippocampal cell loss was found in the ipsilateral dentate hilar region of both TBI groups. Quantitative volume measurements revealed significant decreases in cortical, thalamic and hippocampal volume ipsilateral to the impact in both TBI groups. Lateral ventricles were substantially enlarged in the TBI-normothermia group, an effect which was significantly attenuated by post-TBI hypothermia. The attenuation of lateral ventricular dilation by post-traumatic hypothermia is indicative of chronic neuroprotection in this TBI model. These data provide new information concerning the chronic histopathological consequence of experimental TBI and the relevance of this trauma model to chronic human head injury.	UNIV MIAMI,NEUROTRAUMA RES CTR,MIAMI,FL 33152; UNIV MIAMI,DEPT PSYCHOL,MIAMI,FL 33152	Bramlett, HM (corresponding author), UNIV MIAMI,DEPT NEUROL D4 5,POB 016960,MIAMI,FL 33101, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS027127] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291, NS 27127] Funding Source: Medline		ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CASTEJON OJ, 1980, J NEUROPATHOL EXP NE, V29, P296; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMELBERG HK, 1994, NEUROBIOLOGY CENTRAL, P193; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Li H, 1995, J CEREB BLOOD FLO S1, V15, pS246; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LUCHTER S, 1995, J NEUROTRAUM, V12, P517, DOI 10.1089/neu.1995.12.517; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; MACNAMARA SE, 1992, ARCH CLIN NEUROPSYCH, V7, P275, DOI 10.1016/0887-6177(92)90169-N; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Pierce JES, 1996, J NEUROSCI, V16, P1083; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; SAIJA A, 1988, Journal of Neurotrauma, V5, P161, DOI 10.1089/neu.1988.5.161; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; VALTYSSON J, 1994, ACTA NEUROCHIR, V129, P58, DOI 10.1007/BF01400874; ZILLES L, 1985, CORTEX RAT STEREOTAX	49	164	167	0	3	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	FEB	1997	93	2					190	199		10.1007/s004010050602			10	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	WF880	WOS:A1997WF88000013	9039468				2021-06-18	
J	HOVDA, DA; LEE, SM; SMITH, ML; VONSTUCK, S; BERGSNEIDER, M; KELLY, D; SHALMON, E; MARTIN, N; CARON, M; MAZZIOTTA, J; PHELPS, M; BECKER, DP				HOVDA, DA; LEE, SM; SMITH, ML; VONSTUCK, S; BERGSNEIDER, M; KELLY, D; SHALMON, E; MARTIN, N; CARON, M; MAZZIOTTA, J; PHELPS, M; BECKER, DP			THE NEUROCHEMICAL AND METABOLIC CASCADE FOLLOWING BRAIN INJURY - MOVING FROM ANIMAL-MODELS TO MAN	JOURNAL OF NEUROTRAUMA			English	Article						GLYCOLYSIS; POTASSIUM; CALCIUM; FLUID PERCUSSION; GLUTAMATE; EXCITATORY AMINO ACIDS; POSITRON EMISSION TOMOGRAPHY; CEREBRAL MICRODIALYSIS	CEREBRAL BLOOD-FLOW; GLUCOSE-UTILIZATION; RAT; FLUORODEOXYGLUCOSE	Experimental traumatic brain injury produces a series of cellular events contributing to a neurochemical and neurometabolic cascade. This cascade is defined by the release of neurotransmitters resulting in a massive ionic flux, which, consequently, produces an increase in glycolysis. This increase in glycolysis is followed by a metabolic diaschisis, which is related to the degree and extent of behavioral deficits. Clinical efforts have now determined that a similar cascade occurs in human head injury, validating the animal model as well as providing new assessment strategies for the management and treatment of brain injury.	UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,DEPT NEUROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,DEPT MOLEC & NUCL PHARMACOL,LOS ANGELES,CA 90024	HOVDA, DA (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,DEPT SURG,DIV NEUROSURG,74-140 CHS,LOS ANGELES,CA 90024, USA.		Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739; Martin, Neil/0000-0002-6565-4131	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308] Funding Source: Medline		ACKERMANN RF, 1989, J CEREBR BLOOD F MET, V9, P774, DOI 10.1038/jcbfm.1989.111; ANDERSEN BJ, 1989, INTRACRANIAL PRESSUR, V7, P575; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; KAQWAMATA T, 1995, BRAIN RES, V674, P196; KATAYAMA Y, 1988, Society for Neuroscience Abstracts, V14, P1154; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; LEAR JL, 1988, J CEREBR BLOOD F MET, V8, P575, DOI 10.1038/jcbfm.1988.99; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; OGAWA H, 1993, J CEREB BLOOD FLO S1, V13, pS575; UNTERBERG AW, 1988, J NEUROSURG, V68, P595; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOSHINO A, 1991, J CEREB BLOOD FLO S2, V11, pS343; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	27	164	165	0	9	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1995	12	5					903	906		10.1089/neu.1995.12.903			4	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TE646	WOS:A1995TE64600015	8594218				2021-06-18	
J	KAPUR, N; BARKER, S; BURROWS, EH; ELLISON, D; BRICE, J; ILLIS, LS; SCHOLEY, K; COLBOURN, C; WILSON, B; LOATES, M				KAPUR, N; BARKER, S; BURROWS, EH; ELLISON, D; BRICE, J; ILLIS, LS; SCHOLEY, K; COLBOURN, C; WILSON, B; LOATES, M			HERPES-SIMPLEX ENCEPHALITIS - LONG-TERM MAGNETIC-RESONANCE-IMAGING AND NEUROPSYCHOLOGICAL PROFILE	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TEMPORAL-LOBE; AMNESIC SYNDROME; GLOBAL AMNESIA; LESIONS; MEMORY; HIPPOCAMPUS; IMPAIRMENT; RECOVERY	The first comprehensive in vivo documentation of the long term profile of pathological and spared tissue is described in a group of 10 patients with a diagnosis of herpes simplex encephalitis, who were left with memory difficulties as a major residual sequel of their condition. With a dedicated MRI protocol, which included high resolution images of temporal robe and limbic system areas, data are provided on structures that have recently gained importance as anatomical substrates for amnesia. The major features of the lesion profile were: (1) unilateral or bilateral hippocampal damage never occurred in isolation, and was often accompanied by damage to the parahippocampus, the amygdala, specific temporal robe gyri, and the temporal poles; (2) the insula was always abnormal; (3) neocortical temporal lobe damage was usually unilateral or asymmetric. It never occurred in isolation, and was invariably associated with more medial pathological changes; (4) anterior and inferior temporal robe gyri were damaged more often and more severely than posterior and superior temporal lobe gyri; (5) pronounced abnormality was often present in the substantia innominata (region of the basal forebrain/anterior perforated substance); (6) there was evidence of significant abnormality in the fornix; (7) there was evidence of damage to the mammillary bodies; (8) thalamic nuclei were affected in around 50% of cases, with damage usually unilateral; (9) frontal lobe damage was present in a few patients, and affected medial areas more than dorsolateral areas; (10) there was some involvement of the striatum, although this was usually unilateral and mild; (11) there was usually limited involvement of the cingulate gyrus and of the parietal and occipital robes; (12) the cerebellum and brain stem were never damaged. Lesion covariance analysis indicated a close relation between the presence of abnormalities in temporal lobe and limbic-diencephalic regions. Unlike severe head injury, lesions in the temporal pole were not associated with the presence of lesions in the orbitofrontal cortex. Long term neuropsychological impairments were characterised by a dense amnesia in 60% of cases, and a less severe but noticeable anterograde memory impairment in the others. Naming and problem solving deficits were found in a small number of cases. Only two patients were able to return to open employment. Severity of amnesia showed a significant relation with severity of damage to medial limbic system structures such as the hippocampus, with bilateral damage being particularly important. By contrast, there was a minimal relation between memory loss and severity of damage to the thalamus, to lateral temporal robe areas, or to the frontal robes.	WESSEX NEUROL CTR,SOUTHAMPTON,HANTS,ENGLAND; SOUTHAMPTON GEN HOSP,DEPT NEUROPATHOL,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; KING EDWARD VII HOSP,MIDHURST,ENGLAND; APPL PSYCHOL UNIT,CAMBRIDGE,ENGLAND; UNIV SOUTHAMPTON,DEPT PSYCHOL,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND							ALBERTYN L E, 1990, Australasian Radiology, V34, P117, DOI 10.1111/j.1440-1673.1990.tb02825.x; CERMAK LS, 1976, NEUROPSYCHOLOGIA, V14, P311, DOI 10.1016/0028-3932(76)90025-7; COFFEY CE, 1993, ARCH GEN PSYCHIAT, V50, P7; DAMASIO AR, 1985, ARCH NEUROL-CHICAGO, V42, P252, DOI 10.1001/archneur.1985.04060030070012; DeArmond S.J., 1989, STRUCTURE HUMAN BRAI; DEMAEREL P, 1992, NEURORADIOLOGY, V34, P490, DOI 10.1007/BF00598957; DUYCKAERTS C, 1985, ANN NEUROL, V18, P314, DOI 10.1002/ana.410180307; HIERONS R, 1978, PSYCHOL MED, V8, P21, DOI 10.1017/S0033291700006607; IRLE E, 1992, ANN NEUROL, V31, P473, DOI 10.1002/ana.410310503; JERNIGAN TL, 1993, NEUROPSYCHOLOGY, V7, P14, DOI DOI 10.1037/0894-4105.7.1.14; KRITCHEVSKY M, 1993, NEUROLOGY, V43, P326, DOI 10.1212/WNL.43.2.326; LARCOMIS D, 1991, J COMPUT ASSIST TOMO, V14, P115; LAURENT B, 1990, REV NEUROL-FRANCE, V146, P671; LEE AWM, 1990, CLIN RADIOL, V42, P24, DOI 10.1016/S0009-9260(05)81617-4; LENCZ T, 1992, ANN NEUROL, V31, P629, DOI 10.1002/ana.410310610; McKenna P.W.E., 1983, GRADED NAMING TEST; MILNER B, 1990, DISCUSSIONS NEUROSCI, V6, P101; NAIDICH TP, 1988, BRAIN ANATOMY MAGNET; Nelson H., 1982, NATIONAL ADULT READI; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727; Pandya D.N., 1990, NEUROBIOLOGY HIGHER, P53; PARKIN AJ, 1992, NEUROPSYCHOLOGY MEMO, P122; PENFIELD W, 1974, ARCH NEUROL-CHICAGO, V31, P145, DOI 10.1001/archneur.1974.00490390027001; PIETRINI V, 1988, J NEUROL NEUROSUR PS, V51, P1284, DOI 10.1136/jnnp.51.10.1284; SCHMIDBAUER M, 1991, J COMPUT ASSIST TOMO, V15, P811, DOI 10.1097/00004728-199109000-00016; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; VANHOESEN GW, 1990, BRAIN ORG MEMORY CEL, P234; Victor M, 1990, J Cogn Neurosci, V2, P246, DOI 10.1162/jocn.1990.2.3.246; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; WARRINGTON EK, 1988, BRAIN COGNITION, V7, P184, DOI 10.1016/0278-2626(88)90029-2; WARRINGTON EK, 1992, NEUROPSYCHOLOGIA, V30, P437, DOI 10.1016/0028-3932(92)90091-Y; Warrington EK., 1984, RECOGNITION MEMORY T; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; WILSON J T L, 1992, Brain Injury, V6, P391, DOI 10.3109/02699059209008135; WOODS BT, 1982, J NEUROL NEUROSUR PS, V45, P243, DOI 10.1136/jnnp.45.3.243; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	37	164	166	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	1994	57	11					1334	1342		10.1136/jnnp.57.11.1334			9	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	PQ919	WOS:A1994PQ91900007	7964808	Green Published, Bronze			2021-06-18	
J	CORRIGAN, JD				CORRIGAN, JD			DEVELOPMENT OF A SCALE FOR ASSESSMENT OF AGITATION FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article										CORRIGAN, JD (corresponding author), OHIO STATE UNIV, DEPT PHYS MED, DODD HALL, 471 DODD DR, COLUMBUS, OH 43210 USA.		Corrigan, John D./E-2921-2011				ADAMOVICH BB, 1985, COGNITIVE REHABILITA; ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V9, P219; BOOTH BJ, 1980, REHABILITATION HEAD, P43; Carmines E.G., 1979, RELIABILITY VALIDITY, V17; COPE DN, 1986, J HEAD TRAUMA REHAB, V1, P34; CRONBACH LJ, 1955, PSYCHOL BULL, V52, P281, DOI 10.1037/h0040957; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; FAUMAN MA, 1978, JAMA-J AM MED ASSOC, V240, P380, DOI 10.1001/jama.240.4.380; GOODMAN LA, 1954, J AM STAT ASSOC, V49, P732, DOI 10.2307/2281536; HAYS WL, 1973, STATISTICS SOCIAL SC; JACKSON RD, 1985, ARCH PHYS MED REHAB, V66, P180; Jennett B, 1981, MANAGEMENT HEAD INJU; Kelly G. A., 1955, PSYCHOL PERSONAL CON, VI; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MALKMUS D, 1980, REHABILITATION HEAD; MYSIW WJ, 1988, AM J PHYS MED REHAB, V67, P29, DOI 10.1097/00002060-198802000-00006; Nunnally J.C., 1978, PSYCHOMETRIC THEORY; OLSEN DA, 1983, MANUAL BEHAVIORAL MA; RAY AA, 1982, SAS USERS GUIDE STAT; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; WEINBERG RM, 1983, MANAGEMENT AGITATED	23	164	164	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAR	1989	11	2					261	277		10.1080/01688638908400888			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	T4685	WOS:A1989T468500007	2925835				2021-06-18	
J	Papa, L; Brophy, GM; Welch, RD; Lewis, LM; Braga, CF; Tan, CN; Ameli, NJ; Lopez, MA; Haeussler, CA; Giordano, DIM; Silvestri, S; Giordano, P; Weber, KD; Hill-Pryor, C; Hack, DC				Papa, Linda; Brophy, Gretchen M.; Welch, Robert D.; Lewis, Lawrence M.; Braga, Carolina F.; Tan, Ciara N.; Ameli, Neema J.; Lopez, Marco A.; Haeussler, Crystal A.; Giordano, Diego I. Mendez; Silvestri, Salvatore; Giordano, Philip; Weber, Kurt D.; Hill-Pryor, Crystal; Hack, Dallas C.			Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury	JAMA NEUROLOGY			English	Article							FIBRILLARY ACIDIC PROTEIN; INTRACRANIAL LESIONS; NEUROSURGICAL INTERVENTION; COMPUTED-TOMOGRAPHY	IMPORTANCE Glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) have been widely studied and show promise for clinical usefulness in suspected traumatic brain injury (TBI) and concussion. Understanding their diagnostic accuracy over time will help translate them into clinical practice. OBJECTIVES To evaluate the temporal profiles of GFAP and UCH-L1 in a large cohort of trauma patients seen at the emergency department and to assess their diagnostic accuracy over time, both individually and in combination, for detecting mild to moderate TBI (MMTBI), traumatic intracranial lesions on head computed tomography (CT), and neurosurgical intervention. DESIGN, SETTING, AND PARTICIPANTS This prospective cohort study enrolled adult trauma patients seen at a level I trauma center from March 1, 2010, to March 5, 2014. All patients underwent rigorous screening to determine whether they had experienced an MMTBI (blunt head trauma with loss of consciousness, amnesia, or disorientation and a Glasgow Coma Scale score of 9-15). Of 3025 trauma patients assessed, 1030 met eligibility criteria for enrollment, and 446 declined participation. Initial blood samples were obtained in 584 patients enrolled within 4 hours of injury. Repeated blood sampling was conducted at 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, and 180 hours after injury. MAIN OUTCOMES AND MEASURES Diagnosis of MMTBI, presence of traumatic intracranial lesions on head CT scan, and neurosurgical intervention. RESULTS A total of 1831 blood samples were drawn from 584 patients (mean [SD] age, 40 [16] years; 62.0%[362 of 584] male) over 7 days. Both GFAP and UCH-L1 were detectible within 1 hour of injury. GFAP peaked at 20 hours after injury and slowly declined over 72 hours. UCH-L1 rose rapidly and peaked at 8 hours after injury and declined rapidly over 48 hours. Over the course of 1 week, GFAP demonstrated a diagnostic range of areas under the curve for detecting MMTBI of 0.73 (95% CI, 0.69-0.77) to 0.94 (95% CI, 0.78-1.00), and UCH-L1 demonstrated a diagnostic range of 0.30 (95% CI, 0.02-0.50) to 0.67 (95% CI, 0.53-0.81). For detecting intracranial lesions on CT, the diagnostic ranges of areas under the curve were 0.80 (95% CI, 0.67-0.92) to 0.97 (95% CI, 0.93-1.00) for GFAP and 0.31 (95% CI, 0-0.63) to 0.77 (95% CI, 0.68-0.85) for UCH-L1. For distinguishing patients with and without a neurosurgical intervention, the range for GFAP was 0.91 (95% CI, 0.79-1.00) to 1.00 (95% CI, 1.00-1.00), and the range for UCH-L1 was 0.50 (95% CI, 0-1.00) to 0.92 (95% CI, 0.83-1.00). CONCLUSIONS AND RELEVANCE GFAP performed consistently in detecting MMTBI, CT lesions, and neurosurgical intervention across 7 days. UCH-L1 performed best in the early postinjury period.	[Papa, Linda; Braga, Carolina F.; Tan, Ciara N.; Ameli, Neema J.; Lopez, Marco A.; Haeussler, Crystal A.; Giordano, Diego I. Mendez; Silvestri, Salvatore; Giordano, Philip; Weber, Kurt D.] Orlando Reg Med Ctr Inc, Dept Emergency Med, 86 W Underwood,Ste S-200, Orlando, FL 32806 USA; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Pharmacotherapy & Outcomes Sci, Richmond, VA 23284 USA; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23284 USA; [Welch, Robert D.] Wayne State Univ, Sch Med, Dept Med, Div Emergency Med, Detroit, MI 48201 USA; [Lewis, Lawrence M.] Washington Univ, Sch Med St Louis, Div Emergency Med, St Louis, MO 63130 USA; [Hill-Pryor, Crystal] US Dept Def, Silver Spring, MD USA; [Hack, Dallas C.] Brain Hlth, Harpers Ferry, WV USA	Papa, L (corresponding author), Orlando Reg Med Ctr Inc, Dept Emergency Med, 86 W Underwood,Ste S-200, Orlando, FL 32806 USA.	lpstat@aol.com		Brophy, Gretchen/0000-0002-4749-2693	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676] Funding Source: NIH RePORTER	This study was supported by award R01NS057676 from the National Institute of Neurological Disorders and Stroke (Dr Papa, principal investigator).	Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Papa L., 2012, PROTEOMICS HUMAN DIS; Papa L, 2016, J NEUROTRAUM, V33, P58, DOI 10.1089/neu.2015.3869; Papa L, 2015, ACAD EMERG MED, V22, P1274, DOI 10.1111/acem.12795; Papa L, 2015, J NEUROTRAUM, V32, P661, DOI 10.1089/neu.2014.3655; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2013, J NEUROTRAUM, V30, P324, DOI 10.1089/neu.2012.2545; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511	13	163	170	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	MAY	2016	73	5					551	560		10.1001/jamaneurol.2016.0039			10	Clinical Neurology	Neurosciences & Neurology	DL2JW	WOS:000375461900017	27018834	Bronze	Y	N	2021-06-18	
J	Tang-Schomer, MD; White, JD; Tien, LW; Schmitt, LI; Valentin, TM; Graziano, DJ; Hopkins, AM; Omenetto, FG; Haydon, PG; Kaplan, DL				Tang-Schomer, Min D.; White, James D.; Tien, Lee W.; Schmitt, L. Ian; Valentin, Thomas M.; Graziano, Daniel J.; Hopkins, Amy M.; Omenetto, Fiorenzo G.; Haydon, Philip G.; Kaplan, David L.			Bioengineered functional brain-like cortical tissue	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						electrophysiology; connectivity; silk; scaffold; traumatic brain injury	AMINO-ACIDS; INJURY; SCAFFOLD; METABOLITES; FABRICATION; PROVIDES; IMPACT; NERVE; MODEL	The brain remains one of the most important but least understood tissues in our body, in part because of its complexity as well as the limitations associated with in vivo studies. Although simpler tissues have yielded to the emerging tools for in vitro 3D tissue cultures, functional brain-like tissues have not. We report the construction of complex functional 3D brain-like cortical tissue, maintained for months in vitro, formed from primary cortical neurons in modular 3D compartmentalized architectures with electrophysiological function. We show that, on injury, this brain-like tissue responds in vitro with biochemical and electrophysiological outcomes that mimic observations in vivo. This modular 3D brain-like tissue is capable of real-time nondestructive assessments, offering previously unidentified directions for studies of brain homeostasis and injury.	[Tang-Schomer, Min D.; White, James D.; Tien, Lee W.; Valentin, Thomas M.; Graziano, Daniel J.; Hopkins, Amy M.; Omenetto, Fiorenzo G.; Kaplan, David L.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA; [Omenetto, Fiorenzo G.] Tufts Univ, Dept Phys, Medford, MA 02155 USA; [Schmitt, L. Ian; Haydon, Philip G.] Tufts Univ, Dept Neurosci, Sch Med, Boston, MA 02111 USA	Kaplan, DL (corresponding author), Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA.	david.kaplan@tufts.edu		Tang-Schomer, Min/0000-0001-7585-3890; Schmitt, Luke/0000-0002-1104-2666	National Institutes of Health P41 Tissue Engineering Resource CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EB002520]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB002520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS061764] Funding Source: NIH RePORTER	We thank the laboratory of Dr. Stephen Moss for providing embryonic rat brain tissues, Dr. Michael Whalen for discussing brain injury experiments, Antonio Varone and Dr. Kyongbum Lee for providing liquid chromatography/MS assistance, and Dr. Michaela Reagan and Dr. Biman Mandal for assisting with silk material processing. Special thanks to Donna B. Kaplan for inspiring this work. This work was funded by National Institutes of Health P41 Tissue Engineering Resource Center Grant EB002520.	Bajad SU, 2006, J CHROMATOGR A, V1125, P76, DOI 10.1016/j.chroma.2006.05.019; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Bonandrini B, 2014, TISSUE ENG PT A, V20, P1486, DOI [10.1089/ten.TEA.2013.0269, 10.1089/ten.tea.2013.0269]; Didier A, 2001, P NATL ACAD SCI USA, V98, P6441, DOI 10.1073/pnas.101126398; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858; Gurkan UA, 2013, ADV MATER, V25, P1192, DOI 10.1002/adma.201203261; Hill SL, 2012, P NATL ACAD SCI USA, V109, pE2885, DOI 10.1073/pnas.1202128109; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Hopkins AM, 2013, ADV FUNCT MATER, V23, P5140, DOI 10.1002/adfm.201300435; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; Hussein KH, 2013, TRANSPL P, V45, P3092, DOI 10.1016/j.transproceed.2013.08.016; Imai T, 2009, SCIENCE, V325, P585, DOI 10.1126/science.1173596; Ingalhalikar M, 2014, P NATL ACAD SCI USA, V111, P823, DOI 10.1073/pnas.1316909110; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KORSCHING S, 1993, J NEUROSCI, V13, P2739; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517; Maddah M, 2008, MED IMAGE ANAL, V12, P191, DOI 10.1016/j.media.2007.10.003; Mariani J, 2012, P NATL ACAD SCI USA, V109, P12770, DOI 10.1073/pnas.1202944109; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Mironov V, 2003, TRENDS BIOTECHNOL, V21, P157, DOI 10.1016/S0167-7799(03)00033-7; Moody WJ, 2005, PHYSIOL REV, V85, P883, DOI 10.1152/physrev.00017.2004; Mow VC, 2005, BASIC ORTHOPAEDIC BI, pxvi; Nazarov R, 2004, BIOMACROMOLECULES, V5, P718, DOI 10.1021/bm034327e; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Odawara A, 2013, RSC ADV, V3, P23620, DOI 10.1039/c3ra44757j; Oliet SHR, 2001, SCIENCE, V292, P923, DOI 10.1126/science.1059162; Omenetto F, 2010, SCI AM, V303, P76, DOI 10.1038/scientificamerican1110-76; Petersen TH, 2010, SCIENCE, V329, P538, DOI 10.1126/science.1189345; Rockwood DN, 2011, NAT PROTOC, V6, P1612, DOI 10.1038/nprot.2011.379; Rouwkema J, 2008, TRENDS BIOTECHNOL, V26, P434, DOI 10.1016/j.tibtech.2008.04.009; Schmitt LI, 2012, J NEUROSCI, V32, P4417, DOI 10.1523/JNEUROSCI.5689-11.2012; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Song JJ, 2013, NAT MED, V19, P646, DOI 10.1038/nm.3154; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Tang-Schomer MD, 2014, ADV FUNCT MATER, V24, P1938, DOI 10.1002/adfm.201303196; Wray LS, 2012, BIOMATERIALS, V33, P9214, DOI 10.1016/j.biomaterials.2012.09.017	41	163	169	3	77	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	SEP 23	2014	111	38					13811	13816		10.1073/pnas.1324214111			6	Multidisciplinary Sciences	Science & Technology - Other Topics	AP3PC	WOS:000341988200042	25114234	Green Published, Bronze			2021-06-18	
J	Eisenberg, MA; Andrea, J; Meehan, W; Mannix, R				Eisenberg, Matthew A.; Andrea, John; Meehan, William; Mannix, Rebekah			Time Interval Between Concussions and Symptom Duration	PEDIATRICS			English	Article						brain concussion; emergency medicine; pediatrics; postconcussion syndrome; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; HIGH-SCHOOL; POSTCONCUSSIVE SYMPTOMS; RECOVERY-TIME; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; CONSTRUCT-VALIDITY; TEMPORAL WINDOW; SEX-DIFFERENCES	OBJECTIVE: To test the hypothesis that children with a previous history of concussion have a longer duration of symptoms after a repeat concussion than those without such a history. METHODS: Prospective cohort study of consecutive patients 11 to 22 years old presenting to the emergency department of a children's hospital with an acute concussion. The main outcome measure was time to symptom resolution, assessed by the Rivermead Post-Concussion Symptoms Questionnaire (RPSQ). Patients and providers completed a questionnaire describing mechanism of injury, associated symptoms, past medical history, examination findings, diagnostic studies, and the RPSQ. Patients were then serially administered the RPSQ for 3 months after the concussion or until all symptoms resolved. RESULTS: A total of 280 patients were enrolled over 12 months. Patients with a history of previous concussion had a longer duration of symptoms than those without previous concussion (24 vs 12 days, P = .02). Median symptom duration was even longer for patients with multiple previous concussions (28 days, P = .03) and for those who had sustained a concussion within the previous year (35 days, P = .007) compared with patients without those risk factors. In a multivariate model, previous concussion, absence of loss of consciousness, age >= 13, and initial RPSQ score >18 were significant predictors of prolonged recovery. CONCLUSIONS: Children with a history of a previous concussion, particularly recent or multiple concussions, are at increased risk for prolonged symptoms after concussion. These findings have direct implications on the management of patients with concussion who are at high risk for repeat injuries.	[Eisenberg, Matthew A.; Andrea, John; Meehan, William; Mannix, Rebekah] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Emergency Med, Boston, MA USA	Eisenberg, MA (corresponding author), Boston Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	matthew.eisenberg@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020		Division of Emergency Medicine, Boston Children's Hospital	No external funding. Expenses related to use of research coordinators were paid by the Division of Emergency Medicine, Boston Children's Hospital.	[Anonymous], 2001, BRIT J SPORT MED, V35, P367; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Lannsjo M, 2011, J REHABIL MED, V43, P997, DOI 10.2340/16501977-0875; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Vagnozzi R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	44	163	163	0	33	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUL	2013	132	1					8	17		10.1542/peds.2013-0432			10	Pediatrics	Pediatrics	197HW	WOS:000322841900040	23753087				2021-06-18	
J	Corrigan, JD; Hammond, FM				Corrigan, John D.; Hammond, Flora M.			Traumatic Brain Injury as a Chronic Health Condition	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Chronic brain injury; Disease management; Rehabilitation; Traumatic brain injury		Growing evidence indicates that multiple types of brain injury, including traumatic brain injury, are dynamic conditions that continue to change years after onset. For a subset of individuals who incur these injuries, decline occurs over time and is likely due to progressive neurodegenerative processes, comorbid conditions, aging, behavioral choices, and/or psychosocial factors. Deterioration, whether directly or indirectly associated with the original brain injury, necessitates a clinical approach as a chronic health condition, including identification of risk and protective factors, protocols for early identification, evidence-based preventive and ameliorative treatment, and training in self-management. We propose that the acknowledgment of chronic brain injury will facilitate the research necessary to provide a disease management approach. (C) 2013 by the American Congress of Rehabilitation Medicine	[Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Wexner Med Ctr, Columbus, OH 43210 USA; [Hammond, Flora M.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN USA; [Hammond, Flora M.] Rehabil Hosp Indiana, Indianapolis, IN USA	Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, Wexner Med Ctr, 480 Med Ctr Dr, Columbus, OH 43210 USA.	corrigan.1@osu.edu	Corrigan, John D./E-2921-2011				Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Hammond FM, 2013, BRAIN INJ P IN PRESS, V10; Institute of Medicine, 2012, ESS HLTH BEN BAL COV, DOI 10. 17226/13234; Institute of Medicine, 2009, GULF WAR HLTH, V7; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meyer J, 2008, CHRONIC DIS MANAGEME; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	11	163	168	1	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2013	94	6					1199	1201		10.1016/j.apmr.2013.01.023			3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	158FH	WOS:000319954400023	23402722				2021-06-18	
J	Bigler, ED; Maxwell, WL				Bigler, Erin D.; Maxwell, William L.			Neuropathology of mild traumatic brain injury: relationship to neuroimaging findings	BRAIN IMAGING AND BEHAVIOR			English	Article						Neuropathology; Mild traumatic brain injury; Neuroimaging; Traumatic axonal injury; Diffuse axonal injury; Concussion	DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; CORTICAL SPREADING DEPRESSION; SPORT-RELATED CONCUSSION; WORKING-MEMORY TASK; PIG OPTIC-NERVE; WHITE-MATTER; STRETCH-INJURY; CEREBRAL ATROPHY; INFLAMMATORY RESPONSE	Neuroimaging identified abnormalities associated with traumatic brain injury (TBI) are but gross indicators that reflect underlying trauma-induced neuropathology at the cellular level. This review examines how cellular pathology relates to neuroimaging findings with the objective of more closely relating how neuroimaging findings reveal underlying neuropathology. Throughout this review an attempt will be made to relate what is directly known from post-mortem microscopic and gross anatomical studies of TBI of all severity levels to the types of lesions and abnormalities observed in contemporary neuroimaging of TBI, with an emphasis on mild traumatic brain injury (mTBI). However, it is impossible to discuss the neuropathology of mTBI without discussing what occurs with more severe injury and viewing pathological changes on some continuum from the mildest to the most severe. Historical milestones in understanding the neuropathology of mTBI are reviewed along with implications for future directions in the examination of neuroimaging and neuropathological correlates of TBI.	[Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Neurosci Ctr, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA; [Maxwell, William L.] Univ Glasgow, Dept Anat, Sch Life Sci, Glasgow G12 8QQ, Lanark, Scotland	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA.	erin_bigler@byu.edu; William.Maxwell@glasgow.ac.uk					Agnati LF, 2007, BRAIN RES REV, V55, P167, DOI 10.1016/j.brainresrev.2007.03.004; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barr W. B., 2011, BRAIN INJURY; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Bigler E. D., 2011, INT J PSYCH IN PRESS; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Blankenberg FG, 2008, CURR PHARM DESIGN, V14, P2974, DOI 10.2174/138161208786404353; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bouilleret V, 2009, J NEUROTRAUM, V26, P1999, DOI 10.1089/neu.2009.0943; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brandstack N, 2011, CLIN NEURORADIOL, V21, P75, DOI 10.1007/s00062-011-0058-5; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Budde M. D., 2011, BRAIN J NEUROLOGY; Buki A, 2000, J NEUROSCI, V20, P2825; Chanraud S, 2010, NEUROPSYCHOPHARMACOL, V35, P1868, DOI 10.1038/npp.2010.56; Chanraud S, 2010, NEUROPSYCHOL REV, V20, P209, DOI 10.1007/s11065-010-9129-7; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; COLLEWIJN H, 1966, J PHYSIOL-LONDON, V185, P1; COURVILLE C B, 1952, Bull Los Angel Neuro Soc, V17, P71; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Davenport N. D., 2011, NEUROIMAGE IN PRESS; De Beaumont L., 2011, CEREBRAL CORTEX; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Downes CE, 2010, BRIT J PHARMACOL, V160, P1872, DOI 10.1111/j.1476-5381.2010.00864.x; Duma SM, 2009, IEEE ENG MED BIO, P1123, DOI 10.1109/IEMBS.2009.5333423; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Fuster JM, 2009, J COGNITIVE NEUROSCI, V21, P2047, DOI 10.1162/jocn.2009.21280; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gasparetto EL, 2011, NEUROIMAG CLIN N AM, V21, P115, DOI 10.1016/j.nic.2011.02.003; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Geary E. K., 2011, J INT NEUROPSYCH SOC, P1; Ghosh A, 2009, BRAIN INJURY, V23, P228, DOI 10.1080/02699050802672789; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2000, NEUROLOGIC ATHLETIC, P80; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V1; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Grossman E. J., 2011, J NEUROTRAUMA; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Harrison LCV, 2010, ACAD RADIOL, V17, P696, DOI 10.1016/j.acra.2010.01.005; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hasiloglu ZI, 2011, AM J NEURORADIOL, V32, P99, DOI 10.3174/ajnr.A2250; Helmy A., 2010, J CEREBRAL BLOOD FLO; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; Holli KK, 2010, ACAD RADIOL, V17, P1096, DOI 10.1016/j.acra.2010.04.009; Holli Kirsi K, 2010, BMC Med Imaging, V10, P8, DOI 10.1186/1471-2342-10-8; Hunter J. V., 2011, J NEUROTRAU IN PRESS; Inglese M, 2006, BRAIN INJURY, V20, P15, DOI 10.1080/02699050500309593; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Irimia A, 2011, J NEUROTRAUM, V28, P2287, DOI 10.1089/neu.2011.1920; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jander S, 2001, J CEREBR BLOOD F MET, V21, P218, DOI 10.1097/00004647-200103000-00005; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; Johnson B., 2011, NEUROSCIENCE LETT; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; Kilinc D, 2011, NEUROTOX RES, V19, P149, DOI 10.1007/s12640-010-9152-8; Kilinc D, 2009, EXP NEUROL, V219, P553, DOI 10.1016/j.expneurol.2009.07.014; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kuceyeski A, 2011, NEUROIMAGE, V58, P109, DOI 10.1016/j.neuroimage.2011.05.087; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Lange R. T., 2011, J HEAD TRAUMA REHABI; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; LaPlaca MC, 2011, J NEUROTRAUM, V28, P2201, DOI 10.1089/neu.2011.9944; LaPlaca MC, 2010, J BIOMECH, V43, P71, DOI 10.1016/j.jbiomech.2009.09.011; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Li XH, 2008, BIOCONJUGATE CHEM, V19, P1684, DOI 10.1021/bc800164d; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Lo TP, 2009, J COMP NEUROL, V514, P433, DOI 10.1002/cne.22014; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mao HJ, 2010, BIOMECH MODEL MECHAN, V9, P763, DOI 10.1007/s10237-010-0212-z; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; MATHEW P, 1994, ACTA NEUROCHIR, P428; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P78, DOI 10.1007/BF00427218; MAXWELL WL, 1994, ACTA NEUROCHIR, P465; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer A. R., 2011, HUMAN BRAIN MAPPING; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; McAllister K. A., 2010, FUNDAMENTALS CELLULA; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAuley G, 2010, MAGN RESON MED, V63, P106, DOI 10.1002/mrm.22185; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Medaglia J. D., 2011, HUMAN BRAIN MAPPING; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Messe A., 2010, HUMAN BRAIN MAPPING; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Monnerie H, 2010, EXP NEUROL, V224, P415, DOI 10.1016/j.expneurol.2010.05.001; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morino T, 2003, NEUROSCI RES, V46, P309, DOI 10.1016/S0168-0102(03)00095-6; NILSSON B, 1977, J NEUROSURG, V47, P274, DOI 10.3171/jns.1977.47.2.0274; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Pasco A, 2006, EUR RADIOL, V16, P1501, DOI 10.1007/s00330-005-0086-0; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; Ramlackhansingh A. F., 2011, ANN NEUROLOGY; RINK A, 1995, AM J PATHOL, V147, P1575; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Ruttan L., 2008, ARCH PHYS MED REHAB, V89, pS69; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Smits M., 2010, NEURORADIOLOGY; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Stevens RD, 2008, SEMIN NEUROL, V28, P631, DOI 10.1055/s-0028-1105977; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Strong AJ, 2005, ADV TECH STAND NEUR, V30, P3, DOI 10.1007/3-211-27208-9_1; Sulaiman AM, 2011, J NEUROTRAUM, V28, P383, DOI 10.1089/neu.2010.1707; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Talavage T. M., 2010, J NEUROTRAU IN PRESS; Tang L., 2011, RADIOLOGY; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; TOMEI G, 1990, ACTA NEUROPATHOL, V80, P506, DOI 10.1007/BF00294611; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Tournier J. D., 2011, MAGNETIC RESONANCE M; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; van de Looij Y., 2011, NMR BIOMEDICINE; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Wager-Smith K., 2010, NEUROSCIENCE BIOBEHA; Wang J. A., 2009, AM J PHYSIOL-CELL PH, V297, pC823; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Weight DG, 1998, PSYCHIAT CLIN N AM, V21, P609, DOI 10.1016/S0193-953X(05)70026-5; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Westerhausen R, 2010, NEUROPSYCHOLOGIA, V48, P2075, DOI 10.1016/j.neuropsychologia.2010.03.028; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wu T. C., 2010, DEV NEUROSCIENCE; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Yeo R., 2010, J NEUROTRAUMA; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488; Zhu T, 2011, NEUROIMAGE, V56, P1398, DOI 10.1016/j.neuroimage.2011.02.010; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	215	163	164	1	40	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		108	136		10.1007/s11682-011-9145-0			29	Neuroimaging	Neurosciences & Neurology	967LI	WOS:000305908900002	22434552				2021-06-18	
J	Konrad, C; Geburek, AJ; Rist, F; Blumenroth, H; Fischer, B; Husstedt, I; Arolt, V; Schiffbauer, H; Lohmann, H				Konrad, C.; Geburek, A. J.; Rist, F.; Blumenroth, H.; Fischer, B.; Husstedt, I.; Arolt, V.; Schiffbauer, H.; Lohmann, H.			Long-term cognitive and emotional consequences of mild traumatic brain injury	PSYCHOLOGICAL MEDICINE			English	Article						Brain injury; cognition; depression	POST-CONCUSSION SYNDROME; WORD MEMORY TEST; CLOSED-HEAD-INJURY; NATURAL-HISTORY; NEUROPSYCHOLOGICAL DEFICITS; PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; CORPUS-CALLOSUM; WORKING-MEMORY; AXIS-I	Background. The objective of this study was to investigate long-term cognitive and emotional sequelae of mild traumatic brain injury (mTBI), as previous research has remained inconclusive with respect to their prevalence and extent. Method. Thirty-three individuals who had sustained mTBI on average 6 years prior to the study and 33 healthy control subjects were matched according to age, gender and education. Structural brain damage at time of testing was excluded by magnetic resonance imaging (MRI). A comprehensive neuropsychological test battery was conducted to assess learning, recall, working memory, attention and executive function. Psychiatric symptoms were assessed by the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) and the Beck Depression Inventory (BDI). Possible negative response bias was ruled out by implementing the Word Memory Test (WMT). Results. The mTBI individuals had significant impairments in all cognitive domains compared to the healthy control subjects. Effect sizes of cognitive deficits were medium to large, and could not be accounted for by self-perceived deficits, depression, compensation claims or negative response bias. BDI scores were significantly higher in the patient group, and three patients fulfilled DSM-IV criteria for a mild episode of major depression. Conclusions. Primarily, well-recovered individuals who had sustained a minor trauma more than half a decade ago continue to have long-term cognitive and emotional sequelae relevant for everyday social and professional life. mTBI may lead to a lasting disruption of neurofunctional circuits not detectable by standard structural MRI and needs to be taken seriously in clinical and forensic evaluations.	[Konrad, C.] Univ Marburg, Dept Psychiat & Psychotherapy, D-35039 Marburg, Germany; [Konrad, C.; Geburek, A. J.; Arolt, V.] Univ Munster, Dept Psychiat, D-4400 Munster, Germany; [Geburek, A. J.; Rist, F.] Univ Munster, Dept Psychol, D-4400 Munster, Germany; [Blumenroth, H.; Schiffbauer, H.] Univ Munster, Dept Clin Radiol, D-4400 Munster, Germany; [Fischer, B.] Univ Munster, Dept Neurosurg, D-4400 Munster, Germany; [Husstedt, I.; Lohmann, H.] Univ Munster, Dept Neurol, D-4400 Munster, Germany; [Schiffbauer, H.] Univ Bonn, Dept Radiol, D-5300 Bonn, Germany	Konrad, C (corresponding author), Univ Marburg, Dept Psychiat & Psychotherapy, Rudolf Bultmann Str 8, D-35039 Marburg, Germany.	Carsten.Konrad@med.uni-marburg.de			Medical Faculty of the Westfalische Wilhelms-University Munster, Germany [KO 210710]	This study was supported by an IMF grant from the Medical Faculty of the Westfalische Wilhelms-University Munster, Germany (KO 210710).	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson T, 2006, PRACT NEUROL, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Aschenbrenner S, 2000, REGENSBURGER WORTFLU; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Aubry M., 2002, BRIT J SPORT MED, V36, P3, DOI [DOI 10.1136/BJSM.36.1.6, 10.1136/bjsm.36.1.6]; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bessell AL, 2008, J INT NEUROPSYCH SOC, V14, P63, DOI 10.1017/S1355617708080065; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blanchet S, 2009, BRAIN INJURY, V23, P111, DOI 10.1080/02699050802649688; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; Bordini EJ, 2002, NEUROREHABILITATION, V17, P93; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Datta SGS, 2009, NEUROL INDIA, V57, P594, DOI 10.4103/0028-3886.57810; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Draper K, 2009, NEUROPSYCHOL REHABIL, V19, P645, DOI 10.1080/17405620802613935; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; EVANS RW, 1992, NEUROL CLIN, V10, P815; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 2005, GREENS WORD MEMORY T; Gupta A, 1991, J PERS CLIN STUD, V7, P55; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; HALL S, 1991, PERCEPT MOTOR SKILL, V72, P1295, DOI 10.2466/PMS.72.4.1295-1298; Harting C., 2000, WECHSLER GEDACHTNIST; Hautzinger M., 1995, BECK DEPRESSIONS INV; Helmstaedter C, 1996, VERBALER LERN MERKFA; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Iverson G. L., 1999, J COGNITIVE REHABILI, V17, P4; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Konrad C, 2008, J NEURAL TRANSM, V115, P1327, DOI 10.1007/s00702-008-0073-0; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McHugh T, 2006, BRAIN COGNITION, V60, P209; Merten T, 2005, ARCH CLIN NEUROPSYCH, V20, P719, DOI 10.1016/j.acn.2005.04.004; mTBI Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P68, DOI 10.1097/00001199-200601000-00007; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rickels E, 2006, SCHADEL HIRN VERLETZ; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff R, 2009, J HEAD TRAUMA REHAB, V24, P131, DOI 10.1097/01.HTR.0000348755.42649.e9; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Schoning S, 2009, HUM BRAIN MAPP, V30, P2746, DOI 10.1002/hbm.20702; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Wittchen H.-U., 1997, SKID 1 STRUKTURIERTE; Zimmermann P., 1992, TESTBATTERIE AUFMERK	94	163	163	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917	1469-8978		PSYCHOL MED	Psychol. Med.	JUN	2011	41	6					1197	1211		10.1017/S0033291710001728			15	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	759DP	WOS:000290221200009	20860865				2021-06-18	
J	Cole, JT; Yarnell, A; Kean, WS; Gold, E; Lewis, B; Ren, M; McMullen, DC; Jacobowitz, DM; Pollard, HB; O'Neill, JT; Grunberg, NE; Dalgard, CL; Frank, JA; Watson, WD				Cole, Jeffrey T.; Yarnell, Angela; Kean, William S.; Gold, Eric; Lewis, Bobbi; Ren, Ming; McMullen, David C.; Jacobowitz, David M.; Pollard, Harvey B.; O'Neill, J. Timothy; Grunberg, Neil E.; Dalgard, Clifton L.; Frank, Joseph A.; Watson, William D.			Craniotomy: True Sham for Traumatic Brain Injury, or a Sham of a Sham?	JOURNAL OF NEUROTRAUMA			English	Article						craniotomy; cytokines; magnetic resonance imaging; Neurological Severity Scale; traumatic brain injury	CONTROLLED CORTICAL IMPACT; MARROW STROMAL CELLS; RAT-BRAIN; COGNITIVE DEFICITS; METABOLISM; MICE; MODEL; CHEMOKINES; ASTROCYTES; RESPONSES	Neurological dysfunction after traumatic brain injury (TBI) is caused by both the primary injury and a secondary cascade of biochemical and metabolic events. Since TBI can be caused by a variety of mechanisms, numerous models have been developed to facilitate its study. The most prevalent models are controlled cortical impact and fluid percussion injury. Both typically use "sham" (craniotomy alone) animals as controls. However, the sham operation is objectively damaging, and we hypothesized that the craniotomy itself may cause a unique brain injury distinct from the impact injury. To test this hypothesis, 38 adult female rats were assigned to one of three groups: control (anesthesia only); craniotomy performed by manual trephine; or craniotomy performed by electric dental drill. The rats were then subjected to behavioral testing, imaging analysis, and quantification of cortical concentrations of cytokines. Both craniotomy methods generate visible MRI lesions that persist for 14 days. The initial lesion generated by the drill technique is significantly larger than that generated by the trephine. Behavioral data mirrored lesion volume. For example, drill rats have significantly impaired sensory and motor responses compared to trephine or naive rats. Finally, of the seven tested cytokines, KC-GRO and IFN-gamma showed significant increases in both craniotomy models compared to naive rats. We conclude that the traditional sham operation as a control confers profound proinflammatory, morphological, and behavioral damage, which confounds interpretation of conventional experimental brain injury models. Any experimental design incorporating "sham" procedures should distinguish among sham, experimentally injured, and healthy/naive animals, to help reduce confounding factors.	[Cole, Jeffrey T.; Kean, William S.; McMullen, David C.; Watson, William D.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Silver Spring, MD USA; [Yarnell, Angela; Grunberg, Neil E.] Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, Silver Spring, MD USA; [Ren, Ming; O'Neill, J. Timothy] Uniformed Serv Univ Hlth Sci, Dept Pediat, Silver Spring, MD USA; [Jacobowitz, David M.; Pollard, Harvey B.; Dalgard, Clifton L.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Silver Spring, MD USA; [Gold, Eric; Lewis, Bobbi; Frank, Joseph A.] NIH, Ctr Clin, Bethesda, MD 20892 USA; [Frank, Joseph A.] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD USA	Cole, JT (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, B-3012,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	jeffrey.cole@usuhs.mil	Frank, Joseph/W-2021-2019		Department of DefenseUnited States Department of Defense [60885-CNRM]; Comprehensive National Neuroscience Program (CNNP [W81XWH-07-0679]	This work was supported by a grant from the Department of Defense (60885-CNRM), and was performed at the Center for Neurosciences and Regenerative Medicine (CNRM) and at the National Institutes of Health (NIH). Additional support for this work was provided by the Comprehensive National Neuroscience Program (CNNP, award number W81XWH-07-0679), and the Intramural Research Program in the Clinical Center at the NIH.	Adeleye A, 2010, EUR J PHARMACOL, V629, P25, DOI 10.1016/j.ejphar.2009.11.066; Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; Arcure Jess, 2009, J Spec Oper Med, V9, P22; Baki SGA, 2009, BRAIN RES, V1280, P98, DOI 10.1016/j.brainres.2009.05.034; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; BEDERSON JB, 1986, J NEUROSURG, V64, P795, DOI 10.3171/jns.1986.64.5.0795; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Clausen BH, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-46; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cole JT, 2010, P NATL ACAD SCI USA, V107, P366, DOI 10.1073/pnas.0910280107; CRONE C, 1982, BRAIN RES, V241, P49, DOI 10.1016/0006-8993(82)91227-6; Deshpande LS, 2008, NEUROSCI LETT, V441, P115, DOI 10.1016/j.neulet.2008.05.113; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EDVINSSO.L, 1972, ACTA PATH MICRO IM A, VA 80, P134; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Faria MHG, 2007, ACTA CIR BRAS, V22, P125, DOI 10.1590/S0102-86502007000200009; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Harrington JF, 2005, J NEUROTRAUM, V22, P919, DOI 10.1089/neu.2005.22.919; Janabi N, 1999, J IMMUNOL, V162, P1701; Jia JX, 2010, MOL CELL BIOCHEM, V335, P127, DOI 10.1007/s11010-009-0249-4; Kosaras B, 2009, J COMP NEUROL, V515, P331, DOI 10.1002/cne.22049; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Marti M, 2005, J NEUROSCI, V25, P9591, DOI 10.1523/JNEUROSCI.2546-05.2005; MILLEN JE, 1985, J NEUROSURG, V62, P587, DOI 10.3171/jns.1985.62.4.0587; NAVARI RM, 1978, MICROVASC RES, V16, P304, DOI 10.1016/0026-2862(78)90064-X; OLESEN SP, 1987, ACTA PHYSIOL SCAND, V130, P63, DOI 10.1111/j.1748-1716.1987.tb08112.x; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; Rahman MA, 1997, PHARMACOL BIOCHEM BE, V56, P409, DOI 10.1016/S0091-3057(96)00222-5; Rustay NR, 2003, BEHAV BRAIN RES, V141, P237, DOI 10.1016/S0166-4328(02)00376-5; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Valable S, 2010, J CEREBR BLOOD F MET, V30, P361, DOI 10.1038/jcbfm.2009.222; Valles A, 2006, NEUROBIOL DIS, V22, P312, DOI 10.1016/j.nbd.2005.11.015; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Xiao-Sheng H, 2004, J CLIN NEUROSCI, V11, P402, DOI 10.1016/j.jocn.2004.01.001; Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047; Xiong Y, 2009, NEUROL RES, V31, P496, DOI 10.1179/174313208X353703; Zhai QW, 2004, GLIA, V48, P327, DOI 10.1002/glia.20087; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	49	163	165	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2011	28	3					359	369		10.1089/neu.2010.1427			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	734WD	WOS:000288370600003	21190398	Green Published			2021-06-18	
J	Talving, P; Benfield, R; Hadjizacharia, P; Inaba, K; Chan, LS; Demetriades, D				Talving, Peep; Benfield, Rodd; Hadjizacharia, Pantelis; Inaba, Kenji; Chan, Linda S.; Demetriades, Demetrios			Coagulopathy in Severe Traumatic Brain Injury: A Prospective Study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Head injury; Traumatic brain injury; Coagulopathy; Mechanism of injury; Prognosis; Mortality	DISSEMINATED INTRAVASCULAR COAGULATION; SEVERE HEAD-INJURY; GLASGOW COMA SCALE; TISSUE FACTOR; DISORDERS; MORTALITY; ABNORMALITIES; PREDICTORS; MARKERS; SCORE	Background: The incidence and risk factors for traumatic brain injury (TBI)-associated coagulopathy after severe TBI (sTBI) and the effect of this complication on outcomes have not been evaluated in any large prospective studies. Methods: Prospective study of all patients admitted to the surgical intensive care unit (ICU) of an urban, Level I trauma center from June 2005 through May 2007 with sTBI (head Abbreviated Injury Scale score of; >= 3). Criteria for TBI-coagulopathy included a clinical condition consistent with coagulopathy, i.e. sTBI in conjunction with a platelet count <100,000 mm(3) and/or elevated international normalized ratio and/or activated partial thromboplastin time. The following potential risk factors with p < 0.2 on bivariate analysis were included in a stepwise logistic regression analysis to identify independent risk factors for TBI coagulopathy and its association with mortality: age, mechanism of injury (blunt [B] or penetrating [P]), presence of hypotension upon admission, Injury Severity Score (ISS), Glasgow Coma Scale (GCS), head and other body area Abbreviated Injury Scale, isolated head injury, diffuse axonal injury, cerebral edema, intracranial hemorrhage (intraventricular, parenchymal, subarachnoid, or subdural), pneumocephalus, and presence of midline shift. Results: A total of 436 patients (392 blunt, 44 penetrating) met study criteria, of whom 387 patients had isolated SHI. TBI coagulopathy occurred in 36% of all patients (B: 33%, P: 55%; p < 0.0075) and in 34% of patients with isolated head injury (B: 32%, P: 54%, p = 0.0062). Independent risk factors for TBI-coagulopathy in isolated sTBI were found to include a GCS score of <= 8, ISS >= 16, presence of cerebral edema, subarachnoid hemorrhage, and midline shift. ICU lengths of stay were significantly longer in SHI patients who developed TBI coagulopathy (12.7 vs. 8.8 days; p = 0.006). The development of TBI coagulopathy in SHI was associated with increased mortality, adjusted odds ratio (95% confidence interval): 9.61 (4.06-25.0); p < 0.0001. Conclusion: The incidence of TBI coagulopathy in SHI is high, especially in penetrating injuries. Independent risk factors for coagulopathy in isolated head injuries include GCS score of <= 8, ISS >= 16, hypotension upon admission, cerebral edema, subarachnoid hemorrhage, and midline shift. The development of TBI coagulopathy is associated with longer ICU length of stay and an almost 10-fold increased risk of death.	[Talving, Peep; Benfield, Rodd; Hadjizacharia, Pantelis; Inaba, Kenji; Chan, Linda S.; Demetriades, Demetrios] Univ So Calif, Los Angeles Cty Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90033 USA	Demetriades, D (corresponding author), Univ So Calif, Los Angeles Cty Med Ctr, Dept Surg, Div Trauma & Crit Care, 1200 N State St,Room 1105, Los Angeles, CA 90033 USA.	demetria@usc.edu	INABA, KENJI/AAC-8532-2020; Talving, Peep/G-8621-2015; Talving, Peep/E-6015-2013	Talving, Peep/0000-0002-9741-2073; 			Affonseca CA, 2007, J PEDIAT-BRAZIL, V83, P274, DOI [10.1590/S0021-75572007000400014, 10.2223/JPED.1639]; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; ASTRUP T, 1965, THROMB DIATH HAEMOST, V14, P401; AVIKAINEN V, 1977, ANN CHIR GYNAECOL FE, V66, P269; Bayir A, 2006, NEUROL INDIA, V54, P363, DOI 10.4103/0028-3886.28106; BREDBACKA S, 1992, J NEUROSURG ANESTH, V4, P128, DOI 10.1097/00008506-199204000-00008; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Davis DP, 2007, J TRAUMA, V62, P277, DOI 10.1097/TA.0b013e31802ef4a3; Demetriades D, 2004, ARCH SURG-CHICAGO, V139, P1066, DOI 10.1001/archsurg.139.10.1066; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Gando S, 2001, SEMIN THROMB HEMOST, V27, P585, DOI 10.1055/s-2001-18864; Giesen PLA, 2000, SEMIN THROMB HEMOST, V26, P379, DOI 10.1055/s-2000-8456; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; HOOTS WK, 1996, NEUROTRAUMA, P673; KAUFMAN HH, 1985, CENTRAL NERVOUS SYST, P187; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Kushimoto S, 2001, NEUROSURGERY, V49, P1084, DOI 10.1097/00006123-200111000-00011; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Osterud B, 1997, THROMB HAEMOSTASIS, V78, P755; Pasternak JJ, 2008, J NEUROSURG ANESTH, V20, P15, DOI 10.1097/ANA.0b013e318155b1c4; Pathak A, 2005, Neurol India, V53, P178; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Pondaag W, 1979, Acta Neurochir Suppl (Wien), V28, P98; Schrieber M, 2007, J TRAUMA, V63, P1261; Selley S, 1997, HLTH TECHNOLOGY ASSE, V1, P1; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	35	163	173	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2009	66	1					55	62		10.1097/TA.0b013e318190c3c0			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	395SJ	WOS:000262543500007	19131806				2021-06-18	
J	Murata, Y; Rosell, A; Scannevin, RH; Rhodes, KJ; Wang, XY; Lo, EH				Murata, Yoshihiro; Rosell, Anna; Scannevin, Robert H.; Rhodes, Kenneth J.; Wang, Xiaoying; Lo, Eng H.			Extension of the Thrombolytic Time Window With Minocycline in Experimental Stroke	STROKE			English	Article						cerebral ischemia; hemorrhagic transformation; edema; tPA; neuroprotection	AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; CYTOCHROME-C RELEASE; MATRIX-METALLOPROTEINASE; HEMORRHAGIC TRANSFORMATION; MICROGLIAL ACTIVATION; DELAYED MINOCYCLINE; MILD HYPOTHERMIA; FOCAL ISCHEMIA	Background and Purpose-Thrombolysis with tPA is the only FDA-approved therapy for acute ischemic stroke. But its widespread application remains limited by narrow treatment time windows and the related risks of cerebral hemorrhage. In this study, we ask whether minocycline can prevent tPA-associated cerebral hemorrhage and extend the reperfusion window in an experimental stroke model in rats. Methods-Spontaneously hypertensive rats were subjected to embolic focal ischemia using homologous clots and treated with: saline at 1 hour; early tPA at 1 hour, delayed tPA at 6 hours; minocycline at 4 hours; combined minocycline at 4 hours plus tPA at 6 hours. Infarct volumes and hemorrhagic transformation were quantified at 24 hours. Gelatin zymography was used to measure blood levels of circulating matrix metalloproteinase-9 (MMP-9). Results-Early 1-hour thrombolysis restored perfusion and reduced infarction. Late 6-hour tPA did not decrease infarction but instead worsened hemorrhagic conversion. Combining minocycline with delayed 6-hour tPA decreased plasma MMP-9 levels, reduced infarction, and ameliorated brain hemorrhage. Blood levels of MMP-9 were also significantly correlated with volumes of infarction and hemorrhage. Conclusion-Combination therapy with minocycline may extend tPA treatment time windows in ischemic stroke. (Stroke. 2008; 39: 3372-3377.)	[Murata, Yoshihiro; Rosell, Anna; Wang, Xiaoying; Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab,Dept Neurol, Charlestown, MA USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA; [Scannevin, Robert H.; Rhodes, Kenneth J.] Biogen Idec Inc, Cambridge, MA USA	Lo, EH (corresponding author), Neuroprotect Res Lab, MGH E 149-2401, Charlestown, MA 02129 USA.	Lo@helilx.mgh.harvard.edu		Rosell Novel, Anna/0000-0003-1082-3599; Scannevin, Robert/0000-0002-5749-2785	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS37074, R01-NS48422, R01-NS56548, P50-NS10828]; American Heart AssociationAmerican Heart Association; Ministerio de Educacion y CienciaSpanish GovernmentEuropean Commission [EXT2006/766]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048422, R01NS053560, P50NS010828, R01NS056458, P01NS055104, R01NS037074] Funding Source: NIH RePORTER	This work was supported in part by NIH grants R01-NS37074, R01-NS48422, R01-NS56548, P50-NS10828, and a Bugher award from the American Heart Association. Anna Rosell is the recipient of a postdoctoral grant from Ministerio de Educacion y Ciencia (EXT2006/766).	Asahi M, 2001, J NEUROSCI, V21, P7724; Asahi M, 2001, NEUROREPORT, V12, P3003, DOI 10.1097/00001756-200109170-00050; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P452, DOI 10.1097/00004647-200003000-00002; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Hamann GF, 1996, J CEREBR BLOOD F MET, V16, P1373, DOI 10.1097/00004647-199611000-00036; HAMANN GF, 1995, STROKE, V26, P2120, DOI 10.1161/01.STR.26.11.2120; Justicia C, 2003, J CEREBR BLOOD F MET, V23, P1430, DOI 10.1097/01.WCB.0000090680.07515.C8; Larrue V, 1997, STROKE, V28, P957, DOI 10.1161/01.STR.28.5.957; Lee CZ, 2006, J CEREBR BLOOD F MET, V26, P1157, DOI 10.1038/sj.jcbfm.9600268; Machado LS, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-56; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; MILAN RV, 2003, NEUROSCI LETT, V353, P217; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; Morimoto N, 2005, BRAIN RES, V1044, P8, DOI 10.1016/j.brainres.2005.02.062; Pi RB, 2004, J NEUROCHEM, V91, P1219, DOI 10.1111/j.1471-4159.2004.02796.x; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; Ravina B, 2006, NEUROLOGY, V66, P664; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; Suzuki Y, 2007, J THROMB HAEMOST, V5, P1732, DOI 10.1111/j.1538-7836.2007.02628.x; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Wang CX, 2002, BMC NEUROL, V2, DOI 10.1186/1471-2377-2-2; Wang CX, 2003, BRAIN RES, V963, P327, DOI 10.1016/S0006-8993(02)04045-3; Wang XY, 2003, NAT MED, V9, P1313, DOI 10.1038/nm926; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Xu L, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-7; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhang AG, 1997, J CEREBR BLOOD F MET, V17, P123, DOI 10.1097/00004647-199702000-00001; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	39	163	173	2	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	DEC	2008	39	12					3372	3377		10.1161/STROKEAHA.108.514026			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	377AT	WOS:000261224800036	18927459	Green Accepted, Bronze, Green Published			2021-06-18	
J	Scheid, R; Walther, KR; Guthke, T; Preul, C; von Cramon, DY				Scheid, R; Walther, KR; Guthke, T; Preul, C; von Cramon, DY			Cognitive sequelae of diffuse axonal injury	ARCHIVES OF NEUROLOGY			English	Article							WHITE-MATTER LESIONS; BLUNT HEAD-INJURY; FOCAL LESIONS; DEFICITS; DAMAGE; COMA; MRI	Background: The results of recent studies on cognitive disability after traumatic brain injury-associated diffuse axonal injury (DAI) are inconsistent. In these studies, the diagnosis of DAI relied on cranial computed tomography. Objective: To further clarify the extent and severity of a possibly DAI-associated cognitive impairment by the use of magnetic resonance imaging (MRI) and detailed neuropsychological testing. Design and Participants: From a databank of 299 patients with traumatic brain injury, 18 patients (age range, 17-50 years; median initial Glasgow Coma Scale score, 5) who showed an MRI lesion pattern compatible with pure DAI were identified. All of the patients had undergone MRI on a 3-T system. Pure DAI was defined by the findings of traumatic microbleeds on T2*-weighted gradient-echo images in the absence of otherwise traumatic or nontraumatic MRI abnormalities. Main Outcome Measures: Neuropsychological performance in the categories of attention and psychomotor speed, executive functions, spans, learning and memory, and intelligence 4 to 55 months (median, 9 months) after traumatic brain injury. Results: All of the patients showed impairments of I or more cognitive subfunctions, and no cognitive domain was fundamentally spared. Memory and executive dysfunctions were most frequent, the former reaching a moderate to severe degree in half of the patients. In comparison, deficits of attention, executive functions, and short-term memory were mostly mild. Correlations between the amount of traumatic microbleeds and specific or global cognitive performance were absent. Conclusions: An MRI lesion pattern compatible with isolated DAI is associated with persistent cognitive impairment. The traumatic microbleed load is no sufficient parameter for the assessment of DAI severity or functional outcome.	Univ Leipzig, Day Clin Cognit Neurol, D-04103 Leipzig, Germany; Max Planck Inst Human Cognit & Brain Sci, Leipzig, Germany	Scheid, R (corresponding author), Univ Leipzig, Day Clin Cognit Neurol, Liebigstr 22A, D-04103 Leipzig, Germany.	scheid@cbs.mpg.de					Adams A, 2001, BCS CONF SERIES, P49; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; Bigler ED, 2002, ALZ DIS ASSOC DIS, V16, P161, DOI 10.1097/00002093-200207000-00006; de Groot JC, 2000, ANN NEUROL, V47, P145; Delis DC, 1987, CALIFORNIA VERBAL LE; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Graham DI GT, 2000, HEAD INJURY, P133; Harting C, 2000, WECHSLER GEDACHTNIS; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LEHRL S, 1991, MEHRFACHWAHLWORTSCHA; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Moscovitch M, 1995, ANN NY ACAD SCI, V769, P119, DOI 10.1111/j.1749-6632.1995.tb38135.x; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Norris DG, 2000, JMRI-J MAGN RESON IM, V11, P445, DOI 10.1002/(SICI)1522-2586(200004)11:4<445::AID-JMRI13>3.0.CO;2-T; Roman GC, 1996, STROKE, V27, P1269, DOI 10.1161/01.STR.27.8.1269; Sabri O, 1999, STROKE, V30, P556, DOI 10.1161/01.STR.30.3.556; SAINTCYR JA, 1988, BRAIN, V111, P941, DOI 10.1093/brain/111.4.941; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; SCHEID R, IN PRESS EUR J NEURO; Schmidt K., 1992, WORTSCHATZTEST WST; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Smith CD, 2000, NEUROLOGY, V54, P838, DOI 10.1212/WNL.54.4.838; TEASDALE G, 1974, LANCET, V2, P81; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Wilson BA, 1996, BEHAV ASSESSMENT DYS; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; WOLFRAM H, 1986, PSYCHOL LEISTUNGSTES; Zimmermann P, 1993, TESTBATTERIE AUFMERK	38	163	165	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-9942	1538-3687		ARCH NEUROL-CHICAGO	Arch. Neurol.	MAR	2006	63	3					418	424		10.1001/archneur.63.3.418			7	Clinical Neurology	Neurosciences & Neurology	024ID	WOS:000236187800015	16533969	Bronze, Green Published			2021-06-18	
J	Bayly, PV; Cohen, TS; Leister, EP; Ajo, D; Leuthardt, EC; Genin, GM				Bayly, PV; Cohen, TS; Leister, EP; Ajo, D; Leuthardt, EC; Genin, GM			Deformation of the human brain induced by mild acceleration	JOURNAL OF NEUROTRAUMA			English	Article						acceleration; deformation; magnetic resonance imaging; strain; tagging; traumatic brain injury	MECHANICAL STRETCH; INJURY; STRAIN; MOTION; HEART; MRI	Rapid deformation of brain matter caused by skull acceleration is most likely the cause of concussion, as well as more severe traumatic brain injury (TBI). The inability to measure deformation directly has led to disagreement and confusion about the biomechanics of concussion and TBI. In the present study, brain deformation in human volunteers was measured directly during mild, but rapid, deceleration of the head (20-30 m/sec(2) peak, similar to 40 msec duration), using an imaging technique originally developed to measure cardiac deformation. Magnetic resonance image sequences with imposed "tag" lines were obtained at high frame rates by repeating the deceleration and acquiring a subset of image data each repetition. Displacements of points on tag lines were used to estimate the Lagrangian strain tensor field. Qualitative (visual) and quantitative (strain) results illustrate clearly the deformation of brain matter due to occipital deceleration. Strains of 0.02-0.05 were typical during these events (0.05 strain corresponds roughly to a 5% change in the dimension of a local tissue element). Notably, compression in frontal regions and stretching in posterior regions were observed. The motion of the brain appears constrained by structures at the frontal base of the skull; it must pull away from such constraints before it can compress against the occipital bone. This mechanism is consistent with observations of contrecoup injury in occipital impact.	Washington Univ, Dept Mech & Aerosp Engn, St Louis, MO 63130 USA; Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA; Washington Univ, Dept Neurol Surg, St Louis, MO 63130 USA	Bayly, PV (corresponding author), Washington Univ, Dept Mech & Aerosp Engn, Box 1185, St Louis, MO 63130 USA.	pvb@me.wustl.edu	Cohen, Taylor/C-9927-2016	Cohen, Taylor/0000-0001-9368-0903; Bayly, Philip/0000-0003-4303-0704	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS045237, R01NS055951] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS055951, R01 NS055951-02, R21 NS045237, NS045237, R21 NS045237-01A1, R21 NS045237-02] Funding Source: Medline		AXEL L, 1989, RADIOLOGY, V171, P841, DOI 10.1148/radiology.171.3.2717762; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bayly PV, 2004, J BIOMECH ENG-T ASME, V126, P523, DOI 10.1115/1.1785811; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GURDJIAN ES, 1961, J NEUROSURG, V18, P58, DOI 10.3171/jns.1961.18.1.0058; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Holbourn AHS, 1943, LANCET, V2, P438; JI S, 2004, STAPP CAR CRASH J, V48, P1; Kraitchman DL, 2003, CIRCULATION, V107, P2025, DOI 10.1161/01.CIR.0000062684.47526.47; Kuijer JPA, 2001, MAGN RESON MED, V46, P993; Liu W, 2004, MAGN RESON MED, V52, P1282, DOI 10.1002/mrm.20276; Margulies SS, 1998, HDB BIOMATERIAL PROP, P70; MARGULIES SS, 1990, J BIOMECH, V23, P832, DOI DOI 10.1016/0021-9290(90)90029-3; MARGULIES SS, 1992, J BIOMECH, V25, P7; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Osman NF, 2000, IEEE T MED IMAGING, V19, P186, DOI 10.1109/42.845177; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Smith DH, 1999, J NEUROSCI, V19, P4263; ZERHOUNI EA, 1988, RADIOLOGY, V169, P59, DOI 10.1148/radiology.169.1.3420283; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	25	163	164	1	17	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2005	22	8					845	856		10.1089/neu.2005.22.845			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	955LH	WOS:000231226900001	16083352	Green Accepted			2021-06-18	
J	Gentleman, SM; Leclercq, PD; Moyes, L; Graham, DI; Smith, C; Griffin, WST; Nicoll, JAR				Gentleman, SM; Leclercq, PD; Moyes, L; Graham, DI; Smith, C; Griffin, WST; Nicoll, JAR			Long-term intracerebral inflammatory response after traumatic brain injury	FORENSIC SCIENCE INTERNATIONAL			English	Article						traumatic brain injury; inflammation; neurodegeneration; cytokine cycle	INTERLEUKIN-1-ALPHA GENE POLYMORPHISM; AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; HEAD-INJURY; APOLIPOPROTEIN-E; MICROGLIAL ACTIVATION; ASSOCIATION; BETA; DEPOSITION; ONSET	Epidemiological and pathological studies suggest that head injury is a significant risk factor for subsequent neurodegeneration and cognitive decline in later life. The precise mechanisms for the development of post-traumatic neurodegenerative change are unclear but we hypothesize that persistence of inflammatory processes in the brain may play a key role and that some individuals are more susceptible to such changes based on their genetic make-up. In support of this hypothesis we present evidence of persistent elevated microglial activity in long-term survivors of head injury and the suggestion of an association between the extent of this activity and interleukin-1 genotype. (C) 2004 Elsevier Ireland Ltd. All rights reserved.	Univ London Imperial Coll Sci Technol & Med, Dept Neuropathol, Div Neurosci & Psychol Med, London W6 8RP, England; So Gen Hosp, NHS Trust, Inst Neurol Sci, Div Clin Neurosci,Acad Unit Neuropathol, Glasgow G51 4TF, Lanark, Scotland; Univ Edinburgh, Dept Pathol, Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA; Southampton Gen Hosp, Dept Neuropathol, Southampton SO16 6YD, Hants, England	Gentleman, SM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Neuropathol, Div Neurosci & Psychol Med, Charing Cross Campus,St Dunstans Rd, London W6 8RP, England.	s.gentleman@imperial.ac.uk	Nicoll, James/I-9253-2017	Nicoll, James/0000-0002-9444-7246	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG012411] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12411] Funding Source: Medline		AdleBiassette H, 1996, NEUROBIOL AGING, V17, P415, DOI 10.1016/0197-4580(96)00029-2; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Breteler MMB, 1995, AM J EPIDEMIOL, V142, P1300, DOI 10.1093/oxfordjournals.aje.a117597; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; Combarros O, 2002, J NEUROL, V249, P1242, DOI 10.1007/s00415-002-0819-9; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Du Y, 2000, NEUROLOGY, V55, P480, DOI 10.1212/WNL.55.4.480; Egensperger R, 1998, BRAIN PATHOL, V8, P439; Fidani L, 2002, NEUROSCI LETT, V323, P81, DOI 10.1016/S0304-3940(02)00114-3; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; GENTLEMAN SM, 1999, J NEUROTRAUM, V16, P994; Green EK, 2002, NEUROLOGY, V58, P1566, DOI 10.1212/WNL.58.10.1566; GRIFFIN WST, 1995, J NEUROPATH EXP NEUR, V54, P276; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Grimaldi LME, 2000, ANN NEUROL, V47, P361, DOI 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hedley R, 2002, ANN NEUROL, V51, P795, DOI 10.1002/ana.10196; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Ki CS, 2001, ANN NEUROL, V49, P817, DOI 10.1002/ana.1067; Kolsch H, 2001, ANN NEUROL, V49, P818, DOI 10.1002/ana.1068; Kornman KS, 1997, J CLIN PERIODONTOL, V24, P72, DOI 10.1111/j.1600-051X.1997.tb01187.x; Kuo YM, 2003, ALZ DIS ASSOC DIS, V17, P94, DOI 10.1097/00002093-200304000-00007; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; MCDOWELL TL, 1995, ARTHRITIS RHEUM, V38, P221, DOI 10.1002/art.1780380210; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.3.CO;2-7; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Pirskanen M, 2002, DEMENT GERIATR COGN, V14, P123, DOI 10.1159/000063603; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rebeck GW, 2000, NEUROSCI LETT, V293, P75, DOI 10.1016/S0304-3940(00)01487-7; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROSES AD, 1995, NAT MED, V1, P603, DOI 10.1038/nm0795-603; Sciacca FL, 2003, NEUROBIOL AGING, V24, P927, DOI 10.1016/S0197-4580(03)00011-3; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tsai SJ, 2003, NEUROSCI LETT, V343, P93, DOI 10.1016/S0304-3940(03)00333-1; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	43	163	166	0	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	DEC 16	2004	146	2-3					97	104		10.1016/j.forsciint.2004.06.027			8	Medicine, Legal	Legal Medicine	879OZ	WOS:000225728400005	15542269				2021-06-18	
J	Cirak, B; Ziegfeld, S; Knight, VM; Chang, D; Avellino, AM; Paidas, CN				Cirak, B; Ziegfeld, S; Knight, VM; Chang, D; Avellino, AM; Paidas, CN			Spinal injuries in children	JOURNAL OF PEDIATRIC SURGERY			English	Article						pediatric trauma; spinal injury; spinal cord injury without radiologic abnormality; abuse	CORD-INJURY; RADIOGRAPHIC ABNORMALITY; PEDIATRIC SPINE; TRAUMA; EPIDEMIOLOGY; FRACTURE	Background/Purpose: Traumatic spinal injury (TSI) is an uncommon source of morbidity and mortality in children. The aim of this study was to describe childhood TSI in a single level 1 urban pediatric trauma center. Methods: The authors retrospectively analyzed all children younger than 14 years with TSI, treated at a level I pediatric trauma center between 1991 and 2002 (n = 406, 4% total registry). All children were stratified according to demographics, mechanisms, type and level of injury, radiologic evaluations, associated injuries, and mortality. Results: The mean age was 9.48 +/- 3.81 years. The most common overall mechanism of injury was motor vehicle crash (MVC; 29%) and ranked highest for infants. Falls ranked highest for ages 2 to 9 years. Sports ranked highest in the 10 to 14 year age group. Paravertebral soft tissue injuries were 68%. The most common injury level was the high cervical spine (O-C4). The incidence of spinal cord injury without radiologic abnormality (SCIWORA) was 6%. Traumatic brain injury (37%) was the most common associated injury. Overall mortality rate was 4% in this urban catchment. Conclusions: TSI in children requires a different preventive and therapeutic logarithm compared with that of adults. The potential devastating nature of TSI warrants that the health care team always maintains a high index of suspicion for injury. Future prospective studies are needed to further elucidate injury patterns.	Johns Hopkins Med Inst, Dept Hlth Policy & Management, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Div Pediat, Bloomberg Sch Publ Hlth, Dept Neurosurg, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Pediat Surg, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	Paidas, CN (corresponding author), Dept Pediat Surg, 600 N Wolfe St,CMSC 7-116, Baltimore, MD 21287 USA.						Akbarnia BA, 1999, ORTHOP CLIN N AM, V30, P521, DOI 10.1016/S0030-5898(05)70103-6; ANDERSON JM, 1980, MAYO CLIN PROC, V55, P499; APPLE DF, 1995, CLIN PEDIATR, V34, P90, DOI 10.1177/000992289503400205; Baker C, 1999, AM J EMERG MED, V17, P230, DOI 10.1016/S0735-6757(99)90111-0; Bliss D, 2002, CRIT CARE MED, V30, pS409, DOI 10.1097/00003246-200211001-00005; BONADIO WA, 1993, AM J EMERG MED, V11, P158, DOI 10.1016/0735-6757(93)90112-O; Brown RL, 2001, J PEDIATR SURG, V36, P1107, DOI 10.1053/jpsu.2001.25665; Chang BA, 2002, INJ PREV, V8, P284, DOI 10.1136/ip.8.4.284; Cramer KE, 1996, PEDIATR CLIN N AM, V43, P1035, DOI 10.1016/S0031-3955(05)70449-1; CURRAN C, 1995, J TRAUMA, V39, P729, DOI 10.1097/00005373-199510000-00022; Demetriades D, 2000, J TRAUMA, V48, P724, DOI 10.1097/00005373-200004000-00022; Dowd MD, 2002, CRIT CARE MED, V30, pS385, DOI 10.1097/00003246-200211001-00002; ELEKRAKY MA, 2000, J NEUROSURG S, V92, P12; Franken E A Jr, 1975, Pediatr Radiol, V3, P101, DOI 10.1007/BF01000122; Garcia RA, 2002, AM J PHYS MED REHAB, V81, P458, DOI 10.1097/00002060-200206000-00011; Ghatan S, 2002, NEUROSURG CLIN N AM, V13, P227, DOI 10.1016/S1042-3680(01)00002-X; Givens TG, 1996, J TRAUMA, V41, P310, DOI 10.1097/00005373-199608000-00019; GRABB PA, 1994, NEUROSURGERY, V35, P406, DOI 10.1227/00006123-199409000-00007; Gupta SK, 1999, SPINAL CORD, V37, P726, DOI 10.1038/sj.sc.3100900; Hadley MN, 2002, NEUROSURGERY, V51, P856, DOI 10.1097/00006123-200209000-00063; Hadley MN, 2002, NEUROSURGERY, V50, pS100, DOI 10.1097/00006123-200203001-00017; HAFFNER DL, 1993, SPINE, V18, P679, DOI 10.1097/00007632-199305000-00001; HAMILTON MG, 1992, J NEUROSURG, V77, P700, DOI 10.3171/jns.1992.77.5.0700; Hu R, 1996, SPINE, V21, P492, DOI 10.1097/00007632-199602150-00016; Kokoska ER, 2001, J PEDIATR SURG, V36, P100, DOI 10.1053/jpsu.2001.20022; Kriss VM, 1996, CLIN PEDIATR, V35, P119, DOI 10.1177/000992289603500302; KRUG EG, 2000, AM J PUBLIC HEALTH, V90, P253; LEVENTHAL HR, 1960, J PEDIATR-US, V56, P447, DOI 10.1016/S0022-3476(60)80356-3; Marinier M, 1997, Orthop Nurs, V16, P57; MARINIER M, 1997, ORTHOP NURS, V16, P64; MASSAGLI T L, 1990, Pediatrician, V17, P244; Mower WR, 2002, J TRAUMA, V53, P1198, DOI 10.1097/00005373-200212000-00039; NITECKI S, 1994, J PEDIATR SURG, V29, P1409, DOI 10.1016/0022-3468(94)90131-7; OSENBACH RK, 1992, NEUROSURGERY, V30, P385, DOI 10.1227/00006123-199203000-00012; PANG D, 1982, J NEUROSURG, V57, P114, DOI 10.3171/jns.1982.57.1.0114; Patel JC, 2001, J PEDIATR SURG, V36, P373, DOI 10.1053/jpsu.2001.20720; Rekate HL, 1999, CHILD NERV SYST, V15, P743, DOI 10.1007/s003810050464; Reynolds R, 2000, CURR OPIN PEDIATR, V12, P67, DOI 10.1097/00008480-200002000-00013; Roche C, 2001, PEDIATR RADIOL, V31, P677, DOI 10.1007/s002470100532; Rooks VJ, 1998, PEDIATR RADIOL, V28, P193, DOI 10.1007/s002470050330; RUGE JR, 1988, J NEUROSURG, V68, P25, DOI 10.3171/jns.1988.68.1.0025; Sledge JB, 2001, J PEDIATR ORTHOPED, V21, P288, DOI 10.1097/00004694-200105000-00005; Subach BR, 1998, SPINE, V23, P2174, DOI 10.1097/00007632-199810150-00006; Turgut M, 1996, Eur Spine J, V5, P148, DOI 10.1007/BF00395505; Viccellio P, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e20; Wang MY, 2001, J PEDIATR SURG, V36, P1528, DOI 10.1053/jpsu.2001.27037	46	163	168	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	APR	2004	39	4					607	612		10.1016/j.jpedsurg.2003.12.011			6	Pediatrics; Surgery	Pediatrics; Surgery	811YP	WOS:000220807500021	15065038				2021-06-18	
J	Laskowitz, DT; Thekdi, AD; Thekdi, SD; Han, SKD; Myers, JK; Pizzo, SV; Bennett, ER				Laskowitz, DT; Thekdi, AD; Thekdi, SD; Han, SKD; Myers, JK; Pizzo, SV; Bennett, ER			Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides	EXPERIMENTAL NEUROLOGY			English	Article						apolipoprotein E; microglia; TNF alpha; nitric oxide; peptides	E-DEFICIENT MICE; RECEPTOR-BINDING ACTIVITY; TRAUMATIC BRAIN INJURY; LIPOPROTEIN RECEPTOR; IMMUNOREGULATORY LIPOPROTEIN; ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; TYPE-4 ALLELE; APOPROTEIN-E; HEAD-INJURY	Apolipoprotein E plays an important role in recovery from acute brain injury and risk of developing AZzheimer's disease. We demonstrate that biologically relevant concentrations of apoE suppress microglial activation and release of TNF alpha and NO in a dose-dependent fashion. Peptides derived from the apoE receptor-binding region mimic the effects of the intact protein, whereas deletion of apoE residues 146-149 abolishes peptide bioactivity. These results are consistent with the hypothesis that apoE modulates microglial function by binding specific cell surface receptors and that the immunomodulatory effects of apoE in the central nervous system may account for its role in acute and chronic neurological disease. (C) 2001 Academic Press.	Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA.				NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [1RO3AG16507-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1RO1NS368087-01A2] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R03AG016507] Funding Source: NIH RePORTER		ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; AVILA EM, 1982, J BIOL CHEM, V257, P5900; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CLAY MA, 1995, BIOCHEMISTRY-US, V34, P11142, DOI 10.1021/bi00035a020; Clayton D, 1999, PROTEIN SCI, V8, P1797, DOI 10.1110/ps.8.9.1797; Colton C, 1996, MOL CHEM NEUROPATHOL, V28, P15, DOI 10.1007/BF02815200; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CURTISS LK, 1981, J IMMUNOL, V126, P1382; de Bont N, 1999, J LIPID RES, V40, P680; EDGINGTON TS, 1981, CANCER RES, V41, P3786; ENSPERGER R, 1998, BRAIN PATHOL, V8, P439; Fisher CA, 1999, J LIPID RES, V40, P93; Fleming LM, 1996, EXP NEUROL, V138, P252, DOI 10.1006/exnr.1996.0064; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GALLO G, 1994, AM J PATHOL, V145, P526; GELMAN BB, 1988, ANN CLIN LAB SCI, V18, P46; Gutman CR, 1997, J NEUROSCI, V17, P6114; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V201, P1567, DOI 10.1006/bbrc.1994.1883; Heese K, 1998, J NEUROCHEM, V70, P699; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Howard GC, 1996, J CLIN INVEST, V97, P1193, DOI 10.1172/JCI118533; Hu JR, 1998, J NEUROCHEM, V71, P1626; HUANG DY, 1995, EXP NEUROL, V136, P251, DOI 10.1006/exnr.1995.1101; HUI DY, 1980, J BIOL CHEM, V255, P1775; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1984, J BIOL CHEM, V259, P7261; JANABI N, 1995, NEUROSCI LETT, V195, P105, DOI 10.1016/0304-3940(94)11792-H; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan J, 1998, J NEUROSCI, V18, P195; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; Laskowitz DT, 2000, J LIPID RES, V41, P613; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 1998, NEUROREPORT, V9, P615, DOI 10.1097/00001756-199803090-00010; Licastro F, 1998, J NEUROIMMUNOL, V88, P105, DOI 10.1016/S0165-5728(98)00096-4; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Lombardi VRM, 1998, J NEUROSCI RES, V54, P539, DOI 10.1002/(SICI)1097-4547(19981115)54:4<539::AID-JNR11>3.3.CO;2-H; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Matthews RT, 1996, BRAIN RES, V718, P181, DOI 10.1016/0006-8993(95)01576-0; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Misra U, 1998, FASEB J, V12, pA1459; MISRA UK, 1994, J BIOL CHEM, V269, P18303; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Moulder KL, 1999, J NEUROCHEM, V72, P1069, DOI 10.1046/j.1471-4159.1999.0721069.x; Muller W, 1998, BRAIN PATHOL, V8, P641; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; Overmyer M, 1999, ACTA NEUROPATHOL, V97, P383, DOI 10.1007/s004010051002; PEPE MG, 1986, J IMMUNOL, V136, P3716; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; RAJAVASHISTH TB, 1985, P NATL ACAD SCI USA, V82, P8085, DOI 10.1073/pnas.82.23.8085; Roselaar SE, 1998, J LIPID RES, V39, P1740; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tolar M, 1997, J NEUROSCI, V17, P5678; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249	72	163	166	1	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2001	167	1					74	85		10.1006/exnr.2001.7541			12	Neurosciences	Neurosciences & Neurology	392VH	WOS:000166432900008	11161595				2021-06-18	
J	O'Leary, DM; Movsesyan, V; Vicini, S; Faden, AI				O'Leary, DM; Movsesyan, V; Vicini, S; Faden, AI			Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						group I mGluRs; MPEP; SIB-1893; NMDA receptors; NMDA-induced toxicity; neuroprotection; patch clamp recording	TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; LONG-TERM POTENTIATION; CORTICAL CULTURES; ACTIVATION; RESPONSES; RELEASE; DEATH; NEUROTOXICITY; DERIVATIVES	1 The metabotropic glutamate receptors (mGluRs) are a family of G-protein linked receptors that can be divided into three groups (group I, II and III). A number of studies have implicated group I mGluR activation in acute neuronal injury, but until recently it was not possible to pharmacologically differentiate the roles of the two individual subunits (mGluR1 and mGluR5) in this group. 2 We investigated the role of mGluR5 in acute NMDA and glutamate mediated neurodegeneration in cultured rat cortical cells using the mGluR5 antagonists MPEP and SIB-1893, and found that they provide significant protection at concentrations of 20 or 200 muM. 3 These compounds act as effective mGluR5 antagonists in our cell culture system, as indicated by the ability of STB-1893 to prevent phosphoinositol hydrolysis induced by the specific mGluR5 agonist, (RS)-2-chloro-5-hydroxyphenylglycine (CHPG). 4 However. they also significantly reduce NMDA evoked current recorded from whole cells voltage clamped at -60 mV, and significantly decrease the duration of opening of NMDA channels recorded in the outside out patch configuration. 5 This suggests that although MPEP and SIB-1893 are effective mGluR5 antagonists, they also act as noncompetitive NMDA receptor antagonists. Therefore. the neuroprotective effects of these compounds are most likely mediated through their NMDA receptor antagonist action, and caution should be exercised when drawing conclusions about the roles of mGluR5 based on their use.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Physiol, Washington, DC 20007 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, EP-12,Res Bldg,3900 Reservoir Rd NW, Washington, DC 20007 USA.			Vicini, Stefano/0000-0001-8671-5194	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS037313, R01NS37313] Funding Source: Medline		Agrawal SK, 1998, J NEUROTRAUM, V15, P929, DOI 10.1089/neu.1998.15.929; Anwyl R, 1999, BRAIN RES REV, V29, P83, DOI 10.1016/S0165-0173(98)00050-2; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BRABET I, 1995, NEUROPHARMACOLOGY, V34, P895, DOI 10.1016/0028-3908(95)00079-L; Bruno V, 1999, NEUROPHARMACOLOGY, V38, P199, DOI 10.1016/S0028-3908(98)00159-2; BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J; Bruno V, 1996, EUR J PHARMACOL, V310, P61, DOI 10.1016/0014-2999(96)00358-5; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Doherty AJ, 1997, NEUROPHARMACOLOGY, V36, P265, DOI 10.1016/S0028-3908(97)00001-4; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; Holscher C, 1999, NEUROSCI BIOBEHAV R, V23, P399, DOI 10.1016/S0149-7634(98)00045-1; JOLY C, 1995, J NEUROSCI, V15, P3970; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KINGSTON AE, 1995, NEUROPHARMACOLOGY, V34, P887, DOI 10.1016/0028-3908(95)00069-I; KNOPFEL T, 1995, J MED CHEM, V38, P1417; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; MURASE K, 1989, NEUROSCI LETT, V103, P56, DOI 10.1016/0304-3940(89)90485-0; Nicoletti F, 1996, TRENDS NEUROSCI, V19, P267, DOI 10.1016/S0166-2236(96)20019-0; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Riedel G, 1996, PROG NEURO-PSYCHOPH, V20, P761, DOI 10.1016/0278-5846(96)00058-9; Saugstad JA, 1997, MOL PHARMACOL, V51, P119; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; SCHOEPP DD, 1994, J NEUROCHEM, V63, P769; Strasser U, 1998, EUR J NEUROSCI, V10, P2848, DOI 10.1111/j.1460-9568.1998.00291.x; Toms NJ, 1996, TRENDS PHARMACOL SCI, V17, P429, DOI 10.1016/S0165-6147(96)01006-1; Varney MA, 1999, J PHARMACOL EXP THER, V290, P170	36	163	165	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	DEC	2000	131	7					1429	1437		10.1038/sj.bjp.0703715			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	380RR	WOS:000165717700024	11090117	Green Published			2021-06-18	
J	Bergman, DA; Baltz, RD; Cooley, JR; Coombs, JB; Goldberg, MJ; Homer, CJ; Miles, PV; Nazarian, LF; Riemenschneider, TA; Roberts, KB; Shea, DW; Zurhellen, WM; Coombs, JB; Bell, H; Davis, RL; Ganiats, TG; Hagen, MD; Haller, J; Homer, CJ; Jaffee, DM; James, H; Kleinman, L; Knapp, J; Dean, JM; Nobel, P; Schneider, S; Scherger, JE; Roberts, RG; Hendrickson, RM; Hueston, WJ; Spann, SJ; Gilbert, T; Ganiats, TG; Phillips, WR; Zimmerman, RK; Green, LA; Rodnick, JE; Yawn, BP; Barrett, LL; Jones, EG; Clark, TA; Black, RR; Mabry, LR; Young, HF; Bell, HS				Bergman, DA; Baltz, RD; Cooley, JR; Coombs, JB; Goldberg, MJ; Homer, CJ; Miles, PV; Nazarian, LF; Riemenschneider, TA; Roberts, KB; Shea, DW; Zurhellen, WM; Coombs, JB; Bell, H; Davis, RL; Ganiats, TG; Hagen, MD; Haller, J; Homer, CJ; Jaffee, DM; James, H; Kleinman, L; Knapp, J; Dean, JM; Nobel, P; Schneider, S; Scherger, JE; Roberts, RG; Hendrickson, RM; Hueston, WJ; Spann, SJ; Gilbert, T; Ganiats, TG; Phillips, WR; Zimmerman, RK; Green, LA; Rodnick, JE; Yawn, BP; Barrett, LL; Jones, EG; Clark, TA; Black, RR; Mabry, LR; Young, HF; Bell, HS		Management Minor Closed Head Injur	The management of minor closed head injury in children	PEDIATRICS			English	Article							TRAUMATIC INTRACRANIAL HEMATOMA; CRANIAL COMPUTED-TOMOGRAPHY; INTRA-CEREBRAL HEMATOMAS; EXTRADURAL HEMATOMA; SUBDURAL-HEMATOMA; DELAYED ONSET; CT; DIAGNOSIS; ADMISSION; SCANS	The American Academy of Pediatrics (AAP) and its Committee on Quality Improvement in collaboration with the American Academy of Family Physicians (AAFP) and its Commission on Clinical Policies and Research, and in conjunction with experts in neurology, emergency medicine and critical care, research methodologists, and practicing physicians have developed this practice parameter. This parameter provides recommendations for the management of a previously neurologically healthy child with a minor closed head injury who, at the time of injury, may have experienced temporary loss of consciousness, experienced an impact seizure, vomited, or experienced other signs and symptoms. These recommendations derive from a thorough review of the literature and expert consensus. The methods and results of the literature review and data analyses including evidence tables can be found in the technical report. This practice parameter is not intended as a sole source of guidance for the management of children with minor closed head injuries. Rather, it is designed to assist physicians by providing an analytic framework for the evaluation and management of this condition. It is not intended to replace clinical judgment or establish a protocol for all patients with a minor head injury, and rarely will provide the only appropriate approach to the problem. The practice parameter, "The Management of Minor Closed Head Injury in Children," was reviewed by the AAFP Commission on Clinical Policies and Research and individuals appointed by the AAFP and appropriate committees and sections of the AAP including the Chapter Review Group, a focus group of office-based pediatricians representing each AAP District: Gene R. Adams, MD; Robert M. Corwin, MD; Diane Fuquay, MD; Barbara M. Harley, MD; Thomas J. Herr, MD, Chair; Kenneth E. Matthews, MD; Robert D. Mines, MD; Lawrence C. Pakula, MD; Howard B. Weinblatt, MD; and Delosa A. Young, MD. The supporting data are contained in a technical report available at http://www.pediatrics.org/cgi/content/full/104/6/e78.				Phillips, William R./V-1065-2017	Phillips, William R./0000-0003-2802-4349; Zimmerman, Richard/0000-0001-5941-6092			BOROVICH B, 1985, J NEUROSURG, V63, P30, DOI 10.3171/jns.1985.63.1.0030; BROWN FD, 1978, J NEUROSURG, V48, P1019, DOI 10.3171/jns.1978.48.6.1019; CHEN TY, 1993, NEUROSURGERY, V32, P176, DOI 10.1227/00006123-199302000-00004; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DEITCH D, 1989, NEUROLOGY, V39, P985, DOI 10.1212/WNL.39.7.985; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; FEURMAN T, 1988, NEUROSURGERY, V22, P449; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; HENNES H, 1988, AM J DIS CHILD, V142, P1045, DOI 10.1001/archpedi.1988.02150100039021; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LIPPER MH, 1979, RADIOLOGY, V133, P645, DOI 10.1148/133.3.645; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; POON WS, 1992, NEUROSURGERY, V30, P681; RIVARA F, 1987, PEDIATRICS, V80, P579; ROSENTHAL BW, 1989, J PEDIATR-US, V115, P346, DOI 10.1016/S0022-3476(89)80830-3; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; ZIMMERMAN RA, 1978, AM J ROENTGENOL, V131, P27, DOI 10.2214/ajr.131.1.27	29	163	164	0	6	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	DEC	1999	104	6					1407	1415					9	Pediatrics	Pediatrics	262LP	WOS:000084069000028	10585999				2021-06-18	
J	FAY, GC; JAFFE, KM; POLISSAR, NL; LIAO, S; RIVARA, JB; MARTIN, KM				FAY, GC; JAFFE, KM; POLISSAR, NL; LIAO, S; RIVARA, JB; MARTIN, KM			OUTCOME OF PEDIATRIC TRAUMATIC BRAIN INJURY AT 3 YEARS - A COHORT STUDY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEAD-INJURIES; CHILDREN; SEVERITY; SEQUELAE; RECOVERY		CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,POB 5371,4800 SAND POINT WAY NE,SEATTLE,WA 98105; CHILDRENS HOSP & MED CTR,DIV NEUROL,SEATTLE,WA 98105; UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH SOCIAL WORK,SEATTLE,WA 98195; UNIV WASHINGTON,CTR QUANTITAT SCI,SEATTLE,WA 98195; STAT & EPIDEMIOL RES CORP,SEATTLE,WA					PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR 002299] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; Achenbach TM, 1986, MANUAL TEACHERS REPO; BRUININKS RH, 1985, WOODCOCK JOHNSON PSY; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; DELIS DC, 1989, CALIFORNIA VERBAL LE; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; DRAKE D, 1976, READING PERCEPTION L; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Fisher L, 1993, BIOSTATISTICS METHOD; GAIDOLFI E, 1980, ITAL J NEUROL SCI, V1, P65; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Jastak S, 1984, WIDE RANGE ACHIEVEME; JENNETT B, 1975, LANCET, P480; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KRAUS JF, 1987, PEDIATRICS, V79, P501; MRAZEK D, 1985, 32ND P ANN M AM AC C; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; POLISSAR NL, 1994, BRAIN INJURY, V8, P249, DOI 10.3109/02699059409150977; RATTAN G, 1987, COGNITIVE REHABILITA; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Rosner B., 1990, FUNDAMENTALS BIOSTAT; Snedecor G.W., 1967, STATISTICAL METHODS; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 1974, WECHSLER ADULT INTEL	30	163	163	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	1994	75	7					733	741					9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	NX051	WOS:A1994NX05100001	8024416				2021-06-18	
J	RIEMER, BL; BUTTERFIELD, SL; DIAMOND, DL; YOUNG, JC; RAVES, JJ; COTTINGTON, E; KISLAN, K				RIEMER, BL; BUTTERFIELD, SL; DIAMOND, DL; YOUNG, JC; RAVES, JJ; COTTINGTON, E; KISLAN, K			ACUTE MORTALITY ASSOCIATED WITH INJURIES TO THE PELVIC RING - THE ROLE OF EARLY PATIENT MOBILIZATION AND EXTERNAL FIXATION	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	6TH ANNUAL SCIENTIFIC ASSEMBLY OF THE EASTERN-ASSOC-FOR-THE-SURGERY-OF-TRAUMA	JAN 14-16, 1993	LONGBOAT KEY, FL	E ASSOC SURG TRAUMA			SEVERE HEAD-INJURY; TRANSCATHETER EMBOLIZATION; INTERNAL-FIXATION; FRACTURES; HEMORRHAGE; MANAGEMENT; TRAUMA; CLASSIFICATION; ANGIOGRAPHY; BRAIN	Purpose: To analyze the effect on mortality of a protocol for early mobilization with external fixation of patients with pelvic ring injuries. Methods: From 1981 through 1988, 605 patients with pelvic ring fractures and dislocations were treated. In 1982, a protocol for early external fixation of hemodynamically unstable patients and those with structurally unstable pelvic fracture patterns to achieve early mobilization to an upright chest position was initiated. Mortality rates were compared between 1981 (pre-protocol), 1982 (transitional), and 1983 through 1988, after initiation of a protocol of care that included external fixation of the pelvic injury. No statistical changes occurred from 1983 through 1988. Results: Mortality rates in pelvic ring injury patients fell from 26% in 1981, to 6% in 1983 through 1988 (p < 0.001), whereas during the study period the mean Injury Severity Score (ISS), 23, did not change. The mortality rate of a group of consecutive patients with comparable ISSs, but without pelvic ring injuries did not change. The mortality rate in patients with systolic blood pressure < 100 mm Hg at admission fell from 41% in 1981 to 21% 1983 through 1988 (p = 0.0001). Mortality in patients with closed head injuries associated with pelvic ring injuries fell from 43% in 1981 to 7% from 1983 through 1988 (p = 0.0001). The proportion of patients undergoing external fixation rose from 3% in 1981 to 31% in 1983 through 1988 (p = 0.0001). Conclusions: An organized protocol including external fixation and early patient mobilization to an upright chest position reduced mortality associated with injuries of the pelvic ring. Orthopedic stabilization of major skeletal injuries should be viewed as part of patient resuscitation, not reconstruction.	MED COLL PENN,ALLEGHENY GEN HOSP,ALLEGHENY SINGER RES INST,PITTSBURGH,PA; MED COLL PENN,ALLEGHENY GEN HOSP,DIV GEN SURG,PITTSBURGH,PA; MED COLL PENN,ALLEGHENY GEN HOSP,DEPT ORTHOPAED SURG,PITTSBURGH,PA							APRAHAMIAN C, 1989, J TRAUMA, V29, P549, DOI 10.1097/00005373-198905000-00002; AYELLA RJ, 1978, SURG GYNECOL OBSTET, V147, P849; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; BORDER J R, 1990, P77; BROWNER BD, 1987, J TRAUMA, V27, P998, DOI 10.1097/00005373-198709000-00008; BURGESS AR, 1990, J TRAUMA, V30, P848, DOI 10.1097/00005373-199007000-00015; CHESTNUT RM, 1990, J NEUROSURG, V72, pA360; CONNOLLY JF, 1989, CLIN ORTHOP RELAT R, V240, P115; COTTINGTON EM, 1988, J TRAUMA, V28, P305, DOI 10.1097/00005373-198803000-00005; CRYER HM, 1988, J TRAUMA, V28, P973, DOI 10.1097/00005373-198807000-00011; FLINT LM, 1979, ANN SURG, V189, P709, DOI 10.1097/00000658-197906000-00006; GANZ R, 1991, CLIN ORTHOP RELAT R, V267, P71; GILLILAND MD, 1982, J TRAUMA, V22, P691, DOI 10.1097/00005373-198208000-00007; GILLILAND MG, 1982, AM J SURG, V144, P744, DOI 10.1016/0002-9610(82)90562-1; GOLDSTEIN A, 1986, J TRAUMA, V26, P325; GREEN SA, 1981, COMPLICATIONS EXTERN, P15; HUITTINEN VM, 1973, SURGERY, V73, P454; JOHNSON KD, 1985, J TRAUMA, V25, P375, DOI 10.1097/00005373-198505000-00001; KELLAM JF, 1987, ORTHOP CLIN N AM, V18, P25; KELLAM JF, 1989, CLIN ORTHOP RELAT R, V241, P66; MANSOUR MA, 1990, J TRAUMA, V30, P1417, DOI 10.1097/00005373-199011000-00021; MARGOLIES MN, 1972, NEW ENGL J MED, V287, P317, DOI 10.1056/NEJM197208172870701; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MATALON TS, 1979, AM J MED, V183, P859; MATTA JM, 1989, CLIN ORTHOP RELAT R, V242, P83; MCAVOY JM, 1978, ARCH SURG-CHICAGO, V113, P986; MCMURTRY R, 1980, CLIN ORTHOP RELAT R, V151, P22; MEARS DC, 1983, EXTERNAL SKELETAL FI, P378; MEARS DC, 1980, CLIN ORTHOP RELAT R, V151, P65; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MORENO C, 1986, J TRAUMA, V26, P987, DOI 10.1097/00005373-198611000-00005; MUCHA P, 1984, J TRAUMA, V24, P379, DOI 10.1097/00005373-198405000-00002; MUCHA P, 1988, SURG CLIN N AM, V68, P757; MUCHA P, 1985, INFECT SURG, V11, P53; PANETTA T, 1985, J TRAUMA, V25, P1021; PENNAL GF, 1980, CLIN ORTHOP RELAT R, V151, P12; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PRICE JE, 1972, BR J ACCID SURG, V3, P218; RIEMER BL, 1992, ORTHOPEDICS, V15, P907; RING EJ, 1973, RADIOLOGY, V109, P65, DOI 10.1148/109.1.65; ROTHENBERGER D, 1978, J TRAUMA, V18, P184, DOI 10.1097/00005373-197803000-00006; ROTHENBERGER DA, 1978, SURGERY, V84, P356; SEIBEL R, 1985, ANN SURG, V202, P283, DOI 10.1097/00000658-198509000-00003; SLATIS P, 1980, CLIN ORTHOP RELAT R, V151, P73; TILE M, 1988, J BONE JOINT SURG BR, V70, P1; TILE M, 1984, FRACTURES PELVIS ACE, P70; WILD JJ, 1982, J BONE JOINT SURG AM, V64, P1010, DOI 10.2106/00004623-198264070-00007	49	163	181	0	5	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	1993	35	5					671	677		10.1097/00005373-199311000-00003			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	MJ277	WOS:A1993MJ27700003	8230327				2021-06-18	
J	JIANG, JY; LYETH, BG; KAPASI, MZ; JENKINS, LW; POVLISHOCK, JT				JIANG, JY; LYETH, BG; KAPASI, MZ; JENKINS, LW; POVLISHOCK, JT			MODERATE HYPOTHERMIA REDUCES BLOOD-BRAIN-BARRIER DISRUPTION FOLLOWING TRAUMATIC BRAIN INJURY IN THE RAT	ACTA NEUROPATHOLOGICA			English	Article						TRAUMATIC BRAIN INJURY; HYPOTHERMIA; BLOOD-BRAIN BARRIER; HYPERTENSION; RAT	FLUID-PERCUSSION MODEL; CEREBRAL-ISCHEMIA; HORSERADISH-PEROXIDASE; MILD HYPOTHERMIA; TEMPERATURE; HYPERTENSION; ACIDS	The effects of moderate hypothermia on blood-brain barrier (BBB) permeability and the acute hypertensive response after moderate traumatic brain injury (TBI) in rats were examined. TBI produced increased vascular permeability to endogenous serum albumin (IgG) in normothermic rats (37.5-degrees-C) throughout the dorsal cortical gray and white matter as well as in the underlying hippocampi as visualized by immunocytochemical techniques. Vascular permeability was greatly reduced in hypothermic rats cooled to 30-degrees-C (brain temperature) prior to injury. In hypothermic rats, albumin immunoreactivity was confined to the gray-white interface between cortex and hippocampi with no involvement of the overlying cortices and greatly reduced involvement of the underlying hippocampi. The acute hypertensive response in normothermic rats peaked at 10 s after TBI (187.3 mm Hg) and returned to baseline within 50 s. In contrast, the peak acute hypertensive response was significantly (P < 0.05) reduced in hypothermic rats (154.8 mm Hg, 10 s after TBI) and returned to baseline at 30 s after injury. These results demonstrate that moderate hypothermia greatly reduces endogenous vascular protein-tracer passage into and perhaps through the brain. This reduction may, in part, be related to hypothermia-induced modulation of the systemic blood pressure response to TBI.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROSURG,BOX 693,MCV STN,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,RICHMOND,VA 23298				Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587, R01NS019550, R01NS029469] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29469, NS 12587, NS 19550] Funding Source: Medline		BAKER AJ, 1991, SATELLITE S BRAIN 91, P10; Baker HJ, 1979, LABORATORY RAT, VI, P411; BUSTO R, 1989, STROKE, V20, P1113, DOI 10.1161/01.STR.20.8.1113; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, J CEREB BLOOD FLO S1, V9, P266; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; CHURN S B, 1989, Society for Neuroscience Abstracts, V15, P360; CLIFTON GL, 1989, STROKE, V20, P1545, DOI 10.1161/01.STR.20.11.1545; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEMPSEY RJ, 1987, NEUROSURGERY, V21, P177, DOI 10.1227/00006123-198708000-00007; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; ELLISON MD, 1986, J CEREBR BLOOD F MET, V6, P471, DOI 10.1038/jcbfm.1986.81; ESTRADA C, 1990, J NEUROCHEM, V54, P1467, DOI 10.1111/j.1471-4159.1990.tb01193.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GINSBERG MD, 1989, J CEREB BLOOD FLO S1, V9, P380; HAYES RL, 1991, J NEUROTRAUM, V9, P173; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HOFFMAN WE, 1991, J NEUROSURG ANESTH, V3, P34, DOI 10.1097/00008506-199103000-00006; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JOHANSSON B, 1970, ACTA NEUROPATHOL, V16, P117, DOI 10.1007/BF00687666; KRANTIS A, 1983, ACTA NEUROPATHOL, V60, P61, DOI 10.1007/BF00685348; LYETH B G, 1991, Society for Neuroscience Abstracts, V17, P165; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NAGY Z, 1979, J COMP NEUROL, V185, P579, DOI 10.1002/cne.901850308; PARDRIDGE WM, 1987, METABOLISM, V36, P892, DOI 10.1016/0026-0495(87)90099-0; POVLISHOCK J T, 1989, Society for Neuroscience Abstracts, V15, P1113; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; RAPOPORT SI, 1976, EXP NEUROL, V52, P467, DOI 10.1016/0014-4886(76)90218-1; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; THOMPSON SM, 1985, J NEUROSCI, V5, P817	39	163	176	0	9	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	OCT	1992	84	5					495	500		10.1007/BF00304468			6	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	JT686	WOS:A1992JT68600005	1462764				2021-06-18	
J	McIntosh, TK; Vink, R; Soares, H; Hayes, R; Simon, R				McIntosh, Tracy K.; Vink, Robert; Soares, Holly; Hayes, Ronald; Simon, Roger			Effects of the N-Methyl-D-Aspartate Receptor Blocker MK-801 on Neurologic Function After Experimental Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article							SPINAL-CORD; AMINO-ACIDS; GLUTAMATE; RAT; ANTAGONIST; DAMAGE; EDEMA; INHIBITION; PROTECTION; MODEL	Pharmacologie inhibition of excitatory amino acid (EAA) neurotransmission attenuates cell death in models of global and focal ischemia and hypoglycemia and improves neurologic outcome after experimental traumatic spinal cord injury. The present study examined the effects of the noncompetitive N-methyl-D-aspartate (NMDA) receptor blocker MK-801 on cardiovascular and neurologic function after experimental fluid-percussion (FP) brain injury in the rat. Animals received either an intravenous bolus of MK-801 (1 mg/kg) or saline (equal volume) 15 min prior to FP brain injury or 15 min following FP brain injury. MK-801 pretreatment significantly improved postinjury cardiovascular variables and attenuated postinjury neurologic dysfunction. Postinjury treatment with MK-801 also significantly improved cardiovascular variables, but had little effect on postinjury neurologic scores. These results suggest that EAA neurotransmitters may be involved in the pathophysiological sequelae of traumatic brain injury and that noncompetitive blockade of the NMDA receptor prior to brain injury may reduce EAA-induced damage and limit neurologic dysfunction.	[McIntosh, Tracy K.; Soares, Holly] Univ Connecticut, Ctr Hlth, Dept Surg, Surg Res Ctr, Farmington, CT 06032 USA; [Vink, Robert] James Cook Univ, Dept Chem & Biochem, Townsville, Qld 4811, Australia; [Hayes, Ronald] Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; [Simon, Roger] San Francisco Gen Hosp, Dept Neurol, San Francisco, CA 94110 USA	McIntosh, TK (corresponding author), Univ Connecticut, Ctr Hlth, Dept Surg, Surg Res Ctr, Farmington, CT 06032 USA.		AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS26818]; Sunny von Bulow Coma and Head Trauma Research Foundation [G-3]; Veterans AdministrationUS Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, R55NS026818] Funding Source: NIH RePORTER	This work was supported, in part, by NIH Grant NS26818, a grant (G-3) from the Sunny von Bulow Coma and Head Trauma Research Foundation, and a Veterans Administration Merit Review 74R to Tracy K. Mclntosh. We thank Dr. Alan Foster (Merck, Sharp & Dohme, U.K.) and Dr. Gary Sherman (Merck, Sharp & Dohme, U.S.A.) for gifts of MK-801, and Drs. Alan Faden, Dennis Choi, and Alan Foster for suggestions concerning appropriate dosages of MK-801. We gratefully acknowledge Robert Romhanyi for excellent technical assistance and Mrs. Joanne D'Aprile for preparation of the manuscript. In these studies, we carefully adhered to the animal welfare guidelines set forth in the Guide for the Care and Use of Laboratory Animals, U.S. Department of Health and Human Services, Pub. No. 85-23, 1985.	Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Barbre AB, 2006, BRAIN RES BULL, V69, P639, DOI 10.1016/j.brainresbull.2006.03.009; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Belayev L, 2001, J NEUROTRAUM, V18, P1031, DOI 10.1089/08977150152693728; BOAST CA, 1987, EXCITATORY AMINO ACI, P249; Boris-Moller F, 1998, MOL CHEM NEUROPATHOL, V35, P133, DOI 10.1007/BF02815120; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Browne KD, 2004, J NEUROSCI RES, V77, P878, DOI 10.1002/jnr.20215; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Bullock Ross, 1998, NEUROSURGICAL FOCUS, V5, pE1; Casson RJ, 2006, CLIN EXP OPHTHALMOL, V34, P54, DOI 10.1111/j.1442-9071.2006.01146.x; Celik SE, 2006, J NEUROTRAUM, V23, P1355, DOI 10.1089/neu.2006.23.1355; CHAN PH, 1979, J NEUROCHEM, V33, P1309, DOI 10.1111/j.1471-4159.1979.tb05278.x; Cheney Jessica A., 2001, J CEREBRAL BLOOD FLO, P396; CHOI DW, 1987, J NEUROSCI, V7, P357; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; COYLE JT, 1983, J NEUROCHEM, V41, P1; DEMEDIUK P, 1988, Journal of Neurotrauma, V5, P105, DOI 10.1089/neu.1988.5.105; DEMEDIUK P., 1988, T AM SOC NEUROCHEM, V19, P176; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Du C, 1996, J NEUROTRAUM, V13, P215, DOI 10.1089/neu.1996.13.215; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; FADEN A. I., 1993, J NEUROTRAUMA, V10, P91; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; Fogal B, 2008, J NEUROCHEM, V106, P1, DOI 10.1111/j.1471-4159.2008.05315.x; FOSTER A.C., 1987, BRIT J PHARMACOL, V90, P9; Furukawa T, 2003, J NEUROTRAUM, V20, P269, DOI 10.1089/089771503321532851; GERMANO IM, 1987, ANN NEUROL, V22, P730, DOI 10.1002/ana.410220609; GOLDING EM, 1995, MOL CHEM NEUROPATHOL, V24, P137, DOI 10.1007/BF02962139; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hamm Robert J., 1994, J NEUROSURGERY, V81, P267; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES R.L., 1989, NEUR ABSTR, V14, P1153; Hewett SJ, 2006, PHARMACOL THERAPEUT, V112, P335, DOI 10.1016/j.pharmthera.2005.04.011; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hogg S, 1998, BEHAV BRAIN RES, V93, P157, DOI 10.1016/S0166-4328(97)00145-9; Hogg S, 1998, J NEUROTRAUM, V15, P545, DOI 10.1089/neu.1998.15.545; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; Kanungo AK, 2009, NEUROSCIENCE, V158, P1364, DOI 10.1016/j.neuroscience.2008.10.062; KATAYAMA Y., 1988, NEUR ABSTR, V14, P1154; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Lea PM, 2001, MENT RETARD DEV D R, V7, P235, DOI 10.1002/mrdd.1033; LEMKE M, 1987, BIOCHEM BIOPH RES CO, V147, P1170, DOI 10.1016/S0006-291X(87)80192-4; Leonard JR, 1997, EXP NEUROL, V143, P177, DOI 10.1006/exnr.1996.6366; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LIU SL, 1994, J NEUROTRAUM, V11, P73, DOI 10.1089/neu.1994.11.73; Lorber A, 2000, J NEUROSURG ANESTH, V12, P345, DOI 10.1097/00008506-200010000-00007; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; LUCAS DR, 1957, ARCH OPHTHALMOL-CHIC, V58, P193; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; LYETH BG, 1995, NEUROPEPTIDES, V29, P11, DOI 10.1016/0143-4179(95)90051-9; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Maldonado P.D., 2009, J NEUROSCIENCE RES; MARION DONALD W., 1996, J NEUROTRAUMA, V13, P139; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARTINIAK J, 1985, PHYSIOL BOHEMOSLOV, V34, P11; MATTSON MARK P., 1994, J NEUROTRAUMA, V11, P3; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; McINTOSH T., 1988, NEUROL NEUR, P653; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; McINTOSH TRACY K., 1993, J NEUROTRAUMA, V10, P215; McINTOSH TRACY K., 1996, J NEUROTRAUMA, V13, P767; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; Merola A, 2002, J ORTHOP TRAUMA, V16, P155, DOI 10.1097/00005131-200203000-00003; Mesenge C, 1996, J NEUROTRAUM, V13, P11, DOI 10.1089/neu.1996.13.11; MESENGE CHRISTIAN, 1996, J NEUROTRAUMA, V13, P209; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; MORRISON B, ANNU REV BIOMED ENG, V13, P91, DOI DOI 10.1146/ANNUREV-BIOENG-071910-124706; Movsesyan VA, 2006, J NEUROTRAUM, V23, P117, DOI 10.1089/neu.2006.23.117; MYSEROS J. S., 1995, ANN NEW YORK ACAD SC, V765, P262; Nilsson P., 1996, J CEREBRAL BLOOD FLO, P262; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; Ohman J, 2001, J NEUROTRAUM, V18, P1313, DOI 10.1089/08977150152725614; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; OLNEY J, 1987, EUR J PHARMACOL, V141, P357, DOI 10.1016/0014-2999(87)90552-8; Olney J, 1978, KAINIC ACID TOOL NEU, P95; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Ooba S, 2008, NEUROSCI RES, V62, P195, DOI 10.1016/j.neures.2008.08.005; Opreanu RC, 2010, J AM COLL SURGEONS, V210, P997, DOI 10.1016/j.jamcollsurg.2010.01.036; OZYURT E, 1988, J CEREBR BLOOD F MET, V8, P138, DOI 10.1038/jcbfm.1988.18; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PARK C., 1987, NEUR ABSTR, V13, P1029; Phillips LL, 1997, J NEUROSCI RES, V49, P197; PHILLIS JW, 1993, BRAIN RES BULL, V31, P547, DOI 10.1016/0361-9230(93)90122-R; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; PORCELLA A, 1991, BRAIN RES, V549, P205, DOI 10.1016/0006-8993(91)90459-9; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Schmitt U, 1996, J NEUROTRAUM, V13, P791, DOI 10.1089/neu.1996.13.791; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SIMON RP, 1986, NEUROSCI LETT, V71, P361, DOI 10.1016/0304-3940(86)90648-8; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; SUN FY, 1994, BRAIN RES, V661, P63, DOI 10.1016/0006-8993(94)91181-9; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SWAN JH, 1988, J CEREBR BLOOD F MET, V8, P64, DOI 10.1038/jcbfm.1988.9; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Temple MD, 2001, J NEUROTRAUM, V18, P47, DOI 10.1089/089771501750055767; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, J BIOL CHEM, V263, P757; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; WESTERBERG E, 1989, J NEUROSCI, V9, P798; WIELOCH T, 1985, SCIENCE, V230, P681, DOI 10.1126/science.2996146; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG KY, 1994, J NEUROTRAUM, V11, P523, DOI 10.1089/neu.1994.11.523; Yi JH, 2005, GLIA, V49, P121, DOI 10.1002/glia.20099; Young W, 1987, Cent Nerv Syst Trauma, V4, P27; YUAN X-Q., 1989, J NEUROTRAUM, P303; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	151	163	163	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	WIN	1989	6	4					247	U101		10.1089/neu.1989.6.247			19	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	V22HB	WOS:000208265200005	2559212				2021-06-18	
J	Zlokovic, BV				Zlokovic, Berislav V.			Cerebrovascular Effects of Apolipoprotein E Implications for Alzheimer Disease	JAMA NEUROLOGY			English	Article							AMYLOID-BETA-PEPTIDE; BLOOD-BRAIN-BARRIER; PERICYTES; CLEARANCE; TRANSPORT; PATHWAYS; APOE	Human apolipoprotein E (apoE) has 3 isoforms: apoE2, apoE3, and apoE4. APOE4 is a major genetic risk factor for Alzheimer disease and is associated with dementia in Down syndrome and poor neurological outcome after traumatic brain injury, cerebral hemorrhage, and other neuropathological disorders. While apoE4 can induce neuropathology by participating in various cellular and molecular pathways, herein I review data supporting the hypothesis that apoE4 has direct toxic effects on the cerebrovascular system that in turn can lead to secondary neuronal dysfunction and degeneration as well as accumulation of neurotoxins in brain such as beta-amyloid (A beta) in Alzheimer disease. I review A beta-independent cerebrovascular effects of apoE, particularly activation of a proinflammatory cyclophilin A-mediated pathway in brain vascular pericytes by apoE4 that has recently been shown to lead to a loss of cerebrovascular integrity and blood-brain barrier breakdown causing neuronal injury. I also review A beta-dependent cerebrovascular effects of apoE such as faulty A beta clearance from brain to circulation by apoE4. Finally, I discuss isoform-specific interactions of apoE with low-density lipoprotein receptor-related protein 1 on brain vascular cells (ie, endothelial cells, pericytes), which play an important role in A beta-independent and A beta-dependent effects of apoE on cerebral vasculature.	[Zlokovic, Berislav V.] Univ So Calif, Ctr Neurodegenerat & Regenerat, Zilkha Neurogenet Inst, Los Angeles, CA USA; [Zlokovic, Berislav V.] Univ So Calif, Dept Physiol & Biophys, Los Angeles, CA 90089 USA	Zlokovic, BV (corresponding author), Zilkha Neurogenet Inst, 1501 San Pablo St,Room 101, Los Angeles, CA 90089 USA.	berislav.zlokovic@med.usc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG039452, AG23084, NS34467]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS034467, R01NS034467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG039452, R01AG023084, RF1AG039452, R37AG023084] Funding Source: NIH RePORTER	This work was supported by grants AG039452, AG23084, and NS34467 from the National Institutes of Health.	Bell RD, 2007, J CEREBR BLOOD F MET, V27, P909, DOI 10.1038/sj.jcbfm.9600419; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Castellano JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002156; Deane R, 2008, J CLIN INVEST, V118, P4002, DOI 10.1172/JCI36663; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Genin E, 2011, MOL PSYCHIATR, V16, P903, DOI 10.1038/mp.2011.52; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kim J, 2009, NEURON, V63, P287, DOI 10.1016/j.neuron.2009.06.026; MAHLEY RW, 2009, J LIPID RES S, V50; Sengillo JD, 2013, BRAIN PATHOL, V23, P303, DOI 10.1111/bpa.12004; Tanzi RE, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006296; Verghese PB, 2011, LANCET NEUROL, V10, P241, DOI 10.1016/S1474-4422(10)70325-2; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946; Zipser BD, 2007, NEUROBIOL AGING, V28, P977, DOI 10.1016/j.neurobiolaging.2006.05.016; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114; ZLOKOVIC BV, 1987, J NEUROCHEM, V49, P310, DOI 10.1111/j.1471-4159.1987.tb03431.x	18	162	163	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	APR	2013	70	4					440	444		10.1001/jamaneurol.2013.2152			5	Clinical Neurology	Neurosciences & Neurology	160NS	WOS:000320127000003	23400708	Green Accepted, Bronze			2021-06-18	
J	Rangel-Castillo, L; Gopinath, S; Robertson, CS				Rangel-Castillo, Leonardo; Gopinath, Shankar; Robertson, Claudia S.			Management of intracranial hypertension	NEUROLOGIC CLINICS			English	Article							TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; PERFUSION-PRESSURE; SUBARACHNOID HEMORRHAGE; HYPERTONIC SALINE; BARBITURATE-COMA; CONTROLLED-TRIAL; CLINICAL-TRIAL	Effective management of intracranial hypertension involves meticulous avoidance of factors that precipitate or aggravate increased intracranial pressure. When intracranial pressure becomes elevated, it is important to rule out new mass lesions that should be surgically evacuated. Medical management of increased intracranial pressure should include sedation, drainage of cerebrospinal fluid, and osmotherapy With either mannitol or hypertonic saline. For intracranial hypertension refractory to initial medical management, barbiturate coma, hypothermia, or decompressive craniectomy should be considered. Steroids are not indicated and may be harmful in the treatment of intracranial hypertension resulting from traumatic brain injury.	[Gopinath, Shankar; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Rangel-Castillo, Leonardo] Univ Texas Med Branch, Dept Neurosurg, Galveston, TX USA	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS 38660, P01 NS038660-08, P01 NS038660] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER		Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS28; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; ANDREWS BT, 1988, J NEUROSURG, V69, P518, DOI 10.3171/jns.1988.69.4.0518; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Bader MK, 2005, AACN ADV CRIT CARE, V16, P526, DOI 10.1097/00044067-200510000-00009; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Biousse V, 2003, AM J OPHTHALMOL, V135, P437, DOI 10.1016/S0002-9394(02)02062-7; Bor-Seng-Shu E, 2006, J NEUROSURG, V104, P93, DOI 10.3171/jns.2006.104.1.93; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Caricato A, 2005, J TRAUMA, V58, P571, DOI 10.1097/01.TA.0000152806.19198.DB; Cheung A, 2005, NEUROCRIT CARE, V3, P216, DOI 10.1385/NCC:3:3:216; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cruz J, 2004, J NEUROSURG, V100, P376, DOI 10.3171/jns.2004.100.3.0376; Cruz J, 2001, NEUROSURGERY, V49, P864; Czosnyka M, 1996, NEUROSURGERY, V38, P219, DOI 10.1097/00006123-199601000-00053; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Digre K, 2005, NEUROLOGY, V64, P1827; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; DOCZI T, 1993, ACTA NEUROCHIR, V121, P1, DOI 10.1007/BF01405174; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Edwards P, 2005, LANCET, V365, P1957; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; ENGBERG M, 1989, ACTA ANAESTH SCAND, V33, P642, DOI 10.1111/j.1399-6576.1989.tb02983.x; Feigin VL, 2005, COCHRANE DB SYST REV, V20, P3; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; Friedman DI, 2005, AM J CLIN DERMATOL, V6, P29, DOI 10.2165/00128071-200506010-00004; GOBIET W, 1975, ACTA NEUROCHIR, V32, P13, DOI 10.1007/BF01405899; GOPINATH SP, 1995, NEUROSURGERY, V36, P1137, DOI 10.1227/00006123-199506000-00011; GUDEMAN SK, 1979, J NEUROSURG, V51, P301, DOI 10.3171/jns.1979.51.3.0301; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hlatky R, 2005, NEUROSURGERY, V57, P917, DOI 10.1227/01.NEU.0000180025.43747.fc; Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Jacob S, 2005, HEADACHE, V45, P75, DOI 10.1111/j.1526-4610.2005.05013.x; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Joseph DK, 2004, J TRAUMA, V57, P687, DOI 10.1097/01.TA.0000140645.84897.F2; Kaal ECA, 2004, CURR OPIN ONCOL, V16, P593, DOI 10.1097/01.cco.0000142076.52721.b3; KISHORE PRS, 1981, AM J ROENTGENOL, V137, P829, DOI 10.2214/ajr.137.4.829; Knapp JM, 2005, AACN ADV CRIT CARE, V16, P199, DOI 10.1097/00044067-200504000-00011; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; Lee ST, 1997, CAN J NEUROL SCI, V24, P40, DOI 10.1017/S0317167100021077; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; Marchuk G, 2005, CAN J NEUROL SCI, V32, pS22; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; Miller J D, 1979, Int Anesthesiol Clin, V17, P19, DOI 10.1097/00004311-197917020-00005; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; Nates JL, 1997, ANAESTH INTENS CARE, V25, P502, DOI 10.1177/0310057X9702500509; Ng I, 2004, NEUROSURGERY, V54, P593, DOI 10.1227/01.NEU.0000108639.16783.39; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; NORTH JB, 1974, ARCH NEUROL-CHICAGO, V31, P338, DOI 10.1001/archneur.1974.00490410086010; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; Park P, 2004, NEUROSURGERY, V55, P594, DOI 10.1227/01.NEU.0000134289.04500.EE; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; PRIELIPP RC, 1995, ANESTH ANALG, V81, P3, DOI 10.1097/00000539-199507000-00002; ROBERTSON CS, 1983, J NEUROSURG, V59, P455, DOI 10.3171/jns.1983.59.3.0455; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; SATO M, 1991, ACTA NEUROCHIR, V110, P174, DOI 10.1007/BF01400687; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; SCHALEN W, 1992, ACTA NEUROCHIR, V117, P153, DOI 10.1007/BF01400613; Schramm WM, 1998, ANESTH ANALG, V86, P123, DOI 10.1097/00000539-199801000-00025; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; SELHORST JB, 1985, NEUROSURGERY, V16, P357, DOI 10.1227/00006123-198503000-00013; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEMPKIN NR, 1990, NEW ENGL J MED, V323, P497; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WELCH K, 1980, J NEUROSURG, V52, P693, DOI 10.3171/jns.1980.52.5.0693; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6; Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725	87	162	176	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	MAY	2008	26	2					521	+		10.1016/j.ncl.2008.02.003			22	Clinical Neurology; Neurosciences	Neurosciences & Neurology	320CG	WOS:000257210700010	18514825	Green Accepted			2021-06-18	
J	Smith, MJ; Stiefel, MF; Magge, S; Frangos, S; Bloom, S; Gracias, V; Le Roux, PD				Smith, MJ; Stiefel, MF; Magge, S; Frangos, S; Bloom, S; Gracias, V; Le Roux, PD			Packed red blood cell transfusdon increases local cerebral oxygenation	CRITICAL CARE MEDICINE			English	Article						transfusion; monitoring; subarachnoid hemorrhage; brain injuries; brain oxygen; anemia	BRAIN-TISSUE OXYGENATION; INJURED PATIENTS; CRITICAL-CARE; HEAD-INJURY; PRESSURE; RESUSCITATION; REACTIVITY; FAILURE; SHOCK; PO2	Objective. To determine a) whether packed red blood cell transfusion (RBCT) increases local brain tissue oxygen partial pressure (Pbto(2)) in a neurocritical care population; and b) what (if any) demographic, clinical, or physiologic variables mediate the assumed change. Design: Prospective observational study. Setting: A neurosurgical intensive care unit at a university-based level I trauma center and tertiary care hospital. Patients. Thirty-five consecutive volume-resuscitated patients with subarachnoid hemorrhage or traumatic brain injury, without cardiac disease, requiring Pbto(2) monitoring and receiving RBCT were studied between October 2001 and December 2003. Interventions. None. Measurements and Main Results. The following physiologic variables were measured and compared 1 hr before and after RBCT: Pbto(2), intracranial pressure, cerebral perfusion pressure, hemoglobin oxygen saturation (Sao(2)), FIO2, hemoglobin, and hematocrit. An increase in Pbto(2) was observed in 26 of the 35 patients (74%). In nine patients, Pbto(2) decreased after RBCT. The mean (&PLUSMN; SD) increase in Pbto(2) for all patients was 3.2 &PLUSMN; 8.8 mm Hg (p =.02), a 15% change from baseline (1 hr before RCBT). This Pbto(2) increase was associated with a significant mean increase in hemoglobin and hematocrit after RBCT (1.4 &PLUSMN; 1.1 g/dL and 4.2% &PLUSMN; 3.3%, respectively; both p &LT;.001). Cerebral perfusion pressure, Sao(2), and FIO2 were similar before and after RBCT. Among the 26 patients whose Pbto(2) increased, the mean increase in Pbto(2) was 5.1 &PLUSMN; 9.4 mm Hg or a 49% mean increase (p &LT;.01). Conclusions: RBCT is associated with an increase in Pbto(2) in most patients with subarachnoid hemorrhage or traumatic brain injury. This mean increase appears to be independent of cerebral perfusion pressure, Sao(2), and FIO2. Further study is required to determine why Pbto(2) decreases in some patients after RBCT.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Surg, Div Trauma & Surg Crit Care, Philadelphia, PA 19104 USA	Smith, MJ (corresponding author), Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.						[Anonymous], 2000, J Neurotrauma, V17, P537; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; CHESTNUT RM, 2000, HEAD INJURY, P229; CONRAD SA, 1990, CIRC SHOCK, V31, P419; CORWIN HL, 1995, CHEST, V108, P767, DOI 10.1378/chest.108.3.767; Couture DE, 2002, STROKE, V33, P994, DOI 10.1161/hs0402.105296; Filippi R, 2000, NEUROSURG REV, V23, P94; Fitzgerald RD, 1997, CRIT CARE MED, V25, P726, DOI 10.1097/00003246-199705000-00004; GROEGER JS, 1993, CRIT CARE MED, V21, P279, DOI 10.1097/00003246-199302000-00022; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Lane P, 2002, NAT MED, V8, P657, DOI 10.1038/nm0702-657; Le Roux PD, 2001, NEUROSURGERY, V49, P1068, DOI 10.1097/00006123-200111000-00009; MAAS AIR, 1996, YB INTENSIVE CARE EM, P707; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; McKhann GM, 2004, MANAGEMENT CEREBRAL, P431; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Procaccio F, 2000, J Neurosurg Sci, V44, P11; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL, P5103; Sahuquillo J, 2000, ACT NEUR S, V76, P457; Schneider GH, 1998, ACT NEUR S, V71, P62; SHAH DM, 1982, J TRAUMA, V22, P741, DOI 10.1097/00005373-198209000-00004; Smith GE, 1910, LANCET, V1, P1; Song DK, 1997, NEUROCHEM RES, V22, P1111, DOI 10.1023/A:1027313218258; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Winn HR., 2004, MANAGEMENT CEREBRAL, P303; Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1	29	162	167	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAY	2005	33	5					1104	1108		10.1097/01.CCM.0000162685.60609.49			5	Critical Care Medicine	General & Internal Medicine	925PO	WOS:000229065200028	15891343				2021-06-18	
J	Peterson, B; Khanna, S; Fisher, B; Marshall, L				Peterson, B; Khanna, S; Fisher, B; Marshall, L			Prolonged hypernatremia controls elevated intracranial pressure in head-injured pediatric patients	CRITICAL CARE MEDICINE			English	Article						hypertonic saline; mannitol; intracranial pressure; sodium; osmolarity; creatinine; Glasgow Coma Scale; Glasgow Outcome Scale; computed tomography; closed head injury	LACTATED RINGERS SOLUTION; HYPERTONIC SALINE; HEMORRHAGIC-SHOCK; 3-PERCENT SALINE; BRAIN-DAMAGE; RESUSCITATION; TRAUMA; MANAGEMENT; HYPONATREMIA; HYPERTENSION	Objective: To determine the effects continuous infusions of hypertonic saline (3% NaCl) on intracranial pressure (ICP) control and describe the physiologic effects of hypertonic saline administered to closed head injury children. Design: Retrospective chart review. Settings: Pediatric intensive care unit of a children's hospital. Patients: Sixty-eight children with closed head injury. Intervention: Intravenous infusion of 3% hypertonic saline to increase serum sodium to levels necessary to reduce ICP less than or equal to 20 mm Hg. Measurements and Main Results:The patients enrolled had similar injury Severity Scares. Treatment effectively lowered ICP in these patients and ICP was under goad control a majority of the time. Only three patients (4%) died of uncontrolled elevation of ICP, No adverse effects of supraphysiologic hyperosmolarity such as renal failure, pulmonary edema, or central pontine demyelination, were noted. Conclusions: Hypertonic saline administration to children with closed head injury appears to be a promising therapy for control of cerebral edema. Further controlled trials are required to determine the optimal duration of treatment before widespread use is advocated.	San Diego Childrens Hosp, Dept Anesthesia & Crit Care, San Diego, CA 92123 USA; Univ Calif San Diego, Med Ctr, Dept Neurosurg, La Jolla, CA 92093 USA	Peterson, B (corresponding author), Dept Crit Care, 3030 Childrens Way,Suite 115, San Diego, CA 92123 USA.						ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ARAI T, 1986, CRIT CARE MED, V14, P634, DOI 10.1097/00003246-198607000-00010; ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; BAKAY L, 1954, SURG GYNECOL OBSTET, V99, P48; BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BAUE AE, 1967, J TRAUM, V7, P743, DOI 10.1097/00005373-196709000-00012; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Chesnut R M, 1995, New Horiz, V3, P581; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FINBERG L, 1959, PEDIATRICS, V23, P46; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; GROSS JS, 1989, J TRAUMA, V29, P817; GUNNAR W, 1988, SURGERY, V103, P398; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; HARTWELL RC, 1993, NEUROSURGERY, V32, P444, DOI 10.1227/00006123-199303000-00017; HOLCROFT JW, 1987, ANN SURG, V206, P279, DOI 10.1097/00000658-198709000-00006; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KIRBY RR, 1990, POCKET COMPANION CRI, P28; KOHAN DE, 1989, MANUAL MED THERAPEUT, P52; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; NAKAYAMA DK, 1991, J TRAUMA, V31, P1521, DOI 10.1097/00005373-199111000-00010; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SHACKFORD SR, 1987, SURG GYNECOL OBSTET, V164, P127; SHACKFORD SR, 1990, J INTENSIVE CARE MED, V5, P59; SHENKIN HA, 1976, J NEUROSURG, V45, P432, DOI 10.3171/jns.1976.45.4.0432; SHENKIN HA, 1969, J NEUROSURG, V31, P400, DOI 10.3171/jns.1969.31.4.0400; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Soupart A, 1996, J NEUROPATH EXP NEUR, V55, P106, DOI 10.1097/00005072-199601000-00011; STERNS RH, 1986, NEW ENGL J MED, V314, P1535, DOI 10.1056/NEJM198606123142402; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; VONBERENBERG P, 1994, ACTA NEUROCHIR, P531; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011	45	162	171	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2000	28	4					1136	1143		10.1097/00003246-200004000-00037			8	Critical Care Medicine	General & Internal Medicine	311AV	WOS:000086862800037	10809295				2021-06-18	
J	Schatz, J; Kramer, JH; Ablin, A; Matthay, KK				Schatz, J; Kramer, JH; Ablin, A; Matthay, KK			Processing speed, working memory, and IQ: A developmental model of cognitive deficits following cranial radiation therapy	NEUROPSYCHOLOGY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; LONG-TERM SURVIVORS; CENTRAL NERVOUS-SYSTEM; SCHOOL-AGE-CHILDREN; CLOSED HEAD-INJURY; CHILDHOOD LEUKEMIA; NEUROPSYCHOLOGICAL PERFORMANCE; PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; ARTICULATION TIME	IQ decrements following cranial radiation therapy (CRT) for acute lymphoblastic leukemia (ALL) are most apparent years after treatment. The authors examined a developmental model for delayed deficits by evaluating the relationship between processing speed, working memory, and IQ in long-term survivors of childhood ALL (n = 27) compared with demographically matched controls (n = 27). The ALL group treated with CRT showed deficits in IQ, working memory, and processing speed relative to controls. Differences in IQ between the CRT group and controls were mediated by differences in working memory. Processing speed did not fully account for the working memory deficit in the CRT group. Participants with ALL heated only with chemotherapy showed similar working memory and processing speed as matched controls. Data suggest that deficits in processing speed and working memory following CRT may underlie declines in IQ.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Childrens Canc Program, San Francisco, CA 94143 USA	Schatz, J (corresponding author), Univ S Carolina, Dept Psychol, Columbia, SC 29208 USA.	schatz@sc.edu					ANDERSON V, 1994, ARCH DIS CHILD, V70, P476, DOI 10.1136/adc.70.6.476; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; BANICH MT, 1990, NEUROPSYCHOLOGIA, V28, P35, DOI 10.1016/0028-3932(90)90084-2; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BECKER MG, 1987, DEV NEUROPSYCHOL, V3, P275, DOI 10.1080/87565648709540381; BROUWERS P, 1984, J CLIN NEUROPSYCHOL, V6, P325, DOI 10.1080/01688638408401222; BROUWERS P, 1990, AM J PEDIAT HEMATOL, V12, P174; BROWN RT, 1993, J LEARN DISABIL, V26, P74, DOI 10.1177/002221949302600201; CARPENTER PA, 1990, PSYCHOL REV, V97, P404, DOI 10.1037/0033-295X.97.3.404; CERELLA J, 1985, PSYCHOL BULL, V98, P67, DOI 10.1037/0033-2909.98.1.67; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHRISTIE D, 1995, ARCH DIS CHILD, V73, P136, DOI 10.1136/adc.73.2.136; CIESIELSKI KT, 1994, ARCH NEUROL-CHICAGO, V51, P985, DOI 10.1001/archneur.1994.00540220031012; COOPER JA, 1994, BRAIN, V117, P517, DOI 10.1093/brain/117.3.517; COPELAND DR, 1988, J CHILD NEUROL, V3, P53, DOI 10.1177/088307388800300113; COPELAND DR, 1985, PEDIATRICS, V75, P745; COUSENS P, 1988, J CHILD PSYCHOL PSYC, V29, P839, DOI 10.1111/j.1469-7610.1988.tb00757.x; COUSENS P, 1991, J PEDIATR PSYCHOL, V16, P475, DOI 10.1093/jpepsy/16.4.475; CUMMINGS JL, 1986, BRIT J PSYCHIAT, V149, P682, DOI 10.1192/bjp.149.6.682; Dennis M, 1996, J NEURO-ONCOL, V29, P91, DOI 10.1007/BF00165522; DUNCOMBE ME, 1994, NEUROPSYCHOLOGIA, V32, P1383, DOI 10.1016/0028-3932(94)00071-9; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; FINGER S, 1982, BRAIN DAMAGE RECOVER; FLETCHER JM, 1988, J CLIN EXP NEUROPSYC, V10, P495, DOI 10.1080/01688638808408255; Fry AF, 1996, PSYCHOL SCI, V7, P237, DOI 10.1111/j.1467-9280.1996.tb00366.x; GATHERCOLE SE, 1989, J MEM LANG, V28, P200, DOI 10.1016/0749-596X(89)90044-2; GATHERCOLE SE, 1990, BRIT J PSYCHOL, V81, P439, DOI 10.1111/j.2044-8295.1990.tb02371.x; Hale S, 1996, NEUROPSYCHOLOGY, V10, P228, DOI 10.1037/0894-4105.10.2.228; HALE S, 1993, DEV PSYCHOL, V29, P880; Hale S, 1997, DEV PSYCHOL, V33, P364, DOI 10.1037/0012-1649.33.2.364; Harila-Saari AH, 1998, CANCER, V83, P2608, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2608::AID-CNCR28>3.0.CO;2-L; Hertzberg H, 1997, MED PEDIATR ONCOL, V28, P387, DOI 10.1002/(SICI)1096-911X(199706)28:6<387::AID-MPO1>3.0.CO;2-C; Hill DE, 1997, J PEDIATR PSYCHOL, V22, P861, DOI 10.1093/jpepsy/22.6.861; Horn J. L., 1985, HDB INTELLIGENCE THE, P267; HORN JL, 1968, PSYCHOL REV, V75, P242, DOI 10.1037/h0025662; HORN JL, 1987, SPEED INFORMATION PR, P201; JANKOVIC M, 1994, LANCET, V344, P224, DOI 10.1016/S0140-6736(94)92997-1; JUNQUE C, 1990, ARCH NEUROL-CHICAGO, V47, P151, DOI 10.1001/archneur.1990.00530020047013; KAIL R, 1992, DEV PSYCHOL, V28, P899, DOI 10.1037/0012-1649.28.5.899; KAIL R, 1994, J EXP CHILD PSYCHOL, V57, P281, DOI 10.1006/jecp.1994.1013; KAIL R, 1994, ACTA PSYCHOL, V86, P199, DOI 10.1016/0001-6918(94)90003-5; Kail R, 1998, J CLIN EXP NEUROPSYC, V20, P98, DOI 10.1076/jcen.20.1.98.1483; Kail R, 1997, J EXP CHILD PSYCHOL, V67, P57, DOI 10.1006/jecp.1997.2393; KAIL R, 1995, J EXPT CHILD PSYCHOL, V64, P67; Kaufman AS, 1985, KAUFMAN BRIEF INTELL; KINGMA A, 1993, AM J PEDIAT HEMATOL, V15, P231; KLEINMAN SN, 1994, NEUROPSYCHOLOGY, V8, P464; KRAMER JH, 1988, CANCER, V61, P928, DOI 10.1002/1097-0142(19880301)61:5<928::AID-CNCR2820610512>3.0.CO;2-O; LUDWIG R, 1987, J CANCER RES CLIN, V113, P235, DOI 10.1007/BF00396379; MOORE IMK, 1991, CANCER, V68, P1913; MULHERN RK, 1991, J CLIN ONCOL, V9, P1348, DOI 10.1200/JCO.1991.9.8.1348; OCHS J, 1991, J CLIN ONCOL, V9, P145, DOI 10.1200/JCO.1991.9.1.145; OTT N, 1988, AM J PEDIAT HEMATOL, V10, P191; PAAKKO E, 1994, NEURORADIOLOGY, V36, P652; PAPAGNO C, 1991, J MEM LANG, V30, P331, DOI 10.1016/0749-596X(91)90040-Q; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; PHILLIPS PC, 1991, ANN NEUROL, V29, P263, DOI 10.1002/ana.410290306; PRICE RA, 1978, CANCER, V42, P717, DOI 10.1002/1097-0142(197808)42:2<717::AID-CNCR2820420244>3.0.CO;2-3; PRIEST JR, 1980, CANCER, V46, P1548, DOI 10.1002/1097-0142(19801001)46:7<1548::AID-CNCR2820460709>3.0.CO;2-7; RAFAL RD, 1984, BRAIN, V107, P1083, DOI 10.1093/brain/107.4.1083; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P471, DOI 10.1080/01688638908400907; ROBAIN O, 1984, J NEUROL NEUROSUR PS, V47, P65, DOI 10.1136/jnnp.47.1.65; RODGERS J, 1992, ARCH DIS CHILD, V67, P266, DOI 10.1136/adc.67.3.266; Rourke B.P., 1994, LEARNING DISABILITIE; ROURKE BP, 1987, CLIN NEUROPSYCHOL, V56, P801; RUBENSTEIN CL, 1990, J DEV BEHAV PEDIATR, V11, P301; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TAYLOR HG, 1990, NEW ENGL J MED, V323, P1657, DOI 10.1056/NEJM199012133232403; Thorndike EL., 1944, TEACHERS WORD BOOK 3; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; Uberall MA, 1996, NEUROPEDIATRICS, V27, P130, DOI 10.1055/s-2007-973763; Ueberall MA, 1996, PEDIATR NEUROL, V15, P293, DOI 10.1016/S0887-8994(96)00232-9; WABER DP, 1994, DEV NEUROPSYCHOL, V10, P349, DOI 10.1080/87565649409540589; WABER DP, 1995, J CLIN ONCOL, V13, P2490, DOI 10.1200/JCO.1995.13.10.2490; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; WHITE DA, 1977, AGING NEUROPSYCHOL C, V4, P166; Wilkinson GS., 1993, WRAT3 ADM MANUAL; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	81	162	165	1	20	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	APR	2000	14	2					189	200		10.1037//0894-4105.14.2.189			12	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	321XM	WOS:000087480700003	10791859				2021-06-18	
J	Lovell, MR; Iverson, GL; Collins, MW; McKeag, D; Maroon, JC				Lovell, MR; Iverson, GL; Collins, MW; McKeag, D; Maroon, JC			Does loss of consciousness predict neuropsychological decrements after concussion?	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						brain, wounds and injuries; concussion; trauma; trauma, psychological effects	ORIENTATION; INJURY	Objective: To investigate the importance of loss of consciousness (LOC) in predicting neuropsychological test performance in a large sample of patients with head injury. Design: Retrospective comparison of neuropsychological test results for patients who suffered traumatic LOC, no LOC, or uncertain LOC. Setting: Allegheny General Hospital, Pittsburgh, Pennsylvania. Patients: The total number of patients included in this study was 383. Main Outcome Measures: Neuropsychological test measures, including the visual reproduction, digit span, and logical memory subtests of the Wechsler memory scale (revised), the Trail Making test, Wisconsin Card Sorting test, Hopkins Verbal Learning test, Controlled Oral Word Association, and the Galveston Orientation and Amnesia test (GOAT). Results: No significant differences were found between the LOC, no LOC, or uncertain LOC groups for any of the neuropsychological measures used. Patients who had experienced traumatic LOC did not perform more poorly on neuropsychological testing than those with no LOC or uncertain LOC. All three groups demonstrated mildly decreased performance on formal tests of speed of information processing, attentional process, and memory. Conclusion: The results of this study cast doubt on the importance of LOC as a predictor of neuropsychological test performance during the acute phase of recovery from mild traumatic brain injury. Neuropsychological testing procedures have been shown to be sensitive in measuring cognitive sequelae of mild traumatic brain injury (concussion) in athletes. The failure of this study to find any relationship between LOC and neuropsychological functioning in a large sample of patients with mild head trauma calls into question the assignment of primary importance to LOC in grading severity of concussion. This study also does not provide support for the use of guidelines that rely heavily on LOC in making return-to-play decisions. Continued research is necessary to determine the relative importance of markers of concussion in athletes.	Henry Ford Hlth Syst, Div Neuropsychol 1E, Detroit, MI 48202 USA; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Riverview Hosp, Vancouver, BC, Canada; Indiana Univ, Dept Family Med, Indianapolis, IN 46204 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA	Lovell, MR (corresponding author), Henry Ford Hlth Syst, Div Neuropsychol 1E, Detroit, MI 48202 USA.			Iverson, Grant/0000-0001-7348-9570			BAILES J, 1998, SPORTS RELATED CONCU; Benton AL, 1978, MULTILINGUAL APHASIA; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; BROOKS J, 1998, EPIDEMIOLOGY PREVENT; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; COLLINS MW, 1999, JAMA-J AM MED ASSOC, V282, P971; COLLINS MW, 1998, AM MED SOC SPORTS ME; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; JENNETT B, 1975, LANCET, V1, P480; JORDAN BD, 1994, NAT ATHL TRAIN ASS R; Kelly JP, 1997, NEUROLOGY, V48, P581; LENINGER BR, 1991, J NEUROL NEUROSUR PS, V54, P846; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; LOVELL MR, 1998, SPORTS RELATED CONCU; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RICE SG, 1998, AM MED SOC SPORTS ME; Torg JS, 1982, ATHLETIC INJURIES HE; Wechsler D., 1987, WECHSLER MEMORY SCAL; Yarnell P R, 1988, Brain Inj, V2, P255, DOI 10.3109/02699058809150950	29	162	163	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	OCT	1999	9	4					193	198		10.1097/00042752-199910000-00002			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	259LB	WOS:000083894400002	10593212				2021-06-18	
J	Hayes, AE; Davidson, MC; Keele, SW; Rafal, RD				Hayes, AE; Davidson, MC; Keele, SW; Rafal, RD			Toward a functional analysis of the basal ganglia	JOURNAL OF COGNITIVE NEUROSCIENCE			English	Article							CLOSED-HEAD INJURY; PARKINSONS-DISEASE; COVERT ORIENTATION; MOTOR CONTROL; ATTENTION; PERFORMANCE; SET; FORCE; BRADYKINESIA; DYSFUNCTION	Parkinson patients were tested in two paradigms to test the hypothesis that the basal ganglia are involved in the shifting of attentional set. Set shifting means a respecification of the conditions that regulate responding, a process sometimes referred to as an executive process. In one paradigm, upon the appearance of each stimulus, subjects were instructed to respond either to its color or to its shape. In a second paradigm, subjects learned to produce short sequences of three keypresses in response to two arbitrary stimuli. Reaction times were compared for the cases where set either remained the same or changed for two successive stimuli. Parkinson patients were slow to change set compared to controls. Parkinson patients were also less able to filter the competing but irrelevant set than were control subjects. The switching deficit appears to be dopamine based; the magnitude of the shifting deficit was related to the degree to which 1-dopa-based medication ameliorated patients' motor symptoms. Moreover, temporary withholding of medication, a so-called off manipulation, increased the time to switch. Using the framework of equilibrium point theory of movement, we discuss how a set switching deficit may also underlie clinical motor disturbances seen in Parkinson's disease.	Univ Oregon, Eugene, OR 97403 USA; Univ Calif Davis, Davis, CA USA	Hayes, AE (corresponding author), Vet Adm Med Ctr, Neurol 127,150 Muir Rd, Martinez, CA 94553 USA.	ahayes@ebire.org			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2 P01 NS17778] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS017778] Funding Source: NIH RePORTER		ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ALLPORT A, 1994, ATTENTION PERFORM, V15, P421; BIZZI E, 1976, J NEUROPHYSIOL, V39, P435; BIZZI E, 1984, J NEUROSCI, V4, P2738; BOWEN FP, 1975, NEUROLOGY, V25, P701, DOI 10.1212/WNL.25.8.701; BROWN RG, 1988, BRAIN, V111, P323, DOI 10.1093/brain/111.2.323; BROWN RG, 1990, TRENDS NEUROSCI, V13, P21, DOI 10.1016/0166-2236(90)90058-I; CLARK CR, 1989, NEUROPSYCHOLOGIA, V27, P131, DOI 10.1016/0028-3932(89)90166-8; COOLS AR, 1980, BEHAV BRAIN RES, V1, P361, DOI 10.1016/0166-4328(80)90035-2; COOLS AR, 1984, J NEUROL NEUROSUR PS, V47, P443, DOI 10.1136/jnnp.47.5.443; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; Corcos DM, 1996, ANN NEUROL, V39, P79, DOI 10.1002/ana.410390112; DOWNES JJ, 1989, NEUROPSYCHOLOGIA, V27, P1329, DOI 10.1016/0028-3932(89)90128-0; DOWNES JJ, 1993, BRAIN, V116, P887, DOI 10.1093/brain/116.4.887; DUBOIS B, 1991, HDB NEUROPSYCHOLOGY, V5, P195; FELDMAN AG, 1986, J MOTOR BEHAV, V18, P17; FILOTEO JV, 1994, NEUROPSYCHOLOGY, V8, P210; FLOWERS KA, 1985, J NEUROL NEUROSUR PS, V48, P517, DOI 10.1136/jnnp.48.6.517; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FUSTER JM, 1985, CEREB CORTEX, V4, P151; GOLDMANRAKIC PS, 1990, TRENDS NEUROSCI, V13, P241, DOI 10.1016/0166-2236(90)90103-H; GOLDMANRAKIC PS, 1995, MODELS INFORMATION P, P277; HALLETT M, 1980, BRAIN, V103, P301, DOI 10.1093/brain/103.2.301; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; HORAK FB, 1984, J NEUROPHYSIOL, V52, P290; Houk J. C., 1993, Neuroscience: From Neural Networks to Artificial Intelligence Proceeding of a U.S.-Mexico Seminar, P452; KEELE SW, 1990, ATTENTION PERFORM, P77; KEELE SW, 1986, HDB PERCEPTION HUMAN, V2, P1; LANGE KW, 1992, PSYCHOPHARMACOLOGY, V107, P394, DOI 10.1007/BF02245167; MacKay D. G., 1987, ORG PERCEPTION ACTIO; Maddox WT, 1996, NEUROPSYCHOLOGY, V10, P197, DOI 10.1037/0894-4105.10.2.197; MARGOLIN DI, 1983, ACTA PSYCHOL, V54, P263, DOI 10.1016/0001-6918(83)90039-2; MARSDEN CD, 1994, BRAIN, V117, P877, DOI 10.1093/brain/117.4.877; Meiran N, 1996, J EXP PSYCHOL LEARN, V22, P1423, DOI 10.1037/0278-7393.22.6.1423; MINK JW, 1991, J NEUROPHYSIOL, V65, P330; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; OWEN AM, 1993, BRAIN, V116, P1159, DOI 10.1093/brain/116.5.1159; PARENT A, 1990, TRENDS NEUROSCI, V13, P254, DOI 10.1016/0166-2236(90)90105-J; Posner M., 1975, ATTENTION PERFORMANC, P669; POSNER MI, 1994, TRENDS NEUROSCI, V17, P75, DOI 10.1016/0166-2236(94)90078-7; POSNER MI, IN PRESS ATTENTIVE B; Rafal R, 1996, NEUROPSYCHOLOGIA, V34, P1197, DOI 10.1016/0028-3932(96)00045-0; RAFAL RD, 1984, BRAIN, V107, P1083, DOI 10.1093/brain/107.4.1083; ROBERTSON C, 1990, J NEUROL NEUROSUR PS, V53, P583, DOI 10.1136/jnnp.53.7.583; ROGERS RD, 1995, J EXP PSYCHOL GEN, V124, P207, DOI 10.1037/0096-3445.124.2.207; ROSENBAUM DA, 1987, PSYCHOL LEARN MOTIV, V21, P153; Saint-Cyr J A, 1995, Adv Neurol, V65, P1; SHARPE MH, 1990, CORTEX, V26, P515, DOI 10.1016/S0010-9452(13)80301-2; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STELMACH GE, 1988, NEUROPSYCHOLOGIA, V26, P93, DOI 10.1016/0028-3932(88)90033-4; Stern M. B., 1988, COMPREHENSIVE MANAGE, P3; WING AM, 1988, NEUROPSYCHOLOGIA, V26, P479, DOI 10.1016/0028-3932(88)90100-5; WRIGHT MJ, 1990, NEUROPSYCHOLOGIA, V28, P151, DOI 10.1016/0028-3932(90)90097-8	55	162	165	0	11	MIT PRESS	CAMBRIDGE	ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA	0898-929X	1530-8898		J COGNITIVE NEUROSCI	J. Cogn. Neurosci.	MAR	1998	10	2					178	198		10.1162/089892998562645			21	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	ZG744	WOS:000073035000003	9555106				2021-06-18	
J	BOUMA, GJ; MUIZELAAR, JP				BOUMA, GJ; MUIZELAAR, JP			CEREBRAL BLOOD-FLOW, CEREBRAL BLOOD-VOLUME, AND CEREBROVASCULAR REACTIVITY AFTER SEVERE HEAD-INJURY	JOURNAL OF NEUROTRAUMA			English	Article							CEREBROSPINAL-FLUID SYSTEM; CENTRAL-NERVOUS-SYSTEM; AUTO-REGULATION; PERFUSION-PRESSURE; BRAIN EDEMA; INTRAVENTRICULAR PRESSURE; SYMPATHETIC-STIMULATION; COMPARTMENTAL ANALYSIS; INTRACRANIAL-PRESSURE; ARTERIAL-PRESSURE	Traumatic brain injury (TBI) often causes disturbances of the cerebrovascular circulation, which contribute to the infliction of secondary injury, although the complex nature of the mechanisms involved is not fully understood. First, the role of ischemia in TBI is still controversial. Despite experimental and pathologic data suggesting important interactions between ischemia and trauma, evidence for posttraumatic ischemia with CBF measurements in patients so far had eluded most investigators. Recent data, however, indicate that low CBF and ischemia probably only occur within the first few hours after injury, yet have important impact on neurologic status and outcome. Similarly, the clinical significance of posttraumatic hyperemia is unclear. A relationship between raised intracranial pressure (ICP) and hyperemia has been suspected, but reports have not been consistent, possibly due to a dissociation between CBF and CBV in head-injured patients. Measurements of CBV in the acute stage of severe head injury now have confirmed this concept, and also suggest that increased CBV may contribute to brain stiffness and elevated ICP. Impairment of cerebrovascular CO2 reactivity and autoregulation often occurs after TBI. Although no correlation with the severity of injury or outcome has been established, it is obvious that diminished adaptive responses of the cerebral vasculature render the brain more vulnerable to additional systemic insults, such as derangements of blood pressure, altered rheology, or hypoxia. The posttraumatic status of vascular reactivity and autoregulation also has important implications with regard to the treatment of high ICP, in particular for the use of hyperventilation and pharmacologic management of blood pressure, which are discussed in detail.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV NEUROSURG, RICHMOND, VA 23298 USA							ADAMS HP, 1972, SCI F NEUROLOGY, P488; Allen G S, 1976, Surg Neurol, V6, P63; ASTRUP J, 1982, J NEUROSURG, V56, P482, DOI 10.3171/jns.1982.56.4.0482; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; ASTRUP J, 1978, CIBA F S, V56, P313; AUSTIN G, 1975, CEREBRAL CIRCULATION, P391; AVEZAAT CJJ, 1980, J NEUROL NEUROSUR PS, V43, P222, DOI 10.1136/jnnp.43.3.222; BAUMBACH GL, 1983, CIRC RES, V52, P527, DOI 10.1161/01.RES.52.5.527; BAUMBACH GL, 1986, NEURAL REGULATION BR, P607; BEVAN JA, 1985, ANN BIOMED ENG, V13, P281, DOI 10.1007/BF02584245; BILL A, 1976, ACTA PHYSIOL SCAND, V96, P114, DOI 10.1111/j.1748-1716.1976.tb10176.x; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1992, 1ST P INT C STABL XE; BRODERSEN P, 1973, ARCH NEUROL-CHICAGO, V28, P334, DOI 10.1001/archneur.1973.00490230070010; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; COLD GE, 1989, ACTA NEUROCHIR, V98, P153, DOI 10.1007/BF01407342; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P359, DOI 10.1111/j.1399-6576.1977.tb01232.x; CROCKARD HA, 1977, SURG NEUROL, V7, P281; CUEVAS P, 1987, SURG NEUROL, V27, P113, DOI 10.1016/0090-3019(87)90281-3; DARBY JM, 1988, NEUROSURGERY, V23, P84, DOI 10.1227/00006123-198807000-00014; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; EDVINSSON L, 1976, BRAIN RES, V117, P519, DOI 10.1016/0006-8993(76)90760-5; EDVINSSON L, 1976, ACTA PHYSL SCAND   S, V427, P1; ENEVOLDSEN EM, 1977, J NEUROSURG, V47, P699, DOI 10.3171/jns.1977.47.5.0699; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FARACI FM, 1990, CIRC RES, V66, P8, DOI 10.1161/01.RES.66.1.8; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; FITCH W, 1975, CIRC RES, V37, P550, DOI 10.1161/01.RES.37.5.550; Fog M, 1937, ARCH NEURO PSYCHIATR, V37, P351, DOI 10.1001/archneurpsyc.1937.02260140137007; Fog M, 1939, ARCH NEURO PSYCHIATR, V41, P260, DOI 10.1001/archneurpsyc.1939.02270140046003; GEE W, 1983, J NEUROSURG, V59, P46, DOI 10.3171/jns.1983.59.1.0046; GRAHAM DI, 1971, LANCET, V1, P265; GRAY WJ, 1987, J NEUROSURG, V67, P369, DOI 10.3171/jns.1987.67.3.0369; GRAY WJ, 1987, J NEUROSURG, V67, P377, DOI 10.3171/jns.1987.67.3.0377; GRUBB RL, 1978, ANN NEUROL, V4, P322, DOI 10.1002/ana.410040407; HARPER AM, 1966, J NEUROL NEUROSUR PS, V29, P398, DOI 10.1136/jnnp.29.5.398; HEISTAD DD, 1983, HDB PHYSL 2, V3, P137; HOFF JT, 1972, LANCET, V2, P1337; HOFF JT, 1986, J NEUROSURG, V65, P579, DOI 10.3171/jns.1986.65.5.0579; HOUGAARD K, 1983, ACTA PHYSIOL SCAND, V117, P585, DOI 10.1111/j.1748-1716.1983.tb07231.x; HUDAK ML, 1989, AM J PHYSIOL, V257, pH912; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1973, CEREBROVASC DIS, P163; JOHANSSON PO, 1983, ENVIRON PLANN C, V1, P107, DOI 10.1068/c010107; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KASOFF SS, 1972, J NEUROSURG, V36, P463, DOI 10.3171/jns.1972.36.4.0463; KATUSIC ZS, 1987, AM J PHYSIOL, V252, pH671; KENNEDY C, 1957, J CLIN INVEST, V36, P1130, DOI 10.1172/JCI103509; KONTOS HA, 1978, AM J PHYSIOL, V234, pH582; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; KONTOS HA, 1989, INTRACRANIAL PRESSUR, V7, P787; KRAUSE GS, 1986, AM HEART J, V111, P768, DOI 10.1016/0002-8703(86)90114-6; KUHL DE, 1980, J NEUROSURG, V52, P309, DOI 10.3171/jns.1980.52.3.0309; Langfitt T W, 1981, Prog Neurol Surg, V10, P14, DOI 10.1159/000384767; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; LASSEN NA, 1963, ARCH NEUROL-CHICAGO, V9, P615, DOI 10.1001/archneur.1963.00460120065007; LASSEN NA, 1959, PHYSIOL REV, V39, P183; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LASSEN NA, 1974, CIRC RES, V34, P749, DOI 10.1161/01.RES.34.6.749; LEECH P, 1974, J NEUROL NEUROSUR PS, V37, P1009; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MARION DW, 1990, J NEUROSURG; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523; MARMAROU A, 1987, J NEUROSURG, V66, P883, DOI 10.3171/jns.1987.66.6.0883; MARSHALL LF, 1990, CURR OPIN NEUROL NEU, V3, P4; MARSHALL WJ, 1969, ARCH NEUROL-CHICAGO, V21, P545, DOI 10.1001/archneur.1969.00480170117012; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; MCCULLOCH J, 1984, Trends in Neurosciences, V7, P135, DOI 10.1016/S0166-2236(84)80122-8; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MILLER JD, 1975, J NEUROL NEUROSUR PS, V38, P657, DOI 10.1136/jnnp.38.7.657; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1986, STROKE, V17, P44, DOI 10.1161/01.STR.17.1.44; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; MUIZELAAR JP, 1984, ADV NEUROTRAUMATOLOG, P92; MUIZELAAR JP, 1989, INTRACRANIAL PRESSUR, V7, P825; Nilsson B, 1980, CEREBRAL ARTERIAL SP, V488-95; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1975, STROKE, V6, P245, DOI 10.1161/01.STR.6.3.245; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1981, J NEUROSURG, V55, P63, DOI 10.3171/jns.1981.55.1.0063; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PAULSON OB, 1989, AM J CARDIOL, V63, pC2, DOI 10.1016/0002-9149(89)90396-2; PULSINELLI WA, 1983, STROKE, V14, P130; PURVES MJ, 1978, CIRC RES, V43, P485, DOI 10.1161/01.RES.43.4.485; RAICHLE ME, 1976, ARCH NEUROL-CHICAGO, V33, P523, DOI 10.1001/archneur.1976.00500080001001; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; SCHMIDLEY JW, 1990, STROKE, V21, P1086, DOI 10.1161/01.STR.21.7.1086; SCHRADER J, 1980, PFLUG ARCH EUR J PHY, V387, P245, DOI 10.1007/BF00580977; SIESJO BK, 1972, KIDNEY INT, V1, P360, DOI 10.1038/ki.1972.47; SIESJO BK, 1984, J NEUROSURG, V60, P883, DOI 10.3171/jns.1984.60.5.0883; SIMARD JM, 1989, AM J CARDIOL, V63, pC32, DOI 10.1016/0002-9149(89)90403-7; SOKOLOFF L, 1981, J CEREBR BLOOD F MET, V1, P7, DOI 10.1038/jcbfm.1981.4; STRANDGAARD S, 1984, STROKE, V15, P413, DOI 10.1161/01.STR.15.3.413; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; TAGAKI H, 1980, INTRACRANIAL PRESSUR, V4, P163; TAMAKI K, 1986, HYPERTENSION, V8, P911, DOI 10.1161/01.HYP.8.10.911; WAHL M, 1979, PFLUG ARCH EUR J PHY, V382, P203, DOI 10.1007/BF00583703; WAHL M, 1970, PFLUG ARCH EUR J PHY, V316, P152, DOI 10.1007/BF00586483; Ward JD, 1989, INTRACRANIAL PRESSUR, P630; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WINN HR, 1981, AM J PHYSIOL, V241, pH235; WINN HR, 1980, AM J PHYSIOL, V239, pH636; WINN HR, 1981, J CEREBR BLOOD F MET, V1, P239, DOI 10.1038/jcbfm.1981.29; YONAS H, 1984, STROKE, V15, P443, DOI 10.1161/01.STR.15.3.443; YOSHINO E, 1985, J NEUROSURG, V63, P830, DOI 10.3171/jns.1985.63.6.0830; Zimmerman RC, 1987, STROKE MICROCIRCULAT, P303	120	162	162	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	1992	9			1			S333	S348					16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HN806	WOS:A1992HN80600034	1588625				2021-06-18	
J	Neselius, S; Brisby, H; Theodorsson, A; Blennow, K; Zetterberg, H; Marcusson, J				Neselius, Sanna; Brisby, Helena; Theodorsson, Annette; Blennow, Kaj; Zetterberg, Henrik; Marcusson, Jan			CSF-Biomarkers in Olympic Boxing: Diagnosis and Effects of Repetitive Head Trauma	PLOS ONE			English	Article							CHRONIC BRAIN-DAMAGE; FIBRILLARY ACIDIC PROTEIN; DIFFUSE AXONAL INJURY; CEREBROSPINAL-FLUID; CONCUSSION; S100B; MILD; LEAD; FOOTBALL; SPORTS	Background: Sports-related head trauma is common but still there is no established laboratory test used in the diagnostics of minimal or mild traumatic brain injuries. Further the effects of recurrent head trauma on brain injury markers are unknown. The purpose of this study was to investigate the relationship between Olympic (amateur) boxing and cerebrospinal fluid (CSF) brain injury biomarkers. Methods: The study was designed as a prospective cohort study. Thirty Olympic boxers with a minimum of 45 bouts and 25 non-boxing matched controls were included in the study. CSF samples were collected by lumbar puncture 1-6 days after a bout and after a rest period for at least 14 days. The controls were tested once. Biomarkers for acute and chronic brain injury were analysed. Results: NFL (mean +/- SD, 5326 +/- 553 vs 135 +/- 51 ng/L p = 0.001), GFAP (496 +/- 238 vs 247 +/- 147 ng/L p<0.001), T-tau (58 +/- 26 vs 49 +/- 21 ng/L p<0.025) and S-100B (0.76 +/- 0.29 vs 0.60 +/- 0.23 ng/L p = 0.03) concentrations were significantly increased after boxing compared to controls. NFL (402 +/- 434 ng/L p = 0.004) and GFAP (369 +/- 113 ng/L p = 0.001) concentrations remained elevated after the rest period. Conclusion: Increased CSF levels of T-tau, NFL, GFAP, and S-100B in >80% of the boxers demonstrate that both the acute and the cumulative effect of head trauma in Olympic boxing may induce CSF biomarker changes that suggest minor central nervous injuries. The lack of normalization of NFL and GFAP after the rest period in a subgroup of boxers may indicate ongoing degeneration. The recurrent head trauma in boxing may be associated with increased risk of chronic traumatic brain injury.	[Neselius, Sanna; Brisby, Helena] Sahlgrens Univ Hosp, Dept Orthopaed, Gothenburg, Sweden; [Neselius, Sanna; Brisby, Helena] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Gothenburg, Sweden; [Theodorsson, Annette] Linkoping Univ Hosp, Neurosurg Sect, S-58185 Linkoping, Sweden; [Theodorsson, Annette; Marcusson, Jan] Linkoping Univ, Inst Clin & Expt Med, Linkoping, Sweden; [Blennow, Kaj; Zetterberg, Henrik] Sahlgrens Univ Hosp, Clin Neurochem Lab, Dept Psychiat & Neurochem, Gothenburg, Sweden; [Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Inst Neurosci & Physiol, Sahlgrenska Acad, Gothenburg, Sweden; [Marcusson, Jan] Linkoping Univ Hosp, Geriatr Sect, S-58185 Linkoping, Sweden	Neselius, S (corresponding author), Sahlgrens Univ Hosp, Dept Orthopaed, Gothenburg, Sweden.	sanna.neselius@vgregion.se			Marianne and Marcus Wallenberg Foundation, Sweden; County Council of Vastra Gotaland, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Gothenburg Medical Society, Sweden; County Council of Ostergotland, Sweden; Swedish Research CouncilSwedish Research CouncilEuropean Commission	This study has been funded by the Marianne and Marcus Wallenberg Foundation, Sweden; ALF Grants, County Council of Vastra Gotaland, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Gothenburg Medical Society, Sweden; ALF Grants, County Council of Ostergotland, Sweden and The Swedish Research Council. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Blennow K, 2010, NAT REV NEUROL, V6, P131, DOI 10.1038/nrneurol.2010.4; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; CHARNAS L, 1986, HOSP PRACT, V21, P30; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P245; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jagoda AS, 2010, PSYCHIAT CLIN N AM, V33, P797, DOI 10.1016/j.psc.2010.09.004; Jordan BD, 1996, AM J SPORT MED, V24, P704, DOI 10.1177/036354659602400526; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; KASTE M, 1982, LANCET, V2, P1186; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Michetti F, 2012, J NEUROCHEM, V120, P644, DOI 10.1111/j.1471-4159.2011.07612.x; Olsson A, 2005, CLIN CHEM, V51, P336, DOI 10.1373/clinchem.2004.039347; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Pelsers MMAL, 2004, CLIN CHEM, V50, P1568, DOI 10.1373/clinchem.2003.030361; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Putukian M, 2011, CLIN SPORT MED, V30, P49, DOI 10.1016/j.csm.2010.09.005; Raftery AE, 1997, J AM STAT ASSOC, V92, P179, DOI 10.2307/2291462; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Rosengren LE, 1996, J NEUROCHEM, V67, P2013, DOI 10.1046/j.1471-4159.1996.67052013.x; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	41	161	163	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2012	7	4							e33606	10.1371/journal.pone.0033606			8	Multidisciplinary Sciences	Science & Technology - Other Topics	953GO	WOS:000304855200018	22496755	DOAJ Gold, Green Published			2021-06-18	
J	Frugier, T; Morganti-Kossmann, MC; O'Reilly, D; McLean, CA				Frugier, Tony; Morganti-Kossmann, Maria Cristina; O'Reilly, David; McLean, Catriona A.			In Situ Detection of Inflammatory Mediators in Post Mortem Human Brain Tissue after Traumatic Injury	JOURNAL OF NEUROTRAUMA			English	Article						cytokines; human brain; inflammation; post mortem tissue; traumatic brain injury	NECROSIS-FACTOR-ALPHA; NERVE GROWTH-FACTOR; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; AXONAL INJURY; NEUTROPHIL INFILTRATION; INTERLEUKIN-6 LEVELS; BARRIER DYSFUNCTION; RAT-BRAIN; TNF-ALPHA	Little is known about the molecular events following severe traumatic brain injury (TBI) in humans and to date there are no efficient therapies for the treatment of patients. In this study, the first of its kind in human tissue, a total of 21 post mortem trauma brain samples were analyzed. The inflammatory response within the brain tissue was explored by measuring the expression of various inflammatory cytokines at the mRNA and protein levels. These mediators were interleukin (IL)-1 beta, IL-2, IL-4, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, and granulocyte-macrophage colony-stimulating factor (GM-CSF). This study shows for the first time in human brain tissue that 1) pro-inflammatory mediator protein levels are significantly increased in situ following acute brain injury while anti-inflammatory cytokines protein levels remain unchanged; 2) the cerebral inflammatory response begins within minutes of acute TBI, much earlier than previously thought; 3) IL-6, IL-8, TNF-alpha, and IL-1 beta mRNA levels are significantly increased following injury; 4) the rise in cytokine protein level coincides with increased levels of their mRNAs suggesting that traumatic injury elicits an immediate cerebral inflammatory response. Altogether these data confirm and extend previous observations on the release of cytokines in the cerebrospinal fluid of severe TBI patients. Finally, this study highlights the need to characterize the cell source of cytokines and elucidate their mode of action.	[Frugier, Tony; Morganti-Kossmann, Maria Cristina; O'Reilly, David] Monash Univ, Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Frugier, Tony; Morganti-Kossmann, Maria Cristina; O'Reilly, David] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia; [Frugier, Tony; O'Reilly, David; McLean, Catriona A.] Monash Univ, Alfred Hosp, Dept Anat Pathol, Melbourne, Vic 3181, Australia	Frugier, T (corresponding author), Monash Univ, Alfred Hosp, Natl Trauma Res Inst, Level 4 Burnet Tower,89 Commercial Rd, Melbourne, Vic 3004, Australia.	t.frugier@alfred.org.au		Frugier, Tony/0000-0002-1275-5158; Morganti-Kossmann, Cristina/0000-0002-0807-2063	Victorian Neurotrauma Initiative; National Trauma Research Institute; University of MelbourneUniversity of Melbourne; Mental Health Research Institute of Victoria; Victorian Institute of Forensic Medicine; Victorian Neurotrauma Initiative, Neurosciences Australia; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC)	We thank Dr. Edwin Yan for his help with the Bio-plex cytokine assays and Dr. Nicole Bye for her valuable comments on the manuscript. This study was supported by the Victorian Neurotrauma Initiative. Tissues were received from the Victorian Brain Bank Network, supported by The National Trauma Research Institute, The University of Melbourne, The Mental Health Research Institute of Victoria, The Victorian Institute of Forensic Medicine and funded by the Victorian Neurotrauma Initiative, Neurosciences Australia, and the National Health and Medical Research Council of Australia.	[Anonymous], 2004, WORLD REP TRAFF INJ; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Clark RSB, 1999, FASEB J, V13, P813; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Cole TB, 2004, JAMA-J AM MED ASSOC, V291, P2531, DOI 10.1001/jama.291.21.2531; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Helps Y., 2008, INJURY RES STAT SERI, V45; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; MERRILL JE, 1991, DEV NEUROSCI-BASEL, V13, P130, DOI 10.1159/000112150; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Morganti-Kossmann MC, 2009, INFLAMMATORY DIS CEN, P185; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; WOLVERS DAW, 1993, EUR CYTOKINE NETW, V4, P377; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Zhang C., 2003, INT J INTELL CONTROL, V8, P8	53	161	164	2	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2010	27	3					497	507		10.1089/neu.2009.1120			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	575PJ	WOS:000276079100004	20030565				2021-06-18	
J	Carlson, KF; Nelson, D; Orazem, RJ; Nugent, S; Cifu, DX; Sayer, NA				Carlson, Kathleen F.; Nelson, David; Orazem, Robert J.; Nugent, Sean; Cifu, David X.; Sayer, Nina A.			Psychiatric Diagnoses Among Iraq and Afghanistan War Veterans Screened for Deployment-Related Traumatic Brain Injury	JOURNAL OF TRAUMATIC STRESS			English	Article							POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSIVE SYMPTOMS; SEQUELAE; MANAGEMENT; MECHANISMS; BLAST; CARE	The authors examined/psychiatric diagnoses in administrative records for 13,201 United States military veterans who were screened for traumatic brain injury (TBI) in Department of Veterans Affairs facilities. Over 80% of, the veterans with positive TBI screens had psychiatric diagnoses. Compared to veterans with negative TBI screens, those with positive screens, but without confirmed TBI status, were three times more likely to have a posttraumatic stress disorder (PTSD) diagnosis and were two times more likely to have depression and substance-related diagnoses. Among veterans with positive TBI screens, those with clinically confirmed. TBI status were more likely than those without confirmed TBI status to have diagnoses for PTSD, anxiety, and adjustment disorders. These findings have implications for health care delivery and provider education.	[Carlson, Kathleen F.; Nelson, David; Orazem, Robert J.; Nugent, Sean; Sayer, Nina A.] VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55417 USA; [Carlson, Kathleen F.; Nelson, David; Sayer, Nina A.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; [Cifu, David X.] Hunter Holmes McGuire VA Med Ctr, Phys Med & Rehabil Serv, Vet Hlth Adm, Richmond, VA USA; [Cifu, David X.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA	Carlson, KF (corresponding author), VA Med Ctr, Ctr Chron Dis Outcomes Res, 152-2E,1 Vet Dr, Minneapolis, MN 55417 USA.	kathleen.carlson@va.gov	Sayer, Nina/E-3249-2016	Cifu, David/0000-0003-1600-9387			BABCOCKPARZIALE JL, 2009, HSR D STUDY EVALUATI; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Corrigan JD, 2008, JAMA-J AM MED ASSOC, V300, P720, DOI 10.1001/jama.300.6.720; *DEP VET AFF, 2009, COMPR TBI EV SUMM RE; Department of Veterans Affairs, 2008, OFF RES DEV PROGR AN; Department of Veterans Affairs and Department of Defense, 2009, VA DOD CLIN PRACT GU; Desai RA, 2005, MED CARE, V43, P1208, DOI 10.1097/01.mlr.0000185747.79104.90; EVANS RW, 1992, NEUROL CLIN, V10, P815; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; International Classification of Diseases, 2008, INT CLASS DIS; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kang H. K., 2008, ANAL VA HLTH CARE UT; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2007, J REHABIL RES DEV, V44, pVII; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Mohamed S, 2008, AM J GERIAT PSYCHIAT, V16, P804, DOI 10.1097/JGP.0b013e318173f617; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Rosenheck R, 2003, AM J PSYCHIAT, V160, P1684, DOI 10.1176/appi.ajp.160.9.1684; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seal KH, 2008, AM J PUBLIC HEALTH, V98, P714, DOI 10.2105/AJPH.2007.115519; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Sigford B., 2008, NAT POL SYST CAR C E; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thurman DJ., 1995, GUIDELINES SURVEILLA; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; *VET HLTH ADM, 2008, FACT SHEET INT COD G	37	161	161	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-9867	1573-6598		J TRAUMA STRESS	J. Trauma Stress	FEB	2010	23	1					17	24		10.1002/jts.20483			8	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	571FW	WOS:000275738100004	20127725				2021-06-18	
J	Chen, XH; Johnson, VE; Uryu, K; Trojanowski, JQ; Smith, DH				Chen, Xiao-Han; Johnson, Victoria E.; Uryu, Kunihiro; Trojanowski, John Q.; Smith, Douglas H.			A Lack of Amyloid beta Plaques Despite Persistent Accumulation of Amyloid beta in Axons of Long-Term Survivors of Traumatic Brain Injury	BRAIN PATHOLOGY			English	Article						amyloid-precursor protein; BACE; beta-amyloid; diffuse axonal injury; dystrophic neurites; human; kinesin; neprilysin; PS-1; traumatic brain injury	NONMISSILE HEAD-INJURY; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; RISK-FACTOR; NEUROFILAMENT SUBUNITS; A-BETA; TRANSPORT; PEPTIDE; NEPRILYSIN; NEUROPATHOLOGY	Traumatic brain injury (TBI) is a risk factor for developing Alzheimer's disease (AD). Additionally, TBI induces AD-like amyloid beta (A beta) plaque pathology within days of injury potentially resulting from massive accumulation of amyloid precursor protein (APP) in damaged axons. Here, progression of A beta accumulation was examined using brain tissue from 23 cases with post-TBI survival of up to 3 years. Even years after injury, widespread axonal pathology was consistently observed and was accompanied by intra-axonal co-accumulations of APP with its cleavage enzymes, beta-site APP cleaving enzyme and presenilin-1 and their product, A beta. However, in marked contrast to the plaque pathology noted in short-term cases post TBI, virtually no A beta plaques were found in long-term survivors. A potential mechanism for A beta plaque regression was suggested by the post-injury accumulation of an A beta degrading enzyme, neprilysin. These findings fail to support the premise that progressive plaque pathology after TBI ultimately results in AD.	[Chen, Xiao-Han; Johnson, Victoria E.; Trojanowski, John Q.; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19104 USA; [Chen, Xiao-Han; Johnson, Victoria E.; Trojanowski, John Q.; Smith, Douglas H.] Univ Penn, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Uryu, Kunihiro; Trojanowski, John Q.] Univ Penn, Ctr Neurodegenerat Dis Res Pathol & Lab Med, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Inst Aging, Philadelphia, PA 19104 USA	Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	smith, douglas/A-1321-2007		Academic Unit of Neuropathology, Division of Clinical Neuroscience, Institute of Neurological Sciences, Southern General Hospital NHS Trust, Glasgow, UK; The Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38104, NS056202]; National Institute of AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG10124, AF11542]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202, R01NS038104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG011542, P30AG010124] Funding Source: NIH RePORTER	We thank the families of patients whose generosity made this research possible. We would also like to thank Dr David I. Graham (Academic Unit of Neuropathology, Division of Clinical Neuroscience, Institute of Neurological Sciences, Southern General Hospital NHS Trust, Glasgow, UK) for his generous efforts in providing access to the Glasgow Brain Archive, and Dr V.M.-Y. Lee (The Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine) for her generous contribution of antibodies. This work was supported by grants from the National Institutes of Health, including the National Institute of Neurological Disorders and Stroke (NS38104 and NS056202 to D.H.S.) and National Institute of Aging (AG10124 and AF11542 to J.Q.T.). J.Q.T. is the William Maul Measey-Truman G Schnabel, Jr, Professor of Geriatric Medicine and Gerontology.	ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Akiyama H, 1996, NEUROSCI LETT, V206, P169, DOI 10.1016/S0304-3940(96)12474-5; BICKEL U, 1994, BIOCONJUGATE CHEM, V5, P119, DOI 10.1021/bc00026a003; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hama E, 2004, J BIOL CHEM, V279, P30259, DOI 10.1074/jbc.M401891200; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Iwata N, 2000, NAT MED, V6, P143; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Lazarov O, 2005, J NEUROSCI, V25, P2386, DOI 10.1523/JNEUROSCI.3089-04.2005; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; Raby CA, 1998, J NEUROCHEM, V71, P2505; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROQUES BP, 1993, PHARMACOL REV, V45, P87; Roy S, 2005, ACTA NEUROPATHOL, V109, P5, DOI 10.1007/s00401-004-0952-x; Saido TC, 2006, NEUROSCI RES, V54, P235, DOI 10.1016/j.neures.2005.12.015; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Stokin GB, 2006, ANNU REV BIOCHEM, V75, P607, DOI 10.1146/annurev.biochem.75.103004.142637; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Terwel D, 2002, NEUROMOL MED, V2, P151, DOI 10.1385/NMM:2:2:151; Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; WISNIEWSKI HM, 1989, ACTA NEUROPATHOL, V78, P22, DOI 10.1007/BF00687398; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	55	161	164	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	APR	2009	19	2					214	223		10.1111/j.1750-3639.2008.00176.x			10	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	415BK	WOS:000263909100005	18492093	Green Accepted			2021-06-18	
J	Mathias, JL; Wheaton, P				Mathias, Jane L.; Wheaton, Patricia			Changes in attention and information-processing speed following severe traumatic brain injury: A meta-analytic review	NEUROPSYCHOLOGY			English	Article						attention; information-processing speed; severe traumatic brain injury; meta-analysis; review	CLOSED-HEAD-INJURY; DUAL-TASK PERFORMANCE; AUDITORY ODDBALL TASK; DIVIDED ATTENTION; REACTION-TIME; SELECTIVE ATTENTION; EVERYDAY ATTENTION; VISUAL-ATTENTION; DEFICITS; MEMORY	Deficits in attention are frequently reported following severe traumatic brain injury (TBI). However, methodological differences make it difficult to reconcile inconsistencies in the research findings in order to undertake an evidence-based assessment of attention. The current study therefore undertook a meta-analytic review of research examining attention following severe TBI. A search of the PsycINFO and PubMed databases spanning the years 1980 to 2005 was undertaken with 24 search terms. Detailed inclusion and exclusion criteria were used to screen all articles, leaving 41 studies that were included in the current meta-analysis. Weighted Cohen's d effect sizes, percentage overlap statistics, and confidence intervals were calculated for the different tests of attention. Fail-safe Ns were additionally calculated to address the bias introduced by the tendency to publish significant results. Large and significant deficits were found in specific measures of information-processing speed, attention span, focused/selective attention, sustained attention, and supervisory attentional control following severe TBI. Finally, age, education, and postinjury interval were not significantly related to these deficits in attention.	Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia	Mathias, JL (corresponding author), Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia.	jane.mathias@adelaide.edu.au	Mathias, J L/L-6295-2013	Mathias, Jane/0000-0001-8957-8594			Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; Brouwer W, 2001, BRAIN COGNITION, V46, P54, DOI 10.1016/S0278-2626(01)80033-6; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P695, DOI 10.1076/jcen.24.5.695.1003; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 1977, STAT POWER ANAL BEHA, P1; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Freeman J, 2001, BRIT J CLIN PSYCHOL, V40, P221, DOI 10.1348/014466501163562; Geldmacher DS, 1997, BRAIN INJURY, V11, P59, DOI 10.1080/026990597123818; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hedges L.V., 1985, STAT METHODS META AN; Hedges L. V., 1994, HDB RES SYNTHESIS; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; Hills EC, 1998, BRAIN INJURY, V12, P69, DOI 10.1080/026990598122872; Hunter, 1982, METAANALYSIS CUMULAT, V4; Keller I, 1995, COGNITIVE BRAIN RES, V3, P9, DOI 10.1016/0926-6410(95)00013-5; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Lengenfelder J, 2002, J HEAD TRAUMA REHAB, V17, P26, DOI 10.1097/00001199-200202000-00005; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lipsey M.W., 2001, PRACTICAL METAANALYS, V49; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; MATHIAS JL, IN PRESS BRIT J CLIN; MATTSON AJ, 1994, J NEUROL NEUROSUR PS, V57, P818, DOI 10.1136/jnnp.57.7.818; Morris PG, 2005, BRIT J CLIN PSYCHOL, V44, P209, DOI 10.1348/014466505X34174; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ries M, 2005, NEUROPSYCHOLOGY, V19, P476, DOI 10.1037/0894-4105.19.4.476; Riley GA, 2003, BRIT J CLIN PSYCHOL, V42, P319, DOI 10.1348/01446650360703410; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; ROSENTHAL R, 1995, PSYCHOL BULL, V118, P183, DOI 10.1037/0033-2909.118.2.183; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; Sarno S, 2003, BRAIN INJURY, V17, P413, DOI 10.1080/0269905031000070161; Schmitter-Edgecombe M, 2001, J INT NEUROPSYCH SOC, V7, P615, DOI 10.1017/S1355617701755099; Schmitter-Edgecombe M, 2000, NEUROPSYCHOLOGY, V14, P559; Schmitter-Edgecombe M, 1998, J INT NEUROPSYCH SOC, V4, P144, DOI 10.1017/S1355617798001441; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; SchmitterEdgecombe M, 1997, NEUROPSYCHOLOGY, V11, P296, DOI 10.1037/0894-4105.11.2.296; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Sharpe D, 1997, CLIN PSYCHOL REV, V17, P881, DOI 10.1016/S0272-7358(97)00056-1; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; SHUM DHK, 1994, J CLIN EXP NEUROPSYC, V16, P547, DOI 10.1080/01688639408402666; Simpson A, 2000, NEUROPSYCHOLOGY, V14, P310, DOI 10.1037//0894-4105.14.2.310; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; Spreen O., 1998, COMPENDIUM NEUROPSYC; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Steel PD, 2002, J APPL PSYCHOL, V87, P96, DOI 10.1037//0021-9010.87.1.96; Tilley A, 1996, INTRO PSYCHOL RES ST; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; VAKIL E, 1991, J CLIN EXP NEUROPSYC, V13, P291, DOI 10.1080/01688639108401044; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; van Zomeren AH, 1992, HDB NEUROPSYCHOLOGIC, P241; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; Williamson D. J. G., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [10.1037/10198-001, DOI 10.1037/10198-001]; Willison J, 2006, ARCH CLIN NEUROPSYCH, V21, P41, DOI 10.1016/j.acn.2005.07.005; Wilson BA, 1999, BRAIN INJURY, V13, P505, DOI 10.1080/026990599121412; WITHAAR FK, 2003, Z NEUROPSYCHOL, V14, P203; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924; Zakzanis K, 1999, NEUROPSYCHOLOGICAL D; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	75	161	162	1	46	AMER PSYCHOLOGICAL ASSOC/EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	MAR	2007	21	2					212	223		10.1037/0894-4105.21.2.212			12	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	146YJ	WOS:000244970300007	17402821				2021-06-18	
J	Covassin, T; Swanik, CB; Sachs, M; Kendrick, Z; Schatz, P; Zillmer, E; Kaminaris, C				Covassin, T.; Swanik, C. B.; Sachs, M.; Kendrick, Z.; Schatz, P.; Zillmer, E.; Kaminaris, C.			Sex differences in baseline neuropsychological function and concussion symptoms of collegiate athletes	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							VERBAL MEMORY; HEAD-INJURY; IMPACT; PERFORMANCE; SPORT; STATEMENT; RECOVERY	Objective: To investigate sex differences in baseline neuropsychological function and concussion symptoms between male and female collegiate athletes. Methods: A post-test only design was used to examine baseline neuropsychological test scores and concussion symptoms. A total of 1209 NCAA Division I collegiate athletes from five northeastern universities in the USA completed a baseline ImPACT test. ImPACT, a computerised neuropsychological test battery, was administered during an athlete's pre-season. Results: Female athletes performed significantly better than male athletes on baseline verbal memory scores ( p = 0.001), while male athletes performed significantly better than female athletes on baseline visual memory scores ( p = 0.001). Female athletes endorsed a significant number of mild baseline symptoms as compared to male athletes. Conclusions: Male and female athletes exhibit differences on baseline neuropsychological test performance and concussion symptoms.	Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; Univ Delaware, Dept Hlth Nutr & Exercise Sci, Newark, DE USA; Temple Univ, Dept Kinesiol, Philadelphia, PA USA; St Josephs Univ, Dept Psychol, Philadelphia, PA USA; Drexel Univ, Dept Psychol, Philadelphia, PA USA	Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA.	covassin@msu.edu	Swanik, Charles/C-4377-2014	Swanik, Charles/0000-0001-9701-2005; Schatz, Philip/0000-0002-6222-6545			Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barth JT., 1989, MILD HEAD INJURY, P257; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; Kimura D, 2002, PSYCHOL REP, V91, P1137, DOI 10.2466/PR0.91.7.1137-1142; LEWIS RS, 1987, BRAIN COGNITION, V6, P142, DOI 10.1016/0278-2626(87)90115-1; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2001, IMMEDIATE POSTCONCUS; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maki PM, 2001, AM J PSYCHIAT, V158, P227, DOI 10.1176/appi.ajp.158.2.227; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Murphy DGM, 1996, ARCH GEN PSYCHIAT, V53, P585; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Weiss EM, 2003, PERS INDIV DIFFER, V35, P863, DOI 10.1016/S0191-8869(02)00288-X; IMPACT CLIN INTERPRE	23	161	162	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	NOV	2006	40	11					923	927		10.1136/bjsm.2006.029496			5	Sport Sciences	Sport Sciences	098BH	WOS:000241494700010	16990442	Green Published			2021-06-18	
J	Cicerone, K; Levin, H; Malec, J; Stuss, D; Whyte, J				Cicerone, Keith; Levin, Harvey; Malec, James; Stuss, Donald; Whyte, John			Cognitive rehabilitation interventions for executive function: Moving from bench to bedside in patients with traumatic brain injury	JOURNAL OF COGNITIVE NEUROSCIENCE			English	Article							FRONTAL-LOBE; PREFRONTAL CORTEX; WORKING-MEMORY; GOAL MANAGEMENT; HEAD-INJURY; DEFICITS; PERFORMANCE; DISTURBANCE; ATTENTION; AWARENESS	Executive function mediated by prefrontally driven distributed networks is frequently impaired by traumatic brain injury (TBI) as a result of diffuse axonal injury and focal lesions. In addition to executive cognitive functions such as planning and working memory, the effects of TBI impact social cognition and motivation processes. To encourage application of cognitive neuroscience methods to studying recovery from TBI, associated reorganization of function, and development of interventions, this article reviews the pathophysiology of TBI, critiques currently employed methods of assessing executive function, and evaluates promising interventions that reflect advances in cognitive neuroscience. Brain imaging to identify neural mechanisms mediating executive dysfunction and response to interventions following TBI is also discussed.	Baylor Coll Med, Houston, TX 77030 USA; Mayo Clin, Rochester, MN 55905 USA; Univ Toronto, Toronto, ON, Canada; Moss Rehabil Res Inst, Philadelphia, PA USA	Cicerone, K (corresponding author), NINDS, 6001 Execut Blvd,Room 3305, Bethesda, MD 20892 USA.			Whyte, John/0000-0002-4381-1474			Adair JC, 1996, NEUROLOGY, V46, P842; ALDERMAN N, 1995, NEUROPSYCHOL REHABIL, V5, P193, DOI 10.1080/09602019508401467; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BJORKLUND DF, 1990, DEV REV, V10, P48, DOI 10.1016/0273-2297(90)90004-N; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; CAMPS M, 1989, NEUROSCIENCE, V28, P275, DOI 10.1016/0306-4522(89)90179-6; Cazalis F, 2001, J INT NEUROPSYCH SOC, V7, P795, DOI 10.1017/S1355617701777028; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Cicerone KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; Dias R, 1996, NATURE, V380, P69, DOI 10.1038/380069a0; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; FOXX RM, 1989, BEHAV THER, V20, P61, DOI 10.1016/S0005-7894(89)80118-2; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Godefroy O, 1997, NEUROLOGY, V49, P695, DOI 10.1212/WNL.49.3.695; Grigsby J, 1998, J AM GERIATR SOC, V46, P590, DOI 10.1111/j.1532-5415.1998.tb01075.x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Kimberg DY, 1997, NEUROREPORT, V8, P3581, DOI 10.1097/00001756-199711100-00032; Leahy B, 2003, CLIN NEUROPSYCHOL, V17, P474, DOI 10.1076/clin.17.4.474.27941; Lengfelder A, 2001, NEUROPSYCHOLOGY, V15, P80, DOI 10.1037//0894-4105.15.1.80; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Pandya DN, 1996, RES PER NEUROSCI, P13; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Perlstein WM, 2003, BIOL PSYCHIAT, V53, P25, DOI 10.1016/S0006-3223(02)01675-X; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rebmann MJ, 1995, REHABIL PSYCHOL, V40, P279, DOI 10.1037/0090-5550.40.4.279; Robbins Trevor W., 1995, P703; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Robertson IH, 1991, TEST EVERYDAY ATTENT; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; SOHLBERG MM, 1988, COGNITIVE REHABILITA, V6, P36; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; STUSS DT, IN PRESS HUMAN FRONT; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; Whyte J, 2002, NEUROPSYCHOLOGICAL INTERVENTIONS, P59; Whyte J., 1997, PROMISE OUTCOMES RES, P43; WOODS JR, 1989, ANN INTERN MED, V110, P560, DOI 10.7326/0003-4819-110-7-560; YOUNGJOHN JR, 1989, REHABIL PSYCHOL, V34, P217, DOI 10.1037//0090-5550.34.3.217	63	161	163	0	35	MIT PRESS	CAMBRIDGE	ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA	0898-929X	1530-8898		J COGNITIVE NEUROSCI	J. Cogn. Neurosci.	JUL	2006	18	7					1212	1222		10.1162/jocn.2006.18.7.1212			11	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	064MM	WOS:000239093800014	16839293				2021-06-18	
J	Anson, K; Ponsford, J				Anson, Katie; Ponsford, Jennie			Coping and emotional adjustment following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						coping; emotional adjustment; traumatic brain injury	SICKNESS IMPACT PROFILE; SELF-AWARENESS; DEPRESSION SCALE; HOSPITAL ANXIETY; PSYCHOSOCIAL ADJUSTMENT; HEAD-INJURY; VALIDATION; STRATEGIES; DEFICITS; ILLNESS	Objectives: To examine the association between coping style and emotional adjustment following traumatic brain injury. Participants: Thirty three individuals who had sustained a traumatic brain injury (mean duration of posttraumatic amnesia = 32 days) between 11 months and almost 7 years previously. Measures: Coping Scale for Adults, Hospital Anxiety and Depression Scale, Rosenberg Self-Esteem Scale, State-Trait Anger Expression Inventory and the Sickness Impact Profile. Results: Approximately 50% of the sample reported clinically significant levels of anxiety and depression. Coping characterized by avoidance, worry, wishful thinking, self-blame, and using drugs and alcohol was associated with higher levels of anxiety, depression, and psychosocial dysfunction and lower levels of self-esteem. Coping characterized by actively working on the problem and using humor and enjoyable activities to manage stress was associated with higher self-esteem. Lower premorbid intelligence (measured via the National Adult Reading Test) and greater self-awareness (measured via the Self-Awareness of Deficits Interview) were associated with an increased rate of maladaptive coping. Conclusions: The strong association between the style of coping used to manage stress and emotional adjustment suggests the possibility that emotional adjustment might be improved by the facilitation of more adaptive coping styles. It is also possible that improving emotional adjustment may increase adaptive coping. The development and evaluation of interventions aimed at facilitating adaptive coping and decreasing emotional distress represent important and potentially fruitful contributions to enhancing long-term outcome following brain injury.	Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton, Vic 3168, Australia; Epworth Med Fdn, Melbourne, Vic, Australia	Anson, K (corresponding author), DPsych Clin Neuropsychol, 36 Auburn Parade, E Hawthorn, Vic 3123, Australia.	katie.anson@gmail.com					ARIDI AS, 2002, DISS ABSTR INT B, V63, P1580; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; BLASCOVICH J, 1993, MEASURES PERSONALITY, P115; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; BOMBARDIER CH, 1990, BEHAV RES THER, V28, P297, DOI 10.1016/0005-7967(90)90081-S; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; BRUDERMATTSON SF, 1990, J CLIN PSYCHOL, V46, P557, DOI 10.1002/1097-4679(199009)46:5<557::AID-JCLP2270460503>3.0.CO;2-1; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; BUCKELEW SP, 1990, REHABIL PSYCHOL, V35, P101, DOI 10.1037/0090-5550.35.2.101; CONNORS S, 1999, DISS ABST INT B, V59, P3685; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DOUGLAS J, 2002, 25 ANN C AUSTR SOC S; Finset A, 2000, BRAIN INJURY, V14, P887; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; FRYDENBERG E, 1996, COPING SCLAE ADULTS; GODFREY HP, 1995, FAMILY SUPPORT PROGR; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; GrayLittle B, 1997, PERS SOC PSYCHOL B, V23, P443, DOI 10.1177/0146167297235001; Hayes SC, 1996, J CONSULT CLIN PSYCH, V64, P1152, DOI 10.1037/0022-006X.64.6.1152; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Herrmann M, 2000, DISABIL REHABIL, V22, P539, DOI 10.1080/096382800416788; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Johnston M, 2000, J PSYCHOSOM RES, V48, P579, DOI 10.1016/S0022-3999(00)00102-1; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KENDALL E, 2001, BRAIN IMPAIR, V2, P81; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kortte KB, 2003, REHABIL PSYCHOL, V48, P131, DOI 10.1037/0090-5550.48.3.131; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LABOUVIEVIEF G, 1987, PSYCHOL AGING, V2, P286, DOI 10.1037/0882-7974.2.3.286; LAZARUS RS, 1993, PSYCHOSOM MED, V55, P234, DOI 10.1097/00006842-199305000-00002; LAZARUS RS, 1984, STRESS APPRASIAL COP; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; Mullis RL, 2000, J SOC PSYCHOL, V140, P539, DOI 10.1080/00224540009600494; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Pelletier PM, 2000, BRAIN COGNITION, V44, P45; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Ptacek JT, 2003, REHABIL PSYCHOL, V48, P113, DOI 10.1037/0090-5550.48.2.113; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Simmond M, 2003, BRAIN INJURY, V17, P325, DOI 10.1080/0269905021000013219; SNAITH RP, 1994, HOSPITAL ANXIETY DEP; Spielberger C.D., 1999, STATE TRAIT ANGER EX; Spreen O., 1998, COMPENDIUM NEUROPSYC; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; TERRY DJ, 1992, BRIT J CLIN PSYCHOL, V31, P1; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Wallace CA, 2000, BRAIN INJURY, V14, P549; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Wilson, 1991, NATL ADULT READING T; Wilson BA, 1996, BEHAV ASSESSMENT DYS	63	161	162	0	38	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2006	21	3					248	259		10.1097/00001199-200605000-00005			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	044YL	WOS:000237709600005	16717502				2021-06-18	
J	Santhakumar, V; Aradi, I; Soltesz, I				Santhakumar, V; Aradi, I; Soltesz, I			Role of mossy fiber sprouting and mossy cell loss in hyperexcitability: A network model of the dentate gyrus incorporating cell types and axonal topography	JOURNAL OF NEUROPHYSIOLOGY			English	Article							TEMPORAL-LOBE EPILEPSY; CA3 PYRAMIDAL CELLS; GAMMA-AMINOBUTYRIC-ACID; GUINEA-PIG HIPPOCAMPUS; TRAUMATIC BRAIN-INJURY; METHYL-D-ASPARTATE; GRANULE CELLS; RAT HIPPOCAMPUS; IN-VIVO; SYNAPTIC INPUT	Mossy cell loss and mossy fiber sprouting are two characteristic consequences of repeated seizures and head trauma. However, their precise contributions to the hyperexcitable state are not well understood. Because it is difficult, and frequently impossible, to independently examine using experimental techniques whether it is the loss of mossy cells or the sprouting of mossy fibers that leads to dentate hyperexcitability, we built a biophysically realistic and anatomically representative computational model of the dentate gyrus to examine this question. The 527-cell model, containing granule, mossy, basket, and hilar cells with axonal projections to the perforant-path termination zone, showed that even weak mossy fiber sprouting ( 10 - 15% of the strong sprouting observed in the pilocarpine model of epilepsy) resulted in the spread of seizure-like activity to the adjacent model hippocampal laminae after focal stimulation of the perforant path. The simulations also indicated that the spatially restricted, lamellar distribution of the sprouted mossy fiber contacts reported in in vivo studies was an important factor in sustaining seizure-like activity in the network. In contrast to the robust hyperexcitability-inducing effects of mossy fiber sprouting, removal of mossy cells resulted in decreased granule cell responses to perforant-path activation in agreement with recent experimental data. These results indicate the crucial role of mossy fiber sprouting even in situations where there is only relatively weak mossy fiber sprouting as is the case after moderate concussive experimental head injury.	Univ Calif Los Angeles, Dept Anat & Neurobiol, Los Angeles, CA 90095 USA	Santhakumar, V (corresponding author), Univ Calif Los Angeles, Dept Anat & Neurobiol, Box 951763,63-314 CHS, Los Angeles, CA 90095 USA.	vsanthakumar@mednet.ucla.edu	Santhakumar, Vijayalakshmi/M-4192-2013; Santhakumar, Viji/K-4856-2019	Santhakumar, Viji/0000-0001-6278-4187	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-35915] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035915, R29NS035915, R37NS035915] Funding Source: NIH RePORTER		Aaron GB, 2001, SYNAPSE, V42, P199, DOI 10.1002/syn.10004; Acsady L, 1998, EUR J NEUROSCI, V10, P41; Acsady L, 1998, J NEUROSCI, V18, P3386; AMARAL DG, 1978, J COMP NEUROL, V182, P851, DOI 10.1002/cne.901820508; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Aradi I, 2002, J PHYSIOL-LONDON, V538, P227, DOI 10.1113/jphysiol.2001.013054; Aradi I, 1999, J COMPUT NEUROSCI, V6, P215, DOI 10.1023/A:1008801821784; Bartos M, 2001, J NEUROSCI, V21, P2687, DOI 10.1523/JNEUROSCI.21-08-02687.2001; Bikson M, 2003, J NEUROPHYSIOL, V90, P2402, DOI 10.1152/jn.00467.2003; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Bruton CJ, 1988, NEUROPATHOLOGY TEMPO; Buckmaster PS, 1996, J COMP NEUROL, V366, P270, DOI 10.1002/(SICI)1096-9861(19960304)366:2<270::AID-CNE7>3.0.CO;2-2; BUCKMASTER PS, 1992, HIPPOCAMPUS, V2, P349, DOI 10.1002/hipo.450020403; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; BUCKMASTER PS, 1993, J NEUROPHYSIOL, V70, P1281; Buckmaster PS, 2002, J NEUROSCI, V22, P6650; Buckmaster PS, 1999, J NEUROPHYSIOL, V81, P712; Buckmaster PS, 2002, J COMP NEUROL, V445, P360, DOI 10.1002/cne.10183; Buhl EH, 1996, SCIENCE, V271, P369, DOI 10.1126/science.271.5247.369; Bush PC, 1999, J NEUROPHYSIOL, V82, P1748; Chen K, 1999, NAT MED, V5, P888, DOI 10.1038/11330; Chen K, 2001, NAT MED, V7, P331, DOI 10.1038/85480; COLLINGRIDGE GL, 1984, J PHYSIOL-LONDON, V356, P551, DOI 10.1113/jphysiol.1984.sp015482; Coulter DA, 2001, INT REV NEUROBIOL, V45, P237; Coulter DA, 1999, EPILEPSIA, V40, pS23, DOI 10.1111/j.1528-1157.1999.tb00875.x; Coulter DA, 2000, EPILEPSIA, V41, pS96, DOI 10.1111/j.1528-1157.2000.tb01565.x; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; DESMOND NL, 1985, NEUROSCI LETT, V54, P219, DOI 10.1016/S0304-3940(85)80082-3; Destexhe A, 2001, NEUROSCIENCE, V107, P13, DOI 10.1016/S0306-4522(01)00344-X; Feng L, 2003, J NEUROSCI, V23, P5381; Foldy C, 2004, EUR J NEUROSCI, V19, P119, DOI 10.1046/j.1460-9568.2003.03096.x; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; FRICKE RA, 1984, J NEUROPHYSIOL, V51, P195; Geiger JRP, 1997, NEURON, V18, P1009, DOI 10.1016/S0896-6273(00)80339-6; Golarai G, 2001, J NEUROSCI, V21, P8523; Gutierrez R, 2002, J NEUROPHYSIOL, V87, P2562, DOI 10.1152/jn.2002.87.5.2562; HAMA K, 1994, MICROSC RES TECHNIQ, V29, P357, DOI 10.1002/jemt.1070290506; Harney SC, 2002, NEUROPHARMACOLOGY, V43, P584, DOI 10.1016/S0028-3908(02)00169-7; HEINEMANN U, 1992, EPILEPSY RES, P273; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; Houser C R, 1999, Adv Neurol, V79, P743; Ishizuka S, 1998, NEUROREPORT, V9, P193, DOI 10.1097/00001756-199801260-00004; Jennett B, 1975, EPILEPSY NONMISSILE; Jeub M, 1999, NEUROSCIENCE, V94, P465, DOI 10.1016/S0306-4522(99)00249-3; Johnston D, 1996, ANNU REV NEUROSCI, V19, P165, DOI 10.1146/annurev.ne.19.030196.001121; KNEISLER TB, 1995, J PHYSIOL-LONDON, V487, P125, DOI 10.1113/jphysiol.1995.sp020866; KNEISLER TB, 1995, HIPPOCAMPUS, V5, P151, DOI 10.1002/hipo.450050302; Kraushaar U, 2000, J NEUROSCI, V20, P5594; Lawrence JJ, 2004, J PHYSIOL-LONDON, V554, P175, DOI 10.1113/jphysiol.2003.049551; LOTHMAN EW, 1992, EPILEPSY RES, P301; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lubke J, 1998, J NEUROPHYSIOL, V79, P1518, DOI 10.1152/jn.1998.79.3.1518; Lytton WW, 1998, ARTIF INTELL MED, V13, P81, DOI 10.1016/S0933-3657(98)00005-0; MACVICAR BA, 1982, J NEUROPHYSIOL, V47, P579; Maex R, 2003, J NEUROSCI, V23, P10503; Magee JC, 2000, NAT REV NEUROSCI, V1, P181, DOI 10.1038/35044552; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; Masukawa L M, 1999, Adv Neurol, V79, P781; Mathern GW, 1997, NEUROSCIENCE, V77, P1003, DOI 10.1016/S0306-4522(96)00516-7; MATHERN GW, 1995, J NEUROSURG, V82, P220, DOI 10.3171/jns.1995.82.2.0220; MIGLIORE M, 1995, J NEUROPHYSIOL, V73, P1157; MILES R, 1987, J PHYSIOL-LONDON, V388, P611, DOI 10.1113/jphysiol.1987.sp016634; MILES R, 1986, J PHYSIOL-LONDON, V373, P397, DOI 10.1113/jphysiol.1986.sp016055; Molnar P, 2001, BRAIN RES, V910, P205, DOI 10.1016/S0006-8993(01)02720-2; Molnar P, 1999, J NEUROPHYSIOL, V82, P1883; Mott DD, 1997, J NEUROSCI, V17, P3990; Nadler JV, 2003, NEUROCHEM RES, V28, P1649, DOI 10.1023/A:1026004904199; Nissinen Jari P. T., 2003, Epilepsia, V44, P175; PATTON PE, 1995, HIPPOCAMPUS, V5, P245, DOI 10.1002/hipo.450050402; RALL W, 1992, PHYSIOL REV, V72, pS159; Ratzliff ADH, 2004, J NEUROSCI, V24, P2259, DOI 10.1523/JNEUROSCI.5191-03.2004; Ratzliff ADH, 2002, TRENDS NEUROSCI, V25, P140, DOI 10.1016/S0166-2236(00)02122-6; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; Santhakumar V, 2003, J NEUROSCI, V23, P5865; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; SCHARFMAN HE, 1991, J NEUROSCI, V11, P1660; SCHARFMAN HE, 1995, J NEUROPHYSIOL, V74, P179; Scharfman HE, 2001, NEUROSCIENCE, V104, P741, DOI 10.1016/S0306-4522(01)00132-4; SCHARFMAN HE, 1993, J NEUROPHYSIOL, V70, P742; Sik A, 1997, EUR J NEUROSCI, V9, P573, DOI 10.1111/j.1460-9568.1997.tb01634.x; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1994, ANN NEUROL, V35, P640, DOI 10.1002/ana.410350604; Sloviter RS, 2003, J COMP NEUROL, V459, P44, DOI 10.1002/cne.10630; STALEY KJ, 1992, J NEUROPHYSIOL, V67, P1346; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; SUTULA TP, 1992, EPILEPSY RES, P251; Toth Z, 1997, J NEUROSCI, V17, P8106; TRAUB RD, 1987, NEUROSCIENCE, V21, P457, DOI 10.1016/0306-4522(87)90135-7; TRAUB RD, 1994, J PHYSIOL-LONDON, V478, P379, DOI 10.1113/jphysiol.1994.sp020259; Walker MC, 2001, NEURON, V29, P703, DOI 10.1016/S0896-6273(01)00245-8; Wang XJ, 2004, P NATL ACAD SCI USA, V101, P1368, DOI 10.1073/pnas.0305337101; Wenzel HJ, 1997, HIPPOCAMPUS, V7, P559; Wenzel HJ, 2000, HIPPOCAMPUS, V10, P244, DOI 10.1002/1098-1063(2000)10:3<244::AID-HIPO5>3.0.CO;2-7; White JA, 1998, J COMPUT NEUROSCI, V5, P5, DOI 10.1023/A:1008841325921; Zhang NH, 1999, J COMP NEUROL, V405, P472	96	161	164	1	12	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077	1522-1598		J NEUROPHYSIOL	J. Neurophysiol.	JAN	2005	93	1					437	453		10.1152/jn.00777.2004			17	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	880GV	WOS:000225777900038	15342722				2021-06-18	
J	Lu, DY; Goussev, A; Chen, JL; Pannu, P; Li, Y; Mahmood, A; Chopp, M				Lu, DY; Goussev, A; Chen, JL; Pannu, P; Li, Y; Mahmood, A; Chopp, M			Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						atorvastatin; neuronal survival; neuroplasticity; rat; traumatic brain injury	CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; COA REDUCTASE INHIBITOR; NITRIC-OXIDE SYNTHASE; MARROW STROMAL CELLS; STROKE; MOUSE; STATINS; DAMAGE; TRANSPLANTATION	Statins administered postischemia promote functional improvement in rats, independent of their capability to lower cholesterol. We therefore tested the effect of statin treatment on traumatic brain injury (TBI) in rats. Atorvastatin was orally administered (1 mg/kg/day) to Wistar rats starting 1 day after TBI for 7 consecutive days. Control animals received saline. Modified Neurological Severity Scores and Corner tests were utilized to evaluate functional response to treatment. Bromodeoxyuridine (BrdU, 100 mg/kg) was also intraperitoneally injected daily for 14 consecutive days to label the newly generated endothelial cells. Rats were sacrificed at day 14 after TBI, and the brain samples were processed for immunohistochemical staining. Atorvastatin administration after brain injury significantly reduced the neurological functional deficits, increased neuronal survival and synaptogenesis in the boundary zone of the lesion and in the CA3 regions of the hippocampus, and induced angiogenesis in these regions. The results suggest that atorvastatin may provide beneficial effects in experimental TBI.	Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MN USA	Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 40255] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P01 42345] Funding Source: Medline		Aktas O, 2003, J EXP MED, V197, P725, DOI 10.1084/jem.20021425; BARTH TM, 1987, EXP NEUROL, V95, P661, DOI 10.1016/0014-4886(87)90307-4; BARTH TM, 1990, BRAIN RES, V18, P73; Becher A, 1999, J NEUROSCI, V19, P1922; Biros MH., 1998, EMERGENCY MED CONCEP, P416; CHAPIN JK, 1984, J COMP NEUROL, V229, P199, DOI 10.1002/cne.902290206; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; DALLA NE, 2003, AM J ENDOCRINOL INVE, V26, P73; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hixon ML, 2000, J CLIN INVEST, V106, P1011, DOI 10.1172/JCI8252; Hua Y, 2002, STROKE, V33, P2478, DOI 10.1161/01.STR.0000032302.91894.0F; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Murohara T, 2002, ANTIOXID REDOX SIGN, V4, P825, DOI 10.1089/152308602760598981; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Paxinos G., 1995, RAT NERVOUS SYSTEM; REH T, 1982, J COMP NEUROL, V211, P276, DOI 10.1002/cne.902110306; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sparks D L, 2002, J Nutr Health Aging, V6, P324; Sterzer P, 2001, STROKE, V32, P2817, DOI 10.1161/hs1201.099663; Vaughan CJ, 1999, STROKE, V30, P1969, DOI 10.1161/01.STR.30.9.1969; Wassmann S, 2001, HYPERTENSION, V37, P1450, DOI 10.1161/01.HYP.37.6.1450; Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhang RL, 2001, ANN NEUROL, V50, P602, DOI 10.1002/ana.1249; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460	41	161	168	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2004	21	1					21	32		10.1089/089771504772695913			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	766GU	WOS:000188368700003	14987462				2021-06-18	
J	Ponsford, J; Olver, J; Ponsford, M; Nelms, R				Ponsford, J; Olver, J; Ponsford, M; Nelms, R			Long-term adjustment of families following traumatic brain injury where comprehensive rehabilitation has been provided	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; PSYCHOLOGICAL DISTRESS; ASSESSMENT DEVICE; SOCIAL RECOVERY; RELATIVES; IMPACT; INDIVIDUALS; BURDEN; STRESS	Objectives: The present study aimed to examine long-term family and emotional adjustment in close relatives of individuals with TBI, who had access to comprehensive rehabilitation services. It also examined the relative influence thereon of factors including injury severity, handicap and cognitive and behavioural changes in the injured person, relationship with the injured person and caregiver status. Methods: Participants were 143 TBI individuals and their close relatives. They completed the Family Assessment Device (FAD), Leeds Scales of Anxiety and Depression, Structured Outcome Questionnaire, CHART, SIP Psychosocial Dimension and Novaco Anger Control Questionnaire 2-5 years post-injury. Results: Results showed that families were, on average, functioning in the normal range on the FAD. Anxiety and depression were more likely to be present in those responsible for care of their injured relative. There were no differences between spouses and parents. Presence of cognitive, behavioural and emotional changes was the strongest predictor of anxiety and depression in relatives and of unhealthy family functioning. Conclusions: Every attempt should be made to develop models of long-term support and care that alleviate these sources of burden on relatives.	Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; Monash Univ, Melbourne, Vic 3004, Australia	Ponsford, J (corresponding author), Epworth Med Fdn, Dept Psychol, Bethesda Rehabil Ctr, 30 Erin St, Richmond, Vic 3121, Australia.			Olver, John/0000-0001-7069-1191			ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOAKE C, 1996, AM J PHYSICAL MED RE, V75, P1; Bragg RM, 1992, J HEAD TRAUMA REHAB, V7, P94; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; DOUGLAS J, 1994, THESIS U VICTORIA BR; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LAMONT M, 1993, THESIS LA TROBE U ME; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Maitz E.A., 1991, HEAD INJURY FAMILY M, P65; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MINTZ MC, 1995, BRAIN INJURY, V9, P173, DOI 10.3109/02699059509008190; MOORE A, 1993, BRAIN INJURY, V7, P247, DOI 10.3109/02699059309029677; Novaco R.W., 1975, ANGER CONTROL DEV EV; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; OLSON DH, 1982, FAMILY SATISFACTION; ORSILLO JS, 1997, BRAIN INJURY, V11, P11; Panting A., 1972, REHABILITATION, V38, P33; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; PERLESZ A, 1997, THESIS LATROBE U MEL; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; Snaith RP, 1976, LEEDS SCALES SELF AS; Sokol DK, 1996, BRAIN INJURY, V10, P439, DOI 10.1080/026990596124296; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P117; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TYERMAN A, 1994, 4 C INT ASS STUD TRA; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	50	161	163	1	20	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2003	17	6					453	468		10.1080/0269905031000070143			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	672GG	WOS:000182512400001	12745702				2021-06-18	
J	Bryant, RA				Bryant, RA			Early predictors of posttraumatic stress disorder	BIOLOGICAL PSYCHIATRY			English	Article; Proceedings Paper	Annual Meeting of the Anxiety-Disorders-Association-of-America	MAR, 2002	NEW YORK, NEW YORK	Anixiety Disorders Assoc Amer		acute stress disorder; posttraumatic stress disorder; trauma	MOTOR-VEHICLE ACCIDENTS; 2-YEAR PROSPECTIVE EVALUATION; THOUGHT CONTROL STRATEGIES; TRAUMATIC BRAIN INJURY; NATURAL DISASTER; COGNITIVE BIAS; PTSD SYMPTOMS; VIOLENT CRIME; FOLLOW-UP; VICTIMS	The benefits of providing early intervention for people recently exposed to trauma have highlighted the need to develop means to identify people who will develop chronic posttraumatic stress disorder (PTSD). This review provides an overview of prospective studies that have indexed the acute reactions to trauma that are predictive of chronic posttraumatic stress disorder. Ten studies of the predictive power of the acute stress disorder diagnosis indicate that this diagnosis does not have adequate predictive power. There is no convergence across studies on any constellation of acute symptoms that predict posttraumatic stress disorder. A review of biological and cognitive mechanisms occurring in the acute posttraumatic phase suggests that these factors may provide more accurate means of predicting chronic posttraumatic stress disorder. Recommendations for future research to facilitate identification of key markers of acutely traumatized people who will develop posttraumatic stress disorder are discussed. Biol Psychiatry 2003;53:789-795 (C) 2003 Society of Biological Psychiatry.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			Andrews B, 2000, J ABNORM PSYCHOL, V109, P69, DOI 10.1037/0021-843X.109.1.69; BERAH EF, 1984, AUST NZ J PSYCHIAT, V18, P354, DOI 10.3109/00048678409158797; Blanchard EB, 1996, BEHAV RES THER, V34, P775, DOI 10.1016/0005-7967(96)00038-1; Blanchard EB, 2002, J TRAUMA STRESS, V15, P199, DOI 10.1023/A:1015299126858; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; Bryant RA, 2000, J ABNORM PSYCHOL, V109, P341, DOI 10.1037/0021-843X.109.2.341; Bryant RA, 1999, AM J PSYCHIAT, V156, P1780; Bryant RA, 1998, J CONSULT CLIN PSYCH, V66, P862, DOI 10.1037/0022-006X.66.5.862; Bryant RA, 2001, BEHAV RES THER, V39, P961, DOI 10.1016/S0005-7967(00)00086-3; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1996, J TRAUMA STRESS, V9, P223, DOI 10.1002/jts.2490090206; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2002, AUST NZ J PSYCHIAT, V36, P205, DOI 10.1046/j.1440-1614.2002.01009.x; Bryant RA, 2001, AM J PSYCHIAT, V158, P600, DOI 10.1176/appi.ajp.158.4.600; Buckley TC, 1996, J ABNORM PSYCHOL, V105, P617, DOI 10.1037/0021-843X.105.4.617; Butler LD, 1996, AM J PSYCHIAT, V153, P42; CARDENA E, 1993, AM J PSYCHIAT, V150, P474; CHARNEY DS, 1993, ARCH GEN PSYCHIAT, V50, P294; CREAMER M, 1992, J ABNORM PSYCHOL, V101, P452, DOI 10.1037/0021-843X.101.3.452; CREAMER MC, IN PRESS BEHAV RES T; Dancu CV, 1996, J TRAUMA STRESS, V9, P253, DOI 10.1002/jts.2490090208; Delahanty DL, 1997, J CONSULT CLIN PSYCH, V65, P560, DOI 10.1037/0022-006X.65.4.560; Delahanty DL, 2000, BIOL PSYCHIAT, V48, P940, DOI 10.1016/S0006-3223(00)00896-9; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Engelhard IM, 2002, BEHAV RES THER, V40, P1415, DOI 10.1016/S0005-7967(02)00018-9; Falsetti SA, 1997, J TRAUMA STRESS, V10, P683, DOI 10.1002/jts.2490100414; FEINSTEIN A, 1989, AM J PSYCHIAT, V146, P665; FOA EB, 1995, J CONSULT CLIN PSYCH, V63, P948, DOI 10.1037/0022-006X.63.6.948; FREINKEL A, 1994, AM J PSYCHIAT, V151, P1335; Guthrie R, 2000, BEHAV RES THER, V38, P899, DOI 10.1016/S0005-7967(99)00120-5; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P500, DOI 10.1037/0022-006X.66.3.500; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 2002, PSYCHOL BULL, V128, P886, DOI 10.1037//0033-2909.128.6.886; HILLMAN RG, 1981, AM J PSYCHIAT, V138, P1193; Holeva V, 2001, BEHAV THER, V32, P65, DOI 10.1016/S0005-7894(01)80044-7; KOLB LC, 1987, AM J PSYCHIAT, V144, P989; KOOPMAN C, 1994, AM J PSYCHIAT, V151, P888; Koren D, 1999, AM J PSYCHIAT, V156, P367; Koren D, 2002, AM J PSYCHIAT, V159, P855, DOI 10.1176/appi.ajp.159.5.855; LEDOUX JE, 1988, J NEUROSCI, V8, P2517; MADAKASIRA S, 1987, J NERV MENT DIS, V175, P286, DOI 10.1097/00005053-198705000-00008; Marshall RD, 1999, AM J PSYCHIAT, V156, P1677; McFarlane AC, 1997, ANN NY ACAD SCI, V821, P437, DOI 10.1111/j.1749-6632.1997.tb48299.x; MCFARLANE AC, 1988, J NERV MENT DIS, V176, P22, DOI 10.1097/00005053-198801000-00003; MCFARLANE AC, 1992, J NERV MENT DIS, V180, P439, DOI 10.1097/00005053-199207000-00006; Moulds ML, 2002, J ABNORM PSYCHOL, V111, P175, DOI 10.1037//0021-843X.111.1.175; MOULDS ML, IN PRESS J TRAUMA ST; NIXON R, IN PRESS BEHAV RES T; North CS, 1989, J TRAUMA STRESS, V2, P353, DOI DOI 10.1002/JTS.2490020309; NOYES R, 1977, J NERV MENT DIS, V164, P401, DOI 10.1097/00005053-197706000-00005; NOYES R, 1977, COMPR PSYCHIAT, V18, P375, DOI 10.1016/0010-440X(77)90010-4; PERRY S, 1992, AM J PSYCHIAT, V149, P931; Pitman R. K., 2000, NEW COGNITIVE NEUROS; Post RM, 1995, NEUROBIOLOGICAL CLIN; RIGGS DS, 1995, J INTERPERS VIOLENCE, V10, P201, DOI 10.1177/0886260595010002005; ROTHBAUM BO, 1992, J TRAUMA STRESS, V5, P455, DOI 10.1007/BF00977239; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; SHALEV AY, 1992, J NERV MENT DIS, V180, P505, DOI 10.1097/00005053-199208000-00005; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; Shalev AY, 1997, BRIT J PSYCHIAT, V170, P558, DOI 10.1192/bjp.170.6.558; SHALEV AY, 1993, AM J PSYCHIAT, V150, P620; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Sloan P, 1988, J TRAUMA STRESS, V1, P211, DOI DOI 10.1002/JTS.2490010208; Smith K, 2000, BEHAV RES THER, V38, P709, DOI 10.1016/S0005-7967(99)00096-0; Staab JP, 1996, ANXIETY, V2, P219, DOI 10.1002/(SICI)1522-7154(1996)2:5<219::AID-ANXI3>3.0.CO;2-H; Warda G, 1998, BEHAV RES THER, V36, P1171, DOI 10.1016/S0005-7967(98)00082-5; Warda G, 1998, BEHAV RES THER, V36, P1177, DOI 10.1016/S0005-7967(98)00071-0; WEISAETH L, 1989, ACTA PSYCHIAT SCAND, V80, P25, DOI 10.1111/j.1600-0447.1989.tb05251.x; Yehuda R, 1997, ANN NY ACAD SCI, V821, P57, DOI 10.1111/j.1749-6632.1997.tb48269.x; Zatzick DF, 2002, AM J PSYCHIAT, V159, P941, DOI 10.1176/appi.ajp.159.6.941	73	161	171	1	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223			BIOL PSYCHIAT	Biol. Psychiatry	MAY 1	2003	53	9					789	795		10.1016/S0006-3223(02)01895-4			7	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	672VV	WOS:000182544400004	12725971				2021-06-18	
J	Holsinger, T; Steffens, DC; Phillips, C; Helms, MJ; Havlik, RJ; Breitner, JCS; Guralnik, JM; Plassman, BL				Holsinger, T; Steffens, DC; Phillips, C; Helms, MJ; Havlik, RJ; Breitner, JCS; Guralnik, JM; Plassman, BL			Head injury in early adulthood and the lifetime risk of depression	ARCHIVES OF GENERAL PSYCHIATRY			English	Article; Proceedings Paper	Annual Meeting of the American-Association-for-Geriatric-Psychiatry	FEB 23-26, 2001	SAN FRANCISCO, CALIFORNIA	Amer Assoc Geriatr Psychiat			TRAUMATIC BRAIN INJURY; PSYCHIATRIC-DISORDERS; ALZHEIMERS-DISEASE; PERFORMANCE-CHARACTERISTICS; FUNCTIONAL DISABILITY; DEMENTIA; SYMPTOMS; HEALTH; QUESTIONNAIRE; ASSOCIATION	Background: Depressive symptoms are common and can be debilitating in the months after head injury. Head injury can also have long-term cognitive effects, but little is known about the long-term risk of depression associated with head injury. We investigated the lifetime rates of depressive illness 50 years after closed head injury. Methods: Participants were male World War II veterans who served during 1944-1945 and were hospitalized at that time for a head injury, pneumonia, or laceration, puncture, or incision wounds. We used military medical records to establish the presence and severity of closed head injuries. Veterans with (n=520) and without (n=1198) head injuries were inter-viewed in 19961997 for their lifetime history of depressive illness. Men,with dementia were excluded. Results: Veterans with head injury were more likely to report major depression in subsequent years and were more often currently depressed. Using logistic regression and controlling for age and education, the lifetime prevalence of major depression in the head injured group was 18.5% vs 13.4% in those with no head injury (odds ratio=1.54, 95% confidence interval=1.17-2.04). Current major depression was detected in 11.2% of the veterans with head injuries vs 8.5% of those without head injury (odds ratio= 1.63, 95% confidence interval=1.07-2.50). This increase in depression could not be explained by a history of myocardial infarction, a history of cerebrovascular accident, or history of alcohol abuse. The lifetime risk of depression increased with severity of the head injury. Conclusion: The risk of depression remains elevated for decades following head injury and seems to be highest in those who have had a severe head injury.	Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA; NIA, Epidemiol Demog & Biometry Program, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA	Plassman, BL (corresponding author), 905 W Main St,Box 41, Durham, NC USA.		Plassman, Brenda L/K-2620-2015				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Arfken CL, 1999, J GERONTOL A-BIOL, V54, pM152, DOI 10.1093/gerona/54.3.M152; Brandt J., 1988, NEUROPSY NEUROPSY BE, V1, P111, DOI DOI 10.1159/000264678; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; Cohen HJ, 1997, J GERONTOL A-BIOL, V52, pM201, DOI 10.1093/gerona/52A.4.M201; Covinsky KE, 1999, ANN INTERN MED, V130, P563, DOI 10.7326/0003-4819-130-7-199904060-00004; Deb S, 1999, AM J PSYCHIAT, V156, P374; Dentino AN, 1999, J AM GERIATR SOC, V47, P6, DOI 10.1111/j.1532-5415.1999.tb01894.x; Elliott R, 1997, PSYCHOL MED, V27, P931, DOI 10.1017/S0033291797005187; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GALLO JJ, 1995, PSYCHOL MED, V25, P1211, DOI 10.1017/S0033291700033183; GRAFMAN J, 1996, NEUROPSYCHIATRY, P935; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JORM AF, 1989, PSYCHOL MED, V19, P1015, DOI 10.1017/S0033291700005742; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Khachaturian AS, 2000, J CLIN EPIDEMIOL, V53, P531, DOI 10.1016/S0895-4356(99)00196-1; KLERMAN GL, 1988, CLIN CHEM, V34, P807; Koenig H G, 1992, Clin Geriatr Med, V8, P235; Koenig HG, 1999, AM J GERIAT PSYCHIAT, V7, P124; Koenig HG, 1998, AM J PSYCHIAT, V155, P871, DOI 10.1176/ajp.155.7.871; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, P28; *NAT CTR INJ PREV, 2000, TRAUM BRAIN INJ; Piccinelli M, 1999, J PSYCHOSOM RES, V46, P455, DOI 10.1016/S0022-3999(98)00126-3; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Steffens DC, 1999, STROKE, V30, P2159, DOI 10.1161/01.STR.30.10.2159; Steffens DC, 1997, BIOL PSYCHIAT, V41, P851, DOI 10.1016/S0006-3223(96)00247-8; Steffens DC, 2000, ARCH GEN PSYCHIAT, V57, P601, DOI 10.1001/archpsyc.57.6.601; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; WELSH KA, 1993, NEUROPSY NEUROPSY BE, V6, P103; WITTCHEN HU, 1994, BRIT J PSYCHIAT, V165, P16, DOI 10.1192/S0007125000293240	37	161	163	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-990X			ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	JAN	2002	59	1					17	22		10.1001/archpsyc.59.1.17			6	Psychiatry	Psychiatry	508XV	WOS:000173115800004	11779276	Bronze			2021-06-18	
J	Steadman-Pare, D; Colantonio, A; Ratcliff, G; Chase, S; Vernich, L				Steadman-Pare, D; Colantonio, A; Ratcliff, G; Chase, S; Vernich, L			Factors associated with perceived quality of life many years after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						quality of life; traumatic brain injury	INDIVIDUALS; RELIABILITY; SATISFACTION; OUTCOMES; SF-36	Objectives: To explore factors associated with perceived quality of life (QOL) 8 to 24 years after traumatic brain injury (TBI). Design: Retrospective cohort study. Participants: Two hundred seventy-five individuals who sustained moderate to severe TBI who were discharged from a rehabilitation hospital participated in this study. We interviewed consenting participants up to 24 years after injury. Outcome Measures: Self-rated Quality of Life Scale. Results: Multivariate linear regression analyses revealed that perceived mental health, self-rated health, gender (women rating QOL higher), participation in work and leisure. and the availability of emotional support were significantly associated with QOL (P < .05). Conclusion: The importance of designing ongoing support programs to further reintegrate TBI survivors several years after injury is discussed.	Univ Toronto, Fac Med, Grad Dept Rehabil Sci, Toronto, ON M5T 1W5, Canada; Grey Bruce Hlth Serv, Owen Sound, ON, Canada; Dept Neuropsychol, Neurobehav Program, Pittsburgh, PA USA; Working Order, Pittsburgh, PA USA	Colantonio, A (corresponding author), Univ Toronto, Fac Med, Grad Dept Rehabil Sci, 256 McCaul St, Toronto, ON M5T 1W5, Canada.	angela.colantonio@utoronto.ca			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F33AG005856] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F33 AGO5856-01A] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34740-2] Funding Source: Medline		Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Crisp R., 1993, DISABILITY HANDICAP, V8, P393, DOI [DOI 10.1080/02674649366780371, 10.1080/02674649366780371]; D'Ambrosio C, 1999, CHEST, V115, P123, DOI 10.1378/chest.115.1.123; Dean S, 2000, PSYCHOL REP, V86, P653, DOI 10.2466/pr0.2000.86.2.653; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; HADORN DC, 1995, J CLIN EPIDEMIOL, V48, P619, DOI 10.1016/0895-4356(94)00186-T; Halstead WC, 1985, HALSTEAD REITAN NEUR; Harwood R H, 1994, Qual Health Care, V3, P11, DOI 10.1136/qshc.3.1.11; Harwood RH, 1995, MANUAL LONDON HANDIC; HORTON AM, 1995, PERCEPT MOTOR SKILL, V80, P336, DOI 10.2466/pms.1995.80.1.336; JENKINSON C, 1994, QUAL LIFE RES, V3, P7, DOI 10.1007/BF00647843; Kempen GIJM, 1997, AM J PUBLIC HEALTH, V87, P38, DOI 10.2105/AJPH.87.1.38; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; Litwin MS, 1997, J UROLOGY, V157, P1608, DOI 10.1016/S0022-5347(01)64807-9; Lundberg O, 1996, SCAND J SOC MED, V24, P218, DOI 10.1177/140349489602400314; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MINAIRE P, 1993, VITAL HLTH STAT, V5, P9; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Patrick D., 1993, HLTH STATUS HLTH POL; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stewart AL, 1992, MEASURING FUNCTIONIN; Stratton M C, 1995, Rehabil Nurs, V20, P323; Testa MA, 1998, DIABETES CARE, V21, pC44, DOI 10.2337/diacare.21.3.C44; Thirlby RC, 1998, ARCH SURG-CHICAGO, V133, P826, DOI 10.1001/archsurg.133.8.826; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Warren L, 1996, J REHABIL RES DEV, V33, P404; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460	35	161	164	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	2001	16	4					330	342		10.1097/00001199-200108000-00004			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	459YA	WOS:000170278000004	11461656				2021-06-18	
J	PRIGATANO, GP				PRIGATANO, GP			PERSONALITY DISTURBANCES ASSOCIATED WITH TRAUMATIC BRAIN INJURY	JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY			English	Article							CLOSED HEAD-INJURY; FOLLOW-UP; DYSFUNCTION; AGGRESSION; DISORDERS	Personality disturbances associated with traumatic brain injury are reviewed. The varied structural pathology of the brain in this patient group makes it difficult to specify how different brain lesions may result in specific emotional and motivational disturbances. However, an attempt to clarify terms and review empirical findings is made. Longitudinal prospective studies that utilize appropriate control groups are needed. Future research may especially benefit by considering the long-term effects of early agitation following traumatic brain injury as well as the problem of aspontaneity and impairment of self-awareness.		PRIGATANO, GP (corresponding author), ST JOSEPHS HOSP, BARROW NEUROL INST, DEPT NEUROL, 350 W THOMAS RD, PHOENIX, AZ 85013 USA.						ADAMS JH, 1975, HDB CLINICAL NEUROLO, V23, P35; BAKCHINE S, 1989, NEUROLOGY, V39, P777, DOI 10.1212/WNL.39.6.777; BECKER DP, 1985, CENTRAL NERVOUS SYST; Bigler E D, 1989, Brain Inj, V3, P73, DOI 10.3109/02699058909008077; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CASSIDY JW, 1990, J HEAD TRAUMA REHAB, V5, P83; Chandler M C, 1988, Brain Inj, V2, P309; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P382; DIKMEN SS, 1989, MILD HEAD INJURY, P229; Dollard J., 1950, PERSONALITY PSYCHOTH; EAMES P, 1988, J HEAD TRAUMA REHAB, V3, P1; EICHELMAN B, 1983, NEUROSCI BIOBEHAV R, V7, P391, DOI 10.1016/0149-7634(83)90044-1; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; ELLIOTT FA, 1982, J NERV MENT DIS, V170, P680, DOI 10.1097/00005053-198211000-00007; ELSASS L, 1991, THESIS TROBE U BUNDO; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GLENN MB, 1989, AM J PHYS MED REHAB, V68, P221, DOI 10.1097/00002060-198910000-00004; Goldstein K, 1952, PSYCHIATR, V15, P245, DOI 10.1080/00332747.1952.11022878; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; HALL CS, 1978, THEORIES PERSONALITY; HATHAWAY SR, 1970, MINNESOTA MULTIPHASI; HEINRICHS RW, 1989, BIOL PSYCHIAT, V25, P174, DOI 10.1016/0006-3223(89)90161-3; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; JARVIE HF, 1954, J NEUROL NEUROSUR PS, V17, P14, DOI 10.1136/jnnp.17.1.14; Jennett B, 1981, MANAGEMENT HEAD INJU; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KOZOL HL, 1946, ARCH NEURO PSYCHIATR, V56, P245, DOI 10.1001/archneurpsyc.1946.02300200002001; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Levin HS, 1989, MILD HEAD INJURY; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; Luria A. R., 1963, RESTORATION FUNCTION; MACCI G, 1989, HDB NEUROPSYCHOLOGY, V3, P283; MALKMUS D, 1980, REHABILITATION HEAD; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Meyer A, 1904, AM J INSANITY, V60, P373, DOI 10.1176/ajp.60.3.373; Miller GA., 1960, PLANS STRUCTURE BEHA; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OTA Y, 1969, LATE EFFECTS HEAD IN, P110; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G.P, 1988, BNI Q, V4, P40; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Prigatano GP, 1986, CLIN NEUROPSYCHOLOGY, P135; PRIGATANO GP, 1988, J HEAD TRAUMA REHAB, V3, P23; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; ROBERTS AH, 1979, SEVERE ACCIDENTAL HE; ROBINSON RG, 1985, CRC CR REV CL NEUROB, V1, P285; ROSENBAUM A, 1989, AM J PSYCHIAT, V146, P1048; ROSENTHAL M, 1990, REHABILITATION ADULT; Schacter D. L., 1991, AWARENESS DEFICIT BR, P258; Schilder P, 1934, AM J PSYCHIAT, V91, P155, DOI 10.1176/ajp.91.1.155; SHUKLA S, 1987, AM J PSYCHIAT, V144, P93; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; SIMON HA, 1967, PSYCHOL REV, V74, P29, DOI 10.1037/h0024127; SLAGLE DA, 1990, INT J PSYCHIAT MED, V20, P1, DOI 10.2190/BE6W-DCY1-V71N-N7J7; SQUIRE LR, 1988, J CLIN EXP NEUROPSYC, V10, P727, DOI 10.1080/01688638808402810; STOREY PB, 1970, BRIT J PSYCHIAT, V117, P129, DOI 10.1192/S0007125000192815; Stuss D.T., 1986, FRONTAL LOBES; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TUCKER DM, 1989, HDB NEUROPSYCHOLOGY, V3, P443; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO; YUDOFSKY SC, 1987, PSYCHIAT ANN, V17, P397, DOI 10.3928/0048-5713-19870601-11	71	161	161	1	11	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0022-006X	1939-2117		J CONSULT CLIN PSYCH	J. Consult. Clin. Psychol.	JUN	1992	60	3					360	368		10.1037/0022-006X.60.3.360			9	Psychology, Clinical	Psychology	HW628	WOS:A1992HW62800006	1619090				2021-06-18	
S	Isgro, MA; Bottoni, P; Scatena, R		Scatena, R		Isgro, Maria Antonietta; Bottoni, Patrizia; Scatena, Roberto			Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects	ADVANCES IN CANCER BIOMARKERS: FROM BIOCHEMISTRY TO CLINIC FOR A CRITICAL REVISION	Advances in Experimental Medicine and Biology		English	Article; Book Chapter						ENO1; ENO2; ENO3; Neuron-specific enolase (NSE); NSE as biomarker; NSE assays in body fluids; NSE biochemical properties; NSE clinical indications; NSE in brain damage; NSE in gastroenteropancreatic neuroendocrine tumours; NSE in lung cancer; NSE in melanoma; NSE in neuroblastoma; NSE in neuroendocrine tumours; NSE in seminoma; NSE mapping and gene function; Tissue NSE expression	CELL LUNG-CANCER; ACUTE ISCHEMIC-STROKE; MARKERS CHROMOGRANIN-A; CEREBROSPINAL-FLUID; TUMOR-MARKERS; YEAST ENOLASE; NEUROENDOCRINE TUMORS; ENZYME-IMMUNOASSAY; PROGNOSTIC VALUE; GAMMA-ENOLASE	Neuron-specific enolase (NSE) is known to be a cell specific isoenzyme of the glycolytic enzyme enolase. In vertebrate organisms three isozymes of enolase, expressed by different genes, are present: enolase alpha is ubiquitous; enolase beta is muscle-specific and enolase gamma is neuron-specific. The expression of NSE, which occurs as gamma gamma- and alpha gamma-dimer, is a late event in neural differentiation, thus making it a useful index of neural maturation. NSE is a highly specific marker for neurons and peripheral neuroendocrine cells. As a result of the findings of NSE in specific tissues under normal conditions, increased body fluids levels of NSE may occur with malignant proliferation and thus can be of value in diagnosis, staging and treatment of related neuroendocrine tumours (NETs). NSE is currently the most reliable tumour marker in diagnosis, prognosis and follow-up of small cell lung cancer (SCLC), even though increased levels of NSE have been reported also in non-small cell lung cancer (NSCLC). The level of NSE correlates with tumour burden, number of metastatic sites and response to treatment. NSE can be also useful at diagnosis of NETs and gastroenteropancreatic (GEP)-NETs. Raised serum levels of NSE have been found in all stages of neuroblastoma, although the incidence of increased concentration is greater in widespread and metastatic disease. Moreover, NSE determination in cord blood offers an early postnatal possibility of confirming the diagnosis of neuroblastoma in newborns. NSE has been demonstrated to provide quantitative measures of brain damage and/or to improve the diagnosis and the outcome evaluation in ischaemic stroke, intracerebral hemorrhage, seizures, comatose patients after cardiopulmonary resuscitation for cardiac arrest and traumatic brain injury. Increased NSE serum levels have also been found associated with melanoma, seminoma, renal cell carcinoma, Merkel cell tumour, carcinoid tumours, dysgerminomas and immature teratomas, malignant phaechro-mocytoma, Guillain-Barre syndrome and Creutzfeldt-Jakob disease.	[Isgro, Maria Antonietta] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Largo Agostino Gemelli 8, I-00168 Rome, Italy; [Isgro, Maria Antonietta] Univ Cattolica Sacro Cuore, Dept Diagnost & Mol Med, I-00168 Rome, Italy; [Bottoni, Patrizia; Scatena, Roberto] Univ Cattolica Sacro Cuore, Sch Med, Inst Biochem & Clin Biochem, I-00168 Rome, Italy	Isgro, MA (corresponding author), Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Largo Agostino Gemelli 8, I-00168 Rome, Italy.	mariantoniettaisgro@yahoo.it		Bottoni, Patrizia/0000-0001-5427-8903			Ahmad O, 2012, CEREBROVASC DIS, V33, P47, DOI 10.1159/000332810; Aksamit AJ, 2001, NEUROLOGY, V57, P728, DOI 10.1212/WNL.57.4.728; ANASTASIADES KD, 1987, AM J CLIN PATHOL, V87, P245, DOI 10.1093/ajcp/87.2.245; ANDOH M, 1994, INTERNAL MED, V33, P271, DOI 10.2169/internalmedicine.33.271; [Anonymous], 1982, Am J Clin Pathol, V77, P123; Bajetta E, 1999, CANCER, V86, P858, DOI 10.1002/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8; Baudin E, 1998, BRIT J CANCER, V78, P1102, DOI 10.1038/bjc.1998.635; Baudin E, 1999, J CLIN ENDOCR METAB, V84, P69, DOI 10.1210/jc.84.1.69; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOCK E, 1975, SCAND J IMMUNOL, P31; BODY JJ, 1992, CLIN CHEM, V38, P748; Braga F, 2013, CLIN BIOCHEM, V46, P148, DOI 10.1016/j.clinbiochem.2012.09.005; Brea D, 2009, CLIN CHEM LAB MED, V47, P1513, DOI 10.1515/CCLM.2009.337; BREWER JM, 1966, J BIOL CHEM, V241, P2550; BREWER JM, 1985, FEBS LETT, V182, P8, DOI 10.1016/0014-5793(85)81143-1; BREWER JM, 1971, BIOCHIM BIOPHYS ACTA, V250, P251, DOI 10.1016/0005-2744(71)90140-9; BROERS JLV, 1985, P NATL ACAD SCI USA, V82, P4409, DOI 10.1073/pnas.82.13.4409; Brouns R, 2010, CLIN CHEM, V56, P451, DOI 10.1373/clinchem.2009.134122; CARNEY DN, 1988, EUR J CANCER CLIN ON, V24, P825, DOI 10.1016/0277-5379(88)90190-3; Chai GQ, 2004, J MOL BIOL, V341, P1015, DOI 10.1016/j.jmb.2004.05.068; Chen SH, 1984, J NEUROGENET, V1, P159, DOI 10.3109/01677068409107081; COOK PJL, 1979, CYTOGENET CELL GENET, V25, P9, DOI 10.1159/000131394; COOPER EH, 1985, BRIT J CANCER, V52, P333, DOI 10.1038/bjc.1985.198; Cotterill SJ, 2000, EUR J CANCER, V36, P901, DOI 10.1016/S0959-8049(00)00058-7; CRAIG SP, 1990, CYTOGENET CELL GENET, V54, P71, DOI 10.1159/000132960; CUNNINGHAM RT, 1992, CLIN CHIM ACTA, V212, P123, DOI 10.1016/0009-8981(92)90179-T; DIEZ M, 1993, ONCOLOGY, V50, P127; Dittadi R, 2013, CLIN BIOCHEM, V46, P1145, DOI 10.1016/j.clinbiochem.2013.04.010; Ebert W, 1998, CLIN LAB, V44, P871; EGAN MF, 1992, PSYCHIAT RES, V43, P187, DOI 10.1016/0165-1781(92)90133-N; Eriksson B, 2000, DIGESTION, V62, P33, DOI 10.1159/000051853; ESSCHER T, 1985, THORAX, V40, P85, DOI 10.1136/thx.40.2.85; FALLER LD, 1974, P NATL ACAD SCI USA, V71, P1083, DOI 10.1073/pnas.71.4.1083; FALLER LD, 1977, BIOCHEMISTRY-US, V16, P3864, DOI 10.1021/bi00636a023; FEO S, 1990, GENOMICS, V6, P192, DOI 10.1016/0888-7543(90)90467-9; Ferolla P, 2008, J ENDOCRINOL INVEST, V31, P277, DOI 10.1007/BF03345602; Fu XL, 2012, ANAL CHIM ACTA, V722, P114, DOI 10.1016/j.aca.2012.02.007; GERBITZ KD, 1984, CLIN CHEM, V30, P382; GERBITZ KD, 1986, J CLIN CHEM CLIN BIO, V24, P1009; GIALLONGO A, 1986, P NATL ACAD SCI USA, V83, P6741, DOI 10.1073/pnas.83.18.6741; GIOVANELLA L, 1995, INT J BIOL MARKER, V10, P156; Giovanella L, 2001, INT J BIOL MARKER, V16, P50; Giovanella L, 1997, INT J BIOL MARKER, V12, P22; Gonzalez-Garcia S, 2012, CLIN BIOCHEM, V45, P1302, DOI 10.1016/j.clinbiochem.2012.07.094; GRONOWITZ JS, 1990, CANCER, V66, P722, DOI 10.1002/1097-0142(19900815)66:4<722::AID-CNCR2820660421>3.0.CO;2-J; GROUZMANN E, 1990, CANCER, V66, P1833, DOI 10.1002/1097-0142(19901015)66:8<1833::AID-CNCR2820660831>3.0.CO;2-9; GRZESCHIK KH, 1976, CYTOGENET CELL GENET, V16, P142, DOI 10.1159/000130576; HAIMOTO H, 1985, LAB INVEST, V52, P257; HANLON DP, 1969, BIOCHEMISTRY-US, V8, P4255, DOI 10.1021/bi00839a005; HARDING M, 1990, BRIT J CANCER, V61, P605, DOI 10.1038/bjc.1990.134; Jiang SX, 1998, AM J SURG PATHOL, V22, P526, DOI 10.1097/00000478-199805000-00002; Jorgensen LGM, 1996, BRIT J CANCER, V74, P463, DOI 10.1038/bjc.1996.383; KAWATA M, 1989, GYNECOL ONCOL, V32, P191, DOI 10.1016/S0090-8258(89)80032-0; KHAN P M, 1974, Cytogenetics and Cell Genetics, V13, P130; KIMURA S, 1986, J IMMUNOL METHODS, V94, P51, DOI 10.1016/0022-1759(86)90214-0; KIMURA S, 1984, Journal of Applied Biochemistry, V6, P319; Kintzel K, 1998, CLIN CHEM LAB MED, V36, P245, DOI 10.1515/CCLM.1998.042; Kulpa J, 2002, CLIN CHEM, V48, P1931; LAW ML, 1982, J CELL SCI, V53, P245; Lee SY, 2010, J NEUROL, V257, P1708, DOI 10.1007/s00415-010-5608-2; Li GZ, 2013, ANAL SCI, V29, P1195, DOI 10.2116/analsci.29.1195; MARANGOS PJ, 1979, J NEUROCHEM, V33, P319, DOI 10.1111/j.1471-4159.1979.tb11735.x; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; MARANGOS PJ, 1980, BRAIN RES, V190, P185, DOI 10.1016/0006-8993(80)91168-3; MARANGOS PJ, 1978, BRAIN RES, V150, P117, DOI 10.1016/0006-8993(78)90657-1; MARANGOS PJ, 1976, BIOCHEM BIOPH RES CO, V68, P1309, DOI 10.1016/0006-291X(76)90339-9; MARANGOS PJ, 1975, ARCH BIOCHEM BIOPHYS, V170, P289, DOI 10.1016/0003-9861(75)90119-8; MCALEESE SM, 1988, EUR J BIOCHEM, V178, P413, DOI 10.1111/j.1432-1033.1988.tb14465.x; MERCER DW, 1990, CLIN CHEM, V36, P1519; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; MOKUNO K, 1994, ACTA NEUROL SCAND, V89, P27; MOORE BW, 1965, J BIOL CHEM, V240, P1647; Muley T, 2003, CLIN CHEM LAB MED, V41, P95, DOI 10.1515/CCLM.2003.017; Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331; Nobels FRE, 1997, J CLIN ENDOCR METAB, V82, P2622, DOI 10.1210/jc.82.8.2622; OCONNOR TP, 1992, CANCER-AM CANCER SOC, V70, P1514, DOI 10.1002/1097-0142(19920915)70:6<1514::AID-CNCR2820700612>3.0.CO;2-C; Oh SH, 2003, ARCH NEUROL-CHICAGO, V60, P37, DOI 10.1001/archneur.60.1.37; OLIVA D, 1991, GENOMICS, V10, P157, DOI 10.1016/0888-7543(91)90496-2; Paone G, 1997, BRIT J CANCER, V75, P448, DOI 10.1038/bjc.1997.75; PAONE G, 1995, EUR RESPIR J, V8, P1136, DOI 10.1183/09031936.95.08071136; PARMA AM, 1981, J NEUROCHEM, V36, P1093, DOI 10.1111/j.1471-4159.1981.tb01704.x; PAUS E, 1989, CLIN CHEM, V35, P2034; PEARSE AGE, 1969, J HISTOCHEM CYTOCHEM, V17, P303, DOI 10.1177/17.5.303; Petrovic M, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0823-1; PICKEL VM, 1976, BRAIN RES, V105, P184, DOI 10.1016/0006-8993(76)90936-7; Planche V, 2010, ANN BIOL CLIN-PARIS, V68, P239, DOI 10.1684/abc.2010.0422; PLOWMAN PN, 1989, CLIN RADIOL, V40, P542, DOI 10.1016/S0009-9260(89)80288-0; Poyner RR, 2001, BIOCHEMISTRY-US, V40, P8009, DOI 10.1021/bi0103922; PRINZ RA, 1982, SURGERY, V92, P887; Pujol JL, 2001, LUNG CANCER, V31, P221, DOI 10.1016/S0169-5002(00)00186-0; Quoix E, 2000, LUNG CANCER-J IASLC, V30, P127, DOI 10.1016/S0169-5002(00)00131-8; Ramont L, 2005, CLIN CHEM LAB MED, V43, P1215, DOI 10.1515/CCLM.2005.210; RIDER CC, 1974, BIOCHIM BIOPHYS ACTA, V365, P285, DOI 10.1016/0005-2795(74)90273-6; Riley RD, 2004, CLIN CANCER RES, V10, P4, DOI 10.1158/1078-0432.CCR-1051-2; SAKIMURA K, 1987, GENE, V60, P103, DOI 10.1016/0378-1119(87)90218-6; SCHMECHEL D, 1978, SCIENCE, V199, P313, DOI 10.1126/science.339349; SCHMECHEL DE, 1980, BRAIN RES, V190, P195, DOI 10.1016/0006-8993(80)91169-5; Schmechel DE, 1978, J ANAT, V4, P126; Schmitt UM, 1996, EUR J CLIN CHEM CLIN, V34, P679; SHINE BSF, 1990, BRIT J OPHTHALMOL, V74, P427, DOI 10.1136/bjo.74.7.427; SPINAZZI A, 1990, J NUCL MED ALLIED S, V34, P141; Takada M, 1996, BRIT J CANCER, V73, P1227, DOI 10.1038/bjc.1996.235; TAKASHI M, 1989, J UROLOGY, V141, P830, DOI 10.1016/S0022-5347(17)41024-X; TANAKA M, 1985, BIOCHEM BIOPH RES CO, V133, P868, DOI 10.1016/0006-291X(85)91215-X; Tandstad T, 2003, ACTA ONCOL, V42, P202, DOI 10.1080/02841860310010727; Tiseo M, 2008, ANTICANCER RES, V28, P507; Tofani A, 1997, ACTA ONCOL, V36, P761, DOI 10.3109/02841869709001351; Torsetnes SB, 2013, J CHROMATOGR B, V929, P125, DOI 10.1016/j.jchromb.2013.04.010; VANOBBERGHEN E, 1988, J NEUROSCI RES, V19, P450, DOI 10.1002/jnr.490190409; VERMUYTEN K, 1989, ACTA NEUROL BELG, V89, P318; VIALLARD JL, 1986, CLIN CHIM ACTA, V161, P1, DOI 10.1016/0009-8981(86)90257-3; VIALLARD JL, 1986, CLIN CHEM, V32, P593; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; WEVERS RA, 1983, CLIN CHIM ACTA, V135, P159, DOI 10.1016/0009-8981(83)90131-6; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; WOLD F, 1957, J BIOL CHEM, V227, P313; Wunderlich MT, 2006, CLIN NEUROL NEUROSUR, V108, P558, DOI 10.1016/j.clineuro.2005.12.006; Yan HJ, 2014, J BUON, V19, P153; Yao JC, 2010, J CLIN ONCOL, V28, P69, DOI 10.1200/JCO.2009.24.2669; Zaheer S, 2013, ANN INDIAN ACAD NEUR, V16, P504, DOI 10.4103/0972-2327.120442; ZELTZER PM, 1986, CANCER, V57, P1230, DOI 10.1002/1097-0142(19860315)57:6<1230::AID-CNCR2820570628>3.0.CO;2-#; ZELTZER PM, 1983, LANCET, V2, P361	124	160	170	1	38	SPRINGER	DORDRECHT	PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS	0065-2598	2214-8019	978-94-017-7215-0; 978-94-017-7214-3	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2015	867						125	143		10.1007/978-94-017-7215-0_9	10.1007/978-94-017-7215-0		19	Biochemistry & Molecular Biology; Oncology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Oncology; Research & Experimental Medicine	BE2YW	WOS:000370341700010	26530364				2021-06-18	
J	Sarkar, C; Zhao, ZR; Aungst, S; Sabirzhanov, B; Faden, AI; Lipinski, MM				Sarkar, Chinmoy; Zhao, Zaorui; Aungst, Stephanie; Sabirzhanov, Boris; Faden, Alan I.; Lipinski, Marta M.			Impaired autophagy flux is associated with neuronal cell death after traumatic brain injury	AUTOPHAGY			English	Article						autophagy; autophagy flux; lysosome; neuronal cell death; traumatic brain injury	LYSOSOMAL STORAGE DISORDERS; NEURODEGENERATIVE DISEASE; PARKINSONS-DISEASE; CEREBRAL-CORTEX; RAT MODEL; MICE; DEGRADATION; EXPRESSION; UBIQUITIN; PATHWAY	Dysregulation of autophagy contributes to neuronal cell death in several neurodegenerative and lysosomal storage diseases. Markers of autophagy are also increased after traumatic brain injury (TBI), but its mechanisms and function are not known. Following controlled cortical impact (CCI) brain injury in GFP-Lc3 (green fluorescent protein-LC3) transgenic mice, we observed accumulation of autophagosomes in ipsilateral cortex and hippocampus between 1 and 7 d. This accumulation was not due to increased initiation of autophagy but rather to a decrease in clearance of autophagosomes, as reflected by accumulation of the autophagic substrate SQSTM1/p62 (sequestosome 1). This was confirmed by ex vivo studies, which demonstrated impaired autophagic flux in brain slices from injured as compared to control animals. Increased SQSTM1 peaked at d 1-3 but resolved by d 7, suggesting that the defect in autophagy flux is temporary. The early impairment of autophagy is at least in part caused by lysosomal dysfunction, as evidenced by lower protein levels and enzymatic activity of CTSD (cathepsin D). Furthermore, immediately after injury both autophagosomes and SQSTM1 accumulated predominantly in neurons. This was accompanied by appearance of SQSTM1 and ubiquitin-positive puncta in the affected cells, suggesting that, similar to the situation observed in neurodegenerative diseases, impaired autophagy may contribute to neuronal injury. Consistently, GFP-LC3 and SQSTM1 colocalized with markers of both caspase-dependent and caspase-independent cell death in neuronal cells proximal to the injury site. Taken together, our data indicated for the first time that autophagic clearance is impaired early after TBI due to lysosomal dysfunction, and correlates with neuronal cell death.	[Sarkar, Chinmoy; Zhao, Zaorui; Aungst, Stephanie; Sabirzhanov, Boris; Faden, Alan I.; Lipinski, Marta M.] Univ Maryland, Dept Anesthesiol, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA; [Faden, Alan I.; Lipinski, Marta M.] Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA	Lipinski, MM (corresponding author), Univ Maryland, Dept Anesthesiol, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA.	mlipinski@anes.umm.edu	Sarkar, Chinmoy/AAI-2461-2019	Lipinski, Marta/0000-0002-7537-9014; Faden, Alan I./0000-0003-0128-2348	Department of Anesthesiology, University of Maryland School of Medicine, Baltimore MD [R01 NS06183901A2]	This work was supported by startup funds from the Department of Anesthesiology, University of Maryland School of Medicine, Baltimore MD to MML and R01 NS06183901A2 to AIF.	Bjorkoy G, 2006, AUTOPHAGY, V2, P138, DOI 10.4161/auto.2.2.2405; Butler D, 2006, AUTOPHAGY, V2, P234, DOI 10.4161/auto.2729; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chang CP, 2013, CELL DEATH DIFFER, V20, P515, DOI 10.1038/cdd.2012.146; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Dehay B, 2013, MOVEMENT DISORD, V28, P725, DOI 10.1002/mds.25462; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Harding HP, 1999, NATURE, V397, P271; Higgins GC, 2012, FREE RADICAL BIO MED, V53, P1960, DOI 10.1016/j.freeradbiomed.2012.08.586; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Ichimura Y, 2008, AUTOPHAGY, V4, P1063, DOI 10.4161/auto.6826; Janda E, 2012, MOL NEUROBIOL, V46, P639, DOI 10.1007/s12035-012-8318-1; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DJ, 2006, NATURE, V441, P819, DOI 10.1038/441819a; Klionsky DJ, 2004, NATURE, V431, P31, DOI 10.1038/431031a; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lieberman AP, 2012, AUTOPHAGY, V8, P719, DOI 10.4161/auto.19469; Lipinski MM, 2010, P NATL ACAD SCI USA, V107, P14164, DOI 10.1073/pnas.1009485107; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; McMahon J, 2012, J NEUROSCI, V32, P15704, DOI 10.1523/JNEUROSCI.2392-12.2012; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Nakanishi H, 2003, AGEING RES REV, V2, P367, DOI 10.1016/S1568-1637(03)00027-8; Ni HM, 2011, AUTOPHAGY, V7, P188, DOI 10.4161/auto.7.2.14181; Nixon RA, 2006, TRENDS NEUROSCI, V29, P528, DOI 10.1016/j.tins.2006.07.003; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Norberg E, 2010, BIOCHEM BIOPH RES CO, V396, P95, DOI 10.1016/j.bbrc.2010.02.163; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Riley BE, 2010, J CELL BIOL, V191, P537, DOI 10.1083/jcb.201005012; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Settembre C, 2008, AUTOPHAGY, V4, P113, DOI 10.4161/auto.5227; Settembre C, 2008, HUM MOL GENET, V17, P119, DOI 10.1093/hmg/ddm289; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008; Yang QA, 2010, APOPTOSIS, V15, P1410, DOI 10.1007/s10495-010-0475-y; Yao XL, 2008, J NEUROCHEM, V104, P353, DOI 10.1111/j.1471-4159.2007.04970.x; Yao XL, 2007, BRAIN RES, V1182, P116, DOI 10.1016/j.brainres.2007.08.076; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Zhou XG, 2011, BIOCHEM BIOPH RES CO, V411, P271, DOI 10.1016/j.bbrc.2011.06.117	55	160	164	3	17	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1554-8627	1554-8635		AUTOPHAGY	Autophagy	DEC	2014	10	12					2208	2222		10.4161/15548627.2014.981787			15	Cell Biology	Cell Biology	CA0HN	WOS:000348598200009	25484084	Green Published, Bronze			2021-06-18	
J	Schneider, KJ; Meeuwisse, WH; Nettel-Aguirre, A; Barlow, K; Boyd, L; Kang, J; Emery, CA				Schneider, Kathryn J.; Meeuwisse, Willem H.; Nettel-Aguirre, Alberto; Barlow, Karen; Boyd, Lara; Kang, Jian; Emery, Carolyn A.			Cervicovestibular rehabilitation in sport-related concussion: a randomised controlled trial	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							WHIPLASH-ASSOCIATED DISORDERS; DYNAMIC VISUAL-ACUITY; VESTIBULAR REHABILITATION; INTERNATIONAL-CONFERENCE; NECK PAIN; CONSENSUS STATEMENT; MANUAL THERAPY; CLINICAL-TEST; RATING-SCALE; NUMERIC PAIN	Background/aim Concussion is a common injury in sport. Most individuals recover in 7-10 days but some have persistent symptoms. The objective of this study was to determine if a combination of vestibular rehabilitation and cervical spine physiotherapy decreased the time until medical clearance in individuals with prolonged postconcussion symptoms. Methods This study was a randomised controlled trial. Consecutive patients with persistent symptoms of dizziness, neck pain and/or headaches following a sport-related concussion (12-30 years, 18 male and 13 female) were randomised to the control or intervention group. Both groups received weekly sessions with a physiotherapist for 8 weeks or until the time of medical clearance. Both groups received postural education, range of motion exercises and cognitive and physical rest until asymptomatic followed by a protocol of graded exertion. The intervention group also received cervical spine and vestibular rehabilitation. The primary outcome of interest was medical clearance to return to sport, which was evaluated by a study sport medicine physician who was blinded to the treatment group. Results In the treatment group, 73% (11/15) of the participants were medically cleared within 8 weeks of initiation of treatment, compared with 7% (1/14) in the control group. Using an intention to treat analysis, individuals in the treatment group were 3.91 (95% CI 1.34 to 11.34) times more likely to be medically cleared by 8 weeks. Conclusions A combination of cervical and vestibular physiotherapy decreased time to medical clearance to return to sport in youth and young adults with persistent symptoms of dizziness, neck pain and/or headaches following a sport-related concussion.	[Schneider, Kathryn J.; Meeuwisse, Willem H.; Kang, Jian; Emery, Carolyn A.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB T2N 1N4, Canada; [Schneider, Kathryn J.; Nettel-Aguirre, Alberto; Barlow, Karen; Emery, Carolyn A.] Univ Calgary, Fac Med, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth, Calgary, AB T2N 1N4, Canada; [Meeuwisse, Willem H.; Nettel-Aguirre, Alberto; Emery, Carolyn A.] Univ Calgary, Fac Med, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada; [Nettel-Aguirre, Alberto] Univ Calgary, Fac Med, Dept Pediat, Calgary, AB T2N 1N4, Canada; [Boyd, Lara] Univ British Columbia, UBC Hosp, Dept Phys Therapy, Vancouver, BC V5Z 1M9, Canada; [Boyd, Lara] Univ British Columbia, UBC Hosp, Brain Res Ctr, Vancouver, BC V5Z 1M9, Canada	Schneider, KJ (corresponding author), Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	kjschnei@ucalgary.ca	Emery, Carolyn/AAI-2761-2020; Barlow, Karen/I-6492-2019; Barlow, Karen/C-1323-2014	Barlow, Karen/0000-0003-2612-8507; Schneider, Kathryn/0000-0002-5951-5899; Nettel-Aguirre, Alberto/0000-0001-6604-0652	Alberta Centre for Child, Family and Community Research [09SM-Emery]; IOC; Alberta Heritage FoundationAlberta Heritage Foundation for Medical Research; Alberta Children's Hospital Research Institute; Alberta Innovates Health Solutions Population Health Investigator Award; Children's Hospital Foundation (Alberta Children's Hospital Research Institute for Child and Maternal Health); Alberta Innovates [201201160] Funding Source: researchfish	This study was funded by the Alberta Centre for Child, Family and Community Research, grant number 09SM-Emery. The Sport Injury Prevention Research Centre is one of the International Research Centres for Prevention of Injury and Protection of Athlete Health supported by the IOC. KJS was supported by an Alberta Heritage Foundation for Medical Research Studentship Award and was a Post-Doctoral Fellow supported by the Alberta Children's Hospital Research Institute. CAE is funded by an Alberta Innovates Health Solutions Population Health Investigator Award and a Professorship in Pediatric Rehabilitation funded by the Children's Hospital Foundation (Alberta Children's Hospital Research Institute for Child and Maternal Health).	Akin FW, 2003, J REHABIL RES DEV, V40, P415, DOI 10.1682/JRRD.2003.09.0415; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Bialosky JE, 2009, MANUAL THER, V14, P531, DOI 10.1016/j.math.2008.09.001; Bogduk N, 2004, NEUROL CLIN, V22, P151, DOI 10.1016/S0733-8619(03)00100-2; Carroll LJ, 2008, SPINE, V33, pS83, DOI 10.1097/BRS.0b013e3181643eb8; Childs JD, 2005, SPINE, V30, P1331, DOI 10.1097/01.brs.0000164099.92112.29; Cleland JA, 2008, ARCH PHYS MED REHAB, V89, P69, DOI 10.1016/j.apmr.2007.08.126; Dannenbaum E, 2005, J OTOLARYNGOL, V34, P13, DOI 10.2310/7070.2005.03105; Dannenbaum E, 2009, OTOL NEUROTOL, V30, P368, DOI 10.1097/MAO.0b013e31819bda35; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Furman JM, 2000, PHYS THER, V80, P179, DOI 10.1093/ptj/80.2.179; Goldberg LD, 2006, SPORTS MED ARTHROSC, V14, P199, DOI 10.1097/01.jsa.0000212326.23560.09; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Harvey SA, 1997, AM J OTOL, V18, P207; Hecht JS, 2004, J HEAD TRAUMA REHAB, V19, P58, DOI 10.1097/00001199-200401000-00006; Herdman S J, 2007, VESTIBULAR REHABILIT; Hillier SL, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005397.pub2; HILTON M, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003162.PUB2; HORAK FB, 1992, OTOLARYNG HEAD NECK, V106, P175, DOI 10.1177/019459989210600220; Hurwitz EL, 2008, SPINE, V33, pS123, DOI 10.1097/BRS.0b013e3181644b1d; Hynes LM, 2006, BRAIN INJURY, V20, P179, DOI 10.1080/02699050500443707; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Kay TM, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004250.pub3; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; KREBS DE, 1993, OTOLARYNG HEAD NECK, V109, P735, DOI 10.1177/019459989310900417; Kristjansson E, 2009, J ORTHOP SPORT PHYS, V39, P364, DOI 10.2519/jospt.2009.2834; Kumbhare DA, 2005, DISABIL REHABIL, V27, P801, DOI 10.1080/09638280400020615; Kurre A, 2009, OTOL NEUROTOL, V30, P359, DOI 10.1097/MAO.0b013e3181977e09; Mak MK, 2007, ARCH PHYS MED REHAB, V88, P496, DOI 10.1016/j.apmr.2007.01.018; Mallinson AI, 1998, AM J OTOL, V19, P814; Maskell F, 2006, BRAIN INJURY, V20, P293, DOI 10.1080/02699050500488041; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Mintken PE, 2009, J SHOULDER ELB SURG, V18, P920, DOI 10.1016/j.jse.2008.12.015; Olson LE, 2006, J MANIP PHYSIOL THER, V29, P134, DOI 10.1016/j.jmpt.2005.12.009; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Rahman Mohammed Izad, 2012, J Nat Sci Biol Med, V3, P105, DOI 10.4103/0976-9668.95987; Reid SA, 2005, MANUAL THER, V10, P4, DOI 10.1016/j.math.2004.03.006; Reid SA, 2008, MANUAL THER, V13, P357, DOI 10.1016/j.math.2007.03.006; REVEL M, 1994, ARCH PHYS MED REHAB, V75, P895, DOI 10.1016/0003-9993(94)90115-5; Scherer M, 2008, J VESTIBUL RES-EQUIL, V18, P147; Schneider K, 2009, CLIN J SPORT MED, V19, P265; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Schneider KJ, 2014, BJSM, V48, P658; Schneider KJ, 2014, BJSM, V48, P659, DOI DOI 10.1136/BJSP0RTS-2014-093494.264; Schubert MC, 2004, PHYS THER, V84, P151, DOI 10.1093/ptj/84.2.151; SHEPARD NT, 1993, ANN OTO RHINOL LARYN, V102, P198, DOI 10.1177/000348949310200306; Statacorp, 2008, STATA STATISTICAL SO; TRELEAVEN J, 1994, CEPHALALGIA, V14, P273, DOI 10.1046/j.1468-2982.1994.1404273.x; Vereeck L, 2006, B-ENT, V2, P75; Whitney SL, 2005, OTOL NEUROTOL, V26, P1027, DOI 10.1097/01.mao.0000185066.04834.4e; Whitney SL, 2004, OTOL NEUROTOL, V25, P139, DOI 10.1097/00129492-200403000-00010; Wrisley DM, 2004, PHYS THER, V84, P906, DOI 10.1093/ptj/84.10.906	58	160	160	1	74	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	SEP	2014	48	17					1294	U55		10.1136/bjsports-2013-093267			6	Sport Sciences	Sport Sciences	AM9ZQ	WOS:000340241000007	24855132				2021-06-18	
J	Unden, J; Ingebrigtsen, T; Romner, B				Unden, Johan; Ingebrigtsen, Tor; Romner, Bertil		Scandinavian Neurotrauma Comm	Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults: an evidence and consensus-based update	BMC MEDICINE			English	Article						computed tomography; GRADE; guidelines; head/brain injury/trauma; management; prediction rule; routines; S100/S100B/S100BB	TRAUMATIC BRAIN-INJURY; EMERGENCY-DEPARTMENT DISCHARGE; COMPUTED-TOMOGRAPHY; DECISION-MAKING; S100B; CT; METAANALYSIS; MULTICENTER; RELIABILITY; PHYSICIAN	Background: The management of minimal, mild and moderate head injuries is still controversial. In 2000, the Scandinavian Neurotrauma Committee (SNC) presented evidence-based guidelines for initial management of these injuries. Since then, considerable new evidence has emerged. Methods: General methodology according to the Appraisal of Guidelines for Research and Evaluation (AGREE) II framework and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Systematic evidence-based review according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology, based upon relevant clinical questions with respect to patient-important outcomes, including Quality Assessment of Diagnostic Accuracy Studies (QUADAS) and Centre of Evidence Based Medicine (CEBM) quality ratings. Based upon the results, GRADE recommendations, guidelines and discharge instructions were drafted. A modified Delphi approach was used for consensus and relevant clinical stakeholders were consulted. Conclusions: We present the updated SNC guidelines for initial management of minimal, mild and moderate head injury in adults including criteria for computed tomography (CT) scan selection, admission and discharge with suggestions for monitoring routines and discharge advice for patients. The guidelines are designed to primarily detect neurosurgical intervention with traumatic CT findings as a secondary goal. For elements lacking good evidence, such as in-hospital monitoring, routines were largely based on consensus. We suggest external validation of the guidelines before widespread clinical use is recommended.	[Unden, Johan] Inst Clin Sci, Dept Intens Care & Perioperat Med, S-20502 Malmo, Sweden; [Ingebrigtsen, Tor] Inst Clin Med, Dept Neurosurg, N-9038 Tromso, Norway; [Romner, Bertil] Inst Clin Med, Dept Neurosurg, DK-2100 Copenhagen, Denmark	Unden, J (corresponding author), Inst Clin Sci, Dept Intens Care & Perioperat Med, Sodra Forstadsgatan 101, S-20502 Malmo, Sweden.	dr.johan.unden@gmail.com	Juul, Niels/AAF-1378-2020	Sundstrom, Terje/0000-0002-6503-7141; Ingebrigtsen, Tor/0000-0001-5966-9786	Roche Diagnostics Scandinavia AB; Region Skane, in Sweden; Sodra Sjukvardsregionen, in Sweden; Vetenskapsradet Hallands Sjukhus, in Sweden	JU and BR are organizers of the international BMBD conference (http://www.bmbd.org) concerning neurological biomarkers in brain injury. Some SNC meetings have been sponsored by Roche Diagnostics Scandinavia AB. These sponsors have had no involvement or influence on any aspects of the SNC work. JU and BR have been invited to speak at educational meetings arranged by Roche Diagnostics Scandinavia AB but Roche have always remained strictly independent from the scientific program and content and these took place before the present work was initiated. JU, TI and BR have in previous research received compensation for travel expenses and lab analysis from Roche AB, Diasorin AB and Sangtec Medical AB. None of these had any involvement or influence on any scientific aspects.; SNC working group: Carsten Kock-Jensen (SNC president), Hammel, Denmark; Johan Unden, Malmo, Sweden; Bertil Romner, Copenhagen, Denmark; Tor Ingebrigtsen, Tromso, Norway; Terje Sundstrom, Bergen, Norway; Jacob Springborg, Copenhagen, Denmark; Knut Wester, Bergen, Norway; Per Olof Grande, Lund, Sweden; Vagn Eskesen, Copenhagen, Denmark; Snorre Sollid, Tromso, Norway; Niels Juul, Aarhus, Denmark; Bo-Michael Bellander, Stockholm, Sweden; Bent Dahl, Aarhus, Denmark; Christina Rosenlund, Aarhus, Denmark; Peter Reinstrup, Lund, Sweden. Additional clinical stakeholders: Per Wihlborg, Malmo, Sweden; Louis Riddez, Stockholm, Sweden; Steen Mejdahl, Copenhagen, Denmark; Jesper Erdal, Copenhagen, Denmark; Ole Molgaard, Aarhus, Denmark; Knut Melhuus, Oslo, Norway; Martine Enger, Oslo, Norway; Kenneth Thors, Stavanger, Norway. This work was funded by the non-commercial Swedish state sources of: Region Skane, Sodra Sjukvardsregionen and Vetenskapsradet Hallands Sjukhus, all in Sweden. None of the funding bodies had any involvement or influence on any aspects of the work.	af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; Bellner J, 1999, ACTA NEUROL SCAND, V100, P355; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Brouwers MC, 2010, J CLIN EPIDEMIOL, V63, P1308, DOI 10.1016/j.jclinepi.2010.07.001; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Fabbri A, 2010, J NEUROL NEUROSUR PS, V81, P1275, DOI 10.1136/jnnp.2009.197467; Fung M, 2006, BRAIN INJURY, V20, P889, DOI 10.1080/02699050600831934; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Heneghan Carl, 2009, Evid Based Med, V14, P67, DOI 10.1136/ebm.14.3.67; Heskestad B, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-32; Heskestad B, 2008, J TRAUMA, V65, P1309, DOI 10.1097/TA.0b013e31815e40cd; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Lutz W, 2008, NATURE, V451, P716, DOI 10.1038/nature06516; Moore MM, 2012, J TRAUMA ACUTE CARE, V73, P126, DOI 10.1097/TA.0b013e31824b01af; Morton MJ, 2012, ANN EMERG MED, V60, P361, DOI 10.1016/j.annemergmed.2011.12.026; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; Ono K, 2007, NEUROL MED-CHIR, V47, P291, DOI 10.2176/nmc.47.291; Pelinka LE, 2003, SHOCK, V19, P422, DOI 10.1097/01.shk.0000055345.58165.52; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saab M, 1996, J ACCID EMERG MED, V13, P208; Schriger DL, 2012, ANN EMERG MED, V59, P219, DOI 10.1016/j.annemergmed.2011.08.015; Schunemann HJ, 2008, BMJ-BRIT MED J, V336, P1106, DOI 10.1136/bmj.39500.677199.AE; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; Smits M, 2007, RADIOLOGY, V245, P831, DOI 10.1148/radiol.2452061509; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Soreide K, 2007, WORLD J SURG, V31, P2092, DOI 10.1007/s00268-007-9226-9; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Tauber M, 2009, J TRAUMA, V67, P521, DOI 10.1097/TA.0b013e3181a7c184; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Yates D, 2007, BMJ-BRIT MED J, V335, P719, DOI 10.1136/bmj.39331.702951.47; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	45	160	164	0	18	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1741-7015			BMC MED	BMC Med.	FEB 25	2013	11								50	10.1186/1741-7015-11-50			13	Medicine, General & Internal	General & Internal Medicine	137JR	WOS:000318432400001	23432764	DOAJ Gold, Green Published			2021-06-18	
J	Mouzon, B; Chaytow, H; Crynen, G; Bachmeier, C; Stewart, J; Mullan, M; Stewart, W; Crawford, F				Mouzon, Benoit; Chaytow, Helena; Crynen, Gogce; Bachmeier, Corbin; Stewart, Janice; Mullan, Michael; Stewart, William; Crawford, Fiona			Repetitive Mild Traumatic Brain Injury in a Mouse Model Produces Learning and Memory Deficits Accompanied by Histological Changes	JOURNAL OF NEUROTRAUMA			English	Article						behavior; immunohistochemistry; in vivo studies; models of injury; TBI	CLOSED-HEAD INJURY; PROFESSIONAL FOOTBALL PLAYERS; DIFFUSE AXONAL INJURY; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; ALZHEIMERS-DISEASE; LEAGUE PLAYER; NEONATAL PIG; RISK-FACTOR; MICE	Concussion or mild traumatic brain injury (mTBI) represents the most common type of brain injury. However, in contrast with moderate or severe injury, there are currently few non-invasive experimental studies that investigate the cumulative effects of repetitive mTBI using rodent models. Here we describe and compare the behavioral and pathological consequences in a mouse model of single (s-mTBI) or repetitive injury (r-mTBI, five injuries given at 48 h intervals) administered by an electromagnetic controlled impactor. Our results reveal that a single mTBI is associated with transient motor and cognitive deficits as demonstrated by rotarod and the Barnes Maze respectively, whereas r-mTBI results in more significant deficits in both paradigms. Histology revealed no overt cell loss in the hippocampus, although a reactive gliosis did emerge in hippocampal sector CA1 and in the deeper cortical layers beneath the injury site in repetitively injured animals, where evidence of focal injury also was observed in the brainstem and cerebellum. Axonal injury, manifest as amyloid precursor protein immunoreactive axonal profiles, was present in the corpus callosum of both injury groups, though more evident in the r-mTBI animals. Our data demonstrate that this mouse model of mTBI is reproducible, simple, and noninvasive, with behavioral impairment after a single injury and increasing deficits after multiple injuries accompanied by increased focal and diffuse pathology. As such, this model may serve as a suitable platform with which to explore repetitive mTBI relevant to human brain injury.	[Mouzon, Benoit; Chaytow, Helena; Crynen, Gogce; Bachmeier, Corbin; Mullan, Michael; Crawford, Fiona] Roskamp Inst, Sarasota, FL 34243 USA; [Mouzon, Benoit; Bachmeier, Corbin; Mullan, Michael; Crawford, Fiona] James A Haley Vet Adm Med Ctr, Tampa, FL 33612 USA; [Mouzon, Benoit; Crynen, Gogce; Bachmeier, Corbin; Mullan, Michael; Crawford, Fiona] Open Univ, Dept Life Sci, Milton Keynes MK7 6AA, Bucks, England; [Chaytow, Helena] Univ Cardiff, Sch Biosci, Cardiff, S Glam, Wales; [Stewart, Janice; Stewart, William] So Gen Hosp, Inst Neurol Sci, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; [Stewart, William] Univ Glasgow, Dept Neuropathol, Glasgow, Lanark, Scotland	Mouzon, B (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	bmouzon@rfdn.org		Stewart, William/0000-0003-2199-2582; Crynen, Gogce/0000-0001-6066-9900; Chaytow, Helena/0000-0003-2257-7620; Mullan, Michael/0000-0002-1473-7527	Department of DefenseUnited States Department of Defense [W81XWH-10-1-0759]; Roskamp Foundation	This research was funded by a Department of Defense award (W81XWH-10-1-0759) to Dr. Fiona Crawford and by the Roskamp Foundation.	Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Eakin K, 2012, J NEUROTRAUM, V29, P1180, DOI 10.1089/neu.2011.2192; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Forstl H., 2010, J FORENSIC NURS, V6, P40; Franklin KBJ, 2001, MOUSE BRAIN STEREOTA; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Haselkorn ML, 2010, J NEUROTRAUM, V27, P901, DOI 10.1089/neu.2009.1075; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nakajima Y, 2010, TOHOKU J EXP MED, V221, P229, DOI 10.1620/tjem.221.229; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Pierce JES, 1996, J NEUROSCI, V16, P1083; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2012, J NEUROTRAUM, V29, P354, DOI 10.1089/neu.2011.2055; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Thored P, 2009, GLIA, V57, P835, DOI 10.1002/glia.20810; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134	64	160	160	0	42	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2012	29	18					2761	2773		10.1089/neu.2012.2498			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	050ZE	WOS:000312092800005	22900595	Green Accepted			2021-06-18	
J	Freund, P; Weiskopf, N; Ward, NS; Hutton, C; Gall, A; Ciccarelli, O; Craggs, M; Friston, KJ; Thompson, AJ				Freund, Patrick; Weiskopf, Nikolaus; Ward, Nick S.; Hutton, Chloe; Gall, Angela; Ciccarelli, Olga; Craggs, Michael; Friston, Karl J.; Thompson, Alan J.			Disability, atrophy and cortical reorganization following spinal cord injury	BRAIN			English	Article						spinal cord injury; atrophy; cortical reorganization; disability	VOXEL-BASED MORPHOMETRY; AGE-RELATED-CHANGES; SOMATOSENSORY CORTEX; MULTIPLE-SCLEROSIS; MOTOR CORTEX; ANTIBODY TREATMENT; ADULT MONKEYS; WHITE-MATTER; TIME-SERIES; BRAIN	The impact of traumatic spinal cord injury on structural integrity, cortical reorganization and ensuing disability is variable and may depend on a dynamic interaction between the severity of local damage and the capacity of the brain for plastic reorganization. We investigated trauma-induced anatomical changes in the spinal cord and brain, and explored their relationship to functional changes in sensorimotor cortex. Structural changes were assessed using cross-sectional cord area, voxel-based morphometry and voxel-based cortical thickness of T-1-weighted images in 10 subjects with cervical spinal cord injury and 16 controls. Cortical activation in response to right-sided (i) handgrip; and (ii) median and tibial nerve stimulation were assessed using functional magnetic resonance imaging. Regression analyses explored associations between cord area, grey and white matter volume, cortical activations and thickness, and disability. Subjects with spinal cord injury had impaired upper and lower limb function bilaterally, a 30% reduced cord area, smaller white matter volume in the pyramids and left cerebellar peduncle, and smaller grey matter volume and cortical thinning in the leg area of the primary motor and sensory cortex compared with controls. Functional magnetic resonance imaging revealed increased activation in the left primary motor cortex leg area during handgrip and the left primary sensory cortex face area during median nerve stimulation in subjects with spinal cord injury compared with controls, but no increased activation following tibial nerve stimulation. A smaller cervical cord area was associated with impaired upper limb function and increased activations with handgrip and median nerve stimulation, but reduced activations with tibial nerve stimulation. Increased sensory deficits were associated with increased activations in the left primary sensory cortex face area due to median nerve stimulation. In conclusion, spinal cord injury leads to cord atrophy, cortical atrophy of primary motor and sensory cortex, and cortical reorganization of the sensorimotor system. The degree of cortical reorganization is predicted by spinal atrophy and is associated with significant disability.	[Freund, Patrick; Ciccarelli, Olga; Thompson, Alan J.] UCL, Dept Brain Repair & Rehabil, UCL Inst Neurol, London WC1N 3BG, England; [Freund, Patrick; Weiskopf, Nikolaus; Hutton, Chloe; Friston, Karl J.] UCL, Wellcome Trust Ctr Neuroimaging, UCL Inst Neurol, London WC1N 3BG, England; [Freund, Patrick; Gall, Angela; Craggs, Michael] UCL, Spinal Cord Injury Ctr, Royal Natl Orthopaed Hosp, Stanmore HA7 4LP, Middx, England; [Freund, Patrick] Swiss Parapleg Res, CH-6207 Nottwil, Switzerland; [Ward, Nick S.] UCL, Sobell Dept Motor Neurosci, UCL Inst Neurol, London WC1N 3BG, England	Freund, P (corresponding author), UCL, Dept Brain Repair & Rehabil, UCL Inst Neurol, London WC1N 3BG, England.	p.freund@ion.ucl.ac.uk	Weiskopf, Nikolaus/ABI-5713-2020; Weiskopf, Nikolaus/B-9357-2008; Freund, Patrick/D-4193-2013; Calabrese, Massimiliano/I-6195-2012; Friston, Karl/D-9230-2011; Thompson, Alan J/C-2654-2008; Ciccarelli, Olga/AAY-3328-2020	Weiskopf, Nikolaus/0000-0001-5239-1881; Weiskopf, Nikolaus/0000-0001-5239-1881; Freund, Patrick/0000-0002-4851-2246; Friston, Karl/0000-0001-7984-8909; Thompson, Alan J/0000-0002-4333-8496; Ward, Nick/0000-0002-7688-9649; Ciccarelli, Olga/0000-0001-7485-1367	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBFR33-120920]; Schweizerische Stiftung fur medizinische und biologische [PASMP3-124194]; Swiss Paraplegic Research (Nottwil); Wellcome TrustWellcome TrustEuropean Commission; Department of Health's NIHR Biomedical Research CentreNational Institute for Health Research (NIHR)	Swiss National Science Foundation (grant no. PBFR33-120920); Schweizerische Stiftung fur medizinische und biologische Stipendien (grant no. PASMP3-124194); Swiss Paraplegic Research (Nottwil); Wellcome Trust. This work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme.	Andersson JLR, 2001, NEUROIMAGE, V13, P903, DOI 10.1006/nimg.2001.0746; Ashburner J, 2003, LANCET NEUROL, V2, P79, DOI 10.1016/S1474-4422(03)00304-1; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Barkhof F, 2010, NEUROLOGY, V74, P1033, DOI 10.1212/WNL.0b013e3181d7d651; Beaud ML, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-5; Calancie B, 1996, ELECTROMYOGR MOTOR C, V101, P304, DOI 10.1016/0924-980X(96)95194-2; Ciccarelli O, 2005, EXP BRAIN RES, V166, P31, DOI 10.1007/s00221-005-2335-5; Curt A, 2002, BRAIN, V125, P2567, DOI 10.1093/brain/awf250; Deichmann R, 2004, NEUROIMAGE, V21, P757, DOI 10.1016/j.neuroimage.2003.09.062; Dietz V, 2006, LANCET NEUROL, V5, P688, DOI 10.1016/S1474-4422(06)70522-1; Duggal N, 2010, NEUROLOGY, V74, P1048, DOI 10.1212/WNL.0b013e3181d6b0ea; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; ELBERT T, 1995, SCIENCE, V270, P305, DOI 10.1126/science.270.5234.305; Ellaway PH, 2011, BRAIN RES BULL, V84, P343, DOI 10.1016/j.brainresbull.2010.08.007; Ferretti A, 2003, NEUROIMAGE, V20, P1625, DOI 10.1016/j.neuroimage.2003.07.004; Fields RD, 2008, TRENDS NEUROSCI, V31, P361, DOI 10.1016/j.tins.2008.04.001; FREUND P, 2009, CHRONIC SPINAL CORD; Freund P, 2006, NAT MED, V12, P790, DOI 10.1038/nm1436; Freund PAB, 2010, J MAGN RESON IMAGING, V32, P1242, DOI 10.1002/jmri.22340; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Furkiewicz MT, 2007, NEUROREHAB NEURAL RE, V21, P527, DOI 10.1177/1545968307301872; Ghosh A, 2010, NAT NEUROSCI, V13, P97, DOI 10.1038/nn.2448; Hains BC, 2003, J COMP NEUROL, V462, P328, DOI 10.1002/cne.10733; Hoogervorst ELJ, 2002, ARCH NEUROL-CHICAGO, V59, P113, DOI 10.1001/archneur.59.1.113; Hutton C, 2008, NEUROIMAGE, V40, P1701, DOI 10.1016/j.neuroimage.2008.01.027; Hutton C, 2009, NEUROIMAGE, V48, P371, DOI 10.1016/j.neuroimage.2009.06.043; Jain N, 2000, P NATL ACAD SCI USA, V97, P5546, DOI 10.1073/pnas.090572597; Jones EG, 2000, ANNU REV NEUROSCI, V23, P1, DOI 10.1146/annurev.neuro.23.1.1; JOSEPHS O, 2000, P INT SOC MAGN RESON, V8, P1517; Jurkiewicz MT, 2010, NEUROREHAB NEURAL RE, V24, P136, DOI 10.1177/1545968309347680; Jurkiewicz MT, 2006, NEUROLOGY, V66, P762, DOI 10.1212/01.wnl.0000201276.28141.40; Kim BG, 2006, EXP NEUROL, V198, P401, DOI 10.1016/j.expneurol.2005.12.010; Kokotilo KJ, 2009, J NEUROTRAUM, V26, P2113, DOI 10.1089/neu.2008.0688; Losseff NA, 1996, BRAIN, V119, P701, DOI 10.1093/brain/119.3.701; Lundell H, 2011, SPINAL CORD, V49, P70, DOI 10.1038/sc.2010.87; Lundell H, 2011, NEUROIMAGE, V54, P1254, DOI 10.1016/j.neuroimage.2010.09.009; LYLE RC, 1981, INT J REHABIL RES, V4, P483, DOI 10.1097/00004356-198112000-00001; Moore CI, 2000, P NATL ACAD SCI USA, V97, P14703, DOI 10.1073/pnas.250348997; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; Shoham S, 2001, NATURE, V413, P793, DOI 10.1038/35101651; Talelli P, 2008, NEUROIMAGE, V40, P1772, DOI 10.1016/j.neuroimage.2008.01.039; Tseng GF, 1996, J NEUROPHYSIOL, V75, P248; Turner JA, 2003, NEUROREHAB NEURAL RE, V17, P37, DOI 10.1177/0888439002250443; Ward NS, 2003, BRAIN, V126, P873, DOI 10.1093/brain/awg071; Weiskopf N, 2007, MAGN RESON IMAGING, V25, P989, DOI 10.1016/j.mri.2007.02.007; Wrigley PJ, 2009, PAIN, V141, P52, DOI 10.1016/j.pain.2008.10.007; Wrigley PJ, 2009, CEREB CORTEX, V19, P224, DOI 10.1093/cercor/bhn072	52	160	173	1	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUN	2011	134		6				1610	1622		10.1093/brain/awr093			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	770CF	WOS:000291063900005	21586596	Green Published, Bronze			2021-06-18	
J	Lowenstein, DH				Lowenstein, Daniel H.			Epilepsy after head injury: An overview	EPILEPSIA			English	Article						Epilepsy; Seizures; Traumatic brain injury; Epileptogenesis; Biomarkers	TRAUMATIC BRAIN-INJURY; LATE POSTTRAUMATIC SEIZURES; RISK-FACTORS; IRAQ; WAR; POPULATION; PREDICTION	Traumatic brain injury (TBI) has been recognized as a cause of epilepsy since antiquity, and it remains one of the most common and important causes of acquired epilepsy today. Epidemiologic studies have demonstrated a clear relationship between the severity of injury and the likelihood of developing epilepsy, with the risk approaching 50% in TBI cases associated with direct injury to brain parenchyma. Importantly, many TBI victims develop epilepsy months or years following the initial injury, making this patient population a prime target for the development of antiepileptogenesis therapies. However, progress in this area of clinical research is hindered by the lack of reliable and valid biomarkers. Given current events in the Middle East and elsewhere, the importance of TBI and epilepsy deserves special attention due to the increase in severe head trauma associated with modern warfare.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	Lowenstein, DH (corresponding author), Univ Calif San Francisco, Dept Neurol, Box 0114, San Francisco, CA 94143 USA.	lowenstein@medsch.ucsf.edu	Ritter, Stefanie L/D-9312-2012				AARABI B, 1990, NEUROSURGERY, V27, P692, DOI 10.1227/00006123-199011000-00004; Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Ascroft PB, 1941, BMJ-BRIT MED J, V1941, P739, DOI 10.1136/bmj.1.4193.739; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; Breasted JH, 1930, E SMITH SURG PAPYRUS; CAVENESS WF, 1962, J NEUROSURG, V19, P122, DOI 10.3171/jns.1962.19.2.0122; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; CAVINESS VS, 1966, HEAD INJURY C P, P220; Credner L, 1930, Z GESAMTE NEUROL PSY, V126, P721, DOI 10.1007/BF02864129; DALESSANDRO R, 1982, J NEUROL NEUROSUR PS, V45, P1153, DOI 10.1136/jnnp.45.12.1153; DESAI BT, 1983, EPILEPSIA, V24, P289, DOI 10.1111/j.1528-1157.1983.tb04892.x; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; JENNETT B, 1975, EPILEPSIA, V16, P251, DOI 10.1111/j.1528-1157.1975.tb06055.x; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Kumar R, 2003, AM J NEURORADIOL, V24, P218; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; RUSSELL WR, 1952, J NEUROL NEUROSUR PS, V15, P93, DOI 10.1136/jnnp.15.2.93; SALAZAR A, 1987, ADV EPILEPTOL, P627; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALAZAR AM, 1999, MISSILE WOUNDS HEAD, V2, P281; Spratling WP, 1904, EPILEPSY ITS TREATME; Stiglitz J.E., 2008, 3 TRILLION DOLLAR WA; TAYLOR AR, 1971, POSTTRAUMATIC SYMPTO; Temkin O., 1945, FALLING SICKNESS HIS; WALKER E, 1969, HEAD INJURED MED; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003	38	160	168	1	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia		2009	50			2			4	9		10.1111/j.1528-1167.2008.02004.x			6	Clinical Neurology	Neurosciences & Neurology	399VN	WOS:000262827500002	19187288				2021-06-18	
J	Ghigo, E; Masel, B; Aimaretti, G; Leon-Carrion, J; Casanueva, FF; Dominguez-Morales, MR; Elovic, E; Perrone, K; Stalla, G; Thompson, C; Urban, R				Ghigo, E; Masel, B; Aimaretti, G; Leon-Carrion, J; Casanueva, FF; Dominguez-Morales, MR; Elovic, E; Perrone, K; Stalla, G; Thompson, C; Urban, R			Consensus guidelines on screening for hypopituitarism following traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; head trauma; hypopituitarism; growth hormone efficiency	GROWTH-HORMONE DEFICIENCY; HEAD-INJURY; POSTTRAUMATIC HYPOPITUITARISM; SUBARACHNOID HEMORRHAGE; EPIDEMIOLOGY; DIAGNOSIS; GH; DYSFUNCTION; RISK; PREVALENCE	Primary objective: The goal of this consensus statement is to increase awareness among endocrinologists and physicians treating patients with traumatic brain injury (TBI) of the incidence and risks of hypopituitarism among patients with TBI. Rationale: TBI poses significant risk to the pituitary gland, leading to elevated risks of diabetes, hypopituitarism and other endocrinopathies. Signs and symptoms associated with hypopituitarism often mimic the sequellae of TBI, although the severity of symptoms is not necessarily related to the severity of the injury. Patients with TBI-induced hypopituitarism may benefit both physically and psychologically from appropriate hormone replacement therapy (HRT). Participants at this unique consensus meeting attempted to define and spearhead an approach to increase awareness of the risks of TBI-induced endocrinopathies, in particular growth hormone deficiency (GHD), and to outline necessary and practical objectives for managing this condition. Recommendations: Systematic screening of pituitary function is recommended for all patients with moderate-to-severe TBI at risk of developing pituitary deficits. Patients with hypopituitarism benefit from appropriate hormonal replacement and prospects for rehabilitation of patients with TBI-induced hypopituitarism may be enhanced by appropriate HRT. Further exploration of this possibility requires: (1) active collaboration between divisions of endocrinology and rehabilitation at the local level to perform a screening of pituitary function in patients after TBI, (2) creation of a consultancy service by endocrine societies for use by rehabilitation centres, (3) development of continuing medical education (CME) programmes that can be offered as crossover training to the physicians who manage the care of patients with TBIs, (4) targeting of patient organizations with educational information for dissemination to patients and their families, (5) continued efforts to more clearly define the population at greatest risk of TBI-induced hypopituitarism and (6) monitor results of efficacy studies as they become available to evaluate whether and how much replacement therapy can improve the symptoms of individuals with TBI-induced hypopituitarism.	Transit Learning Ctr Galveston, Galveston, TX 77550 USA; Univ Turin, Dept Internal Med, Turin, Italy; Univ Seville, Dept Expt Psychol, Seville, Spain; Univ Santiago Compostela, Dept Med, Div Endocrine, Santiago, Spain; Ctr Brain Injury Rehabil, Seville, Spain; Kessler Med Rehabil, W Orange, NJ USA; Presidio Osped Ausiliatrice, Turin, Italy; Max Planck Inst Psychiat, D-80804 Munich, Germany; Beaumont Hosp, Beaumont Private Clin, Dublin 9, Ireland; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77550 USA	Masel, B (corresponding author), Transit Learning Ctr Galveston, 1528 PO St, Galveston, TX 77550 USA.	bmasel@tlc-galveston.org					Aimaretti G, 1998, J ENDOCRINOL INVEST, V21, P506, DOI 10.1007/BF03347336; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; ALTMAN R, 1961, ANN INTERN MED, V55, P149, DOI 10.7326/0003-4819-55-1-149; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; CYTOWIC RE, 1986, NEW ENGL J MED, V314, P715; Daniel PM, 1961, MOD TRENDS ENDOCR, P55; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; Deijen JB, 1996, PSYCHONEUROENDOCRINO, V21, P313, DOI 10.1016/0306-4530(95)00050-X; EDWARDS OM, 1986, MEDICINE, V65, P281; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; Freda PU, 1998, J CLIN ENDOCR METAB, V83, P3808, DOI 10.1210/jc.83.11.3808; Ghigo E, 2001, ENDOCRINE, V15, P29, DOI 10.1385/ENDO:15:1:029; Gibney J, 1999, J CLIN ENDOCR METAB, V84, P2596, DOI 10.1210/jc.84.8.2596; Giustina A, 2000, J CLIN ENDOCR METAB, V85, P526, DOI 10.1210/jc.85.2.526; GUNN IR, 1991, ANN CLIN BIOCHEM, V28, P327, DOI 10.1177/000456329102800402; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hillier SL, 1997, BRAIN INJURY, V11, P649; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KLEIN MJ, 2004, EMEDICINE       0726; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kusanagi Hiroaki, 2000, Journal of Nippon Medical School, V67, P130, DOI 10.1272/jnms.67.130; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leon-Carrion J, 2001, BRAIN INJURY, V15, P175, DOI 10.1080/026990501458407; Lieberman SA, 1996, J PEDIATR-US, V128, pS58, DOI 10.1016/S0022-3476(96)70013-6; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; NELL V, 1991, SOC SCI MED, V33, P289, DOI 10.1016/0277-9536(91)90363-H; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Peacey SR, 2001, J CLIN ENDOCR METAB, V86, P259, DOI 10.1210/jc.86.1.259; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; ROSEN T, 1994, CLIN ENDOCRINOL, V40, P111, DOI 10.1111/j.1365-2265.1994.tb02452.x; Servadei F, 2002, NEUROEPIDEMIOLOGY, V21, P297, DOI 10.1159/000065523; Shalet SM, 1998, ENDOCR REV, V19, P203, DOI 10.1210/er.19.2.203; Simmonds M, 1914, DEUT MED WOCHENSCHR, V40, P322, DOI 10.1055/s-0029-1190185; Springer J, 2001, LANCET, V357, P1848, DOI 10.1016/S0140-6736(00)04953-9; Swearingen B, 1998, J CLIN ENDOCR METAB, V83, P3419, DOI 10.1210/jc.83.10.3419; THURMAN DJ, 1999, FOCUS CLIN RES PRA 2, V14, P602; URBAN RJ, IN PRESS BRAIN INJUR; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084	53	160	170	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2005	19	9					711	724		10.1080/02699050400025315			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	945EH	WOS:000230484600009	16195185				2021-06-18	
J	Diringer, MN				Diringer, MN		Neurocritical Care Fever Reduction	Treatment of fever in the neurologic intensive care unit with a catheter-based heat exchange system	CRITICAL CARE MEDICINE			English	Article						fever; head injury; subarachnoid hemorrhage; intracerebral hemorrhage; ischernic stroke; central venous catheter	ACUTE ISCHEMIC-STROKE; SPECIAL WRITING GROUP; SUBARACHNOID HEMORRHAGE; BODY-TEMPERATURE; CLINICAL-TRIAL; BRAIN INJURY; GUIDELINES; HYPERTHERMIA; MANAGEMENT; ACETAMINOPHEN	Context: Elevated temperature worsens injury in experimental focal and global ischemia and brain trauma. Fever is common in patients with acute neurologic illness and independently predicts poor outcome. Conventional means of treating fever are not very effective in this population. Objective: To study the effectiveness of a catheter-based heat exchange system in reducing elevated temperatures in critically ill neurologic and neurosurgical patients. Design, Intervention, Setting, and Population: This was a prospective randomized, nonblinded trial that compared conventional treatment of fever (acetaminophen and cooling blankets) with conventional treatment plus an intravascular catheter-based heat exchange system (Alsius, Irvine, CA). Patients admitted to one of 13 neurologic intensive care units in academic medical centers were eligible if they a) suffered subarachnoid hemorrhage, intracerebral hemorrhage, ischemic infarction, or traumatic brain injury; b) had a temperature >38degreesC on two occasions or for >4 continuous hrs; and c) required central venous access. Main Outcome Measure: The fever burden (area under the curve >38degreesC) for 72 hrs was compared in an intention to treat analysis. Safety of the catheter system was monitored. Results: A total of 296 patients were enrolled over 20 months. Forty-one percent had subarachnoid hemorrhage, 24% had traumatic brain injury, 23% had intracerebral hemorrhage, and 13% had ischemic stroke. The groups Were matched in terms of age, body mass index, sex, and Glasgow Coma Scale score distribution. Fever burden was 7.92 vs. 2.87degreesC-hrs in the conventional group and catheter groups, respectively (64% reduction, p < .01). There was no higher rate of infection or the use of sedatives, narcotics, or antibiotics in the catheter group. The catheter did not significantly increase risk to the patient beyond that of a central catheter. Conclusions: The addition of this catheter-based cooling system to conventional management significantly improves fever reduction in neurologic intensive care unit patients.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Diringer, MN (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.		Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537			ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Bullock MR, 1996, J NEUROTRAUM, V13, P643; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CAIRNS SJ, 2002, CURR OPIN CRIT CARE, V8, P106; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Dippel DWJ, 2001, STROKE, V32, P1607, DOI 10.1161/01.STR.32.7.1607; Diringer MN, 2001, CRIT CARE MED, V29, P1792, DOI 10.1097/00003246-200109000-00023; Georgiadis D, 2001, STROKE, V32, P2550, DOI 10.1161/hs1101.097382; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Lenhardt R, 1999, AM J MED, V106, P550, DOI 10.1016/S0002-9343(99)00068-6; Lewis CA, 1997, J VASC INTERV RADIOL, V8, P475, DOI 10.1016/S1051-0443(97)70592-X; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MAYBERG MR, 1994, CIRCULATION, V90, P2592, DOI 10.1161/01.CIR.90.5.2592; Mayer SA, 2001, NEUROLOGY, V56, P292, DOI 10.1212/WNL.56.3.292; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; STEELE RW, 1970, J PEDIATR-US, V77, P824, DOI 10.1016/S0022-3476(70)80242-6; TERENT A, 1981, UPSALA J MED SCI, V86, P63, DOI 10.3109/03009738109179211; VARGAS R, 1994, J CLIN PHARMACOL, V34, P848, DOI 10.1002/j.1552-4604.1994.tb02050.x; WALSON PD, 1989, CLIN PHARMACOL THER, V46, P9, DOI 10.1038/clpt.1989.100; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013; Weimar C, 2002, J NEUROL, V249, P888, DOI 10.1007/s00415-002-0755-8	28	160	167	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	FEB	2004	32	2					559	564		10.1097/01.CCM.0000108868.97433.3F			6	Critical Care Medicine	General & Internal Medicine	774ME	WOS:000188982600036	14758179				2021-06-18	
J	Palchak, MJ; Holmes, JF; Vance, CW; Gelber, RE; Schauer, BA; Harrison, MJ; Willis-Shore, J; Wootton-Gorges, SL; Derlet, RW; Kuppermann, N				Palchak, MJ; Holmes, JF; Vance, CW; Gelber, RE; Schauer, BA; Harrison, MJ; Willis-Shore, J; Wootton-Gorges, SL; Derlet, RW; Kuppermann, N			A decision rule for identifying children at low risk for brain injuries after blunt head trauma	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine (SAEM)	MAY 19-23, 2002	ST LOUIS, MO	Soc Acad Emergency Med			COMPUTED-TOMOGRAPHY; INTRACRANIAL INJURY; EMERGENCY PHYSICIANS; CLINICAL INDICATORS; SKULL FRACTURE; PREDICTORS; MANAGEMENT; SEDATION; INFANTS; YOUNGER	Study objective: Computed tomography (CT) is frequently used in evaluating children with blunt head trauma. Routine use of CT, however, has disadvantages. Therefore, we sought to derive a decision rule for identifying children at low risk for traumatic brain injuries. Methods: We enrolled children with blunt head trauma at a pediatric trauma center in an observational cohort study between July 1998 and September 2001. We evaluated clinical predictors of traumatic brain injury on CT scan and traumatic brain injury requiring acute intervention, defined by a neurosurgical procedure, antiepileptic medications for more than 1 week, persistent neurologic deficits, or hospitalization for at least 2 nights. We performed recursive partitioning to create clinical decision rules. Results: Two thousand forty-three children were enrolled, 1,271 (62%) underwent CT, 98 (7.7%; 95% confidence interval [CI] 6.3% to 9.3%) had traumatic brain injuries on CT scan, and 105 (5.1%; 95% CI 4.2% to 6.2%) had traumatic brain injuries requiring acute intervention. Abnormal mental status, clinical signs of skull fracture, history of vomiting, scalp hematoma (in children less than or equal to2 years of age), or headache identified 97/98 (99%; 95% Cl 94% to 100%) of those with traumatic brain injuries on CT scan and 105/105 (100%; 95% CI 97% to 100%) of those with traumatic brain injuries requiring acute intervention. Of the 304 (24%) children undergoing CT who had none of these predictors, only 1 (0.3%; 95% Cl 0% to 1.8%) had traumatic brain injury on CT, and that patient was discharged from the ED without complications. Conclusion: Important factors for identifying children at low risk for traumatic brain injuries after blunt head trauma included the absence of: abnormal mental status, clinical signs of skull fracture, a history of vomiting, scalp hematoma (in children :52 years of age), and headache.	Univ Calif Davis, Med Ctr, Sch Med, Div Emergency Med,Dept Internal Med, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Dept Radiol, Sacramento, CA 95817 USA; Oregon Hlth & Sci Univ, Dept Emergency Med, Sch Med, Portland, OR 97201 USA	Kuppermann, N (corresponding author), Univ Calif Davis, Med Ctr, Sch Med, Div Emergency Med,Dept Internal Med, PSSB 2100,2315 Stockton Blvd, Sacramento, CA 95817 USA.	nkuppermann@ucdavis.edu					Aitken ME, 1998, ARCH PEDIAT ADOL MED, V152, P1176; Bergman DA, 1999, PEDIATRICS, V104, P1407; BONADIO WA, 1989, AM J DIS CHILD, V143, P194, DOI 10.1001/archpedi.1989.02150140084025; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; BRIEMAN L, 1994, CLASSIFICATION REGRE; Brody AS, 2002, PEDIATR ANN, V31, P643, DOI 10.3928/0090-4481-20021001-08; *CDCP, 2002, VIT HLTH STAT SER, V13; Conners GP, 1999, PEDIATR EMERG CARE, V15, P241; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; DURCH JS, 1993, EMERGENCY MED SERVIC; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; Greenes DS, 1997, ANN EMERG MED, V30, P253, DOI 10.1016/S0196-0644(97)70158-6; Greenes DS, 1998, ANN EMERG MED, V32, P680, DOI 10.1016/S0196-0644(98)70067-8; Greenes DS, 2001, PEDIATR EMERG CARE, V17, P88, DOI 10.1097/00006565-200104000-00002; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Hall EJ, 2002, PEDIATR RADIOL, V32, P700, DOI 10.1007/S00247-002-0774-8; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; HENNES H, 1988, AM J DIS CHILD, V142, P1045, DOI 10.1001/archpedi.1988.02150100039021; Hoffman GM, 2002, PEDIATRICS, V109, P236, DOI 10.1542/peds.109.2.236; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; HOYERT DL, 2001, FINAL DATA 1999 NATL, V49; Infante-Rivard C, 2000, ENVIRON HEALTH PERSP, V108, P495, DOI 10.2307/3454609; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAMES HE, 1986, PEDIATR ANN, V15, P16, DOI 10.3928/0090-4481-19860101-05; KADISH HA, 1995, ANN EMERG MED, V26, P37, DOI 10.1016/S0196-0644(95)70235-0; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Langlois J., 2001, TRAUMATIC BRAIN INJU, P1; MITCHELL KA, 1994, J PEDIATR SURG, V29, P851, DOI 10.1016/0022-3468(94)90001-9; Moro-Sutherland DM, 2000, ACAD EMERG MED, V7, P1370, DOI 10.1111/j.1553-2712.2000.tb00494.x; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; *NAT VIT STAT SYST, 1999, 10 LEAD DEATH US 199; National Center for Injury Prevention and Control, 2002, TRAUM BRAIN INJ US A; Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; RAMUNDO ML, 1995, PEDIATR EMERG CARE, V11, P1, DOI 10.1097/00006565-199502000-00001; RIVARA F, 1987, PEDIATRICS, V80, P579; Schulman S, 1996, HAEMOPHILIA, V2, P160, DOI 10.1111/j.1365-2516.1996.tb00160.x; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Seidel JS, 1999, ANN EMERG MED, V33, P206, DOI 10.1016/S0196-0644(99)70395-1; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X	48	160	162	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	OCT	2003	42	4					492	506		10.1067/S0196-0644(03)00425-6			15	Emergency Medicine	Emergency Medicine	729CC	WOS:000185752700006	14520320				2021-06-18	
J	Friberg, H; Wieloch, T				Friberg, H; Wieloch, T			Mitochondrial permeability transition in acute neurodegeneration	BIOCHIMIE			English	Article						mitochondria; ischemia; brain; neuronal death; cyclosporin; permeability transition	FOCAL CEREBRAL-ISCHEMIA; ADENINE-NUCLEOTIDE TRANSLOCATOR; TRAUMATIC BRAIN INJURY; NITRIC-OXIDE SYNTHASE; IN-VIVO EVIDENCE; CYCLOSPORINE-A; CELL-DEATH; INNER MEMBRANE; RAT HIPPOCAMPUS; GLUTAMATE NEUROTOXICITY	Acute neurodegeneration in man is encountered during and following stroke, transient cardiac arrest, brain trauma, insulin-induced hypoglycemia and status epilepticus. All these severe clinical conditions are characterized by neuronal calcium overload, aberrant cell signaling, generation of free radicals and elevation of cellular free fatty acids, conditions that favor activation of the mitochondrial permeability transition pore (mtPTP). Cyclosporin A (CsA) and its analog N-methyl-valine-4-cyclosporin A (MeValCsA) are potent blockers of the mtPTP and protect against neuronal death following excitotoxicity and oxygen glucose deprivation. Also, CsA and MeValCsA diminish cell death following cerebral ischemia. trauma, and hypoglycemia. Here we present data that strongly imply the mtPT in acute neurodegeneration in vivo. Compounds that readily pass the blood-brain-barrier (131313) and block the mtPT may be neuroprotective in stroke. (C) 2002 Societe francaise de biochimie et biologie moleculaire / Editions scientifiques et medicales Elsevier SAS. All rights reserved.	Wallenberg Neurosci Ctr, Expt Brain Res Lab, S-22184 Lund, Sweden	Wieloch, T (corresponding author), Wallenberg Neurosci Ctr, Expt Brain Res Lab, BMC A13, S-22184 Lund, Sweden.	tadeusz.wieloch@expbr.lu.se		Wieloch, Tadeusz/0000-0002-7669-2520			Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Almeida A, 2001, J NEUROCHEM, V77, P676, DOI 10.1046/j.1471-4159.2001.00276.x; Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; AOKI M, 1995, BRAIN RES, V669, P189, DOI 10.1016/0006-8993(94)01227-9; AUER RN, 1984, DIABETES, V33, P1090, DOI 10.2337/diabetes.33.11.1090; AUER RN, 1988, ANN NEUROL, V24, P699, DOI 10.1002/ana.410240602; Back T, 2000, ANN NEUROL, V47, P485, DOI 10.1002/1531-8249(200004)47:4<485::AID-ANA12>3.3.CO;2-#; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; Berman SB, 2000, EXP NEUROL, V164, P415, DOI 10.1006/exnr.2000.7438; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Bernardi P, 1999, PHYSIOL REV, V79, P1127; BERNAREGGI A, 1991, J PHARMACOKINET BIOP, V19, P21, DOI 10.1007/BF01062191; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Buckman JF, 2001, J NEUROSCI, V21, P5054, DOI 10.1523/JNEUROSCI.21-14-05054.2001; Butcher SP, 1997, J NEUROSCI, V17, P6939; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; CONNERN CP, 1992, BIOCHEM J, V284, P381, DOI 10.1042/bj2840381; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; Connern CP, 1996, BIOCHEMISTRY-US, V35, P8172, DOI 10.1021/bi9525177; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Du YS, 1997, J NEUROCHEM, V69, P1382; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Ferrand-Drake M, 1999, NEUROSCIENCE, V90, P1325, DOI 10.1016/S0306-4522(98)00559-4; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friberg H, 1998, J NEUROSCI, V18, P5151; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Garcia-Ruiz C, 2000, FASEB J, V14, P847; GINSBERG MD, 1989, STROKE, V20, P1627, DOI 10.1161/01.STR.20.12.1627; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Halestrap AP, 1999, BIOCHEM SOC SYMP, V66, P181, DOI 10.1042/bss0660181; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; HARRIS RJ, 1984, J CEREBR BLOOD F MET, V4, P187, DOI 10.1038/jcbfm.1984.27; Hata R, 1999, METAB BRAIN DIS, V14, P117, DOI 10.1023/A:1020709814456; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Khaspekov L, 1999, EUR J NEUROSCI, V11, P3194, DOI 10.1046/j.1460-9568.1999.00743.x; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuroda S, 1996, NEUROSCI RES COMMUN, V19, P83; LEQUOC K, 1988, ARCH BIOCHEM BIOPHYS, V265, P249, DOI 10.1016/0003-9861(88)90125-7; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Moynagh PN, 1995, ESSAYS BIOCHEM, V30, P1; Murchison D, 2000, BRAIN RES, V854, P139, DOI 10.1016/S0006-8993(99)02297-0; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Petersen A, 2000, BRAIN RES, V857, P20, DOI 10.1016/S0006-8993(99)02320-3; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; Ruiz F, 2000, EUR J PHARMACOL, V404, P29, DOI 10.1016/S0014-2999(00)00584-7; SAKATA A, 1994, BIOCHEM PHARMACOL, V48, P1989, DOI 10.1016/0006-2952(94)90601-7; Schinder AF, 1996, J NEUROSCI, V16, P6125; Seaton TA, 1998, BRAIN RES, V809, P12, DOI 10.1016/S0006-8993(98)00790-2; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Shimazaki K, 2000, GENE THER, V7, P1244, DOI 10.1038/sj.gt.3301211; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1985, PROG BRAIN RES, V63, P121; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SIMON RP, 1984, J CEREBR BLOOD F MET, V4, P350, DOI 10.1038/jcbfm.1984.52; Snyder SH, 1998, NEURON, V21, P283, DOI 10.1016/S0896-6273(00)80538-3; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Tanveer A, 1996, EUR J BIOCHEM, V238, P166, DOI 10.1111/j.1432-1033.1996.0166q.x; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; VERCESI AE, 1984, BIOCHEM BIOPH RES CO, V119, P305, DOI 10.1016/0006-291X(84)91652-8; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; VONHANWEHR R, 1986, J NEUROCHEM, V46, P331; VONLUBITZ DKJE, 1982, NEUROPATH APPL NEURO, V8, P197; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wieckowski MR, 2000, FEBS LETT, V484, P61, DOI 10.1016/S0014-5793(00)02127-X; WIELOCH T, 1982, PATHOL BIOL, V30, P269; WIELOCH T, 1984, J NEUROCHEM, V43, P160, DOI 10.1111/j.1471-4159.1984.tb06692.x; Wiessner C, 1999, NEUROSCI LETT, V268, P119, DOI 10.1016/S0304-3940(99)00392-4; Xu DG, 1999, J NEUROSCI, V19, P5026; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zhong J, 2001, ONCOGENE, V20, P4807, DOI 10.1038/sj.onc.1204614; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	100	160	167	0	3	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0300-9084	1638-6183		BIOCHIMIE	Biochimie	FEB-MAR	2002	84	2-3					241	250	PII S0300-9084(02)01381-0	10.1016/S0300-9084(02)01381-0			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	552YV	WOS:000175648600016	12022955				2021-06-18	
J	Jordan, BD				Jordan, BD			Chronic traumatic brain injury associated with boxing	SEMINARS IN NEUROLOGY			English	Article						chronic traumatic brain injury; Alzheimer's disease; apolipoprotein E; boxing; sports neurology; dementia	APOLIPOPROTEIN-E EPSILON-4; ACTIVE AMATEUR BOXERS; AMYLOID BETA-PROTEIN; HEAD-INJURY; DEMENTIA-PUGILISTICA; NEUROFIBRILLARY TANGLES; PROFESSIONAL BOXERS; COMPUTED-TOMOGRAPHY; ALZHEIMERS-DISEASE; CHOLINERGIC NEURONS	Chronic traumatic brain injury (CTBI) associated with boxing occurs in approximately 20% of professional boxers. Risk factors associated with CTBI include increased exposure (i.e., duration of career, age of retirement, total number of bouts), poor performance, increased sparring, and apolipoprotein (APOE) genotype. Clinically, boxers exhibiting CTBI will present with varying degrees of motor, cognitive, and/or behavioral impairments. The severe form of CTBI is referred to as dementia pugilistica. The diagnosis of CTBI is dependent upon documenting a progressive neurological condition that is consistent with the clinical symptomatology of CTBI attributable to brain trauma and unexplainable by an alternative pathophysiological process. Pathologically, CTBI shares many characteristics with Alzheimer's disease (i.e,, neurofibrillary triangles, diffuse amyloid plaques, acetylcholine deficiency, and/or tau immunoreactivity), The mainstay of treatment of CTBI is prevention, however medications used in the treatment of Alzheimer's disease and/or parkinsonism may be utilized.	Burke Rehabil Hosp, Brain Injury Program, White Plains, NY 10605 USA; Cornell Univ Med Coll, Dept Neurol, New York, NY USA	Jordan, BD (corresponding author), Burke Rehabil Hosp, Brain Injury Program, 785 Mamaroneck Ave, White Plains, NY 10605 USA.						Bodensteiner JB, 1997, SPORTS MED, V24, P361, DOI 10.2165/00007256-199724060-00002; BOGDANOFF B, 1989, NEUROLOGY, V39, P991, DOI 10.1212/WNL.39.7.991; BROOKS N, 1987, J NEUROL NEUROSUR PS, V50, P997, DOI 10.1136/jnnp.50.8.997; BUTLER RJ, 1993, J NEUROL NEUROSUR PS, V56, P1055, DOI 10.1136/jnnp.56.10.1055; BUTLER RJ, 1994, BRIT J SPORT MED, V28, P187, DOI 10.1136/bjsm.28.3.187; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CASSON IR, 1982, J NEUROL NEUROSUR PS, V45, P170, DOI 10.1136/jnnp.45.2.170; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; COLOSIMO C, 1995, LANCET, V346, P647, DOI 10.1016/S0140-6736(95)91486-2; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORSELLIS JAN, 1978, SENILE DEMENTIA RELA, P125; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; DAVIE CA, 1995, J NEUROL NEUROSUR PS, V58, P688, DOI 10.1136/jnnp.58.6.688; DREW RH, 1986, J CLIN PSYCHOL, V42, P520, DOI 10.1002/1097-4679(198605)42:3<520::AID-JCLP2270420319>3.0.CO;2-6; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; GOLDBERG E, 1982, ARCH NEUROL-CHICAGO, V39, P581, DOI 10.1001/archneur.1982.00510210051012; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HEILBRONNER RL, 1991, AM J SPORT MED, V19, P376, DOI 10.1177/036354659101900409; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; jordan B. D., 1999, J NEUROIMAGING, V9, P59; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 1998, PHYSICIAN SPORTSMED, V26, P25, DOI 10.3810/psm.1998.02.928; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; JORDAN BD, 1993, MED ASPECTS BOXING, P147; JORDAN BD, 1992, J NEUROIMAGING, V2, P181; JORDAN BD, 1998, BOXING, P351; KASTE M, 1982, LANCET, V2, P1186; Katzman R, 1996, NEUROLOGY, V46, P889; LACAVA G, 1963, J Sports Med Phys Fitness, V3, P87; LEVIN HS, 1987, J NEUROSURG, V67, P657, DOI 10.3171/jns.1987.67.5.0657; LEVIN HS, 1993, MED ASPECTS BOXING, P197; *MA GEN HOSP, 1999, NEW ENGL J MED, V340, P1269; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCLATCHIE G, 1987, J NEUROL NEUROSUR PS, V50, P96, DOI 10.1136/jnnp.50.1.96; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; MERZ B, 1989, JAMA-J AM MED ASSOC, V261, P2597; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; Seliger G, 1997, NEUROLOGY, V48, P28001; Sironi V A, 1982, J Neurosurg Sci, V26, P165; SMITH CM, 1978, ANN NEUROL, V3, P471, DOI 10.1002/ana.410030602; STEWART WF, 1994, AM J EPIDEMIOL, V139, P573, DOI 10.1093/oxfordjournals.aje.a117047; Taverni JP, 1998, BRAIN INJURY, V12, P77; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; UHL GR, 1982, ANN NEUROL, V12, P99	61	160	165	0	13	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.		2000	20	2					179	185		10.1055/s-2000-9826			7	Clinical Neurology	Neurosciences & Neurology	339NU	WOS:000088484300005	10946737				2021-06-18	
J	Povlishock, JT; Marmarou, A; McIntosh, T; Trojanowski, JQ; Moroi, J				Povlishock, JT; Marmarou, A; McIntosh, T; Trojanowski, JQ; Moroi, J			Impact acceleration injury in the rat: Evidence for focal axolemmal change and related neurofilament sidearm alteration	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						axolemmal permeability; cytoskeleton; immunocytochemistry; rat; traumatic brain injury	DIFFUSE AXONAL INJURY; AMYLOID PRECURSOR PROTEIN; NONMISSILE HEAD-INJURY; TRAUMATIC BRAIN INJURY; PHOSPHORYLATION STATE; SUBUNITS; HUMANS; DAMAGE; ASSAULT; NEURONS	Recently we reported that traumatic brain injury evokes local changes in the axolemma's permeability, in concert with local cytoskeletal changes involving neurofilament (NF) compaction and sidearm loss, all of which contribute to the genesis of reactive axonal change. Since it was of concern that these events may be either injury model- or species-specific, we sought to address these phenomena in a different but well-characterized animal model and species. Further, to provide more compelling insight into the potential for NF compaction and sidearm alteration, we also employed antibodies specific for the NF rod domains, which are readily visualized only when the NF sidearms are disturbed. Rats were subjected to impact acceleration injury. To assess the potential for altered axolemmal permeability, 5 animals received intrathecal horseradish peroxidase (HRP), normally excluded by the intact axolemma. To assess the potential for NF sidearm alteration, another 14 animals were processed for the visualization of antibodies targeting the NF rod domain at 5 minutes (min) to 24 hours (h) postinjury. All animals were evaluated at the LM and EM levels. Those animals receiving intrathecal HRP showed immediate focal alterations in the axolemma's permeability to the normally excluded tracer. Over a 2 h period, these axons demonstrated NF compaction. Antibodies targeted to the rod domains revealed focal intra-axonal immunoreactivity in sites closely correlated with those showing altered axolemmal permeability. These same sites also demonstrated evidence of NF compaction and sidearm loss/perturbation. Collectively, these findings suggest that occurrence of altered axolemmal permeability and concomitant cytoskeletal change are features common to traumatic brain injury in various animal models and species. Further, these studies underscore the utility of antibodies targeting the rod domain for the early detection of traumatically induced reactive change.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV NEUROSURG, RICHMOND, VA 23298 USA; UNIV PENN, DEPT NEUROSURG, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PATHOL, PHILADELPHIA, PA 19104 USA	Povlishock, JT (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT ANAT, POB 980709, RICHMOND, VA 23298 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG011542] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG-11542] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193] Funding Source: Medline		ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; BILLGER M, 1988, CELL CALCIUM, V9, P33, DOI 10.1016/0143-4160(88)90036-X; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; COTTIN P, 1991, BIOCHIM BIOPHYS ACTA, V1079, P139, DOI 10.1016/0167-4838(91)90118-J; CROOKS DA, 1992, MED SCI LAW, V32, P109, DOI 10.1177/106002809203200204; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P149, DOI 10.1016/0165-5728(87)90049-X; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; HALL GF, 1995, J COMP NEUROL, V353, P38, DOI 10.1002/cne.903530106; IMAJO T, 1984, AM J FOREN MED PATH, V5, P217, DOI 10.1097/00000433-198409000-00005; IMAJO T, 1987, AM J FOREN MED PATH, V8, P217, DOI 10.1097/00000433-198708030-00004; ISHIZAKI Y, 1994, J NEUROSCI, V14, P3934; JOB D, 1981, P NATL ACAD SCI-BIOL, V78, P4679, DOI 10.1073/pnas.78.8.4679; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; LEE VMY, 1987, J NEUROSCI, V7, P3474; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; MITCHELL DE, 1973, LANCET, V2, P215; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; STRICH SJ, 1970, J CLIN PATHOL S4, V23, P166; TU PH, 1995, J CELL BIOL, V129, P1629, DOI 10.1083/jcb.129.6.1629; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	51	160	163	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	APR	1997	56	4					347	359		10.1097/00005072-199704000-00003			13	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	WR827	WOS:A1997WR82700003	9100665	Bronze			2021-06-18	
J	Barzo, P; Marmarou, A; Fatouros, P; Corwin, F; Dunbar, J				Barzo, P; Marmarou, A; Fatouros, P; Corwin, F; Dunbar, J			Magnetic resonance imaging monitored acute blood-brain barrier changes in experimental traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						blood-brain barrier; magnetic resonance imaging; traumatic brain injury; gadolinium; secondary insult	FLUID-PERCUSSION MODEL; GD-DTPA; HEAD-INJURY; PLASMA-PROTEINS; RAT-BRAIN; EDEMA; PERMEABILITY; BREAKDOWN; EXTRAVASATION; RESOLUTION	The authors posit that cellular edema is the major contributor to brain swelling in diffuse head injury and that the contribution of vasogenic edema may be overemphasized. The objective of this study was to determine the early time course of blood-brain barrier (BBB) changes in diffuse closed head injury and to what extent barrier permeability is affected by the secondary insults of hypoxia and hypotension. The BBB disruption was quantified and visualized using T-1-weighted magnetic resonance (MR) imaging following intravenous administration of the MR contrast agent gadolinium-diethylenetriamine pentaacetic acid. To avoid the effect of blood volume changes, the maximum signal intensity (SI) enhancement was used to calculate the difference in BBB disruption. A new impact-acceleration model was used to induce closed head injury. Forty-five adult Sprague-Dawley rats were separated into four groups: Group T, sham operated (four animals), Group II, hypoxia and hypotension (four animals), Group III, trauma only (23 animals), and Group IV, trauma coupled with hypoxia and hypotension (14 animals). After trauma was induced, a 30-minute insult of hypoxia (PaO2 40 mm Hg) and hypotension (mean arterial blood pressure sure 30 mm Hg) was imposed, after which the animals were resuscitated. In the trauma-induced animals, the SI increased dramatically immediately after impact. By 15 minutes permeability decreased exponentially and by 30 minutes it was equal to that of control animals. When trauma was coupled with secondary insult, the SI enhancement was lower after the trauma, consistent with reduced blood pressure and blood flow. However, the SI increased dramatically on reperfusion and was equal to that of control by 60 minutes after the combined insult. In conclusion, the authors suggest that closed head injury is associated with a rapid and transient BBB opening that begins at the time of the trauma and lasts no more than 30 minutes. It has also been shown that addition of posttraumatic secondary insult-hypoxia and hypotension-prolongs the time of BBB breakdown after closed head injury. The authors further conclude that MR imaging is an excellent technique to follow (time resolution 1-1.5 minutes) the evolution of trauma-induced BBB damage noninvasively from as early as a few minutes up to hours or even longer after the trauma occurs.	VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA, DIV NEUROSURG, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA, DEPT RADIOL, RICHMOND, VA 23298 USA					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019235, R56NS019235] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19235-11] Funding Source: Medline		AIRD RB, 1952, J NEUROSURG, V9, P331, DOI 10.3171/jns.1952.9.4.0331; Broman T., 1949, PERMEABILITY CEREBRO; BULLOCK R, 1990, ACT NEUR S, V51, P286; CASSEN B, 1960, AM J PHYSIOL, V198, P1296; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GILBERT JC, 1993, MAGN RESON IMAGING, V11, P1155, DOI 10.1016/0730-725X(93)90243-7; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; GROEGER U, 1989, ACTA NEUROCHIR, V101, P134, DOI 10.1007/BF01410529; HAYAKAWA K, 1990, ACTA RADIOL, V31, P203; HAYES CE, 1985, J MAGN RESON, V63, P622, DOI 10.1016/0022-2364(85)90257-4; ITO U, 1975, ACTA NEUROPATHOL, V34, P1; KITA H, 1994, ACTA NEUROCHIR, P452; Klatzo I, 1980, Adv Neurol, V28, P359; KUROIWA T, 1985, ACTA NEUROPATHOL, V68, P122, DOI 10.1007/BF00688633; LANENS D, 1993, MAGN RESON IMAGING, V11, P675, DOI 10.1016/0730-725X(93)90009-3; LANG DA, 1990, ACT NEUR S, V51, P293; LARSSON HBW, 1992, MAGNET RESON MED, V24, P174, DOI 10.1002/mrm.1910240119; LARSSON HBW, 1990, MAGNET RESON MED, V16, P117, DOI 10.1002/mrm.1910160111; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MARMAROU A, 1994, ACTA NEUROCHIR, P421; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miller GG, 1927, ARCH SURG-CHICAGO, V14, P891, DOI 10.1001/archsurg.1927.01130160100005; NAWASHIRO H, 1994, ACTA NEUROCHIR, P440; NORMAN AB, 1991, BRAIN RES BULL, V26, P593, DOI 10.1016/0361-9230(91)90100-X; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; RAMADAN NM, 1989, STROKE, V20, P1279, DOI 10.1161/01.STR.20.9.1279; REULEN HJ, 1977, J NEUROSURG, V46, P24, DOI 10.3171/jns.1977.46.1.0024; RHINE WD, 1993, J COMPUT ASSIST TOMO, V17, P563, DOI 10.1097/00004728-199307000-00008; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; RUNGE V M, 1985, Magnetic Resonance Imaging, V3, P43, DOI 10.1016/0730-725X(85)90008-6; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SU MY, 1994, MAGN RESON MED, V32, P714, DOI 10.1002/mrm.1910320606; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TODD NV, 1990, ACT NEUR S, V51, P296; TORNHEIM PA, 1985, BRAIN RES, V337, P81, DOI 10.1016/0006-8993(85)91611-7; VANDENBRINK WA, 1994, ACT NEUR S, V60, P456	44	160	165	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	1996	85	6					1113	1121		10.3171/jns.1996.85.6.1113			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	VU233	WOS:A1996VU23300019	8929504				2021-06-18	
J	Robertson, NJ; Faulkner, S; Fleiss, B; Bainbridge, A; Andorka, C; Price, D; Powell, E; Lecky-Thompson, L; Thei, L; Chandrasekaran, M; Hristova, M; Cady, EB; Gressens, P; Golay, X; Raivich, G				Robertson, Nicola J.; Faulkner, Stuart; Fleiss, Bobbi; Bainbridge, Alan; Andorka, Csilla; Price, David; Powell, Elizabeth; Lecky-Thompson, Lucy; Thei, Laura; Chandrasekaran, Manigandan; Hristova, Mariya; Cady, Ernest B.; Gressens, Pierre; Golay, Xavier; Raivich, Gennadij			Melatonin augments hypothermic neuroprotection in a perinatal asphyxia model	BRAIN			English	Article						hypoxia-ischaemia; therapeutic hypothermia; neuroprotection; melatonin; neonatal encephalopathy	FOCAL CEREBRAL-ISCHEMIA; MILD SYSTEMIC HYPOTHERMIA; TRAUMATIC BRAIN-INJURY; ACUTE HYPOXIA-ISCHEMIA; WHITE-MATTER; NEONATAL ENCEPHALOPATHY; GENE-EXPRESSION; ENERGY FAILURE; MODERATE HYPOTHERMIA; OXIDATIVE STRESS	Despite treatment with therapeutic hypothermia, almost 50% of infants with neonatal encephalopathy still have adverse outcomes. Additional treatments are required to maximize neuroprotection. Melatonin is a naturally occurring hormone involved in physiological processes that also has neuroprotective actions against hypoxic-ischaemic brain injury in animal models. The objective of this study was to assess neuroprotective effects of combining melatonin with therapeutic hypothermia after transient hypoxia-ischaemia in a piglet model of perinatal asphyxia using clinically relevant magnetic resonance spectroscopy biomarkers supported by immunohistochemistry. After a quantified global hypoxic-ischaemic insult, 17 newborn piglets were randomized to the following: (i) therapeutic hypothermia (33.5 degrees C from 2 to 26 h after resuscitation, n = 8) and (ii) therapeutic hypothermia plus intravenous melatonin (5 mg/kg/h over 6 h started at 10 min after resuscitation and repeated at 24 h, n = 9). Cortical white matter and deep grey matter voxel proton and whole brain P-31 magnetic resonance spectroscopy were acquired before and during hypoxia-ischaemia, at 24 and 48 h after resuscitation. There was no difference in baseline variables, insult severity or any physiological or biochemical measure, including mean arterial blood pressure and inotrope use during the 48 h after hypoxia-ischaemia. Plasma levels of melatonin were 10 000 times higher in the hypothermia plus melatonin than hypothermia alone group. Melatonin-augmented hypothermia significantly reduced the hypoxic-ischaemic-induced increase in the area under the curve for proton magnetic resonance spectroscopy lactate/N-acetyl aspartate and lactate/total creatine ratios in the deep grey matter. Melatonin-augmented hypothermia increased levels of whole brain P-31 magnetic resonance spectroscopy nucleotide triphosphate/exchangeable phosphate pool. Correlating with improved cerebral energy metabolism, TUNEL-positive nuclei were reduced in the hypothermia plus melatonin group compared with hypothermia alone in the thalamus, internal capsule, putamen and caudate, and there was reduced cleaved caspase 3 in the thalamus. Although total numbers of microglia were not decreased in grey or white matter, expression of the prototypical cytotoxic microglial activation marker CD86 was decreased in the cortex at 48 h after hypoxia-ischaemia. The safety and improved neuroprotection with a combination of melatonin with cooling support phase II clinical trials in infants with moderate and severe neonatal encephalopathy.	[Robertson, Nicola J.; Faulkner, Stuart; Andorka, Csilla; Powell, Elizabeth; Lecky-Thompson, Lucy; Thei, Laura; Chandrasekaran, Manigandan; Hristova, Mariya; Raivich, Gennadij] UCL, Inst Womens Hlth, London WC1E 6AU, England; [Fleiss, Bobbi; Gressens, Pierre] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Ctr Dev Brain, Inst Reprod & Dev Biol, London W12 ONN, England; [Fleiss, Bobbi; Gressens, Pierre] Hop Robert Debre, INSERM, U676, F-75019 Paris, France; [Fleiss, Bobbi; Gressens, Pierre] Univ Paris Diderot, Fac Med, F-75205 Paris, France; [Bainbridge, Alan; Price, David; Cady, Ernest B.] Univ Coll London Hosp NHS Fdn Trust, Dept Med Phys & Bioengn, London WC1E 6DB, England; [Golay, Xavier] UCL Inst Neurol, London WC1N 3BG, England	Robertson, NJ (corresponding author), UCL, Inst Womens Hlth, 74 Huntley St, London WC1E 6AU, England.	n.robertson@ucl.ac.uk	gressens, pierre/M-7557-2017; Golay, Xavier/AAJ-8094-2021; Fleiss, Bobbi/F-9899-2011	gressens, pierre/0000-0002-0909-4221; Golay, Xavier/0000-0002-6447-4446; Fleiss, Bobbi/0000-0001-7828-673X; Chandrasekaran, Manigandan/0000-0002-9403-6906; Thei, Laura/0000-0002-9472-731X	Wellbeing of Women, UKWellbeing of Women (WoW); UK Department of Health's National Institute for Health Research Biomedical Research Centre; Wellbeing of WomenWellbeing of Women (WoW) [RG1666] Funding Source: researchfish	The study was funded by Wellbeing of Women, UK. This work was undertaken at University College Hospital/University College London, which received a proportion of funding from the UK Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme.	Acuna-Castroviejo D, 2001, J PINEAL RES, V30, P65, DOI 10.1034/j.1600-079X.2001.300201.x; ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; Altun A, 2007, INT J CLIN PRACT, V61, P835, DOI 10.1111/j.1742-1241.2006.01191.x; Andrabi SA, 2004, FASEB J, V18, P869, DOI 10.1096/fj.03-1031fje; AZZOPARDI D, 1989, PEDIATR RES, V25, P445, DOI 10.1203/00006450-198905000-00004; Azzopardi D, NEUROPROTECTIVE EFFE; Azzopardi D, 2010, EARLY HUM DEV, V86, P345, DOI 10.1016/j.earlhumdev.2010.05.008; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Battin MR, 2009, PEDIATRICS, V123, P1031, DOI 10.1542/peds.2008-1610; BENITEZKING G, 1993, EXPERIENTIA, V49, P635; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bona E, 1998, PEDIATR RES, V43, P738, DOI 10.1203/00006450-199806000-00005; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; Bubenik GA, 2011, J PHYSIOL PHARMACOL, V62, P13; Cheong JLY, 2006, AM J NEURORADIOL, V27, P1546; Cheung RTF, 2006, J PINEAL RES, V41, P337, DOI 10.1111/j.1600-079X.2006.00372.x; Cinar Mehmet Ulas, 2012, BMC Res Notes, V5, P107, DOI 10.1186/1756-0500-5-107; CLAUSTRAT B, 1984, BIOL PSYCHIAT, V19, P1215; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; de Vries LS, 2005, ARCH DIS CHILD-FETAL, V90, P201, DOI 10.1136/adc.2004.062745; Edwards AD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c363; Faulkner S, 2011, ANN NEUROL, V70, P133, DOI 10.1002/ana.22387; Favrais G, 2007, NEUROBIOL DIS, V25, P496, DOI 10.1016/j.nbd.2006.10.012; Fulia F, 2001, J PINEAL RES, V31, P343, DOI 10.1034/j.1600-079X.2001.310409.x; Gitto E, 2001, PEDIATR RES, V50, P756, DOI 10.1203/00006450-200112000-00021; Gitto E, 2004, J PEDIATR SURG, V39, P184, DOI 10.1016/j.jpedsurg.2003.10.003; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gressens P, 2008, EUR J PHARMACOL, V588, P58, DOI 10.1016/j.ejphar.2008.04.016; Hughes JE, 2008, CIRC RES, V102, P950, DOI 10.1161/CIRCRESAHA.107.170779; Husson I, 2002, ANN NEUROL, V51, P82, DOI 10.1002/ana.10072; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Jahnke G, 1999, TOXICOL SCI, V50, P271, DOI 10.1093/toxsci/50.2.271; Jatana M, 2006, PEDIATR RES, V59, P684, DOI 10.1203/01.pdr.0000215045.91122.44; Joo JY, 1998, RESTOR NEUROL NEUROS, V13, P185; Kendall GS, 2010, ARCH DIS CHILD-FETAL, V95, pF408, DOI 10.1136/adc.2010.187211; Kerenyi A, 2012, PEDIATR RES, V71, P573, DOI 10.1038/pr.2012.8; Kilic U, 2005, J PINEAL RES, V38, P67, DOI 10.1111/j.1600-079X.2004.00178.x; Koh PO, 2008, J VET MED SCI, V70, P747, DOI 10.1292/jvms.70.747; Kristian T, 2004, CELL CALCIUM, V36, P221, DOI 10.1016/j.ceca.2004.02.016; Lee EJ, 2005, J PINEAL RES, V38, P42, DOI 10.1111/j.1600-079X.2004.00173.x; Lee EJ, 2004, J PINEAL RES, V36, P33, DOI 10.1046/j.1600-079X.2003.00093.x; Lee MY, 2007, J PINEAL RES, V42, P297, DOI 10.1111/j.1600-079X.2007.00420.x; Leon J, 2004, LIFE SCI, V75, P765, DOI 10.1016/j.lfs.2004.03.003; LEWY AJ, 1980, SCIENCE, V210, P1267, DOI 10.1126/science.7434030; Ling X, 1999, ACTA PHARMACOL SIN, V20, P409; Liu YQ, 2004, STROKE, V35, P1460, DOI 10.1161/01.STR.0000128029.50221.fa; LOREK A, 1994, PEDIATR RES, V36, P699, DOI 10.1203/00006450-199412000-00003; Luchetti F, 2010, FASEB J, V24, P3603, DOI 10.1096/fj.10-154450; LYNCH HJ, 1975, SCIENCE, V187, P169, DOI 10.1126/science.1167425; Manev H, 1996, FASEB J, V10, P1546; Miller SL, 2005, DEV NEUROSCI-BASEL, V27, P200, DOI 10.1159/000085993; Milne G, 2007, METHOD ENZYMOL, V72, P1419; Mistraletti G, 2010, J PINEAL RES, V48, P142, DOI 10.1111/j.1600-079X.2009.00737.x; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; National Institute for Clinical Excellence, THER HYP INTR TEMP M; O'Brien FE, 2006, PEDIATRICS, V117, P1549, DOI 10.1542/peds.2005-1649; Pei Z, 2002, J PINEAL RES, V32, P168, DOI 10.1034/j.1600-079x.2002.1o847.x; Pei Z, 2003, STROKE, V34, P770, DOI 10.1161/01.STR.0000057460.14810.3E; Penrice J, 1997, PEDIATR RES, V41, P443, DOI 10.1203/00006450-199703000-00024; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Qin H, 2007, J IMMUNOL, V179, P5966, DOI 10.4049/jimmunol.179.9.5966; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Reiter RJ, 2003, ACTA BIOCHIM POL, V50, P1129; Reiter RJ, 2004, ANN NY ACAD SCI, V1035, P179, DOI 10.1196/annals.1332.012; Reiter RJ, 2010, PROG BRAIN RES, V181, P127, DOI 10.1016/S0079-6123(08)81008-4; Robertson NJ, 1999, PEDIATR RES, V46, P287, DOI 10.1203/00006450-199909000-00007; RYBAKOWSKI C, 1995, EUR J OBSTET GYN R B, V62, P107, DOI 10.1016/0301-2115(95)02117-P; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Thayyil S, 2010, PEDIATRICS, V125, pE382, DOI 10.1542/peds.2009-1046; THORESEN M, 1995, PEDIATR RES, V37, P667, DOI 10.1203/00006450-199505000-00019; Thoresen M, 2010, PEDIATRICS, V126, pE131, DOI 10.1542/peds.2009-2938; Toet MC, 1999, ARCH DIS CHILD-FETAL, V81, pF19, DOI 10.1136/fn.81.1.F19; Tsai MC, 2011, J PINEAL RES, V51, P233, DOI 10.1111/j.1600-079X.2011.00885.x; van den Broek MPH, 2010, CLIN PHARMACOKINET, V49, P277, DOI 10.2165/11319360-000000000-00000; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244; Villapol S, 2011, PEDIATR RES, V69, P51, DOI 10.1203/PDR.0b013e3181fcb40b; Wang X, 2009, CNS NEUROSCI THER, V15, P345, DOI 10.1111/j.1755-5949.2009.00105.x; Weishaupt JH, 2006, J PINEAL RES, V41, P313, DOI 10.1111/j.1600-079X.2006.00377.x; Welin AK, 2007, PEDIATR RES, V61, P153, DOI 10.1203/01.pdr.0000252546.20451.1a; Werner A, 2001, CELL TISSUE RES, V305, P25, DOI 10.1007/s004410100393; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174	84	159	162	1	26	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JAN	2013	136		1				90	105		10.1093/brain/aws285			16	Clinical Neurology; Neurosciences	Neurosciences & Neurology	089KR	WOS:000314909900009	23183236	Bronze			2021-06-18	
J	Grossman, EJ; Ge, YL; Jensen, JH; Babb, JS; Miles, L; Reaume, J; Silver, JM; Grossman, RI; Inglese, M				Grossman, Elan J.; Ge, Yulin; Jensen, Jens H.; Babb, James S.; Miles, Laura; Reaume, Joseph; Silver, Jonathan M.; Grossman, Robert I.; Inglese, Matilde			Thalamus and Cognitive Impairment in Mild Traumatic Brain Injury: A Diffusional Kurtosis Imaging Study	JOURNAL OF NEUROTRAUMA			English	Article						cognitive impairment; diffusion tensor imaging; mild traumatic brain injury; thalamus; white matter	GAUSSIAN WATER DIFFUSION; AXONAL INJURY; HEAD-INJURY; PERFORMANCE; MEMORY; NEUROPSYCHOLOGY; DYSFUNCTION; CONSTRUCT; PERFUSION; RECOVERY	Conventional imaging is unable to detect damage that accounts for permanent cognitive impairment in patients with mild traumatic brain injury (mTBI). While diffusion tensor imaging (DTI) can help to detect diffuse axonal injury (DAI), it is a limited indicator of tissue complexity. It has also been suggested that the thalamus may play an important role in the development of clinical sequelae in mTBI. The purpose of this study was to determine if diffusional kurtosis imaging (DKI), a novel quantitative magnetic resonance imaging (MRI) technique, can provide early detection of damage in the thalamus and white matter (WM) of mTBI patients, and can help ascertain if thalamic injury is associated with cognitive impairment. Twenty-two mTBI patients and 14 controls underwent MRI and neuropsychological testing. Mean kurtosis (MK), fractional anisotropy (FA), and mean diffusivity (MD) were measured in the thalamus and several WM regions classically identified with DAI. Compared to controls, patients examined within 1 year after injury exhibited variously altered DTI- and DKI-derived measures in the thalamus and the internal capsule, while in addition to these regions, patients examined more than 1 year after injury also showed similar differences in the splenium of the corpus callosum and the centrum semiovale. Cognitive impairment was correlated with MK in the thalamus and the internal capsule. These findings suggest that combined use of DTI and DKI provides a more sensitive tool for identifying brain injury. In addition, MK in the thalamus might be useful for early prediction of permanent brain damage and cognitive outcome.	[Inglese, Matilde] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; [Grossman, Elan J.; Ge, Yulin; Jensen, Jens H.; Babb, James S.; Miles, Laura; Reaume, Joseph; Grossman, Robert I.] NYU, Sch Med, Ctr Biomed Imaging, Dept Radiol, New York, NY USA; [Grossman, Elan J.; Jensen, Jens H.] NYU, Sch Med, Dept Physiol & Neurosci, New York, NY USA; [Miles, Laura] NYU, Sch Med, Rusk Inst Rehabil Med, New York, NY USA; [Silver, Jonathan M.] NYU, Sch Med, Dept Psychiat, New York, NY USA	Inglese, M (corresponding author), Mt Sinai Sch Med, Dept Neurol, 1428 Madison Ave,2nd Floor,Room B215, New York, NY 10029 USA.	matilde.inglese@mssm.edu	Ge, Yulin/L-7052-2019; Ge, Yulin/D-9060-2019; Inglese, Matilde/AAH-3189-2020; Ritter, Stefanie L/D-9312-2012; Jensen, Jens H/A-8334-2009	Ge, Yulin/0000-0002-2320-6031; Inglese, Matilde/0000-0002-9610-0297; Jensen, Jens H/0000-0003-3219-4287; Babb, James/0000-0003-1798-1186	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS039135, R01NS051623]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039135, R01NS051623] Funding Source: NIH RePORTER	The authors would like to thank Drs. Stewart Bloomfield, Qun Chen, Henry Rusinek, and Edward Ziff of the New York University School of Medicine for advice on this study, and Dr. Hanzhang Lu of the University of Texas Southwestern Medical Center for developing the MATLAB scripts used to process the DKI data. This work was supported by the National Institutes of Health grant numbers R01NS039135 and R01NS051623.	Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Arboix A, 2000, CEREBROVASC DIS, V10, P229, DOI 10.1159/000016061; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; Bates D.M., 1988, NONLINEAR REGRESSION; Bigler Erin D., 2012, BRAIN IMAGING BEHAV; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Erlanger DM, 2002, J HEAD TRAUMA REHAB, V17, P458, DOI 10.1097/00001199-200210000-00007; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Feig SL, 2000, EUR J NEUROSCI, V12, P2195, DOI 10.1046/j.1460-9568.2000.00093.x; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Guillery RW, 2009, EXPLORING THALAMUS I; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Helpern JA, 2011, J MAGN RESON IMAGING, V33, P17, DOI 10.1002/jmri.22397; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jensen JH, 2011, NMR BIOMED, V24, P452, DOI 10.1002/nbm.1610; Jensen JH, 2010, NMR BIOMED, V23, P698, DOI 10.1002/nbm.1518; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Kan EM, 2012, BRAIN RES BULL, V87, P359, DOI 10.1016/j.brainresbull.2012.01.007; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lu H, 2006, P INT SOC MAGN RESON, V14, P723; Lu HZ, 2006, NMR BIOMED, V19, P236, DOI 10.1002/nbm.1020; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McHugh T, 2006, BRAIN COGNITION, V60, P209; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Pare N, 2009, NEUROPSYCHOL REHABIL, V19, P110, DOI 10.1080/09602010802106486; Raab P, 2010, RADIOLOGY, V254, P876, DOI 10.1148/radiol.09090819; Ramani A., 2007, P INT SOC MAG RESON, P648; RAO SM, 1995, CURR OPIN NEUROL, V8, P216, DOI 10.1097/00019052-199506000-00010; Rath JF, 2004, ARCH CLIN NEUROPSYCH, V19, P613, DOI 10.1016/j.acn.2003.08.006; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Ruff RM, 1997, BRAIN LANG, V57, P394, DOI 10.1006/brln.1997.1755; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Skare S, 2000, J MAGN RESON, V147, P340, DOI 10.1006/jmre.2000.2209; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; TATEMICHI TK, 1992, NEUROLOGY, V42, P1966, DOI 10.1212/WNL.42.10.1966; Tay SY, 2010, J NEUROTRAUM, V27, P77, DOI 10.1089/neu.2009.1074; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Tsirka V, 2010, INT J NEUROSCI, V120, P184, DOI 10.3109/00207450903585308; Van der Werf YD, 2000, NEUROPSYCHOLOGIA, V38, P613, DOI 10.1016/S0028-3932(99)00104-9; Van der Werf YD, 2001, COGNITIVE BRAIN RES, V11, P377, DOI 10.1016/S0926-6410(01)00010-6; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; WOOD DMG, 1995, BRAIN RES BULL, V38, P545, DOI 10.1016/0361-9230(95)02026-0; Wu EX, 2010, NMR BIOMED, V23, P836, DOI 10.1002/nbm.1506; Xing GQ, 2012, NEUROSCI LETT, V525, P140, DOI 10.1016/j.neulet.2012.07.055; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	60	159	167	1	38	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2012	29	13					2318	+		10.1089/neu.2011.1763			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	000PU	WOS:000308399900007	21639753	Green Published			2021-06-18	
J	Walker, CL; Walker, MJ; Liu, NK; Risberg, EC; Gao, X; Chen, JH; Xu, XM				Walker, Chandler L.; Walker, Melissa J.; Liu, Nai-Kui; Risberg, Emelie C.; Gao, Xiang; Chen, Jinhui; Xu, Xiao-Ming			Systemic Bisperoxovanadium Activates Akt/mTOR, Reduces Autophagy, and Enhances Recovery following Cervical Spinal Cord Injury	PLOS ONE			English	Article							PROTEIN-KINASE-B; TYROSINE-PHOSPHATASE INHIBITION; CONTUSION INJURY; UP-REGULATION; CELL-DEATH; PTEN; SURVIVAL; AKT; EXPRESSION; BRAIN	Secondary damage following primary spinal cord injury extends pathology beyond the site of initial trauma, and effective management is imperative for maximizing anatomical and functional recovery. Bisperoxovanadium compounds have proven neuroprotective effects in several central nervous system injury/disease models, however, no mechanism has been linked to such neuroprotection from bisperoxovanadium treatment following spinal trauma. The goal of this study was to assess acute bisperoxovanadium treatment effects on neuroprotection and functional recovery following cervical unilateral contusive spinal cord injury, and investigate a potential mechanism of the compound's action. Two experimental groups of rats were established to 1) assess twice-daily 7 day treatment of the compound, potassium bisperoxo (picolinato) vanadium, on long-term recovery of skilled forelimb activity using a novel food manipulation test, and neuroprotection 6 weeks following injury and 2) elucidate an acute mechanistic link for the action of the drug post-injury. Immunofluorescence and Western blotting were performed to assess cellular signaling 1 day following SCI, and histochemistry and forelimb functional analysis were utilized to assess neuroprotection and recovery 6 weeks after injury. Bisperoxovanadium promoted significant neuroprotection through reduced motorneuron death, increased tissue sparing, and minimized cavity formation in rats. Enhanced forelimb functional ability during a treat-eating assessment was also observed. Additionally, bisperoxovanadium significantly enhanced downstream Akt and mammalian target of rapamycin signaling and reduced autophagic activity, suggesting inhibition of the phosphatase and tensin homologue deleted on chromosome ten as a potential mechanism of bisperoxovanadium action following traumatic spinal cord injury. Overall, this study demonstrates the efficacy of a clinically applicable pharmacological therapy for rapid initiation of neuroprotection post-spinal cord injury, and sheds light on the signaling involved in its action.	[Walker, Chandler L.; Xu, Xiao-Ming] Indiana Univ Sch Med, Dept Anat & Cell Biol, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Walker, Melissa J.; Xu, Xiao-Ming] Indiana Univ Sch Med, Med Neurosci Grad Program, Stark Neurosci Res Inst, Indianapolis, IN USA; [Walker, Chandler L.; Walker, Melissa J.; Liu, Nai-Kui; Risberg, Emelie C.; Gao, Xiang; Chen, Jinhui; Xu, Xiao-Ming] Indiana Univ Sch Med, Spinal Cord & Brain Injury Res Grp, Stark Neurosci Res Inst, Indianapolis, IN USA	Walker, CL (corresponding author), Indiana Univ Sch Med, Dept Anat & Cell Biol, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA.	xu26@iupui.edu	Walker, Chandler L./D-2256-2014	Walker, Chandler L./0000-0002-8616-8263; Xu, Xiao-ming/0000-0002-7229-0081	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS36350, NS52290, NS50243]; Mari Hulman George Endowment Fund; State of Indiana; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052290, R01NS050243, R01NS036350] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (NS36350, NS52290, and NS50243 to X-M.X.]; Mari Hulman George Endowment Fund; and the State of Indiana. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KD, 2004, J NEUROTRAUM, V21, P1371, DOI 10.1089/neu.2004.21.1371; Cai QY, 2009, ANAT REC, V292, P498, DOI 10.1002/ar.20834; Casella GTB, 2006, EXP NEUROL, V202, P8, DOI 10.1016/j.expneurol.2006.05.028; Cheng HC, 2011, J NEUROSCI, V31, P2125, DOI 10.1523/JNEUROSCI.5519-10.2011; Cho JY, 2002, NEUROSCI LETT, V334, P131, DOI 10.1016/S0304-3940(02)01122-9; Codeluppi S, 2009, J NEUROSCI, V29, P1093, DOI 10.1523/JNEUROSCI.4103-08.2009; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dummler BA, 2005, J BIOL CHEM, V280, P13304, DOI 10.1074/jbc.M408194200; Gensel JC, 2006, J NEUROTRAUM, V23, P36, DOI 10.1089/neu.2006.23.36; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Han S, 2010, BRAIN, V133, P1026, DOI 10.1093/brain/awq034; Harrington EP, 2010, ANN NEUROL, V68, P703, DOI 10.1002/ana.22090; Irvine K.-A., 2010, JOVE-J VIS EXP, DOI [10.3791/2246, DOI 10.3791/2246]; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanno H, 2011, SPINE, V36, pE1427, DOI 10.1097/BRS.0b013e3182028c3a; Kanno H, 2009, NEUROBIOL DIS, V33, P143, DOI 10.1016/j.nbd.2008.09.009; Lehman JA, 2002, BIOCHEM BIOPH RES CO, V293, P463, DOI 10.1016/S0006-291X(02)00238-3; Liu C, 2010, J NEUROCHEM, V112, P1500, DOI 10.1111/j.1471-4159.2009.06561.x; Liu K, 2010, NAT NEUROSCI, V13, P1075, DOI 10.1038/nn.2603; Liu LZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019139; Liu NK, 2006, ANN NEUROL, V59, P606, DOI 10.1002/ana.20798; Lu K, 2010, J NEUROCHEM, V114, P237, DOI 10.1111/j.1471-4159.2010.06747.x; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Martinez M, 2009, J NEUROTRAUM, V26, P1043, DOI 10.1089/neu.2008.0717; Nakashima S, 2008, J NEUROSCI, V28, P7293, DOI 10.1523/JNEUROSCI.1826-08.2008; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Ning K, 2010, HUM MOL GENET, V19, P3159, DOI 10.1093/hmg/ddq226; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Park JH, 2011, ONCOGENE, V30, P4578, DOI 10.1038/onc.2011.174; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Rami A, 2008, AUTOPHAGY, V4, P422, DOI 10.4161/auto.5778; Schmid AC, 2004, FEBS LETT, V566, P35, DOI 10.1016/j.febslet.2004.03.102; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Shi GD, 2011, BIOCHEM BIOPH RES CO, V404, P941, DOI 10.1016/j.bbrc.2010.12.085; Song WY, 2010, J NEUROSCI, V30, P15608, DOI 10.1523/JNEUROSCI.2581-10.2010; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sury MD, 2011, NEUROBIOL DIS, V41, P201, DOI 10.1016/j.nbd.2010.09.007; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Xu JT, 2010, BRAIN RES, V1336, P46, DOI 10.1016/j.brainres.2010.04.010; Yan P, 2003, EXP NEUROL, V183, P286, DOI 10.1016/S0014-4886(03)00135-3; Yan P, 1999, J NEUROSCI, V19, P9355; Yang P, 2007, EUR J NEUROSCI, V25, P1332, DOI 10.1111/j.1460-9568.2007.05384.x; Yu FS, 2005, NEUROBIOL DIS, V20, P491, DOI 10.1016/j.nbd.2005.04.004; Zhang QG, 2007, FEBS LETT, V581, P495, DOI 10.1016/j.febslet.2006.12.055; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	55	159	172	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2012	7	1					315	326	e30012	10.1371/journal.pone.0030012			12	Multidisciplinary Sciences	Science & Technology - Other Topics	906OA	WOS:000301353900033	22253859	DOAJ Gold, Green Published			2021-06-18	
J	Godefroy, O; Azouvi, P; Robert, P; Roussel, M; LeGall, D; Meulemans, T				Godefroy, Olivier; Azouvi, Philippe; Robert, Philippe; Roussel, Martine; LeGall, Didier; Meulemans, Thierry		Grp Reflexion Evaluation Fonctions	Dysexecutive Syndrome: Diagnostic Criteria and Validation Study	ANNALS OF NEUROLOGY			English	Article							MILD COGNITIVE IMPAIRMENT; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; DEMENTIA; STROKE; PERFORMANCE; MECHANISMS; GUIDELINES; DECISION; DEFICIT	Objective: Disorders of executive functions are among the most frequent cognitive deficits, but they remain poorly defined and are subject to heterogeneous assessment. To address this major issue, the Groupe de Reflexion sur l'Evaluation des Fonctions Executives (GREFEX) group has proposed criteria for behavioral and cognitive dysexecutive syndromes and has designed a battery including a specific heteroquestionnaire and 7 cognitive tests. We investigated the frequency of behavioral and cognitive dysexecutive disorders in patients suffering from various diseases and the association or these disorders with loss of autonomy. Methods: A total of 461 patients aged between 16 and 90 years with severe traumatic brain injury, stroke, mild cognitive impairment, Alzheimer disease, multiple sclerosis, and Parkinson disease were recruited into this prospective cohort study by 21 centers between September 2003 and June 2006. Behavioral and cognitive dysexecutive disorders were examined using the GREFEX battery. Results: A dysexecutive syndrome was observed in 60% of patients, concerning both behavioral and cognitive domains in 26% and dissociated in 34%. All behavioral and cognitive dysexecutive disorders discriminated (p = 0.001, all) patients from controls. The pattern of cognitive syndrome differed (p = 0.0001) according to the disease. Finally, behavioral (odds ratio [OR] 4.6; 95% confidence interval [CI], 2. 3-9.1; p = 0.0001) and cognitive (OR, 3.36; 95% CI, 1.7-6.6; p = 0.001) dysexecutive syndromes and Mini Mental State Examination score (OR, 0.79; 95% CI, 0.68-0.91; p = 0.002) were independent predictors of loss of autonomy. Interpretation: This study provided criteria of dysexecutive syndrome and showed that both behavioral and cognitive syndromes contribute to loss of autonomy. Profiles vary across patients and diseases, and therefore systematic assessment of behavioral and cognitive disorders in reference to diagnostic criteria is needed. ANN NEUROL 2010;68:855-864	[Godefroy, Olivier; Roussel, Martine] Univ Hosp Amiens, Dept Neurol, Lab Funct Neurosci, Amiens, France; [Azouvi, Philippe] Univ Hosp Garches, Dept Rehabil, Garches, France; [Robert, Philippe] Univ Hosp Nice, Acad Memory Clin, Nice, France; [LeGall, Didier] Univ Angers, Dept Neurol, Angers, France; [LeGall, Didier] Univ Angers, Dept Psychol, Angers, France; [Meulemans, Thierry] Univ Liege, Dept Psychol, Liege, Belgium	Godefroy, O (corresponding author), CHU Nord, Serv Neurol, F-80054 Amiens, France.	godefroy.olivier@chu-amiens.fr	Godefroy, Olivier/D-6117-2012; LICEND, CEMND/F-1296-2015; LEYS, Didier/G-2955-2016	LEYS, Didier/0000-0003-4408-4392; Verny, Marc/0000-0001-7960-9705; Godefroy, Olivier/0000-0001-6789-6620	Centre National pour la Recherche Scientifique	The project was funded by the Centre National pour la Recherche Scientifique.	ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Azouvi P, 2001, REV NEUROPSYCHOL, V11, P383; BADDELEY A, 1986, Q J EXP PSYCHOL-A, V38, P603, DOI 10.1080/14640748608401616; BADDELEY A, 1988, BRAIN COGNITION, V7, P212, DOI 10.1016/0278-2626(88)90031-0; Bailon O, 2010, DEMENT GERIATR COGN, V29, P388, DOI 10.1159/000305095; BARBERGERGATEAU P, 1992, J AM GERIATR SOC, V40, P1129, DOI 10.1111/j.1532-5415.1992.tb01802.x; Bechara A, 1998, J NEUROSCI, V18, P428; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Burgess PW, 1996, CORTEX, V32, P241, DOI 10.1016/S0010-9452(96)80049-9; CARDEBAT D, 1990, ACTA NEUROL BELG, V90, P207; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Godefroy et Groupe de Reflexion pour l'evaluation des Fonctions EXecutives, 2008, FONCT EX PATH NEUR P; Godefroy O, 1999, CORTEX, V35, P1, DOI 10.1016/S0010-9452(08)70782-2; Godefroy O, 2004, REV NEUROL-FRANCE, V160, P899; Godefroy O, 2003, J NEUROL, V250, P1, DOI 10.1007/s00415-003-0918-2; Godefroy O, 2002, NEUROPSYCHOLOGIA, V40, P2234, DOI 10.1016/S0028-3932(02)00109-4; Godefroy O, 2009, EUR NEUROL, V61, P223, DOI 10.1159/000197107; Godefroy O, 1998, BRAIN, V121, P1545, DOI 10.1093/brain/121.8.1545; Godefroy O, 2007, BEHAVIORAL AND COGNITIVE NEUROLOGY OF STROKE, P369, DOI 10.1017/CBO9780511544880.020; Godefroy O, 2010, CEREBROVASC DIS, V29, P508, DOI 10.1159/000297968; Godefroy O, 2010, EXP AGING RES, V36, P169, DOI 10.1080/03610731003613615; HUGHES AJ, 1993, ARCH NEUROL-CHICAGO, V50, P140, DOI 10.1001/archneur.1993.00540020018011; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; Luria A. R., 1966, HIGHER CORTICAL FUNC; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Perin B, 2010, BRAIN COGNITION, V72, P271, DOI 10.1016/j.bandc.2009.09.010; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Stoquart-ElSankari S, 2010, CLIN NEUROL NEUROSUR, V112, P226, DOI 10.1016/j.clineuro.2009.11.017; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2007, PHILOS T R SOC B, V362, P901, DOI 10.1098/rstb.2007.2096; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Vataja R, 2003, EUR J NEUROL, V10, P625, DOI 10.1046/j.1468-1331.2003.00676.x; Weschler D., 1955, WESCHLER ADULT INTEL; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583	43	159	161	0	36	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	DEC	2010	68	6					855	864		10.1002/ana.22117			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	703DE	WOS:000285953500013	21194155				2021-06-18	
J	Ramdani, S; Seigle, B; Lagarde, J; Bouchara, F; Bernard, PL				Ramdani, Sofiane; Seigle, Benoit; Lagarde, Julien; Bouchara, Frederic; Bernard, Pierre Louis			On the use of sample entropy to analyze human postural sway data	MEDICAL ENGINEERING & PHYSICS			English	Article						Human posture; Center of pressure velocity; Sample entropy; Time series analysis; Surrogate data tests	OF-PRESSURE TRAJECTORIES; APPROXIMATE ENTROPY; CEREBRAL CONCUSSION; HEALTHY-YOUNG; TIME-SERIES; OPEN-LOOP; COMPLEXITY; NONLINEARITY; DIMENSION; SYSTEM	We analyze the irregularity of human postural sway data during quiet standing using the sample entropy (SampEn) algorithm. By considering recent methodological developments. we show that the SampEn parameter is able to characterize the irregularity of the center of pressure fluctuations through the analysis of the velocity variable We present a practical method to select the input parameters of the SampEn algorithm We show that the Computed SampEn successfully discriminates two sensory conditions (eyes-open and eyes-closed) in a group of healthy young adults We also perform surrogate data tests to investigate the nature of the underlying dynamics of our experimental data Finally, the results of the proposed approach are compared to those obtained with the multiscale entropy algorithm. (C) 2009 IPEM. Published by Elsevier Ltd. All rights reserved	[Ramdani, Sofiane; Seigle, Benoit; Lagarde, Julien; Bernard, Pierre Louis] Univ Montpellier I, EA Efficience & Deficience Motrices 2991, Montpellier, France; [Bouchara, Frederic] Univ Sud Toulon Var, CNRS, UMR 6168, LSIS, La Garde, France	Ramdani, S (corresponding author), Univ Montpellier I, EA Efficience & Deficience Motrices 2991, 700 Av Pic St Loup, Montpellier, France.						Al-Angari HM, 2007, IEEE T BIO-MED ENG, V54, P1900, DOI 10.1109/TBME.2006.889772; Beran J., 1994, STAT LONG MEMORY PRO; Blaszczyk JW, 2001, ACTA NEUROBIOL EXP, V61, P105; CARROLL JP, 1993, J BIOMECH, V26, P409, DOI 10.1016/0021-9290(93)90004-X; Cavanaugh JT, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-42; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen WT, 2009, MED ENG PHYS, V31, P61, DOI 10.1016/j.medengphy.2008.04.005; Chen X, 2005, P ANN INT IEEE EMBS, P4212; COLLINS JJ, 1995, EXP BRAIN RES, V104, P480, DOI 10.1007/BF00231982; COLLINS JJ, 1993, EXP BRAIN RES, V95, P308, DOI 10.1007/BF00229788; COLLINS JJ, 1995, EXP BRAIN RES, V103, P151, DOI 10.1007/BF00241972; COLLINS JJ, 1994, PHYS REV LETT, V73, P764, DOI 10.1103/PhysRevLett.73.764; Costa M, 2007, EPL-EUROPHYS LETT, V77, DOI 10.1209/0295-5075/77/68008; Costa M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.068102; Delignieres D, 2006, J MATH PSYCHOL, V50, P525, DOI 10.1016/j.jmp.2006.07.004; Donker SF, 2008, EXP BRAIN RES, V184, P363, DOI 10.1007/s00221-007-1105-y; Donker SF, 2007, EXP BRAIN RES, V181, P1, DOI 10.1007/s00221-007-0905-4; Doyle Tim L A, 2004, Int J Med Sci, V1, P11; Doyle TL, 2005, ARCH PHYS MED REHAB, V86, P2034, DOI 10.1016/j.apmr.2005.05.014; Duarte M, 2001, PHYS LETT A, V283, P124, DOI 10.1016/S0375-9601(01)00188-8; ECKMANN JP, 1985, REV MOD PHYS, V57, P617, DOI 10.1103/RevModPhys.57.617; Ehlers CL, 1998, J NEUROSCI, V18, P7474; EKE A, 2000, PFLUGERS ARCH, V50, P403; FLIGNER MA, 1981, J AM STAT ASSOC, V76, P162, DOI 10.2307/2287062; Goldberger AL, 2000, CIRCULATION, V101, pE215, DOI 10.1161/01.CIR.101.23.e215; Govindan RB, 2007, PHYSICA A, V376, P158, DOI 10.1016/j.physa.2006.10.077; GRASSBERGER P, 1983, PHYS REV A, V28, P2591, DOI 10.1103/PhysRevA.28.2591; Jeka J, 2004, J NEUROPHYSIOL, V92, P2368, DOI 10.1152/jn.00983.2003; Kantz H, 2004, NONLINEAR TIME SERIE; Kiemel T, 2002, BIOL CYBERN, V87, P262, DOI 10.1007/s00422-002-0333-2; KOLMOGOROV AN, 1958, DOKL AKAD NAUK SSSR+, V119, P861; KUO AD, 1995, IEEE T BIO-MED ENG, V42, P87, DOI 10.1109/10.362914; Ladislao L, 2007, MED BIOL ENG COMPUT, V45, P679, DOI 10.1007/s11517-007-0213-y; Lake DE, 2002, AM J PHYSIOL-REG I, V283, pR789, DOI 10.1152/ajpregu.00069.2002; MANDELBROT BB, 1968, SIAM REV, V10, P422, DOI 10.1137/1010093; MYKLEBUST JB, 1995, ANN BIOMED ENG, V23, P711, DOI 10.1007/BF02584470; Newell KM, 1997, EXP BRAIN RES, V113, P158, DOI 10.1007/BF02454152; NEWELL KM, 1998, APPL NONLINEAR DYNAM; PACKARD NH, 1980, PHYS REV LETT, V45, P712, DOI 10.1103/PhysRevLett.45.712; Pascolo P, 2006, CHAOS SOLITON FRACT, V27, P1339, DOI 10.1016/j.chaos.2005.04.111; Pascolo PB, 2005, CHAOS SOLITON FRACT, V24, P1343, DOI 10.1016/j.chaos.2004.09.062; Pellecchia G., 2005, TUTORIALS CONT NONLI, P95; Pilgram B, 1998, PHYSICA D, V114, P108, DOI 10.1016/S0167-2789(97)00188-7; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; PRICHARD D, 1994, PHYS LETT A, V191, P245, DOI 10.1016/0375-9601(94)90134-1; Prieto TE, 1996, IEEE T BIO-MED ENG, V43, P956, DOI 10.1109/10.532130; Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039; Riley MA, 1999, GAIT POSTURE, V9, P65, DOI 10.1016/S0966-6362(98)00044-7; Roerdink M, 2006, EXP BRAIN RES, V174, P256, DOI 10.1007/s00221-006-0441-7; Sabatini AM, 2000, MED BIOL ENG COMPUT, V38, P617, DOI 10.1007/BF02344866; Schreiber T, 1996, PHYS REV LETT, V77, P635, DOI 10.1103/PhysRevLett.77.635; Schreiber T, 2000, PHYSICA D, V142, P346, DOI 10.1016/S0167-2789(00)00043-9; SINAI I, 1959, DOKL AKAD NAUK SSSR+, V124, P768; Stergiou Nicholas, 2006, J Neurol Phys Ther, V30, P120; Takens F., 1981, LECT NOTES MATH, V898; TAKENS F, 1983, ATAS 13 COL BRASILIE; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; Theiler J, 1993, CHAOS, V3, P771, DOI 10.1063/1.165936; TRUJILLOORTIZ A, 2003, FPTEST NONPARAMETRIC; Vaillancourt DE, 2002, NEUROBIOL AGING, V23, P1, DOI 10.1016/S0197-4580(01)00247-0; Yamada N, 1995, HUM MOVEMENT SCI, V14, P711, DOI 10.1016/0167-9457(95)00032-1	62	159	160	0	19	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1350-4533	1873-4030		MED ENG PHYS	Med. Eng. Phys.	OCT	2009	31	8					1023	1031		10.1016/j.medengphy.2009.06.004			9	Engineering, Biomedical	Engineering	512BV	WOS:000271218400018	19608447				2021-06-18	
J	Baguley, IJ; Cooper, J; Felmingham, K				Baguley, IJ; Cooper, J; Felmingham, K			Aggressive Behavior following traumatic brain injury - How common is common?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aggression; follow up; predictors; prevalence; traumatic brain injury	HEAD-INJURY; PRACTICAL SCALE; AGITATION; DEPRESSION; RESTLESSNESS; MANAGEMENT; INVENTORY	Objective: To assess the prevalence and predictors of aggressive behavior among traumatic brain injury (TBI) survivors at 6, 24, and 60 months postdischarge. Design: Mixed cross-sectional and longitudinal data from a 5-year follow-tip study of discharged TBI patients analyzed retrospectively. Setting: A specialized Brain Injury Rehabilitation Service of a tertiary referral hospital. Patients: Two hundred twenty-eight (228) patients with moderate to severe TBI. Main Outcome Measures: The Overt Aggression Scale; injury-related variables (in particular, Glasgow Coma and Outcome scales and posttraumatic amnesia duration); and a battery of postdischarge questionnaires (Beck Depression Inventory, Trauma Complaints List, General Health Questionnaire, etc). Results: At any given follow-tip period, 25% of the participants were classified as aggressive. Aggression, where present, was consistently associated with depression, concurrent traumatic complaints, younger age at injury, and low satisfaction with life rather than with injury, demographic, or premorbid characteristics. Depression was the factor that was most significantly associated with aggressive behavior at all times postinjury followed by a younger age at the time of injury. Conclusions: Aggression is a common, fluctuating, and long-term problem following TBI. The underlying association between aggression and psychosocial variables lends support to the provision of ongoing Outreach services and psychological and behavioral interventions for all affected TBI survivors.	Univ New S Wales, Sch Psychol, Sydney, NSW, Australia; Westmead Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia	Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Baguley, Ian J/0000-0001-5650-3705			Alderman N, 1999, BRAIN INJURY, V13, P669; Babor TF, 1989, ALCOHOL USE DISORDER; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; CASSIDY JW, 1994, J HEAD TRAUMA REHAB, V9, P43, DOI 10.1097/00001199-199409000-00005; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; DIENER ED, 1985, PSYCHOL ASSESSMENT, V5, P164; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; GALSKI T, 1994, ARCH PHYS MED REHAB, V75, P380, DOI 10.1016/0003-9993(94)90158-9; GLENN MB, 1987, J HEAD TRAUMA REHAB, V2, P71; Goldberg D.P, 1972, DETECTION PSYCHIAT I; Hall K. M., 1992, NEUROREHABILITATION, V2, DOI [10.3233/NRE-1992-2410, DOI 10.3233/NRE-1992-2410]; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; JENNETT B, 1975, LANCET, V1, P480; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; Marosszeky NEV, 1998, PTA PROTOCOL GUIDELI; MILLER L, 1991, COG REHABIL, V9, P6; MILLER L, 1990, PSYCHOTHERAPY PRIVAT, V8, P1; O'Leary CA, 2000, BEHAV INTERVENT, V15, P205, DOI 10.1002/1099-078X(200007/09)15:3<205::AID-BIN56>3.3.CO;2-B; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Plylar P A, 1989, J Neurosci Nurs, V21, P353; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SHORES EA, 1995, APPL NEUROPSYCHOL, V2, P67; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; TEASDALE G, 1974, LANCET, V2, P81; TENNANT C, 1977, MED J AUSTRALIA, V2, P392, DOI 10.5694/j.1326-5377.1977.tb114568.x; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	38	159	162	1	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2006	21	1					45	56		10.1097/00001199-200601000-00005			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	004WW	WOS:000234784300005	16456391				2021-06-18	
J	McCrory, P; Collie, A; Anderson, V; Davis, G				McCrory, P; Collie, A; Anderson, V; Davis, G			Can we manage sport related concussion in children the same as in adults?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							MILD HEAD-INJURY; TRAUMATIC BRAIN-INJURY; DELAYED DETERIORATION; FOOTBALL; RECOVERY; CONSCIOUSNESS; PLAYERS; SCHOOL; RISK		Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia; Univ Melbourne, Brain Res Inst, Parkville, Vic 3010, Australia; CogState Ltd, Carlton, Vic 3053, Australia; Univ Melbourne, Ctr Neurosci, Parkville, Vic 3010, Australia; Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Austin & Repatriat Med Ctr, Dept Neurosurg, Heidelberg, Vic 3084, Australia	McCrory, P (corresponding author), British Journal Sports Med, 200 Berkeley St, Carlton, Vic 3053, Australia.	pmccrory@compuserve.com	McCrory, Paul/Q-8688-2019	Collie, Alex/0000-0003-2617-9339			ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bergman DA, 1999, PEDIATRICS, V104, P1407; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1984, BRIT MED J, V289, P715, DOI 10.1136/bmj.289.6447.715; CLAPPERTON A, 2003, HAZARD VICTORIAN INJ, P1; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIS G, 2004, IN PRESS BR J SPORTS; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Finch CF, 2003, J SCI MED SPORT, V6, P505, DOI 10.1016/S1440-2440(03)80275-X; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; PICKLES W, 1950, NEW ENGL J MED, V242, P607, DOI 10.1056/NEJM195004202421602; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; RUTTER M, 1983, DEV NEUROPSYCHIATRY, P77; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; Wrightson P, 1998, NEW ZEAL MED J, V111, P99; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	45	159	159	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	OCT 1	2004	38	5					516	519		10.1136/bjsm.2004.014811			4	Sport Sciences	Sport Sciences	856PE	WOS:000224056300002	15388528	Green Published, Bronze			2021-06-18	
J	Georgiadis, D; Schwarz, S; Kollmar, R; Schwab, S				Georgiadis, D; Schwarz, S; Kollmar, R; Schwab, S			Endovascular cooling for moderate hypothermia in patients with acute stroke - First results of a novel approach	STROKE			English	Article						stroke, acute; stroke management	FOCAL CEREBRAL-ISCHEMIA; HEAD-INJURY; MILD; BRAIN; INFARCTION; RELEASE; RATS	Background and Purpose-We undertook this study to evaluate the feasibility of inducing and maintaining moderate hypothermia with the use of endovascular rather than surface cooling. Methods-Six patients with severe acute ischemic stroke were treated with moderate hypothermia. This was induced and maintained by circulating temperature-adjusted normal saline in a closed-loop system entailing 3 balloons located near the tip of a central line, which dwelled in the inferior vena cava. Results-The mean SD initial temperature of the patients was 37 +/- 1 degreesC (range, 35.5 degreesC to 38.4 degreesC). The pace of cooling was 1.4 +/- 0.6 degreesC/h, and target temperature was reached after 3 +/- 1 hours (range, 2 to 4.5 hours). During hypothermia, the maximal temperature observed was 33.4 degreesC, and the minimal temperature was 32.2 degreesC. Temperature deviations >0.2 degreesC or >0.3 degreesC were observed during 21% or 10% of the hours under hypothermia, respectively. Singultus was the only device-related complication encountered. Pulmonary infection, arterial hypotension, bradycardia, arrhythmia, and thrombocytopenia were the most common side effects. Conclusions-Induction and maintenance of hypothermia with an intravenous cooling device are feasible. The safety of this approach remains to be evaluated.	Univ Heidelberg, Dept Neurol, D-69120 Heidelberg, Germany	Schwab, S (corresponding author), Univ Heidelberg, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.						BAKER KZ, 1994, ANESTHESIOLOGY, V81, P361, DOI 10.1097/00000542-199408000-00014; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; Frietsch T, 2000, ANESTHESIOLOGY, V92, P754, DOI 10.1097/00000542-200003000-00019; Gartshore G, 1997, EXP NEUROL, V147, P353, DOI 10.1006/exnr.1997.6635; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Huh PW, 2000, J NEUROSURG, V92, P91, DOI 10.3171/jns.2000.92.1.0091; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; Mayer SA, 2001, NEUROLOGY, V56, P292, DOI 10.1212/WNL.56.3.292; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; Piepgras A, 1998, NEUROSURGERY, V42, P311, DOI 10.1097/00006123-199802000-00058; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Yanamoto H, 2001, STROKE, V32, P232, DOI 10.1161/01.STR.32.1.232; Zeiner A, 2000, STROKE, V31, P86, DOI 10.1161/01.STR.31.1.86	17	159	162	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	NOV	2001	32	11					2550	2553		10.1161/hs1101.097382			4	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	490PG	WOS:000172059800018	11692015	Bronze			2021-06-18	
J	Rossi, S; Zanier, ER; Mauri, I; Columbo, A; Stocchetti, N				Rossi, S; Zanier, ER; Mauri, I; Columbo, A; Stocchetti, N			Brain temperature, body core temperature, and intracranial pressure in acute cerebral damage	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						head injury; subarachnoid haemorrhaged; brain temperature; intracranial pressure	ISCHEMIC NEURONAL INJURY; INTRACEREBRAL TEMPERATURE; NEUROSURGICAL PATIENTS; MODERATE HYPOTHERMIA; METABOLISM	Objectives-To assess the frequency of hyperthermia in a population of acute neurosurgical patients; to assess the relation between brain temperature (ICT) and core temperature (Tc); to investigate the effect of changes in brain temperature on intracranial pressure (ICP). Methods-The study involved 20 patients (10 severe head injury, eight subarachnoid haemorrhage, two neoplasms) with median Glasgow coma score (GCS) 6. ICP and ICT were monitored by an intraventricular catheter coupled with a thermistor. Internal Tc was measured in the pulmonary artery by a Swan-Ganz catheter. Results-Mean ICT was 38.4 (SD 0.8) and mean Tc 38.1 (SD 0.8)degreesC; 73% of ICT and 57.5% of Tc measurements were greater than or equal to 38 degreesC. The mean difference between ICT and Tc was 0.3 (SD 0.3)degreesC (range -0.7 to 2.3 degreesC) (p=0. 0001). Only in 12% of patients was Tc higher than ICT. The main reason for the differences between ICT and Tc was body core temperature: the difference between ICT and Tc increased significantly with body core temperature and fell significantly when this was lowered. The mean gradient between ICT and Tc was 0.16 (SD 0.31)degreesC before febrile episodes (ICT being higher than Tc), and 0.41 (SD 0.38)degreesC at the febrile peak (p<0.05). When changes in temperature were considered, ICT had a profound influence on ICP. Increases in ICT were associated with a significant rise in ICP, from 14.9 (SD 7.9) to 22 (SD 10.4) mm Hg (p<0.05). As the fever ebbed there was a significant decrease in ICP, from 17.5 (SD 8.62) to 16 (SD 7.76) mm. Hg (p=0.02). Conclusions-Fever is extremely frequent during acute cerebral damage and ICT is significantly higher than Tc. Moreover, Te may underestimate ICT during the phases when temperature has the most impact on the intracranial system because of the close association between increases in ICT and ICP.	Osped Maggiore Policlin IRCCS, Terapia Intens Neurosci Serv Anestesia & Rianimaz, Dept Anesthesia & Intens Care, I-20122 Milan, Italy	Stocchetti, N (corresponding author), Osped Maggiore Policlin IRCCS, Terapia Intens Neurosci Serv Anestesia & Rianimaz, Dept Anesthesia & Intens Care, Via F Sforza 35, I-20122 Milan, Italy.		Stocchetti, Nino/O-7444-2017; Zanier, Elisa/AAA-8095-2020	Stocchetti, Nino/0000-0003-3250-6834; Zanier, Elisa/0000-0002-3011-8718; Rossi, Sandra/0000-0002-9963-8121			BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; BUSTO R, 1989, STROKE, V20, P1113, DOI 10.1161/01.STR.20.8.1113; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CLASEN RA, 1974, J NEUROSURG, V41, P576, DOI 10.3171/jns.1974.41.5.0576; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; FITCH W, 1994, ANESTHESIA NEUROSURG, P1; Hirashima Y, 1998, J NEUROL NEUROSUR PS, V64, P792, DOI 10.1136/jnnp.64.6.792; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MELLERGARD P, 1990, NEUROSURGERY, V27, P654, DOI 10.1227/00006123-199010000-00029; MELLERGARD P, 1990, British Journal of Neurosurgery, V4, P31, DOI 10.3109/02688699009000679; MELLERGARD P, 1991, NEUROSURGERY, V28, P709, DOI 10.1227/00006123-199105000-00012; MELLERGARD P, 1995, SURG NEUROL, V43, P91, DOI 10.1016/0090-3019(95)80049-M; MICHENFELDER JD, 1991, ANESTHESIOLOGY, V75, P130, DOI 10.1097/00000542-199107000-00021; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; ROSSI S, 1998, INTENS CARE MED, V24, P61; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; TAKAGI K, 1996, AM J PHYSIOL, V266, pH1770; Zhao WZ, 1999, J NEUROSURG, V90, P510, DOI 10.3171/jns.1999.90.3.0510	25	159	170	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	2001	71	4					448	454		10.1136/jnnp.71.4.448			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	478ZQ	WOS:000171379800007	11561026	Green Published, Bronze			2021-06-18	
J	Schwartz, G; Fehlings, MG				Schwartz, G; Fehlings, MG			Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole	JOURNAL OF NEUROSURGERY			English	Article						spinal cord injury; motor function; riluzole; phenytoin; rat	AMYOTROPHIC-LATERAL-SCLEROSIS; RAT NEOCORTICAL CULTURES; FOCAL CEREBRAL-ISCHEMIA; SYSTEM WHITE MATTER; ANTIEPILEPTIC DRUGS; NA+ CHANNELS; GLUCOSE DEPRIVATION; NA+-CA2+ EXCHANGER; LOCAL-ANESTHETICS; CONTROLLED TRIAL	Object. Persistent activation of voltage-sensitive Na+ channels is associated with cellular toxicity and may contribute to the degeneration of neural tissue following traumatic brain and spinal cord injury (SCI). Pharmacological blockade of these channels can attenuate secondary pathophysiology and reduce functional deficits acutely. Methods. To determine the therapeutic effects of Na+ channel blockers on long-term tissue sparing and functional neurological recovery after traumatic SCI, the authors injected Wistar rats intraperitoneally with riluzole (5 mg/kg), phenytoin (30 mg/kg), CNS5546A, a novel Na+ channel blocker(15 mg/kg), or vehicle (2-HP beta CD; 5 mg/kg) 15 minutes after induction of compressive SCI at C7-T1. Functional neurological recovery of coordinated hindlimb function and strength, assessed 1 week postinjury and weekly thereafter for 6 weeks, was significantly enhanced in animals treated with riluzole compared with the other treatment groups. Seven weeks postinjury the preservation of residual tissue and integrity of descending axons were determined with digital morphometrical and fluorescent histochemical analysis. All three Na+ channel blockers significantly enhanced residual tissue area at the injury epicenter compared with control. Riluzole significantly reduced tissue loss in rostrocaudal regions surrounding the epicenter, with overall sparing of gray matter and selective sparing of white matter. Also, counts of red nuclei neurons retrogradely labeled with fluorogold introduced caudal to the injury site were significantly increased in the riluzole group. Conclusions. Systemic Na+ channel blockers, in particular riluzole, can confer significant neuroprotection after in vivo SCI and result in behavioral recovery and sparing of both gray and white matter.	Toronto Western Hosp, Res Inst, Div Cell & Mol Biol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Div Neurosurg, Toronto, ON, Canada	Fehlings, MG (corresponding author), Toronto Western Hosp, Res Inst, Div Cell & Mol Biol, McLaughlin Pavil 2-417,399 Bathurst St, Toronto, ON M5T 2S8, Canada.			Fehlings, Michael/0000-0002-5722-6364			Agrawal SK, 1997, J NEUROTRAUM, V14, P81, DOI 10.1089/neu.1997.14.81; Agrawal SK, 1996, J NEUROSCI, V16, P545; BALENTINE JD, 1978, LAB INVEST, V39, P236; BALENTINE JD, 1978, LAB INVEST, V39, P254; BANIK NL, 1987, NEUROCHEM PATHOL, V7, P57, DOI 10.1007/BF02834292; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BENAVIDES J, 1985, NEUROPHARMACOLOGY, V24, P1085, DOI 10.1016/0028-3908(85)90196-0; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Browne TR, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.5_Suppl_4.S2; Bryson HM, 1996, DRUGS, V52, P549, DOI 10.2165/00003495-199652040-00010; Calabresi P, 1999, STROKE, V30, P171, DOI 10.1161/01.STR.30.1.171; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CATTERALL WA, 1987, TRENDS PHARMACOL SCI, V8, P57, DOI 10.1016/0165-6147(87)90011-3; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHOI DW, 1987, J NEUROSCI, V7, P369; DEBONO MW, 1993, EUR J PHARMACOL, V235, P283, DOI 10.1016/0014-2999(93)90147-A; Della Paschoa OE, 1998, J PHARMACOL EXP THER, V284, P460; DeVivo MJ, 1997, SPINAL CORD, V35, P809, DOI 10.1038/sj.sc.3100501; Douglas S. M., 1996, Society for Neuroscience Abstracts, V22, P230; ESTEVEZ AG, 1995, EUR J PHARMACOL, V280, P47, DOI 10.1016/0014-2999(95)00186-O; EVANS DE, 1989, J NEUROSURG, V70, P97, DOI 10.3171/jns.1989.70.1.0097; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FEHLINGS MG, 1992, BRAIN RES, V579, P32, DOI 10.1016/0006-8993(92)90738-U; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; FEHLINGS MG, 1995, SPINE, V20, P2187, DOI 10.1097/00007632-199510001-00002; FRIEDMAN JE, 1994, BRAIN RES, V663, P329, DOI 10.1016/0006-8993(94)91281-5; GOLDIN AL, 1994, HDB RECEPTORS CHANNE, P73; GRIFFITHS IR, 1983, J NEUROL SCI, V58, P335, DOI 10.1016/0022-510X(83)90093-X; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; GUSOVSKY F, 1986, P NATL ACAD SCI USA, V83, P3003, DOI 10.1073/pnas.83.9.3003; HAYS SJ, 1994, J PHARM SCI, V83, P1425, DOI 10.1002/jps.2600831013; KEYNES RD, 1994, TRENDS NEUROSCI, V17, P58, DOI 10.1016/0166-2236(94)90075-2; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; KOBRINE AI, 1984, J NEUROSURG, V60, P595, DOI 10.3171/jns.1984.60.3.0595; KOCH RA, 1994, J NEUROSCI, V14, P2585; Krassioukov AV, 1999, NEUROSCIENCE, V88, P959, DOI 10.1016/S0306-4522(98)00267-X; LEACH MJ, 1986, EPILEPSIA, V27, P490, DOI 10.1111/j.1528-1157.1986.tb03573.x; Leigh PN, 1996, NEUROLOGY, V47, pS221, DOI 10.1212/WNL.47.6_Suppl_4.221S; Li S, 1999, J Neurosci, V19, pRC16; LOLIN YI, 1994, EPILEPSY RES, V19, P99, DOI 10.1016/0920-1211(94)90020-5; LoPachin RM, 1999, J NEUROPHYSIOL, V82, P2143; LOSCHER W, 1991, EPILEPSIA, V32, P560, DOI 10.1111/j.1528-1157.1991.tb04693.x; LOTHMAN EW, 1991, EPILEPSY RES, V9, P11, DOI 10.1016/0920-1211(91)90042-E; LUCAS LF, 1989, J NEUROSCI METH, V28, P47, DOI 10.1016/0165-0270(89)90008-3; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; MIDHA R, 1987, BRAIN RES, V410, P299, DOI 10.1016/0006-8993(87)90328-3; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; Obrenovitch TP, 1997, INT REV NEUROBIOL, V40, P109; PAXINOS G, 1994, RAT NERVOUS SYSTEM; Peluffo H, 1997, NEUROSCI LETT, V228, P207, DOI 10.1016/S0304-3940(97)00384-4; Perucca E, 1999, EPILEPSIA, V40, pS7, DOI 10.1111/j.1528-1157.1999.tb02088.x; PRATT J, 1992, NEUROSCI LETT, V140, P225, DOI 10.1016/0304-3940(92)90108-J; Probert AW, 1997, NEUROPHARMACOLOGY, V36, P1031, DOI 10.1016/S0028-3908(97)00072-5; Ragsdale DS, 1998, BRAIN RES REV, V26, P16, DOI 10.1016/S0165-0173(97)00054-4; RANSOM BR, 1990, STROKE, V21, P52; RATAUD J, 1994, NEUROSCI LETT, V172, P19, DOI 10.1016/0304-3940(94)90652-1; REGAN RF, 1991, NEUROSCIENCE, V43, P585, DOI 10.1016/0306-4522(91)90317-H; REITHMEIER RAF, 1994, CURR OPIN CELL BIOL, V6, P583, DOI 10.1016/0955-0674(94)90080-9; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Rose CR, 1997, J NEUROPHYSIOL, V78, P3249; ROTHMAN SM, 1985, J NEUROSCI, V5, P1483; SCHALLER KL, 1995, J NEUROSCI, V15, P3231; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; SCHWARTZ G, 1999, J NEUROTRAUM, V16, P984; Song JH, 1997, J PHARMACOL EXP THER, V282, P707; Stefani A, 1997, EXP NEUROL, V147, P115, DOI 10.1006/exnr.1997.6554; Stutzmann JM, 1996, NEUROREPORT, V7, P387, DOI 10.1097/00001756-199601310-00003; STYS PK, 1992, J NEUROPHYSIOL, V67, P236; STYS PK, 1991, ANN NEUROL, V30, P375, DOI 10.1002/ana.410300309; STYS PK, 1992, J NEUROSCI, V12, P430; Stys PK, 1998, NEUROSCIENCE, V82, P21; TAFT WC, 1989, BRAIN RES, V483, P143, DOI 10.1016/0006-8993(89)90045-0; TATOR CH, 1984, CAN J SURG, V27, P289; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TATOR CH, 1984, CAN J SURG, V27, P296; TAYLOR CP, 1992, NEUROSCI LETT, V145, P197, DOI 10.1016/0304-3940(92)90021-X; TAYLOR CP, 1995, TRENDS PHARMACOL SCI, V16, P309, DOI 10.1016/S0165-6147(00)89060-4; Teng YD, 1997, J NEUROSCI, V17, P4359; THERIAULT E, 1994, J COMP NEUROL, V342, P249, DOI 10.1002/cne.903420208; URENJAK J, 1997, REV CONTEMP PHARMACO, V8, P237; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; WAHL F, 1993, EUR J PHARMACOL, V230, P209, DOI 10.1016/0014-2999(93)90804-Q; Waters R L, 1998, J Spinal Cord Med, V21, P195; WEBER ML, 1994, BRAIN RES, V664, P167, DOI 10.1016/0006-8993(94)91967-4; WILLOW M, 1982, MOL PHARMACOL, V22, P627; Wokke J, 1996, LANCET, V348, P795, DOI 10.1016/S0140-6736(96)03181-9; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; XIE YX, 1994, BRAIN RES, V652, P216, DOI 10.1016/0006-8993(94)90230-5	95	159	160	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	APR	2001	94	2		S			245	256		10.3171/spi.2001.94.2.0245			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	420QV	WOS:000168016400010	11302627				2021-06-18	
J	Gaetz, M; Goodman, D; Weinberg, H				Gaetz, M; Goodman, D; Weinberg, H			Electrophysiological evidence for the cumulative effects of concussion	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; EVENT-RELATED POTENTIALS; AXONAL INJURY; NEUROFILAMENT SUBUNITS; POSTTRAUMATIC AMNESIA; CEREBRAL CONCUSSION; P300; ATTENTION; PROBABILITY; PLAYERS	Purpose: A study was initiated with the intent of demonstrating the cumulative effects of concussion in junior hockey players using visual event-related potentials and post-concussion syndrome (PCS) self-reports. Methods: Players were assessed at the beginning of the season (pre-injury) and at various times postinjury. Results: The results suggest that players with three or more concussions differed significantly on the several cognitive PCS symptoms as well as for the latency of the P3 response compared to those with no concussion history. Discussion: Event-related potentials are useful indices of the cumulative damage that can occur following multiple concussions. These measures correlate significantly with cognitive self-reports of PCS symptoms. Conclusions: This pattern of results is consistent with the position that each concussion potentially causes brain damage. Cumulative damage can be detected using electrophysiological measures of brain function.	Simon Fraser Univ, Sch Kinesiol, Brain Behav Lab, Burnaby, BC V5A 1S6, Canada; Simon Fraser Univ, Sch Kinesiol, Human Motor Syst Lab, Burnaby, BC V5A 1S6, Canada; Univ British Columbia, Sch Human Kinet, Allan McGavin Sports Med Clin, Vancouver, BC V5Z 1M9, Canada	Gaetz, M (corresponding author), Simon Fraser Univ, Sch Kinesiol, Brain Behav Lab, Burnaby, BC V5A 1S6, Canada.						Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; BERNAD PG, 1988, CLIN ELECTROENCEPHAL, V19, P174; BRUNIA CHM, 1993, PSYCHOPHYSIOLOGY, V30, P327, DOI 10.1111/j.1469-8986.1993.tb02054.x; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DESALLES AAF, 1987, J NEUROSURG, V66, P102, DOI 10.3171/jns.1987.66.1.0102; DRAKE ME, 1987, CLIN EVOKED POTENTIA, V5, P19; DUNCANJOHNSON CC, 1977, PSYCHOPHYSIOLOGY, V14, P456, DOI 10.1111/j.1469-8986.1977.tb01312.x; FOLTZ EL, 1956, J NEUROSURG, V13, P145, DOI 10.3171/jns.1956.13.2.0145; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRONWALL D, 1975, LANCET, V2, P995; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ONOFRJ M, 1991, ACTA NEUROL SCAND, V83, P273, DOI 10.1111/j.1600-0404.1991.tb04700.x; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PARKINSON D, 1992, MED HYPOTHESES, V37, P37, DOI 10.1016/0306-9877(92)90010-A; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P251, DOI 10.1016/0013-4694(86)90093-3; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; RIZZO PA, 1978, ELECTROEN CLIN NEURO, V45, P281, DOI 10.1016/0013-4694(78)90012-3; Rockstroh B., 1989, SLOW CORTICAL POTENT; ROSAHL SK, 1995, CEREB CORTEX, V5, P123, DOI 10.1093/cercor/5.2.123; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; UNTERHARNSCHEID.FJ, 1975, HDB CLIN NEUROLOGY, P527; UNTERHARNSCHEIDT F, 1970, TEX REP BIOL MED, V28, P421; Weight DG, 1998, PSYCHIAT CLIN N AM, V21, P609, DOI 10.1016/S0193-953X(05)70026-5; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	38	159	160	0	14	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2000	14	12					1077	1088					12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	380YW	WOS:000165736100005	11147580				2021-06-18	
J	Okonkwo, DO; Buki, A; Siman, R; Povlishock, JT				Okonkwo, DO; Buki, A; Siman, R; Povlishock, JT			Cyclosporin A limits calcium-induced axonal damage following traumatic brain injury	NEUROREPORT			English	Article						axonal injury; calpain; cyclosporin A; mitochondrial permeability transition; PT pore; trauma	AXOLEMMAL PERMEABILITY; MECHANISMS; RAT; MITOCHONDRIA; ISCHEMIA	IN traumatic axonal injury, Ca2+ influx across a focally damaged axolemma precipitates local mitochondrial failure, degradation of the subaxolemmal spectrin network and compaction of neurofilaments, which collectively contribute to axonal failure. In previous studies, cyclosporin A pretreatment preserved mitochondrial integrity and attenuated axonal failure following trauma. Here we investigate whether this CsA-linked protection was related to the concomitant blunting of intra-axonal, Ca2+-induced cytoskeletal changes in traumatic axonal injury, assessed with antibodies targeting spectrin proteolysis and neurofilament compaction. CsA pretreatment dramatically reduced Ca2+-induced cytoskeletal damage following injury; CsA-treated rats, compared with vehicle-treated rats, displayed a 70% decrease in immunoreactive/damaged profiles. We suggest that CsA-mediated preservation of mitochondrial integrity enables the restoration of ionic and metabolic homeostasis thereby short-circuiting Ca2+-induced proteolysis in injured axons. (C) 1999 Lippincott Williams & Wilkins.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Univ Pecs, Sch Med, Dept Neurosurg, H-7624 Pecs, Hungary; Cephalon, W Chester, PA 19380 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Box 980-709, Richmond, VA 23298 USA.		Buki, Andras/B-1960-2010		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER		Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; Buki A., 1998, Society for Neuroscience Abstracts, V24, P252; CHADHURI B, 1995, BIOCHEM BIOPH RES CO, V215, P781; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Friberg H, 1998, J NEUROSCI, V18, P5151; Gogarten W, 1998, J NEUROSURG ANESTH, V10, P101, DOI 10.1097/00008506-199804000-00006; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; LEE VMY, 1987, J NEUROSCI, V7, P3474; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; OKONKWO DO, 1998, IN PRESS J CEREBR BL; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; SIMAN R, 1989, J NEUROSCI, V9, P1579; STONE JP, 1998, IN PRESS ACTA NEUROP; STYS PK, 1992, J NEUROSCI, V12, P430; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	25	159	162	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	FEB 5	1999	10	2					353	358		10.1097/00001756-199902050-00026			6	Neurosciences	Neurosciences & Neurology	180NX	WOS:000079393000027	10203334				2021-06-18	
J	Sherer, M; Boake, C; Levin, E; Silver, BV; Ringholz, G; High, WM				Sherer, M; Boake, C; Levin, E; Silver, BV; Ringholz, G; High, WM			Characteristics of impaired awareness after traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						impaired awareness; traumatic brain injury; characteristics; measurement; awareness questionnaire	CLOSED-HEAD INJURY; BEHAVIORAL LIMITATIONS; RATING-SCALE; ADULTS; REHABILITATION; DYSFUNCTION; RELATIVES; DEFICITS; RECOVERY; MEMORY	Impaired awareness of the effects of brain injury is a commonly observed and poorly understood finding in traumatic brain injury survivors. Nonetheless, impaired awareness has been identified as a major factor in determining outcome for traumatic brain injury survivors. Review of previous studies of impaired awareness in this patient population revealed a number of preliminary findings regarding the nature of this phenomenon. The present paper presents the results of 2 new studies with a total of 111 traumatic brain injury patients conducted to bring further clarity to this area. Findings confirmed and extended many results of previous investigations. Specific findings included patient overestimation of functioning as compared to family member ratings, patient report of greater physical than nonphysical impairment, greater patient-family agreement on specific ratings of patient functioning than on general ratings, greater agreement of family and clinician ratings of patient functioning with each other than with patient self-ratings, and partial disagreement of different methods of measuring impaired awareness.	Inst Rehabil & Res, Houston, TX USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Houston, TX USA	Sherer, M (corresponding author), Mississippi Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	marks@mmrcrehab.org					ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Damasio A. R., 1993, CLIN NEUROPSYCHOLOGY, V3, P409; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; Gasquoine PG, 1994, J HEAD TRAUMA REHAB, V9, P16, DOI DOI 10.1097/00001199-199412000-00004; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Goldstein K., 1939, ORGANISM; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; Heiles C., 1993, PROTOSTARS PLANETS, P279; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; HERRMANN DJ, 1982, PSYCHOL BULL, V92, P434, DOI 10.1037/0033-2909.92.2.434; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Priddy D A, 1988, Brain Inj, V2, P249, DOI 10.3109/02699058809150949; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Schacter D. L., 1991, AWARENESS DEFICIT BR, P258; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; TEASDALE G, 1974, LANCET, V2, P81; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; Weinstein EA, 1955, DENIAL ILLNESS	36	159	159	0	5	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	1998	4	4					380	387		10.1017/S1355617798003804			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	104ZF	WOS:000075046600008	9656611				2021-06-18	
J	Rao, VLR; Baskaya, MK; Dogan, A; Rothstein, JD; Dempsey, RJ				Rao, VLR; Baskaya, MK; Dogan, A; Rothstein, JD; Dempsey, RJ			Traumatic brain injury down-regulates glial glutamate transporter (GLT-1 and GLAST) proteins in rat brain	JOURNAL OF NEUROCHEMISTRY			English	Article						traumatic brain injury; glutamate; uptake; transporters; GLT-1; GLAST	EXCITATORY AMINO-ACIDS; EXPRESSION; SUBTYPES; RELEASE; NEUROTRANSMITTER; HIPPOCAMPUS; ACIDOSIS; MODEL	Excess activation of NMDA receptors is felt to participate in secondary neuronal damage after traumatic brain injury (TBI). Increased extracellular glutamate is active in this process and may result from either increased release or decreased reuptake. The two high-affinity sodium-dependent glial transporters [glutamate transporter 1 (GLT-1) and glutamate aspartate transporter (GLAST)] mediate the bulk of glutamate transport. We studied the protein levels of GLT-1 and GLAST in the brains of rats after controlled cortical impact-induced TBI. With use of subtype-specific antibodies, GLT-1 and GLAST proteins were quantitated by immunoblotting in the ipsilateral and contralateral cortex at 2, 6, 24, 72, and 168 h after the injury. Sham-operated rats served as control. TBI resulted in a significant decrease in GLT-1 (by 20-45%; p < 0.05) and GLAST (by 30-50%; p < 0.05) protein levels between 6 and 72 h after the injury. D-[H-3]Aspartate binding also decreased significantly (by 30-50%; p < 0.05) between 6 and 72 h after the injury. Decreased glial glutamate transporter function may contribute to the increased extracellular glutamate that may mediate the excitotoxic neuronal damage after TBI. This is a first report showing altered levels of glutamate transporter proteins after TBI.	Univ Wisconsin, Dept Neurol Surg, Madison, WI 53792 USA; Vet Affairs Hosp, Madison, WI USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA	Dempsey, RJ (corresponding author), Univ Wisconsin, Dept Neurol Surg, H4-336 CSC,600 Highland Ave, Madison, WI 53792 USA.		rothstein, jeffrey d/C-9470-2013; Dogan, Aclan/AAF-8305-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS31220, R01-NS28000] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS028000, P01NS031220] Funding Source: NIH RePORTER		Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Baskaya MK, 1996, J NEUROTRAUM, V13, P85, DOI 10.1089/neu.1996.13.85; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; CASADO M, 1993, J BIOL CHEM, V268, P27313; CHAUDHRY FA, 1995, NEURON, V15, P717; Chesnut R M, 1995, New Horiz, V3, P366; CHOI DW, 1997, PRIMER CEREBROVASCUL, P187; Conradt M, 1997, J NEUROCHEM, V68, P1244, DOI 10.1046/j.1471-4159.1997.68031244.x; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; Diamond JS, 1997, J NEUROSCI, V17, P4672; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dogan A, 1997, J NEUROSURG, V87, P921, DOI 10.3171/jns.1997.87.6.0921; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; ERECINSKA M, 1987, BIOCHEM PHARMACOL, V36, P3547, DOI 10.1016/0006-2952(87)90001-3; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Gegelashvili G, 1997, MOL PHARMACOL, V52, P6; GIFFARD RG, 1990, BRAIN RES, V530, P138, DOI 10.1016/0006-8993(90)90670-7; GINSBERG SD, 1995, J NEUROCHEM, V65, P2800; Ginsberg SD, 1996, J NEUROCHEM, V67, P1208; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Homayoun P, 1997, J NEUROCHEM, V69, P199; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kanai Y, 1997, NEUROTRANSMITTER TRA, P171; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Knecht K, 1997, NEUROSCI LETT, V229, P201, DOI 10.1016/S0304-3940(97)00444-8; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Li S, 1997, J NEUROPATH EXP NEUR, V56, P901, DOI 10.1097/00005072-199708000-00008; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lyeth BG, 1996, BRAIN RES, V742, P63, DOI 10.1016/S0006-8993(96)01002-5; Manzoni C, 1997, PHARMACOL RES, V35, P149, DOI 10.1006/phrs.1997.0129; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; Miller HP, 1997, J NEUROCHEM, V68, P1564; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Norenberg MD, 1997, GLIA, V21, P124; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Peghini P, 1997, EMBO J, V16, P3822, DOI 10.1093/emboj/16.13.3822; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; POGUN S, 1994, SYNAPSE, V18, P21, DOI 10.1002/syn.890180104; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; SAKAMOTO KI, 1997, J NEUROTRAUM, V14, P49; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Smith D H, 1995, New Horiz, V3, P562; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stahl SM, 1997, J CLIN PSYCHIAT, V58, P247, DOI 10.4088/JCP.v58n0601; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SWANSON RA, 1995, J CEREBR BLOOD F MET, V15, P417, DOI 10.1038/jcbfm.1995.52; Swanson RA, 1997, J NEUROSCI, V17, P932; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; TORP R, 1995, EXP BRAIN RES, V103, P51; Trotti D, 1996, J BIOL CHEM, V271, P5976, DOI 10.1074/jbc.271.11.5976; Trotti D, 1997, EUR J NEUROSCI, V9, P1236, DOI 10.1111/j.1460-9568.1997.tb01478.x; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Vink R, 1996, J NEUROCHEM, V66, P2477; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561	72	159	161	2	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0022-3042			J NEUROCHEM	J. Neurochem.	MAY	1998	70	5					2020	2027					8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	ZJ393	WOS:000073210500028	9572288				2021-06-18	
J	Hall, KM; Mann, N; High, WM; Wright, J; Kreutzer, JS; Wood, D				Hall, KM; Mann, N; High, WM; Wright, J; Kreutzer, JS; Wood, D			Functional measures after traumatic brain injury: Ceiling effects of FIM, FIM+FAM, DRS, and CIQ	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Community Integration Questionnaire; Disability Rating Scale; Functional Assessment Measure; Functional Independence Measure	COMMUNITY INTEGRATION QUESTIONNAIRE; DISABILITY RATING-SCALE; INDEPENDENCE MEASURE; REHABILITATION OUTCOMES; HEAD-INJURY; RECOVERY; COMA	Objective: The characteristics of the Disability Rating Scale (DRS), Functional Independence Measure (RM), Functional Independence Measure and Functional Assessment Measure (FIM+FAM), and Community Integration Questionnaire (CIQ) are examined, especially in regard to a ''ceiling effect'' after rehabilitation discharge (ie, how well each of the instruments detects meaningful change in level of function). Design: Data were collected prospectively at admission and discharge from acute inpatient rehabilitation and at pears 1 and 2 after injury (the CIQ was collected only at years 1 and 2). Analyses are reported on a subsample of cases with listwise deletion, although the analyses were also done using all data available, and results compared to ensure stability of findings between samples. Setting: National database of the four Traumatic Brain Injury (TBI) Model Systems in San Jose, Calif; Detroit, Mich; Richmond, Va; and Houston, Tex. Patients: All consenting patients with TBI age 16 and older admitted to a Model System within 24 hours of injury and receiving inpatient rehabilitation within the Model System qualified for the study. Data on 612 individuals were collected, with a minimum of 80 cases having complete data over time. Main Outcome Measures: The DRS, FIM. FIM+FAM, and CIQ. Results: There is a substantial ceiling effect of the FIM, even by inpatient rehabilitation discharge (ie, one half of the cases have an average score of 6 to 7 [''independent or modified independence-no helper''] across the 18 FIM items). The FIM+FAM shows a ceiling effect in one third of the cases. The DRS shows less ceiling effect at discharge, 1 fear, and 2 years than the FIM or the FIM+FAM. CIQ scores have a ceiling effect on home and social integration subscales when compared with scores from a sample of individuals without disabilities. The productivity subscale remains well below the norm. Conclusions: Ceiling effects for the FIM, FIM+FAM, and two of the three CIQ subscales indicate that these measures are not as sensitive to changes, especially in the community, as may be needed to assess progress in areas most commonly causing dysfunction for the TBI population. More emphasis must be placed on improved measurement of relevant goals in the postacute and home settings with brief and precise scales.	REHABIL INST MICHIGAN,DETROIT,MI; INST REHABIL & RES,HOUSTON,TX; VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,RICHMOND,VA	Hall, KM (corresponding author), SANTA CLARA VALLEY MED CTR,TBI,SCI,MODEL SYST PROJECT,BOX 70,SAN JOSE,CA 95128, USA.						Bowers D, 1989, ARCH PHYS MED REHAB, V70, pA58; BURKE DC, 1995, BRAIN INJURY, V9, P735, DOI 10.3109/02699059509008229; Cope D., 1993, J HEAD TRAUMA REHAB, V8, P1; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; EMHOFF TA, 1991, J TRAUMA, V9, P1227; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; GOKA RS, 1994, BRAIN INJ REHABIL, V26, P420; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Hall K M, 1994, NeuroRehabilitation, V4, P76, DOI 10.3233/NRE-1994-4204; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Hamilton B., 1987, REHABILITATION OUTCO; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; HEDRICK WP, 1995, BRAIN INJURY, V9, P563, DOI 10.3109/02699059509008215; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; Heinemann AW, 1994, TOP STROKE REHABIL, V1, P1; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; KILGORE KM, 1995, ARCH PHYS MED REHAB, V76, pSC21; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; LONG WB, 1994, ARCH PHYS MED REHAB, V75, P144; Malec JF., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; NOVACK TA, 1992, J HEAD TRAUMA REHAB, V6, P69; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAO N, 1990, ARCH PHYS MED REHAB, V71, P763; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCRANTON J, 1970, Archives of Physical Medicine and Rehabilitation, V51, P1; TEASDALE G, 1974, LANCET, V2, P81; WHITENECK GG, 1994, ARCH PHYS MED REHAB, V75, P1073, DOI 10.1016/0003-9993(94)90080-9; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA	40	159	161	0	12	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1996	11	5					27	39		10.1097/00001199-199610000-00004			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VP053	WOS:A1996VP05300004					2021-06-18	
J	KREUTZER, JS; GERVASIO, AH; CAMPLAIR, PS				KREUTZER, JS; GERVASIO, AH; CAMPLAIR, PS			PATIENT CORRELATES OF CAREGIVERS DISTRESS AND FAMILY FUNCTIONING AFTER TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; ASSESSMENT DEVICE; RELATIVES VIEW; REHABILITATION; BARTHEL	This study examined the relationship of patient variables to caregiver distress and family functioning after TBI in 62 families. An extension of Kreutzer et al. 1994 (in press), the present investigation used four categories of predictor variables: indices of injury severity, neuropsychological tests, neurobehavioural problem checklist scales, and kinship of caregiver (i.e. spouse vs. parent). Caregiver distress and family functioning were measured by the Brief Symptom Inventory (BSI) and Family Assessment Device (FAD), respectively. Regression analyses revealed that indices of injury severity did not predict BSI scores. Time post-injury predicted several FAD subscales. The number of the patient's neurobehavioural problems predicted BSI subscale scores most consistently, particularly the Global Severity Index, Somatic, Obsessive-Compulsive and Depression scales. Scores on the behaviour problem subscale predicted BSI scores better than other kinds of problems, and also had some relation to several FAD subscales. Of the 10 neuropsychological test scores, those which measured verbal abilities were more predictive of caregiver's BSI scores. Kinship (i.e. being a spouse) predicted Depression scores, even when other variables were partialled out. Research findings are integrated with European studies and clinical implications for understanding caregiver distress are discussed.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT NEUROL SURG, RICHMOND, VA 23298 USA; HAMILTON COLL, DEPT PSYCHOL, CLINTON, NY 13323 USA; TUALATIN VALLEY MENTAL HLTH CTR, HILLSBORO, OR USA	KREUTZER, JS (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHYS MED & REHABIL, MCV BOX 542, RICHMOND, VA 23298 USA.						ALLEN K, UNPUB FAMILY BURDEN; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; CAMPLAIR PS, 1989, THESIS VIRGINIA COMM; CAMPLAIR PS, 1990, COMMUNITY INTEGRATIO, P207; Carlson CI, 1987, J FAMILY PSYCHOL, V1, P23, DOI DOI 10.1037/H0080437; DEPOMPEI R, 1991, HEAD INJURY FAMILY M, P101; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Derogatis LR, 1975, BRIEF SYMPTOM INVENT; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EPSTEIN NB, 1978, J MARRIAGE FAM COUNS, V4, P19, DOI 10.1111/j.1752-0606.1978.tb00537.x; Gervasio AH, 1988, NEUROPSYCHOLOGY, V2, P161; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P145; Hall K. M., 1992, NEUROREHABILITATION, V2, DOI [10.3233/NRE-1992-2410, DOI 10.3233/NRE-1992-2410]; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; KREUTZER J, IN PRESS J HEAD TRAU; KREUTZER J, 1994, BRAIN INJURY, V8; KREUTZER JS, 1987, GENERAL HLTH HIST QU; LARZELERE RE, 1977, PSYCHOL BULL, V84, P557, DOI 10.1037/0033-2909.84.3.557; Lazarus R.S., 1984, STRESS APPRAISAL COP; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCGINNIS GE, 1986, ARCH PHYS MED REHAB, V67, P123, DOI 10.1016/0003-9993(86)90121-8; McKinlay W W, 1987, Brain Inj, V1, P3, DOI 10.3109/02699058709034438; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Panting A., 1972, REHABILITATION, V38, P33; PETERS L C, 1992, Brain Injury, V6, P461, DOI 10.3109/02699059209008141; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VITALIANO PP, 1991, PSYCHOL AGING, V6, P392, DOI 10.1037/0882-7974.6.3.392; WAALAND PK, 1993, BRAIN INJURY, V7, P135, DOI 10.3109/02699059309008167	40	159	159	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	1994	8	3					211	230		10.3109/02699059409150974			20	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ND714	WOS:A1994ND71400003	8004080				2021-06-18	
J	VOLLMER, DG; TORNER, JC; JANE, JA; SADOVNIC, B; CHARLEBOIS, D; EISENBERG, HM; FOULKES, MA; MARMAROU, A; MARSHALL, LF				VOLLMER, DG; TORNER, JC; JANE, JA; SADOVNIC, B; CHARLEBOIS, D; EISENBERG, HM; FOULKES, MA; MARMAROU, A; MARSHALL, LF			AGE AND OUTCOME FOLLOWING TRAUMATIC COMA - WHY DO OLDER PATIENTS FARE WORSE	JOURNAL OF NEUROSURGERY			English	Article						TRAUMATIC COMA DATA BANK; HEAD INJURY; COMA; AGE; OUTCOME	SEVERE HEAD-INJURY; ACUTE SUBDURAL-HEMATOMA; DATA-BANK; CLINICAL EXAMINATION; PROGNOSIS; PREDICTION; CHILDREN; ADULT; BRAIN	To better understand the relationship between patient age and clinical outcome following traumatic coma, the data for 661 patients, aged 15 years or older at the time of receiving a nonpenetrating head injury, were analyzed. All patients were prospectively followed and the information was entered into the Traumatic Coma Data Bank. This information was statistically analyzed to determine trends and interactions between patient age and other prognostic indicators. Older patients had higher rates of mortality overall; vegetative survival was seen in 4.8% to 8.0% of patients and did not exhibit a trend related to age. Injury severity, as assessed by motor score or Glasgow Coma Scale score, did not significantly differ according to age. The injury mechanism was age-related, with a greater frequency of falls and pedestrian accidents in older patients. Multiple injury was less frequent in older patients. Medical complications and systemic trauma were considered to be the primary cause of death in less than 25% of patients, with the exception of those between 45 and 55 years of age. When the data were studied in univariate fashion, no factor was identified that accounts for the adverse effect of age on head-injury outcome. Multivariate logistic regression, performed to assess the combined effect of multiple variables on outcome, failed to eliminate patient age as an independent predictor. Based upon this analysis, it is likely that the effect of age on outcome following head injury is dependent upon an alteration in the pathophysiological response of the aging central nervous system to severe trauma and not an increased incidence of non-neurological complications or other clinical parameters.	UNIV VIRGINIA,MED CTR,SCH MED,DEPT NEUROSURG,CHARLOTTESVILLE,VA 22901; UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550; NINCDS,BIOMETRY & FIELD STUDIES BRANCH,BETHESDA,MD 20892; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT NEUROSURG,RICHMOND,VA 23298; UNIV CALIF SAN DIEGO,MED CTR,DIV NEUROSURG,LA JOLLA,CA 92093	VOLLMER, DG (corresponding author), WASHINGTON UNIV,SCH MED,DEPT NEUROSURG,660 S EUCLID,CB 8057,ST LOUIS,MO 63110, USA.						ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ARMITAGE P, 1971, STATISTICAL METHODS, P363; Baker S P, 1985, Clin Geriatr Med, V1, P501; BAXT WG, 1987, J TRAUMA, V27, P602, DOI 10.1097/00005373-198706000-00003; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRICOLO A, 1977, J NEUROSURG, V47, P680, DOI 10.3171/jns.1977.47.5.0680; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; EDNA TH, 1983, ACTA NEUROCHIR, V69, P15, DOI 10.1007/BF02055848; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; EISENBERG HM, 1983, INTRACRANIAL PRESSUR, V5, P549; ESPERSEN JO, 1982, ACTA NEUROCHIR, V65, P81, DOI 10.1007/BF01405444; FELL DA, 1975, J NEUROSURG, V42, P37, DOI 10.3171/jns.1975.42.1.0037; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; FREEMAN DH, 1987, APPLIED CATEGORICAL, P72; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1985, TRAUMA CENTRAL NERVO, P169; GROSS CR, 1985, TRAUMA CENTRAL NERVO, P19; Hadley E, 1985, Clin Geriatr Med, V1, P497; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MCKISSOCK W, 1960, LANCET, V1, P1365; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OVERGAARD J, 1973, LANCET, V2, P631; PAZZAGLIA P, 1975, J NEUROL NEUROSUR PS, V38, P149, DOI 10.1136/jnnp.38.2.149; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1982, HEAD INJURY BASIC CL, P213; YOUNG HA, 1984, NEUROSURGERY, V14, P22, DOI 10.1227/00006123-198401000-00006; 1985, ABBREVIATED INJURY S	47	159	162	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	1991	75			S			S37	S49		10.3171/sup.1991.75.1s.0s37			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GN584	WOS:A1991GN58400007					2021-06-18	
J	CANTU, RC				CANTU, RC			GUIDELINES FOR RETURN TO CONTACT SPORTS AFTER A CEREBRAL CONCUSSION	PHYSICIAN AND SPORTSMEDICINE			English	Article										CANTU, RC (corresponding author), NEUROL SURG INC,LEVEL 4,CUMING BLDG,CONCORD,MA 01742, USA.							0	159	160	0	20	MCGRAW HILL HEALTHCARE PUBLICATIONS	MINNEAPOLIS	4530 WEST 77TH ST, MINNEAPOLIS, MN 55435-5000	0091-3847			PHYSICIAN SPORTSMED	Physician Sportsmed.	OCT	1986	14	10					75	&		10.1080/00913847.1986.11709197			0	Primary Health Care; Orthopedics; Sport Sciences	General & Internal Medicine; Orthopedics; Sport Sciences	E2062	WOS:A1986E206200005	27432133				2021-06-18	
J	Sanghavi, BJ; Varhue, W; Chavez, JL; Chou, CF; Swami, NS				Sanghavi, Bankim J.; Varhue, Walter; Chavez, Jorge L.; Chou, Chia-Fu; Swami, Nathan S.			Electrokinetic Preconcentration and Detection of Neuropeptides at Patterned Graphene-Modified Electrodes in a Nanochannel	ANALYTICAL CHEMISTRY			English	Article							PHYSIOLOGICAL MEDIA; PERFORMANCE; DEPRESSION; PLASMA; DEVICE; ACID	Neuropeptides are vital to the transmission and modulation of neurological signals, with Neuropeptide Y (NPY) and Orexin A (OXA) offering diagnostic information on stress, depression, and neurotrauma. NPY is an especially significant biomarker, since it can be noninvasively collected from sweat, but its detection has been limited by poor sensitivity, long assay times, and the inability to scale-down sample volumes. Herein, we apply electrokinetic preconcentration of the neuropeptide onto patterned graphene-modified electrodes in a nanochannel by frequency-selective dielectrophoresis for 10 s or by electrochemical adsorptive accumulation for 300 s, to enable the electrochemical detection of NPY and OXA at picomolar levels from subnanoliter samples, with sufficient signal sensitivity to avoid interferences from high levels of dopamine and ascorbic acid within biological matrices. Given the high sensitivity of the methodology within small volume samples, we envision its utility toward off-line detection from droplets collected by microdialysis for the eventual measurement of neuropeptides at high spatial and temporal resolutions.	[Sanghavi, Bankim J.; Varhue, Walter; Swami, Nathan S.] Univ Virginia, Dept Elect & Comp Engn, Charlottesville, VA 22904 USA; [Chavez, Jorge L.] Air Force Res Lab, Human Effectiveness Directorate, Dayton, OH 45433 USA; [Chou, Chia-Fu] Acad Sinica, Inst Phys, Taipei 11529, Taiwan	Swami, NS (corresponding author), Univ Virginia, Dept Elect & Comp Engn, Charlottesville, VA 22904 USA.	nswami@virginia.edu	Chou, Chia-Fu/H-4084-2013	Chou, Chia-Fu/0000-0003-0070-5556; Swami, Nathan/0000-0002-0492-1160	AOARD [114083, FA2386-12-1-4002]; NSF EAPSI program; National Science Council, TaiwanMinistry of Science and Technology, Taiwan [102-2112-M-001-005-MY3]	Support was from AOARD Grants Nos. 114083 and FA2386-12-1-4002, NSF EAPSI program, and the National Science Council, Taiwan (102-2112-M-001-005-MY3). We thank Dr. Kuo-Tang Liao for assistance on nanofabrication and Dr. Nancy Kelley-Loughnane and Dr. Joshua A. Hagen of the Air Force Research Laboratory for valuable discussions.	Andrews JA, 2012, J NEUROCHEM, V120, P26, DOI 10.1111/j.1471-4159.2011.07545.x; [Anonymous], 1996, ICH HARM TRIP GUID V; Chaurey V, 2013, ELECTROPHORESIS, V34, P1097, DOI 10.1002/elps.201200456; Chaurey V, 2012, BIOMICROFLUIDICS, V6, DOI 10.1063/1.3676069; Cizza G, 2008, BIOL PSYCHIAT, V64, P907, DOI 10.1016/j.biopsych.2008.05.035; Crespi F, 2011, BRAIN RES, V1407, P27, DOI 10.1016/j.brainres.2011.05.033; Gruber SHM, 2006, EUR NEUROPSYCHOPHARM, V16, P592, DOI 10.1016/j.euroneuro.2006.01.009; Hebert NE, 2003, ANAL CHEM, V75, P4265, DOI 10.1021/ac026425g; Heilig M, 2004, J PSYCHIATR RES, V38, P113, DOI 10.1016/S0022-3956(03)00101-8; Jia M, 2012, ANAL CHEM, V84, P6508, DOI 10.1021/ac3014548; Leichle T, 2012, SENSOR ACTUAT B-CHEM, V161, P805, DOI 10.1016/j.snb.2011.11.036; Li Q, 2009, ANAL CHEM, V81, P2242, DOI 10.1021/ac802391b; Li SJ, 2012, MICROCHIM ACTA, V177, P325, DOI 10.1007/s00604-012-0782-9; Liao KT, 2012, ELECTROPHORESIS, V33, P1958, DOI 10.1002/elps.201100707; Liao KT, 2012, J AM CHEM SOC, V134, P8742, DOI 10.1021/ja3016523; Malva JO, 2012, NEUROPEPTIDES, V46, P299, DOI 10.1016/j.npep.2012.09.001; MOORE DS, 1985, BIOCHEM EDUC, V13, P10, DOI 10.1016/0307-4412(85)90114-1; Nie J, 2010, ANAL CHEM, V82, P7852, DOI 10.1021/ac101723x; Perry M, 2009, ANAL CHIM ACTA, V653, P1, DOI 10.1016/j.aca.2009.08.038; Polk BJ, 2006, SENSOR ACTUAT B-CHEM, V114, P239, DOI 10.1016/j.snb.2005.03.121; Racaityte K, 2000, J CHROMATOGR A, V890, P135; Rappel C, 2009, ANAL CHEM, V81, P385, DOI 10.1021/ac801814a; Sanghavi BJ, 2013, ANAL CHEM, V85, P8158, DOI 10.1021/ac4011205; Sanghavi BJ, 2010, ELECTROCHIM ACTA, V55, P8638, DOI 10.1016/j.electacta.2010.07.093; Schoch RB, 2007, NANO LETT, V7, P3895, DOI 10.1021/nl0724788; Swami N, 2009, LAB CHIP, V9, P3212, DOI 10.1039/b910598k; Swami NS, 2005, LANGMUIR, V21, P1937, DOI 10.1021/la0493767; Venton BJ, 2003, ANAL CHEM, V75, p414A, DOI 10.1021/ac031421c	28	158	158	4	138	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700	1520-6882		ANAL CHEM	Anal. Chem.	MAY 6	2014	86	9					4120	4125		10.1021/ac500155g			6	Chemistry, Analytical	Chemistry	AG9DW	WOS:000335719900009	24697740				2021-06-18	
J	Chang, CP; Chio, CC; Cheong, CU; Chao, CM; Cheng, BC; Lin, MT				Chang, Ching-Ping; Chio, Chung-Ching; Cheong, Chong-Un; Chao, Chien-Ming; Cheng, Bor-Chieh; Lin, Mao-Tsun			Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury	CLINICAL SCIENCE			English	Article						hypoxic preconditioning; mesenchymal stem cell; paracrine; secretome; traumatic brain injury	STROMAL CELLS; TISSUE-REPAIR; GROWTH-FACTOR; EXPRESSION; TRANSPLANTATION; RATS; PROTECT; STROKE; MET	Bone-marrow-derived human MSCs (mesenchymal stem cells) support repair when administered to animals with TBI (traumatic brain injury) in large part through secreted trophic factors. We directly tested the ability of the culture medium (or secretome) collected from human MSCs under normoxic or hypoxic conditions to protect neurons in a rat model of TBI. Concentrated conditioned medium from cultured human MSCs or control medium was infused through the tail vein of rats subjected to TBI. We have demonstrated that MSCs cultured in hypoxia were superior to those cultured in normoxia in inducing expression of both HGF (hepatocyte growth factor) and VEGF (vascular endothelial growth factor) in the cultured medium. We showed further that rats treated with the secretome from both normoxic- and hypoxic-preconditioned MSCs performed significantly better than the controls in both motor and cognitive functional test. Subsequent post-mortem evaluation of brain damage at the 4-day time point confirmed that both normoxic- and hypoxic-preconditioned MSC secretome-treated rats had significantly greater numbers of newly forming neurons, but significantly less than the controls in brain damaged volume and apoptosis. The TBI rats treated with hypoxic-preconditioned MSC secretome performed significantly better in both motor and cognitive function tests and neurogenesis, and had significantly less brain damage than the TBI rats treated with the normoxic-preconditioned MSC secretome. Collectively, these findings suggest that MSCs secrete bioactive factors, including HGF and VEGF, that stimulate neurogenesis and improve outcomes of TBI in a rat model. Hypoxic preconditioning enhances the secretion of these bioactive factors from the MSCs and the therapeutic potential of the cultured MSC secretome in experimental TBI.	[Chang, Ching-Ping; Cheng, Bor-Chieh] So Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Chio, Chung-Ching; Cheong, Chong-Un; Chao, Chien-Ming; Cheng, Bor-Chieh] Chi Mei Med Ctr, Dept Surg, Tainan, Taiwan; [Cheong, Chong-Un; Chao, Chien-Ming] Chi Mei Med Ctr, Dept Intens Care Med, Tainan, Taiwan; [Lin, Mao-Tsun] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan	Chio, CC (corresponding author), Chi Mei Med Ctr, Dept Surg, Tainan, Taiwan.	chiocc@ms28.hinet.net			National Science Council of ROCMinistry of Science and Technology, Taiwan [NSC 99-2314-B-384-006-MY2, NSC 99-2314-B-384-004-MY3, NSC 98-2314-B-218-MY2]; Department of Health of ROC [DOH99-TD-B-111-003]; Center of Excellence for Clinical Trial and Research in Neuroscience	This work was supported, in part, by the National Science Council of ROC [grant numbers NSC 99-2314-B-384-006-MY2, NSC 99-2314-B-384-004-MY3, NSC 98-2314-B-218-MY2], the Department of Health of ROC [grant number DOH99-TD-B-111-003], and the Center of Excellence for Clinical Trial and Research in Neuroscience.	Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Campagnoli C, 2001, BLOOD, V98, P2396, DOI 10.1182/blood.V98.8.2396; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Chacko SM, 2010, AM J PHYSIOL-CELL PH, V299, pC1562, DOI 10.1152/ajpcell.00221.2010; Chang CF, 2000, EXP NEUROL, V166, P298, DOI 10.1006/exnr.2000.7506; Chang MW, 2008, J NEUROSCI METH, V168, P186, DOI 10.1016/j.jneumeth.2007.09.013; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Estrada R, 2009, J CELL PHYSIOL, V219, P563, DOI 10.1002/jcp.21701; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Hu XY, 2008, J THORAC CARDIOV SUR, V135, P799, DOI 10.1016/j.jtcvs.2007.07.071; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Neuss S, 2004, STEM CELLS, V22, P405, DOI 10.1634/stemcells.22-3-405; Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637; Romanko MJ, 2004, PROG NEUROBIOL, V74, P77, DOI 10.1016/j.pneurobio.2004.07.001; Rosova I, 2008, STEM CELLS, V26, P2173, DOI 10.1634/stemcells.2007-1104; Sato T, 1999, JPN CIRC J, V63, P906, DOI 10.1253/jcj.63.906; Wei X, 2009, STEM CELLS, V27, P478, DOI 10.1634/stemcells.2008-0333	25	158	171	0	35	PORTLAND PRESS LTD	LONDON	CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND	0143-5221	1470-8736		CLIN SCI	Clin. Sci.	FEB	2013	124	3-4					165	176		10.1042/CS20120226			12	Medicine, Research & Experimental	Research & Experimental Medicine	078FC	WOS:000314083000004	22876972				2021-06-18	
J	Kerr, ZY; Marshall, SW; Harding, HP; Guskiewicz, KM				Kerr, Zachary Y.; Marshall, Stephen W.; Harding, Herndon P., Jr.; Guskiewicz, Kevin M.			Nine-Year Risk of Depression Diagnosis Increases With Increasing Self-Reported Concussions in Retired Professional Football Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						mental health; injury; epidemiology; traumatic brain injury	TRAUMATIC BRAIN-INJURY; RECURRENT MAJOR DEPRESSION; AUTOBIOGRAPHICAL MEMORY; SPORTS CONCUSSION; UNITED-STATES; SYMPTOMS; OUTCOMES; HISTORY; DECLINE; SOCCER	Background: Concussions may accelerate the progression to long-term mental health outcomes such as depression in athletes. Purpose: To prospectively determine the effects of recurrent concussions on the clinical diagnosis of depression in a group of retired football players. Study Design: Cohort study; Level of evidence, 2. Methods: Members of the National Football League Retired Players Association responded to a baseline General Health Survey (GHS) in 2001. They also completed a follow-up survey in 2010. Both surveys asked about demographic information, number of concussions sustained during their professional football career, physical/mental health, and prevalence of diagnosed medical conditions. A physical component summary (Short Form 36 Measurement Model for Functional Assessment of Health and Well-Being [SF-36 PCS]) was calculated from responses for physical health. The main exposure, the history of concussions during the professional playing career (self-report recalled in 2010), was stratified into 5 categories: 0 (referent), 1 to 2, 3 to 4, 5 to 9, and 101 concussions. The main outcome was a clinical diagnosis of depression between the baseline and follow-up GHS. Classic tabular methods computed crude risk ratios. Binomial regression with a Poisson residual and robust variance estimation to stabilize the fitting algorithm estimated adjusted risk ratios. x 2 analyses identified associations and trends between concussion history and the 9-year risk of a depression diagnosis. Results: Of the 1044 respondents with complete data from the baseline and follow-up GHS, 106 (10.2%) reported being clinically diagnosed as depressed between the baseline and follow-up GHS. Approximately 65% of all respondents self-reported sustaining at least 1 concussion during their professional careers. The 9-year risk of a depression diagnosis increased with an increasing number of self-reported concussions, ranging from 3.0% in the "no concussions" group to 26.8% in the "10+'' group (linear trend: P < .001). A strong dose-response relationship was observed even after controlling for confounders (years retired from professional football and 2001 SF-36 PCS). Retired athletes with a depression diagnosis also had a lower SF-36 PCS before diagnosis. The association between concussions and depression was independent of the relationship between decreased physical health and depression. Conclusion: Professional football players self-reporting concussions are at greater risk for having depressive episodes later in life compared with those retired players self-reporting no concussions.	[Kerr, Zachary Y.; Marshall, Stephen W.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew A Gfeller Sport Related Traumat Brain Inj, Chapel Hill, NC 27599 USA; [Kerr, Zachary Y.; Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA; [Kerr, Zachary Y.; Marshall, Stephen W.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Ctr Study Retired Athletes, Chapel Hill, NC 27599 USA	Guskiewicz, KM (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Matthew A Gfeller Sport Related Traumat Brain Inj, CB 8700, Chapel Hill, NC 27599 USA.	gus@email.unc.edu		Marshall, Stephen/0000-0002-2664-9233; Kerr, Zachary/0000-0003-1423-1259; Guskiewicz, Kevin/0000-0002-8682-2130	NFL Players Association; Matthew A. Gfeller Sport-Related Traumatic Brain Injury Research a; Center for the Study of Retired Athletes; National Football League (NFL) Charities; National Operating Committee on Standards for Athletic Equipment (NOCSAE); Medtronic IncMedtronic; Martek Biosciences Inc.	The authors acknowledge the support of the NFL Players Association. The Matthew A. Gfeller Sport-Related Traumatic Brain Injury Research and The Center for the Study of Retired Athletes are funded by private donations and various grant funding agencies interested in understanding the late-life consequences and benefits of playing sports. The authors thank the staff at The Matthew A. Gfeller Sport-Related Traumatic Brain Injury Research and The Center for the Study of Retired Athletes, particularly Amy Matthews, Candice Goerger, and Dr Jason Mihalik, for their input.; One or more of the authors has declared the following potential conflict of interest or source of funding: The Center for the Study of Retired Athletes and its associated studies are funded in part by the National Football League Players Association (NFLPA), National Football League (NFL) Charities, and several foundations and corporations such as the National Operating Committee on Standards for Athletic Equipment (NOCSAE), Medtronic Inc, and Martek Biosciences Inc. This study was not funded solely by any one of these entities.	Atchley R. C., 2004, SOCIAL FORCES AGING; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Baumann B, 1999, J NEUROPSYCH CLIN N, V11, P71, DOI 10.1176/jnp.11.1.71; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Dave D, 2008, SOUTH ECON J, V75, P497; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza E, 2005, BRIT J SPORT MED, V39, P212, DOI 10.1136/bjsm.2004.011973; Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221; Guskiewicz K. M., 2003, Medicine & Science in Sports & Exercise, V35, pS50, DOI 10.1097/00005768-200305001-00277; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hoge CW, 2011, NEW ENGL J MED, V365, P860, DOI 10.1056/NEJMc1107891; Holcomb TF, 2010, HANDBOOK OF STRESSFUL TRANSITIONS ACROSS THE LIFESPAN, P133, DOI 10.1007/978-1-4419-0748-6_7; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; KUYKEN W, 1995, BRIT J CLIN PSYCHOL, V34, P89, DOI 10.1111/j.2044-8260.1995.tb01441.x; Lacerda ALT, 2004, BIOL PSYCHIAT, V55, P353, DOI 10.1016/j.biopsych.2003.08.021; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; MOORE RG, 1988, BRIT J CLIN PSYCHOL, V27, P275, DOI 10.1111/j.2044-8260.1988.tb00790.x; NAUTA W J H, 1972, Acta Neurobiologiae Experimentalis (Warsaw), V32, P125; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Penninx BWJH, 1998, JAMA-J AM MED ASSOC, V279, P1720, DOI 10.1001/jama.279.21.1720; Puffet A, 1995, EUR PSYCHIAT, V6, P141; Rajkowska G, 1999, BIOL PSYCHIAT, V45, P1085, DOI 10.1016/S0006-3223(99)00041-4; Register-Mihalik J, 2011, J ATHL TRAINING, V46, pS16; Register-Mihalik JK, 2010, J ATHL TRAINING, V45, pS; Rothman KJ, 2008, MODERN EPIDEMIOLOGY; Sadek JR, 2004, NEUROPSYCHOLOGY, V18, P692, DOI 10.1037/0894-4105.18.4.692; Sheline YI, 1996, P NATL ACAD SCI USA, V93, P3908, DOI 10.1073/pnas.93.9.3908; Sheline YI, 1999, J NEUROSCI, V19, P5034; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188; Unutzer J, 1997, JAMA-J AM MED ASSOC, V277, P1618, DOI 10.1001/jama.277.20.1618; Vaidya VA, 1999, NEUROSCI LETT, V262, P1, DOI 10.1016/S0304-3940(99)00006-3; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P1167, DOI 10.1016/S0895-4356(98)00108-5; WILLIAMS JMG, 1988, PSYCHOL MED, V18, P689, DOI 10.1017/S0033291700008370; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	44	158	158	2	118	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	OCT	2012	40	10					2206	2212		10.1177/0363546512456193			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	014BV	WOS:000309351000007	22922518				2021-06-18	
J	Jackson, JC; Girard, TD; Gordon, SM; Thompson, JL; Shintani, AK; Thomason, JWW; Pun, BT; Canonico, AE; Dunn, JG; Bernard, GR; Dittus, RS; Ely, EW				Jackson, James C.; Girard, Timothy D.; Gordon, Sharon M.; Thompson, Jennifer L.; Shintani, Ayumi K.; Thomason, Jason W. W.; Pun, Brenda T.; Canonico, Angelo E.; Dunn, Janet G.; Bernard, Gordon R.; Dittus, Robert S.; Ely, E. Wesley			Long-term Cognitive and Psychological Outcomes in the Awakening and Breathing Controlled Trial	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						sedation; cognitive impairment; depression; PTSD	INTENSIVE-CARE-UNIT; RESPIRATORY-DISTRESS-SYNDROME; POSTTRAUMATIC-STRESS-DISORDER; CRITICALLY-ILL PATIENTS; MECHANICALLY VENTILATED PATIENTS; CONFUSION ASSESSMENT METHOD; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; CRITICAL ILLNESS; INFORMANT QUESTIONNAIRE	Rationale: Studies have shown that reducing sedation of critically ill patients shortens time on the ventilator and in the intensive care unit (ICU). Little is known, however, of how such strategies affect long-term cognitive, psychological, and functional outcomes. Objectives: To determine the long-term effects of a wake up and breathe protocol that interrupts and reduces sedative exposure in the ICU. Methods: In this a priori planned substudy conducted at one tertiary care hospital during the Awakening and Breathing Controlled Trial, a multicenter randomized controlled trial, we assessed cognitive, psychological, and functional/quality-of-life outcomes 3 and 12 months postdischarge among 180 medical ICU patients randomized to paired daily spontaneous awakening trials with spontaneous breathing trials (SBTs) or to sedation per usual care plus daily SBTs. Measurements and Main Results: Cognitive impairment was less common in the intervention group at 3-month follow-up (absolute risk reduction, 20.2%; 95% confidence interval, 1.5-36.1%.; P = 0.03) but not at 12-month follow-up (absolute risk reduction, -1.9%; 95% CI, -21.3 to 27.1%; P = 0.89). Composite cognitive scores, alternatively, were similar in the two groups at 3-month and 12-month follow-up (P = 0.80 and 0.61, respectively), as were symptoms of depression (P = 0.59 and 0.82) and posttraumatic stress disorder (P = 0.59 and 0.97). Activities of daily living, functional status, and mental and physical quality of life were similar between groups throughout follow-up. Conclusions: In this trial, management of mechanically ventilated medical ICU patients with a wake up and breathe protocol resulted in similar cognitive, psychological, and functional outcomes among patients tested 3 and 12 months post-ICU. The proven benefits of this protocol, including improved 1-year survival, were not offset by adverse long-term outcomes.	[Jackson, James C.] Vanderbilt Univ, Med Ctr, Ctr Hlth Serv Res, Div Allergy Pulm & Crit Care Med,Sch Med,Dept Med, Nashville, TN 37232 USA; [Jackson, James C.] Vanderbilt Univ, Dept Psychiat, Sch Med, Nashville, TN 37232 USA; [Thompson, Jennifer L.; Shintani, Ayumi K.; Ely, E. Wesley] Vanderbilt Univ, Dept Biostat, Sch Med, Nashville, TN 37232 USA; [Jackson, James C.] Tennessee Valley Healthcare Syst, Dept Vet Affairs Med Ctr, Clin Res Ctr Excellence, Nashville, TN USA; [Girard, Timothy D.; Gordon, Sharon M.; Dittus, Robert S.] Tennessee Valley Healthcare Syst, Dept Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr GRECC Serv, Nashville, TN USA; [Thomason, Jason W. W.] Salem Chest Specialists, Winston Salem, NC USA; [Canonico, Angelo E.] St Thomas Hosp, Dept Med, Nashville, TN USA; [Dunn, Janet G.] St Thomas Hosp, St Thomas Res Inst, Nashville, TN USA	Jackson, JC (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Hlth Serv Res, Div Allergy Pulm & Crit Care Med,Sch Med,Dept Med, 6th Floor Med Ctr E 6109, Nashville, TN 37232 USA.	james.c.jackson@vanderbilt.edu	Girard, Timothy/I-3008-2019; Ely, E. Wesley/Z-2018-2019	Girard, Timothy/0000-0002-9833-4871; Ely, E. Wesley/0000-0003-3957-2172	Saint Thomas Foundation (Nashville, TN); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG001023, HL007123, RR024975]; Veterans Affairs Tennessee Valley Geriatric Research, Education, and Clinical Center (GRECC); Hartford Geriatrics Health Outcomes Research Scholars Award Program; Vanderbilt Physician Scientist Development Program; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024975] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG001023, K23AG031322] Funding Source: NIH RePORTER	Supported by the Saint Thomas Foundation (Nashville, TN); National Institutes of Health grants AG001023, HL007123, and RR024975; Veterans Affairs Tennessee Valley Geriatric Research, Education, and Clinical Center (GRECC); Hartford Geriatrics Health Outcomes Research Scholars Award Program; and Vanderbilt Physician Scientist Development Program.	ALSAIDI F, 2003, AM J RESP CRIT CARE, V167, pA737; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Arroliga AC, 2008, CRIT CARE MED, V36, P1083, DOI 10.1097/CCM.0B013E3181653895; Beck AT, 1996, BDI 2 DEPRESSION INV; Brochard L, 2008, LANCET, V371, P95, DOI 10.1016/S0140-6736(08)60082-3; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Christie JD, 2006, J CRIT CARE, V21, P125, DOI 10.1016/j.jcrc.2005.11.004; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Davydow DS, 2009, INTENS CARE MED, V35, P796, DOI 10.1007/s00134-009-1396-5; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Gale SD, 2004, J INT NEUROPSYCH SOC, V10, P60; GIRARD TD, WAKE BREATHE FLOWCHA; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Girard TD, 2007, CRIT CARE, V11, DOI 10.1186/cc5708; Hammon JW, 1997, ANN THORAC SURG, V63, P1613, DOI 10.1016/S0003-4975(97)00261-0; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heffner JE, 2000, NEW ENGL J MED, V342, P1520, DOI 10.1056/NEJM200005183422011; Helzner EP, 2009, ARCH NEUROL-CHICAGO, V66, P343, DOI 10.1001/archneur.66.3.343; Herridge MS, 2008, CRIT CARE CLIN, V24, P179, DOI 10.1016/j.ccc.2007.11.002; Hilsabeck RC, 2002, HEPATOLOGY, V35, P440, DOI 10.1053/jhep.2002.31257; Hopkins RO, 2006, CHEST, V130, P869, DOI 10.1378/chest.130.3.869; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Hopkins RO, 2004, J INT NEUROPSYCH SOC, V10, P1005, DOI 10.1017/S135561770410711X; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; Ihaka R., 1996, J COMPUT GRAPH STAT, V5, P299, DOI [DOI 10.1080/10618600.1996.10474713, 10.1080/10618600.1996.10474713]; Jackson JC, 2007, CRIT CARE, V11, DOI 10.1186/cc5707; Jackson JC, 2007, J TRAUMA, V62, P80, DOI 10.1097/TA.0b013e31802ce9bd; Jackson JC, 2004, INTENS CARE MED, V30, P2009, DOI 10.1007/s00134-004-2422-2; Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94; Jones C, 2001, CRIT CARE MED, V29, P573, DOI 10.1097/00003246-200103000-00019; Jones C, 2006, INTENS CARE MED, V32, P923, DOI 10.1007/s00134-006-0112-y; JORM AF, 1989, PSYCHOL MED, V19, P1015, DOI 10.1017/S0033291700005742; JORM AF, 1991, PSYCHOL MED, V21, P785, DOI 10.1017/S0033291700022418; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; Jorm AF, 2004, INT PSYCHOGERIATR, V16, P275, DOI 10.1017/S1041610204000390; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; MARQUIS K, 2000, AM J RESP CRIT CARE, V161, pA383; Mathiesen HK, 2006, ARCH NEUROL-CHICAGO, V63, P533, DOI 10.1001/archneur.63.4.533; Mollica CM, 2004, HUM PSYCHOPHARM CLIN, V19, P445, DOI 10.1002/hup.624; MURKIN JM, 1995, ANN THORAC SURG, V59, P1289, DOI 10.1016/0003-4975(95)00106-U; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; NEWMAN MF, 1994, CIRCULATION, V90, P243; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Rasmussen LS, 2001, ACTA ANAESTH SCAND, V45, P275, DOI 10.1034/j.1399-6576.2001.045003275.x; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; Samra SK, 2007, STROKE, V38, P1864, DOI 10.1161/STROKEAHA.106.477448; Scarmeas N, 2006, J NEUROL NEUROSUR PS, V77, P308, DOI 10.1136/jnnp.2005.072306; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Spreen O., 1998, COMPENDIUM NEUROPSYC; Spreen O, 1969, NEUROSENSORY CTR COM; Stoll C, 1999, INTENS CARE MED, V25, P697, DOI 10.1007/s001340050932; SUCHYTA MR, 2004, AM J RESP CRIT CARE, V169, pA18; Sukantarat KT, 2005, ANAESTHESIA, V60, P847, DOI 10.1111/j.1365-2044.2005.04148.x; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Treggiari MM, 2009, CRIT CARE MED, V37, P2527, DOI 10.1097/CCM.0b013e3181a5689f; Vardy J, 2006, SUPPORT CARE CANCER, V14, P1111, DOI 10.1007/s00520-006-0037-6; Ware JE., 1994, SF 36 PHYS MENTAL HL, V1st; Wechsler D, 1997, WAIS 3 ADM SCORING M; Weinert CR, 2007, CRIT CARE MED, V35, P393, DOI 10.1097/01.CCM.0000254339.18639.1D	70	158	165	0	22	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUL	2010	182	2					183	191		10.1164/rccm.200903-0442OC			9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	629NN	WOS:000280206700009	20299535	Green Published			2021-06-18	
J	Benson, RR; Meda, SA; Vasudevan, S; Kou, ZF; Govindarajan, KA; Hanks, RA; Millis, SR; Makki, M; Latif, Z; Coplin, W; Meythaler, J; Haacke, EM				Benson, Randall R.; Meda, Shashwath A.; Vasudevan, Sriram; Kou, Zhifeng; Govindarajan, Koushik A.; Hanks, Robin A.; Millis, Scott R.; Makki, Malek; Latif, Zahid; Coplin, William; Meythaler, Jay; Haacke, E. Mark			Global white matter analysis of diffusion tensor images is predictive of injury severity in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						DAI; diffusion tensor imaging; DTI; fractional anisotropy; TBI	AMYLOID PRECURSOR PROTEIN; AXONAL INJURY; HEAD-INJURY; COGNITIVE DECLINE; CORPUS-CALLOSUM; PRACTICAL SCALE; DAMAGE; AGE; ANISOTROPY; AMNESIA	Conventional clinical neuroimaging is insensitive to axonal injury in traumatic brain injury (TBI). Immunocytochemical staining reveals changes to axonal morphology within hours, suggesting potential for diffusion-weighted magnetic resonance (MR) in early diagnosis and management of TBI. Diffusion tensor imaging (DTI) characterizes the three-dimensional (3D) distribution of water diffusion, which is highly anisotropic in white matter fibers owing to axonal length. Recently, DTI has been used to investigate traumatic axonal injury (TAI), emphasizing regional analysis in more severe TBI. In the current study, we hypothesized that a global white matter (WM) analysis of DTI data would be sensitive to TAI across a spectrum of TBI severity and injury to scan interval. To investigate this, we compared WM-only histograms of a scalar, fractional anisotropy (FA), between. 20 heterogeneous TBI patients recruited from Detroit Medical Center, including six mild TBI (GCS 13-15), and 14 healthy age-matched controls. FA histogram parameters were correlated with admission GCS and posttraumatic amnesia (PTA). In all cases, including mild TBI, patients' FA histograms were globally decreased compared with control histograms. The shape of the TBI histograms also differed from controls, being more peaked and skewed. The mean FA, kurtosis and skewness were highly correlated suggesting a common mechanism. FA histogram properties also correlated with injury severity indexed by GCS and PTA, with mean FA being the best predictor and duration of PTA (r = 0.64) being superior to GCS (r = 0.47). Therefore, in this heterogeneous sample, the FA mean accounted for 40% of the variance in PTA. Increased diffusion in the short axis dimension, likely reflecting dysmyelination and swelling of axons, accounted for most of the FA decrease. FA is globally deceased in WM, including mild TBI, possibly reflecting widespread involvement. FA changes appear to be correlated with injury severity suggesting a role in early diagnosis and prognosis of TBI.	Wayne State Univ, DMC, Dept Neurol, Univ Hlth Ctr, Detroit, MI 48201 USA; Wayne State Univ, DMC, Dept Biomed Engn, Univ Hlth Ctr, Detroit, MI 48201 USA; Wayne State Univ, DMC, Dept Diagnost Radiol, Univ Hlth Ctr, Detroit, MI 48201 USA; Wayne State Univ, DMC, Dept Pediat & Radiol, Univ Hlth Ctr, Detroit, MI 48201 USA; Hartford Hosp, Inst Living OL, Olin Neuropsychiat Res Ctr, Hartford, CT 06115 USA; Kennedy Krieger Inst, Baltimore, MD USA	Benson, RR (corresponding author), Wayne State Univ, DMC, Dept Neurol, Univ Hlth Ctr, 8D,4201 St Antoine, Detroit, MI 48201 USA.	rbenson@med.wayne.edu	Makki, Malek/AAJ-1132-2021; Govindarajan, Koushik Athreya/L-9758-2019	Makki, Malek/0000-0002-6574-8242; Govindarajan, Koushik/0000-0001-8397-1360	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HI33A020515] Funding Source: Medline		Adams J H, 1988, Curr Top Pathol, V76, P1; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; [Center for Disease Control CDC], 2006, INC EC BURD INJ US; Charlton RA, 2006, NEUROLOGY, V66, P217, DOI 10.1212/01.wnl.0000194256.15247.83; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Conturo TE, 1996, MAGNET RESON MED, V35, P399, DOI 10.1002/mrm.1910350319; Filippi M, 2001, NEUROLOGY, V56, P304, DOI 10.1212/WNL.56.3.304; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Gurdjian ES, 1945, MENT ADV DIS, V24, P28; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; Holbourn AHS, 1943, LANCET, V2, P438; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; MACDONALD CL, 2006, 24 ANN NATIL NEUROTR; MARR A, 2001, CENTRAL NEROVOUS SYS; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MCLELLAN DR, 1990, COMA EMERGING PATIEN, P389; Meda SA, 2006, ANN M INT SOC MAGN R; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; NEWCOMBE V, 2006, 24 ANN NATL NEUR SOC; OMMAYA AK, 1969, ACCIDENT PATHOLOGY; Ota M, 2006, NEUROIMAGE, V31, P1445, DOI 10.1016/j.neuroimage.2006.02.008; Persson J, 2006, CEREB CORTEX, V16, P907, DOI 10.1093/cercor/bhj036; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pfefferbaum A, 2006, NEUROBIOL AGING, V27, P994, DOI 10.1016/j.neurobiolaging.2005.05.007; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Salat DH, 2005, ANN NY ACAD SCI, V1064, P37, DOI 10.1196/annals.1340.009; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Shimony JS, 1999, RADIOLOGY, V212, P770, DOI 10.1148/radiology.212.3.r99au51770; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Sorensen AG, 1999, RADIOLOGY, V212, P785, DOI 10.1148/radiology.212.3.r99se24785; Sullivan EV, 2006, CEREB CORTEX, V16, P1030, DOI 10.1093/cercor/bhj045; TEASDALE G, 1974, LANCET, V2, P81; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0; ZOROYA G, 2005, KEY IRAQ WOUND BRAIN	58	158	173	0	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2007	24	3					446	459		10.1089/neu.2006.0153			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	152RQ	WOS:000245379900002	17402851				2021-06-18	
J	Sato, M; Chang, E; Igarashi, T; Noble, LJ				Sato, M; Chang, E; Igarashi, T; Noble, LJ			Neuronal injury and loss after traumatic brain injury: time course and regional variability	BRAIN RESEARCH			English	Article						traumatic brain injury; Fluoro-Jade; neuronal degeneration	CORTICAL IMPACT INJURY; FLUORO-JADE; RAT-BRAIN; DNA FRAGMENTATION; CELL-DEATH; DEGENERATION; APOPTOSIS; MOUSE; METHAMPHETAMINE; VULNERABILITY	We have examined regional neuronal injury after traumatic brain injury using Fluoro-Jade, an acidic dye that exhibits a marked affinity for both the degenerating neuronal cell body and its processes and have determined the extent to which early injury corresponds to regional patterns of neuronal loss. Rats (n=45) were subjected to lateral fluid percussion brain injury and euthanized at 3 h to 28 days post injury. Complementary Fluoro-Jade, silver impregnation methods and TUNEL were used to assess neuronal injury. Neuronal loss was evaluated in sections immunostained for NeuN, a neuronal specific nuclear protein. Overt neuronal cell loss was evident by 7 days post injury in the cortex, hippocampus and thalamus. Injured neurons were apparent in the ipsilateral cortex bordering the impact site, hippocampus (CAI and dentate), thalamus, and vermis of the cerebellum as early as 3 h post injury. Degenerating neurons were maximal by 1 and 3 days in the cortex and hippocampus, by 3 and 7 days in the cerebellum, and by 7 days in the thalamus, The regional distribution of Fluoro-Jade-labeled neurons corresponded to a similar pattern of silver and TUNEL staining. Together, these findings demonstrate a regionally specific temporal pattern of neuronal injury that results in overt neuronal cell loss within both cortical and subcortical regions. (C) 2001 Elsevier Science B.V. All rights reserved.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	Noble, LJ (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 521 Parnassus Ave,Room C224, San Francisco, CA 94143 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 14543] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS014543, P50NS014543] Funding Source: NIH RePORTER		AUER R, 1985, ACTA NEUROPATHOL, V67, P279, DOI 10.1007/BF00687813; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Eisch AJ, 1998, SYNAPSE, V30, P329, DOI 10.1002/(SICI)1098-2396(199811)30:3<329::AID-SYN10>3.3.CO;2-H; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Freyaldenhoven TE, 1997, BRAIN RES, V759, P9, DOI 10.1016/S0006-8993(97)00045-0; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hornfelt M, 1999, NEUROSCI LETT, V265, P87, DOI 10.1016/S0304-3940(99)00046-4; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; KONNO H, 1989, J NEUROIMMUNOL, V25, P151, DOI 10.1016/0165-5728(89)90132-X; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Noble LJ, 1996, J COMP NEUROL, V376, P542; OHEARN E, 1995, NEUROREPORT, V6, P1611, DOI 10.1097/00001756-199508000-00006; Paxinos G., 1995, RAT NERVOUS SYSTEM; Poirier JL, 2000, NEUROSCIENCE, V97, P59, DOI 10.1016/S0306-4522(00)00026-9; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Schmued L, 1999, TOXICOL SCI, V48, P100, DOI 10.1093/toxsci/48.1.100; Schmued LC, 1997, BRAIN RES, V759, P135, DOI 10.1016/S0006-8993(97)00173-X; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	30	158	161	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 26	2001	917	1					45	54		10.1016/S0006-8993(01)02905-5			10	Neurosciences	Neurosciences & Neurology	486HR	WOS:000171812800004	11602228				2021-06-18	
J	Fortin, A; Cregan, SP; MacLaurin, JG; Kushwaha, N; Hickman, ES; Thompson, CS; Hakim, A; Albert, PR; Cecconi, F; Helin, K; Park, DS; Slack, RS				Fortin, A; Cregan, SP; MacLaurin, JG; Kushwaha, N; Hickman, ES; Thompson, CS; Hakim, A; Albert, PR; Cecconi, F; Helin, K; Park, DS; Slack, RS			APAF1 is a key transcriptional target for p53 in the regulation of neuronal cell death	JOURNAL OF CELL BIOLOGY			English	Article						apoptosis; neurodegeneration; neurons; bax; caspase 3	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN INJURY; TUMOR-SUPPRESSOR; NERVOUS-SYSTEM; CYTOCHROME-C; P53-INDUCED APOPTOSIS; HIPPOCAMPAL-NEURONS; TRANSGENIC MICE; MESSENGER-RNA; DNA-DAMAGE	P53 is a transcriptional activator which has been implicated as a key regulator of neuronal cell death after acute injury. We have shown previously that p53-mediated neuronal cell death involves a Bax-dependent activation of caspase 3; however, the transcriptional targets involved in the regulation of this process have not been identified. In the present study, we demonstrate that p53 directly upregulates Apaf1 transcription as a critical step in the induction of neuronal cell death. Using DNA microarray analysis of total RNA isolated from neurons undergoing p53-induced apoptosis a 5-6-fold upregulation of Apaf1 mRNA was detected. Induction of neuronal cell death by camptothecin, a DNA-damaging agent that functions through a p53-dependent mechanism, resulted in increased Apaf1 mRNA in p53-positive, but not p53-deficient neurons. In both in vitro and in vivo neuronal cell death processes of p53-induced cell death, Apaf1 protein levels were increased. We addressed whether p53 directly regulates Apaf1 transcription via the two p53 consensus binding sites in the Apaf1 promoter. Electrophoretic mobility shift assays demonstrated p53-DNA binding activity at both p53 consensus binding sequences in extracts obtained from neurons undergoing p53-induced cell death, but not in healthy control cultures or when p53 or the p53 binding sites were inactivated by mutation. In transient transfections in a neuronal cell line with p53 and Apaf1 promoter-luciferase constructs, p53 directly activated the Apaf1 promoter via both p53 sites. The importance of Apaf1 as a p53 target gene in neuronal cell death was evaluated by examining p53-induced apoptotic pathways in primary cultures of Apaf1-deficient neurons. Neurons treated with camptothecin were significantly protected in the absence of Apaf1 relative to those derived from wild-type littermates. Together, these results demonstrate that Apaf1 is a key transcriptional target for p53 that plays a pivotal role in the regulation of apoptosis after neuronal injury.	Univ Ottawa, Ottawa Hlth Res Inst Neurosci, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy	Slack, RS (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst Neurosci, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	rslack@uottawa.ca	Helin, Kristian/K-2526-2019; Cecconi, Francesco/K-3969-2016; Albert, Paul/E-4804-2010; Cregan, Sean/M-3205-2013	Cecconi, Francesco/0000-0002-5614-4359; Albert, Paul/0000-0002-1809-3554; Helin, Kristian/0000-0003-1975-6097; Park, David/0000-0002-4490-3784; Slack, Ruth/0000-0002-1552-2835	TelethonFondazione Telethon [TCP99038] Funding Source: Medline; Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		Banasiak KJ, 1998, BRAIN RES, V797, P295, DOI 10.1016/S0006-8993(98)00286-8; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Cregan SP, 2000, GENE THER, V7, P1200, DOI 10.1038/sj.gt.3301208; Cregan SP, 1999, J NEUROSCI, V19, P7860; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Gillardon F, 1997, MOL BRAIN RES, V50, P16, DOI 10.1016/S0169-328X(97)00162-9; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Henderson CE, 1996, NEURON, V17, P579, DOI 10.1016/S0896-6273(00)80191-9; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Hughes PE, 1997, NEUROREPORT, V8, pR5; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; Keramaris E, 2000, MOL CELL NEUROSCI, V15, P368, DOI 10.1006/mcne.2000.0838; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LEE HJ, 1990, J NEUROSCI, V10, P1779; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LI Y, 1994, STROKE, V25, P849, DOI 10.1161/01.STR.25.4.849; LI Y, 1995, AM J PATHOL, V146, P1045; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; McGahan L, 1998, MOL BRAIN RES, V56, P133, DOI 10.1016/S0169-328X(98)00038-2; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morrison RS, 1996, J NEUROSCI, V16, P1337; NAGASAWA H, 1989, STROKE, V20, P1037, DOI 10.1161/01.STR.20.8.1037; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Ni BH, 1998, J CEREBR BLOOD F MET, V18, P248, DOI 10.1097/00004647-199803000-00003; NITATORI T, 1995, J NEUROSCI, V15, P1001; O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Prives C, 1999, J PATHOL, V187, P112; RINK A, 1995, AM J PATHOL, V147, P1575; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sakhi S, 1996, NEUROREPORT, V7, P493, DOI 10.1097/00001756-199601310-00028; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; Slack RS, 1996, J CELL BIOL, V135, P1085, DOI 10.1083/jcb.135.4.1085; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; Storring JM, 1999, J NEUROCHEM, V72, P2238, DOI 10.1046/j.1471-4159.1999.0722238.x; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Watanabe H, 1999, BRAIN RES, V837, P38, DOI 10.1016/S0006-8993(99)01652-2; Xiang H, 1996, J NEUROSCI, V16, P6753; Xiang H, 1998, J NEUROSCI, V18, P1363; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	53	158	168	0	7	ROCKEFELLER UNIV PRESS	NEW YORK	950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA	0021-9525	1540-8140		J CELL BIOL	J. Cell Biol.	OCT 15	2001	155	2					207	216		10.1083/jcb.200105137			10	Cell Biology	Cell Biology	483TH	WOS:000171651600005	11591730	Green Published, Bronze			2021-06-18	
J	Groswasser, Z; Cohen, M; Keren, O				Groswasser, Z; Cohen, M; Keren, O			Female TBI patients recover better than males	BRAIN INJURY			English	Article							CONTUSION INJURY; BRAIN EDEMA; RATS	The purpose of the present study was to look at possible gender differences in outcome after severe traumatic brain injury. Three hundred and thirty four consecutive patients, 72 females and 262 males, age range 5-65 years, were included in the study. Age range and severity of injury, evaluated by duration of unconsciousness, did not differ between male and female patients. Predicted outcome at the time of discharge from an in-patient rehabilitation programme was evaluated according to work capacity. Female TBI patients had a better predicted outcome (p < 0.015). It is suggested that progesterone, acting as a neuroprotective agent, may explain this difference in outcome.	Loewenstein Hosp & Rehabil Ctr, Dept Brain Injury Rehabil, IL-43100 Raanana, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Groswasser, Z (corresponding author), Loewenstein Hosp & Rehabil Ctr, Dept Brain Injury Rehabil, 278 Achuza St,POB 3, IL-43100 Raanana, Israel.						ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; BADWE RA, 1991, LANCET, V337, P1261, DOI 10.1016/0140-6736(91)92927-T; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; KIMURA D, 1987, CAN PSYCHOL, V28, P133, DOI 10.1037/h0079885; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3	12	158	164	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	1998	12	9					805	808		10.1080/026990598122197			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	117ET	WOS:000075768500008	9755371				2021-06-18	
J	Kampfl, A; Schmutzhard, E; Franz, G; Pfausler, B; Haring, HP; Ulmer, H; Felber, S; Golaszewski, S; Alchner, F				Kampfl, A; Schmutzhard, E; Franz, G; Pfausler, B; Haring, HP; Ulmer, H; Felber, S; Golaszewski, S; Alchner, F			Prediction of recovery from post-traumatic vegetative state with cerebral magnetic-resonance imaging	LANCET			English	Article							CLOSED-HEAD INJURY; MR; FEATURES; COMA	Background The early post-traumatic vegetative state (VS) is compatible with recovery. Various clinical and laboratory tests have failed to predict recovery so we assessed the value of cerebral magnetic-resonance imaging (MRI) in prediction of recovery. Methods 80 adult patients in post-traumatic VS had cerebral MRI between 6 weeks and 8 weeks after injury. MRIs were reviewed by three neuroradiologists for the number, sizes, and location of brain lesions. Three neurologists assessed the patients at the time of MRI and at 2 months, 3 months, 6 months, 9 months, and 12 months after injury using the Glasgow Outcome Scale. Findings At 12 months, 38 patients had recovered while 42 patients remained in the VS. The demographic characteristics and causes and severity of injury were similar in patients in persistent VS (PVS) and those who recovered (NPVS). An average of 6.1 different brain areas were injured in patients in PVS compared with 4.6 areas in patients who had NPVS. Patients in PVS revealed a significantly higher frequency of corpus callosum, corona radiata, and dorsolateral brainstem injuries than did patients who recovered. Logistic regression analysis showed that corpus callosum and dorsolateral brainstem injuries were predictive of non-recovery. The adjusted odds ratios for non-recovery of patients with a corpus callosum lesion and dorsolateral brainstem injury were 213.8 (95% CI 14.2-3213.3), and 6.9 (1.1-42.9), respectively. In contrast, clinical characteristics, such as initial score on the Glasgow Coma Scale, age, and pupillary abnormalities failed to predict recovery. Interpretation Cerebral MRI findings in the subacute stage after head injury can predict the outcome of the posttraumatic VS. Corpus callosum and dorsolateral brainstem lesions are highly significant in predicting non-recovery.	Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria; Univ Innsbruck Hosp, Dept Biostat, A-6020 Innsbruck, Austria; Univ Innsbruck Hosp, Dept Magnet Resonance & Spect, A-6020 Innsbruck, Austria	Kampfl, A (corresponding author), Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria.		Ulmer, Hanno/S-6615-2019	Ulmer, Hanno/0000-0001-5911-1002			ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; AGARDH CD, 1983, ANN NEUROL, V14, P482, DOI 10.1002/ana.410140414; AHMED I, 1988, CLIN ELECTROENCEPHAL, V19, P78, DOI 10.1177/155005948801900209; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; FRENCH JD, 1952, AMA ARCH NEUROL PSY, V68, P727, DOI 10.1001/archneurpsyc.1952.02320240002001; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1994, RADIOLOGY, V191, P1; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; HANSOTIA PL, 1985, ARCH NEUROL-CHICAGO, V42, P1048, DOI 10.1001/archneur.1985.04060100030015; JELLINGER K, 1977, APALLIC SYNDROME, P89; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; ODER W, 1991, INTENS CARE MED, V17, P49; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Payne K, 1996, ANN INTERN MED, V125, P104, DOI 10.7326/0003-4819-125-2-199607150-00004; PETERS G, 1977, APALLIC SYNDROME, P78; RAMADAN NM, 1989, STROKE, V20, P1279, DOI 10.1161/01.STR.20.9.1279; WUILLEMUIER P, 1995, NEUROCHIRURGIE, V41, P98; Zeman A, 1997, LANCET, V350, P795, DOI 10.1016/S0140-6736(97)06447-7; 1996, J R COLL PHYSICIANS, V30, P19	30	158	168	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1763	1767		10.1016/S0140-6736(97)10301-4			5	Medicine, General & Internal	General & Internal Medicine	ZU444	WOS:000074197600009	9635948				2021-06-18	
J	MARIN, RS; FOGEL, BS; HAWKINS, J; DUFFY, J; KRUPP, B				MARIN, RS; FOGEL, BS; HAWKINS, J; DUFFY, J; KRUPP, B			APATHY - A TREATABLE SYNDROME	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							BEHAVIOR; DISEASE	Apathy occurs frequently in neuropsychiatric disorders both as a symptom of other syndromes and as a syndrome per se. Histories are presented of patients with a syndrome of apathy who showed clinically significant, sustained benefit from pharmacological treatment. Etiologies included non-Alzheimer's frontal lobe dementia, cerebral infarction, intracranial hemorrhage, alcoholism, and traumatic brain injury. Agents included amantadine, amphetamine, bromocriptine, bupropion, methylphenidate, and selegiline. These histories support the suggestion that apathy is a discriminable dimension of behavior having its own pathophysiology and implications for psychiatric care. They raise the possibility of treatment for many patients previously thought untreatable. Studying the treatment of apathy may contribute to the clinical care and scientific understanding of neuropsychiatric disorders throughout the life span.	BROWN UNIV,CTR GERONTOL,PROVIDENCE,RI 02912; ALLGEHENY NEUROPSYCHIATR INST,OAKDALE,PA; VET AFFAIRS MED CTR,PALO ALTO,CA	MARIN, RS (corresponding author), UNIV PITTSBURGH,WESTERN PSYCHIAT INST & CLIN,3811 OHARA ST,PITTSBURGH,PA 15213, USA.						Atkinson J. W., 1978, INTRO MOTIVATION; BACHMAN DL, 1984, BRAIN PATHOLOGY, V1, P91; BURNS A, 1990, J NERV MENT DIS, V178, P20, DOI 10.1097/00005053-199001000-00004; CARPENTER WT, 1985, SCHIZOPHRENIA BULL, V11, P440, DOI 10.1093/schbul/11.3.440; CHIARELLO RJ, 1987, ARCH GEN PSYCHIAT, V44, P286; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; DARVILL FT, 1959, JAMA-J AM MED ASSOC, V169, P1739, DOI 10.1001/jama.1959.03000320041011; FANCHAMPS A, 1982, AGING, V23; Gainotti G, 1972, Cortex, V8, P41; GELENBERG A, 1991, BIOL THERAPIES PSYCH, V14, P925; GERRING JP, 1993, OCT ANN M AM AC CHIL; GILMAN AG, 1990, PHARM BASIS THERAPEU; Gurian Bennett, 1993, Am J Geriatr Psychiatry, V1, P171, DOI 10.1097/00019442-199300120-00011; HAWKINS JW, 1992, BIOL PSYCHIAT, V31, pA250; HEILMAN KM, 1985, HDB CLIN NEUROLOGY, V1, P153; HOEHNSARIC R, 1990, J CLIN PSYCHOPHARM, V10, P343; HOLLIDAY AR, 1965, J NEW DRUGS, V5, P257; JACOBSON A, 1958, PSYCHIAT QUART, V32, P474, DOI 10.1007/BF01563517; JAFFE GV, 1961, PRACTITIONER, V186, P492; KAPLITZ SE, 1975, J AM GERIATR SOC, V23, P271, DOI 10.1111/j.1532-5415.1975.tb00317.x; KLEIN DF, 1980, DIAGNOSIS TREATMENT; LANDRY S, 1990, DEV BEHAVIORAL PEDIA, V41, P306; Maletta Gabe J, 1993, Am J Geriatr Psychiatry, V1, P234, DOI 10.1097/00019442-199300130-00008; MARIN RS, 1993, J AFFECT DISORDERS, V28, P117, DOI 10.1016/0165-0327(93)90040-Q; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; MARIN RS, 1994, J NERV MENT DIS, V182, P235, DOI 10.1097/00005053-199404000-00008; MARSDEN CD, 1977, LANCET, V1, P345; OVERALL JE, 1963, J PSYCHIATR RES, V1, P239; Pritchard J G, 1975, Curr Med Res Opin, V3, P26, DOI 10.1185/03007997509113641; REISBERG B, 1983, CLIN PRESENTATION DI; RIFKIN A, 1975, ARCH GEN PSYCHIAT, V32, P672, DOI 10.1001/archpsyc.1975.01760230138011; ROLLS ET, 1985, SCI BASIS CLIN NEURO; ROSS ED, 1981, NEUROLOGY, V31, P1435, DOI 10.1212/WNL.31.11.1435; RUBIN EH, 1987, PSYCHIAT RES, V21, P55, DOI 10.1016/0165-1781(87)90062-X; SCHNEIDER LS, 1994, DIAGNOSIS TREATMENT; SCHULTERBRANDT JG, 1974, PSYCHOL REP, V34, P23, DOI 10.2466/pr0.1974.34.1.23; STARKSTEIN SE, 1993, STROKE, V24, P1625, DOI 10.1161/01.STR.24.11.1625; Ullmann LP, 1969, PSYCHOL APPROACH ABN	40	158	161	0	10	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	1995	7	1					23	30					8	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	QD727	WOS:A1995QD72700004	7711487				2021-06-18	
J	SUTTON, RL; LESCAUDRON, L; STEIN, DG				SUTTON, RL; LESCAUDRON, L; STEIN, DG			UNILATERAL CORTICAL CONTUSION INJURY IN THE RAT - VASCULAR DISRUPTION AND TEMPORAL DEVELOPMENT OF CORTICAL NECROSIS	JOURNAL OF NEUROTRAUMA			English	Article							TRAUMATIC BRAIN INJURY; AMINO-ACIDS; HEAD-INJURY; BLOOD-FLOW; RESPONSES; DAMAGE; LIGHT	Cerebrovascular disruption and cortical pathology resulting from either moderate (M-TBI) or severe (S-TBI) traumatic brain injury produced by a pneumatically-driven cortical contusion device were assessed in adult male rats sacrificed at 6 and 24 h or 8 and 30 days after injury to the right sensorimotor cortex. Epidural, subdural, subarachnoid, petechial (cortex and corpus callosum), and/or intraventricular hemorrhage was present in all animals, more extensively and severely following S-TBI. At 6 or 24 h after TBI, acidophilic (acid fuchsin-positive) neurons were numerous and widespread (S-TBI > M-TBI) in the ipsilateral contused cortex. By 8 days few acidophilic neurons were present in peri-impact regions of the ipsilateral neocortex, and none were detected in cortex 30 days postinjury. Both M-TBI and S-TBI groups had enlarged ipsilateral cortical volumes (edema) at 6 and 24 h postcontusion. Eight and 30 days after injury the mean volume of cortical necrosis was significantly larger in S-TBI than in M-TBI rats, and cortical necrosis in both TBI conditions increased between 8 to 30 days postinjury. These results indicate that this pneumatically-driven contusion device produces reliable and consistent primary and secondary cortical histopathology, the extent of which is related to the severity of initial injury.	UNIV MINNESOTA, DEPT NEUROSURG, MINNEAPOLIS, MN 55455 USA; UNIV NANTES, FAC SCI & TECHNIQ,CNRS,URA 1340,SERV PHYSIOL ANIM, NANTES 03, FRANCE	SUTTON, RL (corresponding author), UNIV MINNESOTA, HENNEPIN CTY MED CTR, DEPT SURG, 701 PK AVE S, MINNEAPOLIS, MN 55415 USA.		Stein, Donald/AAJ-5139-2020				AUER RN, 1985, ACTA NEUROPATHOL, V67, P13, DOI 10.1007/BF00688120; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DIENEL GA, 1984, J NEUROCHEM, V43, P913, DOI 10.1111/j.1471-4159.1984.tb12825.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; LEES GJ, 1989, ACTA NEUROPATHOL, V77, P519, DOI 10.1007/BF00687254; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MACDONALD RL, 1991, J NEUROSURG, V75, P415, DOI 10.3171/jns.1991.75.3.0415; MITCHELL DE, 1973, LANCET, V2, P215; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; Strich S J, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P166; SUTTON RL, UNPUB UNILATERAL COR; SUTTON RL, 1987, J HEAD TRAUMA REHAB, V2, P50; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TORNHEIM PA, 1984, J NEUROSURG, V60, P473, DOI 10.3171/jns.1984.60.3.0473; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	29	158	161	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SUM	1993	10	2					135	149		10.1089/neu.1993.10.135			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	LM056	WOS:A1993LM05600005	8411217				2021-06-18	
J	Kassebaum, N; Kyu, HH; Zoeckler, L; Olsen, H; Thomas, K; Pinho, C; Bhutta, ZA; Dandona, L; Ferrari, A; Ghiwot, TT; Hay, SI; Kinfu, Y; Liang, XF; Lopez, A; Malta, DC; Mokdad, AH; Naghavi, M; Patton, GC; Salomon, J; Sartorius, B; Topor-Madry, R; Vollset, SE; Werdecker, A; Whiteford, HA; Abate, KH; Abbas, K; Damtew, SA; Ahmed, MB; Akseer, N; Al-Raddadi, R; Alemayohu, MA; Altirkawi, K; Abajobir, AA; Amare, AT; Antonio, CAT; Amlov, J; Al Artaman; Asayesh, H; Avokpaho, EFGA; Awasthi, A; Quintanilla, BPA; Bacha, U; Betsu, BD; Barac, A; Bamighausen, TW; Baye, E; Bedi, N; Bensenor, IM; Berhane, A; Bernabe, E; Bernal, OA; Beyene, AS; Biadgilign, S; Bikbov, B; Boyce, CA; Brazinova, A; Hailu, GB; Carter, A; Castaneda-Orjuela, CA; Catala-Lopez, F; Charlson, FJ; Chitheer, AA; Choi, JYJ; Ciobanu, LG; Crump, J; Dandona, R; Dellavalle, RP; Deribew, A; Deveber, G; Dicker, D; Ding, EL; Dubey, M; Endries, AY; Erskine, HE; Faraon, EJA; Faro, A; Farzadfar, F; Fernandes, JC; Fijabi, DO; Fitzmaurice, C; Fleming, TD; Flor, LS; Foreman, KJ; Franklin, RC; Fraser, MS; Frostad, JJ; Fullman, N; Gebregergs, GB; Gebru, AA; Geleijnse, JM; Gibney, KB; Yihdego, MG; Ginawi, IAM; Gishu, MD; Gizachew, TA; Glaser, E; Gold, AL; Goldberg, E; Gona, P; Goto, A; Gugnani, HC; Jiang, GH; Gupta, R; Tesfay, FH; Hankey, GJ; Havmoeller, R; Hijar, M; Horino, M; Hosgood, HD; Hu, GQ; Jacobsen, KH; Jakovljevic, MB; Jayaraman, SP; Jha, V; Jibat, T; Johnson, CO; Jonas, J; Kasaeian, A; Kawakami, N; Keiyoro, PN; Khalil, I; Khang, YH; Khubchandani, J; Ahmad Kiadaliri, AA; Kieling, C; Kim, D; Kissoon, N; Knibbs, LD; Koyanagi, A; Krohn, KJ; Defo, BK; Bicer, BK; Kulikoff, R; Kumar, A; Lal, DK; Lam, HY; Larson, HJ; Larsson, A; Laryea, DO; Leung, J; Lim, SS; Lo, LT; Lo, WD; Looker, KJ; Lotufo, PA; El Razek, HMA; Malekzadeh, R; Shifti, DM; Mazidi, M; Meaney, PA; Meles, KG; Memiah, P; Mendoza, W; Mengistie, MA; Mengistu, G; Mensah, GA; Miller, TR; Mock, C; Mohammadi, A; Mohammed, S; Monasta, L; Mueller, U; Nagata, C; Naheed, A; Nguyen, G; Le Nguyen, Q; Nsoesie, E; Oh, IH; Okoro, A; Olusanya, JO; Olusanya, BO; Ortiz, A; Paudel, D; Pereira, DM; Perico, N; Petzold, M; Phillips, MR; Polanczyk, GV; Pourmalek, F; Qorbani, M; Rafay, A; Rahimi-Movaghar, V; Rahman, M; Rai, RK; Ram, U; Rankin, Z; Remuzzi, G; Renzaho, AMN; Roba, HS; Rojas-Rueda, D; Ronfani, L; Sagar, R; Sanabria, JR; Mohammed, MSK; Santos, IS; Satpathy, M; Sawhney, M; Ben Schottker; Schwebel, DC; Scott, JG; Sepanlou, SG; Shaheen, A; Shaikh, MA; She, J; Shiri, R; Shiue, I; Sigfusdottir, ID; Singh, J; Silpakit, N; Smith, A; Sreeramareddy, C; Stanaway, JD; Stein, DJ; Steiner, C; Sufiyan, MB; Swaminathan, S; Tabares-Seisdedos, R; Tabb, KM; Tadese, F; Tavakkoli, M; Taye, B; Teeple, S; Tegegne, TK; Shifa, GT; Terkawi, AS; Thomas, B; Thomson, AJ; Tobe-Gai, R; Tonelli, M; Tran, BX; Troeger, C; Ukwaja, KN; Uthman, O; Vasankari, T; Venketasubramanian, N; Vlassov, VV; Weiderpass, E; Weintraub, R; Gebrehiwot, SW; Westerman, R; Williams, HC; Wolfe, CDA; Woodbrook, R; Yano, Y; Yonemoto, N; Yoon, SJ; Younis, MZ; Yu, CH; Zaki, MES; Zegeye, EA; Zuhlke, LJ; Murray, CJL; Vos, T				Kassebaum, Nicholas; Hmwe Kyu, Hmwe; Zoeckler, Leo; Elizabeth Olsen, Helen; Thomas, Katie; Pinho, Christine; Bhutta, Zulfiqar A.; Dandona, Lalit; Ferrari, Alize; Ghiwot, Tsegaye Tewelde; Hay, Simon I.; Kinfu, Yohannes; Liang, Xiaofeng; Lopez, Alan; Carvalho Malta, Deborah; Mokdad, Ali H.; Naghavi, Mohsen; Patton, George C.; Salomon, Joshua; Sartorius, Benn; Topor-Madry, Roman; Vollset, Stein Emil; Werdecker, Andrea; Whiteford, Harvey A.; Abate, Kalkidan Hasen; Abbas, Kaja; Damtew, Solomon Abrha; Ahmed, Muktar Beshir; Akseer, Nadia; Al-Raddadi, Rajaa; Alemayohu, Mulubirhan Assefa; Altirkawi, Khalid; Abajobir, Amanuel Alemu; Amare, Azmeraw T.; Antonio, Carl A. T.; Amlov, Johan; Al Artaman; Asayesh, Hamid; Avokpaho, Euripide Frinel G. Arthur; Awasthi, Ashish; Quintanilla, Beatriz Paulina Ayala; Bacha, Umar; Betsu, Balem Demtsu; Barac, Aleksandra; Bamighausen, Till Winfried; Baye, Estifanos; Bedi, Neeraj; Bensenor, Isabela M.; Berhane, Adugnaw; Bernabe, Eduardo; Alberto Bernal, Oscar; Beyene, Addisu Shunu; Biadgilign, Sibhatu; Bikbov, Boris; Anne Boyce, Cheryl; Brazinova, Alexandra; Hailu, Gessessew Bugssa; Carter, Austin; Castaneda-Orjuela, Carlos A.; Catala-Lopez, Ferran; Charlson, Fiona J.; Chitheer, Abdulaal A.; Choi, Jee-Young Jasmine; Ciobanu, Liliana G.; Crump, John; Dandona, Rakhi; Dellavalle, Robert P.; Deribew, Amare; deveber, Gabrielle; Dicker, Daniel; Ding, Eric L.; Dubey, Manisha; Endries, Amanuel Yesuf; Erskine, Holly E.; Faraon, Emerito Jose Aquino; Faro, Andre; Farzadfar, Farshad; Fernandes, Joao C.; Obadare Fijabi, Daniel; Fitzmaurice, Christina; Fleming, Thomas D.; Sorio Flor, Luisa; Foreman, Kyle J.; Franklin, Richard C.; Fraser, Maya S.; Frostad, Joseph J.; Fullman, Nancy; Gebregergs, Gebremedhin Berhe; Gebru, Alemseged Aregay; Geleijnse, Johanna M.; Gibney, Katherine B.; Yihdego, Mahari Gidey; Ginawi, Ibrahim Abdelmageem Mohamed; Gishu, Melkamu Dedefo; Gizachew, Tessema Assefa; Glaser, Elizabeth; Gold, Audra L.; Goldberg, Ellen; Gona, Philimon; Goto, Atsushi; Gugnani, Harish Chander; Jiang, Guohong; Gupta, Rajeev; Tesfay, Fisaha Haile; Hankey, Graeme J.; Havmoeller, Rasmus; Hijar, Martha; Horino, Masako; Hosgood, H. Dean; Hu, Guoqing; Jacobsen, Kathryn H.; Jakovljevic, Mihajlo B.; Jayaraman, Sudha P.; Jha, Vivekanand; Jibat, Tariku; Johnson, Catherine O.; Jonas, Jost; Kasaeian, Amir; Kawakami, Norito; Keiyoro, Peter N.; Khalil, Ibrahim; Khang, Young-Ho; Khubchandani, Jagdish; Ahmad Kiadaliri, Aliasghar A.; Kieling, Christian; Kim, Daniel; Kissoon, Niranjan; Knibbs, Luke D.; Koyanagi, Ai; Krohn, Kristopher J.; Defo, Barthelemy Kuate; Bicer, Burcu Kucuk; Kulikoff, Rachel; Kumar, Anil; Lal, Dharmesh Kumar; Lam, Hilton Y.; Larson, Heidi J.; Larsson, Anders; Laryea, Dennis Odai; Leung, Janni; Lim, Stephen S.; Lo, Loon-Tzian; Lo, Warren D.; Looker, Katharine J.; Lotufo, Paulo A.; El Razek, Hassan Magdy Abd; Malekzadeh, Reza; Shifti, Desalegn Markos; Mazidi, Mohsen; Meaney, Peter A.; Meles, Kidanu Gebremariam; Memiah, Peter; Mendoza, Walter; Mengistie, Mubarek Abera; Mengistu, Gebremichael Welday; Mensah, George A.; Miller, Ted R.; Mock, Charles; Mohammadi, Alireza; Mohammed, Shafiu; Monasta, Lorenzo; Mueller, Ulrich; Nagata, Chie; Naheed, Aliya; Nguyen, Grant; Le Nguyen, Quyen; Nsoesie, Elaine; Oh, In-Hwan; Okoro, Anselm; Olusanya, Jacob Olusegun; Olusanya, Bolajoko O.; Ortiz, Alberto; Paudel, Deepak; Pereira, David M.; Perico, Norberto; Petzold, Max; Phillips, Michael Robert; Polanczyk, Guilherme V.; Pourmalek, Farshad; Qorbani, Mostafa; Rafay, Anwar; Rahimi-Movaghar, Vafa; Rahman, Mahfuzar; Rai, Rajesh Kumar; Ram, Usha; Rankin, Zane; Remuzzi, Giuseppe; Renzaho, Andre M. N.; Roba, Hirbo Shore; Rojas-Rueda, David; Ronfani, Luca; Sagar, Rajesh; Sanabria, Juan Ramon; Mohammed, Muktar Sano Kedir; Santos, Itamar S.; Satpathy, Maheswar; Sawhney, Monika; Ben Schottker; Schwebel, David C.; Scott, James G.; Sepanlou, Sadaf G.; Shaheen, Amira; Shaikh, Masood Ali; She, June; Shiri, Rahman; Shiue, Ivy; Sigfusdottir, Inga Dora; Singh, Jasvinder; Silpakit, Naris; Smith, Alison; Sreeramareddy, Chandrashekhar; Stanaway, Jeffrey D.; Stein, Dan J.; Steiner, Caitlyn; Sufiyan, Muawiyyah Babale; Swaminathan, Soumya; Tabares-Seisdedos, Rafael; Tabb, Karen M.; Tadese, Fentaw; Tavakkoli, Mohammad; Taye, Bineyam; Teeple, Stephanie; Tegegne, Teketo Kassaw; Shifa, Girma Temam; Terkawi, Abdullah Sulieman; Thomas, Bernadette; Thomson, Alan J.; Tobe-Gai, Ruoyan; Tonelli, Marcello; Tran, Bach Xuan; Troeger, Christopher; Ukwaja, Kingsley N.; Uthman, Olalekan; Vasankari, Tommi; Venketasubramanian, Narayanaswamy; Vlassov, Vasiliy Victorovich; Weiderpass, Elisabete; Weintraub, Robert; Gebrehiwot, Solomon Weldemariam; Westerman, Ronny; Williams, Hywel C.; Wolfe, Charles D. A.; Woodbrook, Rachel; Yano, Yuichiro; Yonemoto, Naohiro; Yoon, Seok-Jun; Younis, Mustafa Z.; Yu, Chuanhua; Zaki, Maysaa El Sayed; Zegeye, Elias Asfaw; Zuhlke, Liesl Joanna; Murray, Christopher J. L.; Vos, Theo			Child and Adolescent Health From 1990 to 2015 Findings From the Global Burden of Diseases, Injuries, and Risk Factors 2015 Study	JAMA PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; SYSTEMATIC ANALYSIS; DISABILITY WEIGHTS; LIFE EXPECTANCY; UNITED-STATES; FOLLOW-UP; MORTALITY; POPULATION; SURVIVAL; NEWBORN	IMPORTANCE Comprehensive and timely monitoring of disease burden in all age groups, including children and adolescents, is essential for improving population health. OBJECTIVE To quantify and describe levels and trends of mortality and nonfatal health outcomes among children and adolescents from 1990 to 2015 to provide a framework for policy discussion. EVIDENCE REVIEW Cause-specific mortality and nonfatal health outcomes were analyzed for 195 countries and territories by age group, sex, and year from 1990 to 2015 using standardized approaches for data processing and statistical modeling, with subsequent analysis of the findings to describe levels and trends across geography and time among children and adolescents 19 years or younger. A composite indicator of income, education, and fertility was developed (Socio-demographic Index [SDI]) for each geographic unit and year, which evaluates the historical association between SDI and health loss. FINDINGS Global child and adolescent mortality decreased from 14.18 million (95% uncertainty interval [UI], 14.09 million to 14.28 million) deaths in 1990 to 7.26 million (95% UI, 7.14 million to 7.39 million) deaths in 2015, but progress has been unevenly distributed. Countries with a lower SDI had a larger proportion of mortality burden (75%) in 2015 than was the case in 1990 (61%). Most deaths in 2015 occurred in South Asia and sub-Saharan Africa. Global trends were driven by reductions in mortality owing to infectious, nutritional, and neonatal disorders, which in the aggregate led to a relative increase in the importance of noncommunicable diseases and injuries in explaining global disease burden. The absolute burden of disability in children and adolescents increased 4.3%(95% UI, 3.1%-5.6%) from 1990 to 2015, with much of the increase owing to population growth and improved survival for children and adolescents to older ages. Other than infectious conditions, many top causes of disability are associated with long-term sequelae of conditions present at birth (eg, neonatal disorders, congenital birth defects, and hemoglobinopathies) and complications of a variety of infections and nutritional deficiencies. Anemia, developmental intellectual disability, hearing loss, epilepsy, and vision loss are important contributors to childhood disability that can arise from multiple causes. Maternal and reproductive health remains a key cause of disease burden in adolescent females, especially in lower-SDI countries. In low-SDI countries, mortality is the primary driver of health loss for children and adolescents, whereas disability predominates in higher-SDI locations; the specific pattern of epidemiological transition varies across diseases and injuries. CONCLUSIONS AND RELEVANCE Consistent international attention and investment have led to sustained improvements in causes of health loss among children and adolescents in many countries, although progress has been uneven. The persistence of infectious diseases in some countries, coupled with ongoing epidemiologic transition to injuries and noncommunicable diseases, require all countries to carefully evaluate and implement appropriate strategies to maximize the health of their children and adolescents and for the international community to carefully consider which elements of child and adolescent health should be monitored.	[Kassebaum, Nicholas; Hmwe Kyu, Hmwe; Zoeckler, Leo; Elizabeth Olsen, Helen; Thomas, Katie; Pinho, Christine; Dandona, Lalit; Hay, Simon I.; Mokdad, Ali H.; Naghavi, Mohsen; Carter, Austin; Dicker, Daniel; Fitzmaurice, Christina; Fleming, Thomas D.; Foreman, Kyle J.; Fraser, Maya S.; Frostad, Joseph J.; Fullman, Nancy; Gold, Audra L.; Goldberg, Ellen; Johnson, Catherine O.; Khalil, Ibrahim; Krohn, Kristopher J.; Kulikoff, Rachel; Lim, Stephen S.; Nguyen, Grant; Nsoesie, Elaine; Rankin, Zane; Silpakit, Naris; Smith, Alison; Stanaway, Jeffrey D.; Steiner, Caitlyn; Teeple, Stephanie; Thomas, Bernadette; Troeger, Christopher; Woodbrook, Rachel; Murray, Christopher J. L.; Vos, Theo] Univ Washington, Inst Hlth Metr & Evaluat, 2301 5th Ave,Ste 600, Seattle, WA 98121 USA; [Bhutta, Zulfiqar A.] Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, Pakistan; [Dandona, Lalit] Publ Hlth Fdn India, Gurgaon 122002, India; [Ferrari, Alize; Whiteford, Harvey A.; Abajobir, Amanuel Alemu; Charlson, Fiona J.; Knibbs, Luke D.; Larson, Heidi J.; Leung, Janni] Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia; [Ghiwot, Tsegaye Tewelde; Abate, Kalkidan Hasen; Ahmed, Muktar Beshir; Mengistie, Mubarek Abera] Jimma Univ, Jimma, Ethiopia; [Hay, Simon I.] Univ Oxford, Li Ka Shing Ctr Hlth Informat & Discovery, Oxford Big Data Inst, Oxford, England; [Kinfu, Yohannes] Univ Canberra, Ctr Res & Action Publ Hlth, Canberra, ACT, Australia; [Liang, Xiaofeng] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China; [Lopez, Alan] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia; [Carvalho Malta, Deborah] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil; [Patton, George C.] Univ Melbourne, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Salomon, Joshua; Bamighausen, Till Winfried; Ding, Eric L.] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Sartorius, Benn] Univ KwaZulu Natal, South African Med Res Council, Sch Nursing & Publ Hlth, Durban, South Africa; [Sartorius, Benn] Univ KwaZulu Natal, Gastrointestinal Canc Res Ctr, Durban, South Africa; [Topor-Madry, Roman] Jagiellonian Univ, Med Coll, Fac Hlth Sci, Inst Publ Hlth, Krakow, Poland; [Vollset, Stein Emil] Norwegian Inst Publ Hlth, Ctr Dis Burden, Bergen, Norway; [Werdecker, Andrea; Mueller, Ulrich; Westerman, Ronny] Fed Inst Populat Res, Wiesbaden, Germany; [Abbas, Kaja] Virginia Tech, Dept Populat Hlth, Blacksburg, VA USA; [Damtew, Solomon Abrha] Wolaita Soda Univ, Wolaita Sodo, Ethiopia; [Akseer, Nadia; deveber, Gabrielle] Hosp Sick Children, Ctr Child Hlth, Toronto, ON, Canada; [Al-Raddadi, Rajaa] Minist Hlth, Jeddah, Saudi Arabia; [Alemayohu, Mulubirhan Assefa; Betsu, Balem Demtsu; Hailu, Gessessew Bugssa; Gebregergs, Gebremedhin Berhe; Gebru, Alemseged Aregay; Tesfay, Fisaha Haile; Meles, Kidanu Gebremariam; Mengistu, Gebremichael Welday; Gebrehiwot, Solomon Weldemariam] Mekelle Univ, Mekelle, Ethiopia; [Altirkawi, Khalid] King Saud Univ, Riyadh, Saudi Arabia; [Amare, Azmeraw T.; Ciobanu, Liliana G.; Gizachew, Tessema Assefa] Univ Adelaide, Adelaide, SA, Australia; [Antonio, Carl A. T.; Faraon, Emerito Jose Aquino] Univ Philippines, Dept Hlth Policy & Adm, Manila, Philippines; [Amlov, Johan; Larsson, Anders] Uppsala Univ, Dept Med Serv, Uppsala, Sweden; [Amlov, Johan] Dalarna Univ, Uppsala, Sweden; [Al Artaman] Univ Manitoba, Winnipeg, MB, Canada; [Asayesh, Hamid] Qom Univ Med Sci, Qom, Iran; [Avokpaho, Euripide Frinel G. Arthur] Inst Rech Clin Benin, Cotonou, Benin; [Awasthi, Ashish] Sanjay Gandhi Postgrad Inst Med Sci, Lucknow, Uttar Pradesh, India; [Quintanilla, Beatriz Paulina Ayala] La Trobe Univ, Judith Lumley Ctr Mother Infant & Family Hlth Res, Melbourne, Vic, Australia; [Bacha, Umar] Univ Management & Technol, Sch Hlth Sci, Lahore, Pakistan; [Barac, Aleksandra] Univ Belgrade, Fac Med, Belgrade, Serbia; [Baye, Estifanos] Monash Univ, Melbourne, Vic, Australia; [Bedi, Neeraj] Coll Publ Hlth & Trop Med, Jazan, Saudi Arabia; [Bensenor, Isabela M.; Polanczyk, Guilherme V.; Santos, Itamar S.] Univ Sao Paulo, Sao Paulo, Brazil; [Berhane, Adugnaw; Lotufo, Paulo A.] Debre Berhan Univ, Coll Hlth Sci, Debre Berhan, Ethiopia; [Bernabe, Eduardo] Kings Coll London, London, England; [Alberto Bernal, Oscar; Wolfe, Charles D. A.] Univ Andes, Bogota, Colombia; [Beyene, Addisu Shunu; Roba, Hirbo Shore] Haramaya Univ, Dire Dawa, Ethiopia; [Biadgilign, Sibhatu; Gishu, Melkamu Dedefo] Independent Publ Hlth Consultants, Addis Ababa, Ethiopia; [Bikbov, Boris] VI Shumakov Fed Res Ctr Transplantol & Artificial, Dept Nephrol Issues Transplanted Kidney, Moscow, Russia; [Anne Boyce, Cheryl; Mensah, George A.] NIH, Natl Heart Lung & Blood Inst, Bldg 10, Bethesda, MD 20892 USA; [Brazinova, Alexandra] Trnava Univ, Dept Publ Hlth, Fac Hlth Sci & SocialWork, Trnava, Slovakia; [Castaneda-Orjuela, Carlos A.] Inst Nacl Salud, Bogota, Colombia; [Catala-Lopez, Ferran; Tabares-Seisdedos, Rafael] Univ Valencia, Valencia, Spain; [Catala-Lopez, Ferran] Hlth Res Inst, Valencia, Spain; [Catala-Lopez, Ferran] CIBERSAM, Valencia, Spain; [Chitheer, Abdulaal A.] Minist Hlth, Baghdad, Iraq; [Choi, Jee-Young Jasmine; Khang, Young-Ho] Seoul Natl Univ, Seoul, South Korea; [Crump, John] Univ Otago, Dept Ctr Int Hlth, Dunedin, New Zealand; [Dandona, Rakhi; Lal, Dharmesh Kumar] Publ Hlth Fdn India, New Delhi, India; [Dellavalle, Robert P.] Univ Colorado, Sch Publ Hlth, Sch Med, Aurora, CO USA; [Deribew, Amare] Univ Oxford, Nuffield Dept Med, Oxford, England; [Dubey, Manisha; Ram, Usha] Int Inst Populat Sci, Mumbai, Maharashtra, India; [Endries, Amanuel Yesuf; Shifa, Girma Temam] Arba Minch Univ, Arba Minch, Ethiopia; [Erskine, Holly E.] Queensland Ctr Mental Hlth Res, Brisbane, Qld, Australia; [Faro, Andre] Univ Fed Sergipe, Aracaju, Brazil; [Farzadfar, Farshad; Kasaeian, Amir; Malekzadeh, Reza; Rahimi-Movaghar, Vafa; Sepanlou, Sadaf G.] Univ Tehran Med Sci, Noncommunicable Dis Res Ctr, Tehran, Iran; [Fernandes, Joao C.] Catholic Univ Portugal, Ctr Biotechnol & Fine Chem, Porto, Portugal; [Obadare Fijabi, Daniel; Glaser, Elizabeth] Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA USA; [Sorio Flor, Luisa] Escola Nacl Saude Publica, Sergio Arouca Fiocruz, Rio De Janeiro, Brazil; [Franklin, Richard C.] James Cook Univ, Townsville, Qld, Australia; [Geleijnse, Johanna M.; Jibat, Tariku] Wageningen Univ, Wageningen, Netherlands; [Gibney, Katherine B.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia; [Yihdego, Mahari Gidey; Jibat, Tariku] Addis Ababa Univ, Addis Ababa, Ethiopia; [Yihdego, Mahari Gidey; Mohammed, Muktar Sano Kedir] Mizan Tepi Univ, Dept Publ Hlth, Mizan Teferi, Ethiopia; [Ginawi, Ibrahim Abdelmageem Mohamed] Univ Hail, Coll Med, Hail, Saudi Arabia; [Gona, Philimon] Univ Massachusetts, Boston, MA USA; [Goto, Atsushi] Natl Canc Ctr, Tokyo, Japan; [Gugnani, Harish Chander] St James Sch Med, Dept Microbiol, Dept Epidemiol, Quarter, Anguilla; [Gugnani, Harish Chander] St James Sch Med, Dept Microbiol, Dept Biostat, Quarter, Anguilla; [Jiang, Guohong] Tianjin Med Univ, Sch Publ Hlth, Tianjin, Peoples R China; [Gupta, Rajeev] Eternal Heart Care Ctr & Res Inst, Jaipur, Rajasthan, India; [Hankey, Graeme J.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA, Australia; [Havmoeller, Rasmus] Karolinska Inst, Stockholm, Sweden; [Hijar, Martha] Fdn Entornos, Cuernavaca, Morelos, Mexico; [Horino, Masako] Nevada Div Publ & Behav Hlth, Carson, CA USA; [Hosgood, H. Dean] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Hu, Guoqing] Cent S Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R China; [Jacobsen, Kathryn H.] George Mason Univ, Dept Global & Community Hlth, Fairfax, VA 22030 USA; [Jakovljevic, Mihajlo B.] Univ Kragujevac, Kragujevac, Serbia; [Jayaraman, Sudha P.] Virginia Commonwealth Univ, Med Coll Virginia Campus, Richmond, VA USA; [Jha, Vivekanand] George Inst Global Hlth, New Delhi, India; [Jha, Vivekanand] Univ Oxford, Oxford, England; [Jonas, Jost] Ruprecht Karlas Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany; [Kawakami, Norito] Univ Tokyo, Sch Publ Hlth, Tokyo, Japan; [Keiyoro, Peter N.] Univ Nairobi, Nairobi, Kenya; [Khubchandani, Jagdish] Ball State Univ, Muncie, IN 47306 USA; [Ahmad Kiadaliri, Aliasghar A.] Lund Univ, Dept Clin Sci, Lund, Sweden; [Kieling, Christian] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil; [Kieling, Christian] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil; [Kim, Daniel] Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USA; [Kissoon, Niranjan; Pourmalek, Farshad] Univ British Columbia, Vancouver, BC, Canada; [Koyanagi, Ai] Parc Sanitari Sant Joan Deu, Res & Dev Unit, Barcelona, Spain; [Defo, Barthelemy Kuate] Univ Montreal, Montreal, PQ, Canada; [Bicer, Burcu Kucuk] Hacettepe Univ, Inst Publ Hlth, Ankara, Turkey; [Lam, Hilton Y.] NIH, Inst Hlth Policy & Dev Studies, Manila, Philippines; [Larson, Heidi J.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England; [Laryea, Dennis Odai] Komfo Anokye Teaching Hosp, Kumasi, Ghana; [Lo, Loon-Tzian] UnionHealth Assoc LLC, St Louis, MO USA; [Lo, Loon-Tzian] Alton Mental Hlth Ctr, Alton, IL USA; [Lo, Warren D.] Ohio State Univ, Dept Neurol, Dept Pediat, Columbus, OH 43210 USA; [Looker, Katharine J.] Univ Bristol, Bristol, Avon, England; [El Razek, Hassan Magdy Abd; Zaki, Maysaa El Sayed] Mansoura Univ, Fac Med, Mansoura, Egypt; [Shifti, Desalegn Markos] MaddaWalabu Univ, Robe, Ethiopia; [Mazidi, Mohsen] Chinese Acad Sci, Key State Lab Mol Dev Biol, Inst Genet & Dev Biol, Beijing, Peoples R China; [Meaney, Peter A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Memiah, Peter] Univ West Florida, Pensacola, FL 32514 USA; [Mendoza, Walter] United Nations Populat Fund, Lima, Peru; [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA; [Mock, Charles] Univ Washington, Sch Global Hlth, Sch Med, Seattle, WA 98195 USA; [Mohammadi, Alireza; Sufiyan, Muawiyyah Babale] Baqiyatallah Univ Med Sci, Tehran, Iran; [Mohammed, Shafiu] Ahmadu Bello Univ, Zaria, Kaduna, Nigeria; [Monasta, Lorenzo; Ronfani, Luca] Inst Maternal & Child Hlth IRCCS Burlo Garofolo, Trieste, Italy; [Nagata, Chie; Tobe-Gai, Ruoyan] Natl Ctr Child Hlth & Dev, Tokyo, Japan; [Naheed, Aliya] Int Ctr Diarrheal Dis Res, Dhaka, Bangladesh; [Le Nguyen, Quyen] Duy Tan Univ, Inst Global Hlth, Da Nang, Vietnam; [Oh, In-Hwan] Kyung Hee Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; [Okoro, Anselm] Soc Family Hlth, Abuja, Nigeria; [Olusanya, Jacob Olusegun] Ctr Healthy Start Initiat, Lagos, Nigeria; [Olusanya, Bolajoko O.; Ortiz, Alberto] IIS Fdn Jimenez Diaz UAM, Madrid, Spain; [Paudel, Deepak] UK Dept Int Dev, Lalitpur, Nepal; [Pereira, David M.] Univ Porto, Porto, Portugal; [Perico, Norberto] Ist Rich Farmacol Mario Negri, Bergamo, Italy; [Petzold, Max] Univ Gothenburg, Hlth Metr Unit, Gothenburg, Sweden; [Phillips, Michael Robert] Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R China; [Qorbani, Mostafa] Alborz Univ Med Sci, Sch Med, Karaj, Iran; [Rafay, Anwar] Contect Int Hlth Consultants, Lahore, Punjab, Pakistan; [Rahman, Mahfuzar] Res & Evaluat Div, Bldg Resources Access Communities, Dhaka, Bangladesh; [Rai, Rajesh Kumar] Soc Hlth & Demog Surveillance, Suri, India; [Remuzzi, Giuseppe] Int Soc Nephrol, Brussels, Belgium; [Renzaho, Andre M. N.] Western Sydney Univ, Penrith, NSW, Australia; [Rojas-Rueda, David] ISGlobal Inst Salud Global Barcelona, Barcelona, Spain; [Sagar, Rajesh; Satpathy, Maheswar] India Inst Med Sci, New Delhi, India; [Sanabria, Juan Ramon; Sawhney, Monika] Marshall Univ, Huntington, WV USA; [Ben Schottker] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany; [Ben Schottker] FOM Univ, Inst Hlth Care & Social Sci, Essen, Germany; [Schwebel, David C.; Singh, Jasvinder] Univ Alabama Birmingham, Birmingham, AL USA; [Scott, James G.] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia; [Shaheen, Amira] An Najah Univ, Dept Publ Hlth, Nablus, Palestine; [Shaikh, Masood Ali] Independent Consultant, Karachi, Pakistan; [She, June] Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai, Peoples R China; [Shiri, Rahman] Univ Helsinki, Work Organizat Disabil Program, Finnish Inst Occupat Hlth, Helsinki, Finland; [Shiue, Ivy] Northumbria Univ, Fac Hlth & Life Sci, Newcastle Upon Tyne, Tyne & Wear, England; [Sigfusdottir, Inga Dora] Reykjavik Univ, Reykjavik, Iceland; [Sreeramareddy, Chandrashekhar] Int Med Univ, Dept Community Med, Kuala Lumpur, Selangor, Malaysia; [Stein, Dan J.] Univ Cape Town, Dept Psychiat, Cape Town, South Africa; [Swaminathan, Soumya] Indian Council Med Res, Chennai, Tamil Nadu, India; [Tabb, Karen M.] Univ Illinois, Champaign, IL 61820 USA; [Tadese, Fentaw; Tegegne, Teketo Kassaw] Debre Markos Univ, Debre Markos, Ethiopia; [Tavakkoli, Mohammad] New York Med Ctr, Valhalla, NY USA; [Taye, Bineyam] Colgate Univ, Dept Biol, Hamilton, NY 13346 USA; [Terkawi, Abdullah Sulieman] Univ Virginia, Charlottesville, VA USA; [Thomson, Alan J.] Adapt Knowledge Management, Victoria, BC, Canada; [Tonelli, Marcello] Univ Calgary, Calgary, AB, Canada; [Tran, Bach Xuan] Johns Hopkins Univ, Baltimore, MD USA; [Ukwaja, Kingsley N.] Fed Teaching Hosp, Abakaliki, Nigeria; [Uthman, Olalekan] Univ Warwick, Coventry, W Midlands, England; [Vasankari, Tommi] Inst Hlth Promot Res, Tampere, Finland; [Venketasubramanian, Narayanaswamy] Raffles Hosp, Raffles Neurosci Ctr, Singapore, Singapore; [Vlassov, Vasiliy Victorovich] Natl Res Univ, Higher Sch Econ, Moscow, Russia; [Weiderpass, Elisabete] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Weiderpass, Elisabete] Canc Registry Norway, Inst Populat Based Canc Res, Oslo, Norway; [Weintraub, Robert] Royal Childrens Hosp, Melbourne, Vic, Australia; [Williams, Hywel C.] Univ Nottingham, Nottingham, England; [Yano, Yuichiro] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA; [Yonemoto, Naohiro] Kyoto Univ, Kyoto, Japan; [Yoon, Seok-Jun] Korea Univ, Sch Med, Dept Prevent Med, Seoul, South Korea; [Younis, Mustafa Z.] Jackson State Univ, Jackson, MS USA; [Yu, Chuanhua] Wuhan Univ, Wuhan, Peoples R China; [Zegeye, Elias Asfaw] Univ KwaZulu Natal, Durban, South Africa; [Zuhlke, Liesl Joanna] Red CrossWar Mem Childrens Hosp, Cape Town, South Africa	Kassebaum, N (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, 2301 5th Ave,Ste 600, Seattle, WA 98121 USA.	nickjk@uw.edu	Ertan, Asli/AAE-6201-2021; Ukwaja, Kingsley N./A-7794-2013; Barac, Aleksandra/W-9785-2019; Jacobsen, Kathryn H./B-5857-2008; Ahmed, Muktar/AAY-6783-2020; Knibbs, Luke/C-7865-2012; Lopez, Alan D/F-1487-2010; Crump, John A./AAZ-6412-2020; Geleijnse, Johanna Marianna M/B-5749-2012; Hay, Simon I/F-8967-2015; Patton, George C/B-5246-2013; Sagar, Rajesh/L-7775-2016; Rahimi-Movaghar, Vafa/L-6339-2019; Khubchandani, Jagdish/D-1831-2014; Kasaeian, Amir/C-8290-2017; Castaneda-Orjuela, Carlos/N-2601-2017; Kedir, Muktar Sano/Z-2951-2019; Kissoon, Niranjan/AAC-6140-2021; Koyanagi, Ai/D-3833-2018; Altirkawi, Khalid A/D-7302-2017; Antonio, Carl Abelardo/AAP-4280-2020; Rojas-Rueda, David/AAK-2184-2020; Alemayohu, Mulubirhan Assefa/ABB-1567-2020; Arnlov, Johan/AAF-2746-2019; Zaki, Maysaa El Sayed/C-1522-2013; Abbas, Kaja M/E-6590-2017; Santos, Itamar S/K-7055-2012; Mohammed, Shafiu/AAR-7889-2020; Gona, Philimon/K-1477-2019; Satpathy, Maheswar/J-3135-2017; Oh, In Hwan/AAI-9070-2020; Quintanilla, Beatriz Paulina Ayala/C-8325-2016; Leung, Janni/H-1003-2012; Al-Raddadi, Rajaa/F-8337-2010; Bicer, Burcu Kucuk/G-4922-2017; Singh, Jasvinder/R-6172-2019; Amare, Azmeraw T./B-9487-2018; Mohammed, Shafiu/P-2016-2014; N, Bedi/H-2838-2019; Malta, Deborah Carvalho/L-2491-2019; Scott, James Graham/D-5900-2012; Brazinova, Alexandra/C-4265-2016; Monasta, Lorenzo/B-1388-2012; Ginawi, Ibrahim/N-1286-2019; Weiderpass, Elisabete/M-4029-2016; Pourmalek, Farshad/A-8188-2010; Mohammadi, Alireza/R-9202-2016; Bikbov, Boris/I-4594-2013; Stein, Dan J/A-1752-2008; Crump, John A./AAZ-6289-2020; Roba, Hirbo Shore/AAA-3995-2021; Uthman, Olalekan/N-5584-2019; Topor-Madry, Roman/ABF-5449-2020; Jakovljevic, Mihajlo B/B-3002-2014; Sepanlou, Sadaf G/H-9343-2016; Phillips, Michael Robert/AAE-7585-2021; Tonelli, Marcello/B-3028-2009; Renzaho, Andre M.N./AAH-7679-2021; Faro, Andre/J-1696-2014; Salomon, Joshua/S-1929-2019; Weiderpass, Elisabete/AAP-2747-2021; ortiz, alberto/Y-7582-2018; Catala-Lopez, Ferran/N-6018-2018; Polanczyk, Guilherme V./AAF-6142-2021; Schottker, Ben/F-8183-2014; Terkawi, Abdullah Suleiman/AAC-1113-2019; Kumar, Anil/AAN-2476-2021; Ferrari, Alize J/G-1746-2011; Zaki, Maysaa El Sayed/H-3049-2019; Hankey, Graeme J/H-4968-2014; Jayaraman, Sudha/AAH-3059-2019; Perico, Norberto/ABH-3222-2020; Qorbani, Mostafa/M-8171-2017; Memiah, Peter/P-3115-2017; Defo, Barthelemy Kuate/I-4818-2017; Ronfani, Luca/B-6668-2013; Bernabe, Eduardo/R-3441-2017; Ding, Eric L./K-1118-2019; Santos, Itamar/M-2208-2019; Malta, Deborah C/H-7880-2012; Olusanya, Bolajoko O./F-4504-2012; Naohiro, Yonemoto/Y-3761-2019; Pereira, David M./M-9286-2013; Ahmed, Muktar B/G-6184-2019; Polanczyk, Guilherme V/C-2345-2012; Kedir, Muktar Sano/N-3369-2017; Ram, Usha/AAS-4140-2020; Charlson, Fiona/R-8963-2019; Fernandes, Joao C/AAF-2091-2019; Malekzadeh, Reza/U-1382-2017; Kinfu, Yohannes/AAC-8054-2020; Awasthi, Ashish/Y-5915-2019; Franklin, Richard Charles/H-1731-2012; Whiteford, Harvey A/A-4840-2009; Tabares-Seisdedos, Rafael/H-6432-2013; Kieling, Christian/U-3905-2019; Charlson, Fiona/F-5290-2011; Remuzzi, Giuseppe/V-9766-2017; Larson, Heidi/N-1018-2017; Vlassov, Vasiliy/B-4036-2014	Ukwaja, Kingsley N./0000-0002-1974-8735; Jacobsen, Kathryn H./0000-0002-4198-6246; Ahmed, Muktar/0000-0002-9524-7027; Lopez, Alan D/0000-0001-5818-6512; Crump, John A./0000-0002-4529-102X; Geleijnse, Johanna Marianna M/0000-0001-7638-0589; Hay, Simon I/0000-0002-0611-7272; Patton, George C/0000-0001-5039-8326; Khubchandani, Jagdish/0000-0002-9058-4278; Kasaeian, Amir/0000-0003-2018-9368; Castaneda-Orjuela, Carlos/0000-0002-8735-6223; Kedir, Muktar Sano/0000-0003-2365-6523; Koyanagi, Ai/0000-0002-9565-5004; Altirkawi, Khalid A/0000-0002-7331-4196; Antonio, Carl Abelardo/0000-0001-7476-0553; Rojas-Rueda, David/0000-0001-5854-2484; Arnlov, Johan/0000-0002-6933-4637; Zaki, Maysaa El Sayed/0000-0001-5431-0248; Abbas, Kaja M/0000-0003-0563-1576; Santos, Itamar S/0000-0003-3212-8466; Mohammed, Shafiu/0000-0001-5715-966X; Satpathy, Maheswar/0000-0003-3521-4781; Oh, In Hwan/0000-0002-5450-9887; Quintanilla, Beatriz Paulina Ayala/0000-0002-2630-4569; Leung, Janni/0000-0001-5816-2959; Al-Raddadi, Rajaa/0000-0002-8921-9628; Bicer, Burcu Kucuk/0000-0002-5615-264X; Singh, Jasvinder/0000-0003-3485-0006; Amare, Azmeraw T./0000-0002-7940-0335; Mohammed, Shafiu/0000-0001-5715-966X; Malta, Deborah Carvalho/0000-0002-8214-5734; Scott, James Graham/0000-0002-0744-0688; Brazinova, Alexandra/0000-0003-0625-256X; Monasta, Lorenzo/0000-0001-7774-548X; Ginawi, Ibrahim/0000-0001-8628-1840; Weiderpass, Elisabete/0000-0003-2237-0128; Pourmalek, Farshad/0000-0002-2134-0771; Mohammadi, Alireza/0000-0002-1004-5339; Bikbov, Boris/0000-0002-1925-7506; Stein, Dan J/0000-0001-7218-7810; Crump, John A./0000-0002-4529-102X; Uthman, Olalekan/0000-0002-8567-3081; Jakovljevic, Mihajlo B/0000-0002-9160-6846; Sepanlou, Sadaf G/0000-0002-3669-5129; Phillips, Michael Robert/0000-0002-5973-2439; Tonelli, Marcello/0000-0002-0846-3187; Faro, Andre/0000-0002-7348-6297; Salomon, Joshua/0000-0003-3929-5515; Weiderpass, Elisabete/0000-0003-2237-0128; ortiz, alberto/0000-0002-9805-9523; Catala-Lopez, Ferran/0000-0002-3833-9312; Polanczyk, Guilherme V./0000-0003-2311-3289; Schottker, Ben/0000-0002-1217-4521; Terkawi, Abdullah Suleiman/0000-0001-8734-2748; Ferrari, Alize J/0000-0002-7863-9117; Zaki, Maysaa El Sayed/0000-0001-5431-0248; Hankey, Graeme J/0000-0002-6044-7328; Jayaraman, Sudha/0000-0003-1094-5836; Perico, Norberto/0000-0002-3147-4327; Memiah, Peter/0000-0002-3067-188X; Defo, Barthelemy Kuate/0000-0002-6589-0564; Ronfani, Luca/0000-0001-5710-3914; Bernabe, Eduardo/0000-0002-1858-3713; Ding, Eric L./0000-0002-5881-8097; Santos, Itamar/0000-0003-3212-8466; Malta, Deborah C/0000-0002-8214-5734; Olusanya, Bolajoko O./0000-0002-3826-0583; Pereira, David M./0000-0003-0384-7592; Ahmed, Muktar B/0000-0002-9524-7027; Polanczyk, Guilherme V/0000-0003-2311-3289; Ram, Usha/0000-0001-6722-7347; Fernandes, Joao C/0000-0003-1556-1698; Malekzadeh, Reza/0000-0002-9820-6335; Awasthi, Ashish/0000-0002-9308-9782; Franklin, Richard Charles/0000-0003-1864-4552; Whiteford, Harvey A/0000-0003-4667-6623; Kieling, Christian/0000-0001-7691-4149; Barac, Aleksandra/0000-0002-0132-2277; Kinfu, Yohannes/0000-0001-9607-6891; Smith, Alison Grace Carswell/0000-0002-9402-7786; Olusanya, Jacob/0000-0002-1566-9554; Knibbs, Luke/0000-0002-0399-2370; Dandona, Rakhi/0000-0003-0926-788X; Jha, Vivekanand/0000-0002-8015-9470; Miller, Ted/0000-0002-0958-2639; Carter, Austin/0000-0002-3588-6142; Charlson, Fiona/0000-0003-2876-5040; Woodbrook, Rachel/0000-0002-4548-944X; Remuzzi, Giuseppe/0000-0002-6194-3446; Chitheer, Abdulaal/0000-0003-4899-6196; Shiri, Rahman/0000-0002-9312-3100; FARAON, EMERITO JOSE A./0000-0001-6157-5930; Qorbani, Mostafa/0000-0001-9465-7588; Meaney, Peter/0000-0001-9898-6928; Okoro, Anselm/0000-0003-3952-1172; Kissoon, Niranjan/0000-0001-8847-9973; Kim, Daniel/0000-0001-8907-6420; Naheed, Aliya/0000-0002-6016-5603; Larson, Heidi/0000-0002-8477-7583; Tabb Dina, Karen/0000-0002-4722-9502; RENZAHO, ANDRE/0000-0002-6844-0833; Sufiyan, Muawiyyah Babale/0000-0003-3630-6995; Biadgilign, Sibhatu/0000-0002-7582-5977; Tabares-Seisdedos, Rafael/0000-0002-1089-2204; Berhane, Adugnaw/0000-0003-2160-958X; , bennsartorius/0000-0001-6761-2325; Baye, Estifanos/0000-0002-2937-356X; Ciobanu, Liliana/0000-0002-4768-5452; Gishu, Melkamu Dedefo/0000-0002-3466-1232; LARYEA, DENNIS/0000-0003-2212-084X; Vlassov, Vasiliy/0000-0001-5203-549X; /0000-0002-4565-5364; Abajobir, Amanuel Alemu/0000-0002-6878-0627; Bacha, Umar/0000-0002-4156-1125; Khang, Young-Ho/0000-0002-9585-8266; Farzadfar, Farshad/0000-0001-8288-4046; Stanaway, Jeffrey/0000-0003-2209-8478	GlaxoSmithKlineGlaxoSmithKline; MerckMerck & Company	Dr Larson reported that her research group at the London School of Hygiene and Tropical Medicine has received funding from GlaxoSmithKline and Merck to convene research symposia, that she has received funding from GlaxoSmithKline for advising on issues related to vaccine hesitancy, and that she has have served on the Merck Vaccines Strategy Advisory Board. No other disclosures were reported.	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Alkema L, 2011, DEMOGRAPHY, V48, P815, DOI 10.1007/s13524-011-0040-5; Ashley MJ, 2016, TRAUMATIC BRAIN INJU; Belli PC, 2003, EC BENEFITS INVESTIN; Bol KA, 2006, PEDIATRICS, V117, P803, DOI 10.1542/peds.2005-1364; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Cha ES, 2016, INT J EPIDEMIOL, V45, P470, DOI 10.1093/ije/dyv304; Chowdhury MM, 2007, BRIT J SURG, V94, P145, DOI 10.1002/bjs.5714; de Sousa A, 2012, B WORLD HEALTH ORGAN, V90, P183, DOI 10.2471/BLT.11.093989; Department of Health Social Services and Public Safety, 2010, HLTH CHILD HLTH FUTU; Dieleman JL, 2016, LANCET, V387, P2536, DOI 10.1016/S0140-6736(16)30168-4; Fajardo-Gutierrez A, 2016, SALUD PUBLICA MEXICO, V58, P162, DOI 10.21149/spm.v58i2.7785; Fasfous AF, 2013, J MUSLIM MENT HEALTH, V7, P47, DOI 10.3998/jmmh.10381607.0007.203; Fassa A G, 2000, Int J Occup Environ Health, V6, P55; Field DJ, 2008, BMJ-BRIT MED J, V336, P1221, DOI 10.1136/bmj.39555.670718.BE; Flaxman AD, 2014, INT MET FRAM DESCR E; Gunnell D, 2007, INT J EPIDEMIOL, V36, P1235, DOI 10.1093/ije/dym164; Gupta N, 2011, HUM RESOUR HEALTH, V9, DOI 10.1186/1478-4491-9-16; Heckman JJ, 2006, SCIENCE, V312, P1900, DOI 10.1126/science.1128898; Hill K, 2015, LANCET GLOB HEALTH, V3, pE609, DOI 10.1016/S2214-109X(15)00044-3; Hillner BE, 2000, J CLIN ONCOL, V18, P2327, DOI 10.1200/JCO.2000.18.11.2327; Hoofien D, 2001, BRAIN INJURY, V15, P189; Huicho L, 2010, B WORLD HEALTH ORGAN, V88, P357, DOI 10.2471/BLT.09.070920; Iaccarino Mary Alexis, 2015, Handb Clin Neurol, V127, P411, DOI 10.1016/B978-0-444-52892-6.00026-X; IHME, 2015, FIN GLOB HLTH 2014 S; Institute for Health Metrics and Evaluation (IHME), 2013, FIN GLOB HLTH 2012 E; Italia Y, 2015, J MED SCREEN, V22, P1, DOI 10.1177/0969141314557372; Jakovljevic M, 2016, HLTH EC POLICY CHALL, P1; Javouhey E, 2006, ACCIDENT ANAL PREV, V38, P225, DOI 10.1016/j.aap.2005.08.001; Johnson P, 2013, HUM RESOUR HEALTH, V11, DOI 10.1186/1478-4491-11-42; Kassebaum NJ, 2016, LANCET, V388, P1775, DOI 10.1016/S0140-6736(16)31470-2; Kassebaum NJ, 2016, LANCET, V388, P1603, DOI 10.1016/S0140-6736(16)31460-X; Kellermann AL, 1998, ANNU REV PUBL HEALTH, V19, P271, DOI 10.1146/annurev.publhealth.19.1.271; Knudsen EI, 2006, P NATL ACAD SCI USA, V103, P10155, DOI 10.1073/pnas.0600888103; Kyu HH, 2016, JAMA PEDIATR, V170, P267, DOI 10.1001/jamapediatrics.2015.4276; Lim SS, 2016, LANCET, V388, P1813, DOI 10.1016/S0140-6736(16)31467-2; Linden M, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011020.pub2; Makene CL, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/s12884-014-0381-3; McGann PT, 2015, J PEDIATR-US, V167, P1314, DOI 10.1016/j.jpeds.2015.08.068; Meara JG, 2015, LANCET, V386, P569, DOI 10.1016/S0140-6736(15)60160-X; Mokdad AH, 2016, LANCET, V387, P2383, DOI 10.1016/S0140-6736(16)00648-6; Papile LA, 2012, PEDIATRICS, V130, P587, DOI 10.1542/peds.2012-1999; Patton GC, 2016, LANCET, V387, P2423, DOI 10.1016/S0140-6736(16)00579-1; Philip AGS, 2005, PEDIATR RES, V58, P799, DOI 10.1203/01.PDR.0000151693.46655.66; Raftery AE, 2012, P NATL ACAD SCI USA, V109, P13915, DOI 10.1073/pnas.1211452109; SALOMON JA, 2013, LANCET, V381, P628; Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8; Salomon JA, 2012, LANCET, V380, P2129, DOI 10.1016/S0140-6736(12)61680-8; Scott JG., 2016, MENTAL NEUROLOGICAL, V4; Shaw PH, 2015, J PEDIAT HEMATOL ONC, V37, P161, DOI 10.1097/MPH.0000000000000318; SLOAN JH, 1990, NEW ENGL J MED, V322, P369, DOI 10.1056/NEJM199002083220605; Smith ER, 2004, NEUROSURGERY, V54, P553, DOI 10.1227/01.NEU.0000108421.69822.67; Stevens GA, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002056; Thangaratinam S, 2012, LANCET, V379, P2459, DOI 10.1016/S0140-6736(12)60107-X; United Nations, 1989, CONV RIGHTS CHILD, P3; United Nations, 2015, MILL DEV GOALS 2015; Ursin M., 2014, CONTEMP DRUG PROBL, V41, P171, DOI [DOI 10.1177/009145091404100203, 10.1177/009145091404100203]; Vos T, 2016, LANCET, V388, P1545, DOI 10.1016/S0140-6736(16)31678-6; Wang HD, 2016, LANCET, V388, P1725, DOI 10.1016/S0140-6736(16)31575-6; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Wang HD, 2016, LANCET HIV, V3, pE361, DOI 10.1016/S2352-3018(16)30087-X; World Health Organization, 2013, DEF KEY TERMS; World Health Organization, GLOB STRAT WOM CHILD; Wren C, 2001, HEART, V85, P438, DOI 10.1136/heart.85.4.438; Yuko-Jowi CA, 2012, CARDIOVASC DIAGN THE, V2, P231, DOI 10.3978/j.issn.2223-3652.2012.07.04; Zhu JL, 2013, GENET MED, V15, P64, DOI 10.1038/gim.2012.93; Zuhlke L, 2013, HEART, V99, P1554, DOI 10.1136/heartjnl-2013-303896	67	157	160	4	61	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	JUN	2017	171	6					573	592		10.1001/jamapediatrics.2017.0250			20	Pediatrics	Pediatrics	EW7SB	WOS:000402714300018	28384795	Green Published, Other Gold, Green Accepted	Y	N	2021-06-18	
J	Szaflarski, JP; Sangha, KS; Lindsell, CJ; Shutter, LA				Szaflarski, Jerzy P.; Sangha, Kiranpal S.; Lindsell, Christopher J.; Shutter, Lori A.			Prospective, Randomized, Single-Blinded Comparative Trial of Intravenous Levetiracetam Versus Phenytoin for Seizure Prophylaxis	NEUROCRITICAL CARE			English	Article						Levetiracetam; Phenytoin; Fosphenytoin; Seizure prevention; ICU; SAH; TBI; Long-term outcomes; GCS; GOS; DRS	TRAUMATIC BRAIN-INJURY; ELECTROGRAPHIC SEIZURES; TOLERABILITY; EXPERIENCE; EFFICACY; STROKE; MODEL	Anti-epileptic drugs are commonly used for seizure prophylaxis after neurological injury. We performed a study comparing intravenous (IV) levetiracetam (LEV) to IV phenytoin (PHT) for seizure prophylaxis after neurological injury. In this prospective, single-center, randomized, single-blinded comparative trial of LEV versus PHT (2:1 ratio) in patients with severe traumatic brain injury (sTBI) or subarachnoid hemorrhage (NCT00618436) patients received IV load with either LEV or fosphenytoin followed by standard IV doses of LEV or PHT. Doses were adjusted to maintain therapeutic serum PHT concentrations or if patients had seizures. Continuous EEG (cEEG) monitoring was performed for the initial 72 h; outcome data were collected. A total of 52 patients were randomized (LEV = 34; PHT = 18); 89% with sTBI. When controlling for baseline severity, LEV patients experienced better long-term outcomes than those on PHT; the Disability Rating Scale score was lower at 3 months (P = 0.042) and the Glasgow Outcomes Scale score was higher at 6 months (P = 0.039). There were no differences between groups in seizure occurrence during cEEG (LEV 5/34 vs. PHT 3/18; P = 1.0) or at 6 months (LEV 1/20 vs. PHT 0/14; P = 1.0), mortality (LEV 14/34 vs. PHT 4/18; P = 0.227). There were no differences in side effects between groups (all P > 0.15) except for a lower frequency of worsened neurological status (P = 0.024), and gastrointestinal problems (P = 0.043) in LEV-treated patients. This study of LEV versus PHT for seizure prevention in the NSICU showed improved long-term outcomes of LEV-treated patients vis-A -vis PHT-treated patients. LEV appears to be an alternative to PHT for seizure prophylaxis in this setting.	[Szaflarski, Jerzy P.; Shutter, Lori A.] Univ Cincinnati, Dept Neurol, Acad Hlth Ctr, Cincinnati, OH 45267 USA; [Szaflarski, Jerzy P.] Univ Hosp, Cincinnati Epilepsy Ctr, Cincinnati, OH USA; [Szaflarski, Jerzy P.; Shutter, Lori A.] Univ Cincinnati, Inst Neurosci, Cincinnati, OH 45267 USA; [Sangha, Kiranpal S.] Univ Hosp, Dept Pharm Serv, Cincinnati, OH USA; [Sangha, Kiranpal S.] Univ Cincinnati, James L Winkle Coll Pharm, Cincinnati, OH 45267 USA; [Lindsell, Christopher J.] Univ Cincinnati, Dept Emergency Med, Acad Hlth Ctr, Cincinnati, OH 45267 USA; [Shutter, Lori A.] Univ Cincinnati, Dept Neurosurg, Acad Hlth Ctr, Cincinnati, OH 45267 USA	Szaflarski, JP (corresponding author), Univ Cincinnati, Dept Neurol, Acad Hlth Ctr, 260 Stetson St,Rm 2350, Cincinnati, OH 45267 USA.	jerzy.szaflarski@uc.edu	Shutter, Lori A/G-2957-2013	Lindsell, Christopher/0000-0002-3297-2811; Shutter, Lori/0000-0002-1390-0628	UCB Inc.UCB Pharma SA	This study was supported by a grant from UCB Inc., Principal Investigator: Lori A. Shutter, MD. This study was presented in part at the Neurocritical Care Society Meetings in 2008 and 2009. Data Safety Monitoring Board included Drs. Andrew Ringer, MD (Department of Neurosurgery) and Michael D. Privitera, MD (Department of Neurology).	Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Fountain NB, 2009, EPILEPSY CURR, V9, P71, DOI 10.1111/j.1535-7511.2009.01297.x; Hanon E, 2001, SEIZURE-EUR J EPILEP, V10, P287, DOI 10.1053/seiz.2000.0511; Hesdorffer D, 2007, EPILEPSY COMPREHENSI, V57-63; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Kilbride RD, 2009, ARCH NEUROL-CHICAGO, V66, P723, DOI 10.1001/archneurol.2009.100; KILPATRICK CJ, 1992, ARCH NEUROL-CHICAGO, V49, P509, DOI 10.1001/archneur.1992.00530290097017; Klitgaard H, 1998, EUR J PHARMACOL, V353, P191, DOI 10.1016/S0014-2999(98)00410-5; Loscher W, 1998, J PHARMACOL EXP THER, V284, P474; Loscher W, 2000, EPILEPSY RES, V40, P63, DOI 10.1016/S0920-1211(00)00108-X; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Marini H, 2004, LIFE SCI, V74, P1253, DOI 10.1016/j.lfs.2003.08.006; Michaelides C, 2008, EPILEPSY RES, V81, P143, DOI 10.1016/j.eplepsyres.2008.05.004; Milligan TA, 2008, NEUROLOGY, V71, P665, DOI 10.1212/01.wnl.0000324624.52935.46; Orta DS, 2009, ARCH NEUROL-CHICAGO, V66, P985, DOI 10.1001/archneurol.2009.137; Patel NC, 2006, SEIZURE-EUR J EPILEP, V15, P137, DOI 10.1016/j.seizure.2005.12.003; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Rhoney DH, 2000, NEUROLOGY, V55, P258, DOI 10.1212/WNL.55.2.258; Ruegg S, 2008, EPILEPSY BEHAV, V12, P477, DOI 10.1016/j.yebeh.2008.01.004; So EL, 1996, NEUROLOGY, V46, P350, DOI 10.1212/WNL.46.2.350; Stratton SC, 2003, EPILEPSY RES, V53, P95, DOI 10.1016/S0920-1211(02)00254-1; Szaflarski JP, 2008, EPILEPSIA, V49, P974, DOI 10.1111/j.1528-1167.2007.01513.x; Szaflarski JP, 2007, NEUROCRIT CARE, V7, P140, DOI 10.1007/s12028-007-0042-8; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Vespa P, 2006, NEUROCRIT CARE, V4, P99, DOI 10.1385/NCC:4:2:99; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750	30	157	162	1	11	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2010	12	2					165	172		10.1007/s12028-009-9304-y			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	573IL	WOS:000275905800005	19898966				2021-06-18	
J	Shafi, S; Diaz-Arrastia, R; Madden, C; Gentilello, L				Shafi, Shahid; Diaz-Arrastia, Ramon; Madden, Christopher; Gentilello, Larry			Intracranial pressure monitoring in brain-injured patients is associated with worsening of survival	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 28-30, 2006	New Orleans, LA	Amer Assoc Surg Trauma		traumatic brain injury; intracranial pressure monitoring; outcomes	SEVERE HEAD-INJURY; CRITICALLY ILL PATIENTS; INTENSIVE-CARE; UNITED-STATES; TRAUMA CARE; GUIDELINES; MANAGEMENT; HYPERVENTILATION; HYPERTENSION; MORTALITY	Background: The Brain Trauma Foundation (BTF) recommends intracranial pressure (ICP) monitoring in traumatic brain injury (TBI) patients with Glasgow Coma Scale (GCS) of 8 or less, and an abnormal brain computed tomography. However, benefits of ICP monitoring have not been documented. We hypothesized that BTF criteria for ICP monitoring in blunt TBI do not identify patients who are likely to benefit from it. Methods: The National Trauma Data Bank (1994 - 2001) was analyzed. Inclusion criteria were blunt TBI, head-abbreviated injury score (AIS) 3 to 6, age 20 to 50 years, GCS <= 8, abnormal brain computed tomographic scan, and intensive care unit admission for 3 days or more. Early deaths (< 48 hours) and delayed admissions (> 24 hours after injury) were excluded. Patients who underwent ICP monitoring (n=708) were compared with those did not (n=938). Multivariate logistic regression was used to determine the relationship between ICP monitoring and survival, while controlling for overall injury severity, TBI severity, craniotomy, associated injuries, comorbidities, and complications. Results: ICP monitoring was performed in only 43% of patients who met BTF criteria. There were no group differences in age, gender, or GCS. After adjusting for multiple potential confounding factors including, admission GCS, age, blood pressure, head AIS, and injury severity score (ISS), ICP monitoring was associated with a 45% reduction in survival (OR=0.55; 95% CI, 0.39 - 0.76; p < 0.001). Conclusions: ICP monitoring in accordance with current BTF criteria is associated with worsening of survival in TBI patients. A prospective randomized controlled trial of ICP-guided therapy is needed. Until then, the use of ICP monitoring should not be used as a quality benchmark.	[Shafi, Shahid; Gentilello, Larry] Univ Texas SW Med Sch Dallas, Dept Surg, Div Burns, Dallas, TX USA; [Diaz-Arrastia, Ramon] Univ Texas SW Med Sch Dallas, Dept Neurol, Dallas, TX USA; [Madden, Christopher] Univ Texas SW Med Sch Dallas, Dept Neurol Surg, Dallas, TX USA	Shafi, S (corresponding author), 5323 Harry Hines Blvd, Dallas, TX USA.	shahid.shafi@utsouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BarrientosVega R, 1997, CRIT CARE MED, V25, P33, DOI 10.1097/00003246-199701000-00009; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock RM, 2000, J NEUROTRAUM, V17, P449; BUXTON RL, 1970, LANCET, V2, P498; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Dings J, 1996, ZBL NEUROCHIR, V57, P177; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; Grossman M, 2003, J TRAUMA, V55, P26, DOI 10.1097/01.TA.0000072109.52351.0D; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1987, ACTA NEUROCHIR, V85, P80, DOI 10.1007/BF01456102; Mortifee PRS, 1996, ARCH PHYS MED REHAB, V77, P436, DOI 10.1016/S0003-9993(96)90030-1; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NORTH B, 1986, NEUROSURGERY, V18, P730, DOI 10.1227/00006123-198606000-00009; Sandham JD, 2003, NEW ENGL J MED, V348, P5, DOI 10.1056/NEJMoa021108; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Shafer A, 1998, CRIT CARE MED, V26, P947, DOI 10.1097/00003246-199805000-00034; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vukic M, 1999, ACTA NEUROCHIR, V141, P1203, DOI 10.1007/s007010050419; 2004, ICD 9 CM EXP HOSP, V13	34	157	161	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2008	64	2					335	340		10.1097/TA.0b013e31815dd017			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	264KV	WOS:000253287100018	18301195				2021-06-18	
J	Cantor, JB; Ashman, T; Gordon, W; Ginsberg, A; Engmann, C; Egan, M; Spielman, L; Dijkers, M; Flanagan, S				Cantor, Joshua B.; Ashman, Teresa; Gordon, Wayne; Ginsberg, Annika; Engmann, Clara; Egan, Matthew; Spielman, Lisa; Dijkers, Marcel; Flanagan, Steve			Fatigue after traumatic brain injury and its impact on participation and quality of life	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						depression; fatigue; health; pain; sleep quality; participation; quality of life; traumatic brain injury	MCGILL PAIN QUESTIONNAIRE; HEALTH SURVEY QUESTIONNAIRE; RHEUMATOID-ARTHRITIS; MENTAL EFFORT; SURVEY SF-36; HEAD-INJURY; INSOMNIA; VALIDITY; DEPRESSION; ATTENTION	Objectives: To examine the relationships between post-TBI fatigue (PTBIF) and comorbid conditions, participation in activities, quality of life, and demographic and injury variables. Participants: 223 community-dwelling individuals with mild to severe TBI and 85 noninjured controls. Measures: Global Fatigue Index (GFI), Beck Depression Inventory (BDI-II), McGill Pain Questionnaire (MPQ), Pittsburgh Sleep Quality Inventory (PSQI), Participation Objective Participation Subjective (POPS), SF-36, Life-3. Method: Data were collected through interviews and administration of self-report measures as part of a study of PTBIF. Results: Fatigue was more severe and prevalent in individuals with TBI, and more severe among women. It was not correlated with other demographic and injury variables. Once overlap in measurement instruments' content was removed, depression, pain, and sleep problems accounted for approximately 23% of the variance in fatigue in those with TBI compared to 58% of the variance in the control group. PTBIF was correlated with health-related quality of life and overall quality of life, but was not generally related to participation in major life activities. Conclusions: PTBIF has significant impact on well-being and quality of life and cannot be accounted for by comorbid conditions alone, suggesting that it is related to brain injury itself It appears to be unrelated to demographic and injury variables other than gender. PTBIF does not limit the quantity and frequency of participation. Future research should focus on the relationship between fatigue and the quality of participation.	[Cantor, Joshua B.; Ashman, Teresa; Gordon, Wayne; Ginsberg, Annika; Engmann, Clara; Egan, Matthew; Spielman, Lisa; Dijkers, Marcel; Flanagan, Steve] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Cantor, JB (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave L Levy Pl,Box 1240, New York, NY 10029 USA.		Heinemann, Allen W/K-6283-2012; Ashman, Teresa/B-1621-2013	Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596; Flanagan, Steven/0000-0001-9005-5897			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andrews F. M., 1976, SOCIAL INDICATORS WE; ARCINIEGAS DB, 2000, CURRENT TREATMENT OP, V2, P169; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BELZA BL, 1995, J RHEUMATOL, V22, P639; BELZA BL, 1993, NURS RES, V42, P93; Bensing JM, 1999, MED CARE, V37, P1078, DOI 10.1097/00005650-199910000-00011; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bormann J, 2001, J Assoc Nurses AIDS Care, V12, P75, DOI 10.1016/S1055-3290(06)60146-5; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; GARRATT AM, 1993, BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; Goller JL, 1997, ADV PERIT D, V13, P128; GORDON WA, 2003, PARTICIPATION OBJECT; Grady C, 1998, NURS RES, V47, P227, DOI 10.1097/00006199-199807000-00008; GRAHAM C, 1980, PAIN, V8, P377, DOI 10.1016/0304-3959(80)90081-0; HUNTER M, 1979, PAIN, V6, P35, DOI 10.1016/0304-3959(79)90138-6; KLEPAC RK, 1981, PAIN, V11, P241, DOI 10.1016/0304-3959(81)90009-9; KREMER E, 1981, PAIN, V11, P93, DOI 10.1016/0304-3959(81)90142-1; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Lawton MP, 1999, J AGING HEALTH, V11, P169, DOI 10.1177/089826439901100203; LEZAK MD, 1978, AM J PHYS MED REHAB, V57, P9; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Meek PM, 2000, NURS RES, V49, P181, DOI 10.1097/00006199-200007000-00001; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; *QUAL METR INC, 2001, SF 36 PHYS MENT HLTH; READING AE, 1983, PAIN, V16, P375, DOI 10.1016/0304-3959(83)90151-3; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Ruta D A, 1994, Qual Health Care, V3, P180, DOI 10.1136/qshc.3.4.180; Schwartz CE, 1996, ARCH PHYS MED REHAB, V77, P165, DOI 10.1016/S0003-9993(96)90162-8; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Taylor RR, 2002, PSYCHOSOM MED, V64, P319, DOI 10.1097/00006842-200203000-00016; TOOMEY TC, 1983, PAIN, V17, P289, DOI 10.1016/0304-3959(83)90101-X; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; van Mens-Verhulst J, 1997, WOMEN HEALTH, V26, P51; Van Mens-Verhulst J, 1998, SOC SCI MED, V47, P621, DOI 10.1016/S0277-9536(98)00116-6; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; WOLFE F, 1995, J RHEUMATOL, V22, P151; Yunus M B, 2001, Curr Rheumatol Rep, V3, P128; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	60	157	160	0	33	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2008	23	1					41	51		10.1097/01.HTR.0000308720.70288.af			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	256HS	WOS:000252719800008	18219234				2021-06-18	
J	Mushkudiani, NA; Engel, DC; Steyerberg, EW; Butcher, I; Lu, J; Marmarou, A; Slieker, F; McHugh, GS; Murray, GD; Maas, AIR				Mushkudiani, Nino A.; Engel, Doortje C.; Steyerberg, Ewout W.; Butcher, Isabella; Lu, Juan; Marmarou, Anthony; Slieker, Frans; McHugh, Gillian S.; Murray, Gordon D.; Maas, Andrew I. R.			Prognostic value of demographic characteristics in traumatic brain injury: Results from the IMPACT study	JOURNAL OF NEUROTRAUMA			English	Article						age; demographic characteristics; education; gender; outcome; prognosis; race; traumatic brain injury	SEVERE HEAD-INJURY; GLASGOW COMA SCALE; OUTCOME PREDICTION; MORTALITY RISK; AGE; EPIDEMIOLOGY; SURVIVAL; EXPERIENCE; MANAGEMENT; VARIABLES	Outcome following traumatic brain injury (TBI) is not only dependent on the nature and severity of injury and subsequent treatment, but also on constituent characteristics of injured individuals. We aimed to describe and quantify the relationship between demographic characteristics and six month outcome assessed by the Glasgow Outcome Scale (GOS) after TBI. Individual patient data on age (n = 8719), gender (n = 8720), race (n = 5320), and education (n = 2201) were extracted from eight therapeutic Phase III randomized clinical trials and three surveys in moderate or severe TBI, contained in the IMPACT database. The strength of prognostic effects was analyzed with binary and proportional odds regression analysis and expressed as an odds ratio. Age was analyzed as a continuous variable with spline functions, and the odds ratio calculated over the difference between the 75(th) and 25(th) percentiles. Associations with other predictors were explored. Increasing age was strongly related to poorer outcome (OR 2.14; 95% CI 2.00-2.28) in a continuous fashion that could be approximated by a linear function. No gender differences in outcome were found (OR: 1.01; CI 0.92-1.11), and exploratory analysis failed to show any gender/age interaction. The studies included predominantly Caucasians (83%); outcome in black patients was poorer relative to this group (OR 1.30; CI 1.09-1.56). This relationship was sustained on adjusted analyses, and requires further study into mediating factors. Higher levels of education were weakly related to a better outcome (OR: 0.70; CI 0.52-0.94). On multivariable analysis adjusting for age, motor score, and pupils, the prognostic effect of race and education were sustained. We conclude that outcome following TBI is dependent on age, race, to a lesser extent on education, but not on gender.	Erasmus MC, Dept Neurosurg, NL-3000 CA Rotterdam, Netherlands; Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, NL-3000 CA Rotterdam, Netherlands; Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland; Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, Richmond, VA USA	Maas, AIR (corresponding author), Erasmus MC, Dept Neurosurg, POB 2040, NL-3000 CA Rotterdam, Netherlands.	airmaas@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Lu, Juan/0000-0002-5389-7603; Murray, Gordon/0000-0001-9866-4734; Steyerberg, Ewout/0000-0002-7787-0122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-042691] Funding Source: Medline		Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Bahloul M, 2004, J TRAUMA, V57, P255, DOI 10.1097/01.TA.0000083004.35231.1E; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRICOLO A, 1977, J NEUROSURG, V47, P680, DOI 10.3171/jns.1977.47.5.0680; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Butcher I, 2007, J NEUROTRAUM, V24, P281, DOI 10.1089/neu.2006.0030; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/s001340050269; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; EDNA TH, 1983, ACTA NEUROCHIR, V69, P15, DOI 10.1007/BF02055848; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; GENTLEMAN D, 1992, INT SURG, V77, P297; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; GORDON E, 1995, J NEUROSURG ANESTH, V7, P235, DOI 10.1097/00008506-199510000-00001; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Johnstone B, 2003, BRAIN INJURY, V17, P95, DOI 10.1080/0269905021000010212; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kannus P, 2001, JAMA-J AM MED ASSOC, V286, P673, DOI 10.1001/jama.286.6.673; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Luukinen H, 1999, J AM GERIATR SOC, V47, P1451, DOI 10.1111/j.1532-5415.1999.tb01566.x; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Munro PT, 2002, BRIT MED J, V325, P1001, DOI 10.1136/bmj.325.7371.1001; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Ogungbo B, 2004, J AM COLL SURGEONS, V198, P852, DOI 10.1016/j.jamcollsurg.2004.02.003; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; Ratanalert S, 2002, BRIT J NEUROSURG, V16, P487, DOI 10.1080/0268869021000030311; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393	60	157	159	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2007	24	2					259	269		10.1089/neu.2006.0028			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	150AL	WOS:000245187900005	17375990				2021-06-18	
J	Garcia-Ovejero, D; Azcoitia, I; DonCarlos, LL; Melcangi, RC; Garcia-Segura, LM				Garcia-Ovejero, D; Azcoitia, I; DonCarlos, LL; Melcangi, RC; Garcia-Segura, LM			Glia-neuron crosstalk in the neuroprotective mechanisms of sex steroid hormones	BRAIN RESEARCH REVIEWS			English	Article; Proceedings Paper	OASI Workshop 2004	MAY 13-17, 2004	Troina, ITALY			astroglia; estradiol; microglia; peripheral-type benzodiazepine receptor; progesterone; testosterone; oligodendroglia; Schwann cells; steroidogenesis; steroidogenic acute regulatory protein	ESTROGEN-RECEPTOR-ALPHA; GROWTH-FACTOR-I; FIBRILLARY ACIDIC PROTEIN; CENTRAL-NERVOUS-SYSTEM; PERIPHERAL BENZODIAZEPINE-RECEPTORS; ACUTE REGULATORY PROTEIN; NIGROSTRIATAL DOPAMINERGIC SYSTEM; AROMATASE-IMMUNOREACTIVE CELLS; HAMSTER FACIAL MOTONEURONS; CULTURED CORTICAL-NEURONS	Proteins involved in the intramitochondrial trafficking of cholesterol, the first step in steroidogenesis, such as the steroidogenic acute regulatory protein (StAR) and the peripheral-type benzodiazepine receptor (PBR), are upregulated in the nervous system after injury. Accordingly, a local increase in the levels of steroids, such as pregnenolone and progesterone, is observed following traumatic injury in the brain and spinal cord. The expression and activity of aromatase, the enzyme that synthesizes estradiol, is also increased in injured brain areas and its inhibition results in an increased neurodegeneration. These findings suggest that an increase in steroidogenesis is part of an overall mechanism used by the nervous tissue to cope with neuro degenerative conditions. Neural steroidogenesis is the result of a coordinated interaction of neurons and glia. For example, after neural injury, there is an upregulation of StAR in neurons and of PBR in microglia and astroglia. Aromatase is expressed in neurons under basal conditions and is upregulated in reactive astrocytes after injury. Some of the steroids produced by glia are neuroprotective. Progesterone and progesterone derivatives produced by Schwarm cells, promote myelin formation and the remyelination and regeneration of injured nerves. In the central nervous system, the steroids produced by glia regulate synaptic function, affect anxiety, cognition, sleep and behavior, and exert neuroprotective and reparative roles. In addition, glial cells are targets for steroids and mediate some of the effects of these molecules on neurons, including the regulation of survival and regeneration. (c) 2005 Elsevier B.V. All rights reserved.	CSIC, Inst Cajal, E-28002 Madrid, Spain; Univ Complutense, Fac Biol, Dept Biol Celular, E-28040 Madrid, Spain; Loyola Univ, Stritch Sch Med, Dept Cell Biol, Maywood, IL 60153 USA; Univ Milan, Dept Endocrinol, I-20133 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy	Garcia-Segura, LM (corresponding author), CSIC, Inst Cajal, Avenida Dr Arce 37, E-28002 Madrid, Spain.	lmgs@cajal.csic.es	Azcoitia, Inigo/A-6208-2011; Garcia-Ovejero, Daniel/H-9090-2019; 谭, 德华 德/D-1910-2009; Garcia-Segura, Luis M/U-3711-2017	Azcoitia, Inigo/0000-0002-5791-9144; Garcia-Ovejero, Daniel/0000-0002-7479-5104; Garcia-Segura, Luis M/0000-0002-2450-2916; MELCANGI, COSIMO ROBERTO/0000-0003-0861-8967	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 62588] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH062588] Funding Source: NIH RePORTER		Agnello D, 2000, J NEUROIMMUNOL, V109, P105, DOI 10.1016/S0165-5728(00)00279-4; AKWA Y, 1993, J CELL BIOL, V121, P135, DOI 10.1083/jcb.121.1.135; ALTAR CA, 1990, EXP NEUROL, V109, P333; Arvanitis DN, 2004, J NEUROSCI RES, V75, P603, DOI 10.1002/jnr.20017; Asthana S, 2001, NEUROLOGY, V57, P605, DOI 10.1212/WNL.57.4.605; Azcoitia I, 1999, J NEUROSCI RES, V58, P815, DOI 10.1002/(SICI)1097-4547(19991215)58:6<815::AID-JNR8>3.0.CO;2-R; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Azcoitia I, 1999, GLIA, V26, P260; Azcoitia I, 2001, Prog Brain Res, V132, P469; Azcoitia I, 2001, J NEUROBIOL, V47, P318, DOI 10.1002/neu.1038; Azcoitia I, 2003, ANN NY ACAD SCI, V1007, P298, DOI 10.1196/annals.1286.028; BALTHAZART J, 1991, CELL TISSUE RES, V263, P71, DOI 10.1007/BF00318401; Balthazart J, 1998, TRENDS NEUROSCI, V21, P243, DOI 10.1016/S0166-2236(97)01221-6; Banasr M, 2001, EUR J NEUROSCI, V14, P1417, DOI 10.1046/j.0953-816x.2001.01763.x; Banati RB, 1997, J NEUROCYTOL, V26, P77, DOI 10.1023/A:1018567510105; Barbaccia ML, 2001, INT REV NEUROBIOL, V46, P243; Barger SW, 2000, J NEUROSCI RES, V62, P503, DOI 10.1002/1097-4547(20001115)62:4<503::AID-JNR4>3.0.CO;2-A; Bastianetto S, 1999, MOL BRAIN RES, V66, P35, DOI 10.1016/S0169-328X(99)00002-9; Behl C, 2002, PROG BRAIN RES, V138, P135, DOI 10.1016/S0079-6123(02)38075-0; Benmessahel Y, 2002, ANN NY ACAD SCI, V973, P83, DOI 10.1111/j.1749-6632.2002.tb04611.x; Berthold AA, 1849, ARCH ANAT PHYSL WISS, P42; Bicknell RJ, 1998, CURR OPIN NEUROL, V11, P667, DOI 10.1097/00019052-199812000-00010; Blurton-Jones M, 2001, J COMP NEUROL, V433, P115, DOI 10.1002/cne.1129; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; Bruce-Keller AJ, 2001, J NEUROCHEM, V78, P1315, DOI 10.1046/j.1471-4159.2001.00511.x; Buchanan CD, 2000, BIOL REPROD, V62, P1710, DOI 10.1095/biolreprod62.6.1710; Cagnin A, 2001, BRAIN, V124, P2014, DOI 10.1093/brain/124.10.2014; Cardona-Gomez GP, 2000, NEUROSCIENCE, V99, P751, DOI 10.1016/S0306-4522(00)00228-1; Cardona-Gomez GP, 2002, J STEROID BIOCHEM, V83, P211, DOI 10.1016/S0960-0760(02)00261-3; Cardona-Gomez GP, 2002, MOL BRAIN RES, V107, P80, DOI 10.1016/S0169-328X(02)00449-7; Cardounel A, 1999, P SOC EXP BIOL MED, V222, P145, DOI 10.1046/j.1525-1373.1999.d01-124.x; Carrer HF, 2002, CELL MOL NEUROBIOL, V22, P479, DOI 10.1023/A:1021825317546; Caruso A, 2004, J NEUROCHEM, V88, P1179, DOI 10.1046/j.1471-4159.2004.02284.x; Chaban VV, 2004, ENDOCRINOLOGY, V145, P3788, DOI 10.1210/en.2004-0149; Chowen JA, 2000, J PEDIATR ENDOCR MET, V13, P1045; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Conway EL, 1998, NEUROSCIENCE, V82, P805; CURRY JJ, 1966, NATURE, V209, P915, DOI 10.1038/209915a0; De Nicola AF, 2003, ANN NY ACAD SCI, V1007, P317, DOI 10.1196/annals.1286.030; Debruyne JC, 2003, EUR J NEUROL, V10, P257, DOI 10.1046/j.1468-1331.2003.00571.x; Dhandapani KM, 2002, BIOL REPROD, V67, P1379, DOI 10.1095/biolreprod.102.003848; di Michele F, 2000, NEUROSCI LETT, V284, P65, DOI 10.1016/S0304-3940(00)00965-4; Dluzen DE, 2003, ENDOCRINE, V21, P67, DOI 10.1385/ENDO:21:1:67; Dluzen DE, 2000, J NEUROCYTOL, V29, P387, DOI 10.1023/A:1007117424491; Dodel RC, 1999, J NEUROCHEM, V73, P1453, DOI 10.1046/j.1471-4159.1999.0731453.x; Dominguez R, 2004, J NEUROSCI, V24, P982, DOI 10.1523/JNEUROSCI.2586-03.2004; Donahue JE, 2000, BRAIN RES, V856, P142, DOI 10.1016/S0006-8993(99)02413-0; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; DUENAS M, 1994, NEUROENDOCRINOLOGY, V59, P528, DOI 10.1159/000126702; Engel SR, 2001, INT REV NEUROBIOL, V46, P321; Escubedo E, 1998, BRAIN RES, V814, P120, DOI 10.1016/S0006-8993(98)01065-8; Finley SK, 1999, J NEUROBIOL, V40, P446; Flores C, 1999, J NEUROSCI, V19, P8665; FOIDART A, 1995, CELL TISSUE RES, V280, P561, DOI 10.1007/s004410050385; Forlano PM, 2001, J NEUROSCI, V21, P8943, DOI 10.1523/JNEUROSCI.21-22-08943.2001; Furukawa A, 1998, J NEUROCHEM, V71, P2231; Gago N, 2001, GLIA, V36, P295, DOI 10.1002/glia.1117; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Garcia-Ovejero D, 2002, J COMP NEUROL, V450, P256, DOI 10.1002/cne.10325; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Garcia-Segura LM, 1999, J NEUROBIOL, V40, P574, DOI 10.1002/(SICI)1097-4695(19990915)40:4<574::AID-NEU12>3.0.CO;2-8; Garcia-Segura LM, 1999, NEUROSCIENCE, V89, P567, DOI 10.1016/S0306-4522(98)00340-6; GARCIAESTRADA J, 1992, BRAIN RES, V592, P343, DOI 10.1016/0006-8993(92)91695-B; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; Gelinas D, 1997, GEN COMP ENDOCR, V106, P155, DOI 10.1006/gcen.1997.6891; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Giachino C, 2003, ANN NY ACAD SCI, V1007, P335, DOI 10.1196/annals.1286.032; Giachino C, 2004, J NEUROBIOL, V58, P493, DOI 10.1002/neu.10290; Gorski RA, 2002, ADV EXP MED BIOL, V511, P57; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Gu F, 2003, J NEUROSCI RES, V72, P709, DOI 10.1002/jnr.10603; Gudino-Cabrera G, 1999, J NEUROBIOL, V40, P458, DOI 10.1002/(SICI)1097-4695(19990915)40:4<458::AID-NEU4>3.0.CO;2-9; Guennoun R, 1997, EUR J NEUROSCI, V9, P2236, DOI 10.1111/j.1460-9568.1997.tb01642.x; Hojo Y, 2004, P NATL ACAD SCI USA, V101, P865, DOI 10.1073/pnas.2630225100; Honda K, 2000, J NEUROSCI RES, V60, P321, DOI 10.1002/(SICI)1097-4547(20000501)60:3<321::AID-JNR6>3.3.CO;2-K; Honda K, 2001, J NEUROSCI RES, V64, P466, DOI 10.1002/jnr.1098; Hosli E, 2001, INT J DEV NEUROSCI, V19, P11, DOI 10.1016/S0736-5748(00)00082-4; HU ZY, 1987, P NATL ACAD SCI USA, V84, P8215, DOI 10.1073/pnas.84.23.8215; Hutchison J B, 1991, Curr Opin Neurobiol, V1, P562, DOI 10.1016/S0959-4388(05)80029-7; Hwang IK, 2004, NEUROCHEM INT, V45, P149, DOI 10.1016/j.neuint.2003.10.006; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; Ibanez C, 2003, PROG NEUROBIOL, V71, P49, DOI 10.1016/j.pneurobio.2003.09.002; Ivanova T, 2002, J NEUROENDOCRINOL, V14, P73, DOI 10.1046/j.0007-1331.2001.00742.x; Ivanova T, 2001, BRAIN RES, V889, P264, DOI 10.1016/S0006-8993(00)03149-8; JAKAB RL, 1993, J STEROID BIOCHEM, V44, P481, DOI 10.1016/0960-0760(93)90253-S; Jakab RL, 2001, J COMP NEUROL, V430, P396, DOI 10.1002/1096-9861(20010212)430:3<396::AID-CNE1039>3.0.CO;2-0; JAKAB RL, 1994, BRAIN RES, V664, P85, DOI 10.1016/0006-8993(94)91957-7; Jones KJ, 1997, NEUROCHEM RES, V22, P1359, DOI 10.1023/A:1022019106417; Jones KJ, 1999, J NEUROBIOL, V40, P560, DOI 10.1002/(SICI)1097-4695(19990915)40:4<560::AID-NEU11>3.0.CO;2-I; Jones KJ, 1997, J NEUROCYTOL, V26, P257, DOI 10.1023/A:1018596316465; JUNGTESTAS I, 1992, J STEROID BIOCHEM, V41, P621, DOI 10.1016/0960-0760(92)90394-X; Kadish I, 2002, J NEUROSCI, V22, P4095, DOI 10.1523/JNEUROSCI.22-10-04095.2002; Kamat A, 2002, TRENDS ENDOCRIN MET, V13, P122, DOI 10.1016/S1043-2760(02)00567-2; Karishma KK, 2002, EUR J NEUROSCI, V16, P445, DOI 10.1046/j.1460-9568.2002.02099.x; Kim HJ, 2002, DEV BRAIN RES, V139, P247, DOI 10.1016/S0165-3806(02)00576-X; Kimonides VG, 1998, P NATL ACAD SCI USA, V95, P1852, DOI 10.1073/pnas.95.4.1852; Kimoto T, 1997, J PHARMACEUT BIOMED, V15, P1231, DOI 10.1016/S0731-7085(96)01987-5; King SR, 2002, J NEUROSCI, V22, P10613; Kipper-Galperin M, 1999, INT J DEV NEUROSCI, V17, P765, DOI 10.1016/S0736-5748(99)00067-2; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kuhl NM, 2003, GLIA, V44, P91, DOI 10.1002/glia.10263; Kuhlmann AC, 1997, BRAIN RES, V751, P281, DOI 10.1016/S0006-8993(96)01409-6; Kuhlmann AC, 2000, J NEUROCHEM, V74, P1694, DOI 10.1046/j.1471-4159.2000.0741694.x; KUJAWA KA, 1991, J NEUROSCI, V11, P3898; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Lacor P, 1999, BRAIN RES, V815, P70, DOI 10.1016/S0006-8993(98)01105-6; Lacor P, 1996, NEUROSCI LETT, V220, P61, DOI 10.1016/S0304-3940(96)13187-6; Lambert JJ, 2001, INT REV NEUROBIOL, V46, P177; Lang S, 2002, CURR MED CHEM, V9, P1411, DOI 10.2174/0929867023369745; LANGUB MC, 1992, ENDOCRINOLOGY, V130, P364, DOI 10.1210/en.130.1.364; Lee SJ, 2001, ANNU REV PHARMACOL, V41, P569, DOI 10.1146/annurev.pharmtox.41.1.569; Lei DL, 2003, NEUROSCIENCE, V121, P659, DOI 10.1016/S0306-4522(03)00245-8; Lephart ED, 1996, BRAIN RES REV, V22, P1; Li R, 2000, J NEUROCHEM, V75, P1447, DOI 10.1046/j.1471-4159.2000.0751447.x; Liang Z, 2002, J NEUROCHEM, V80, P807, DOI 10.1046/j.0022-3042.2002.00779.x; Lieb K, 2003, NEUROCHEM INT, V42, P131, DOI 10.1016/S0197-0186(02)00076-1; Lu AG, 2002, J CEREBR BLOOD F MET, V22, P183, DOI 10.1097/00004647-200202000-00006; Lu YP, 2003, EXP NEUROL, V183, P482, DOI 10.1016/S0014-4886(03)00205-X; MACLUSKY NJ, 1981, SCIENCE, V211, P1294, DOI 10.1126/science.6163211; Magnaghi V, 2001, BRAIN RES REV, V37, P360, DOI 10.1016/S0165-0173(01)00140-0; Malik KJ, 1996, ANN CLIN BIOCHEM, V33, P187, DOI 10.1177/000456329603300302; Mankowski JL, 2003, J NEUROVIROL, V9, P94, DOI 10.1080/13550280390173283; Martini L, 2003, STEROIDS, V68, P825, DOI 10.1016/S0039-128X(03)00134-X; Mayo W, 2003, PROG NEUROBIOL, V71, P43, DOI 10.1016/j.pneurobio.2003.09.006; McCullough LD, 2003, TRENDS ENDOCRIN MET, V14, P228, DOI 10.1016/S1043-2760(03)00076-6; Melcangi R C, 2001, Prog Brain Res, V132, P31; Melcangi RC, 1999, J NEUROBIOL, V40, P471, DOI 10.1002/(SICI)1097-4695(19990915)40:4<471::AID-NEU5>3.3.CO;2-G; Melcangi RC, 1999, J NEUROSCI RES, V56, P349, DOI 10.1002/(SICI)1097-4547(19990515)56:4<349::AID-JNR3>3.3.CO;2-8; MELCANGI RC, 1994, BRAIN RES, V639, P202, DOI 10.1016/0006-8993(94)91731-0; Melcangi RC, 2003, PROG NEUROBIOL, V71, P57, DOI 10.1016/j.pneurobio.2003.09.003; Melcangi RC, 2001, INT REV NEUROBIOL, V46, P145; MELCANGI RC, 2004, BRAIN RES BRAIN RES; Mellon SH, 2001, INT REV NEUROBIOL, V46, P33; Mensah-Nyagan AG, 1999, PHARMACOL REV, V51, P63; Mensah-Nyagan AG, 2001, BRAIN RES REV, V37, P13, DOI 10.1016/S0165-0173(01)00110-2; Menuet A, 2003, J COMP NEUROL, V462, P180, DOI 10.1002/cne.10726; Milner TA, 2001, J COMP NEUROL, V429, P355; Mor G, 1999, J NEUROBIOL, V40, P484, DOI 10.1002/(SICI)1097-4695(19990915)40:4<484::AID-NEU6>3.0.CO;2-C; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; MYDLARSKI MB, 1995, NEUROBIOL AGING, V16, P977, DOI 10.1016/0197-4580(95)02018-7; NAFTOLIN F, 1994, J REPROD MED, V39, P257; NAFTOLIN F, 1971, J CLIN ENDOCR METAB, V33, P368, DOI 10.1210/jcem-33-2-368; NEGRI-CESI P, 1992, BRAIN RES, V589, P327; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; Ormerod BK, 2001, NEUROSCIENCE, V102, P369, DOI 10.1016/S0306-4522(00)00474-7; Paganini-Hill A, 2001, MATURITAS, V38, P243, DOI 10.1016/S0378-5122(01)00167-0; PaganiniHill A, 1996, ARCH INTERN MED, V156, P2213, DOI 10.1001/archinte.156.19.2213; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; Perez-Martin M, 2003, EUR J NEUROSCI, V18, P923, DOI 10.1046/j.1460-9568.2003.02830.x; Peterson RS, 2001, J NEUROENDOCRINOL, V13, P317, DOI 10.1046/j.1365-2826.2001.00647.x; Platania P, 2003, NEUROENDOCRINOLOGY, V77, P334, DOI 10.1159/000070899; PUY L, 1995, J STEROID BIOCHEM, V55, P197, DOI 10.1016/0960-0760(95)00165-V; Quesada A, 2004, J NEUROSCI RES, V75, P107, DOI 10.1002/jnr.10833; RAGHAVENDRA RV, 2000, EXP NEUROL, V161, P102, DOI DOI 10.1006/exnr.1999.7269; Rao VLR, 2001, J NEUROSCI RES, V64, P493, DOI 10.1002/jnr.1101; Robert F, 2001, EUR J NEUROSCI, V13, P916, DOI 10.1046/j.0953-816x.2001.01463.x; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rozovsky I, 2002, NEUROSCI LETT, V323, P191, DOI 10.1016/S0304-3940(02)00146-5; Rozovsky I, 2002, ENDOCRINOLOGY, V143, P636, DOI 10.1210/en.143.2.636; SANTAGATI S, 1994, J NEUROCHEM, V63, P2058; Sato K, 2003, J NEUROCHEM, V86, P1498, DOI 10.1046/j.1471-4159.2003.01953.x; Saunders-Pullman R, 2003, ENDOCRINE, V21, P81, DOI 10.1385/ENDO:21:1:81; Savaskan E, 2001, BRAIN RES, V908, P113, DOI 10.1016/S0006-8993(01)02610-5; Sawada H, 2000, FASEB J, V14, P1202; SCHLINGER BA, 1995, J NEUROENDOCRINOL, V7, P187, DOI 10.1111/j.1365-2826.1995.tb00746.x; SCHLINGER BA, 1994, J NEUROSCI, V14, P7541; SchulzeKegel D, 1996, SOL ENERGY, V58, P77, DOI 10.1016/0038-092X(96)00017-5; Schumacher M, 2001, BRAIN RES REV, V37, P343, DOI 10.1016/S0165-0173(01)00139-4; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Sierra A, 2003, EUR J NEUROSCI, V18, P1458, DOI 10.1046/j.1460-9568.2003.02872.x; Simpson ER, 2001, ENDOCRINOLOGY, V142, P4589, DOI 10.1210/en.142.11.4589; Sinchak K, 2003, DEV NEUROSCI-BASEL, V25, P343, DOI 10.1159/000073511; Singer CA, 1999, J NEUROSCI, V19, P2455; Sortino MA, 2004, ENDOCRINOLOGY, V145, P5080, DOI 10.1210/en.2004-0973; STEPHENSON DT, 1995, J NEUROSCI, V15, P5263; Stocco DM, 2000, BBA-MOL CELL BIOL L, V1486, P184, DOI 10.1016/S1388-1981(00)00056-1; Stocco DM, 2000, J ENDOCRINOL, V164, P247, DOI 10.1677/joe.0.1640247; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; Stone DJ, 1997, EXP NEUROL, V143, P313, DOI 10.1006/exnr.1996.6360; Stone DJ, 1998, J NEUROSCI, V18, P3180; Stone DJ, 2000, EXP NEUROL, V165, P46, DOI 10.1006/exnr.2000.7455; Storer PD, 2003, EXP NEUROL, V184, P939, DOI 10.1016/S0014-4886(03)00339-X; Takahashi N, 2004, NEUROSCI LETT, V369, P9, DOI 10.1016/j.neulet.2004.07.042; Takao T, 2004, J NEUROCHEM, V89, P660, DOI 10.1111/j.1471-4159.2004.02370.x; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; Tanzer L, 1999, J NEUROBIOL, V39, P438, DOI 10.1002/(SICI)1097-4695(19990605)39:3<438::AID-NEU9>3.0.CO;2-G; Thi AD, 1998, J STEROID BIOCHEM, V67, P201; Thomson M, 2003, BIOESSAYS, V25, P252, DOI 10.1002/bies.10243; Tomas-Camardiel M, 2002, NEUROSCIENCE, V109, P569, DOI 10.1016/S0306-4522(01)00502-4; Toran-Allerand CD, 1999, FRONT NEUROENDOCRIN, V20, P97, DOI 10.1006/frne.1999.0177; TORANALLERAND CD, 1988, DEV BRAIN RES, V41, P87, DOI 10.1016/0165-3806(88)90172-1; Vallee M, 2001, INT REV NEUROBIOL, V46, P273; Vegeto E, 2003, P NATL ACAD SCI USA, V100, P9614, DOI 10.1073/pnas.1531957100; Vegeto E, 2001, J NEUROSCI, V21, P1809, DOI 10.1523/JNEUROSCI.21-06-01809.2001; Vegeto E, 1999, FASEB J, V13, P793; Veiga S, 2003, J NEUROBIOL, V56, P398, DOI 10.1002/neu.10249; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Viviani B, 2002, J NEUROCHEM, V83, P1180, DOI 10.1046/j.1471-4159.2002.01235.x; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Wehrenberg U, 2001, J NEUROCHEM, V76, P1879, DOI 10.1046/j.1471-4159.2001.00207.x; Wilson ME, 2002, MOL BRAIN RES, V102, P48, DOI 10.1016/S0169-328X(02)00181-X; Wise PM, 2000, J NEUROCYTOL, V29, P401, DOI 10.1023/A:1007169408561; Wise PM, 2003, PROG NEUROBIOL, V69, P181, DOI 10.1016/S0301-0082(03)00035-2; Xu Y, 2003, J NEUROSCI RES, V74, P1, DOI 10.1002/jnr.10725; Yaffe K, 2003, JAMA-J AM MED ASSOC, V289, P2717, DOI 10.1001/jama.289.20.2717; Yang SH, 2003, ANN NY ACAD SCI, V1007, P101, DOI 10.1196/annals.1286.010; Zhang L, 2002, MOL BRAIN RES, V103, P1; Zhang L, 2001, NEUROREPORT, V12, P1919, DOI 10.1097/00001756-200107030-00030; Zhang Y, 2001, J NEUROSCI, V21, part. no.; Zhang Z, 2004, J NEUROCHEM, V89, P674, DOI 10.1111/j.1471-4159.2004.02388.x; Znamensky V, 2003, J NEUROSCI, V23, P2340; Zsarnovszky A, 2002, BRAIN RES, V958, P488, DOI 10.1016/S0006-8993(02)03771-X; Zwain IH, 1997, BBA-GEN SUBJECTS, V1334, P338, DOI 10.1016/S0304-4165(96)00115-8; Zwain IH, 1999, ENDOCRINOLOGY, V140, P3843, DOI 10.1210/en.140.8.3843	217	157	164	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0173	1872-6321		BRAIN RES REV	Brain Res. Rev.	APR	2005	48	2			SI		273	286		10.1016/j.brainresrev.2004.12.018			14	Neurosciences	Neurosciences & Neurology	933KV	WOS:000229628200017	15850667				2021-06-18	
J	Tolias, CM; Reinert, M; Seiler, R; Gilman, C; Scharf, A; Bullock, MR				Tolias, CM; Reinert, M; Seiler, R; Gilman, C; Scharf, A; Bullock, MR			Normobaric hyperoxia-induced improvement in cerebral metabolism and reduction in intracranial pressure in patients with severe head injury: a prospective historical cohort-matched study	JOURNAL OF NEUROSURGERY			English	Article						brain metabolism; glucose; head injury; hyperoxia; lactate; microdialysis	TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; TISSUE OXYGEN; INTRACEREBRAL MICRODIALYSIS; BLOOD-FLOW; SUBARACHNOID HEMORRHAGE; MITOCHONDRIAL-FUNCTION; BEDSIDE MICRODIALYSIS; GLUCOSE-UTILIZATION; SUBSTRATE DELIVERY	Object. The effect of normobaric hyperoxia (fraction of inspired O-2 [FIO2] concentration 100%) in the treatment of patients with traumatic brain injury (TBI) remains controversial. The aim of this study was to investigate the effects of normobaric hyperoxia on five cerebral metabolic indices, which have putative prognostic significance following TBI in humans. Methods. At two independent neurointensive care units, the authors performed a prospective study of 52 patients with severe TBI who were treated for 24 hours with 100% FIO2, starting within 6 hours of admission. Data for these patients were compared with data for a cohort of 112 patients who were treated in the past; patients in the historical control group matched the patients in our study according to their Glasgow Coma Scale scores after resuscitation and their intracranial pressure within the first 8 hours after admission. Patients were monitored with the aid of intracerebral microdialysis and tissue O-2 probes. Normobaric hyperoxia treatment resulted in a significant improvement in biochemical markers in the brain compared with the baseline measures for patients treated in our study (patients acting as their own controls) and also compared with findings from the historical control group. In the dialysate the glucose levels increased (369.02 20.1 p,mol/L in the control group and 466.9 +/- 20.39 mumol/L in the 100% O-2 group, p = 0.001), whereas the glutamate and lactate levels significantly decreased (p < 0.005). There were also reductions in the lactate/glucose and lactate/pyruvate ratios. Intracranial pressure in the treatment group was reduced significantly both during and after hyperoxia treatment compared with the control groups (15.03 +/- 0.8 mm Hg in the control group and 12.13 +/- 0.75 mm Hg in the 100% O-2 group, p < 0.005) with no changes in cerebral perfusion pressure. Outcomes of the patients in the treatment group improved. Conclusions. The results of the study support the hypothesis that normobaric hyperoxia in patients with severe TBI improves the indices of brain oxidative metabolism. Based on these data further mechanistic studies and a prospective randomized controlled trial are warranted.	Virginia Commonwealth Univ, Harold F Young Neurosurg Ctr, Med Coll Virginia, Richmond, VA 23298 USA; Univ Bern, Inselspital Bern, Neurochirurg Klin, Bern, Switzerland	Bullock, MR (corresponding author), Virginia Commonwealth Univ Med Coll Virginia, Harold F Young Neurosurg Ctr, West Hosp, 1200 E Broad St,POB 980-631, Richmond, VA 23298 USA.	robulloc@mail2.vcu.edu	Reinert, Michael/E-4964-2011; Reinert, Michael/AAA-3929-2019	Reinert, Michael/0000-0002-0971-9543	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline		Adcock KH, 2002, DEV NEUROSCI-BASEL, V24, P382, DOI 10.1159/000069043; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Alessandri B, 1999, ACT NEUR S, V75, P21; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bullock MR, 2003, J NEUROSURG, V98, P943, DOI 10.3171/jns.2003.98.5.0943; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen T, 2000, ACT NEUR S, V76, P359; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Cornford EM, 2002, EPILEPSIA, V43, P1360, DOI 10.1046/j.1528-1157.2002.01602.x; Daugherty WP, 2003, J NEUROTRAUM, V20, P1126; DURING MJ, 1993, LANCET, V341, P1607; EDVINSSON L, 1993, CEREBRAL BLOOD FLOW, P140; Erecinska M, 2001, RESP PHYSIOL, V128, P263, DOI 10.1016/S0034-5687(01)00306-1; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HEMPEL FG, 1977, J APPL PHYSIOL, V43, P873; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; IZUMI Y, 1994, NEUROREPORT, V5, P617, DOI 10.1097/00001756-199401000-00021; JENNETT B, 1975, LANCET, V1, P480; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; Johnston AJ, 2003, BRIT J ANAESTH, V90, P774, DOI 10.1093/bja/aeg104; LEVASSEUR J, 1999, J NEUROTRAUM, V16, P991; Levasseur JE, 2003, J NEUROTRAUM, V20, P1126; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; NAKAJIMA S, 1983, ARCH NEUROL-CHICAGO, V40, P271, DOI 10.1001/archneur.1983.04050050039004; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Povlishock J T, 1992, Hum Cell, V5, P345; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Sakas DE, 1996, J NEUROSURG, V85, P248, DOI 10.3171/jns.1996.85.2.0248; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; SIESJO BK, 1973, ARCH NEUROL-CHICAGO, V29, P400, DOI 10.1001/archneur.1973.00490300062008; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SILVER IA, 1994, J NEUROSCI, V14, P5068; Singhal AB, 2002, NEUROLOGY, V58, P945, DOI 10.1212/WNL.58.6.945; Singhal AB, 2002, J CEREBR BLOOD F MET, V22, P861, DOI 10.1097/00004647-200207000-00011; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; VANDERKOOI JM, 1991, AM J PHYSIOL, V260, pC1131; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; WEINSTEIN PR, 1987, NEUROSURGERY, V20, P518, DOI 10.1227/00006123-198704000-00002; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	67	157	163	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2004	101	3					435	444		10.3171/jns.2004.101.3.0435			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	851NF	WOS:000223691100013	15352601				2021-06-18	
J	Zohar, O; Schreiber, S; Getslev, V; Schwartz, JP; Mullins, PG; Pick, CG				Zohar, O; Schreiber, S; Getslev, V; Schwartz, JP; Mullins, PG; Pick, CG			Closed-head minimal traumatic brain injury produces long-term cognitive deficits in mice	NEUROSCIENCE			English	Article						time course; force dependent; learning rate; Morris water maze; memory; minimal traumatic brain injury (mTBI); animal model	CONTROLLED CORTICAL IMPACT; SELECTIVE VULNERABILITY; PERFORMANCE; NEURONS; MODELS; DAMAGE	Victims of minimal traumatic brain injury (mTBI) do not show clear morphological brain defects, but frequently suffer lasting cognitive deficits, emotional difficulties and behavioral disturbances. In the present study we adopted a non-invasive closed-head weight-drop mouse model to produce mTBI. We examined the effects of 20,25, or 30 g weight drop 7, 30, 60 and 90 days following injury on mice's ability to perform the Morris water maze. The mice suffered profound long-lasting learning and memory deficits that were force- and time-dependent. Although the injured mice could acquire the task, they could not improve their initial escape latency by more than 50%, while normal mice improved by up to 450% (P<0.001). In order to directly compare the learning ability of individual mice following our mTBI we have devised a new measure which we term learning rate. We define learning rate as the rate the mouse improved its own performance in consecutive trials in a given experimental day. The learning rate of control mice increased linearly throughout the testing period with a slope of approximately 0.9. Injured mice that sustained 20 and 25 g weight drop could also improve their learning rate linearly but with a slope of only 0.2. Mice who sustained 30 g weight drop could not improve their learning rate linearly and reached a plateau after the third experimental learning day. These results indicate that the severity of injury may correlate with the degree of integration of the learning task. These cognitive deficits occurred without any other clear neurological damage, no evident brain edema, no notable damage to the blood-brain barrier and no early anatomical changes to the brain (observed by magnetic resonance imaging imaging). These results demonstrate that persistent deficits of cognitive learning abilities in mice, similar to those observed in human post-concussive syndrome, can follow mTBI without any anatomical damage to the brain and its surrounding tissue. (C) 2003 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; Blanchette Rockefeller Neurosci Inst, Rockville, MD 20850 USA; Tel Aviv Sourasky Med Ctr, Dept Psychiat, IL-69978 Tel Aviv, Israel; NINDS, Neurotroph Factors Sect, NIH, Bethesda, MD 20892 USA; Univ New Mexico, Clin Magnet Resonance Res Ctr, Albuquerque, NM 87131 USA	Pick, CG (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	pickc@post.tau.ac.il	Pick, Chaim/D-4789-2009; Schreiber, Shaul/E-5821-2010	Schreiber, Shaul/0000-0002-2189-0693; Mullins, Paul/0000-0002-1339-6361			Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; ASHANI Y, 1985, LIFE SCI, V36, P493, DOI 10.1016/0024-3205(85)90263-2; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Carty H, 1997, EUR RADIOL, V7, P1365, DOI 10.1007/s003300050303; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Fagerlund MDJ, 1995, ANN MED, V27, P657, DOI 10.3109/07853899509019252; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P201, DOI 10.1007/BF00691853; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Royle SJ, 1999, BRAIN RES, V816, P337, DOI 10.1016/S0006-8993(98)01122-6; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith MA, 1997, J NEUROSCI, V17, P2653; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509	32	157	165	3	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2003	118	4					949	955		10.1016/S0306-4522(03)00048-4			7	Neurosciences	Neurosciences & Neurology	679MT	WOS:000182926900007	12732240				2021-06-18	
J	Gibbs, RW				Gibbs, RW			A new look at literal meaning in understanding what is said and implicated	JOURNAL OF PRAGMATICS			English	Article						figurative language; literal meaning; conversational implicatures; psycholinguistics	LEXICAL AMBIGUITY RESOLUTION; BRAIN-DAMAGED PATIENTS; CLOSED-HEAD-INJURY; INDIRECT REQUESTS; PRAGMATIC THEORY; COMPREHENSION; CONTEXT; LANGUAGE; METAPHOR; IRONY	What role does literal meaning play in language comprehension? This question has been vigorously debated in research on figurative language understanding. The standard pragmatic view proposes that people must analyze the complete literal meaning of indirect and figurative utterances before pragmatic information is consulted to infer speakers' nonliteral messages. Most of the psycholinguistic research shows, however, that given sufficient context people understand nonliteralmeanings without first analyzing the complete literal meaning of an expression (i.e., the direct access view). Several lines of research have recently attempted to demonstrate that people still analyze aspects of literal meaning when understanding metaphors, irony, idioms, and proverbs. I critically evaluate this new work and suggest that it does not contribute sufficient evidence against the direct access view. Nonetheless, I argue that other research suggests how people analyze aspects of what speakers say as part of inferring what speakers implicate. This conclusion has several implications for specifying the role of pragmatics in ordinary utterance interpretation. (C) 2002 Published by Elsevier Science B.V.	Univ Calif Santa Cruz, Dept Psychol, Santa Cruz, CA 95064 USA	Gibbs, RW (corresponding author), Univ Calif Santa Cruz, Dept Psychol, Santa Cruz, CA 95064 USA.						BIHRLE AM, 1986, BRAIN COGNITION, V5, P399, DOI 10.1016/0278-2626(86)90042-4; BLASKO DG, 1993, J EXP PSYCHOL LEARN, V19, P295, DOI 10.1037/0278-7393.19.2.295; BROWNELL HH, 1983, BRAIN LANG, V18, P20, DOI 10.1016/0093-934X(83)90002-0; BROWNELL HH, 1990, NEUROPSYCHOLOGIA, V28, P375, DOI 10.1016/0028-3932(90)90063-T; BURGESS C, 1989, J EXP PSYCHOL LEARN, V15, P620, DOI 10.1037/0278-7393.15.4.620; CACCIARI C, 1988, J MEM LANG, V27, P668, DOI 10.1016/0749-596X(88)90014-9; Cappelen H, 1997, MIND LANG, V12, P278, DOI 10.1111/1468-0017.00049; CARSTON R, 1993, LINGUA, V90, P27, DOI 10.1016/0024-3841(93)90059-6; DASCAL M, 1987, COGNITIVE SCI, V11, P259, DOI 10.1207/s15516709cog1103_1; FREGE G, 1952, PHILOS WRITINGS GOTT, P56; Gibbs Jr Raymond W, 1994, POETICS MIND FIGURAT; GIBBS R, IN PRESS METAREPRESE; Gibbs R., 1980, MEM COGNITION, V8, P449; Gibbs Raymond, 1979, DISCOURSE PROCESS, V2, P1, DOI [10.1080/01638537909544450, DOI 10.1080/01638537909544450]; Gibbs RW, 1997, COGNITION, V62, P51, DOI 10.1016/S0010-0277(96)00724-X; GIBBS RW, 1986, ACTA PSYCHOL, V62, P41, DOI 10.1016/0001-6918(86)90004-1; GIBBS RW, 1986, J EXP PSYCHOL GEN, V115, P3, DOI 10.1037/0096-3445.115.1.3; Gibbs RW, 1999, COGNITION, V69, P355; GIBBS RW, 1989, COGNITIVE SCI, V13, P243, DOI 10.1016/0364-0213(89)90006-2; GIBBS RW, 1993, DISCOURSE PROCESS, V16, P387, DOI 10.1080/01638539309544846; GIBBS RW, 1986, DISCOURSE PROCESS, V9, P17, DOI 10.1080/01638538609544629; GIBBS RW, 1984, COGNITIVE SCI, V8, P275, DOI 10.1016/S0364-0213(84)80004-X; GIBBS RW, 1983, J EXP PSYCHOL LEARN, V9, P524, DOI 10.1037/0278-7393.9.3.524; GIBBS RW, 1995, J SEMANTICS, V11, P231; GIORA R, 1995, DISCOURSE PROCESS, V19, P239, DOI 10.1080/01638539509544916; Giora R., 1999, METAPHOR SYMBOL, V4, P241, DOI [DOI 10.1207/S15327868MS1404_, 10.1207/S15327868MS1404_1]; Giora R., 1997, COGN LINGUIST, V7, P183, DOI [DOI 10.1515/COGL.1997.8.3.183, 10.1515/cogl.1997.8.3.183]; Glucksberg S, 1998, CURR DIR PSYCHOL SCI, V7, P39, DOI 10.1111/1467-8721.ep13175582; GLUCKSBERG S, 1986, J EXP PSYCHOL LEARN, V12, P323; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; Grice H.P, 1989, STUDIES WAY WORDS; GROEFSEMA M, 1992, LINGUA, V87, P103, DOI 10.1016/0024-3841(92)90028-H; HAMBLIN J, UNPUB PROCESSING MEA; Honeck R. P., 1997, PROVERB MIND COGNITI; Johnson M., 1987, BODY MIND; Kaplan David, 1989, THEMES KAPLAN, P565; Katz A. N., 1998, FIGURATIVE LANGUAGE; KATZ AN, 1993, METAPHOR SYMB ACT, V8, P257, DOI 10.1207/s15327868ms0804_1; Katz AN., 1997, METAPHOR SYMBOL, V12, P19, DOI [10.1207/s15327868ms1201_3., DOI 10.1207/S15327868MS1201_3, 10.1207/s15327868ms1201_3]; KEMPER S, 1981, J PSYCHOLINGUIST RES, V10, P179, DOI 10.1007/BF01068037; Kempson, 1988, MENTAL REPRESENTATIO, P155; Lakoff G., 1980, METAPHORS LIVE; Lakoff G., 1989, MORE COOL REASON FIE; LAKOFF G., 1987, WOMEN FIRE DANGEROUS; LUCARIELLO J, 1994, J EXP PSYCHOL GEN, V123, P129, DOI 10.1037/0096-3445.123.2.129; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; Nicolle S, 1999, COGNITION, V69, P337; PAPAFRAGOU A, 1996, LINGUA, V94, P169; PEARCE S, 1995, J INT NEUROPSYCH SOC, V1, P342; Pynte J, 1996, BRAIN LANG, V55, P293, DOI 10.1006/brln.1996.0107; RECANATI F, 1995, COGNITIVE SCI, V19, P207, DOI 10.1207/s15516709cog1902_2; Recanati F., 1993, DIRECT REFERENCE LAN; Recanati Francois, 1989, MIND LANG, V4, P295, DOI DOI 10.1111/J.1468-0017.1989.TB00258.X; SCHRAW G, 1995, J PSYCHOLINGUIST RES, V24, P23, DOI 10.1007/BF02146098; Schwartz, 1998, METAPHOR SYMBOL, V13, P83, DOI DOI 10.1207/S15327868MS1302_; Searle J., 1979, METAPHOR THOUGHT, P92; Searle J, 1983, INTENTIONALITY; Searle JR., 1978, ERKENNTNIS, V13, P207, DOI [10.1007/BF00160894, DOI 10.1007/BF00160894]; SHINJO M, 1987, J MEM LANG, V26, P226, DOI 10.1016/0749-596X(87)90125-2; Simpson G.B., 1994, HDB PSYCHOLINGUISTIC, VVol. 22, P359; Sperber D., 1986, RELEVANCE COMMUNICAT; Sweetser E., 1990, ETYMOLOGY PRAGMATICS; SWINNEY DA, 1979, J VERB LEARN VERB BE, V18, P545; TABOSSI P, 1993, J MEM LANG, V32, P359, DOI 10.1006/jmla.1993.1019; TABOSSI P, 1993, IDIOMS PROCESSING ST, P145; Temple JG, 1999, J PSYCHOLINGUIST RES, V28, P41, DOI 10.1023/A:1023287420088; VANLANCKER D, 1990, BEHAV NEUROL, V3, P69; Vu H, 1998, MEM COGNITION, V26, P979, DOI 10.3758/BF03201178; WILLIAMS JN, 1992, J PSYCHOLINGUIST RES, V21, P193, DOI 10.1007/BF01068072; WILSON D, 1993, LINGUA, V90, P1, DOI 10.1016/0024-3841(93)90058-5	72	157	163	1	25	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-2166			J PRAGMATICS	J. Pragmat.	APR	2002	34	4					457	486	PII S0378-2166(01)00046-7	10.1016/S0378-2166(01)00046-7			30	Linguistics; Language & Linguistics	Linguistics	534NM	WOS:000174592500007					2021-06-18	
J	Diringer, MN; Videen, TO; Yundt, K; Zazulia, AR; Aiyagari, V; Dacey, RG; Grubb, RL; Powers, WJ				Diringer, MN; Videen, TO; Yundt, K; Zazulia, AR; Aiyagari, V; Dacey, RG; Grubb, RL; Powers, WJ			Regional cerebrovascular and metabolic effects of hyperventilation after severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						cerebral blood flow; cerebral metabolism; positron emission tomography; hyperventilation; brain injury	CEREBRAL BLOOD-FLOW; POSITRON EMISSION TOMOGRAPHY; SEVERE HEAD-INJURY; INTRAVENOUS (H2O)-O-15; O-15 RADIOTRACERS; COMATOSE PATIENTS; CARBON-DIOXIDE; ISCHEMIA; HUMANS; VOLUME	Object, Recently, concern has been raised that hyperventilation following severe traumatic brain injury (TBI) could lead to cerebral ischemia. In acute ischemic stroke, in which the baseline metabolic rate is normal, reduction in cerebral blood flow (CBF) below a threshold of 18 to 20 ml/100 g/min is associated with energy failure. In severe TBI, however, the metabolic rate of cerebral oxygen (CMRO2) is low. The authors previously reported that moderate hyperventilation lowered global hemispheric CBF to 25 ml/100 g/min but did not alter CMRO2. In the present study they sought to determine if hyperventilation lowers CBF below the ischemic threshold of 18 to 20 ml/100 g/ min in any brain region and if those reductions cause energy failure (defined as a fall in CMRO2). Methods. Two groups of patients were studied. The moderate hyperventilation group (nine patients) underwent hyperventilation to PaCO2 of 30 +/- 2 mm Hg early after TBI, regardless of intracranial pressure (ICP). The severe hyperventilation group (four patients) underwent hyperventilation to PaCO2 of 25 +/- 2 mm Hg 1 to 5 days postinjury while ICP was elevated (20-30 mm Hg). The ICP, mean arterial blood pressure, and jugular venous 0, content were monitored, and cerebral perfusion pressure was maintained at 70 mm Hg or higher by using vasopressors when needed, All data are given as the mean standard deviation unless specified otherwise. The moderate hyperventilation group was studied 11.2 +/- 1.6 hours (range 8-14 hours) postinjury, the admission Glasgow Coma Scale (GCS) score was 5.6 +/- 1.8, the mean age was 27 +/- 9 years, and eight of the nine patients were men. In the severe hyperventilation group, the admission GCS score was 4.3 +/- 1.5, the mean age was 31 +/- 6 years, and all patients were men. Positron emission tomography measurements of regional CBF, cerebral blood volume, CMRO3, and oxygen extraction fraction (OEF) were obtained before and during hyperventilation. In all 13 patients an automated search routine was used to identify 2.1-cm spherical nonoverlapping regions with CBF values below thresholds of 20, 15, and 10 ml/100 g/min during hyperventilation, and the change in CMRO2 in those regions was determined. In the regions in which CBF was less than 20 ml/100 g/min during hyperventilation, it fell from 26 +/- 6.2 to 13.7 +/- 1 ml/ 100 g/min (p < 0.0001), OEF rose from 0.31 to 0.59 (p < 0.0001), and CMRO2 was unchanged (1.12 +/- 0.29 compared with 1.14 +/- 0.03 ml/100 g/min, p = 0.8). In the regions in which CBF was less than 15 ml/100 g/min during hyperventilation, it fell from 23.3 +/- 6.6 to 11.1 +/- 1.2 ml/100 g/min (p < 0.0001), OEF rose from 0.31 to 0.63 (p < 0.0001), and CMRO2, was unchanged (0.98 +/- 0.19 compared with 0.97 +/- 0.23 ml/100 g/min; p = 0.92). In (he regions in which CBF was less than 10 ml/100 g/min during hyperventilation, it fell from 18.2 +/- 4.5 to 8.1 +/- 0 ml/100 g/min (p < 0.0001), OEF rose from 0.3 to 0.71 (p < 0.0001), and CMRO2 was unchanged (0.78 +/- 0.26 compared with 0.84 +/- 0.32 ml/100 g/min; p = 0.64). Conclusions. After severe TBI, brief hyperventilation produced large reductions in CBF but not energy failure, even in regions in which CBF fell below the threshold for energy failure defined in acute ischemia. Oxygen metabolism was preserved due to the low baseline metabolic rate and compensatory increases in OEF; thus, these reductions in CBF are unlikely to cause further brain injury.	Washington Univ, Sch Med, Dept Neurol & Neurol Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Radiol, Neurol Neurosurg Intens Care Unit, St Louis, MO 63110 USA	Diringer, MN (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.		Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS035966, P01NS035966] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35966] Funding Source: Medline		ALTMAN DI, 1991, J NUCL MED, V32, P1738; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; BULLOCK R, 1995, USE HYPERVENTILATION; de Nadal M, 2000, ANESTHESIOLOGY, V92, P11, DOI 10.1097/00000542-200001000-00008; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Grubb RL, 1998, JAMA-J AM MED ASSOC, V280, P1055, DOI 10.1001/jama.280.12.1055; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; HEISS WD, 1983, ANN NEUROL, V14, P294, DOI 10.1002/ana.410140307; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; HOFF JT, 1975, STROKE, V6, P28, DOI 10.1161/01.STR.6.1.28; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Martin M L, 1986, Emerg Med Clin North Am, V4, P131; MARTIN WRW, 1987, J CEREBR BLOOD F MET, V7, P421, DOI 10.1038/jcbfm.1987.85; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MINTUN MA, 1984, J NUCL MED, V25, P177; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; RAICHLE ME, 1970, ARCH NEUROL-CHICAGO, V23, P394, DOI 10.1001/archneur.1970.00480290014002; RAICHLE ME, 1983, J NUCL MED, V24, P790; TEASDALE G, 1974, LANCET, V2, P81; VANRIJEN PC, 1989, MAGN RESON MED, V10, P182, DOI 10.1002/mrm.1910100204; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; VIDEEN TO, 1987, J CEREBR BLOOD F MET, V7, P513, DOI 10.1038/jcbfm.1987.97; WIENHARD K, 1994, J COMPUT ASSIST TOMO, V18, P110, DOI 10.1097/00004728-199401000-00023; WILSON DA, 1985, CIRC RES, V56, P596, DOI 10.1161/01.RES.56.4.596; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024; YOUNG WL, 1989, ANESTH ANALG, V68, P712	34	157	158	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JAN	2002	96	1					103	108		10.3171/jns.2002.96.1.0103			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	508FY	WOS:000173079100016	11794590				2021-06-18	
J	Zhukareva, V; Newell, KL; Lee, VMY; Trojanowski, JQ				Zhukareva, V; Newell, KL; Lee, VMY; Trojanowski, JQ			Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer's disease	ACTA NEUROPATHOLOGICA			English	Article						tauopathies; traumatic brain injury; punch drunk syndrome	TRAUMATIC BRAIN INJURY; AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; AXONAL INJURY; BETA-PROTEIN; DEPOSITION; EPITOPES; SITES	Insights into mechanisms of familial Alzheimer's disease (AD) caused by genetic mutations have emerged rapidly compared to sporadic AD. Indeed, despite identification of several sporadic AD risk factors, it remains enigmatic how or why they predispose to neurodegenerative disease. For example, traumatic brain injury (TBI) predisposes to AD, and recurrent TBI in career boxers may cause a progressive memory disorder associated with AD-like brain pathology known as dementia pugilistica (DP). Although the reasons for this are unknown, repeated TBI may cause DP by mechanisms similar to those involved in AD. To investigate this possibility, we compared the molecular profile of tau pathologies in DP with those in AD and showed that the same tau epitopes map to filamentous tau inclusions in AD and DP brains, while the abnormal tau proteins isolated from DP brains are indistinguishable from the six abnormally phosphorylated brain tau isoforms in AD brains. Thus, these data suggest that recurrent TBI may cause DP by activating pathological mechanisms similar to those that cause brain degeneration due to accumulations of filamentous tau lesions in AD, and similar, albeit attenuated, activation of these processes by a single TBI may increase susceptibility to sporadic AD decades after the event.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Trojanowski, JQ (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, 3rd Floor HUP,Maloney Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.				NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG10124, AG09215] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010124, P01AG009215] Funding Source: NIH RePORTER		Baba M, 1998, AM J PATHOL, V152, P879; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Drachman DA, 1999, NEW ENGL J MED, V340, P1269, DOI 10.1056/NEJM199904223401609; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; HONG M, 2000, NEURODEGENERATIVE DE, P161; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; MawalDewan M, 1996, J NEUROPATH EXP NEUR, V55, P1051, DOI 10.1097/00005072-199655100-00005; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; PAPASOZOMENOS SC, 1987, CELL MOTIL CYTOSKEL, V8, P210, DOI 10.1002/cm.970080303; Reed LA, 1998, J NEUROPATH EXP NEUR, V57, P588, DOI 10.1097/00005072-199806000-00006; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Schmidt ML, 1996, J NEUROPATH EXP NEUR, V55, P534, DOI 10.1097/00005072-199605000-00006; SCHMIDT ML, 1987, LAB INVEST, V56, P282; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813	32	157	158	0	8	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	MAY	2001	101	5					518	524					7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	446UU	WOS:000169533200013	11484824				2021-06-18	
J	Roof, RL; Hall, ED				Roof, RL; Hall, ED			Estrogen-related gender difference in survival rate and cortical blood flow after impact-acceleration head injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						blood pressure; closed-head injury; laser Doppler flowmetry; ovariectomy; sex difference; TBI; 17 beta-estradiol	TRAUMATIC BRAIN INJURY; CEREBRAL-ARTERY OCCLUSION; AMYLOID (25-35)-INDUCED TOXICITY; TRANSIENT FOREBRAIN ISCHEMIA; VASCULAR SMOOTH-MUSCLE; LIPID-PEROXIDATION; NITRIC-OXIDE; ESTRADIOL PROTECTS; OXIDATIVE STRESS; PROSTACYCLIN SYNTHASE	While a number of laboratories have begun to examine gender differences in outcome following experimental stroke, little is known about the relative response of male and female brains to traumatic injury. In the following series of experiments, we used the Marmarou impact-acceleration head injury model (with a 500-g, 1.5-m weight drop) to compare the pathophysiological responses of male and female rats to closed-head injury. Cortical blood flow (CBF; laser-doppler flowmetry), mean arterial blood pressure (MAP), blood gas levels, blood pH, and body temperature were measured preinjury and at regular intervals postinjury. Acute survival was assessed 1 h after injury. The role of estrogen in the observed gender differences was assessed by examining these physiological measures after injury in ovariectomized females, with or without 17 beta -estradiol, replacement, and in intact males, with or without exogenous 17 beta -estradiol administration. In the first experiment, significantly more females (100%) survived the acute injury period (60 min) after injury than did males (72 %). Survival appeared related to the magnitude and persistence of the posttraumatic drop in MAP. In a second experiment, females showed a less dramatic reduction in and better recovery of CBF than males. The gender difference in CBF was paralleled to some degree by differences in the pattern of MAP changes after injury. Differences in body weight, blood gas levels, or blood pH did not account for the gender difference in CBF. Postinjury CBF was higher in female and male rats given 2 weeks of daily 17 beta -estradiol injections prior to injury compared to those given the vehicle only. However, 17 beta -estradiol administration did not alter MAP, suggesting that the gender difference in CBF was not strictly due to MAP changes. Our findings suggest that estrogen plays a role in maintaining adequate cerebral perfusion in the acute period following closed-head injury. This protective mechanism may underlie the gender difference in acute survival observed in this study, and may help explain observations of better outcome in females than in males after brain injury. We conclude that CBF preservation is one mechanism by which estrogen is neuroprotective following traumatic brain injury. We hypothesize, based upon known effects of estrogen, that the beneficial microvascular effects of estrogen most likely involve a combination of endothelial nitric oxide synthase induction and an antioxidant effect.	Pfizer Global Res & Dev, Neurosci Therapeut, Ann Arbor Labs, Ann Arbor, MI 48105 USA	Roof, RL (corresponding author), Pfizer Global Res & Dev, Neurosci Therapeut, Ann Arbor Labs, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.	robin.roof@pfizer.com	Hall, Edward D/F-8930-2013				Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; Behl C, 1997, MOL PHARMACOL, V51, P535; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; BERRY K, 1975, J NEUROL SCI, V25, P75, DOI 10.1016/0022-510X(75)90188-4; BISHOP J, 1995, BRAIN RES BULL, V36, P315, DOI 10.1016/0361-9230(94)00208-I; BUTCHER RL, 1974, ENDOCRINOLOGY, V117, P1195; CHANG WC, 1980, BIOCHIM BIOPHYS ACTA, V620, P472; Chen J, 1998, NEUROSCIENCE, V87, P817, DOI 10.1016/S0306-4522(98)00198-5; Culmsee C, 1999, J CEREBR BLOOD F MET, V19, P1263, DOI 10.1097/00004647-199911000-00011; Demiryurek AT, 1998, PHARMACOL TOXICOL, V82, P113, DOI 10.1111/j.1600-0773.1998.tb01408.x; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Farhat MY, 1996, FASEB J, V10, P615; FERRIS DC, 1995, NEUROREPORT, V6, P1485, DOI 10.1097/00001756-199507310-00005; FOGELBERG M, 1990, EUR J CLIN INVEST, V20, P105, DOI 10.1111/j.1365-2362.1990.tb01799.x; GISCLARD V, 1988, J PHARMACOL EXP THER, V244, P19; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Goss SPA, 1997, J BIOL CHEM, V272, P21647, DOI 10.1074/jbc.272.34.21647; Green PS, 1996, NEUROSCI LETT, V218, P165, DOI 10.1016/S0304-3940(96)13148-7; Gridley KE, 1997, BRAIN RES, V778, P158, DOI 10.1016/S0006-8993(97)01056-1; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; HALL ED, 1996, NEUROTRAUMA, P1405; HALL ED, 1998, ANN M SOC NEUR LOS A; HAMER J, 1973, ACTA NEUROCHIR, V28, P95, DOI 10.1007/BF01405406; HARDER DR, 1979, J CELL PHYSIOL, V100, P375, DOI 10.1002/jcp.1041000218; Hawk T, 1998, BRAIN RES, V796, P296, DOI 10.1016/S0006-8993(98)00327-8; HAYASHI T, 1992, P NATL ACAD SCI USA, V89, P11259, DOI 10.1073/pnas.89.23.11259; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Heath DL, 1996, NEUROSCI RES COMMUN, V18, P163; Hoffman SW, 1997, STROKE, V28, P844, DOI 10.1161/01.STR.28.4.844; HURN PD, 1995, J CEREBR BLOOD F MET, V15, P666, DOI 10.1038/jcbfm.1995.82; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kauser K, 1997, AM J PHYSIOL-HEART C, V273, pH506; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; KITA H, 1994, ACTA NEUROCHIR, P452; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Kondo Y, 1997, NEUROSCI LETT, V238, P45, DOI 10.1016/S0304-3940(97)00847-1; Kume-Kick J, 1998, BRAIN RES, V803, P105, DOI 10.1016/S0006-8993(98)00628-3; KumeKick J, 1996, BRAIN RES, V738, P8, DOI 10.1016/0006-8993(96)00744-5; Lammie GA, 1999, J NEUROTRAUM, V16, P603, DOI 10.1089/neu.1999.16.603; MADDOX YT, 1987, J PHARMACOL EXP THER, V240, P392; Marla SS, 1997, P NATL ACAD SCI USA, V94, P14243, DOI 10.1073/pnas.94.26.14243; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mehl M, 1999, NEUROSCI LETT, V271, P187, DOI 10.1016/S0304-3940(99)00558-3; MENDELOW AD, 1983, BRIT J SURG, V70, P641, DOI 10.1002/bjs.1800701102; MENDELSON ME, 1994, CURR OPIN CARDIOL, V9, P619, DOI 10.1097/00001573-199409000-00018; MIKKOLA T, 1995, J CLIN ENDOCR METAB, V80, P1832, DOI 10.1210/jc.80.6.1832; PAYAN HM, 1977, STROKE, V8, P194, DOI 10.1161/01.STR.8.2.194; Pelligrino DA, 1998, NEUROREPORT, V9, P3285, DOI 10.1097/00001756-199810050-00026; Regan RF, 1997, BRAIN RES, V764, P133, DOI 10.1016/S0006-8993(97)00437-X; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; RUSA R, 1998, 23 INT JOINT C STROK; SADOSHIMA S, 1988, BRAIN RES, V454, P238, DOI 10.1016/0006-8993(88)90823-2; Shi J, 1997, EXP BRAIN RES, V117, P200, DOI 10.1007/s002210050216; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; Singer CA, 1999, J NEUROSCI, V19, P2455; Singer CA, 1996, NEUROSCI LETT, V212, P13, DOI 10.1016/0304-3940(96)12760-9; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; STALLONE JN, 1991, AM J PHYSIOL, V260, pH453; STUBLEY L, 1998, ANN M SOC NEUR LOS A; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; VANDENBRINK WA, 1994, BRAIN EDEMA PATHOGEN, V52, P456; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x; Wang Q, 1999, STROKE, V30, P630, DOI 10.1161/01.STR.30.3.630; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; White R, 1998, METH MOL B, V100, P215; ZHANG A, 1992, BRIT J PHARMACOL, V105, P305, DOI 10.1111/j.1476-5381.1992.tb14250.x; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	94	157	165	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2000	17	12					1155	1169		10.1089/neu.2000.17.1155			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	379MB	WOS:000165644900004	11186229				2021-06-18	
J	Kilpatrick, MM; Lowry, DW; Firlik, AD; Yonas, H; Marion, DW				Kilpatrick, MM; Lowry, DW; Firlik, AD; Yonas, H; Marion, DW			Hyperthermia in the neurosurgical intensive care unit	NEUROSURGERY			English	Article						fever; hyperthermia; subarachnoid hemorrhage; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; BRAIN TEMPERATURE MODULATION; FOREBRAIN ISCHEMIA; NEURONAL DAMAGE; ACUTE STROKE; MODERATE HYPOTHERMIA; MILD HYPERTHERMIA; BODY-TEMPERATURE; GLOBAL-ISCHEMIA; INJURY	OBJECTIVE: In patients with traumatic or ischemic brain injury, hyperthermia is thought to worsen the neurological injury. We studied fever in the neurosurgical intensive care unit (ICU) population using a definition common to surgical practice (rectal temperature > 38.5 degrees C). We sought to determine fever incidence, fever duration, and peak temperature and to quantify the use of antipyretic therapy. We also attempted to determine the patient subgroups that are at highest risk for development of fever. METHODS: In a retrospective chart review of a 6-month period, all febrile episodes that occurred in a consecutive series of neurosurgical ICU patients in a university hospital setting were studied. A febrile episode was defined as a rectal temperature of at least 38.5 degrees C; an episode lasted until the temperature fell below this threshold. RESULTS: The 428 patients studied had 946 febrile episodes. Fever occurred in 47% of patients, with a mean of 4.7 febrile episodes in each febrile patient. Fevers occurred in more than 50% of patients who were admitted to the ICU for subarachnoid hemorrhage, a central nervous system infection, seizure control, or hemorrhagic stroke, but they occurred in only 27% of patients admitted for spinal disorders. Fevers occurred in 15% of the patients who stayed in the ICU less than 24 hours, but in 93% of those who remained longer than 14 days. Despite the use of antipyretic therapy for 86% of the febrile episodes, 57% lasted longer than 4 hours and 5% lasted longer than 12 hours. CONCLUSION: Fever is common in critically ill neurosurgical patients, especially those with a prolonged length of stay in the ICU or a cranial disease. If hyperthermia worsens the functional outcome after a primary ischemic or traumatic injury, as has been suggested by several studies of stroke patients, treatment of fever is a clinical issue that requires better management.	Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA	Lowry, DW (corresponding author), Great Lakes Neurosurg Associates, 414 Plymouth NE, Grand Rapids, MI 49505 USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702; Lowry, David/0000-0003-1037-8739			Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; BUSTO R, 1994, J NEUROCHEM, V63, P1095; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Castillo J, 1999, CEREBROVASC DIS, V9, P22, DOI 10.1159/000015891; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; CASTILLO J, 1994, CEREBROVASC DIS, V4, P56; CHOPP M, 1988, STROKE, V19, P1521, DOI 10.1161/01.STR.19.12.1521; CHURN SB, 1990, STROKE, V21, P1715, DOI 10.1161/01.STR.21.12.1715; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Coimbra C, 1996, STROKE, V27, P1578, DOI 10.1161/01.STR.27.9.1578; Coimbra C, 1996, ACTA NEUROPATHOL, V92, P447, DOI 10.1007/s004010050545; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; Eguchi Y, 1997, J NEUROTRAUM, V14, P109, DOI 10.1089/neu.1997.14.109; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; GINSBERG MD, 1992, DRUG RES RELATED NEU, V32, P207; GLOBUS MYT, 1991, NEUROSCI LETT, V127, P39, DOI 10.1016/0304-3940(91)90889-2; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; KUROIWA T, 1990, J CEREBR BLOOD F MET, V10, P550, DOI 10.1038/jcbfm.1990.97; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MEDEN P, 1994, BRAIN RES, V647, P131, DOI 10.1016/0006-8993(94)91407-9; MEMEZAWA H, 1995, BRAIN RES, V670, P48, DOI 10.1016/0006-8993(94)01251-C; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; Morimoto T, 1997, BRAIN RES, V746, P43, DOI 10.1016/S0006-8993(96)01154-7; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; STERNAU LL, 1992, ROLE OF NEUROTRANSMITTERS IN BRAIN INJURY, P33; TAKAGI K, 1994, AM J PHYSIOL, V226, pH1770; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013	38	157	164	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	OCT	2000	47	4					850	855		10.1097/00006123-200010000-00011			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	356HM	WOS:000089437900029	11014424				2021-06-18	
J	Saatman, KE; Contreras, PC; Smith, DH; Raghupathi, R; McDermott, KL; Fernandez, SC; Sanderson, KL; Voddi, M; McIntosh, TK				Saatman, KE; Contreras, PC; Smith, DH; Raghupathi, R; McDermott, KL; Fernandez, SC; Sanderson, KL; Voddi, M; McIntosh, TK			Insulin-like growth factor-1 (IGF-1) improves both neurological motor and cognitive outcome following experimental brain injury	EXPERIMENTAL NEUROLOGY			English	Article							TRANSIENT FOREBRAIN ISCHEMIA; NERVOUS-SYSTEM MYELINATION; RECEPTOR GENE-EXPRESSION; RAT SCIATIC-NERVE; FACTOR-I; CORTICAL CONTUSION; NEURITE FORMATION; MESSENGER-RNA; HEAD-INJURY; AMINO-ACIDS	We evaluated the efficacy of insulin-like growth factor-1 (IGF-1) in attenuating neurobehavioral deficits following lateral fluid percussion (FP) brain injury, Male Sprague-Dawley rats (345-425 g, n = 88) were anesthetized and subjected to FP brain injury of moderate severity (2.4-2.9 atm). In Study 1, IGF-1 (1.0 mg/kg, n = 9) or vehicle (n = 14) was administered by subcutaneous injection at 15 min postinjury and similarly at 12-h intervals for 14 days, In animals evaluated daily for 14 days, IGF-1 treatment attenuated motor dysfunction over the 2-week period (P < 0.02). In Study 2, ICF-1 (4 mg/kg/day, n = 8 uninjured, n = 13 injured) or vehicle (n = 8 uninjured, n = 13 injured) was administered for 2 weeks via a subcutaneous pump implanted 15 min postinjury. IGF-1 administration was associated with increased body weight and mild, transient hypoglycemia which was more pronounced in brain-injured animals, At 2 weeks postinjury (P < 0.05), but not at 48 h or 1 week, brain-injured animals receiving IGF-1 showed improved neuromotor function compared with those receiving vehicle. IGF-1 administration also enhanced learning ability (P < 0.03) and memory retention (P < 0.01) in brain-injured animals at 2 weeks postinjury. Taken together these data suggest that chronic, posttraumatic administration of the trophic factor IGF-1 may be efficacious in ameliorating neurobehavioral dysfunction associated with traumatic brain injury. (C) 1997 Academic Press.	UNIV PENN, CTR INJURY RES, DEPT BIOENGN, PHILADELPHIA, PA 19104 USA; CEPHALON INC, W CHESTER, PA USA	Saatman, KE (corresponding author), UNIV PENN, CTR INJURY RES, DEPT NEUROSURG, PHILADELPHIA, PA 19104 USA.		smith, douglas/A-1321-2007		NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS08803, R01-NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER		BACH MA, 1991, MOL BRAIN RES, V10, P43; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BASKIN DG, 1988, TRENDS NEUROSCI, V11, P107, DOI 10.1016/0166-2236(88)90155-5; BOHANNON NJ, 1988, BRAIN RES, V444, P205, DOI 10.1016/0006-8993(88)90931-6; BONDY C, 1992, NEUROSCIENCE, V46, P909, DOI 10.1016/0306-4522(92)90193-6; BONDY CA, 1993, ANN NY ACAD SCI, V692, P33; BOZYCZKOCOYNE D, 1993, ANN NY ACAD SCI, V692, P311; BULLOCK R, 1994, J NEUROTRAUMA, V11, P214; CARONI P, 1990, J CELL BIOL, V110, P1307, DOI 10.1083/jcb.110.4.1307; CARSON MJ, 1993, NEURON, V10, P729, DOI 10.1016/0896-6273(93)90173-O; CHENG B, 1992, J NEUROSCI, V12, P1558; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CONTI AC, 1996, J NEUROTRAUM, V13, P595; CONTRERAS PC, 1995, J PHARMACOL EXP THER, V274, P1443; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FERNYHOUGH P, 1989, MOL BRAIN RES, V6, P109, DOI 10.1016/0169-328X(89)90044-2; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GALLI C, 1995, J NEUROSCI, V15, P1172; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; Guan J, 1996, ENDOCRINOLOGY, V137, P893, DOI 10.1210/en.137.3.893; GUAN J, 1993, J CEREBR BLOOD F MET, V13, P609, DOI 10.1038/jcbfm.1993.79; GULER HP, 1988, P NATL ACAD SCI USA, V85, P4889, DOI 10.1073/pnas.85.13.4889; HAN VKM, 1987, J NEUROSCI, V7, P501; HANSSON HA, 1993, ANN NY ACAD SCI, V692, P161; HANTAI D, 1995, J NEUROL SCI, V129, P122, DOI 10.1016/0022-510X(95)00081-C; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; KANJE M, 1989, BRAIN RES, V486, P396, DOI 10.1016/0006-8993(89)90531-3; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; KNUSEL B, 1990, J NEUROSCI, V10, P558; KOMOLY S, 1992, P NATL ACAD SCI USA, V89, P1894, DOI 10.1073/pnas.89.5.1894; LEMMEY AB, 1991, AM J PHYSIOL, V260, pE213; LENOIR D, 1983, DEV BRAIN RES, V7, P205, DOI 10.1016/0165-3806(83)90177-3; LEROITH D, 1993, ANN NY ACAD SCI, V692, P22; LESNIAK MA, 1988, ENDOCRINOLOGY, V123, P2089, DOI 10.1210/endo-123-4-2089; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; MATTSON MP, 1993, STROKE, V24, pI136; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCMORRIS FA, 1993, ANN NY ACAD SCI, V692, P321; Nakao N, 1996, EXP NEUROL, V138, P144, DOI 10.1006/exnr.1996.0053; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1992, J NEUROTRAUM, V9, P47, DOI 10.1089/neu.1992.9.47; PARDRIDGE WM, 1993, ANN NY ACAD SCI, V692, P126; Pierce J. E. S., 1994, Society for Neuroscience Abstracts, V20, P196; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; RECIOPINTO E, 1988, J NEUROSCI RES, V19, P312, DOI 10.1002/jnr.490190306; REINHARDT RR, 1994, ENDOCRINOLOGY, V135, P1753, DOI 10.1210/en.135.5.1753; RINK A, 1995, AM J PATHOL, V147, P1575; SASTMAN KE, 1996, P NATL ACAD SCI USA, V93, P3428; SCHWANDER JC, 1983, ENDOCRINOLOGY, V113, P297, DOI 10.1210/endo-113-1-297; SHAPIRA Y, 1989, Neurological Research, V11, P169; SINSON G, 1995, J NEUROCHEM, V65, P2209; SJOBERG J, 1989, BRAIN RES, V485, P102, DOI 10.1016/0006-8993(89)90671-9; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STRONG AJ, 1990, J NEUROL NEUROSUR PS, V53, P847, DOI 10.1136/jnnp.53.10.847; SVRZIC D, 1990, BIOCHEM BIOPH RES CO, V172, P54, DOI 10.1016/S0006-291X(05)80172-X; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TOMAS FM, 1991, J ENDOCRINOL, V128, P97, DOI 10.1677/joe.0.1280097; Vink R, 1997, J CEREBR BLOOD F MET, V17, P50, DOI 10.1097/00004647-199701000-00007; VOLL CL, 1989, STROKE, V20, P646, DOI 10.1161/01.STR.20.5.646; WANG C, 1992, MOL BRAIN RES, V13, P289, DOI 10.1016/0169-328X(92)90212-T; YAMAGUCHI T, 1995, NEUROCHEM INT, V26, P255, DOI 10.1016/0197-0186(94)00127-G; YING Z, 1993, J CEREBR BLOOD F MET, V13, P378, DOI 10.1038/jcbfm.1993.51; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG B, 1992, J NEUROTRAUM, V9, pS375; ZHU CZ, 1994, J CEREBR BLOOD F MET, V14, P237, DOI 10.1038/jcbfm.1994.30	78	157	160	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	1997	147	2					418	427		10.1006/exnr.1997.6629			10	Neurosciences	Neurosciences & Neurology	YC680	WOS:A1997YC68000022	9344566				2021-06-18	
J	HAMILL, RW; WOOLF, PD; MCDONALD, JV; LEE, LA; KELLY, M				HAMILL, RW; WOOLF, PD; MCDONALD, JV; LEE, LA; KELLY, M			CATECHOLAMINES PREDICT OUTCOME IN TRAUMATIC BRAIN INJURY	ANNALS OF NEUROLOGY			English	Article									UNIV ROCHESTER,MED CTR,DEPT NEUROL,ROCHESTER,NY 14642; UNIV ROCHESTER,MED CTR,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,MED CTR,DEPT NEUROSURG,ROCHESTER,NY 14642; UNIV ROCHESTER,MED CTR,DEPT BRAIN RES,ROCHESTER,NY 14642; MONROE COMMUNITY HOSP,ROCHESTER,NY 14603							ANDERSON DW, 1980, NATIONAL HEAD SPINAL; BENEDICT CR, 1978, J NEUROL NEUROSUR PS, V41, P113, DOI 10.1136/jnnp.41.2.113; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BROWN BW, 1977, STATISTICS BIOMEDICA; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; COLGAN FJ, 1983, CRIT CARE MED, V11, P368, DOI 10.1097/00003246-198305000-00010; COLTON T, 1974, STATISTICS MED; CONNOR RCR, 1969, AM HEART J, V78, P145, DOI 10.1016/0002-8703(69)90001-5; FULTON RL, 1975, SURG GYNECOL OBSTET, V140, P179; HACKENBERRY LE, 1982, CRIT CARE MED, V10, P641; JENNETT B, 1981, CONT NEUROLOGY SERIE, V20; JOHNSTON I H, 1970, Lancet, V2, P433; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MCLEOD AA, 1982, BRIT HEART J, V47, P221; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NEILDWYER G, 1974, J NEUROL SCI, V22, P375, DOI 10.1016/0022-510X(74)90008-2; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; ROBERTSON CS, 1983, J NEUROSURG, V59, P455, DOI 10.3171/jns.1983.59.3.0455; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076	26	157	159	0	4	LITTLE BROWN CO	BOSTON	34 BEACON STREET, BOSTON, MA 02108-1493	0364-5134			ANN NEUROL	Ann. Neurol.	MAY	1987	21	5					438	443		10.1002/ana.410210504			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	H2632	WOS:A1987H263200003	3592639				2021-06-18	
J	Kumar, A; Stoica, BA; Sabirzhanov, B; Burns, MP; Faden, AI; Loane, DJ				Kumar, Alok; Stoica, Bogdan A.; Sabirzhanov, Boris; Burns, Mark P.; Faden, Alan I.; Loane, David J.			Traumatic brain injury in aged animals increases lesion size and chronically alters microglial/macrophage classical and alternative activation states	NEUROBIOLOGY OF AGING			English	Article						Microglia/macrophage; Alternative activation; Traumatic brain injury; Aging; NADPH oxidase; Neurodegeneration; Ym1	NADPH OXIDASE; OXIDATIVE STRESS; MICROGLIAL ACTIVATION; INFLAMMATORY RESPONSE; COGNITIVE DEFICITS; SYNAPTIC PROTEINS; MANNOSE RECEPTOR; EXPRESSION; NEUROINFLAMMATION; HIPPOCAMPUS	Traumatic brain injury (TBI) causes chronic microglial activation that contributes to subsequent neurodegeneration, with clinical outcomes declining as a function of aging. Microglia/macrophages (MG/M phi) have multiple phenotypes, including a classically activated, proinflammatory (M1) state that might contribute to neurotoxicity, and an alternatively activated (M2) state that might promote repair. In this study we used gene expression, immunohistochemical, and stereological analyses to show that TBI in aged versus young mice caused larger lesions associated with an M1/M2 balance switch and increased numbers of reactive (bushy and hypertrophic) MG/M phi in the cortex, hippocampus, and thalamus. Chitinase3- like 3 (Ym1), an M2 phenotype marker, displayed heterogeneous expression after TBI with amoeboid-like Ym1-positive MG/M phi at the contusion site and ramified Ym1-positive MG/M phi at distant sites; this distribution was age-related. Aged-injured mice also showed increased MG/M phi expression of major histocompatibility complex II and NADPH oxidase, and reduced antioxidant enzyme expression which was associated with lesion size and neurodegeneration. Thus, altered relative M1/M2 activation and an nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase)-mediated shift in redox state might contribute to worse outcomes observed in older TBI animals by creating a more proinflammatory M1 MG/M phi activation state. (C) 2013 Elsevier Inc. All rights reserved.	[Kumar, Alok; Stoica, Bogdan A.; Sabirzhanov, Boris; Faden, Alan I.; Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Kumar, Alok; Stoica, Bogdan A.; Sabirzhanov, Boris; Faden, Alan I.; Loane, David J.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Burns, Mark P.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA	Loane, DJ (corresponding author), 655 West Baltimore St,Room 6-011, Baltimore, MD 21201 USA.	dloane@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Burns, Mark P/0000-0003-4750-2000; Loane, David/0000-0003-0393-3503	National Capital Area Rehabilitation Research Network [R24HD050845]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082308, R01NS081068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028747] Funding Source: NIH RePORTER	The authors thank Dr Shruti Kabadi for helpful discussion. This work is supported by a pilot award from the National Capital Area Rehabilitation Research Network (R24HD050845) (DJL).	Anderson J, 2009, J NEUROTRAUM, V26, P1557, DOI [10.1089/neu.2008.0765, 10.1089/neu.2008-0765]; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Badan I, 2003, J CEREBR BLOOD F MET, V23, P845, DOI 10.1097/01.WCB.0000071883.63724.A7; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Bruce-Keller AJ, 2010, ANTIOXID REDOX SIGN, V12, P1371, DOI 10.1089/ars.2009.2823; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Chen H, 2011, NEUROBIOL DIS, V42, P341, DOI 10.1016/j.nbd.2011.01.027; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Chieppa M, 2003, J IMMUNOL, V171, P4552, DOI 10.4049/jimmunol.171.9.4552; Choi SH, 2012, J NEUROCHEM, V120, P292, DOI 10.1111/j.1471-4159.2011.07572.x; Colton CA, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-27; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Conde JR, 2006, NEUROBIOL AGING, V27, P1451, DOI 10.1016/j.neurobiolaging.2005.07.012; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Downer EJ, 2010, NEUROBIOL AGING, V31, P118, DOI 10.1016/j.neurobiolaging.2008.03.017; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fenn AM, 2012, BRAIN BEHAV IMMUN, V26, P766, DOI 10.1016/j.bbi.2011.10.003; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GALBRAITH S, 1987, BRIT MED J, V294, P325, DOI 10.1136/bmj.294.6568.325; Gao HM, 2003, J NEUROSCI, V23, P6181; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Hung SL, 2002, J LEUKOCYTE BIOL, V72, P72; Jimenez S, 2008, J NEUROSCI, V28, P11650, DOI 10.1523/JNEUROSCI.3024-08.2008; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; Liu TJ, 2004, AM J PATHOL, V164, P1315, DOI 10.1016/S0002-9440(10)63218-X; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, NEUROBIOL AGING, V30, P920, DOI 10.1016/j.neurobiolaging.2007.09.001; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Lynch MA, 2009, MOL NEUROBIOL, V40, P139, DOI 10.1007/s12035-009-8077-9; Mander PK, 2006, J IMMUNOL, V176, P1046, DOI 10.4049/jimmunol.176.2.1046; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Miller KR, 2007, NEURON GLIA BIOL, V3, P245, DOI 10.1017/S1740925X08000136; Moor E, 2006, EXP GERONTOL, V41, P303, DOI 10.1016/j.exger.2005.12.006; Munder M, 1999, J IMMUNOL, V163, P3771; Nair MG, 2009, J EXP MED, V206, P937, DOI 10.1084/jem.20082048; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Pesce JT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000393; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Popa-Wagner A, 2007, CURR NEUROVASC RES, V4, P216; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; Raes G, 2002, J LEUKOCYTE BIOL, V71, P597; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Sandhir R, 2010, NEUROCHEM INT, V56, P188, DOI 10.1016/j.neuint.2009.10.002; Sedgwick JD, 1998, J IMMUNOL, V160, P5320; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Shimohama S, 2000, BIOCHEM BIOPH RES CO, V273, P5, DOI 10.1006/bbrc.2000.2897; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Taylor PR, 2005, TRENDS IMMUNOL, V26, P104, DOI 10.1016/j.it.2004.12.001; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Wong AM, 2005, NEUROSCI LETT, V390, P76, DOI 10.1016/j.neulet.2005.07.058; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	68	156	159	0	33	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	MAY	2013	34	5					1397	1411		10.1016/j.neurobiolaging.2012.11.013			15	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	100UM	WOS:000315729500008	23273602	Green Accepted			2021-06-18	
J	Yang, LJ; Kress, BT; Weber, HJ; Thiyagarajan, M; Wang, BZ; Deane, R; Benveniste, H; Iliff, JJ; Nedergaard, M				Yang, Lijun; Kress, Benjamin T.; Weber, Harris J.; Thiyagarajan, Meenakshisundaram; Wang, Baozhi; Deane, Rashid; Benveniste, Helene; Iliff, Jeffrey J.; Nedergaard, Maiken			Evaluating glymphatic pathway function utilizing clinically relevant intrathecal infusion of CSF tracer	JOURNAL OF TRANSLATIONAL MEDICINE			English	Article						Intrathecal infusion; Cerebrospinal fluid (CSF); Perivascular space; Neurodegenerative disease; Alzheimer's disease; Traumatic brain injury	INTERSTITIAL FLUID; ALZHEIMERS-DISEASE; FLOW; AGGREGATION; ANESTHESIA; HYPOTHESIS; PHYSIOLOGY; MEDICINE; DRAINAGE; DELIVERY	Background: Neurodegenerative diseases such as Alzheimer's are associated with the aggregation of endogenous peptides and proteins that contribute to neuronal dysfunction and loss. The glymphatic system, a brain-wide perivascular pathway along which cerebrospinal fluid (CSF) and interstitial fluid (ISF) rapidly exchange, has recently been identified as a key contributor to the clearance of interstitial solutes from the brain, including amyloid beta. These findings suggest that measuring changes in glymphatic pathway function may be an important prognostic for evaluating neurodegenerative disease susceptibility or progression. However, no clinically acceptable approach to evaluate glymphatic pathway function in humans has yet been developed. Methods: Time-sequenced ex vivo fluorescence imaging of coronal rat and mouse brain slices was performed at 30-180 min following intrathecal infusion of CSF tracer (Texas Red-dextran-3, MW 3 kD; FITC- dextran-500, MW 500 kD) into the cisterna magna or lumbar spine. Tracer influx into different brain regions (cortex, white matter, subcortical structures, and hippocampus) in rat was quantified to map the movement of CSF tracer following infusion along both routes, and to determine whether glymphatic pathway function could be evaluated after lumbar intrathecal infusion. Results: Following lumbar intrathecal infusions, small molecular weight TR-d3 entered the brain along perivascular pathways and exchanged broadly with the brain ISF, consistent with the initial characterization of the glymphatic pathway in mice. Large molecular weight FITC-d500 remained confined to the perivascular spaces. Lumbar intrathecal infusions exhibited a reduced and delayed peak parenchymal fluorescence intensity compared to intracisternal infusions. Conclusion: Lumbar intrathecal contrast delivery is a clinically useful approach that could be used in conjunction with dynamic contrast enhanced MRI nuclear imaging to assess glymphatic pathway function in humans.	[Yang, Lijun; Kress, Benjamin T.; Weber, Harris J.; Thiyagarajan, Meenakshisundaram; Deane, Rashid; Iliff, Jeffrey J.; Nedergaard, Maiken] Univ Rochester, Med Ctr, Dept Neurosurg, Ctr Translat Neuromed, Rochester, NY 14642 USA; [Yang, Lijun] Hebei Med Univ, Hosp Shijiazhuang 1, Dept Neurosurg, Shijiazhuang 050031, Peoples R China; [Wang, Baozhi] Hebei Med Univ, Dept Human Anat, Shijiazhuang 050012, Peoples R China; [Benveniste, Helene] SUNY Stony Brook, Dept Anesthesiol, Stony Brook, NY USA; [Iliff, Jeffrey J.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA	Iliff, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Neurosurg, Ctr Translat Neuromed, 601 Elmwood Ave, Rochester, NY 14642 USA.	Jeffrey_Iliff@urmc.rochester.edu; Nedergaard@urmc.rochester.edu		kress, Benjamin/0000-0003-2478-4121	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; United States Department of DefenseUnited States Department of Defense; Harold and Leila Y. Mathers Charitable Foundation; American Heart AssociationAmerican Heart Association; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS075177, R01NS078167, R01NS078304] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (MN), the United States Department of Defense (MN), the Harold and Leila Y. Mathers Charitable Foundation (MN) and the American Heart Association (JI).	Abbott NJ, 2004, NEUROCHEM INT, V45, P545, DOI 10.1016/j.neuint.2003.11.006; ADAMS C, 1988, PEDIATR NEUROL, V4, P105, DOI 10.1016/0887-8994(88)90049-5; Begley DJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004611; Begley DJ, 2004, PHARMACOL THERAPEUT, V104, P29, DOI 10.1016/j.pharmthera.2004.08.001; BRADBURY MWB, 1981, AM J PHYSIOL, V240, pF329; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bulat M, 2011, BRAIN RES REV, V65, P99, DOI 10.1016/j.brainresrev.2010.08.002; Burns BJ, 2008, ANN EMERG MED, V51, P704, DOI 10.1016/j.annemergmed.2007.08.028; CSERR HF, 1971, PHYSIOL REV, V51, P273; Daele JJM, 2011, B-ENT, V7, P47; Deane R, 2007, CURR ALZHEIMER RES, V4, P191, DOI 10.2174/156720507780362245; Edsbagge M, 2004, AM J PHYSIOL-REG I, V287, pR1450, DOI 10.1152/ajpregu.00215.2004; ENZMANN DR, 1991, RADIOLOGY, V178, P467, DOI 10.1148/radiology.178.2.1987610; Gehling M, 2009, ANAESTHESIA, V64, P643, DOI 10.1111/j.1365-2044.2008.05817.x; Geraldes CFGC, 2009, CONTRAST MEDIA MOL I, V4, P1, DOI 10.1002/cmmi.265; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hong JY, 2005, ANAESTHESIA, V60, P1168, DOI 10.1111/j.1365-2044.2005.04158.x; Hoxworth JM, 2012, AM J ROENTGENOL, V199, P649, DOI 10.2214/AJR.11.8238; Iliff JJ, 2013, J CLIN INVEST, V123, P1299, DOI 10.1172/JCI67677; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Johnston M, 2003, LYMPHAT RES BIOL, V1, P45; Johnston Miles, 2003, Lymphat Res Biol, V1, P41, DOI 10.1089/15396850360495682; Jucker M, 2011, ANN NEUROL, V70, P532, DOI 10.1002/ana.22615; KAPILA A, 1987, SPINE, V12, P817, DOI 10.1097/00007632-198710000-00020; KEANE JR, 1973, CALIF MED, V119, P10; Kerr JZ, 2001, CRIT REV ONCOL HEMAT, V37, P227, DOI 10.1016/S1040-8428(00)00115-3; Maccioni RB, 2010, ARCH MED RES, V41, P226, DOI 10.1016/j.arcmed.2010.03.007; Mathiisen TM, 2010, GLIA, V58, P1094, DOI 10.1002/glia.20990; Nordberg A, 2010, NAT REV NEUROL, V6, P78, DOI 10.1038/nrneurol.2009.217; Phillips CD, 2002, AM J NEURORADIOL, V23, P337; Popping DM, 2012, PAIN, V153, P784, DOI 10.1016/j.pain.2011.11.028; Praetorius J, 2007, PFLUG ARCH EUR J PHY, V454, P1, DOI 10.1007/s00424-006-0170-6; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Small SA, 2008, NEURON, V60, P534, DOI 10.1016/j.neuron.2008.11.007; Stoodley MA, 1996, BRAIN RES, V707, P155, DOI 10.1016/0006-8993(95)01228-1; Strittmatter WJ, 2013, J CLIN INVEST, V123, P1013, DOI 10.1172/JCI68241; Sykova E, 2008, PHYSIOL REV, V88, P1277, DOI 10.1152/physrev.00027.2007; SZENTISTVANYI I, 1984, AM J PHYSIOL, V246, pF835	39	156	159	1	59	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1479-5876		J TRANSL MED	J. Transl. Med.	MAY 1	2013	11								107	10.1186/1479-5876-11-107			9	Medicine, Research & Experimental	Research & Experimental Medicine	152FT	WOS:000319517300001	23635358	DOAJ Gold, Green Published			2021-06-18	
J	Broglio, SP; Schnebel, B; Sosnoff, JJ; Shin, S; Feng, XD; He, XM; Zimmerman, J				Broglio, Steven P.; Schnebel, Brock; Sosnoff, Jacob J.; Shin, Sunghoon; Feng, Xingdong; He, Xuming; Zimmerman, Jerrad			Biomechanical Properties of Concussions in High School Football	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						MILD TRAUMATIC BRAIN INJURY; HEAD ACCELERATION; SPORT INJURY; CLASSIFICATION AND REGRESSION TREE (CART) ANALYSIS	TRAUMATIC BRAIN-INJURY; HEAD IMPACTS; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; COLLEGIATE; PLAYERS; ACCELERATION; RISK	BROGLIO, S. P., B. SCHNEBEL, J. J. SOSNOFF, S. SHIN, X. FENG, X. HE, and J. ZIMMERMAN. Biomechanical Properties of Concussions in High School Football. Med. Sci. Sports Exerc., Vol. 42, No. 11, pp. 2064-2071, 2010. Introduction: Sport concussion represents the majority of brain injuries occurring in the United States with 1.6-3.8 million cases annually. Understanding the biomechanical properties of this injury will support the development of better diagnostics and preventative techniques. Methods: We monitored all football related head impacts in 78 high school athletes (mean age = 16.7 yr) from 2005 to 2008 to better understand the biomechanical characteristics of concussive impacts. Results: Using the Head Impact Telemetry System, a total of 54,247 impacts were recorded, and 13 concussive episodes were captured for analysis. A classification and regression tree analysis of impacts indicated that rotational acceleration (>5582.3 rad.s(-2)), linear acceleration (>96.1g), and impact location (front, top, and back) yielded the highest predictive value of concussion. Conclusions: These threshold values are nearly identical with those reported at the collegiate and professional level. If the Head Impact Telemetry System were implemented for medical use, sideline personnel can expect to diagnose one of every five athletes with a concussion when the impact exceeds these tolerance levels. Why all athletes did not sustain a concussion when the impacts generated variables in excess of our threshold criteria is not entirely clear, although individual differences between participants may play a role. A similar threshold to concussion in adolescent athletes compared with their collegiate and professional counterparts suggests an equal concussion risk at all levels of play.	[Broglio, Steven P.] Univ Illinois, Neurotrauma Res Lab, Urbana, IL 61801 USA; [Schnebel, Brock] Univ Oklahoma, Dept Orthoped, Norman, OK 73019 USA; [Schnebel, Brock] Univ Oklahoma, Dept Athlet, Norman, OK 73019 USA; [Sosnoff, Jacob J.; Shin, Sunghoon] Univ Illinois, Motor Control Lab, Urbana, IL 61801 USA; [He, Xuming] Univ Illinois, Dept Stat, Urbana, IL 61801 USA; [Feng, Xingdong] Natl Inst Stat Sci, Res Triangle Pk, NC USA; [Zimmerman, Jerrad] Carle Fdn Hosp, Dept Sports Med, Urbana, IL USA	Broglio, SP (corresponding author), 906 S Goodwin Ave, Urbana, IL 61801 USA.	broglio@illinois.edu	Shin, Sunghoon/O-2070-2019; Sosnoff, Jacob/P-3397-2019	Shin, Sunghoon/0000-0001-5355-2157; Sosnoff, Jacob/0000-0002-0286-9207	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA129671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM080503] Funding Source: NIH RePORTER	Xuming He received funding for this work from the National Institutes of Health. This project would not have been possible without the strong support of Scott Hamilton and the Unity Rockets football team (Tolono, IL); John Storsved, ATC; Susan Mantel, M. D.; and the coaches and players of the Cassidy High School football team.	Arbogast KB, 1999, J BIOMECH, V32, P865, DOI 10.1016/S0021-9290(99)00042-1; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Breiman L., 1984, CLASSIFICATION REGRE, P1, DOI [10.1201/9781315139470, DOI 10.1201/9781315139470]; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P65, DOI 10.1007/0-387-32565-4_4; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HOLLISTER NR, 1958, WADC TECH REP US AIR, V1, P58; Kelly JP, 1997, NEUROLOGY, V48, P581; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Littell R. C., 2006, SAS MIXED MODELS, P525; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ONUSIC H, 1995, INT J VEHICLE DES, V16, P194; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Takhounts EG, 2008, STAPP CAR C, V52, P1; ZATSIORSKY VM, 2002, KINETICS HUMAN MOTIO, P577; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	34	156	157	4	35	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	NOV	2010	42	11					2064	2071		10.1249/MSS.0b013e3181dd9156			8	Sport Sciences	Sport Sciences	667XZ	WOS:000283231900013	20351593	Green Accepted			2021-06-18	
J	Yeates, KO; Taylor, HG; Walz, NC; Stancin, T; Wade, SL				Yeates, Keith Owen; Taylor, H. Gerry; Walz, Nicolay Chertkoff; Stancin, Terry; Wade, Shari L.			The Family Environment as a Moderator of Psychosocial Outcomes Following Traumatic Brain Injury in Young Children	NEUROPSYCHOLOGY			English	Article						parenting; home; behavior; social competence; adaptive functioning	CLOSED-HEAD-INJURY; SOCIAL-BEHAVIOR; EARLY-CHILDHOOD; SHORT-TERM; FUNCTIONAL RECOVERY; CONSTRUCT-VALIDITY; HOME; PREDICTORS; RELIABILITY; SEVERITY	Objective: This study sought to determine whether the family environment moderates psychosocial outcomes after traumatic brain injury (TBI) in young children. Method: Participants were recruited prospectively from consecutive hospital admissions of 3- to 6-year-old children, and included 19 with severe TBI, 56 with complicated mild/moderate TBI, and 99 with orthopedic injuries (OI). They completed 4 assessments across the first 18 months postinjury. The initial assessment included measures of parenting style. family functioning, and the quality of the home. Children's behavioral adjustment, adaptive functioning, and social competence were assessed at each occasion. Mixed model analyses examined the relationship of the family environment to psychosocial outcomes across time. Results: The OI and TBI groups differed significantly in social competence, but the family environment did not moderate the group difference, which was of medium magnitude. In contrast, group differences in behavioral adjustment became more pronounced across time at high levels of authoritarian and permissive parenting; among children with severe TBI, however, even those with low levels of permissive parenting showed increases in behavioral problems. For adaptive functioning, better home environments provided some protection following TB!, but not over time for the severe TBI group. These 3-way interactions of group, family environment, and time postinjury were all of medium magnitude. conclusion: The findings indicate that the family environment moderates the psychosocial outcomes of TBI in young children, but the moderating influence may wane with time among children with severe TBI.	[Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Ctr Biobehav Hlth, Res Inst, Columbus, OH 43205 USA; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Div Dev & Behav Pediat & Pediat Psychol, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Cleveland, OH USA; [Walz, Nicolay Chertkoff] Cincinnati Childrens Hosp, Med Ctr, Div Behav Med & Clin Psychol, Dept Pediat, Cincinnati, OH USA; [Walz, Nicolay Chertkoff; Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; [Stancin, Terry] Case Western Reserve Univ, Div Pediat Psychol, Dept Pediat, Sch Med, Cleveland, OH 44106 USA; [Stancin, Terry] Metrohlth Med Ctr, Cleveland, OH USA; [Wade, Shari L.] Cincinnati Childrens Hosp, Div Pediat Rehabil, Med Ctr, Cincinnati, OH USA	Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Ctr Biobehav Hlth, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD42729, K02 HD44099]; United States Public Health Service National Institutes of HealthUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA [M01 RR 08084]; State of Ohio Emergency Medical Services; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER	The research reported here was supported by Grant R01 HD42729 to Shari L. Wade from the National Institute of Child Health and Human Development, in part by the United States Public Health Service National Institutes of Health Grant M01 RR 08084, and by Trauma Research grants from the State of Ohio Emergency Medical Services. Keith Owen Yeates received support from career development grant K02 HD44099 from the National Institute of Child Health and Human Development during the conduct of the research. The Cincinnati Children's Medical Center Trauma Registry, Rainbow Pediatric Trauma Center, Rainbow Babies & Children's Hospital, Nationwide Children's Hospital Trauma Program, and Metro-Health Center Department of Pediatrics and Trauma Registry provided assistance with recruitment. We acknowledge the contributions of Christine Abraham, Andrea Beebe, Lori Bernard, Anne Birnbaum, Beth Bishop, Tammy Matecun, Karen Oberjohn, Elizabeth Roth, and Elizabeth Shaver in data collection and coding. We also thank Nori Minich for her assistance in data analysis.	Achenbach T. M., 2000, MANUAL ASEBA PRESCHO; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; BAUMRIND D, 1971, DEV PSYCHOL, V4, P1, DOI 10.1037/h0030372; BENDERSKY M, 1994, DEV PSYCHOL, V30, P484, DOI 10.1037/0012-1649.30.4.484; BRADLEY RH, 1984, DEV PSYCHOL, V20, P315, DOI 10.1037/0012-1649.20.2.315; BRESLAU N, 1995, EPIDEMIOL REV, V17, P96, DOI 10.1093/oxfordjournals.epirev.a036191; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Caldarella, 2002, HOME COMMUNITY SOCIA; Caldwell B. M., 1984, HOME OBSERVATION MEA; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collins WA, 2000, AM PSYCHOL, V55, P218, DOI 10.1037/0003-066X.55.2.218; Elliott C.D., 1990, DIFFERENTIAL ABILITY; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gottfried A. W., 1984, HOME ENV EARLY COGNI, P57, DOI [10.1016/B978-0-12-293460-5.50008-0, DOI 10.1016/B978-0-12-293460-5.50008-0]; HACK M, 1992, J DEV BEHAV PEDIATR, V13, P412; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Landry SH, 2003, DEV NEUROPSYCHOL, V24, P559, DOI 10.1207/S15326942DN242&3_04; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lund J, 2001, J PSYCHOEDUC ASSESS, V19, P112, DOI 10.1177/073428290101900201; MCCLELLAND GH, 1993, PSYCHOL BULL, V114, P376, DOI 10.1037/0033-2909.114.2.376; Merrell K.W., 2002, PRESCHOOL KINDERGART; Merrell KW, 1996, J EARLY INTERVENTION, V20, P132, DOI 10.1177/105381519602000205; Merrell KW, 2001, PSYCHOL SCHOOLS, V38, P313, DOI 10.1002/pits.1021; Merrell KW, 2001, J EMOT BEHAV DISORD, V9, P260, DOI 10.1177/106342660100900406; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Oakland T, 2008, PRACT RESOUR MENT, P3; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Robinson C, 2001, HDB FAMILY MEASURES, V3, P319, DOI DOI 10.1177/0192513X09357555; ROBINSON CC, 1995, PSYCHOL REP, V77, P819, DOI 10.2466/pr0.1995.77.3.819; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Smith KE, 2005, J CONSULT CLIN PSYCH, V73, P711, DOI 10.1037/0022-006X.73.4.711; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Stancin T, 2001, J TRAUMA, V51, P69, DOI 10.1097/00005373-200107000-00011; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2008, REHABIL PSYCHOL, V53, P180, DOI 10.1037/0090-5550.53.2.180; Wade SL, 2009, J HEAD TRAUMA REHAB, V24, P239, DOI 10.1097/HTR.0b013e3181ad6680; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	55	156	156	1	15	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2010	24	3					345	356		10.1037/a0018387			12	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	587IW	WOS:000276985500007	20438212	Green Accepted			2021-06-18	
J	Narotam, PK; Morrison, JF; Nathoo, N				Narotam, Pradeep K.; Morrison, John F.; Nathoo, Narendra			Brain tissue oxygen monitoring in traumatic brain injury and major trauma: outcome analysis of a brain tissue oxygen-directed therapy Clinical article	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure monitoring; traumatic brain injury; critical care guide; brain injury outcome; brain tissue oxygenation; oxygen	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; AGGRESSIVE TREATMENT; COMATOSE PATIENTS; INSPIRED OXYGEN; INTENSIVE-CARE; MANAGEMENT; PO2; EXPERIENCE	Object. Cerebral ischemia is the leading cause of preventable death in cases of major trauma with severe traumatic brain injury (TBI). Intracranial pressure (ICP) control and cerebral perfusion pressure (CPP) manipulation have significantly reduced the mortality but not the morbidity rate in these patients. In this study, the authors describe their 5-year experience with brain tissue oxygen (PbtO(2)) monitoring, and the effect of a brain tissue oxygen-directed critical care guide (PbtO(2)-CCG) on the 6-month clinical outcome (based on the 6-month Glasgow Outcome Scale score) in patients with TBIs. Methods. One hundred thirty-nine patients admitted to Creighton University Medical Center with major traumatic injuries (Injury Severity Scale [ISS] scores >= 16) and TBI underwent prospective evaluation. All patients were treated with a PbtO(2)-CCG to maintain a brain oxygen level > 20 mm Hg, and control ICP < 20 mm Hg. The role of demographic, clinical, and imaging parameters in the identification of patients at risk for cerebral hypooxygenation and the influence of hypooxygenation on clinical outcome were recorded. Outcomes were compared with those in a historical ICP/CPP patient cohort. Subgroup analysis of severe TBI was performed and compared to data reported in the Traumatic Coma Data Bank. Results. The majority of injuries were sustained in motor vehicle crashes (63%), and diffuse brain injury was the most common abnormality (58%). Mechanism of injury, severity of TBI, pathological entity, neuroimaging results, and trauma indices were not predictive of ischemia. Factors affecting death included gunshot injury, poor trauma indices, subarachnoid hemorrhage, and coma. After standard resuscitation, 65% of patients had an initially low PbtO(2). Data are presented as means +/- SDs. Treatment with the PbtO(2)-CCG resulted in a 44% improvement in mean PbtO2 (16.21 +/- 12.30 vs 23.65 +/- 14.40 mm Hg; p < 0.001), control of ICP (mean 12.76 +/- 6.42 mm Hg), and the maintenance of CPP (mean 76.13 +/- 15.37 mm Hg). Persistently low cerebral oxygenation was seen in 37% of patients at 2 hours, 31% at 24 hours, and 18% at 48 hours of treatment. Thus elevated ICP and a persistent low PbtO(2) after 2 hours represented increasing odds of death (OR 14.3 at 48 hours). Survivors and patients with good outcomes generally had significantly higher mean daily PbtO(2) and CPP values compared to nonsurvivors. Polytrauma, associated with higher ISS scores, presented an increased risk of vegetative outcome (OR 9.0). Compared to the ICP/CPP cohort, the mean Glasgow Outcome Scale score at 6 months in patients treated with PbtO(2)-CCG was higher (3.55 +/- 1.75 vs 2.71 +/- 1.65, p < 0.01; OR for good outcome 2.09, 95% CI 1.031-4.24) as was the reduction in mortality rate (25.9 vs 41.50%; relative risk reduction 37%), despite higher ISS scores in the PbtO(2) group (31.6 +/- 13.4 vs 27.1 +/- 8.9; p < 0.05). Subgroup analysis of severe closed TBI revealed a significant relative risk reduction in mortality rate of 37-51% compared with the Traumatic Coma Data Bank data, and an increased OR for good outcome especially in patients with diffuse brain injury without mass lesions (OR 4.9, 95% CI 2.9-8.4). Conclusions. The prevention and aggressive treatment of cerebral hypooxygenation and control of ICP with a PbtO(2)-directed protocol reduced the mortality rate after TBI in major trauma, but more importantly, resulted in improved 6-month clinical outcomes over the standard ICP/CPP-directed therapy at the authors' institution. (DOI: 10.3171/2009.4.JNS081150)	[Narotam, Pradeep K.] Union Hosp Neurosci, Terre Haute, IN USA; [Narotam, Pradeep K.; Morrison, John F.; Nathoo, Narendra] Creighton Univ, Med Ctr, Div Neurosurg, Omaha, NE USA; [Narotam, Pradeep K.; Morrison, John F.; Nathoo, Narendra] Creighton Univ, Med Ctr, Div Trauma, Omaha, NE USA; [Nathoo, Narendra] Council Bluffs, Iowa City, IA USA	Narotam, PK (corresponding author), 1530 N 7th St,106, Terre Haute, IN 47807 USA.	narotam@mac.com					Andrews PJD, 2005, CRIT CARE, V9, P638, DOI 10.1186/cc3922; Atzema C, 2006, J TRAUMA, V60, P1010, DOI 10.1097/01.ta.0000218038.28064.9d; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Bardt TF, 1998, ACT NEUR S, V71, P153; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bruzzone P, 1998, ACT NEUR S, V71, P111; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Celli P, 1997, Minerva Chir, V52, P1467; Chesnut R M, 1995, New Horiz, V3, P366; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Cormio M, 1999, J NEUROSURG, V90, P9, DOI 10.3171/jns.1999.90.1.0009; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Demetriades D, 2006, J TRAUMA, V61, P868, DOI 10.1097/01.ta.0000219135.33398.f3; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Fandino J, 2000, J CLIN NEUROSCI, V7, P226, DOI 10.1054/jocn.1999.0202; Filippi R, 2000, NEUROSURG REV, V23, P94; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; Hong WC, 2006, SURG NEUROL, V66, pS8, DOI 10.1016/j.surneu.2006.07.006; Huang SJ, 2006, J CLIN NEUROSCI, V13, P818, DOI 10.1016/j.jocn.2005.11.034; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kiening KL, 1998, ACT NEUR S, V71, P172; Lane PL, 2000, CAN J SURG, V43, P442; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1987, J NEUROSURG, V67, P952; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; McDonagh M, 2004, ARCH PHYS MED REHAB, V85, P1198, DOI 10.1016/j.apmr.2003.12.026; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; Narotam PK, 2008, J NEUROSURG, V109, P1065, DOI 10.3171/JNS.2008.109.12.1065; Neugebauer E, 1999, RESTOR NEUROL NEUROS, V14, P83; Ng I., 1998, Annals Academy of Medicine Singapore, V27, P332; OVERGAARD J, 1983, J NEUROSURG, V59, P439, DOI 10.3171/jns.1983.59.3.0439; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Rondina C, 2005, J HEAD TRAUMA REHAB, V20, P368, DOI 10.1097/00001199-200507000-00008; Sahuquillo J, 2000, ACT NEUR S, V76, P457; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; Sarrafzadeh AS, 2003, BRIT J NEUROSURG, V17, P340, DOI 10.1080/02688690310001601234; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Schneider GH, 1998, ACT NEUR S, V71, P62; SIGNORINI DF, 2000, COCHRANE DB SYST REV, V2, P1048; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Stocchetti N, 1998, ACT NEUR S, V71, P162; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; TEASDALE G, 1974, LANCET, V2, P81; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van den Brink WA, 1998, ACT NEUR S, V71, P190; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; VISVANATHAN R, 1994, AUST NZ J SURG, V64, P527, DOI 10.1111/j.1445-2197.1994.tb02278.x; Vukic M, 1999, ACTA NEUROCHIR, V141, P1203, DOI 10.1007/s007010050419; Yang X, 2001, Chin J Traumatol, V4, P93; Zhi DS, 1999, SURG NEUROL, V52, P393, DOI 10.1016/S0090-3019(99)00101-9	67	156	165	1	17	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2009	111	4					672	682		10.3171/2009.4.JNS081150			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	503PL	WOS:000270550000008	19463048				2021-06-18	
J	Hesdorffer, DC; Benn, EKT; Cascino, GD; Hauser, WA				Hesdorffer, Dale C.; Benn, Emma K. T.; Cascino, Gregory D.; Hauser, W. Allen			Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure	EPILEPSIA			English	Article						Acute symptomatic seizure; Epidemiology; Epilepsy; Seizure recurrence; Mortality	MINNESOTA; ROCHESTER	To compare mortality and subsequent unprovoked seizure risk in a population-based study of acute symptomatic seizure and first unprovoked seizure due to static brain lesions. We ascertained all first episodes of acute symptomatic seizure and unprovoked seizure due to central nervous system (CNS) infection, stroke, and traumatic brain injury (TBI). Subjects were residents of Rochester, Minnesota, identified through the Rochester Epidemiology Project's records-linkage system between 1/1/55 and 12/31/84. Information was collected on age, gender, seizure type, etiology, status epilepticus (SE), 30-day and 10-year mortality, and subsequent episodes of unprovoked seizure. Two hundred sixty-two individuals experienced a first acute symptomatic seizure and 148 individuals experienced a first unprovoked seizure, all due to static brain lesions. Individuals with a first acute symptomatic seizure were 8.9 times more likely to die within 30 days compared to those with a first unprovoked seizure [95% confidence intervals (CI) = 3.5-22.5] after adjustment for age, gender, and SE. Among 30-day survivors, the risk of 10-year mortality did not differ. Over the 10-year period, individuals with a first acute symptomatic seizure were 80% less likely to experience a subsequent unprovoked seizure compared with individuals with a first unprovoked seizure [adjusted rate ratio (RR) = 0.2, 95% CI = 0.2-0.4]. The prognosis of first acute symptomatic seizures differs from that of first unprovoked seizure when the etiology is stroke, TBI, and CNS infection. Acute symptomatic seizures have a higher early mortality and a lower risk for subsequent unprovoked seizure. These differences argue against the inclusion of acute symptomatic seizures as epilepsy.	[Hesdorffer, Dale C.] Columbia Univ, Mailman Sch Publ Hlth, Gertrude H Sergievsky Ctr, Dept Epidemiol, New York, NY 10032 USA; [Benn, Emma K. T.] Columbia Univ, Mailman Sch Publ Hlth, Gertrude H Sergievsky Ctr, Dept Biostat, New York, NY 10032 USA; [Cascino, Gregory D.] Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA; [Hauser, W. Allen] Columbia Univ, Mailman Sch Publ Hlth, Gertrude H Sergievsky Ctr, Dept Neurol, New York, NY 10032 USA; [Hauser, W. Allen] Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA	Hesdorffer, DC (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Gertrude H Sergievsky Ctr, Dept Epidemiol, 630 W 168th St,P&S Box 16, New York, NY 10032 USA.	dch5@columbia.edu	Hauser, W Allen/AAB-5277-2020	Benn, Emma/0000-0001-7051-5841			ANNEGERS JF, 1995, EPILEPSIA, V36, P327, DOI 10.1111/j.1528-1157.1995.tb01005.x; [Anonymous], 1993, EPILEPSIA, V34, P592; Berg AT, 2006, EPILEPSY RES, V70, pS11, DOI 10.1016/j.eplepsyres.2005.11.015; Breslow N. E., 1987, STATISTICAL METHODS, VII, P65; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Hauser WA, 1998, NEW ENGL J MED, V338, P429, DOI 10.1056/NEJM199802123380704; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; HAUSER WA, 1982, STATUS EPILEPTICUS M, P3	9	156	164	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	MAY	2009	50	5					1102	1108		10.1111/j.1528-1167.2008.01945.x			7	Clinical Neurology	Neurosciences & Neurology	441LG	WOS:000265770000018	19374657	Bronze			2021-06-18	
J	Whittaker, R; Kemp, S; House, A				Whittaker, Robert; Kemp, Steven; House, Allan			Illness perceptions and outcome in mild head injury: a longitudinal study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; SCALE; QUESTIONNAIRE	Background: A range of neuropathological and psychosocial factors have been implicated in the aetiology and maintenance of post-concussional syndrome (PCS), with a growing consensus in the literature that this is a complex, multifactorial condition. The role of patients' perceptions in PCS has not been examined to date. Objective: This longitudinal study examines the role of illness perceptions in predicting outcome following mild head injury, controlling for severity of injury, post-traumatic stress symptoms, anxiety and depression, using a logistic regression analysis. Method: 73 patients were admitted to an accident and emergency department with mild head injury (Glasgow Coma Scale score 13-15; loss of consciousness < 20 min; post-traumatic amnesia < 24 h). Data on PCS symptomatology, illness perceptions, post-traumatic stress symptoms, anxiety and depression were collected after the injury and at the 3 month follow-up. Logistic regression analysis was used to evaluate predictors of outcome. Results: Following a mild head injury, symptomatic patients who believe that their symptoms have serious negative consequences on their lives and will continue to do so, are at heightened risk of experiencing significant enduring post-concussional symptoms (p < 0.001). Adding measures of severity of injury, post-traumatic stress symptoms, anxiety and depression to the regression model did not improve prediction of outcome. Conclusion: Whatever other physical or psychological factors may be involved, patients' perceptions of their illness early after head injury play a part in the persistence of PCS.	St Lukes Hosp, Dept Clin Hlth Psychol, Bradford Teaching Hosp Fdn Trust, Bradford BD5 0NA, W Yorkshire, England; St James Univ Hosp, Leeds, W Yorkshire, England; Univ Leeds, Inst Hlth Sci & Publ Hlth Res, Acad Unit Psychiat & Behav Sci, Leeds, W Yorkshire, England	Whittaker, R (corresponding author), St Lukes Hosp, Dept Clin Hlth Psychol, Bradford Teaching Hosp Fdn Trust, Little Horton Lane, Bradford BD5 0NA, W Yorkshire, England.	robert.whittaker@bradfordhospitals.nhs.uk		House, Allan/0000-0001-8721-8026			Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Hosmer D. W., 2000, APPL LOGISTIC REGRES; KAPTEIN AA, 2003, SELF REGULATION HLTH; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Leventhal H., 1980, MED PSYCHOL, V2, P7; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Manu P., 1998, FUNCTIONAL SOMATIC S; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; MOSSMORRIS R, 2003, SELF REGULATION HLTH; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TEASDALE G, 1974, LANCET, V2, P81; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	17	156	157	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	2007	78	6					644	646		10.1136/jnnp.2006.101105			3	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	169LO	WOS:000246593900025	17507448	Green Published			2021-06-18	
J	Chi, JH; Knudson, MM; Vassar, MJ; McCarthy, MC; Shapiro, MB; Mallet, S; Holcroft, JJ; Moncrief, H; Noble, J; Wisner, D; Kaups, KL; Bennick, LD; Manley, GT				Chi, John H.; Knudson, M. Margaret; Vassar, Mary J.; McCarthy, Mary C.; Shapiro, Michael B.; Mallet, Susan; Holcroft, John J.; Moncrief, Hugh; Noble, Jennifer; Wisner, David; Kaups, Krista L.; Bennick, Lynn D.; Manley, Geoffrey T.			Prehospital hypoxia affects outcome in patients with traumatic brain injury: A prospective multicenter study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	National Meeting of the American-College-of-Surgeons-Committee-on-Trauma	MAR 04, 2005	Washington, DC	Amer Coll Surg Comm Trauma		traumatic brain injury; hypoxia; prehospital; prospective study; outcome	SEVERE HEAD-INJURY; NEUROGENIC PULMONARY-EDEMA; RAPID-SEQUENCE INTUBATION; SUBARACHNOID HEMORRHAGE; ENDOTRACHEAL INTUBATION; MULTIPLE INJURIES; CARDIAC INJURY; INSULTS; HYPOTENSION; CARE	Background: The goals of this study were to determine the incidence and duration of hypotension and hypoxia in the prehospital setting in patients with potentially survivable brain injuries, and to prospectively examine the association of these secondary insults with mortality and disability at hospital discharge. Methods: Trauma patients with suspected brain injuries underwent continuous blood pressure and pulse oximetry monitoring during helicopter transport. Postadmission inclusion criteria were (1) diagnosis of acute traumatic brain injury (TBI) confirmed by computed tomography (CT) scan, operative findings, or autopsy findings; and (2) Head Abbreviated Injury Scale (AIS) score of >= 3 or Glasgow Coma Scale (GCS) score of <= 12 within the first 24 hours of admission. Patients were excluded with (1) no abnormal intracranial findings on the patient's CT scan; (2) determination of a nonsurvivable injury (based on an AIS score of 6 for any body region; or, (3) death in less than 12 hours after injury. Primary outcome measures included mortality and Disability Rating Scale score at discharge. Results: We enrolled 150 patients into the study. Fifty-seven patients had at least one secondary insult; 37 had only hypoxic episodes, 14 had only hypotensive episodes, and 6 patients had both. Demographics and injury characteristics did not differ between those with and those without secondary insults. The mortality for patients without secondary insults was 20%, compared with 37% for patients with hypoxic episodes, 8% for patients with bypotensive episodes, and 24% for patients with both. The Disability Rating Scale score at discharge was significantly higher in patients with secondary insults. Using multivariate analysis, the calculated odds ratio of mortality caused by prehospital hypoxia after head injury was 2.66 (p < 0.05). Conclusions: Secondary insults after TBI are common, and these insults are associated with disability. Hypoxia in the prehospital setting significantly increases the odds of mortality after brain injury controlled for multiple variables.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; San Francisco Injury Ctr Res & Prevent, San Francisco, CA USA; Miami Valley Med Ctr, Dept Surg, Dayton, OH USA; Northwestern Univ, Dept Surg, Sch Med, Chicago, IL 60611 USA; Univ Calif Davis, Dept Surg, Med Ctr, Davis, CA 95616 USA; Univ Calif San Francisco, Univ Hosp, Dept Surg, Fresno, CA USA	Chi, JH (corresponding author), Univ Calif San Francisco, Dept Surg, 505 Parnassus Ave,M779,Box 0112, San Francisco, CA 94143 USA.	chijo@neurosurg.ucsf.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR903697] Funding Source: Medline		Atkinson JLD, 1998, J TRAUMA, V45, P941, DOI 10.1097/00005373-199811000-00016; BELVISI MG, 1989, J APPL PHYSIOL, V66, P268; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; CARREL M, 1994, ANN FR ANESTH, V13, P326, DOI 10.1016/S0750-7658(94)80041-3; Centers for Disease Control, 2001, TRAUM BRAIN INJ US R; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CHI J, 2003, TREATMENT CLOSED HEA, V14, P71; COHEN JA, 1976, ANGIOLOGY, V27, P280, DOI 10.1177/000331977602700502; Cooper A, 2001, Semin Pediatr Surg, V10, P3, DOI 10.1053/spsu.2001.19379; COOPER KR, 1983, CHEST, V84, P29, DOI 10.1378/chest.84.1.29; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DETTBARN CL, 1989, HEART LUNG, V18, P583; Di Bartolomeo S, 2001, ARCH SURG-CHICAGO, V136, P1293, DOI 10.1001/archsurg.136.11.1293; Fontes RBV, 2003, J NEUROSURG ANESTH, V15, P144, DOI 10.1097/00008506-200304000-00013; FROMAN C, 1968, BRIT J ANAESTH, V40, P354, DOI 10.1093/bja/40.5.354; Garner AA, 2002, INJURY, V33, P329, DOI 10.1016/S0020-1383(02)00011-6; Grmec S, 2004, EMERG MED J, V21, P518, DOI 10.1136/emj.2002.001974; Helm M, 2003, BRIT J ANAESTH, V90, P327, DOI 10.1093/bja/aeg069; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; LEWIN CF, 1992, COST DISORDERS BRAIN; MALACRIDA RL, 1993, INJURY, V24, P451, DOI 10.1016/0020-1383(93)90147-X; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Miss JC, 2004, NEUROSURGERY, V55, P1244, DOI 10.1227/01.NEU.0000143165.50444.7F; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Poste Jennifer C, 2004, Air Med J, V23, P36, DOI 10.1016/j.amj.2004.04.006; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROGERS FB, 1995, J TRAUMA, V39, P860, DOI 10.1097/00005373-199511000-00009; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P591; Tung P, 2004, STROKE, V35, P548, DOI 10.1161/01.STR.0000114874.96688.54; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592; York J, 2000, J TRAUMA, V48, P376, DOI 10.1097/00005373-200003000-00002; Zaroff JG, 2000, J AM SOC ECHOCARDIOG, V13, P774, DOI 10.1067/mje.2000.105763	43	156	162	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2006	61	5					1134	1141		10.1097/01.ta.0000196644.64653.d8			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	105TB	WOS:000242054100018	17099519				2021-06-18	
J	Anderson, VA; Catroppa, C; Dudgeon, P; Morse, SA; Haritou, F; Rosenfeld, JV				Anderson, VA; Catroppa, C; Dudgeon, P; Morse, SA; Haritou, F; Rosenfeld, JV			Understanding predictors of functional recovery and outcome 30 months following early childhood head injury	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; children; behavior; adaptive abilities; family	TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; ACADEMIC-PERFORMANCE; FRONTAL LOBES; SHORT-TERM; CHILDREN; FAMILY; ADOLESCENTS; SEQUELAE; SKILLS	Much is known about outcome following traumatic brain injury (TBI) in school-age children; however, recovery in early childhood is less well understood. Some argue that such injuries should lead to good outcome, because of the plasticity of the developing brain. Other purport that the young brain is vulnerable, with injury likely to result in a substantial impairment (H. G. Taylor & J. Alden, 1997). The aim of this study was to examine outcomes following TBI during early childhood, to plot recovery over the 30 months postinjury, and to identify predictors of outcome. The study compared 3 groups of children sustaining mild, moderate, and severe TBI, ages 2.0 to 6.11 years at injury, with healthy controls. Groups were comparable for preinjury adaptive and behavioral function, psychosocial characteristics, age, and gender. Results suggested a strong association between injury severity and outcomes across all domains. Further, 30-month outcome was predicted by injury severity, family factors, and preinjury levels of child function. In conclusion, children with more severe injuries and lower preinjury adaptive abilities, and whose families are coping poorly, are at greatest risk of long-term impairment in day-to-day skills, even several years postinjury.	Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Psychol, Melbourne, Vic 3052, Australia; Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; Alfred Hosp, Melbourne, Vic, Australia; Monash Univ, Melbourne, Vic 3004, Australia	Anderson, VA (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Rosenfeld, Jeffrey V/B-7249-2011	Dudgeon, Paul/0000-0003-4934-6144			AMACHER AL, 1988, PEDIAT HEAD INJURIES; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson V.A, 2001, DEV NEUROPSYCHOLOGY; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson-Parente JK, 1990, COGNITIVE REHABILITA, P22; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Bayley N., 1969, BAYLEY SCALES INFANT; BEGALI V, 1992, HEAD INJURY CHILDREN; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; BRESLAU N, 1990, ARCH GEN PSYCHIAT, V47, P15; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P85; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Eslinger PJ, 2000, DEV NEUROPSYCHOL, V18, P297, DOI 10.1207/S1532694203Eslinger; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Fenwick T, 1999, CHILD NEUROPSYCHOL, V5, P213, DOI 10.1076/0929-7049(199912)05:04;1-R;FT213; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; Lachar D, 1992, PERSONALITY INVENTOR; LARSON CP, 1988, AM J DIS CHILD, V142, P1052, DOI 10.1001/archpedi.1988.02150100046023; Lenneberg Eric H., 1967, BIOL FDN LANGUAGE; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVINE MA, 1988, PHYS SCRIPTA, VT22, P157, DOI 10.1088/0031-8949/1988/T22/024; MAX J, 1997, J AM ACAD CHILD ADOL, V36, P83; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1998, BRAIN INJURY, V12, P41; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; NOLLER P, 1988, UNPUB ICPS FAMILY FU; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sparrow S., 1984, VINELAND ADAPTIVE BE; Stuss DT, 2004, BRAIN COGNITION, V55, P69, DOI 10.1016/s0278-2626(03)00271-9; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Todd JA, 1996, NEUROPSYCHOL REHABIL, V6, P81, DOI 10.1080/713755500; VARGHAKHADEM F, 1992, BRAIN, V115, P315, DOI 10.1093/brain/115.1.315; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wechsler D, 1991, MANUAL WECHSLER SCAL; WECHSLER D, 1987, MANUAL PRESCHOOL PRI; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	83	156	156	0	29	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JAN	2006	20	1					42	57		10.1037/0894-4105.20.1.42			16	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	011UK	WOS:000235293700005	16460221				2021-06-18	
J	Iverson, GL; Brooks, BL; Lovell, MR; Collins, MW				Iverson, GL; Brooks, BL; Lovell, MR; Collins, MW			No cumulative effects for one or two previous concussions	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							CHRONIC BRAIN-DAMAGE; AMATEUR BOXING LEAD; COLLEGIATE FOOTBALL PLAYERS; PROFESSIONAL FOOTBALL; COGNITIVE IMPAIRMENT; SOCCER; RECOVERY; SPORTS; IMPACT; NEUROPSYCHOLOGY	Background: Sports medicine clinicians and the general public are interested in the possible cumulative effects of concussion. Objective: To examine whether athletes with a history of one or two previous concussions differed in their preseason neuropsychological test performances or symptom reporting. Method: Participants were 867 male high school and university amateur athletes who completed preseason testing with ImPACT version 2.0. They were sorted into three groups on the basis of number of previous concussions. There were 664 athletes with no previous concussions, 149 with one previous concussion, and 54 with two previous concussions. Multivariate analysis of variance was conducted using the verbal memory, visual memory, reaction time, processing speed, and postconcussion symptom composite scores as dependent variables and group membership as the independent variable. Results: There was no significant multivariate effect, nor were there any significant main effects for individual scores. There was no measurable effect of one or two previous concussions on athletes' preseason neuropsychological test performance or symptom reporting. Conclusion: If there is a cumulative effect of one or two previous concussions, it is very small and undetectable using this methodology.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; Riverview Hosp, Coquitlam, BC, Canada; Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; Hinton-Bayre AD, 2004, J SCI MED SPORT, V7, P400, DOI 10.1016/S1440-2440(04)80035-5; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; Iverson GL, 2004, STUD NEUROPSYCHOL DE, P323; IVERSON GL, 2004, COMPUTERIZED NEUROPS; IVERSON GL, 2003, SENSITIVITY COMPUTER; Janusz A, 2004, BRIT J SPORT MED, V38, P659; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; KEMP PM, 1995, J NEUROL NEUROSUR PS, V59, P368, DOI 10.1136/jnnp.59.4.368; Koh JO, 2004, CLIN J SPORT MED, V14, P72, DOI 10.1097/00042752-200403000-00004; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; LOVELL MR, 2005, IN PRESS APPL NEUROP; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Mangus Brent C, 2004, Sports Biomech, V3, P209, DOI 10.1080/14763140408522841; Marshall SW, 2001, J ATHL TRAINING, V36, P334; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory Paul, 2002, Curr Sports Med Rep, V1, P28; Miele VJ, 2004, MED SCI SPORT EXER, V36, P1852, DOI 10.1249/01.MSS.0000145470.16938.7A; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Porter MD, 2003, CLIN J SPORT MED, V13, P339, DOI 10.1097/00042752-200311000-00002; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Rodriguez G, 1998, ITAL J NEUROL SCI, V19, P367, DOI 10.1007/BF02341784; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52; Zillmer EA, 2003, APPL NEUROPSYCHOL, V10, P23, DOI 10.1207/S15324826AN1001_4	55	156	158	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2006	40	1					72	75		10.1136/bjsm.2005.020651			4	Sport Sciences	Sport Sciences	995YG	WOS:000234140600017	16371496	Green Published, Bronze			2021-06-18	
J	Walilko, TJ; Viano, DC; Bir, CA				Walilko, TJ; Viano, DC; Bir, CA			Biomechanics of the head for Olympic boxer punches to the face	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PROFESSIONAL FOOTBALL; CONCUSSION; INJURIES; ACCELERATION; IMPACTS	Objective: The biomechanics of the head for punches to the jaw and the risk of head injury from translational and rotational acceleration were studied. Methods: Seven Olympic boxers from five weight classes delivered 18 straight punches to the frangible face of the Hybrid III dummy. Translational and rotational head acceleration, neck responses, and jaw pressure distribution were measured. High speed video recorded each blow and was used to determine punch velocity. Equilibrium was used to determine punch force, energy transfer, and power. Results: Punch force averaged 3427 ( standard deviation (SD) 811) N, hand velocity 9.14 ( SD 2.06) m/s, and effective punch mass 2.9 ( SD 2.0) kg. Punch force was higher for the heavier weight classes, due primarily to a higher effective mass of the punch. Jaw load was 876 ( SD 288) N. The peak translational acceleration was 58 ( SD 13) g, rotational acceleration was 6343 ( SD 1789) rad/s(2), and neck shear was 994 ( SD 318) N. Conclusions: Olympic boxers deliver straight punches with high impact velocity and energy transfer. The severity of the punch increases with weight class.	Wayne State Univ, Dept Biomed Engn, Sports Biomech Lab, Detroit, MI 48201 USA	Viano, DC (corresponding author), ProBiomech LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net		Bir, Cynthia/0000-0002-0777-0951			Allsop D. L., 1988, 881719 SAE; ATHA J, 1985, BRIT MED J, V291, P1756, DOI 10.1136/bmj.291.6511.1756; Clauser C. E., 1969, AMRLTR6970 WRIGHT PA; Foster J. K., 1977, 21 STAPP CAR CRASH C; GADD CW, 1966, 8 STAPP CAR CRASH C; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; Gennarelli TA, 1987, 31 STAPP CAR CRASH C; Goldsmith W, 1984, BIOMECHANICS IMPACT, P149; GURDJIAN ES, 1975, 7 STAPP CAR CRASH C, P470; Holbourn AHS, 1943, LANCET, V2, P438; Joch W, 1981, BIOMECHANICS A, P343; JOHNSON J, 1975, MED BIOL ENG, V13, P396, DOI 10.1007/BF02477111; LISSNER HR, 1960, SURG GYNECOL OBSTET, V111, P329; MELVIN JW, 1995, 28 STAPP CAR CRASH C; Nakayama M., 1966, DYNAMIC KARATE; NEWMAN JA, 1984, 28 STAPP CAR CRASH C; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; PINCEMAILLE Y, 1989, 33 STAPP CAR CRASH; PRASAD P, 1985, 851246 SAE; Roberts AH., 1969, BRAIN DAMAGE BOXERS; *SAE, 2001, J2112 SAE; *SAE, 1998, J14602 SAE; SHEE TR, 1994, J BIOMECHANICAL ENG, V116, P37; Smith MS, 2000, J SPORT SCI, V18, P445, DOI 10.1080/02640410050074377; SMITH PK, 1986, J HUM MOVEMENT STUD, V12, P153; SMITH T, 1988, P IRCOBI C, P271; Society of Auto Engineers, 1986, J885 SAE; Society of Automotive Engineers (SAE), 1995, J2111 SAE; UNTERHARNSCHEID.F, 1970, TEX REP BIOL MED, V28, P435; Unterharnscheidt F, 1995, Rev Neurol, V23, P661; VIANO DC, 1986, 30 STAPP CAR CRASH C; WALKER JD, 1975, AM J PHYS, V43, P845, DOI 10.1119/1.9966; Zazryn TR, 2003, BRIT J SPORT MED, V37, P321, DOI 10.1136/bjsm.37.4.321	36	156	158	0	30	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	OCT	2005	39	10					710	719		10.1136/bjsm.2004.014126			10	Sport Sciences	Sport Sciences	967CJ	WOS:000232068800008	16183766	Bronze, Green Published			2021-06-18	
J	Zygun, DA; Kortbeek, JB; Fick, GH; Laupland, KB; Doig, CJ				Zygun, DA; Kortbeek, JB; Fick, GH; Laupland, KB; Doig, CJ			Non-neurologic organ dysfunction in severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; multiple organ dysfunction syndrome; outcome; critical care	DISSEMINATED INTRAVASCULAR COAGULATION; NEUROGENIC PULMONARY-EDEMA; SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; NOSOCOMIAL PNEUMONIA; NEUTROPHIL ELASTASE; CEREBROSPINAL-FLUID; CARDIAC INJURY; INTENSIVE-CARE; SEPTIC SHOCK	Objective: To describe the incidence of non-neurologic organ dysfunction and its association with outcome in patients with severe traumatic brain injury admitted to intensive care. Design. Observational cohort study. Setting. Foothills Medical Centre, which is the only neurosurgical service in southern Alberta (population similar to 1.3 million). Patients. Patients were 209 consecutive patients with severe traumatic brain injury. Interventions. None. Measurements and Main Results., Non-neurologic organ dysfunction was measured by the maximum modified multiple organ dysfunction score. Organ system failure was defined as a component score of >= 3on any day during the patient's intensive care unit stay. One hundred and eighty-five patients (89%) developed dysfunction of at least one non-neurologic organ system. Ninety-six organ system failures were identified in 74 patients (35%). Respiratory failure was the most common non-neurologic organ system failure, occurring in 23% of patients, whereas cardiovascular failure occurred in 18%. Eight patients (4%) had failure of the coagulation system. One patient had renal failure, whereas no patient developed hepatic failure. In a multivariate model, non-neurologic organ dysfunction was independently associated with hospital mortality (odds ratio for hospital mortality, 1.63; 95% confidence interval, 1.34, 1.98 for one maximum modified multiple organ dysfunction score point). Non-neurologic organ dysfunction was also independently associated with dichotomized Glasgow Outcome Score, as a measure of neurologic outcome (odds ratio for unfavorable neurologic outcome, 1.53; 95% confidence interval, 1.22,1.98 for one maximum modified multiple organ dysfunction score point). The timing of the organ dysfunction did not appear to be important in the prediction of outcome. Conclusions. Non-neurologic organ dysfunction is common in patients with severe traumatic brain injury and is independently associated with worse outcome.	Univ Calgary, Dept Crit Care Med, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Med, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Surg, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada	Zygun, DA (corresponding author), Univ Calgary, Dept Crit Care Med, Calgary, AB T2N 1N4, Canada.		Kortbeek, John B/AAO-5298-2020; Laupland, kevin/AAJ-6339-2020; Doig, Christopher/AAC-7949-2020; Laupland, Kevin/AAG-3656-2020	Laupland, kevin/0000-0002-1205-5354; Doig, Christopher/0000-0002-8576-9139; 			ATTAR S, 1969, J TRAUM, V9, P939, DOI 10.1097/00005373-196911000-00004; Bell MJ, 1997, ACT NEUR S, V70, P96; BREDBACKA S, 1994, J NEUROSURG ANESTH, V6, P75; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; CONNOR RCR, 1969, AM HEART J, V78, P145, DOI 10.1016/0002-8703(69)90001-5; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; DAVIDSON JT, 1973, CHEST, V63, P250, DOI 10.1378/chest.63.2.250; Doig CJ, 2004, CRIT CARE MED, V32, P384, DOI 10.1097/01.CCM.0000108881.14082.10; DUCKER TB, 1968, J NEUROSURG, V28, P118, DOI 10.3171/jns.1968.28.2.0118; Dujardin KS, 2001, J HEART LUNG TRANSPL, V20, P350, DOI 10.1016/S1053-2498(00)00193-5; GANDO S, 1995, J TRAUMA, V39, P660, DOI 10.1097/00005373-199510000-00007; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; HEARD S, 1992, J INTENSIVE CARE MED, V7, P4; HEARD S, 1991, J INTENSIVE CARE MED, V6, P4; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Hirashima Y, 1997, NEUROCHEM RES, V22, P1249, DOI 10.1023/A:1021985030331; Hoth JJ, 2003, J TRAUMA, V55, P249, DOI 10.1097/01.TA.0000083334.93868.65; KIKUCHI T, 1995, NEUROL RES, V17, P106, DOI 10.1080/01616412.1995.11740296; KONO T, 1994, J AM COLL CARDIOL, V24, P636, DOI 10.1016/0735-1097(94)90008-6; KOSSMANN T, 1997, 5 WIGG BERN C 1996 B, P263; Leone M, 2002, CRIT CARE MED, V30, P1741, DOI 10.1097/00003246-200208000-00011; Loop T, 2003, ANESTHESIOLOGY, V99, P360, DOI 10.1097/00000542-200308000-00017; Macmillan CSA, 2002, INTENS CARE MED, V28, P1012, DOI 10.1007/s00134-002-1382-7; Marshall J, 1997, CRIT CARE MED, V25, P1765, DOI 10.1097/00003246-199711000-00001; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562; MAYER SA, 1994, NEUROLOGY, V44, P815, DOI 10.1212/WNL.44.5.815; McKeating EG, 1997, BRIT J ANAESTH, V78, P520; MULLERBERGHAUS G, 1989, SEMIN THROMB HEMOST, V15, P58, DOI 10.1055/s-2007-1002690; Naredi S, 2000, STROKE, V31, P901, DOI 10.1161/01.STR.31.4.901; Parr MJA, 1996, BRIT MED J, V313, P681; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PITTET D, 1995, INTENS CARE MED, V21, P302, DOI 10.1007/BF01705408; Raymer K, 1997, CAN J ANAESTH, V44, P515, DOI 10.1007/BF03011941; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; SCHELL AR, 1987, ARCH INTERN MED, V147, P591, DOI 10.1001/archinte.147.3.591; SHANAHAN WT, 1908, NY MED J, V37, P54; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Smith WS, 1997, CHEST, V111, P1326, DOI 10.1378/chest.111.5.1326; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; SZABO MD, 1993, ANESTH ANALG, V76, P253, DOI 10.1213/00000539-199302000-00009; Takahashi H, 2000, J TRAUMA, V49, P86, DOI 10.1097/00005373-200007000-00013; TOUHO H, 1989, NEUROSURGERY, V25, P762, DOI 10.1227/00006123-198911000-00011; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; Williams J. G., 1992, J INTENSIVE CARE MED, V7, P53; Zaroff JG, 2000, J AM SOC ECHOCARDIOG, V13, P774, DOI 10.1067/mje.2000.105763	46	156	166	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAR	2005	33	3					654	660		10.1097/01.ccm.0000155911.01844.54			7	Critical Care Medicine	General & Internal Medicine	907CD	WOS:000227691800025	15753760				2021-06-18	
J	Mayer, SA; Kowalski, RG; Presciutti, M; Ostapkovich, ND; McGann, E; Fitzsimmons, BF; Yavagal, DR; Du, YE; Naidech, AM; Janjua, NA; Claassen, J; Kreiter, KT; Parra, A; Commichau, C				Mayer, SA; Kowalski, RG; Presciutti, M; Ostapkovich, ND; McGann, E; Fitzsimmons, BF; Yavagal, DR; Du, YE; Naidech, AM; Janjua, NA; Claassen, J; Kreiter, KT; Parra, A; Commichau, C			Clinical trial of a novel surface cooling system for fever control in neurocritical care patients	CRITICAL CARE MEDICINE			English	Article						fever; cooling blankets; intracerebral hemorrhage; subarachnoid hemorrhage; stroke	BODY-TEMPERATURE; ACUTE STROKE; BRAIN TEMPERATURE; CORE TEMPERATURE; UNIT; HYPERTHERMIA; HYPOTHERMIA; HEMORRHAGE; THRESHOLD; MORTALITY	Objective: To compare the efficacy of a novel water-circulating surface cooling System with conventional measures for treating fever in neuro-intensive care unit patients. Design: Prospective, unblinded, randomized controlled trial. Setting. Neurologic intensive care unit in an urban teaching hospital. Patients: Forty-seven patients, the majority of whom were mechanically ventilated and sedated, with fever greater than or equal to38.3degreesC for >2 consecutive hours after receiving 650 mg of acetaminophen. Interventions: Subjects were randomly assigned to 24 hrs of treatment with a conventional water-circulating cooling blanket placed over the patient (Cincinnati Subzero, Cincinnati OH) or the Arctic. Sun Temperature Management System (Medivance, Louisville CO), which employs hydrogel-coated water-circulating energy transfer pads applied directly to the trunk and thighs. Measurements and Main Results. Diagnoses included subarachnoid hemorrhage (60%), cerebral infarction (23%), intracerebral hemorrhage (11%), and traumatic brain injury (4%). The groups were matched in terms of baseline variables, although mean temperature was slightly higher at baseline in the Arctic Sun group (38.8 vs. 38.3degreesC, p = .046). Compared with patients treated with the Subzero blanket (n = 24), Arctic Sun-treated patients (n = 23) experienced a 75% reduction in fever burden (median 4.1 vs. 16.1 Cdegrees-hrs, p = .001). Arctic Sun-treated patients also spent less percent time febrile (T greater than or equal to38.3degreesC, 8% vs. 42%, p < .001), spent more percent time normothermic (T less than or equal to37.2degreesC, 59% vs. 3%, p < .001), and attained normothermia faster than the Sub-Zero group median (2.4 vs. 8.9 hrs, p = .008). Shivering occurred more frequently in the Arctic Sun group (39% vs. 8%, p = .013). Conclusion: The Arctic Sun Temperature Management System is superior to conventional cooling-blanket therapy for controlling fever in critically ill neurologic patients.	Columbia Univ, Sch Publ Hlth, Neurol Intens Care Unit, Dept Neurol, New York, NY USA; Columbia Univ, Sch Publ Hlth, Neurol Intens Care Unit, Dept Neurosurg, New York, NY USA; Columbia Univ, Sch Publ Hlth, Coll Phys & Surg, Dept Biostat, New York, NY USA; New York Presbyterian Hosp, Dept Nursing, New York, NY USA	Mayer, SA (corresponding author), Neurol Inst, Div Crit Care Neurol, 710 W 168th St,Unit 39, New York, NY 10032 USA.	sam14@columbia.edu	Claassen, Jan/AAA-5451-2020				Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; BUSTO R, 1987, J CEREB BLOOD FLOW M, V7, P129; Carhuaporna JR, 2003, J NEUROSURG ANESTH, V15, P313, DOI 10.1097/00008506-200310000-00004; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Circiumaru B, 1999, INTENS CARE MED, V25, P668, DOI 10.1007/s001340050928; DIRINGER MN, IN PRESS CRIT CARE M; Doufas AG, 2003, STROKE, V34, P1736, DOI 10.1161/01.STR.0000077014.47422.DB; Georgiadis D, 2001, STROKE, V32, P2550, DOI 10.1161/hs1101.097382; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; HORROW JC, 1988, ANESTHESIOLOGY, V69, P986, DOI 10.1097/00000542-198812000-00037; Iaizzo PA, 1999, J NEUROSURG ANESTH, V11, P231, DOI 10.1097/00008506-199910000-00002; ISAACS SN, 1990, AM J MED, V88, P31, DOI 10.1016/0002-9343(90)90124-V; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; Klein NC, 1996, INFECT DIS CLIN N AM, V10, P211, DOI 10.1016/S0891-5520(05)70295-6; Lenhardt R, 1999, AM J MED, V106, P550, DOI 10.1016/S0002-9343(99)00068-6; Mayer SA, 2002, NEUROLOGY, V58, pA93; Mayer SA, 2001, NEUROLOGY, V56, P292, DOI 10.1212/WNL.56.3.292; MEKJAVIC IB, 1985, ACTA PHYSIOL SCAND, V125, P633, DOI 10.1111/j.1748-1716.1985.tb07765.x; O'Grady NP, 1998, CRIT CARE MED, V26, P392, DOI 10.1097/00003246-199802000-00046; ODonnell J, 1997, CLIN INFECT DIS, V24, P1208, DOI 10.1086/513660; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; POULOS DA, 1981, FED PROC, V40, P2825; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Rossi S, 2001, J NEUROL NEUROSUR PS, V71, P448, DOI 10.1136/jnnp.71.4.448; Schmitz T, 1995, Am J Crit Care, V4, P286; Schmutzhard E, 2002, CRIT CARE MED, V30, P2481, DOI 10.1097/00003246-200211000-00013; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354; STONE JG, 1995, ANESTHESIOLOGY, V82, P344, DOI 10.1097/00000542-199502000-00004; Sweney MT, 2001, ANESTHESIOLOGY, V95, P1089, DOI 10.1097/00000542-200111000-00011; VARGAS R, 1994, J CLIN PHARMACOL, V34, P848, DOI 10.1002/j.1552-4604.1994.tb02050.x; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404	34	156	164	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	DEC	2004	32	12					2508	2515		10.1097/01.CCM.0000147441.39670.37			8	Critical Care Medicine	General & Internal Medicine	881NG	WOS:000225873600022	15599159				2021-06-18	
J	Rice, AC; Khaldi, A; Harvey, HB; Salman, NJ; White, F; Fillmore, H; Bullock, MR				Rice, AC; Khaldi, A; Harvey, HB; Salman, NJ; White, F; Fillmore, H; Bullock, MR			Proliferation and neuronal differentiation of mitotically active cells following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						lateral fluid percussion injury; flow cytometry; bromodeoxyuridine; neurogenesis; confocal microscopy	NEURAL STEM-CELLS; ADULT-MOUSE BRAIN; FIBROBLAST GROWTH FACTOR-2; FOCAL CEREBRAL-ISCHEMIA; FLUID-PERCUSSION MODEL; CENTRAL-NERVOUS-SYSTEM; HUMAN LEUKEMIA-CELLS; SUBVENTRICULAR ZONE; DENTATE GYRUS; PROGENITOR CELLS	Recent studies have identified endogenous neural stem cells in adult rodent brains. The present study characterizes the early response of mitotically active cells in the brain to traumatic brain injury. Animals were subjected to lateral fluid percussion injury and sacrificed at various times after injury. To examine increases in cell proliferation animals were injected with the mitotic marker bromodeoxyuridine (BrdU) 24 h before sacrifice. Increased numbers of mitotically active cells were observed at 2 days in the subgranular zone (SGZ) and the subependymal zone (SEZ) under the injury site. To characterize the differentiation potential of these cells, animals were injected with BrdU 18 and 20 h after injury, then sacrificed at multiple time points after injury. Histologically, co-localization with betaIII-tubulin (neuronal marker) and BrdU was evident at 10 and 15 days postinjury in the SGZ. Flow cytometry analysis was used to quantitatively assess neurogenesis in the SEZ. Animals were sacrificed 1, 5, or 10 days after injury and tissue sections extracted, grown in tissue culture for 24 h, fixed, and stained for nestin and betaIII-tubulin to identify newly formed neurons. The percentage of cells expressing both markers was determined using flow cytometry analysis. There was a significant increase in newly differentiated neurons by 10 days postinjury in the SEZ. Thus, we conclude that traumatic brain injury stimulates an increase in proliferation of endogenous neural stem/progenitor cells and that a significant number of these express a neuronal marker. This response may be the brain's way of trying to heal itself after injury. (C) 2003 Elsevier Science (USA). All rights reserved.	Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Pediat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Flow & Imaging Cytometry Facil, Richmond, VA 23298 USA	Rice, AC (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, Box 980631, Richmond, VA 23298 USA.			Fillmore, Helen/0000-0003-4131-579X	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA016059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA16059] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline		Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Buytaert KA, 2001, BRAIN RES, V894, P121, DOI 10.1016/S0006-8993(01)01987-4; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Conti AC, 1998, J NEUROSCI, V18, P5663; Craig CG, 1996, J NEUROSCI, V16, P2649; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; Hilton G, 1994, Orthop Nurs, V13, P25, DOI 10.1097/00006416-199407000-00006; Iwai M, 2002, J CEREBR BLOOD F MET, V22, P411, DOI 10.1097/00004647-200204000-00005; IWATA A, 1997, J NEUROTRAUM, V14, P2201; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Krum JM, 1999, EXP NEUROL, V160, P348, DOI 10.1006/exnr.1999.7222; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Law AKT, 1999, DEV BIOL, V216, P622, DOI 10.1006/dbio.1999.9498; Laywell ED, 1999, EXP NEUROL, V156, P430, DOI 10.1006/exnr.1999.7029; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Levison SW, 2001, DEV NEUROSCI-BASEL, V23, P234, DOI 10.1159/000046149; Liu JL, 1998, J NEUROSCI, V18, P7768; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McLaren FH, 2001, J NEUROIMMUNOL, V112, P35, DOI 10.1016/S0165-5728(00)00410-0; MORSHEAD CM, 1992, J NEUROSCI, V12, P249; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Murayama A, 2002, J NEUROSCI RES, V69, P837, DOI 10.1002/jnr.10339; Nakagawa E, 2000, EPILEPSIA, V41, P10, DOI 10.1111/j.1528-1157.2000.tb01498.x; Palmer TD, 1999, J NEUROSCI, V19, P8487; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Parent JM, 1999, J NEUROSCI, V19, P4508; Parent JM, 1997, J NEUROSCI, V17, P3727; Parent JM, 2002, J NEUROSCI, V22, P3174, DOI 10.1523/JNEUROSCI.22-08-03174.2002; Paxinos G, 1986, RAT BRAIN STEREOTAXI; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDS LJ, 1992, P NATL ACAD SCI USA, V89, P8591, DOI 10.1073/pnas.89.18.8591; Roy NS, 2000, J NEUROSCI RES, V59, P321, DOI 10.1002/(SICI)1097-4547(20000201)59:3<321::AID-JNR5>3.0.CO;2-9; Soares HD, 1995, J NEUROSCI, V15, P8223; Takagi Y, 1999, BRAIN RES, V831, P283, DOI 10.1016/S0006-8993(99)01411-0; Takasawa K, 2002, J CEREBR BLOOD F MET, V22, P299, DOI 10.1097/00004647-200203000-00007; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tzeng SF, 1999, NEUROREPORT, V10, P2287, DOI 10.1097/00001756-199908020-00012; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Vrana JA, 1999, BIOCHEM PHARMACOL, V58, P121, DOI 10.1016/S0006-2952(99)00077-5; Wang S, 2000, DEV NEUROSCI-BASEL, V22, P167, DOI 10.1159/000017437; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998	55	156	165	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	OCT	2003	183	2					406	417		10.1016/S0014-4886(03)00241-3			12	Neurosciences	Neurosciences & Neurology	728PB	WOS:000185724600017	14552881				2021-06-18	
J	Franz, G; Beer, R; Kampfl, A; Engelhardt, K; Schmutzhard, M; Ulmer, H; Deisenhammer, F				Franz, G; Beer, R; Kampfl, A; Engelhardt, K; Schmutzhard, M; Ulmer, H; Deisenhammer, F			Amyloid beta 1-42, and tau in cerebrospinal fluid after severe traumatic brain injury	NEUROLOGY			English	Article							AMYLOID-BETA-PROTEIN; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; VEGETATIVE STATE; AXONAL INJURY; HUMANS; DAMAGE; MICE; CSF	Objective: To determine whether CSF amyloid beta 1-42 (Abeta-42) and tau have predictive value for prognosis after head injury. Methods: CSF samples were collected from 29 patients with severe head trauma between 1 and 284 days post-trauma. Abeta-42 and tau levels were measured using sandwich ELISA techniques and compared with CSF levels in patients with cognitive disorders and headache. Results: At all time points, concentrations of Abeta-42 were significantly lower in patients with traumatic brain injury (TBI) than in control groups. A significant correlation existed for Abeta-42 levels and outcome of patients. Below a cutoff of 230 pg/mL, the sensitivity of Abeta-42 to discriminate between good outcome (Glasgow Outcome Score 4 and 5) and poor outcome (Glasgow Outcome Score I through 3) was 100% at a specificity of 82%. CSF tau levels were significantly higher in patients with TBI than in any control group. In patients with multiple CSF samples collected at various time points between 1 and 32 days after the trauma, tau levels increased early after TBI, peaked in the second week post-trauma, and slowly decreased thereafter. Independent of outcome, all patients had normal tau levels when CSF was collected more than 43 days post-trauma. Conclusions: Abeta-42 and tau may play a potential role in the pathophysiology of TBI. Furthermore, the results of this study suggest that Abeta-42 may be a supportive early predictor for recovery after severe head injury.	Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Biostat, A-6020 Innsbruck, Austria	Deisenhammer, F (corresponding author), Univ Innsbruck, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.	florian.deisenhammer@uibk.ac.at	Ulmer, Hanno/S-6615-2019	Ulmer, Hanno/0000-0001-5911-1002			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Andreasen N, 2001, ARCH NEUROL-CHICAGO, V58, P373, DOI 10.1001/archneur.58.3.373; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GENTRY LR, 1994, RADIOLOGY, V191, P1; GOEDERT M, 1995, BIOCHEM SOC T, V23, P80, DOI 10.1042/bst0230080; Hulstaert F, 1999, NEUROLOGY, V52, P1555, DOI 10.1212/WNL.52.8.1555; JENNETT B, 1972, LANCET, V1, P734; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; Otto M, 1997, NEUROSCI LETT, V225, P210, DOI 10.1016/S0304-3940(97)00215-2; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raby CA, 1998, J NEUROCHEM, V71, P2505; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Rothoerl RD, 2000, ACT NEUR S, V76, P97; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sjogren M, 2001, CLIN CHEM, V47, P1776; Small DH, 1999, J NEUROCHEM, V73, P443, DOI 10.1046/j.1471-4159.1999.0730443.x; Tamaoka A, 1997, J NEUROL SCI, V148, P41, DOI 10.1016/S0022-510X(96)00314-0; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zhang H, 2001, CLIN CHEM, V47, P1458	28	156	160	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	MAY 13	2003	60	9					1457	1461		10.1212/01.WNL.0000063313.57292.00			5	Clinical Neurology	Neurosciences & Neurology	676LT	WOS:000182754100013	12743231				2021-06-18	
J	Starr, AJ; Griffin, DR; Reinert, CM; Frawley, WH; Walker, J; Whitlock, SN; Borer, DS; Rao, AV; Jones, AL				Starr, AJ; Griffin, DR; Reinert, CM; Frawley, WH; Walker, J; Whitlock, SN; Borer, DS; Rao, AV; Jones, AL			Pelvic ring disruptions: Prediction of associated injuries, transfusion requirement, pelvic arteriography, complications, and mortality	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						pelvic fracture; shock; Revised Trauma Score; age; fracture classification	MULTIPLE TRAUMA; SEVERITY SCORE; FRACTURES; MANAGEMENT; EMERGENCY; MECHANISM; EPIDEMIOLOGY	Objective: To determine if age, fracture pattern, systolic blood pressure on arrival, base deficit, or the Revised Trauma Score is predictive of mortality, transfusion requirements, use of pelvic arteriography, later complications, or injuries associated with the pelvic ring disruption. Study Design: Retrospective review of a prospectively collected database. Methods: All closed pelvic ring disruptions seen between November 1, 1997 and November 30, 1999 were included. Predictive variables and outcome variables were recorded for each patient. Statistical analysis was used to determine if the above variables were predictive. Results: Shock on arrival and the Revised Trauma Score were significantly associated with mortality, transfusion requirement, Injury Severity Score, and all the Abbreviated Injury Scores except the one for skin. In addition, the Revised Trauma Score was significantly associated with the use of pelvic arteriography and predicted more complications than did shock on arrival. Age was significantly associated with transfusion requirement, Injury Severity Score, the chest and skin Abbreviated Injury Scores, use of arteriography, and death. The mortality rate among patients who presented in shock was 57 percent. A Revised Trauma Score of less than I I predicted mortality with a sensitivity and specificity of 58 percent and 92 percent, respectively. Shock on arrival predicted mortality with a sensitivity and specificity of 27 percent and 96 percent, respectively. Age greater than sixty years predicted mortality with a sensitivity and specificity of 26 percent and 91 percent, respectively. In our analysis of the fracture patterns, we were unable to demonstrate consistent, meaningful links between specific fracture classes and the outcome variables. Conclusions: Shock on arrival and the Revised Trauma Score are useful predictors of mortality and transfusion requirements, Injury Severity Score, and Abbreviated Injury Scores for the head and neck, face, chest, abdomen, and extremities. In addition, the Revised Trauma Score predicts the use of pelvic arteriography and later complications. Age predicted transfusion requirement, Injury Severity Score, the chest and skin Abbreviated Injury Scores, use of arteriography, and death.	Univ Texas, SW Med Ctr, Dept Orthopaed Surg, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Acad Comp, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Radiol, Dallas, TX 75235 USA; Ctr Shock Trauma, Baltimore, MD USA; Univ Oxford, Nuffield Dept Orthopaed Surg, Oxford, England	Starr, AJ (corresponding author), Univ Texas, SW Med Ctr, Dept Orthopaed Surg, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.						BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bassam D, 1998, AM SURGEON, V64, P862; BOSSE MJ, 1996, ORTHOPAEDIC KNOWLEDG; Briccoli A, 1997, Chir Organi Mov, V82, P183; Broos P, 1993, Acta Orthop Belg, V59, P130; BURGESS AR, 1991, ROCKWOOD GREENS FRAC, P1399; Chong K H, 1997, Iowa Orthop J, V17, P110; Coppola PT, 2000, EMERG MED CLIN N AM, V18, P1, DOI 10.1016/S0733-8627(05)70106-1; DALAL SA, 1989, J TRAUMA, V29, P981, DOI 10.1097/00005373-198907000-00012; Davis JW, 1996, J TRAUMA, V41, P769, DOI 10.1097/00005373-199611000-00001; Euler E, 1997, ORTHOPADE, V26, P354; FAILINGER MS, 1992, J BONE JOINT SURG AM, V74A, P781, DOI 10.2106/00004623-199274050-00020; Gansslen A, 1996, INJURY, V27, P13, DOI 10.1016/S0020-1383(96)90106-0; GILLILAND MD, 1982, J TRAUMA, V22, P691, DOI 10.1097/00005373-198208000-00007; GILPIN DA, 1991, INJURY, V22, P35, DOI 10.1016/0020-1383(91)90158-B; GOKCEN EC, 1994, J TRAUMA, V36, P789, DOI 10.1097/00005373-199406000-00007; GRUEN GS, 1994, J TRAUMA, V36, P706, DOI 10.1097/00005373-199405000-00019; Heckbert SR, 1998, J TRAUMA, V45, P545, DOI 10.1097/00005373-199809000-00022; HEINZE K, 1996, COST ENG S, V27, P1; Hollander M., 1999, NONPARAMETRIC STAT M; Kregor PJ, 1999, INJURY, V30, pS19; Meek S, 1998, J ACCID EMERG MED, V15, P2; MUCHA P, 1984, J TRAUMA, V24, P379, DOI 10.1097/00005373-198405000-00002; Nerlich M, 1996, INJURY, V27, P29, DOI 10.1016/S0020-1383(96)90109-6; ONeill PA, 1996, CLIN ORTHOP RELAT R, P60; Pohlemann T, 1996, UNFALLCHIRURG, V99, P160; POHLEMANN T, 1994, CLIN ORTHOP RELAT R, V305, P69; POOLE GV, 1994, ORTHOPEDICS, V17, P691; RIEMER BL, 1993, J TRAUMA, V35, P671, DOI 10.1097/00005373-199311000-00003; Rommens PM, 1996, ACTA CHIR BELG, V96, P78; ROUTT MLC, 1995, CLIN ORTHOP RELAT R, P61; Stephen DJG, 1999, J TRAUMA, V47, P638, DOI 10.1097/00005373-199910000-00006; Tile M, 1999, J BONE JOINT SURG BR, V81B, P941, DOI 10.1302/0301-620X.81B6.10474; TSCHERNE H, 1998, CLIN ORTHOP RELAT R, V347, P62; VANVEEN IHPAA, 1995, INJURY, V26, P81, DOI 10.1016/0020-1383(95)92181-9; Whitbeck MG, 1997, J ORTHOP TRAUMA, V11, P82, DOI 10.1097/00005131-199702000-00002; YOUNG JWR, 1987, RADIOLOGIC MANAGMENT; ZAR Jh, 2009, BIOSTATISTICAL ANAL	40	156	174	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	SEP	2002	16	8					553	561		10.1097/00005131-200209000-00003			9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	597PH	WOS:000178229600003	12352563				2021-06-18	
J	Duncan, J; Johnson, R; Swales, M; Freer, C				Duncan, J; Johnson, R; Swales, M; Freer, C			Frontal lobe deficits after head injury: Unity and diversity of function	COGNITIVE NEUROPSYCHOLOGY			English	Article							CEREBRAL BLOOD-FLOW; DYSEXECUTIVE SYNDROME; COMPUTED-TOMOGRAPHY; LESIONS; CORTEX; MEMORY; BRAIN; INTELLIGENCE; PERFORMANCE; DYSFUNCTION	Deficits of ''executive function'' are commonly described following either focal frontal lobe lesions or the diffuse pathology of closed head injury. Here, correlational methods were used to investigate common elements in different tests conventionally used to measure executive deficits. Conventional executive (CONVEX) tests, sometimes adapted to give a variety of performance scores, were administered to a sample of 90 head-injured patients, along with a range of other clinical and neuropsychological measures. Following on from previous reports showing deficits in general intelligence or Spearman's g after frontal lobe lesions, tests relating to g were administered in a more detailed follow-up of 24 patients. The data showed uniformly low correlations between CONVEX tests, no higher indeed than correlations with others tests in the battery. Extracting more detailed scores in search of executive subfunctions such as switching or impulse control simply produced yet lower correlations. Though correlations between CONVEX tests were weak, the common element that these tests did share was closely related to g and to a phenomenon we call goal neglect, or disregard of a known task requirement. In this head-injured sample, goal neglect and g were related more to generalised atrophy than to focal lesions. We suggest that g reflects a process of forming an effective task plan by activation of multiple goals or action constraints. Most tests, including CONVEX tests, are to some extent sensitive to this process. Beyond this very general component, individual CONVEX tests may measure little of broad significance.	ADDENBROOKES HOSP,CAMBRIDGE,ENGLAND; UNIV WALES,BANGOR,GWYNEDD,WALES	Duncan, J (corresponding author), MRC,APPL PSYCHOL UNIT,15 CHAUCER RD,CAMBRIDGE CB2 2EF,ENGLAND.			Duncan, John/0000-0002-9695-2764; Duncan, John S/0000-0002-1373-0681			ALDERMAN N, 1993, J CLIN EXP NEUROPSYC, V15, P69; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; ANNETT M, 1974, NEUROPSYCHOLOGIA, V12, P527, DOI 10.1016/0028-3932(74)90083-9; BADDELEY A, 1988, BRAIN COGNITION, V7, P212, DOI 10.1016/0278-2626(88)90031-0; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; Benton AL, 1978, MULTILINGUAL APHASIA; BURGESS PW, 1994, REV NEUROPSYCHOL, V4, P345; Butler R.W., 1993, NEUROPSYCHOLOGY, V7, DOI [DOI 10.1037/0894-4105.7.4.519, https://doi.org/10.1037/0894-4105.7.4.519]; Carroll J. B., 1993, HUMAN COGNITIVE ABIL; Cattell R.B., 1971, ABILITIES THEIR STRU; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; DELLASALA S, 1991, NEUROPSYCHOLOGIA, V29, P1113, DOI 10.1016/0028-3932(91)90081-I; DREWE E A, 1974, Cortex, V10, P159; DUNCAN J, 1995, NEUROPSYCHOLOGIA, V33, P261, DOI 10.1016/0028-3932(94)00124-8; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; ESLINGER PJ, 1994, NEUROPSYCHOLOGIA, V32, P729, DOI 10.1016/0028-3932(94)90032-9; Fuster J, 1989, PREFRONTAL CORTEX; Goldberg E., 1987, FRONTAL LOBES REVISI, P159; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; GOPHER D, 1971, PERCEPT MOTOR SKILL, V33, P1335, DOI 10.2466/pms.1971.33.3f.1335; HUGHES CP, 1981, RADIOLOGY, V139, P391, DOI 10.1148/radiology.139.2.6971454; HYMAS N, 1991, BRAIN, V114, P2203, DOI 10.1093/brain/114.5.2203; Institute for Personality and Ability Testing, 1973, MEAS INT CULT FAIR T; JAGUST WJ, 1992, BRAIN, V115, P521, DOI 10.1093/brain/115.2.521; KONOW A, 1970, NEUROPSYCHOLOGIA, V8, P489, DOI 10.1016/0028-3932(70)90044-8; KOPELMAN MD, 1991, BRAIN, V114, P117; KOWALSKA DM, 1991, NEUROPSYCHOLOGIA, V29, P583, DOI 10.1016/0028-3932(91)90012-W; Luria A. R., 1966, HIGHER CORTICAL FUNC; LURIA AR, 1964, NEUROPSYCHOLOGIA, V2, P257, DOI 10.1016/0028-3932(64)90034-X; MCCARTHY RA, 1990, COGNITIVE NEUROPSYCH; McKenna P.W.E., 1983, GRADED NAMING TEST; MILNER B, 1965, NEUROPSYCHOLOGIA, V3, P317, DOI 10.1016/0028-3932(65)90005-9; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; MISHKIN M, 1978, BRAIN RES, V143, P313, DOI 10.1016/0006-8993(78)90571-1; Nelson H., 1982, NATIONAL ADULT READI; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NEWCOMBE F, 1988, COGNITIVE NEUROPSYCH, V5, P545; OCarroll R, 1995, NEUROCASE, V1, P83, DOI 10.1080/13554799508402350; PARKIN AJ, 1994, NEUROPSYCHOLOGIA, V32, P1523, DOI 10.1016/0028-3932(94)90124-4; PAUS T, 1991, BRAIN, V114, P2051, DOI 10.1093/brain/114.5.2051; PAUS T, 1993, J NEUROPHYSIOL, V70, P453; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; RAMIER AM, 1970, REV NEUROL, V123, P17; Raven J.C., 1988, MANUAL RAVENS PROGR; Rey A, 1964, EXAMEN CLIN PSYCHOL; RICCI C, 1990, NEUROPSYCHOLOGIA, V28, P1163, DOI 10.1016/0028-3932(90)90052-P; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; SACERDOTI ED, 1974, ARTIF INTELL, V5, P115, DOI 10.1016/0004-3702(74)90026-5; SEGALOWITZ SJ, 1992, J CLIN EXP NEUROPSYC, V14, P545, DOI 10.1080/01688639208402844; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; Shimamura Arthur P., 1995, P803; Spearman C., 1927, ABILITIES MAN; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; TEUBER H-L, 1972, Acta Neurobiologiae Experimentalis (Warsaw), V32, P615; VANDERSCHEER E, 1988, THESIS UTRECHT U; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y; WARRINGTON E K, 1973, Cortex, V9, P152; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL; Wechsler D., 1945, WECHSLER MEMORY SCAL; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WIENS AN, 1988, CLIN NEUROPSYCHOL, V2, P67, DOI DOI 10.1080/13854048808520087; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8; WILSON BA, 1985, 8 EUR C INT NEUR SOC	68	156	157	0	28	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE, EAST SUSSEX, ENGLAND BN3 2FA	0264-3294			COGNITIVE NEUROPSYCH	Cogn. Neuropsychol.		1997	14	5					713	741		10.1080/026432997381420			29	Psychology; Psychology, Experimental	Psychology	YK165	WOS:A1997YK16500003					2021-06-18	
J	Ozonoff, S; Miller, JN				Ozonoff, S; Miller, JN			An exploration of right-hemisphere contributions to the pragmatic impairments of autism	BRAIN AND LANGUAGE			English	Article							BRAIN-DAMAGED PATIENTS; CLOSED HEAD-INJURY; LEARNING-DISABILITIES; INFANTILE-AUTISM; CHILDREN; LANGUAGE; ADULTS; DYSFUNCTION; DISCOURSE; ABILITIES	This study examined the potential contribution of the right hemisphere to the communicative impairments of autism. Pragmatic language measures sensitive to right-hemisphere damage were administered to nonretarded adults with autism and to controls matched on age and intellectual ability. The experimental battery included measures of humor, inference, and indirect request comprehension. Autistic subjects performed significantly less well than controls on all measures, replicating results of an earlier investigation by Rumsey and Hanahan (Journal of Clinical and Experimental Neuropsychology, 12, 81, 1990). The performance of the autistic group on the three tasks was also similar to that of right-hemisphere stroke patients reported previously (Molloy, Brownell, & Gardner, in Y. Joanette and H. M. Brownell (Eds.), Discourse ability and brain damage: Theoretical and empirical perspectives, New York: Springer-Verlag, 1990, pp. 113-130). Generalizability of these results and implications for the neuropathology of autism are discussed. (C) 1996 Academic Press, Inc.		Ozonoff, S (corresponding author), UNIV UTAH,DEPT PSYCHOL,502 BEHAV SCI BLDG,SALT LAKE CITY,UT 84112, USA.						ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; ARNOLD G, 1983, J AUTISM DEV DISORD, V13, P129, DOI 10.1007/BF01531814; BARONCOHEN S, 1988, J AUTISM DEV DISORD, V18, P379, DOI 10.1007/BF02212194; BEEMAN M, 1993, BRAIN LANG, V44, P80, DOI 10.1006/brln.1993.1006; BIHRLE AM, 1986, BRAIN COGNITION, V5, P399, DOI 10.1016/0278-2626(86)90042-4; BISHOP DVM, 1989, BRIT J DISORD COMMUN, V24, P107; BROOK SL, 1992, J AUTISM DEV DISORD, V22, P61, DOI 10.1007/BF01046403; BROWNELL HH, 1983, BRAIN LANG, V18, P20, DOI 10.1016/0093-934X(83)90002-0; BROWNELL HH, 1986, BRAIN LANG, V27, P310, DOI 10.1016/0093-934X(86)90022-2; BROWNELL HH, 1988, LAUGHING MATTERS SER, P17; DAMASIO AR, 1978, ARCH NEUROL-CHICAGO, V35, P777, DOI 10.1001/archneur.1978.00500360001001; DAWSON G, 1983, J AUTISM DEV DISORD, V13, P269, DOI 10.1007/BF01531566; DAWSON G, 1986, CHILD DEV, V57, P1440, DOI 10.1111/j.1467-8624.1986.tb00469.x; Dawson G, 1988, BRAIN LATERALIZATION, P437; DENCKLA MB, 1983, ARCH NEUROL-CHICAGO, V40, P461, DOI 10.1001/archneur.1983.04210070001002; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DEWEY P, 1974, J AUTISM CHILD SCHIZ, V4, P348; EALES MJ, 1993, J AUTISM DEV DISORD, V23, P593, DOI 10.1007/BF01046104; FEIN D, 1984, PSYCHOL BULL, V95, P258, DOI 10.1037/0033-2909.95.2.258; FOLDI NS, 1987, BRAIN LANG, V31, P88, DOI 10.1016/0093-934X(87)90062-9; Frith U, 1989, AUTISM EXPLAINING EN; GEDYE A, 1991, MED HYPOTHESES, V34, P174, DOI 10.1016/0306-9877(91)90189-6; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; HIER DB, 1979, J AUTISM DEV DISORD, V9, P153, DOI 10.1007/BF01531531; HIRST W, 1984, BRAIN LANG, V23, P26, DOI 10.1016/0093-934X(84)90003-8; HOUGH MS, 1990, BRAIN LANG, V38, P253, DOI 10.1016/0093-934X(90)90114-V; Joanette Y, 1990, RIGHT HEMISPHERE VER; LOVELAND KA, 1990, BRIT J DEV PSYCHOL, V8, P9, DOI 10.1111/j.2044-835X.1990.tb00818.x; MCDONALD S, 1986, BRAIN LANG, V29, P68, DOI 10.1016/0093-934X(86)90034-9; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; Molloy R, 1990, DISCOURSE ABILITY BR, P113; MORENO SJ, 1991, HIGH FUNCTIONING IND; Moscovitch M., 1983, COGNITIVE PROCESSING, P57; NOVOA OP, 1987, BRAIN LANG, V30, P206, DOI 10.1016/0093-934X(87)90099-X; OZONOFF S, 1991, J CHILD PSYCHOL PSYC, V32, P1081, DOI 10.1111/j.1469-7610.1991.tb00351.x; OZONOFF S, 1994, J CHILD PSYCHOL PSYC, V35, P1015, DOI 10.1111/j.1469-7610.1994.tb01807.x; Ozonoff S., 1995, LEARNING COGNITION A, P199; PRIOR M, 1990, J AUTISM DEV DISORD, V20, P581, DOI 10.1007/BF02216063; PRIOR MR, 1979, J ABNORM CHILD PSYCH, V7, P357, DOI 10.1007/BF00917609; RUMSEY JM, 1985, J AUTISM DEV DISORD, V15, P23, DOI 10.1007/BF01837896; RUMSEY JM, 1990, J CLIN EXP NEUROPSYC, V12, P81; SATTLER JM, 1992, ASSESSMENT CHILDRENS; SEMRUDCLIKEMAN M, 1990, PSYCHOL BULL, V107, P196, DOI 10.1037/0033-2909.107.2.196; SHAH A, 1993, J CHILD PSYCHOL PSYC, V34, P1351, DOI 10.1111/j.1469-7610.1993.tb02095.x; SHIELDS J, 1991, BRIT J DISORD COMMUN, V26, P383; Suls JM., 1972, PSYCHOL HUMOR THEORE, P81, DOI DOI 10.1016/B978-0-12-288950-9.50010-9; TAGERFLUSBERG H, 1981, J AUTISM DEV DISORD, V11, P45, DOI 10.1007/BF01531340; TAGERFLUSBERG H, 1991, J CHILD PSYCHOL PSYC, V32, P1123, DOI 10.1111/j.1469-7610.1991.tb00353.x; Tsai L., 1988, FOCUS AUTISTIC BEHAV, V2, P1; VANBOURGONDIEN ME, 1987, J AUTISM DEV DISORD, V17, P417, DOI 10.1007/BF01487070; WEINTRAUB S, 1983, ARCH NEUROL-CHICAGO, V40, P463, DOI 10.1001/archneur.1983.04210070003003; WETHERBY AM, 1986, J AUTISM DEV DISORD, V16, P295, DOI 10.1007/BF01531661; Weylman S T, 1988, Res Publ Assoc Res Nerv Ment Dis, V66, P229; WEYLMAN ST, 1989, BRAIN LANG, V36, P580, DOI 10.1016/0093-934X(89)90087-4	54	156	156	1	20	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0093-934X			BRAIN LANG	Brain Lang.	MAR	1996	52	3					411	434		10.1006/brln.1996.0022			24	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	UC242	WOS:A1996UC24200001	8653388				2021-06-18	
J	GIULIAN, D; LI, J; LEARA, B; KEENEN, C				GIULIAN, D; LI, J; LEARA, B; KEENEN, C			PHAGOCYTIC MICROGLIA RELEASE CYTOKINES AND CYTOTOXINS THAT REGULATE THE SURVIVAL OF ASTROCYTES AND NEURONS IN CULTURE	NEUROCHEMISTRY INTERNATIONAL			English	Article							CENTRAL-NERVOUS-SYSTEM; MONONUCLEAR PHAGOCYTES; AMEBOID MICROGLIA; TRAUMATIC INJURY; MAMMALIAN BRAIN; INTERLEUKIN-1; RECEPTORS; GROWTH	Numerous studies have now shown that microglia secrete factors which may influence the growth and survival of cells in the CNS. We employed glia-neuron co-cultures to investigate the net effect of soluble products from secretory microglia upon astroglia and neurons following microglial activation by a phagocytic signal. Stimulation of microglia produced soluble factors that both increase the number of astroglia and decrease the number of neurons. The astroglial proliferating activity was blocked when incubated with an interleukin-1 (IL-1) receptor antagonist while the neurotoxic effect was inhibited by a N-methyl-D-aspartate (NMDA) receptor antagonist. Recombinant IL-1 served as a potent mitogen for cultured astroglia and promoted neuron survival by indirect actions upon astrocytes. These observations suggest that reactive microglia mediate both astrogliosis and neuronal injury through the simultaneous release of cell growth factors and poisons. The net effect of secretion products from phagocytic microglia is to diminish neuronal survival.		GIULIAN, D (corresponding author), BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS023113, R01NS025637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG008664] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG08664] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS23113, NS25637] Funding Source: Medline		Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; DINGLEDINE R, 1986, TRENDS NEUROSCI, V9, P47, DOI 10.1016/0166-2236(86)90017-2; FAGAN AM, 1990, EXP NEUROL, V110, P105, DOI 10.1016/0014-4886(90)90055-W; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GIULIAN D, 1986, J NEUROSCI, V6, P2163; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GIULIAN D, 1993, STROKE, V24, P184; Giulian D., 1992, CURRENT TOPICS NEURO, V12, P23; HONORE T, 1989, MED RES REV, V9, P1, DOI 10.1002/med.2610090102; MANTHORPE M, 1989, NERVE GROWTH FACTORS, P31; OPP MR, 1992, P NATL ACAD SCI USA, V89, P3726, DOI 10.1073/pnas.89.9.3726; RIOHORTEGA P, 1932, CYTOLOGY CELLULAR PA, P481; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; VACA K, 1989, J NEUROSCI RES, V23, P55, DOI 10.1002/jnr.490230108	22	156	160	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0197-0186			NEUROCHEM INT	Neurochem. Int.	SEP	1994	25	3					227	233		10.1016/0197-0186(94)90066-3			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	PH035	WOS:A1994PH03500003	7833791				2021-06-18	
J	GLOSSER, G; DESER, T				GLOSSER, G; DESER, T			PATTERNS OF DISCOURSE PRODUCTION AMONG NEUROLOGICAL PATIENTS WITH FLUENT LANGUAGE DISORDERS	BRAIN AND LANGUAGE			English	Article							CLOSED HEAD-INJURY; ALZHEIMERS-DISEASE; NARRATIVE DISCOURSE; TEXT COMPREHENSION; APHASIA; COHESION; MEMORY; COHERENCE; DEMENTIA		BOSTON UNIV,SCH MED,DEPT NEUROL,APHASIA RES CTR,BOSTON,MA 02118	GLOSSER, G (corresponding author), MED COLL PENN EASTERN PENN PSYCHIAT INST,DEPT PSYCHIAT,3200 HENRY AVE,PHILADELPHIA,PA 19129, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-06209] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS006209] Funding Source: NIH RePORTER		AGAR M, 1982, DISCOURSE PROCESS, V5, P1, DOI 10.1080/01638538209544529; APPELL J, 1982, BRAIN LANG, V17, P73, DOI 10.1016/0093-934X(82)90006-2; Bayles K. A., 1987, COMMUNICATION COGNIT; BLUMSTEIN SE, 1981, HDB CLIN NEUROPSYCHO, P227; BRUN A, 1981, HISTOPATHOLOGY, V5, P549, DOI 10.1111/j.1365-2559.1981.tb01818.x; CARAMAZZA A, 1978, PSYCHOL BULL, V85, P898, DOI 10.1037/0033-2909.85.4.898; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GLEASON JB, 1980, J SPEECH HEAR RES, V23, P370, DOI 10.1044/jshr.2302.370; GLOSSER G, 1989, BRAIN LANG, V37, P357, DOI 10.1016/0093-934X(89)90025-4; GLOSSER G, 1988, J SPEECH HEAR DISORD, V53, P115, DOI 10.1044/jshd.5302.115; GLOSSER G, 1990, AM PSYCHOL ASS ANN C; Goodglass H., 1983, ASSESSMENT APHASIA R; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Halliday Michael A. K., 1976, COHESION ENGLISH; Hunt K. W, 1965, GRAMMATICAL STRUCTUR; Hutchinson JM, 1980, LANG COMMUN, P59; Irigaray Luce, 1973, LANGAGE DEMENTS; JOANETTE Y, 1986, BRAIN LANG, V29, P81, DOI 10.1016/0093-934X(86)90035-0; KEENAN JM, 1984, J VERB LEARN VERB BE, V23, P115, DOI 10.1016/S0022-5371(84)90082-3; KEMPLER D, 1987, J SPEECH HEAR RES, V30, P343, DOI 10.1044/jshr.3003.343; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; LAHEY M, 1984, DISCOURSE PROCESS, V7, P419, DOI 10.1080/01638538409544599; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Loban W, 1963, LANGUAGE ELEMENTARY; MARTIN RC, 1986, BRAIN LANG, V28, P196, DOI 10.1016/0093-934X(86)90102-1; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MOLLOY R, 1965, DISCOURSE ABILITY BR, P113; MURDOCH BE, 1987, BRAIN LANG, V31, P122, DOI 10.1016/0093-934X(87)90064-2; NEBES RD, 1984, J ABNORM PSYCHOL, V93, P321, DOI 10.1037/0021-843X.93.3.321; NICHOLAS M, 1985, J SPEECH HEAR RES, V28, P405, DOI 10.1044/jshr.2803.405; Obler L. K., 1984, ACQUIRED APHASIA, P385; PEACH RK, 1986, ANN M AM SPEECH LANG; RIPICH DN, 1988, J SPEECH HEAR DISORD, V53, P8, DOI 10.1044/jshd.5301.08; SCHWARTZ MF, 1979, BRAIN LANG, V7, P277, DOI 10.1016/0093-934X(79)90024-5; SHEKIM LO, 1984, INT NEUROPSYCHOLOGIC; STACHOWIAK FJ, 1977, BRAIN LANG, V4, P177, DOI 10.1016/0093-934X(77)90016-5; TRACY K, 1984, DISCOURSE PROCESS, V7, P447, DOI 10.1080/01638538409544600; ULATOWSKA HK, 1981, BRAIN LANG, V13, P345, DOI 10.1016/0093-934X(81)90100-0; ULATOWSKA HK, 1986, BRAIN LANG, V28, P24, DOI 10.1016/0093-934X(86)90088-X; ULATOWSKA HK, 1983, BRAIN LANG, V19, P317, DOI 10.1016/0093-934X(83)90074-3; Van Dijk, 1977, TEXT CONTEXT; Van Dijk T, 1980, MACROSTRUCTURES; WATTS AF, 1948, LANGUAGE MENTAL DEV; WILCOX MJ, 1978, BRAIN LANG, V6, P362, DOI 10.1016/0093-934X(78)90069-X	50	156	161	0	18	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0093-934X			BRAIN LANG	Brain Lang.	JAN	1991	40	1					67	88		10.1016/0093-934X(91)90117-J			22	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	EW705	WOS:A1991EW70500003	2009448				2021-06-18	
J	Hagger, MS; Koch, S; Chatzisarantis, NLD; Orbell, S				Hagger, Martin S.; Koch, Severine; Chatzisarantis, Nikos L. D.; Orbell, Sheina			The Common Sense Model of Self-Regulation: Meta-Analysis and Test of a Process Model	PSYCHOLOGICAL BULLETIN			English	Article						chronic illness; coping procedures; illness cognition; illness perceptions; parallel-processing model	QUALITY-OF-LIFE; ILLNESS PERCEPTION QUESTIONNAIRE; IRRITABLE-BOWEL-SYNDROME; CHRONIC-FATIGUE-SYNDROME; MEDICALLY UNEXPLAINED SYMPTOMS; COGNITIVE-BEHAVIORAL MODEL; TRAUMATIC BRAIN-INJURY; CORONARY-HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; ONSET RHEUMATOID-ARTHRITIS	According to the common-sense model of self-regulation, individuals form lay representations of illnesses that guide coping procedures to manage illness threat. We meta-analyzed studies adopting the model to (a) examine the intercorrelations among illness representation dimensions, coping strategies, and illness outcomes; (h) test the sufficiency of a process model in which relations between illness representations and outcomes were mediated by coping strategies; and (c) test effects of moderators on model relations. Studies adopting the common-sense model in chronic illness (k = 254) were subjected to random-effects meta-analysis. The pattern of zero-order corrected correlations among illness representation dimensions (identity, consequences, timeline, perceived control, illness coherence, emotional representations), coping strategies (avoidance, cognitive reappraisal, emotion venting, problem-focused generic, problem-focused specific, seeking social support), and illness outcomes (disease state, distress, well-being, physical, role, and social functioning) was consistent with previous analyses. Meta-analytic path analyses supported a process model that included direct effects of illness representations on outcomes and indirect effects mediated by coping. Emotional representations and perceived control were consistently related to illness-related and functional outcomes via, respectively, lower and greater employment of coping strategies to deal with symptoms or manage treatment. Representations signaling threat (consequences, identity) had specific positive and negative indirect effects on outcomes through problem- and emotion-focused coping strategies. There was little evidence of moderation of model effects by study design, illness type and context, and study quality. A revised process model is proposed to guide future research which includes effects of moderators, individual differences, and beliefs about coping and treatment.	[Hagger, Martin S.; Koch, Severine; Chatzisarantis, Nikos L. D.] Curtin Univ, Hlth Psychol & Behav Med Res Grp, GPO Box U1987, Perth, WA 6845, Australia; [Hagger, Martin S.; Koch, Severine; Chatzisarantis, Nikos L. D.] Curtin Univ, Lab Self Regulat, Sch Psychol & Speech Pathol, Perth, WA, Australia; [Hagger, Martin S.] Univ Jyvaskyla, Fac Sport & Hlth Sci, Jyvaskyla, Finland; [Orbell, Sheina] Univ Essex, Dept Psychol, Colchester, Essex, England	Hagger, MS (corresponding author), Curtin Univ, Hlth Psychol & Behav Med Res Grp, GPO Box U1987, Perth, WA 6845, Australia.; Hagger, MS (corresponding author), Curtin Univ, Lab Self Regulat, Sch Psychol & Speech Pathol, Fac Hlth Sci, GPO Box U1987, Perth, WA 6845, Australia.	martin.hagger@curtin.edu.au	Hagger, Martin S./G-5211-2012	Hagger, Martin S./0000-0002-2685-1546; Chatzisarantis, Nikos/0000-0001-7059-6805	TEKES, the Finnish funding agency for innovationFinnish Funding Agency for Technology & Innovation (TEKES)	Martin S. Hagger's contribution was supported by a Finland Distinguished Professor (FiDiPro) award from TEKES, the Finnish funding agency for innovation. We thank Associate Editor Blair T. Johnson for helpful comments on earlier drafts of this article. We are grateful to Angela Carroll for her help with the literature search. We also thank the following authors who provided additional data for the current meta-analysis: Ab-dolaziz Aflakseir, Seher Aral, Vera Araiijo-Soares. Yael Benyammi. Becky Bih-O Lee, Felicity Bishop, Tore Bonsaksen, Noel T. Brewer, Elizabeth Broadbent, Trudie Chalder, Joseph Chilcot, Jimmy Chong, Arden Corter, Erin Costanzo, Francis Creed, Nicola Dalbeth, Martin Dempster, Aleid dc Rooij, Alex Federman, Maarten Fischer, Nadine Foster, Lana Fu, Milena Gandy, Rinie Geenen. David Gillanders. Prosenjit Giri, Lesley Glover, Christopher Graham, Konstadina Griva, Ann Marie Groarke, Brooks Gump, Jorine Hartman. John Harvey, Ankie Heerema-Poelman, Susan Hill, Alex Holmes, Joanna Hudson, Thomas Hyphantis, Egil Jonsbu, Rebecca Knibb, Dcirdrc Lane, Margaret Lau-Walker, Valeric Lawson, Yvonne Leung, Carrie Llewellyn, Sean Lynch, Julie Machines, Pamela McCabe, Elaine McColl, Ausra Mickeviciene, Gerry Molloy, Kevin Morgan, Rona Moss-Morris, Stanton Newman, Arie Nouwen, Ronan O'Carroll, Agnieszka Olchow ska-Kotala, Catherine O'Leary, Patricia Pinto, Heather Powell, Yolanda Quiles, Gwyneth Rees, Orna Reges, Jillian Riley, Tina Rochelle, Michael Rose, Reza Sadjadi, Gregory Sawicki, Margreet Scharloo, Stefanie Schroeder, Louise Sharpe, Timothy Skinner, Debbie Snell, Lesley Stafford, Susan Stott, Use Stuive, Elaine Thomas, Barbara Tomenson, Amy Turriff, Maureen Twiddy, Mike van der Have, Tinavan der Velde, Firdous Var, Manja Vollmann, Ken Watkins, Robert Whittaker. Wendy Woith, and Urska Zugelj.	Aalto AM, 2005, J PSYCHOSOM RES, V58, P393, DOI 10.1016/j.jpsychores.2005.03.001; Ackroyd K, 2011, J CLIN PSYCHOL MED S, V18, P372, DOI 10.1007/s10880-011-9265-0; Aflakseir A, 2012, J DIABETES, V4, P243, DOI 10.1111/j.1753-0407.2012.00183.x; Ajzen i, 2009, PREDICTING CHANGING; Alsen P, 2010, J CARDIOVASC NURS, V25, pE1, DOI 10.1097/JCN.0b013e3181c6dcfd; Anagnostopoulos F, 2012, J CLIN PSYCHOL MED S, V19, P147, DOI 10.1007/s10880-011-9272-1; Arat S, 2012, MUSCULOSKELET CARE, V10, P18, DOI 10.1002/msc.223; BAGOZZI RP, 1981, MULTIVAR BEHAV RES, V16, P323, DOI 10.1207/s15327906mbr1603_4; Balck F, 2012, Z PSYCHOSOM MED PSYC, V58, P357, DOI 10.13109/zptm.2012.58.4.357; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Barnes Lucy, 2004, N Z Med J, V117, pU743; BAUMANN LJ, 1989, HEALTH PSYCHOL, V8, P449, DOI 10.1037/0278-6133.8.4.449; Bean D, 2007, PSYCHOL HEALTH, V22, P787, DOI 10.1080/14768320600976240; Benyamini Y, 2004, COGNITIVE THER RES, V28, P577, DOI 10.1023/B:COTR.0000045566.97966.22; Benyamini Y, 2007, PSYCHOL HEALTH, V22, P765, DOI 10.1080/14768320601070639; Benyamini Y, 2012, CONTACT DERMATITIS, V67, P193, DOI 10.1111/j.1600-0536.2012.02071.x; Bishop FL, 2008, BRIT J HEALTH PSYCH, V13, P701, DOI 10.1348/135910707X249570; Bishop FL, 2006, PSYCHOL HEALTH, V21, P683, DOI 10.1080/14768320500444216; BISHOP GD, 1986, HEALTH PSYCHOL, V5, P95, DOI 10.1037/0278-6133.5.2.95; Bonsaksen T, 2014, INT J CHRONIC OBSTR, V9, P41, DOI 10.2147/COPD.S52700; Bonsaksen T, 2012, SCAND J PSYCHOL, V53, P333, DOI 10.1111/j.1467-9450.2012.00959.x; Boot CRL, 2008, INT ARCH OCC ENV HEA, V82, P13, DOI 10.1007/s00420-007-0298-5; Borenstein M., 2011, COMPREHENSIVE META A; Borenstein M, 2017, RES SYNTH METHODS, V8, P5, DOI 10.1002/jrsm.1230; Brandes K, 2014, HEALTH PSYCHOL REV, V8, P129, DOI 10.1080/17437199.2013.820986; Brewer NT, 2002, BRIT J HEALTH PSYCH, V7, P433, DOI 10.1348/135910702320645408; Broadbent E, 2006, J PSYCHOSOM RES, V60, P631, DOI 10.1016/j.jpsychores.2005.10.020; Broadbent E, 2015, PSYCHOL HEALTH, V30, P1361, DOI 10.1080/08870446.2015.1070851; Broadbent E, 2011, DIABETES CARE, V34, P338, DOI 10.2337/dc10-1779; Brown SP, 2005, J APPL PSYCHOL, V90, P792, DOI 10.1037/0021-9010.90.4.792; Buck F, 2007, J LARYNGOL OTOL, V121, P31, DOI 10.1017/S0022215106004002; Bucks RS, 2009, J PEDIATR PSYCHOL, V34, P893, DOI 10.1093/jpepsy/jsn135; Byrne M, 2005, J PSYCHOSOM RES, V58, P403, DOI 10.1016/j.jpsychores.2004.11.010; Cameron LD, 2005, PSYCHOSOM MED, V67, P584, DOI 10.1097/01.psy.0000170834.54970.f5; Carlisle ACS, 2005, BRIT J HEALTH PSYCH, V10, P571, DOI 10.1348/135910705X52309; Cartwright T, 2009, BRIT J DERMATOL, V160, P1034, DOI 10.1111/j.1365-2133.2008.09014.x; Cartwright T., 1999, BRIT PSYCH LOG SOC D; CARVER CS, 1992, HOSTILITY, COPING & HEALTH, P167, DOI 10.1037/10105-012; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Chaboyer W, 2010, J ADV NURS, V66, P2743, DOI 10.1111/j.1365-2648.2010.05431.x; Chalder T, 2003, PSYCHOL MED, V33, P283, DOI 10.1017/S0033291702007006; Chan JCY, 2009, J PLAST RECONSTR AES, V62, P927, DOI 10.1016/j.bjps.2007.11.057; Chen SL, 2011, INT J NURS STUD, V48, P235, DOI 10.1016/j.ijnurstu.2010.07.005; Chen SL, 2009, J CLIN NURS, V18, P2234, DOI 10.1111/j.1365-2702.2008.02706.x; Cheung GW, 2002, STRUCT EQU MODELING, V9, P233, DOI 10.1207/S15328007SEM0902_5; Chilcot J, 2013, BEHAV RES THER, V51, P690, DOI 10.1016/j.brat.2013.07.007; Chilcot J, 2013, ANN BEHAV MED, V45, P78, DOI 10.1007/s12160-012-9410-5; Chilcot J, 2012, PSYCHOL HEALTH MED, V17, P578, DOI 10.1080/13548506.2011.647702; Chilcot J, 2011, J HEALTH PSYCHOL, V16, P1127, DOI 10.1177/1359105311401672; Chilcot J, 2011, AM J NEPHROL, V33, P358, DOI 10.1159/000326752; Chilcot J, 2010, J PSYCHOSOM RES, V68, P203, DOI 10.1016/j.jpsychores.2009.08.010; Chong J, 2012, DISABIL REHABIL, V34, P2053, DOI 10.3109/09638288.2012.669021; COCHRAN WG, 1952, ANN MATH STAT, V23, P315, DOI 10.1214/aoms/1177729380; Cooper Myra, 2007, Eat Behav, V8, P474, DOI 10.1016/j.eatbeh.2007.01.003; Corter AL, 2013, BRIT J HEALTH PSYCH, V18, P168, DOI 10.1111/bjhp.12003; Costanzo ES, 2011, PSYCHO-ONCOLOGY, V20, P53, DOI 10.1002/pon.1707; Covic A, 2004, NEPHROL DIAL TRANSPL, V19, P2078, DOI 10.1093/ndt/gfh254; Dalbeth N, 2011, ARTHRIT CARE RES, V63, P1605, DOI 10.1002/acr.20570; Daleboudt GMN, 2011, ARTHRIT CARE RES, V63, P342, DOI 10.1002/acr.20411; De Filippis S, 2008, J HEADACHE PAIN, V9, P349, DOI 10.1007/s10194-008-0072-4; de Rooij A, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-133; Deary V, 2007, CLIN PSYCHOL REV, V27, P781, DOI 10.1016/j.cpr.2007.07.002; DeJong H, 2012, J HEALTH PSYCHOL, V17, P399, DOI 10.1177/1359105311416874; Dempster M, 2015, J PSYCHOSOM RES, V79, P506, DOI 10.1016/j.jpsychores.2015.10.006; Dempster M, 2012, DIS ESOPHAGUS, V25, P222, DOI 10.1111/j.1442-2050.2011.01233.x; Dempster M, 2011, J PSYCHOSOM RES, V70, P432, DOI 10.1016/j.jpsychores.2010.07.007; Dempster M, 2011, J HEALTH PSYCHOL, V16, P500, DOI 10.1177/1359105310386633; Dennison L, 2010, J PSYCHOSOM RES, V69, P353, DOI 10.1016/j.jpsychores.2010.04.009; Dickens C, 2008, GEN HOSP PSYCHIAT, V30, P414, DOI 10.1016/j.genhosppsych.2008.04.003; Dickens C, 2011, J CARDIOPULM REHABIL, V31, P105, DOI 10.1097/HCR.0b013e318207d32b; DiMatteo MR, 2012, HEALTH PSYCHOL REV, V6, P74, DOI 10.1080/17437199.2010.537592; Ditlevsen S, 2005, EPIDEMIOLOGY, V16, P114, DOI 10.1097/01.ede.0000147107.76079.07; Dorrian A, 2009, INFLAMM BOWEL DIS, V15, P47, DOI 10.1002/ibd.20583; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Edgar KA, 2003, J PEDIATR PSYCHOL, V28, P485, DOI 10.1093/jpepsy/jsg039; Edwards R, 2001, J PSYCHOSOM RES, V50, P65, DOI 10.1016/S0022-3999(00)00204-X; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Eiser JR, 2001, PSYCHOL HEALTH, V16, P99, DOI 10.1080/08870440108405492; Erblich J, 2003, HEALTH PSYCHOL, V22, P235, DOI 10.1037/0278-6133.22.3.235; Evans D, 2009, PSYCHOL HEALTH, V24, P1181, DOI 10.1080/08870440802398188; Fabbri S, 2001, PSYCHOSOMATICS, V42, P74, DOI 10.1176/appi.psy.42.1.74; Fan SY, 2013, PSYCHO-ONCOLOGY, V22, P1353, DOI 10.1002/pon.3146; Fennessy MM, 2013, J CARDIOVASC NURS, V28, P573, DOI 10.1097/JCN.0b013e31825d6060; Field AP, 2001, PSYCHOL METHODS, V6, P161, DOI 10.1037//1082-989X.6.2.161; Figueiras MJ, 2007, PSYCHOL HEALTH, V22, P143, DOI 10.1080/14768320600774462; Fischer M, 2010, BRIT J HEALTH PSYCH, V15, P887, DOI 10.1348/135910710X492693; Fischer MJ, 2013, BRIT J HEALTH PSYCH, V18, P526, DOI 10.1111/j.2044-8287.2012.02100.x; Fischer MJ, 2009, RESP MED, V103, P1564, DOI 10.1016/j.rmed.2008.11.020; Fitzgerald JT, 1996, EVAL HEALTH PROF, V19, P208, DOI 10.1177/016327879601900205; Folkman S., 1988, WAYS COPING QUESTION; Ford S, 2012, BRIT J HEALTH PSYCH, V17, P743, DOI 10.1111/j.2044-8287.2012.02069.x; Fortune DG, 2000, BRIT J HEALTH PSYCH, V5, P71, DOI 10.1348/135910700168775; Foster NE, 2008, PAIN, V136, P177, DOI 10.1016/j.pain.2007.12.007; Foster NE, 2010, PAIN, V148, P398, DOI 10.1016/j.pain.2009.11.002; Fowler C, 2006, NEPHROL NURS J, V33, P173; French DP, 2008, DIABETIC MED, V25, P1218, DOI 10.1111/j.1464-5491.2008.02569.x; French DP, 2006, J PSYCHOSOM RES, V61, P757, DOI 10.1016/j.jpsychores.2006.07.029; French DP, 2013, J PSYCHOSOM RES, V74, P327, DOI 10.1016/j.jpsychores.2012.12.008; French DP, 2005, J PSYCHOSOM RES, V59, P315, DOI 10.1016/j.jpsychores.2005.03.010; Fu L, 2011, EYE, V25, P1322, DOI 10.1038/eye.2011.158; Galli U, 2010, EUR J PAIN, V14, P550, DOI 10.1016/j.ejpain.2009.08.011; Gandy M, 2013, J PSYCHOSOM RES, V74, P227, DOI 10.1016/j.jpsychores.2012.11.001; Gaston AM, 2012, CHILD CARE HLTH DEV, V38, P513, DOI 10.1111/j.1365-2214.2011.01269.x; Gervais Will, 2015, PUTTING PET PEESE TE; Gillanders DT, 2013, EUR J PAIN, V17, P893, DOI 10.1002/j.1532-2149.2012.00248.x; Giri P, 2009, OCCUP MED-OXFORD, V59, P550, DOI 10.1093/occmed/kqp123; Glasgow RE, 1997, DIABETES CARE, V20, P556, DOI 10.2337/diacare.20.4.556; Glattacker M, 2010, BRIT J HEALTH PSYCH, V15, P367, DOI 10.1348/135910709X466315; Glover L, 2002, J PSYCHOSOM OBST GYN, V23, P237; Goldstein LH, 2011, PSYCHOL HEALTH, V26, P751, DOI 10.1080/08870446.2010.493217; Goldstein LH, 2005, EPILEPSY RES, V67, P1, DOI 10.1016/j.eplepsyres.2005.06.008; Goodman D, 2005, BEHAV CHANGE, V22, P156, DOI 10.1375/bech.2005.22.3.156; Goodman RA, 2013, PREV CHRONIC DIS, V10, DOI 10.5888/pcd10.120239; Gould RV, 2010, PSYCHOL HEALTH, V25, P633, DOI 10.1080/08870440902811163; Gourounti K, 2012, REPROD BIOMED ONLINE, V24, P670, DOI 10.1016/j.rbmo.2012.03.002; Grace SL, 2005, J PSYCHOSOM RES, V59, P153, DOI 10.1016/j.jpsychores.2005.05.005; Graham CD, 2014, CLIN REHABIL, V28, P508, DOI 10.1177/0269215513511340; Graves H, 2009, J PSYCHOSOM RES, V67, P417, DOI 10.1016/j.jpsychores.2009.01.006; Gray LJ, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-56; Gray SE, 2007, PSYCHOL HEALTH, V22, P159, DOI 10.1080/14768320600774595; Grayson PC, 2013, ARTHRIT CARE RES, V65, P1835, DOI 10.1002/acr.22069; Griva K, 2000, PSYCHOL HEALTH, V15, P733, DOI 10.1080/08870440008405578; Griva K, 2012, BRIT J HEALTH PSYCH, V17, P812, DOI 10.1111/j.2044-8287.2012.02076.x; Griva K, 2010, J PSYCHOSOM RES, V69, P363, DOI 10.1016/j.jpsychores.2010.04.008; Griva K, 2009, BRIT J HEALTH PSYCH, V14, P17, DOI 10.1348/135910708X292355; Groarke A, 2004, RHEUMATOLOGY, V43, P1142, DOI 10.1093/rheumatology/keh262; Groarke AM, 2005, PSYCHOL HEALTH, V20, P597, DOI 10.1080/14768320500094177; Gump BB, 2001, J AM GERIATR SOC, V49, P284, DOI 10.1046/j.1532-5415.2001.4930284.x; Hagger MS, 2006, EUR J SPORT SCI, V6, P103, DOI 10.1080/17461390500528527; Hagger MS, 2016, PREV MED, V89, P154, DOI 10.1016/j.ypmed.2016.05.020; Hagger MS, 2016, PSYCHOL HEALTH, V31, P814, DOI 10.1080/08870446.2016.1146719; Hagger MS, 2016, INT J BEHAV MED, V23, P282, DOI 10.1007/s12529-015-9531-x; Hagger MS, 2016, REV EDUC RES, V86, P360, DOI 10.3102/0034654315585005; Hagger MS, 2006, PSYCHOL HEALTH, V21, P183, DOI 10.1080/14768320500223339; Hagger MS, 2005, J APPL SOC PSYCHOL, V35, P2345, DOI 10.1111/j.1559-1816.2005.tb02106.x; Hagger MS, 2005, PSYCHOL HEALTH, V20, P161, DOI 10.1080/0887044042000334724; Hagger MS, 2003, PSYCHOL HEALTH, V18, P141, DOI 10.1080/088704403100081321; Hallas CN, 2011, HEART LUNG, V40, P111, DOI 10.1016/j.hrtlng.2009.12.008; HAMPSON SE, 1990, HEALTH PSYCHOL, V9, P632, DOI 10.1037/0278-6133.9.5.632; HAMPSON SE, 1995, DIABETES EDUCATOR, V21, P300, DOI 10.1177/014572179502100407; Hampson SE, 2000, BRIT J HEALTH PSYCH, V5, P27, DOI 10.1348/135910700168748; HAMPSON SE, 1994, J BEHAV MED, V17, P143, DOI 10.1007/BF01858102; Han SW, 2005, INFLAMM BOWEL DIS, V11, P24, DOI 10.1097/00054725-200501000-00004; Hartman JE, 2013, ARCH PHYS MED REHAB, V94, P2396, DOI 10.1016/j.apmr.2013.06.029; Heerema-Poelman A, 2013, J CARDIOPULM REHABIL, V33, P419, DOI 10.1097/HCR.0b013e3182a5274a; Heijmans M, 1998, J Health Psychol, V3, P523, DOI 10.1177/135910539800300406; Heijmans M, 1999, BRIT J HEALTH PSYCH, V4, P137, DOI 10.1348/135910799168533; Heijmans M, 1998, J BEHAV MED, V21, P485, DOI 10.1023/A:1018788427100; Heijmans MJWM, 1998, J PSYCHOSOM RES, V45, P39, DOI 10.1016/S0022-3999(97)00265-1; Helder DI, 2002, BRIT J HEALTH PSYCH, V7, P449, DOI 10.1348/135910702320645417; Hemphill RC, 2013, PSYCHOL HEALTH, V28, P139, DOI 10.1080/08870446.2012.685740; Henderson CJ, 2007, HEALTH PSYCHOL, V26, P165, DOI 10.1037/0278-6133.26.2.165; Henderson CJ, 2009, HEALTH PSYCHOL, V28, P101, DOI 10.1037/a0013690; Hermele Sandy, 2007, Psychol Health Med, V12, P580, DOI 10.1080/13548500601162705; Heyhoe J, 2009, PSYCHOL HEALTH MED, V14, P726, DOI 10.1080/13548500903431477; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hill S, 2007, RHEUMATOLOGY, V46, P944, DOI 10.1093/rheumatology/kem015; Horne R, 2002, PSYCHOL HEALTH, V17, P17, DOI 10.1080/08870440290001502; Horne R, 1999, PSYCHOL HEALTH, V14, P1, DOI 10.1080/08870449908407311; Horne R., 1997, PERCEPTIONS HLTH ILL; HORNE R, 2001, EUR HLTH PSYCH SOC B; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Howard C, 2009, BEHAV RES THER, V47, P71, DOI 10.1016/j.brat.2008.10.004; Hudson J. M., 2013, THESIS; Hudson JL, 2014, J PSYCHOSOM RES, V76, P265, DOI 10.1016/j.jpsychores.2014.02.004; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; Hunter J. E., 2004, METHODS META ANAL RE; Hunter JE, 2000, INT J SELECT ASSESS, V8, P275, DOI 10.1111/1468-2389.00156; Hunter M, 1999, PATIENT EDUC COUNS, V38, P249, DOI 10.1016/S0738-3991(98)00143-8; Husain Mohammed O, 2008, Clin Pract Epidemiol Ment Health, V4, P4, DOI 10.1186/1745-0179-4-4; Husebo AML, 2013, J CLIN NURS, V22, P4, DOI 10.1111/j.1365-2702.2012.04322.x; Hyphantis T, 2013, CLIN RHEUMATOL, V32, P635, DOI 10.1007/s10067-012-2162-6; Ireland JA, 2005, INT J STD AIDS, V16, P667, DOI 10.1258/095646205774357334; Jack K, 2010, MANUAL THER, V15, P220, DOI 10.1016/j.math.2009.12.004; Jackson J, 2006, J PSYCHOSOM RES, V60, P357, DOI 10.1016/j.jpsychores.2006.02.006; Janse AJ, 2005, ARCH DIS CHILD, V90, P486, DOI 10.1136/adc.2004.051722; Jansen DL, 2010, BMC NEPHROL, V11, DOI 10.1186/1471-2369-11-35; Jessop DC, 2003, PSYCHOL HEALTH, V18, P595, DOI 10.1080/0887044031000097009; Johnson BT, 2015, PSYCHOL HEALTH, V30, P135, DOI 10.1080/08870446.2014.953533; Johnson BT, 2014, HANDBOOK OF RESEARCH METHODS IN SOCIAL AND PERSONALITY PSYCHOLOGY, SECOND EDITION, P677; Jonsbu E, 2013, BEHAV COGN PSYCHOTH, V41, P398, DOI 10.1017/S1352465813000179; Jonsbu E, 2012, BIOPSYCHOSOC MED, V6, DOI 10.1186/1751-0759-6-19; Jopson NM, 2003, J PSYCHOSOM RES, V54, P503, DOI 10.1016/S0022-3999(02)00455-5; Juergens MC, 2010, J PSYCHOSOM RES, V68, P553, DOI 10.1016/j.jpsychores.2009.10.004; Kaptein AA, 2007, QUAL LIFE RES, V16, P793, DOI 10.1007/s11136-007-9194-4; Kaptein AA, 2006, PSYCHOL HEALTH, V21, P431, DOI 10.1080/14768320500456947; Karademas EC, 2013, J HEALTH PSYCHOL, V18, P419, DOI 10.1177/1359105312436765; Karademas EC, 2013, PSYCHOL HEALTH, V28, P67, DOI 10.1080/08870446.2012.713954; Karademas EC, 2012, J HEALTH PSYCHOL, V17, P36, DOI 10.1177/1359105311405554; Karademas EC, 2011, PSYCHOL HEALTH, V26, P567, DOI 10.1080/08870441003653488; Karademas EC, 2011, J HEALTH PSYCHOL, V16, P510, DOI 10.1177/1359105310392093; Karademas EC, 2009, STRESS HEALTH, V25, P405, DOI 10.1002/smi.1252; Keeling M, 2013, PSYCHO-ONCOLOGY, V22, P1421, DOI 10.1002/pon.3158; Kemp S, 1999, BRIT J CLIN PSYCHOL, V38, P43, DOI 10.1348/014466599162656; Kemp Steven, 2007, Psychol Health Med, V12, P107, DOI 10.1080/14622200500358937; Kesler A, 2009, EUR J NEUROL, V16, P931, DOI 10.1111/j.1468-1331.2009.02625.x; Khunti K, 2008, DIABETIC MED, V25, P1454, DOI 10.1111/j.1464-5491.2008.02620.x; Kiebles JL, 2010, INFLAMM BOWEL DIS, V16, P1685, DOI 10.1002/ibd.21215; Kim Y, 2012, NEPHROL NURS J, V39, P39; Kim Youngmee, 2010, Nephrol Nurs J, V37, P271; Kirby B, 2001, J AM ACAD DERMATOL, V45, P72, DOI 10.1067/mjd.2001.114592; Kirby SE, 2009, J PSYCHOSOM RES, V66, P111, DOI 10.1016/j.jpsychores.2008.05.027; Knibb RC, 2008, BRIT J HEALTH PSYCH, V13, P103, DOI 10.1348/135910706X173278; Kohler T, 2015, ORGAN RES METHODS, V18, P355, DOI 10.1177/1094428114563617; Kotsis K, 2012, ARTHRIT CARE RES, V64, P1593, DOI 10.1002/acr.21725; Lane DA, 2009, J PSYCHOSOM RES, V66, P203, DOI 10.1016/j.jpsychores.2008.10.007; LAU RR, 1989, HEALTH PSYCHOL, V8, P195, DOI 10.1037/0278-6133.8.2.195; Lau RR, 1983, HEALTH PSYCHOL, P167, DOI [10.1037/0278-6133.2.2.167, DOI 10.1037/0278-6133.2.2.167]; Lau-Walker M, 2004, J ADV NURS, V48, P216, DOI 10.1111/j.1365-2648.2004.03190.x; Lau-Walker M, 2007, J ADV NURS, V60, P187, DOI 10.1111/j.1365-2648.2007.04398.x; Lau-Walker M, 2006, BRIT J HEALTH PSYCH, V11, P643, DOI 10.1348/135910705X72802; Lau-Walker MO, 2009, J CLIN NURS, V18, P63, DOI 10.1111/j.1365-2702.2008.02386.x; Law GU, 2013, J PSYCHOSOM RES, V74, P334, DOI 10.1016/j.jpsychores.2012.12.009; Law GU, 2014, HEALTH PSYCHOL REV, V8, P362, DOI 10.1080/17437199.2012.747123; Lawson VL, 2010, BRIT J HEALTH PSYCH, V15, P623, DOI 10.1348/135910709X478664; Lawson VL, 2007, PSYCHOL HEALTH, V22, P175, DOI 10.1080/14768320600774546; Lawson VL, 2004, BRIT J HEALTH PSYCH, V9, P241, DOI 10.1348/135910704773891078; Lazarus R.S., 1984, HDB BEHAV MED, P282; Lee BO, 2008, J NURS SCHOLARSHIP, V40, P83, DOI 10.1111/j.1547-5069.2008.00210.x; Lehto RH, 2009, CANCER NURS, V32, P2, DOI 10.1097/01.NCC.0000343363.75752.f1; Leung YW, 2010, J HEALTH PSYCHOL, V15, P1049, DOI 10.1177/1359105309360577; LEVENTHAL H, 1992, COGNITIVE THER RES, V16, P143, DOI 10.1007/BF01173486; LEVENTHAL H, 1980, PSYCHOL BULL, V88, P370, DOI 10.1037/0033-2909.88.2.370; Leventhal H, 1998, PSYCHOL HEALTH, V13, P717, DOI 10.1080/08870449808407425; Leventhal H., 1980, MED PSYCHOL, V2, P7; Leventhal H., 2003, SELF REGULATION HLTH, P42; Leventhal H., 1997, PERCEPTIONS HLTH ILL, P19; Leventhal H, 2016, J BEHAV MED, V39, P935, DOI 10.1007/s10865-016-9782-2; Leventhal H, 2011, ANN BEHAV MED, V41, P152, DOI 10.1007/s12160-010-9246-9; Li L, 2004, STAT MED, V23, P271, DOI 10.1002/sim.1715; Limburg K., 2016, J CLIN PSYCHOL; Linz D., 1982, 20 INT C APPL PSCH E; Ljosaa TM, 2012, J EUR ACAD DERMATOL, V26, P29, DOI 10.1111/j.1468-3083.2011.04000.x; Llewellyn CD, 2007, BRIT J HEALTH PSYCH, V12, P421, DOI 10.1348/135910706X118422; Llewellyn CD, 2006, BRIT J ORAL MAX SURG, V44, P351, DOI 10.1016/j.bjoms.2005.06.033; Llewellyn CD, 2008, J PSYCHOSOM RES, V65, P525, DOI 10.1016/j.jpsychores.2008.03.014; Llewellyn CD, 2007, J PSYCHOSOM RES, V63, P17, DOI 10.1016/j.jpsychores.2007.01.013; Llewellyn CD, 2003, PSYCHOL HEALTH, V18, P185, DOI 10.1080/0887044031000098198; Lobban F, 2005, BRIT J CLIN PSYCHOL, V44, P163, DOI 10.1348/014466504X19785; Luyckx K, 2010, J BEHAV MED, V33, P228, DOI 10.1007/s10865-010-9249-9; MacInnes J, 2013, EUR J CARDIOVASC NUR, V12, P536, DOI 10.1177/1474515112473872; Marke V, 2013, BRIT J CLIN PSYCHOL, V52, P70, DOI 10.1111/bjc.12001; Marques M, 2013, INT J BEHAV MED, V20, P229, DOI 10.1007/s12529-012-9265-y; Martin R, 2003, BLACKW SER HLTH PSYC, P199; Mc Sharry J, 2011, DIABETIC MED, V28, P1300, DOI 10.1111/j.1464-5491.2011.03298.x; McCabe PJ, 2012, J CARDIOVASC NURS, V27, P431, DOI 10.1097/JCN.0b013e31821e7ab1; McCabe PJ, 2011, PACE, V34, P810, DOI 10.1111/j.1540-8159.2011.03105.x; McCarthy SC, 2003, PSYCHOL HEALTH, V18, P109, DOI 10.1080/0887044031000080674; McGrady ME, 2010, J CLIN PSYCHOL MED S, V17, P349, DOI 10.1007/s10880-010-9214-3; Mickeviciene A, 2013, MEDICINA-LITHUANIA, V49, P235; Miglioretti M, 2008, J PSYCHOSOM RES, V65, P603, DOI 10.1016/j.jpsychores.2008.05.012; Molloy GJ, 2009, EUR J HEART FAIL, V11, P715, DOI 10.1093/eurjhf/hfp059; Moreno SG, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-2; Morgan K, 2003, J PSYCHOSOM RES, V54, P21, DOI 10.1016/S0022-3999(02)00569-X; Morris A, 2012, PSYCHOL HEALTH MED, V17, P285, DOI 10.1080/13548506.2011.608804; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; Moss-Morris R, 2011, PSYCHOL MED, V41, P1099, DOI 10.1017/S003329171000139X; Moss-Morris R, 2007, CLIN J PAIN, V23, P558, DOI 10.1097/AJP.0b013e318093fcab; MossMorris R, 1996, BRIT J HEALTH PSYCH, V1, P15, DOI 10.1111/j.2044-8287.1996.tb00488.x; Mulligan K, 2012, BRIT J HEALTH PSYCH, V17, P447, DOI 10.1111/j.2044-8287.2011.02047.x; Murphy H, 1999, J PSYCHOSOM RES, V46, P155, DOI 10.1016/S0022-3999(98)00073-7; Muthen L. K., 2012, MPLUS STAT ANAL LATE; Naab F, 2013, J NURS SCHOLARSHIP, V45, P132, DOI 10.1111/jnu.12013; National Institutes of Health, 2014, QUAL ASS TOOL OBS CO; Neter E, 2009, PSYCHOL HEALTH, V24, P175, DOI 10.1080/08870440701668665; Nicklas LB, 2010, PSYCHOL HEALTH, V25, P601, DOI 10.1080/08870440902783610; Nouwen A, 2009, PSYCHOL HEALTH, V24, P1071, DOI 10.1080/08870440802254597; O'Carroll R, 2011, ANN BEHAV MED, V41, P383, DOI 10.1007/s12160-010-9257-6; O'Connor SM, 2008, J PSYCHOSOM RES, V65, P191, DOI 10.1016/j.jpsychores.2008.02.008; O'Leary CJ, 2004, J PSYCHOSOM RES, V57, P465, DOI 10.1016/j.jpsychores.2004.03.012; Olchowska-Kotala A, 2013, EUR J INTEGR MED, V5, P347, DOI 10.1016/j.eujim.2013.03.008; Olchowska-Kotala A, 2010, ADV CLIN EXP MED, V19, P503; Oluka OC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094419; Orbell S, 1998, SOC SCI MED, V47, P93, DOI 10.1016/S0277-9536(97)10132-0; Orbell S, 1997, PERS SOC PSYCHOL B, V23, P945, DOI 10.1177/0146167297239004; Orbell S, 2008, SOC SCI MED, V67, P1465, DOI 10.1016/j.socscimed.2008.06.039; Orbell S, 2006, HEALTH PSYCHOL, V25, P604, DOI 10.1037/0278-6133.25.5.604; Orbell S, 2015, ANN BEHAV MED, V49, P918, DOI 10.1007/s12160-015-9719-y; Paddison CAM, 2008, INT J BEHAV MED, V15, P180, DOI 10.1080/10705500802222295; Paschalides C, 2004, J PSYCHOSOM RES, V57, P557, DOI 10.1016/j.jpsychores.2004.03.006; Paterson J, 1999, PSYCHOL HEALTH, V14, P117, DOI 10.1080/08870449908407318; Peters GJY, 2013, HEALTH PSYCHOL REV, V7, pS8, DOI 10.1080/17437199.2012.703527; Petricek G, 2009, CROAT MED J, V50, P583, DOI 10.3325/cmj.2009.50.583; Petrie KJ, 2012, CURR DIR PSYCHOL SCI, V21, P60, DOI 10.1177/0963721411429456; Petrie KJ, 2002, PSYCHOSOM MED, V64, P580, DOI 10.1097/00006842-200207000-00007; Petrie KJ, 1996, BRIT MED J, V312, P1191; Philip EJ, 2009, DEPRESS ANXIETY, V26, P575, DOI 10.1002/da.20451; Pinto PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073917; Pinto PR, 2012, J PAIN, V13, P1045, DOI 10.1016/j.jpain.2012.07.014; Podsakoff PM, 2003, J APPL PSYCHOL, V88, P879, DOI 10.1037/0021-9010.88.5.879; Pollak L, 2012, AM J OTOLARYNG, V33, P221, DOI 10.1016/j.amjoto.2011.07.002; Powell H, 2013, J ASTHMA, V50, P383, DOI 10.3109/02770903.2012.757777; Preacher KJ, 2011, PSYCHOL METHODS, V16, P93, DOI 10.1037/a0022658; Price A, 2012, J PAIN SYMPTOM MANAG, V43, P819, DOI 10.1016/j.jpainsymman.2011.05.013; Quiles Y, 2011, J HEALTH PSYCHOL, V16, P208, DOI 10.1177/1359105310373411; Rees G, 2001, SOC SCI MED, V52, P1433, DOI 10.1016/S0277-9536(00)00248-3; Rees G, 2012, CLIN EXP OPTOM, V95, P371, DOI 10.1111/j.1444-0938.2012.00745.x; Rees G, 2010, OPHTHALMOLOGY, V117, P903, DOI 10.1016/j.ophtha.2009.10.038; Reges O, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-956; Richards HL, 2003, ARTHRIT RHEUM-ARTHR, V49, P689, DOI 10.1002/art.11385; Riley JP, 2012, J ADV NURS, V68, P1050, DOI 10.1111/j.1365-2648.2011.05809.x; Rochelle TL, 2013, J HEALTH PSYCHOL, V18, P972, DOI 10.1177/1359105312459094; RODIN J, 1989, ANNU REV PSYCHOL, V40, P533, DOI 10.1146/annurev.ps.40.020189.002533; Rogan C, 2013, NEUROPSYCHOL REHABIL, V23, P639, DOI 10.1080/09602011.2013.799076; Rose MR, 2012, MUSCLE NERVE, V46, P351, DOI 10.1002/mus.23320; Rosenthal MLC, 1994, HDB RES SYNTHESIS, P85; Rozema H, 2009, PSYCHO-ONCOLOGY, V18, P849, DOI 10.1002/pon.1488; Rutter C. L., 2001, UNPUB; Rutter CL, 2002, BRIT J HEALTH PSYCH, V7, P377, DOI 10.1348/135910702320645372; Rutter CL, 2007, J HEALTH PSYCHOL, V12, P141, DOI 10.1177/1359105307071748; Saltapidas H, 2008, BRAIN IMPAIR, V9, P1, DOI 10.1375/brim.9.1.1; Sawieki GS, 2011, J PSYCHOSOM RES, V70, P161, DOI 10.1016/j.jpsychores.2010.06.005; Scharloo M, 2005, HEAD NECK-J SCI SPEC, V27, P857, DOI 10.1002/hed.20251; Scharloo M, 1998, J PSYCHOSOM RES, V44, P573, DOI 10.1016/S0022-3999(97)00254-7; Scharloo M, 2000, BRIT J DERMATOL, V142, P899, DOI 10.1046/j.1365-2133.2000.03469.x; Scharloo M, 2007, J ASTHMA, V44, P575, DOI 10.1080/02770900701537438; Scharloo M, 2010, SUPPORT CARE CANCER, V18, P1137, DOI 10.1007/s00520-009-0728-x; Schiaffino KM, 1998, HEALTH PSYCHOL, V17, P262, DOI 10.1037/0278-6133.17.3.262; Schreurs P. J. G., 1988, ULTRECHTSE COPING LI; Schroeder S, 2012, PSYCHOSOM MED, V74, P861, DOI 10.1097/PSY.0b013e31826ae4ae; SCHWARZER R, 2008, APPL PSYCHOL INT REV, V57, P1; Sciacchitano L., 2009, J RATION-EMOT COGN-B, V27, P23; Searle A, 2007, BRIT J HEALTH PSYCH, V12, P621, DOI 10.1348/135910706X164935; Seaton M, 2010, AM EDUC RES J, V47, P390, DOI 10.3102/0002831209350493; Sharpe L, 2001, J PSYCHOSOM RES, V51, P713, DOI 10.1016/S0022-3999(01)00266-5; Sharpe L, 2001, PAIN, V89, P275, DOI 10.1016/S0304-3959(00)00379-1; Shiloh S., 2001, UNPUB; Shiyanbola Olayinka O, 2011, S D Med, V64, P365; Silva SM, 2012, PSYCHO-ONCOLOGY, V21, P409, DOI 10.1002/pon.1913; Simpson J, 2013, CHRONIC ILLN, V9, P165, DOI 10.1177/1742395313478219; Skinner TC, 2006, PATIENT EDUC COUNS, V64, P369, DOI 10.1016/j.pec.2006.04.007; Skinner TC, 2003, DIABETIC MED, V20, P283, DOI 10.1046/j.1464-5491.2003.00923.x; Skinner TC, 1998, J ADOLESCENCE, V21, P703, DOI 10.1006/jado.1998.0190; Skinner TC, 2002, HEALTH PSYCHOL, V21, P61, DOI 10.1037//0278-6133.21.1.61; Skinner T, 2013, SLEEP BREATH, V17, P1229, DOI 10.1007/s11325-013-0828-1; Sluiter JK, 2008, INT ARCH OCC ENV HEA, V81, P495, DOI 10.1007/s00420-007-0222-z; Snell DL, 2013, NEUROPSYCHOL REHABIL, V23, P333, DOI 10.1080/09658211.2012.758419; Snell DL, 2011, BRAIN INJURY, V25, P1126, DOI 10.3109/02699052.2011.607786; Sniehotta FF, 2010, PSYCHOL HEALTH, V25, P839, DOI 10.1080/08870440902915915; Sofianou A, 2013, J GEN INTERN MED, V28, P67, DOI 10.1007/s11606-012-2160-z; Spain LA, 2007, ACTA NEUROL SCAND, V116, P293, DOI 10.1111/j.1600-0404.2007.00895.x; Spence MJ, 2007, GUT, V56, P1066, DOI 10.1136/gut.2006.108811; Stafford L, 2008, PSYCHOSOM MED, V70, P942, DOI 10.1097/PSY.0b013e318187e22e; Stafford L, 2009, J PSYCHOSOM RES, V66, P211, DOI 10.1016/j.jpsychores.2008.09.005; Stamogiannou I, 2005, INT J IMPOT RES, V17, P142, DOI 10.1038/sj.ijir.3901220; Stauffer JM, 1996, EDUC PSYCHOL MEAS, V56, P675, DOI 10.1177/0013164496056004009; Steed L, 1999, BRIT J HEALTH PSYCH, V4, P337, DOI 10.1348/135910799168687; Stein M. J., 2001, PAPER PRESENTED AT T; STEWART AL, 1992, MEASURING FUNCTIONIN, P345; Stockford K, 2007, BRIT J CLIN PSYCHOL, V46, P139, DOI 10.1348/014466506X115786; Stuifbergen AK, 2006, WOMEN HEALTH ISS, V16, P353, DOI 10.1016/j.whi.2006.05.003; Targosz SA, 2001, IRISH J PSYCHOL MED, V18, P16, DOI 10.1017/S0790966700006169; Thune-Boyle ICV, 2006, BEHAV MED, V32, P19, DOI 10.3200/BMED.32.1.19-29; Tiemensma J, 2011, J CLIN ENDOCR METAB, V96, P3550, DOI 10.1210/jc.2011-1645; Traeger L, 2009, J PSYCHOSOM RES, V67, P389, DOI 10.1016/j.jpsychores.2009.03.013; Treharne G J, 2008, Psychol Health Med, V13, P494, DOI 10.1080/13548500701796931; Treharne GJ, 2007, MUSCULOSKELET CARE, V5, P51, DOI 10.1002/msc.99; Treharne GJ, 2005, J HEALTH PSYCHOL, V10, P457, DOI 10.1177/1359105305051416; Trovato GM, 2010, HEART VESSELS, V25, P82, DOI 10.1007/s00380-009-1163-0; TURK DC, 1986, J BEHAV MED, V9, P453, DOI 10.1007/BF00845133; Turriff A, 2011, GENET MED, V13, P966, DOI 10.1097/GIM.0b013e3182227576; Twiddy M, 2012, J PSYCHOSOM RES, V72, P220, DOI 10.1016/j.jpsychores.2011.12.004; US Department of Health and Human Services, 2011, HLTH US 2010 SPEC FE; US Department of Health and Human Services, 2013, MULT CHRON COND STRA; van der Have Mike, 2013, J Crohns Colitis, V7, pe292, DOI 10.1016/j.crohns.2012.11.002; van der Velde JL, 2011, ALLERGY, V66, P1580, DOI 10.1111/j.1398-9995.2011.02726.x; van Os S, 2012, PSYCHOL HEALTH MED, V17, P427, DOI 10.1080/13548506.2011.626432; van Wilgen CP, 2008, ARTHRITIS RHEUM-US, V58, P3618, DOI 10.1002/art.23959; van Wilgen CP, 2010, DISABIL REHABIL, V32, P1576, DOI 10.3109/09638281003596857; Var FA, 2012, INDIAN J PSYCHOL MED, V34, P223, DOI 10.4103/0253-7176.106014; Vaughan R, 2003, BRIT J HEALTH PSYCH, V8, P287, DOI 10.1348/135910703322370860; VEIT CT, 1983, J CONSULT CLIN PSYCH, V51, P730, DOI 10.1037/0022-006X.51.5.730; VITALIANO PP, 1985, MULTIVAR BEHAV RES, V20, P3, DOI 10.1207/s15327906mbr2001_1; Vollmann M, 2014, PSYCHOL HEALTH, V29, P81, DOI 10.1080/08870446.2013.828294; Vollmann M, 2012, J PSYCHOSOM RES, V73, P108, DOI 10.1016/j.jpsychores.2012.04.009; Walsh JC, 2004, J PSYCHOSOM RES, V56, P67, DOI 10.1016/S0022-3999(03)00082-5; Wamsteker EW, 2005, J AM DIET ASSOC, V105, P441, DOI 10.1016/j.jada.2004.12.031; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Watkins KW, 2000, DIABETES CARE, V23, P1511, DOI 10.2337/diacare.23.10.1511; Wearden A, 2008, BRIT J HEALTH PSYCH, V13, P189, DOI 10.1348/135910708X295613; Weinman J, 1996, PSYCHOL HEALTH, V11, P431, DOI 10.1080/08870449608400270; Wenninger K, 2013, PSYCHO-ONCOLOGY, V22, P854, DOI 10.1002/pon.3073; Whitmarsh A, 2003, BRIT J HEALTH PSYCH, V8, P209, DOI 10.1348/135910703321649178; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wikman A, 2011, PSYCHOL HEALTH, V26, P974, DOI 10.1080/08870446.2010.512663; Woith WM, 2008, INT J NURS STUD, V45, P1163, DOI 10.1016/j.ijnurstu.2007.07.014; Wu LM, 2013, PSYCHOL HEALTH, V28, P355, DOI 10.1080/08870446.2012.722219; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zivkovic MV, 2008, COLLEGIUM ANTROPOL, V32, P75; Zugelj U, 2010, J PEDIATR PSYCHOL, V35, P1049, DOI 10.1093/jpepsy/jsq027	391	155	158	10	182	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0033-2909	1939-1455		PSYCHOL BULL	Psychol. Bull.	NOV	2017	143	11					1117	1154		10.1037/bul0000118			38	Psychology; Psychology, Multidisciplinary	Psychology	FK2DG	WOS:000413292200001	28805401	Green Accepted, Green Published	Y	N	2021-06-18	
J	Gelaye, B; Williams, MA; Lemma, S; Deyessa, N; Bahretibeb, Y; Shibre, T; Wondimagegn, D; Lemenhe, A; Fann, JR; Vander Stoep, A; Zhou, XHA				Gelaye, Bizu; Williams, Michelle A.; Lemma, Seblewengel; Deyessa, Negussie; Bahretibeb, Yonas; Shibre, Teshome; Wondimagegn, Dawit; Lemenhe, Asnake; Fann, Jesse R.; Vander Stoep, Ann; Zhou, Xiao-Hua Andrew			Validity of the patient health questionnaire-9 for depression screening and diagnosis in East Africa	PSYCHIATRY RESEARCH			English	Article						PHQ-9; Validation; Africa; Ethiopia; Depression	COMMON MENTAL-DISORDERS; RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; PRIMARY-CARE; CLINICAL-ASSESSMENT; MAJOR DEPRESSION; LOW-INCOME; PRIME-MD; PHQ-9; VALIDATION	Depression is often underdiagnosed and undertreated in primary care settings, particularly in developing countries. This is, in part, due to challenges resulting from lack of skilled mental health workers, stigma associated with mental illness, and lack of cross-culturally validated screening instruments. We conducted this study to evaluate the reliability and validity of the Patient Health Questionnaire-9 (PHQ-9) as a screen for diagnosing major depressive disorder among adults in Ethiopia, the second most populous country in sub-Saharan Africa. A total of 926 adults attending outpatient departments in a major referral hospital in Ethiopia participated in this study. We assessed criterion validity and performance characteristics against an independent, blinded, and psychiatrist administered semi-structured Schedules for Clinical Assessment in Neuropsychiatry (SCAN) interview. Overall, the PHQ-9 items showed good internal (Cronbach's alpha=0.81) and test re-test reliability (intraclass correlation coefficient=0.92). A factor analysis confirmed a one-factor structure. Receiver Operating Characteristics (ROC) analysis showed that a PHQ-9 threshold score of 10 offered optimal discriminatory power with respect to diagnosis of major depressive disorder via the clinical interview (sensitivity=86% and specificity=67%). The PHQ-9 appears to be a reliable and valid instrument that may be used to diagnose major depressive disorders among Ethiopian adults. (C) 2013 Elsevier Ireland Ltd. All rights reserved.	[Gelaye, Bizu; Williams, Michelle A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Gelaye, Bizu; Vander Stoep, Ann] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA; [Lemma, Seblewengel] Addis Continental Inst Publ Hlth, Addis Ababa, Ethiopia; [Deyessa, Negussie; Bahretibeb, Yonas; Shibre, Teshome; Wondimagegn, Dawit; Lemenhe, Asnake] Univ Addis Ababa, Fac Med, Addis Ababa, Ethiopia; [Fann, Jesse R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Fann, Jesse R.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Fann, Jesse R.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Zhou, Xiao-Hua Andrew] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA	Gelaye, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave,5th Floor, Boston, MA 02115 USA.	bgelaye@hsph.harvard.edu		Gelaye, Bizu/0000-0001-7934-548X	National Institutes of Health, National Institute of Minority Health and Health Disparities [T37-MD001449]; National Institute on Minority Health and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [T37MD001449] Funding Source: NIH RePORTER	This research was supported, in part, by an award from the National Institutes of Health, National Institute of Minority Health and Health Disparities (T37-MD001449). The authors wish to thank the staff of Addis Continental Institute of Public Health for their expert technical assistance. The authors would also like to thank Saint Paul Hospital for granting access to conduct the study. This research was done as partial fulfillment for the requirements of a PhD degree by one of the authors (B.G.) in the Department of Epidemiology, University of Washington, School of Public Health, Seattle, Washington, USA.	Aboraya A, 1998, W V Med J, V94, P326; Adewuya AO, 2006, J AFFECT DISORDERS, V96, P89, DOI 10.1016/j.jad.2006.05.021; Alem A, 2004, ETHIOPIAN MED J, V42, P137; Alem A, 2001, ETHIOPIAN MED J, V39, P153; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 2008, STEPS MAN; Araya R, 2003, LANCET, V361, P995, DOI 10.1016/S0140-6736(03)12825-5; Arroll B, 2010, ANN FAM MED, V8, P348, DOI 10.1370/afm.1139; BEGG CB, 1983, BIOMETRICS, V39, P207, DOI 10.2307/2530820; Belew M, 2000, ETHIOPIAN MED J, V38, P11; Bhugra D, 2006, ACTA PSYCHIAT SCAND, V113, P17, DOI 10.1111/j.1600-0447.2005.00712.x; Bhui K, 1997, BRIT J HOSP MED, V57, P492; Bolton P, 2003, JAMA-J AM MED ASSOC, V289, P3117, DOI 10.1001/jama.289.23.3117; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; Capps R., 2011, NEW STREAMS BLACK AF; Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F; Cheng ATA, 2001, BRIT J PSYCHIAT, V178, P567, DOI 10.1192/bjp.178.6.567; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P818, DOI 10.1016/j.apmr.2010.12.008; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Giel R, 1999, ACTA PSYCHIAT SCAND, V100, P2, DOI 10.1111/j.1600-0447.1999.tb10686.x; Huang FY, 2006, J GEN INTERN MED, V21, P547, DOI 10.1111/j.1525-1497.2006.00409.x; Hyphantis T, 2011, ARTHRIT CARE RES, V63, P1313, DOI 10.1002/acr.20505; KALIX P, 1987, BRIT J ADDICT, V82, P47; Kalpakjian CZ, 2009, J SPINAL CORD MED, V32, P147, DOI 10.1080/10790268.2009.11760766; Kessler RC, 2008, WHO WORLD MENTAL HLT; Kinder LS, 2004, PSYCHOSOM MED, V66, P316, DOI 10.1097/01.psy.0000124755.91880.f4; Krisanaprakornkit Thawatchai, 2006, Journal of the Medical Association of Thailand, V89, P205; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006; Linacre J. M., 2007, WINSTEPS MINISTEP RA; Liu SI, 2011, COMPR PSYCHIAT, V52, P96, DOI 10.1016/j.comppsych.2010.04.013; Lotrakul M, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-46; Lowe B, 2004, J AFFECT DISORDERS, V78, P131, DOI 10.1016/S0165-0327(02)00237-9; Manea L, 2012, CAN MED ASSOC J, V184, pE191, DOI 10.1503/cmaj.110829; Marx RG, 2003, J CLIN EPIDEMIOL, V56, P730, DOI 10.1016/S0895-4356(03)00084-2; Mastrogianni A, 2003, INT J SOC PSYCHIATR, V49, P163, DOI 10.1177/00207640030493001; Moller-Leimkuhler AM, 2010, WORLD J BIOL PSYCHIA, V11, P922, DOI 10.3109/15622975.2010.523481; Monahan PO, 2009, J GEN INTERN MED, V24, P189, DOI 10.1007/s11606-008-0846-z; Ngoma MC, 2003, BRIT J PSYCHIAT, V183, P349, DOI 10.1192/bjp.183.4.349; Okulate GT, 2004, BRIT J PSYCHIAT, V184, P422, DOI 10.1192/bjp.184.5.422; Omoro SAO, 2006, INT J PSYCHIAT MED, V36, P367, DOI 10.2190/8W7Y-0TPM-JVGV-QW6M; Patel V, 2008, PSYCHOL MED, V38, P221, DOI 10.1017/S0033291707002334; Patel V, 2003, LANCET, V361, P33, DOI 10.1016/S0140-6736(03)12119-8; Patel V, 2008, LANCET, V372, P1354, DOI 10.1016/S0140-6736(08)61556-1; Patel V, 2008, CURR OPIN PSYCHIATR, V21, P109, DOI 10.1097/YCO.0b013e3282f43c7f; Patel V, 2007, BRIT MED BULL, V81-82, P81, DOI 10.1093/bmb/ldm010; Patel V, 2010, JAMA-J AM MED ASSOC, V303, P1976, DOI 10.1001/jama.2010.616; Patel V, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000159; Pepe MS, 2003, STAT EVALUATION MED; RASHID E, 1996, ETHIOP J HEALTH DEV, V10, P69; Richardson LP, 2010, PEDIATRICS, V126, P1117, DOI 10.1542/peds.2010-0852; Saxena S, 2001, QUAL LIFE RES, V10, P711, DOI 10.1023/A:1013867826835; SIMON G, 1995, AM J PSYCHIAT, V152, P352; Smith AB, 2009, PSYCHO-ONCOLOGY, V18, P195, DOI 10.1002/pon.1423; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Spitzer RL, 2000, AM J OBSTET GYNECOL, V183, P759, DOI 10.1067/mob.2000.106580; Thompson B., 2004, EXPLORATORY CONFIRMA; van Steenbergen-Weijenburg KM, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-235; WHO, 2004, GLOB BURD DIS 2004 U; Wig NN, 2000, B WORLD HEALTH ORGAN, V78, P502; Williams RT, 2009, REHABIL PSYCHOL, V54, P198, DOI 10.1037/a0015529; WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589; World Bank T.W., 2012, WHO BANK ETH OV; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Yu XN, 2012, COMPR PSYCHIAT, V53, P95, DOI 10.1016/j.comppsych.2010.11.002; Zhou H., 2011, MATH STAT; Zhou X.-H., 2011, STAT METHODS DIAGNOS	69	155	157	0	34	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	DEC 15	2013	210	2					653	661		10.1016/j.psychres.2013.07.015			9	Psychiatry	Psychiatry	273EU	WOS:000328518600045	23972787	Green Accepted			2021-06-18	
J	Yue, JK; Vassar, MJ; Lingsma, HF; Cooper, SR; Okonkwo, DO; Valadka, AB; Gordon, WA; Maas, AIR; Mukherjee, P; Yuh, EL; Puccio, AM; Schnyer, DM; Manley, GT; Casey, SS; Cheong, M; Dams-O'Connor, K; Hricik, AJ; Knight, EE; Kulubya, ES; Menon, DK; Morabito, DJ; Pacheco, JL; Sinha, TK				Yue, John K.; Vassar, Mary J.; Lingsma, Hester F.; Cooper, Shelly R.; Okonkwo, David O.; Valadka, Alex B.; Gordon, Wayne A.; Maas, Andrew I. R.; Mukherjee, Pratik; Yuh, Esther L.; Puccio, Ava M.; Schnyer, David M.; Manley, Geoffrey T.; Casey, Scott S.; Cheong, Maxwell; Dams-O'Connor, Kristen; Hricik, Allison J.; Knight, Emily E.; Kulubya, Edwin S.; Menon, David K.; Morabito, Diane J.; Pacheco, Jennifer L.; Sinha, Tuhin K.		TRACK-TBI Investigators	Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot: Multicenter Implementation of the Common Data Elements for Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						CDEs; human studies; prospective study; TBI	DEFICIT HYPERACTIVITY DISORDER; GLASGOW OUTCOME SCALE; WORKING GROUP; HEAD-INJURY; RECOMMENDATIONS; MILD; DEMOGRAPHICS; BIOSPECIMENS; ADOLESCENTS; PROGNOSIS	Traumatic brain injury (TBI) is among the leading causes of death and disability worldwide, with enormous negative social and economic impacts. The heterogeneity of TBI combined with the lack of precise outcome measures have been central to the discouraging results from clinical trials. Current approaches to the characterization of disease severity and outcome have not changed in more than three decades. This prospective multicenter observational pilot study aimed to validate the feasibility of implementing the TBI Common Data Elements (TBI-CDEs). A total of 650 subjects who underwent computed tomography (CT) scans in the emergency department within 24h of injury were enrolled at three level I trauma centers and one rehabilitation center. The TBI-CDE components collected included: 1) demographic, social and clinical data; 2) biospecimens from blood drawn for genetic and proteomic biomarker analyses; 3) neuroimaging studies at 2 weeks using 3T magnetic resonance imaging (MRI); and 4) outcome assessments at 3 and 6 months. We describe how the infrastructure was established for building data repositories for clinical data, plasma biomarkers, genetics, neuroimaging, and multidimensional outcome measures to create a high quality and accessible information commons for TBI research. Risk factors for poor follow-up, TBI-CDE limitations, and implementation strategies are described. Having demonstrated the feasibility of implementing the TBI-CDEs through successful recruitment and multidimensional data collection, we aim to expand to additional study sites. Furthermore, interested researchers will be provided early access to the Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) data set for collaborative opportunities to more precisely characterize TBI and improve the design of future clinical treatment trials. (ClinicalTrials.gov Identifier NCT01565551.)	[Yue, John K.; Vassar, Mary J.; Cooper, Shelly R.; Mukherjee, Pratik; Yuh, Esther L.; Casey, Scott S.; Morabito, Diane J.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Yue, John K.; Vassar, Mary J.; Manley, Geoffrey T.; Casey, Scott S.; Morabito, Diane J.; Sinha, Tuhin K.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; [Cooper, Shelly R.; Mukherjee, Pratik; Yuh, Esther L.; Cheong, Maxwell] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94110 USA; [Lingsma, Hester F.] Erasmus MC Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [Okonkwo, David O.; Puccio, Ava M.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA; [Okonkwo, David O.; Puccio, Ava M.; Hricik, Allison J.] Univ Pittsburgh, Med Ctr, Neurotrauma Clin Trials Ctr, Pittsburgh, PA USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Gordon, Wayne A.; Dams-O'Connor, Kristen; Kulubya, Edwin S.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Schnyer, David M.; Knight, Emily E.; Pacheco, Jennifer L.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Cooper, Shelly/0000-0003-0026-6688; Schnyer, David/0000-0002-7472-2853; Mukherjee, Pratik/0000-0001-7473-7409	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS069409]; One Mind for Research; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409] Funding Source: NIH RePORTER	This study was supported by NIH/NINDS grants NS069409 (to Dr. Manley) and One Mind for Research. We acknowledge and appreciate the following contributors to the development of the TRACK-TBI database and repositories by organization and alphabetical order by last name.	Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; Berger RP, 2012, J NEUROTRAUM, V29, P672, DOI 10.1089/neu.2011.1861; Cancelliere C, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-17; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Groenman AP, 2013, ADDICTION, V108, P1503, DOI 10.1111/add.12188; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Kaloupek DG, 2010, ARCH PHYS MED REHAB, V91, P1684, DOI 10.1016/j.apmr.2010.06.032; Leow AD, 2006, NEUROIMAGE, V31, P627, DOI 10.1016/j.neuroimage.2005.12.013; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; Miller AC, 2012, J NEUROTRAUM, V29, P634, DOI 10.1089/neu.2011.1932; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Okonkwo DO, 2013, J NEUROTRAUMA; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shin H, 2010, AM COMMUNITY SURVEY; STALLINGS G, 1995, J CLIN EXP NEUROPSYC, V17, P706, DOI 10.1080/01688639508405160; Szalma S, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-68; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Topolovec-Vranic J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1059; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	38	155	155	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2013	30	22					1831	1844		10.1089/neu.2013.2970			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	243PH	WOS:000326328400001	23815563	Green Published			2021-06-18	
J	Rowson, S; Duma, SM				Rowson, Steven; Duma, Stefan M.			Development of the STAR Evaluation System for Football Helmets: Integrating Player Head Impact Exposure and Risk of Concussion	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; Mild traumatic brain injury; Acceleration; Risk; Exposure; HITS; Impact	CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL FOOTBALL; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; NEXT-GENERATION; BRAIN-INJURIES; DIVISION-I; COLLEGIATE; EPIDEMIOLOGY; ASSOCIATION	In contrast to the publicly available data on the safety of automobiles, consumers have no analytical mechanism to evaluate the protective performance of football helmets. The objective of this article is to fill this void by introducing a new equation that can be used to evaluate helmet performance by integrating player head impact exposure and risk of concussion. The Summation of Tests for the Analysis of Risk (STAR) equation relates on-field impact exposure to a series of 24 drop tests performed at four impact locations and six impact energy levels. Using 62,974 head acceleration data points collected from football players, the number of impacts experienced for one full season was translated to 24 drop test configurations. A new injury risk function was developed from 32 measured concussions and associated exposure data to assess risk of concussion for each impact. Finally, the data from all 24 drop tests is combined into one number using the STAR formula that incorporates the predicted exposure and injury risk for one player for one full season of practices and games. The new STAR evaluation equation will provide consumers with a meaningful metric to assess the relative performance of football helmets.	[Rowson, Steven; Duma, Stefan M.] Wake Forest Univ, Sch Biomed Engn & Sci, Virginia Tech, Blacksburg, VA 24061 USA	Rowson, S (corresponding author), Wake Forest Univ, Sch Biomed Engn & Sci, Virginia Tech, 440 ICTAS Bldg,Stanger St, Blacksburg, VA 24061 USA.	srowson@vt.edu	Duma, Stefan/A-8368-2012; Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596	National Highway Traffic Safety Administration; National Institutes of Health (National Institute for Child Health and Human Development)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER	The authors gratefully acknowledge our sponsors for this research, including the National Highway Traffic Safety Administration and National Institutes of Health (National Institute for Child Health and Human Development) (Contract No. R01HD048638).	Booher MA, 2003, CLIN J SPORT MED, V13, P93, DOI 10.1097/00042752-200303000-00005; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2011, CURR SPORT MED REP, V10, P7, DOI 10.1249/JSR.0b013e318205e063; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dick R, 2007, J ATHL TRAINING, V42, P221; Domenico L. D, 2003, SAE TECHNICAL PAPER, VSAE 2003-01-1362; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Duma SM, 2009, IEEE ENG MED BIO, P1123, DOI 10.1109/IEMBS.2009.5333423; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Gadd CW, 1966, P 10 STAPP CAR CRASH; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Gwin JT, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000249; Hackney J.R, 1995, SAE TECHNICAL PAPER; Hanlon E, 2010, J APPL BIOMECH, V26, P424, DOI 10.1123/jab.26.4.424; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Kent RW, 2004, SAE TECHNICAL PAPER; King A.I., 2003, P INT RES C BIOM IMP; Laituri TR, 2010, TRAFFIC INJ PREV, V11, P371, DOI 10.1080/15389581003739685; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; *NOCSAE, 2009, ND00108M10 NOCSAE; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; PELLMAN EJ, 2003, NEUROSURGERY, V53, P814; Rowson S, 2008, CLIN J SPORT MED, V18, P316, DOI 10.1097/JSM.0b013e31817f016a; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2010, CLIN J SPORT MED, V20, P344, DOI 10.1097/JSM.0b013e3181ed7e50; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shain KS, 2010, CLIN J SPORT MED, V20, P422, DOI 10.1097/JSM.0b013e3181f7db25; Takhounts EG, 2008, STAPP CAR C, V52, P1; Williamson I. J., 2006, BRIT J SPORT MED, V40, P132; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	49	155	156	0	31	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	AUG	2011	39	8					2130	2140		10.1007/s10439-011-0322-5			11	Engineering, Biomedical	Engineering	785YK	WOS:000292268900003	21553135				2021-06-18	
J	Salazar, DL; Uchida, N; Hamers, FPT; Cummings, BJ; Anderson, AJ				Salazar, Desiree L.; Uchida, Nobuko; Hamers, Frank P. T.; Cummings, Brian J.; Anderson, Aileen J.			Human Neural Stem Cells Differentiate and Promote Locomotor Recovery in an Early Chronic Spinal coRd Injury NOD-scid Mouse Model	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; OLFACTORY ENSHEATHING CELLS; RESTRICTED PRECURSOR CELLS; TRAUMATIC BRAIN-INJURY; DELAYED TRANSPLANTATION; STEM/PROGENITOR CELLS; AXONAL REGENERATION; FUNCTIONAL RECOVERY; WHITE-MATTER; IN-VITRO	Background: Traumatic spinal cord injury (SCI) results in partial or complete paralysis and is characterized by a loss of neurons and oligodendrocytes, axonal injury, and demyelination/dysmyelination of spared axons. Approximately 1,250,000 individuals have chronic SCI in the U. S.; therefore treatment in the chronic stages is highly clinically relevant. Human neural stem cells (hCNS-SCns) were prospectively isolated based on fluorescence-activated cell sorting for a CD133(+) and CD24(-/lo) population from fetal brain, grown as neurospheres, and lineage restricted to generate neurons, oligodendrocytes and astrocytes. hCNS-SCns have recently been transplanted sub-acutely following spinal cord injury and found to promote improved locomotor recovery. We tested the ability of hCNS-SCns transplanted 30 days post SCI to survive, differentiate, migrate, and promote improved locomotor recovery. Methods and Findings: hCNS-SCns were transplanted into immunodeficient NOD-scid mice 30 days post spinal cord contusion injury. hCNS-SCns transplanted mice demonstrated significantly improved locomotor recovery compared to vehicle controls using open field locomotor testing and CatWalk gait analysis. Transplanted hCNS-SCns exhibited long-term engraftment, migration, limited proliferation, and differentiation predominantly to oligodendrocytes and neurons. Astrocytic differentiation was rare and mice did not exhibit mechanical allodynia. Furthermore, differentiated hCNS-SCns integrated with the host as demonstrated by co-localization of human cytoplasm with discrete staining for the paranodal marker contactin-associated protein. Conclusions: The results suggest that hCNS-SCns are capable of surviving, differentiating, and promoting improved locomotor recovery when transplanted into an early chronic injury microenvironment. These data suggest that hCNS-SCns transplantation has efficacy in an early chronic SCI setting and thus expands the "window of opportunity" for intervention.	[Salazar, Desiree L.; Anderson, Aileen J.] Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA; [Salazar, Desiree L.; Cummings, Brian J.; Anderson, Aileen J.] Univ Calif Irvine, Sue & Bill Gross Stem Cell Res Ctr, Irvine, CA USA; [Salazar, Desiree L.; Cummings, Brian J.; Anderson, Aileen J.] Univ Calif Irvine, Reeve Irvine Res Ctr, Irvine, CA USA; [Uchida, Nobuko] StemCells Inc, Palo Alto, CA USA; [Hamers, Frank P. T.] Rehabil Hosp Tolbrug, sHertogenbosch, Netherlands; [Cummings, Brian J.; Anderson, Aileen J.] Univ Calif Irvine, Dept Phys Med & Rehabil, Irvine, CA USA	Salazar, DL (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.	aja@uci.edu	Anderson, Aileen J/H-5926-2012; Cummings, Brian J/C-9180-2012	Cummings, Brian J/0000-0003-3628-5290; Salazar, Desiree L./0000-0003-2912-6611	National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R43 NS046975, R01 NS049885]; CRF [AAC-2005]; CIRMCalifornia Institute for Regenerative Medicine [T1-00008]; NSFNational Science Foundation (NSF) [HRD0450366]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R43NS046975, R01NS049885] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) R43 NS046975, NIH/NINDS R01 NS049885, and CRF AAC-2005 to A.J. Anderson. D.L. Salazar was supported by CIRM stem cell training grant T1-00008 and UC AGEP fellowship NSF HRD0450366. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bambakidis Nicholas C, 2004, Spine J, V4, P16, DOI 10.1016/j.spinee.2003.07.004; Barakat DJ, 2005, CELL TRANSPLANT, V14, P225, DOI 10.3727/000000005783983106; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Blakemore WF, 2000, BRAIN, V123, P1543, DOI 10.1093/brain/123.8.1543; BLIGHT AR, 1989, BRAIN RES BULL, V22, P47, DOI 10.1016/0361-9230(89)90126-3; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Cao QL, 2002, EXP NEUROL, V177, P349, DOI 10.1006/exnr.2002.7981; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chow SY, 2000, BRAIN RES, V874, P87, DOI 10.1016/S0006-8993(00)02443-4; Coumans JV, 2001, J NEUROSCI, V21, P9334, DOI 10.1523/JNEUROSCI.21-23-09334.2001; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; Cummings BJ, 2006, NEUROL RES, V28, P474, DOI 10.1179/016164106X115116; Davies SJA, 1997, NATURE, V390, P680; Engesser-Cesar C, 2005, J NEUROTRAUM, V22, P157, DOI 10.1089/neu.2005.22.157; Engesser-Cesar C, 2007, EUR J NEUROSCI, V25, P1931, DOI 10.1111/j.1460-9568.2007.05469.x; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Fawcett JW, 2006, J NEUROTRAUM, V23, P371, DOI 10.1089/neu.2006.23.371; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fitch MT, 1999, J NEUROSCI, V19, P8182; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Fraidakis MJ, 2004, EXP NEUROL, V188, P33, DOI 10.1016/j.expneurol.2004.01.032; Galvan MD, 2008, J NEUROSCI, V28, P13876, DOI 10.1523/JNEUROSCI.2823-08.2008; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Greiner DL, 1998, STEM CELLS, V16, P166, DOI 10.1002/stem.160166; Guest JD, 2005, EXP NEUROL, V192, P384, DOI 10.1016/j.expneurol.2004.11.033; Hamers FPT, 2001, J NEUROTRAUM, V18, P187, DOI 10.1089/08977150150502613; Heine W, 2004, EXP NEUROL, V189, P231, DOI 10.1016/j.expneurol.2004.06.014; Hill CE, 2004, EXP NEUROL, V190, P289, DOI 10.1016/j.expneurol.2004.05.043; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Hooshmand MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005871; Houle JD, 2003, EXP NEUROL, V182, P247, DOI 10.1016/S0014-4886(03)00029-3; Ishii K, 2006, J NEUROSCI RES, V84, P1669, DOI 10.1002/jnr.21079; Jakovcevski I, 2005, J NEUROSCI, V25, P10064, DOI 10.1523/JNEUROSCI.2324-05.2005; Kakulas B A, 1999, J Spinal Cord Med, V22, P119; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Karimi-Abdolrezaee S, 2004, EUR J NEUROSCI, V19, P577, DOI 10.1111/j.0953-816X.2004.03164.x; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; Keyvan-Fouladi N, 2003, J NEUROSCI, V23, P9428; Lasiene J, 2008, J NEUROSCI, V28, P3887, DOI 10.1523/JNEUROSCI.4756-07.2008; Liu Y, 1999, J NEUROSCI, V19, P4370; Liu Y, 2002, EXP NEUROL, V178, P150, DOI 10.1006/exnr.2002.7977; Llado J, 2004, MOL CELL NEUROSCI, V27, P322, DOI 10.1016/j.mcn.2004.07.010; Lu J, 2002, BRAIN, V125, P14, DOI 10.1093/brain/awf014; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Luchetti S, 2010, J NEUROTRAUM, V27, P411, DOI 10.1089/neu.2009.0930; Macias MY, 2006, EXP NEUROL, V201, P335, DOI 10.1016/j.expneurol.2006.04.035; Marsala M, 2004, EUR J NEUROSCI, V20, P2401, DOI 10.1111/j.1460-9568.2004.03702.x; Miura K, 2009, NAT BIOTECHNOL, V27, P743, DOI 10.1038/nbt.1554; Mothe AJ, 2008, CELL TRANSPLANT, V17, P735, DOI 10.3727/096368908786516756; Nishi RA, 2007, J NEUROTRAUM, V24, P674, DOI 10.1089/neu.2006.0204; Norenberg MD, 2004, J NEUROTRAUM, V21, P429, DOI 10.1089/089771504323004575; Ogawa D, 2009, J NEUROSCI RES, V87, P307, DOI 10.1002/jnr.21843; Okano H, 2003, SEMIN CELL DEV BIOL, V14, P191, DOI 10.1016/S1084-9521(03)00011-9; Okano H, 2007, NEUROCHEM INT, V51, P68, DOI 10.1016/j.neuint.2007.04.013; Pallini R, 2005, NEUROSURGERY, V57, P1014, DOI 10.1227/01.NEU.0000180058.58372.4c; Parr AM, 2007, J NEUROTRAUM, V24, P835, DOI 10.1089/neu.2006.3771; Piao JH, 2006, J NEUROSCI RES, V84, P471, DOI 10.1002/jnr.20955; Plant GW, 2003, J NEUROTRAUM, V20, P1, DOI 10.1089/08977150360517146; Poliak S, 2003, NAT REV NEUROSCI, V4, P968, DOI 10.1038/nrn1253; PROCHAZKA M, 1992, DIABETES, V41, P98, DOI 10.2337/diabetes.41.1.98; Salazar DL, 2008, DEV DEGENERATION REG, P297; SERREZE DV, 1995, DIABETES, V44, P1392, DOI 10.2337/diabetes.44.12.1392; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shi RY, 1997, EXP NEUROL, V148, P495, DOI 10.1006/exnr.1997.6706; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith PM, 2006, BRAIN PATHOL, V16, P99, DOI 10.1111/j.1750-3639.2006.00001.x; Su HX, 2007, EXP NEUROL, V206, P296, DOI 10.1016/j.expneurol.2007.05.018; Tan AM, 2007, EXP NEUROL, V206, P257, DOI 10.1016/j.expneurol.2007.05.013; Tarasenko YI, 2007, J NEUROSCI RES, V85, P47, DOI 10.1002/jnr.21098; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Tobias CA, 2003, EXP NEUROL, V184, P97, DOI 10.1016/S0014-4886(03)00394-7; Tripathi R, 2007, GLIA, V55, P698, DOI 10.1002/glia.20491; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Vroemen M, 2003, EUR J NEUROSCI, V18, P743, DOI 10.1046/j.1460-9568.2003.02804.x; Wu P, 2002, GENE THER, V9, P245, DOI 10.1038/sj.gt.3301646; Yan J, 2007, PLOS MED, V4, P318, DOI 10.1371/journal.pmed.0040039; Zurita M, 2001, SURG NEUROL, V55, P249, DOI 10.1016/S0090-3019(01)00442-6	80	155	162	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2010	5	8							e12272	10.1371/journal.pone.0012272			15	Multidisciplinary Sciences	Science & Technology - Other Topics	639XY	WOS:000281011600030	20806064	DOAJ Gold, Green Published			2021-06-18	
J	Schafer, DP; Jha, S; Liu, FD; Akella, T; McCullough, LD; Rasband, MN				Schafer, Dorothy P.; Jha, Smita; Liu, Fudong; Akella, Trupti; McCullough, Louise D.; Rasband, Matthew N.			Disruption of the Axon Initial Segment Cytoskeleton Is a New Mechanism for Neuronal Injury	JOURNAL OF NEUROSCIENCE			English	Article							BETA-IV-SPECTRIN; ACTION-POTENTIAL INITIATION; FOCAL CEREBRAL-ISCHEMIA; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; ANKYRIN-G; CALPAIN INHIBITORS; HIPPOCAMPAL-NEURONS; SUPERNUMERARY AXONS; PYRAMIDAL NEURONS	Many factors contribute to nervous system dysfunction and failure to regenerate after injury or disease. Here, we describe a previously unrecognized mechanism for nervous system injury. We show that neuronal injury causes rapid, irreversible, and preferential proteolysis of the axon initial segment (AIS) cytoskeleton independently of cell death or axon degeneration, leading to loss of both ion channel clusters and neuronal polarity. Furthermore, we show this is caused by proteolysis of the AIS cytoskeletal proteins ankyrinG and beta IV spectrin by the calcium-dependent cysteine protease calpain. Importantly, calpain inhibition is sufficient to preserve the molecular organization of the AIS both in vitro and in vivo. We conclude that loss of AIS ion channel clusters and neuronal polarity are important contributors to neuronal dysfunction after injury, and that strategies to facilitate recovery must preserve or repair the AIS cytoskeleton.	[Jha, Smita; Rasband, Matthew N.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [Schafer, Dorothy P.; Liu, Fudong; Akella, Trupti; McCullough, Louise D.; Rasband, Matthew N.] Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06032 USA	Rasband, MN (corresponding author), Baylor Coll Med, Dept Neurosci, 1 Baylor Plaza, Houston, TX 77030 USA.	Rasband@bcm.edu	McCullough, Louise/R-2824-2019	Rasband, Matthew/0000-0001-8184-2477	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS044916, NS050505, NS055215, 5T32NS041224]; Department of DefenseUnited States Department of Defense [W81XWH-08-2-0145]; Dr. Miriam and Sheldon Adelson Medical Research Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS044916, T32NS041224, R01NS050505, R01NS055215, R37NS044916] Funding Source: NIH RePORTER	This research was supported by grants from the National Institutes of Health [NS044916 (M.N.R.), NS050505 (L. D. M.), and NS055215 (L. D. M.)], the Department of Defense [W81XWH-08-2-0145 (M.N.R.)], the Dr. Miriam and Sheldon Adelson Medical Research Foundation, and Mission Connect. D. P. S. was supported in part by National Institutes of Health Training Grant 5T32NS041224. M.N.R. is a Harry Weaver Neuroscience Scholar of the National Multiple Sclerosis Society. We thank Dr. Sandra Hewett for helpful discussions and the use of her anaerobic chamber. We thank Drs. Michael Stankewich, Stephen Crocker, Elior Peles, and Peter Saggau for helpful discussions. We thank Drs. Yang Yang and Larry Benowitz for providing retinas from animals with optic nerve crush.	Alarcon M, 2008, AM J HUM GENET, V82, P150, DOI 10.1016/j.ajhg.2007.09.005; Ango F, 2004, CELL, V119, P257, DOI 10.1016/j.cell.2004.10.004; Ardelt AA, 2005, STROKE, V36, P337, DOI 10.1161/01.STR.0000153795.38388.72; Benn SC, 2004, NAT REV NEUROSCI, V5, P686, DOI 10.1038/nrn1477; Berghs S, 2000, J CELL BIOL, V151, P985, DOI 10.1083/jcb.151.5.985; Bevers MB, 2008, J CEREBR BLOOD F MET, V28, P655, DOI 10.1038/sj.jcbfm.9600595; Bjartmar C, 2001, CURR OPIN NEUROL, V14, P271, DOI 10.1097/00019052-200106000-00003; Buddle M, 2003, BRAIN RES, V978, P38, DOI 10.1016/S0006-8993(03)02758-6; Burkarth N, 2007, MOL CELL NEUROSCI, V36, P59, DOI 10.1016/j.mcn.2007.06.001; Cuerrier D, 2007, J BIOL CHEM, V282, P9600, DOI 10.1074/jbc.M610372200; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; Davoli MA, 2002, NEUROSCIENCE, V115, P125, DOI 10.1016/S0306-4522(02)00376-7; Donkor IO, 2000, CURR MED CHEM, V7, P1171, DOI 10.2174/0929867003374129; Duckworth EAM, 2005, BRAIN RES, V1042, P29, DOI 10.1016/j.brainres.2005.02.021; Dzhashiashvili Y, 2007, J CELL BIOL, V177, P857, DOI 10.1083/jcb.200612012; Ferreira MAR, 2008, NAT GENET, V40, P1056, DOI 10.1038/ng.209; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Garrido JJ, 2003, SCIENCE, V300, P2091, DOI 10.1126/science.1085167; Gerriets T, 2003, STROKE, V34, P2234, DOI 10.1161/01.STR.0000087171.34637.A9; Goldberg EM, 2008, NEURON, V58, P387, DOI 10.1016/j.neuron.2008.03.003; Gomis-Ruth S, 2008, CURR BIOL, V18, P992, DOI 10.1016/j.cub.2008.06.026; Guyton MK, 2005, J NEUROSCI RES, V81, P53, DOI 10.1002/jnr.20470; Harada K, 1997, J NEUROCHEM, V69, P371; Hassen GW, 2006, J NEUROIMMUNOL, V180, P135, DOI 10.1016/j.jneuroim.2006.08.005; HAVTON L, 1987, NATURE, V325, P711, DOI 10.1038/325711a0; Hedstrom KL, 2007, J CELL BIOL, V178, P875, DOI 10.1083/jcb.200705119; Hedstrom KL, 2008, J CELL BIOL, V183, P635, DOI 10.1083/jcb.200806112; Hoang TX, 2005, NEUROSCIENCE, V136, P417, DOI 10.1016/j.neuroscience.2005.08.022; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; Khaliq ZM, 2006, J NEUROSCI, V26, P1935, DOI 10.1523/JNEUROSCI.4664-05.2006; Kole MHP, 2008, NAT NEUROSCI, V11, P178, DOI 10.1038/nn2040; Komada M, 2002, J CELL BIOL, V156, P337, DOI 10.1083/jcb.200110003; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Lacas-Gervais S, 2004, J CELL BIOL, V166, P983, DOI 10.1083/jcb.200408007; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; McCullough LD, 2005, J BIOL CHEM, V280, P20493, DOI 10.1074/jbc.M409985200; Meeks JP, 2007, J NEUROPHYSIOL, V97, P3460, DOI 10.1152/jn.01288.2006; Neffe AT, 2005, CURR OPIN DRUG DISC, V8, P684; Ogawa Y, 2008, CURR OPIN NEUROBIOL, V18, P307, DOI 10.1016/j.conb.2008.08.008; Ogawa Y, 2006, J NEUROSCI, V26, P5230, DOI 10.1523/JNEUROSCI.0425-06.2006; Palmer LM, 2006, J NEUROSCI, V26, P1854, DOI 10.1523/JNEUROSCI.4812-05.2006; Pan ZM, 2006, J NEUROSCI, V26, P2599, DOI 10.1523/JNEUROSCI.4314-05.2006; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Schafer DP, 2004, J NEUROSCI, V24, P3176, DOI 10.1523/JNEUROSCI.5427-03.2004; Schwartz G, 2001, J NEUROSURG, V94, P245, DOI 10.3171/spi.2001.94.2.0245; Sedarous M, 2003, J BIOL CHEM, V278, P26031, DOI 10.1074/jbc.M302833200; Shah MM, 2008, P NATL ACAD SCI USA, V105, P7869, DOI 10.1073/pnas.0802805105; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Song AH, 2009, CELL, V136, P1148, DOI 10.1016/j.cell.2009.01.016; Susuki K, 2008, EXP BIOL MED, V233, P394, DOI 10.3181/0709-MR-243; Szabadics J, 2006, SCIENCE, V311, P233, DOI 10.1126/science.1121325; Tureyen K, 2004, J NEUROSCI METH, V139, P203, DOI 10.1016/j.jneumeth.2004.04.029; Uemoto Y, 2007, J BIOL CHEM, V282, P6548, DOI 10.1074/jbc.M609223200; Uliasz TF, 2000, J NEUROSCI METH, V100, P157, DOI 10.1016/S0165-0270(00)00248-X; Wang K K, 1997, Adv Pharmacol, V37, P117; WHITE M, 2000, FAMILY THERAPY FIELD, V1, P33; Winckler B, 1999, NATURE, V397, P698, DOI 10.1038/17806; Yang Y, 2004, J NEUROSCI, V24, P7230, DOI 10.1523/JNEUROSCI.2125-04.2004; Yang Y, 2007, J CELL BIOL, V176, P509, DOI 10.1083/jcb.200610128; Yiu G, 2003, CURR OPIN NEUROBIOL, V13, P545, DOI 10.1016/j.conb.2003.09.006; Yoshida K, 1997, J BIOCHEM-TOKYO, V122, P279; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	65	155	156	0	6	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	OCT 21	2009	29	42					13242	13254		10.1523/JNEUROSCI.3376-09.2009			13	Neurosciences	Neurosciences & Neurology	509GI	WOS:000271002600018	19846712	Green Accepted, Green Published, Bronze			2021-06-18	
J	Beer, R; Lackner, P; Pfausler, B; Schmutzhard, E				Beer, R.; Lackner, P.; Pfausler, B.; Schmutzhard, E.			Nosocomial ventriculitis and meningitis in neurocritical care patients	JOURNAL OF NEUROLOGY			English	Article; Proceedings Paper	16th Annual Meeting of the European-Neurological-Society	MAY 27-31, 2006	Lausanne, SWITZERLAND	European Neurol Soc		central nervous system infection; external ventricular drainage; meningitis; neurological critical care; ventriculitis	VENTRICULOSTOMY-RELATED INFECTIONS; CATHETER-RELATED INFECTIONS; NERVOUS-SYSTEM INFECTION; CEREBROSPINAL-FLUID; RISK-FACTORS; BACTERIAL-MENINGITIS; NEUROSURGICAL PATIENTS; SILVER NANOPARTICLES; SERUM PROCALCITONIN; DRAIN CATHETERS	External ventricular drainage (EVD) is frequently necessary in neurological and neurosurgical intensive care patients. A major complication of this procedure is an EVD-related venticulitis or meningitis. The purpose of this review is (1) to address the magnitude of the problem in the neurocritical care patient population, (2) to discuss the difficulties in providing an appropriate and timely diagnosis of this disease entity and (3) to propose an algorithm for both rapid diagnosis and appropriate therapy. A MEDLINE literature search was carried out for studies from January 1990 through March 2008 reporting on ventriculostomy, EVD-related central nervous system infections, in particular ventriculitis and meningitis. EVD-related ventriculitis is a serious nosocomial complication in the neurocritical care setting where EVD catheters are frequently used for the management of elevated ICP secondary to acute hydrocephalus primarily caused by subarachnoid and intraventricular hemorrhage or traumatic brain injury. Infection rate is high with reported incidences in the range of 5 % up to more than 20 %. Predisposing factors for infection are non-adherence to rigid insertion and maintenance protocols, leakage of cerebrospinal fluid (CSF), catheter irrigation and the frequency of EVD manipulation. Diagnosis is frequently impaired either by the presence of systemic inflammation due to the primary disease or because the hemorrhagic CSF itself may cause an inflammatory reaction. Furthermore, the most common pathogens involved in EVD-related infections, i. e., staphylococci, initially provoke only a mild inflammatory response in the CSF and therefore patients rarely present with clear-cut clinical signs indicating severe central nervous system infection, in particular, ventriculitis. Nosocomial EVD-related ventriculitis is a significant cause of morbidity and mortality in critically ill neurological patients. Rapid diagnosis and prompt initiation of appropriate antimicrobial therapy is needed. A stepwise algorithm for the management of EVD-related ventriculitis is proposed.	[Beer, R.; Lackner, P.; Pfausler, B.; Schmutzhard, E.] Innsbruck Med Univ, Dept Neurol, Neurol Crit Care Unit, A-6020 Innsbruck, Austria	Schmutzhard, E (corresponding author), Innsbruck Med Univ, Dept Neurol, Neurol Crit Care Unit, Anichstr 35, A-6020 Innsbruck, Austria.	erich.schmutzhard@i-med.ac.at					Arabi Y, 2005, AM J INFECT CONTROL, V33, P137, DOI 10.1016/j.ajic.2004.11.008; AUCOIN PJ, 1986, AM J MED, V80, P369, DOI 10.1016/0002-9343(86)90708-4; Beer R, 2007, ANTIMICROB AGENTS CH, V51, P379, DOI 10.1128/AAC.00515-06; Berger C, 2002, CRIT CARE MED, V30, P1778, DOI 10.1097/00003246-200208000-00017; BOGDAHN U, 1992, NEUROSURGERY, V31, P898, DOI 10.1227/00006123-199211000-00011; Dettenkofer M, 2001, J NEUROL, V248, P959, DOI 10.1007/s004150170048; Elvy J, 2008, J ANTIMICROB CHEMOTH, V61, P461, DOI 10.1093/jac/dkm501; Frontera JA, 2008, NEUROSURGERY, V62, P80, DOI 10.1227/01.NEU.0000311064.18368.EA; Furno F, 2004, J ANTIMICROB CHEMOTH, V54, P1019, DOI 10.1093/jac/dkh478; Hanna H, 2004, INFECT CONT HOSP EP, V25, P646, DOI 10.1086/502455; Hoefnagel D, 2008, ACTA NEUROCHIR, V150, P209, DOI 10.1007/s00701-007-1458-9; Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419; Houck PM, 2004, ARCH INTERN MED, V164, P637, DOI 10.1001/archinte.164.6.637; Ibrahim EH, 2000, CHEST, V118, P146, DOI 10.1378/chest.118.1.146; Iregui M, 2002, CHEST, V122, P262, DOI 10.1378/chest.122.1.262; Korinek AM, 2005, ACTA NEUROCHIR, V147, P39, DOI 10.1007/s00701-004-0416-z; Lackner P, 2008, NEUROCRIT CARE, V8, P360, DOI 10.1007/s12028-008-9071-1; Linden P, 2007, DRUG SAFETY, V30, P657, DOI 10.2165/00002018-200730080-00002; Lo CH, 2007, J NEUROSURG, V106, P378, DOI 10.3171/jns.2007.106.3.378; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; Lu CH, 2002, CLIN NEUROL NEUROSUR, V104, P352, DOI 10.1016/S0303-8467(02)00052-5; Lyke KE, 2001, CLIN INFECT DIS, V33, P2028, DOI 10.1086/324492; Malacarne P, 2007, J CHEMOTHERAPY, V19, P90, DOI 10.1179/joc.2007.19.1.90; Martinez R, 2002, INTENS CARE MED, V28, P208, DOI 10.1007/s00134-001-1176-3; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; Mermel LA, 2001, INFECT CONT HOSP EP, V22, P222, DOI 10.1086/501893; Muttaiyah S, 2008, J MED MICROBIOL, V57, P207, DOI 10.1099/jmm.0.47518-0; Myrianthefs P, 2006, ANTIMICROB AGENTS CH, V50, P3971, DOI 10.1128/AAC.00051-06; Ntziora F, 2007, ANN PHARMACOTHER, V41, P296, DOI 10.1345/aph.1H307; Nucci M, 1998, INFECT CONT HOSP EP, V19, P846, DOI 10.1086/647743; Pfausler B, 2004, J ANTIMICROB CHEMOTH, V53, P848, DOI 10.1093/jac/dkh158; Pfausler B, 2004, ACTA NEUROCHIR, V146, P477, DOI 10.1007/s00701-004-0258-8; Pfausler B, 2003, J NEUROSURG, V98, P1040, DOI 10.3171/jns.2003.98.5.1040; Pfisterer W, 2003, J NEUROL NEUROSUR PS, V74, P929, DOI 10.1136/jnnp.74.7.929; PRESTON SL, 1993, ANN PHARMACOTHER, V27, P870, DOI 10.1177/106002809302700709; Raad I, 2007, LANCET INFECT DIS, V7, P645, DOI 10.1016/S1473-3099(07)70235-9; Schade RP, 2006, J NEUROSURG, V104, P101, DOI 10.3171/jns.2006.104.1.101; Schade RP, 2005, J NEUROSURG, V102, P229, DOI 10.3171/jns.2005.102.2.0229; Schultz M, 1993, J Neurosci Nurs, V25, P158; WONG VK, 1991, PEDIATR INFECT DIS J, V10, P122, DOI 10.1097/00006454-199102000-00009; WYLER AR, 1972, J NEUROSURG, V37, P185, DOI 10.3171/jns.1972.37.2.0185; Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725; Ziai WC, 2006, CRIT CARE CLIN, V22, P661, DOI 10.1016/j.ccc.2006.11.009	43	155	165	2	13	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	NOV	2008	255	11					1617	1624		10.1007/s00415-008-0059-8			8	Clinical Neurology	Neurosciences & Neurology	397GR	WOS:000262651400001	19156484				2021-06-18	
J	Neumann, J; Sauerzweig, S; Roenicke, R; Gunzer, F; Dinkel, K; Ullrich, O; Gunzer, M; Reymann, KG				Neumann, Jens; Sauerzweig, Steven; Roenicke, Raik; Gunzer, Frank; Dinkel, Klaus; Ullrich, Oliver; Gunzer, Matthias; Reymann, Klaus G.			Microglia cells protect neurons by direct engulfment of invading neutrophil granulocytes: A new mechanism of CNS immune privilege	JOURNAL OF NEUROSCIENCE			English	Article						neuroinflammation; stroke; microglia; polymorphonuclear granulocytes; PMN; phagocytosis; time-lapse imaging	FOCAL CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; BRAIN-INJURY; MYELOPEROXIDASE ACTIVITY; LEUKOCYTE INFILTRATION; FUNCTIONAL DEFICITS; REPERFUSION INJURY; APOPTOTIC CELLS; T-CELLS; STROKE	Microglial cells maintain the immunological integrity of the healthy brain and can exert protection from traumatic injury. During ischemic tissue damage such as stroke, peripheral immune cells acutely infiltrate the brain and may exacerbate neurodegeneration. Whether and how microglia can protect from this insult is unknown. Polymorphonuclear neutrophils (PMNs) are a prominent immunologic infiltrate of ischemic lesions in vivo. Here, we show in organotypic brain slices that externally applied invading PMNs massively enhance ischemic neurotoxicity. This, however, is counteracted by additional application of microglia. Time-lapse imaging shows that microglia exert protection by rapid engulfment of apoptotic, but, strikingly, also viable, motile PMNs in cell culture and within brain slices. PMN engulfment is mediated by integrin- and lectin-based recognition. Interference with this process using RGDS peptides and N-acteyl-glucosamine blocks engulfment of PMNs and completely abrogates the neuroprotective function of microglia. Thus, engulfment of invading PMNs by microglia may represent an entirely new mechanism of CNS immune privilege.	[Neumann, Jens; Sauerzweig, Steven; Roenicke, Raik; Dinkel, Klaus; Reymann, Klaus G.] Leibniz Inst Neurobiol, Project Grp Neuropharmacol, D-39118 Magdeburg, Germany; [Ullrich, Oliver; Gunzer, Matthias] Otto Von Guericke Univ, Inst Immunol, D-39118 Magdeburg, Germany; [Gunzer, Frank] German Univ Cairo, Cairo 11771, Egypt; [Ullrich, Oliver] Univ Zurich, Fac Med, Inst Anat, CH-8057 Zurich, Switzerland; [Gunzer, Matthias] Helmholtz Ctr Infect Res, Jr Res Grp Immunodynam, D-38124 Braunschweig, Germany; [Reymann, Klaus G.] Inst Appl Neurosci, Inst Angew Neurowissensch FAN gGmbH, D-39120 Magdeburg, Germany	Neumann, J (corresponding author), Leibniz Inst Neurobiol, Project Grp Neuropharmacol, Brenneckestr 6, D-39118 Magdeburg, Germany.	jens.neumann@sciencetoday.de; matthias.gunzer@med.ovgu.de; reymann@fan-neuroscience.com	Reymann, Klaus G/J-8507-2013	Gunzer, Matthias/0000-0002-5534-6055			Arai H, 2004, J BIOL CHEM, V279, P51647, DOI 10.1074/jbc.M407328200; Arumugam TV, 2005, NEUROMOL MED, V7, P229, DOI 10.1385/NMM:7:3:229; Baldauf K, 2005, BRAIN RES, V1056, P158, DOI 10.1016/j.brainres.2005.07.035; BANATI RB, 1994, DEV NEUROSCI-BASEL, V16, P114, DOI 10.1159/000112098; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; Beray-Berthat V, 2003, BRAIN RES, V987, P32, DOI 10.1016/S0006-8993(03)03224-4; Beray-Berthat V, 2003, EXP NEUROL, V182, P446, DOI 10.1016/S0014-4886(03)00106-7; Chan A, 2006, J NEUROSCI RES, V84, P1217, DOI 10.1002/jnr.21029; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; del Zoppo GJ, 2001, ARCH NEUROL-CHICAGO, V58, P669, DOI 10.1001/archneur.58.4.669; Denes A, 2007, J CEREBR BLOOD F MET, V27, P1941, DOI 10.1038/sj.jcbfm.9600495; Dinkel K, 2004, P NATL ACAD SCI USA, V101, P331, DOI 10.1073/pnas.0303510101; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, J IMMUNOL, V161, P6250; Fassbender K, 2002, CEREBROVASC DIS, V13, P198, DOI 10.1159/000047776; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; FEUERSTEIN G, 1998, CEREBROVASCULAR DIS; Feuerstein GZ, 2001, ARCH NEUROL-CHICAGO, V58, P672, DOI 10.1001/archneur.58.4.672; Fordyce CB, 2005, J NEUROSCI, V25, P7139, DOI 10.1523/JNEUROSCI.1251-05.2005; GIULIAN D, 1993, J NEUROSCI, V13, P29; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; Harris AK, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-49; Hayashi Y, 2006, NEUROSCIENCE, V142, P87, DOI 10.1016/j.neuroscience.2006.06.003; Hayward NJ, 1996, EXP NEUROL, V139, P188, DOI 10.1006/exnr.1996.0093; HEINEL LA, 1994, BRAIN RES BULL, V34, P137, DOI 10.1016/0361-9230(94)90010-8; Huang Y, 2005, ACTA PHARMACOL SIN, V26, P952, DOI 10.1111/j.1745-7254.2005.00136.x; Jean WC, 1998, NEUROSURGERY, V43, P1382, DOI 10.1097/00006123-199812000-00076; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Kim WK, 1998, J NEUROSCI RES, V54, P17, DOI 10.1002/(SICI)1097-4547(19981001)54:1<17::AID-JNR3>3.0.CO;2-K; Kitamura Y, 2004, J PHARMACOL SCI, V94, P203, DOI 10.1254/jphs.94.203; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; Kohl A, 2003, EXP NEUROL, V181, P1, DOI 10.1016/S0014-4886(02)00049-3; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lehnardt S, 2007, J NEUROIMMUNOL, V190, P28, DOI 10.1016/j.jneuroim.2007.07.023; Lim MC, 2003, BRAIN RES BULL, V61, P183, DOI 10.1016/S0361-9230(03)00113-8; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; Meszaros AJ, 1999, J LEUKOCYTE BIOL, V65, P35; Miljkovic-Lolic M, 2003, BRAIN RES, V971, P90, DOI 10.1016/S0006-8993(03)02364-3; Minghetti L, 2004, NEUROCHEM RES, V29, P965, DOI 10.1023/B:NERE.0000021241.90133.89; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Mitrasinovic OM, 2005, J NEUROSCI, V25, P4442, DOI 10.1523/JNEUROSCI.0514-05.2005; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; Prestigiacomo CJ, 1999, STROKE, V30, P1110, DOI 10.1161/01.STR.30.5.1110; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Rogove AD, 1998, CURR BIOL, V8, P19, DOI 10.1016/S0960-9822(98)70016-8; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; Shaked I, 2005, J NEUROCHEM, V92, P997, DOI 10.1111/j.1471-4159.2004.02954.x; SHARKEY J, 1995, J NEUROSCI METH, V60, P125, DOI 10.1016/0165-0270(95)00003-D; Stolzing A, 2004, FASEB J, V18, P743, DOI 10.1096/fj.03-0374fje; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611; Tang LL, 2007, J INT MED RES, V35, P517, DOI 10.1177/147323000703500411; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Wang Q, 2006, BRAIN RES, V1090, P182, DOI 10.1016/j.brainres.2006.03.060; Weston RM, 2007, J CEREBR BLOOD F MET, V27, P100, DOI 10.1038/sj.jcbfm.9600324; Yanaka K, 1996, J CEREBR BLOOD F MET, V16, P1120, DOI 10.1097/00004647-199611000-00005; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496	66	155	162	0	10	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 4	2008	28	23					5965	5975		10.1523/JNEUROSCI.0060-08.2008			11	Neurosciences	Neurosciences & Neurology	308QF	WOS:000256404400011	18524901	Other Gold, Green Accepted, Green Published			2021-06-18	
J	Ewing-Cobbs, L; Prasad, MR; Kramer, L; Cox, CS; Baumgartner, J; Fletcher, S; Mendez, D; Barnes, M; Zhang, XL; Swank, P				Ewing-Cobbs, Linda; Prasad, Mary R.; Kramer, Larry; Cox, Charles S., Jr.; Baumgartner, James; Fletcher, Stephen; Mendez, Donna; Barnes, Marcia; Zhang, Xiaoling; Swank, Paul			Late intellectual and academic outcomes following traumatic brain injury sustained during early childhood	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; shaken baby syndrome; academic performance; cognitive outcome; pediatric neurosurgery	CLOSED-HEAD-INJURY; YOUNG-CHILDREN; PLASTICITY; INFANTS; SEQUELAE; BEHAVIOR; TERM; CONSEQUENCES; ACHIEVEMENT; PLACEMENT	Object. Although long-term neurological outcomes after traumatic brain injury (TBI) sustained early in life are generally unfavorable, the effect of TBI on the development of academic competencies is unknown. The present study characterizes intelligence quotient (IQ) and academic outcomes an average of 5.7 years after injury in children who sustained moderate to severe TBI prior to 6 years of age. Methods. Twenty-three children who suffered inflicted or noninflicted TBI between the ages of 4 and 71 months were enrolled in a prospective, longitudinal cohort study. Their mean age at injury was 21 months; their mean age at assessment was 89 months. The authors used general linear modeling approaches to compare IQ and standardized academic achievement test scores from the TBI group and a community comparison group (21 children). Children who sustained early TBI scored significantly lower than children in the comparison group on intelligence tests and in the reading, mathematical, and language domains of achievement tests. Forty-eight percent of the TBI group had IQs below the 10th percentile. During the approximately 5-year follow-up period, longitudinal IQ testing revealed continuing deficits and no recovery of function. Both IQ and academic achievement test scores were significantly related to the number of intracranial lesions and the lowest postresuscitation Glasgow Coma Scale score but not to age at the time of injury. Nearly 50 % of the TBI group failed a school grade and/or required placement in self-contained special education classrooms; the odds of unfavorable academic performance were 18 times higher for the TBI group than the comparison group. Conclusions. Traumatic brain injury sustained early in life has significant and persistent consequences for the development of intellectual and academic functions and deleterious effects on academic performance.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Radiol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Emergency Med, Houston, TX 77030 USA; Univ Guelph, Dept Psychol, Guelph, ON N1G 2W1, Canada	Ewing-Cobbs, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, 7400 Fannin,Suite 2401, Houston, TX 77030 USA.	linda.ewing-cobbs@uth.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029462, R01NS046308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS029462-09, R01-NS-29462-09, R01 NS046308, R01 NS029462] Funding Source: Medline		Abidin RR., 1995, PARENTING STRESS IND; Anderson SW, 1999, NAT NEUROSCI, V2, P1032; ANDERSON V, 1994, ARCH DIS CHILD, V70, P476, DOI 10.1136/adc.70.6.476; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; ARAM DM, 1988, NEUROPSYCHOLOGIA, V26, P903, DOI 10.1016/0028-3932(88)90058-9; ASHCRAFT MH, 1992, BRAIN COGNITION, V19, P208, DOI 10.1016/0278-2626(92)90046-O; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; BARRIOS D, 1999, CONSTR APPROX, V15, P1; Bates E, 1999, CHANGING NERVOUS SYSTEM, P214; Bayley N., 2006, BAYLEY SCALES INFANT; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; DUNST CJ, 1987, CHILD CARE HLTH DEV, V13, P111, DOI 10.1111/j.1365-2214.1987.tb00528.x; Eslinger PJ, 2000, DEV NEUROPSYCHOL, V18, P297, DOI 10.1207/S1532694203Eslinger; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Ewing-Cobbs L, 2003, DEV NEUROPSYCHOL, V24, P669, DOI 10.1207/S15326942DN242&3_08; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; Goldman PS, 1974, PLASTICITY RECOVERY; HUTTENLOCHER PR, 1990, NEUROPSYCHOLOGIA, V28, P517, DOI 10.1016/0028-3932(90)90031-I; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JENNETT B, 1975, LANCET, V1, P480; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kolb B, 2004, BRAIN COGNITION, V55, P104, DOI 10.1016/s0278-2626(03)00278-1; Kolb B, 2000, DEV NEUROPSYCHOL, V18, P423, DOI 10.1207/S1532694208Kolb; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Muszynski CA, 2005, J NEUROSURG, V102, P374, DOI 10.3171/ped.2005.102.4.0374; Pascual-Leone A, 2005, ANNU REV NEUROSCI, V28, P377, DOI 10.1146/annurev.neuro.27.070203.144216; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; RADCLIFFE J, 1994, INT J DEV NEUROSCI, V12, P327, DOI 10.1016/0736-5748(94)90081-7; ROVET JF, 1992, J PEDIATR PSYCHOL, V17, P187, DOI 10.1093/jpepsy/17.2.187; Stiles J, 2000, DEV NEUROPSYCHOL, V18, P237, DOI 10.1207/S15326942DN1802_5; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; TAYLOR HG, 1993, J CLIN CHILD PSYCHOL, V22, P196, DOI 10.1207/s15374424jccp2202_6; TEASDALE G, 1974, LANCET, V2, P81; Thomas B, 2005, BRAIN, V128, P2562, DOI 10.1093/brain/awh600; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Thorndike RL., 1986, STANFORD BINET INTEL, V4; Weiderholt JL., 2001, GRAY ORAL READING TE, V4th; Woodcock R.W., 2001, WOODCOCK JOHNSON 3 T; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	57	155	156	1	24	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2006	105	4		S			287	296		10.3171/ped.2006.105.4.287			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	093WO	WOS:000241201200010	17328279	Green Accepted			2021-06-18	
J	Hartl, R; Gerber, LM; Iacono, L; Ni, QH; Lyons, K; Ghajar, J				Hartl, Roger; Gerber, Linda M.; Iacono, Laura; Ni, Quanhong; Lyons, Kerry; Ghajar, Jamshid			Direct transport within an organized state trauma system reduces mortality in patients with severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						traumatic brain injury; transport; mortality; prehospital	SEVERE HEAD-INJURY; ENDOTRACHEAL INTUBATION; MAJOR TRAUMA; SURVIVAL; CHILDREN; HYPOXIA; CENTERS; DEATHS; IMPACT	Background. Prehospital management of traumatic brain injury (TBI) and trauma system development and organization are aspects of TBI care that have the potential to significantly impact patient outcome. This multi-center study was conducted to explore the effect of prehospital management decisions on early mortality after severe TBI. Methods: This report is based on 1449 patients with severe TBI (GCS < 9) treated at 22 trauma centers enrolled in a New York State quality improvement (QI) program between 2000 and 2004. The prehospital data collected on these patients include time of injury, time of arrival to the trauma center, mode of transport, type of EMS provider, direct or indirect transport, blood pressure and pulse oximetry values, GCS score, pupillary assessment, and airway management procedures. Results: After exclusion criteria were applied, a total of 1,123 patients were eligible for analysis. The majority of patients were male (75%) with a mean age of 36 years. After controlling for arterial hypotension, age, pupillary status, and initial GCS score, direct transport was found to result in significantly lower mortality than indirect transport. Transport mode, time to admission, and prehospital intubation were not found to be related to 2-week mortality. Conclusions: The present study provides class II evidence that demonstrates a 50% increase in mortality associated with indirect transfer of TBI patients. Patients with severe TBI should be transported directly to a Level I or Level II trauma center with capabilities as delineated in the Guidelines for the Prehospital Management of Traumatic Brain Injury, even if this center may not be the closest hospital.	Brain Trauma Fdn, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Neurol Surg, Ithaca, NY 14853 USA; Cornell Univ, Weill Med Coll, Dept Publ Hlth, Ithaca, NY 14853 USA	Hartl, R (corresponding author), Brain Trauma Fdn, 523 E 72nd St,8th Floor, New York, NY 10021 USA.	roger@hartlmd.net					Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Johnson DL, 1996, PEDIATR NEUROSURG, V25, P309, DOI 10.1159/000121145; KREIS DJ, 1986, J TRAUMA, V26, P649, DOI 10.1097/00005373-198607000-00010; McConnell KJ, 2005, HEALTH SERV RES, V40, P435, DOI 10.1111/j.1475-6773.2005.0u367.x; MENDELOFF JM, 1991, ANNU REV PUBL HEALTH, V12, P401; MITCHELL T, 2005, AANS; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Nathens AB, 2003, J TRAUMA, V55, P444, DOI 10.1097/01.TA.0000047809.64699.59; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Sampalis JS, 1997, J TRAUMA, V43, P288, DOI 10.1097/00005373-199708000-00014; WILSON DS, 1992, J TRAUMA, V32, P45, DOI 10.1097/00005373-199201000-00010; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592; Young JS, 1998, AM SURGEON, V64, P88; 2000, GUIDELINES PREHOSPIT	17	155	156	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2006	60	6					1250	1256		10.1097/01.ta.0000203717.57821.8d			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	053TR	WOS:000238328700023	16766968				2021-06-18	
J	Holland, MC; Mackersie, RC; Morabito, D; Campbell, AR; Kivett, VA; Patel, R; Erickson, VR; Pittet, JF				Holland, MC; Mackersie, RC; Morabito, D; Campbell, AR; Kivett, VA; Patel, R; Erickson, VR; Pittet, JF			The development of acute lung injury is associated with worse neurologic outcome in patients with severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	31st Annual Meeting of the Western-Trauma-Association	FEB 24-MAR 01, 2001	BIG SKY, MONTANA	Western Trauma Assoc		head injury; acute lung injury; inflammatory response; outcome	SEVERE HEAD-INJURY; HYPOXIA; INSUFFICIENCY; HYPOTENSION; CARE	Objective. The purpose of this study was to determine the incidence of acute lung injury (ALI) in trauma patients with severe traumatic brain injury (TBI), to evaluate the impact of ALI on mortality and neurologic outcome after severe traumatic brain injury (TBI), and to identify whether the development of ALI correlates with the severity of TBI. Methods. Clinical data were collected prospectively over a 4-year period in a Level I trauma center. Patients included in the study met the following criteria: mechanical ventilation > 24 hours, head Abbreviated Injury Scale score greater than or equal to 3, no other body region Abbreviated Injury Scale score greater than or equal to 3, and age between 18 and 54 years. ALI was defined using international consensus criteria. Glasgow Outcome Scale scores were assessed at 3 and 12 months. Bivariate comparisons were made between ALI and non-ALL groups. Multivariate analysis with stepwise logistical regression was used to assess independent factors on mortality. The patient's admission head computed tomographic (CT) scan was graded using the Marshall system, and the presence and size of specific intracranial abnormality was noted. Glasgow Coma Scale (GCS) score, Marshall CT scan score, and intracranial abnormality were correlated with the development of ALI. Results. One hundred thirty-seven patients with isolated head trauma were enrolled in the study over a 4-year period. Thirty-one percent of patients with severe TBI developed ALI. Head trauma patients with ALI had a significantly higher ISS, a greater number of days on the ventilator, and a worse neurologic outcome for those who survived their hospitalization. Mortality was 38% in the ALI group and 15% in the non-ALL group (p = 0.004). Only 3 of 16 (19%) of the deaths within the ALI group were directly related to ALI. By multivariate analysis, only the presence of ALI, older age, and lower initial GCS score were associated with higher mortality. There was no association between ISS, the presence of arterial hypotension (arterial systolic pressure < 90 nun Hg) at admission to the hospital, or the amount of blood transfused and mortality. No correlation was found between the severity of head injury (GCS score, Marshall score, or intracranial abnormality) and development of ALI. Conclusion. The development of ALI is a critical independent factor affecting mortality in patients suffering traumatic brain injury and is associated with a worse long-term neurologic outcome in survivors. The risk of developing ALI is not associated with specific anatomic lesions diagnosed by cranial CT scanning.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Anesthesia, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Dept Neurosurg, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Dept Surg, San Francisco, CA 94110 USA	Pittet, JF (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Anesthesia, CARE 3C-38,1001 Potrero Ave, San Francisco, CA 94110 USA.						BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Eberhard LW, 2000, CRIT CARE MED, V28, P125, DOI 10.1097/00003246-200001000-00021; FULTON RL, 1975, SURG GYNECOL OBSTET, V140, P179; GEAN AD, 1994, IMAGING HEAD TRAUMA, P220; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; LeTulzo Y, 1997, J CLIN INVEST, V99, P1516, DOI 10.1172/JCI119314; MACKERSIE RC, 1983, J TRAUMA, V23, P968, DOI 10.1097/00005373-198311000-00002; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mascia L, 1998, INTENS CARE MED, V24, P1115, DOI 10.1007/s001340050727; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; SIMMONS RL, 1969, ANN SURG, V170, P39, DOI 10.1097/00000658-196907000-00005; TEASDALE G, 1974, LANCET, V2, P81; Vollmer DG, 1991, J NEUROSURG S, V75, P37; Weisman SJ, 1939, SURGERY, V6, P722	20	155	172	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2003	55	1					106	111		10.1097/01.TA.0000071620.27375.BE			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	753YT	WOS:000187276500017	12855888				2021-06-18	
J	Jones, TB; Basso, DM; Sodhi, A; Pan, JZ; Hart, RP; MacCallum, RC; Lee, S; Whitacre, CC; Popovich, PG				Jones, TB; Basso, DM; Sodhi, A; Pan, JZ; Hart, RP; MacCallum, RC; Lee, S; Whitacre, CC; Popovich, PG			Pathological CNS autoimmune disease triggered by traumatic spinal cord injury: Implications for autoimmune vaccine therapy	JOURNAL OF NEUROSCIENCE			English	Article						protective autoimmunity; neuroprotection; CNS injury; spinal cord injury; myelin basic protein; autoimmune disease	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL-ALLERGIC-ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; CD4(+) T-CELLS; INFLAMMATORY BRAIN-LESIONS; RECEPTOR TRANSGENIC MICE; MULTIPLE-SCLEROSIS; CYTOKINE PROFILE; FACIAL NUCLEUS; LEWIS RATS	Lymphocytes respond to myelin proteins after spinal cord injury (SCI) and may contribute to post-traumatic secondary degeneration. However, there is increasing evidence that autoreactive T-lymphocytes may also convey neuroprotection and promote functional recovery after CNS injury. To clarify the role of myelin autoreactive lymphocytes after SCI, we performed contusion injuries in the thoracic spinal cord of transgenic (Tg) mice in which >95% of all CD4+ T-lymphocytes are reactive with myelin basic protein (MBP). We observed significantly impaired recovery of locomotor and reflex function in Tg mice compared with non-Tg (nTg) littermates. Measures of functional impairment in Tg mice correlated with significantly less white matter at the injury site, and morphometric comparisons of injured Tg and nTg spinal cords revealed increased rostrocaudal lesion expansion (i.e., secondary degeneration) in Tg mice. Rostrocaudal to the impact site in SCI-nTg mice, demyelination was restricted to the dorsal funiculus, i.e., axons undergoing Wallerian degeneration. The remaining white matter appeared normal. In contrast, lymphocytes were colocalized with regions of demyelination and axon loss throughout the white matter of SCI-Tg mice. Impaired neurological function and exacerbated neuropathology in SCI-Tg mice were associated with increased intraspinal production of proinflammatory cytokine mRNA; neurotrophin mRNA was not elevated. These data suggest that endogenous MBP-reactive lymphocytes, activated by traumatic SCI, can contribute to tissue injury and impair functional recovery. Any neuroprotection afforded by myelin-reactive T-cells is likely to be an indirect effect mediated by other non-CNS-reactive lymphocytes. Similar to the Tg mice in this study, a subset of humans that are genetically predisposed to autoimmune diseases of the CNS may be adversely affected by vaccine therapies designed to boost autoreactive lymphocyte responses after CNS trauma. Consequently, the safe implementation of such therapies requires that future studies define the mechanisms that control T-cell function within the injured CNS.	Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Neurosci Grad Studies Program, Columbus, OH 43210 USA; Ohio State Univ, Sch Allied Med Profess, Div Phys Therapy, Columbus, OH 43210 USA; Ohio State Univ, Coll Social & Behav Sci, Dept Psychol, Columbus, OH 43210 USA; New Jersey Inst Technol, Dept Sci Biol, Newark, NJ 07102 USA; Rutgers State Univ, Newark, NJ 07102 USA; Rutgers State Univ, WM Keck Ctr Collaborat Neurosci, Piscataway, NJ 08854 USA	Popovich, PG (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Virol Immunol & Med Genet, 2078 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.		Popovich, Phillip/C-9187-2009; Hart, Ronald/G-6530-2019; Basso, Michele/B-3817-2011	Popovich, Phillip/0000-0003-1329-7395; Hart, Ronald/0000-0003-4836-8712; 			Ahmed Z, 2001, AM J PATHOL, V158, P2127, DOI 10.1016/S0002-9440(10)64684-6; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Balashov KE, 1997, P NATL ACAD SCI USA, V94, P599, DOI 10.1073/pnas.94.2.599; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Bell MD, 1996, NEUROSCIENCE, V74, P283, DOI 10.1016/0306-4522(96)00083-8; Benson JM, 1999, J IMMUNOL, V162, P6247; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Cohen IR, 1999, J NEUROIMMUNOL, V100, P111, DOI 10.1016/S0165-5728(99)00190-3; CROSS AH, 1990, LAB INVEST, V63, P162; Crowder M.J., 1990, ANAL REPEATED MEASUR; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Falcone M, 1997, J EXP MED, V185, P901, DOI 10.1084/jem.185.5.901; Fisher J, 2001, J NEUROSCI, V21, P136, DOI 10.1523/JNEUROSCI.21-01-00136.2001; GOLDBERGER ME, 1990, EXP NEUROL, V107, P113, DOI 10.1016/0014-4886(90)90149-M; Goldstein H, 1995, MULTILEVEL STAT MODE; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2001, J CLIN INVEST, V108, P591, DOI 10.1172/JCI12837; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; Heese K, 1998, J NEUROCHEM, V70, P699; Hirschberg DL, 1998, J NEUROIMMUNOL, V89, P88, DOI 10.1016/S0165-5728(98)00118-0; Irani DN, 1997, J IMMUNOL, V158, P2318; Jakeman LB, 2000, J NEUROTRAUM, V17, P299, DOI 10.1089/neu.2000.17.299; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; Kil K, 1999, J NEUROIMMUNOL, V98, P201, DOI 10.1016/S0165-5728(99)00057-0; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; Krakowski ML, 1997, EUR J IMMUNOL, V27, P2840, DOI 10.1002/eji.1830271115; Kuhn PL, 1998, J NEUROTRAUM, V15, P125, DOI 10.1089/neu.1998.15.125; LAFAILLE JJ, 1994, CELL, V78, P399, DOI 10.1016/0092-8674(94)90419-7; Lassmann S, 2001, J IMMUNOL, V167, P5485, DOI 10.4049/jimmunol.167.9.5485; Liebl DJ, 2001, EXP NEUROL, V167, P15, DOI 10.1006/exnr.2000.7548; MAGNUS R., 1926, LARYNGOSCOPE, V36, P701; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; Moalem G, 2000, J NEUROIMMUNOL, V106, P189, DOI 10.1016/S0165-5728(00)00240-X; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moalem G, 1999, FASEB J, V13, P1207; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; Olivares-Villagomez D, 1998, J EXP MED, V188, P1883, DOI 10.1084/jem.188.10.1883; OLSSON T, 1993, J NEUROL SCI, V117, P130, DOI 10.1016/0022-510X(93)90165-U; OLSSON T, 1992, AUTOIMMUNITY, V13, P117, DOI 10.3109/08916939209001912; PELLIS SM, 1991, BEHAV BRAIN RES, V45, P185, DOI 10.1016/S0166-4328(05)80084-1; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 2001, J NEUROTRAUM, V18, P957, DOI 10.1089/089771501750451866; POSER CM, 1994, CLIN NEUROL NEUROSUR, V96, P103, DOI 10.1016/0303-8467(94)90042-6; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; Schwartz M, 1999, J MOL MED, V77, P713, DOI 10.1007/s001099900047; SCHWARTZ M, 1991, BRAIN RES, V545, P334, DOI 10.1016/0006-8993(91)91309-O; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Smith T, 1996, J AUTOIMMUN, V9, P167, DOI 10.1006/jaut.1996.0020; Steinman L, 1996, P NATL ACAD SCI USA, V93, P2253, DOI 10.1073/pnas.93.6.2253; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Van de Keere F, 1998, J EXP MED, V188, P1875, DOI 10.1084/jem.188.10.1875; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001	62	155	161	1	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 1	2002	22	7					2690	2700		10.1523/JNEUROSCI.22-07-02690.2002			11	Neurosciences	Neurosciences & Neurology	535BU	WOS:000174626000032	11923434	Green Published, Bronze			2021-06-18	
J	Fann, JR; Uomoto, JM; Katon, WJ				Fann, JR; Uomoto, JM; Katon, WJ			Cognitive improvement with treatment of depression following mild traumatic brain injury	PSYCHOSOMATICS			English	Article							MINOR HEAD-INJURY; MAJOR DEPRESSION; IMPAIRMENT; DYSFUNCTION; ANTIDEPRESSANTS; PERFORMANCE; RECOVERY; MEMORY; TESTS	The authors examined the effect of antidepressant treatment on cognitive performances in people with mild traumatic brain injury. An 8-week nonrandomized, single-blind placebo run-in trial of sertraline was completed and neuropsychological testing measures were compared before and after the treatment trial. Results showed improvements in psychomotor speed, recent verbal memory, recent visual memory, and general cognitive efficiency. Improvements were also seen in self-perception of cognitive symptomatology. it appears that successful depression treatment resulted in significant alleviation of cognitive impairments, which may not have been accounted for by natural recovery alone.	Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Seattle Pacific Univ, Dept Grad Psychol, Seattle, WA 98119 USA	Fann, JR (corresponding author), Univ Washington, Dept Psychiat & Behav Sci, Box 356560, Seattle, WA 98195 USA.		Uomoto, Jay/AAF-4809-2019				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Austin MP, 1999, PSYCHOL MED, V29, P73, DOI 10.1017/S0033291798007788; AUSTIN MP, 1992, J AFFECT DISORDERS, V25, P21, DOI 10.1016/0165-0327(92)90089-O; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Beats BC, 1996, PSYCHOL MED, V26, P591, DOI 10.1017/S0033291700035662; Beck A.T., 1987, BECK DEPRESSION INVE; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DOLAN RJ, 1994, PSYCHOL MED, V24, P849, DOI 10.1017/S0033291700028944; Elliott R, 1996, PSYCHOL MED, V26, P975, DOI 10.1017/S0033291700035303; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KOPELMAN MD, 1986, BRIT J PSYCHIAT, V148, P517, DOI 10.1192/bjp.148.5.517; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Oxman TE, 1996, J CLIN PSYCHIAT, V57, P38; Previc FH, 1999, BRAIN COGNITION, V41, P299, DOI 10.1006/brcg.1999.1129; REIFLER BV, 1982, AM J PSYCHIAT, V139, P623; Reitan RM., 1985, HALSTEAD REITAN NEUR; RICHELSON E, 1994, MAYO CLIN PROC, V69, P1069, DOI 10.1016/S0025-6196(12)61375-5; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ROBINSON RG, 1986, BRIT J PSYCHIAT, V148, P541, DOI 10.1192/bjp.148.5.541; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Sivian A. B, 1992, BENTON VISUAL RETENT; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spreen O, 1969, NEUROSENSORY CTR COM; STECKLER T, 1995, BEHAV BRAIN RES, V67, P165, DOI 10.1016/0166-4328(94)00157-B; STOUDEMIRE A, 1995, J NEUROPSYCH CLIN N, V7, P31; TEASDALE G, 1974, LANCET, V2, P81; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206	41	155	157	0	6	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0033-3182			PSYCHOSOMATICS	Psychosomatics	JAN-FEB	2001	42	1					48	54		10.1176/appi.psy.42.1.48			7	Psychiatry; Psychology	Psychiatry; Psychology	391RN	WOS:000166369100008	11161121				2021-06-18	
J	Ikonomidou, C; Stefovska, V; Turski, L				Ikonomidou, C; Stefovska, V; Turski, L			Neuronal death enhanced by N-methyl-D-aspartate antagonists	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article							EXCITATORY AMINO-ACIDS; NEUROTROPHIC FACTOR; BRAIN INJURY; QUINOLINIC ACID; MESSENGER-RNAS; BASAL GANGLIA; GROWTH-FACTOR; EXPRESSION; TOXICITY; DISEASE	Glutamate promotes neuronal survival during brain development and destroys neurons after injuries in the mature brain. Glutamate antagonists are in human clinical trials aiming to demonstrate limitation of neuronal injury after head trauma, which consists of both rapid and slowly progressing neurodegeneration. Furthermore, glutamate antagonists are considered for neuroprotection in chronic neurodegenerative disorders with slowly progressing cell death only. Therefore, humans suffering from Huntington's disease. characterized by slowly progressing neurodegeneration of the basal ganglia. are subjected to trials with glutamate antagonists. Here we demonstrate that progressive neurodegeneration in the basal ganglia induced by the mitochondrial toxin 3-nitro-propionate or in the hippocampus by traumatic brain injury is enhanced by N-methyl-D-aspartate antagonists but ameliorated by alpha -amino-3-hydroxy-5-methyl-4-isoxazole-propionate antagonists. These observations reveal that N-methyl-D-aspartate antagonists may increase neurodestruction in mature brain undergoing slowly progressing neurodegeneration. whereas blockade of the action of glutamate at alpha -amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors may be neuroprotective.	Humboldt Univ, Charite Virchow Clin, Childrens Hosp, Dept Pediat Neurol, D-13353 Berlin, Germany; UCL, Eisai London Res Labs, London WC1E 6BT, England	Ikonomidou, C (corresponding author), Humboldt Univ, Charite Virchow Clin, Childrens Hosp, Dept Pediat Neurol, Augustenburger Pl 1, D-13353 Berlin, Germany.	hrissanthi.ikonomidou@charite.de					Arrowsmith JE, 1998, STROKE, V29, P2357, DOI 10.1161/01.STR.29.11.2357; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BLOOM FE, 1990, PHARMACOL BASIS THER, P244; BROUILLET E, 1995, P NATL ACAD SCI USA, V92, P7105, DOI 10.1073/pnas.92.15.7105; Brouillet E, 1999, PROG NEUROBIOL, V59, P427, DOI 10.1016/S0301-0082(99)00005-2; COMELLI MC, 1992, NEUROREPORT, V3, P473, DOI 10.1097/00001756-199206000-00004; CRUZORIVE LM, 1990, AM J PHYSIOL, V258, pL148; Davis SM, 1997, LANCET, V349, P32, DOI 10.1016/S0140-6736(05)62166-6; FINK ROBERT P., 1967, BRAIN RES, V4, P369, DOI 10.1016/0006-8993(67)90166-7; French SJ, 1999, MOL BRAIN RES, V67, P124, DOI 10.1016/S0169-328X(99)00048-0; FRIM DM, 1994, P NATL ACAD SCI USA, V91, P5104, DOI 10.1073/pnas.91.11.5104; Herrling P, 1997, EXCITATORY AMINO ACI; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Kafitz KW, 1999, NATURE, V401, P918, DOI 10.1038/44847; KLOCKGETHER T, 1993, ANN NEUROL, V34, P585, DOI 10.1002/ana.410340413; KLOCKGETHER T, 1989, TRENDS NEUROSCI, V12, P285, DOI 10.1016/0166-2236(89)90007-6; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; Lancelot E, 1998, PROG BRAIN RES, V116, P331, DOI 10.1016/S0079-6123(08)60446-X; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; McBurney RN, 1997, INT REV NEUROBIOL, V40, P173; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Misztal M, 1996, EUR J PHARMACOL, V296, P1, DOI 10.1016/0014-2999(95)00682-6; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; Parsons CG, 1998, DRUG NEWS PERSPECT, V11, P523, DOI 10.1358/dnp.1998.11.9.863689; ROCAMORA N, 1994, MOL BRAIN RES, V26, P89, DOI 10.1016/0169-328X(94)90078-7; Sharma HS, 1998, AMINO ACIDS, V14, P121, DOI 10.1007/BF01345252; Swanson L.W., 1992, BRAIN MAPS STRUCTURE; Wu DF, 1999, P NATL ACAD SCI USA, V96, P254, DOI 10.1073/pnas.96.1.254; XINGJIE L, 1992, Biomedical and Environmental Sciences, V5, P161; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; ZEEVALK GD, 1995, J NEUROCHEM, V64, P455	35	155	165	0	5	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	NOV 7	2000	97	23					12885	12890		10.1073/pnas.220412197			6	Multidisciplinary Sciences	Science & Technology - Other Topics	372GK	WOS:000165225800096	11058158	Green Published, Bronze			2021-06-18	
J	Ehrlich, LC; Hu, SX; Sheng, WS; Sutton, RL; Rockswold, GL; Peterson, PK; Chao, CC				Ehrlich, LC; Hu, SX; Sheng, WS; Sutton, RL; Rockswold, GL; Peterson, PK; Chao, CC			Cytokine regulation of human microglial cell IL-8 production	JOURNAL OF IMMUNOLOGY			English	Article							TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; NEUTROPHIL CHEMOTACTIC FACTOR; CEREBROSPINAL-FLUID; BACTERIAL-MENINGITIS; FACTOR-ALPHA; PROINFLAMMATORY CYTOKINES; LEUKOCYTE RECRUITMENT; DIFFERENT ETIOLOGIES; INTERLEUKIN-8 IL-8	IL-8 involvement in neutrophil activation and chemotaxis may be important in inflammatory responses within the central nervous system, secondary to meningitis, encephalitis, and traumatic injury, The source of IL-8 within the brain during these inflammatory processes, however, is unknown, To explore the role of microglia in the production of IL-8, human fetal microglia, which are the resident macrophages of the brain, were treated with LPS and pro-and anti-inflammatory cytokines to determine their effects on IL-8 production. We found that IL-8 protein levels increased in response to LPS or IL-1 beta or to TNF-alpha, which also corresponded to elevated IL-8 mRNA levels by RT-PCR, Pretreatment with IL-4 IL-10, or TGF-beta 1 potently inhibited the stimulatory effects of these proinflammatory agents. These findings indicate that human microglia synthesize IL-8 in response to proinflammatory stimuli, and that anti-inflammatory cytokines down-regulate the production of this chemokine, These results mag hale important therapeutic implications for certain central nervous system insults involving inflammation.	Minneapolis Med Res Fdn Inc, Neuroimmunol & Host Def Lab, Minneapolis, MN 55404 USA; Minneapolis Med Res Fdn Inc, Neurotrauma Res Lab, Minneapolis, MN 55404 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55404 USA	Chao, CC (corresponding author), Minneapolis Med Res Fdn Inc, Neuroimmunol & Host Def Lab, 914 S 8th St,D-3, Minneapolis, MN 55404 USA.	chaox002@mroon.tc.umn.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-09924, DA-04381] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA004381, R01DA009924] Funding Source: NIH RePORTER		Adams DH, 1997, LANCET, V349, P490, DOI 10.1016/S0140-6736(96)07524-1; ALOISI F, 1992, J IMMUNOL, V149, P2358; ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BAGGIOLINI M, 1994, CHEST, V105, pS95, DOI 10.1378/chest.105.3_Supplement.95S; Bell MD, 1996, NEUROSCIENCE, V74, P283, DOI 10.1016/0306-4522(96)00083-8; Benveniste Etty N., 1995, P700; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CASSATELLA MA, 1993, J EXP MED, V178, P2207, DOI 10.1084/jem.178.6.2207; Chao CC, 1996, J NEUROVIROL, V2, P234, DOI 10.3109/13550289609146886; CHAO CC, 1992, J INFECT DIS, V166, P847, DOI 10.1093/infdis/166.4.847; CHAO CC, 1995, CRIT REV NEUROBIOL, V9, P189; CHAO CC, 1994, DEV NEUROSCI-BASEL, V16, P172, DOI 10.1159/000112104; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; CHAO CC, 1992, J CLIN INVEST, V90, P1786, DOI 10.1172/JCI116053; Chen CC, 1996, CYTOKINE, V8, P58, DOI 10.1006/cyto.1995.0008; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Del Rio-Hortega P., 1932, CYTOLOGY CELLULAR PA, P481; GITTER BD, 1995, P NATL ACAD SCI USA, V92, P10738, DOI 10.1073/pnas.92.23.10738; GLABINSKI AR, 1995, INT J DEV NEUROSCI, V13, P153, DOI 10.1016/0736-5748(95)00017-B; GLIMAKER M, 1993, J INFECT DIS, V167, P882, DOI 10.1093/infdis/167.4.882; HALSTENSEN A, 1993, J INFECT DIS, V167, P471, DOI 10.1093/infdis/167.2.471; Harada A, 1996, MOL MED TODAY, V2, P482; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559; HU SX, 1995, GLIA, V13, P45, DOI 10.1002/glia.440130106; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; Koedel U, 1996, J IMMUNOL, V157, P5185; Kornelisse RF, 1996, J INFECT DIS, V173, P1498, DOI 10.1093/infdis/173.6.1498; LOPEZCORTES LF, 1995, J INFECT DIS, V172, P581, DOI 10.1093/infdis/172.2.581; MASTROIANNI CM, 1994, PEDIATR INFECT DIS J, V13, P1008; MATSUSHIMA K, 1992, CHEM IMMUNOL, V51, P236; MCCRACKEN GH, 1989, PEDIATR INFECT DIS J, V8, P155; MEDA L, 1995, J NEUROIMMUNOL, V59, P29, DOI 10.1016/0165-5728(95)00021-S; METZNER B, 1995, J INVEST DERMATOL, V104, P789, DOI 10.1111/1523-1747.ep12606993; MUSTAFA MM, 1989, J PEDIATR-US, V115, P208, DOI 10.1016/S0022-3476(89)80067-8; MUSTAFA MM, 1989, J CLIN INVEST, V84, P1253, DOI 10.1172/JCI114292; OSSEGE LM, 1994, J NEUROL, V242, P14, DOI 10.1007/BF00920569; Ostergaard C, 1996, EUR J CLIN MICROBIOL, V15, P166, DOI 10.1007/BF01591492; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Peterson P, 1997, DEFENSE BRAIN CURREN, P31; Peterson PK, 1997, J INFECT DIS, V175, P478, DOI 10.1093/infdis/175.2.478; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Saez-Llorens X, 1997, DEFENSE BRAIN NEW CO, P107; Smith WB, 1996, J IMMUNOL, V157, P360; Spanaus KS, 1997, J IMMUNOL, V158, P1956; Streit Wolfgang J., 1995, P85; Taub D D, 1994, Ther Immunol, V1, P229; Taub DD, 1996, J CLIN INVEST, V97, P1931, DOI 10.1172/JCI118625; TAUBER MG, 1997, DEFENSE BRAIN, P124; TUNKEL AR, 1993, ANNU REV MED, V44, P103, DOI 10.1146/annurev.me.44.020193.000535; VAN MEIR E, 1992, CANCER RES, V52, P4297; vanFurth AM, 1996, INFECT IMMUN, V64, P4883, DOI 10.1128/IAI.64.12.4883-4890.1996; VANFURTH AM, 1995, CLIN INFECT DIS, V21, P220, DOI 10.1093/clinids/21.1.220; WAAGE A, 1989, J EXP MED, V170, P1859, DOI 10.1084/jem.170.6.1859; YOSHIMURA T, 1987, J IMMUNOL, V139, P788	55	155	157	0	6	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	FEB 15	1998	160	4					1944	1948					5	Immunology	Immunology	ZN995	WOS:000073704800050	9469457				2021-06-18	
J	KAWAMATA, T; KATAYAMA, Y; HOVDA, DA; YOSHINO, A; BECKER, DP				KAWAMATA, T; KATAYAMA, Y; HOVDA, DA; YOSHINO, A; BECKER, DP			LACTATE ACCUMULATION FOLLOWING CONCUSSIVE BRAIN INJURY - THE ROLE OF IONIC FLUXES INDUCED BY EXCITATORY AMINO-ACIDS	BRAIN RESEARCH			English	Article						CONCUSSION; IONIC FLUX; LACTATE; EXCITATORY AMINO ACID; GLUCOSE METABOLISM; MICRODIALYSIS; GLYCOLYSIS	EXPERIMENTAL HEAD-INJURY; FLUID-PERCUSSION MODEL; CEREBRAL GLUCOSE-UTILIZATION; EXTRACELLULAR POTASSIUM; ENERGY-METABOLISM; QUINOLINIC ACID; RAT HIPPOCAMPUS; ISCHEMIC BRAIN; KYNURENIC ACID; CELL-DAMAGE	During the first few minutes following traumatic brain injury, cells are exposed to an indiscriminate release of glutamate from nerve terminals resulting in a massive tonic flux (e.g., K+ efflux) via stimulation of excitatory amino acid (EAA)-coupled ion channels. The present study was undertaken to elucidate the causal relationship between these ionic shifts and lactate accumulation in the injured brain, by examining the effects of ouabain (an inhibitor of Na+/K+-ATPase), Ba2+ (an inhibitor of non-energy-dependent glial K+ uptake) and kynurenic acid (KYN; a broad-spectrum EAA antagonist) on lactate accumulation. Two microdialysis probes were placed bilaterally in the rat parietal cortex. One was perfused with a test drug (1.0 mM ouabain, 2.0 mM Ba2+ or 10 mM KYN) and the other with Ringer's solution (control) for 30 min prior to injury. Following a 2.2-2.7 atm fluid-percussion injury, lactate levels in the dialysate increased (up to 116.6% above baseline) for the first 16 min and returned to baseline levels within 20 min after injury. This lactate accumulation was attenuated by preinjury administration of ouabain and KYN and was prolonged by Ba2+ administration. These findings indicate that lactate accumulation following concussive brain injury is a result of increased glycolysis which supports ion-pumping mechanisms, thereby, restoring the ionic balance which was disrupted by stimulation of EAA-coupled ion channels.		KAWAMATA, T (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DIV NEUROSURG,CHS 74-140,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308, R01 NS27544] Funding Source: Medline		ACKERMANN RF, 1989, J CEREBR BLOOD F MET, V9, P774, DOI 10.1038/jcbfm.1989.111; AHMED N, 1989, NEUROCHEM RES, V14, P179, DOI 10.1007/BF00969636; ALBERS RW, 1989, BASIC NEUROCHEMISTRY, P52; AMES A, 1992, J NEUROSCI, V12, P4234; ANDERSEN BJ, 1989, INTRACRANIAL PRESSUR, V7, P575; ASTRUP J, 1982, J NEUROSURG, V56, P482, DOI 10.3171/jns.1982.56.4.0482; ASTRUP J, 1981, STROKE, V726, P730; BALLANYI K, 1987, J PHYSIOL-LONDON, V382, P159, DOI 10.1113/jphysiol.1987.sp016361; DESALLES A A F, 1986, Society for Neuroscience Abstracts, V12, P967; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; DUFFY TE, 1975, J NEUROCHEM, V24, P925, DOI 10.1111/j.1471-4159.1975.tb03657.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRIEDLI C, 1978, ADV EXP MED BIOL, V94, P747; GALVAN M, 1979, BRAIN RES, V160, P544, DOI 10.1016/0006-8993(79)91084-9; GANONG AH, 1986, J PHARMACOL EXP THER, V236, P293; GANONG AH, 1983, BRAIN RES, V273, P170, DOI 10.1016/0006-8993(83)91108-3; Hayes R L, 1988, Brain Inj, V2, P31, DOI 10.3109/02699058809150930; HOUNSGAARD J, 1983, J PHYSIOL-LONDON, V340, P359, DOI 10.1113/jphysiol.1983.sp014767; HUBSCHMANN OR, 1983, J NEUROSURG, V59, P289, DOI 10.3171/jns.1983.59.2.0289; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; KATAYAMA Y, 1991, BRAIN RES, V567, P57, DOI 10.1016/0006-8993(91)91435-4; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KRIVANEK J, 1961, J NEUROCHEM, V6, P183, DOI 10.1111/j.1471-4159.1961.tb13463.x; KRNJEVIC K, 1971, J PHYSIOL-LONDON, V215, P223, DOI 10.1113/jphysiol.1971.sp009466; KUHR WG, 1988, J CEREBR BLOOD F MET, V8, P130, DOI 10.1038/jcbfm.1988.17; LJUNGGREN B, 1974, BRAIN RES, V73, P277, DOI 10.1016/0006-8993(74)91049-X; MATA M, 1980, J NEUROCHEM, V34, P213, DOI 10.1111/j.1471-4159.1980.tb04643.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEYER JS, 1970, J NEUROSURG, V32, P304, DOI 10.3171/jns.1970.32.3.0304; Myers RE, 1979, ADV PERINATAL NEUROL, V1, P85; Nelson S, 1966, HEAD INJURY, P444; NICHOLSON C, 1976, BRAIN RES, V113, P606, DOI 10.1016/0006-8993(76)90063-9; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; PAN WJ, 1994, J NEUROSCI, V14, P1114; PASCHEN W, 1987, J NEUROCHEM, V48, P154, DOI 10.1111/j.1471-4159.1987.tb13140.x; PERKINS MN, 1982, BRAIN RES, V247, P184, DOI 10.1016/0006-8993(82)91048-4; PRINCE DA, 1981, ION SELECTIVE MICROE, P247; QUISTORFF B, 1979, ACTA PHYSIOL SCAND, V105, pA42; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; ROSENTHAL M, 1982, HEAD INJURY BASIC CL, P69; SHAH KR, 1983, NEUROSCI LETT, V40, P287, DOI 10.1016/0304-3940(83)90053-8; SHINOHARA M, 1979, SCIENCE, V203, P188, DOI 10.1126/science.758688; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; SIHRA TS, 1993, J NEUROCHEM, V61, P1220, DOI 10.1111/j.1471-4159.1993.tb13612.x; SOKOLOFF L, 1981, J CEREBR BLOOD F MET, V1, P7, DOI 10.1038/jcbfm.1981.4; SOMJEN GG, 1984, BRAIN RES, V311, P186, DOI 10.1016/0006-8993(84)91416-1; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; THOMAS S, 1991, Society for Neuroscience Abstracts, V17, P166; Tsubokawa T, 1983, No Shinkei Geka, V11, P563; VINK R, 1988, MAGNET RESON MED, V7, P95, DOI 10.1002/mrm.1910070111; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WALZ W, 1984, NEUROSCIENCE, V13, P945, DOI 10.1016/0306-4522(84)90108-8; WARD AA, 1966, CLIN NEUROSURG, V12, P95; WHITTAM R, 1967, NEUROSCIENCES, P313; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	62	155	157	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 20	1995	674	2					196	204		10.1016/0006-8993(94)01444-M			9	Neurosciences	Neurosciences & Neurology	QN223	WOS:A1995QN22300003	7540925				2021-06-18	
J	SHOHAMI, E; NOVIKOV, M; BASS, R				SHOHAMI, E; NOVIKOV, M; BASS, R			LONG-TERM EFFECT OF HU-211, A NOVEL NONCOMPETITIVE NMDA ANTAGONIST, ON MOTOR AND MEMORY FUNCTIONS AFTER CLOSED-HEAD INJURY IN THE RAT	BRAIN RESEARCH			English	Article						CLOSED-HEAD INJURY; EDEMA; MEMORY; HU-211; RAT	TRAUMATIC BRAIN INJURY; CEREBRAL-ISCHEMIA; GLUTAMATE; ASPARTATE; DAMAGE; HIPPOCAMPUS; RECEPTORS; MK-801; EDEMA	HU-211 is a synthetic, non-psychotropic cannabinoid which acts as a non-competitive NMDA antagonist and antioxidant. We studied the drug's therapeutic window as well as its long-term effect on cognitive and motor functions in a model of closed head injury (CHI) in the rat. A weight-drop device was used to induce CHI in ether anesthetized male rats. HU-211 (5 mg/kg) was administered i.v. to the experimental groups. For the therapeutic window study, drug was injected at 4 or 6 h after CHI. Edema (water content) and clinical status (neurological severity score, NSS) were evaluated at 24 h. Reduction of edema was slight, whereas improvement of NSS was significant when the drug was administered at 4 or 6 h (P=0.0023 and 0.059, respectively). To determine the drug's long-term effect, it was administered 1 h after CHI and additional doses were later given. NSS was evaluated for a period of 30 d. A single dose of HU-211 given 1 h post-CHI improved the clinical outcome during the 30 d period (P<0.01). Repetitive doses of HU-211 injected during the post traumatic period had similar effects. Cognitive functions were evaluated in the Morris water maze, with rats trained either before or after CHI. CHI resulted in a highly significant impairment of these abilities, whereas HU-211 treatment 1 h after CHI improved performance. Our results indicate that HU-211 is a potent cerebroprotective agent, with a therapeutic window of about 4 h. The beneficial response obtained even after a single dose was long lasting, and ameliorated impairment of both motor and cognitive functions following CHI.		SHOHAMI, E (corresponding author), HEBREW UNIV JERUSALEM,SCH PHARM,DEPT PHARMACOL,JERUSALEM,ISRAEL.						BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BENVENISTE H, 1989, J CEREBR BLOOD F MET, V9, P629, DOI 10.1038/jcbfm.1989.90; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BUCHAN AM, 1990, CEREBROVAS BRAIN MET, V2, P1; CHOI DW, 1993, PROG BRAIN RES, V96, P137; DIEMER NH, 1993, PROG BRAIN RES, V96, P105; ESHHAR N, 1993, NEUROREPORT, V5, P237, DOI 10.1097/00001756-199312000-00013; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; GASQUOINE P G, 1991, Brain Injury, V5, P169, DOI 10.3109/02699059109008087; GILL R, 1987, J NEUROSCI, V7, P3343; GILL R, 1988, NEUROSCIENCE, V25, P847, DOI 10.1016/0306-4522(88)90040-1; HAMM RJ, 1988, J NEUROTRAUM, V5, P11; LEE SM, 1993, 23RD SOC NEUR ANN M; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LIPPERT K, 1992, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1992, P147; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MADDEN KP, 1993, STROKE, V24, P1068, DOI 10.1161/01.STR.24.7.1068; MELDRUM B, 1990, CEREBROVAS BRAIN MET, V2, P27; MELDRUM BS, 1992, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1992, P115; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Olney J. W., 1978, KAINIC ACID TOOL NEU, P37; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; PULSINELLI W, 1993, PROG BRAIN RES, V96, P125; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1993, J CEREBR BLOOD F MET, V13, P962, DOI 10.1038/jcbfm.1993.120; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; Smith D. H., 1992, Society for Neuroscience Abstracts, V18, P170; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007	39	155	161	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 13	1995	674	1					55	62		10.1016/0006-8993(94)01433-I			8	Neurosciences	Neurosciences & Neurology	QM434	WOS:A1995QM43400006	7773695				2021-06-18	
J	YAGHMAI, A; POVLISHOCK, J				YAGHMAI, A; POVLISHOCK, J			TRAUMATICALLY INDUCED REACTIVE CHANGE AS VISUALIZED THROUGH THE USE OF MONOCLONAL-ANTIBODIES TARGETED TO NEUROFILAMENT SUBUNITS	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						AXONAL SWELLING; BRAIN TRAUMA; IMMUNOCYTOCHEMISTRY; MONOCLONAL ANTIBODIES; NEUROFILAMENT SUBUNITS	DIFFUSE AXONAL INJURY; FLUID-PERCUSSION MODEL; HEAD-INJURY; BRAIN INJURY; GANGLION NEURONS; NERVOUS-SYSTEM; CELL NEURONS; NF-H; PROTEINS; DAMAGE	Reactive axonal change has long been recognized as a feature of traumatic brain injury. To date, the histological methods used to identify reactive axons have been of limited utility, and they have not provided insight into the initial intraaxonal event that triggers reactive change. In this investigation, monoclonal antibodies to the 68, 150, and 200 kilodalton (kD) neurofilament subunits have been used to follow the progression of reactive axonal change. Anesthetized rats and cats were subjected to moderate traumatic brain injury. One to 72 hours (h) postinjury, their brains were processed for the light (LM) and electron (EM) microscopic immunocytochemical visualization of the various neurofilament subunits. Although all of the chosen antibodies revealed some degree of immunoreactivity within the reactive axon, the 68 kD antibody revealed a dramatic increase in immunoreactivity following injury. Within one h of injury, intensely 68 kD-immunoreactive axonal segments were observed with LM, and parallel EM microscopic analyses demonstrated that this increased immunoreactivity was associated with an increased number of 68 kD-immunoreactive neurofilaments, the majority of which coursed in an axis parallel to the axon's course. Over 2-6 h postinjury, these 68 kD-immunoreactive filaments demonstrated increasingly disordered alignment in relation to the axon's long axis, withdrawing from the focus of injury while becoming encompassed by an expanding organelle cap. It is posited that this increased 68 kD immunoreactivity is associated with a traumatically-induced increase in subunit exchange which contributes to cytoskeletal dysfunction leading to organelle accumulation, focal swelling and ultimate axonal detachment.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROL SURG,RICHMOND,VA 23298					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER		Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ANGELIDES KJ, 1989, J CELL BIOL, V108, P1495, DOI 10.1083/jcb.108.4.1495; BALENTINE J, 1985, CENTRAL NERVOUS SYST, V31, P455; BALENTINE JD, 1978, LAB INVEST, V39, P254; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Cheng CLY, 1988, J NEUROTRAUM, V5, P47, DOI 10.1089/neu.1988.5.47; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ERB D, 1991, EXP BRAIN RES, V3, P253; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P135, DOI 10.1016/0165-5728(87)90048-8; GRIFFIN JW, 1988, ANN NEUROL, V23, P3, DOI 10.1002/ana.410230103; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HSAW G, 1986, EUR J CELL BIOL, V42, P1; LANGLEY OK, 1988, BRAIN RES, V457, P12, DOI 10.1016/0006-8993(88)90052-2; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEWIS SE, 1988, J CELL BIOL, V107, P2689, DOI 10.1083/jcb.107.6.2689; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MAXWELL WL, 1990, J NEUROCYTOL, V19, P235, DOI 10.1007/BF01217301; NIXON RA, 1987, J NEUROSCI, V7, P1145; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; POLZ P, 1983, ACTA NEUROCHIR, V32, P119; POVLISHOCK J, 1985, ADV NEUROTRAUMA RES; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; ROSENFELD J, 1987, J NEUROPATH EXP NEUR, V46, P269, DOI 10.1097/00005072-198705000-00004; SCHLAEPFER WW, 1987, J NEUROPATH EXP NEUR, V46, P117, DOI 10.1097/00005072-198703000-00001; SCHLAEPFER WW, 1985, PROG BRAIN RES, V63, P185; SCHLAEPFER WW, 1979, PROGR NEUROPATHOLOGY, V4, P101; SHARP GA, 1982, EXP CELL RES, V137, P403, DOI 10.1016/0014-4827(82)90042-8; SHAW G, 1988, BRAIN RES, V460, P227, DOI 10.1016/0006-8993(88)90367-8; SLOAN KE, 1987, BRAIN RES, V437, P365, DOI 10.1016/0006-8993(87)91653-2; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TETZLAFF W, 1989, NEUROSCIENCE, V29, P659, DOI 10.1016/0306-4522(89)90138-3; TROJANOWSKI JQ, 1985, J HISTOCHEM CYTOCHEM, V33, P557, DOI 10.1177/33.6.3889140; TROJANOWSKI JQ, 1984, ANN NEUROL, V16, P349, DOI 10.1002/ana.410160312; TROJANOWSKI JQ, 1986, J NEUROSCI, V6, P650; WOOD JN, 1985, J NEUROCHEM, V44, P149, DOI 10.1111/j.1471-4159.1985.tb07124.x	50	155	158	0	2	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	1992	51	2					158	176		10.1097/00005072-199203000-00006			19	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	HH070	WOS:A1992HH07000006	1538240				2021-06-18	
J	CLIFTON, GL; GROSSMAN, RG; MAKELA, ME; MINER, ME; HANDEL, S; SADHU, V				CLIFTON, GL; GROSSMAN, RG; MAKELA, ME; MINER, ME; HANDEL, S; SADHU, V			NEUROLOGICAL COURSE AND CORRELATED COMPUTERIZED-TOMOGRAPHY FINDINGS AFTER SEVERE CLOSED HEAD-INJURY	JOURNAL OF NEUROSURGERY			English	Article									UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550; UNIV TEXAS,SCH PUBL HLTH,HOUSTON,TX 77025; UNIV TEXAS,SCH MED,DEPT RADIOL,HOUSTON,TX 77025; UNIV TEXAS,SCH MED,DIV NEUROSURG,HOUSTON,TX 77025							BARATHAM G, 1972, J NEUROL NEUROSUR PS, V35, P698, DOI 10.1136/jnnp.35.5.698; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BROWN FD, 1978, J NEUROSURG, V48, P1019, DOI 10.3171/jns.1978.48.6.1019; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Courville CB, 1940, ARCH SURG-CHICAGO, V41, P1; GALBRAITH S, 1976, BMJ-BRIT MED J, V1, P1438, DOI 10.1136/bmj.1.6023.1438; GUTTERMAN P, 1970, J NEUROSURG, V32, P330, DOI 10.3171/jns.1970.32.3.0330; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; JAMIESON KG, 1972, J NEUROSURG, V37, P137, DOI 10.3171/jns.1972.37.2.0137; JAMIESON KG, 1968, J NEUROSURG, V29, P13, DOI 10.3171/jns.1968.29.1.0013; JENNETT B, 1976, LANCET, V1, P1031; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MORIN MA, 1970, J NEUROSURG, V33, P542, DOI 10.3171/jns.1970.33.5.0542; PAGNI CA, 1973, J NEUROSURG SCI, V17, P289; PAZZAGLIA P, 1975, J NEUROL NEUROSUR PS, V38, P149, DOI 10.1136/jnnp.38.2.149; REILLY PL, 1975, LANCET, V2, P375; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; SWEET RC, 1978, NEUROSURGERY, V3, P16, DOI 10.1227/00006123-197807000-00003; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1979, ACTA NEUROCHIR   S28, V1, P205	24	155	155	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1980	52	5					611	624		10.3171/jns.1980.52.5.0611			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	JQ118	WOS:A1980JQ11800001	7373389				2021-06-18	
J	Roberts, I; Shakur-Still, H; Aeron-Thomas, A; Belli, A; Brenner, A; Chaudary, MA; Chaudhri, R; Jamaluddin, SFB; Frimley, L; Javaid, K; Jooma, R; Kayani, A; Leech, C; Mahmood, K; Mansukhani, R; Noor, JM; Mejia-Mantilla, J; Moss, P; Pott, J; Sandercock, P; Shokunbi, T; Vallecilla, L; Hartzenberg, HB; Joshipura, M; Aeron-Thomas, A; Perel, P; Shakur-Still, H; Clarke, MJ; Ohaegbulam, SC; Rodgers, A; Brady, T; Dewan, Y; Edwards, P; Komolafe, EO; Mejia-Mantilla, J; Perel, P; Austin, E; Balogun, E; Barneston, L; Barrow, C; Beaumont, D; Benyahia, M; Brenner, A; Brooks, I; Cargill, M; Carrington, L; Cook, L; Cornu-Hewitt, B; Edwards, P; Frimley, L; Geer, A; Gilbert, D; Gilliam, C; Gil-Onandia, J; Hetherington, D; Howe, C; Hughes, C; I'anson, D; Jackson, R; Kansagra, S; Kawahara, T; Ker, K; Kostrov, S; Mahmood, A; Mansukhani, R; Miah, H; Ndungu, B; Needham, K; Okusi, C; Outtandy, A; Pardinaz-Solis, R; Pearson, D; Pepple, T; Pisani, C; Pott, J; Prieto-Merino, D; Prowse, D; Quashi, N; Quinn, A; Ramos, M; Reid, M; Roukas, C; Scrapa, G; Squires, C; Tanner, J; Thayne, A; Vidaurre, L; Woods, E; Fawole, B; Adetayo, O; Okunade, O; Shokunbi, T; Chaudhri, R; Javaid, K; Jooma, R; Kayani, A; Chaudhri, R; Jooma, R; Noor, JM; Gogichaishvili, T; Munoz-Sanchez, MD; Fawole, B; Shokunbi, T; Mejia-Mantilla, J; Vallecilla, L; Olldashi, F; Krishnan, S; Djientcheu, V; Castellanos, JL; Rasulo, F; Hama, Q; Mulla, Y; Florian, IS; Tobar, J; Khamis, H; Deasy, C; Wellsh, B; Williams-Johnson, J; Chandra, S; Mutiso, V				Roberts, Ian; Shakur-Still, Haleema; Aeron-Thomas, Amy; Belli, Antonio; Brenner, Amy; Chaudary, Muhammad Anwar; Chaudhri, Rizwana; Jamaluddin, Sabariah Faizah Bt; Frimley, Lauren; Javaid, Kiran; Jooma, Rashid; Kayani, Aasia; Leech, Caroline; Mahmood, Khalid; Mansukhani, Raoul; Noor, Julina Md; Mejia-Mantilla, Jorge; Moss, Phil; Pott, Jason; Sandercock, Peter; Shokunbi, Temitayo; Vallecilla, Liliana; Hartzenberg, Henry Benjamin; Joshipura, Manjul; Aeron-Thomas, Amy; Perel, Pablo; Shakur-Still, Haleema; Clarke, Michael J.; Ohaegbulam, Samuel C.; Rodgers, Anthony; Brady, Tony; Dewan, Yashbir; Edwards, Phil; Komolafe, Edward O.; Mejia-Mantilla, Jorge; Perel, Pablo; Austin, Emma; Balogun, Eni; Barneston, Lin; Barrow, Collette; Beaumont, Danielle; Benyahia, Myriam; Brenner, Amy; Brooks, Imogen; Cargill, Madeleine; Carrington, Laura; Cook, Lisa; Cornu-Hewitt, Beatrice; Edwards, Phil; Frimley, Lauren; Geer, Amber; Gilbert, Daniel; Gilliam, Catherine; Gil-Onandia, Julio; Hetherington, Daniel; Howe, Courtenay; Hughes, Carolyn; I'anson, David; Jackson, Rob; Kansagra, Sneha; Kawahara, Taemi; Ker, Katharine; Kostrov, Sergey; Mahmood, Abda; Mansukhani, Raoul; Miah, Hakim; Ndungu, Bernard; Needham, Kelly; Okusi, Cecilia; Outtandy, Aroudra; Pardinaz-Solis, Raul; Pearson, Daniel; Pepple, Tracey; Pisani, Claude; Pott, Jason; Prieto-Merino, David; Prowse, Danielle; Quashi, Nigel; Quinn, Anna; Ramos, Maria; Reid, Mia; Roukas, Chris; Scrapa, Giulia; Squires, Chelci; Tanner, Jemma; Thayne, Andrew; Vidaurre, Lesley; Woods, Elizabeth; Fawole, Bukola; Adetayo, Olusade; Okunade, Olujide; Shokunbi, Temitayo; Chaudhri, Rizwana; Javaid, Kiran; Jooma, Rashid; Kayani, Aasia; Chaudhri, Rizwana; Jooma, Rashid; Noor, Julina Md; Gogichaishvili, Tamar; de los Angeles Munoz-Sanchez, Maria; Fawole, Bukola; Shokunbi, Temitayo; Mejia-Mantilla, Jorge; Vallecilla, Liliana; Olldashi, Fatos; Krishnan, Satish; Djientcheu, Vincent; Loria Castellanos, Jorge; Rasulo, Frank; Hama, Qadamkhear; Mulla, Yakub; Florian, Ioan Stefan; Tobar, Juan; Khamis, Hussein; Deasy, Conor; Wellsh, Bobby; Williams-Johnson, Jean; Chandra, Susilo; Mutiso, Vincent		CRASH-3 Trial Collaborators	Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial	LANCET			English	Article							INTRACEREBRAL HEMORRHAGE	Background Tranexamic acid reduces surgical bleeding and decreases mortality in patients with traumatic extracranial bleeding. Intracranial bleeding is common after traumatic brain injury (TBI) and can cause brain herniation and death. We aimed to assess the effects of tranexamic acid in patients with TBI. Methods This randomised, placebo-controlled trial was done in 175 hospitals in 29 countries. Adults with TBI who were within 3 h of injury, had a Glasgow Coma Scale (GCS) score of 12 or lower or any intracranial bleeding on CT scan, and no major extracranial bleeding were eligible. The time window for eligibility was originally 8 h but in 2016 the protocol was changed to limit recruitment to patients within 3 h of injury. This change was made blind to the trial data, in response to external evidence suggesting that delayed treatment is unlikely to be effective. We randomly assigned (1:1) patients to receive tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over 8 h) or matching placebo. Patients were assigned by selecting a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was head injury-related death in hospital within 28 days of injury in patients treated within 3 h of injury. We prespecified a sensitivity analysis that excluded patients with a GCS score of 3 and those with bilateral unreactive pupils at baseline. All analyses were done by intention to treat. This trial was registered with ISRCTN (ISRCTN15088122), ClinicalTrials.gov (NCT01402882), EudraCT (2011-003669-14), and the Pan African Clinical Trial Registry (PACTR20121000441277). Results Between July 20, 2012, and Jan 31, 2019, we randomly allocated 12 737 patients with TBI to receive tranexamic acid (6406 [50.3%] or placebo [6331 [49.7%], of whom 9202 (72.2%) patients were treated within 3 h of injury. Among patients treated within 3 h of injury, the risk of head injury-related death was 18.5% in the tranexamic acid group versus 19.8% in the placebo group (855 vs 892 events; risk ratio [RR] 0.94 [95% CI 0.86-1.02]). In the prespecified sensitivity analysis that excluded patients with a GCS score of 3 or bilateral unreactive pupils at baseline, the risk of head injury-related death was 12.5% in the tranexamic acid group versus 14.0% in the placebo group (485 vs 525 events; RR 0.89 [95% CI 0.80-1.00]). The risk of head injury-related death reduced with tranexamic acid in patients with mild-to-moderate head injury (RR 0. 78 [95% CI 0 .64-0. 95]) but not in patients with severe head injury (0.99 [95% CI 0.91-1.07]; p value for heterogeneity 0.030). Early treatment was more effective than was later treatment in patients with mild and moderate head injury (p= 0.005) but time to treatment had no obvious effect in patients with severe head injury (p=0. 73). The risk of vascular occlusive events was similar in the tranexamic acid and placebo groups (RR 0.98 (0.74-1.28). The risk of seizures was also similar between groups (1.09 [95% CI 0.90-1.33]). Interpretation Our results show that tranexamic acid is safe in patients with TBI and that treatment within 3 h of injury reduces head injury-related death. Patients should be treated as soon as possible after injury. Copyright (C) 2019 The Author(s). Published by Elsevier Ltd.		Roberts, I (corresponding author), London Sch Hyg & Trop Med, Clin Trials Unit, London WC1 E7HT, England.	crash@lshtm.ac.uk	Belli, Antonio/I-3799-2015; Needham, Kelly/C-8298-2019; Florian, Ioan Stefan I/D-5934-2016; senda, atsushi/AAL-7607-2021; JAMALUDDIN, SABARIAH FAIZAH/AAY-2902-2020; Jamaluddin, Sabariah/ABB-6372-2020; Thapa, Amit/L-3769-2013; Roukas, Chris/AAF-1894-2020; LORIA-CASTELLANOS, JORGE/J-2410-2016; Skene, Imogen/D-6153-2018	Belli, Antonio/0000-0002-3211-9933; Needham, Kelly/0000-0003-2340-5994; Florian, Ioan Stefan I/0000-0001-7127-0946; senda, atsushi/0000-0002-0128-6800; Thapa, Amit/0000-0003-1896-3115; Boyle, Adrian/0000-0002-9009-5423; LORIA-CASTELLANOS, JORGE/0000-0001-9269-0034; Bloom, Ben/0000-0002-3016-4925; Edwards, Phil/0000-0003-4431-8822; Mahmood, Abda/0000-0002-3267-4590; Okusi, Cecilia/0000-0002-5575-8527; Skene, Imogen/0000-0001-5215-2899	National Institute for Health Research Health Technology Assessment; JP Moulton Charitable Trust; Department of Health and Social Care; Department for International Development; Global Challenges Research Fund; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission; Wellcome TrustWellcome TrustEuropean Commission	National Institute for Health Research Health Technology Assessment, JP Moulton Charitable Trust, Department of Health and Social Care, Department for International Development, Global Challenges Research Fund, Medical Research Council, and Wellcome Trust (Joint Global Health Trials scheme).	Dewan MC, 2019, J NEUROSURG, V130, P1080, DOI 10.3171/2017.10.JNS17352; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Gayet-Ageron A, 2018, LANCET, V391, P125, DOI 10.1016/S0140-6736(17)32455-8; Hijazi N, 2015, BLOOD, V125, P2558, DOI 10.1182/blood-2014-08-588442; Medcalf RL, 2015, BLOOD, V125, P2457, DOI 10.1182/blood-2015-02-629808; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Perel P, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16130; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; Roberts I, 2018, WELLCOME OPEN RES, V3, P86, DOI [10.12688/wellcomeopenres.14700.2, DOI 10.12688/wellcomeopenres.14700.2]; Roberts I, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0685-8; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X; RODGERS A, 1995, THROMB HAEMOSTASIS, V73, P167; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; *WORLD MED ASS, 2018, WMA DECL HELS ETH PR; Yutthakasemsunt S, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-20; Zhang J, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011774	17	154	154	4	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 9	2019	394	10210					1713	1723		10.1016/S0140-6736(19)32233-0			11	Medicine, General & Internal	General & Internal Medicine	JN5DZ	WOS:000496920300027	31623894	Green Accepted, Green Published, Other Gold	Y	Y	2021-06-18	
J	Collins, MW; Kontos, AP; Reynolds, E; Murawski, CD; Fu, FH				Collins, Michael W.; Kontos, Anthony P.; Reynolds, Erin; Murawski, Christopher D.; Fu, Freddie H.			A comprehensive, targeted approach to the clinical care of athletes following sport-related concussion	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Concussion; Mild-traumatic brain injury; Neurocognitive testing; Return to play	PREDICT PROTRACTED RECOVERY; TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; POSTURAL STABILITY; FOOTBALL; SYMPTOMS; SCORES; TIME	The purpose of this paper is to discuss risk and prognostic factors for concussion outcomes, review comprehensive approaches to assessment, and describe a new method for conceptualizing treatment for sport-related concussion using clinical experience. Based on the current literature of sport-related concussion and clinical experience, an approach for conceptualizing concussion care using clinical trajectories and targeted treatments was developed. A comprehensive approach to assessment and targeted treatments for sport-related concussion was developed using specific clinical trajectories. Sport-related concussions are heterogeneous and require an individualized clinical approach. The use of a comprehensive approach for assessing specific clinical trajectories following a sport-related concussion will help clinicians better conceptualize this injury. Clinicians can then match targeted treatment pathways to specific clinical trajectories to accelerate safe return to play for athletes following a sport-related concussion. V.	[Collins, Michael W.; Kontos, Anthony P.; Reynolds, Erin] UPMC Sports Med Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA 15203 USA; [Murawski, Christopher D.; Fu, Freddie H.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, Pittsburgh, PA 15213 USA	Fu, FH (corresponding author), Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, 3471 Fifth Ave,Suite 1011, Pittsburgh, PA 15213 USA.	ffu@upmc.edu		Kontos, Anthony/0000-0002-3749-4310			Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McGrath N, 2013, BRAIN INJURY, V27, P103, DOI 10.3109/02699052.2012.729282; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Naguib MB, 2012, J LARYNGOL OTOL, V126, P26, DOI 10.1017/S002221511100291X; NASHNER LM, 1982, J NEUROSCI, V2, P536; Pardini D., 2004, BR J SPORTS MED, V38, P661; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Reddy CC, 2013, J HEAD TRAUMA REHAB, V28, P260, DOI 10.1097/HTR.0b013e318257fbc6; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sandel NK, 2013, APPL NEUROPSYCH-CHIL, V2, P64, DOI 10.1080/21622965.2012.670580; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940	43	154	154	0	28	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	FEB	2014	22	2					235	246		10.1007/s00167-013-2791-6			12	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	AA1EA	WOS:000330837900002	24337463				2021-06-18	
J	Spence, RD; Hamby, ME; Umeda, E; Itoh, N; Du, SM; Wisdom, AJ; Cao, Y; Bondar, G; Lam, J; Ao, Y; Sandoval, F; Suriany, S; Sofroniew, MV; Voskuhl, RR				Spence, Rory D.; Hamby, Mary E.; Umeda, Elizabeth; Itoh, Noriko; Du, Sienmi; Wisdom, Amy J.; Cao, Yuan; Bondar, Galyna; Lam, Jeannie; Ao, Yan; Sandoval, Francisco; Suriany, Silvie; Sofroniew, Michael V.; Voskuhl, Rhonda R.			Neuroprotection mediated through estrogen receptor-alpha in astrocytes	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						multiple sclerosis; astrogliosis; conditional knockout	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SPINAL-CORD-INJURY; MULTIPLE-SCLEROSIS; THERAPEUTIC IMPLICATIONS; REACTIVE ASTROCYTES; BRAIN INJURY; RAT-BRAIN; ER-BETA; DISEASE; EXPRESSION	Estrogen has well-documented neuroprotective effects in a variety of clinical and experimental disorders of the CNS, including autoimmune inflammation, traumatic injury, stroke, and neurodegenerative diseases. The beneficial effects of estrogens in CNS disorders include mitigation of clinical symptoms, as well as attenuation of histopathological signs of neurodegeneration and inflammation. The cellular mechanisms that underlie these CNS effects of estrogens are uncertain, because a number of different cell types express estrogen receptors in the peripheral immune system and the CNS. Here, we investigated the potential roles of two endogenous CNS cell types in estrogen-mediated neuroprotection. We selectively deleted estrogen receptor-a (ERa) from either neurons or astrocytes using well-characterized Cre-loxP systems for conditional gene knockout in mice, and studied the effects of these conditional gene deletions on ERa ligand-mediated neuroprotective effects in a wellcharacterized model of adoptive experimental autoimmune encephalomyelitis (EAE). We found that the pronounced and significant neuroprotective effects of systemic treatment with ERa ligand on clinical function, CNS inflammation, and axonal loss during EAE were completely prevented by conditional deletion of ERa from astrocytes, whereas conditional deletion of ERa from neurons had no significant effect. These findings show that signaling through ERa in astrocytes, but not through ERa in neurons, is essential for the beneficial effects of ERa ligand in EAE. Our findings reveal a unique cellular mechanism for estrogen-mediated CNS neuroprotective effects by signaling through astrocytes, and have implications for understanding the pathophysiology of sex hormone effects in diverse CNS disorders.	[Hamby, Mary E.; Bondar, Galyna; Ao, Yan; Sofroniew, Michael V.] Univ Calif Los Angeles, Dept Neurobiol, Multiple Sclerosis Program, Los Angeles, CA 90095 USA; [Spence, Rory D.; Umeda, Elizabeth; Itoh, Noriko; Du, Sienmi; Wisdom, Amy J.; Cao, Yuan; Lam, Jeannie; Sandoval, Francisco; Suriany, Silvie; Voskuhl, Rhonda R.] Univ Calif Los Angeles, Dept Neurol, Multiple Sclerosis Program, Los Angeles, CA 90095 USA	Sofroniew, MV (corresponding author), Univ Calif Los Angeles, Dept Neurobiol, Multiple Sclerosis Program, Los Angeles, CA 90095 USA.	sofroniew@mednet.ucla.edu; rvoskuhl@ucla.edu	Sofroniew, Michael/ABE-8857-2020	Wisdom, Amy/0000-0002-6098-5353	National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [RG4033, RG4364, CA1028]; Adelson Medical Research Foundation; National Institutes of Health and National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 062117, NS057624]; Skirball Foundation; Hilton Foundation; Sherak Family Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM065823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K24NS062117, R01NS057624] Funding Source: NIH RePORTER	We thank members of the R.R.V. and M.V.S. laboratories, as well as Dr. Tiwari-Woodruff, for discussion and assistance, and Dr. Pierre Chambon for his generosity in sharing the estrogen receptor-alpha floxed mice. This work was supported by Grants RG4033, RG4364, and CA1028 from the National Multiple Sclerosis Society (to R.R.V.), the Adelson Medical Research Foundation (R.R.V. and M.V.S.), National Institutes of Health and National Institute of Neurological Disorders and Stroke Grants NS 062117 (to R.R.V.) and NS057624 (to M.V.S.), and the Skirball Foundation, Hilton Foundation, and Sherak Family Foundation.	Barres BA, 2008, NEURON, V60, P430, DOI 10.1016/j.neuron.2008.10.013; Brinton RD, 2008, ADV DRUG DELIVER REV, V60, P1504, DOI 10.1016/j.addr.2008.06.003; Cerciat M, 2010, GLIA, V58, P93, DOI 10.1002/glia.20904; Chaovipoch P, 2006, J NEUROTRAUM, V23, P830, DOI 10.1089/neu.2006.23.830; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Dupont S, 2000, DEVELOPMENT, V127, P4277; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; Freeman MR, 2010, SCIENCE, V330, P774, DOI 10.1126/science.1190928; Garcia-Ovejero D, 2002, J COMP NEUROL, V450, P256, DOI 10.1002/cne.10325; Garidou L, 2004, J IMMUNOL, V173, P2435, DOI 10.4049/jimmunol.173.4.2435; Giraud SN, 2010, P NATL ACAD SCI USA, V107, P8416, DOI 10.1073/pnas.0910627107; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Jazin E, 2010, NAT REV NEUROSCI, V11, P9, DOI 10.1038/nrn2754; Kim S, 1999, NEUROLOGY, V52, P1230, DOI 10.1212/WNL.52.6.1230; Kwon CH, 2006, GENESIS, V44, P130, DOI 10.1002/gene.20197; Lee SJ, 2001, ANNU REV PHARMACOL, V41, P569, DOI 10.1146/annurev.pharmtox.41.1.569; Mitra SW, 2003, ENDOCRINOLOGY, V144, P2055, DOI 10.1210/en.2002-221069; Morales LBJ, 2006, J NEUROSCI, V26, P6823, DOI 10.1523/JNEUROSCI.0453-06.2006; Perez SE, 2003, DEV BRAIN RES, V145, P117, DOI 10.1016/S0165-3806(03)00223-2; Polanczyk M, 2003, AM J PATHOL, V163, P1599, DOI 10.1016/S0002-9440(10)63516-X; Sherwin BB, 2007, J STEROID BIOCHEM, V106, P151, DOI 10.1016/j.jsbmb.2007.05.016; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Tiwari-Woodruff S, 2007, P NATL ACAD SCI USA, V104, P14813, DOI 10.1073/pnas.0703783104; Trapp BD, 2008, ANNU REV NEUROSCI, V31, P247, DOI 10.1146/annurev.neuro.30.051606.094313; Voskuhl RR, 2009, J NEUROSCI, V29, P11511, DOI 10.1523/JNEUROSCI.1514-09.2009; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2; Wujek JR, 2002, J NEUROPATH EXP NEUR, V61, P23, DOI 10.1093/jnen/61.1.23	27	154	158	0	10	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	MAY 24	2011	108	21					8867	8872		10.1073/pnas.1103833108			6	Multidisciplinary Sciences	Science & Technology - Other Topics	768CB	WOS:000290908000068	21555578	Green Published, Bronze			2021-06-18	
J	Nutley, SB; Soderqvist, S; Bryde, S; Thorell, LB; Humphreys, K; Klingberg, T				Nutley, Sissela Bergman; Soderqvist, Stina; Bryde, Sara; Thorell, Lisa B.; Humphreys, Keith; Klingberg, Torkel			Gains in fluid intelligence after training non-verbal reasoning in 4-year-old children: a controlled, randomized study	DEVELOPMENTAL SCIENCE			English	Article							WORKING-MEMORY CAPACITY; TRAUMATIC BRAIN-INJURY; EXECUTIVE FUNCTIONS; IMPAIRMENTS; EXPECTANCY; ACTIVATION; PLASTICITY; MECHANISM; DEFICITS; SPAN	Fluid intelligence (Gf) predicts performance on a wide range of cognitive activities, and children with impaired Gf often experience academic difficulties. Previous attempts to improve Gf have been hampered by poor control conditions and single outcome measures. It is thus still an open question whether Gf can be improved by training. This study included 4-year-old children (N = 101) who performed computerized training (15 min/day for 25 days) of either non-verbal reasoning, working memory, a combination of both, or a placebo version of the combined training. Compared to the placebo group, the non-verbal reasoning training group improved significantly on Gf when analysed as a latent variable of several reasoning tasks. Smaller gains on problem solving tests were seen in the combination training group. The group training working memory improved on measures of working memory, but not on problem solving tests. This study shows that it is possible to improve Gf with training, which could have implications for early interventions in children.	[Nutley, Sissela Bergman] Karolinska Inst, Dept Neurosci, Retzius Lab, Stockholm, Sweden; [Nutley, Sissela Bergman; Soderqvist, Stina; Bryde, Sara; Thorell, Lisa B.; Klingberg, Torkel] Karolinska Inst, Stockholm Brain Inst, Stockholm, Sweden; [Thorell, Lisa B.] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Thorell, Lisa B.] Karolinska Inst, Ctr Neurodev Disorders, Stockholm, Sweden; [Humphreys, Keith] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden	Nutley, SB (corresponding author), Karolinska Inst, Dept Neurosci, Retzius Lab, Stockholm, Sweden.	sissela.bergman.nutley@ki.se	Thorell, Lisa B/E-5259-2011	Thorell, Lisa B/0000-0002-7417-6637; Klingberg, Torkel/0000-0002-3175-2171			Alloway T. P., 2007, AUTOMATED WORKING ME; Bengtsson SL, 2005, NAT NEUROSCI, V8, P1148, DOI 10.1038/nn1516; Buehner M, 2005, INTELLIGENCE, V33, P251, DOI 10.1016/j.intell.2005.01.002; Conway ARA, 2003, TRENDS COGN SCI, V7, P547, DOI 10.1016/j.tics.2003.10.005; Crone EA, 2009, DEVELOPMENTAL SCI, V12, P825, DOI 10.1111/j.1467-7687.2009.00918.x; Dahlin E, 2008, SCIENCE, V320, P1510, DOI 10.1126/science.1155466; Dahlin E, 2009, RESTOR NEUROL NEUROS, V27, P405, DOI 10.3233/RNN-2009-0492; Dalen K, 2008, NEUROPEDIATRICS, V39, P146, DOI 10.1055/s-0028-1085463; DICKSTEIN LS, 1972, PSYCHOL REP, V30, P207, DOI 10.2466/pr0.1972.30.1.207; Edin F, 2007, J COGNITIVE NEUROSCI, V19, P750, DOI 10.1162/jocn.2007.19.5.750; Edin F, 2009, P NATL ACAD SCI USA, V106, P6802, DOI 10.1073/pnas.0901894106; Engle RW, 1999, J EXP PSYCHOL GEN, V128, P309, DOI 10.1037/0096-3445.128.3.309; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Hall P, 2004, BMJ-BRIT MED J, V328, P19, DOI 10.1136/bmj.328.7430.19; Hamers JHM, 1998, CONTEMP EDUC PSYCHOL, V23, P132, DOI 10.1006/ceps.1998.0966; Hempel A, 2004, AM J PSYCHIAT, V161, P745, DOI 10.1176/appi.ajp.161.4.745; HERRNSTEIN RJ, 1986, AM PSYCHOL, V41, P1279; Holmes J, 2010, APPL COGNITIVE PSYCH, V24, P827, DOI 10.1002/acp.1589; HORN JL, 1966, J EDUC PSYCHOL, V57, P253, DOI 10.1037/h0023816; Jaeggi SM, 2008, P NATL ACAD SCI USA, V105, P6829, DOI 10.1073/pnas.0801268105; Jolles DD, 2010, NEUROIMAGE, V52, P658, DOI 10.1016/j.neuroimage.2010.04.028; Kane MJ, 2004, J EXP PSYCHOL GEN, V133, P189, DOI 10.1037/0096-3445.133.2.189; Klauer KJ, 2002, CONTEMP EDUC PSYCHOL, V27, P1, DOI 10.1006/ceps.2001.1079; Klingberg T, 2002, J CLIN EXP NEUROPSYC, V24, P781, DOI 10.1076/jcen.24.6.781.8395; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Klingberg T, 2010, TRENDS COGN SCI, V14, P317, DOI 10.1016/j.tics.2010.05.002; KYLLONEN PC, 1990, INTELLIGENCE, V14, P389, DOI 10.1016/S0160-2896(05)80012-1; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Lynn R, 2007, J BIOSOC SCI, V39, P861, DOI 10.1017/S0021932007001964; Martinussen R, 2005, J AM ACAD CHILD PSY, V44, P377, DOI 10.1097/01.chi.0000153228.72591.73; McLean JF, 1999, J EXP CHILD PSYCHOL, V74, P240, DOI 10.1006/jecp.1999.2516; Mcnab F, 2008, NEUROPSYCHOLOGIA, V46, P2668, DOI 10.1016/j.neuropsychologia.2008.04.023; McNab F, 2009, SCIENCE, V323, P800, DOI 10.1126/science.1166102; Moody DE, 2009, INTELLIGENCE, V37, P327, DOI 10.1016/j.intell.2009.04.005; Moore CD, 2006, J NEUROSCI, V26, P11187, DOI 10.1523/JNEUROSCI.1873-06.2006; Nudo RJ, 1996, J NEUROSCI, V16, P785; Nutley SB, 2010, DEV NEUROPSYCHOL, V35, P81, DOI 10.1080/87565640903325741; Oken BS, 2008, J CLIN EXP NEUROPSYC, V30, P7, DOI 10.1080/13803390701775428; Olesen PJ, 2004, NAT NEUROSCI, V7, P75, DOI 10.1038/nn1165; Owen AM, 2010, NATURE, V465, P775, DOI 10.1038/nature09042; PLEMONS JK, 1978, J GERONTOL, V33, P224, DOI 10.1093/geronj/33.2.224; Raven J., 1998, MANUAL RAVENS PROGRE; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031; Roid G.H., 1997, LEITER INT PERFORMAN; Rueda MR, 2005, P NATL ACAD SCI USA, V102, P14931, DOI 10.1073/pnas.0506897102; STANKOV L, 1986, INTELLIGENCE, V10, P209, DOI 10.1016/0160-2896(86)90016-4; Sternberg RJ, 2008, P NATL ACAD SCI USA, V105, P6791, DOI 10.1073/pnas.0803396105; Strauss E., 2006, COMPENDIUM NEUROPSCY; Takeuchi H, 2010, J NEUROSCI, V30, P3297, DOI 10.1523/JNEUROSCI.4611-09.2010; Thompson-Schill SL, 2009, CURR DIR PSYCHOL SCI, V18, P259, DOI 10.1111/j.1467-8721.2009.01648.x; Thorell LB, 2006, INFANT CHILD DEV, V15, P503, DOI 10.1002/icd.475; Thorell LB, 2009, DEVELOPMENTAL SCI, V12, P106, DOI 10.1111/j.1467-7687.2008.00745.x; Wartenburger I, 2009, NEUROIMAGE, V48, P291, DOI 10.1016/j.neuroimage.2009.06.025; Wechsler D., 1991, WECHSLER INTELLIGENC; Wechsler D, 2004, WECHSLER PRESCHOOL P; Westerberg H, 2004, CHILD NEUROPSYCHOL, V10, P155, DOI 10.1080/09297040490911014; Wright SB, 2008, FRONT HUM NEUROSCI, V1, DOI 10.3389/neuro.09.008.2007	57	154	157	3	41	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1363-755X	1467-7687		DEVELOPMENTAL SCI	Dev. Sci.	MAY	2011	14	3					591	601		10.1111/j.1467-7687.2010.01022.x			11	Psychology, Developmental; Psychology, Experimental	Psychology	747ED	WOS:000289302200013	21477197				2021-06-18	
J	Schatz, P				Schatz, Philip			Long-Term Test-Retest Reliability of Baseline Cognitive Assessments Using ImPACT	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; neurocognitive testing; neuropsychological testing; baseline assessment	SPORT-RELATED CONCUSSION; COMPUTER-BASED ASSESSMENT; NEUROPSYCHOLOGICAL ASSESSMENT; PROFESSIONAL FOOTBALL; AGREEMENT STATEMENT; TEST-PERFORMANCE; SEX-DIFFERENCES; RECOVERY; MANAGEMENT; SYMPTOMS	Background: Computer-based assessment programs are commonly used to document baseline cognitive performance for comparison with postconcussion testing. There are currently no guidelines for how often baseline assessments should be updated, and no data documenting the test-retest stability of baseline measures over relevant time periods. Purpose: To establish long-term test-retest reliability of baseline assessments using ImPACT, and to compare various statistical methods for establishing test-retest reliability. Study Design: Case series; Level Of evidence, 4. Methods: Participants were 95 collegiate varsity athletes completing baseline cognitive testing at 2 time periods, approximately 2 years apart. No participant sustained a concussion between assessments. All athletes completed the ImPACT test battery; dependent measures were the composite scores and total symptom scale score. Results: Intraclass correlation coefficient estimates for visual memory (.65), processing speed (.74), and reaction time (.68) composite scores reflected stability over the 2-year period, with greater variability in verbal memory (.46) and symptom scale (.43) scores. Using reliable change indices and regression-based methods, only a small percentage of participants' scores showed "reliable" or "significant" change on the composite scores (0%-6%), or symptom scale scores (5%-10%). Conclusion: The current results suggest that college athletes' cognitive performance at baseline remains considerably stable over a 2-year period. These data help establish the effects of longer, clinically pragmatic testing intervals on test-retest reliability. Clinical Implications: The current results suggest that stretching the time between baseline assessments from 1 to 2 years may have little effect on the clinical management of concussions in collegiate athletes. These results should not be generalized to collegiate football players, who were not included in this sample. Youth athletes (high school and younger) should continue to receive annually updated baseline assessments until prospective study of the stability of baseline assessments for this younger age group can be completed.	St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA	Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 222 Post Hall,5600 City Ave, Philadelphia, PA 19131 USA.	pschatz@sju.edu		Schatz, Philip/0000-0002-6222-6545			ALVES WM, 1987, CLIN SPORT MED, V6, P211; Anastasi A., 1998, PSYCHOL TESTING; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BARR WB, 2002, CNS SPECTRUMS, V7, P304; Barr William B, 2002, CNS Spectr, V7, P300; Barth JT., 1989, MILD HEAD INJURY, P257; Baumgartner T.A., 2001, MEAS PHYS EDUC EXERC, V5, P179, DOI [10.1207/S15327841MPEE0503_4, DOI 10.1207/S15327841MPEE0503_4]; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Crawford JR, 2006, NEUROPSYCHOLOGY, V20, P259, DOI 10.1037/0894-4105.20.3.259; ECHEMENDIA R, 2006, NEUROPSYCHOLOGY ASSE; FLEISHMAN J, 1987, EDUC PSYCHOL MEAS, V47, P925, DOI 10.1177/0013164487474008; Guskiewicz KM, 2004, NEUROSURGERY, V55, P891, DOI 10.1227/01.NEU.0000143800.49798.19; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; Iverson GL, 2001, LUPUS, V10, P266, DOI 10.1191/096120301680416959; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kelly JP, 1997, NEUROLOGY, V48, P581; LEHMAN LB, 1987, AM J SPORT MED, V15, P494, DOI 10.1177/036354658701500512; LOVELL M, 2002, IMPACT VERSION 2 0 C; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MACCIOCCHI SN, 1990, J CLIN PSYCHOL, V46, P628, DOI 10.1002/1097-4679(199009)46:5<628::AID-JCLP2270460514>3.0.CO;2-V; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; Maruff P, 2004, BRIT J SPORT MED, V38, P654; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Portney L., 2015, FDN CLIN RES APPL PR, V3rd ed.; Randolph C, 2005, J ATHL TRAINING, V40, P139; RODGERS JL, 1988, AM STAT, V42, P59, DOI 10.2307/2685263; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Swanik CB, 2007, AM J SPORT MED, V35, P943, DOI 10.1177/0363546507299532; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Wilk CM, 2002, AM J PSYCHIAT, V159, P838, DOI 10.1176/appi.ajp.159.5.838; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	53	154	154	0	25	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JAN	2010	38	1					47	53		10.1177/0363546509343805			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	539XT	WOS:000273293300005	19789333				2021-06-18	
J	Geeraerts, T; Newcombe, VFJ; Coles, JP; Abate, MG; Perkes, IE; Hutchinson, PJA; Outtrim, JG; Chatfield, DA; Menon, DK				Geeraerts, Thomas; Newcombe, Virginia F. J.; Coles, Jonathan P.; Abate, Maria Giulia; Perkes, Iain E.; Hutchinson, Peter J. A.; Outtrim, Jo G.; Chatfield, Dot A.; Menon, David K.			Use of T2-weighted magnetic resonance imaging of the optic nerve sheath to detect raised intracranial pressure	CRITICAL CARE			English	Article							TRANSORBITAL SONOGRAPHIC EVALUATION; SUBARACHNOID SPACE; HYPERTENSION; INJURY; ULTRASONOGRAPHY; AUTOREGULATION; FUNDAMENTALS; PAPILLEDEMA; ULTRASOUND; EXPANSION	Introduction The dural sheath surrounding the optic nerve communicates with the subarachnoid space, and distends when intracranial pressure is elevated. Magnetic resonance imaging (MRI) is often performed in patients at risk for raised intracranial pressure (ICP) and can be used to measure precisely the diameter of optic nerve and its sheath. The objective of this study was to assess the relationship between optic nerve sheath diameter (ONSD), as measured using MRI, and ICP. Methods We conducted a retrospective blinded analysis of brain MRI images in a prospective cohort of 38 patients requiring ICP monitoring after severe traumatic brain injury (TBI), and in 36 healthy volunteers. ONSD was measured on T2-weighted turbo spin-echo fat-suppressed sequence obtained at 3 Tesla MRI. ICP was measured invasively during the MRI scan via a parenchymal sensor in the TBI patients. Results Measurement of ONSD was possible in 95% of cases. The ONSD was significantly greater in TBI patients with raised ICP (> 20 mmHg; 6.31 +/- 0.50 mm, 19 measures) than in those with ICP of 20 mmHg or less (5.29 +/- 0.48 mm, 26 measures; P < 0.0001) or in healthy volunteers (5.08 +/- 0.52 mm; P < 0.0001). There was a significant relationship between ONSD and ICP (r = 0.71, P < 0.0001). Enlarged ONSD was a robust predictor of raised ICP (area under the receiver operating characteristic curve = 0.94), with a best cut-off of 5.82 mm, corresponding to a negative predictive value of 92%, and to a value of 100% when ONSD was less than 5.30 mm. Conclusions When brain MRI is indicated, ONSD measurement on images obtained using routine sequences can provide a quantitative estimate of the likelihood of significant intracranial hypertension.	[Geeraerts, Thomas; Newcombe, Virginia F. J.; Coles, Jonathan P.; Abate, Maria Giulia; Perkes, Iain E.; Outtrim, Jo G.; Chatfield, Dot A.; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Univ Div Anaesthesia, Cambridge CB2 2QQ, England; [Geeraerts, Thomas; Newcombe, Virginia F. J.; Coles, Jonathan P.; Abate, Maria Giulia; Perkes, Iain E.; Hutchinson, Peter J. A.; Outtrim, Jo G.; Chatfield, Dot A.; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; [Geeraerts, Thomas] AP HP, Dept Anesthesie Reanimat Chirurgicale, F-94275 Le Kremlin Bicetre, France; [Geeraerts, Thomas] Univ Paris Sud, Ctr Hosp Univ Bicetre, F-94275 Le Kremlin Bicetre, France; [Hutchinson, Peter J. A.] Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England	Geeraerts, T (corresponding author), Univ Cambridge, Addenbrookes Hosp, Univ Div Anaesthesia, Hills Rd, Cambridge CB2 2QQ, England.	thgeeraerts@hotmail.com	Perkes, Iain/J-7001-2017	Perkes, Iain/0000-0001-8028-9032; Newcombe, Virginia/0000-0001-6044-9035	Societe Francaise d'Anesthesie et de Reanimation (SFAR); Journees d'Enseignement Post-Universitaire d'Anesthesie-Reanimation (JEPU)-Novo NordiskNovo Nordisk; Academy of Medical Sciences/ Health Foundation Clinician Scientist Fellowship (UK); Academy of Medical Science/Health Foundation Senior Surgical Scientist Fellowship (UK); Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); Royal College of Anaesthetists; Wellcome TrustWellcome TrustEuropean Commission; Evelyn Trust; Queens' College Cambridge; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0601025, G0600986, G9439390] Funding Source: researchfish	This research was conducted within the frameworks of a Medical Research Council (UK) Program Grant (Acute brain injury: heterogeneity of mechanisms, therapeutic targets and outcome effects [G9439390 ID 65883]) and of the Biomedical Research Center, Addenbrooke's Hospital, Cambridge, UK. TG is supported by grants from the Societe Francaise d'Anesthesie et de Reanimation (SFAR) and from Journees d'Enseignement Post-Universitaire d'Anesthesie-Reanimation (JEPU)-Novo Nordisk. VFJN is supported by the Gates Cambridge Trust and an Overseas Research Studentship. JPC is supported by an Academy of Medical Sciences/ Health Foundation Clinician Scientist Fellowship (UK). PJAH is supported by an Academy of Medical Science/Health Foundation Senior Surgical Scientist Fellowship (UK). DKM is supported by grants from the Medical Research Council (UK), Royal College of Anaesthetists, Wellcome Trust, the Evelyn Trust, and Queens' College Cambridge.	Agid R, 2006, NEURORADIOLOGY, V48, P521, DOI 10.1007/s00234-006-0095-y; Bergman R, 2008, RESUSCITATION, V76, P142, DOI 10.1016/j.resuscitation.2007.06.011; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Brodsky MC, 1998, OPHTHALMOLOGY, V105, P1686, DOI 10.1016/S0161-6420(98)99039-X; Calvo A, 2003, BRIT J NEUROSURG, V17, P450, DOI 10.1080/02688690310001611242; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; Friedman DI, 2002, NEUROLOGY, V59, P1492, DOI 10.1212/01.WNL.0000029570.69134.1B; Gass A, 1996, NEURORADIOLOGY, V38, P769, DOI 10.1007/s002340050344; GEERAERTS T, 2008, INTENSIVE C IN PRESS; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc6893; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Hansen HC, 1996, SURG RADIOL ANAT, V18, P323, DOI 10.1007/BF01627611; HAYREH S S, 1964, Br J Ophthalmol, V48, P522, DOI 10.1136/bjo.48.10.522; Helmke K, 2000, TRANSPLANTATION, V70, P392, DOI 10.1097/00007890-200007270-00029; Helmke K, 1996, PEDIATR RADIOL, V26, P706, DOI 10.1007/BF01383384; Helmke K, 1996, PEDIATR RADIOL, V26, P701, DOI 10.1007/BF01383383; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Lam BL, 1997, OPHTHALMOLOGY, V104, P1629, DOI 10.1016/S0161-6420(97)30085-2; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mashima Y, 1996, ARCH OPHTHALMOL-CHIC, V114, P1197, DOI 10.1001/archopht.1996.01100140397006; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Newcombe VFJ, 2008, J NEUROSURG, V109, P159, DOI 10.3171/JNS/2008/109/7/0159; Newton CRJC, 1997, ARCH DIS CHILD, V76, P219, DOI 10.1136/adc.76.3.219; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; Ozgen A, 2000, J COMPUT ASSIST TOMO, V24, P493, DOI 10.1097/00004728-200005000-00025; Pedersen M, 2007, J APPL PHYSIOL, V102, P72, DOI 10.1152/japplphysiol.00697.2006; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; Soldatos T, 2008, CRIT CARE, V12, DOI 10.1186/cc6897; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; WARE AJ, 1971, GASTROENTEROLOGY, V61, P877; Watanabe A, 2008, AM J NEURORADIOL, V29, P863, DOI 10.3174/ajnr.A1027; Weigel M, 2006, INVEST RADIOL, V41, P83, DOI 10.1097/01.rli.0000195820.98062.c5; Winkler F, 2002, J NEUROL, V249, P1292, DOI 10.1007/s00415-002-0844-8	37	154	161	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2008	12	5							R114	10.1186/cc7006			7	Critical Care Medicine	General & Internal Medicine	381UJ	WOS:000261561100002	18786243	DOAJ Gold, Green Published			2021-06-18	
J	Lundin, A; Boussard, C; Edman, G; Borg, J				Lundin, A.; De Boussard, C.; Edman, G.; Borg, J.			Symptoms and disability until 3 months after mild TBI	BRAIN INJURY			English	Article						mild TBI; symptoms; disability	TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; FOLLOW-UP; CONCUSSION; QUESTIONNAIRE	Objective: Examine frequency, character and course of symptoms until 3 months after MTBI and the relation between symptoms and disability. Methods: Prospective cohort study of 122 consecutive patients with MTBI. Symptom assessment after 1, 7 and 14 days and 3 months post-injury by use of Rivermead Post-concussional Questionnaire. Disability assessment by use of Rivermead Head Injury Follow-up Questionnaire. Results: Patients reporting one or more symptoms declined from 86% on day 1 to 49% 3 months post-injury, when 25% also reported change in one or more domains of everyday activities. Poor memory, sleep disturbance and fatigue were most commonly reported. Symptom and disability scores were correlated (tau=0.60; p < 0.001). Early symptom load correlated with late symptom load (tau=0.38; p < 0.01). Conclusions: Symptoms gradually decline post-injury. Symptoms correlate with disability at 3 months. Patients with early high symptom load are at risk for developing persisting complaints.	Karolinska Inst, Danderyd Hosp, Dept Psychiat, Stockholm, Sweden; Karolinska Inst, Danderyd Hosp, Dept Rehabil Med, Stockholm, Sweden; Univ Uppsala Hosp, Dept Neurosci Rehabil Med, Uppsala, Sweden	Lundin, A (corresponding author), Karolinska Inst, Danderyd Hosp, Psychiat Clin, R&D Sect, S-18287 Danderyd, Sweden.	anders.lundin@ds.se		Borg, Jorgen/0000-0002-2372-7478			Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CARROLL LJ, WHO COLLABORATING CT; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LIDVALL HF, 1974, ACTA NEUROLOGICA S56, V50; LOWDON IMR, 1989, INJURY, V20, P193, DOI 10.1016/0020-1383(89)90109-5; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	22	154	154	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2006	20	8					799	806		10.1080/02699050600744327			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	081ZO	WOS:000240356300003	17060147				2021-06-18	
J	Eby, GA; Eby, KL				Eby, GA; Eby, KL			Rapid recovery from major depression using magnesium treatment	MEDICAL HYPOTHESES			English	Article							NITRIC-OXIDE; BRAIN-INJURY; CALCIUM; SERUM; DISORDERS; SUPPLEMENTATION; BIOAVAILABILITY; ASSOCIATION; PREVALENCE; CHILDREN	Major depression is a mood disorder characterized by a sense of inadequacy, despondency, decreased activity, pessimism, anhedonia and sadness where these symptoms severely disrupt and adversely affect the person's life, sometimes to such an extent that suicide is attempted or results. Antidepressant drugs are not always effective and some have been accused of causing an increased number of suicides particularly in young people. Magnesium deficiency is well known to produce neuropathotogies. Only 16% of the magnesium found in whole wheat remains in refined flour, and magnesium has been removed from most drinking water supplies, setting a stage for human magnesium deficiency. Magnesium ions regulate calcium ion flow in neuronal calcium channels, helping to regulate neuronal nitric oxide production. In magnesium deficiency, neuronal requirements for magnesium may not be met, causing neuronal damage which could manifest as depression. Magnesium treatment is hypothesized to be effective in treating major depression resulting from intraneuronal magnesium deficits. These magnesium ion neuronal deficits may be induced by stress hormones, excessive dietary calcium as well as dietary deficiencies of magnesium. Case histories are presented showing rapid recovery (less than 7 days) from major depression using 125-300 mg of magnesium (as glycinate and taurinate) with each meat and at bedtime. Magnesium was found usually effective for treatment of depression in general use. Related and accompanying mental illnesses in these case histories including traumatic brain injury, headache, suicidal ideation, anxiety, irritability, insomnia, postpartum depression, cocaine, alcohol and tobacco abuse, hypersensitivity to calcium, short-term memory loss and IQ toss were also benefited. Dietary deficiencies of magnesium, coupled with excess calcium and stress may cause many cases of other related symptoms including agitation, anxiety, irritability, confusion, asthenia, sleeplessness, headache, delirium, hallucinations and hyperexcitability, with each of these having been previously documented. The possibility that magnesium deficiency is the cause of most major depression and related mental health problems including IQ loss and addiction is enormously important to public health and is recommended for immediate further study. Fortifying refined grain and drinking water with biologically available magnesium to pre-twentieth century levels is recommended. (c) 2006 Elsevier Ltd. All rights reserved.	George Eby Res, Austin, TX 78736 USA	Eby, GA (corresponding author), George Eby Res, 14909-C Fitzhugh Rd, Austin, TX 78736 USA.	george.eby@coldcure.com					Aaserud M, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-68; Al-Khathami AD, 2002, SAUDI MED J, V23, P721; Al-Shammari SA, 1999, INT J GERIATR PSYCH, V14, P739, DOI 10.1002/(SICI)1099-1166(199909)14:9<739::AID-GPS998>3.0.CO;2-1; Altura BM, 1999, ALCOHOL, V19, P119, DOI 10.1016/S0741-8329(99)00025-7; [Anonymous], 1999, WORLD HLTH REP MAK D; Banki C M, 1986, Ann N Y Acad Sci, V487, P221, DOI 10.1111/j.1749-6632.1986.tb27901.x; Begon S, 2001, BRIT J PHARMACOL, V134, P1227, DOI 10.1038/sj.bjp.0704354; Brown ES, 2004, BIOL PSYCHIAT, V55, P1, DOI 10.1016/S0006-3223(03)00473-6; Cernak I, 2000, MAGNESIUM RES, V13, P29; Coudray C, 2003, J NUTR, V133, P1; DEAN C, 2003, MIRACLE MAGNESIUM; Dube L, 2003, CAN J ANAESTH, V50, P732, DOI 10.1007/BF03018719; DURLACH D, 1997, MINERAL METAL NEUROT, pCH20; Firoz M, 2001, MAGNESIUM RES, V14, P257; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Held K, 2002, PHARMACOPSYCHIATRY, V35, P135, DOI 10.1055/s-2002-33195; Hollister LE, 1999, CAN J PSYCHIAT, V44, P658, DOI 10.1177/070674379904400702; Imada Y, 2002, PSYCHIAT CLIN NEUROS, V56, P509, DOI 10.1046/j.1440-1819.2002.01046.x; Joffe RT, 1996, BIOL PSYCHIAT, V40, P428, DOI 10.1016/0006-3223(96)00063-7; Kalinin VV, 2004, ZH NEVROPATOL PSIKH, V104, P51; Lazard EM, 1925, AM J OBSTET GYNECOL, V9, P178, DOI 10.1016/S0002-9378(25)90068-3; Levine J, 1999, NEUROPSYCHOBIOLOGY, V39, P63, DOI 10.1159/000026562; LINDBERG JS, 1990, J AM COLL NUTR, V9, P48; Margolin A, 2003, J ADDICT DIS, V22, P49, DOI 10.1300/J069v22n02_04; Mark LP, 2001, AM J NEURORADIOL, V22, P1813; MEACHAM SL, 1995, AM J CLIN NUTR, V61, P341; MEYER JS, 2005, PSYCHOPHARMACOLOGY D, P386; Mousain-Bosc M, 2004, J AM COLL NUTR, V23, p545S, DOI 10.1080/07315724.2004.10719400; Murck H, 2002, NUTR NEUROSCI, V5, P375, DOI 10.1080/1028415021000039194; Murray T D, 1997, Va Med Q, V124, P184; Nechifor M, 2004, MAGNESIUM RES, V17, P176; Papadopol V, 2001, MAGNESIUM RES, V14, P27; Paul IA, 2001, HUM PSYCHOPHARM CLIN, V16, P71, DOI 10.1002/hup.186; Penland James G., 1995, Magnesium Research, V8, P341; Sapolsky RM, 1992, STRESS AGING BRAIN M, P192; Seelig M, 2003, MAGNESIUM FACTOR; SEELIG MS, 1980, MAGNESIUM DEFICIENCY; SHEALY CN, 1992, AM J PAIN MANAGEMENT, V2, P13; Singewald N, 2004, NEUROPHARMACOLOGY, V47, P1189, DOI 10.1016/j.neuropharm.2004.08.010; Tomita R, 2002, DIS COLON RECTUM, V45, P593, DOI 10.1007/s10350-004-6251-8; van den Heuvel Corinna, 2004, Clin Calcium, V14, P9; Varley CK, 2006, CNS DRUGS, V20, P1, DOI 10.2165/00023210-200620010-00001; WACKER WEC, 1968, NEW ENGL J MED, V278, P712, DOI 10.1056/NEJM196803282781306; Walker AF, 2003, MAGNESIUM RES, V16, P183; WESTON PG, 1921, AM J PSYCHIAT, V78, P637; Young LT, 1996, NEUROPSYCHOBIOLOGY, V34, P26; 2002, HARVARD HEART LETT, P2	47	154	159	0	39	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877			MED HYPOTHESES	Med. Hypotheses		2006	67	2					362	370		10.1016/j.mehy.2006.01.047			9	Medicine, Research & Experimental	Research & Experimental Medicine	057WD	WOS:000238625000030	16542786				2021-06-18	
J	Agha, A; Thornton, E; O'Kelly, P; Tormey, W; Phillips, J; Thompson, CJ				Agha, A; Thornton, E; O'Kelly, P; Tormey, W; Phillips, J; Thompson, CJ			Posterior pituitary dysfunction after traumatic brain injury	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							ANTI-DIURETIC HORMONE; DIABETES-INSIPIDUS; HEAD-INJURY; INAPPROPRIATE SECRETION; VASOPRESSIN RELEASE; PRACTICAL SCALE; HYPOPITUITARISM; HYPONATREMIA; DIAGNOSIS; THIRST	Disorders of water balance are well recognized after traumatic brain injury (TBI), but there are no reliable data on their true prevalence in post-TBI patients. We aimed to evaluate the prevalence of posterior pituitary dysfunction in a large cohort of survivors of TBI. One hundred two consecutive patients ( 85 males) who suffered severe or moderate TBI were evaluated for diabetes insipidus (DI) at a median of 17 months ( range 6 - 36 months) after the event, using the 8-h water deprivation test (WDT). Their results were compared against normative data obtained from 27 matched, healthy controls. Patients' medical records were retrospectively reviewed for the presence of abnormalities of salt and water balance in the immediate post-TBI period. Twenty-two patients (21.6%) developed DI in the immediate post-TBI period ( acute DI group), of whom five had abnormal WDT on later testing. In total, seven patients (6.9%) had abnormal WDT ( permanent DI group), five of whom had partial DI. Patients in the acute and permanent DI groups were more likely to have more severe TBI, compared with the rest of the cohort ( P < 0.05). In the immediate post-TBI period, 13 patients (12.9%) had syndrome of inappropriate secretion of antidiuretic hormone, which persisted in one patient, and one other patient developed cerebral salt wasting. Diabetes insipidus and syndrome of inappropriate secretion of antidiuretic hormone were common in the immediate post-TBI period. Permanent DI was present in 6.9% of patients who survived severe or moderate TBI, which is higher than traditionally thought. Identification of patients with partial posttraumatic DI is important because appropriate treatment may reduce morbidity and optimize the potential for recovery.	Beaumont Hosp, Acad Dept Endocrinol, Dublin 9, Ireland; Beaumont Hosp, Acad Dept Renal Med, Dublin 9, Ireland; Beaumont Hosp, Acad Dept Clin Chem, Dublin 9, Ireland; Beaumont Hosp, Acad Dept Neurosurg, Dublin 9, Ireland	Thompson, CJ (corresponding author), Beaumont Hosp, Dept Endocrinol, Beaumont Rd, Dublin 9, Ireland.	christhompson@beaumont.ie					Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; AGHA A, IN PRESS J CLIN ENDO; Alaca R, 2002, AM J PHYS MED REHAB, V81, P788, DOI 10.1097/00002060-200210000-00013; Baylis P, 2001, PRINCIPLES PRACTICE; Baylis PH, 1998, J ROY COLL PHYS LOND, V32, P108; BECKER RM, 1973, J TRAUMA, V13, P112, DOI 10.1097/00005373-197302000-00003; BOHNEN N, 1993, EUR NEUROL, V33, P77, DOI 10.1159/000116907; BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; DASHE AM, 1963, JAMA-J AM MED ASSOC, V185, P699, DOI 10.1001/jama.1963.03060090031011; DOCZI T, 1982, NEUROSURGERY, V10, P685, DOI 10.1227/00006123-198206010-00001; EDWARDS OM, 1986, MEDICINE, V65, P281; JENNETT B, 1975, LANCET, V1, P480; KAUFMAN HH, 1993, MED CLIN N AM, V77, P43, DOI 10.1016/S0025-7125(16)30271-1; KLASBEEK WD, 1980, J NEUROSURG, V53, P519; Moore K, 2003, CLIN MED, V3, P28, DOI 10.7861/clinmedicine.3-1-28; NOTMAN DD, 1980, J TRAUMA, V20, P599, DOI 10.1097/00005373-198007000-00009; Robertson G.L., 1985, FRONTIERS HORMONE RE, P176; SECKL J, 1989, BRIT MED J, V298, P2, DOI 10.1136/bmj.298.6665.2; Smith D, 2002, J CLIN ENDOCR METAB, V87, P4564, DOI 10.1210/jc.2002-020090; Smith DM, 2000, CLIN ENDOCRINOL, V52, P667, DOI 10.1046/j.1365-2265.2000.01027.x; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1992, J NEUROTRAUM, V9, pS249; THOMPSON CJ, 1986, CLIN SCI, V71, P651, DOI 10.1042/cs0710651; THOMPSON CJ, 1987, Q J MED, V65, P853; THOMPSON CJ, 1991, AM J PHYSIOL, V260, pR533; TWIJNSTRA A, 1980, CLIN NEUROL NEUROSUR, V82, P263, DOI 10.1016/0303-8467(80)90018-9; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; VERBALIS JG, 1989, BAILLIERE CLIN ENDOC, V3, P499, DOI 10.1016/S0950-351X(89)80013-8; VERBALIS JG, 2001, PRINCIPLES PRACTICE, P293; VIGERHOETS F, 1988, ACTA NEUROCHIR, V91, P50; Wong M. F. M., 1998, Annals Academy of Medicine Singapore, V27, P340; World Health Organization, 1980, INT CLASS IMP DIS HA; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	33	154	169	1	6	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0021-972X	1945-7197		J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	DEC	2004	89	12					5987	5992		10.1210/jc.2004-1058			6	Endocrinology & Metabolism	Endocrinology & Metabolism	876KJ	WOS:000225495400018	15579748	Bronze			2021-06-18	
J	Cicerone, KD; Mott, T; Azulay, J; Friel, JC				Cicerone, KD; Mott, T; Azulay, J; Friel, JC			Community integration and satisfaction with functioning after intensive cognitive rehabilitation for traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; outcome and process assessment (health care); quality of life; rehabilitation	QUALITY-OF-LIFE; PERCEIVED SELF-EFFICACY; OUTCOMES; QUESTIONNAIRE; RECOMMENDATIONS; PERFORMANCE; PERSPECTIVE; PROGRAM; IMPACT	Objective: To evaluate the effectiveness of an intensive cognitive rehabilitation program (ICRP) compared with Standard neurorehabilitation (SRP) for persons with traumatic brain injury (TBI). Design: Nonrandomized controlled intervention trial. Setting: Community-based, postacute outpatient brain injury rehabilitation program. Participants: Fifty-six persons with TBI. Interventions: Participants in ICRP (n=27) received an intensive, highly structured program of integrated cognitive and psychosocial interventions based on principles of holistic neuropsychologic rehabilitation. Participants in SRP (n=29) received comprehensive neurorehabilitation consisting primarily of physical therapy, occupational therapy, speech therapy, and neuropsycholoaic treatment. Duration of treatment was approximately 4 months for both interventions. Main Outcome Measures: Community Integration Questionnaire (CIQ); and Quality of Community Integration Questionnaire assessing satisfaction with community functioning and satisfaction with cognitive functioning. Neuropsychologic functioning was evaluated for the ICRP participants. Results: Both groups showed significant improvement on the CIQ, with the ICRP group exhibiting a significant treatment effect compared with the SRP group. Analysis of clinically significant improvement indicated that ICRP participants were over twice as likely to show clinical benefit on the CIQ (odds ratio=2.=11: 9590 confidence interval, 0.8-7.2). ICRP participants showed significant improvement in overall neuropsychologic functioning: participants with clinically significant improvement on the CIQ also showed greater improvement of neuropsychologic functioning. Satisfaction with community functioning was not related to community integration after treatment. Satisfaction with cognitive functioning made a significant contribution to posttreatment community integration; this finding may reflect the mediating effects of perceived self-efficacy on functional outcome. Conclusions: Intensive, holistic, cognitive rehabilitation is an effective form of rehabilitation, particularly for persons with TBI who have previously been unable to resume community functioning. Perceived self-efficacy may have significant impact on functional outcomes after TBI rehabilitation. Measures of social participation and subjective well-being appear to represent distinct and separable rehabilitation outcomes after TBI.	JFK Johnson Rehabil Inst, Cognit Rehabil Dept, Edison, NJ 08820 USA	Cicerone, KD (corresponding author), JFK Johnson Rehabil Inst, Cognit Rehabil Dept, 2048 Oak Tree Rd, Edison, NJ 08820 USA.	kcicerone@solarishs.org			NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [H133 AO 20518] Funding Source: Medline		AZOUVI P, 2001, 4 WORLD C BRAIN INJ; Bandura A, 1998, PSYCHOL HEALTH, V13, P623, DOI 10.1080/08870449808407422; BANDURA A, 1989, DEV PSYCHOL, V25, P729, DOI 10.1037/0012-1649.25.5.729; Bandura A., 1997, SELF EFFICACY EXERCI; BENYISHAY Y, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P194; Bergquist TF, 1994, J HEAD TRAUMA REHAB, V9, P50, DOI 10.1097/00001199-199412000-00007; BERRY JM, 1989, DEV PSYCHOL, V25, P701, DOI 10.1037/0012-1649.25.5.701; Bezner JR, 2001, ARCH PHYS MED REHAB, V82, P787, DOI 10.1053/apmr.2001.23269; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Delis DC, 1987, CALIFORNIA VERBAL LE; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; DIJKERS M, 1997, ASSESSING MED REHABI, P153; EVANS C, 2003, J INT NEUROPSYCH SOC, V9, P253; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; GIST ME, 1992, ACAD MANAGE REV, V17, P183, DOI 10.2307/258770; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Heaton R.K., 1991, COMPREHENSIVE NORMS; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; HOLDEN G, 1991, SOC WORK HEALTH CARE, V16, P53; HOLROYD KA, 1984, J CONSULT CLIN PSYCH, V52, P1039, DOI 10.1037/0022-006X.52.6.1039; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Johnston MV, 2002, ARCH PHYS MED REHAB, V83, pS26, DOI 10.1053/apmr.2002.37100; Kohler CL, 2002, HEALTH PSYCHOL, V21, P610, DOI 10.1037/0278-6133.21.6.610; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LACHMAN ME, 1992, J GERONTOL, V47, pP293, DOI 10.1093/geronj/47.5.P293; LACHMAN ME, 1987, PSYCHOL AGING, V2, P266, DOI 10.1037/0882-7974.2.3.266; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Malec JF, 2002, ARCH PHYS MED REHAB, V83, P1759, DOI 10.1053/apmr.2002.36072; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; MEYERS JE, 1995, COMPLEX FIGURE TEST; Millis S R, 1994, Int J Neurosci, V79, P165; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; REBOK GW, 1989, DEV PSYCHOL, V25, P714, DOI 10.1037/0012-1649.25.5.714; Robinson-Smith G, 2000, ARCH PHYS MED REHAB, V81, P460, DOI 10.1053/mr.2000.3863; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; Schiaffino K M, 1991, Arthritis Care Res, V4, P150; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Smith J, 1998, CANADIAN J REHABILIT, V11, P131; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	51	154	155	0	19	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2004	85	6					943	950		10.1016/j.apmr.2003.07.019			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	826NK	WOS:000221835600012	15179648				2021-06-18	
J	Jantzen, KJ; Anderson, B; Steinberg, FL; Kelso, JAS				Jantzen, KJ; Anderson, B; Steinberg, FL; Kelso, JAS			A prospective functional MR imaging study of mild traumatic brain injury in college football players	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							SUPPLEMENTARY MOTOR AREA; POSITRON-EMISSION-TOMOGRAPHY; WORKING-MEMORY; PARIETAL CORTEX; CEREBRAL CONCUSSION; MENTAL SUBTRACTION; FINGER MOVEMENTS; BASAL GANGLIA; HEAD-INJURIES; COORDINATION	BACKGROUND AND PURPOSE: Although concussion is common among athletes, evidence-based methods for clinical evaluation, treatment, and recovery are lacking. We used a prospective, functional neuroimaging approach to assess sports-related concussion in which imaging was performed before injury so that brain changes resulting from concussion could be better understood. METHODS: Neurophysiologic correlates of sports-related concussion were investigated in eight college football players by using functional MR imaging. Preseason baseline levels of blood oxygen level-dependent (BOLD) activity were acquired. during the performance of a test battery that included mathematical, memory, and sensorimotor coordination tasks. Four players who had a concussion repeated these baseline procedures within 1 week of injury. The remaining control players were retested at the end of the season. RESULTS: Specific neural signatures of concussion were detected in individual players by comparing postconcussion results to preconcussion baseline values. The validity of these indicators was confirmed by comparing them with the same measures in noninjured control subjects. When compared with control subjects, concussed players had marked within-subject increases in the amplitude and extent of BOLD activity during, a finger-sequencing task. Effects were observed primarily in the parietal and lateral frontal and cerebellar regions. CONCLUSION: Differences in neural functioning were observed in the absence of observed deficits in behavioral performance, suggesting that this approach may increase sensitivity to concussion compared with neuropsychological evaluation alone. Though preliminary, the proposed prospective neuroimaging approach may have great potential for understanding mild traumatic brain injury and identifying mechanisms underlying recovery.	Florida Atlantic Univ, Ctr Complex Syst & Brain Sci, Boca Raton, FL 33431 USA; Florida Atlantic Univ, Athlet Dept, Boca Raton, FL 33431 USA; Florida Atlantic Univ, Univ MRI, Boca Raton, FL 33431 USA; Florida Atlantic Univ, Diagnost Imaging Ctr, Boca Raton, FL 33431 USA	Jantzen, KJ (corresponding author), Florida Atlantic Univ, Ctr Complex Syst & Brain Sci, Boca Raton, FL 33431 USA.				NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH042900, R37 MH042900, MH42900, MH01386] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R37MH042900, R01MH042900] Funding Source: NIH RePORTER		Aguirre GK, 1998, NEUROIMAGE, V8, P360, DOI 10.1006/nimg.1998.0369; Andersen RA, 1997, ANNU REV NEUROSCI, V20, P303, DOI 10.1146/annurev.neuro.20.1.303; Boecker H, 1998, J NEUROPHYSIOL, V79, P1070; Burbaud P, 1999, NEUROSCI LETT, V273, P195, DOI 10.1016/S0304-3940(99)00641-2; Burbaud P, 2000, NEUROSCI LETT, V287, P76, DOI 10.1016/S0304-3940(00)01099-5; Buxton R.B, 2002, INTRO FUNCTIONAL MAG; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Catalan MJ, 1998, BRAIN, V121, P253, DOI 10.1093/brain/121.2.253; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Cox RW, 1997, NMR BIOMED, V10, P171, DOI 10.1002/(SICI)1099-1492(199706/08)10:4/5<171::AID-NBM453>3.0.CO;2-L; Dehaene S, 1997, CORTEX, V33, P219, DOI 10.1016/S0010-9452(08)70002-9; Dehaene S, 1998, TRENDS NEUROSCI, V21, P355, DOI 10.1016/S0166-2236(98)01263-6; Deiber MP, 1996, J NEUROPHYSIOL, V75, P233; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GENNARELLI TA, 1993, HEAD INJURY, P127; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; Jancke L, 2000, COGNITIVE BRAIN RES, V10, P51, DOI 10.1016/S0926-6410(00)00022-7; Jantzen KJ, 2002, NEUROSCI LETT, V332, P205, DOI 10.1016/S0304-3940(02)00956-4; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Jueptner M, 1998, BRAIN, V121, P1437, DOI 10.1093/brain/121.8.1437; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Karzmark P, 2000, INT J GERIATR PSYCH, V15, P677, DOI 10.1002/1099-1166(200008)15:8<677::AID-GPS177>3.3.CO;2-W; Kelly JP, 1997, NEUROLOGY, V48, P581; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Mayville JM, 2002, HUM BRAIN MAPP, V17, P214, DOI 10.1002/hbm.10065; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCloskey DP, 2001, BRAIN RES, V891, P168, DOI 10.1016/S0006-8993(00)03200-5; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McGonigle DJ, 2000, NEUROIMAGE, V11, P708, DOI 10.1006/nimg.2000.0562; Nair DG, 2003, COGNITIVE BRAIN RES, V15, P250, DOI 10.1016/S0926-6410(02)00197-0; Ogawa S, 1998, ANNU REV BIOPH BIOM, V27, P447, DOI 10.1146/annurev.biophys.27.1.447; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PARKINSON D, 1992, MED HYPOTHESES, V37, P37, DOI 10.1016/0306-9877(92)90010-A; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1989, MILD HEAD INJURY; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Ramnani N, 2001, NEUROIMAGE, V14, P899, DOI 10.1006/nimg.2001.0885; RUEKERT L, 1996, NEUROIMAGE, V3, P97; Rushworth MFS, 1997, EXP BRAIN RES, V117, P292, DOI 10.1007/s002210050224; Sadato N, 1997, J NEUROSCI, V17, P9667; SHIBASAKI H, 1993, BRAIN, V116, P1387, DOI 10.1093/brain/116.6.1387; Shima K, 1998, J NEUROPHYSIOL, V80, P3247; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Stephen KM, 1999, EXP BRAIN RES, V128, P243, DOI 10.1007/s002210050844; Talairach J., 1988, COPLANAR STEREOTAXIC; Tegeler C, 1999, HUM BRAIN MAPP, V7, P267, DOI 10.1002/(SICI)1097-0193(1999)7:4<267::AID-HBM5>3.0.CO;2-3; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Young CC, 1997, CLIN J SPORT MED, V7, P196, DOI 10.1097/00042752-199707000-00008	66	154	155	0	16	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	MAY	2004	25	5					738	745					8	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	821ZZ	WOS:000221503500011	15140712				2021-06-18	
J	Saporta, S; Kim, JJ; Willing, AE; Fu, ES; Davis, CD; Sanberg, PR				Saporta, S; Kim, JJ; Willing, AE; Fu, ES; Davis, CD; Sanberg, PR			Human umbilical cord blood stem cells infusion in spinal cord injury: Engraftment and beneficial influence on behavior	JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH			English	Article							CENTRAL-NERVOUS-SYSTEM; BONE-MARROW; FUNCTIONAL RECOVERY; CONTUSION INJURY; RATING-SCALE; ADULT-RAT; TRANSPLANTATION; EXPRESSION; BRAIN; DIFFERENTIATE	The use of human umbilical cord blood (hUCB)-a rich source of nonembryonic or adult stem cells-has recently been reported to ameliorate behavioral consequences of stroke. In this study, we tested whether human cord blood leukocytes also ameliorate behavioral impairments of spinal cord injury. Rats were divided into five groups: (1) laminectomy (without spinal cord injury) only; (2) laminectomy + cord blood infusion; (3) spinal cord injury + cord blood infused 1 day post injury; (4) spinal cord injury + cord blood infused 5 days post injury; and (5) spinal cord injury only. Spinal cord injury was induced by compressing the spinal cord for 1 min with an aneurysm clip calibrated to a closing pressure of 55 g. Open-field behavior was assessed 1, 2, and 3 weeks after intravenous injection of prelabeled human cord blood cells. Open-field test scores of spinal cord injured rats treated with human cord blood at 5 days were significantly improved as compared to scores of rats similarly injured but treated at day 1 as well as the otherwise untreated injured group. The results suggest that cord blood stem cells are beneficial in reversing the behavioral effects of spinal cord injury, even when infused 5 days after injury. Human cord blood-derived cells were observed in injured areas, but not in noninjured areas, of rat spinal cords, and were never seen in corresponding areas of spinal cord of noninjured animals. The results are consistent with the hypothesis that cord blood-derived stem cells migrate to and participate in the healing of neurological defects caused by traumatic assault.	Univ S Florida, Dept Anat, Coll Med, Hlth Sci Ctr, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Ctr Aging & Brain Repair, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Neurosurg, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Anesthesiol, Tampa, FL 33612 USA; Chosun Univ, Sch Med, Dept Anat, Gwangju 501759, South Korea; Saneron CCEL Therapeut Inc, Tampa, FL 33612 USA	Saporta, S (corresponding author), Univ S Florida, Dept Anat, Coll Med, Hlth Sci Ctr, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	ssaporta@hsc.usf.edu	Willing, Alison/I-4946-2012; Willing, Alison/AAP-7759-2021				Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Belvedere O, 2000, STEM CELLS, V18, P245, DOI 10.1634/stemcells.18-4-245; Bicknese AR, 2002, CELL TRANSPLANT, V11, P261; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Broxmeyer H E, 1996, Cancer Treat Res, V84, P139; Buzanska L, 2002, J CELL SCI, V115, P2131; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Coumans JV, 2001, J NEUROSCI, V21, P9334, DOI 10.1523/JNEUROSCI.21-23-09334.2001; COWEN T, 1985, HISTOCHEMISTRY, V82, P205, DOI 10.1007/BF00501396; Giesert C, 2001, ANN NY ACAD SCI, V938, P175; Ha Y, 2001, NEUROREPORT, V12, P3523, DOI 10.1097/00001756-200111160-00030; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lu J, 2001, BRAIN RES, V889, P344, DOI 10.1016/S0006-8993(00)03235-2; Lu L, 1996, CRIT REV ONCOL HEMAT, V22, P61, DOI 10.1016/1040-8428(96)88370-3; Mayani H, 1998, STEM CELLS, V16, P153, DOI 10.1002/stem.160153; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Quirici N, 2001, BRIT J HAEMATOL, V115, P186, DOI 10.1046/j.1365-2141.2001.03077.x; REIER PJ, 1992, J NEUROTRAUM, V9, pS223; REIER PJ, 1988, PROG BRAIN RES, V78, P173; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Sanchez-Ramos JR, 2001, EXP NEUROL, V171, P109, DOI 10.1006/exnr.2001.7748; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; Saporta S, 2002, J NEUROSURG, V97, P63, DOI 10.3171/spi.2002.97.1.0063; Scheff SW, 2002, J NEUROTRAUM, V19, P1251, DOI 10.1089/08977150260338038; Taupin P, 2002, J NEUROSCI RES, V69, P745, DOI 10.1002/jnr.10378; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Weidner N, 1999, J COMP NEUROL, V413, P495, DOI 10.1002/(SICI)1096-9861(19991101)413:4<495::AID-CNE1>3.0.CO;2-Z; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Xu XM, 1999, EUR J NEUROSCI, V11, P1723, DOI 10.1046/j.1460-9568.1999.00591.x; Zigova T, 2002, CELL TRANSPLANT, V11, P265	33	154	172	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1525-8165			J HEMATOTH STEM CELL	J. Hematother. Stem Cell Res.	JUN	2003	12	3					271	278		10.1089/152581603322023007			8	Hematology; Medicine, Research & Experimental; Transplantation	Hematology; Research & Experimental Medicine; Transplantation	693NK	WOS:000183723500003	12857368				2021-06-18	
J	Berger, RP; Pierce, MC; Wisniewski, SR; Adelson, PD; Clark, RSB; Ruppel, RA; Kochanek, PM				Berger, RP; Pierce, MC; Wisniewski, SR; Adelson, PD; Clark, RSB; Ruppel, RA; Kochanek, PM			Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children	PEDIATRICS			English	Article						head trauma; child abuse; apoptosis; delayed neuronal death; abusive head trauma	SEVERE HEAD-INJURY; S-100 PROTEIN MEASUREMENTS; NERVOUS-SYSTEM; SERUM; DAMAGE; MARKERS; CSF; LUMBAR; DISEASE; ARREST	Background. Traumatic brain injury (TBI) is a leading cause of death and disability in children. Considerable insight into the mechanisms involved in secondary injury after TBI has resulted from analysis of ventricular cerebrospinal fluid (CSF) obtained in children with severe noninflicted and inflicted TBI (nTBI and iTBI, respectively). Neuron-specific enolase (NSE) is a glycolytic enzyme that is localized primarily to the neuronal cytoplasm. S100B is a calcium-binding protein localized to astroglial cells. In adults, CSF and serum concentrations of NSE and S100B have served as markers of neuronal damage after TBI. Neither NSE nor S100B has previously been studied in CSF after TBI in infants or children. Objective. To compare the time course and magnitude of neuronal and astroglial death after nTBI and iTBI by measuring CSF concentrations of NSE and S100B using a rapid enzyme-linked immunosorbent assay. Methods. Severe nTBI and iTBI were defined by strict clinical criteria. Serial ventricular CSF samples (n = 35) were obtained from children 1.5 to 9 years with severe nTBI (n = 5) and children 0.2 to 1.5 years (n = 5) with severe iTBI. Lumbar CSF samples from 5 children 0.1 to 2.3 years evaluated for meningitis were used as a comparison group. CSF NSE and S100B concentrations were quantified by an enzyme-linked immunosorbent assay (SynX Pharma Inc, Ontario, Canada). Results. There was no difference in age between patients with iTBI (median [range]: 0.2 years [0.2-1.8]), nTBI (2.0 years [1.5-9]), and the comparison group (0.2 years [0.2-1.8]). The initial Glasgow Coma Scale score was higher in the iTBI group (9 [4-14]) versus the nTBI group (3 [3-7]). NSE was increased in TBI versus the comparison group in 34 of 35 samples. Mean NSE was markedly increased (mean +/- SEM, 117.1 +/- 12.0 ng/mL vs 3.5 +/- 1.4 ng/mL). After nTBI, a transient peak in NSE was seen at a median of 11 hours after injury (range: 5-20 hours). After iTBI, an increase in admission NSE was followed by a sustained and delayed peak at a median of 63 hours after injury (range: 7-94). The magnitude of peak NSE was similar in nTBI and iTBI. S100B was increased versus the comparison group in 35 of 35 samples. Mean S100B was markedly increased in TBI versus the comparison group (1.67 +/- 0.2 ng/mL vs 0.02 +/- 0.0 ng/mL). S100B showed a single peak at 27 hours (range: 5- 63 hours) after both nTBI and iTBI. The mean S100B concentration, peak S100B concentration, and the time to peak were not associated with mechanism of injury. Conclusions. Markers of neuronal and astroglial death are markedly increased in CSF after severe nTBI and iTBI. ITBI produces a unique time course of NSE, characterized by both an early and late peak, presumably representing 2 waves of neuronal death, the second of which may represent apoptosis. Delayed neuronal death may represent an important therapeutic target in iTBI. NSE and S100B may also be useful as markers to identify occult iTBI, help differentiate nTBI and iTBI, and assist in determining the time of injury in cases of iTBI.	Childrens Hosp Pittsburgh, Pittsburgh Child Advocacy Ctr, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA USA; Childrens Hosp Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Berger, RP (corresponding author), Childrens Hosp Pittsburgh, Pittsburgh Child Advocacy Ctr, Dept Pediat, 3705 5th Ave, Pittsburgh, PA 15213 USA.	rberger@pitt.edu	Adelson, David/W-2083-2019; Pierce, Mary Clyde/AAQ-3509-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00084] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000084] Funding Source: NIH RePORTER		Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Berger Rachel, 2001, Pediatric Research, V49, p157A; Bhattacharya K, 1999, ANN THORAC SURG, V68, P1225, DOI 10.1016/S0003-4975(99)00536-6; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; DAUBERSCHMIDT R, 1983, CLIN CHIM ACTA, V131, P165, DOI 10.1016/0009-8981(83)90085-2; DEGIORGIO CM, 1995, NEUROLOGY, V45, P1134, DOI 10.1212/WNL.45.6.1134; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Gajjar A, 1999, J CLIN ONCOL, V17, P1825, DOI 10.1200/JCO.1999.17.6.1825; Gerber J, 1998, NEUROLOGY, V51, P1710, DOI 10.1212/WNL.51.6.1710; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Janesko K. L., 2000, Journal of Neurotrauma, V17, P956; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; JIMI T, 1992, CLIN CHIM ACTA, V211, P37, DOI 10.1016/0009-8981(92)90103-W; KARKELA J, 1993, J NEUROL SCI, V116, P100, DOI 10.1016/0022-510X(93)90095-G; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; MISSLER U, 1995, EUR J CLIN CHEM CLIN, V33, P743; Nygaard O, 1998, SCAND J CLIN LAB INV, V58, P183; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; RUBALCAVA MA, 1995, NEUROSURGERY, V37, P668, DOI 10.1227/00006123-199510000-00009; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; SANCHEZRODRIGUEZ VF, 1995, AM J FOREN MED PATH, V16, P210, DOI 10.1097/00000433-199509000-00004; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; VANDEPOL M, 1994, J NEURO-ONCOL, V19, P149, DOI 10.1007/BF01306456; VANENGELEN BGM, 1992, CLIN CHEM, V38, P813; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	39	154	161	1	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2002	109	2							e31	10.1542/peds.109.2.e31			6	Pediatrics	Pediatrics	517FV	WOS:000173601200013	11826241	Bronze			2021-06-18	
J	Grilli, M; Barbieri, I; Basudev, H; Brusa, R; Casati, C; Lozza, G; Ongini, E				Grilli, M; Barbieri, I; Basudev, H; Brusa, R; Casati, C; Lozza, G; Ongini, E			Interleukin-10 modulates neuronal threshold of vulnerability to ischaemic damage	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						cerebral ischaemia; cytokines; interleukin-10; knock-out mice; neurodegeneration; neuroprotection	KAPPA-B ACTIVATION; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN INJURY; ISCHEMIA-REPERFUSION; GENE-EXPRESSION; NERVOUS-SYSTEM; TNF-ALPHA; IL-10; CYTOKINES; MICE	Interleukin-10 (IL-10) is a powerful suppressor of cellular immune responses, with a postulated role in brain inflammation. First, we have evaluated the role of this cytokine in ischaemic brain damage using IL-10 knockout (IL-10(-/-)) mice. The middle cerebral artery (MCA) was occluded in either IL-10(-/-) or wild-type animals of corresponding strain (C57Bl/6) and age. Infarct volume was assessed 24 h later in serial brain sections. Brain infarct produced by MCA occlusion was 30% larger in the IL-10(-/-) than in wild-type mice (21.8 +/- 1.2 vs. 16.9 +/- 1.0 mm(3), respectively; P < 0.01; Student's t-test). To further characterize these findings, studies were extended to in vitro models. Primary neuronal cortical cultures derived from IL-10(-/-) animals were more susceptible to both excitotoxicity and combined oxygen-glucose deprivation compared with cell cultures from wild-type mice. Moreover, when added to the culture medium, recombinant murine IL-10 (0.1-100 ng/mL) exerted a concentration-dependent prevention of neuronal damage induced by excitotoxicity in both cortical and cerebellar granule cell cultures taken from either strain. The accordance of in vivo and in vitro data allows us to suggest a potential neuroprotective role of IL-10 against cerebral ischaemia when administered exogenously or made available from endogenous sources.	Schering Plough Res Inst, Dept CNS CV Res, I-20132 Milan, Italy	Grilli, M (corresponding author), Schering Plough Res Inst, Dept CNS CV Res, San Raffaele Sci Pk,Via Olgettina 58, I-20132 Milan, Italy.		grilli, mariagrazia/ABF-1542-2020	grilli, mariagrazia/0000-0001-9165-5827			BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Bell MJ, 1997, ACT NEUR S, V70, P96; BENVENISTE EN, 1995, INT J DEV NEUROSCI, V13, P341, DOI 10.1016/0736-5748(94)00061-7; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; BERKMAN N, 1995, J IMMUNOL, V155, P4412; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Brodie C, 1996, FEBS LETT, V394, P117, DOI 10.1016/0014-5793(96)00911-8; CHAO CC, 1992, J IMMUNOL, V149, P2736; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; Diab A, 1997, J NEUROPATH EXP NEUR, V56, P641; DiSanto E, 1997, EUR J PHARMACOL, V336, P197, DOI 10.1016/S0014-2999(97)01225-9; Ehrlich LC, 1998, NEUROREPORT, V9, P1723, DOI 10.1097/00001756-199806010-00010; Engles RE, 1997, J SURG RES, V69, P425, DOI 10.1006/jsre.1997.5109; Feuerstein GZ, 1996, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1996, P405; FEUERSTEIN GZ, 1998, ROLE CYTOKINE CHEMOK, P507; Fuchs AC, 1996, J CLIN IMMUNOL, V16, P291, DOI 10.1007/BF01541395; GOLDBERG MP, 1990, STROKE, V21, P75; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Hayward R, 1997, EUR J PHARMACOL, V334, P157, DOI 10.1016/S0014-2999(97)01149-7; KLINE JN, 1995, AM J PHYSIOL-LUNG C, V269, pL92; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LEVI G, 1991, J NEUROCHEM, V56, P199, DOI 10.1111/j.1471-4159.1991.tb02581.x; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MOSMANN TR, 1994, ADV IMMUNOL, V56, P1, DOI 10.1016/S0065-2776(08)60449-6; PIANI D, 1992, EUR J IMMUNOL, V22, P2429, DOI 10.1002/eji.1830220936; RENNICK D, 1995, CLIN IMMUNOL IMMUNOP, V76, pS174, DOI 10.1016/S0090-1229(95)90144-2; Rennick DM, 1997, J LEUKOCYTE BIOL, V61, P389; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SANNA A, 1998, SOC NEUR ABSTR, V24, P1787; Savman K, 1998, PEDIATR RES, V43, P746; SHENG WS, 1995, CLIN DIAGN LAB IMMUN, V2, P604, DOI 10.1128/CDLI.2.5.604-608.1995; SHRIKANT P, 1995, J IMMUNOL, V155, P1489; Spera PA, 1998, NEUROSCI LETT, V251, P189, DOI 10.1016/S0304-3940(98)00537-0; Tarkowski E, 1997, CLIN EXP IMMUNOL, V110, P492, DOI 10.1046/j.1365-2249.1997.4621483.x; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; Williams K, 1996, NEUROCHEM INT, V29, P55, DOI 10.1016/0197-0186(95)00138-7; Zhai QH, 1997, J NEUROL SCI, V152, P119, DOI 10.1016/S0022-510X(97)00154-8	38	154	174	0	12	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	JUL	2000	12	7					2265	2272		10.1046/j.1460-9568.2000.00090.x			8	Neurosciences	Neurosciences & Neurology	336NW	WOS:000088310300008	10947805				2021-06-18	
J	Liu, AY; Maldjian, JA; Bagley, LJ; Sinson, GP; Grossman, RI				Liu, AY; Maldjian, JA; Bagley, LJ; Sinson, GP; Grossman, RI			Traumatic brain injury: Diffusion-weighted MR imaging findings	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							APPEARING WHITE-MATTER; CLOSED-HEAD INJURY; CEREBRAL-ISCHEMIA; AXONAL INJURY; TIME-COURSE; HISTOPATHOLOGIC CORRELATION; MULTIPLE-SCLEROSIS; HUMAN STROKE; DAMAGE; EDEMA	BACKGROUND AND PURPOSE: Diffuse axonal injury (DAI) accounts for a significant portion of primary intra-axial lesions in cases of traumatic brain injury, The goal of this study was to nse diffusion-weighted MR imaging to characterize DAI in the setting of acute and subacute traumatic brain injury. METHODS: Nine patients ranging in age from 26 to 78 years were examined with conventional MR imaging (including fast spin-echo T2-weighted, fluid-attenuated inversion-recovery, and gradient-echo sequences) as well as echo-planar diffusion-weighted MR imaging 1 to 18 days after traumatic injury, Lesions were characterized as DAI on the basis of their location and their appearance on conventional MR images. Trace apparent diffusion coefficient (ADC) maps were computed off-line with the diffusion-weighted and base-line images. Areas of increased signal were identified on the diffusion-weighted images, and regions of interests were used to obtain trace ADC values. RESULTS: In the nine patients studied, isotropic diffusion-weighted images showed areas of increased signal with correspondingly decreased ADC, In one case, decreased ADC was seen 18 days after the initial event, CONCLUSION: Decreased ADC can be demonstrated in patients with DAI in the acute setting and may persist into the subacute period, beyond that described for cytotoxic edema in ischemia.	Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Maldjian, JA (corresponding author), Hosp Univ Penn, Dept Radiol, 3400 Spruce St,Ground Floor Founders, Philadelphia, PA 19104 USA.			Maldjian, Joseph/0000-0002-6384-1072	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-08803] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BENVENISTE H, 1992, STROKE, V23, P746, DOI 10.1161/01.STR.23.5.746; BRANSTON NM, 1976, STROKE, V7, P151, DOI 10.1161/01.STR.7.2.151; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHIEN D, 1992, AM J NEURORADIOL, V13, P1097; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Ebisu T, 1997, RADIOLOGY, V203, P823, DOI 10.1148/radiology.203.3.9169711; FADEN A, 1989, SCIENCE, P244; Filippi M, 1998, ANN NEUROL, V43, P809, DOI 10.1002/ana.410430616; GENTRY LR, 1994, RADIOLOGY, V191, P1; Ginsberg MD, 1997, AM J NEURORADIOL, V18, P1435; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KETTENMANN H, 1985, J NEUROSCI, V5, P3295; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; KIMELBERG HK, 1989, J NEUROSCI, V9, P1141; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; LOEVNER LA, 1995, RADIOLOGY, V196, P511, DOI 10.1148/radiology.196.2.7617869; Lutsep HL, 1997, ANN NEUROL, V41, P574, DOI 10.1002/ana.410410505; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Schlaug G, 1997, NEUROLOGY, V49, P113, DOI 10.1212/WNL.49.1.113; SEVICK RJ, 1992, RADIOLOGY, V185, P687, DOI 10.1148/radiology.185.3.1438745; SIESJO BK, 1993, PROG BRAIN RES, V96, P23; SUZUKI S, 1977, ACTA NEUROCHIR, V39, P1, DOI 10.1007/BF01405236; Warach S, 1996, STROKE, V27, P1254; WARACH S, 1995, P SOC MAGN RESON, V1, P82	38	154	160	0	4	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	OCT	1999	20	9					1636	1641					6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	250ER	WOS:000083376500013	10543633				2021-06-18	
J	Novikov, L; Novikova, L; Kellerth, JO				Novikov, L; Novikova, L; Kellerth, JO			Brain-derived neurotrophic factor promotes axonal regeneration and long-term survival of adult rat spinal motoneurons in vivo	NEUROSCIENCE			English	Article						motor axons; ventral root avulsion; retrograde cell death; neurotrophins; nitric oxide synthase; fluorescent tracers	CENTRAL-NERVOUS-SYSTEM; VENTRAL ROOT AVULSION; NITRIC-OXIDE SYNTHASE; AMYOTROPHIC-LATERAL-SCLEROSIS; INDUCED CELL-DEATH; MOTOR-NEURONS; AXOTOMIZED MOTONEURONS; SCIATIC-NERVE; IN-VIVO; INJURY	This study shows that in adult rat spinal motoneurons brain-derived neurotrophic factor exerts a neuroprotective effect which extends several weeks beyond the duration of treatment. In addition, brain-derived neurotrophic factor strongly enhances regeneration of avulsed motor axons across the border between the central and peripheral nervous systems. Treatment with brain-derived neurotrophic factor is known to rescue adult rat spinal motoneurons from retrograde cell death induced by ventral root avulsion. The present experiments were designed to test whether this survival effect remains over an extended period of time following cessation of treatment and, also, whether brain-derived neurotrophic factor promotes regeneration of avulsed motor axons. After avulsion of a spinal ventral root, four weeks of treatment with brain-derived neurotrophic factor (10 mu g/day) or vehicle was initiated. By using different retrograde tracers to obtain pre- and postoperative labelling of avulsed and regenerating motoneurons, respectively, the number of surviving motoneurons as well as the extent of motor axonal regeneration could be analysed. The expression of nitric oxide synthase in the lesioned motoneurons was also studied. In the vehicle-treated rats, only 10% of the avulsed motoneurons remained at 12 weeks postoperatively, 20-40% of which displayed nitric oxide synthase activity. Treatment with brain-derived neurotrophic factor during the initial four postoperative weeks resulted in 45% motoneuron survival and a complete blockage of nitric oxide synthase expression at 12 weeks postoperatively. Brain-derived neurotrophic factor also induced abundant regeneration of the avulsed motor axons, which formed extensive fibre bundles along the surface of the spinal cord and adjacent ventral roots. The long-term effect by brain-derived neurotrophic factor seemed to be even stronger on motor axonal regeneration than on motoneuron survival. The present results indicate a therapeutic potential for brain-derived neurotrophic factor in the early treatment of traumatic injuries to spinal nerves and roots. (C) 1997 IBRO. Published by Elsevier Science Ltd.	UMEA UNIV, DEPT ANAT, S-90187 UMEA, SWEDEN			Novikov, Lev/I-1983-2012	Novikov, Lev/0000-0001-5520-3890			Anand P, 1996, PHILOS T ROY SOC B, V351, P449, DOI 10.1098/rstb.1996.0041; APPEL SH, 1993, EXP NEUROL, V124, P100, DOI 10.1006/exnr.1993.1180; BARINAGA M, 1994, SCIENCE, V264, P772, DOI 10.1126/science.8171331; BROWN MC, 1981, ANNU REV NEUROSCI, V4, P17, DOI 10.1146/annurev.ne.04.030181.000313; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CARLSTEDT T, 1986, ACTA PHYSIOL SCAND, V128, P645, DOI 10.1111/j.1748-1716.1986.tb08024.x; CARLSTEDT TP, 1995, MICROSURG, V16, P13, DOI 10.1002/micr.1920160106; CEDARBAUM JM, 1995, CLIN NEUROPHARMACOL, V18, P515; CLATTERBUCK RE, 1994, J COMP NEUROL, V342, P45, DOI 10.1002/cne.903420106; DAWSON TM, 1994, PROG BRAIN RES, V103, P365; DISTEFANO PS, 1994, PROG BRAIN RES, V103, P35; FAGNI L, 1994, PROG BRAIN RES, V103, P381; FISHER TJ, 1989, NEUROSCIENCE, V28, P755, DOI 10.1016/0306-4522(89)90020-1; FRIEDMAN B, 1995, J NEUROSCI, V15, P1044; HAVTON L, 1987, NATURE, V325, P711, DOI 10.1038/325711a0; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HOFFMANN CFE, 1993, CLIN NEUROL NEUROSUR, V95, pS39; HORIKAWA K, 1988, J NEUROSCI METH, V25, P1, DOI 10.1016/0165-0270(88)90114-8; KOLIATSOS VE, 1994, J COMP NEUROL, V342, P35, DOI 10.1002/cne.903420105; LI LX, 1995, P NATL ACAD SCI USA, V92, P9771, DOI 10.1073/pnas.92.21.9771; LINDA H, 1985, BRAIN RES, V358, P329, DOI 10.1016/0006-8993(85)90978-3; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; Lindsay RM, 1996, PHILOS T ROY SOC B, V351, P365, DOI 10.1098/rstb.1996.0030; LINDSAY RM, 1994, PROG BRAIN RES, V103, P3; LIPTON SA, 1994, PROG BRAIN RES, V103, P359; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; NOVIKOV L, 1995, NEUROSCI LETT, V200, P45, DOI 10.1016/0304-3940(95)12078-I; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; Oyesiku NM, 1996, J COMP NEUROL, V364, P68, DOI 10.1002/(SICI)1096-9861(19960101)364:1<68::AID-CNE6>3.0.CO;2-Q; PARK MJ, 1994, NEUROSCI LETT, V165, P125, DOI 10.1016/0304-3940(94)90725-0; PIEHL F, 1994, NEUROREPORT, V5, P697, DOI 10.1097/00001756-199402000-00009; RISLING M, 1983, EXP NEUROL, V82, P568, DOI 10.1016/0014-4886(83)90081-X; RISLING M, 1991, RESTOR NEUROL NEUROS, V3, P157, DOI 10.3233/RNN-1991-3304; RUAN RS, 1995, BRAIN RES, V698, P163, DOI 10.1016/0006-8993(95)00887-V; RUSSELL DS, 1995, NEUROSCIENTIST, V1, P119; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SMITH KJ, 1988, PROG BRAIN RES, V78, P193; SON YJ, 1995, NEURON, V14, P133, DOI 10.1016/0896-6273(95)90247-3; SWETT JE, 1986, EXP NEUROL, V93, P227, DOI 10.1016/0014-4886(86)90161-5; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TUSZYNSKI MH, 1995, P NATL ACAD SCI USA, V92, P4621, DOI 10.1073/pnas.92.10.4621; ULENKATE HJLM, 1994, ACTA NEUROPATHOL, V88, P558; VARON SS, 1995, RESTOR NEUROL NEUROS, V8, P85, DOI 10.3233/RNN-1995-81221; VEJSADA R, 1995, EUR J NEUROSCI, V7, P108, DOI 10.1111/j.1460-9568.1995.tb01025.x; WU W, 1994, NEUROSCIENCE, V61, P719, DOI 10.1016/0306-4522(94)90394-8; WU WT, 1994, EXP NEUROL, V129, P335, DOI 10.1006/exnr.1994.1176; XU XM, 1995, EXP NEUROL, V134, P261, DOI 10.1006/exnr.1995.1056; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1993, J NEUROBIOL, V24, P1555, DOI 10.1002/neu.480241202; YAN Q, 1994, J NEUROSCI, V14, P5281	51	154	169	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	AUG	1997	79	3					765	774		10.1016/S0306-4522(96)00665-3			10	Neurosciences	Neurosciences & Neurology	XG251	WOS:A1997XG25100012	9219940				2021-06-18	
J	Starkstein, SE; Robinson, RG				Starkstein, SE; Robinson, RG			Mechanism of disinhibition after brain lesions	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article							SECONDARY MANIA; INJURY; DEMENTIA	Disinhibition syndromes, ranging from mildly inappropriate social behavior to full blown mania, may result from lesions to specific brain areas. Several studies in patients with closed head injuries, brain tumors, stroke lesions, and focal epilepsy have demonstrated a significant association between disinhibition syndromes and dysfunction of orbitofrontal and basotemporal cortices of the right hemisphere. Based on the phylogenetic origin of these cortical areas and their main connections with dorsal regions related to visuospatial functions, somatosensation, and spatial memory, the orbitofrontal and basotemporal cortices may selectively inhibit or release motor, instinctive, affective, and intellectual behaviors elaborated in the dorsal cortex. Thus, dysfunction of these heteromodal ventral brain areas may result in disinhibited behaviors.	UNIV IOWA,DEPT PSYCHIAT,IOWA CITY,IA 52242	Starkstein, SE (corresponding author), RAUL CARREA INST NEUROL RES,DEPT NEUROPSYCHIAT,MONTANESES 2325,RA-1428 BUENOS AIRES,DF,ARGENTINA.						American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BARCZAK P, 1988, BRIT J PSYCHIAT, V152, P137, DOI 10.1192/bjp.152.1.137; Bianchi L, 1922, MECH BRAIN FUNCTION; Blumer D., 1975, PSYCHIAT ASPECTS NEU; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; DRAKE ME, 1988, PSYCHOSOMATICS, V29, P354, DOI 10.1016/S0033-3182(88)72379-8; FORNAZZARI L, 1992, J NEUROPSYCH CLIN N, V4, P42; GILLIG P, 1988, EPILEPSIA, V29, P26, DOI 10.1111/j.1528-1157.1988.tb05093.x; GOLDAR JC, 1993, ANATOMIA MENTE; JASTROWITZ M, 1888, DEUT MED WOCHENSCHR, V14, P81, DOI DOI 10.1055/S-0029-1207725; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; Kennard MA, 1941, J NEUROPHYSIOL, V4, P512; KLING A, 1976, BRAIN BEHAV EVOLUT, V13, P216, DOI 10.1159/000123811; Kluver H, 1939, ARCH NEURO PSYCHIATR, V42, P979; KRAUTHAMMER C, 1978, ARCH GEN PSYCHIAT, V35, P1333; KUMAR A, 1990, J PSYCHIAT RES, V24, P97, DOI 10.1016/0022-3956(90)90050-Z; LAPIERRE D, 1995, NEUROPSYCHOLOGIA, V33, P139, DOI 10.1016/0028-3932(94)00110-B; MIGLIORELLI R, 1993, J NEUROPSYCH CLIN N, V5, P379; NEARY D, 1988, J NEUROL NEUROSUR PS, V51, P353, DOI 10.1136/jnnp.51.3.353; Oppenheim H., 1890, ARCH PSYCHIAT NERVEN, V21, P560; PETRIDES M, 1994, HDB NEUROPSYCHOLOGY, V9, P17; RAINE A, 1994, BIOL PSYCHIAT, V36, P365, DOI 10.1016/0006-3223(94)91211-4; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; ROBINSON RG, 1979, SCIENCE, V205, P707, DOI 10.1126/science.462179; RYLANDER G, 1939, PERSONALITY CHANGES; SANIDES F, 1969, ANN NY ACAD SCI, V167, P404, DOI 10.1111/j.1749-6632.1969.tb20459.x; Sartorius N, 1974, MEASUREMENT CLASSIFI; STARKSTEIN SE, 1991, BIOL PSYCHIAT, V29, P149, DOI 10.1016/0006-3223(91)90043-L; STARKSTEIN SE, 1990, ANN NEUROL, V27, P652, DOI 10.1002/ana.410270612; STARKSTEIN SE, 1987, ARCH NEUROL-CHICAGO, V44, P1069, DOI 10.1001/archneur.1987.00520220065019; STARKSTEIN SE, 1988, J NERV MENT DIS, V176, P87, DOI 10.1097/00005053-198802000-00004; STARKSTEIN SE, 1988, BRAIN RES, V473, P74, DOI 10.1016/0006-8993(88)90317-4; STARKSTEIN SE, 1994, J NEUROL NEUROSUR PS, V57, P790, DOI 10.1136/jnnp.57.7.790; TONKONOGY TM, 1991, J NEUROPSYCHIAT, V3, P189; WELT L, 1888, DTSCH ARCH KLIN MED, V42, P339	36	154	159	0	11	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	FEB	1997	185	2					108	114		10.1097/00005053-199702000-00007			7	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	WH346	WOS:A1997WH34600007	9048703				2021-06-18	
J	Plenger, PM; Dixon, CE; Castillo, RM; Frankowski, RF; Yablon, SA; Levin, HS				Plenger, PM; Dixon, CE; Castillo, RM; Frankowski, RF; Yablon, SA; Levin, HS			Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury: A preliminary double-blind placebo-controlled study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CLOSED-HEAD-INJURY; RATING-SCALE; AMNESIA; MEMORY	Objective: To determine the effect of subacute administration of methylphenidate on recovery from moderate to moderately severe closed head injury. Design: Double-blind placebo-controlled with random assignment. Patients were enrolled when their Galveston Orientation and Amnesia Test score was at least 65. Drug/placebo treatment began the day following baseline cognitive assessment and continued for 30 consecutive days. Follow-up evaluations were conducted at 30 and 90 days after baseline, after discontinuation of drug/placebo. Setting: A level I trauma center. Patients: Twenty-three patients ranging in age from 16 to 64 years. Head injury severity ranged from moderately severe (Glasgow Coma Score [GCS] less than or equal to 8, no intracranial pressure monitor) to ''complicated mild'' (GCS from 13 to 15 with positive computed tomography brain scan). Thirty-day follow-up was based on 12 patients, whereas 90-day evaluation was based on 9 patients, with complicated mild head injuries excluded from the analyses. Interventions: Methylphenidate administered twice daily at a dose of .30 mg/kg, placebo administered according to the same schedule in identical pill form. Main Outcome Measures: The Disability Rating Scale (DRS) and tests of attention, memory, and vigilance. Results: The methylphenidate group was significantly better at 30 days on the DRS (p < .02), and on tests of attention (p < .03) and motor performance (p, .05). No significant differences were noted between groups at 90 days. Conclusions: Subacute administration of methylphenidate after moderately severe head injury appeared to enhance the rate but not the ultimate level of recovery as measured by the DRS and tests of vigilance. Problems with possible selection bias and small sample size limit generalization of results. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	UNIV TEXAS,SCH MED,SCH PUBL HLTH,DEPT BIOMETRY,HOUSTON,TX 77030; BAYLOR COLL MED,INST REHABIL & RES,HOUSTON,TX 77030	Plenger, PM (corresponding author), UNIV TEXAS,SCH MED,DEPT NEUROSURG,6431 FANNIN,SUITE 7148,HOUSTON,TX 77030, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49-CCR-303547] Funding Source: Medline		*AM SOC HOSP PHARM, 1987, AM HOSP FORM SERV; BARKLEY RA, 1990, PEDIATRICS, V86, P184; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1992, NEUROSURGERY, V31, P93; COLOHAN ART, 1992, J NEUROTRAUM, V9, pS529; COPE DN, 1994, J HEAD TRAUMA REHAB, V9, P1, DOI 10.1097/00001199-199409000-00003; DESONNEVILLE LMJ, 1991, J CHILD PSYCHOL PSYC, V32, P285; Dixon C. E., 1992, Society for Neuroscience Abstracts, V18, P171; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DOBKIN BH, 1993, ANN NEUROL, V33, P313, DOI 10.1002/ana.410330315; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; *FORTH LTD, 1991, VIG SOFTW ASS ATT CO; GAIQUINTO S, 1992, ACTA NEUROL, V14, P547; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MALEC J, 1984, BEHAVIORAL ASSESSMEN, P121; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; OBRIEN PC, 1988, MAYO CLIN PROC, V63, P1140, DOI 10.1016/S0025-6196(12)65511-6; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Porteus S.D., 1965, PORTEUS MAZE TEST 50; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUFF RM, 1986, PERCEPT MOTOR SKILL, V62, P407, DOI 10.2466/pms.1986.62.2.407; SOHLBERG M M, 1992, Brain Injury, V6, P139, DOI 10.3109/02699059209029652; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; WECHSLER D, 1987, WMSR WECHSLER MEMORY; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WROBLEWSKI BA, 1994, J HEAD TRAUMA REHAB, V9, P19, DOI 10.1097/00001199-199409000-00004	35	154	155	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1996	77	6					536	540		10.1016/S0003-9993(96)90291-9			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	UP731	WOS:A1996UP73100002	8831468				2021-06-18	
J	HALL, ED; BRAUGHLER, JM; YONKERS, PA; SMITH, SL; LINSEMAN, KL; MEANS, ED; SCHERCH, HM; VONVOIGTLANDER, PF; LAHTI, RA; JACOBSEN, EJ				HALL, ED; BRAUGHLER, JM; YONKERS, PA; SMITH, SL; LINSEMAN, KL; MEANS, ED; SCHERCH, HM; VONVOIGTLANDER, PF; LAHTI, RA; JACOBSEN, EJ			U-78517F - A POTENT INHIBITOR OF LIPID-PEROXIDATION WITH ACTIVITY IN EXPERIMENTAL BRAIN INJURY AND ISCHEMIA	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							NERVOUS-SYSTEM TRAUMA; NONGLUCOCORTICOID 21-AMINOSTEROID U74006F; CEREBRAL VASOSPASM; SUBARACHNOID HEMORRHAGE; VITAMIN-E; RADICALS; INVOLVEMENT; STROKE	U-78517F {2-[4-[2,6-di-(1-pyrrolidinyl)-4-pyrimidinyl)-1-piperazinyl]methyl]-3,4-dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran-6-ol, dihydrochloride}, which combines the antioxidant ring portion of alpha-tocopherol together with the amine of the previously described 21-aminosteroids (e.g., U-74006F), is a novel inhibitor of iron-catalyzed lipid peroxidation. U-78517F was found to have a 50% inhibitory concentration (IC50) of 0.6-mu-M against 200-mu-M ferrous chloride-initiated lipid peroxidation in rat brain homogenates, compared to 8-mu-M for U-74006F, 28-mu-M for alpha-tocopherol and 43-mu-M for the ring portion of alpha-tocopherol (i.e., trolox). Both stereoisomers of the racemic U-78517F proved to be equally active antioxidants. Against lipid peroxidation initiated by xanthine/xanthine oxidase, U-78517F was even more potent, with an IC50 of 0.01-mu-M. U-78517F was also observed to protect cultured mouse spinal neurons against iron-induced damage, with an IC50 of approximately 0.5-mu-M. When administered to male CF-1 mice i.v. at 5 min after a severe concussive head injury, U-78517F produced a dose-related improvement in the 1-hr neurological recovery. The minimum effective i.v. dose was 1.0-mu-g/kg. Measurement of U-78517 concentrations in the brains of mice after administration of a 10-mg/kg i.v. dose revealed effective antioxidant levels for as long as 2 hr. Evidence of an in vivo antioxidant action was provided by the attentuation of iron-induced blood-brain barrier disruption (i.e., Evans' blue extravasation) in rats pretreated with U-78517F. When administered to male gerbils at an i.p. dose of 10 mg/kg at 10 min before, and again at the end of a 3-hr period of unilateral carotid artery occlusion, U-78517F was shown to decrease 24-hr postischemic cortical neuronal necrosis. In the medial portion of the cortex, neuronal density was increased from 34.2% of normal in vehicle-treated animals to 86.3% in the U-78517F-treated animals. In the lateral cortical area, the vehicle group showed only 3.3% neuronal survival vs. 48.2% in the drug-related group. U-78517F neither exhibited hypothermic activity nor antagonized excitatory amino acid (e.g., N-methyl-D-aspartate, kainate, quisqualate)-induced seizures in mice. Moreover, it showed no significant interaction with known neurotransmitter receptors (e.g., acetylcholine, norepinephrine, dopamine, 5-hydroxytryptamine, opiate and benzodiazepine). These results document the cerebroprotective efficacy of a novel and potent inhibitor of iron-catalyzed lipid peroxidation, and further support a key role of oxygen radicals in post-traumatic and postischemic pathophysiology.		HALL, ED (corresponding author), UPJOHN CO,301 HENRIETTA ST,KALAMAZOO,MI 49001, USA.		Hall, Edward D/F-8930-2013				ANDERSON DK, 1988, J NEUROSURG, V69, P562, DOI 10.3171/jns.1988.69.4.0562; BRAUGHLER J M, 1989, Drugs of the Future, V14, P143; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; BRAUGHLER JM, 1985, J NEUROCHEM, V44, P1282, DOI 10.1111/j.1471-4159.1985.tb08755.x; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V7, P125, DOI 10.1016/0891-5849(89)90003-8; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BURTON GW, 1981, J AM CHEM SOC, V103, P6472, DOI 10.1021/ja00411a035; BUXSER S, 1981, INFECT IMMUN, V31, P929, DOI 10.1128/IAI.31.3.929-934.1981; HALL ED, 1988, J NEUROSURG, V68, P462, DOI 10.3171/jns.1988.68.3.0462; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1988, STROKE, V19, P997, DOI 10.1161/01.STR.19.8.997; HALL ED, 1988, EXP NEUROL, V102, P244, DOI 10.1016/0014-4886(88)90100-8; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; LAHTI RA, 1983, NEUROPHARMACOLOGY, V22, P1277, DOI 10.1016/0028-3908(83)90200-9; MCCAY PB, 1985, ANNU REV NUTR, V5, P323, DOI 10.1146/annurev.nu.05.070185.001543; NATALE JE, 1988, STROKE, V19, P1371, DOI 10.1161/01.STR.19.11.1371; SILVIA RC, 1987, NEUR ABST, V13, P1499; STEINKE DE, 1989, NEUROSURGERY, V24, P179, DOI 10.1227/00006123-198902000-00005; VOLLMER DG, 1989, SURG NEUROL, V31, P190, DOI 10.1016/0090-3019(89)90115-8; VONVOIGTLANDER PF, 1987, J PHARMACOL EXP THER, V243, P542; ZUCCARELLO M, 1989, J NEUROSURG, V71, P98, DOI 10.3171/jns.1989.71.1.0098; ZUCCARELLO M, 1988, STROKE, V20, P367	23	154	154	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	AUG	1991	258	2					688	694					7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GB325	WOS:A1991GB32500044	1865365				2021-06-18	
J	Bath, PMW; Lees, KR; Schellinger, PD; Altman, H; Bland, M; Hogg, C; Howard, G; Saver, JL				Bath, Philip M. W.; Lees, Kennedy R.; Schellinger, Peter D.; Altman, Hernan; Bland, Martin; Hogg, Cheryl; Howard, George; Saver, Jeffrey L.		European Stroke Org Outcomes Worki	Statistical Analysis of the Primary Outcome in Acute Stroke Trials	STROKE			English	Article						acute Rx; outcomes; randomized controlled trials	RANDOMIZED CONTROLLED-TRIALS; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; SAMPLE-SIZE CALCULATIONS; TRAUMATIC BRAIN-INJURY; POST HOC ANALYSIS; ENTIRE RANGE; THROMBOLYTIC THERAPY; CLINICAL-TRIALS; END-POINTS	Common outcome scales in acute stroke trials are ordered categorical or pseudocontinuous in structure but most have been analyzed as binary measures. The use of fixed dichotomous analysis of ordered categorical outcomes after stroke (such as the modified Rankin Scale) is rarely the most statistically efficient approach and usually requires a larger sample size to demonstrate efficacy than other approaches. Preferred statistical approaches include sliding dichotomous, ordinal, or continuous analyses. Because there is no best approach that will work for all acute stroke trials, it is vital that studies are designed with a full understanding of the type of patients to be enrolled (in particular their case mix, which will be critically dependent on their age and severity), the potential mechanism by which the intervention works (ie, will it tend to move all patients somewhat, or some patients a lot, and is a common hazard present), a realistic assessment of the likely effect size, and therefore the necessary sample size, and an understanding of what the intervention will cost if implemented in clinical practice. If these approaches are followed, then the risk of missing useful treatment effects for acute stroke will diminish. (Stroke. 2012; 43: 1171-1178.)	[Lees, Kennedy R.] Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland; [Bath, Philip M. W.; Hogg, Cheryl] Univ Nottingham, Nottingham NG7 2RD, England; [Schellinger, Peter D.] JW Klinikum Minden, Minden, Germany; [Altman, Hernan] Brainsgate, Caesarea, Israel; [Bland, Martin] Univ York, York YO10 5DD, N Yorkshire, England; [Howard, George] Univ Alabama Birmingham, Birmingham, AL USA; [Saver, Jeffrey L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA	Lees, KR (corresponding author), Univ Glasgow, Western Infirm, 44 Church St, Glasgow G11 6NT, Lanark, Scotland.	k.r.lees@clinmed.gla.ac.uk	LEYS, Didier/G-2955-2016; Toni, Danilo/K-3151-2016; Bath, Philip/F-9020-2011	LEYS, Didier/0000-0003-4408-4392; Toni, Danilo/0000-0003-2735-8427; Kaste, Markku/0000-0001-6557-6412; Saver, Jeffrey/0000-0001-9141-2251; Bath, Philip/0000-0003-2734-5132; Howard, George/0000-0002-3068-5720	European Stroke Organisation (ESO)	The workshop was sponsored by the European Stroke Organisation (ESO) with administrative assistance supplied by Marisa Kretschi on behalf of the ESO.	Adams HP, 2008, STROKE, V39, P87, DOI 10.1161/STROKEAHA.106.476648; Adams HP, 2004, CEREBROVASC DIS, V18, P124, DOI 10.1159/000079260; Bath P, 2009, STROKE, V40, P888, DOI 10.1161/STROKEAHA.108.519207; Bath PMW, 2008, STROKE, V39, P2817, DOI 10.1161/STROKEAHA.107.509893; Bath PMW, 2007, STROKE, V38, P1911, DOI 10.1161/STROKEAHA.106.474080; Bath PMW, 2011, INT J STROKE, V6, P472, DOI 10.1111/j.1747-4949.2011.00614.x; Bolland K, 2004, CEREBROVASC DIS, V17, P111, DOI 10.1159/000075778; Clarke J, 2005, LANCET, V365, P764; DeDeyn PP, 1997, STROKE, V28, P2347, DOI 10.1161/01.STR.28.12.2347; den Hertog HM, 2008, BMC CARDIOVASC DISOR, V8, DOI 10.1186/1471-2261-8-29; den Hertog HM, 2009, LANCET NEUROL, V8, P434, DOI 10.1016/S1474-4422(09)70051-1; Fedorov V, 2009, PHARM STAT, V8, P50, DOI 10.1002/pst.331; Fisher M, 2005, STROKE, V36, P1808, DOI 10.1161/01.STR.0000173403.60553.27; Guan XLD, STROKE IN PRESS; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hacke W, 1998, STROKE, V29, P2073, DOI 10.1161/01.STR.29.10.2073; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; HALEY EC, 1994, STROKE, V25, P418; Hong KS, 2009, STROKE, V40, P3828, DOI 10.1161/STROKEAHA.109.561365; Kennedy J, 2007, LANCET NEUROL, V6, P961, DOI 10.1016/S1474-4422(07)70250-8; Lansberg MG, 2009, STROKE, V40, P2079, DOI 10.1161/STROKEAHA.108.540708; Lees KR, 2012, STROKE, V43, P1163, DOI 10.1161/STROKEAHA.111.641423; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Li N, 2010, STAT MED, V29, P546, DOI 10.1002/sim.3798; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; Mendelow AD, 2005, LANCET, V365, P387; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; NOETHER GE, 1987, J AM STAT ASSOC, V82, P645, DOI 10.2307/2289477; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Optimising Anal Stroke Trials OAST, 2008, INT J STROKE, V3, P78, DOI 10.1111/j.1747-4949.2008.00184.x; Payne R., 1993, GENSTAT REFERENCE MA; POCOCK SJ, 1987, BIOMETRICS, V43, P487, DOI 10.2307/2531989; Roozenbeek B, 2009, CRIT CARE MED, V37, P2683, DOI 10.1097/CCM.0b013e3181ab85ec; Roozenbeek B, 2009, J NEUROTRAUM, V26, P1069, DOI 10.1089/neu.2008.0569; Samsa GP, 1999, J CLIN EPIDEMIOL, V52, P259, DOI 10.1016/S0895-4356(98)00151-6; Samsa GP, 2001, STROKE, V32, P669, DOI 10.1161/01.STR.32.3.669; Sandercock P, 1997, LANCET, V349, P1569; Sandset EC, 2011, LANCET, V377, P741, DOI 10.1016/S0140-6736(11)60104-9; Saver JL, 2007, STROKE, V38, P3055, DOI 10.1161/STROKEAHA.107.488536; Saver JL, 2007, STROKE, V38, P1515, DOI 10.1161/01.STR.0000263135.47779.9e; Saver JL, 2009, NEUROLOGY, V72, P1310, DOI 10.1212/01.wnl.0000341308.73506.b7; Saver JL, 2004, ARCH NEUROL-CHICAGO, V61, P1066, DOI 10.1001/archneur.61.7.1066; Savitz SI, 2007, STROKE, V38, P3205, DOI 10.1161/STROKEAHA.107.489351; Shuaib A, 2007, NEW ENGL J MED, V357, P562, DOI 10.1056/NEJMoa070240; Siegel S., 1988, NONPARAMETRIC STAT B; Stingele R, 2001, CEREBROVASC DIS, V11, P30, DOI 10.1159/000047608; Tibshirani, 1994, INTRO BOOTSTRAP, DOI 10.1201/9780429246593; Tilley BC, 1996, STROKE, V27, P2136, DOI 10.1161/01.STR.27.11.2136; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Walter SD, 2001, STAT MED, V20, P3947, DOI 10.1002/sim.1173; Walters Stephen J, 2004, Health Qual Life Outcomes, V2, P26, DOI 10.1186/1477-7525-2-26; Weaver CS, 2004, STROKE, V35, P1216, DOI 10.1161/01.STR.0000125010.70652.93; Weir CJ, 2004, STROKE, V35, P2111, DOI 10.1161/01.STR.0000136556.34438.b3; Weir CJ, 2003, STAT MED, V22, P705, DOI 10.1002/sim.1366; WHITEHEAD J, 1993, STAT MED, V12, P2257, DOI 10.1002/sim.4780122404; Young FB, 2005, STROKE, V36, P597, DOI 10.1161/01.STR.0000154856.42135.85	60	153	157	1	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	APR	2012	43	4					1171	1178		10.1161/STROKEAHA.111.641456			8	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	916ST	WOS:000302124200051	22426314	Bronze, Green Published, Green Accepted			2021-06-18	
J	Crisco, JJ; Wilcox, BJ; Beckwith, JG; Chu, JJ; Duhaime, AC; Rowson, S; Duma, SM; Maerlender, AC; McAllister, TW; Greenwald, RM				Crisco, Joseph J.; Wilcox, Bethany J.; Beckwith, Jonathan G.; Chu, Jeffrey J.; Duhaime, Ann-Christine; Rowson, Steven; Duma, Stefan M.; Maerlender, Arthur C.; McAllister, Thomas W.; Greenwald, Richard M.			Head impact exposure in collegiate football players	JOURNAL OF BIOMECHANICS			English	Article						Biomechanics; Frequency; Severity; Acceleration; Helmet; Concussion	HIGH-SCHOOL; PROFESSIONAL FOOTBALL; UNITED-STATES; ACCELERATION; INJURIES; LOCATION; EPIDEMIOLOGY; CONCUSSION	In American football, impacts to the helmet and the resulting head accelerations are the primary cause of concussion injury and potentially chronic brain injury. The purpose of this study was to quantify exposures to impacts to the head (frequency, location and magnitude) for individual collegiate football players and to investigate differences in head impact exposure by player position. A total of 314 players were enrolled at three institutions and 286,636 head impacts were recorded over three seasons. The 95th percentile peak linear and rotational acceleration and HITsp (a composite severity measure) were 62.7 g, 4378 rad/s(2) and 32.6, respectively. These exposure measures as well as the frequency of impacts varied significantly by player position and by helmet impact location. Running backs (RB) and quarter backs (QB) received the greatest magnitude head impacts, while defensive line (DL), offensive line (OL) and line backers (LB) received the most frequent head impacts (more than twice as many than any other position). Impacts to the top of the helmet had the lowest peak rotational acceleration (2387 rad/s(2)), but the greatest peak linear acceleration (72.4 g), and were the least frequent of all locations (13.7%) among all positions. OL and QB had the highest (49.2%) and the lowest (23.7%) frequency, respectively, of front impacts. QB received the greatest magnitude (70.8 g and 5428 rad/s(2)) and the most frequent (44% and 38.9%) impacts to the back of the helmet. This study quantified head impact exposure in collegiate football, providing data that is critical to advancing the understanding of the biomechanics of concussive injuries and sub-concussive head impacts. (C) 2011 Elsevier Ltd. All rights reserved.	[Crisco, Joseph J.; Wilcox, Bethany J.] Brown Univ, Warren Alpert Med Sch, Bioengn Lab, Dept Orthopaed, Providence, RI 02903 USA; [Crisco, Joseph J.; Wilcox, Bethany J.] Rhode Isl Hosp, Providence, RI 02903 USA; [Beckwith, Jonathan G.; Chu, Jeffrey J.; Greenwald, Richard M.] Simbex, Lebanon, NH USA; [Duhaime, Ann-Christine] Childrens Hosp Dartmouth, Dartmouth Hitchcock Med Ctr, Hanover, NH USA; [Rowson, Steven; Duma, Stefan M.] Virginia Tech Wake Forest, Ctr Injury Biomech, Blacksburg, VA USA; [Maerlender, Arthur C.] Dartmouth Med Sch, Pediat Neuropsychol Serv, Lebanon, NH USA; [McAllister, Thomas W.] Dartmouth Med Sch, Dept Psychiat, Lebanon, NH USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA	Crisco, JJ (corresponding author), Brown Univ, Warren Alpert Med Sch, Bioengn Lab, Dept Orthopaed, Providence, RI 02903 USA.	joseph_crisco@brown.edu	Rowson, Steven/B-1270-2012; Duma, Stefan/A-8368-2012	Rowson, Steven/0000-0002-3227-0596; 	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD048638, R01NS055020, R25GM083270, R25GM 033270-S1]; National Operating Committee on Standards for Athletic Equipment [NOCSAE 04-07]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R25GM083270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	NIH R01HD048638, R01NS055020, R25GM083270 and R25GM 033270-S1, and the National Operating Committee on Standards for Athletic Equipment (NOCSAE 04-07).	Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; CRISCO JJ, J APPL BIOM IN PRESS; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Gadd C. W., 1966, P 10 STAPP CAR CRASH, P164; Gennarelli TA, 1972, P 16 STAPP CAR CRASH, P296; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; HODGSON VR, 1970, STAPP CAR CRASH J; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Moon D W, 1971, Med Sci Sports, V3, P44; Ng TP, 2006, BIOMED SCI INSTRUM, V42, P25; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Reid S E, 1974, J Sports Med, V2, P86; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003	28	153	153	1	32	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	OCT 13	2011	44	15					2673	2678		10.1016/j.jbiomech.2011.08.003			6	Biophysics; Engineering, Biomedical	Biophysics; Engineering	843QW	WOS:000296688300012	21872862	Green Accepted, Green Published			2021-06-18	
J	Moss, WC; King, MJ; Blackman, EG				Moss, William C.; King, Michael J.; Blackman, Eric G.			Skull Flexure from Blast Waves: A Mechanism for Brain Injury with Implications for Helmet Design	PHYSICAL REVIEW LETTERS			English	Article							CONCUSSION	Traumatic brain injury (TBI) has become a signature injury of current military conflicts, with debilitating, costly, and long-lasting effects. Although mechanisms by which head impacts cause TBI have been well researched, the mechanisms by which blasts cause TBI are not understood. From numerical hydrodynamic simulations, we have discovered that nonlethal blasts can induce sufficient skull flexure to generate potentially damaging loads in the brain, even without a head impact. The possibility that this mechanism may contribute to TBI has implications for injury diagnosis and armor design.	[Moss, William C.; King, Michael J.] Lawrence Livermore Natl Lab, Livermore, CA 94551 USA; [Blackman, Eric G.] Univ Rochester, Dept Phys & Astron, Rochester, NY 14627 USA	Moss, WC (corresponding author), Lawrence Livermore Natl Lab, Livermore, CA 94551 USA.			Blackman, Eric/0000-0002-9405-8435	DOD/ DOE Joint Munitions ProgramUnited States Department of Defense; U.S. Department of Energy by Lawrence Livermore National LaboratoryUnited States Department of Energy (DOE) [DE-AC52-07NA27344]	W. C. M. thanks M. Moss for reading R. Glasser's article in the San Jose Mercury News [4-15-07] entitled "The Hidden Wounds of the Iraq War'' and saying "You can simulate that, can't you?'' We thank B. Watkins for support from the DOD/ DOE Joint Munitions Program, M. Hale and S. Lisanby for discussions as part of the Defense Science Study Group of the Institute for Defense Analyses ( E. G. B. also a member), and T. Gay and T. Matula for reading the manuscript. This work was performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract No. DE-AC52-07NA27344.	Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; BOWEN IG, 1968, DASA2113 DOD, P73901; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; CHOROS J, 1979, J APPL MECH-T ASME, V46, P175, DOI 10.1115/1.3424492; CUNNINGHAM OJ, 1933, AM J PHYSIOL, V107, P164; *EPAPS, EPRLTAO103033937 EPA, P73901; FUTRAL WS, 1999, UCRLJC132166 LLNL, P73901; GLASSTONE S, 1977, EFFECTS NUCL WEAPONS, V549, P73901; GROSS AG, 1958, J NEUROSURG, V15, P548, DOI 10.3171/jns.1958.15.5.0548; HORGAN TJ, 2005, THESIS U COLL DUBLIN, P73901; LUBOCK P, 1980, J BIOMECH, V13, P1041, DOI 10.1016/0021-9290(80)90048-2; McArthur DL, 2004, BRAIN PATHOL, V14, P185, DOI 10.1111/j.1750-3639.2004.tb00052.x; MCLEAN AJ, 1997, HEAD INJURY, pCH2; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; ONO K, 1980, P 24 STAPP CAR CRASH, P101; PRASAD P, 1985, 851246 SAE, P73901; REYNOSA MA, 1999, PERSONNEL ARMOR SYST, P73901; RUAN JS, 1993, P 37 STAPP CAR CRASH, P69; STUHMILLER JH, 2008, TXB MILITARY MED, P73901; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WOOD JL, 1971, J BIOMECH, V4, P1, DOI 10.1016/0021-9290(71)90010-8; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	24	153	157	1	31	AMER PHYSICAL SOC	COLLEGE PK	ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA	0031-9007			PHYS REV LETT	Phys. Rev. Lett.	SEP 4	2009	103	10							108702	10.1103/PhysRevLett.103.108702			4	Physics, Multidisciplinary	Physics	492FH	WOS:000269639800064	19792349				2021-06-18	
J	Festoff, BW; Ameenuddin, S; Arnold, PM; Wong, A; Santacruz, KS; Citron, BA				Festoff, Barry W.; Ameenuddin, Syed; Arnold, Paul M.; Wong, Andrea; Santacruz, Karen S.; Citron, Bruce A.			Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; caspase inhibition; locomotor rating score; tetracycline	TUMOR-NECROSIS-FACTOR; AMYOTROPHIC-LATERAL-SCLEROSIS; IMPROVES FUNCTIONAL RECOVERY; TRANSGENIC MOUSE MODEL; CYTOCHROME-C RELEASE; APOPTOTIC CELL-DEATH; MOTOR-NEURONS; TETRACYCLINE DERIVATIVES; TRAUMATIC INJURY; CONTUSION INJURY	Minocycline, a clinically used tetracycline for over 40 years, crosses the blood-brain barrier and prevents caspase up-regulation. It reduces apoptosis in mouse models of Huntington's disease and familial amyotrophic lateral sclerosis (ALS) and is in clinical trial for sporadic ALS. Because apoptosis also occurs after brain and spinal cord (SCI) injury, its prevention may be useful in improving recovery. We analyzed minocycline's neuroprotective effects over 28 days following contusion SCI and found significant functional recovery compared to tetracycline. Histology, immunocytochemistry, and image analysis indicated statistically significant tissue sparing, reduced apoptosis and microgliosis, and less activated caspase-3 and substrate cleavage. Since our original report in abstract form, others have published both positive and negative effects of minocycline in various rodent models of SCI and with various routes of administration. We have since found decreased tumor necrosis factor-alpha, as well as caspase-3 mRNA expression, as possible mechanisms of action for minocycline's ameliorative action. These results support reports that modulating apoptosis, caspases, and microglia provide promising therapeutic targets for prevention and/or limiting the degree of functional loss after CNS trauma. Minocycline, and more potent chemically synthesized tetracyclines, may find a place in the therapeutic arsenal to promote recovery early after SCI in humans.	Heartland Vet Hlth Network, Dept Vet Affairs Med Ctr, Neurobiol Res Lab, Kansas City, MO USA; Univ Kansas, Ctr Med, Dept Neurol, Kansas City, KS USA; Univ Kansas, Ctr Med, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS USA; Univ Kansas, Ctr Med, Dept Pathol, Kansas City, KS USA; Univ Kansas, Ctr Med, Dept Surg, Kansas City, KS USA	Festoff, BW (corresponding author), Univ Minnesota, Sch Med, VA Med Ctr, Neurobiol Res Lab 151, 4801 Linwood Blvd, Minneapolis, MN 55455 USA.	bfestoff@kumc.edu					Agrawal SK, 1997, J NEUROSCI, V17, P1055; Amin AR, 1996, P NATL ACAD SCI USA, V93, P14014, DOI 10.1073/pnas.93.24.14014; Anthes DL, 1996, NEUROSURGERY, V39, P804, DOI 10.1097/00006123-199610000-00032; Anthony DC, 1997, BRAIN, V120, P435, DOI 10.1093/brain/120.3.435; Arnold PM, 2001, SOC NEUR ABSTR, V27, P396; ARONSON AL, 1980, J AM VET MED ASSOC, V176, P1061; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; Bracken M B, 1991, J Neurotrauma, V8 Suppl 1, pS47; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; Carmel JB, 2001, PHYSIOL GENOMICS, V7, P201, DOI 10.1152/physiolgenomics.00074.2001; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Citron BA, 1997, NEUROSCI LETT, V230, P25, DOI 10.1016/S0304-3940(97)00468-0; Citron BA, 2000, J NEUROTRAUM, V17, P1191, DOI 10.1089/neu.2000.17.1191; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Engel S, 1996, Acta Neurochir Suppl, V66, P89; Engelhardt B, 2004, EUR J IMMUNOL, V34, P2955, DOI 10.1002/eji.200425327; Festoff BW, 2004, J NEUROTRAUM, V21, P907, DOI 10.1089/0897715041526168; Festoff BW, 2002, J NEUROCHEM, V81, P708, DOI 10.1046/j.1471-4159.2002.00850.x; Giuliani F, 2005, J NEUROIMMUNOL, V165, P83, DOI 10.1016/j.jneuroim.2005.04.020; Golub L M, 1998, Adv Dent Res, V12, P12; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hamada Y, 1996, J NEUROCHEM, V66, P1525; Hamers FPT, 2001, J NEUROTRAUM, V18, P187, DOI 10.1089/08977150150502613; HAMERS FPT, 1999, J NEUROTRAUM, V16, P1010; HAMERS FPT, 1998, J NEUROTRAUM, V15, P873; Hauben E, 2003, J NEUROSCI, V23, P8808; IWASA K, 1989, FREE RADICAL BIO MED, V6, P599, DOI 10.1016/0891-5849(89)90067-1; Jones TB, 2002, J NEUROSCI, V22, P2690, DOI 10.1523/JNEUROSCI.22-07-02690.2002; Koistinaho J, 2004, E SCHERING RES FDN W, V47, P101; Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559; Lankhorst AJ, 1999, J NEUROTRAUM, V16, P323, DOI 10.1089/neu.1999.16.323; Lee SM, 2004, J NEUROCHEM, V91, P568, DOI 10.1111/j.1471-4159.2004.02780.x; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Lee YL, 2000, NEUROCHEM INT, V36, P417, DOI 10.1016/S0197-0186(99)00133-3; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Metz GAS, 2000, J NEUROTRAUM, V17, P1, DOI 10.1089/neu.2000.17.1; Nicholls DG, 2000, PHYSIOL REV, V80, P315; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; Plunkett JA, 2001, EXP NEUROL, V168, P144, DOI 10.1006/exnr.2000.7604; Popovich PG, 2000, PROG BRAIN RES, V128, P43; PRICE C, 1994, AM J EPIDEMIOL, V139, P37, DOI 10.1093/oxfordjournals.aje.a116933; Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399; Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187; Riedout HJ, 2001, HISTOL HISTOPATHOL, V16, P895, DOI 10.14670/HH-16.895; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; Short DJ, 2000, SPINAL CORD, V38, P273, DOI 10.1038/sj.sc.3100986; Siman R, 1999, NEUROSCIENCE, V92, P1425, DOI 10.1016/S0306-4522(99)00034-2; Smirnova IV, 1998, J NEUROBIOL, V36, P64, DOI 10.1002/(SICI)1097-4695(199807)36:1<64::AID-NEU6>3.0.CO;2-8; Smirnova IV, 1998, J MOL NEUROSCI, V10, P31, DOI 10.1007/BF02737083; Smirnova IV, 2001, J NEUROBIOL, V48, P87, DOI 10.1002/neu.1044.abs; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Taoka Y, 1998, J NEUROSCI, V18, P1393; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tikka T, 2001, J NEUROCHEM, V78, P1409, DOI 10.1046/j.1471-4159.2001.00543.x; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; VANDERLUGT W, 2000, PLASMAS IONS, V3, P3; Von Bernhardi R, 2001, BIOL RES, V34, P123; Vukosavic S, 2000, J NEUROSCI, V20, P9119; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; YOUNG W, 1994, ANN NY ACAD SCI, V743, P241, DOI 10.1111/j.1749-6632.1994.tb55796.x; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	80	153	164	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2006	97	5					1314	1326		10.1111/j.1471-4159.2006.03799.x			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	042GU	WOS:000237516700009	16638021	Bronze			2021-06-18	
J	Pelinka, LE; Kroepfl, A; Schmidhammer, R; Krenn, M; Buchinger, W; Redl, H; Raabe, A				Pelinka, LE; Kroepfl, A; Schmidhammer, R; Krenn, M; Buchinger, W; Redl, H; Raabe, A			Glial fibrillary acidic protein injury and multiple trauma in serum after traumatic brain	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						secondary brain damage; multiple trauma; brain specificity; intracranial pressure cerebral perfusion; pressure; outcome	NEURON-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; S-100 PROTEIN; RELEASE; MARKERS; DAMAGE; BLOOD; SPECT; S100B; MRI	Background. This study aimed to determine whether glial fibrillary acidic protein (GFAP) is released after traumatic brain injury (TBI), whether GFAP is related to brain injury severity and outcome after TBI, and whether GFAP is released after multiple trauma without TBI. Methods:. This prospective study enrolled 114 patients who had TBI with or without multiple trauma (n = 101) or multiple trauma without TBI (n 13), as verified by computerized tomography. Daily GFAP measurement began at admission (< 12 hours after trauma) and continued for the duration of intensive care (1-22 days). Documentation included categorization of computerized tomography according to Marshall classification, based on daily highest intracranial pressure (ICP), lowest cerebral perfusion pressure (CPP), lowest mean arterial pressure (MAP), and 3-month Glasgow Outcome Score (GOS). Results: The GFAP concentration was lower for diffuse injury 2 than for diffuse injury 4 (p < 0.0005) or nonevacuated mass lesions larger than than 25 mL (p < 0.005), lower for a ICP less than 25 mm Hg than for a ICP of 25 mm Hg or more, lower for a CPP of 60 mm Hg or more than for a CPP of 60 mm Hg or less, lower for a MAP of 60 mm Hg or more than for a MAP less than 60 mm Hg (all p < 0.0005), and lower for a GOS of 1 or 2 than for a GOS of 3, 4 (p < 0.05), or 5 (p < 0.0005). After TBI, GFAP was higher in nonsurvivors (n = 39) than in survivors (n = 62) (p < 0.005). After multiple trauma without TBI, GFAP remained normal. Conclusion: The findings showed that GFAP is released after TBI, that GFAP is related to brain injury severity and outcome after TBI, and that GFAP is not released after multiple trauma without brain injury.	Ludwig Boltzmann Inst Expt & Clin Traumatol, Austrian Workers Compensat Board, A-1200 Vienna, Austria; AUVA, Trauma Hosp Liz, Linz, Austria; Mistelbach Gen Hosp, Dept Traumatol, Mistelbach, Austria; Waldviertel Clin, Dept Traumatol, Horn, Austria; Goethe Univ Frankfurt, Neuroctr, Dept Neurosurg, D-6000 Frankfurt, Germany	Pelinka, LE (corresponding author), Ludwig Boltzmann Inst Expt & Clin Traumatol, Austrian Workers Compensat Board, Donaueschingenstr 13, A-1200 Vienna, Austria.	lindapel@via.at	Redl, Heinz/AAD-8157-2019				Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; ALBRECHTSEN M, 1985, J NEUROCHEM, V44, P560, DOI 10.1111/j.1471-4159.1985.tb05449.x; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027; CHESNUT RM, 1997, J TRAUMA S, V42, P4; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; Jacobs A, 1996, J NUCL MED, V37, P1605; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KRAUS JF, 1996, NEUROTRAUMA, P13; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Missler U, 1999, CLIN CHEM, V45, P138; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; NOPPE M, 1986, CLIN CHIM ACTA, V155, P143, DOI 10.1016/0009-8981(86)90275-5; PELINKA L, 2003, IN PRESS SHOCK; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Petersson KH, 2002, PEDIATR RES, V51, P768, DOI 10.1203/01.PDR.0000017486.64723.D1; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Regner A, 2001, J NEUROTRAUM, V18, P783, DOI 10.1089/089771501316919148; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; VALADKA AB, 1996, TRAUMA, P267; van Geel WJA, 2002, CLIN CHIM ACTA, V326, P151, DOI 10.1016/S0009-8981(02)00330-3; Webster MJ, 2001, BRAIN BEHAV IMMUN, V15, P388, DOI 10.1006/brbi.2001.0646; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	32	153	160	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2004	57	5					1006	1012		10.1097/01.TA.0000108998.48026.C3			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	878QD	WOS:000225660600014	15580024				2021-06-18	
J	Hayakata, T; Shiozaki, T; Tasaki, O; Ikegawa, H; Inoue, Y; Toshiyuki, F; Hosotubo, H; Kieko, F; Yamashita, T; Tanaka, H; Shimazu, T; Sugimoto, H				Hayakata, T; Shiozaki, T; Tasaki, O; Ikegawa, H; Inoue, Y; Toshiyuki, F; Hosotubo, H; Kieko, F; Yamashita, T; Tanaka, H; Shimazu, T; Sugimoto, H			Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury	SHOCK			English	Article						S100B; cytokine; cerebrospinal fluid; head injury; prognosis	NEURON-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; S-100 PROTEIN; TNF-ALPHA; SERUM; DAMAGE; RELEASE; MARKER; IL-6; INTERLEUKIN-6	S100B protein (S100B) has been described as a marker of brain injury. Various cytokines also increase in the cerebrospinal fluid (CSF) of patients with severe traumatic brain injury (TBI). Thus, we investigated early changes in the concentrations of CSF S100B and various cytokines after TBI and evaluated the relations of both S100B and cytokines to intracranial pressure (ICP) and prognosis. Twenty-three patients with severe TBI and a Glasgow Coma Scale score of 8 or less on admission were included in this study. CSF and serum samples were obtained on admission and at 6, 12, 24, 48, 72, and 96 h after injury. CSF concentrations of S100B and CSF and serum concentrations of five cytokines (IL-1beta, TNF-alpha, IL-6, IL-8, and IL-10) were measured and compared. The CSF S100B concentration was increased for 6 h after injury and decreased thereafter. The CSF concentrations of IL-6 and IL-8 peaked within 6 h after injury; other cytokines (IL-1beta, TNF-alpha, and IL-10) were elevated for 24 h after injury and gradually decreased thereafter. Peak CSF S100B concentrations correlated significantly with ICP determined at the time CSF samples were taken (r(2) = 0.729, P < 0.0001). For the cytokines investigated, only the peak CSF IL-1beta concentration correlated significantly and positively with the peak CSF S100B concentration (r(2) = 0.397, P < 0.005). Peak CSF concentrations of S100B (1649 +/- 415 mug/L, mean +/- SEM) and IL-1beta (16.5 +/- 3.3 pg/mL) in the 6 patients with high ICP were significantly higher than those (233 +/- 67 mug/L, 7.6 +/- 1.7 pg/mL, respectively) in the 17 patients with low ICP (P < 0.05). The CSF S100B concentration (1231 +/- 378 mug/L) in eight patients with an unfavorable outcome was significantly higher than that (267 +/- 108 mug/L) in 15 patients with a favorable outcome (P < 0.05). The CSF IL-1beta concentration (14.8 +/- 3.4 pg/mL) in eight patients with an unfavorable outcome tended to be higher than that (7.3 +/- 1.5 pg/mL) in 15 patients with a favorable outcome (P = 0.057). CSF concentrations of S100B and cytolkines peak within 24 h after severe TBI and decrease gradually thereafter. CSF S100B and IL-1beta may be useful as predictors of outcome in cases of severe TBI.	Osaka Univ, Grad Sch Med, Dept Traumatol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Neurosurg, Suita, Osaka 5650871, Japan; Mitsubishi Kagaku Bioclin Labs Inc, Tokyo, Japan	Shiozaki, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Traumatol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	shiozaki@hp-emerg.med.osaka-u.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15390545] Funding Source: KAKEN		Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bianchi R, 1996, BBA-MOL CELL RES, V1313, P258, DOI 10.1016/0167-4889(96)00098-5; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Clatterbuck RE, 1997, NEUROSURGERY, V40, P339, DOI 10.1097/00006123-199702000-00019; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Gaetani P, 1998, NEUROL RES, V20, P337, DOI 10.1080/01616412.1998.11740528; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; JENNETT B, 1975, LANCET, V1, P480; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; RICKMANN M, 1995, HISTOCHEM CELL BIOL, V103, P135, DOI 10.1007/BF01454011; ROSSANO F, 1992, IMMUNOPHARM IMMUNOT, V14, P439, DOI 10.3109/08923979209005403; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Tarkowski E, 1997, CLIN EXP IMMUNOL, V110, P492, DOI 10.1046/j.1365-2249.1997.4621483.x; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TEASDALE G, 1974, LANCET, V2, P81; Vos PE, 2002, SHOCK, V18, P481, DOI 10.1097/00024382-200211000-00017; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	34	153	165	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	AUG	2004	22	2					102	107		10.1097/01.shk.0000131193.80038.f1			6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	839DC	WOS:000222762500002	15257081				2021-06-18	
J	Savola, O; Pyhtinen, J; Leino, TK; Siitonen, S; Niemela, O; Hillbom, M				Savola, O; Pyhtinen, J; Leino, TK; Siitonen, S; Niemela, O; Hillbom, M			Effects of head and extracranial injuries on serum protein S100B levels in trauma patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						S100B; brain injury; extracranial injury	BRAIN-DAMAGE; NEUROBIOCHEMICAL MARKERS; COMPUTERIZED-TOMOGRAPHY; OUTCOME PREDICTION; S-100B PROTEIN; RELEASE; TISSUE	Background: Serum protein S100B determinations have been recently suggested as markers of traumatic brain injury. However, little is known about the effects of extracranial injuries on S100B levels in trauma patients. Methods: We studied 224 patients with head trauma (54 of whom also had extracranial injuries), 155 patients with various types of extracranial injuries, and 8 healthy pilots exposed to high Gz forces. The head trauma patients had either no brain injury (n = 35), mild brain injury (n = 165), or moderate to severe brain injury (n = 24). The extracranial injuries were divided into small and large injuries. Serum protein S100B levels were determined from samples taken within 6 hours after the trauma event. Results: The head trauma patients had a significantly higher median S100B (0.17 mug/L) than the patients with extracranial injuries (0.07 mug/L) (p < 0.001). Serum S100B levels also correlated with the severity of brain injury (p < 0.001), the highest values occurring in the patients with moderate to severe brain injury (1.27 mug/L). However, large extracranial injuries also elevated S100B levels (0.35 mug/L), whereas small extracranial injuries in the absence of head trauma did not significantly affect S100B levels (0.07 mug/L). Above the cutoff level of 0.13 mug/L, there were 61% of the head trauma patients and 26% of those with extracranial injuries (Pearson chi(2) test, p < 0.001). However, only 4% of the patients with purely extracranial injuries had a concentration of S100B above the cutoff level of 0.50 mug/L, whereas the head trauma patients with moderate to severe brain injury exceeded this cutoff in 67% of the cases. Exposure to high Gz forces did not influence serum S100B levels in healthy individuals. Conclusion: We conclude that serum S100B is a sensitive marker of brain injury, which correlates with the severity of the injury. Large extracranial injuries also elevate S100B levels. However, S100B has a high negative predictive power, and the finding of a normal S100B value shortly after trauma should thus exclude significant brain injury with a high accuracy.	Oulu Univ Hosp, Dept Neurol, FIN-90020 Oulu, Finland; Oulu Univ Hosp, Dept Radiol, FIN-90020 Oulu, Finland; Oulu Univ Hosp, Dept Otorhinolaryngol, FIN-90020 Oulu, Finland; Finnish Def Forces, Res Inst Mil Med, Dept Aviat Med, Helsinki, Finland; Tampere Univ, Dept Lab Med, FIN-33101 Tampere, Finland; Seinajoki Cent Hosp, Seinajoki, Finland	Savola, O (corresponding author), Oulu Univ Hosp, Dept Neurol, Box 25, FIN-90020 Oulu, Finland.	osavola@paju.oulu.fi					Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; HAIMOTO H, 1987, LAB INVEST, V57, P489; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2001, NEUROSURGERY, V49, P1272, DOI 10.1097/00006123-200111000-00058; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; HIDAKA H, 1983, J BIOL CHEM, V258, P2705; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raabe A, 2001, NEUROSURGERY, V49, P1491, DOI 10.1097/00006123-200112000-00055; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Rothoerl RD, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00054; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; SIITONEN S, 2000, THESIS KUOPIO UFINAL, P204; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	28	153	157	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2004	56	6					1229	1234		10.1097/01.TA.0000096644.08735.72			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	839UT	WOS:000222811100011	15211130				2021-06-18	
J	Coles, JP; Fryer, TD; Smielewski, P; Chatfield, DA; Steiner, LA; Johnston, AJ; Downey, SPMJ; Williams, GB; Aigbirhio, F; Hutchinson, PJ; Rice, K; Carpenter, TA; Clark, JC; Pickard, JD; Menon, DK				Coles, JP; Fryer, TD; Smielewski, P; Chatfield, DA; Steiner, LA; Johnston, AJ; Downey, SPMJ; Williams, GB; Aigbirhio, F; Hutchinson, PJ; Rice, K; Carpenter, TA; Clark, JC; Pickard, JD; Menon, DK			Incidence and mechanisms of cerebral ischemia in early clinical head injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						trauma; head injury; positron emission tomography; cerebral ischemia; traumatic penumbra	TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; BLOOD-FLOW; MAGNETIC-RESONANCE; OXYGEN-CONSUMPTION; ENERGY-METABOLISM; ACUTE ANEMIA; HYPERVENTILATION; DAMAGE; PET	Antemortem demonstration of ischemia has proved elusive in head injury because regional CBF reductions may represent hypoperfusion appropriately coupled to hypometabolism. Fifteen patients underwent positron emission tomography within 24 hours of head injury to map cerebral blood flow (CBF), cerebral oxygen metabolism (CMRO2), and oxygen extraction fraction (OEF). We estimated the volume of ischemic brain (IBV) and used the standard deviation of the OFF distribution to estimate the efficiency of coupling between CBF and CMRO2. The lBV in patients was significantly higher than controls (67 +/- 69 vs. 2 +/- 3 mL; P < 0.01). The coexistence of relative ischemia and hyperemia in some patients implies mismatching of perfusion to oxygen use. Whereas the saturation of jugular bulb blood (SjO(2)) correlated with the lBV (r = 0.8, P < 0.01), SjO(2) values of 50% were only achieved at an IBV of 170 +/- 63 mL (mean +/-95% CI), which equates to 13 +/- 5% of the brain. Increases in IBV correlated with a poor Glasgow Outcome Score 6 months after injury (rho = -0.6, P < 0.05). These results suggest significant ischemia within the first day after head injury. The ischemic burden represented by this "traumatic penumbra" is poorly detected by bedside clinical monitors and has significant associations with outcome.	Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England; Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England	Menon, DK (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Box 93,Hills Rd, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk	Steiner, Luzius/J-1987-2019; Steiner, Luzius/C-9836-2011; Rice, Kenneth M/A-4150-2013	Rice, Kenneth M/0000-0001-5779-4495; Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G9439390] Funding Source: Medline		Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Baron JC, 1999, CEREBROVASC DIS, V9, P193, DOI 10.1159/000015955; BARON JC, 1989, J CEREBR BLOOD F MET, V9, P723, DOI 10.1038/jcbfm.1989.105; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Chesnut R M, 1995, New Horiz, V3, P366; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; COLES JP, 2003, IN PRESS J CEREB BLO; CORREIA JA, 1985, J CEREBR BLOOD F MET, V5, P591, DOI 10.1038/jcbfm.1985.88; CRUZ J, 1994, CRIT CARE MED, V22, P1465, DOI 10.1097/00003246-199409000-00018; CRUZ J, 1993, CRIT CARE MED, V21, P1218, DOI 10.1097/00003246-199308000-00024; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Garcia JH, 1996, STROKE, V27, P761, DOI 10.1161/01.STR.27.4.761; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Gibbs EL, 1942, J BIOL CHEM, V144, P325; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; HERSCOVITCH P, 1983, J CEREBR BLOOD F MET, V3, P407, DOI 10.1038/jcbfm.1983.66; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; JENNETT B, 1975, LANCET, V1, P480; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P372, DOI 10.1038/jcbfm.1987.75; LEBRUNGRANDIE P, 1983, ARCH NEUROL-CHICAGO, V40, P230, DOI 10.1001/archneur.1983.04050040060010; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Marchal G, 1999, BRAIN, V122, P2387, DOI 10.1093/brain/122.12.2387; Marchal G, 1996, STROKE, V27, P599, DOI 10.1161/01.STR.27.4.599; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Metz C, 1998, J CEREBR BLOOD F MET, V18, P332, DOI 10.1097/00004647-199803000-00012; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PHELPS ME, 1979, J NUCL MED, V20, P328; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; Robertson C S, 1995, New Horiz, V3, P410; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SMIELEWSKI P, 2003, J CLIN MONITOR COMP, V17, P427; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; Studholme C, 1996, Med Image Anal, V1, P163, DOI 10.1016/S1361-8415(96)80011-9; Studholme C, 1997, MED PHYS, V24, P25, DOI 10.1118/1.598130; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927; Talairach J., 1998, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6; 2000, J NEUROTRAUMA, V17, P457	61	153	161	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2004	24	2					202	211		10.1097/01.WCB.0000103022.98348.24			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	772CG	WOS:000188822600008	14747747	Bronze			2021-06-18	
J	Smith, DH; Chen, XH; Iwata, A; Graham, DI				Smith, DH; Chen, XH; Iwata, A; Graham, DI			Amyloid beta accumulation in axons after traumatic brain injury in humans	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; axonal injury; amyloid; amyloid precursor protein	HEAD-INJURY; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; APOLIPOPROTEIN-E; RISK FACTOR; PEPTIDE; DEPOSITION; GENOTYPE; DAMAGE; ONSET	Object. Although plaques composed of amyloid beta (Abeta) have been found shortly after traumatic brain injury (TBI) in humans, the source for this Abeta has not been identified. In the present study, the authors explored the potential relationship between Abeta accumulation in damaged axons and associated Abeta plaque formation. Methods. The authors performed an immunohistochemical analysis of paraffin-embedded sections of brain from 12 patients who died after TBI and from two control patients by using antibodies selective for Abeta peptides, amyloid precursor protein (APP), and neurofilament (NF) proteins. In nine brain-injured patients, extensive colocalizations of Abeta, APP, and NF protein were found in swollen axons. Many of these immunoreactive axonal profiles were present close to Abeta plaques or were surrounded by Abeta staining, which spread out into the tissue. Immunoreactive profiles were not found in the brains of the control patients. Conclusions. The results of this study indicate that damaged axons can serve as a large reservoir of Abeta, which may contribute to Abeta plaque formation after TBI in humans.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; So Gen Hosp, Inst Neurol Sci, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland	Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.		smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS038104, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG021527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG21527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS38104] Funding Source: Medline		ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; AdleBiassette H, 1996, NEUROBIOL AGING, V17, P415, DOI 10.1016/0197-4580(96)00029-2; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gottlieb S, 2000, BRIT MED J, V321, P1100; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, P28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Raby CA, 1998, J NEUROCHEM, V71, P2505; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069	29	153	160	1	6	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	2003	98	5					1072	1077		10.3171/jns.2003.98.5.1072			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	674CJ	WOS:000182619000024	12744368				2021-06-18	
J	Wu, A; Molteni, R; Ying, Z; Gomez-Pinilla, F				Wu, A; Molteni, R; Ying, Z; Gomez-Pinilla, F			A saturated-fat diet aggravates the outcome of traumatic brain injury on hippocampal plasticity and cognitive function by reducing brain-derived neurotrophic factor	NEUROSCIENCE			English	Article						fluid percussion injury; neuroplaisticity; cognition; BDNF; synapsin 1; CREB	LONG-TERM POTENTIATION; ELEMENT-BINDING PROTEIN; SYNAPSIN-I; SYNAPTIC PLASTICITY; GENE-EXPRESSION; NEURONAL PLASTICITY; RAT HIPPOCAMPUS; UP-REGULATION; CREB; BDNF	We have conducted studies to determine the potential of dietary factors to affect the capacity of the brain to compensate for insult. Rats were fed with a high-fat sucrose (HFS) diet, a popularly consumed diet in industrialized western societies, for 4 weeks before a mild fluid percussion injury (FPI) or sham surgery was performed. FPI impaired spatial learning capacity in the Morris water maze, and these effects were aggravated by previous exposure of the rats to the action of the HFS diet. Learning performance decreased according to levels of brain-derived neurotrophic factor (BDNF) in individual rats, such that rats with the worst learning efficacy showed the lowest levels of BDNF in the hippocampus. BDNF immunohistochemistry localized the decreases in BDNF to the CA3 and clentate gyrus of the hippocampal formation. BDNF has a strong effect on synaptic plasticity via the action of synapsin I and cAMP-response element-binding protein (CREB), therefore, we assessed changes in synapsin I and CREB in conjunction with BDNF. Levels of synapsin I and CREB decreased in relation to decreases in BDNF levels. The combination of FPI and the HFS diet had more dramatic effects on the active state (phosphorylated) of synapsin I and CREB. There were no signs of neurodegeneration in the hippocampus of any rat group assessed with Fluoro-Jade B staining. The results suggest that FPI and diet impose a risk factor to the molecular machinery in charge of maintaining neuronal function under homeostatic and challenging situations. (C) 2003 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA 90095 USA	Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.		Molteni, Raffaella/Q-5011-2017	Molteni, Raffaella/0000-0002-5481-7572	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [38978, 39522] Funding Source: Medline		Akagi S, 1996, HISTOCHEM CELL BIOL, V105, P365, DOI 10.1007/BF01463657; BAEKELANDT V, 1994, EUR J NEUROSCI, V6, P754, DOI 10.1111/j.1460-9568.1994.tb00987.x; Beltowski J, 2000, J PHYSIOL PHARMACOL, V51, P883; Bolton MM, 2000, PROG BRAIN RES, V128, P203; Conti AC, 2002, J NEUROSCI, V22, P3262, DOI 10.1523/JNEUROSCI.22-08-03262.2002; Conti AC, 1998, J NEUROSCI, V18, P5663; Croll SD, 1998, BRAIN RES, V812, P200, DOI 10.1016/S0006-8993(98)00993-7; Dawson TM, 2002, NAT MED, V8, P450, DOI 10.1038/nm0502-450; Faure P, 1997, J NUTR, V127, P103; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Gomez-Pinilla F, 2001, BRAIN RES, V904, P13, DOI 10.1016/S0006-8993(01)02394-0; Hall J, 2000, NAT NEUROSCI, V3, P533; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Joseph JA, 1999, J NEUROSCI, V19, P8114; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kesslak JP, 1998, BEHAV NEUROSCI, V112, P1012, DOI 10.1037/0735-7044.112.4.1012; KOROL DL, 1993, HIPPOCAMPUS, V3, P127, DOI 10.1002/hipo.450030204; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Kovalchuk Y, 2002, SCIENCE, V295, P1729, DOI 10.1126/science.1067766; Kubova H, 2001, J NEUROSCI, V21, P3593, DOI 10.1523/JNEUROSCI.21-10-03593.2001; Linnarsson S, 1997, EUR J NEUROSCI, V9, P2581, DOI 10.1111/j.1460-9568.1997.tb01687.x; Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Medhurst AD, 2000, J NEUROSCI METH, V98, P9, DOI 10.1016/S0165-0270(00)00178-3; MELLONI RH, 1994, NEUROSCIENCE, V58, P683, DOI 10.1016/0306-4522(94)90448-0; Mizuno M, 2000, J NEUROSCI, V20, P7116, DOI 10.1523/JNEUROSCI.20-18-07116.2000; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Nibuya M, 1996, J NEUROSCI, V16, P2365; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Takei Y, 1995, J CELL BIOL, V131, P1789, DOI 10.1083/jcb.131.6.1789; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Tully T, 1997, P NATL ACAD SCI USA, V94, P4239, DOI 10.1073/pnas.94.9.4239; WANG T, 1995, J NEUROSCI, V15, P4796; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yin JCP, 1996, CURR OPIN NEUROBIOL, V6, P264, DOI 10.1016/S0959-4388(96)80082-1; Ying SW, 2002, J NEUROSCI, V22, P1532, DOI 10.1523/JNEUROSCI.22-05-01532.2002	49	153	162	1	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2003	119	2					365	375		10.1016/S0306-4522(03)00154-4			11	Neurosciences	Neurosciences & Neurology	688DP	WOS:000183418100005	12770552				2021-06-18	
J	Bathgate, A; Best, JP; Craig, G; Jamieson, M				Bathgate, A; Best, JP; Craig, G; Jamieson, M			A prospective study of injuries to elite Australian rugby union players	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PERFORMANCE PROJECT; FOOTBALL INJURIES; EPIDEMIOLOGY	Objectives: To assess injury patterns and incidence in the Australian Wallabies rugby union players from 1994 to 2000. To compare these patterns and rates with those seen at other levels of play, and to see how they have changed since the beginning of the professional era. Methods: Prospective data were recorded from 1994 to 2000. All injuries to Australian Wallabies rugby union players were recorded by the team doctor. An injury was defined as one that forced a player to either leave the field or miss a subsequent game. Results: A total of 143 injuries were recorded from 91 matches. The overall injury rate was 69/1000 player hours of game play. The injury rates in the periods before (1994-1995) and after (1996-2000) the start of the professional era were 4711000 player hours and 7411000 player hours respectively. The lock was the most injured forward, and the number 10 the most injured back. Most injuries were soft tissue, closed injuries (55%), with the head being the most commonly injured region (25.1%). The phase of play responsible for most injuries was the tackle (58.7%). Injuries were more likely to occur in the second half of the game, specifically the third quarter (40%). The vast majority of injuries were acute (90%), with the remainder being either chronic or recurrent. Conclusions: Injury rate increases at higher levels of play in rugby union. Injury rates have increased in the professional era. Most injuries are now seen in the third quarter of the game, a finding that may reflect new substitution laws. There is a need for standardised collection of injury data in rugby union.	Eastern Suburbs Sports Med Ctr, Sydney, NSW 2002, Australia; Australian Rugby Union, Sydney, NSW, Australia	Bathgate, A (corresponding author), Eastern Suburbs Sports Med Ctr, Sydney, NSW 2002, Australia.						Addley K, 1988, Br J Sports Med, V22, P22; *AUSTR RUGB UN, 1999, ANN REP 1999 RUGB DI, P35; BEST JP, 2000, C HDB AUSTR COLL SPO, P16; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Bottini E, 2000, BRIT J SPORT MED, V34, P94, DOI 10.1136/bjsm.34.2.94; Carson JD, 1999, CLIN J SPORT MED, V9, P75, DOI 10.1097/00042752-199904000-00006; CLARK DR, 1990, S AFR MED J, V77, P559; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; DURIE RM, 2000, NZ J SPORTS MED, V28, P84; EDGAR M, 1995, LANCET, V345, P1452, DOI 10.1016/S0140-6736(95)91031-X; GARRAWAY M, 1995, LANCET, V345, P1485; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Garraway WM, 2000, BRIT J SPORT MED, V34, P348, DOI 10.1136/bjsm.34.5.348; GERRARD DF, 1994, BRIT J SPORT MED, V28, P229, DOI 10.1136/bjsm.28.4.229; GROWDEN G, 2001, SYDNEY MORNING  0412, P42; Hughes DC, 1994, CLIN J SPORT MED, V4, P249, DOI 10.1097/00042752-199410000-00007; *INT RUGB BOARD, 1999, IRB C GAM 1999 DUBL; *INT RUGB BOARD, 2001, ANN REP 2001, P21; JAKOET I, 1997, S AFR MED J, V87, P45; Lee AJ, 1996, BRIT J SPORT MED, V30, P213, DOI 10.1136/bjsm.30.3.213; MCINTOSH AS, 2000, REV MED ASPECTS LAW, P41; McManus A, 2000, BRIT J SPORT MED, V34, P342, DOI 10.1136/bjsm.34.5.342; MYERS PT, 1980, MED J AUSTRALIA, V2, P17, DOI 10.5694/j.1326-5377.1980.tb131804.x; ROUX CE, 1987, S AFR MED J, V71, P307; Secin FP, 1999, BRIT J SPORT MED, V33, P33, DOI 10.1136/bjsm.33.1.33; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; Sparks J P, 1985, Br J Sports Med, V19, P71; Targett SGR, 1998, CLIN J SPORT MED, V8, P280, DOI 10.1097/00042752-199810000-00005; TAYLOR TKF, 1987, MED J AUSTRALIA, V147, P112, DOI 10.5694/j.1326-5377.1987.tb133298.x; Wilson B D, 1999, J Sci Med Sport, V2, P153, DOI 10.1016/S1440-2440(99)80195-9	30	153	157	0	34	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	AUG	2002	36	4					265	269		10.1136/bjsm.36.4.265			5	Sport Sciences	Sport Sciences	580RU	WOS:000177249300009	12145116	Green Published, Bronze			2021-06-18	
J	Klorman, R; Hazel-Fernandez, LA; Shaywitz, SE; Fletcher, JM; Marchione, KE; Holahan, JM; Stuebing, KK; Shaywitz, BA				Klorman, R; Hazel-Fernandez, LA; Shaywitz, SE; Fletcher, JM; Marchione, KE; Holahan, JM; Stuebing, KK; Shaywitz, BA			Executive functioning deficits in attention-deficit hyperactivity disorder are independent of oppositional defiant or reading disorder	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						executive functions; attention-deficit/hyperactivity disorder; hyperactivity-impulsivity; reading disorder; oppositional defiant disorder	LEARNING-DISABLED CHILDREN; RETARDED YOUNG-ADULTS; FRONTAL-LOBE LESIONS; CLOSED-HEAD INJURY; NONRETARDED-CHILDREN; PROCESSING DEFICITS; SUSTAINED ATTENTION; WORKING MEMORY; DISABILITY; TOWER	Objective: To evaluate deficits of executive functions in children with attention-deficit/hyperactivity disorder (ADHD) classified by type (combined [CT] or predominantly inattentive [IT]) and comorbidity with oppositional defiant disorder (ODD) and reading disorder (RD), Method: The Wisconsin Card Sorting Test (WCST) and Tower of Hanoi (TOH) were administered to 28 community volunteers and 359 children (7.5-13.5 years old) divided into ADHD types, RD, and ODD. Results: ADHD/CT children solved fewer puzzles and violated more rules on the TOH than ADHD/IT or non-ADHD subjects. On the WCST there were no differences between diagnostic samples in perseverativeness, but ADHD/CT patients made more nonperseverative errors than ADHD/IT children. ODD was associated with moderately better TOH performance and RD with excessive rule breaks. Conclusions: Executive functioning deficits were found for only ADHD/CT children and were independent of comorbidity with RD or ODD.	Univ Rochester, Dept Clin & Social Sci Psychol, Rochester, NY 14620 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; Univ Texas, Dept Pediat, Houston, TX USA	Klorman, R (corresponding author), Univ Rochester, Dept Clin & Social Sci Psychol, RC Box 270266,Meliora Hall, Rochester, NY 14620 USA.	klorman@psych.rochester.edu	Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P50HD025802] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH047333] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD25802] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH47333] Funding Source: Medline		ACKERMAN PT, 1986, BRAIN COGNITION, V5, P22, DOI 10.1016/0278-2626(86)90060-6; AGRONIN ME, 1992, ATTENTION DEFICIT DI, P89; Aman CJ, 1998, DEV PSYCHOL, V34, P956, DOI 10.1037/0012-1649.34.5.956; AUGUST GJ, 1990, J ABNORM CHILD PSYCH, V18, P29, DOI 10.1007/BF00919454; AUGUST GJ, 1987, J ABNORM CHILD PSYCH, V15, P429, DOI 10.1007/BF00916459; Barkley R. A., 1997, ADHD NATURE SELF CON; Barkley R.A, 2006, ATTENTION DEFICIT HY; BARKLEY RA, 1989, J AM ACAD CHILD PSY, V28, P873, DOI 10.1097/00004583-198911000-00011; BARKLEY RA, 1992, J ABNORM CHILD PSYCH, V20, P163, DOI 10.1007/BF00916547; BARKLEY RA, 1990, J CONSULT CLIN PSYCH, V58, P775, DOI 10.1037/0022-006X.58.6.775; BARKLEY RA, 1991, PEDIATRICS, V87, P519; BORYS SV, 1982, J EXP CHILD PSYCHOL, V33, P87, DOI 10.1016/0022-0965(82)90008-X; Cantwell D. P., 1992, ATTENTION DEFICIT DI, P145; CHANG HT, IN PRESS J ABNORM CH; DAINER KB, 1981, J ABNORM CHILD PSYCH, V9, P79, DOI 10.1007/BF00917859; DREWE E A, 1974, Cortex, V10, P159; Dykman R. A., 1992, ATTENTION DEFICIT DI, P165; EPSTEIN M, 1992, ATTENTION DEFICIT DI, P197; FELTON RH, 1989, J LEARN DISABIL, V22, P3, DOI 10.1177/002221948902200102; Fletcher J., 1998, LEARNING DISABILITIE, V13, P186; FLETCHER JM, 1994, J EDUC PSYCHOL, V86, P6, DOI 10.1037//0022-0663.86.1.6; Giancola PR, 1998, J ABNORM PSYCHOL, V107, P629, DOI 10.1037/0021-843X.107.4.629; GOEL V, 1995, NEUROPSYCHOLOGIA, V33, P623, DOI 10.1016/0028-3932(95)90866-P; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; HALPERIN JM, 1990, J CHILD PSYCHOL PSYC, V31, P455, DOI 10.1111/j.1469-7610.1990.tb01582.x; HALPERIN JM, 1984, J ABNORM CHILD PSYCH, V12, P1, DOI 10.1007/BF00913458; Harris M. E., 1990, WISCONSIN CARD SORTI; Heaton R. K, 1981, WISCONSIN CARD SORTI; KELLY MS, 1989, BRAIN COGNITION, V11, P275, DOI 10.1016/0278-2626(89)90022-5; KEPPEL G, 1991, DESIGN ANAL; KLORMAN R, 1988, J ABNORM PSYCHOL, V97, P413, DOI 10.1037/0021-843X.97.4.413; KLORMAN R, 1994, J ABNORM PSYCHOL, V103, P206, DOI 10.1037/0021-843X.103.2.206; KUPIETZ SS, 1990, J ABNORM CHILD PSYCH, V18, P357, DOI 10.1007/BF00917640; LAHEY BB, 1991, J LEARN DISABIL, V24, P110, DOI 10.1177/002221949102400208; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LONEY J, 1987, ADV CLIN CHILD PSYCH, V10, P99; MCGEE R, 1989, J ABNORM CHILD PSYCH, V17, P37, DOI 10.1007/BF00910769; Milner B., 1963, ARCH NEUROL-CHICAGO, V9, P100, DOI DOI 10.1001/ARCHNEUR.1963.00460070100010; Moffitt T. E., 1989, DEV PSYCHOPATHOL, V1, P105, DOI DOI 10.1017/S0954579400000298; Myers Jerome L., 1995, RES DESIGN STAT ANAL; Nigg JT, 1998, J ABNORM PSYCHOL, V107, P468, DOI 10.1037/0021-843X.107.3.468; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; PENNINGTON BF, 1993, DEV PSYCHOL, V29, P512; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; SEGUIN JR, 1995, J ABNORM PSYCHOL, V104, P614, DOI 10.1037/0021-843X.104.4.614; SEMRUDCLIKEMAN M, 1992, J AM ACAD CHILD PSY, V31, P439, DOI 10.1097/00004583-199205000-00009; Shaffer D, 1996, J AM ACAD CHILD PSY, V35, P865, DOI 10.1097/00004583-199607000-00012; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shaywitz BA, 1995, CHILD NEUROPSYCHOL, V1, P170, DOI 10.1080/09297049508400223; SHAYWITZ SE, 1992, NEW ENGL J MED, V326, P145, DOI 10.1056/NEJM199201163260301; SIEGEL LS, 1989, CHILD DEV, V60, P973, DOI 10.1111/j.1467-8624.1989.tb03528.x; SIEGEL LS, 1988, DEV PSYCHOL, V24, P28, DOI 10.1037/0012-1649.24.1.28; SIMON HA, 1975, COGNITIVE PSYCHOL, V7, P268, DOI 10.1016/0010-0285(75)90012-2; SPITZ HH, 1985, AM J MENT DEF, V90, P46; SWANSON HL, 1983, J ABNORM CHILD PSYCH, V11, P415, DOI 10.1007/BF00914249; TANT JL, 1982, J ABNORM CHILD PSYCH, V10, P285, DOI 10.1007/BF00912323; TARNOWSKI KJ, 1986, J ABNORM PSYCHOL, V95, P341, DOI 10.1037/0021-843X.95.4.341; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; WANSART WL, 1990, J LEARN DISABIL, V23, P164, DOI 10.1177/002221949002300306; Ward G, 1997, Q J EXP PSYCHOL-A, V50, P49, DOI 10.1080/027249897392224; Wechsler D., 1974, MANUAL WECHSLER INTE; WELSH MC, 1991, COGNITIVE DEV, V6, P59, DOI 10.1016/0885-2014(91)90006-Y; WEYANDT LL, 1994, DEV NEUROPSYCHOL, V10, P27, DOI 10.1080/87565649409540564; WOODCOCK RW, 1978, DEV STANDARDIZATION	68	153	167	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	SEP	1999	38	9					1148	1155		10.1097/00004583-199909000-00020			8	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	230DY	WOS:000082237600019	10504814				2021-06-18	
J	Suarez, JI; Qureshi, AI; Bhardwaj, A; Williams, MA; Schnitzer, MS; Mirski, M; Hanley, DF; Ulatowski, JA				Suarez, JI; Qureshi, AI; Bhardwaj, A; Williams, MA; Schnitzer, MS; Mirski, M; Hanley, DF; Ulatowski, JA			Treatment of refractory intracranial hypertension with 23.4% saline	CRITICAL CARE MEDICINE			English	Article						cerebral edema; saline; intracranial hypertension; hypertonic solutions; serum sodium; neurointensive care	SEVERE HEAD-INJURIES; HYPERTONIC SALINE; AGGRESSIVE TREATMENT; PRESSURE; BRAIN; TRAUMA; HYPOTENSION; INFUSION; FAILURE	Objective: To evaluate the effect of intravenous bolus administration of 23.4% saline (8008 mOsm/L) on refractory intracranial hypertension (RIH) in patients with diverse intracranial diseases. Design: Retrospective chart review. Setting: A neurosciences intensive care unit in a university hospital. Patients: We present eight patients and a total of 20 episodes of increased intracranial pressure (ICP) resistant to standard modes of therapy. Five patients had subarachnoid hemorrhage, one patient had traumatic brain injury, one had a brain tumor, and another had spontaneous basal ganglia hemorrhage. Seven patients had intraventricular catheters, and one had a subarachnoid pressure screw placed. We monitored continuously mean ICP, serum sodium concentrations, mean arterial pressure, cerebral perfusion pressure (CPP), central venous pressure, and urine output before and after the administration of hypertonic saline (HS). Post mortem examination of the brain was performed in two patients. Intervention: Intravenous bolus administration of 30 mt of 23.4% saline. Measurements and Main Results: There was a significant (p <.05) decrease in ICP from a median of 41.5 mm Hg before HS to 17 mm Hg at 1 hr, 16 mm Hg at 2 hrs, and 14 mm Hg at 3 hrs after HS administration. In 80% of cases, ICP decreased by >50% of the pretreatment value over a duration of 21.2 +/-: 10.3 mins. ICP decreased to <20 mm Hg in 65% of all cases and the mean time for it to again exceed 20 mm Hg was 6.3 +/- 4.9 hrs. There was a significant improvement in CPP, from 64.7+/-19 (SD) mm Hg before HS to 85.6 +/- 18 mm Hg (1 hr) and 83 +/- 18 mm Hg (3 hrs) after HS. There were no significant differences in the other variables measured. The post mortem examinations showed no white matter changes or subdural collections. Conclusions: This preliminary case series suggests that the intravenous bolus administration of 23.4% saline reduces ICP and augments CPP in patients with resistant increased ICP. This reduction can be maintained for several hours while other therapeutic measures are being considered. The patient population most likely to respond to this therapy needs to be further defined. Although more research is needed, this treatment is promising as a new modality for RIH because of its ICP-lowering effect without intravascular volume depletion.	Johns Hopkins Med Inst, Div Neurosci Crit Care, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Neurosurg, Baltimore, MD 21205 USA	Suarez, JI (corresponding author), Johns Hopkins Med Inst, Div Neurosci Crit Care, Baltimore, MD 21205 USA.		Williams, Michael/O-4075-2019	Qureshi, Adnan/0000-0003-4962-540X; Williams, Michael/0000-0002-7284-8014			BINGAMAN WE, 1995, NEUROL CLIN, V13, P479, DOI 10.1016/S0733-8619(18)30031-8; BLECK TP, 1995, MAYO CLIN PROC, V70, P195, DOI 10.4065/70.2.195; COTE CJ, 1979, ANESTHESIOLOGY, V50, P30, DOI 10.1097/00000542-197901000-00007; DENCHEV D, 1994, INTRACRANIAL PRESSUR, V9, P658; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Gemma M, 1996, J NEUROSURG ANESTH, V8, P137, DOI 10.1097/00008506-199604000-00007; Hariri R J, 1994, Neurosurg Clin N Am, V5, P687; JENNETT B, 1975, LANCET, V1, P480; KIEN ND, 1991, ANESTH ANALG, V73, P597; Lang E W, 1994, Neurosurg Clin N Am, V5, P573; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NAKAYAMA SI, 1985, J SURG RES, V38, P180, DOI 10.1016/0022-4804(85)90025-3; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; Ritter A M, 1994, Neurosurg Clin N Am, V5, P633; Schell RM, 1996, J NEUROSURG ANESTH, V8, P178, DOI 10.1097/00008506-199604000-00022; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; Weed LH, 1919, AM J PHYSIOL, V48, P531; WHELAN TV, 1984, ARCH INTERN MED, V144, P2053, DOI 10.1001/archinte.144.10.2053; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	25	153	167	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JUN	1998	26	6					1118	1122		10.1097/00003246-199806000-00038			5	Critical Care Medicine	General & Internal Medicine	ZT944	WOS:000074144100032	9635664				2021-06-18	
J	Cecil, KM; Hills, EC; Sandel, E; Smith, DH; McIntosh, TK; Mannon, LJ; Sinson, GP; Bagley, LJ; Grossman, RI; Lenkinski, RE				Cecil, KM; Hills, EC; Sandel, E; Smith, DH; McIntosh, TK; Mannon, LJ; Sinson, GP; Bagley, LJ; Grossman, RI; Lenkinski, RE			Proton magnetic resonance spectroscopy for detection of axonal injury in the splenium of the corpus callosum of brain-injured patients	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; magnetic resonance spectroscopy; splenium; diffuse axonal injury; N-acetyl aspartate	LOCALIZED H-1-NMR SPECTRA; CLOSED-HEAD INJURY; L-ASPARTIC ACID; N-ACETYLASPARTATE; RAT-BRAIN; MR; TRAUMA; GLUTAMATE; FEATURES; LESIONS	Object. This study was conducted to determine whether proton magnetic resonance spectroscopy (MRS) is a sensitive method for detecting diffuse axonal injury, which is a primary sequela of traumatic brain injury (TBI). Diffuse axonal injury is characterized by selective damage to white matter tracts that is caused in part by the severe inertial strain created by rotational acceleration and deceleration, which is often associated with motor vehicle accidents. This axonal injury is typically difficult to detect by using conventional imaging techniques because it is microscopic in nature. The splenium was selected because it is a site vulnerable to shearing forces that product diffuse axonal injury. Methods. The authors used proton MRS to evaluate the splenium, the posterior commissure of the corpus callosum, in normal control volunteers and in patients with TBI. Proton MRS provided an index of neuronal and axonal viability by measuring levels of N-acetyl aspartate (NAA). Conclusions. A majority of mildly brain injured patients, as well as those more severely injured, showed diminished NAA/creatine (Cr) levels in the splenium compared with normal control volunteers. The patients displaying lowered NAA/Cr in the splenium were also likely to exhibit lowered NAA/Cr in lobar white matter. Also. the levels of NAA/Cr in the splenium of normal volunteers were higher compared with those found in lobar white matter. Decreases in NAA/Cr levels in the splenium may be a marker for diffuse injury. A proton MRS examination may be particularly useful in evaluating mildly injured patients with unexplained neurological and cognitive deficits. It is concluded that MRS is a sensitive tool in detecting axonal injury.	Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; Univ Penn, Dept Rehabil Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Lenkinski, RE (corresponding author), Univ Penn, Dept Radiol, 1 Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.		smith, douglas/A-1321-2007; Lenkinski, Robert/F-9045-2014	Lenkinski, Robert/0000-0001-7371-5048; Cecil, Kim/0000-0001-8233-5485	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR002305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, P50NS008803] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR02305] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-08803] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; ADAMS JH, 1982, RECENT ADV NEUROPATH, V2, P165; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; BURRI R, 1991, DEV NEUROSCI-BASEL, V13, P403, DOI 10.1159/000112191; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; CLARKE DD, 1975, J NEUROCHEM, V24, P479, DOI 10.1111/j.1471-4159.1975.tb07665.x; DADAMO AF, 1973, J NEUROCHEM, V20, P1275, DOI 10.1111/j.1471-4159.1973.tb00097.x; FRAHM J, 1991, NMR BIOMED, V4, P201, DOI 10.1002/nbm.1940040408; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1985, TRAUMA CENTRAL NERVO, P169; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gentry LR., 1996, MAGNETIC RESONANCE I, P611; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Hochachka P. W., 1980, LIVING OXYGEN CLOSED; KOLLER KJ, 1984, J NEUROCHEM, V43, P1136, DOI 10.1111/j.1471-4159.1984.tb12854.x; Lenkinski R. E., 1996, MAGNETIC RESONANCE I, V2nd, P1619; LopezVillegas D, 1996, NMR BIOMED, V9, P297, DOI 10.1002/(SICI)1099-1492(199610)9:7<297::AID-NBM433>3.0.CO;2-4; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MIYAKE M, 1981, J NEUROCHEM, V36, P804, DOI 10.1111/j.1471-4159.1981.tb01665.x; MOATS RA, 1995, J COMPUT ASSIST TOMO, V19, P480, DOI 10.1097/00004728-199505000-00025; MOFFETT JR, 1991, NEUROREPORT, V2, P131, DOI 10.1097/00001756-199103000-00005; RABINOWITZ JL, 1976, BIOCHEM J, V157, P271, DOI 10.1042/bj1570271; Ross BD, 1996, NMR BIOMED, V9, P279, DOI 10.1002/(SICI)1099-1492(199610)9:7<279::AID-NBM435>3.0.CO;2-V; ROTHMAN DL, 1992, MAGNET RESON MED, V25, P94, DOI 10.1002/mrm.1910250110; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; SEUBERT W, 1973, MOL CELL BIOCHEM, V1, P29, DOI 10.1007/BF01659936; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; TEASDALE G, 1974, LANCET, V2, P81; URENJAK J, 1992, J NEUROCHEM, V59, P55, DOI 10.1111/j.1471-4159.1992.tb08875.x; WEBB PG, 1994, MAGNET RESON MED, V31, P365, DOI 10.1002/mrm.1910310404; WHEREAT AF, 1967, J BIOL CHEM, V242, P4013	39	153	166	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	1998	88	5					795	801		10.3171/jns.1998.88.5.0795			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	ZJ709	WOS:000073244500001	9576245				2021-06-18	
J	Giacino, JT; Kalmar, K				Giacino, JT; Kalmar, K			The vegetative and minimally conscious states: A comparison of clinical features and functional outcome	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							DISABILITY RATING-SCALE; SEVERE HEAD-INJURY; COMA DATA-BANK; TRAUMATIC BRAIN INJURY; RECOVERY; PROGNOSIS; PROFILE; ADULTS	To compare the vegetative (VS) and minimally conscious states (MCS) with regard to the incidence of specific clinical features and differences in functional outcome across the first year post injury. It was hypothesized that patients diagnosed with MCS on admission to rehabilitation would have more favorable outcomes at 1 year post injury relative to patients diagnosed with VS and that this difference would be more pronounced for traumatic (TBI) versus nontraumatic brain injury (NTBI). Design: Retrospective analysis of clinical findings collected using a standardized methodology (ie, Coma Recovery Scale). Findings were utilized to determine diagnosis and functional outcome at 1, 3, 6, and 12 months post injury. Setting: Acute and extended care brain injury rehabilitation hospital. Patients: 104 patients (62 male, 42 female; mean age = 37 years; mean weeks post injury to admission = 10) with severe TBI or NTBI (VS = 55; MCS = 49) admitted to a rehabilitation-based coma intervention program. Results: Functional outcome at 3, 6, and 12 months post injury was significantly more favorable for patients diagnosed with MCS relative to those with an admitting diagnosis of VS, and this difference was greatest for patients in MCS following TBI. Visual tracking and motor agitation were found to occur in VS but were of low frequency in comparison to MCS. Conclusions: In patients with severe disorders of consciousness, those diagnosed with MCS show more continuous improvement and attain significantly more favorable outcomes by 1 year post injury than those diagnosed with VS. The presence of specific clinical features, particularly visual tracking, may contribute additional information to differential diagnosis in patients whose level of behavioral responsiveness is severely diminished.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT PHYS MED & REHABIL, PISCATAWAY, NJ 08854 USA	Giacino, JT (corresponding author), JFK JOHNSON REHABIL INST, CTR HEAD INJURIES, COGNIT REHABIL PROGRAM, 2048 OAK TREE RD, EDISON, NJ 08820 USA.		Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698			Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597; Ansell B. J., 1993, J HEAD TRAUMA REHAB, V8, P88, DOI DOI 10.1097/00001199-199309000-00011; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; ANSELL BJ, 1995, ARCH PHYS MED REHAB, V76, P726, DOI 10.1016/S0003-9993(95)80526-5; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; *ASP CONS C, 1996, ASP CONS C WORKGR VE; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; CELESIA, 1993, ANN NEUROL, V33, P386; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Cranford R, 1996, BRIT MED J, V313, P5, DOI 10.1136/bmj.313.7048.5; DiPasquale MC, 1996, J HEAD TRAUMA REHAB, V11, P9, DOI 10.1097/00001199-199612000-00004; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Giacino JT, 1993, ARCH PHYS MED REHAB, V74, P662; GIACINO JT, 1994, ARCH PHYS MED REHAB, V75, P723; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HAGAN C, 1979, REHABILITATION HEAD; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1996, CATASTROPHIC BRAIN I; KALMAR K, 1995, ARCH PHYS MED REHAB, V76, P597; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; ODell MW, 1996, J HEAD TRAUMA REHAB, V11, P61, DOI 10.1097/00001199-199606000-00009; ODell MW, 1996, NEUROREHABILITATION, V6, P45, DOI 10.3233/NRE-1996-6106; Plum F., 1983, DIAGNOSIS STUPOR COM; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RAPPAPORT M, 1996, MED REHABILITATION T; RAPPAPORT M, 1986, J HEAD TRAUMA REHABI, P00015, DOI DOI 10.1097/00001199-198603000-00005; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; SAZBON L, 1993, J NEUROL NEUROSUR PS, V56, P407, DOI 10.1136/jnnp.56.4.407; SAZBON L, 1991, Brain Injury, V5, P3, DOI 10.3109/02699059108998505; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; TESCH DD, 1991, ARCH INTERN MED, V151, P930; WHYTE J, IN PRESS REHABILITAT	51	153	160	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1997	12	4					36	51		10.1097/00001199-199708000-00005			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XP104	WOS:A1997XP10400005					2021-06-18	
J	Martin, PK; Schroeder, RW; Odland, AP				Martin, Phillip K.; Schroeder, Ryan W.; Odland, Anthony P.			Neuropsychologists' Validity Testing Beliefs and Practices: A Survey of North American Professionals	CLINICAL NEUROPSYCHOLOGIST			English	Article						Malingering; Effort; Validity; Survey; Neuropsychology	MALINGERED NEUROCOGNITIVE DYSFUNCTION; ALBANY CONSISTENCY INDEX; TRAUMATIC BRAIN-INJURY; FALSE-POSITIVE RATES; WORD MEMORY TEST; SYMPTOM VALIDITY; PERFORMANCE VALIDITY; MULTIPLE PERFORMANCE; RESPONSE BIAS; DIGIT SPAN	Objective: The current study investigated changes in neuropsychologists' validity testing beliefs and practices since publication of the last North American survey targeting these issues in 2007 and explored emerging issues in validity testing that had not been previously addressed in the professional survey literature. Methods: Licensed North American neuropsychologists (n=316), who primarily evaluate adults, were surveyed in regard to the following topics: (1) comparison of objective validity testing, qualitative data, and clinical judgment; (2) approaches to validity test administration; (3) formal communication in cases of suspected malingering; (4) reporting of validity test results; (5) suspected causes of invalidity; (6) integration of stand-alone, embedded, and symptom-report validity measures; (7) multiple performance validity test interpretation; (8) research practices; and (9) popularity of specific validity instruments. Results: Overall, findings from the current survey indicated that all but a small minority of respondents routinely utilize validity testing in their examinations. Furthermore, nearly all neuropsychologists surveyed believed formal validity testing to be mandatory in forensic evaluations and at least desirable in clinical evaluations. While results indicated general agreement among neuropsychologists across many aspects of validity testing, responses regarding some facets of validity test implementation, interpretation, and reporting were more variable. Validity testing utilization generally did not differ according to level of forensic involvement but did vary in respect to respondent literature consumption. Conclusions: Study findings differ significantly from past professional surveys and indicate an increased utilization of validity testing, suggesting a pronounced paradigm shift in neuropsychology validity testing beliefs and practices.	[Martin, Phillip K.; Schroeder, Ryan W.] Univ Kansas, Sch Med, Dept Psychiat & Behav Sci, Wichita, KS 67206 USA; [Odland, Anthony P.] Rush Univ, Med Ctr, Dept Behav Sci, Chicago, IL 60612 USA; [Odland, Anthony P.] Sanford Hlth, Sanford Neurosci Clin, Fargo, ND USA	Martin, PK (corresponding author), Univ Kansas, Sch Med, 7829 E Rockhill,Suite 105, Wichita, KS 67206 USA.	pmartin4@kumc.edu					American Psychiatric Association, 2013, DIAGN STAT MAN MENT; Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; ARKES HR, 1980, J EXP PSYCHOL-HUM L, V6, P568, DOI 10.1037/0278-7393.6.5.568; Ben-Porath Y. S., 2008, MMPI 2 RESTRUCTURED; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Bigler ED, 2014, BRAIN INJURY, V28, P1623, DOI 10.3109/02699052.2014.947627; Bilder RM, 2014, CLIN NEUROPSYCHOL, V28, P1212, DOI 10.1080/13854046.2014.969774; Boone, 2007, ASSESSMENT FEIGNED C; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Buddin WH, 2014, CLIN NEUROPSYCHOL, V28, P525, DOI 10.1080/13854046.2014.906658; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Dandachi-FitzGerald B, 2013, ARCH CLIN NEUROPSYCH, V28, P771, DOI 10.1093/arclin/act073; Dandachi-FitzGerald B, 2011, CLIN NEUROPSYCHOL, V25, P812, DOI 10.1080/13854046.2011.583280; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1224, DOI 10.1080/13854046.2014.987167; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Garb H. N., 1998, STUDYING CLIN JUDGME, DOI [10.1037/10299-000, DOI 10.1037/10299-000]; Garb HN, 1996, PROF PSYCHOL-RES PR, V27, P272, DOI 10.1037/0735-7028.27.3.272; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, GREENS WORD MEMORY T; Green P., 2013, MILD TRAUMATIC BRAIN, P73; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Greiffenstein MF, 2008, ARCH CLIN NEUROPSYCH, V23, P801, DOI 10.1016/j.acn.2008.07.005; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Guilmette T. J., 2013, MILD TRAUMATIC BRAIN, P31; Gunner JH, 2012, ARCH CLIN NEUROPSYCH, V27, P1, DOI 10.1093/arclin/acr089; Harrison AG, 2010, ASSESSMENT, V17, P283, DOI 10.1177/1073191109348590; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Johnson SC, 2012, CLIN NEUROPSYCHOL, V26, P1230, DOI 10.1080/13854046.2012.709886; Kemp S, 2008, J PSYCHOSOM RES, V65, P319, DOI 10.1016/j.jpsychores.2008.02.010; Kirkwood MW, 2011, ARCH CLIN NEUROPSYCH, V26, P377, DOI 10.1093/arclin/acr040; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, CLIN NEUROPSYCHOL, V28, P1230, DOI 10.1080/13854046.2014.988754; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; LIDZ CW, 1993, JAMA-J AM MED ASSOC, V269, P1007, DOI 10.1001/jama.269.8.1007; Locke DEC, 2008, NEUROREHABILITATION, V23, P273; Marshall P, 2010, CLIN NEUROPSYCHOL, V24, P1204, DOI 10.1080/13854046.2010.514290; Martin PK, 2015, ARCH CLIN NEUROPSYCH, V30, P377, DOI 10.1093/arclin/acv032; McCarter RJ, 2009, CLIN NEUROPSYCHOL, V23, P1050, DOI 10.1080/13854040802665790; Medici R, 2013, J FORENSIC PSYCHOL P, V13, P68, DOI 10.1080/15228932.2013.746909; Merchkelbach H., 2013, APPL NUEROPSYCHOLOGY, V22, P16; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; Millis S. R., 2009, NEUROPSYCHOLOGY MALI, P21; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; Odland AP, 2015, PSYCHOL INJ LAW, V8, P46, DOI 10.1007/s12207-015-9216-4; Ortega A, 2012, ARCH CLIN NEUROPSYCH, V27, P453, DOI 10.1093/arclin/acs038; Pankratz L., 1988, CLIN ASSESSMENT MALI, P223; Peck CP, 2013, CLIN NEUROPSYCHOL, V27, P693, DOI 10.1080/13854046.2013.779032; POOLE DA, 1995, J CONSULT CLIN PSYCH, V63, P426, DOI 10.1037/0022-006X.63.3.426; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Rogers R., 2011, HDB FORENSIC ASSESSM, P659, DOI [10.1002/9781118093399.ch29, DOI 10.1002/9781118093399]; Rogers R., 2008, CLIN ASSESSMENT MALI, P1; Ruocco AC, 2008, CLIN NEUROPSYCHOL, V22, P547, DOI 10.1080/13854040701336444; Salazar X. F., 2007, ASSESSMENT FEIGNED C, P205; Schroeder RW, 2013, ARCH CLIN NEUROPSYCH, V28, P21, DOI 10.1093/arclin/acs094; Schroeder RW, 2012, COGN BEHAV NEUROL, V25, P139, DOI 10.1097/WNN.0b013e31826b71c1; Schroeder RW, 2012, ASSESSMENT, V19, P21, DOI 10.1177/1073191111428764; Schroeder RW, 2012, CLIN NEUROPSYCHOL, V26, P129, DOI 10.1080/13854046.2011.639314; Schroeder RW, 2011, CLIN NEUROPSYCHOL, V25, P437, DOI 10.1080/13854046.2011.556668; Schroeder RW, 2010, CLIN NEUROPSYCHOL, V24, P326, DOI 10.1080/13854040903369441; Schutte C., 2013, MILD TRAUMATIC BRAIN, P159; Schutte C, 2011, CLIN NEUROPSYCHOL, V25, P454, DOI 10.1080/13854046.2010.550635; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Sherman E.M., 2013, MILD TRAUMATIC BRAIN, P57; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Suchy Y, 2012, CLIN NEUROPSYCHOL, V26, P1296, DOI 10.1080/13854046.2012.722230; Thomas ML, 2009, CLIN NEUROPSYCHOL, V23, P1067, DOI 10.1080/13854040902795000; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; Van Dyke SA, 2013, CLIN NEUROPSYCHOL, V27, P1234, DOI 10.1080/13854046.2013.835447; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Whiteside D, 2011, CLIN NEUROPSYCHOL, V25, P287, DOI 10.1080/13854046.2010.538436; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791; Young G, 2014, INT LIBR ETH LAW NEW, V56, P1, DOI 10.1007/978-94-007-7899-3; Young JC, 2012, ARCH CLIN NEUROPSYCH, V27, P159, DOI 10.1093/arclin/acr109	86	152	152	1	23	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG 18	2015	29	6					741	776		10.1080/13854046.2015.1087597			36	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	CV8SA	WOS:000364556800002	26390099		Y	N	2021-06-18	
J	Helmerhorst, HJF; Roos-Blom, MJ; van Westerloo, DJ; de Jonge, E				Helmerhorst, Hendrik J. F.; Roos-Blom, Marie-Jose; van Westerloo, David J.; de Jonge, Evert			Association Between Arterial Hyperoxia and Outcome in Subsets of Critical Illness: A Systematic Review, Meta-Analysis, and Meta-Regression of Cohort Studies	CRITICAL CARE MEDICINE			English	Article						critical care medicine; functional outcome; hyperoxia; meta-analysis; mortality; oxygen; systematic review	INTENSIVE-CARE-UNIT; IN-HOSPITAL MORTALITY; CARDIAC-ARREST; VENTILATED PATIENTS; CARBON-DIOXIDE; PARTIAL-PRESSURE; OXYGEN-THERAPY; RESUSCITATION; TENSION	Objective: Oxygen is vital during critical illness, but hyperoxia may harm patients. Our aim was to systematically evaluate the methodology and findings of cohort studies investigating the effects of hyperoxia in critically ill adults. Data Source: A meta-analysis and meta-regression analysis of cohort studies published between 2008 and 2015 was conducted. Electronic databases of MEDLINE, EMBASE, and Web of Science were systematically searched for the keywords hyperoxia and mortality or outcome. Study Selection: Publications assessing the effect of arterial hyperoxia on outcome in critically ill adults (>= 18 yr) admitted to critical care units were eligible. We excluded studies in patients with chronic obstructive pulmonary disease, extracorporeal life support or hyperbaric oxygen therapy, and animal studies. Due to a lack of data, no studies dedicated to patients with acute lung injury, sepsis, shock, or multiple trauma could be included. Data Extraction: Studies were included independent of admission diagnosis and definition of hyperoxia. The primary outcome measure was in-hospital mortality, and results were stratified for relevant subgroups (cardiac arrest, traumatic brain injury, stroke, post-cardiac surgery, and any mechanical ventilation). The effects of arterial oxygenation on functional outcome, long-term mortality, and discharge variables were studied as secondary outcomes. Data Synthesis: Twenty-four studies were included of which five studies were only for a subset of the analyses. Nineteen studies were pooled for meta-analyses and showed that arterial hyperoxia during admission increases hospital mortality: adjusted odds ratio, 1.21 (95% CI, 1.08-1.37) (p = 0.001). Functional outcome measures were diverse and generally showed a more favorable outcome for normoxia. Conclusions: In various subsets of critically ill patients, arterial hyperoxia was associated with poor hospital outcome. Considering the substantial heterogeneity of included studies and the lack of a clinical definition, more evidence is needed to provide optimal oxygen targets to critical care physicians.	[Helmerhorst, Hendrik J. F.; van Westerloo, David J.; de Jonge, Evert] Leiden Univ, Dept Intens Care Med, Med Ctr, Leiden, Netherlands; [Helmerhorst, Hendrik J. F.] Univ Amsterdam, Acad Med Ctr, Lab Expt Intens Care & Anesthesiol, NL-1105 AZ Amsterdam, Netherlands; [Roos-Blom, Marie-Jose] Univ Amsterdam, Acad Med Ctr, Dept Med Informat, NL-1105 AZ Amsterdam, Netherlands	Helmerhorst, HJF (corresponding author), Leiden Univ, Dept Intens Care Med, Med Ctr, Leiden, Netherlands.	h.j.f.helmerhorst@lumc.nl	Helmerhorst, Hendrik/S-4684-2019	Helmerhorst, Hendrik/0000-0001-7921-0825; Roos-Blom, Marie-Jose/0000-0003-4066-607X			Altemeier WA, 2007, CURR OPIN CRIT CARE, V13, P73, DOI 10.1097/MCC.0b013e32801162cb; Arts D, 2002, INTENS CARE MED, V28, P656, DOI 10.1007/s00134-002-1272-z; Asher SR, 2013, J NEUROSURG ANESTH, V25, P168, DOI 10.1097/ANA.0b013e318283d350; Bak Z, 2007, ACTA PHYSIOL, V191, P15, DOI 10.1111/j.1748-1716.2007.01710.x; Bellomo R, 2011, CRIT CARE, V15, DOI 10.1186/cc10090; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; Brenner M, 2012, ARCH SURG-CHICAGO, V147, P1042, DOI 10.1001/archsurg.2012.1560; Brower RG, 2004, NEW ENGL J MED, V351, P327; Cornet AD, 2013, CRIT CARE, V17, DOI 10.1186/cc12554; Damiani E, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0711-x; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; de Graaff AE, 2011, INTENS CARE MED, V37, P46, DOI 10.1007/s00134-010-2025-z; de Jonge E, 2008, CRIT CARE, V12, DOI 10.1186/cc7150; Eastwood G, 2012, INTENS CARE MED, V38, P91, DOI 10.1007/s00134-011-2419-6; Elmer J, 2015, INTENS CARE MED, V41, P49, DOI 10.1007/s00134-014-3555-6; Farquhar H, 2009, AM HEART J, V158, P371, DOI 10.1016/j.ahj.2009.05.037; Forkner IF, 2007, ANESTHESIOLOGY, V106, P1051, DOI 10.1097/01.anes.0000265167.14383.44; Gore A, 2010, J IMMUNOTOXICOL, V7, P239, DOI 10.3109/1547691X.2010.492254; Helmerhorst HJ, 2014, INTENS CARE MED, V40, pS236; Helmerhorst HJF, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/s13613-014-0023-y; Ihle JF, 2013, CRIT CARE RESUSC, V15, P186; Janz DR, 2012, CRIT CARE MED, V40, P3135, DOI 10.1097/CCM.0b013e3182656976; Jeon SB, 2014, J NEUROL NEUROSUR PS, V85, P1301, DOI 10.1136/jnnp-2013-307314; Kilgannon JH, 2011, CIRCULATION, V123, P2717, DOI 10.1161/CIRCULATIONAHA.110.001016; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Lee BK, 2014, AM J EMERG MED, V32, P55, DOI 10.1016/j.ajem.2013.09.044; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Nelskyla A, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-35; Patroniti N, MECH VENTILATION SKI; Pilcher J, 2012, RESUSCITATION, V83, P417, DOI 10.1016/j.resuscitation.2011.12.021; Raj R, 2013, CRIT CARE, V17, DOI 10.1186/cc12856; Rincon F, 2014, J NEUROL NEUROSUR PS, V85, P799, DOI 10.1136/jnnp-2013-305505; Rincon F, 2014, CRIT CARE MED, V42, P387, DOI 10.1097/CCM.0b013e3182a27732; Roberts BW, 2013, CIRCULATION, V127, P2107, DOI 10.1161/CIRCULATIONAHA.112.000168; Schneider AG, 2013, RESUSCITATION, V84, P927, DOI 10.1016/j.resuscitation.2013.02.014; Spindelboeck W, 2013, RESUSCITATION, V84, P770, DOI 10.1016/j.resuscitation.2013.01.012; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Sutton ADJ, 2014, ANAESTH INTENS CARE, V42, P730, DOI 10.1177/0310057X1404200608; Suzuki S, 2013, J CRIT CARE, V28, P647, DOI 10.1016/j.jcrc.2013.03.010; Vaahersalo J, 2014, CRIT CARE MED, V42, P1463, DOI 10.1097/CCM.0000000000000228; Wang CH, 2014, RESUSCITATION, V85, P1142, DOI 10.1016/j.resuscitation.2014.05.021; Wells GA., NEWCASTLE OTTAWA SCA; Young P, 2012, CRIT CARE RESUSC, V14, P14	43	152	156	0	34	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUL	2015	43	7					1508	1519		10.1097/CCM.0000000000000998			12	Critical Care Medicine	General & Internal Medicine	CN2XK	WOS:000358285900018	25855899				2021-06-18	
J	Koliatsos, VE; Cernak, I; Xu, LY; Song, YJ; Savonenko, A; Crain, BJ; Eberhart, CG; Frangakis, CE; Melnikova, T; Kim, H; Lee, D				Koliatsos, Vassilis E.; Cernak, Ibolja; Xu, Leyan; Song, Yeajin; Savonenko, Alena; Crain, Barbara J.; Eberhart, Charles G.; Frangakis, Constantine E.; Melnikova, Tatiana; Kim, Hyunsu; Lee, Deidre			A Mouse Model of Blast Injury to Brain: Initial Pathological, Neuropathological, and Behavioral Characterization	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Axonal degeneration; Diffuse axonal injury; Military; Motor coordination; Social recognition; Spatial memory; Traumatic brain injury	INTRAAXONAL NEUROFILAMENT COMPACTION; TRAUMATIC AXONAL INJURY; CENTRAL-NERVOUS-SYSTEM; HEAD-INJURY; INDUCED NEUROTRAUMA; COGNITIVE DEFICITS; EXPLOSIVE BLAST; SPATIAL MEMORY; RAT-BRAIN; MICE	The increased use of explosives in recent wars has increased the number of veterans with blast injuries. Of particular interest is blast injury to the brain, and a key question is whether the primary overpressure wave of the blast is injurious or whether brain injury from blast is mostly due to secondary and tertiary effects. Using a shock tube generating shock waves comparable to open-field blast waves, we explored the effects of blast on parenchymatous organs of mice with emphasis on the brain. The main injuries in nonbrain organs were hemorrhages in the lung interstitium and alveolar spaces and hemorrhagic infarcts in liver, spleen, and kidney. Neuropathological and behavioral outcomes of blast were studied at mild blast intensity, that is, 68 +/- 8 kPag (9.9 +/- 1.2 psig) static pressure, 103 kPag (14.9 psig) total pressure and 183 +/- 14 kPag (26.5 +/- 2.1 psig) membrane rupture pressure. Under these conditions, we observed multifocal axonal injury, primarily in the cerebellum/brainstem, the corticospinal system, and the optic tract. We also found prolonged behavioral and motor abnormalities, including deficits in social recognition and spatial memory and in motor coordination. Shielding of the torso ameliorated axonal injury and behavioral deficits. These findings indicate that long CNS axon tracts are particularly vulnerable to the effects of blast, even at mild intensities that match the exposure of most veterans in recent wars. Prevention of some of these neurological effects by torso shielding may generate new ideas as to how to protect military and civilian populations in blast scenarios.	[Koliatsos, Vassilis E.; Xu, Leyan; Song, Yeajin; Crain, Barbara J.; Eberhart, Charles G.; Melnikova, Tatiana; Kim, Hyunsu; Lee, Deidre] Johns Hopkins Med Inst, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA; [Koliatsos, Vassilis E.] Johns Hopkins Med Inst, Dept Neurol, Div Neuropathol, Baltimore, MD 21205 USA; [Koliatsos, Vassilis E.] Johns Hopkins Med Inst, Dept Psychiat & Behav Sci, Div Neuropathol, Baltimore, MD 21205 USA; [Eberhart, Charles G.] Johns Hopkins Med Inst, Dept Ophthalmol, Div Neuropathol, Baltimore, MD 21205 USA; [Eberhart, Charles G.] Johns Hopkins Med Inst, Dept Oncol, Div Neuropathol, Baltimore, MD 21205 USA; [Cernak, Ibolja] Johns Hopkins Univ, Appl Phys Lab, Baltimore, MD 21218 USA; [Frangakis, Constantine E.] Johns Hopkins Sch Publ Hlth, Dept Biostat, Baltimore, MD USA	Koliatsos, VE (corresponding author), Johns Hopkins Med Inst, Dept Pathol, Div Neuropathol, Richard Star Ross Res Bldg 5633,720 Rutland Ave, Baltimore, MD 21205 USA.	koliat@jhmi.edu		Ibolja, Cernak/0000-0003-3214-698X	JHU/APL-JHMI; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD042854] Funding Source: NIH RePORTER	This work was supported by a JHU/APL-JHMI partnership grant.	Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; CRAMER F, 1949, ARCH NEURO PSYCHIATR, V61, P1; Crawley JN, 1999, BRAIN RES, V835, P18, DOI 10.1016/S0006-8993(98)01258-X; Dellu F, 1997, NEUROBIOL LEARN MEM, V67, P112, DOI 10.1006/nlme.1997.3746; Dellu F, 2000, NEUROBIOL LEARN MEM, V73, P31, DOI 10.1006/nlme.1999.3919; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Elsayed NM, 2007, TOXICOL SCI, V95, P289, DOI 10.1093/toxsci/kfl138; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; FABING HD, 1947, ARCH NEURO PSYCHIATR, V57, P14, DOI 10.1001/archneurpsyc.1947.02300240030002; Ferguson JN, 2002, FRONT NEUROENDOCRIN, V23, P200, DOI 10.1006/frne.2002.0229; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GALLYAS F, 1980, STAIN TECHNOL, V55, P291, DOI 10.3109/10520298009067257; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HALL GF, 1995, J COMP NEUROL, V353, P38, DOI 10.1002/cne.903530106; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; KOLIATSOS VE, 1989, BRAIN RES, V482, P205, DOI 10.1016/0006-8993(89)91183-9; Leibovici D, 1996, J TRAUMA, V41, P1030, DOI 10.1097/00005373-199612000-00015; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Liu ZP, 2001, J COMP NEUROL, V441, P1, DOI 10.1002/cne.1393; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Macleod AD, 2004, J ROY SOC MED, V97, P86, DOI 10.1258/jrsm.97.2.86; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Melnikova T, 2006, NEUROSCIENCE, V141, P1149, DOI 10.1016/j.neuroscience.2006.05.001; Mott FW, 1916, LANCET, V1, P331; Mott FW, 1916, LANCET, V1, P545; Mott FW, 1919, BRIT MED J, V1919, P439; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Ramon y Cajal S, 1928, DEGENERATION REGENER; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P565, DOI 10.2307/2288402; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Savonenko AV, 2008, P NATL ACAD SCI USA, V105, P5585, DOI 10.1073/pnas.0710373105; Schilling G, 2004, HUM MOL GENET, V13, P1599, DOI 10.1093/hmg/ddh175; SHARPNACK DD, 1991, TXB MILITARY MED 1; SHARPNACK DD, 1991, TXB MILITARY MED 5; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Tsokos M, 2003, AM J RESP CRIT CARE, V168, P549, DOI 10.1164/rccm.200304-528OC; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Yelverton JT, 1996, J TRAUMA, V40, pS111, DOI 10.1097/00005373-199603001-00025	65	152	157	4	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAY	2011	70	5					399	416		10.1097/NEN.0b013e3182189f06			18	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	753JX	WOS:000289769600007	21487304	Bronze			2021-06-18	
J	Cohen-Adad, J; El Mendili, MM; Lehericy, S; Pradat, PF; Blancho, S; Rossignol, S; Benali, H				Cohen-Adad, J.; El Mendili, M-M.; Lehericy, S.; Pradat, P-F.; Blancho, S.; Rossignol, S.; Benali, H.			Demyelination and degeneration in the injured human spinal cord detected with diffusion and magnetization transfer MRI	NEUROIMAGE			English	Article						Spinal cord injury; Diffusion-weighted MRI; Magnetization transfer; Atrophy; ASIA	MULTIPLE-SCLEROSIS BRAIN; INDUCED B-0 FLUCTUATIONS; WHITE-MATTER PATHOLOGY; ANGULAR RESOLUTION; AXONAL INJURY; WALLERIAN DEGENERATION; MULTIEXPONENTIAL T-2; TENSOR TRACTOGRAPHY; FIBER ORIENTATIONS; CORPUS-CALLOSUM	Characterizing demyelination/degeneration of spinal pathways in traumatic spinal cord injured (SCI) patients is crucial for assessing the prognosis of functional rehabilitation. Novel techniques based on diffusion-weighted (DW) magnetic resonance imaging (MRI) and magnetization transfer (MT) imaging provide sensitive and specific markers of white matter pathology. In this paper we combined for the first time high angular resolution diffusion-weighted imaging (HARDI), MT imaging and atrophy measurements to evaluate the cervical spinal cord of fourteen SCI patients and age-matched controls. We used high in-plane resolution to delineate dorsal and ventrolateral pathways. Significant differences were detected between patients and controls in the normal-appearing white matter for fractional anisotropy (FA, p < 0.0001), axial diffusivity (p < 0.05), radial diffusivity (p < 0.05), generalized fractional anisotropy (GFA, p < 0.0001), magnetization transfer ratio (MTR, p < 0.0001) and cord area (p < 0.05). No significant difference was detected in mean diffusivity (p = 0.41), T1-weighted (p = 0.76) and 12-weighted (p = 0.09) signals. MRI metrics were remarkably well correlated with clinical disability (Pearson's correlations, FA: p < 0.01, GFA: p < 0.01, radial diffusivity: p = 0.01, MTR: p = 0.04 and atrophy: p < 0.01). Stepwise linear regressions showed that measures of MTR in the dorsal spinal cord predicted the sensory disability whereas measures of MTR in the ventrolateral spinal cord predicted the motor disability (ASIA score). However, diffusion metrics were not specific to the sensorimotor scores. Due to the specificity of axial and radial diffusivity and MT measurements, results suggest the detection of demyelination and degeneration in SCI patients. Combining HARDI with MT imaging is a promising approach to gain specificity in characterizing spinal cord pathways in traumatic injury. (C) 2011 Elsevier Inc. All rights reserved.	[Cohen-Adad, J.] Harvard Univ, AA Martinos Ctr Biomed Imaging, Sch Med, Massachusetts Gen Hosp, Charlestown, MA 02129 USA; [Cohen-Adad, J.; El Mendili, M-M.; Benali, H.] Hop La Pitie Salpetriere, UMR 678, INSERM UPMC, Paris, France; [Lehericy, S.] Grp Hosp Pitie Salpetriere, Ctr Neuroimaging Res CENIR, Inst Cerveau & Moelle Epiniere,Ctr Rech, UPMC,UMR 5975,INSERM U975,CNRS UMR 7225, F-75634 Paris, France; [Pradat, P-F.] Hop La Pitie Salpetriere, AP HP, Paris, France; [Blancho, S.] Inst Rech Moelle Epiniere & Encephale, Paris, France; [Rossignol, S.] Univ Montreal, Fac Med, GRSNC, Montreal, PQ H3C 3J7, Canada	Cohen-Adad, J (corresponding author), Harvard Univ, AA Martinos Ctr Biomed Imaging, Sch Med, Massachusetts Gen Hosp, 149 13 St, Charlestown, MA 02129 USA.	jcohen@nmr.mgh.harvard.edu			Association Francaise contre les Myopathies (AFM)Association Francaise contre les Myopathies; Institut pour la Recherche sur la Moelle epiniere et l'Encephale (IRME)	We thank Dr. Maxime Descoteaux for providing the code to compute the Q-Ball ODF and Dr. Henrik Lundell for providing the code to measure the cord area. We also thank Drs. Stephane Ouary, Olivier Freund, Kevin Nigaud, Alexandre Vignaud and Eric Bardinet for helping with the project. We thank Drs. Thierry Albert, Bertrand Baussart, Caroline Hugeron, Hugues Pascal Moussellard, Frederic Petit and Marc-Antoine Rousseau for helping with patient recruitment and we thank all subjects. We also thank the reviewers for their helpful comments that greatly improved the quality of the manuscript. This study was supported by the Association Francaise contre les Myopathies (AFM) and by the Institut pour la Recherche sur la Moelle epiniere et l'Encephale (IRME). S.R. received a special fellowship from the IRME to participate in these studies during a sabbatical leave in Paris.	Agosta F, 2007, BRAIN, V130, P2211, DOI 10.1093/brain/awm110; Anderson AW, 2005, MAGN RESON MED, V54, P1194, DOI 10.1002/mrm.20667; ASIA, INT STAND NEUR CLASS; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Barmpoutis A, 2009, NEUROIMAGE, V45, pS153, DOI 10.1016/j.neuroimage.2008.10.056; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Beirowski B, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-6; Budde MD, 2008, NMR BIOMED, V21, P589, DOI 10.1002/nbm.1229; Budde MD, 2007, MAGN RESON MED, V57, P688, DOI 10.1002/mrm.21200; Budde MD, 2009, J NEUROSCI, V29, P2805, DOI 10.1523/JNEUROSCI.4605-08.2009; CALLOT V, 2009, P 17 SCI M INT SOC M, P1302; Chen JT, 2007, NEUROIMAGE, V36, P1152, DOI 10.1016/j.neuroimage.2007.03.073; Ciccarelli O, 2007, BRAIN, V130, P2220, DOI 10.1093/brain/awm152; Cohen-Adad J, 2008, NEUROIMAGE, V42, P739, DOI 10.1016/j.neuroimage.2008.04.243; Cohen-Adad J, 2008, NEUROIMAGE, V40, P685, DOI 10.1016/j.neuroimage.2007.11.031; Cohen-Adad J, 2010, NEUROIMAGE, V50, P1074, DOI 10.1016/j.neuroimage.2009.12.122; COHENADAD J, 2009, P 17 ANN M ISMRM HON, V3582; COHENADAD J, 2009, 39 ANN M SOC NEUR CH; COHENADAD J, 2010, P 16 ANN M OHBM BARC, P3694; COHENADAD J, 2009, 14 ANN M ORG HUM BRA, P51; Cooke FJ, 2004, MAGN RESON MED, V51, P1122, DOI 10.1002/mrm.20084; Davies GR, 2003, MULT SCLER J, V9, P246, DOI 10.1191/1352458503ms911oa; Deboy CA, 2007, BRAIN, V130, P2199, DOI 10.1093/brain/awm122; Deloire-Grassin MSA, 2000, J NEUROL SCI, V178, P10, DOI 10.1016/S0022-510X(00)00331-2; Deo AA, 2006, J NEUROSCI RES, V83, P801, DOI 10.1002/jnr.20783; DESCOTEAUX M, 2007, LINEAR REGULARIZED O, P1; Descoteaux M, 2007, MAGN RESON MED, V58, P497, DOI 10.1002/mrm.21277; Descoteaux M, 2006, MAGN RESON MED, V56, P395, DOI 10.1002/mrm.20948; Ducreux D, 2007, NEUROIMAG CLIN N AM, V17, P137, DOI 10.1016/j.nic.2006.11.005; Ellingson BM, 2008, AM J NEURORADIOL, V29, P1976, DOI 10.3174/ajnr.A1272; Ellingson BM, 2007, ACAD RADIOL, V14, P847, DOI 10.1016/j.acra.2007.04.006; Fujiyoshi K, 2007, J NEUROSCI, V27, P11991, DOI 10.1523/JNEUROSCI.3354-07.2007; Ghosh A, 2008, LECT NOTES COMPUT SC, V5241, P858, DOI 10.1007/978-3-540-85988-8_102; Griswold MA, 2002, MAGN RESON MED, V47, P1202, DOI 10.1002/mrm.10171; Herrera JJ, 2008, J NEUROSCI RES, V86, P443, DOI 10.1002/jnr.21481; Hess CP, 2006, MAGN RESON MED, V56, P104, DOI 10.1002/mrm.20931; Hofling AA, 2009, NMR BIOMED, V22, P1100, DOI 10.1002/nbm.1420; Hosey T, 2005, MAGN RESON MED, V54, P1480, DOI 10.1002/mrm.20723; Hui ES, 2008, NEUROIMAGE, V42, P122, DOI 10.1016/j.neuroimage.2008.04.237; Inglese M, 2002, AM J NEURORADIOL, V23, P267; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Kim JH, 2007, MAGN RESON MED, V58, P253, DOI 10.1002/mrm.21316; Kolind SH, 2008, NEUROIMAGE, V40, P77, DOI 10.1016/j.neuroimage.2007.11.033; Kozlowski P, 2008, MAGN RESON MED, V59, P796, DOI 10.1002/mrm.21527; Kreher BW, 2005, MAGNET RESON MED, V54, P1216, DOI 10.1002/mrm.20670; KUCHARCZYK W, 1994, RADIOLOGY, V192, P521, DOI 10.1148/radiology.192.2.8029426; Lammertse D, 2007, J SPINAL CORD MED, V30, P205, DOI 10.1080/10790268.2007.11753928; Laule C, 2006, MULT SCLER, V12, P747, DOI 10.1177/1352458506070928; Levesque IR, 2009, MAGN RESON MED, V62, P1487, DOI 10.1002/mrm.22131; Lindberg PG, 2007, NEUROREHAB NEURAL RE, V21, P551, DOI 10.1177/1545968307301886; Losseff NA, 1996, BRAIN, V119, P2009, DOI 10.1093/brain/119.6.2009; Lundell H, 2011, SPINAL CORD, V49, P70, DOI 10.1038/sc.2010.87; LUNDELL H, 2009, P 17 ANN M ISMRM HON, V1497; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Maier IC, 2006, PHILOS T R SOC B, V361, P1611, DOI 10.1098/rstb.2006.1890; McCreary CR, 2009, NEUROIMAGE, V45, P1173, DOI 10.1016/j.neuroimage.2008.12.071; Merkler D, 2005, NMR BIOMED, V18, P395, DOI 10.1002/nbm.972; Minty EP, 2009, MAGN RESON MED, V61, P883, DOI 10.1002/mrm.21936; Mottershead JP, 2003, J NEUROL, V250, P1293, DOI 10.1007/s00415-003-0192-3; Nevo U, 2001, MAGN RESON MED, V45, P1, DOI 10.1002/1522-2594(200101)45:1<1::AID-MRM1001>3.0.CO;2-I; Ohgiya Y, 2007, EUR RADIOL, V17, P2499, DOI 10.1007/s00330-007-0672-4; Onu M, 2010, J MAGN RESON IMAGING, V31, P829, DOI 10.1002/jmri.22101; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Pike GB, 2000, RADIOLOGY, V215, P824, DOI 10.1148/radiology.215.3.r00jn02824; Plank C, 2007, NEURORADIOLOGY, V49, P977, DOI 10.1007/s00234-007-0275-4; Reich DS, 2007, NEUROIMAGE, V38, P271, DOI 10.1016/j.neuroimage.2007.07.049; Ries M, 2000, MAGNET RESON MED, V44, P884, DOI 10.1002/1522-2594(200012)44:6<884::AID-MRM9>3.0.CO;2-Q; Rossignol S, 2007, J NEUROSCI, V27, P11782, DOI 10.1523/JNEUROSCI.3444-07.2007; Saritas EU, 2008, MAGN RESON MED, V60, P468, DOI 10.1002/mrm.21640; Schmierer K, 2004, ANN NEUROL, V56, P407, DOI 10.1002/ana.20202; Schmierer K, 2007, J MAGN RESON IMAGING, V26, P41, DOI 10.1002/jmri.20984; Schwartz ED, 2005, J NEUROTRAUM, V22, P1388, DOI 10.1089/neu.2005.22.1388; Sen PN, 2005, BIOPHYS J, V89, P2927, DOI 10.1529/biophysj.105.063016; Shen HY, 2007, INT ORTHOP, V31, P375, DOI 10.1007/s00264-006-0175-y; Smith SA, 2010, NMR BIOMED, V23, P207, DOI 10.1002/nbm.1447; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Summers P, 2006, AM J NEURORADIOL, V27, P1952; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Thurnher MM, 2006, SEMIN ROENTGENOL, V41, P294, DOI 10.1053/j.ro.2006.07.003; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Valsasina P, 2005, NEUROIMAGE, V26, P822, DOI 10.1016/j.neuroimage.2005.02.033; Van de Moortele PF, 2002, MAGNET RESON MED, V47, P888, DOI 10.1002/mrm.10145; van Gelderen P, 2007, MAGN RESON MED, V57, P362, DOI 10.1002/mrm.21136; Van Hecke W, 2008, J MAGN RESON IMAGING, V27, P978, DOI 10.1002/jmri.21338; Vargas MI, 2008, NEURORADIOLOGY, V50, P25, DOI 10.1007/s00234-007-0309-y; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Wilm BJ, 2009, NMR BIOMED, V22, P174, DOI 10.1002/nbm.1298; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90; XU J, 2010, P 18 ANN M ISMRM STO, V2458; Zackowski KM, 2009, BRAIN, V132, P1200, DOI 10.1093/brain/awp032; Zhang JY, 2009, J NEUROSCI, V29, P3160, DOI 10.1523/JNEUROSCI.3941-08.2009	96	152	155	0	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	APR 1	2011	55	3					1024	1033		10.1016/j.neuroimage.2010.11.089			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	734DQ	WOS:000288313800017	21232610				2021-06-18	
J	Prins, ML; Hales, A; Reger, M; Giza, CC; Hovda, DA				Prins, M. L.; Hales, A.; Reger, M.; Giza, C. C.; Hovda, D. A.			Repeat Traumatic Brain Injury in the Juvenile Rat Is Associated with Increased Axonal Injury and Cognitive Impairments	DEVELOPMENTAL NEUROSCIENCE			English	Article						Traumatic brain injury; Concussion; Repeat brain injury; Age; Axonal injury	SCHOOL FOOTBALL PLAYERS; PROFESSIONAL FOOTBALL; HEAD-INJURY; RECURRENT CONCUSSION; RECOVERY; ADOLESCENTS; DEFICITS; DTI; ENCEPHALOPATHY; POPULATION	Among the enormous population of head-injured children and young adults are a growing subpopulation who experience repeat traumatic brain injury (RTBI). The most common cause of RTBI in this age group is sports-related concussions, and athletes who have experienced a head injury are at greater risk for subsequent TBI, with consequent long-term cognitive dysfunction. While several animal models have been proposed to study RTBI, they have been shown to either produce injuries too severe, were conducted in adults, involved craniotomy, or failed to show behavioral deficits. A closed head injury model for postnatal day 35 rats was established, and single and repeat TBI (1-day interval) were examined histologically for axonal injury and behaviorally by the novel object recognition (NOR) task. The results from the current study demonstrate that an experimental closed head injury in the rodent with low mortality rates and absence of gross pathology can produce measurable cognitive deficits in a juvenile age group. The introduction of a second injury 24 h after the first impact resulted in increased axonal injury, astrocytic reactivity and increased memory impairment in the NOR task. The histological evidence demonstrates the potential usefulness of this RTBI model for studying the impact and time course of RTBI as it relates to the pediatric and young adult population. This study marks the first critical step in experimentally addressing the consequences of concussions and the cumulative effects of RTBI in the developing brain. Copyright (C) 2010 S. Karger AG, Basel	[Prins, M. L.; Hales, A.; Reger, M.; Giza, C. C.; Hovda, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Giza, C. C.] Univ Calif Los Angeles, David Geffen Sch Med, Div Pediat Neurol, Los Angeles, CA 90095 USA; [Hovda, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Prins, M. L.; Giza, C. C.; Hovda, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Interdept Program Neurosci, Los Angeles, CA 90095 USA; [Giza, C. C.; Hovda, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Interdept Program Biomed Engn, Los Angeles, CA 90095 USA; [Hales, A.; Reger, M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychol, Los Angeles, CA 90095 USA	Prins, ML (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, NPI 18-228, Los Angeles, CA 90095 USA.	mprins@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	UCLA Brain Injury Research Institute; UCLA Faculty Research Grant; Child Neurology Foundation/Winokur Family Foundation [NS058489, NS027544, NS057420]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489, R01NS027544, K02NS057420] Funding Source: NIH RePORTER	The authors would like to thank for the support from the UCLA Brain Injury Research Institute, the UCLA Faculty Research Grant and the Child Neurology Foundation/Winokur Family Foundation (NS058489, NS027544 and NS057420).	ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Baldwin SA, 1996, GLIA, V16, P266; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Copeland SA, 2008, ANN NEUROL, V64, pS128; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Muller E, 1967, Monatsschr Unfallheilkd Versicher Versorg Verkehrsmed, V70, P422; NEHLIG A, 1988, J NEUROSCI, V8, P2321; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Povlishock JT, 1996, ACT NEUR S, V66, P81; Reger ML, 2009, DEV PSYCHOBIOL, V51, P672, DOI 10.1002/dev.20402; Regner A, 2001, J NEUROTRAUM, V18, P783, DOI 10.1089/089771501316919148; ROMIJN HJ, 1991, EARLY HUM DEV, V26, P61, DOI 10.1016/0378-3782(91)90044-4; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Van Landeghem FKH, 2006, J NEUROTRAUM, V23, P1518, DOI 10.1089/neu.2006.23.1518; Wakade C, 2010, J NEUROSURG; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004	46	152	153	2	9	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					510	518		10.1159/000316800			9	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900019	20829578	Bronze, Green Published			2021-06-18	
J	Rutgers, DR; Fillard, P; Paradot, G; Tadie, M; Lasjaunias, P; Ducreux, D				Rutgers, D. R.; Fillard, P.; Paradot, G.; Tadie, M.; Lasjaunias, P.; Ducreux, D.			Diffusion Tensor Imaging Characteristics of the Corpus Callosum in Mild, Moderate, and Severe Traumatic Brain Injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							WHITE-MATTER INJURY; CLOSED-HEAD INJURY; AXONAL INJURY; WEIGHTED MRI; FEATURES; LESIONS; TRACKING; SEQUELAE; IMAGES; SCORE	BACKGROUND AND PURPOSE: The corpus callosum is an important predilection site for traumatic axonal injury but may be unevenly affected in head trauma. We hypothesized that there were local differences in axonal injury within the corpus callosum as investigated with diffusion tenser imaging (DTI), varying among patients with differing severity of traumatic brain injury (TBI). MATERIALS AND METHODS: Ethics committee approval and informed consent were obtained. Ten control subjects (7 men, 3 women, mean age, 37 +/- 9 years) and 39 patients with TBI (27 men, 12 women; 34 +/- 12 years) were investigated, of whom 24 had mild; 9, moderate; and 6, severe TBI. Regions of interest were selected in the callosal genu, body, and splenium to calculate fractional anisotropy (FA), apparent diffusion coefficient (ADC), and the number of fibers passing through, Statistical comparison was made through analysis of variance with the Scheffe post hoc analysis. RESULTS: Compared with controls, patients with mild TBI investigated < 3 months posttrauma (n = 12) had reduced FA (P < .01) and increased ADC (P < .05) in the genu, whereas patients with mild TBI investigated >= 3 months posttrauma (n = 12) showed no significant differences. Patients with moderate and severe TBI, all investigated < 3 months posttrauma, had reduced FA (P < .001) and increased ADC (P < .01) in the genu compared with controls and reduced FA in the splenium (P < .001) without significant ADC change. CONCLUSION: Mild TBI is associated with DTI abnormalities in the genu < 3 months posttrauma. In more severe TBI, both the genu and splenium are affected. DTI suggests a larger contribution of vasogenic edema in the genu than in the splenium in TBI.	[Rutgers, D. R.; Lasjaunias, P.; Ducreux, D.] CHU Bicetre, Dept Neuroradiol, F-94270 Le Kremlin Bicetre, France; [Paradot, G.; Tadie, M.] CHU Bicetre, Dept Neurosurg, F-94270 Le Kremlin Bicetre, France; [Fillard, P.] Inst Natl Rech Informat & Automat, Sophia Antipolis, France	Ducreux, D (corresponding author), CHU Bicetre, Dept Neuroradiol, 78 Rue Gen Leclerc, F-94270 Le Kremlin Bicetre, France.	denis.ducreux@bct.ap-hop-paris.fr			Institut pour la Recherche sur la Moelle epiniere at l'Encephale, Paris, France; Catharijne Stichting Utrecht and Sara Lee International	This work was supported by the Institut pour la Recherche sur la Moelle epiniere at l'Encephale, Paris, France. D.R. Rutgers was supported by a grant from the Catharijne Stichting Utrecht and Sara Lee International.	Abe O, 2004, J COMPUT ASSIST TOMO, V28, P533, DOI 10.1097/00004728-200407000-00016; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Fillard P, 2003, LECT NOTES COMPUT SC, V2879, P967; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Haselgrove JC, 1996, MAGNET RESON MED, V36, P960, DOI 10.1002/mrm.1910360620; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Westin CF, 2002, MED IMAGE ANAL, V6, P93, DOI 10.1016/S1361-8415(02)00053-1; Xu DR, 2002, NEUROIMAGE, V17, P1131, DOI 10.1006/nimg.2002.1285	28	152	162	0	7	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	OCT	2008	29	9					1730	1735		10.3174/ajnr.A1213			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	359YI	WOS:000260023800024	18617586	Other Gold, Green Published			2021-06-18	
J	Ozaki, Y; Nishimura, M; Sekiya, K; Suehiro, F; Kanawa, M; Nikawa, H; Hamada, T; Kato, Y				Ozaki, Yoshie; Nishimura, Masahiro; Sekiya, Kensuke; Suehiro, Fumio; Kanawa, Masami; Nikawa, Hiroki; Hamada, Taizo; Kato, Yukio			Comprehensive analysis of chemotactic factors for bone marrow mesenchymal stem cells	STEM CELLS AND DEVELOPMENT			English	Article							FIBROBLAST-GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; TRAUMATIC BRAIN-INJURY; STROMAL CELLS; ARTICULAR-CARTILAGE; FACTOR-ALPHA; FACTOR-BB; IN-VITRO; OSTEOGENESIS IMPERFECTA; FACTOR-BETA	To understand which growth factors/cytokines can affect migration of mesenchymal stem cells (MSCs) to injured tissues, we compared the effects of many (26) growth factors/cytokines on the migration activity of rabbit and human MSCs using a microchemotaxis chamber. Among them, platelet-derived growth factor (PDGF)-BB, PDGF-AB, epidermal growth factor (EGF), HB-EGF, transforming growth factor (TGF-alpha), insulin growth factor (IGF-I), hepatocyte growth factor (HGF), fibroblast growth factor (FGF-2), and thrombin consistently enhanced the migration of rabbit and human MSCs at appropriate concentrations. PDGF-BB showed the greatest effect on migration. Various combinations of these factors further enhanced the migration of MSCs, whereas combinations of factors that shared common cell-surface receptors did not induce the additive stimulation. On the other hand, some combinations, including that of FGF-2 or thrombin with PDGF-BB, suppressed the migration activity of MSCs. These findings suggest that combinations of growth factors are important to eliciting the maximal chemotactic effect. The factors that induced the migration of MSCs also enhanced their proliferation, suggesting that migration and proliferation can take place simultaneously. The above factors were also effective in stimulating the migration of fibroblasts, but thrombin alone selectively enhanced the migration of MSCs, suggesting that thrombin is useful to stimulate migration of MSCs without migration of fibroblasts.	Hiroshima Univ, Dept Prosthet Dent, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Dept Dent, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Nat Sci Ctr Basic Res & Dev, Hiroshima 7348553, Japan; Hiroshima Univ, Fac Dent, Inst Oral Hlth Sci, Dept Med Design & Engn, Hiroshima 7348553, Japan	Nishimura, M (corresponding author), Hiroshima Univ, Dept Prosthet Dent, Grad Sch Biomed Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	maakun@hiroshima-u.ac.jp	Nishimura, Masahiro/ABD-7504-2020	Nishimura, Masahiro/0000-0001-5552-0693; Kanawa, Masami/0000-0003-2289-9320			Andresen JL, 1998, CURR EYE RES, V17, P79; Bischoff R, 1997, DEV DYNAM, V208, P505, DOI 10.1002/(SICI)1097-0177(199704)208:4<505::AID-AJA6>3.0.CO;2-M; Blom IE, 2001, NEPHROL DIAL TRANSPL, V16, P1139, DOI 10.1093/ndt/16.6.1139; Cao HQ, 2006, AM J PHYSIOL-CELL PH, V290, pC172, DOI 10.1152/ajpcell.00284.2005; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Choi YS, 2005, BIOMATERIALS, V26, P5855, DOI 10.1016/j.biomaterials.2005.02.022; Chuma H, 2004, OSTEOARTHR CARTILAGE, V12, P834, DOI 10.1016/j.joca.2004.07.003; Chwieralski CE, 2004, AM J RESP CELL MOL, V31, P528, DOI 10.1165/rcmb.2003-0433OC; Corti S, 2001, EXP CELL RES, V268, P36, DOI 10.1006/excr.2001.5267; Devine MJ, 2002, J ORTHOP RES, V20, P1232, DOI 10.1016/S0736-0266(02)00051-7; Facchiano A, 2000, J CELL SCI, V113, P2855; Fiedler J, 2004, J CELL BIOCHEM, V93, P990, DOI 10.1002/jcb.20219; Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856; Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644; Guo XM, 2004, TISSUE ENG, V10, P1818, DOI 10.1089/ten.2004.10.1818; Hatakeyama J, 2003, ORAL MICROBIOL IMMUN, V18, P14, DOI 10.1034/j.1399-302X.2003.180103.x; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399; Ishii M, 2005, BIOCHEM BIOPH RES CO, V332, P297, DOI 10.1016/j.bbrc.2005.04.118; KATO Y, 1983, EUR J BIOCHEM, V129, P685; KOYAMA N, 1994, CIRC RES, V75, P682, DOI 10.1161/01.RES.75.4.682; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Leeb SN, 2002, GROWTH FACTORS, V20, P81, DOI 10.1080/08977190290031941; LIND M, 1995, APMIS, V103, P140, DOI 10.1111/j.1699-0463.1995.tb01089.x; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; NODAHEINY H, 1995, AM J PHYSIOL-CELL PH, V268, pC1195; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; PANAGAKOS FS, 1994, BIOCHEM MOL BIOL INT, V33, P643; Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516; Quintavalla J, 2002, BIOMATERIALS, V23, P109, DOI 10.1016/S0142-9612(01)00086-2; Ray AK, 2003, J PERIODONTOL, V74, P1320, DOI 10.1902/jop.2003.74.9.1320; Rombouts WJC, 2003, LEUKEMIA, V17, P160, DOI 10.1038/sj.leu.2402763; Ruster B, 2005, STEM CELLS DEV, V14, P231, DOI 10.1089/scd.2005.14.231; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; Tsutsumi S, 2001, BIOCHEM BIOPH RES CO, V288, P413, DOI 10.1006/bbrc.2001.5777; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9	41	152	158	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	FEB	2007	16	1					119	129		10.1089/scd.2006.0032			11	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	144GC	WOS:000244783500012	17348810				2021-06-18	
J	Cavanaugh, JT; Guskiewicz, KM; Giuliani, C; Marshall, S; Mercer, VS; Stergiou, N				Cavanaugh, James T.; Guskiewicz, Kevin M.; Giuliani, Carol; Marshall, Stephen; Mercer, Vicki S.; Stergiou, Nicholas			Recovery of postural control after cerebral concussion: New insights using approximate entropy	JOURNAL OF ATHLETIC TRAINING			English	Article						cerebral concussion; nonlinear dynamics; measurement	COLLEGIATE FOOTBALL PLAYERS; MILD HEAD-INJURY; NCAA CONCUSSION; TIME-SERIES; STABILITY; REGULARITY; COMPLEXITY; DYNAMICS	Context. The return-to-play decision after sport-related cerebral concussion depends in part on knowing when an athlete has fully recovered postural control after injury. Objective: To describe the postconcussion recovery of postural control using approximate entropy (ApEn), a regularity statistic from nonlinear dynamics. Design: Retrospective case series analysis. Setting: Sports medicine research laboratory. Patients or Other Participants: Collegiate athletes from whom center-of-pressure and symptom data were collected at preseason, less than 48 hours after injury, and 48 to 96 hours after injury. Main Outcome Measure(s): Approximate entropy values reflecting the amount of randomness contained in center-of-pressure oscillations were calculated for anterior-posterior (AP) and medial-lateral (ML) time series. Equilibrium scores reflecting the amplitude of center-of-pressure AP oscillations were used to indicate postural stability. The number and severity of symptoms were described. Results: Compared with the healthy preseason state, ApEn values for the AP and ML time series generally declined immediately after injury in both steady and unsteady injured athletes. At 48 to 96 hours after injury, ApEn values for the ML time series remained significantly depressed (mean difference compared with preseason = -0.268, standard error = 0.072), even among athletes whose initial postural instability had resolved. We found few significant relationships between changes in ApEn values and changes in symptoms before and after injury. Conclusions: The effects of cerebral concussion on postural control appear to persist for longer than 3 to 4 days, even among athletes with no signs of unsteadiness. Our results may reflect changes in neurophysiologic or mechanical constraints on postural control. Approximate entropy provides a theoretically distinct, valuable measurement alternative that may prove useful for reducing uncertainty in the return-to-play decision.	Duke Univ, Ctr Med, Dept Phys Therapy & Occupat Therapy, Durham, NC 27710 USA; Vet Affairs Med Ctr, Durham, NC USA; Univ N Carolina, Chapel Hill, NC USA; Univ Nebraska, Omaha, NE 68182 USA	Cavanaugh, JT (corresponding author), Duke Univ, Ctr Med, Dept Phys Therapy & Occupat Therapy, Box 3965, Durham, NC 27710 USA.	Jim.Cavanaugh@duke.edu	Mercer, Vicki/AAN-6669-2021	Guskiewicz, Kevin/0000-0002-8682-2130; Cavanaugh, James/0000-0001-7132-6313; Marshall, Stephen/0000-0002-2664-9233			Blaszczyk JW, 2001, ACTA NEUROBIOL EXP, V61, P105; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Cavanaugh JT, 2004, GAIT POSTURE S1, V20, pS55; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; Guskiewicz KM, 2002, ORTHOP PHYS THER CLI, V11, P143; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; Neurocom, 1991, EQ SYST DAT INT MAN; Newell K., 1998, APPL NONLINEAR DYNAM, P80; PINCUS SM, 1994, AM J PHYSIOL, V266, pH1643, DOI 10.1152/ajpheart.1994.266.4.H1643; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; PINCUS SM, 1991, J CLIN MONITOR, V7, P335, DOI 10.1007/BF01619355; Pincus Steven M., 1995, QUANT NEUROENDOCRINO, V28, P336; Portney L., 2015, FDN CLIN RES APPL PR, V3rd ed.; Rapp Paul E., 1994, Integrative Physiological and Behavioral Science, V29, P311, DOI 10.1007/BF02691335; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Riley MA, 2002, J MOTOR BEHAV, V34, P99, DOI 10.1080/00222890209601934; Schiff Steven J., 1994, Integrative Physiological and Behavioral Science, V29, P246, DOI 10.1007/BF02691329; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Stergiou N, 2004, INNOVATIVE ANAL HUMA, P63; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; Theiler J, 1996, ELECTROEN CLIN NEURO, V98, P213, DOI 10.1016/0013-4694(95)00240-5	27	152	152	0	10	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2006	41	3					305	313					9	Sport Sciences	Sport Sciences	082ON	WOS:000240396300014	17043699				2021-06-18	
J	Hughes, DG; Jackson, A; Mason, DL; Berry, E; Hollis, S; Yates, DW				Hughes, DG; Jackson, A; Mason, DL; Berry, E; Hollis, S; Yates, DW			Abnormalities on magnetic resonance imaging seen acutely following mild traumatic brain injury: correlation with neuropsychological tests and delayed recovery	NEURORADIOLOGY			English	Article						magnetic resonance imaging; mild traumatic brain injury; neuropsychology	MINOR HEAD-INJURY; POST-CONCUSSIVE SYNDROME; DIFFUSE AXONAL INJURY; COMPUTED-TOMOGRAPHY; POSTCONCUSSION SYNDROME; UNIFIED DEFINITION; MR; CT; SPECT; PERFORMANCE	Mild traumatic brain injury (MTBI) is a common reason for hospital attendance and is associated with significant delayed morbidity. We studied a series of 80 persons with MTBI. Magnetic resonance imaging (MRI) and neuropsychological testing were used in the acute phase and a questionnaire for post-concussion syndrome (PCS) and return to work status at 6 months. In 26 subjects abnormalities were seen on MRI, of which 5 were definitely traumatic. There was weak correlation with abnormal neuropsychological tests for attention in the acute period. There was no significant correlation with a questionnaire for PCS and return to work status. Although non-specific abnormalities are frequently seen, standard MRI techniques are not helpful in identifying patients with MTBI who are likely to have delayed recovery.	Hope Hosp, Dept Neuroradiol, Salford M6 8HD, Lancs, England; Hope Hosp, Dept Behav Med, Salford M6 8HD, Lancs, England; Univ Lancaster, Med Stat Unit, Lancaster, England; Hope Hosp, Dept Emergency Med, Salford M6 8HD, Lancs, England	Hughes, DG (corresponding author), Hope Hosp, Dept Neuroradiol, Salford M6 8HD, Lancs, England.	david.hughes@srht.nhs.uk		Hollis, Sally/0000-0003-0156-9189			Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Arciniegas DB, 2001, BRAIN INJURY, V15, P649, DOI 10.1080/02699050010019800; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Feinstein A, 2000, CAN J PUBLIC HEALTH, V91, P325, DOI 10.1007/BF03404799; GawneCain ML, 1997, NEURORADIOLOGY, V39, P243, DOI 10.1007/s002340050402; HADLEY DM, 1988, CLIN RADIOL, V39, P131; HAYMAN LA, 1991, AM J NEURORADIOL, V12, P899; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Inamasu J, 2000, AM J EMERG MED, V18, P810, DOI 10.1053/ajem.2000.18111; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Laforce R, 2001, PERCEPT MOTOR SKILL, V93, P281, DOI 10.2466/PMS.93.5.281-288; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nelson HE, 1982, NATL ADULT READING T; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff RM, 1999, BRAIN INJURY, V13, P943; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Sinson G, 2001, AM J NEURORADIOL, V22, P143; SKLAR EM, 1999, RADIOL CLIN N AM, V30, P353; Stewart DP, 1996, ACAD EMERG MED, V3, P21, DOI 10.1111/j.1553-2712.1996.tb03297.x; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Tellier A, 1999, BRAIN INJURY, V13, P463; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Uchino Y, 2001, ACTA NEUROCHIR, V143, P1031, DOI 10.1007/s007010170008; Umile EM, 1998, BRAIN INJURY, V12, P577; van der Naalt J, 2000, BRAIN INJURY, V14, P781; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Voller B, 2001, BRAIN INJURY, V15, P107, DOI 10.1080/026990501458344; Von Wild K, 2001, BRAIN INJURY, V15, P273; Wakamoto H, 1998, NEUROL SURG TOKYO, V26, P985; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Weight DG, 1998, PSYCHIAT CLIN N AM, V21, P609, DOI 10.1016/S0193-953X(05)70026-5; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007	58	152	154	0	20	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	JUL	2004	46	7					550	558		10.1007/s00234-004-1227-x			9	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	838CT	WOS:000222691500004	15185054				2021-06-18	
J	Mulcahy, NJ; Ross, J; Rothwell, NJ; Loddick, SA				Mulcahy, NJ; Ross, J; Rothwell, NJ; Loddick, SA			Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						interleukin-1; interleukin-1 receptor antagonist; stroke; reversible; transient; protection; ischaemia	ARTERY OCCLUSION; BRAIN-DAMAGE; SPONTANEOUS HYPERTHERMIA; TRIAL; NEUROPROTECTION; TEMPERATURE; DIFFUSION; STROKE; VOLUME; FEVER	1 The cytokine interleukin-1 (IL-1) has been implicated in ischaemic, excitotoxic and traumatic brain damage in rodents. The naturally occurring IL-1 receptor antagonist (IL-1ra) markedly reduces neuronal injury in these conditions. However, the effects of IL-1ra on focal, transient cerebral ischaemia in the rat, which is of major clinical relevance, have not been reported. 2 The objectives of this study were to test the effects of IL-1ra on cell death after temporary cerebral ischaemia, and to investigate the therapeutic time window for IL-1ra treatment. 3 Ischaemia was induced by temporary (60 min) occlusion of the middle cerebral artery (MCAO) in rats, via surgical insertion (and subsequent removal) of a thread into the internal carotid artery. Damage was quantified at various times after MCAO to investigate the temporal progression of damage and establish an appropriate time to assess the effects of IL-1ra on cell death. 4 Cell death was complete 18-24 h after temporary MCAO. Intracerebroventricular injection of IL-1ra (10 mug) at the time of MCAO and 60 min later reduced the lesion volume measured 24 h (57% reduction) or 48 h (52% reduction) after MCAO. Cell death was also significantly reduced when IL-1ra (20 mug) was administered as a single injection, 1 h (47%), 2 h (57%) or 3 h (46%) after MCAO, when compared to vehicle. 5 These data show that IL-1ra markedly reduces cell death even when administration is delayed until 3 h after induction of reversible, focal cerebral ischaemia in the rat, and support our proposal that IL-1ra may be of therapeutic benefit in stroke.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Hope Hosp, Greater Manchester Neurosci Ctr, Salford M6 8HD, Lancs, England	Rothwell, NJ (corresponding author), Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England.	nancy.rothwell@man.ac.uk					Abraham H, 2002, EXP BRAIN RES, V142, P131, DOI 10.1007/s00221-001-0909-4; Albers GW, 2001, STROKE, V32, P1598, DOI 10.1161/01.STR.32.7.1598; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Beaulieu C, 1999, ANN NEUROL, V46, P568, DOI 10.1002/1531-8249(199910)46:4<568::AID-ANA4>3.0.CO;2-R; Boutin H, 2001, J NEUROSCI, V21, P5528; Calabrese LH, 2002, ANN PHARMACOTHER, V36, P1204; Cartmell T, 2001, J PHYSIOL-LONDON, V531, P171, DOI 10.1111/j.1469-7793.2001.0171j.x; CHEN H, 1991, NEUROLOGY, V41, P1133, DOI 10.1212/WNL.41.7.1133; COYLE P, 1982, ANAT REC, V203, P397, DOI 10.1002/ar.1092030309; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; GARCIA JH, 1995, AM J PATHOL, V147, P1477; GARCIA JH, 1995, STROKE, V26, P636, DOI 10.1161/01.STR.26.4.636; Grotta J, 2002, STROKE, V33, P306, DOI 10.1161/str.33.1.306; GUTIERREZ EG, 1994, J NEUROIMMUNOL, V55, P153, DOI 10.1016/0165-5728(94)90005-1; KIM DC, 1995, J PHARM SCI, V84, P575, DOI 10.1002/jps.2600840511; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; Konsman JP, 2000, NEUROSCIENCE, V101, P957, DOI 10.1016/S0306-4522(00)00403-6; Lawrence CB, 1998, EUR J NEUROSCI, V10, P1188, DOI 10.1046/j.1460-9568.1998.00136.x; Lees KR, 2002, STROKE, V33, P308, DOI 10.1161/str.33.1.308; Legos JJ, 2002, J NEUROSCI METH, V113, P159, DOI 10.1016/S0165-0270(01)00488-5; Li FH, 1999, STROKE, V30, P2464, DOI 10.1161/01.STR.30.11.2464; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Luheshi G, 1996, AM J PHYSIOL-ENDOC M, V270, pE91; Opal SM, 1997, CRIT CARE MED, V25, P1115, DOI 10.1097/00003246-199707000-00010; Reglodi D, 2000, EXP NEUROL, V163, P399, DOI 10.1006/exnr.2000.7367; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Schwetz BA, 2002, JAMA-J AM MED ASSOC, V287, P33, DOI 10.1001/jama.287.1.33-b; Stroemer RP, 1998, J CEREBR BLOOD F MET, V18, P833, DOI 10.1097/00004647-199808000-00003; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Touzani O, 2001, CURR OPIN NEUROL, V14, P83, DOI 10.1097/00019052-200102000-00013; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; ZHAO Q, 1994, BRAIN RES, V649, P253, DOI 10.1016/0006-8993(94)91071-5	38	152	158	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	OCT	2003	140	3					471	476		10.1038/sj.bjp.0705462			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	729XF	WOS:000185799800005	12970087	Green Published, Bronze			2021-06-18	
J	BARTHOLDI, D; SCHWAB, ME				BARTHOLDI, D; SCHWAB, ME			METHYLPREDNISOLONE INHIBITS EARLY INFLAMMATORY PROCESSES BUT NOT ISCHEMIC CELL-DEATH AFTER EXPERIMENTAL SPINAL-CORD LESION IN THE RAT	BRAIN RESEARCH			English	Article						SPINAL CORD INJURY; METHYLPREDNISOLONE; LESION SITE; SECONDARY INJURY; INFLAMMATORY REACTION; MACROPHAGE INVASION; CNS	CENTRAL-NERVOUS-SYSTEM; (NA+ + K+)-ATPASE; LIPID-PEROXIDATION; DOSE-RESPONSE; BLOOD-FLOW; INJURY; TRAUMA; BRAIN; CAT; GLUTAMATE	Experimental studies and clinical observations show that spinal cord lesions are greatly enlarged by a process called secondary cell death. A detailed understanding of the molecular and cellular processes underlying these events is still lacking. In clinical studies using methylprednisolone in spinal cord injured patients a mega-dose of methylprednisolone applied during the first few hours after injury was found to improve the neurological outcome. In the present study the possible neuroprotective mechanism of methylprednisolone was assessed by histologically studying its effect on the extent of secondary cell death and on early inflammatory reactions following partial transection of the spinal cord in the rat. Our results show that a single high dose of 30 or 60 mg/kg methylprednisolone affects neither the time course nor the extent of secondary cell death. In contrast, methylprednisolone markedly suppressed the invasion of the injured spinal cord tissue by polymorphonuclear granulocytes and macrophages. The role of these inflammatory cells in traumatic CNS lesions is very unclear at present. It is possible that they lead to further damage of the injured spinal cord tissue and that the beneficial effect of methylprednisolone is at least partially due to its anti-inflammatory effect, thereby inhibiting bystander damage of invading inflammatory cells.		BARTHOLDI, D (corresponding author), UNIV ZURICH, BRAIN RES INST, AUGUST FOREL STR 1, CH-8029 ZURICH, SWITZERLAND.		Schwab, Martin E/B-6818-2016				Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; ANDERSON DK, 1988, J NEUROSURG, V69, P562, DOI 10.3171/jns.1988.69.4.0562; BALENTINE JD, 1978, LAB INVEST, V39, P236; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.251.1.45; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BRAUGHLER JM, 1982, J NEUROSURG, V56, P838, DOI 10.3171/jns.1982.56.6.0838; BUNGE RP, 1993, ADV NEUROLOGY, V59; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Clark R. A. F., 1988, MOL CELLULAR BIOL WO; COFFEY PJ, 1988, NEUROSCI LETT, V84, P178, DOI 10.1016/0304-3940(88)90404-1; CRONSTEIN BN, 1992, P NATL ACAD SCI USA, V89, P9991, DOI 10.1073/pnas.89.21.9991; DELABAUME S, 1981, NEUROSCIENCE, V6, P315, DOI 10.1016/0306-4522(81)90125-1; DELEY G, 1993, J NEUROTRAUM, V10, P25, DOI 10.1089/neu.1993.10.25; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GOLDMAN SS, 1983, EXP NEUROL, V82, P650, DOI 10.1016/0014-4886(83)90087-0; GREENSPAN FS, 1991, BASIC CLIN ENDOCRINO; HALL ED, 1981, EXP NEUROL, V73, P321, DOI 10.1016/0014-4886(81)90067-4; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; HALL ED, 1984, J NEUROSURG, V61, P124, DOI 10.3171/jns.1984.61.1.0124; Hall ED, 1991, J NEUROTRAUM, V8, P86; HOLTZ A, 1990, ACTA NEUROL SCAND, V82, P68; HSU C Y, 1990, Journal of Neurotrauma, V7, P115, DOI 10.1089/neu.1990.7.115; JANSSEN L, 1989, SPINE, V14, P23, DOI 10.1097/00007632-198901000-00005; KIWERSKI JE, 1993, INJURY, V24, P457, DOI 10.1016/0020-1383(93)90149-Z; LASSMANN H, 1991, REV NEUROL-FRANCE, V147, P763; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; MEANS ED, 1981, J NEUROSURG, V55, P200, DOI 10.3171/jns.1981.55.2.0200; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; STELLAR JR, 1991, BRAIN RES, V541, P29, DOI 10.1016/0006-8993(91)91070-H; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; YOUNG W, 1980, J NEUROSURG, V52, P64, DOI 10.3171/jns.1980.52.1.0064; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	49	152	153	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 20	1995	672	1-2					177	186		10.1016/0006-8993(94)01410-J			10	Neurosciences	Neurosciences & Neurology	QJ465	WOS:A1995QJ46500021	7749740				2021-06-18	
J	LEVIN, HS; CULHANE, KA; MENDELSOHN, D; LILLY, MA; BRUCE, D; FLETCHER, JM; CHAPMAN, SB; HARWARD, H; EISENBERG, HM				LEVIN, HS; CULHANE, KA; MENDELSOHN, D; LILLY, MA; BRUCE, D; FLETCHER, JM; CHAPMAN, SB; HARWARD, H; EISENBERG, HM			COGNITION IN RELATION TO MAGNETIC-RESONANCE-IMAGING IN HEAD-INJURED CHILDREN AND ADOLESCENTS	ARCHIVES OF NEUROLOGY			English	Article							PERFORMANCE	To investigate the relationship between cognitive sequelae and magnetic resonance imaging (MRI) findings following closed head injury of varying severity in the pediatric age range, 76 head-injured children and adolescents were studied at least 3 months after trauma and compared with 57 normal controls. Problem solving, planning, verbal and design fluency, memory, and response modulation were assessed. Significant effects of injury were obtained on all of the cognitive measures. Cognitive impairment was more consistently present on the various outcome measures in children who were 6 to 10 years old at the time of the study than in the older children and adolescents. Magnetic resonance imaging disclosed areas of abnormal signal in the frontal lobes of 42 patients, whereas focal lesions restricted to the extrafrontal region were found in 15 children. Regression analyses disclosed that taking into account the size of frontal lobe lesion enhanced the relationship between cognitive performance and the severity of injury.	UNIV TEXAS, HLTH SCI CTR, SW MED SCH, DEPT RADIOL, DALLAS, TX 75235 USA; UNIV TEXAS, HLTH SCI CTR, SW MED SCH, DEPT NEUROSURG, DALLAS, TX 75235 USA; UNIV TEXAS, CALLIER CTR COMMUN DISORDERS, DALLAS, TX 75230 USA; UNIV TEXAS, SCH MED, DEPT PEDIAT, HOUSTON, TX 77025 USA	LEVIN, HS (corresponding author), UNIV TEXAS, MED BRANCH, DIV NEUROSURG, D73, GALVESTON, TX 77555 USA.		fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Damasio H., 1989, LESION ANAL NEUROPSY; DAMASIO HC, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P92; DELIS D, 1986, CALIFORNIA VERBAL LE; DENNEY DR, 1973, DEV PSYCHOL, V9, P275, DOI 10.1037/h0035092; DREWE E A, 1975, Cortex, V11, P8; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Heaton R. K, 1981, WISCONSIN CARD SORTI; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; Kennard MA, 1942, ARCH NEURO PSYCHIATR, V48, P227, DOI 10.1001/archneurpsyc.1942.02290080073002; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1974, WECHSLER ADULT INTEL	22	152	154	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-9942	1538-3687		ARCH NEUROL-CHICAGO	Arch. Neurol.	SEP	1993	50	9					897	905		10.1001/archneur.1993.00540090008004			9	Clinical Neurology	Neurosciences & Neurology	LV723	WOS:A1993LV72300004	8363443				2021-06-18	
J	GRADY, MS; MCLAUGHLIN, MR; CHRISTMAN, CW; VALADKA, AB; FLIGNER, CL; POVLISHOCK, JT				GRADY, MS; MCLAUGHLIN, MR; CHRISTMAN, CW; VALADKA, AB; FLIGNER, CL; POVLISHOCK, JT			THE USE OF ANTIBODIES TARGETED AGAINST THE NEUROFILAMENT SUBUNITS FOR THE DETECTION OF DIFFUSE AXONAL INJURY IN HUMANS	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						AXONAL SWELLING; BRAIN TRAUMA; HUMAN; IMMUNOCYTOCHEMISTRY; MONOCLONAL ANTIBODIES; NEUROFILAMENT SUBUNITS	NONMISSILE HEAD-INJURY; MONOCLONAL-ANTIBODIES; TRAUMA; DAMAGE	Axonal injury is a common feature of human traumatic brain injury. Typically, damaged axons cannot be recognized unless a patient survives the injury by at least 10- 1 2 hours (h). Limitations associated with the use of the traditional silver methods have been linked with this inability to recognize early posttraumatic reactive axonal change. Recently, we reported that antibodies targeting the neurofilament subunits proved useful in recognizing early traumatically induced axonal change in traumatically brain-injured animals. Accordingly, in the present communication, we employed antibodies to detect at the light microscopic level the 68 kD Nf-L and 170-200 kD Nf-H neurofilament subunits in head-injured patients who survived the traumatic event for periods ranging from 6 h to 59 days. Antibodies targeting all of the above-described subunits revealed a progression of reactive axonal change. Antibodies to the 68 kD subunit proved most useful, as they were not complicated by concomitant immunoreactivity in surrounding nuclei and/or dendritic and somatic elements. These immunocytochemical strategies revealed, at 6 h postinjury, focally swollen axons which appeared intact. By 12 h, this focal swelling had progressed to disconnection, with the immunoreactive swelling undergoing further expansion over 1 week postinjury. These findings demonstrate the utility of the previously described immunocytochemical strategies for detecting reactive axonal change in brain-injured humans, particularly in the early posttraumatic course. More importantly, these methods also demonstrate in humans that reactive axonal change is not necessarily caused by traumatically induced tearing.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,POB 709,MCV STN,RICHMOND,VA 23298; UNIV WASHINGTON,KINGS CTY MED EXAMINERS OFF,DEPT NEUROSURG,SEATTLE,WA 98195; UNIV WASHINGTON,KINGS CTY MED EXAMINERS OFF,DEPT PATHOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193, K08NS001371] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193, NS01371] Funding Source: Medline		ADAMS H, 1977, BRAIN, V100, P487; Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P135, DOI 10.1016/0165-5728(87)90048-8; IMAJO T, 1987, AM J FOREN MED PATH, V8, P217, DOI 10.1097/00000433-198708030-00004; LANGLEY OK, 1988, BRAIN RES, V457, P12, DOI 10.1016/0006-8993(88)90052-2; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 1985, CENTRAL NERVOUS SYST, P443; POVLISHOCK JT, 1991, J NEUROTRAUMA S1, V9, pS189; SAHUQUILLO J, 1989, ACTA NEUROCHIR, V101, P149, DOI 10.1007/BF01410531; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; SHAW G, 1986, EUR J CELL BIOL, V42, P1; SHAW G, 1988, BRAIN RES, V460, P227, DOI 10.1016/0006-8993(88)90367-8; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; STRICH SJ, 1961, LANCET, V2, P443; VANEZIS P, 1987, FORENSIC SCI INT, V35, P1, DOI 10.1016/0379-0738(87)90018-1; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	27	152	156	2	6	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	1993	52	2					143	152		10.1097/00005072-199303000-00007			10	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	KQ771	WOS:A1993KQ77100007	8440996				2021-06-18	
J	Estraneo, A; Moretta, P; Loreto, V; Lanzillo, B; Santoro, L; Trojano, L				Estraneo, A.; Moretta, P.; Loreto, V.; Lanzillo, B.; Santoro, L.; Trojano, L.			Late recovery after traumatic, anoxic, or hemorrhagic long-lasting vegetative state	NEUROLOGY			English	Article							MINIMALLY CONSCIOUS STATE; POSTTRAUMATIC HYDROCEPHALUS; BRAIN-INJURY; DISORDERS; COMA; REHABILITATION; PREDICTORS; DIAGNOSIS; CONSENSUS; ACCURACY	Objectives: Late recovery of awareness in vegetative state (VS) is considered as an exceptional outcome, and has been reported prevalently after traumatic brain injury (TBI). The present prospective study aimed to verify frequency of late recovery (later than 1 year postonset in TBI and 3 months postonset in patients without TBI) of responsiveness and consciousness in traumatic and nontraumatic long-lasting (more than 6 months after onset) VS. Methods: Fifty inpatients with long-lasting VS (36% TBI, 36% hemorrhagic, and 28% anoxic) were enrolled and followed up for a mean of 25.7 months from onset (5 patients for more than 4 years). Level of responsiveness and functional disability were evaluated by means of validated scales (Coma Recovery Scale-Revised and Disability Rating Scale). Results: At the end of the study, 21 patients (42%) had died, 17 patients (34%) were in VS, and 2 patients with TBI (4%) had recovered responsiveness within 12 months postonset. The remaining 10 (20%) patients with TBI and patients without TBI showed late recovery of responsiveness; 6 of them (12%) further progressed to consciousness. Late recovery was significantly associated with younger age and was relatively more frequent in TBI. Functional abilities were severely impaired in all patients. Conclusions: This clinical study demonstrates that late recovery of responsiveness and consciousness is not exceptional in patients with traumatic and nontraumatic VS, although with residual severe disability. Neurology (R) 2010;75:239-245	[Trojano, L.] Univ Naples 2, Dept Psychol, Neuropsychol Lab, I-81100 Caserta, Italy; [Estraneo, A.; Moretta, P.; Loreto, V.; Lanzillo, B.; Trojano, L.] Univ Naples Federico II, Salvatore Maugeri Fdn, Naples, Italy; [Santoro, L.] Univ Naples Federico II, IRCCS, Sci Inst Telese Terme BN, Telese Terme BN,Dept Neurol Sci, Naples, Italy	Trojano, L (corresponding author), Univ Naples 2, Dept Psychol, Neuropsychol Lab, Via Vivaldi 43, I-81100 Caserta, Italy.	luigi.trojano@unina2.it	bernardo, lanzillo/F-1496-2019; Trojano, Luigi/F-2396-2016; Moretta, Pasquale/AAE-5162-2021	bernardo, lanzillo/0000-0001-5473-0701; Trojano, Luigi/0000-0002-0328-9642; Moretta, Pasquale/0000-0003-2244-254X; Santoro, Lucio/0000-0001-9507-2303	TelethonFondazione Telethon; Italian Ministry of HealthMinistry of Health, Italy	Dr. Estraneo, Dr. Moretta, Dr. Loreto, and Dr. Lanzillo report no disclosures. Prof. Santoro has received research support from Telethon. Prof. Trojano receives royalties from the publication of Neuropsicologia dei Lobi Frontali: Sindrome Disesecutive e Disturbi del Comportamento (Il Mulino, 2005) and Lineamenti di Neuropsicologia Clinica (Carocci Editore, 2002) and has received research support from the Italian Ministry of Health.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Annas GJ, 2005, NEW ENGL J MED, V352, P1710, DOI 10.1056/NEJMlim050643; [Anonymous], 2003, Clin Med (Lond), V3, P249; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Avesani R, 2006, BRAIN INJURY, V20, P333, DOI 10.1080/02699050500487605; Bernat JL, 2006, LANCET, V367, P1181, DOI 10.1016/S0140-6736(06)68508-5; Childs NL, 1996, NEW ENGL J MED, V334, P24, DOI 10.1056/NEJM199601043340105; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Dyer C, 1997, BRIT MED J, V314, P993, DOI 10.1136/bmj.314.7086.993; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Faran S, 2006, J NEUROL NEUROSUR PS, V77, P998, DOI 10.1136/jnnp.2005.076554; Fins JJ, 2009, PROG BRAIN RES, V177, P371, DOI 10.1016/S0079-6123(09)17726-9; Giacino JT, 2009, PROG BRAIN RES, V177, P33, DOI 10.1016/S0079-6123(09)17704-X; Giacino JT, 2004, NEUROREHABILITATION, V19, P293; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; Li G, 2008, BRAIN INJURY, V22, P333, DOI 10.1080/02699050801958353; Missori P, 2006, NEUROSURG REV, V29, P224, DOI 10.1007/s10143-006-0027-7; Owen AM, 2009, PROG BRAIN RES, V177, P399, DOI 10.1016/S0079-6123(09)17728-2; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; Sancisi E, 2009, BRAIN INJURY, V23, P163, DOI 10.1080/02699050802660446; Schnakers C, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.124099; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Taira T, 2009, PROG BRAIN RES, V177, P317, DOI 10.1016/S0079-6123(09)17721-X; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Whyte J, 2009, PROG BRAIN RES, V177, P63, DOI 10.1016/S0079-6123(09)17706-3; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Whyte J, 2007, AM J PHYS MED REHAB, V86, P86, DOI 10.1097/PHM.0b013e31802f0434; Zafonte R, 2009, PROG BRAIN RES, V177, P293, DOI 10.1016/S0079-6123(09)17720-8	35	151	158	0	29	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUL 20	2010	75	3					239	245		10.1212/WNL.0b013e3181e8e8cc			7	Clinical Neurology	Neurosciences & Neurology	628ES	WOS:000280097900009	20554941				2021-06-18	
J	Redell, JB; Liu, Y; Dash, PK				Redell, John B.; Liu, Yin; Dash, Pramod K.			Traumatic Brain Injury Alters Expression of Hippocampal MicroRNAs: Potential Regulators of Multiple Pathophysiological Processes	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						miRNA; microarray; hippocampus; TBI	PROTEIN REFERENCE DATABASE; TRANSIENT FOCAL ISCHEMIA; GENE-EXPRESSION; MESSENGER-RNA; TARGET PREDICTIONS; ALZHEIMERS-DISEASE; ANGIOGENESIS; TRANSCRIPTOME; IMPACT; ATLAS	Multiple cellular, molecular, and biochemical changes contribute to outcome after traumatic brain injury (TBI). MicroRNAs (miRNAs) are known to influence many important cellular processes, including proliferation, apoptosis, neurogenesis, angiogenesis, and morphogenesis, all processes that are involved in TBI pathophysiology. However, it has not yet been determined whether miRNA expression is altered after TBI. In the present study, we used a microarray platform to examine changes in the hippocampal expression levels of 444 verified rodent miRNAs at 3 and 24 hr after controlled cortical impact injury. Our analysis found 50 miRNAs exhibited decreased expression levels and 35 miRNAs exhibited increased expression levels in the hippocampus after injury. We extended the microarray findings using quantitative polymerase chain reaction analysis for a subset of the miRNAs with altered expression levels (miR-107, -130a, -223, -292-5p, -433-3p, -451, -541, and -711). Bioinformatic analysis of the predicted targets for this panel of miRNAs revealed an overrepresentation of proteins involved in several biological processes and functions known to be initiated after injury, including signal transduction, transcriptional regulation, proliferation, and differentiation. Our results indicate that multiple protein targets and biological processes involved in TBI pathophysiology may be regulated by miRNAs. (C) 2008 Wiley-Liss, Inc.	[Redell, John B.; Liu, Yin; Dash, Pramod K.] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Dash, Pramod K.] Univ Texas Houston, Sch Med, Dept Neurosurg, Houston, TX USA; [Dash, Pramod K.] Univ Texas Houston, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX USA	Dash, PK (corresponding author), Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457, NS049160]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH072933]; Mission Connect/TIRR Foundation; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH072933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049160, R21NS078596, R01NS035457] Funding Source: NIH RePORTER	Contract grant sponsor: National Institute of Neurological Disorders and Stroke; Contract grant number: NS35457 (to P.K.D.); Contract grant sponsor: National Institute of Neurological Disorders and Stroke; Contract grant number: NS049160 (to P.K.D.); Contract grant sponsor: National Institute of Mental Health; Contract grant number: MH072933 (to P.K.D.); Contract grant sponsor: Mission Connect/TIRR Foundation (to P.K.D.).	An JJ, 2008, CELL, V134, P175, DOI 10.1016/j.cell.2008.05.045; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bekinschtein P, 2008, NEUROSCIENTIST, V14, P147, DOI 10.1177/1073858407305850; Berezikov E, 2006, NAT GENET, V38, P1375, DOI 10.1038/ng1914; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Borchert GM, 2006, NAT STRUCT MOL BIOL, V13, P1097, DOI 10.1038/nsmb1167; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Carson JP, 2005, J MICROSC-OXFORD, V217, P275, DOI 10.1111/j.1365-2818.2005.01450.x; Carson JP, 2002, CURR OPIN NEUROBIOL, V12, P562, DOI 10.1016/S0959-4388(02)00356-2; Chen Y, 2008, BLOOD, V111, P1217, DOI 10.1182/blood-2007-07-104133; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Dieci G, 2007, TRENDS GENET, V23, P614, DOI 10.1016/j.tig.2007.09.001; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gao XL, 2004, BIOPOLYMERS, V73, P579, DOI 10.1002/bip.20005; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Jeyaseelan K, 2008, STROKE, V39, P959, DOI 10.1161/STROKEAHA.107.500736; Ji RR, 2007, CIRC RES, V100, P1579, DOI 10.1161/CIRCRESAHA.106.141986; Joglekar MV, 2007, TRENDS ENDOCRIN MET, V18, P393, DOI 10.1016/j.tem.2007.10.001; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607; Karginov FV, 2007, P NATL ACAD SCI USA, V104, P19291, DOI 10.1073/pnas.0709971104; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Kloosterman WP, 2006, NAT METHODS, V3, P27, DOI 10.1038/NMETH843; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916; Kuzin A, 2007, DEV BIOL, V310, P35, DOI 10.1016/j.ydbio.2007.07.012; Kye MJ, 2007, RNA, V13, P1224, DOI 10.1261/rna.480407; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lu Y, 2008, NEUROBIOL LEARN MEM, V89, P312, DOI 10.1016/j.nlm.2007.08.018; Ma L, 2003, BRAIN RES, V966, P167, DOI 10.1016/S0006-8993(02)04149-5; Masaki S, 2007, BIOCHEM BIOPH RES CO, V364, P509, DOI 10.1016/j.bbrc.2007.10.077; Mellios N, 2008, HUM MOL GENET, V17, P3030, DOI 10.1093/hmg/ddn201; Mishra GR, 2006, NUCLEIC ACIDS RES, V34, pD411, DOI 10.1093/nar/gkj141; Nelson PT, 2008, BRAIN PATHOL, V18, P130, DOI 10.1111/j.1750-3639.2007.00120.x; O'Brien KP, 2005, NUCLEIC ACIDS RES, V33, pD476, DOI 10.1093/nar/gki107; Peri S, 2003, GENOME RES, V13, P2363, DOI 10.1101/gr.1680803; Poliseno L, 2006, BLOOD, V108, P3068, DOI 10.1182/blood-2006-01-012369; Quintana A, 2008, DEV NEUROBIOL, V68, P195, DOI 10.1002/dneu.20584; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; Suarez Y, 2007, CIRC RES, V100, P1164, DOI 10.1161/01.RES.0000265065.26744.17; Tang FC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj009; Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Victor NA, 2006, EUR J NEUROSCI, V24, P1653, DOI 10.1111/j.1460-9568.2006.05037.x; Visel A, 2004, NUCLEIC ACIDS RES, V32, pD552, DOI 10.1093/nar/gkh029; Wang WX, 2008, J NEUROSCI, V28, P1213, DOI 10.1523/JNEUROSCI.5065-07.2008; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yamada K, 2002, LIFE SCI, V70, P735, DOI 10.1016/S0024-3205(01)01461-8; Yang WJ, 2005, J BIOL CHEM, V280, P9330, DOI 10.1074/jbc.M413394200; Yaylaoglu MB, 2005, DEV DYNAM, V234, P371, DOI 10.1002/dvdy.20441; Zhan M, 2007, EXP HEMATOL, V35, P1015, DOI 10.1016/j.exphem.2007.03.014; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhu Qi, 2007, V382, P287, DOI 10.1007/978-1-59745-304-2_19	66	151	161	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAY 1	2009	87	6					1435	1448		10.1002/jnr.21945			14	Neurosciences	Neurosciences & Neurology	429FX	WOS:000264907400016	19021292	Green Accepted			2021-06-18	
J	Ates, O; Cayli, S; Altinoz, E; Gurses, I; Yucel, N; Sener, M; Kocak, A; Yologlu, S				Ates, Ozkan; Cayli, Suleyman; Altinoz, Eyup; Gurses, Iclal; Yucel, Neslihan; Sener, Metin; Kocak, Ayhan; Yologlu, Saim			Neuroprotection by resveratrol against traumatic brain injury in rats	MOLECULAR AND CELLULAR BIOCHEMISTRY			English	Article; Proceedings Paper	19th Annual Congress of Turkish-Neurosurgery-Society	MAY 27-31, 2005	Antalya, TURKEY	Turkish Neurosurg Soc		glutathione; malondialdehyde; nitric oxide; oxidative stress; resveratrol; traumatic brain injury; xanthine oxidase	SPONTANEOUSLY HYPERTENSIVE RATS; XANTHINE-OXIDASE ACTIVITY; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; NITRIC-OXIDE; LIPID-PEROXIDATION; OXIDATIVE STRESS; TISSUE NECROSIS; REPERFUSION	Oxidative stress after traumatic brain injury may contribute to many of the pathophysiologic changes. Resveratrol, naturally present at high concentration in grape skin, seeds, and red wine, has significant antioxidant properties in a variety of in vitro and in vivo models. In this study, we investigate the effect of resveratrol on oxidative stress after traumatic brain injury in rat model. A total of 54 adult Wistar albino male rats weighing 250-300 g were used. The rats were allocated into three groups. The first group was control (sham-operated) group in which only a craniotomy was performed, the others were trauma and resveratrol groups. A 100 mg/kg single dose of resveratrol, freshly prepared by dissolving in 50% ethanol and diluted in physiological saline (2%), for resveratrol group, and 1 ml ethanol (2%) for trauma group, was administered intraperitoneally immediately after trauma. Weight-drop method was used for achieving head trauma. Then, all groups were separated into three subgroups for biochemical analysis, brain water content and histopathological assessment following trauma. Twenty-four hours after trauma brain water content and malondialdehyde (MDA), glutathione (GSH), nitric oxide (NO), xanthine oxidase (XO) levels of traumatic hemisphere were evaluated. Quantitative histopathological analysis was performed on 14th day postinjury. Trauma caused a significant increase in MDA, XO, NO levels and decrease in GSH level as compared to control group. Resveratrol administration significantly reduced MDA, XO and NO levels, increased GSH level, and also attenuated tissue lesion area. Our results indicate that treatment with resveratrol immediately after traumatic brain injury reduce oxidative stress and lesion volume. Future studies involving different doses and the dose-response relationship could promise better results.	Inonu Univ, Turgut Ozal Med Ctr, Dept Neurosurg, Sch Med, TR-44069 Malatya, Turkey; Inonu Univ, Sch Med, Dept Biochem, Malatya, Turkey; Inonu Univ, Sch Med, Dept Pathol, Malatya, Turkey; Inonu Univ, Sch Med, Dept Emergency Med, Malatya, Turkey; Inonu Univ, Sch Med, Dept Biostat, Malatya, Turkey	Ates, O (corresponding author), Inonu Univ, Turgut Ozal Med Ctr, Dept Neurosurg, Sch Med, TR-44069 Malatya, Turkey.	atesozkan@hotmail.com	Altinoz, Eyup/AAM-2378-2020; Yucel, Neslihan/ABI-3412-2020; Gurses, Iclal/AAH-8552-2021; Yologlu, Saim/ABI-8014-2020	Yucel, Neslihan/0000-0001-5845-2614; Yologlu, Saim/0000-0002-9619-3462; Altinoz, Eyup/0000-0002-3991-9773			ANDERSON D K, 1985, Journal of Free Radicals in Biology and Medicine, V1, P59, DOI 10.1016/0748-5514(85)90030-3; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BLOOMFIELD RH, 2001, CIRCULATION, V103, P2828; Chander V, 2005, TOXICOLOGY, V210, P55, DOI 10.1016/j.tox.2005.01.011; Chanvitayapongs S, 1997, NEUROREPORT, V8, P1499, DOI 10.1097/00001756-199704140-00035; Daniel O, 1999, ENVIRON HEALTH PERSP, V107, P109, DOI 10.2307/3434477; DELLACOR.E, 1972, BIOCHEM J, V126, P739, DOI 10.1042/bj1260739; DEMEDIUK P, 1985, PROG BRAIN RES, V63, P211; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ERISKAT J, 1994, ACTA NEUROCHIR, P425; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HILLE R, 1995, FASEB J, V9, P995; Huang LX, 2003, J NEUROSURG, V99, P198, DOI 10.3171/spi.2003.99.2.0198; Huang SS, 2001, LIFE SCI, V69, P1057, DOI 10.1016/S0024-3205(01)01195-X; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Inoue H, 2000, J BIOL CHEM, V275, P28028; Inoue H, 2003, NEUROSCI LETT, V352, P203, DOI 10.1016/j.neulet.2003.09.001; Inoue H, 1999, BIOCHEM BIOPH RES CO, V254, P292, DOI 10.1006/bbrc.1998.9939; ITOH T, 1986, STROKE, V17, P1284, DOI 10.1161/01.STR.17.6.1284; Jungersten L, 1996, CLIN PHYSIOL, V16, P369, DOI 10.1111/j.1475-097X.1996.tb00726.x; KANEMITSU H, 1989, BRAIN RES, V499, P367, DOI 10.1016/0006-8993(89)90786-5; KIMURA Y, 1985, BIOCHIM BIOPHYS ACTA, V834, P275; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; Marklund N., 1997, NEUROREPORT, V717, P109; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Mizutani K, 2001, CLIN EXP PHARMACOL P, V28, P55, DOI 10.1046/j.1440-1681.2001.03415.x; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Nishio S, 1997, ACT NEUR S, V70, P84; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Olas B, 2002, THROMB RES, V106, P143, DOI 10.1016/S0049-3848(02)00101-9; Ozbek E, 2000, EUR UROL, V37, P172, DOI 10.1159/000020135; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; Plesnila N, 2003, NEUROSCI LETT, V345, P85, DOI 10.1016/S0304-3940(03)00396-3; PRAJDA N, 1975, FEBS LETT, V59, P245, DOI 10.1016/0014-5793(75)80385-1; Ray PS, 1999, FREE RADICAL BIO MED, V27, P160, DOI 10.1016/S0891-5849(99)00063-5; Sinha K, 2002, LIFE SCI, V71, P655, DOI 10.1016/S0024-3205(02)01691-0; Sobolev VS, 1999, J AGR FOOD CHEM, V47, P1435, DOI 10.1021/jf9809885; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Solaroglu I, 2003, CHILD NERV SYST, V19, P19, DOI 10.1007/s00381-002-0680-2; Soleas GJ, 1997, J CLIN LAB ANAL, V11, P287, DOI 10.1002/(SICI)1098-2825(1997)11:5<287::AID-JCLA6>3.0.CO;2-4; Stoffel M, 2004, J NEUROTRAUM, V21, P733, DOI 10.1089/0897715041269678; Tadolini B, 2000, FREE RADICAL RES, V33, P105, DOI 10.1080/10715760000300661; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6; Yakovlev Alexander G, 2004, NeuroRx, V1, P5, DOI 10.1007/BF03206563; Yang YB, 2003, ACTA PHARMACOL SIN, V24, P703; Yukido I, 1990, NEUROSURGERY, V27, P1; ZEBALLOS GA, 1995, CIRCULATION, V91, P2982, DOI 10.1161/01.CIR.91.12.2982; Zini R, 1999, DRUG EXP CLIN RES, V25, P87	55	151	159	2	25	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-8177	1573-4919		MOL CELL BIOCHEM	Mol. Cell. Biochem.	JAN	2007	294	1-2					137	144		10.1007/s11010-006-9253-0			8	Cell Biology	Cell Biology	127YE	WOS:000243621500016	16924419				2021-06-18	
J	Grady, MS; Charleston, JS; Maris, D; Witgen, BM; Lifshitz, J				Grady, MS; Charleston, JS; Maris, D; Witgen, BM; Lifshitz, J			Neuronal and glial cell number in the hippocampus after experimental traumatic brain injury: Analysis by stereological estimation	JOURNAL OF NEUROTRAUMA			English	Article						Cavalieri; fluid percussion; hippocampus; optical disector; optical fractionator; stereology; traumatic brain injury	FLUID-PERCUSSION INJURY; CONTROLLED CORTICAL IMPACT; RAT HIPPOCAMPUS; COGNITIVE IMPAIRMENT; ARBITRARY PARTICLES; MEMORY DYSFUNCTION; ALZHEIMERS-DISEASE; OPTICAL DISSECTOR; PARIETAL CORTEX; HILAR NEURONS	Fluid percussion (FP) brain injury causes spatial memory dysfunction in rats regardless of injury location (midline vs. lateral). Standard histological analysis of the injured brains shows hippocampal neuronal loss after lateral, but not midline FP injury. We have used the optical volume fractionator (OVF) stereological procedure to quantify neuronal loss and glial proliferation within specific subregions of the hippocampus after midline or lateral FP injury. The OVF method is a design-based cell counting procedure, which combines cellular numerical density estimates (from the optical disector) with volume estimates (generated by point counting and the fractionator stereology method) to produce an estimate of the absolute cell number. Fifteen adult male Sprague-Dawley rats were randomly divided into 3 groups (n = 5/group): midline injury, lateral injury and naive. A single fluid percussion pulse was delivered to anesthetized rats in the injured groups. At 14 days post-injury, strict morphological criteria enabled the estimation of neurons, astrocytes, oligodendrocytes, and microglia in defined hippocampal subregions. The results confirm that hippocampal neurons are selectively vulnerable to brain injury, particularly observed as a significant loss in the hilus following both types of injury and in area CA3 after lateral injury. In contrast, the number of astrocytes and oligodendrocytes remains unaffected by brain injury, regardless of subregion. However, the significant increase in microglia number (bilaterally after midline and ipsilateral following lateral injury) suggests that underlying cellular processes continue weeks following injury. The implications of the observed cell population changes are discussed in relation to the reported cognitive deficits associated with both lateral and midline FP brain injury.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Biogenet Ventures, Spokane, WA USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA	Grady, MS (corresponding author), Hosp Univ Penn, Dept Neurosurg, 5th Floor Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS R0-133107, NS R01-30305, NS R01-30306] Funding Source: Medline		AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Benes FM, 2001, TRENDS NEUROSCI, V24, P11, DOI 10.1016/S0166-2236(00)01660-X; BJUGN R, 1993, J COMP NEUROL, V328, P406, DOI 10.1002/cne.903280307; BOLENDER RP, 1993, MICROSC RES TECHNIQ, V25, P314, DOI 10.1002/jemt.1070250408; BRAENDGAARD H, 1990, J MICROSC-OXFORD, V157, P285, DOI 10.1111/j.1365-2818.1990.tb02967.x; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Calhoun ME, 1998, NEUROBIOL AGING, V19, P599, DOI 10.1016/S0197-4580(98)00098-0; CHARLESTON JS, 1994, TOXICOL APPL PHARM, V129, P196, DOI 10.1006/taap.1994.1244; CHARLESTON JS, 2000, CURRENT PROTOCOLS TO, V1; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P3; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; INIGUEZ C, 1985, J NEUROSCI METH, V13, P77, DOI 10.1016/0165-0270(85)90045-7; JUCKER M, 1990, PHYSIOL BEHAV, V47, P207, DOI 10.1016/0031-9384(90)90062-9; KAMETANI H, 1989, BEHAV NEUROSCI, V103, P84, DOI 10.1037/0735-7044.103.1.84; LANDIS DMD, 1994, ANNU REV NEUROSCI, V17, P133, DOI 10.1146/annurev.ne.17.030194.001025; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Long JM, 1998, NEUROBIOL AGING, V19, P497, DOI 10.1016/S0197-4580(98)00088-8; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MADEIRA MD, 1988, J HIRNFORSCH, V29, P643; Marmarou A, 1990, Adv Neurol, V52, P233; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; MITCHELL Y, 2002, NEUROPATHOL APPL NEU, V28, P160; Muller GJ, 2001, EXP BRAIN RES, V141, P380, DOI 10.1007/s002210100879; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pitkanen A, 1999, EPILEPSY RES, V33, P67, DOI 10.1016/S0920-1211(98)00074-6; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rapp PR, 1996, P NATL ACAD SCI USA, V93, P9926, DOI 10.1073/pnas.93.18.9926; Rasmussen T, 1996, NEUROBIOL AGING, V17, P143, DOI 10.1016/0197-4580(95)02032-2; SASS KJ, 1990, NEUROLOGY, V40, P1694, DOI 10.1212/WNL.40.11.1694; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; SCHARFMAN HE, 1991, J NEUROSCI, V11, P1660; SCHARFMAN HE, 1990, NEUROSCIENCE, V37, P693, DOI 10.1016/0306-4522(90)90100-I; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Simic G, 1997, J COMP NEUROL, V379, P482, DOI 10.1002/(SICI)1096-9861(19970324)379:4<482::AID-CNE2>3.0.CO;2-Z; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Toth Z, 1997, J NEUROSCI, V17, P8106; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Tuunanen J, 2000, EPILEPSY RES, V39, P171, DOI 10.1016/S0920-1211(99)00123-0; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; WEST MJ, 1994, LANCET, V344, P769, DOI 10.1016/S0140-6736(94)92338-8; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; WEST MJ, 1993, NEUROBIOL AGING, V14, P287, DOI 10.1016/0197-4580(93)90113-P; WINOCUR G, 1990, BEHAV BRAIN RES, V38, P145, DOI 10.1016/0166-4328(90)90012-4; Xavier GF, 1999, HIPPOCAMPUS, V9, P668, DOI 10.1002/(SICI)1098-1063(1999)9:6<668::AID-HIPO8>3.0.CO;2-9; Yamaki T, 1997, BRAIN RES, V752, P151, DOI 10.1016/S0006-8993(96)01469-2; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	75	151	157	1	8	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2003	20	10					929	941		10.1089/089771503770195786			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	734RX	WOS:000186072300002	14588110				2021-06-18	
J	Molina-Holgado, F; Pinteaux, E; Moore, JD; Molina-Holgado, E; Guaza, C; Gibson, RM; Rothwell, NJ				Molina-Holgado, F; Pinteaux, E; Moore, JD; Molina-Holgado, E; Guaza, C; Gibson, RM; Rothwell, NJ			Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia	JOURNAL OF NEUROSCIENCE			English	Article						cytokine; cannabinoid; neuroprotection; IL-1ra; excitotoxicity; nitric oxide	RAT MICROGLIAL CELLS; NITRIC-OXIDE; BRAIN INJURY; IL-1; EXPRESSION; ASTROCYTES; INHIBITION; CULTURES; HU-211; VIRUS	Interleukin-1 receptor antagonist (IL-1ra) is an important anti-inflammatory cytokine that blocks allknownactions of IL-1 and markedly protects against experimentally induced ischemic, excitotoxic, and traumatic brain insults. Cannabinoids (CBs) also exert potent anti-inflammatory and neuroprotective effects, but the mechanisms of their actions are unknown. Here we tested the hypothesis that the actions of CBs are mediated by endogenous IL-1ra. We report for the first time that both CB1 and CB2 receptors modulate release of endogenous IL-1ra from primary cultured glial cells. Activation of CB1 or CB2 receptors increased lipopolysaccharide-induced IL-1ra release, and specific CB1 or CB2 antagonists blocked lipopolysaccharide-induced production of IL-1ra from glial cells. Comparison of neuronal cultures from wild-type mice and mice lacking IL-1ra ( knock-out) indicates that endogenous IL-1ra is essential for the neuroprotective effects of CBs against excessive activation of glutamate receptors ( excitotoxicity) in response to S-AMPA or NMDA. Similarly, analysis of mixed glial cultures from IL-1ra knock-out mice indicates that endogenous IL-1ra is required for the CB-induced inhibition of nitric oxide production in response to bacterial lipopolysaccharide. These data suggest a novel neuroprotective mechanism of action for CBs in response to inflammatory or excitotoxic insults that is mediated by both CB1 and CB2 receptor-dependent pathways.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; CSIC, Inst Cajal, E-28002 Madrid, Spain	Rothwell, NJ (corresponding author), Univ Manchester, Sch Biol Sci, 1-124 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Molina-Holgado, Eduardo/C-2714-2008; Molina-Holgado, Francisco/B-8893-2008	Molina-Holgado, Eduardo/0000-0001-6693-1682; Molina-Holgado, Francisco/0000-0003-1838-2222; Pinteaux, Emmanuel/0000-0002-9986-4401	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Cabral GA, 2001, ADV EXP MED BIOL, V493, P207; Davies CA, 1999, J CEREBR BLOOD F MET, V19, P87, DOI 10.1097/00004647-199901000-00010; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Hobbs AJ, 1999, ANNU REV PHARMACOL, V39, P191, DOI 10.1146/annurev.pharmtox.39.1.191; Horai R, 1998, J EXP MED, V187, P1463, DOI 10.1084/jem.187.9.1463; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; JORDAN M, 1995, J IMMUNOL, V154, P4081; Josephs MD, 2000, AM J PHYSIOL-REG I, V278, pR824; Klein TW, 2000, P SOC EXP BIOL MED, V225, P1, DOI 10.1046/j.1525-1373.2000.22501.x; Loddick SA, 1997, BIOCHEM BIOPH RES CO, V234, P211, DOI 10.1006/bbrc.1997.6436; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; Mechoulam R, 2002, SCI STKE, P1; Molina-Holgado F, 1998, FEBS LETT, V433, P139, DOI 10.1016/S0014-5793(98)00851-5; Molina-Holgado F, 2002, J NEUROSCI RES, V67, P829, DOI 10.1002/jnr.10165; MolinaHolgado F, 1997, NEUROREPORT, V8, P1929, DOI 10.1097/00001756-199705260-00027; Moore JD, 2002, BRIT J PHARMACOL, V135, P1069, DOI 10.1038/sj.bjp.0704538; NADLER V, 1993, BRAIN RES, V622, P79, DOI 10.1016/0006-8993(93)90804-V; Nagayama T, 1999, J NEUROSCI, V19, P2987; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pertwee RG, 2002, PHARMACOL THERAPEUT, V95, P165, DOI 10.1016/S0163-7258(02)00255-3; Puffenbarger RA, 2000, GLIA, V29, P58, DOI 10.1002/(SICI)1098-1136(20000101)29:1<58::AID-GLIA6>3.3.CO;2-N; SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265, DOI 10.1111/j.1476-5381.1995.tb15035.x; Shen MX, 1998, MOL PHARMACOL, V54, P459; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Yuan M, 2002, J NEUROIMMUNOL, V133, P124, DOI 10.1016/S0165-5728(02)00370-3	30	151	158	0	2	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 23	2003	23	16					6470	6474					5	Neurosciences	Neurosciences & Neurology	704DX	WOS:000184323900009	12878687				2021-06-18	
J	Huisman, TAGM; Sorensen, AG; Hergan, K; Gonzalez, RG; Schaefer, PW				Huisman, TAGM; Sorensen, AG; Hergan, K; Gonzalez, RG; Schaefer, PW			Diffusion-weighted Imaging for the evaluation of diffuse axonal injury in closed head injury	JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY			English	Article						diffuse axonal injury; shearing injury; head trauma; diffusion-weighted imaging; magnetic resonance imaging	TRAUMATIC BRAIN INJURY; MR; EDEMA; HUMANS; STROKE; CT	Purpose: The purpose of this work was to compare diffusion-weighted imaging (DWI) with conventional MRI in the detection of shearing injuries in acute closed head injuries. Method: Twenty-five patients (19 male, 6 female) were examined within 48 h of trauma. Conventional MRI included T2-weighted fast spin echo, fluid-attenuated inversion recovery (FLAIR), and T2*-weighted gradient echo sequences. Full tensor DWI with calculation of apparent diffusion coefficient (ADC) maps was also performed. Lesions were identified and compared on all sequences. Results: Four hundred twenty-seven lesions were counted by the combined use of all sequences. DWI identified 70 lesions not seen on conventional MRI. DWI identified 310 shearing injuries, followed by T2/FLAIR (n = 248) and T2* (n = 202). The majority of DWI-positive lesions showed decreased diffusion (65%). Conclusion: DWI is valuable in closed head injury because it identifies additional shearing injuries not visible on T2/FLAIR or T2* sequences. Furthermore, DWI/ADC maps differentiate between lesions with decreased or increased diffusion. DWI is less sensitive than T2* imaging for detecting hemorrhagic lesions.	Harvard Univ, Sch Med, Charlestown, MA USA; MGH, Dept Radiol, Neuroradiol Sect, Charlestown, MA USA	Huisman, TAGM (corresponding author), MGH, NMR Ctr, Bldg 149,13th St,Mailcode 149-2301, Charlestown, MA USA.		Schaefer, Pamela/AAA-1323-2019				ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; CLIFTON GL, 1983, CLIN NEUROSCIENCES, V2, P1269; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; GEAN AD, 1994, IMAGING HEAD TRAUMA, P207; GENNARELLI TA, 1991, J EMERGENCY MED, V11, P5; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Gonzalez RG, 1999, RADIOLOGY, V210, P155, DOI 10.1148/radiology.210.1.r99ja02155; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Marmarou A, 2000, ACT NEUR S, V76, P349; Murray JG, 1996, SEMIN ULTRASOUND CT, V17, P185, DOI 10.1016/S0887-2171(96)90035-9; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Provenzale JM, 1999, AM J ROENTGENOL, V173, P1459, DOI 10.2214/ajr.173.6.10584783; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Sorensen AG, 1999, RADIOLOGY, V212, P785, DOI 10.1148/radiology.212.3.r99se24785; STRICH SJ, 1961, LANCET, V1, P2443; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	27	151	169	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0363-8715			J COMPUT ASSIST TOMO	J. Comput. Assist. Tomogr.	JAN-FEB	2003	27	1					5	11		10.1097/00004728-200301000-00002			7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	638FT	WOS:000180561500001	12544235				2021-06-18	
J	Mangeot, S; Armstrong, K; Colvin, AN; Yeates, KO; Taylor, HG				Mangeot, S; Armstrong, K; Colvin, AN; Yeates, KO; Taylor, HG			Long-term executive function deficits in children with traumatic brain injuries: Assessment using the Behavior Rating Inventory of Executive Function (BRIEF)	CHILD NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; NEUROBEHAVIORAL SYMPTOMS; RELIABILITY; CHILDHOOD; VALIDITY; RECOVERY; OUTCOMES	Long-term deficits in executive functions following childhood traumatic brain injuries (TBI) were examined using the Behavior Rating Inventory of Executive Function (BRIEF). Parents completed the BRIEF approximately 5 years postinjury as part of a prospective study of children injured between the ages of 6 and 12. The children were between 10 and 19 years of age at the time of the assessment, and included 33 with severe TBI, 31 with moderate TBI, and 34 with orthopedic injuries. Parents also rated children's adaptive functioning and completed several other measures of parent and family functioning. Children were administered a neuropsychological test battery that included several measures of executive functions. The groups displayed a significant linear trend in BRIEF scores, with the largest deficits in executive functions reported in children with severe TBI. BRIEF scores were related consistently across groups to a test of working memory, but not to other neuropsychological measures. BRIEF scores also predicted children's adaptive functioning and behavioral adjustment, as well as parent psychological distress, perceived family burden, and general family functioning. The findings indicate that TBI results in long-term deficits in executive functions that are related to children's psychosocial outcomes, as well as to parent and family functioning.	Childrens Hosp, Dept Psychol, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA	Yeates, KO (corresponding author), Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43205 USA.	yeates.1@osu.edu	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5 R01 NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ 390611] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Anderson P., 2000, CLIN NEUROPSYCHOL AS, V1, P247, DOI DOI 10.1076/chin.8.4.231.13509; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; BARKLEY RA, 1994, CLIN NEUROPSYCHOL, V8, P121, DOI 10.1080/13854049408401552; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bernstein JH., 1996, DEV SCORING SYSTEM R; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Carney N, 1999, REHABILITATION TRAUM; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P339, DOI 10.1080/01688639408402644; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Doyle AE, 2000, J CONSULT CLIN PSYCH, V68, P477, DOI [10.1037//0022-006X.68.3.477, 10.1037/0022-006X.68.3.477]; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1994, FRAMES REFERENCE ASS, P103; FRANCIS DJ, 1994, NEUROPSYCHOL REV, V4, P199, DOI 10.1007/BF01874892; Gioia G.A., 2000, BEHAV RATING INVENTO; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Paniak C, 1997, CLIN NEUROPSYCHOL, V11, P198, DOI 10.1080/13854049708407051; Pennington B. F., 1997, DEV PREFRONTAL CORTE, P265; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; ROURKE BP, 1977, J ABNORM CHILD PSYCH, V5, P9, DOI 10.1007/BF00915756; Sattler J. M., 1992, ASSESSMENT CHILDREN; SCHEIBEL RS, 1997, DEV PREFRONTAL CORTE, P241; SHAYWITZ SE, 1994, TOP LANG DISORD, V14, P1, DOI 10.1097/00011363-199408000-00003; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Sparrow S., 1984, VINELAND ADAPTIVE BE; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stancin T, 2001, J TRAUMA, V51, P69, DOI 10.1097/00005373-200107000-00011; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Stuss D.T., 1986, FRONTAL LOBES; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 1998, CHILD NEUROPSYCHOL, V4, P21, DOI 10.1076/chin.4.1.21.3188; Taylor HG, 1996, DEV NEUROPSYCHOL, V12, P35, DOI 10.1080/87565649609540639; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wechsler D., 1991, WECHSLER INTELLIGENC; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; YEATES KO, IN PRESS NEUROPSYCHO; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P303	50	151	152	1	21	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	DEC	2002	8	4					271	284		10.1076/chin.8.4.271.13503			14	Clinical Neurology	Neurosciences & Neurology	680QW	WOS:000182989700006	12759824				2021-06-18	
J	Matzilevich, DA; Rall, JM; Moore, AN; Grill, RJ; Dash, PK				Matzilevich, DA; Rall, JM; Moore, AN; Grill, RJ; Dash, PK			High-density microarray analysis of hippocampal gene expression following experimental brain injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						hippocampus; spatial memory; plasticity; genes; microarray; brain injury	LONG-TERM POTENTIATION; CONTROLLED CORTICAL IMPACT; NITRIC-OXIDE SYNTHASE; SPATIAL MEMORY DEFICITS; PROGRAMMED CELL-DEATH; RAT-BRAIN; MESSENGER-RNA; NEUROTROPHIC FACTOR; PROTEIN; NEURONS	Behavioral, biophysical, and pharmacological studies have implicated the hippocampus in the formation and storage of spatial memory. Traumatic brain injury (TBI) often causes spatial memory deficits, which are thought to arise from the death as well as the dysfunction of hippocampal neurons. Cell death and dysfunction are commonly associated with and often caused by altered expression of specific genes. The identification of the genes involved in these processes, as well as those participating in postinjury cellular repair and plasticity, is important for the development of mechanism-based therapies. To monitor the expression levels of a large number of genes and to identify genes not previously implicated in TBI pathophysiology, a high-density oligonucleotide array containing 8,800 genes was interrogated. RNA samples were prepared from ipsilateral hippocampi 3 hr and 24 hr following lateral cortical impact injury and compared to samples from sham-operated controls. Cluster analysis was employed using statistical algorithms to arrange the genes according to similarity in patterns of expression. The study indicates that the genomic response to TBI is complex, affecting approximately 6% (at the time points examined) of the total number of genes examined. The identity of the genes revealed that TBI affects many aspects of cell physiology, including oxidative stress, metabolism, inflammation, structural changes, and cellular signaling. The analysis revealed genes whose expression levels have been reported to be altered in response to injury as well as several genes not previously implicated in TBI pathophysiology. (C) 2002 Wiley-Liss, Inc.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Neurosurg, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, Vivian L Smith Ctr Neurol Res, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Rall, Jason/0000-0001-7538-2099	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS023327] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH49662] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS23327, NS3545] Funding Source: Medline		Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BAKI A, 1999, J NEUROPATHOL EXP NE, V58, P365; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; DASH PK, 1995, J NEUROSCI, V15, P2030; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dash PK, 2000, NEUROREPORT, V11, P2811, DOI 10.1097/00001756-200008210-00040; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DomanskaJanik K, 1996, ACTA NEUROBIOL EXP, V56, P579; DOUGLASS J, 1995, J NEUROSCI, V15, P2471; Fabian RH, 1998, J NEUROTRAUM, V15, P433, DOI 10.1089/neu.1998.15.433; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAN L, 1995, MOL BRAIN RES, V30, P125; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Fukunaga K, 1998, MOL NEUROBIOL, V16, P79, DOI 10.1007/BF02740604; Ghirnikar RS, 1996, J NEUROSCI RES, V46, P727; HALL ED, 1992, J NEUROTRAUM, V9, pS425; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jorgensen OS, 1997, EXP NEUROL, V144, P326, DOI 10.1006/exnr.1996.6372; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; Kato A, 1997, FEBS LETT, V412, P183, DOI 10.1016/S0014-5793(97)00775-8; KONOS HA, 1986, CENT NERV SYST TRAUM, V3, P257; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; LYETH BG, 1995, NEUROPEPTIDES, V29, P11, DOI 10.1016/0143-4179(95)90051-9; MCINTOSH TK, 1992, J CEREBR BLOOD F MET, V12, P697, DOI 10.1038/jcbfm.1992.95; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NEWLON PG, 1991, BRAIN RES, V544, P320, DOI 10.1016/0006-8993(91)90072-4; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Park DS, 2000, NEUROBIOL AGING, V21, P771, DOI 10.1016/S0197-4580(00)00220-7; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.0.CO;2-L; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Povlishock J T, 1992, Hum Cell, V5, P345; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; SUZUKI WA, 1993, J NEUROSCI, V13, P2430; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Tsui CC, 1996, J NEUROSCI, V16, P2463; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Waxham MN, 1996, J CEREBR BLOOD F MET, V16, P1, DOI 10.1097/00004647-199601000-00001; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Xu BJ, 2000, J NEUROSCI, V20, P6888, DOI 10.1523/JNEUROSCI.20-18-06888.2000; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484; ZOLAMORGAN S, 1990, ANN NY ACAD SCI, V608, P434, DOI 10.1111/j.1749-6632.1990.tb48905.x	82	151	157	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAR 1	2002	67	5					646	663		10.1002/jnr.10157			18	Neurosciences	Neurosciences & Neurology	527BV	WOS:000174166400010	11891777				2021-06-18	
J	Koskinen, S				Koskinen, S			Quality of life 10 years after a very severe traumatic brain injury (TBI): the perspective of the injured and the closest relative	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; FOLLOW-UP; FAMILY; RECOVERY; PATIENT; REHABILITATION; AWARENESS; SEQUELAE; DAMAGE; VIEW	This study is a further follow-up of a group of 15 very severely injured TBI patients who have earlier been followed-up 5 years after the injury, and their closest relatives. The aim of this study was to evaluate the factors related to the quality of life of the injured and the strain felt by the relatives. The information was gathered by questionnaires for the injured and the relative and clinical ratings based on the observations of a clinician. The self-reported quality of life of both the injured and their closest relatives was rather high in spite of the various physical, cognitive and emotional/behavioural disturbances. However, the strain felt by many of the relatives was still high 10 years after the injury although it had decreased over the years. The neurobehavioural and emotional disturbances had the most significant effect on the quality of life of the injured and strain felt by the relative. The relationship between the quality of life of the injured and strain felt by the relative was not linear. The implications of the findings for developing different forms of rehabilitation and support systems is discussed.	Natl Assoc Disabled Finland, Kapyla Rehabil Ctr, FIN-00610 Helsinki, Finland	Koskinen, S (corresponding author), Natl Assoc Disabled Finland, Kapyla Rehabil Ctr, Koskelantie 22, FIN-00610 Helsinki, Finland.						Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Bergquist TF, 1994, J HEAD TRAUMA REHAB, V9, P50, DOI 10.1097/00001199-199412000-00007; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS N, 1988, SCAND J REHABIL MED, P41; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROOKS N, 1993, INT S NEUR PERSP FUT, P13; CICHOWSKI K, 1992, RIC FAS, V3; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; Fleming JM, 1996, BRAIN INJURY, V10, P1; GOODGOLD J, 1988, REHABILITATION MED; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Leathem J, 1996, BRAIN INJURY, V10, P27; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; LINGE FR, 1997, INJURED BRAINS MED M, P324; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marsh NV, 1990, NEUROPSYCHOLOGY, V4, P13, DOI 10.1037/0894-4105.4.1.13; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCKINLAY WW, 1990, QUESTIONNAIRE RELATI; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Prigatano G. P., 1987, NEUROPSYCHOL REHABIL, P355; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P381; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RONTY H, 1988, ACTA U OULUENSIS D, P182; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VIITANEN M, 1988, SCAND J REHABIL MED, V20, P17; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643	44	151	152	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	1998	12	8					631	648		10.1080/026990598122205			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	108AN	WOS:000075243800001	9724835				2021-06-18	
J	BERGER, TD; TRINKAUS, E				BERGER, TD; TRINKAUS, E			PATTERNS OF TRAUMA AMONG THE NEANDERTALS	JOURNAL OF ARCHAEOLOGICAL SCIENCE			English	Article						NEANDERTALS; TRAUMA; STRESS; HUMAN PALEONTOLOGY	SEXUAL DIFFERENCES; LIBBEN SITE; KRAPINA; REMAINS; LEVANT; COUNTY; OHIO	A high frequency of traumatic lesions and post-traumatic degenerative changes have been noted in Neandertal skeletons. To asses the implications of the anatomical distribution of these lesions, we have assigned them to one of seven regions: head/neck, trunk, shoulder/arm, hand, pelvis, leg and foot. The resultant distributions, both including and deleting injuries indicated only by post-traumatic degenerations and from Shanidar 1, were compared to anatomical lesion distributions for three Recent human archaeological samples (Bt-5, Libben and a pooled Nubian one), three modern clinical samples (late 20th century Albuquerque, early 20th century London and late 19th century New York City), and a specialized athletic sample (North American Rodeo performers). The majority of the Neandertal samples (as adjusted) are highly significantly different from the six normal Recent human samples, with only the most trimmed Neandertal sample being non-significantly different from the New York sample. However, all of the Neandertal distributions provide a close match to the Rodeo traumatic lesion pattern, primarily as a result of a high incidence of head sr neck trauma. Although small sample size, preservation and a dearth of older individuals with inhibited mobility may contribute to the Neandertal lesion distribution, the similarity to the Rodeo lesion distribution suggests frequent close encounters with large ungulates unkindly disposed to the humans involved. (C) 1995 Academic Press Limited	UNIV BORDEAUX 1, ANTHROPOL LAB, CNRS, URA 376, F-33405 TALENCE, FRANCE	BERGER, TD (corresponding author), UNIV NEW MEXICO, DEPT ANTHROPOL, ALBUQUERQUE, NM 87131 USA.		Klein, Richard G/B-5910-2009				Andrews D., 1992, PRCA 10 YEAR INJURY; BARYOSEF O, 1994, INTERD CONT, P23; BELOVICH S, 1993, AM J PHYSICAL ANTH S, V16, P55; Beyries S., 1987, MAIN OUTIL MANCHES E, P55; Bonnet R., 1919, DILUVIALE MENSCHENFU, P11; Brain C. K., 1981, HUNTERS HUNTED INTRO; Brennan M.U., 1991, THESIS NEW YORK U NE; BRIDGES PS, 1994, AM J PHYS ANTHROPOL, V93, P83, DOI 10.1002/ajpa.1330930106; BRIDGES PS, 1992, ANNU REV ANTHROPOL, V21, P67; CHASE PG, 1986, BAR SERIES S, V286, P1; CHURCHILL SE, 1990, AM J PHYS ANTHROPOL, V83, P147, DOI 10.1002/ajpa.1330830203; CHURCHILL SE, 1993, HUNTING ANIMAL EXPLO, V4, P11; Churchill SE, 1994, THESIS U NEW MEXICO; Dastugue J., 1967, ANTHROPOLOGIE, V71, P479; DAWSON JE, 1995, AM J PHYSICAL ANTH S, V20, P81; Duday H., 1991, SQUELETTE MOUSTERIEN, P179; EVERITT BS, 1975, ANAL CONTINGENCY TAB; FARIZY C, 1994, GALLIA PREHISTOIRE S, V30, P1; FRAYER DW, 1985, ANNU REV ANTHROPOL, V14, P429, DOI 10.1146/annurev.an.14.100185.002241; GORJANOVICKRAMB.D, 1908, KORRESPONDENZBLATT D, V39, P108; HEIM JL, 1983, ANTHROPOLOGIE, V87, P5; Heim JL, 1982, ARCH I PALEONTOLOGIE, V38, P1; Hoffman M., 1979, EGYPT PHAROAHS; HUBLIN JJ, 1990, MEMOIRES MUSEE PREHI, V3, P29; Jacob-Friesen K. H., 1956, JB ROMISCH GERMANISC, V3, P1; JAMES TGH, 1979, INTRO ANCIENT EGYPT; Jelinek J, 1954, ANTHROPOZOIKUM, V3, P37; JURMAIN RD, 1980, AM J PHYS ANTHROPOL, V53, P143, DOI 10.1002/ajpa.1330530119; KOZOWSKI JK, 1990, HUMAN REVOLUTION BEH, P419; LIEBERMAN DE, 1993, CURR ANTHROPOL, V34, P599, DOI 10.1086/204209; LOVEJOY CO, 1977, SCIENCE, V198, P291, DOI 10.1126/science.198.4314.291; LOVEJOY CO, 1981, AM J PHYS ANTHROPOL, V55, P529, DOI 10.1002/ajpa.1330550414; MARKS A, 1983, BRIT ARCHAEOLOGICAL, V164, P13; Martin H, 1923, HOMME FOSSILE QUINA; McCown T. D., 1939, STONE AGE MOUNT CARM; MEHTA C, 1992, STATXACT TURBO 21; MELLARS P, 1989, HUMAN REVOLUTION, P338; *NM WORK COMP ADM, 1993, 1993 ANN REP; Oakley K., 1977, P PREHIST SOC, V43, P13; OGILVIE MD, 1989, AM J PHYS ANTHROPOL, V79, P25, DOI 10.1002/ajpa.1330790104; Radovcic J, 1988, KRAPINA HOMINIDS ILL; Rak Yoel, 1993, P523; SCHAAFFHAUSEN H, 1958, ARCH FUER ANATOMIE P, V25, P453; SCHWALBE G, 1901, BONNER JB, V106, P1; SHEA J, 1990, THESIS HARVARD U CAM; SHEA JJ, 1988, J FIELD ARCHAEOL, V15, P441, DOI 10.1179/jfa.1988.15.4.441; SMITH FH, 1980, J HUM EVOL, V9, P359, DOI 10.1016/0047-2484(80)90048-2; SMITH GE, 1910, ARCHAEOLOGICAL SURVE, V2; Steward T. D., 1979, 1 AM ORIGINS AFFINIT, P257; STINER MC, 1993, ANNU REV ANTHROPOL, V22, P55; STINER MC, 1992, CURR ANTHROPOL, V33, P433, DOI 10.1086/204095; Stiner MC, 1990, THESIS U NEW MEXICO; Trigger B. G., 1983, ANCIENT EGYPT SOCIAL; TRINKAUS E, 1980, J HUM EVOL, V9, P377, DOI 10.1016/0047-2484(80)90049-4; TRINKAUS E, 1985, J HUM EVOL, V14, P203, DOI 10.1016/S0047-2484(85)80007-5; TRINKAUS E, 1994, AM J PHYS ANTHROPOL, V93, P1, DOI 10.1002/ajpa.1330930102; TRINKAUS E, 1991, ANTHROPOLOGIE, V95, P535; TRINKAUS E, 1985, AM J PHYS ANTHROPOL, V67, P19, DOI 10.1002/ajpa.1330670105; TRINKAUS E, 1995, J ARCHAEOL SCI, V22, P121, DOI 10.1016/S0305-4403(95)80170-7; TRINKAUS E, 1995, MOUSTERIENS CHARENTI; Trinkaus E., 1983, SHANIDAR NEANDERTALS; Trinkaus E., 1992, EVOLUTION DISPERSAL, P277; Trinkaus E., 1993, CURR ANTHROPOL, V34, P620; VLCEK E, 1991, ARCHAOLOGIE MUSEUM, V22, P1; Vlcek E, 1969, NEANDERTALER TSCHECH; Volkman PW, 1983, BAR SERIES B, V164, P35; Weidenreich F., 1943, Palaeontologia Sinica, VD 10, P1; Weidenreich F., 1951, ANTHROPOL PAP AM MUS, V43, P201; WOOD JF, 1910, ARCHAEOLOGICAL SURVE, V2, P293	69	151	156	0	45	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0305-4403			J ARCHAEOL SCI	J. Archaeol. Sci.	NOV	1995	22	6					841	852		10.1016/0305-4403(95)90013-6			12	Anthropology; Archaeology; Geosciences, Multidisciplinary	Anthropology; Archaeology; Geology	TH673	WOS:A1995TH67300013					2021-06-18	
J	YAMAKAMI, I; MCINTOSH, TK				YAMAKAMI, I; MCINTOSH, TK			ALTERATIONS IN REGIONAL CEREBRAL BLOOD-FLOW FOLLOWING BRAIN INJURY IN THE RAT	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						BRAIN INJURY; CEREBRAL BLOOD FLOW; FLUID PERCUSSION; RADIOLABELED MICROSPHERE; RAT	FLUID-PERCUSSION MODEL; MISSILE HEAD-INJURY; OXYGEN-CONSUMPTION; ENERGY-METABOLISM; AUTO-REGULATION; DAMAGE; MICROSPHERES; OCCLUSION; ARTERY; CATS	To elucidate the temporal changes in regional cerebral blood flow (rCBF) after experimental traumatic brain injury, serial rCBF measurements were made during a 24-h period following fluid-percussion (F-P) traumatic brain injury in the rat. Brain injury of 2.2 atm was induced over the left parietal cortex and serial measurements of rCBF were performed using the radiolabeled microsphere method. rCBF values were obtained prior to injury and at 15 and 30 min and 1, 2, 4, and 24 h postinjury. At 15 min postinjury, there was a profound, wide-spread reduction in rCBF in all brain regions studied (p < 0.05). At 30 min and 1 h postinjury, all brain regions except pons-medulla and cerebellum showed significantly reduced rCBF compared to the preinjury values (p < 0.05). By 2 h postinjury, however, a significant focal reduction of rCBF was observed only in the cerebral tissue surrounding the trauma site (p < 0.05); rCBF in the remaining brain regions had recovered to the preinjury levels. By 4 h postinjury, rCBF had returned to normal in all brain regions studied. This recovery of rCBF was still evident at 24 h postinjury. The present study demonstrates that, following the experimental traumatic brain injury in the rat, (a) an initial global suppression of rCBF occurs up to 1 h postinjury; (b) at the trauma site, a more persistent focal reduction of rCBF occurs; and (c) these alterations in rCBF after trauma dissolve by 4 h postinjury. The result was discussed in the context of the neurological, electroencephalographic, magnetic resonance spectroscopic, and pathological findings observed in our lateral F-P brain injury rat model.	UNIV CONNECTICUT, CTR HLTH, DEPT SURG, SURG RES CTR, FARMINGTON, CT 06032 USA	YAMAKAMI, I (corresponding author), CHIBA UNIV, SCH MED, DEPT NEUROSURG, INOHANA 1-8-1, CHIBA 280, JAPAN.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 26818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R55NS026818, R01NS026818] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; BAER RW, 1984, AM J PHYSIOL, V246, pH418; BRANSTON NM, 1974, EXP NEUROL, V45, P195, DOI 10.1016/0014-4886(74)90112-5; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EGER EI, 1984, BRIT J ANAESTH, V56, pS71; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; Glantz S.A., 1987, PRIMER BIOSTATISTICS; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HEISS WD, 1976, ARCH NEUROL-CHICAGO, V33, P813, DOI 10.1001/archneur.1976.00500120017003; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; HEYMANN MA, 1977, PROG CARDIOVASC DIS, V20, P55, DOI 10.1016/S0033-0620(77)80005-4; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MALIK AB, 1976, J APPL PHYSIOL, V40, P472; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MICHENFE.JD, 1974, ANESTHESIOLOGY, V41, P231, DOI 10.1097/00000542-197409000-00004; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PIERCE EC, 1962, J CLIN INVEST, V41, P1664, DOI 10.1172/JCI104623; RUDOLPH AM, 1967, CIRC RES, V21, P163, DOI 10.1161/01.RES.21.2.163; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TODD MM, 1984, ANESTHESIOLOGY, V60, P276, DOI 10.1097/00000542-198404000-00002; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	34	151	151	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	1991	11	4					655	660		10.1038/jcbfm.1991.117			6	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	FT182	WOS:A1991FT18200016	2050753	Bronze			2021-06-18	
J	Kroshus, E; Garnett, B; Hawrilenko, M; Baugh, CM; Calzo, JP				Kroshus, Emily; Garnett, Bernice; Hawrilenko, Matt; Baugh, Christine M.; Calzo, Jerel P.			Concussion under-reporting and pressure from coaches, teammates, fans, and parents	SOCIAL SCIENCE & MEDICINE			English	Article						Injury; Sport; Concussion; Symptom reporting	HIGH-SCHOOL; SOCIAL SUPPORT; SPORT INJURY; COLLEGE; RETURN; RISK; EPIDEMIOLOGY; KNOWLEDGE; EDUCATION; PLAY	Concussions from sport present a substantial public health burden given the number of youth, adolescent and emerging adult athletes that participate in contact or collision sports. Athletes who fail to report symptoms of a suspected concussion and continue play are at risk of worsened symptomatology and potentially catastrophic neurologic consequences if another impact is sustained during this vulnerable period. Understanding why athletes do or do not report their symptoms is critical for developing efficacious strategies for risk reduction. Psychosocial theories and frameworks that explicitly incorporate context, as a source of expectations about the outcomes of reporting and as a source of behavioral reinforcement, are useful in framing this problem. The present study quantifies the pressure that athletes experience to continue playing after a head impact-from coaches, teammates, parents, and fans-and assesses how this pressure, both independently and as a system, is related to future concussion reporting intention. Participants in the study were 328 male and female athletes from 19 teams competing in one of seven sports (soccer, lacrosse, basketball, softball, baseball, volleyball, field hockey) at four colleges in the northeast region of the United States. Results found that more than one-quarter of the sample had experienced pressure from at least one source to continue playing after a head impact during the previous year. Results of a latent profile mixture model indicated that athletes who experienced pressure from all four of the measured sources were significantly more likely to intend to continue playing in the future than were athletes who had not experienced pressure from all sources, or only pressure from coaches and teammates. These findings underscore the importance of designing interventions that address the system in which athletes make decisions about concussion reporting, including athletes' parents, rather than focusing solely on modifying the individual's reporting cognitions. (C) 2015 Elsevier Ltd. All rights reserved.	[Kroshus, Emily] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA; [Kroshus, Emily] Natl Collegiate Athlet Assoc, Sport Sci Inst, Newport News, VA USA; [Kroshus, Emily; Baugh, Christine M.] Harvard Univ, Edmond J Safra Ctr Eth, Boston, MA 02115 USA; [Garnett, Bernice] Univ Vermont, Coll Educ & Social Serv, Dept Educ, Burlington, VT 05405 USA; [Hawrilenko, Matt] Clark Univ, Dept Clin Psychol, Worcester, MA 01610 USA; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Boston, MA 02115 USA; [Baugh, Christine M.] Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Calzo, Jerel P.] Boston Childrens Hosp, Div Adolescent & Young Adult Med, Boston, MA USA; [Calzo, Jerel P.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Kroshus, E (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington Ave, Boston, MA 02115 USA.	emk329@mail.harvard.edu; bgarnett@uvm.edu; mhawrilenko@clarku.edu; cbaugh@g.harvard.edu; jerel.calzo@childrens.harvard.edu	Meijer, Anna/K-5118-2016; Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Calzo, Jerel/0000-0002-4656-1052; Kroshus, Emily/0000-0002-7484-2601	National Institute of Mental Health of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [K01DA034753] Funding Source: NIH RePORTER	Christine M. Baugh was supported by the National Institute of Mental Health of the National Institutes of Health under Award Number T32MH019733. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Abgarov A., 2012, Journal of Intercollegiate Sport, V5, P213; Abrams D., 1990, EUR REV SOC PSYCHOL, V1, P195, DOI [10.1080/14792779108401862, DOI 10.1080/14792779108401862]; Ajzen I, 2011, BASIC APPL SOC PSYCH, V33, P101, DOI 10.1080/01973533.2011.568834; Anderson E, 2012, MEN MASC, V15, P152, DOI 10.1177/1097184X11430127; Asparouhov T, 2014, STRUCT EQU MODELING, V21, P329, DOI 10.1080/10705511.2014.915181; Bandura A, 2004, HEALTH EDUC BEHAV, V31, P143, DOI 10.1177/1090198104263660; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Baugh CM, 2014, J LAW MED ETHICS, V42, P297, DOI 10.1111/jlme.12147; Baugh CM, 2014, J LAW MED ETHICS, V42, P314, DOI 10.1111/jlme.12148; Bauman J, 2005, CLIN J SPORT MED, V15, P432, DOI 10.1097/01.jsm.0000186682.21040.82; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Bianco T, 2001, RES Q EXERCISE SPORT, V72, P376, DOI 10.1080/02701367.2001.10608974; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Brock S. C., 1994, QUAL HEALTH RES, V4, P411, DOI DOI 10.1177/104973239400400405; Caron J.G., 2013, BR J SPORTS MED, V47, pe1; Chrisman SP, 2014, AM J SPORT MED, V42, P1190, DOI 10.1177/0363546513519073; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Cialdini RB, 2004, ANNU REV PSYCHOL, V55, P591, DOI 10.1146/annurev.psych.55.090902.142015; Concussion in Sport Group, 2013, BRIT J SPORT MED, V47, P259; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; CURRY TJ, 1993, SYMB INTERACT, V16, P273, DOI 10.1525/si.1993.16.3.273; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Delaney JS, 2015, CLIN J SPORT MED, V25, P113, DOI 10.1097/JSM.0000000000000112; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Figner B, 2009, J EXP PSYCHOL LEARN, V35, P709, DOI 10.1037/a0014983; Graham R., 2014, SPORTS RELATED CONCU; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kerr Zachary Y, 2014, Inj Epidemiol, V1, P28; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Kroshus E, 2014, CLIN J SPORT MED; Kroshus E., 2015, ANN BEHAV MED; Kroshus E, 2015, ANN BEHAV MED, V49, P95, DOI 10.1007/s12160-014-9636-5; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Malinauskas R, 2008, J SPORT MED PHYS FIT, V48, P107; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Masyn K. E., 2013, OXFORD HDB QUANTITAT, P551, DOI [DOI 10.1093/0XF0RDHB/9780199934898.013.0025, 10.1093/oxfordhb/9780199934898.013.0025]; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGannon K.R., 2013, UNDERSTANDING CONCUS; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Meier TB, 2014, J SCI MED SPORT; Merriam S. B., 2001, NEW DIRECTIONS ADULT, V2001, P3, DOI 10.1002/ace.3; MEZIROW J, 1981, ADULT ED, V32, P3, DOI 10.1177/074171368103200101; Moreau M. S., 2014, INT J EXERCISE SCI, V7, P62; Muthen L.K., 1998, MPLUS USERS GUIDE, V8th; National Collegiate Athletic Association, 2014, DIV 1 STEER COMM GOV; National Collegiate Athletic Association, 2013, 198182201213 NCAA; National Federation of High School Sports, 2014, HIGH SCH SPORT PART; Niven A, 2007, J SPORT REHABIL, V16, P93, DOI 10.1123/jsr.16.2.93; Nixon H.L., 1996, J SPORT SOC ISSUES, V20, P33, DOI DOI 10.1177/019372396020001004; Nixon H. L., 1994, J SPORT SOC ISSUES, V18, P340, DOI DOI 10.1177/019372394018004004; Nixon H.L., 1992, J SPORT SOCIAL ISSUE, V16, P127, DOI [DOI 10.1177/019372359201600208, 10.1177/019372359201600208]; NIXON HL, 1993, SOCIOL SPORT J, V10, P183, DOI 10.1123/ssj.10.2.183; Podlog L, 2007, J APPL SPORT PSYCHOL, V19, P207, DOI 10.1080/10413200701188951; Podlog L, 2014, PHYS MED REH CLIN N, V25, P915, DOI 10.1016/j.pmr.2014.06.011; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Reyna VF, 2006, PSYCHOL SCI, P1, DOI 10.1111/j.1529-1006.2006.00026.x; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Roderick M., 2000, International Review for the Sociology of Sport, V35, P165, DOI 10.1177/101269000035002003; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Vermunt JK, 2010, POLIT ANAL, V18, P450, DOI 10.1093/pan/mpq025; Wilder D.A., 1986, ADV EXPT SOCIAL PSYC, V19, P291, DOI [10.1016/S0065-2601(08)60217-8, DOI 10.1016/S0065-2601(08)60217-8]; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Yang JZ, 2010, J ATHL TRAINING, V45, P372, DOI 10.4085/1062-6050-45.4.372; Young K., 1995, Journal of Sport and Social Issues, V19, P45, DOI 10.1177/019372395019001004; YOUNG K, 1994, SOCIOL SPORT J, V11, P175, DOI 10.1123/ssj.11.2.175	80	150	150	7	87	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0277-9536			SOC SCI MED	Soc. Sci. Med.	JUN	2015	134						66	75		10.1016/j.socscimed.2015.04.011			10	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Public, Environmental & Occupational Health; Biomedical Social Sciences	CJ3AY	WOS:000355357000008	25917137	Green Accepted	Y	N	2021-06-18	
J	Giuliani, D; Ottani, A; Zaffe, D; Galantucci, M; Strinati, F; Lodi, R; Guarini, S				Giuliani, Daniela; Ottani, Alessandra; Zaffe, Davide; Galantucci, Maria; Strinati, Flavio; Lodi, Renzo; Guarini, Salvatore			Hydrogen sulfide slows down progression of experimental Alzheimer's disease by targeting multiple pathophysiological mechanisms	NEUROBIOLOGY OF LEARNING AND MEMORY			English	Article						Alzheimer's disease; Pathophysiological pathways; Learning and memory; Hydrogen sulfide; Spa-waters; Neuroprotection	TRAUMATIC BRAIN-INJURY; NEURODEGENERATIVE DISEASES; CEREBRAL-ISCHEMIA; RAT MODEL; SYNAPTIC DYSFUNCTION; COGNITIVE DEFICITS; DELAYED TREATMENT; MOUSE MODEL; MELANOCORTINS; NEUROPROTECTION	It has been previously reported that brain hydrogen sulfide (H2S) synthesis is severely decreased in Alzheimer's disease (AD) patients, and plasma H2S levels are negatively correlated with the severity of AD. Here we extensively investigated whether treatment with a H2S donor and spa-waters rich in H2S induces neuroprotection and slows down progression of AD. Studies with sodium hydrosulfide (a H2S donor) and Tabiano's spa-water were carried out in three experimental models of AD. Short-term and long-term treatments with sodium hydrosulfide and/or Tabiano's spa-water significantly protected against impairment in learning and memory in rat models of AD induced by brain injection of beta-amyloid(1-40) (A beta) or streptozotocin, and in an AD mouse model harboring human transgenes APP(Swe), PS1(M146V) and tau(P301L) (3xTg-AD mice). The improvement in behavioral performance was associated with hippocampus was size of A beta plaques and preservation of the morphological picture, as found in AD rats. Further, lowered concentration/phosphorylation levels of proteins thought to be the central events in AD pathophysiology, namely amyloid precursor protein, presenilin-1, A beta(1-42) and tau phosphorylated at Thr181, Ser396 and Ser202, were detected in 3xTg-AD mice treated with spa-water. The excitotoxicity-triggered oxidative and nitrosative stress was counteracted in 3xTg-AD mice, as indicated by the decreased levels of malondialdehyde and nitrites in the cerebral cortex. Hippocampus reduced activity of c-jun N-terminal kinases, extracellular signal-regulated kinases and p38, which have an established role not only in phosphorylation of tau protein but also in inflammation and apoptosis, was also found. Consistently, decrease in tumor necrosis factor-alpha level, up-regulation of Bcl-2, and down-regulation of BAX and the downstream executioner caspase-3, also occurred in the hippocampus of 3xTg-AD mice after treatment with Tabiano's spa-water, thus suggesting that it is also able to modulate inflammation and apoptosis. Our findings indicate that appropriate treatments with H2S donors and Tabiano's spa-waters, and may be other spa-waters rich in H2S content, might represent an innovative approach to slow down AD progression in humans by targeting multiple pathophysiological mechanisms. (C) 2013 Elsevier Inc. All rights reserved.	[Giuliani, Daniela; Ottani, Alessandra; Galantucci, Maria; Guarini, Salvatore] Univ Modena & Reggio Emilia, Sect Pharmacol & Mol Med, Dept Biomed Metab & Neural Sci, I-41125 Modena, Italy; [Zaffe, Davide] Univ Modena & Reggio Emilia, Sect Human Morphol, Dept Biomed Metab & Neural Sci, I-41125 Modena, Italy; [Strinati, Flavio] Tabianos Spa, Tabiano, Italy; [Lodi, Renzo] Univ Modena & Reggio Emilia, Dept Gen Surg & Surg Specialties, I-41125 Modena, Italy	Giuliani, D (corresponding author), Univ Modena & Reggio Emilia, Sect Pharmacol & Mol Med, Dept Biomed Metab & Neural Sci, Via G Campi 287, I-41125 Modena, Italy.	daniela.giuliani@unimore.it; salvatore.guarini@unimore.it	Ottani, Alessandra/G-7316-2016; GUARINI, SALVATORE/O-3139-2013; Giuliani, Daniela/B-2968-2016; Zaffe, Davide/G-1181-2016	Ottani, Alessandra/0000-0002-1676-051X; GUARINI, SALVATORE/0000-0002-1164-1706; Giuliani, Daniela/0000-0001-6061-5662; Zaffe, Davide/0000-0003-1241-385X	Fondazione per la Ricerca Scientifica Termale, Roma, Italy	This work was supported by grants from Fondazione per la Ricerca Scientifica Termale, Roma, Italy.	Artusi G C, 1982, G Clin Med, V63, P482; Bagheri M, 2011, NEUROBIOL LEARN MEM, V95, P270, DOI 10.1016/j.nlm.2010.12.001; Beug ST, 2012, TRENDS IMMUNOL, V33, P535, DOI 10.1016/j.it.2012.06.004; Bitto A, 2012, CRIT CARE MED, V40, P945, DOI 10.1097/CCM.0b013e318236efde; Blennow K, 2010, NAT MED, V16, P1218, DOI 10.1038/nm.2221; Cole SL, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-22; Coruzzi G, 2010, PHARMACOLOGY, V85, P146, DOI 10.1159/000280603; Cotella D, 2012, J NEUROSCI, V32, P4133, DOI 10.1523/JNEUROSCI.6153-11.2012; Craig-Schapiro R, 2009, NEUROBIOL DIS, V35, P128, DOI 10.1016/j.nbd.2008.10.003; D'Amelio M, 2011, NAT NEUROSCI, V14, P69, DOI 10.1038/nn.2709; Erdelmeier I, 1998, CHEM RES TOXICOL, V11, P1184, DOI 10.1021/tx970180z; Eto K, 2002, BIOCHEM BIOPH RES CO, V293, P1485, DOI 10.1016/S0006-291X(02)00422-9; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Galimberti D., 2013, J NEUROLOGICAL SCI; Gao HM, 2012, TRENDS PHARMACOL SCI, V33, P295, DOI 10.1016/j.tips.2012.03.008; Giuliani D, 2006, ENDOCRINOLOGY, V147, P1126, DOI 10.1210/en.2005-0692; Giuliani D, 2007, EUR J PHARMACOL, V570, P57, DOI 10.1016/j.ejphar.2007.05.025; Giuliani D, 2012, FRONT NEUROENDOCRIN, V33, P179, DOI 10.1016/j.yfrne.2012.04.001; Giuliani D, 2011, ACTA NEUROPATHOL, V122, P443, DOI 10.1007/s00401-011-0873-4; Giuliani D, 2009, BRAIN BEHAV IMMUN, V23, P844, DOI 10.1016/j.bbi.2009.03.009; Glat MJ, 2013, STEM CELLS DEV, V22, P1490, DOI 10.1089/scd.2012.0633; Grunblatt E, 2004, J NEURAL TRANSM, V111, P367, DOI 10.1007/s00702-003-0030-x; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; Hanisch K, 2010, J PROTEOME RES, V9, P1476, DOI 10.1021/pr901002t; Iqbal K, 2011, ACTA NEUROPATHOL, V122, P543, DOI 10.1007/s00401-011-0878-z; Iqbal K, 2010, ALZHEIMERS DEMENT, V6, P420, DOI 10.1016/j.jalz.2010.04.006; Ittner LM, 2011, NAT REV NEUROSCI, V12, P67, DOI 10.1038/nrn2967; Kamoun P, 2004, AMINO ACIDS, V26, P243, DOI 10.1007/s00726-004-0072-x; Kida K, 2011, ANTIOXID REDOX SIGN, V15, P343, DOI 10.1089/ars.2010.3671; Kumar A, 2012, BRAIN RES, V1471, P13, DOI 10.1016/j.brainres.2012.06.050; Liu Xiang-qin, 2008, Zhonghua Yi Xue Za Zhi, V88, P2246; Lowicka E, 2007, PHARMACOL REP, V59, P4; Martelli A, 2012, MED RES REV, V32, P1093, DOI 10.1002/med.20234; Miguel-Hidalgo JJ, 2002, BRAIN RES, V958, P210, DOI 10.1016/S0006-8993(02)03731-9; Munoz L, 2010, NEUROPHARMACOLOGY, V58, P561, DOI 10.1016/j.neuropharm.2009.11.010; Nicholson CK, 2010, PHARMACOL RES, V62, P289, DOI 10.1016/j.phrs.2010.06.002; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Ottani A, 2009, J CEREBR BLOOD F MET, V29, P512, DOI 10.1038/jcbfm.2008.140; Salkovic-Petrisic M, 2011, J NEURAL TRANSM, V118, P765, DOI 10.1007/s00702-011-0651-4; Sanchez PE, 2012, P NATL ACAD SCI USA, V109, pE2895, DOI 10.1073/pnas.1121081109; Schioth HB, 2012, MOL NEUROBIOL, V46, P4, DOI 10.1007/s12035-011-8229-6; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Sperling RA, 2013, NAT REV NEUROL, V9, P54, DOI 10.1038/nrneurol.2012.241; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P917, DOI 10.1038/nrd2425; Tayeb HO, 2012, PHARMACOL THERAPEUT, V134, P8, DOI 10.1016/j.pharmthera.2011.12.002; Vale C, 2010, CELL MOL NEUROBIOL, V30, P577, DOI 10.1007/s10571-009-9482-3; Wang JM, 2010, P NATL ACAD SCI USA, V107, P6498, DOI 10.1073/pnas.1001422107; Wolfe MS, 2009, J BIOL CHEM, V284, P6021, DOI 10.1074/jbc.R800013200; Xuan AG, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-202; Yu Y, 2009, J NEUROCHEM, V108, P1480, DOI 10.1111/j.1471-4159.2009.05882.x; Zhang H, 2011, NEUROCHEM INT, V58, P169, DOI 10.1016/j.neuint.2010.11.010; Zipp F, 2006, TRENDS NEUROSCI, V29, P518, DOI 10.1016/j.tins.2006.07.006	52	150	160	4	47	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1074-7427	1095-9564		NEUROBIOL LEARN MEM	Neurobiol. Learn. Mem.	SEP	2013	104						82	91		10.1016/j.nlm.2013.05.006			10	Behavioral Sciences; Neurosciences; Psychology; Psychology, Multidisciplinary	Behavioral Sciences; Neurosciences & Neurology; Psychology	202BR	WOS:000323189000010	23726868				2021-06-18	
J	Kesler, S; Hosseini, SMH; Heckler, C; Janelsins, M; Palesh, O; Mustian, K; Morrow, G				Kesler, Shelli; Hosseini, S. M. Hadi; Heckler, Charles; Janelsins, Michelle; Palesh, Oxana; Mustian, Karen; Morrow, Gary			Cognitive Training for Improving Executive Function in Chemotherapy-Treated Breast Cancer Survivors	CLINICAL BREAST CANCER			English	Article						Chemotherapy; Cognitive flexibility; Memory; Processing speed; Rehabilitation	RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; OF-THE-LITERATURE; WORKING-MEMORY; ADJUVANT CHEMOTHERAPY; LONGITUDINAL ASSESSMENT; WHITE-MATTER; REHABILITATION; DYSFUNCTION; PERFORMANCE	Difficulties with thinking and problem solving are very common among breast cancer survivors. We tested a computerized cognitive training program for 41 breast cancer survivors. The training program was associated with significant improvements in thinking and problem-solving skills. Our findings demonstrate potential for our online, home-based cognitive training program to improve cognitive difficulties among breast cancer survivors. Background: A majority of breast cancer (BC) survivors, particularly those treated with chemotherapy, experience long-term cognitive deficits that significantly reduce quality of life. Among the cognitive domains most commonly affected include executive functions (EF), such as working memory, cognitive flexibility, multitasking, planning, and attention. Previous studies in other populations have shown that cognitive training, a behavioral method for treating cognitive deficits, can result in significant improvements in a number of cognitive skills, including EF. Materials and Methods: In this study, we conducted a randomized controlled trial to investigate the feasibility and preliminary effectiveness of a novel, online EF training program in long-term BC survivors. A total of 41 BC survivors (21 active, 20 wait list) completed the 48 session training program over 12 weeks. The participants were, on average, 6 years after therapy. Results: Cognitive training led to significant improvements in cognitive flexibility, verbal fluency and processing speed, with marginally significant downstream improvements in verbal memory as assessed via standardized measures. Self-ratings of EF skills, including planning, organizing, and task monitoring, also were improved in the active group compared with the wait list group. Conclusions: Our findings suggest that EF skills may be improved even in long-term survivors by using a computerized, home-based intervention program. These improvements may potentially include subjective EF skills, which suggest a transfer of the training program to real-world behaviors.	[Kesler, Shelli; Hosseini, S. M. Hadi; Palesh, Oxana] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; [Kesler, Shelli; Palesh, Oxana] Stanford Canc Inst, Palo Alto, CA USA; [Heckler, Charles; Janelsins, Michelle; Mustian, Karen; Morrow, Gary] Univ Rochester, Dept Radiat Oncol, Rochester, NY USA	Kesler, S (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, 401 Quarry Rd,MC5795, Stanford, CA 94305 USA.	skesler@stanford.edu	Hosseini, Hadi/AAF-7095-2020		National Institutes of Health New Innovator AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1DP2 OD004445-01]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [K07CA168886] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DP2OD004445] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes of Health New Innovator Award (1DP2 OD004445-01) (S.K.). We thank Della Koovakkattu and Mika Pritchard-Berman for their assistance with project coordination and data management.	Aghakhani A., 2007, J PSYCHOEDUC ASSESSM, V2007 25, P416; Ahles TA, 2010, J CLIN ONCOL, V28, P4434, DOI 10.1200/JCO.2009.27.0827; American Cancer Society, 2010, AC CANC FACTS FIG; Boykoff N, 2009, J CANCER SURVIV, V3, P223, DOI 10.1007/s11764-009-0098-x; Bruno J, 2012, NEUROBIOL DIS, V48, P329, DOI 10.1016/j.nbd.2012.07.009; Buschkuehl M, 2008, PSYCHOL AGING, V23, P743, DOI 10.1037/a0014342; Castellon SA, 2004, J CLIN EXP NEUROPSYC, V26, P955, DOI 10.1080/13803390490510905; Castellon S, 2009, BREAST CANCER RES TR, V116, P125, DOI 10.1007/s10549-008-0211-2; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Correa DD, 2008, CANCER J, V14, P396, DOI 10.1097/PPO.0b013e31818d8769; Crouch Z, 2009, AM J HEALTH-SYST PH, V66, P1180, DOI 10.2146/ajhp080214; de Ruiter MB, 2011, HUM BRAIN MAPP, V32, P1206, DOI 10.1002/hbm.21102; Deprez S, 2012, J CLIN ONCOL, V30, P274, DOI 10.1200/JCO.2011.36.8571; Dunkin JJ, 2000, J AFFECT DISORDERS, V60, P13, DOI 10.1016/S0165-0327(99)00157-3; Fan HGM, 2008, SUPPORT CARE CANCER, V16, P577, DOI 10.1007/s00520-007-0341-9; Ferguson RJ, 2012, PSYCHO-ONCOLOGY, V21, P176, DOI 10.1002/pon.1878; Fisher M, 2010, SCHIZOPHRENIA BULL, V36, P869, DOI 10.1093/schbul/sbn170; Green CS, 2008, PSYCHOL AGING, V23, P692, DOI 10.1037/a0014345; Hanna-Pladdy B, 2007, J Neurol Phys Ther, V31, P119; Homack S, 2005, J CLIN EXP NEUROPSYC, V27, P599, DOI 10.1080/13803390490918444; Hong D, 2009, DEV DISABIL RES REV, V15, P270, DOI 10.1002/ddrr.79; Hosseini SMH, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-28; Inagaki M, 2007, CANCER, V109, P146, DOI 10.1002/cncr.22368; Jaeggi SM, 2008, P NATL ACAD SCI USA, V105, P6829, DOI 10.1073/pnas.0801268105; Jean L, 2010, AM J GERIAT PSYCHIAT, V18, P281, DOI 10.1097/JGP.0b013e3181c37ce9; Jolles DD, 2010, NEUROIMAGE, V52, P658, DOI 10.1016/j.neuroimage.2010.04.028; Kesler S, 2013, BRAIN BEHAV IMMUN, V30, pS109, DOI 10.1016/j.bbi.2012.05.017; Kesler SR, 2011, ARCH NEUROL-CHICAGO, V68, P1447, DOI 10.1001/archneurol.2011.245; Kesler SR, 2011, BRAIN INJURY, V25, P101, DOI 10.3109/02699052.2010.536194; Klingberg T, 2010, TRENDS COGN SCI, V14, P317, DOI 10.1016/j.tics.2010.05.002; Klusmann V, 2010, J GERONTOL A-BIOL, V65, P680, DOI 10.1093/gerona/glq053; Koppelmans V, 2012, BREAST CANCER RES TR, V132, P1099, DOI 10.1007/s10549-011-1888-1; Kurz A, 2009, INT J GERIATR PSYCH, V24, P163, DOI 10.1002/gps.2086; Li SC, 2008, PSYCHOL AGING, V23, P731, DOI 10.1037/a0014343; Lie CH, 2006, NEUROIMAGE, V30, P1038, DOI 10.1016/j.neuroimage.2005.10.031; McDonald BC, 2013, BRAIN BEHAV IMMUN, V30, pS117, DOI 10.1016/j.bbi.2012.05.007; McDonald BC, 2010, BREAST CANCER RES TR, V123, P819, DOI 10.1007/s10549-010-1088-4; Morris Jeri, 2007, Phys Med Rehabil Clin N Am, V18, P27, DOI 10.1016/j.pmr.2006.11.003; Mowszowski L, 2010, INT PSYCHOGERIATR, V22, P537, DOI 10.1017/S1041610209991748; Mozolic JL, 2011, NEUROBIOL AGING, V32, P655, DOI 10.1016/j.neurobiolaging.2009.04.013; Mozolic JL, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/neuro.09.016.2010; Norman G, 2009, MED TEACH, V31, P807, DOI 10.1080/01421590903049814; Nyhus E, 2009, BRAIN COGNITION, V71, P437, DOI 10.1016/j.bandc.2009.03.005; Ouimet LA, 2009, J CLIN EXP NEUROPSYC, V31, P73, DOI 10.1080/13803390801992725; Ownsworth T, 2010, WORK, V36, P381, DOI 10.3233/WOR-2010-1041; Poppelreuter M, 2009, J PSYCHOSOC ONCOL, V27, P274, DOI 10.1080/07347330902776044; Roth R.M., 2005, BEHAV RATING INVENTO; Rozzini L, 2007, INT J GERIATR PSYCH, V22, P356, DOI 10.1002/gps.1681; Salminen T, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00166; Schmiedek F, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00027; Serino A, 2006, BRAIN COGNITION, V60, P213; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Sohlberg MM., 2011, OPTIMIZING COGNITIVE; Stewart A, 2008, PSYCHO-ONCOLOGY, V17, P122, DOI 10.1002/pon.1210; Stilley CS, 2010, HEALTH PSYCHOL, V29, P50, DOI 10.1037/a0016940; Strangman GE, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00182; Takeuchi H, 2010, J NEUROSCI, V30, P3297, DOI 10.1523/JNEUROSCI.4611-09.2010; Tarter RE, 2004, DRUG ALCOHOL DEPEN, V76, pS45, DOI 10.1016/j.drugalcdep.2004.08.006; Thorell LB, 2009, DEVELOPMENTAL SCI, V12, P106, DOI 10.1111/j.1467-7687.2008.00745.x; Vardy J, 2009, CANCER TREAT RES, P387, DOI 10.1007/978-0-387-75115-3_24; Von Ah D, 2012, BREAST CANCER RES TR, V135, P799, DOI 10.1007/s10549-012-2210-6; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wefel JS, 2012, CURR NEUROL NEUROSCI, V12, P267, DOI 10.1007/s11910-012-0264-9; Wefel JS, 2010, CANCER-AM CANCER SOC, V116, P3348, DOI 10.1002/cncr.25098; Willis SL, 2006, JAMA-J AM MED ASSOC, V296, P2805, DOI 10.1001/jama.296.23.2805; Wolf TJ, 2010, WORK, V36, P371, DOI 10.3233/WOR-2010-1038; Wolinsky FD, 2006, J GERONTOL A-BIOL, V61, P1324, DOI 10.1093/gerona/61.12.1324; Woods SP, 2007, BRAIN LANG, V102, P46, DOI 10.1016/j.bandl.2006.11.005; Yamada TH, 2010, J NEUROPSYCH CLIN N, V22, P48, DOI 10.1176/appi.neuropsych.22.1.48; Zelinski EM, 2011, J AM GERIATR SOC, V59, P258, DOI 10.1111/j.1532-5415.2010.03277.x	70	150	154	0	44	CIG MEDIA GROUP, LP	DALLAS	3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA	1526-8209	1938-0666		CLIN BREAST CANCER	Clin. Breast Cancer	AUG	2013	13	4					299	306		10.1016/j.clbc.2013.02.004			8	Oncology	Oncology	175OI	WOS:000321239600011	23647804	Green Accepted			2021-06-18	
J	Andriessen, TMJC; Horn, J; Franschman, G; van der Naalt, J; Haitsma, I; Jacobs, B; Steyerberg, EW; Vos, PE				Andriessen, Teuntje M. J. C.; Horn, Janneke; Franschman, Gaby; van der Naalt, Joukje; Haitsma, Iain; Jacobs, Bram; Steyerberg, Ewout W.; Vos, Pieter E.			Epidemiology, Severity Classification, and Outcome of Moderate and Severe Traumatic Brain Injury: A Prospective Multicenter Study	JOURNAL OF NEUROTRAUMA			English	Article						epidemiology; mortality; multicenter study; outcome; TBI	GLASGOW COMA SCALE; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; COMPUTED-TOMOGRAPHY; PREDICTIVE-VALUE; INTENSIVE-CARE; DATA-BANK; MANAGEMENT; GUIDELINES; MORTALITY	Changes in the demographics, approach, and treatment of traumatic brain injury (TBI) patients require regular evaluation of epidemiological profiles, injury severity classification, and outcomes. This prospective multicenter study provides detailed information on TBI-related variables of 508 moderate-to-severe TBI patients. Variability in epidemiology and outcome is examined by comparing our cohort with previous multicenter studies. Additionally, the relation between outcome and injury severity classification assessed at different time points is studied. Based on the emergency department Glasgow Coma Scale (GCS), 339 patients were classified as having severe and 129 as having moderate TBI. In 15%, the diagnosis differed when the accident scene GCS was used for classification. In-hospital mortality was higher if severe TBI was diagnosed at both time points (44%) compared to moderate TBI at one or both time points (7-15%, p < 0.001). Furthermore, 14% changed diagnosis when a threshold (6 h) for impaired consciousness was used as a criterion for severe TBI: In-hospital mortality was < 5% when impaired consciousness lasted for < 6 h. This suggests that combining multiple clinical assessments and using a threshold for impaired consciousness may improve the classification of injury severity and prediction of outcome. Compared to earlier multicenter studies, our cohort demonstrates a different case mix that includes a higher age (mean = 47.3 years), more diffuse (Traumatic Coma Databank [TCDB] I-II) injuries (58%), and more major extracranial injuries (40%), with relatively high 6 month mortality rates for both severe (46%) and moderate (21%) TBI. Our results confirm that TBI epidemiology and injury patterns have changed in recent years whereas case fatality rates remain high.	[Andriessen, Teuntje M. J. C.; Vos, Pieter E.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; [Horn, Janneke] Univ Amsterdam, Acad Med Ctr, Dept Intens Care Med, NL-1105 AZ Amsterdam, Netherlands; [Franschman, Gaby] Vrije Univ Amsterdam Med Ctr, Dept Anesthesiol, Amsterdam, Netherlands; [van der Naalt, Joukje; Jacobs, Bram] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 AV Groningen, Netherlands; [Haitsma, Iain] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; [Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands	Vos, PE (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Neurol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	P.Vos@neuro.umcn.nl	Vos, Pieter/A-6043-2012; Steyerberg, Ewout/C-1509-2018	Steyerberg, Ewout/0000-0002-7787-0122	Dutch Brain Foundation [Hersenstichting - HSN-07-01]	The POCON study is funded by the Dutch Brain Foundation (Hersenstichting - HSN-07-01). The authors express their gratitude to Dick Drost, Annemiek Coers, Annelou van der Veen, Joshua Field, Vivian de Ruijter, and Heleen Biersteker for their help with data collection. Amon Heijne is thanked for his help with development and maintenance of the POCON database.	American College of Surgeons Committee on Trauma, 2008, ATLS ADV TRAUM LIF S; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Compagnone C, 2009, NEUROSURGERY, V64, P690, DOI 10.1227/01.NEU.0000340796.18738.F7; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Edwards P, 2005, LANCET, V365, P1957; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Ho KM, 2010, CRIT CARE MED, V38, P1562, DOI 10.1097/CCM.0b013e3181e2ccd8; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jacobs B, 2010, J NEUROTRAUM, V27, P331, DOI 10.1089/neu.2009.1105; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Leitgeb J, 2007, WIEN KLIN WOCHENSCHR, V119, P56, DOI 10.1007/s00508-006-0764-1; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mauritz W, 2008, EUR J PUBLIC HEALTH, V18, P575, DOI 10.1093/eurpub/ckn079; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nijboer JMM, 2007, J TRAUMA, V63, P670, DOI 10.1097/01.ta.0000228890.65522.53; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Rosso A, 2007, WIEN KLIN WOCHENSCHR, V119, P29, DOI 10.1007/s00508-006-0761-4; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Salim A, 2008, AM SURGEON, V74, P1088; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; WINKLER J V, 1984, Journal of Emergency Medicine, V2, P1, DOI 10.1016/0736-4679(84)90038-6; Zuercher M, 2009, BRAIN INJURY, V23, P371, DOI 10.1080/02699050902926267	51	150	158	0	21	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2019	2031		10.1089/neu.2011.2034			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500003	21787177				2021-06-18	
J	Donnelly, DJ; Longbrake, EE; Shawler, TM; Kigerl, KA; Lai, WM; Tovar, CA; Ransohoff, RM; Popovich, PG				Donnelly, Dustin J.; Longbrake, Erin E.; Shawler, Todd M.; Kigerl, Kristina A.; Lai, Wenmin; Tovar, C. Amy; Ransohoff, Richard M.; Popovich, Phillip G.			Deficient CX3CR1 Signaling Promotes Recovery after Mouse Spinal Cord Injury by Limiting the Recruitment and Activation of Ly6C(lo)/iNOS(+) Macrophages	JOURNAL OF NEUROSCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FRACTALKINE RECEPTOR CX(3)CR1; SKELETAL-MUSCLE INJURY; INFLAMMATORY RESPONSE; MICROGLIAL ACTIVATION; CEREBRAL-ISCHEMIA; MONOCYTE SUBSETS; BRAIN-DAMAGE; MICE	Macrophages exert divergent effects in the injured CNS, causing either neurotoxicity or regeneration. The mechanisms regulating these divergent functions are not understood but can be attributed to the recruitment of distinct macrophage subsets and the activation of specific intracellular signaling pathways. Here, we show that impaired signaling via the chemokine receptor CX3CR1 promotes recovery after traumatic spinal cord injury (SCI) in mice. Deficient CX3CR1 signaling in intraspinal microglia and monocyte-derived macrophages (MDMs) attenuates their ability to synthesize and release inflammatory cytokines and oxidative metabolites. Also, impaired CX3CR1 signaling abrogates the recruitment or maturation of MDMs with presumed neurotoxic effects after SCI. Indeed, in wild-type mice, Ly6C(lo)/iNOS(+)/MHCII+/CD11c(-) MDMs dominate the lesion site, whereas CCR2(+)/Ly6C(hi)/MHCII-/CD11c(+) monocytes predominate in the injured spinal cord of CX3CR1-deficient mice. Replacement of wild-type MDMs with those unable to signal via CX3CR1 resulted in anatomical and functional improvements after SCI. Thus, blockade of CX3CR1 signaling represents a selective anti-inflammatory therapy that is able to promote neuroprotection, in part by reducing inflammatory signaling in microglia and MDMs and recruitment of a novel monocyte subset.	[Donnelly, Dustin J.; Longbrake, Erin E.; Kigerl, Kristina A.; Lai, Wenmin; Tovar, C. Amy; Popovich, Phillip G.] Ohio State Univ, Ctr Brain & Spinal Cord Repair, Columbus, OH 43210 USA; [Donnelly, Dustin J.; Longbrake, Erin E.; Popovich, Phillip G.] Ohio State Univ, Integrated Biomed Sci Grad Program, Columbus, OH 43210 USA; [Donnelly, Dustin J.; Longbrake, Erin E.; Popovich, Phillip G.] Ohio State Univ, Med Scientist Program, Columbus, OH 43210 USA; [Shawler, Todd M.; Popovich, Phillip G.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Kigerl, Kristina A.; Lai, Wenmin; Tovar, C. Amy; Popovich, Phillip G.] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; [Ransohoff, Richard M.] Cleveland Clin, Lerner Res Inst, Dept Neurosci, Neuroinflammat Res Ctr, Cleveland, OH 44195 USA	Popovich, PG (corresponding author), 786 Biomed Res Tower,460 W 12th Ave, Columbus, OH 43210 USA.	phillip.popovich@osumc.edu		Kigerl, Kristina/0000-0002-1652-0882; Longbrake, Erin/0000-0002-1179-3937	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH R01 NS37846, NIH F31 NS064725, P30-NS045758]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045758, R01NS047175, R01NS037846, F31NS064725] Funding Source: NIH RePORTER	This work was funded by grants from the National Institutes of Health: NIH R01 NS37846 (P.G.P.), NIH F31 NS064725 (D.J.D.), and P30-NS045758. We thank Zhen Guan, Ming Wang, Ping Wei, Violeta McGaughy, and Pat Walters for technical assistance.	Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Ancuta P, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-403; Ancuta P, 2006, J LEUKOCYTE BIOL, V80, P1156, DOI 10.1189/jlb.0206125; Apostolakis S, 2009, ATHEROSCLEROSIS, V207, P8, DOI 10.1016/j.atherosclerosis.2009.03.044; Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075; Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557; Austin PJ, 2010, J NEUROIMMUNOL, V229, P26, DOI 10.1016/j.jneuroim.2010.08.013; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Beg AA, 2002, TRENDS IMMUNOL, V23, P509, DOI 10.1016/S1471-4906(02)02317-7; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Boddeke EWGH, 1999, EUR J PHARMACOL, V374, P309, DOI 10.1016/S0014-2999(99)00307-6; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Chapman GA, 2000, J NEUROSCI, V20; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Combadiere C, 2008, CIRCULATION, V117, P1649, DOI 10.1161/CIRCULATIONAHA.107.745091; Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692; Davis CN, 2004, MOL PHARMACOL, V66, P1431, DOI 10.1124/mol.104.003277; Denes A, 2008, J CEREBR BLOOD F MET, V28, P1707, DOI 10.1038/jcbfm.2008.64; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Dorgham K, 2009, J LEUKOCYTE BIOL, V86, P903, DOI 10.1189/jlb.0308158; Fraticelli P, 2001, J CLIN INVEST, V107, P1173, DOI 10.1172/JCI11517; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Gaupp S, 2003, AM J PATHOL, V162, P139, DOI 10.1016/S0002-9440(10)63805-9; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Genovese T, 2006, J NEUROSURG-SPINE, V4, P145, DOI 10.3171/spi.2006.4.2.145; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Gris P, 2009, J NEUROIMMUNOL, V209, P104, DOI 10.1016/j.jneuroim.2009.02.002; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HOWARD CV, 1998, UNBIASED STEREOLOGY; Huang D, 2006, FASEB J, V20, P896, DOI 10.1096/fj.05-5465com; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Inoue A, 2005, ARTHRITIS RHEUM-US, V52, P1522, DOI 10.1002/art.21007; Isaksson J, 2005, SPINAL CORD, V43, P167, DOI 10.1038/sj.sc.3101672; Ishida Y, 2008, J IMMUNOL, V181, P4208, DOI 10.4049/jimmunol.181.6.4208; Jakeman LB, 2000, J NEUROTRAUM, V17, P299, DOI 10.1089/neu.2000.17.299; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; King IL, 2009, BLOOD, V113, P3190, DOI 10.1182/blood-2008-07-168575; Kostadinova FI, 2010, J LEUKOCYTE BIOL, V88, P133, DOI 10.1189/jlb.1109768; Le WD, 2001, J NEUROSCI, V21, P8447; Lee MY, 2009, J NEUROSCI RES, V87, P937, DOI 10.1002/jnr.21901; Lesnik P, 2003, J CLIN INVEST, V111, P333, DOI 10.1172/JCI200315555; Lin SL, 2009, J IMMUNOL, V183, P6733, DOI 10.4049/jimmunol.0901473; Longbrake EE, 2007, J NEUROCHEM, V102, P1083, DOI 10.1111/j.1471-4159.2007.04617.x; Lu HY, 2011, FASEB J, V25, P358, DOI 10.1096/fj.10-171579; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Mildner A, 2009, BRAIN, V132, P2487, DOI 10.1093/brain/awp144; Mizuno T, 2003, BRAIN RES, V979, P65, DOI 10.1016/S0006-8993(03)02867-1; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Nanki T, 2004, J IMMUNOL, V173, P7010, DOI 10.4049/jimmunol.173.11.7010; Oh DJ, 2008, AM J PHYSIOL-RENAL, V294, pF264, DOI 10.1152/ajprenal.00204.2007; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Pachot A, 2008, J IMMUNOL, V180, P6421, DOI 10.4049/jimmunol.180.9.6421; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Popovich PG, 2001, J NEUROPATH EXP NEUR, V60, P676, DOI 10.1093/jnen/60.7.676; Popovich P, 2009, NAT MED, V15, P736, DOI 10.1038/nm0709-736; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Robbins CS, 2010, CELL MOL LIFE SCI, V67, P2685, DOI 10.1007/s00018-010-0375-x; Rodero M, 2008, J CLIN ONCOL, V26, P5957, DOI 10.1200/JCO.2008.17.2833; Saiwai H, 2010, AM J PATHOL, V176, P2352, DOI 10.2353/ajpath.2010.090839; Sakurai T, 1997, EUR J PHARMACOL, V334, P255, DOI 10.1016/S0014-2999(97)01191-6; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Soriano SG, 2002, J NEUROIMMUNOL, V125, P59, DOI 10.1016/S0165-5728(02)00033-4; Stirling DP, 2008, J NEUROSCI RES, V86, P1944, DOI 10.1002/jnr.21659; Streit Wolfgang J., 2005, Current Alzheimer Research, V2, P187, DOI 10.2174/1567205053585765; Sunderkotter C, 2004, J IMMUNOL, V172, P4410, DOI 10.4049/jimmunol.172.7.4410; Sunnemark D, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-17; Tarozzo G, 2002, EUR J NEUROSCI, V15, P1663, DOI 10.1046/j.1460-9568.2002.02007.x; Urra X, 2009, J CEREBR BLOOD F MET, V29, P994, DOI 10.1038/jcbfm.2009.25; Yang QW, 2008, J CEREBR BLOOD F MET, V28, P1588, DOI 10.1038/jcbfm.2008.50; Zhu B, 2007, J IMMUNOL, V179, P5228, DOI 10.4049/jimmunol.179.8.5228; Zujovic V, 2000, GLIA, V29, P305, DOI 10.1002/(SICI)1098-1136(20000215)29:4<305::AID-GLIA2>3.0.CO;2-V	78	150	151	0	14	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 6	2011	31	27					9910	9922		10.1523/JNEUROSCI.2114-11.2011			13	Neurosciences	Neurosciences & Neurology	789OE	WOS:000292524400015	21734283	Bronze, Green Accepted, Green Published			2021-06-18	
J	Bulger, EM; May, S; Brasel, KJ; Schreiber, M; Kerby, JD; Tisherman, SA; Newgard, C; Slutsky, A; Coimbra, R; Emerson, S; Minei, JP; Bardarson, B; Kudenchuk, P; Baker, A; Christenson, J; Idris, A; Davis, D; Fabian, TC; Aufderheide, TP; Callaway, C; Williams, C; Banek, J; Vaillancourt, C; van Heest, R; Sopko, G; Hata, JS; Hoyt, DB				Bulger, Eileen M.; May, Susanne; Brasel, Karen J.; Schreiber, Martin; Kerby, Jeffrey D.; Tisherman, Samuel A.; Newgard, Craig; Slutsky, Arthur; Coimbra, Raul; Emerson, Scott; Minei, Joseph P.; Bardarson, Berit; Kudenchuk, Peter; Baker, Andrew; Christenson, Jim; Idris, Ahamed; Davis, Daniel; Fabian, Timothy C.; Aufderheide, Tom P.; Callaway, Clifton; Williams, Carolyn; Banek, Jane; Vaillancourt, Christian; van Heest, Rardi; Sopko, George; Hata, J. Steven; Hoyt, David B.		ROC Investigators	Out-of-Hospital Hypertonic Resuscitation Following Severe Traumatic Brain Injury A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLASGOW OUTCOME SCALE; RAPID-SEQUENCE INTUBATION; DISABILITY RATING-SCALE; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; SALINE RESUSCITATION; CONSENSUS CONFERENCE; PROSTAGLANDIN E(2); SEPSIS; SCORE	Context Hypertonic fluids restore cerebral perfusion with reduced cerebral edema and modulate inflammatory response to reduce subsequent neuronal injury and thus have potential benefit in resuscitation of patients with traumatic brain injury (TBI). Objective To determine whether out-of-hospital administration of hypertonic fluids improves neurologic outcome following severe TBI. Design, Setting, and Participants Multicenter, double-blind, randomized, placebo-controlled clinical trial involving 114 North American emergency medical services agencies within the Resuscitation Outcomes Consortium, conducted between May 2006 and May 2009 among patients 15 years or older with blunt trauma and a prehospital Glasgow Coma Scale score of 8 or less who did not meet criteria for hypovolemic shock. Planned enrollment was 2122 patients. Intervention A single 250-mL bolus of 7.5% saline/6% dextran 70 (hypertonic saline/dextran), 7.5% saline (hypertonic saline), or 0.9% saline (normal saline) initiated in the out-of-hospital setting. Main Outcome Measure Six-month neurologic outcome based on the Extended Glasgow Outcome Scale (GOSE) (dichotomized as >4 or <= 4). Results The study was terminated by the data and safety monitoring board after randomization of 1331 patients, having met prespecified futility criteria. Among the 1282 patients enrolled, 6-month outcomes data were available for 1087 (85%). Baseline characteristics of the groups were equivalent. There was no difference in 6-month neurologic outcome among groups with regard to proportions of patients with severe TBI (GOSE <= 4) (hypertonic saline/dextran vs normal saline: 53.7% vs 51.5%; difference, 2.2% [95% CI, -4.5% to 9.0%]; hypertonic saline vs normal saline: 54.3% vs 51.5%; difference, 2.9% [95% CI, -4.0% to 9.7%]; P=.67). There were no statistically significant differences in distribution of GOSE category or Disability Rating Score by treatment group. Survival at 28 days was 74.3% with hypertonic saline/dextran, 75.7% with hypertonic saline, and 75.1% with normal saline (P=.88). Conclusion Among patients with severe TBI not in hypovolemic shock, initial resuscitation with either hypertonic saline or hypertonic saline/dextran, compared with normal saline, did not result in superior 6-month neurologic outcome or survival.	[Bulger, Eileen M.] Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; [May, Susanne; Emerson, Scott] Univ Washington, Dept Biostat, Seattle, WA 98104 USA; [Kudenchuk, Peter] Univ Washington, Dept Med, Seattle, WA 98104 USA; [Bardarson, Berit] Univ Washington, Clin Trials Ctr, Seattle, WA 98104 USA; [Brasel, Karen J.] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA; [Aufderheide, Tom P.] Med Coll Wisconsin, Dept Emergency Med, Milwaukee, WI 53226 USA; [Schreiber, Martin] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA; [Newgard, Craig] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA; [Newgard, Craig] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA; [Kerby, Jeffrey D.; Williams, Carolyn] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA; [Tisherman, Samuel A.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [Callaway, Clifton] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA; [Slutsky, Arthur] Univ Toronto, Dept Med, Toronto, ON, Canada; [Baker, Andrew] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Baker, Andrew] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; [Coimbra, Raul] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; [Davis, Daniel] Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; [Minei, Joseph P.; Idris, Ahamed] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Christenson, Jim] Emergency & Hlth Serv Commiss, Vancouver, BC, Canada; [Fabian, Timothy C.] Univ Tennessee, Dept Surg, Memphis, TN USA; [Banek, Jane; Vaillancourt, Christian] Ottawa Res Inst, Dept Emergency Med, Ottawa, ON, Canada; [van Heest, Rardi] Royal Columbia Hosp, Trauma Serv, New Westminster, BC, Canada; [Sopko, George] NHLBI, NIH, Bethesda, MD 20892 USA; [Hata, J. Steven] Univ Iowa, Div Crit Care, Iowa City, IA USA; [Hoyt, David B.] Amer Coll Surg, Chicago, IL USA	Bulger, EM (corresponding author), Univ Washington, Harborview Med Ctr, Dept Surg, 325 9th Ave,POB 359796, Seattle, WA 98104 USA.	ebulger@u.washington.edu	Hata, J./ABI-1484-2020; Slutsky, Arthur/M-3325-2019; Coimbra, Raul/AAP-3019-2020; Tisherman, Samuel A./AAK-9377-2020; Cheskes, Sheldon/I-4456-2015; Welsford, Michelle/H-5535-2017	Coimbra, Raul/0000-0002-3759-6851; Tisherman, Samuel A./0000-0003-3810-3729; Cheskes, Sheldon/0000-0001-7835-3074; Hostler, David/0000-0002-7711-4001; Welsford, Michelle/0000-0003-2682-641X; Idris, Ahamed/0000-0001-7113-6499; Callaway, Clifton/0000-0002-3309-1573; Gabriel, Erin/0000-0002-0504-8404	National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5U01 HL077863, HL077881, HL077871, HL077872, HL077866, HL077908, HL077867, HL077885, HL077887, HL077873, HL077865]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC); Canadian Institutes of Health Research (CIHR) Institute of Circulatory and Respiratory HealthCanadian Institutes of Health Research (CIHR); Defence Research and Development Canada; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077873, U01HL077887, U01HL077885, U01HL077863, U01HL077881, U01HL077908, U01HL077867, U01HL077871, U01HL077866, U01HL077865, U01HL077872] Funding Source: NIH RePORTER	The Resuscitation Outcome Consortium is supported by a series of cooperative agreements with 10 regional clinical centers and 1 data coordinating center (5U01 HL077863, HL077881, HL077871, HL077872, HL077866, HL077908, HL077867, HL077885, HL077887, HL077873, HL077865) from the National Heart, Lung, and Blood Institute in partnership with the National Institute of Neurological Disorders and Stroke, US Army Medical Research and Materiel Command, the Canadian Institutes of Health Research (CIHR) Institute of Circulatory and Respiratory Health, Defence Research and Development Canada, and the Heart and Stroke Foundation of Canada.	BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Brasel KJ, 2008, J AM COLL SURGEONS, V206, P220, DOI 10.1016/j.jamcollsurg.2007.07.020; Bulger EM, 2009, ANN EMERG MED, V53, P341, DOI 10.1016/j.annemergmed.2008.07.021; Calandra T, 2005, CRIT CARE MED, V33, P1538, DOI 10.1097/01.CCM.0000168253.91200.83; Coimbra R, 1996, J SURG RES, V64, P203, DOI 10.1006/jsre.1996.0329; Coimbra R, 1997, J TRAUMA, V42, P602, DOI 10.1097/00005373-199704000-00004; COIMBRA R, 1995, SHOCK, V4, P45, DOI 10.1097/00024382-199507000-00007; COOKE RS, 1995, INJURY, V26, P399, DOI 10.1016/0020-1383(95)00064-G; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Davis DP, 2007, PREHOSP EMERG CARE, V11, P369, DOI 10.1080/10903120701537147; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; *GLUE GRANT, 2009, INFL HOST RESP INJ C; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Gross CP, 1999, NEW ENGL J MED, V340, P1881, DOI 10.1056/NEJM199906173402406; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Inoue Y, 2008, CRIT CARE MED, V36, P2569, DOI 10.1097/CCM.0b013e3181841a91; JUNGER WG, 1994, CIRC SHOCK, V42, P190; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kittelson JM, 1999, BIOMETRICS, V55, P874, DOI 10.1111/j.0006-341X.1999.00874.x; Loomis WH, 2003, J BIOL CHEM, V278, P4590, DOI 10.1074/jbc.M207868200; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Rubin DB., 1987, MULTIPLE IMPUTATION; Sell SL, 2008, ANESTHESIOLOGY, V108, P873, DOI 10.1097/ALN.0b013e31816c8a15; Sheffe H., 1959, ANAL VARIANCE; Tisherman SA, 2008, CIRCULATION, V118, P1585, DOI 10.1161/CIRCULATIONAHA.107.764084; Tyagi R, 2007, NEUROSURG REV, V30, P277, DOI 10.1007/s10143-007-0091-7; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wakai A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub2; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170; WANG SK, 1987, BIOMETRICS, V43, P193, DOI 10.2307/2531959; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	41	150	160	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	2010	304	13					1455	1464		10.1001/jama.2010.1405			10	Medicine, General & Internal	General & Internal Medicine	658SO	WOS:000282509900021	20924011	Green Accepted, Bronze			2021-06-18	
J	Davis, DP; Peay, J; Sise, MJ; Vilke, GM; Kennedy, F; Eastman, AB; Velky, T; Hoyt, DB				Davis, DP; Peay, J; Sise, MJ; Vilke, GM; Kennedy, F; Eastman, AB; Velky, T; Hoyt, DB			The impact of prehospital endotracheal intubation on outcome in moderate to severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 29-OCT 02, 2004	Maui Isl, HI	Amer Assoc Surg Trauma		prehospital intubation; traumatic brain injury; outcome; mortality; hypoxia	RAPID-SEQUENCE INTUBATION; SEVERE HEAD-INJURY; RESPIRATORY-DISTRESS-SYNDROME; INDUCED LUNG INJURY; CEREBRAL BLOOD-FLOW; MECHANICAL VENTILATION; TISSUE PO2; HYPERVENTILATION; ISCHEMIA; HYPOTENSION	Background: Although early intubation to prevent the mortality that accompanies hypoxia is considered the standard of care for severe traumatic brain injury (TBI), the efficacy of this approach remains unproven. Methods: Patients with moderate to severe TBI (Head/Neck Abbreviated Injury Scale [AIS] score 3+) were identified from our county trauma registry. Logistic regression was used to explore the impact of prehospital intubation on outcome, controlling for age, gender, mechanism, Glasgow Coma Scale score, Head/Neck AIS score, Injury Severity Score, and hypotension. Neural network analysis was performed to identify patients predicted to benefit from prehospital intubation. Results: A total of 13,625 patients from five trauma centers were included; overall mortality was 22.9%, and 19.3% underwent prehospital intubation. Logistic regression revealed an increase in mortality with prehospital intubation (odds ratio, 0.36; 95% confidence interval, 0.32-0.42; p &LT; 0.001). This was true for all patients, for those with severe TBI (Head/ Neck AIS score 4+ and/or Glasgow Coma Scale score of 3-8), and with exclusion of patients transported by aeromedical crews. Patients intubated in the field versus the emergency department had worse outcomes. Neural network analysis identified a subgroup of patients with more significant injuries as potentially benefiting from prehospital intubation. Conclusion: Prehospital intubation is associated with a decrease in survival among patients with moderate-to-severe TBI. More critically injured patients may benefit from prehospital intubation but may be difficult to identify prospectively. Traumatic brain injury, Outcome, Mortality, Hypoxia.	Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; Univ Calif San Diego, Div Trauma, Dept Surg, San Diego, CA 92103 USA; Scripps Mercy Hosp, San Diego, CA USA; San Diego Cty Emergency Med Serv, San Diego, CA USA; Sharp Mem Hosp & Rehabil Ctr, San Diego, CA USA; Palomar Med Ctr, San Diego, CA USA	Davis, DP (corresponding author), Univ Calif San Diego, Dept Emergency Med, 200 W Arbor Dr,Suite 8676, San Diego, CA 92103 USA.	davismd@cox.net					Atkinson JLD, 2000, MAYO CLIN PROC, V75, P37, DOI 10.4065/75.1.37; Ausina A, 1998, ACT NEUR S, V71, P1; BOCHICCHIO GV, J TRAUMA; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DAVIS DP, 2004, IN PRESS J TRAUMA; DAVIS DP, 2004, IN PRESS NEUROCRIT C; Dings J, 1996, ZBL NEUROCHIR, V57, P177; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Douzinas EE, 2001, INTENS CARE MED, V27, P269, DOI 10.1007/s001340000796; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Feng ZC, 1998, RESUSCITATION, V37, P33, DOI 10.1016/S0300-9572(98)00031-8; FERCAKOVA A, 1995, J BRAIN RES, V36, P297; Flynn EP, 2002, ANN NEUROL, V52, P566, DOI 10.1002/ana.10322; Fortune JB, 1995, J TRAUMA, V39, P1091, DOI 10.1097/00005373-199512000-00014; GABIG TG, 1979, BLOOD, V53, P1133; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hatley T, 1998, J Emerg Med, V16, P731, DOI 10.1016/S0736-4679(98)00087-0; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; MACIVER IN, 1958, LANCET, V1, P390; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Moore C, 1993, Axone, V15, P30; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; Pepe PE, 2003, J TRAUMA, V54, P1048, DOI 10.1097/01.TA.0000064280.05372.7C; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Schneider GH, 1998, ACT NEUR S, V71, P62; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Slutsky A S, 2000, Respir Res, V1, P73, DOI 10.1186/rr15; SMITH JP, 1985, JAMA-J AM MED ASSOC, V253, P544, DOI 10.1001/jama.253.4.544; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Stockinger ZT, 2004, J TRAUMA, V56, P531, DOI 10.1097/01.TA.0000111755.94642.29; Tremblay LN, 2002, CRIT CARE MED, V30, P1693, DOI 10.1097/00003246-200208000-00003; Uhlig S, 2002, AM J PHYSIOL-LUNG C, V282, pL892, DOI 10.1152/ajplung.00124.2001; VADEBONCOEUR TF, 2004, IN PRESS J EMERG MED; WALLS RM, 1993, ANN EMERG MED, V22, P1008, DOI 10.1016/S0196-0644(05)82743-X; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Weckesser M, 1999, MAGN RESON MED, V41, P213, DOI 10.1002/(SICI)1522-2594(199901)41:1<213::AID-MRM31>3.0.CO;2-S; Wilson MR, 2003, J APPL PHYSIOL, V95, P1385, DOI 10.1152/japplphysiol.00213.2003; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6; Zhang HB, 2002, ANESTHESIOLOGY, V97, P1426, DOI 10.1097/00000542-200212000-00014	53	150	154	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2005	58	5					933	939		10.1097/01.TA.0000162731.53812.58			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	932PU	WOS:000229566600014	15920406				2021-06-18	
J	Bochicchio, GV; Ilahi, O; Joshi, M; Bochicchio, K; Scalea, TM				Bochicchio, GV; Ilahi, O; Joshi, M; Bochicchio, K; Scalea, TM			Endotracheal intubation in the field does not improve outcome in trauma patients who present without an acutely lethal traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	32nd Annual Meeting of the Western-Trauma-Association	FEB 24-MAR 01, 2002	WHISTLER-BLACKCOMBE, CANADA	Western Trauma Assoc		endotracheal intubation; traumatic brain injury; acute lethal injury; outcome	SEVERE HEAD-INJURY; SURVIVAL	Objectives. There is an absence of prospective data evaluating the impact of prehospital intubation in adult trauma patients. Our objectives were to determine the outcome of trauma patients intubated in the field who did not have an acutely lethal traumatic brain injury (death within 48 hours) compared with patients who were intubated immediately on arrival to the hospital. Methods. Prospective data were collected on 191 consecutive patients admitted to the trauma center with a field Glasgow Coma Scale score less than or equal to 8 and a head Abbreviated Injury Scale score greater than or equal to 3 who were either intubated in the field or intubated immediately at admission to the hospital. Patients who died within 48 hours of admission and transfers were excluded from the study. Results. Of the 191 patients, 176 (92%) sustained blunt trauma and 25 (8%) were victims of penetrating trauma. Seventy-eight (41%) of the 191 patients were intubated in the field and 113 (59%) were intubated immediately at admission. There was no significant difference in age, Glasgow Coma Scale score, head Abbreviated Injury Scale score, or Injury Severity Score between the two groups. Patients who were intubated in the field had a significantly higher morbidity (ventilator days, 14.7 vs. 10.4; hospital days, 20.2 vs. 16.7; and intensive care unit days, 15.2 vs. 11.7) compared with patients intubated on immediate arrival to the hospital and nearly double the mortality (23% vs. 12.4). Field-intubated patients had a 1.5 times greater risk of nosocomial pneumonia compared with hospital-intubated patients. Conclusion. Prehospital intubation is associated with a significant increase in morbidity and mortality in trauma patients with traumatic brain injury who are admitted to the hospital without an acutely lethal injury. A randomized, prospective study is warranted to confirm these results.	R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA	Bochicchio, GV (corresponding author), R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.						Bochicchio GV, 2000, SHOCK, V14, P338, DOI 10.1097/00024382-200014030-00017; Cooper A, 2001, Semin Pediatr Surg, V10, P3, DOI 10.1053/spsu.2001.19379; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Gerich TG, 1998, J TRAUMA, V45, P312, DOI 10.1097/00005373-199808000-00017; Karch SB, 1996, AM J EMERG MED, V14, P617, DOI 10.1016/S0735-6757(96)90073-X; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; PEPE PE, 1985, ANN EMERG MED, V14, P1085, DOI 10.1016/S0196-0644(85)80927-6; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	9	150	154	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2003	54	2					307	311		10.1097/01.TA.0000046252.97590.BE			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	644KL	WOS:000180916400015	12579056				2021-06-18	
J	MacKenzie, JD; Siddiqi, F; Babb, JS; Bagley, LJ; Marmon, LJ; Sinson, GP; Grossman, RI				MacKenzie, JD; Siddiqi, F; Babb, JS; Bagley, LJ; Marmon, LJ; Sinson, GP; Grossman, RI			Brain atrophy in mild or moderate traumatic brain injury: A longitudinal quantitative analysis	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							HEAD-INJURY; ALZHEIMERS-DISEASE; FUZZY-CONNECTEDNESS; HIPPOCAMPAL VOLUME; COGNITIVE DEFICITS; MULTIPLE-SCLEROSIS; N-ACETYLASPARTATE; AXONAL INJURY; LESION VOLUME; MR	BACKGROUND AND PURPOSE: Although mild or moderate traumatic brain injury (TBI) is known to cause persistent neurologic sequelae, the underlying structural changes remain elusive. Our purpose was to assess decreases in the volume of brain parenchyma (VBP) in patients with TBI and to determine if clinical parameters are predictors of the extent of atrophy. METHODS: We retrospectively assessed the total VBP in 14 patients with mild or moderate TBI at more than 3 months after injury and in seven patients at two time points more than 3 months apart. VBP was calculated from whole-brain MR images and then normalized by calculating the percent VBP (%VBP) to correct for intraindividual variations in cranial size. Clinical parameters at the time of trauma were evaluated for potential predictors of atrophy. Findings were compared with those of control subjects of similar ages. RESULTS: In the single time-point analysis, brain volumes, CSF volumes, and %VBP were not significantly different between patients and control subjects. In the longitudinal analysis, the rate of decline in %VBP (0.02 versus 0.0064 U/day, P =.05) and the change in %VBP between the first and second time points (-4.16 +/- 1.68 versus -1.49 +/- 1.7, P = .022 [mean SDI) were significantly greater in patients. Change in %VBP was significantly greater in patients with loss of consciousness (LOC) than in those without LOC (P =.023). CONCLUSION: Whole-brain atrophy occurs after mild or moderate TBI and is evident at an average of 11 months after trauma. Injury that produces LOC leads to more atrophy. These findings may help elucidate an etiology for the persistent or new neurologic deficits that occur months after injury.	Univ Penn, Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Neurosurg, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Grossman, RI (corresponding author), NYU, Sch Med, Dept Radiol, 550 1st St,HW-209, New York, NY 10016 USA.			Babb, James/0000-0003-1798-1186	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039135] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 39135-01] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Arciniegas DB, 2001, J NEUROPSYCH CLIN N, V13, P213, DOI 10.1176/appi.neuropsych.13.2.213; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BECKER DP, 1979, ARCH NEUROL-CHICAGO, V36, P750, DOI 10.1001/archneur.1979.00500480024005; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; CORIA F, 1994, REV NEUROSCIENCE, V5, P275; COX WS, 1978, NEUROLOGICAL PATHOPH; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Ge YL, 2000, RADIOLOGY, V214, P665, DOI 10.1148/radiology.214.3.r00mr30665; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; Gonen O, 2000, NEUROLOGY, V54, P15, DOI 10.1212/WNL.54.1.15; Gonen O, 1998, MAGNET RESON MED, V40, P684, DOI 10.1002/mrm.1910400506; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Hillier SL, 1997, BRAIN INJURY, V11, P661; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENNET B, 1981, MANAGEMENT HEAD INJU; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1987, HEAD INJURY, P1; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; Phillips MD, 1998, AM J NEURORADIOL, V19, P1055; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares HD, 1995, J NEUROSCI, V15, P8223; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Udupa JK, 1996, GRAPH MODEL IM PROC, V58, P246, DOI 10.1006/gmip.1996.0021; Udupa JK, 1996, P SOC PHOTO-OPT INS, V2710, P81, DOI 10.1117/12.237902; Udupa JK, 1997, IEEE T MED IMAGING, V16, P598, DOI 10.1109/42.640750; UDUPA JK, 1994, P SOC PHOTO-OPT INS, V2164, P58, DOI 10.1117/12.174042	49	150	152	0	9	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	OCT	2002	23	9					1509	1515					7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	603NB	WOS:000178565000012	12372740				2021-06-18	
J	Signoretti, S; Marmarou, A; Tavazzi, B; Lazzarino, G; Beaumont, A; Vagnozzi, R				Signoretti, S; Marmarou, A; Tavazzi, B; Lazzarino, G; Beaumont, A; Vagnozzi, R			N-acetylaspartate reduction as a measure of injury severity and mitochondrial dysfunction following diffuse traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						energetic metabolism; high-performance liquid chromatography; Z magnetic resonance spectroscopy; mitochondrial dysfunction; N-acetylaspartate; traumatic brain injury	MAGNETIC-RESONANCE SPECTROSCOPY; SEVERE HEAD-INJURY; PERFORMANCE LIQUID-CHROMATOGRAPHY; CEREBRAL ENERGY-METABOLISM; APPEARING WHITE-MATTER; L-ASPARTIC ACID; IN-VIVO H-1; AXONAL INJURY; ACETYL-ASPARTATE; RAT-BRAIN	N-Acetylaspartate (NAA) is considered a neuron-specific metabolite and its reduction a marker of neuronal loss. The objective of this study was to evaluate the time course of NAA changes in varying grades of traumatic brain injury (TBI), in concert with the disturbance of energy metabolites (ATP). Since NAA is synthesized by the mitochondria, it was hypothesized that changes in NAA would follow ATP. The impact acceleration model was used to produce three grades of TBI. Sprague-Dawley rats were divided into the following four-groups: sham control (n = 12); moderate TBI (n = 36); severe TBI (n = 36); and severe TBI coupled with hypoxia-hypotension (n = 16). Animals were sacrificed at different time points ranging from I min to 120 h postinjury, and the brain was processed for high-performance liquid chromatography (HPLC) analysis of NAA and ATP. After moderate TBI, NAA reduced gradually by 35% at 6 h and 46% at 15 h, accompanied by a 57% and 45% reduction in ATP. A spontaneous recovery of NAA to 86% of baseline at 120 h was paralleled by a restoration in ATP. In severe TBI, NAA fell suddenly and did not recover, showing critical reduction (60%) at 48 h. ATP was reduced by 70% and also did not recover. Maximum NAA and ATP decrease occurred with secondary insult (80% and 90%, respectively, at 48 h). These data show that, at 48 h post diffuse TBI, reduction of NAA is graded according to the severity of insult. NAA recovers if the degree of injury is moderate and not accompanied by secondary insult. The highly similar time course and correlation between NAA and ATP supports the notion that NAA reduction is related to energetic impairment.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00173 Rome, Italy; Univ Catania, Dept Chem Sci, Div Biochem Mol Biol & Pharmacol, I-95129 Catania, Italy; Univ Roma Tor Vergata, Dept Neurosci, I-00173 Rome, Italy	Signoretti, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 95058,Campus Virginia Commonwealth Univ, Richmond, VA 23298 USA.		Signoretti, stefano/AAL-5631-2020; Beaumont, Andrew/AAJ-7457-2020; TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; lazzarino, giuseppe/0000-0002-5917-7279	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2P50 NS 12587, 5R01 NS 19235] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019235, P50NS012587] Funding Source: NIH RePORTER		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1984, LANCET, V2, P1420; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; Alessandri B, 2000, NEUROL RES, V22, P705; BARKER PB, 1993, NMR BIOMED, V6, P89, DOI 10.1002/nbm.1940060114; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Baslow MH, 1997, J NEUROCHEM, V68, P1335; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; Bodjarian N, 1997, NEUROREPORT, V8, P3951, DOI 10.1097/00001756-199712220-00020; Braun KPJ, 1999, J NEUROSURG, V91, P660, DOI 10.3171/jns.1999.91.4.0660; BRENNER RE, 1993, MAGNET RESON MED, V29, P737, DOI 10.1002/mrm.1910290605; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; BURRI R, 1990, NEUROCHEM RES, V15, P1009, DOI 10.1007/BF00965747; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Cendes F, 1997, NEUROLOGY, V49, P1525, DOI 10.1212/WNL.49.6.1525; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; CLARKE DD, 1975, J NEUROCHEM, V24, P479, DOI 10.1111/j.1471-4159.1975.tb07665.x; DADAMO AF, 1968, EXP BRAIN RES, V5, P267; Davie CA, 1997, J NEUROL NEUROSUR PS, V63, P736, DOI 10.1136/jnnp.63.6.736; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; EBISU T, 1994, J CEREBR BLOOD F MET, V14, P373, DOI 10.1038/jcbfm.1994.48; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FATOUROS PP, 2001, ACTA NEUROCHIR S, V76, P535; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Florian CL, 1996, NEUROCHEM RES, V21, P1065, DOI 10.1007/BF02532417; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; GOLDSTEIN FB, 1969, J BIOL CHEM, V244, P4257; Graham D I, 1983, Acta Neurochir Suppl (Wien), V32, P65; Harms L, 1997, J NEUROL NEUROSUR PS, V62, P27, DOI 10.1136/jnnp.62.1.27; HEALES SJR, 1995, NEUROCHEM RES, V20, P31; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Kalra S, 1998, NEUROREPORT, V9, P1757, DOI 10.1097/00001756-199806010-00016; Keevil SF, 1998, MAGN RESON IMAGING, V16, P1093, DOI 10.1016/S0730-725X(98)00118-0; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; KNIZLEY H, 1967, J BIOL CHEM, V242, P4619; KOLLER KJ, 1984, J NEUROCHEM, V43, P1136, DOI 10.1111/j.1471-4159.1984.tb12854.x; KORF J, 1991, ANAL BIOCHEM, V196, P350, DOI 10.1016/0003-2697(91)90477-B; Kushi H, 1999, ACT NEUR S, V75, P67; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; LAZZARINO G, 1991, ANAL BIOCHEM, V197, P191, DOI 10.1016/0003-2697(91)90378-7; LAZZARINO G, 1989, ANAL BIOCHEM, V181, P239, DOI 10.1016/0003-2697(89)90236-4; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MEHTA V, 1995, MOL BRAIN RES, V31, P151, DOI 10.1016/0169-328X(95)00044-S; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; PATEL TB, 1980, BIOCHEM J, V188, P163, DOI 10.1042/bj1880163; Peng TI, 1998, MOL PHARMACOL, V53, P974; Plaschke K, 1999, BRAIN RES, V830, P320, DOI 10.1016/S0006-8993(99)01427-4; RANGO M, 1995, MAGNET RESON MED, V33, P595, DOI 10.1002/mrm.1910330503; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; Sager TN, 1999, J CEREBR BLOOD F MET, V19, P164; SAGER TN, 1995, J CEREBR BLOOD F MET, V15, P639, DOI 10.1038/jcbfm.1995.79; SARAGEA M, 1965, MED PHARMACOL EXP, V13, P74; SHIINO A, 1993, SURG NEUROL, V39, P143, DOI 10.1016/0090-3019(93)90093-G; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Strauss I, 1997, MAGNET RESON MED, V37, P24, DOI 10.1002/mrm.1910370106; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Tavazzi B, 2000, ANAL BIOCHEM, V277, P104, DOI 10.1006/abio.1999.4386; TAYLOR DL, 1995, J NEUROCHEM, V65, P275; Uno Masaaki, 1996, Neurologia Medico-Chirurgica, V36, P560, DOI 10.2176/nmc.36.560; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Valadka AB, 2000, J TRAUMA, V49, P1, DOI 10.1097/00005373-200007000-00001; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487	86	150	158	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2001	18	10					977	991		10.1089/08977150152693683			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	484NG	WOS:000171696000002	11686498				2021-06-18	
J	Xu, J; Kim, GM; Chen, SW; Yan, P; Ahmed, SH; Ku, G; Beckman, JS; Xu, XM; Hsu, CY				Xu, J; Kim, GM; Chen, SW; Yan, P; Ahmed, SH; Ku, G; Beckman, JS; Xu, XM; Hsu, CY			iNOS and nitrotyrosine expression after spinal cord injury	JOURNAL OF NEUROTRAUMA			English	Article						cytokines; inflammation; nitric oxide; oxygen free radicals	NITRIC-OXIDE SYNTHASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRAUMATIC BRAIN INJURY; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; KAPPA-B ACTIVATION; INDUCIBLE FORM; CELL-DEATH; RATS; MICE; METHYLPREDNISOLONE	Secondary tissue damage after spinal cord injury (SCI) may be due to inflammatory mediators. After SCI, the nuclear factor-kappaB (NF-kappaB) transcription factor can activate many pro-inflammatory genes, one of which is inducible nitric oxide synthase (iNOS), iNOS catalyzes the synthesis of nitric oxide (NO), a key inflammatory mediator, which in turn reacts with superoxide to generate peroxynitrite, Peroxynitrite is a strong oxidant that can damage cellular enzymes, membranes, and subcellular organelles through the nitration of tyrosine residues on proteins. The presence of nitrotyrosine (NT) is an indirect chemical indicator of toxic NO and peroxynitrite-induced cellular damage. Using a New York University (NYU) impactor to induce SCI in adult rats, we examined the temporal and cellular expression of iNOS and NT, We observed a progressive increase in;iNOS expression in the injured cord starting at day 1 with maximal expression occurring at day 7, as determined by Western blot analysis. iNOS expression corresponded temporally to an increase in iNOS enzyme activity after SCI, In parallel with the progressive increase in iNOS activity, NT expression also increased with time after SCI, The iNOS and:NT immunoreactivity was localized in neurons, astrocytes, endothelial cells and ependymal cells at the epicenter and adjacent to the region of spinal cord impact and injury. Results from the present study suggest that increased iNOS and peroxynitrite anion, as reflected by the progressive accumulation of NT in the injured impacted spinal cord, may contribute to the secondary injury process after SCI.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63104 USA; Univ Alabama, Sch Med, Dept Anesthesiol & Biochem, Birmingham, AL USA	Hsu, CY (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.			Hsu, Chung Y./0000-0002-5632-2733; Xu, Xiao-ming/0000-0002-7229-0081	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037230, R01NS036350, R01NS040162] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36350, NS37230, NS40162] Funding Source: Medline		Adamson DC, 1996, SCIENCE, V274, P1917, DOI 10.1126/science.274.5294.1917; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; BALENTINE JD, 1978, LAB INVEST, V39, P236; BALENTINE JD, 1978, LAB INVEST, V39, P254; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSL, V271, pC1424; Bethea JR, 1998, J NEUROSCI, V18, P3251; BLIGHT AR, 1995, BRAIN, V118, P735, DOI 10.1093/brain/118.3.735; BLIGHT AR, 1992, J NEUROTRAUMA, V9, P83; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenner T, 1997, J IMMUNOL, V158, P2940; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CROSS AH, 1994, J CLIN INVEST, V93, P2684, DOI 10.1172/JCI117282; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DEMEDIUK P, 1985, P NATL ACAD SCI USA, V82, P7071, DOI 10.1073/pnas.82.20.7071; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; ENDOH M, 1994, BRAIN RES, V651, P92, DOI 10.1016/0006-8993(94)90683-1; FEELISCH M, 1994, NATURE, V368, P62, DOI 10.1038/368062a0; Fujiki M, 1996, J COMP NEUROL, V371, P469; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HALL ED, 1981, EXP NEUROL, V73, P321, DOI 10.1016/0014-4886(81)90067-4; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; Hamada Y, 1996, J NEUROCHEM, V66, P1525; HSU C Y, 1990, Journal of Neurotrauma, V7, P115, DOI 10.1089/neu.1990.7.115; HSU CY, 1985, J NEUROL SCI, V70, P275, DOI 10.1016/0022-510X(85)90169-8; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Liu XZ, 1997, J NEUROSCI, V17, P5395; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Scott GS, 1996, INFLAMM RES, V45, P524, DOI 10.1007/BF02311090; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; SZABO C, 1995, FEBS LETT, V363, P235, DOI 10.1016/0014-5793(95)00322-Z; Vodovotz Y, 1996, J EXP MED, V184, P1425, DOI 10.1084/jem.184.4.1425; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; WAGNER FC, 1981, J NEUROSURG, V54, P802, DOI 10.3171/jns.1981.54.6.0802; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Xu J, 1997, BIOCHEM BIOPH RES CO, V235, P394, DOI 10.1006/bbrc.1997.6800; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x; XU J, 1991, J NEUROCHEM, V57, P975, DOI 10.1111/j.1471-4159.1991.tb08246.x; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355; Zhao WG, 1996, J NEUROIMMUNOL, V64, P123, DOI 10.1016/0165-5728(95)00158-1; ZIELASEK J, 1995, J NEUROIMMUNOL, V58, P81, DOI 10.1016/0165-5728(94)00192-Q	55	150	160	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2001	18	5					523	532		10.1089/089771501300227323			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	435CN	WOS:000168860000005	11393255				2021-06-18	
J	Novack, TA; Bush, BA; Meythaler, JM; Canupp, K				Novack, TA; Bush, BA; Meythaler, JM; Canupp, K			Outcome after traumatic brain injury: Pathway analysis of contributions from premorbid, injury severity, and recovery variables	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; traumatic; treatment outcome; rehabilitation	SEVERE HEAD-INJURY; COMA-DATA-BANK; RATING-SCALE; INDIVIDUALS; PREDICTORS; DISABILITY; COMMUNITY; SEQUELAE; 1-YEAR	Objective: To examine the relationship of premorbid variables, injury severity, and cognitive and functional status to outcome 1 year after traumatic brain injury (TBI) and to assess the feasibility of multivariate path analysis as a way to discover those relationships. Design: Prospective, longitudinal. Settings: Level I trauma center, acute inpatient rehabilitation hospital. Patients: One hundred seven subjects (87 men, 20 women; mean age, 33.91 +/- 14.2 yr) who had experienced severe TBI, typically from motor vehicle crashes. Interventions: Acute medical and rehabilitation care. Main Outcome Measures: Disability Rating Scale, Community Integration Questionnaire, and return to employment. Evaluated in acute rehabilitation, and at 6 and 12 months' postinjury. Results: Path analyses revealed that premorbid factors had significant relationships with injury severity, functional skills, cognitive status, and outcome; injury severity affected cognitive and functional skills; and cognitive status influenced outcome. No significant relationships were found between injury severity and emotional status, injury severity and outcome, emotional status and outcome, and functional skills and outcome. Conclusions: Multivariate analysis is important to understanding outcome after TBI. Injury severity, as measured in this study, is less important to 12-month outcome than the premorbid status of the person and the difficulties (particularly cognitive deficits) exhibited at follow-up 6 months after the trauma.	Univ Alabama, Spain Rehabil Ctr, Dept Phys Med & Rehabil, Birmingham, AL 35233 USA	Novack, TA (corresponding author), Univ Alabama, Spain Rehabil Ctr, Dept Phys Med & Rehabil, 1717 6th Ave S, Birmingham, AL 35233 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD07420] Funding Source: Medline		Benton AL, 1983, MULTILINGUAL APHASIA; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DELIS D, 1987, CALIFORNIA VERBAL LE; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P27; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jennett B, 1981, MANAGEMENT HEAD INJU; Kreutzer JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Millis S R, 1994, Int J Neurosci, V79, P165; Pedhazur E.J., 1982, MULTIPLE REGRESSION, V2nd ed.; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan RM., 1985, HALSTEAD REITAN NEUR; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Schumaker R.E., 1996, BEGINNERS GUIDE STRU; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Willer B, 1999, ARCH PHYS MED REHAB, V80, P399, DOI 10.1016/S0003-9993(99)90276-9; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Wright S, 1934, ANN MATH STAT, V5, P161, DOI 10.1214/aoms/1177732676	32	150	164	0	10	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2001	82	3					300	305		10.1053/apmr.2001.18222			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	407RG	WOS:000167284100002	11245749				2021-06-18	
J	Newcomb, JK; Zhao, X; Pike, BR; Hayes, RL				Newcomb, JK; Zhao, X; Pike, BR; Hayes, RL			Temporal profile of apoptotic-like changes in neurons and astrocytes following controlled cortical impact injury in the rat	EXPERIMENTAL NEUROLOGY			English	Article						apoptosis; astrocyte; central nervous system; DNA damage; necrosis; neuron; rat; traumatic brain injury	TRAUMATIC BRAIN INJURY; CEREBELLAR GRANULE CELLS; FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD INJURY; IN-SITU DETECTION; DNA FRAGMENTATION; ALPHA-SPECTRIN; PROTEASE ACTIVATION; ALZHEIMERS-DISEASE; CAUTIONARY NOTE	Apoptotic cell death has been observed in both neurodegenerative diseases and acute neurological traumas such as ischemia, spinal cord injury, and traumatic brain injury (TBI). Recent studies employing different models of TBI have described morphological and biochemical changes characteristic of apoptosis following injury However, no study has examined the temporal profile of apoptosis following controlled cortical impact (CCI) injury in the rat. In addition, the relative frequency of apoptotic profiles in different cell types (neurons versus glia) following CCI has yet to be investigated. In the present experiments, injured cortex was subjected to DNA electrophoresis, and serial sections from the contusion area were stained with hematoxylin and eosin or Hoechst 33258 or double-labeled with TUNEL and neuronal or glial markers. The results of the present study indicate that CCI produces a substantial amount of DNA damage associated with both apoptotic-like and necrotic-like cell death phenotypes primarily at the site of cortical impact and focal contusion. DNA damage, as measured by TUNEL and DNA electrophoresis, was most apparent 1 day following injury and absent by 14 days post-TBI. However, quantitative analysis showed that the majority of TUNEL-positive cells failed to exhibit apoptotic-like morphology and were probably undergoing necrosis. In addition, apoptotic-like morphology was predominantly observed in neurons compared to astrocytes. The present study provides further evidence that apoptosis is involved in the pathology of TBI and could contribute to some of the ensuing cell death following injury. (C) 1999 Academic Press.	Vivian L Smith Ctr Neurol Res, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Houston, TX 77030 USA	Hayes, RL (corresponding author), Vivian L Smith Ctr Neurol Res, Dept Neurosurg, 6431 Fannin,Suite 7-154, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS21458] Funding Source: Medline		Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; BEHRENS MM, 1995, CELL GROWTH DIFFER, V6, P1375; Bonfoco E, 1996, J NEUROCHEM, V67, P2484; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512000-00014; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Hu JR, 1996, BBA-MOL CELL RES, V1313, P239, DOI 10.1016/0167-4889(96)00095-X; Hu JR, 1997, J NEUROCHEM, V69, P2294; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; Jordan J, 1997, J NEUROCHEM, V68, P1612; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Li WP, 1997, J MOL NEUROSCI, V8, P75, DOI 10.1007/BF02736774; LI Y, 1995, MOL BRAIN RES, V28, P164, DOI 10.1016/0169-328X(94)00220-9; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Linnik MD, 1998, MG CLIN NEUROSC, V16, P89; Liu XZ, 1997, J NEUROSCI, V17, P5395; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MCCONKEY DJ, 1989, FASEB J, V3, P1843; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIZUGUCHI M, 1994, BRAIN RES, V649, P197, DOI 10.1016/0006-8993(94)91064-2; Namura S, 1998, J NEUROSCI, V18, P3659; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NEWCOMB JK, 1997, J NEUROTRAUM, V14, P763; OBarr S, 1996, NEUROBIOL AGING, V17, P131, DOI 10.1016/0197-4580(95)02024-1; OBERHAMMER F, 1993, J CELL SCI, V104, P317; Patel T, 1996, FASEB J, V10, P587; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Shi B, 1996, J CLIN INVEST, V98, P1979, DOI 10.1172/JCI119002; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Su JH, 1996, NEUROREPORT, V7, P437, DOI 10.1097/00001756-199601310-00015; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; TOMINAGA T, 1992, NEUROSCI LETT, V139, P265, DOI 10.1016/0304-3940(92)90568-R; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	63	150	158	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	1999	158	1					76	88		10.1006/exnr.1999.7071			13	Neurosciences	Neurosciences & Neurology	218PW	WOS:000081561800007	10448419				2021-06-18	
J	PONSFORD, JL; OLVER, JH; CURRAN, C; NG, K				PONSFORD, JL; OLVER, JH; CURRAN, C; NG, K			PREDICTION OF EMPLOYMENT STATUS 2 YEARS AFTER TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							DISABILITY RATING-SCALE; SEVERE HEAD TRAUMA; RECOVERY; COMA	The present study used a multivariate approach to investigate which of a range of variables relating to demographic factors, injury severity and degree of disability on admission to rehabilitation were the best predictors of employment status 2 years after traumatic brain injury (TBI). Subjects were 74 TBI patients who had been working prior to injury, had undergone rehabilitation at Bethesda Hospital and attended a review clinic 2 years after injury. A cross-validation sample consisted of a further 50 such subjects. Following preliminary analysis four input variables were selected: age under or over 40 at time of injury, Glasgow Coma Scale score on acute hospital admission, duration of post-traumatic amnesia and total score on the Disability Rating Scale (DRS) on admission to rehabilitation. Stepwise discriminant function analysis resulted in a discriminant function consisting of three variables-total score on the Disability Rating Scale, Glasgow Coma Scale Score and age- which correctly classified 74% of grouped cases. A second analysis using the original discriminant function correctly classified 68% of the cross-validation sample. Chi-square analysis showed no significant difference between these results, thus confirming these variables, in combination, as predictors of employment status 2 years after TBI.	BETHESDA HOSP,MELBOURNE,VIC,AUSTRALIA; LA TROBE UNIV,DEPT PSYCHOL,MELBOURNE,VIC,AUSTRALIA				Olver, John/0000-0001-7069-1191			BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; BRUCKNER FE, 1972, RHEUMATOLOGY PHYSICA, V51, P344; ELIASON MR, 1984, PHYS THER, V64, P1357, DOI 10.1093/ptj/64.9.1357; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; HUMPHREY M, 1981, INJURY, V12, P107; ISHARA SN, 1992, BRAIN INJURY, V6, P373; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MELAMED S, 1992, Brain Injury, V6, P233, DOI 10.3109/02699059209029665; MOORE A D, 1990, Brain Injury, V4, P379, DOI 10.3109/02699059009026191; ODDY M, 1984, CLOSED HEAD INJURY P, P108; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; VOGENTHALER DR, 1992, BRAIN INJURY, V3, P369; VOLLMER DG, 1991, J NEUROSURG, V75, P537; 1990, DISABILITY HANDICAP	18	150	151	0	6	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1995	9	1					11	20		10.3109/02699059509004566			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QB052	WOS:A1995QB05200002	7874091				2021-06-18	
J	FISHER, B; THOMAS, D; PETERSON, B				FISHER, B; THOMAS, D; PETERSON, B			HYPERTONIC SALINE LOWERS RAISED INTRACRANIAL-PRESSURE IN CHILDREN AFTER HEAD TRAUMA	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						HYPERTONIC SALINE; INTRACRANIAL PRESSURE; HEAD TRAUMA	LACTATED RINGERS SOLUTION; SEVERE HEMORRHAGIC-SHOCK; FLUID THERAPY; SODIUM LACTATE; RESUSCITATION; INJURY; SCORE; DOGS	Eighteen pediatric patients who sustained traumatic brain injury were enrolled in a double-blind, crossover study comparing the effects of 3% saline and 0.9% saline infusions on raised intracranial pressure (ICP). After resuscitation, each patient received a bolus of each saline concentration, and ICP was monitored for 2 h. Initial mean ICP before 0.9% saline infusions equaled 19.3 mm Hg and averaged 20.0 mm Hg during the subsequent 2-h trials (p = 0.32). Baseline mean ICP before 3% saline administration equaled 19.9 mm Hg and averaged 15.8 mm Hg for 2 h postinfusion (p = 0.003). Central venous pressure did not change significantly in either group, nor did measurements of renal function. Serum sodium concentrations increased in all 18 trials of 3% saline. Maximal concentrations of serum sodium occurred 30 min after bolus administration of 3% saline. Three percent saline significantly reduces raised ICP after traumatic brain injury when compared with normal saline. Intravascular dehydration, as measured by central venous pressure, did not occur during the study period.	CHILDRENS HOSP,DEPT CRIT CARE,8001 FROST ST,SAN DIEGO,CA 92123							ARAI T, 1986, CRIT CARE MED, V14, P634, DOI 10.1097/00003246-198607000-00010; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BAUE AE, 1967, J TRAUM, V7, P743, DOI 10.1097/00005373-196709000-00012; BAXT WG, 1987, J TRAUMA, V27, P602, DOI 10.1097/00005373-198706000-00003; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BOYD C, 1987, J TRAUMA, V27, P320; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CROSS JS, 1989, J TRAUMA, V29, P817, DOI 10.1097/00005373-198906000-00020; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; DURWARD QJ, 1983, J NEUROSURG, V59, P803, DOI 10.3171/jns.1983.59.5.0803; FINBERG L, 1959, PEDIATRICS, P46; GILDER JH, 1983, PASCAL PROGRAMS SCI, P60; GUNNAR W, 1988, SURGERY, V103, P398; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; PETERS RM, 1986, SURG GYNECOL OBSTET, V163, P219; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; SHACKFORD SR, 1989, J TRAUMA, V29, P894, DOI 10.1097/00005373-198906000-00035; SHACKFORD SR, 1983, SURGERY, V94, P41; SHACKFORD SR, 1987, SURG GYNECOL OBSTET, V164, P127; SHANK AL, 1977, CALCULUS ANAL GEOMET, P374; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; VELASCO IT, 1989, CRIT CARE MED, V17, P261, DOI 10.1097/00003246-198903000-00012; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011	27	150	154	0	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	1992	4	1					4	10		10.1097/00008506-199201000-00002			7	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	HB264	WOS:A1992HB26400002	15815431				2021-06-18	
J	Kovacs, ZI; Kim, S; Jikaria, N; Qureshi, F; Milo, B; Lewis, BK; Bresler, M; Burks, SR; Frank, JA				Kovacs, Zsofia I.; Kim, Saejeong; Jikaria, Neekita; Qureshi, Farhan; Milo, Blerta; Lewis, Bobbi K.; Bresler, Michele; Burks, Scott R.; Frank, Joseph A.			Disrupting the blood-brain barrier by focused ultrasound induces sterile inflammation	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						pulsed focused ultrasound; microbubbles; blood-brain barrier; sterile inflammation; magnetic resonance imaging	FOCAL CEREBRAL-ISCHEMIA; MONOCYTE CHEMOATTRACTANT PROTEIN-1; NF-KAPPA-B; CONTRAST AGENT; IN-VIVO; ACTIVATED CHANNELS; DRUG-DELIVERY; IMMUNE-SYSTEM; MOUSE MODEL; INJURY	MRI-guided pulsed focused ultrasound (pFUS) combined with systemic infusion of ultrasound contrast agent microbubbles (MB) causes localized blood-brain barrier (BBB) disruption that is currently being advocated for increasing drug or gene delivery in neurological diseases. The mechanical acoustic cavitation effects of opening the BBB by low-intensity pFUS+MB, as evidenced by contrast-enhanced MRI, resulted in an immediate damage-associated molecular pattern (DAMP) response including elevations in heat-shock protein 70, IL-1, IL-18, and TNFa indicative of a sterile inflammatory response (SIR) in the parenchyma. Concurrent with DAMP presentation, significant elevations in proinflammatory, antiinflammatory, and trophic factors along with neurotrophic and neurogenesis factors were detected; these elevations lasted 24 h. Transcriptomic analysis of sonicated brain supported the proteomic findings and indicated that the SIR was facilitated through the induction of the NF kappa B pathway. Histological evaluation demonstrated increased albumin in the parenchyma that cleared by 24 h along with TUNEL+ neurons, activated astrocytes, microglia, and increased cell adhesion molecules in the vasculature. Infusion of fluorescent beads 3 d before pFUS+MB revealed the infiltration of CD68(+) macrophages at 6 d postsonication, as is consistent with an innate immune response. pFUS+MB is being considered as part of a noninvasive adjuvant treatment for malignancy or neurodegenerative diseases. These results demonstrate that pFUS+MB induces an SIR compatible with ischemia or mild traumatic brain injury. Further investigation will be required before this approach can be widely implemented in clinical trials.	[Kovacs, Zsofia I.; Kim, Saejeong; Jikaria, Neekita; Qureshi, Farhan; Milo, Blerta; Lewis, Bobbi K.; Bresler, Michele; Burks, Scott R.; Frank, Joseph A.] NIH, Frank Lab, Radiol & Imaging Sci, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA; [Kovacs, Zsofia I.; Frank, Joseph A.] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD 20892 USA	Kovacs, ZI (corresponding author), NIH, Frank Lab, Radiol & Imaging Sci, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.; Kovacs, ZI (corresponding author), Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD 20892 USA.	zsofia.kovacs@nih.gov; jf5z@nih.gov	frank, joseph/AAJ-6680-2020; Frank, Joseph/W-2021-2019	Qureshi, Farhan/0000-0001-5541-1518	Intramural Research Programs of the Clinical Center; National Institute of Biomedical Imaging and Bioengineering at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); CLINICAL CENTER [ZIACL040014] Funding Source: NIH RePORTER	This research was funded by the Intramural Research Programs of the Clinical Center and the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health.	Alvarez S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071477; Amantea D, 2014, CURR MED CHEM, V21, P2098, DOI 10.2174/0929867321666131227162634; Amantea D, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00147; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Baseri B, 2012, PHYS MED BIOL, V57, pN65, DOI 10.1088/0031-9155/57/7/N65; Brough D, 2015, IUBMB LIFE, V67, P323, DOI 10.1002/iub.1377; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Burgess A, 2014, RADIOLOGY, V273, P736, DOI 10.1148/radiol.14140245; Burgess A, 2014, EXPERT OPIN DRUG DEL, V11, P711, DOI 10.1517/17425247.2014.897693; Burks SR, 2015, STEM CELLS, V33, P1241, DOI 10.1002/stem.1965; Burks SR, 2013, STEM CELLS, V31, P2551, DOI 10.1002/stem.1495; Burks SR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024730; Capaldo CT, 2009, BBA-BIOMEMBRANES, V1788, P864, DOI 10.1016/j.bbamem.2008.08.027; Cardoso FL, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0299-3; Cardoso FL, 2010, BRAIN RES REV, V64, P328, DOI 10.1016/j.brainresrev.2010.05.003; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Coste B, 2012, NATURE, V483, P176, DOI 10.1038/nature10812; Daneman R, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020412; Denes A, 2010, BRAIN BEHAV IMMUN, V24, P708, DOI 10.1016/j.bbi.2009.09.010; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Famakin BM, 2014, AGING DIS, V5, P307, DOI 10.14336/AD.2014.0500307; Foley LM, 2009, J NEUROTRAUM, V26, P1509, DOI 10.1089/neu.2008.0747; Gabathuler R, 2010, NEUROBIOL DIS, V37, P48, DOI 10.1016/j.nbd.2009.07.028; Gadani SP, 2015, NEURON, V87, P47, DOI 10.1016/j.neuron.2015.05.019; Ghosh S, 2013, J NEUROSCI, V33, P5053, DOI 10.1523/JNEUROSCI.4361-12.2013; Goertz DE, 2015, INT J HYPERTHER, V31, P134, DOI 10.3109/02656736.2015.1009179; HAWKINS CP, 1990, BRAIN, V113, P365, DOI 10.1093/brain/113.2.365; Hedtjarn M, 2002, J NEUROSCI, V22, P5910; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Huang T, 2014, NEUROREPORT, V25, P1122, DOI 10.1097/WNR.0000000000000236; Hynynen K, 2005, NEUROIMAGE, V24, P12, DOI 10.1016/j.neuroimage.2004.06.046; Hynynen K, 2003, ULTRASOUND MED BIOL, V29, P473, DOI 10.1016/S0301-5629(02)00741-X; Hynynen K, 2001, RADIOLOGY, V220, P640, DOI 10.1148/radiol.2202001804; Ibsen S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9264; Jalali S, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-114; Kelso ML, 2015, J NEUROIMMUNOL, V278, P162, DOI 10.1016/j.jneuroim.2014.11.002; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Konofagou EE, 2012, THERANOSTICS, V2, P1223, DOI 10.7150/thno.5576; Kovacs Z, 2014, J CONTROL RELEASE, V187, P74, DOI 10.1016/j.jconrel.2014.05.033; Krasovitski B, 2011, P NATL ACAD SCI USA, V108, P3258, DOI 10.1073/pnas.1015771108; Kroll RA, 1998, NEUROSURGERY, V42, P1083, DOI 10.1097/00006123-199805000-00082; Leinenga G, 2016, NAT REV NEUROL, V12, P161, DOI 10.1038/nrneurol.2016.13; Leinenga G, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa2512; Li J, 2014, NATURE, V515, P279, DOI 10.1038/nature13701; Lin Y, 2013, INT J MED SCI, V10, P515, DOI 10.7150/ijms.5423; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049; McDannold N, 2005, ULTRASOUND MED BIOL, V31, P1527, DOI 10.1016/j.ultrasmedbio.2005.07.010; Mcdannold N, 2008, ULTRASOUND MED BIOL, V34, P930, DOI 10.1016/j.ultrasmedbio.2007.11.009; McDannold N, 2012, CANCER RES, V72, P3652, DOI 10.1158/0008-5472.CAN-12-0128; McDannold N, 2011, ULTRASOUND MED BIOL, V37, P1259, DOI 10.1016/j.ultrasmedbio.2011.04.019; Mohamed IN, 2015, ANTIOXID REDOX SIGN, V22, P1188, DOI 10.1089/ars.2014.6126; National Research Council, 2011, GUIDE CARE USE LAB A; Neuwelt E, 2008, LANCET NEUROL, V7, P84, DOI 10.1016/S1474-4422(07)70326-5; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Raymond SB, 2007, J CEREBR BLOOD F MET, V27, P393, DOI 10.1038/sj.jcbfm.9600336; Savage CD, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00288; Scarcelli T, 2014, BRAIN STIMUL, V7, P304, DOI 10.1016/j.brs.2013.12.012; Schoknecht K, 2015, SEMIN CELL DEV BIOL, V38, P35, DOI 10.1016/j.semcdb.2014.10.004; Shechter R, 2013, TRENDS MOL MED, V19, P135, DOI 10.1016/j.molmed.2012.11.007; Sheikov N, 2008, ULTRASOUND MED BIOL, V34, P1093, DOI 10.1016/j.ultrasmedbio.2007.12.015; Shin WH, 2004, GLIA, V46, P142, DOI 10.1002/glia.10357; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Singhal G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00315; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Song YS, 2008, J CEREBR BLOOD F MET, V28, P1917, DOI 10.1038/jcbfm.2008.80; Spangenburg EE, 2006, J APPL PHYSIOL, V100, P129, DOI 10.1152/japplphysiol.00619.2005; Stamatovic SM, 2005, J CEREBR BLOOD F MET, V25, P593, DOI 10.1038/sj.jcbfm.9600055; Stamatovic SM, 2008, CURR NEUROPHARMACOL, V6, P179, DOI 10.2174/157015908785777210; Strle K, 2001, CRIT REV IMMUNOL, V21, P427; Stumm RK, 2002, J NEUROSCI, V22, P5865; Suzuki Y, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00002; Takamiya M, 2007, J NEUROTRAUM, V24, P1833, DOI 10.1089/neu.2007.0336; Nhan T, 2013, J CONTROL RELEASE, V172, P274, DOI 10.1016/j.jconrel.2013.08.029; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Thompson WL, 2009, BRAIN RES, V1287, P47, DOI 10.1016/j.brainres.2009.06.081; Tokami H, 2013, BRAIN RES, V1517, P122, DOI 10.1016/j.brainres.2013.04.022; Tu TW, 2014, J NEUROPATH EXP NEUR, V73, P1152, DOI 10.1097/NEN.0000000000000140; Tufail Y, 2010, NEURON, V66, P681, DOI 10.1016/j.neuron.2010.05.008; Tung YS, 2010, PHYS MED BIOL, V55, P6141, DOI 10.1088/0031-9155/55/20/007; Tuttolomondo A, 2014, DRUG DES DEV THER, V8, P2221, DOI 10.2147/DDDT.S67655; Wang H, 2006, EUR J NEUROSCI, V23, P1665, DOI 10.1111/j.1460-9568.2006.04682.x; Yang MS, 2006, J IMMUNOL, V177, P1323, DOI 10.4049/jimmunol.177.2.1323; Yao Y, 2014, CELL MOL LIFE SCI, V71, P683, DOI 10.1007/s00018-013-1459-1; Yin W, 2013, CNS NEUROSCI THER, V19, P145, DOI 10.1111/cns.12049; Zhou J, 2014, CYTOKINE, V69, P29, DOI 10.1016/j.cyto.2014.05.003	88	149	152	7	80	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JAN 3	2017	114	1					E75	E84		10.1073/pnas.1614777114			10	Multidisciplinary Sciences	Science & Technology - Other Topics	EG5OM	WOS:000391093700009	27994152	Green Published, Bronze	Y	N	2021-06-18	
J	Stein, TD; Montenigro, PH; Alvarez, VE; Xia, WM; Crary, JF; Tripodis, Y; Daneshvar, DH; Mez, J; Solomon, T; Meng, GY; Kubilus, CA; Cormier, KA; Meng, S; Babcock, K; Kiernan, P; Murphy, L; Nowinski, CJ; Martin, B; Dixon, D; Stern, RA; Cantu, RC; Kowall, NW; McKee, AC				Stein, Thor D.; Montenigro, Philip H.; Alvarez, Victor E.; Xia, Weiming; Crary, John F.; Tripodis, Yorghos; Daneshvar, Daniel H.; Mez, Jesse; Solomon, Todd; Meng, Gaoyuan; Kubilus, Caroline A.; Cormier, Kerry A.; Meng, Steven; Babcock, Katharine; Kiernan, Patrick; Murphy, Lauren; Nowinski, Christopher J.; Martin, Brett; Dixon, Diane; Stern, Robert A.; Cantu, Robert C.; Kowall, Neil W.; McKee, Ann C.			Beta-amyloid deposition in chronic traumatic encephalopathy	ACTA NEUROPATHOLOGICA			English	Article						Chronic traumatic encephalopathy; Alzheimer's disease; Beta-amyloid; Neurodegenerative disorders; Dementia; Tau	BRAIN-INJURY; ALZHEIMERS-DISEASE; HEAD-INJURY; PROTEIN DEPOSITION; DIFFUSE PLAQUES; PATHOLOGY; RISK; APOE; TAU; AGE	Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with repetitive mild traumatic brain injury. It is defined pathologically by the abnormal accumulation of tau in a unique pattern that is distinct from other tauopathies, including Alzheimer's disease (AD). Although trauma has been suggested to increase amyloid beta peptide (A beta) levels, the extent of A beta deposition in CTE has not been thoroughly characterized. We studied a heterogeneous cohort of deceased athletes and military veterans with neuropathologically diagnosed CTE (n = 114, mean age at death = 60) to test the hypothesis that A beta deposition is altered in CTE and associated with more severe pathology and worse clinical outcomes. We found that A beta deposition, either as diffuse or neuritic plaques, was present in 52 % of CTE subjects. Moreover, A beta deposition in CTE occurred at an accelerated rate and with altered dynamics in CTE compared to a normal aging population (OR = 3.8, p < 0.001). We also found a clear pathological and clinical dichotomy between those CTE cases with A beta plaques and those without. A beta deposition was significantly associated with the presence of the APOE epsilon 4 allele (p = 0.035), older age at symptom onset (p < 0.001), and older age at death (p < 0.001). In addition, when controlling for age, neuritic plaques were significantly associated with increased CTE tauopathy stage (beta = 2.43, p = 0.018), co-morbid Lewy body disease (OR = 5.01, p = 0.009), and dementia (OR = 4.45, p = 0.012). A subset of subjects met the diagnostic criteria for both CTE and AD, and in these subjects both A beta plaques and total levels of A beta 1-40 were increased at the depths of the cortical sulcus compared to the gyral crests. Overall, these findings suggest that A beta deposition is altered and accelerated in a cohort of CTE subjects compared to normal aging and that A beta is associated with both pathological and clinical progression of CTE independent of age.	[Stein, Thor D.; Meng, Gaoyuan; Kowall, Neil W.; McKee, Ann C.] VA Boston Healthcare Syst, Boston, MA 02130 USA; [Stein, Thor D.; Xia, Weiming; McKee, Ann C.] Dept Vet Affairs Med Ctr, Bedford, MA 01730 USA; [Stein, Thor D.; Montenigro, Philip H.; Alvarez, Victor E.; Daneshvar, Daniel H.; Mez, Jesse; Solomon, Todd; Kubilus, Caroline A.; Cormier, Kerry A.; Meng, Steven; Babcock, Katharine; Kiernan, Patrick; Murphy, Lauren; Nowinski, Christopher J.; Martin, Brett; Dixon, Diane; Stern, Robert A.; Kowall, Neil W.; McKee, Ann C.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Stein, Thor D.; McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [Montenigro, Philip H.; Stern, Robert A.; Cantu, Robert C.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Alvarez, Victor E.; Daneshvar, Daniel H.; Mez, Jesse; Solomon, Todd; Kubilus, Caroline A.; Cormier, Kerry A.; Kiernan, Patrick; Murphy, Lauren; Stern, Robert A.; Kowall, Neil W.; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Crary, John F.] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Crary, John F.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA; [Crary, John F.] Icahn Sch Med Mt Sinai, Ronald M Loeb Ctr Alzheimers Dis, New York, NY 10029 USA; [Tripodis, Yorghos] Boston Univ, Sch Med, Dept Biostat, Boston, MA 02118 USA; [Tripodis, Yorghos; Martin, Brett; Dixon, Diane] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA 02118 USA; [Nowinski, Christopher J.; Cantu, Robert C.] Sports Legacy Inst, Waltham, MA 02451 USA; [Stern, Robert A.; Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA 01742 USA	Stein, TD (corresponding author), VA Boston Healthcare Syst, Boston, MA 02130 USA.	tdstein@bu.edu	Kowall, Neil/M-5378-2019; xia, weiming/E-5465-2016; , Bob/ABA-8507-2020	Kowall, Neil/0000-0002-6624-0213; xia, weiming/0000-0002-7463-3295; Stern, Robert/0000-0002-5008-077X; Stein, Thor/0000-0001-6954-4477; Daneshvar, Daniel/0000-0003-3691-9513; Tripodis, Yorghos/0000-0003-2190-7608; Montenigro, Philip/0000-0003-4442-9207	Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development Merit Award; Alzheimer's AssociationAlzheimer's Association [NIRG-305779]; Veterans Affairs Biorepository [CSP 501]; Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering [U01NS086659-01]; National Institute of Aging Boston University AD Center [P30AG13846, 0572063345-5]; Department of Defense Peer Reviewed Alzheimer's Research Program (DoD-PRARP) [13267017]; Sports Legacy Institute; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846, K23AG046377] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER	We gratefully acknowledge the use of resources and facilities at the Edith Nourse Rogers Memorial Veterans Hospital (Bedford, MA) as well as all the individuals whose participation and contributions made this work possible. This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development Merit Award; Alzheimer's Association (NIRG-305779); Veterans Affairs Biorepository (CSP 501); Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B6796-C); National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering (U01NS086659-01); National Institute of Aging Boston University AD Center (P30AG13846; supplement 0572063345-5); Department of Defense Peer Reviewed Alzheimer's Research Program (DoD-PRARP #13267017); Sports Legacy Institute. This work was also supported by unrestricted gifts from the Andlinger Foundation and WWE.	Bloom GS, 2014, JAMA NEUROL, V71, P505, DOI 10.1001/jamaneurol.2013.5847; Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Crary JF, 2014, ACTA NEUROPATHOL, V128, P755, DOI 10.1007/s00401-014-1349-0; Cummings BJ, 1996, NEUROBIOL AGING, V17, P653; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Falcone GJ, 2014, NEUROLOGY, V83, P1139, DOI 10.1212/WNL.0000000000000816; Gandy S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004274; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gomperts SN, 2012, MOVEMENT DISORD, V27, P965, DOI 10.1002/mds.25048; Guntert A, 2006, NEUROSCIENCE, V143, P461, DOI 10.1016/j.neuroscience.2006.08.027; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; Howlett DR, 2013, BRAIN PATHOL, V23, P623, DOI 10.1111/bpa.12057; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kalaitzakis ME, 2009, ACTA NEUROPATHOL, V118, P587, DOI 10.1007/s00401-009-0597-x; Katsnelson A, 2011, NAT MED, V17, P638, DOI 10.1038/nm0611-638; Kern S, 2015, AM J EPIDEMIOL, V181, P214, DOI 10.1093/aje/kwu442; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Masliah E, 2001, P NATL ACAD SCI USA, V98, P12245, DOI 10.1073/pnas.211412398; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; McKay GJ, 2011, AM J EPIDEMIOL, V173, P1357, DOI 10.1093/aje/kwr015; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Mormino EC, 2014, NEUROLOGY, V82, P1760, DOI 10.1212/WNL.0000000000000431; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Perez-Nievas BG, 2013, BRAIN, V136, P2510, DOI 10.1093/brain/awt171; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Shen H, 2015, NATURE, V518, P466, DOI 10.1038/518466a; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Takizawa C, 2015, J ALZHEIMERS DIS, V43, P1271, DOI 10.3233/JAD-141134; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Wirth M, 2014, J NEUROSCI, V34, P8612, DOI 10.1523/JNEUROSCI.4612-13.2014; Xia WM, 2009, ARCH NEUROL-CHICAGO, V66, P190, DOI 10.1001/archneurol.2008.565	51	149	149	0	32	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JUL	2015	130	1					21	34		10.1007/s00401-015-1435-y			14	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CK5EQ	WOS:000356245500002	25943889	Green Accepted			2021-06-18	
J	Mothe, AJ; Tam, RY; Zahir, T; Tator, CH; Shoichet, MS				Mothe, Andrea J.; Tam, Roger Y.; Zahir, Tasneem; Tator, Charles H.; Shoichet, Molly S.			Repair of the injured spinal cord by transplantation of neural stem cells in a hyaluronan-based hydrogel	BIOMATERIALS			English	Article						Hyaluronan; Hydrogel; Neural stem/progenitor cells; Transplantation; Spinal cord injury; Functional recovery	GROWTH-FACTOR-AA; STEM/PROGENITOR CELLS; LOCALIZED DELIVERY; CHITOSAN CHANNELS; DIFFERENTIATION; EXPRESSION; RECOVERY; SURVIVAL; PATHOPHYSIOLOGY; RECEPTOR	Traumatic injury to the spinal cord causes cell death, demyelination, axonal degeneration, and cavitation resulting in functional motor and sensory loss. Stem cell therapy is a promising approach for spinal cord injury (SCI); however, this strategy is currently limited by the poor survival and uncontrolled differentiation of transplanted stem cells. In an attempt to achieve greater survival and integration with the host tissue, we examined the survival and efficacy of adult brain-derived neural stem/progenitor cells (NSPCs) injected within a hydrogel blend of hyaluronan and methyl cellulose (HAMC) into a subacute, clinically relevant model of rat SCI. Prior to use, HAMC was covalently modified with recombinant rat platelet-derived growth factor-A (rPDGF-A) to promote oligodendrocytic differentiation. SCI rats transplanted with NSPCs in HAMC-rPDGF-A showed improved behavioral recovery compared to rats transplanted with NSPCs in media. Rats with NSPC/HAMC-rPDGF-A transplants had a significant reduction in cavitation, improved graft survival, increased oligodendrocytic differentiation, and sparing of perilesional host oligodendrocytes and neurons. These data suggest that HAMC-rPDGF-A is a promising vehicle for cell delivery to the injured spinal cord. (C) 2013 Elsevier Ltd. All rights reserved.	[Mothe, Andrea J.; Tator, Charles H.] Univ Toronto, Toronto Western Res Inst, Div Genet & Dev, Toronto, ON M5T 2S8, Canada; [Mothe, Andrea J.; Tator, Charles H.] Univ Hlth Network, Toronto Western Hosp, Krembil Neurosci Ctr, Toronto, ON, Canada; [Tam, Roger Y.; Zahir, Tasneem; Shoichet, Molly S.] Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON M5S 3E5, Canada; [Tam, Roger Y.; Zahir, Tasneem; Shoichet, Molly S.] Inst Biomat & Biomed Engn, Toronto, ON M5S 3G9, Canada; [Tator, Charles H.] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON M5S 1A1, Canada	Shoichet, MS (corresponding author), Univ Toronto, Donnelly Ctr Cellular & Biomol Res, 160 Coll St,Room 514, Toronto, ON, Canada.	molly.shoichet@utoronto.ca		Tam, Roger/0000-0002-8441-6681	U.S. Department of DefenceUnited States Department of Defense; Krembil Foundation; Canadian Paraplegic Association (Ontario Branch); Ontario government	The authors are grateful to the following individuals for help with behavioral analysis, animal care, cell counts and histology: Peter Poon, Irja Elliot-Donaghue, Linda Lee, Rita van Bendegem, Nusrat Amin, Laureen Hachem, Tanya Barretto, and Karen Giang. Funding for this study was provided by the U.S. Department of Defence (MSS, CHT), the Krembil Foundation (MSS, CHT), the Canadian Paraplegic Association (Ontario Branch, CHT), and the Ontario government for a post-doctoral fellowship to RYE	Aizawa Y, 2008, BIOMATERIALS, V29, P4676, DOI 10.1016/j.biomaterials.2008.08.018; Arany PR, 2011, ORAL DIS, V17, P241, DOI 10.1111/j.1601-0825.2010.01735.x; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Austin JW, 2012, BIOMATERIALS, V33, P4555, DOI 10.1016/j.biomaterials.2012.03.022; Ballios BG, 2010, BIOMATERIALS, V31, P2555, DOI 10.1016/j.biomaterials.2009.12.004; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beckett D, 1999, PROTEIN SCI, V8, P921, DOI 10.1110/ps.8.4.921; Bozkurt G, 2010, NEUROSURGERY, V67, P1733, DOI 10.1227/NEU.0b013e3181f9af35; Casini P, 2010, GENE EXPR PATTERNS, V10, P93, DOI 10.1016/j.gep.2009.12.003; CHENG B, 1995, J NEUROSCI, V15, P7095; Cortivo R, 1996, SEMIN ARTHRITIS RHEU, V26, P492, DOI 10.1016/S0049-0172(96)80030-8; Deyev SM, 2003, NAT BIOTECHNOL, V21, P1486, DOI 10.1038/nbt916; Fisher OZ, 2010, ACCOUNTS CHEM RES, V43, P419, DOI 10.1021/ar900226q; Guo XD, 2012, CELL TRANSPLANT, V21, P1177, DOI 10.3727/096368911X612503; Gupta D, 2006, BIOMATERIALS, V27, P2370, DOI 10.1016/j.biomaterials.2005.11.015; Hains BC, 2004, EXP NEUROL, V188, P365, DOI 10.1016/j.expneurol.2004.04.001; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Hu JG, 2008, NEUROSCIENCE, V151, P138, DOI 10.1016/j.neuroscience.2007.10.050; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; Jones LL, 2001, MICROSC RES TECHNIQ, V54, P317, DOI 10.1002/jemt.1144; Kang CE, 2009, TISSUE ENG PT A, V15, P595, DOI 10.1089/ten.tea.2007.0349; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; Khaing ZZ, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046033; Kim H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021744; Liu Y, 2004, DEV BIOL, V276, P31, DOI 10.1016/j.ydbio.2004.08.018; Macias MY, 2006, EXP NEUROL, V201, P335, DOI 10.1016/j.expneurol.2006.04.035; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Moreno-Manzano V, 2009, STEM CELLS, V27, P733, DOI 10.1002/stem.24; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Moseley R, 2002, BIOMATERIALS, V23, P2255, DOI 10.1016/S0142-9612(01)00360-X; Mothe AJ, 2011, SPINAL CORD, V49, P967, DOI 10.1038/sc.2011.46; Mothe AJ, 2005, J HISTOCHEM CYTOCHEM, V53, P1215, DOI 10.1369/jhc.5A6639.2005; Mothe AJ, 2008, EXP NEUROL, V213, P176, DOI 10.1016/j.expneurol.2008.05.024; Mothe AJ, 2012, J CLIN INVEST, V122, P3824, DOI 10.1172/JCI64124; Nomura H, 2006, J NEUROTRAUM, V23, P496, DOI 10.1089/neu.2006.23.496; Nomura H, 2008, TISSUE ENG PT A, V14, P649, DOI 10.1089/tea.2007.0180; Parr AM, 2008, NEUROSCIENCE, V155, P760, DOI 10.1016/j.neuroscience.2008.05.042; Parr AM, 2007, NEUROSURGERY, V60, P926, DOI 10.1227/01.NEU.0000255441.59612.98; PRESTI D, 1994, CELL BIOCHEM FUNCT, V12, P281, DOI 10.1002/cbf.290120409; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Shoichet MS, 2007, PROG BRAIN RES, V161, P385, DOI 10.1016/S0079-6123(06)61027-3; Tam RY, 2012, J MATER CHEM, V22, P19402, DOI 10.1039/c2jm33680d; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tator CH, 1995, CONT MANAGEMENT SPIN, P9; Tator CH, 2006, NEUROSURGERY, V59, P957, DOI 10.1227/01.NEU.0000245591.16087.89; Tetzlaff W, 2011, J NEUROTRAUM, V28, P1611, DOI 10.1089/neu.2009.1177; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; Wakao N, 2011, NEUROSCI LETT, V488, P299, DOI 10.1016/j.neulet.2010.11.051; Weiss S, 1996, J NEUROSCI, V16, P7599; Wylie RG, 2011, NAT MATER, V10, P799, DOI [10.1038/NMAT3101, 10.1038/nmat3101]	55	149	151	6	169	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	MAY	2013	34	15					3775	3783		10.1016/j.biomaterials.2013.02.002			9	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	120KH	WOS:000317168700005	23465486				2021-06-18	
J	Omalu, B; Hammers, JL; Bailes, J; Hamilton, RL; Kamboh, MI; Webster, G; Fitzsimmons, RP				Omalu, Bennet; Hammers, Jennifer L.; Bailes, Julian; Hamilton, Ronald L.; Kamboh, M. Ilyas; Webster, Garrett; Fitzsimmons, Robert P.			Chronic traumatic encephalopathy in an Iraqi war veteran with posttraumatic stress disorder who committed suicide	NEUROSURGICAL FOCUS			English	Article						posttraumatic stress disorder; Iraq; chronic traumatic encephalopathy; suicide	FRONTOTEMPORAL LOBAR DEGENERATION; AMYOTROPHIC-LATERAL-SCLEROSIS; FOOTBALL-LEAGUE PLAYER; BRAIN-INJURY; APOLIPOPROTEIN-E; TDP-43; BLAST; DISEASE	Following his discovery of chronic traumatic encephalopathy (CTE) in football players in 2002, Dr. Bennet Omalu hypothesized that posttraumatic stress disorder (PTSD) in military veterans may belong to the CTE spectrum of diseases. The CTE surveillance at the Brain Injury Research Institute was therefore expanded to include deceased military veterans diagnosed with PTSD. The authors report the case of a 27-year-old United States Marine Corps (USMC) Iraqi war veteran, an amphibious assault vehicle crewman, who committed suicide by hanging after two deployments to Fallujah and Ramadi. He experienced combat and was exposed to mortar blasts and improvised explosive device blasts less than 50 m away. Following his second deployment he developed a progressive history of cognitive impairment, impaired memory, behavioral and mood disorders, and alcohol abuse. Neuropsychiatric assessment revealed a diagnosis of PTSD with hyperarousal (irritability and insomnia) and numbing. He committed suicide approximately 8 months after his honorable discharge from the USMC. His brain at autopsy appeared grossly unremarkable except for congestive brain swelling. There was no atrophy or remote focal traumatic brain injury such as contusional necrosis or hemorrhage. Histochemical and immunohistochemical brain tissue analysis revealed CTE changes comprising multifocal, neocortical, and subcortical neurofibrillary tangles and neuritic threads (ranging from none, to sparse, to frequent) with the skip phenomenon, accentuated in the depths of sulci and in the frontal cortex. The subcortical white matter showed mild rarefaction, sparse perivascular and neuropil infiltration by histiocytes, and mild fibrillary astrogliosis. Apolipoprotein E genotype was 3/4. The authors report this case as a sentinel case of CTE in an Iraqi war veteran diagnosed with PTSD to possibly stimulate new lines of thought and research in the possible pathoetiology and pathogenesis of PTSD in military veterans as part of the CTE spectrum of diseases, and as chronic sequelae and outcomes of repetitive traumatic brain injuries. (DOI: 10.3171/2011.9.FOCUS11178)	[Omalu, Bennet; Hammers, Jennifer L.; Bailes, Julian; Webster, Garrett; Fitzsimmons, Robert P.] Brain Injury Res Inst, Morgantown, WV USA; [Omalu, Bennet; Webster, Garrett] Univ Calif Davis, Dept Pathol, Davis, CA 95616 USA; [Hammers, Jennifer L.] Off Chief Med Examiner, Boston, MA USA; [Bailes, Julian] W Virginia Univ, Dept Neurosurg, Morgantown, WV 26506 USA; [Hamilton, Ronald L.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; [Kamboh, M. Ilyas] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15260 USA; [Fitzsimmons, Robert P.] Fitzsimmons Law Off, Wheeling, WV USA	Omalu, B (corresponding author), 1132 Junewood Court, Lodi, CA 95242 USA.	bennetomalu@comcast.net		Kamboh, M. Ilyas/0000-0002-3453-1438			American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bales K R, 2002, Mol Interv, V2, P363, DOI 10.1124/mi.2.6.363; Bales KR, 2002, MOL INTERV, V2, P339, DOI DOI 10.1124/MI.2.6.363; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Chen-Plotkin AS, 2010, NAT REV NEUROL, V6, P211, DOI 10.1038/nrneurol.2010.18; *DEP DEF TASK FORC, 2010, CHALL PROM STRENGTH, P233; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Ellison DLS, 2004, NEUROPATHOLOGY REFER; Geser F, 2010, NEUROPATHOLOGY, V30, P103, DOI 10.1111/j.1440-1789.2009.01091.x; Greenfield JG, 2008, GREENFIELDS NEUROPAT; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Ludwig J., 2002, HDB AUTOPSY PRACTICE, V3rd; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Omalu B, 2008, PLAY HARD DIE YOUNG; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Robbins S, 2010, STARS STRIPES   0123; Ropper A, 2011, NEW ENGL J MED, V364, P2156, DOI 10.1056/NEJMe1102187; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Samatovicz RA, 2000, J HEAD TRAUMA REHAB, V15, P869, DOI 10.1097/00001199-200006000-00002; Shalev AY, 2001, J CLIN PSYCHIAT, V62, P4; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yule W, 2001, J CLIN PSYCHIAT, V62, P23	33	149	149	2	43	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2011	31	5							E3	10.3171/2011.9.FOCUS11178			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	844QL	WOS:000296762300004	22044102	Bronze			2021-06-18	
J	Taylor, HG; Dietrich, A; Nuss, K; Wright, M; Rusin, J; Bangert, B; Minich, N; Yeates, KO				Taylor, H. Gerry; Dietrich, Ann; Nuss, Kathryn; Wright, Martha; Rusin, Jerome; Bangert, Barbara; Minich, Nori; Yeates, Keith Owen			Post-Concussive Symptoms in Children With Mild Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article; Proceedings Paper	6th Annual Conference of the American-Academy-of-Clinical-Neuropsychology	JUN, 2008	Boston, MA	Amer Acad Clin Neuropsychol		mild traumatic brain injury; children; postconcussive symptoms; prospective studies	CLOSED-HEAD-INJURY; POSTCONCUSSION SYNDROME; NEUROBEHAVIORAL SYMPTOMS; ADOLESCENTS; SEQUELAE; CLASSIFICATION; EXPECTATION; CHILDHOOD; SEVERITY; ETIOLOGY	To investigate postconcussive symptoms (PCS) following pediatric mild traumatic brain injury (mTBI), 8- to 15-year-old children with mTBI (n = 186) and a comparison group with uncomplicated orthopedic injuries (OI, n = 99) were recruited from two emergency departments. Parent and child ratings of PCS and symptom Counts were obtained within 3 weeks after injury (baseline) and at 1, 3. and 12 months postinjury. The mTBI group also completed magnetic resonance imaging at baseline. Group differences were examined using growth modeling. controlling for age at injury, sex, socioeconomic status, and (for parent-based measures) preinjury symptom levels. Relative to the 01 group, the mTBI group had higher ratings of somatic PCS and parent Counts of PCS at the initial assessments, but higher parent ratings of cognitive PCS and child counts of PCS throughout follow-up. Higher levels of PCS in the mTBI group were associated with motor-vehicle-related trauma. loss of consciousness. neuroimaging abnormalities, and hospitalization. The findings validate both transient and persistent PCS in children with mTBI and document associations of symptoms with injury and noninjury factors.	[Taylor, H. Gerry; Wright, Martha; Minich, Nori] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Wright, Martha] Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathryn; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Dietrich, Ann; Nuss, Kathryn] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH USA; [Bangert, Barbara] Case Western Reserve Univ, Dept Radiol, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA	Taylor, HG (corresponding author), WO Walker Bldg,Suite 3150,10524 Euclid Ave, Cleveland, OH 44106 USA.	hgt2@case.edu	Yeates, Keith/AAJ-4223-2020	Nuss, Kathryn/0000-0003-2185-7364; Yeates, Keith/0000-0001-7680-2892	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD039834, R01 HD039834-01, R01 HD39834, K02HD44099, K02 HD044099] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099, R01HD039834] Funding Source: NIH RePORTER		Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DEANDRADE AF, 2006, SURG NEUROLOGY, V65; Dennis M., 2007, COGNITIVE RESERVE TH, P53; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Falk AC, 2006, ACTA PAEDIATR, V95, P1533, DOI 10.1080/08035250600731957; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FAY TB, J INT NEURO IN PRESS; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mittenberg W., 1997, CLIN NEUROPSYCHOL, V11, P305; Overweg-Plandsoen WCG, 1999, EUR J PEDIATR, V158, P249, DOI 10.1007/s004310051061; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; STEVENS G, 1985, SOC SCI RES, V14, P142, DOI 10.1016/0049-089X(85)90008-0; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Wechsler D., 2011, WECHLSER ABBREVIATED; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	68	149	149	0	19	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2010	24	2					148	159		10.1037/a0018112			12	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	567XV	WOS:000275483100003	20230109	Green Accepted			2021-06-18	
J	Hein, AM; Stasko, MR; Matousek, SB; Scott-McKean, JJ; Maier, SF; Olschowka, JA; Costa, ACS; O'Banion, MK				Hein, Amy M.; Stasko, Melissa R.; Matousek, Sarah B.; Scott-McKean, Jonah J.; Maier, Steven F.; Olschowka, John A.; Costa, Alberto C. S.; O'Banion, M. Kerry			Sustained hippocampal IL-1 beta overexpression impairs contextual and spatial memory in transgenic mice	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Interleukin-1; Inflammation; Learning; Memory; Hippocampus; Gender; Activity-regulated cytoskeletal protein	CYTOSKELETAL-ASSOCIATED PROTEIN; DOWN-SYNDROME; INTERLEUKIN-1-BETA EXPRESSION; ALZHEIMER-DISEASE; RAT HIPPOCAMPUS; IMMUNE-RESPONSE; BRAIN-INJURY; MOUSE-BRAIN; CONSOLIDATION; ARC	Neuroinflammatory conditions such as traumatic brain injury, aging, Alzheimer's disease, and Down syndrome are often associated with cognitive dysfunction. Much research has targeted inflammation as a causative mediator of these deficits, although the diverse cellular and molecular changes that accompany these disorders obscure the link between inflammation and impaired memory. Therefore, we used a transgenic mouse model with a dormant human IL-1 beta excisional activation transgene to direct overexpression of IL-1 beta with temporal and regional control. Two weeks of hippocampal IL-1 beta overexpression impaired long-term contextual and spatial memory in both male and female mice, while hippocampal-independent and short-term memory remained intact. Human IL-1 beta overexpression activated glia, elevated murine IL-1 beta protein and PGE(2) levels, and increased pro-inflammatory cytokine and chemokine mRNAs specifically within the hippocampus, while having no detectable effect on inflammatory mRNAs in the liver. Sustained neuroinflammation also reduced basal and conditioning-induced levels of the plasticity-related gene Arc. (C) 2009 Elsevier Inc. All rights reserved.	[O'Banion, M. Kerry] Univ Rochester, Med Ctr, Dept Neurobiol & Anat, Sch Med & Dent, Rochester, NY 14642 USA; [Stasko, Melissa R.; Scott-McKean, Jonah J.; Costa, Alberto C. S.] Univ Colorado Denver, Dept Med, Div Clin Pharmacol & Toxicol, Aurora, CO 80045 USA; [Stasko, Melissa R.; Scott-McKean, Jonah J.; Costa, Alberto C. S.] Univ Colorado Denver, Neurosci Training Program, Aurora, CO 80045 USA; [Maier, Steven F.] Univ Colorado, Dept Psychol, Boulder, CO 80309 USA; [Maier, Steven F.] Univ Colorado, Ctr Neurosci, Boulder, CO 80309 USA	O'Banion, MK (corresponding author), Univ Rochester, Med Ctr, Dept Neurobiol & Anat, Sch Med & Dent, 601 Elmwood Ave,Box 603, Rochester, NY 14642 USA.	kerry_obanion@urmc.rochester.edu		Costa, Alberto/0000-0002-7855-1190; O'Banion, M. Kerry/0000-0003-1246-3363; Scott-McKean, Jonah/0000-0002-2604-6635	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 AG030149, HD056235, AG028271, T32 NS051152]; Coleman Institute; Anna & John J. Sie Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD056235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS051152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [RF1AG028271, R01AG028271, R01AG030149] Funding Source: NIH RePORTER	We thank S. Kyrkanides and J. Miller for FIV packaging, M. Olschowka and J. Walter for animal colony management, L. Trojancyzk for help with tissue processing, and R. Johnson for assistance with ELISA. The present work was supported by NIH RO1 AG030149, HD056235, and AG028271, the Coleman Institute, and the Anna & John J. Sie Foundation. The present work was supported by NIH RO1 AG030149, HD056235, AG028271, and T32 NS051152, the Coleman Institute, and the Anna & John J. Sie Foundation.	Bird MD, 2008, CELL IMMUNOL, V252, P57, DOI 10.1016/j.cellimm.2007.09.007; Bouman A, 2005, HUM REPROD UPDATE, V11, P411, DOI 10.1093/humupd/dmi008; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Campbell SJ, 2008, NEUROPHARMACOLOGY, V55, P780, DOI 10.1016/j.neuropharm.2008.06.074; Campbell SJ, 2007, NEUROBIOL DIS, V27, P151, DOI 10.1016/j.nbd.2007.04.013; Casadesus G, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-2; Costa ACS, 2008, NEUROPSYCHOPHARMACOL, V33, P1624, DOI 10.1038/sj.npp.1301535; GIBERTINI M, 1995, BRAIN BEHAV IMMUN, V9, P113, DOI 10.1006/brbi.1995.1012; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Guijarro A, 2006, PROG BRAIN RES, V153, P367, DOI 10.1016/S0079-6123(06)53022-5; Guzowski JF, 2001, J NEUROSCI, V21, P5089, DOI 10.1523/JNEUROSCI.21-14-05089.2001; Guzowski JF, 2000, J NEUROSCI, V20, P3993; Hein AM, 2007, NEUROSCIENCE, V150, P754, DOI 10.1016/j.neuroscience.2007.10.003; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; Kent S, 1996, NEUROSCI BIOBEHAV R, V20, P171, DOI 10.1016/0149-7634(95)00037-F; KENT S, 1994, PHYSIOL BEHAV, V56, P1031, DOI 10.1016/0031-9384(94)90339-5; Lai YC, 2006, ARTHRITIS RHEUM-US, V54, P1184, DOI 10.1002/art.21771; Lyketsos CG, 2007, NEUROLOGY, V68, P1800; Moga DE, 2004, NEUROSCIENCE, V125, P7, DOI 10.1016/j.neuroscience.2004.02.004; Montag-Sallaz M, 2003, LEARN MEMORY, V10, P99, DOI 10.1101/lm.53403; Montine TJ, 1999, NEUROLOGY, V53, P1495, DOI 10.1212/WNL.53.7.1495; MOORE AH, 2009, NEUROSCIENCE; Nalbandian G, 2005, IMMUNOL RES, V31, P91, DOI 10.1385/IR:31:2:091; OITZL MS, 1993, BRAIN RES, V613, P160, DOI 10.1016/0006-8993(93)90468-3; Plath N, 2006, NEURON, V52, P437, DOI 10.1016/j.neuron.2006.08.024; Ploski JE, 2008, J NEUROSCI, V28, P12383, DOI 10.1523/JNEUROSCI.1662-08.2008; Pugh CR, 2001, NEUROSCI BIOBEHAV R, V25, P29, DOI 10.1016/S0149-7634(00)00048-8; Pugh CR, 1998, BRAIN BEHAV IMMUN, V12, P212, DOI 10.1006/brbi.1998.0524; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; Rosi S, 2005, J NEUROSCI, V25, P723, DOI 10.1523/JNEUROSCI.4469-04.2005; Rosi S, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-12; Rosi S, 2008, CANCER RES, V68, P9763, DOI 10.1158/0008-5472.CAN-08-1861; Shaftel SS, 2007, J NEUROSCI, V27, P9301, DOI 10.1523/JNEUROSCI.1418-07.2007; Shaftel SS, 2007, J CLIN INVEST, V117, P1595, DOI 10.1172/JCI31450; Stasko MR, 2004, BEHAV BRAIN RES, V154, P1, DOI 10.1016/j.bbr.2004.01.012; Thomson LM, 2005, BRAIN RES BULL, V67, P24, DOI 10.1016/j.brainresbull.2005.05.024; Tonelli LH, 2008, NEUROPSYCHOPHARMACOL, V33, P1038, DOI 10.1038/sj.npp.1301488	37	149	157	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	FEB	2010	24	2					243	253		10.1016/j.bbi.2009.10.002			11	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	542PN	WOS:000273507000013	19825412	Green Accepted			2021-06-18	
J	Rowson, S; Brolinson, G; Goforth, M; Dietter, D; Duma, S				Rowson, Steven; Brolinson, Gunnar; Goforth, Mike; Dietter, Dave; Duma, Stefan			Linear and Angular Head Acceleration Measurements in Collegiate Football	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article						biomechanics; biomedical measurement; brain; patient diagnosis	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; IMPACTS; CONCUSSION; TOLERANCE; PLAYERS	Each year, between 1.6x10(6) and 3.8x10(6) concussions are sustained by athletes playing sports, with football having the highest incidence. The high number of concussions in football provides a unique opportunity to collect biomechanical data to characterize mild traumatic brain injury. Human head acceleration data for a range of impact severities were collected by instrumenting the helmets of collegiate football players with accelerometers. The helmets of ten Virginia Tech football players were instrumented with measurement devices for every game and practice for the 2007 football season. The measurement devices recorded linear and angular accelerations about each of the three axes of the head. Data for each impact were downloaded wirelessly to a sideline data collection system shortly after each impact occurred. Data were collected for 1712 impacts, creating a large and unbiased data set. While a majority of the impacts were of relatively low severity (< 30 g and < 2000 rad/s(2)), 172 impacts were greater than 40 g and 143 impacts were greater than 3000 rad/s(2). No instrumented player sustained a clinically diagnosed concussion during the 2007 season. A large and unbiased data set was compiled by instrumenting the helmets of collegiate football players. Football provides a unique opportunity to collect head acceleration data of varying severity from human volunteers. The addition of concurrent concussive data may advance the understanding of the mechanics of mild traumatic brain injury. With an increased understanding of the biomechanics of head impacts in collegiate football and human tolerance to head acceleration, better equipment can be designed to prevent head injuries.	[Rowson, Steven; Duma, Stefan] Virginia Tech Wake Forest, Ctr Injury Biomech, Blacksburg, VA 24061 USA; [Brolinson, Gunnar] Edward Via Virginia Coll Osteopath Med, Blacksburg, VA 24061 USA; [Goforth, Mike; Dietter, Dave] Virginia Tech, Dept Sports Med, Blacksburg, VA 24061 USA	Rowson, S (corresponding author), Virginia Tech Wake Forest, Ctr Injury Biomech, Blacksburg, VA 24061 USA.		Duma, Stefan/A-8368-2012; Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596	National Highway Safety Administration; Toyota Central Research and Development Labs; National Institutes of Health (National Institute for Child Health and Human Development)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER	The authors gratefully acknowledge our sponsors for this research, including the National Highway Safety Administration, Toyota Central Research and Development Labs, and National Institutes of Health (National Institute for Child Health and Human Development) (Contract No. R01HD048638).	CHU JJ, 2006, J BIOMECH S1, V42, pS534; CRISCO JJ, 2004, ASME, V126, P849; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Gurdjian E S, 1964, Clin Neurosurg, V12, P112; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; King A.I., 2003, P INT RES C BIOM IMP; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Moon D W, 1971, Med Sci Sports, V3, P44; MORRISON WE, 1983, THESIS PENN STATE U; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Newman J. A., 1999, P INT RESEAR C BIOME, P17; NEWMAN JA, 2000, P INT RES C BIOM IMP, P223; Ommaya AK, 1985, BIOMECHANICS TRAUMA; ONO K, 1980, P 24 STAPP CAR CRASH, P101; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; PINCEMAILLE Y, 1989, P 33 STAPP CAR CRASH; RATH AL, 2005, 2005010745 SAE; Reid S E, 1974, J Sports Med, V2, P86; REID SE, 1971, SURG GYNECOL OBSTETR, V133, P929; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	30	149	149	0	35	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	JUN	2009	131	6							061016	10.1115/1.3130454			7	Biophysics; Engineering, Biomedical	Biophysics; Engineering	445FO	WOS:000266035700016	19449970				2021-06-18	
J	Lau, B; Lovell, MR; Collins, MW; Pardini, J				Lau, Brian; Lovell, Mark R.; Collins, Michael W.; Pardini, Jamie			Neurocognitive and Symptom Predictors of Recovery in High School Athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; complex; neurocognitive; symptoms; simple	CONCUSSION; SPORT; IMPACT	Objectives: The Purpose of this Study was to identify specific symptom and neuropsychological test patterns that might serve as prognostic indicators of recovery in concussed high school football players. The recently proposed simple versus complex concussion classification was examined and specific symptom clusters were identified. Design: Case-control study. Setting: High school football. Participants: Subjects were 108 recently concussed male high school football athletes between the ages of 13 and 19 (mean, 16.01) years. Assessment of Risk Factors: Participants were evaluated by utilizing the Immediate Postconcussion Assessment and Cognitive Testing computer-based neurocognitive test battery at before injury and within air average of 2.23 days of injury. All athletes were followed until they met criteria for clinical recovery. Main Outcome Measures: Symptom ratings and neurocognitive test performance. Results: Both neurocognitive test results and self-reported symptom data had prognostic value in determining time to clinical recovery. Self-reported cognitive decline, Immediate Postconcussion Assessment and Cognitive Testing reaction time, and migraine headache symptoms were associated with longer time to clinical recovery. Overall, these difficulties were predictive of concussions that were retrospectively classified as complex. Conclusions: Specific symptom clusters and neurocognitive test results may have predictive value to classifying and managing concussions.	[Lau, Brian] UPMC, Ctr Sports Med, Pittsburgh, PA 15203 USA; [Lovell, Mark R.; Collins, Michael W.; Pardini, Jamie] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, Pittsburgh, PA 15261 USA	Lovell, MR (corresponding author), UPMC, Ctr Sports Med, 3200 S Water St, Pittsburgh, PA 15203 USA.	lovellmr@upmc.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; Iverson GL, 2001, CLIN J SPORT MED, V17, P31; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; PARDINI J, 2004, BRIT J SPORT MED, V38, P661; Randolph C, 2005, J ATHL TRAINING, V40, P139	11	149	150	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2009	19	3					216	221		10.1097/JSM.0b013e31819d6edb			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	443FN	WOS:000265895700004	19423974				2021-06-18	
J	Pellman, EJ; Lovell, MR; Viano, DC; Casson, IR				Pellman, EJ; Lovell, MR; Viano, DC; Casson, IR			Concussion in professional football: Recovery of NFL and high school athletes assessed by computerized neuropsychological testing - Part 12	NEUROSURGERY			English	Article						concussion; neuropsychological testing; sport injury; traumatic brain injury	SPORTS; IMPACTS; GAME; PERFORMANCE; PLAYERS; TIME	OBJECTIVE: Acute recovery from concussion (mild traumatic brain injury) is assessed in samples of NFL and high school athletes evaluated within days of injury. METHODS: All athletes were evaluated within days of injury using a computer-based neuropsychological test and symptom inventory protocol. Test performance was compared to preinjury baseline levels of a similar but not identical group of athletes who had undergone preseason testing. Statistical analyses were completed using Multivariate Analysis of Variance (MANOVA). RESULTS: NFL athletes demonstrated a rapid neuropsychological recovery. As a group, NFL athletes returned to baseline performance in a week with the majority of athletes having normal performance two days after injury. High school athletes demonstrated a slower recovery than NFL athletes. CONCLUSION: Computer-based neuropsychological testing was used within the overall medical evaluation and care of NFL athletes. As found in a prior study using more traditional neuropsychological testing, NFL players did not demonstrate decrements in neuropsychological performance beyond one week of injury. High school players demonstrated more prolonged neuropsychological effects of concussion.	ProBiomech LLC, Bloomfield Hills, MI 48304 USA; ProHLTH Care Associates LLP, Lake Success, NY USA; Univ Pittsburgh, Med Ctr, Dept Orthopaed & Sports Med, Pittsburgh, PA USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; Long Isl Jewish Med Ctr, Dept Neurol, New Hyde Pk, NY 11042 USA	Viano, DC (corresponding author), ProBiomech LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net					ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barr William B, 2002, CNS Spectr, V7, P300; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; MCCLINCY M, IN PRESS BRAIN INJ; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; *NFL COMM, 2005, CURR PLAY STAT; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; *STAT INC, 2001, STATISTICA; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	41	149	150	0	36	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2006	58	2					263	272		10.1227/01.NEU.0000200272.56192.62			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	011CT	WOS:000235246000022	16462480				2021-06-18	
J	Crawford, FC; Vanderploeg, RD; Freeman, MJ; Singh, S; Waisman, M; Michaels, L; Abdullah, L; Warden, D; Lipsky, R; Salazar, A; Mullan, MJ				Crawford, FC; Vanderploeg, RD; Freeman, MJ; Singh, S; Waisman, M; Michaels, L; Abdullah, L; Warden, D; Lipsky, R; Salazar, A; Mullan, MJ			APOE genotype influences acquisition and recall following traumatic brain injury	NEUROLOGY			English	Article							APOLIPOPROTEIN-E; HEAD-INJURY	APOE has been demonstrated to influence traumatic brain injury (TBI) outcome. The relationship between APOE genotype and memory following TBI was examined in 110 participants in the Defense and Veterans' Head Injury Program. Memory performance was worse in those who had an APOE epsilon4 allele (n = 30) than those who did not (n = 80), whereas genotype groups did not differ on demographic or injury variables or on measures of executive functioning. These data support a specific role for the APOE protein in memory outcome following TBI, and suggest an APOE isoform-specific effect on neuronal repair processes.	Univ S Florida, Roskamp Inst, Tampa, FL 33613 USA; James A Haley Vet Hosp, Tampa, FL 33612 USA; Def & Vet Head Injury Program, Tampa, FL USA; Walter Reed Army Med Ctr, Def & Vet Head Injury Program, Washington, DC 20307 USA; NIAAA, Neurogenet Lab, NIH, Bethesda, MD USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	Crawford, FC (corresponding author), Univ S Florida, Roskamp Inst, 3515 E Fletcher Ave, Tampa, FL 33613 USA.			Lipsky, Robert/0000-0001-7753-1473; Mullan, Michael/0000-0002-1473-7527			Fagan AM, 2000, MICROSC RES TECHNIQ, V50, P297, DOI 10.1002/1097-0029(20000815)50:4<297::AID-JEMT9>3.0.CO;2-C; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Small BJ, 2000, NEUROLOGY, V54, P2082, DOI 10.1212/WNL.54.11.2082; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210	10	149	150	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	APR 9	2002	58	7					1115	1118		10.1212/WNL.58.7.1115			4	Clinical Neurology	Neurosciences & Neurology	539JC	WOS:000174865900027	11940706				2021-06-18	
J	Pleines, UE; Morganti-Kossmann, MC; Rancan, M; Joller, H; Trentz, O; Kossmann, T				Pleines, UE; Morganti-Kossmann, MC; Rancan, M; Joller, H; Trentz, O; Kossmann, T			S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						IL-6; inflammation; NSE; s-100 beta; sICAM-1; traumatic brain injury	SEVERE HEAD-INJURY; CEREBROSPINAL-FLUID; COMPUTED-TOMOGRAPHY; TNF-ALPHA; SERUM; PROTEIN; ADHESION; CALCIUM; DAMAGE; CELLS	It has been hypothesized that immunoactivation may contribute to brain damage and affect outcome after traumatic brain injury (TBI). In order to determine the role of inflammation after TBI, we studied the interrelationship of the immune mediators sICAM-1 and IL-6 with the levels of S-100 beta and neuronal specific enolase (NSE), both recognized markers of brain damage. In addition, the extent and type of cerebral injury and the neurological outcome were related to these measured markers of injury. An evident elevation of S-100 beta (range of means: 2.7-81.4 ng/mL) and NSE (range of means: 2.0-81.3 ng/mL) was observed in CSF of all 13 patients during the first 3 posttraumatic days and decreased over 2 weeks. In parallel, the production of sICAM-1 (range of means: 0.7-11.9 ng/mL) and IL-6 (range of means: 0.1-8.2 ng/mL) was also markedly enhanced in CSF. The CSF means of S-100 beta and NSE per patient correlated with IL-6 (r = 0.60, p < 0.05; and r = 0.64, p < 0.05, respectively), whereas the corresponding means in serum showed a significant correlation only between NSE and IL-6 (r = 0.56, p < 0.05), Maximal CSF values of NSE and sICAM-1 Correlated with each other (r = 0.57, p < 0.05). The contusion sizes assessed on the CT scans correlated with the means of S-100 beta (r = 0.63, p < 0.05) and NSE (r = 0.71,p < 0.05) in CSF and with the mean of S-100 beta in serum, although not statistically significant (r = 0.52, p = 0.06), hut not with serum NSE, Interestingly, linear regression analysis demonstrated that means of S-100 beta in CSF (r = 0.78, p = 0.002) and serum (r = 0.82, p < 0.001) correlated with the GOS, These results indicate that the elevation of these parameters in CSF depends on the extent of injury and that S-100<beta> may be a predictor of outcome after TBI, whereas NSE reflects better the inflammatory response.	Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Div Res, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Med, Div Clin Immunol, CH-8091 Zurich, Switzerland	Kossmann, T (corresponding author), Univ Zurich Hosp, Dept Surg, Div Trauma Surg, Ramistr 100, CH-8091 Zurich, Switzerland.			Morganti-Kossmann, Cristina/0000-0002-0807-2063			ALLORE R, 1988, SCIENCE, V239, P1311, DOI 10.1126/science.2964086; BARGER SW, 1992, J BIOL CHEM, V267, P9689; BENVENISTE EN, 1992, AM J PHYSIOL, V263, P1; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; COSGROVE JW, 1983, J NEUROCHEM, V40, P806, DOI 10.1111/j.1471-4159.1983.tb08051.x; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; DelZoppo GJ, 1997, ANN NY ACAD SCI, V823, P132; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; FABRY Z, 1992, J NEUROIMMUNOL, V36, P1, DOI 10.1016/0165-5728(92)90026-H; FROHMAN EM, 1989, J NEUROIMMUNOL, V23, P117, DOI 10.1016/0165-5728(89)90030-1; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; JENNETT B, 1976, LANCET, V1, P1031; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; MAHNKE K, 1995, J LEUKOCYTE BIOL, V57, P63; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; MARSHAK DR, 1990, PROG BRAIN RES, V86, P169; Marshall SB, 1991, J NEUROSURG S, V75, P14; MORGANTIKOSSMAN.MC, 2000, CURR OPIN CRIT CARE, V6, P98; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; RIECKMANN P, 1993, J NEUROIMMUNOL, V47, P133, DOI 10.1016/0165-5728(93)90023-R; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; SELINFREUND RH, 1994, MOL PHARMACOL, V45, P1215; SIESJO BK, 1989, MAGNESIUM, V8, P223; STOCKER R, 1995, INTEGRATED APPROACH, P197; VANKELECOM H, 1993, J HISTOCHEM CYTOCHEM, V41, P151, DOI 10.1177/41.2.8419456; VANKOOYK Y, 1993, CELL ADHES COMMUN, V1, P21, DOI 10.3109/15419069309095679; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345	34	149	162	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2001	18	5					491	498		10.1089/089771501300227297			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	435CN	WOS:000168860000002	11393252				2021-06-18	
J	Adelson, PD; Clyde, B; Kochanek, PM; Wisniewski, SR; Marion, DW; Yonas, H				Adelson, PD; Clyde, B; Kochanek, PM; Wisniewski, SR; Marion, DW; Yonas, H			Cerebrovascular response in infants and young children following severe traumatic brain injury: A preliminary report	PEDIATRIC NEUROSURGERY			English	Article						head injury; cerebral blood flow; xenon computed tomography	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; METABOLISM; ADOLESCENTS; TOMOGRAPHY; SCORE; AGE	To further describe the pathophysiologic processes that occur in infants and young children after severe traumatic brain injury (TBI), we retrospectively reviewed the cerebral blood flow (CBF) values and 6-month Glasgow Outcome Scores (GOS) in 30 children less than or equal to 8 years old (25 were less than or equal to 4 years old) with a Glasgow Coma Score (GCS) on admission of less than or equal to 8. Twelve females and 18 males (mean age 2.1 years, range 1 month to 8 years) underwent 61 CBF studies using stable xenon computed tomography at variable times from admission to 9 days after TBI. In 12 patients, PaCO2 was manipulated an average of 8.4 torr (range 5-11 torr) and a second CBF study performed to determine CO2 vasoreactivity (CO2VR), defined as the percent change in CBF per torr change in PaCO2. CBF on admission (n = 13) was 25.1 +/- 7.7 ml/100 g/min (mean +/- SEM) and was less than or equal to 20 ml/100 g/min in 10 of 13 patients (77%). By 24 h and for up to 6 days after TBI, the mean CBF increased to 55.3 +/- 3.4 ml/100 g/min (range 2-95) which differed significantly from the admission CBF value (p < 0.05); a CBF of > 70 ml/100 g/min tended to be associated with a good outcome. Poor outcome (GOS less than or equal to 3) was seen uniformly in children under the age of 1 year and in patients with a CBF of less than or equal to 20 ml/100 g/min any time after TBI. Poor outcome was seen in 85% of children under the age of 24 months, but in only 41 % of children greater than or equal to 24 months old. Mean CO2VR was 2.1 +/- 0.6%/torr PaCO2 and ranged from 0.02 to 5.98%. Mean CO2VR tended to differ between good and poor outcome children (3.2 +/- 0.9 and 1.17 +/- 0.2%, respectively) and a (COVR)-V-2 of less than or equal to 2% was significantly associated with a poor outcome. Younger age, low CBF in the early period after TBI, and a CO2VR of < 2% was associated with a poor outcome in this subgroup of children. Young children (< 24 months) may represent a particular high-risk group with early hypoperfusion after severe TBI. This finding may be a key factor in the pathophysiology and outcome in this age group, and may need to be addressed in our future therapeutic protocols.	Childrens Hosp Pittsburgh, Dept Pediat Neurosurg, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Dept Publ Hlth, Pittsburgh, PA USA	Adelson, PD (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat Neurosurg, 3705 5th Ave, Pittsburgh, PA 15213 USA.	david-adelson@POPLAR.chp.edu	Marion, Donald/AAR-5749-2021; Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; Marion, Donald/0000-0003-4627-7702	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001809] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08-NS01809-01] Funding Source: Medline		ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BEYDA DH, 1996, CRIT CARE MED, V24, P134; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CHIRON C, 1992, J NUCL MED, V33, P696; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P222; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; GUR D, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P68; JENNETT B, 1975, LANCET, V1, P480; KASOFF SS, 1972, J NEUROSURG, V36, P463, DOI 10.3171/jns.1972.36.4.0463; KOCHANEK PK, 1995, CURRENT CONCEPTS PED; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARMAROU A, 1996, P 10 INT BRAIN ED S, P90; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1993, J CEREB BLOOD FLOW M, V13, P571; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403	26	149	150	0	9	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	APR	1997	26	4					200	207					8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	YP088	WOS:000071240000007	9436831				2021-06-18	
J	Kochanek, OM; Marion, DW; Zhang, WG; Schiding, JK; White, M; Palmer, AM; Clark, RSB; OMalley, ME; Styren, SD; Ho, C; DeKosky, ST				Kochanek, OM; Marion, DW; Zhang, WG; Schiding, JK; White, M; Palmer, AM; Clark, RSB; OMalley, ME; Styren, SD; Ho, C; DeKosky, ST			Severe controlled cortical impact in rats: Assessment of cerebral edema, blood flow, and contusion volume	JOURNAL OF NEUROTRAUMA			English	Article						contusion; head injury; magnetic resonance imaging; trauma, traumatic brain injury	TRAUMATIC BRAIN INJURY; ISCHEMIA; MODEL	Controlled cortical impact (CCI) is a contemporary model of experimental cerebral contusion. We examined the cerebrovascular and neuropathologic effects of a severe CCI in rats. The utility of magnetic resonance imaging (MRI) for the assessment of contusion volume after severe CCI was also established. Severe CCI(3.0 mm depth, 4 m/sec velocity) to the left (L) parietal cortex was produced in anesthetized (isoflurane/N2O/O-2), intubated, and mechanically ventilated male Sprague-Dawley rats (n = 58). Physiologic parameters were controlled. The time coure of alterations in edema [L-R% brain water (% BW) in 3-mm coronal sections through injured and contralateral hemispheres, wet-dry weight] was evaluated at 2 h, 24 h, 48 h, and 7 days posttrauma. Local cerebral blood flow (ICBF, measured in 8 structures in each hemisphere by autoradiography) was evaluated at 2 h, 24 h, and 7 days. Contusion volume (measured by histology and image analysis) was assessed at 14 days and measured in 6 rats by both MRI and histology. The survival rate after severe CCI was 96.2%. The L-R difference in % BW increased to 1.69 +/- 0.18% at 2 h, 3.00 +/- 0.08% at 24 h, 2.69 +/- 0.09% at 48 h, and 0.94 +/- 0.21% at 7 days. These values all differed from the control (p < 0.05). The % BW was greater at 24 h and 48 h than at 2 h and 7 days (p < 0.05). Marked reductions in lCBF were limited to structures in the injured hemisphere and were observed in the parietal cortex (2 and 24 h), subcortical white matter (2 and 24 h), and hippocampus (2 h), (p < 0.05) vs control rats. In the contusion core, ICBF was 19.4 +/- 8.8 mL 100 g(-1) min(-1) at 24 h (p = 0.011 vs normal). Necrosis was seen in large portions of the parietal cortex and subcortical white matter, and portions of the hippocampus and thalamus. Contusion volume was 47.8 +/- 9.2 mm(3), which represented 14.4 +/- 2.1% of the traumatized hemisphere. Estimates of contusion volume by MRI and histology were closely correlated (r = 0.941, p < 0.017). Severe CCI in rats is accompanied by contusion, reproducible edema, and marked hypoperfusion, involving over 14% of the injured hemisphere, and can be produced with minimal mortality. T-2-weighted MRI successfully and noninvasively identifies contusion volume in this model.	UNIV PITTSBURGH,BRAIN TRAUMA RES CTR,PITTSBURGH,PA 15260; UNIV PITTSBURGH,DEPT ANESTHESIOL & CRIT CARE MED,PITTSBURGH,PA 15260; UNIV PITTSBURGH,DEPT NEUROSURG,PITTSBURGH,PA 15260; UNIV PITTSBURGH,DEPT PSYCHIAT,PITTSBURGH,PA 15260; UNIV PITTSBURGH,DEPT NEUROL,PITTSBURGH,PA 15260; UNIV PITTSBURGH,DEPT PEDIAT,PITTSBURGH,PA 15260; CARNEGIE MELLON UNIV,PITTSBURGH NMR CTR BIOMED RES,PITTSBURGH,PA; CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	Kochanek, OM (corresponding author), SAFAR CTR RESUSCITAT RES,201 HILL BLDG,3434 5TH AVE,PITTSBURGH,PA 15260, USA.		Palmer, Alan/AAP-8650-2020; Marion, Donald/AAR-5749-2021; Ho, Chien/O-6112-2016; Kochanek, Patrick M/D-2371-2015	Ho, Chien/0000-0002-4094-9232; Kochanek, Patrick M/0000-0002-2627-913X	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR 03631] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2P50 NS30318-04A1, NS 30318] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR003631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318] Funding Source: NIH RePORTER		ADAMS JH, 1975, HDB CLINICAL NEUROLO, V23, P35; BARONE FC, 1991, BRAIN RES BULL, V26, P285, DOI 10.1016/0361-9230(91)90240-K; Biagas K. V., 1992, Society for Neuroscience Abstracts, V18, P1088; BRYAN RM, 1994, J NEUROTRAUM, V11, P104; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CLARK R, 1994, 1994 P INT RES RES C; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; De Vet AC, 1976, HDB CLIN NEUROLOGY, V24, P351; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, 1994, J NEUROTRAUM, V11, P107; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HOVDA DA, 1993, J CEREB BLOOD FLOW M, V13, pS574; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ITO U, 1979, STROKE, V10, P542, DOI 10.1161/01.STR.10.5.542; JACEWICZ M, 1990, J CEREBR BLOOD F MET, V10, P903, DOI 10.1038/jcbfm.1990.147; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; MEIBOOM S, 1958, REV SCI INSTRUM, V29, P688, DOI 10.1063/1.1716296; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Povlishock J.T., 1994, NEUROBIOLOGY CENTRAL, P109; RIBAS GC, 1992, J NEUROTRAUM, V9, pS265; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOKAL RR, 1981, BIOMETRY, P413; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; VANDENBRINK WA, 1990, ACT NEUR S, V51, P261; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	35	149	150	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1995	12	6					1015	1025		10.1089/neu.1995.12.1015			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TU518	WOS:A1995TU51800002	8742130				2021-06-18	
J	Shahim, P; Gren, M; Liman, V; Andreasson, U; Norgren, N; Tegner, Y; Mattsson, N; Andreasen, N; Ost, M; Zetterberg, H; Nellgard, B; Blennow, K				Shahim, Pashtun; Gren, Magnus; Liman, Victor; Andreasson, Ulf; Norgren, Niklas; Tegner, Yelverton; Mattsson, Niklas; Andreasen, Niels; Ost, Martin; Zetterberg, Henrik; Nellgard, Bengt; Blennow, Kaj			Serum neurofilament light protein predicts clinical outcome in traumatic brain injury	SCIENTIFIC REPORTS			English	Article							CEREBROSPINAL-FLUID; S-100B PROTEIN; S100B; BIOMARKERS; SEVERITY; DAMAGE; GFAP; CSF	Axonal white matter injury is believed to be a major determinant of adverse outcomes following traumatic brain injury (TBI). We hypothesized that measurement of neurofilament light protein (NF-L), a protein found in long white-matter axons, in blood samples, may serve as a suitable biomarker for neuronal damage in TBI patients. To test our hypotheses, we designed a study in two parts: i) we developed an immunoassay based on Single molecule array technology for quantification of NF-L in blood, and ii) in a proof-of-concept study, we tested our newly developed method on serial serum samples from severe TBI (sTBI) patients (n = 72) and controls (n = 35). We also compared the diagnostic and prognostic utility of NF-L with the established blood biomarker S100B. NF-L levels were markedly increased in sTBI patients compared with controls. NF-L at admission yielded an AUC of 0.99 to detect TBI versus controls (AUC 0.96 for S100B), and increased to 1.00 at day 12 (0.65 for S100B). Importantly, initial NF-L levels predicted poor 12-month clinical outcome. In contrast, S100B was not related to outcome. Taken together, our data suggests that measurement of serum NF-L may be useful to assess the severity of neuronal injury following sTBI.	[Shahim, Pashtun; Gren, Magnus; Liman, Victor; Andreasson, Ulf; Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad, Clin Neurochem Lab,Inst Neurosci & Phys, SE-43180 Molndal, Sweden; [Norgren, Niklas] UmanDiagnostics, Umea, Sweden; [Tegner, Yelverton] Lulea Univ Technol, Dept Hlth Sci, Div Med Sci, SE-97187 Lulea, Sweden; [Mattsson, Niklas] Lund Univ, Clin Memory Res Unit, Malmo, Sweden; [Andreasen, Niels] Ctr Alzheimer Res, Inst Care, Dept NVS, Stockholm, Sweden; [Ost, Martin; Nellgard, Bengt] Gothenburg Univ, Sahlgrenska Acad, Inst Clin Sci, Dept Anaesthesiol & Intens Care, Gothenburg, Sweden; [Nellgard, Bengt] UCL, Inst Neurol, Dept Mol Neurosci, London WC1N 1PJ, England	Blennow, K (corresponding author), Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad, Clin Neurochem Lab,Inst Neurosci & Phys, SE-43180 Molndal, Sweden.	kaj.blennow@neuro.gu.se	Mattsson-Carlgren, Niklas/H-7597-2019; Ost, Martin/AAY-5827-2020	Mattsson-Carlgren, Niklas/0000-0002-8885-7724; Tegner, Yelverton/0000-0003-3628-0705	Swedish Research CouncilSwedish Research CouncilEuropean Commission [14002, 2013-2546]; Torsten Soderberg Foundation at the Royal Swedish Academy of Sciences; Swedish Brain Foundation; Centre for Sports Medicine Research, Sweden; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; VinnovaVinnova	This study was supported by the Swedish Research Council (grant # 14002 and 2013-2546), the Torsten Soderberg Foundation at the Royal Swedish Academy of Sciences, the Swedish Brain Foundation, the Centre for Sports Medicine Research, Sweden, the Knut and Alice Wallenberg Foundation and Vinnova. The funding sources had no role in the design, and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. P.S. and K.B. had full access to all the data in the study and had final responsibility for the decision to submit for publication.	Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177; Al Nimer F, 2013, BRAIN BEHAV IMMUN, V27, P109, DOI 10.1016/j.bbi.2012.10.002; Barry DM, 2007, EXP CELL RES, V313, P2110, DOI 10.1016/j.yexcr.2007.03.011; Berger RP, 2010, DEV NEUROSCI-BASEL, V32, P396, DOI 10.1159/000316803; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Eikelenboom MJ, 2003, NEUROLOGY, V60, P219, DOI 10.1212/01.WNL.0000041496.58127.E3; Ercole A, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0614-3; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; JENNETT B, 1975, LANCET, V1, P480; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; Lepinoux-Chambaud C, 2013, HISTOCHEM CELL BIOL, V140, P13, DOI 10.1007/s00418-013-1101-1; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Ljungqvist J., 2016, J NEUROTRAU IN PRESS; Lu CH, 2015, NEUROLOGY, V84, P2247, DOI 10.1212/WNL.0000000000001642; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Martinez-Morillo E, 2015, CLIN CHEM LAB MED, V53, P1575, DOI 10.1515/cclm-2014-0908; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Norgren N, 2003, BRAIN RES, V987, P25, DOI 10.1016/S0006-8993(03)03219-0; Olshen RA, 1984, CLASSIFICATION REGRE; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Raabe A, 2004, NEUROL RES, V26, P440, DOI 10.1179/016164104225015958; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Ryb GE, 2014, BRAIN INJURY, V28, P1430, DOI 10.3109/02699052.2014.919525; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Skillback T, 2014, NEUROLOGY, V83, P1945, DOI 10.1212/WNL.0000000000001015; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Tortorella C, 2015, MULT SCLER J, V21, P396, DOI 10.1177/1352458514546789; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2016, JAMA NEUROL, V73, P60, DOI 10.1001/jamaneurol.2015.3037; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	47	148	149	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	NOV 7	2016	6								36791	10.1038/srep36791			9	Multidisciplinary Sciences	Science & Technology - Other Topics	EB0YP	WOS:000387073100001	27819296	DOAJ Gold, Green Published	Y	N	2021-06-18	
J	Bieniek, KF; Ross, OA; Cormier, KA; Walton, RL; Soto-Ortolaza, A; Johnston, AE; DeSaro, P; Boylan, KB; Graff-Radford, NR; Wszolek, ZK; Rademakers, R; Boeve, BF; McKee, AC; Dickson, DW				Bieniek, Kevin F.; Ross, Owen A.; Cormier, Kerry A.; Walton, Ronald L.; Soto-Ortolaza, Alexandra; Johnston, Amelia E.; DeSaro, Pamela; Boylan, Kevin B.; Graff-Radford, Neill R.; Wszolek, Zbigniew K.; Rademakers, Rosa; Boeve, Bradley F.; McKee, Ann C.; Dickson, Dennis W.			Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank	ACTA NEUROPATHOLOGICA			English	Article						Chronic traumatic encephalopathy; Traumatic brain injury; Sports; Microtubule-associated protein tau; Brain bank	TDP-43 PROTEINOPATHY; E EPSILON-4; HEAD; DISEASE; INJURY; DEGENERATION; EXPRESSION; DEPOSITION; FOOTBALL; FEATURES	Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disorder linked to repetitive traumatic brain injury (TBI) and characterized by deposition of hyperphosphorylated tau at the depths of sulci. We sought to determine the presence of CTE pathology in a brain bank for neurodegenerative disorders for individuals with and without a history of contact sports participation. Available medical records of 1721 men were reviewed for evidence of past history of injury or participation in contact sports. Subsequently, cerebral cortical samples were processed for tau immunohistochemistry in cases with a documented history of sports exposure as well as age- and disease-matched men and women without such exposure. For cases with available frozen tissue, genetic analysis was performed for variants in APOE, MAPT, and TMEM106B. Immunohistochemistry revealed 21 of 66 former athletes had cortical tau pathology consistent with CTE. CTE pathology was not detected in 198 individuals without exposure to contact sports, including 33 individuals with documented single-incident TBI sustained from falls, motor vehicle accidents, domestic violence, or assaults. Among those exposed to contact sports, those with CTE pathology did not differ from those without CTE pathology with respect to noted clinicopathologic features. There were no significant differences in genetic variants for those with CTE pathology, but we observed a slight increase in MAPT H1 haplotype, and there tended to be fewer homozygous carriers of the protective TMEM106B rs3173615 minor allele in those with sports exposure and CTE pathology compared to those without CTE pathology. In conclusion, this study has identified a small, yet significant, subset of individuals with neurodegenerative disorders and concomitant CTE pathology. CTE pathology was only detected in individuals with documented participation in contact sports. Exposure to contact sports was the greatest risk factor for CTE pathology. Future studies addressing clinical correlates of CTE pathology are needed.	[Bieniek, Kevin F.; Ross, Owen A.; Walton, Ronald L.; Soto-Ortolaza, Alexandra; Rademakers, Rosa; Dickson, Dennis W.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA; [Bieniek, Kevin F.] Mayo Clin, Mayo Grad Sch, Rochester, MN 55905 USA; [Cormier, Kerry A.; McKee, Ann C.] VA Boston HealthCare Syst, Boston, MA 02130 USA; [Johnston, Amelia E.; DeSaro, Pamela; Boylan, Kevin B.; Graff-Radford, Neill R.; Wszolek, Zbigniew K.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA; [Boeve, Bradley F.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA; [McKee, Ann C.] Boston Univ, Dept Neurol & Pathol, Alzheimers Dis Ctr, Boston, MA 02118 USA; [McKee, Ann C.] Boston Univ, CTE Program, Sch Med, Boston, MA 02118 USA	Dickson, DW (corresponding author), Mayo Clin, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	dickson.dennis@mayo.edu	Wszolek, Zbigniew K./AAB-1431-2019	Ross, Owen/0000-0003-4813-756X; Bieniek, Kevin/0000-0003-4922-864X	National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P50 NS072187, R01 NS076471, R01 NS078086, UO1 NS086659-01, P30 AG13846, 0572063345-5]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659, R01NS076471, R01NS078086, P50NS072187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG016574, P30AG013846] Funding Source: NIH RePORTER	We would like to thank the patients and their families. Without their generous donation, these studies would not be possible. We would also like to thank Monica Castanedes-Casey, Virginia Philips, and Linda Rousseau for their neurohistologic assistance, Michael DeTure for brain banking, and Deann Gibson for coordination of brain donations. This study was supported by the National Institute of Health (NIH) P50 NS072187 (OAR, ZKW, RR, DWD), R01 NS076471 (RR), R01 NS078086 (OAR), UO1 NS086659-01 (ACM), P30 AG13846 (ACM; supplement 0572063345-5). Other support included an unrestricted gift from Carl Edward Bolch Jr. and Susan Bass Bolch (ZKW), Department of Veterans Affairs (ACM), Veterans Affairs Biorepository CSP 501 (ACM), Sports Legacy Institute (ACM), National Operating Committee on Standards for Athletic Equipment (ACM), the National Football League (ACM), the Andlinger Foundation (ACM), and the WWE (ACM).	Aoki N, 2015, ACTA NEUROPATHOL, V129, P53, DOI 10.1007/s00401-014-1358-z; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Cantu RC, 2009, BRIT J SPORT MED, V43, P981, DOI 10.1136/bjsm.2009.067728; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Fournier CN, 2015, NEUROLOGY, V84, P1788, DOI 10.1212/WNL.0000000000001522; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Houlden H, 2001, NEUROLOGY, V56, P1702, DOI 10.1212/WNL.56.12.1702; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; Josephs KA, 2004, ARCH NEUROL-CHICAGO, V61, P1579, DOI 10.1001/archneur.61.10.1579; King A, 2010, NEUROPATHOLOGY, V30, P408, DOI 10.1111/j.1440-1789.2009.01085.x; Kokjohn TA, 2013, J NEUROTRAUM, V30, P981, DOI 10.1089/neu.2012.2699; Koroshetz W, 2015, REPORT 1 NIH CONSENS; Kovacs GG, 2013, ACTA NEUROPATHOL, V126, P365, DOI 10.1007/s00401-013-1157-y; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Murray ME, 2014, ACTA NEUROPATHOL, V128, P411, DOI 10.1007/s00401-014-1302-2; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Rademakers R, 2005, HUM MOL GENET, V14, P3281, DOI 10.1093/hmg/ddi361; Santa-Maria I, 2012, ACTA NEUROPATHOL, V124, P693, DOI 10.1007/s00401-012-1017-1; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Uchihara T, 2001, ACTA NEUROPATHOL, V102, P462; Van Deerlin VM, 2010, NAT GENET, V42, P234, DOI 10.1038/ng.536; Yu L, 2015, NEUROLOGY, V84, P927, DOI 10.1212/WNL.0000000000001313	37	148	149	2	69	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	DEC	2015	130	6					877	889		10.1007/s00401-015-1502-4			13	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CW9FU	WOS:000365304900009	26518018	Green Accepted			2021-06-18	
J	Barnes, DE; Kaup, A; Kirby, KA; Byers, AL; Diaz-Arrastia, R; Yaffe, K				Barnes, Deborah E.; Kaup, Allison; Kirby, Katharine A.; Byers, Amy L.; Diaz-Arrastia, Ramon; Yaffe, Kristine			Traumatic brain injury and risk of dementia in older veterans	NEUROLOGY			English	Article							ALZHEIMERS-DISEASE; HEAD-INJURY; COGNITIVE DECLINE; DEATH; US	Objectives: Traumatic brain injury (TBI) is common in military personnel, and there is growing concern about the long-term effects of TBI on the brain; however, few studies have examined the association between TBI and risk of dementia in veterans. Methods: We performed a retrospective cohort study of 188,764 US veterans aged 55 years or older who had at least one inpatient or outpatient visit during both the baseline (2000-2003) and follow-up (2003-2012) periods and did not have a dementia diagnosis at baseline. TBI and dementia diagnoses were determined using ICD-9 codes in electronic medical records. Fine-Gray proportional hazards models were used to determine whether TBI was associated with greater risk of incident dementia, accounting for the competing risk of death and adjusting for demographics, medical comorbidities, and psychiatric disorders. Results: Veterans were a mean age of 68 years at baseline. During the 9-year follow-up period, 16% of those with TBI developed dementia compared with 10% of those without TBI (adjusted hazard ratio, 1.57; 95% confidence interval: 1.35-1.83). There was evidence of an additive association between TBI and other conditions on risk of dementia. Conclusions: TBI in older veterans was associated with a 60% increase in the risk of developing dementia over 9 years after accounting for competing risks and potential confounders. Our results suggest that TBI in older veterans may predispose toward development of symptomatic dementia and raise concern about the potential long-term consequences of TBI in younger veterans and civilians.	[Barnes, Deborah E.; Kaup, Allison; Kirby, Katharine A.; Byers, Amy L.; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Barnes, Deborah E.; Kaup, Allison; Kirby, Katharine A.; Byers, Amy L.; Yaffe, Kristine] San Francisco VA Med Ctr, Bethesda, MD USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA; [Diaz-Arrastia, Ramon] Ctr Neurosci & Regenerat Med, Bethesda, MD USA	Barnes, DE (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.	Deborah.barnes@ucsf.edu		Kirby, Katharine/0000-0003-0876-8113; Diaz-Arrastia, Ramon/0000-0001-6051-3594	Department of Defense/NCIREUnited States Department of Defense [W81XWH-11-2-0189, 1610, 1614, W81XWH-12-1-0581]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K24 AG031155]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K24AG031155] Funding Source: NIH RePORTER	Supported by the Department of Defense/NCIRE (Barnes: W81XWH-11-2-0189, project 1610; Byers: W81XWH-11-2-0189, project 1614; Yaffe: W81XWH-12-1-0581) and the NIH (Yaffe: K24 AG031155). The funders did not contribute to the design of the study, analysis or interpretation of data, or decision to publish. The views expressed do not necessarily reflect those of the funders.	Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Breteler MMB, 1995, AM J EPIDEMIOL, V142, P1300, DOI 10.1093/oxfordjournals.aje.a117597; Byers AL, 2012, AM J GERIAT PSYCHIAT, V20, P664, DOI 10.1097/JGP.0b013e31822001c1; Cordts PR, 2008, J TRAUMA, V64, pS14, DOI 10.1097/TA.0b013e31816093bd; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Faul M, 2010, TRAUMATIC BRAIN INJU; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Institute of Medicine of the National Academies, 2008, GULF WAR HLTH, V7; Jawaid A, 2009, NEURODEGENER DIS, V6, P219, DOI 10.1159/000258704; Kalkonde YV, 2012, ALZHEIMERS DEMENT, V8, P204, DOI 10.1016/j.jalz.2011.03.011; Kim HT, 2007, CLIN CANCER RES, V13, P559, DOI 10.1158/1078-0432.CCR-06-1210; Krishnan LL, 2005, DEMENT GERIATR COGN, V20, P245, DOI 10.1159/000087345; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sohn Min-Woong, 2006, Popul Health Metr, V4, P2, DOI 10.1186/1478-7954-4-2; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; VA Dementia Registry Task Force, 2006, VA DEM REG METH REP; VIReC) VIRC, VHA VIT STAT FIL; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61	39	148	148	1	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUL 22	2014	83	4					312	319		10.1212/WNL.0000000000000616			8	Clinical Neurology	Neurosciences & Neurology	AM9YH	WOS:000340236500010	24966406	Green Published			2021-06-18	
J	Rosenthal, JA; Foraker, RE; Collins, CL; Comstock, RD				Rosenthal, Joseph A.; Foraker, Randi E.; Collins, Christy L.; Comstock, R. Dawn			National High School Athlete Concussion Rates From 2005-2006 to 2011-2012	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; high school; athlete; epidemiology	STATES HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; AGREEMENT STATEMENT; CONSENSUS STATEMENT; SEX-DIFFERENCES; SPORTS; SYMPTOMS; EPIDEMIOLOGY; PERFORMANCE; PREVENTION	Background: High school athletes are at risk for concussions. Although a previously published study showed an increase in concussion rates for a single school district, it remains unknown if the rate of concussions among high school athletes is increasing nationally. Purpose: To investigate national high school athlete concussion rates over time. Study Design: Descriptive epidemiologic study. Methods: The rate of concussions per 1000 athlete-exposures was calculated for academic years 2005-2006 through 2011-2012 using the High School Reporting Information Online sports injury surveillance system. Results: During the 7-year period of this study, High School Reporting Information Online captured 4024 concussions with overall concussion diagnosis rates increasing significantly from 0.23 to 0.51 (P = .004). Concussion diagnosis rates increased for each of the 9 sports studied, with 5 sports having statistically significant increases over this 7-year period. Conclusion: The study analysis indicates that national concussion diagnosis rates for high school sports have increased significantly over time.	[Rosenthal, Joseph A.; Foraker, Randi E.; Collins, Christy L.; Comstock, R. Dawn] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH USA	Rosenthal, JA (corresponding author), Ohio State Univ, Wexner Med Ctr, 480 Med Ctr Dr, Columbus, OH 43210 USA.	joseph.rosenthal@osumc.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Centers for Disease Control and Prevention, 2013, HEADS CONC HIGH SCH; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; National Federation of State High School Associations, 2011, NAT FED STAT HIGH SC; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Savitz DA, 2003, INTERPRETING EPIDEMI; Sawyer RJ, 2010, HEALTH PROMOT PRACT, V11, P34, DOI 10.1177/1524839907309377; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020	30	148	148	1	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUL	2014	42	7					1710	1715		10.1177/0363546514530091			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	AN6QT	WOS:000340721900030	24739186				2021-06-18	
J	McAllister, TW; Ford, JC; Flashman, LA; Maerlender, A; Greenwald, RM; Beckwith, JG; Bolander, RP; Tosteson, TD; Turco, JH; Raman, R; Jain, S				McAllister, Thomas W.; Ford, James C.; Flashman, Laura A.; Maerlender, Arthur; Greenwald, Richard M.; Beckwith, Jonathan G.; Bolander, Richard P.; Tosteson, Tor D.; Turco, John H.; Raman, Rema; Jain, Sonia			Effect of head impacts on diffusivity measures in a cohort of collegiate contact sport athletes	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; WHITE-MATTER INTEGRITY; FOOTBALL PLAYERS; MILD; CONCUSSION; ACCELERATION; MAGNITUDE; EXPOSURES; LOCATION	Objective:To determine whether exposure to repetitive head impacts over a single season affects white matter diffusion measures in collegiate contact sport athletes.Methods:A prospective cohort study at a Division I NCAA athletic program of 80 nonconcussed varsity football and ice hockey players who wore instrumented helmets that recorded the acceleration-time history of the head following impact, and 79 non-contact sport athletes. Assessment occurred preseason and shortly after the season with diffusion tensor imaging and neurocognitive measures.Results:There was a significant (p = 0.011) athlete-group difference for mean diffusivity (MD) in the corpus callosum. Postseason fractional anisotropy (FA) differed (p = 0.001) in the amygdala (0.238 vs 0.233). Measures of head impact exposure correlated with white matter diffusivity measures in several brain regions, including the corpus callosum, amygdala, cerebellar white matter, hippocampus, and thalamus. The magnitude of change in corpus callosum MD postseason was associated with poorer performance on a measure of verbal learning and memory.Conclusion:This study suggests a relationship between head impact exposure, white matter diffusion measures, and cognition over the course of a single season, even in the absence of diagnosed concussion, in a cohort of college athletes. Further work is needed to assess whether such effects are short term or persistent.	[McAllister, Thomas W.; Ford, James C.; Flashman, Laura A.; Maerlender, Arthur] Dartmouth Coll, Dept Psychiat, Geisel Sch Med, Hanover, NH 03755 USA; [Tosteson, Tor D.] Dartmouth Coll, Dept Community & Family Med, Geisel Sch Med, Hanover, NH 03755 USA; [Turco, John H.] Dartmouth Coll, Dept Med, Geisel Sch Med, Hanover, NH 03755 USA; [Greenwald, Richard M.; Beckwith, Jonathan G.; Bolander, Richard P.] Simbex LLC, Lebanon, NH USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Raman, Rema; Jain, Sonia] Univ Calif San Diego, Dept Family & Prevent Med, Biostat Res Ctr, San Diego, CA 92103 USA	McAllister, TW (corresponding author), Dartmouth Coll, Dept Psychiat, Geisel Sch Med, Hanover, NH 03755 USA.	twmcalli@iupui.edu	Ford, James/AAF-7039-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD048638, RO1NS055020]; National Operating Committee on Standards for Athletic Equipment [NOCSAE 04-07]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	NIH R01HD048638 and RO1NS055020 and the National Operating Committee on Standards for Athletic Equipment (NOCSAE 04-07).	Alexander MP, 2003, BRAIN, V126, P1493, DOI 10.1093/brain/awg128; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Cantu R., 2012, CONCUSSIONS OUR KIDS; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Farrell JAD, 2007, J MAGN RESON IMAGING, V26, P756, DOI 10.1002/jmri.21053; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Fjordbak BS, 2011, ASHA LEADER; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Johnson EK, 2006, REHABIL COUNS BULL, V50, P35, DOI 10.1177/00343552060500010501; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Nowinski C, SPORTS LEGACY I HIT; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Reuter M, 2011, NEUROIMAGE, V57, P19, DOI 10.1016/j.neuroimage.2011.02.076; Reuter M, 2010, NEUROIMAGE, V53, P1181, DOI 10.1016/j.neuroimage.2010.07.020; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Schmahmann JD, 2004, J NEUROPSYCH CLIN N, V16, P367, DOI 10.1176/appi.neuropsych.16.3.367; Talavage T, J NEUROTRAUMA; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	40	148	148	0	23	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JAN 7	2014	82	1					63	69		10.1212/01.wnl.0000438220.16190.42			7	Clinical Neurology	Neurosciences & Neurology	AJ4ZR	WOS:000337690000014	24336143	Green Published			2021-06-18	
J	Brenner, LA; Ivins, BJ; Schwab, K; Warden, D; Nelson, LA; Jaffee, M; Terrio, H				Brenner, Lisa A.; Ivins, Brian J.; Schwab, Karen; Warden, Deborah; Nelson, Lonnie A.; Jaffee, Michael; Terrio, Heidi			Traumatic Brain Injury, Posttraumatic Stress Disorder, and Postconcussive Symptom Reporting Among Troops Returning From Iraq	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Iraq; postconcussive symptoms; PTSD; soldiers; TBI; traumatic brain injury	MILD HEAD-INJURY; AFGHANISTAN; VETERANS; COMBAT	Objectives: Analyze the contribution of mild traumatic brain injury (mTBI) and/or posttraumatic stress disorder (PTSD) to the endorsement of postconcussive (PC) symptoms during Post Deployment Health Assessment. Determine whether a combination of mTBI and PTSD was more strongly associated with symptoms than either condition alone. Methods: Cross-sectional study design where both the exposure, mTBI and/or PTSD, and the outcomes of interest, PCsymptoms, were ascertained after return from deployment. Subjects were injured soldiers (n = 1247) from one Fort Carson Brigade Combat Team (n = 3973). Main Outcome Measures: Positive history of PC symptoms. Results: PTSD and mTBI together were more strongly associated with having PC symptoms (adjusted prevalence ratio 6.27; 95% CI: 4.13-9.43) than either mTBI alone (adjusted prevalence ratio = 4.03; 95% CI: 2.67-6.07) or PTSD alone (adjusted prevalence ratio = 2.74; 95% CI: 1.58-4.74) after adjusting for age, gender, education, rank, and Military Occupational Specialty. Conclusions: In soldiers with histories of physical injury, mTBI and PTSD were independently associated with PC symptom reporting. Those with both conditions were at greater risk for PC symptoms than those with either PTSD, mTBI, or neither. Findings support the importance of continued screening for both conditions with the aim of early identification and intervention.	[Brenner, Lisa A.] VA VISN 19 Mental Illness Res Educ & Clin Ctr, Denver, CO 80220 USA; [Brenner, Lisa A.] Univ Colorado Denver, Sch Med, Dept Psychiat, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Sch Med, Dept Neurol, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Sch Med, Dept Phys Med & Rehabil, Denver, CO USA; [Nelson, Lonnie A.; Terrio, Heidi] Evans Army Community Hosp, Dept Deployment Hlth, Ft Carson, CO USA	Brenner, LA (corresponding author), VA VISN 19 Mental Illness Res Educ & Clin Ctr, 1055 Clermont St, Denver, CO 80220 USA.	lisa.brenner@va.gov	Brenner, Lisa A./AAG-2442-2019				Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; SMITH TC, 2007, 10 ANN FORC HLTH PRO; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; U.S. Department of Defense, ENH POSTD HLTH ASS P; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; SOLDIER READINESS PR	20	148	148	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2010	25	5					307	312		10.1097/HTR.0b013e3181cada03			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	649JR	WOS:000281765400001	20042982				2021-06-18	
J	Ellison-Wright, I; Ellison-Wright, Z; Bullmore, ET				Ellison-Wright, Ian; Ellison-Wright, Zoee; Bullmore, Edward T.			Structural brain change in Attention Deficit Hyperactivity Disorder identified by meta-analysis	BMC PSYCHIATRY			English	Article							GENOME SCAN METAANALYSIS; FALSE DISCOVERY RATE; DEFICIT/HYPERACTIVITY DISORDER; COGNITIVE CONTROL; ALE METAANALYSIS; ADHD; CHILDREN; MRI; SCHIZOPHRENIA; DYSFUNCTION	Background: The authors sought to map gray matter changes in Attention Deficit Hyperactivity Disorder (ADHD) using a novel technique incorporating neuro-imaging and genetic meta-analysis methods. Methods: A systematic search was conducted for voxel-based structural magnetic resonance imaging studies of patients with ADHD (or with related disorders) in relation to comparison groups. The authors carried out meta-analyses of the co-ordinates of gray matter differences. For the meta-analyses they hybridised the standard method of Activation Likelihood Estimation (ALE) with the rank approach used in Genome Scan Meta-Analysis (GSMA). This system detects three-dimensional conjunctions of co-ordinates from multiple studies and permits the weighting of studies in relation to sample size. Results: For gray matter decreases, there were 7 studies including a total of 114 patients with ADHD (or related disorders) and 143 comparison subjects. Meta-analysis of these studies identified a significant regional gray matter reduction in ADHD in the right putamen/globus pallidus region. Four studies reported gray matter increases in ADHD but no regional increase was identified by meta-analysis. Conclusion: In ADHD there is gray matter reduction in the right putamen/globus pallidus region. This may be an anatomical marker for dysfunction in frontostriatal circuits mediating cognitive control. Right putamen lesions have been specifically associated with ADHD symptoms after closed head injuries in children.	[Ellison-Wright, Ian] Avon & Wiltshire Mental Hlth Partnership NHS Trus, Salisbury, Wilts, England; [Ellison-Wright, Zoee] Dorset Cty Hosp NHS Fdn Trust, Child & Adolescent Mental Hlth Serv, Dorchester, England; [Ellison-Wright, Ian; Bullmore, Edward T.] Univ Cambridge, Brain Mapping Unit, Cambridge, England	Ellison-Wright, I (corresponding author), Avon & Wiltshire Mental Hlth Partnership NHS Trus, Salisbury, Wilts, England.	ian.ew@inbox.com; zoe.ellison-wright@dchft.nhs.uk; etb23@cam.ac.uk	ellison-wright, ian/T-1246-2019; Bullmore, Ed/C-1706-2012	Bullmore, Ed/0000-0002-8955-8283	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354B] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354] Funding Source: Medline		American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; BARR ML, 2004, BARRS HUMAN NERVOUS; Booth JR, 2005, J CHILD PSYCHOL PSYC, V46, P94, DOI 10.1111/j.1469-7610.2004.00337.x; Brieber S, 2007, J CHILD PSYCHOL PSYC, V48, P1251, DOI 10.1111/j.1469-7610.2007.01799.x; Bush G, 2005, BIOL PSYCHIAT, V57, P1273, DOI 10.1016/j.biopsych.2005.01.034; Carmona S, 2005, NEUROSCI LETT, V389, P88, DOI 10.1016/j.neulet.2005.07.020; Casey BJ, 2007, AM J PSYCHIAT, V164, P1729, DOI 10.1176/appi.ajp.2007.06101754; Cho SC, 2007, J PSYCHIATR RES, V41, P459, DOI 10.1016/j.jpsychires.2006.05.011; Dickstein SG, 2006, J CHILD PSYCHOL PSYC, V47, P1051, DOI 10.1111/j.1469-7610.2006.01671.x; Durston S, 2005, MOL PSYCHIATR, V10, P678, DOI 10.1038/sj.mp.4001649; ELLISONWRIGHT I, 2008, AM J PSYCHIAT, DOI DOI 10.1176/APPI.AJP.2008.07101660; Ent DV, 2007, NEUROIMAGE, V35, P1004, DOI 10.1016/j.neuroimage.2007.01.037; Frank MJ, 2007, NEUROPSYCHOPHARMACOL, V32, P1583, DOI 10.1038/sj.npp.1301278; Gur RE, 1998, AM J PSYCHIAT, V155, P1711, DOI 10.1176/ajp.155.12.1711; Guyer AE, 2006, J NEUROSCI, V26, P6399, DOI 10.1523/JNEUROSCI.0666-06.2006; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Jin Z, 2001, NEUROSCI LETT, V315, P45, DOI 10.1016/S0304-3940(01)02315-1; Karnath HO, 2002, BRAIN, V125, P350, DOI 10.1093/brain/awf032; Konrad K, 2006, BIOL PSYCHIAT, V59, P643, DOI 10.1016/j.biopsych.2005.08.013; Koziol JA, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-32; Kwak CH, 2002, MOVEMENT DISORD, V17, P821, DOI 10.1002/mds.10207; Laird AR, 2005, HUM BRAIN MAPP, V25, P155, DOI 10.1002/hbm.20136; Levinson DF, 2003, AM J HUM GENET, V73, P17, DOI 10.1086/376548; Manly T, 2005, J CHILD PSYCHOL PSYC, V46, P1337, DOI 10.1111/j.1469-7610.2005.01432.x; Max JE, 2002, J AM ACAD CHILD PSY, V41, P563, DOI 10.1097/00004583-200205000-00014; McAlonan GM, 2007, PSYCHIAT RES-NEUROIM, V154, P171, DOI 10.1016/j.pscychresns.2006.09.006; Overmeyer S, 2001, PSYCHOL MED, V31, P1425, DOI 10.1017/S0033291701004706; Polanczyk G, 2007, AM J PSYCHIAT, V164, P942, DOI 10.1176/appi.ajp.164.6.942; Rorden C, 2007, J COGNITIVE NEUROSCI, V19, P1081, DOI 10.1162/jocn.2007.19.7.1081; Scheres A, 2007, BIOL PSYCHIAT, V61, P720, DOI 10.1016/j.biopsych.2006.04.042; Silveri MM, 2004, DRUG ALCOHOL DEPEN, V76, P173, DOI 10.1016/j.drugalcdep.2004.04.016; Turkeltaub PE, 2002, NEUROIMAGE, V16, P765, DOI 10.1006/nimg.2002.1131; Vaidya CJ, 2005, AM J PSYCHIAT, V162, P1605, DOI 10.1176/appi.ajp.162.9.1605; Valera EM, 2007, BIOL PSYCHIAT, V61, P1361, DOI 10.1016/j.biopsych.2006.06.011; Vance A, 2007, MOL PSYCHIATR, V12, P826, DOI 10.1038/sj.mp.4001999; Verhoeven KJF, 2005, OIKOS, V108, P643, DOI 10.1111/j.0030-1299.2005.13727.x; Volkow ND, 2007, ARCH GEN PSYCHIAT, V64, P932, DOI 10.1001/archpsyc.64.8.932; Wang J, 2007, AM J NEURORADIOL, V28, P543; Williams PL, 1995, GRAYS ANATOMY ANATOM, V38th; Wise LH, 1999, ANN HUM GENET, V63, P263, DOI 10.1046/j.1469-1809.1999.6330263.x; Wright IC, 2000, AM J PSYCHIAT, V157, P16, DOI 10.1176/ajp.157.1.16	42	148	150	1	27	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-244X			BMC PSYCHIATRY	BMC Psychiatry	JUN 30	2008	8								51	10.1186/1471-244X-8-51			8	Psychiatry	Psychiatry	324MZ	WOS:000257524000001	18590567	DOAJ Gold, Green Published			2021-06-18	
J	Lewine, JD; Davis, JT; Bigler, ED; Thoma, R; Hill, D; Funke, M; Sloan, JH; Hall, S; Orrison, WW				Lewine, Jeffrey David; Davis, John T.; Bigler, Erin D.; Thoma, Robert; Hill, Dina; Funke, Michael; Sloan, John Henry; Hall, Sandra; Orrison, William W.			Objective documentation of traumatic brain injury subsequent to mild head trauma: Multimodal brain Imaging with MEG, SPECT, and MRI	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						head trauma; magnetoencephalography; MEG; MRI; postconcussive syndromes; SPECT; traumatic brain injury	FREQUENCY MAGNETIC ACTIVITY; POST-CONCUSSION SYMPTOMS; COMPUTED-TOMOGRAPHY; DELTA ACTIVITY; SLOW WAVES; LESIONS; EEG; ABNORMALITIES; PERFORMANCE; EXPERIENCE	Objective: To determine to what extent magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), and magnetoencephalography (MEG) can provide objective evidence of brain injury in adult patients with persistent (> 1 year) postconcussive symptoms following mild blunt head trauma. Design: A retrospective and blind review of imaging data with respect to the presence of specific somatic, psychiatric, and cognitive complaints. Setting/Participants: Thirty complete data sets (with MRI, SPECT, MEG, and neuropsychological testing results) were collected between 1994 and 2000 from the MEG programs at the Albuquerque VAMC and the University of Utah. Main Outcome Measures: MRI data were evaluated for focal and diffuse structural abnormalities, SPECT data for regions of hypoperfusion, and resting MEG data for abnormal dipolar slow wave activity (DSWA) and epileptiform transients. Results: Structural MRI was abnormal for 4 patients. SPECT showed regions of hypoperfusion in 12 patients, while MEG showed abnormal activity in 19 patients. None of the imaging methods produced findings statistically associated with postconcussive psychiatric symptoms. A significant association was found between basal ganglia hypoperfusion and postconcussive headaches. For patients with cognitive complaints, abnormalities were more likely to be detected by MEG (86%) than either SPECT (40%) or MRI (18%) (P < .01). MEG also revealed significant (P < .01) associations between temporal lobe DSWA and memory problems, parietal DSWA and attention problems, and frontal DSWA and problems in executive function. Conclusions: Functional brain imaging data collected in a resting state can provide objective evidence of brain injury in mild blunt head trauma patients with persistent postconcussive somatic and/or cognitive symptoms. MEG proved to be particularly informative for patients with cognitive symptoms.	Univ Utah, Sch Med, Dept Radiol, Salt Lake City, UT USA; Univ Kansas, Med Ctr, Dept Neurol, Hoglund Brain Imaging Ctr, Kansas City, KS 66103 USA; Univ Kansas, Med Ctr, Dept Psychiat & Behav Sci, Kansas City, KS 66103 USA; Univ Kansas, Med Ctr, Dept Prevent Med & Publ Hlth, Kansas City, KS 66103 USA; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA; St Josephs Hosp, St Josephs Rehabil Ctr, Albuquerque, NM USA	Lewine, JD (corresponding author), Alexian Bros Med Ctr, Illinois MEG Ctr, Alexian Neurosci Inst, 800 Biesterfield Rd,Suite 610, Elk Grove Village, IL 60007 USA.	Jeffrey.Lewine@abbhh.net					Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Baulieu F, 2001, J NEUROIMAGING, V11, P112, DOI 10.1111/j.1552-6569.2001.tb00020.x; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Collette F, 2006, NEUROSCIENCE, V139, P209, DOI 10.1016/j.neuroscience.2005.05.035; COURJON J, 1972, HDB ELECTROENCEPHALO, P8; de Jongh A, 2003, NEUROIMAGE, V20, P2291, DOI 10.1016/j.neuroimage.2003.07.030; Fehr T, 2001, BIOL PSYCHIAT, V50, P108, DOI 10.1016/S0006-3223(01)01122-2; Fernandez A, 2003, AM J NEURORADIOL, V24, P481; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gallen CC, 1997, EPILEPSIA, V38, P452, DOI 10.1111/j.1528-1157.1997.tb01735.x; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hoofien D, 2001, BRAIN INJURY, V15, P189; ICHISE M, 1994, J NUCL MED, V35, P217; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KWENTUS JA, 1985, PSYCHOSOMATICS, V26, P8, DOI 10.1016/S0033-3182(85)72900-3; Lewine J D, 1995, Neuroimaging Clin N Am, V5, P575; Lewine JD, 1995, STUD APPL ELECTROMAG, V7, P55; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; LEWINE JD, 1995, FUNCTIONAL BRAIN IMA, P369; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Nolte G, 2001, PHYS MED BIOL, V46, P2873, DOI 10.1088/0031-9155/46/11/308; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; PRYOLOVIC D, 2005, PSYCHIAT RES, V140, P97; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUFF R, 1961, BRIT MED J, V1, P919; Ruff R. M., 1989, NEUROPSY NEUROPSY BE, V2, P103; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Stippich C, 2000, NEUROREPORT, V11, P3309, DOI 10.1097/00001756-200010200-00010; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Tesche CD, 1996, BRAIN RES, V729, P253, DOI 10.1016/S0006-8993(96)00555-0; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Umile EM, 1998, BRAIN INJURY, V12, P577; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Vieth J B, 1990, Adv Neurol, V54, P261; Vieth JB, 1996, BRAIN TOPOGR, V8, P215, DOI 10.1007/BF01184772; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267	51	148	151	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2007	22	3					141	155		10.1097/01.HTR.0000271115.29954.27			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	174OH	WOS:000246951100001	17510590				2021-06-18	
J	Dikmen, SS; Bombardier, CH; Machamer, JE; Fann, JR; Temkin, NR				Dikmen, SS; Bombardier, CH; Machamer, JE; Fann, JR; Temkin, NR			Natural history of depression in traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; depression; risk factors; rehabilitation	CLOSED HEAD-INJURY; CES-D SCALE; PSYCHIATRIC-DISORDERS; PRIMARY-CARE; MAJOR DEPRESSION; RANDOMIZED-TRIAL; AXIS-I; SAMPLE; PREVALENCE; ALCOHOLISM	Objective: To examine prospectively the rates, risk factors, and phenomenology of depression over 3 to 5 years after traumatic brain injury (TBI). Design: Inception cohort longitudinal study. Setting: Level I trauma center. Participants: Consecutive admissions of 283 adults with moderate to severe TBI. Interventions: Not applicable. Main Outcome Measure: Center for Epidemiologic Studies Depression (CES-D) Scale. Results: The rates of moderate to severe depression ranged from 31% at 1 month to 17% at 3 to 5 years. With 1 exception, the relation between brain injury severity and depression was negligible. Less than high school education, preinjury unstable work history, and alcohol abuse predicted depression after injury. Examination of CES-D factors indicate that, in addition to somatic symptoms, both depressed affect and lack of positive affect contribute to elevated CES-D scores. Conclusions: High rates of depressive symptoms cannot be dismissed on grounds that somatic symptoms related to brain injury are mistaken for depression. Depressed affect and lack of positive affect are also elevated in persons with TBI. Preinjury psychosocial factors are predictive of depression and knowing them should facilitate efforts to detect, prevent, and treat depression after TBI.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Dikmen, SS (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.	dikmen@u.washington.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD39415, R01 HD33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS19643] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677, R01HD039415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER		*AM PSYCH ASS, 2000, DIAGKN STAT MAN MENT; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; BURTON LA, 1988, J NEUROLOGICAL REHAB, V2, P151; Caracciolo B, 2002, J REHABIL MED, V34, P221, DOI 10.1080/165019702760279215; COMSTOCK GW, 1976, PSYCHOL MED, V6, P551, DOI 10.1017/S0033291700018171; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Deb S, 1999, AM J PSYCHIAT, V156, P374; DICESARE A, 1990, COGNITIVE REHABILITA, V8, P14; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; Fann J, 1999, PSYCHOSOMATICS, V40, P168; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Fava M, 2000, NEURON, V28, P335, DOI 10.1016/S0896-6273(00)00112-4; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Geisser ME, 1997, CLIN J PAIN, V13, P163, DOI 10.1097/00002508-199706000-00011; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Hasin DS, 1996, J AFFECT DISORDERS, V41, P63, DOI 10.1016/0165-0327(96)00068-7; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hoofien D, 2001, BRAIN INJURY, V15, P189; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; KATZ R, 1995, BRIT J PSYCHIAT, V166, P100, DOI 10.1192/bjp.166.1.100; Klinkman MS, 1997, ARCH FAM MED, V6, P567, DOI 10.1001/archfami.6.6.567; Knight RG, 1997, BEHAV RES THER, V35, P373, DOI 10.1016/S0005-7967(96)00107-6; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; Lyness JM, 1997, ARCH INTERN MED, V157, P449, DOI 10.1001/archinte.157.4.449; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; MURRELL SA, 1983, AM J EPIDEMIOL, V117, P173, DOI 10.1093/oxfordjournals.aje.a113528; MYERS JK, 1980, AM J PSYCHIAT, V137, P1081; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; PARIKH RM, 1988, INT J PSYCHIAT MED, V18, P169, DOI 10.2190/BH75-EUYA-4FM1-J7QA; Piccinelli M, 1999, J PSYCHOSOM RES, V46, P455, DOI 10.1016/S0022-3999(98)00126-3; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Riddle AS, 2002, MULTIGROUP INVESTIGA; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Schroevers MJ, 2000, QUAL LIFE RES, V9, P1015, DOI 10.1023/A:1016673003237; SCHULBERG HC, 1985, ARCH GEN PSYCHIAT, V42, P1164; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; Silver M, 1998, Int Psychogeriatr, V10, P25, DOI 10.1017/S1041610298005122; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; VAILLANT GE, 1993, HARVARD REV PSYCHIAT, V1, P94, DOI 10.3109/10673229309017064; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; VANWOERKOM TCAM, 1977, LANCET, V1, P812; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; ZICH JM, 1990, INT J PSYCHIAT MED, V20, P259, DOI 10.2190/LYKR-7VHP-YJEM-MKM2	60	148	149	0	13	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2004	85	9					1457	1464		10.1016/j.apmr.2003.12.041			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	852DW	WOS:000223736400011	15375816				2021-06-18	
J	Rath, JF; Simon, D; Langenbahn, DM; Sherr, RL; Diller, L				Rath, JF; Simon, D; Langenbahn, DM; Sherr, RL; Diller, L			Group treatment of problem-solving deficits in outpatients with traumatic brain injury: A randomised outcome study	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							HEAD-INJURY; VALIDITY; THERAPY; DAMAGE	Sixty higher-level outpatients with traumatic brain injury (TBI), all at least 1 year post-injury, were randomly assigned to either conventional group neuropsychological rehabilitation or an innovative group treatment focused on the treatment of problem-solving deficits. Incorporating strategies for addressing underlying emotional self-regulation and logical thinking/reasoning deficits, the innovative treatment is unique in its attention to both motivational, attitudinal, and affective processes and problem-solving skills in persons with TBI. Participants in the innovative group improved in problem solving as assessed using a variety of measures, including (1) executive function, (2) problem-solving self-appraisal, (3) self-appraised emotional self-regulation and clear thinking, and (4) objective observer ratings of roleplayed scenarios. These improvements were maintained at follow-up. Baseline performance on timed attention tasks was related to improvement; individuals who processed the most slowly benefited the most. These participants did not show improvements on timed attention tasks, but did improve on problem-solving measures. Such findings are consistent with successful compensatory strategy use-the person may still have deficits and symptoms, but now has effective strategies for reducing their impact on daily functioning.	NYU, Sch Med, Dept Rehabil Med, Rusk Inst Rehabil Med, New York, NY 10016 USA	Rath, JF (corresponding author), NYU, Sch Med, Dept Rehabil Med, Rusk Inst Rehabil Med, 400 E 34th St, New York, NY 10016 USA.		Rath, Joseph F./C-4823-2008	Rath, Joseph F./0000-0003-2933-6299; Diller, Leonard/0000-0001-7295-7846			Beck A., 1979, COGNITIVE THERAPY EM; Ben-Yishay Y., 1990, REHABILITATION ADULT, P393; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; BERGER R, 1998, J CLIN BAS CARDIOL, V1, P19; Bruner J. S., 1956, STUDY THINKING; CICERONE KD, 2001, 78 ANN C AM C REH ME; Clum GA, 1996, J PSYCHOPATHOL BEHAV, V18, P119, DOI 10.1007/BF02229112; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; D'Zurilla TJ, 2001, HANDBOOK OF COGNITIVE-BEHAVIORAL THERAPIES, SECOND EDITION, P211; DEROGATIS LR, 1990, BRIEF SYMPTOM INVENT; DESHAZER S, 1986, FAM PROCESS, V25, P207; DILLER L, 1993, ASV STROKE REHABILIT; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; DOWNEY J, 1923, WILL TEMPERAMENT ITS; Duncker K., 1945, PSYCHOL MONOGRAPH, V58; Dunlap WP, 1996, PSYCHOL METHODS, V1, P170, DOI 10.1037/1082-989X.1.2.170; DZurilla T. J., 1997, MANUAL SOCIAL PROBLE; DZurilla T. J., 1982, ADV COGNITIVE BEHAV, V1, P201, DOI DOI 10.1016/B978-0-12-010601-1.50010-3; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; DZURILLA TJ, 1995, BEHAV THER, V26, P409, DOI 10.1016/S0005-7894(05)80091-7; DZURILLA TJ, 1988, HDB COGNITIVE BEHAV, P85; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; Geffen L., 1998, OXFORD HDB SPORTS ME, P152; GOLDSTEIN FC, 1987, NEUROPSYCHOL REHABIL, P327; GOLDSTEIN K, 1941, PSYCHOL MONOGR, V53, P151; HANIG BS, 1993, ADJUNCT SKILLS QUEST; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R. K, 1981, WISCONSIN CARD SORTI; Heppner PP., 1988, PROBLEM SOLVING INVE; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Kohler W., 1947, GESTALT PSYCHOL; LANENBAHN DM, 1999, PSYCHOTHERAPEUTIC IN; LEFTOFF S, 1983, J CLIN NEUROPSYCHOL, V5, P51, DOI 10.1080/01688638308401150; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Luria A. R., 1966, HIGHER CORTICAL FUNC; Luria A. R., 1963, RESTORATION FUNCTION; LURIA AR, 1964, NEUROPSYCHOLOGIA, V2, P95, DOI 10.1016/0028-3932(64)90015-6; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Maier NRF, 1930, J COMP PSYCHOL, V10, P115, DOI 10.1037/h0073232; MEICHENBAUM D, 1974, PSYCHOTHER-THEOR RES, V11, P103, DOI 10.1037/h0086326; MONTGOMERY GF, 2000, ARCH CLIN NEUROPSYCH, V15, P94; Nezu A.M., 1989, PROBLEM SOLVING THER; NEZU AM, 1989, J CONSULT CLIN PSYCH, V57, P408, DOI 10.1037/0022-006X.57.3.408; NEZU AM, 1998, HELPING CANC PATIENT; Paniak C, 2000, BRAIN INJURY, V14, P219; Rath JF, 2000, J HEAD TRAUMA REHAB, V15, P724, DOI 10.1097/00001199-200002000-00010; RATH JF, 2003, UNPUB CONSTRUCT PROB; RATH JF, IN PRESS REHABILITAT; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; Sherr RL, 1998, REHABIL PSYCHOL, V43, P184; SHERR RL, 1996, PROBLEM SOLVING ROLE; SHERR RL, 1992, NEUROPSYCHOLOGY, V6, P417, DOI DOI 10.1037/0894-4105.6.4.417; SHERR RL, 1998, ANN NEUR C STROK TRA; SHERR RL, 1996, UNPUB PROBLEM SOLVIN; Simon D, 2001, REHABIL PSYCHOL, V46, P330; Spreen O., 1977, NEUROSENSORY CTR COM; *STAT U NY BUFF, 1997, GUID UN DAT SET MED; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Von Cramon DY, 1992, NEUROPSYCHOL REHABIL, P203; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Watson G., 1980, WATSONGLASER CRITICA; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Wolpe J., 1990, PRACTICE BEHAV THERA; Yalom I.D., 1995, THEORY PRACTICE GROU	68	148	148	1	50	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	SEP	2003	13	4					461	488		10.1080/09602010343000039			28	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	724KU	WOS:000185487400003					2021-06-18	
J	Corrigan, JD; Harrison-Felix, C; Bogner, J; Dijkers, M; Terrill, MS; Whiteneck, G				Corrigan, JD; Harrison-Felix, C; Bogner, J; Dijkers, M; Terrill, MS; Whiteneck, G			Systematic bias in traumatic brain injury outcome studies because of loss to follow-up	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; outcome assessment (health care); rehabilitation	SELECTION BIAS; COMA; ATTRITION; COMMUNITY; SCALE	Objective: To identify potential sources of selection bias created by subjects lost to follow-up in studies of traumatic brain injury (TBI). Design: Demographic, premorbid, injury-related, and hospital course characteristics were compared for subjects lost and found for 1- and 2-year postinjury follow-ups by using bivariate tests and logistic regression analysis. Setting: Three prospective, longitudinal data sets-a single center, a multicenter, and a statewide incidence surveillance system and follow-up registry. Participants: Adolescents and adults hospitalized with a diagnosis of TBI. Interventions: Not applicable. Main Outcome Measures: Subjects were considered lost when no information was collected from the person with TBI or only limited information could be obtained from a proxy, for any reason, including death, refusal, inability to locate, and inability to interview. Results: At year 1 follow-up, 58.0% to 58.6% of subjects were found; 39.7% to 42.0% of subjects were found by year 2. Variables most frequently associated with loss to follow-up were cause of injury, blood alcohol level, motor function, hospital payer source, and race and ethnicity. Conclusions: TBI follow-up studies may experience selective attrition of subjects who (1) are socioeconomically disadvantaged, (2) have a history of substance abuse, and (3) have violent injury etiologies. These phenomena are mitigated for those with more severe motor deficits. Loss to follow-up may be a problem inherent to this population; however, the high rate and its selective nature are problematic for outcome studies.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Craig Hosp, Res Dept, Englewood, CO USA; Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA	Corrigan, JD (corresponding author), Dodd Hall,480 W 9th Ave, Columbus, OH 43210 USA.		Corrigan, John D./E-2921-2011; Heinemann, Allen W/K-6283-2012; Bogner, Jennifer/E-2773-2011	Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596	ODCDC CDC HHS [U17/CCU812447-06] Funding Source: Medline		BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BOYLE MH, 1991, J AM ACAD CHILD PSY, V30, P449, DOI 10.1097/00004583-199105000-00016; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; Carroll KM, 1997, THERAPEUTIC ALLIANCE, P4; *CDCP, 2001, 2000 BRFSS SUMM DAT; Coen AS, 1996, EVAL PROGRAM PLANN, V19, P309, DOI 10.1016/S0149-7189(96)00024-9; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; COX A, 1977, BRIT J PREV SOC MED, V31, P131; CRIQUI MH, 1979, AM J EPIDEMIOL, V109, P394, DOI 10.1093/oxfordjournals.aje.a112695; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Edwards AGK, 1997, ADDICTION, V92, P1699, DOI 10.1046/j.1360-0443.1997.9212169911.x; FARMER ME, 1994, INT J METHOD PSYCH, V4, P19; Gerstein DR, 2000, SUBST USE MISUSE, V35, P971, DOI 10.3109/10826080009148429; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; GREENLAND S, 1977, AM J EPIDEMIOL, V106, P184, DOI 10.1093/oxfordjournals.aje.a112451; Harrison-Felix C, 1998, PREDICTORS LOSS FOLL; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; *JOINT COMM INJ SC, 1990, ABBR INJ SCAL 1990 R; KLEINBAUM DG, 1981, AM J EPIDEMIOL, V113, P452, DOI 10.1093/oxfordjournals.aje.a113113; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; SENDROY MM, 1999, TRAUMATIC BRAIN INJU; Stover SL, 1999, ARCH PHYS MED REHAB, V80, P1365, DOI 10.1016/S0003-9993(99)90246-0; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ., 1995, GUIDELINES SURVEILLA; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; World Health Organization, 1977, INT CLASS DIS	30	148	148	0	10	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					153	160		10.1053/apmr.2003.50093			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700002	12601644				2021-06-18	
J	Andrews, PJD; Sleeman, DH; Statham, PFX; McQuatt, A; Corruble, V; Jones, PA; Howells, TP; Macmillan, CSA				Andrews, PJD; Sleeman, DH; Statham, PFX; McQuatt, A; Corruble, V; Jones, PA; Howells, TP; Macmillan, CSA			Predicting recovery in patients suffering from traumatic brain injury by using admission variables and physiological data: a comparison between decision tree analysis and logistic regression	JOURNAL OF NEUROSURGERY			English	Article; Proceedings Paper	Joint European Conference on Artificial Intelligence in Medicine and Medical Decision Making (AIMDM 99)	JUN 20-24, 1999	AALBORG, DENMARK			head injury; secondary cerebral insult; decision tree analysis; intensive care unit; outcome	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; SECONDARY INSULTS; INTENSIVE-CARE; INTRAHOSPITAL TRANSPORT; INTRACRANIAL-PRESSURE; MORTALITY; DAMAGE; REGION; SCORE	Object. Decision tree analysis highlights patient subgroups and critical values in variables assessed. Importantly, the results are visually informative and often present clear clinical interpretation about risk factors faced by patients in these subgroups. The aim of this prospective study was to compare results of logistic regression with those of decision tree analysis of an observational, head-injury data set, including a wide range of secondary insults and 12-month outcomes. Methods. One hundred twenty-four adult head-injured patients were studied during their stay in an intensive care unit by using a computerized data collection system. Verified values falling outside threshold limits were analyzed according to insult grade and duration with the aid of logistic regression. A decision tree was automatically produced from root node to target classes (Glasgow Outcome Scale [GOS] score). Among 69 patients, in whom eight insult categories could be assessed, outcome at 12 months was analyzed using logistic regression to determine the relative influence of patient age, admission Glasgow Coma Scale score, Injury Severity Score (ISS), papillary response on admission, and insult duration. The most significant predictors of mortality in this patient set were duration of hypotensive, pyrexic, and hypoxetnic insults. When good and poor outcomes were compared, hypotensive insults and pupillary response on admission were significant. Using decision tree analysis, the authors found that hypotension and low cerebral perfusion pressure (CPP) are the best predictors of death, with a 9.2% improvement in predictive accuracy (PA) over that obtained by simply predicting the largest outcome category as the outcome for each patient. Hypotension was a significant predictor of poor outcome (GOS Score 1-3). Low CPR patient age, hypocarbia, and pupillary response were also good predictors of outcome (good/poor), with a 5.1% improvement in PA. In certain subgroups of patients pyrexia was a predictor of good outcome. Conclusions. Decision tree analysis confirmed some of the results of logistic regression and challenged others. This investigation shows that there is knowledge to be gained from analyzing observational data with the aid of decision tree analysis.	Univ Edinburgh, Western Gen Hosp, Dept Anaesthet, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Western Gen Hosp, Dept Neurosci Neurosurg, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Aberdeen, Dept Comp Sci, Kings Coll, Aberdeen AB9 1FX, Scotland	Andrews, PJD (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Anaesthet, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.						Alvarez M, 1998, CRIT CARE MED, V26, P142, DOI 10.1097/00003246-199801000-00030; Andrews P J, 1998, Curr Opin Anaesthesiol, V11, P473, DOI 10.1097/00001503-199810000-00004; ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bekar A, 1998, NEUROSURG REV, V21, P98, DOI 10.1007/BF02389312; Block EFJ, 1999, NEW HORIZ-SCI PRACT, V7, P10; BLUMER AC, 2002, ID3 DECISION TREE LE; Chesnut R M, 1995, New Horiz, V3, P366; Chesnut R M, 1995, New Horiz, V3, P581; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Davies G, 1996, INJURY, V27, P647, DOI 10.1016/S0020-1383(96)00115-5; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; Dunn LT, 1997, INJURY, V28, P427, DOI 10.1016/S0020-1383(97)00051-X; Dzeroski S, 1996, Technol Health Care, V4, P203; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; JENNETT B, 1975, LANCET, V1, P480; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Knaus WA, 2002, ARCH SURG-CHICAGO, V137, P37, DOI 10.1001/archsurg.137.1.37; Lavrac N, 1999, ARTIF INTELL MED, V16, P3, DOI 10.1016/S0933-3657(98)00062-1; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MCQUATT A, 1998, THESIS U ABERDEEN AB; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; PILAH IA, 1997, INTELLIGENT DATA ANA; Quinlan J. R., 1986, Machine Learning, V1, P81, DOI 10.1007/BF00116251; Quinlan JR, 1999, INT J HUM-COMPUT ST, V51, P497, DOI 10.1006/ijhc.1987.0321; QUINLAN JR, 2002, DATA MINING TOOLS C5; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; SARNAIK AP, 1993, PEDIATR CLIN N AM, V40, P337; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Verweij B H, 1996, J Craniomaxillofac Trauma, V2, P8; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Young JS, 2000, J NEUROSURG, V92, P191	38	148	150	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	AUG	2002	97	2					326	336		10.3171/jns.2002.97.2.0326			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	582LP	WOS:000177352700013	12186460				2021-06-18	
J	Panerai, RB; Deverson, ST; Mahony, P; Hayes, P; Evans, DH				Panerai, RB; Deverson, ST; Mahony, P; Hayes, P; Evans, DH			Effect of CO2 on dynamic cerebral autoregulation measurement	PHYSIOLOGICAL MEASUREMENT			English	Article						cerebral autoregulation; cerebral blood how; transcranial Doppler; end-tidal CO2; cerebral haemodynamics	ARTERIAL BLOOD-PRESSURE; FREQUENCY-DOMAIN ANALYSIS; CARBON-DIOXIDE; FLOW VELOCITY; SPONTANEOUS FLUCTUATIONS; INTRACRANIAL-PRESSURE; AUTO-REGULATION; HEAD-INJURY; HUMANS; OSCILLATIONS	Arterial pCO(2) is known to influence cerebral autoregulation but its effect on the dynamic relationship between mean arterial blood pressure (ABP) and mean cerebral blood flow velocity (CBFV), obtained from spontaneous fluctuations in ABP, has not been established. In 16 normal subjects, ABP was measured non-invasively (Finapres), CBFV was estimated with Doppler ultrasound in the middle cerebral artery, and end-tidal CO2 (EtCO2) was measured with an infrared capnograph. Recordings were made before, during and after breathing a mixture of 5% CO2 in air. The coherence function, amplitude and phase frequency responses, and impulse and step responses For the effects of ABP on CBFV were calculated by spectral analysis of beat-to-beat changes in mean ABP and CBFV before (mean CO2 5.55 +/- 0.38 kPa), during (6.43 +/- 0.31 kPa) and after 5% CO2 (5.43 +/- 0.26 kPa). During 5% CO2, the coherence function and the amplitude frequency response were significantly increased for frequencies below 0.05 Hz and the phase was reduced for the frequency range 0.02-0.1 Hz. The impulse and step responses indicated that 5% COz reduces the efficiency of the autoregulatory mechanism. A 20.7% average increase in CBFV induced by a 14.4% increase in EtCO2 was found to be mediated by a 25.9% reduction in critical closing pressure, while the change in resistance-area product was non-significant.	Univ Leicester, Fac Med, Div Med Phys, Leicester Royal Infirm, Leicester LE1 5WW, Leics, England; Leicester Royal Infirm, Dept Surg, Leicester LE1 5WW, Leics, England	Panerai, RB (corresponding author), Univ Leicester, Fac Med, Div Med Phys, Leicester Royal Infirm, Leicester LE1 5WW, Leics, England.						AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Aaslid R, 1992, TRANSCRANIAL DOPPLER, P49; Bendat J.S., 2010, RANDOM DATA ANAL MEA; BIRCH AA, 1995, STROKE, V26, P834, DOI 10.1161/01.STR.26.5.834; BISHOP CCR, 1986, LANCET, V1, P710; Blaber AP, 1997, STROKE, V28, P1686, DOI 10.1161/01.STR.28.9.1686; BURTON AC, 1951, AM J PHYSIOL, V164, P319; Cencetti S, 1997, STROKE, V28, P1195, DOI 10.1161/01.STR.28.6.1195; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Dawson SL, 1999, J APPL PHYSIOL, V86, P675; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Diehl RR, 1998, CLIN AUTON RES, V8, P7, DOI 10.1007/BF02267598; EKSTROMJODAL B, 1971, EUR NEUROL, V6, P6, DOI 10.1159/000114457; EVANS DH, 1988, ULTRASOUND MED BIOL, V14, P103, DOI 10.1016/0301-5629(88)90176-7; Garnham J, 1999, CEREBROVASC DIS, V9, P146, DOI 10.1159/000015944; Giller CA, 1997, NEUROL RES, V19, P634; GILLER CA, 1993, NEUROSURGERY, V32, P737, DOI 10.1227/00006123-199305000-00006; GILLER CA, 1990, NEUROSURGERY, V27, P362, DOI 10.1227/00006123-199009000-00004; HARPER AM, 1966, J NEUROL NEUROSUR PS, V29, P398, DOI 10.1136/jnnp.29.5.398; HEISTAD DD, 1983, HDB PHYSL 2, V3, P137; Kuo TBJ, 1998, J CEREBR BLOOD F MET, V18, P311, DOI 10.1097/00004647-199803000-00010; LASSEN NA, 1959, PHYSIOL REV, V39, P183; LUNDAR T, 1985, ANN THORAC SURG, V40, P582, DOI 10.1016/S0003-4975(10)60353-0; Mahajan RP, 1998, ANESTH ANALG, V87, P843, DOI 10.1097/00000539-199810000-00018; Menke J, 1997, PEDIATR RES, V42, P690, DOI 10.1203/00006450-199711000-00023; MOLHOEK GP, 1984, BASIC RES CARDIOL, V79, P598, DOI 10.1007/BF01910489; PANERAI RB, 1995, STROKE, V26, P74, DOI 10.1161/01.STR.26.1.74; PANERAI RB, 1993, PHYSIOL MEAS, V14, P411, DOI 10.1088/0967-3334/14/4/002; Panerai RB, 1998, MED BIOL ENG COMPUT, V36, P315, DOI 10.1007/BF02522477; Panerai RB, 1996, IEEE T BIO-MED ENG, V43, P779, DOI 10.1109/10.508541; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Panerai RB, 1998, STROKE, V29, P2341, DOI 10.1161/01.STR.29.11.2341; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; URSINO M, 1991, ANN BIOMED ENG, V19, P15, DOI 10.1007/BF02368459; Zhang R, 1998, J APPL PHYSIOL, V85, P1113; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233	40	148	150	0	8	IOP PUBLISHING LTD	BRISTOL	DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND	0967-3334			PHYSIOL MEAS	Physiol. Meas.	AUG	1999	20	3					265	275		10.1088/0967-3334/20/3/304			11	Biophysics; Engineering, Biomedical; Physiology	Biophysics; Engineering; Physiology	230FY	WOS:000082242200004	10475580				2021-06-18	
J	Toth, Z; Hollrigel, GS; Gorcs, T; Soltesz, I				Toth, Z; Hollrigel, GS; Gorcs, T; Soltesz, I			Instantaneous perturbation of dentate interneuronal networks by a pressure wave-transient delivered to the neocortex	JOURNAL OF NEUROSCIENCE			English	Article						interneuron; GABA; epilepsy; trauma; parvalbumin; cholecystokinin	INHIBITORY POSTSYNAPTIC CURRENTS; LIGHT MICROSCOPIC RESPONSE; CONCUSSIVE HEAD-INJURY; TRAUMATIC BRAIN INJURY; RAT FASCIA-DENTATA; GRANULE CELLS; BASKET CELLS; HIPPOCAMPAL-FORMATION; GABAERGIC INHIBITION; NEURONAL SOMATA	Whole-cell patch-clamp recordings and immunocytochemical experiments were performed to determine the short- and long-term effects of lateral fluid percussion head injury on the perisomatic inhibitory control of dentate granule cells in the adult rat, with special reference to the development of trauma-induced hyperexcitability. One week after the delivery of a single, moderate (2.0-2.2 atm) mechanical pressure wave to the neocortex, the feed-forward inhibitory control of dentate granule cell discharges was compromised, and the frequency of miniature IPSCs was decreased. Consistent with the electrophysiological data, the number of hilar parvalbumin (PV)- and cholecystokinin (CCK)-positive dentate interneurons supplying the inhibitory innervation of the perisomatic region of granule cells was decreased weeks and months after head injury. The initial injury to the hilar neurons took place instantaneously after the impact and did not require the recruitment of active physiological processes. Furthermore, the decrease in the number of PV- and CCK-positive hilar interneurons was similar to the decrease in the number of the AMPA-type glutamate receptor subunit 2/3-immunoreactive messy cells, indicating that the pressure wave-transient causes injurious physical stretching and bending of most cells that are large and not tightly packed in a cell layer. These results reveal for the first time that moderate pressure wave-transients, triggered by traumatic head injury episodes, impact the dentate neuronal network in a unique temporal and spatial pattern, resulting in a net decrease in the perisomatic control of granule cell discharges.	UNIV CALIF IRVINE,DEPT ANAT & NEUROBIOL,IRVINE,CA 92697					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R29NS35916-01A1] Funding Source: Medline		Acsady L, 1997, J COMP NEUROL, V378, P320; AMARAL DG, 1978, J COMP NEUROL, V182, P851, DOI 10.1002/cne.901820508; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BAIMBRIDGE KG, 1982, BRAIN RES, V245, P223, DOI 10.1016/0006-8993(82)90804-6; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; Bolt BA., 1993, EARTHQUAKES; Bruton CJ, 1988, NEUROPATHOLOGY TEMPO; Buckmaster PS, 1996, J NEUROPHYSIOL, V76, P2169; BUCKMASTER PS, 1995, J NEUROSCI, V15, P774; BUHL EH, 1994, J NEUROPHYSIOL, V71, P1289; BUHL EH, 1995, EUR J NEUROSCI, V7, P1989, DOI 10.1111/j.1460-9568.1995.tb00721.x; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; COULTER DA, 1996, EPILEPSY RES, V6, P81; Deller T, 1996, J NEUROSCI, V16, P3322; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FREUND TF, 1996, HIPPOCAMPUS, V6, P345; GALLYAS F, 1990, ACTA NEUROPATHOL, V79, P620, DOI 10.1007/BF00294239; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P394, DOI 10.1007/BF00713531; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P499, DOI 10.1007/BF00310026; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P504, DOI 10.1007/BF00310027; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; Gualtari CT, 1991, BRAIN INJURY, V5, P219; GULYAS AI, 1990, NEUROSCIENCE, V37, P31, DOI 10.1016/0306-4522(90)90189-B; HALASY K, 1993, EUR J NEUROSCI, V5, P411, DOI 10.1111/j.1460-9568.1993.tb00508.x; HAN ZS, 1993, EUR J NEUROSCI, V5, P395, DOI 10.1111/j.1460-9568.1993.tb00507.x; HARRY GJ, 1992, MOL NEUROBIOL, V6, P203; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412; Hollrigel GS, 1997, J NEUROSCI, V17, P5119; Jennet B, 1975, EPILEPSY NONMISSILE; KNEISLER TB, 1995, HIPPOCAMPUS, V5, P151, DOI 10.1002/hipo.450050302; KOH DS, 1995, J PHYSIOL-LONDON, V485, P383, DOI 10.1113/jphysiol.1995.sp020737; Leranth C, 1996, NEUROSCIENCE, V70, P631, DOI 10.1016/S0306-4522(96)83003-X; LERANTH C, 1986, J COMP NEUROL, V254, P51, DOI 10.1002/cne.902540105; LEROUX PD, 1995, ANESTHETIC MANAGEMEN, P1; LEROUX PD, 1995, ANESTHETIC MANAGEMEN, P101; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIETTINEN R, 1992, NEUROSCIENCE, V48, P29, DOI 10.1016/0306-4522(92)90335-Y; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; OBENAUS A, 1993, J NEUROSCI, V13, P4470; OTIS TS, 1992, NEUROSCIENCE, V49, P13, DOI 10.1016/0306-4522(92)90073-B; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; PRASAD MR, 1994, J NEUROCHEM, V63, P773; RempelClower NL, 1996, J NEUROSCI, V16, P5233; RIBAK CE, 1986, J NEUROSCI, V6, P3492; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; SCHUMATE M, 1995, EPILEPSIA S4, V36, P118; SHIGEMOTO R, 1993, NEUROSCI LETT, V153, P157, DOI 10.1016/0304-3940(93)90311-8; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SOLTESZ I, 1995, HIPPOCAMPUS, V5, P120, DOI 10.1002/hipo.450050206; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; SOLTESZ I, 1995, J NEUROPHYSIOL, V73, P1763; SOLTESZ I, 1994, J NEUROSCI, V14, P2365; SORIANO E, 1990, J COMP NEUROL, V293, P1, DOI 10.1002/cne.902930102; STALEY KJ, 1992, J NEUROPHYSIOL, V67, P1346; TOTH K, 1993, J NEUROSCI, V13, P3712; Traub RD, 1991, NEURONAL NETWORKS HI; VANDENPOL AN, 1990, J COMP NEUROL, V296, P654, DOI 10.1002/cne.902960410; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411	64	148	153	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036	0270-6474			J NEUROSCI	J. Neurosci.	NOV 1	1997	17	21					8106	8117					12	Neurosciences	Neurosciences & Neurology	YC947	WOS:A1997YC94700005	9334386				2021-06-18	
J	Gracies, JM; Elovic, E; McGuire, J; Simpson, D				Gracies, JM; Elovic, E; McGuire, J; Simpson, D			Traditional pharmacological treatments for spasticity - Part II: General and regional treatments	MUSCLE & NERVE			English	Article							SPINAL-CORD INJURY; ACTING MUSCLE-RELAXANT; DORSAL HORN NEURONS; DOUBLE-BLIND TRIAL; MULTIPLE-SCLEROSIS; INTRATHECAL BACLOFEN; MALIGNANT HYPERTHERMIA; TIZANIDINE DS103-282; DANTROLENE SODIUM; CLONIDINE	Systemic pharmacologic treatments may be indicated in conditions in which the distribution of muscle overactivity is diffuse Antispastic drugs act in the CNS either by suppression of excitation (glutamate), enhancement of inhibition (GABA, glycine), or a combination of the two. Only four drugs are currently approved by the US FDA as antispactic agents: baclofen, diazepam, dantrolene sodium, and tizanidine. However, there are a number of other drugs available with proven antispastic action. This chapter reviews the pharmacology, physiology of action, dosage, and results from controlled clinical trials on side effects. Efficacy, and indications for 21 drugs in several categories. Categories reviewed include agents acting through the GABAergic system (baclofen, benzodiazepines, piracetam, progabide); drugs affecting ion flux (dantrolene sodium, lamotrigine, riluzole); drugs acting on monoamines (tizanidine, clonidine, thymoxamine, beta blockers, and cyproheptadine); drugs acting on excitatory amino acids (orphenadrine citrate); cannabinoids; inhibitory neuromediators; and other miscellaneous agents. The technique, advantages, and limitations of intrathecal administration of baclofen, morphine, and midazolam are reviewed. Two consistent limitations appear throughout the controlled studies reviewed: the lack of quantitative and sensitive functional assessment and the lack of comparative trials between different agents. In the majority of trials in which meaningful functional assessment was included, the study drug failed to improve function, even though the antispastic action was significant. Placebo-controlled trials of virtually ail major centrally acting antispastic agents have shown that sedation, reduction of global performance, and muscle weakness are frequent side effects. It appears preferable to use centrally acting drugs such as baclofen, tizanidine, and diazepam in spasticity of spinal origin (spinal cord injury and multiple sclerosis), whereas dantrolene sodium, due to its primarily peripheral mechanism of action, may be preferable in spasticity of cerebral origin (stroke and traumatic brain injury) where sensitivity to sedating effects is generally higher. Intrathecal administration of antispastic drugs has been used mainly in cases of muscle overactivity occurring primarily in the lower limbs in nonambulatory, severely disabled patients, but new indications may emerge in spasticity of cerebral origin. Intrathecal therapy is an invasive procedure involving long-term implantation of a foreign device, and the potential disadvantages must be weighed against the level of disability in each patient and the resistance to other forms of antispastic therapy In all forms of treatment of muscle overactivity, one must distinguish between two different goals of therapy: improvement of active function and improvement of hygiene and comfort. The risk of global performance reduction associated with general or regional administration of antispastic drugs may be more acceptable when the primary goal of therapy is hygiene and comfort than when active function is a priority. (C) 1997 John Wiley & Sons, Inc.	Mt Sinai Med Ctr, Dept Neurol, New York, NY 10029 USA; Rehabil Inst Chicago, Chicago, IL 60611 USA; JFK Johnson Rehabil Inst, Ctr Head Injuries, Edison, NJ USA	Gracies, JM (corresponding author), Mt Sinai Med Ctr, Dept Neurol, 1 Gustave L Levy Pl, New York, NY 10029 USA.						ADDISJONES CD, 1973, PRACTITIONER, V210, P429; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; ASHBY P, 1973, J NEUROL SCI, V20, P329, DOI 10.1016/0022-510X(73)90194-9; ASHBY P, 1972, J NEUROL NEUROSUR PS, V35, P599, DOI 10.1136/jnnp.35.5.599; BARBEAU A, 1982, CAN J NEUROL SCI, V9, P141, DOI 10.1017/S0317167100043845; BARBEAU H, 1982, J NEUROL NEUROSUR PS, V45, P923, DOI 10.1136/jnnp.45.10.923; BASMAJIAN JV, 1974, AM J PHYS MED REHAB, V53, P223; BASMAJIAN JV, 1986, ARCH PHYS MED REHAB, V67, P556; BASMAJIAN JV, 1984, ARCH PHYS MED REHAB, V65, P698; BASMAJIAN JV, 1975, AM J PHYS MED REHAB, V54, P175; BASS B, 1988, CAN J NEUROL SCI, V15, P15, DOI 10.1017/S0317167100027104; BECKER WJ, 1995, CAN J NEUROL SCI, V22, P153, DOI 10.1017/S0317167100040233; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Bergamini L, 1966, Minerva Med, V57, P2723; BES A, 1988, CURR MED RES OPIN, V10, P709, DOI 10.1185/03007998809111122; BIRKMAYER W., 1967, WIEN MED WOCHENSCHR, V117, P7; BONICALZI V, 1996, P 8 WORLD C PAIN, P173; BUCHOLZ RD, 1994, STATE ART REV PHYSIC, V8; BURKE D, 1975, J NEUROL NEUROSUR PS, V38, P469, DOI 10.1136/jnnp.38.5.469; CARTLIDGE NE, 1974, J NEUROL SCI, V23, P17, DOI 10.1016/0022-510X(74)90137-3; CASALE R, 1995, ARCH PHYS MED REHAB, V76, P660, DOI 10.1016/S0003-9993(95)80636-9; CASTAIGNE P, 1973, REV NEUROL-FRANCE, V128, P245; CASTANEDA C, 1967, SEM MED MEX, V54, P13; CENDROWSKI W, 1977, EUR NEUROL, V16, P257, DOI 10.1159/000114906; CHYATTE SB, 1971, SOUTHERN MED J, V64, P180, DOI 10.1097/00007611-197102000-00011; CLIFFORD DB, 1983, ANN NEUROL, V13, P669, DOI 10.1002/ana.410130616; COCCHIARELLA ANTONIO, 1967, ARCH PHYS MED REHABIL, V48, P393; COHAN SL, 1980, ARCH NEUROL-CHICAGO, V37, P360, DOI 10.1001/archneur.1980.00500550062008; COOK JB, 1967, J NEUROL SCI, V5, P33, DOI 10.1016/0022-510X(67)90005-6; Corbett M, 1972, Paraplegia, V10, P19; CORSTON RN, 1981, J NEUROL NEUROSUR PS, V44, P1035, DOI 10.1136/jnnp.44.11.1035; COSTA E, 1979, ANNU REV PHARMACOL, V19, P531, DOI 10.1146/annurev.pa.19.040179.002531; COWARD DM, 1984, PHARM PROPERTIES TIZ, P61; DAVIDOFF RA, 1985, ANN NEUROL, V17, P107, DOI 10.1002/ana.410170202; DAVIES J, 1984, NEUROSCI LETT, V48, P197, DOI 10.1016/0304-3940(84)90019-3; DAVIES J, 1984, BRIT J PHARMACOL, V82, P409, DOI 10.1111/j.1476-5381.1984.tb10776.x; DAVIES J, 1982, BRIT J PHARMACOL, V76, P473, DOI 10.1111/j.1476-5381.1982.tb09242.x; Delwaide P. J., 1985, CLIN NEUROPHYSIOL, P185; DELWAIDE PJ, 1971, THESIS BRUXELLES; DONOVAN WH, 1988, ARCH PHYS MED REHAB, V69, P193; DRALLE D, 1985, LANCET, V2, P1003; DUNCAN GW, 1976, NEUROLOGY, V26, P441, DOI 10.1212/WNL.26.5.441; Dunn M, 1974, Paraplegia, V12, P175; ELLIS KO, 1974, ARCH PHYS MED REHAB, V55, P362; EMRE M, 1989, SPASTICITY; ENGLE HA, 1966, DEV MED CHILD NEUROL, V8, P661; ERICKSON DL, 1989, NEUROSURGERY, V24, P236, DOI 10.1227/00006123-198902000-00013; ERICKSON DL, 1985, NEUROSURGERY, V16, P215, DOI 10.1227/00006123-198502000-00015; EYSSETTE M, 1988, CURR MED RES OPIN, V10, P699, DOI 10.1185/03007998809111121; FELDMAN RG, 1978, NEUROLOGY, V28, P1094, DOI 10.1212/WNL.28.11.1094; FLEWELLEN EH, 1983, ANESTHESIOLOGY, V59, P275, DOI 10.1097/00000542-198310000-00002; FROM A, 1975, ACTA NEUROL SCAND, V51, P158; GELENBERG AJ, 1973, NEUROLOGY, V23, P1313, DOI 10.1212/WNL.23.12.1313; GELLER A, 1996, CLIN SCI, V48, P23; GERKIN R, 1986, ANN EMERG MED, V15, P843, DOI 10.1016/S0196-0644(86)80388-2; Glass A, 1974, Paraplegia, V12, P170; GLASS PSA, 1984, ANESTHESIOLOGY, V60, P256, DOI 10.1097/00000542-198403000-00024; GRACIES JM, 1997, MUSCLE NERVE       S, V6, pS61; HANKEY GJ, 1986, MED J AUSTRALIA, V145, P465, DOI 10.5694/j.1326-5377.1986.tb113877.x; HASLAM RHA, 1974, ARCH PHYS MED REHAB, V55, P384; HASSAN N, 1980, J NEUROL NEUROSUR PS, V43, P1132, DOI 10.1136/jnnp.43.12.1132; HEAZLEWOOD V, 1983, EUR J CLIN PHARMACOL, V25, P65, DOI 10.1007/BF00544016; Held J. P., 1969, REEDUCATION MOTRICE, P31; HERMAN R, 1972, AM J PHYS MED REHAB, V51, P296; HILL DR, 1981, NATURE, V290, P149, DOI 10.1038/290149a0; HINDERER SR, 1990, AM J PHYS MED REHAB, V69, P311, DOI 10.1097/00002060-199012000-00007; HOOGSTRATEN MC, 1988, ACTA NEUROL SCAND, V77, P224, DOI 10.1111/j.1600-0404.1988.tb05899.x; HUDGSON P, 1971, BMJ-BRIT MED J, V4, P15, DOI 10.1136/bmj.4.5778.15; HUMEKENDALL P, 1964, Ann Phys Med, V8, P225; HUTCHINSON DR, 1989, J INT MED RES, V17, P565, DOI 10.1177/030006058901700611; JERUSALEM F, 1968, Nervenarzt, V39, P515; JONES RF, 1988, LANCET, V1, P527; JONES RF, 1976, MED J AUSTRALIA, V1, P654, DOI 10.5694/j.1326-5377.1976.tb140942.x; JONES RF, 1970, J NEUROL NEUROSUR PS, V33, P464, DOI 10.1136/jnnp.33.4.464; KAMEYAMA T, 1985, N-S ARCH PHARMACOL, V330, P93, DOI 10.1007/BF00499900; KARP BI, 1994, NEUROLOGY, V44, P70, DOI 10.1212/WNL.44.1.70; KATRAK PH, 1992, ARCH PHYS MED REHAB, V73, P4; KATZ RT, 1994, STATE ART REV PHYSIC, V8; KHORASANI A, 1995, ANESTH ANALG, V80, P1054, DOI 10.1097/00000539-199505000-00038; KIRKLAND LR, 1984, ARCH PHYS MED REHAB, V65, P214; KNUTSSON E, 1982, J NEUROL SCI, V53, P187, DOI 10.1016/0022-510X(82)90005-3; KNUTSSON E, 1973, BRAIN, V96, P29, DOI 10.1093/brain/96.1.29; KOBINGER W, 1967, EUR J PHARMACOL, V2, P155, DOI 10.1016/0014-2999(67)90080-5; LAPIERRE Y, 1987, CAN J NEUROL SCI, V14, P513, DOI 10.1017/S0317167100038026; LEVINE IM, 1977, DIS NERV SYST, V38, P1011; LOSSIUS R, 1985, ACTA NEUROL SCAND, V71, P190; LUISTO M, 1982, ACTA NEUROL SCAND, V65, P355, DOI 10.1111/j.1600-0404.1982.tb03092.x; LUND S, 1965, ACTA PHYSIOL SCAND, V64, P345, DOI 10.1111/j.1748-1716.1965.tb04189.x; MAI J, 1979, ACTA NEUROL SCAND, V59, P309; MAI J, 1978, ACTA NEUROL SCAND, V57, P65, DOI 10.1111/j.1600-0404.1978.tb04498.x; MANN NR, 1985, 47 ANN ASS AM AC PHY; MARITZ NG, 1978, S AFR MED J, V53, P889; MARSH HO, 1965, J AMER MED ASSOC, V191, P797, DOI 10.1001/jama.1965.03080100015003; MATHER LE, 1986, MED J AUSTRALIA, V144, P475, DOI 10.5694/j.1326-5377.1986.tb101055.x; MATTHEWS WB, 1966, J NEUROL NEUROSUR PS, V29, P201, DOI 10.1136/jnnp.29.3.201; MATTHEWS WB, 1972, ACTA NEUROL SCAND, V48, P635, DOI 10.1111/j.1600-0404.1972.tb07580.x; MCLELLAN DL, 1977, J NEUROL NEUROSUR PS, V40, P30, DOI 10.1136/jnnp.40.1.30; MCNAMARA JO, 1996, GOODMAN GILMANS PHAR, P461; MILANOV I, 1992, ACTA NEUROL BELG, V92, P5; MONDRUP K, 1984, ACTA NEUROL SCAND, V69, P200, DOI 10.1111/j.1600-0404.1984.tb07802.x; MONDRUP K, 1984, ACTA NEUROL SCAND, V69, P191, DOI 10.1111/j.1600-0404.1984.tb07801.x; MONSTER AW, 1974, ARCH PHYS MED REHAB, V55, P373; MONSTER AW, 1974, ARCH PHYS MED REHAB, V55, P355; MORALES LR, 1967, MEX MED, V54, P187; MULLER H, 1988, LOCAL SPINAL THERAPY, P143; MULLER H, 1988, LOCAL SPINAL THERAPY, P155; NAKAMURACRAIG M, 1995, PAIN, V63, P33, DOI 10.1016/0304-3959(95)00016-L; NANCE P, 1995, CAN J NEUROL SCI, V22, P22, DOI 10.1017/S0317167100040452; NANCE P, 1994, J AM PARAPLEGIA SOC, V17, P151; NANCE PW, 1989, PARAPLEGIA, V27, P296, DOI 10.1038/sc.1989.44; NANCE PW, 1985, CAN MED ASSOC J, V133, P41; NANCE PW, 1994, NEUROLOGY, V44, P44; NEWMAN PM, 1982, EUR J CLIN PHARMACOL, V23, P31, DOI 10.1007/BF01061374; NOGEN AG, 1976, CHILD BRAIN, V2, P304; O'Shaugnessey WB, 1842, T MED PHYS SOC BOMBA, V8, P421; OCHS G, 1989, J NEUROL NEUROSUR PS, V52, P933, DOI 10.1136/jnnp.52.8.933; OLSEN RW, 1981, J NEUROCHEM, V37, P1, DOI 10.1111/j.1471-4159.1981.tb05284.x; PEDERSEN E, 1970, ACTA NEUROL SCAND, V46, P257, DOI 10.1111/j.1600-0404.1970.tb05791.x; PEDERSEN E, 1974, ARCH PHYS MED REHAB, V55, P344; PEDERSEN E, 1974, ACTA NEUROL SCAND, V50, P665; PENN RD, 1988, ANN NY ACAD SCI, V531, P157, DOI 10.1111/j.1749-6632.1988.tb31822.x; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; PETRO DJ, 1981, J CLIN PHARMACOL, V21, pS413, DOI 10.1002/j.1552-4604.1981.tb02621.x; PINDER RM, 1977, DRUGS, V13, P3, DOI 10.2165/00003495-197713010-00002; PINTO ODS, 1972, POSTGRAD MED J, V48, P18; Reynolds JR, 1890, LANCET, V135, P637; ROMNEY DM, 1984, PSYCHOPHARMACOL BULL, V20, P313; ROUSSAN M, 1985, PHARMATHERAPEUTICA, V4, P278; RUDICK RA, 1987, ARCH NEUROL-CHICAGO, V44, P1033, DOI 10.1001/archneur.1987.00520220039013; SAWA GM, 1979, CAN J NEUROL SCI, V6, P351, DOI 10.1017/S0317167100023994; SAYERS AC, 1980, ARZNEIMITTEL-FORSCH, V30-1, P793; SCHARF MB, 1985, J CLIN PSYCHIAT, V46, P518; SCHMIDT RT, 1976, J NEUROL NEUROSUR PS, V39, P350, DOI 10.1136/jnnp.39.4.350; SCHOMBURG ED, 1988, EXP BRAIN RES, V71, P442; SCHWARZ M, 1983, NEUROSCI LETT, V36, P175, DOI 10.1016/0304-3940(83)90261-6; SERFATY M, 1993, BRIT J PSYCHIAT, V163, P386, DOI 10.1192/bjp.163.3.386; SIEGFRIED J, 1988, SCAND J REHABIL MED, P145; SMITH C, 1994, NEUROLOGY, V44, P34; SMITH CR, 1991, NEUROLOGY, V41, P1829, DOI 10.1212/WNL.41.11.1829; SMOLENSKI C, 1981, CURR MED RES OPIN, V7, P374; STAHL MMS, 1993, BRIT J OBSTET GYNAEC, V100, P185, DOI 10.1111/j.1471-0528.1993.tb15221.x; STARKE K, 1975, EUR J PHARMACOL, V34, P385, DOI 10.1016/0014-2999(75)90268-X; STERN P, 1974, PHARMACOLOGY, V12, P117, DOI 10.1159/000136529; STIEN R, 1987, ACTA NEUROL SCAND, V75, P190, DOI 10.1111/j.1600-0404.1987.tb07916.x; TARDIEU G, 1954, REV NEUROL, V91, P143; TOLOSA ES, 1975, JAMA-J AM MED ASSOC, V233, P1046, DOI 10.1001/jama.1975.03260100016002; TSENG TC, 1971, J PHARMACOL EXP THER, V178, P350; UNNERSTALL JR, 1984, BRAIN RES REV, V7, P69, DOI 10.1016/0165-0173(84)90030-4; UTILI R, 1977, GASTROENTEROLOGY, V72, P610; VANHEMET JCJ, 1980, SPASTICITY DISORDERE; VERRIER M, 1977, ARCH PHYS MED REHAB, V58, P148; WAINBERG M, 1986, SOC NEUROSCI, V308, P1133; WARD A, 1986, DRUGS, V32, P130, DOI 10.2165/00003495-198632020-00003; WEINGARDEN SI, 1992, ARCH PHYS MED REHAB, V73, P876; WEISER R, 1978, PRACTITIONER, V221, P123; WHITE CDB, 1974, LANCET, V1, P686; WHYTE J, 1990, PRACTICAL MANAGEMENT; Wilson L A, 1966, Scott Med J, V11, P46; YABLON SA, 1993, AM J PHYS MED REHAB, V72, P154, DOI 10.1097/00002060-199306000-00009; YUILL GM, 1973, LANCET, V2, P1504; 1994, MED LETT DRUGS THER, V36, P21	161	148	153	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0148-639X	1097-4598		MUSCLE NERVE	Muscle Nerve		1997				6			S92	S120					29	Clinical Neurology; Neurosciences	Neurosciences & Neurology	YQ157	WOS:000071354200007	9826984				2021-06-18	
J	RUFF, RM; CROUCH, JA; TROSTER, AI; MARSHALL, LF; BUCHSBAUM, MS; LOTTENBERG, S; SOMERS, LM				RUFF, RM; CROUCH, JA; TROSTER, AI; MARSHALL, LF; BUCHSBAUM, MS; LOTTENBERG, S; SOMERS, LM			SELECTED CASES OF POOR OUTCOME FOLLOWING A MINOR BRAIN TRAUMA - COMPARING NEUROPSYCHOLOGICAL AND POSITRON EMISSION TOMOGRAPHY ASSESSMENT	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; GLUCOSE METABOLIC-RATE; COMPUTED-TOMOGRAPHY; EXPERIENCE; COMA	Neuropsychological residua are common particularly in the early stages following a minor traumatic brain injury (TBI), however, a minority of individuals complain of persistent deficits following months or years post-accident. Nine such cases are presented with little or no evidence of brain damage demonstrated according to non-functional neuroimaging (for example CT, MRI), yet their neuropsychological examinations were positive. Since the introduction of positron emission tomography (PET), which captures afunctional approach, the question arose as to what extent the two techniques (i.e. PET and neuropsychological examination) are interrelated. All nine minor TBI cases revealed a corroboration between the positive neuropsychological findings confirmed on the PET. The PET procedure documented neuropathology which frequently was pronounced in the frontal and anteriotemporo-frontal regions. Moreover, no significant differences were evident between those five cases with reported loss of consciousness vs. those four cases without.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA; UNIV CALIF IRVINE, IRVINE, CA 92717 USA; SAN DIEGO STATE UNIV, DEPT PSYCHOL, SAN DIEGO, CA 92182 USA; WASHINGTON STATE UNIV, PULLMAN, WA 99164 USA; THOMAS T ANDERSON & ASSOCIATES, INDIO, CA USA							ALAVI A, 1986, J NUCL MED, V27, P919; ALAVI A, 1989, J NEUROPSYCHIAT, V1, P545; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Baser C A, 1987, Arch Clin Neuropsychol, V2, P13, DOI 10.1016/0887-6177(87)90031-X; BUCHSBAUM MS, 1990, BRIT J PSYCHIAT, V156, P216, DOI 10.1192/bjp.156.2.216; BUCHSBAUM MS, 1982, ARCH GEN PSYCHIAT, V39, P251; BUCHSBAUM MS, 1984, ANN NEUROL, V15, pS157; BUCHSBAUM MS, 1989, LIFE SCI, V45, P1349, DOI 10.1016/0024-3205(89)90021-0; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; DEUTSCH G, 1987, J CEREBR BLOOD F MET, V7, P29, DOI 10.1038/jcbfm.1987.5; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DUTREVOU MD, 1987, S AFR J SURG, V25, P95; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; JAMIESON D, 1988, RADIOL CLIN N AM, V26, P1075; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KUHL DE, 1980, J NEUROSURG, V52, P309, DOI 10.3171/jns.1980.52.3.0309; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MATSUI T, 1978, ATLAS HUMAN BRAIN CO; NUECHTERLEIN KH, 1983, SCIENCE, V220, P327, DOI 10.1126/science.6836276; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; Ruff R. M., 1989, NEUROPSY NEUROPSY BE, V2, P103; Ruff RM, 1986, J HEAD TRAUMA REHAB, V1, P43; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; TENJIN H, 1987, NEUROTRAUMATOLOGY, V10, P74; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267	31	148	149	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY-JUN	1994	8	4					297	308		10.3109/02699059409150981			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	NP445	WOS:A1994NP44500001	8081345				2021-06-18	
J	Le Roux, P; Menon, DK; Citerio, G; Vespa, P; Bader, MK; Brophy, GM; Diringer, MN; Stocchetti, N; Videtta, W; Armonda, R; Badjatia, N; Boesel, J; Chesnut, R; Chou, S; Claassen, J; Czosnyka, M; De Georgia, M; Figaji, A; Fugate, J; Helbok, R; Horowitz, D; Hutchinson, P; Kumar, M; McNett, M; Miller, C; Naidech, A; Oddo, M; Olson, D; O'Phelan, K; Provencio, JJ; Puppo, C; Riker, R; Robertson, C; Schmidt, M; Taccone, F				Le Roux, Peter; Menon, David K.; Citerio, Giuseppe; Vespa, Paul; Bader, Mary Kay; Brophy, Gretchen M.; Diringer, Michael N.; Stocchetti, Nino; Videtta, Walter; Armonda, Rocco; Badjatia, Neeraj; Boeesel, Julian; Chesnut, Randall; Chou, Sherry; Claassen, Jan; Czosnyka, Marek; De Georgia, Michael; Figaji, Anthony; Fugate, Jennifer; Helbok, Raimund; Horowitz, David; Hutchinson, Peter; Kumar, Monisha; McNett, Molly; Miller, Chad; Naidech, Andrew; Oddo, Mauro; Olson, DaiWai; O'Phelan, Kristine; Provencio, J. Javier; Puppo, Corinna; Riker, Richard; Robertson, Claudia; Schmidt, Michael; Taccone, Fabio			Consensus summary statement of the International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care	INTENSIVE CARE MEDICINE			English	Article						Consensus development conference; Grading of Recommendations Assessment Development and Evaluation (GRADE); Brain metabolism; Brain oxygen; Clinical trials; Intracranial pressure; Microdialysis; Multimodal monitoring; Neuromonitoring; Traumatic brain injury; Brain physiology; Bioinformatics; Biomarkers; Neurocritical care; Clinical guidelines	TRAUMATIC BRAIN-INJURY; CEREBRAL PERFUSION-PRESSURE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; CRITICALLY-ILL PATIENTS; BULB OXYGEN-SATURATION; GLASGOW COMA SCALE; INTRACRANIAL-PRESSURE; INTENSIVE-CARE; TRANSCRANIAL DOPPLER; INDUCED NORMOTHERMIA	Neurocritical care depends, in part, on careful patient monitoring but as yet there are little data on what processes are the most important to monitor, how these should be monitored, and whether monitoring these processes is cost-effective and impacts outcome. At the same time, bioinformatics is a rapidly emerging field in critical care but as yet there is little agreement or standardization on what information is important and how it should be displayed and analyzed. The Neurocritical Care Society in collaboration with the European Society of Intensive Care Medicine, the Society for Critical Care Medicine, and the Latin America Brain Injury Consortium organized an international, multidisciplinary consensus conference to begin to address these needs. International experts from neurosurgery, neurocritical care, neurology, critical care, neuroanesthesiology, nursing, pharmacy, and informatics were recruited on the basis of their research, publication record, and expertise. They undertook a systematic literature review to develop recommendations about specific topics on physiologic processes important to the care of patients with disorders that require neurocritical care. This review does not make recommendations about treatment, imaging, and intraoperative monitoring. A multidisciplinary jury, selected for their expertise in clinical investigation and development of practice guidelines, guided this process. The GRADE system was used to develop recommendations based on literature review, discussion, integrating the literature with the participants' collective experience, and critical review by an impartial jury. Emphasis was placed on the principle that recommendations should be based on both data quality and on trade-offs and translation into clinical practice. Strong consideration was given to providing pragmatic guidance and recommendations for bedside neuromonitoring, even in the absence of high quality data.	[Le Roux, Peter] Lankenau Med Ctr, Brain & Spine Ctr, Wynnewood, PA 19096 USA; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Neurosci Crit Care Unit, Div Anaesthesia, Cambridge CB2 2QQ, England; [Citerio, Giuseppe] Osped San Gerardo, NeuroIntens Care Unit, Dept Anesthesia & Crit Care, I-20900 Monza, Italy; [Vespa, Paul] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Bader, Mary Kay] Mission Hosp, Neuro Crit Care CNS, Mission Viejo, CA 92691 USA; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Richmond, VA 23298 USA; [Diringer, Michael N.] Washington Univ, Neurocrit Care Sect, Dept Neurol, St Louis, MO 63110 USA; [Stocchetti, Nino] Univ Milan, Dept Physiopathol & Transplant, Neuro ICU, Fdn IRCCS Ca Granda Osped Maggiore Policlin, I-20122 Milan, Italy; [Videtta, Walter] Hosp Nacl Prof A Posadas, ICU Neurocrit Care, Buenos Aires, DF, Argentina; [Armonda, Rocco] Medstar Hlth, Dept Neurosurg, MedStar Georgetown Univ Hosp, Washington, DC 20007 USA; [Badjatia, Neeraj] Univ Maryland, Med Ctr, Dept Neurol, Baltimore, MD 21201 USA; [Boeesel, Julian] Heidelberg Univ, Dept Neurol, Hosp Heidelberg, D-69120 Heidelberg, Germany; [Chesnut, Randall] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA; [Chou, Sherry] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; [Claassen, Jan] Columbia Univ Coll Phys & Surg, Neurol Intens Care Unit, New York, NY 10032 USA; [Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 0QQ, England; [De Georgia, Michael] Case Western Reserve Univ, Sch Med, Neurocrit Care Ctr, Cerebrovasc Ctr,Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Figaji, Anthony] Univ Cape Town, Inst Child Hlth 617, Red Cross Childrens Hosp, ZA-7700 Cape Town, South Africa; [Fugate, Jennifer] Mayo Clin, Rochester, MN 55905 USA; [Helbok, Raimund] Med Univ Innsbruck, Neurocrit Care Unit, Dept Neurol, A-6020 Innsbruck, Austria; [Horowitz, David] Univ Penn Hlth Syst, Philadelphia, PA 19104 USA; [Hutchinson, Peter] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge CB2 2QQ, England; [Kumar, Monisha] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [McNett, Molly] MetroHlth Syst, Nursing Res, Cleveland, OH 44109 USA; [Miller, Chad] Ohio State Univ, Div Cerebrovasc Dis & Neurocrit Care, Columbus, OH 43210 USA; [Naidech, Andrew] Northwestern Univ Feinberg, Dept Neurol, Chicago, IL 60611 USA; [Oddo, Mauro] Univ Lausanne, CHUV Univ Hosp, Dept Intens Care Med, Fac Biol & Med, CH-1011 Lausanne, Switzerland; [Olson, DaiWai] Univ Texas Southwestern, Dallas, TX 75390 USA; [O'Phelan, Kristine] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA; [Provencio, J. Javier] Cleveland Clin, Cerebrovasc Ctr, Lerner Coll Med, Cleveland, OH 44195 USA; [Provencio, J. Javier] Cleveland Clin, Neuroinflammat Res Ctr, Lerner Coll Med, Cleveland, OH 44195 USA; [Puppo, Corinna] Univ Republica, Intens Care Unit, Hosp Clin, Montevideo, Uruguay; [Riker, Richard] Maine Med Ctr, Portland, ME 04102 USA; [Robertson, Claudia] Ben Taub Gen Hosp, Baylor Coll Med, Dept Neurosurg, Ctr Neurosurg Intens Care, Houston, TX 77030 USA; [Schmidt, Michael] Columbia Univ Coll Phys & Surg, Milstein Hosp 8 Garden South, New York, NY 10032 USA; [Taccone, Fabio] Erasme Univ Hosp, Lab Rech Expt, Dept Intens Care, B-1070 Brussels, Belgium	Le Roux, P (corresponding author), Lankenau Med Ctr, Brain & Spine Ctr, Suite 370,Med Sci Bldg,100 East Lancaster Ave, Wynnewood, PA 19096 USA.	lerouxp@mlhs.org; dkm13@wbic.cam.ac.uk; g.citerio@hsgerardo.org; PVespa@mednet.ucla.edu; Marykay.Bader@stjoe.org; gbrophy@vcu.edu; diringerm@neuro.wustl.edu; stocchet@policlinico.mi.it	Provencio, Jose Javier/AAG-5114-2021; Oddo, Mauro/R-3370-2016; Chou, Sherry/G-5779-2015; Stocchetti, Nino/O-7444-2017; Diringer, Michael N/C-1165-2008; Citerio, Giuseppe/B-1839-2015; Helbok, Raimund/AAA-8361-2021; Olson, DaiWai/I-5932-2019; Claassen, Jan/AAA-5451-2020	Provencio, Jose Javier/0000-0003-1298-1806; Oddo, Mauro/0000-0002-6155-2525; Stocchetti, Nino/0000-0003-3250-6834; Diringer, Michael N/0000-0003-2337-5537; Citerio, Giuseppe/0000-0002-5374-3161; Olson, DaiWai/0000-0002-9280-078X; Figaji, Anthony/0000-0002-3357-6490; Chesnut, Randall/0000-0001-6377-3666; Hutchinson, Peter/0000-0002-2796-1835; Brophy, Gretchen/0000-0002-4749-2693	Integra Lifesciences; Dana Foundation; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Neurologica; Bard and Medivance; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Department of Defense (DoD)United States Department of Defense; NovartisNovartis; AIFA; Ministero SaluteMinistry of Health, Italy; Regione LombardiaRegione Lombardia; Haemonetics; Advanced Circulatory Systems; DODUnited States Department of Defense; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025, G0001237, G9439390, G0600986, G1002277] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, NF-SI-0512-10090, NF-SI-0508-10327] Funding Source: researchfish	Peter Le Roux receives research funding from Integra Lifesciences, Neurologica, the Dana Foundation, and the National Institutes of Health (NIH); is a consultant for Integra Lifesciences, Codman, Synthes, and Neurologica; and is a member of the scientific advisory board of Cerebrotech, Brainsgate, Orsan, and Edge Therapeutics.; Neeraj Badjatia receives consulting fees from Bard and Medivance and is a Scientific Advisor to Cumberland Pharmaceuticals.; Gretchen Brophy receives research funding from the NIH and the Department of Defense (DoD); is on the scientific advisory board of Edge Therapeutics; has acted as a consultant for CSL Behring; and has received honoraria from UCB Pharma.; Sherry Chou receives research funding from the NIH and Novartis. Giuseppe Citerio receives speaker honoraria from Codman and has received research funding from Italian government agencies (AIFA, Ministero Salute, Regione Lombardia).; Michael Diringer receives research funding from the NIH and the AHA and is a consultant for Cephalogics LLC.; Monisha Kumar receives research funding from Haemonetics.; J. Javier Provencio receives research funding from the NIH, Bard Medivance, and Advanced Circulatory Systems, and is on the scientific advisory board of Edge Therapeutics and Minnetronix. Nino Stocchetti is a consultant for Orsan.; Paul Vespa receives grant funding from the NIH, DOD; is a consultant for Edge Therapeutics; and has Stock Options with Intouch Health.; Walter Videtta receives NIH funding.	Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; Anderson CT, 2000, CRIT CARE, V4, P207, DOI 10.1186/cc696; Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Arabi YM, 2010, J CRIT CARE, V25, P190, DOI 10.1016/j.jcrc.2009.05.004; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Banki NM, 2005, CIRCULATION, V112, P3314, DOI 10.1161/CIRCULATIONAHA.105.558239; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bekar A, 2009, J CLIN NEUROSCI, V16, P236, DOI 10.1016/j.jocn.2008.02.008; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; BIESTRO AA, 1995, J NEUROSURG, V83, P627, DOI 10.3171/jns.1995.83.4.0627; Cammarata G, 2011, J TRAUMA, V71, P779, DOI 10.1097/TA.0b013e3182220673; Chatelle C, 2012, J NEUROL NEUROSUR PS, V83, P1233, DOI 10.1136/jnnp-2012-302987; Chee YL, 2008, BRIT J HAEMATOL, V140, P496, DOI 10.1111/j.1365-2141.2007.06968.x; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Choi HA, 2011, NEUROCRIT CARE, V14, P389, DOI 10.1007/s12028-010-9474-7; Chou SHY, 2011, TRANSL STROKE RES, V2, P600, DOI 10.1007/s12975-011-0117-x; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Claassen J, 2013, INTENS CARE MED, V39, P1337, DOI 10.1007/s00134-013-2938-4; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coplin WM, 1997, NEUROSURGERY, V41, P101, DOI 10.1097/00006123-199707000-00022; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Damian MS, 2013, INTENS CARE MED, V39, P1405, DOI 10.1007/s00134-013-2960-6; Dansirikul C, 2012, THROMB HAEMOSTASIS, V107, P775, DOI 10.1160/TH11-09-0656; DAVIES KR, 1991, BRIT J ANAESTH, V67, P58, DOI 10.1093/bja/67.1.58; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; De Turck F, 2007, COMPUT BIOL MED, V37, P97, DOI 10.1016/j.compbiomed.2005.10.004; Desachy A, 2008, MAYO CLIN PROC, V83, P400, DOI 10.4065/83.4.400; Diaz-Arrastia R, 2012, BRAIN TISSUE OXYGEN; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Effken JA, 2008, INT J MED INFORM, V77, P765, DOI 10.1016/j.ijmedinf.2008.05.004; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; English SW, 2013, NEUROCRIT CARE, V18, P131, DOI 10.1007/s12028-012-9748-3; Fernandez A, 2007, NEUROLOGY, V68, P1013, DOI 10.1212/01.wnl.0000258543.45879.f5; Ferrie S, 2013, NUTR CLIN PRACT, V28, P463, DOI 10.1177/0884533613486297; Finkielman JDW, 2005, CHEST, V127, P1749, DOI 10.1378/chest.127.5.1749; Gelinas C, 2013, SEMIN RESP CRIT CARE, V34, P236, DOI 10.1055/s-0033-1342986; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; Gesang DZ, 2009, CHINESE MED J-PEKING, V122, P2412, DOI 10.3760/cma.j.issn.0366-6999.2009.20.003; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Goldenberg NA, 2005, ANN INTERN MED, V142, P506, DOI 10.7326/0003-4819-142-7-200504050-00009; Guiza F, 2013, CRIT CARE MED, V41, P554, DOI 10.1097/CCM.0b013e3182742d0a; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hata JS, 2008, NEUROCRIT CARE, V9, P37, DOI 10.1007/s12028-007-9015-1; Helbok R, 2012, CRIT CARE, V16, DOI 10.1186/cc11880; Hsu J, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-62; Hu X, 2010, IEEE T BIO-MED ENG, V57, P1070, DOI 10.1109/TBME.2009.2037607; Jacono FJ, 2010, J HEALTHC ENG, V1, P337, DOI 10.1260/2040-2295.1.3.337; Jaeschke R, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a744; JUBRAN A, 1990, CHEST, V97, P1420, DOI 10.1378/chest.97.6.1420; Kazmierski R, 2012, NEUROLOGY, V79, P1677, DOI 10.1212/WNL.0b013e31826e9a83; Kim MN, 2010, NEUROCRIT CARE, V12, P173, DOI 10.1007/s12028-009-9305-x; Kincaid MS, 2009, J NEUROSURG, V110, P67, DOI 10.3171/2008.4.17520; Knopf L, 2012, NEUROCRIT CARE, V16, P63, DOI 10.1007/s12028-011-9620-x; Koch S, 2010, P HUM FACT ERG SOC A, DOI [DOI 10.1177/15419312100540122, 10.1177/154193121005401227]; Kopelnik A, 2005, NEUROCRIT CARE, V3, P132, DOI 10.1385/NCC:3:2:132; Kosty JA, 2013, ANESTH ANALG, V117, P694, DOI 10.1213/ANE.0b013e31829cc765; Kramer AH, 2013, CAN J ANESTH, V60, P966, DOI 10.1007/s12630-013-0001-0; Kramer AH, 2011, NEUROCRIT CARE, V14, P329, DOI 10.1007/s12028-011-9530-y; Kramer AH, 2009, NEUROCRIT CARE, V10, P157, DOI 10.1007/s12028-008-9171-y; Kramer AA, 2012, CRIT CARE MED, V40, P2671, DOI 10.1097/CCM.0b013e318258fd88; Krisl JC, 2011, ANN PHARMACOTHER, V45, P1433, DOI 10.1345/aph.1Q207; Larach DB, 2011, NEUROCRIT CARE, V15, P609, DOI 10.1007/s12028-011-9517-8; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; Lazaridis C, 2013, NEUROL RES, V35, P138, DOI 10.1179/1743132812Y.0000000150; Levine J, 2010, NEUROSURGERY, V66, P312, DOI 10.1227/01.NEU.0000363747.47587.6C; Lilly CM, 2011, CHEST, V140, P1232, DOI 10.1378/chest.11-0718; Lisman T, 2010, J HEPATOL, V52, P355, DOI 10.1016/j.jhep.2009.12.001; Lonjaret L, 2012, DIABETES METAB, V38, P230, DOI 10.1016/j.diabet.2011.12.003; Lysakowski C, 2001, STROKE, V32, P2292, DOI 10.1161/hs1001.097108; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Mayer SA, 1999, STROKE, V30, P780, DOI 10.1161/01.STR.30.4.780; Mendelson AA, 2012, CAN J NEUROL SCI, V39, P571, DOI 10.1017/S0317167100015286; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; Mitasova A, 2012, CRIT CARE MED, V40, P484, DOI 10.1097/CCM.0b013e318232da12; Mock C, 2005, CURR OPIN CRIT CARE, V11, P568, DOI 10.1097/01.ccx.0000186373.49320.65; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Morris A., 1992, PRINCIPLES CRITICAL, P500; Mun Jong Hyun, 2013, Chonnam Med J, V49, P113, DOI 10.4068/cmj.2013.49.3.113; Mutoh T, 2007, STROKE, V38, P3218, DOI 10.1161/STROKEAHA.107.484634; Naidech AM, 2005, CIRCULATION, V112, P2851, DOI 10.1161/CIRCULATIONAHA.105.533620; Naidech AM, 2009, NEUROCRIT CARE, V11, P177, DOI 10.1007/s12028-009-9223-y; Naidech AM, 2009, STROKE, V40, P2398, DOI 10.1161/STROKEAHA.109.550939; Naidech AM, 2009, ANN NEUROL, V65, P352, DOI 10.1002/ana.21618; Narotam PK, 2014, J NEUROTRAUM, V31, P630, DOI 10.1089/neu.2013.3104; Naval NS, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2012.03.006; Naval NS, 2005, NEUROCRIT CARE, V2, P133, DOI 10.1385/NCC:2:2:133; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; O'Connor E, 2004, ANAESTH INTENS CARE, V32, P465, DOI 10.1177/0310057X0403200402; Oddo M, 2008, CURR OPIN CLIN NUTR, V11, P134, DOI 10.1097/MCO.0b013e3282f37b43; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Oddo M, 2010, NEUROCRIT CARE, V12, P10, DOI 10.1007/s12028-009-9280-2; Oddo M, 2009, STROKE, V40, P1913, DOI 10.1161/STROKEAHA.108.534115; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Pascual JL, 2011, J TRAUMA, V70, P535, DOI 10.1097/TA.0b013e31820b59de; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Pennings FA, 2008, J NEUROTRAUM, V25, P1173, DOI 10.1089/neu.2007.0402; Ponce LL, 2012, NEUROSURGERY, V70, P1492, DOI 10.1227/NEU.0b013e31824ce933; Provencio JJ, 2010, NEUROCRIT CARE, V12, P244, DOI 10.1007/s12028-009-9308-7; Puccio AM, 2009, NEUROCRIT CARE, V11, P82, DOI 10.1007/s12028-009-9213-0; Ragauskas A, 2014, NEUROL RES, V36, P607, DOI 10.1179/1743132813Y.0000000308; Reignier J, 2013, JAMA-J AM MED ASSOC, V309, P249, DOI 10.1001/jama.2012.196377; Resnick DK, 1997, J TRAUMA, V42, P1108, DOI 10.1097/00005373-199706000-00021; Rhodes A, 2012, INTENS CARE MED, V38, P1647, DOI 10.1007/s00134-012-2627-8; Rincon F, 2010, NEUROCRIT CARE, V13, P75, DOI 10.1007/s12028-010-9347-0; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rochwerg B, 2014, INTENS CARE MED, V40, P877, DOI 10.1007/s00134-014-3273-0; Rohlwink UK, 2012, NEUROSURGERY, V70, P1220, DOI 10.1227/NEU.0b013e318243fc59; Rossetti AO, 2012, NEUROLOGY, V78, P796, DOI 10.1212/WNL.0b013e318249f6bb; Rossetti AO, 2010, ANN NEUROL, V67, P301, DOI 10.1002/ana.21984; Sarrafzadeh A, 2012, NEUROL RES, V34, P455, DOI 10.1179/1743132812Y.0000000018; Schefold JC, 2009, RESUSCITATION, V80, P658, DOI 10.1016/j.resuscitation.2009.03.006; SCHNEIDER GH, 1995, ACTA NEUROCHIR, V134, P71, DOI 10.1007/BF01428507; Schoon P, 2002, ACT NEUR S, V81, P285; Schunemann HJ, 2014, CAN MED ASSOC J, V186, pE123, DOI 10.1503/cmaj.131237; Sim S K, 2011, Med J Malaysia, V66, P138; Siman R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028938; Singh V, 2000, J Assoc Physicians India, V48, P898; Sivaganesan A, 2014, NEUROCRIT CARE, V20, P132, DOI 10.1007/s12028-013-9872-8; Skjoth-Rasmussen J, 2004, J NEUROSURG, V100, P8, DOI 10.3171/jns.2004.100.1.0008; Smith Linda S, 2004, Biol Res Nurs, V6, P117, DOI 10.1177/1099800404268917; SMOLLER BR, 1989, AM J CLIN PATHOL, V91, P701, DOI 10.1093/ajcp/91.6.701; Stangier J, 2012, BLOOD COAGUL FIBRIN, V23, P138, DOI 10.1097/MBC.0b013e32834f1b0c; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Suarez JI, 2002, CRIT CARE MED, V30, P1348, DOI 10.1097/00003246-200206000-00035; Sugimoto K, 2013, NEUROSURG REV, V36, P259, DOI 10.1007/s10143-012-0424-z; Sulter G, 2000, J NEUROL SCI, V179, P65, DOI 10.1016/S0022-510X(00)00378-6; Thompson HJ, 2003, J NEUROL NEUROSUR PS, V74, P614, DOI 10.1136/jnnp.74.5.614; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Tsao JW, 2005, ARCH NEUROL-CHICAGO, V62, P1126, DOI 10.1001/archneur.62.7.1126; Tung P, 2004, STROKE, V35, P548, DOI 10.1161/01.STR.0000114874.96688.54; Turek G, 2012, NEUROL NEUROCHIR POL, V46, P233, DOI 10.5114/ninp.2012.29131; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; Varelas PN, 2004, CLIN EEG NEUROSCI, V35, P173, DOI 10.1177/155005940403500406; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2005, CURR OPIN CRIT CARE, V11, P133, DOI 10.1097/01.ccx.0000155353.01489.58; Vora YY, 1999, NEUROSURGERY, V44, P1237, DOI 10.1097/00006123-199906000-00039; West KL, 2011, J NEUROSURG, V114, P9, DOI 10.3171/2010.7.JNS091857; Whitmore RG, 2012, J NEUROSURG, V116, P1106, DOI 10.3171/2012.1.JNS11962; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wilt Timothy J, 2012, Proc Am Thorac Soc, V9, P243, DOI 10.1513/pats.201208-058ST; Woolf S, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-61; Young GB, 1996, NEUROLOGY, V47, P83; Zandbergen EGJ, 2006, NEUROLOGY, V66, P62, DOI 10.1212/01.wnl.0000191308.22233.88; Zhang JJ, 2005, J BIOMED INFORM, V38, P1, DOI 10.1016/j.jbi.2004.12.002; Zweifel C, 2010, J NEUROTRAUM, V27, P1951, DOI 10.1089/neu.2010.1388	160	147	148	0	25	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	SEP	2014	40	9					1189	1209		10.1007/s00134-014-3369-6			21	Critical Care Medicine	General & Internal Medicine	AO5IK	WOS:000341377400001	25138226				2021-06-18	
J	Wright, KM; Britt, TW; Bliese, PD; Adler, AB; Picchioni, D; Moore, D				Wright, Kathleen M.; Britt, Thomas W.; Bliese, Paul D.; Adler, Amy B.; Picchioni, Dante; Moore, DeWayne			Insomnia as Predictor Versus Outcome of PTSD and Depression Among Iraq Combat Veterans	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article						insomnia; posttraumatic stress disorder; longitudinal; combat exposure; postdeployment mental health	POSTTRAUMATIC-STRESS-DISORDER; COVARIANCE STRUCTURE-ANALYSIS; TRAUMATIC BRAIN-INJURY; SLEEP DISTURBANCE; PSYCHIATRIC-DISORDERS; TEST STATISTICS; ACTIVE-DUTY; HALLUCINATIONS; DISSOCIATION; CHECKLIST	Objectives: The study conducted a longitudinal assessment of insomnia as an antecedent versus consequence of posttraumatic stress disorder (PTSD) and depression symptoms among combat veterans. Design: Two postdeployment time points were used in combination with structural equation modeling to examine the relative strength of two possible directions of prediction: insomnia as a predictor of psychological symptoms, and psychological symptoms as a predictor of insomnia. Participants were active duty soldiers (N = 659) in a brigade combat team who were assessed 4 months after their return from a 12-month deployment to Iraq, and then again eight months later. Results: Although both insomnia and psychological symptoms were associated at both time periods and across time periods, insomnia at 4 months postdeployment was a significant predictor of change in depression and PTSD symptoms at 12 months postdeployment, whereas depression and PTSD symptoms at 4 months postdeployment were not significant predictors of change in insomnia at 12 months postdeployment. Conclusions: Results support the role of insomnia in the development of additional psychological problems and highlight the clinical implications for combat veterans, to include the importance of longitudinal assessment and monitoring of sleep disturbances, and the need for early intervention. (C) 2011 Wiley Periodicals, Inc. J Clin Psychol 67: 1240-1258, 2011.	[Wright, Kathleen M.; Britt, Thomas W.; Adler, Amy B.] USA, Med Res Unit Europe, Walter Reed Army Inst Res, Heidelberg, Germany; [Bliese, Paul D.; Picchioni, Dante] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA; [Britt, Thomas W.] Clemson Univ, Dept Psychol, Clemson, SC 29634 USA	Wright, KM (corresponding author), USA, Med Res Unit, APO, AE 09042 USA.	kathleen.wright@us.army.mil; twbritt@clemson.edu		Bliese, paul/0000-0002-5384-8879			ABELSON RP, 1985, PSYCHOL BULL, V97, P129, DOI 10.1037/0033-2909.97.1.129; Adler A. B., 2007, BATTLEMIND TRAINING; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 2005, NIH Consens State Sci Statements, V22, P1; BABKOFF H, 1989, PERCEPT MOTOR SKILL, V68, P787, DOI 10.2466/pms.1989.68.3.787; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Benca RM, 2005, PSYCHIAT SERV, V56, P332, DOI 10.1176/appi.ps.56.3.332; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bliese P. D., 2005, POSTDEPLOYMENT PSYCH; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bliese PD, 2007, PSYCHOL SERV, V4, P141, DOI DOI 10.1037/1541-1559.4.3.141; Breslau N, 1996, BIOL PSYCHIAT, V39, P411, DOI 10.1016/0006-3223(95)00188-3; Castro, 2011, DEPLOYMENT PSYCHOL E, P103, DOI 10.1037/12300-004; Creamer M, 2004, BEHAV RES THER, V42, P315, DOI 10.1016/S0005-7967(03)00141-4; Curran PJ, 1996, PSYCHOL METHODS, V1, P16, DOI 10.1037//1082-989X.1.1.16; DEMENT W, 1969, P775; Dow BM, 1996, BIOL PSYCHIAT, V39, P42, DOI 10.1016/0006-3223(95)00103-4; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Giesbrecht T, 2007, J ABNORM PSYCHOL, V116, P599, DOI 10.1037/0021-843X.116.3.599; Gillin J C, 1975, Int Rev Neurobiol, V17, P297, DOI 10.1016/S0074-7742(08)60212-3; Harvey AG, 2001, CLIN PSYCHOL REV, V21, P1037, DOI 10.1016/S0272-7358(00)00083-0; HAYNES SN, 1981, J ABNORM PSYCHOL, V90, P601, DOI 10.1037/0021-843X.90.6.601; Hobson JA, 1997, SEMIN NEUROL, V17, P121, DOI 10.1055/s-2008-1040921; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Howland RH, 1997, J NERV MENT DIS, V185, P730, DOI 10.1097/00005053-199712000-00003; HU LT, 1992, PSYCHOL BULL, V112, P351, DOI 10.1037/0033-2909.112.2.351; Hublin C, 1999, AM J MED GENET, V88, P329, DOI 10.1002/(SICI)1096-8628(19990820)88:4<329::AID-AJMG8>3.0.CO;2-E; Inman D. J., 1990, J TRAUMA STRESS, V3, P429, DOI [10.1002/jts.2490030311, DOI 10.1007/BF00974782]; JACOBS BL, 1978, NEUROSCI BIOBEHAV R, V2, P59, DOI 10.1016/0149-7634(78)90007-6; Kim PY, 2010, PSYCHIAT SERV, V61, P582, DOI 10.1176/ps.2010.61.6.582; Kline R.B., 2005, PRINCIPLES PRACTICE, V2nd; Lavie P, 1998, BIOL PSYCHIAT, V44, P1060, DOI 10.1016/S0006-3223(98)00037-7; Lavie P, 2001, NEW ENGL J MED, V345, P1825, DOI 10.1056/NEJMra012893; Levi L., 1974, LIFE STRESS ILLNESS, P8; Lichstein KL, 2006, SLEEP MED REV, V10, P3, DOI 10.1016/j.smrv.2005.10.001; Lim JL, 2008, ANN NY ACAD SCI, V1129, P305, DOI 10.1196/annals.1417.002; MACCALLUM RC, 1992, PSYCHOL BULL, V111, P490, DOI 10.1037/0033-2909.111.3.490; Mahowald MW, 1998, DREAMING, V8, P89, DOI 10.1023/B:DREM.0000005899.59224.17; MELLMAN TA, 1995, AM J PSYCHIAT, V152, P110; Morin CM, 2003, PSYCHOSOM MED, V65, P259, DOI 10.1097/01.PSY.0000030391.09558.A3; Morin CM., 1993, INSOMNIA PSYCHOL ASS; Morin CM, 2003, INSOMNIA CLIN GUIDE; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Pace-Schott EF, 2009, SLEEP, V32, P19; Payne JD, 2008, PSYCHOL SCI, V19, P781, DOI 10.1111/j.1467-9280.2008.02157.x; Perlis ML, 1997, J AFFECT DISORDERS, V42, P209, DOI 10.1016/S0165-0327(96)01411-5; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Peterson MJ, 2006, PSYCHIAT CLIN N AM, V29, P1009, DOI 10.1016/j.psc.2006.09.003; Picchioni D, 2010, MIL PSYCHOL, V22, P340, DOI 10.1080/08995605.2010.491844; Pigeon W., 2007, INT J SLEEP DISORD, V1, P82; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Riemann D, 2003, J AFFECT DISORDERS, V76, P255, DOI 10.1016/S0165-0327(02)00072-1; Satorra A, 2001, PSYCHOMETRIKA, V66, P507, DOI 10.1007/BF02296192; Satorra A., 1994, LATENT VARIABLES ANA, P399; Saucerman SA, 1997, SCHIZOPHR RES, V25, P261, DOI 10.1016/S0920-9964(97)00030-3; Schell TL, 2004, J ABNORM PSYCHOL, V113, P189, DOI 10.1037/0021-843X.113.2.189; Shin T, 2009, STRUCT EQU MODELING, V16, P70, DOI 10.1080/10705510802569918; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Stepanski EJ, 2006, SLEEP MED REV, V10, P7, DOI 10.1016/j.smrv.2005.08.002; Stickgold R, 2002, J CLIN PSYCHOL, V58, P61, DOI 10.1002/jclp.1129; STRETCH RH, 1986, J APPL SOC PSYCHOL, V16, P464, DOI 10.1111/j.1559-1816.1986.tb01153.x; Taylor Daniel J, 2003, Behav Sleep Med, V1, P227, DOI 10.1207/S15402010BSM0104_5; Taylor DJ, 2005, SLEEP, V28, P1457, DOI 10.1093/sleep/28.11.1457; Tranter R, 2002, J PSYCHIATR NEUROSCI, V27, P241; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; Walker MP, 2009, ANN NY ACAD SCI, V1156, P168, DOI 10.1111/j.1749-6632.2009.04416.x; Watson D, 2001, J ABNORM PSYCHOL, V110, P526, DOI 10.1037//0021-843X.110.4.526; Weathers F. W., 1993, ANN M INT SOC TRAUM; Weissman MM, 1997, GEN HOSP PSYCHIAT, V19, P245, DOI 10.1016/S0163-8343(97)00056-X	74	147	149	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9762	1097-4679		J CLIN PSYCHOL	J. Clin. Psychol.	DEC	2011	67	12					1240	1258		10.1002/jclp.20845			19	Psychology, Clinical	Psychology	855PJ	WOS:000297576400008	22065464				2021-06-18	
J	Garman, RH; Jenkins, LW; Switzer, RC; Bauman, RA; Tong, LC; Swauger, PV; Parks, SA; Ritzel, DV; Dixon, E; Clark, RSB; Bayir, H; Kagan, V; Jackson, EK; Kochanek, PM				Garman, Robert H.; Jenkins, Larry W.; Switzer, Robert C., III; Bauman, Richard A.; Tong, Lawrence C.; Swauger, Peter V.; Parks, Steven A.; Ritzel, David V.; Dixon, Edward; Clark, Robert S. B.; Bayir, Huelya; Kagan, Valerian; Jackson, Edwin K.; Kochanek, Patrick M.			Blast Exposure in Rats with Body Shielding Is Characterized Primarily by Diffuse Axonal Injury	JOURNAL OF NEUROTRAUMA			English	Article						hypothermia; neurotransmitters; proteomics; receptor antagonists; traumatic brain injury	BRAIN-INJURY; SILVER; NEURODEGENERATION; NEURONS; MODEL	Blast-induced traumatic brain injury (TBI) is the signature insult in combat casualty care. Survival with neurological damage from otherwise lethal blast exposures has become possible with body armor use. We characterized the neuropathologic alterations produced by a single blast exposure in rats using a helium-driven shock tube to generate a nominal exposure of 35 pounds per square inch (PSI) (positive phase duration similar to 4 msec). Using an IACUC-approved protocol, isoflurane-anesthetized rats were placed in a steel wedge (to shield the body) 7 feet inside the end of the tube. The left side faced the blast wave (with head-only exposure); the wedge apex focused a Mach stem onto the rat's head. The insult produced similar to 25% mortality (due to impact apnea). Surviving and sham rats were perfusion-fixed at 24 h, 72 h, or 2 weeks post-blast. Neuropathologic evaluations were performed utilizing hematoxylin and eosin, amino cupric silver, and a variety of immunohistochemical stains for amyloid precursor protein (APP), glial fibrillary acidic protein (GFAP), ionized calcium-binding adapter molecule 1 (Iba1), ED1, and rat IgG. Multifocal axonal degeneration, as evidenced by staining with amino cupric silver, was present in all blast-exposed rats at all time points. Deep cerebellar and brainstem white matter tracts were most heavily stained with amino cupric silver, with the morphologic staining patterns suggesting a process of diffuse axonal injury. Silver-stained sections revealed mild multifocal neuronal death at 24 h and 72 h. GFAP, ED1, and Iba1 staining were not prominently increased, although small numbers of reactive microglia were seen within areas of neuronal death. Increased blood-brain barrier permeability (as measured by IgG staining) was seen at 24 h and primarily affected the contralateral cortex. Axonal injury was the most prominent feature during the initial 2 weeks following blast exposure, although degeneration of other neuronal processes was also present. Strikingly, silver staining revealed otherwise undetected abnormalities, and therefore represents a recommended outcome measure in future studies of blast TBI.	[Garman, Robert H.; Jenkins, Larry W.; Dixon, Edward; Clark, Robert S. B.; Bayir, Huelya; Kagan, Valerian; Jackson, Edwin K.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Clark, Robert S. B.; Bayir, Huelya; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Jenkins, Larry W.; Dixon, Edward] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Garman, Robert H.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA; [Jackson, Edwin K.] Univ Pittsburgh, Sch Med, Dept Med Pharmacol, Pittsburgh, PA 15260 USA; [Kagan, Valerian] Univ Pittsburgh, Sch Med, Dept Environm Occupat Hlth, Pittsburgh, PA 15260 USA; [Bauman, Richard A.; Tong, Lawrence C.] Walter Reed Army Inst Res, Silver Spring, MD USA; [Swauger, Peter V.; Parks, Steven A.] ORA Inc, Fredericksburg, VA USA; [Switzer, Robert C., III] NeuroSci Associates, Knoxville, TN USA; [Ritzel, David V.] Dyn FX Consulting Ltd, Amherstburg, ON, Canada	Garman, RH (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	vetpathol@cs.com	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Jackson, Edwin/0000-0002-8101-6009; Kagan, Valerian E./0000-0002-7245-1885	DARPAUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-10-C-2124]	This work was supported by the DARPA PREVENT blast program N66001-10-C-2124. The views, opinions, and/or findings contained in this manuscript should not be interpreted as representing the official views or policies, either expressed or implied, of DARPA or the Department of Defense. Dr. Switzer has commercial interests in a company (NeuroScience Associates) that performs CNS amino cupric silver stains for academia, government, and industry.	Alexander D., 2010, P SAVIAC 81 SHOCK VI; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; DASILVA FHL, 1990, PHYSIOL REV, V70, P453; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HEIMER LENNART, 1968, BRAIN RES, V8, P337, DOI 10.1016/0006-8993(68)90053-X; Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kaur C, 1996, ARCH HISTOL CYTOL, V59, P239, DOI 10.1679/aohc.59.239; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Oehmichen M., 2009, FORENSIC NEUROPATHOL, P177; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rossi F, 2006, CEREBELLUM, V5, P174, DOI 10.1080/14734220600786444; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smucker P, 2009, NEUROSURGERY, V64, P984, DOI 10.1227/01.NEU.0000342406.43816.13; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Yue Z, 2007, AUTOPHAGY, V3, P139, DOI 10.4161/auto.3602	27	147	147	0	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					947	959		10.1089/neu.2010.1540			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600009	21449683				2021-06-18	
J	Saadoun, S; Bell, BA; Marios, ASV; Papadopoulos, MC				Saadoun, Samira; Bell, B. Anthony; Marios, A. S. Verkman; Papadopoulos, Marios C.			Greatly improved neurological outcome after spinal cord compression injury in AQP4-deficient mice	BRAIN			English	Article						aquaporin-4; astrocyte; oedema; spinal cord injury; water channel	INSENSITIVE WATER CHANNEL; TRAUMATIC BRAIN-INJURY; TIME-COURSE; AQUAPORIN-4 EXPRESSION; HIGH-RESOLUTION; WHITE-MATTER; MOUSE; RAT; DIFFUSION; MODEL	Aquaporin-4 (AQP4) is a water channel protein expressed in astrocytes throughout the CNS. In brain, AQP4 facilitates water balance and glial scar formation, which are important determinants of outcome after injury. Here, we provide evidence for AQP4-dependent spinal cord swelling following compression injury, resulting in remarkably improved outcome in AQP4-null mice. Two days after transient T6 spinal cord compression injury, wild-type mice developed more severe hindlimb weakness than AQP4-null mice, as assayed by the Basso open-field motor score, inclined plane method and footprint analysis. Basso motor scores were 1.3 +/- 0.5 (wild-type) versus 4.9 +/- 0.6 (AQP4-null) (SE, P < 0.001). Improved motor outcome in AQP4-null mice was independent of mouse strain and persisted at least 4 weeks. AQP4-null mice also had improved sensory outcome at 2 days, as assessed by spinal somatosensory evoked responses, with signal amplitudes similar to 10 mu V (uninjured), 1.7 +/- 0.7 mu V (wild-type) and 6.4 +/- 1.3 mu V (AQP4-null) (P < 0.01). The improved motor and sensory indices in AQP4-null mice corresponded to remarkably less neuronal death and myelin vacuolation, as well as reduced spinal cord swelling and intraparenchymal spinal cord pressure measured at T6 at 2 days after injury. AQP4 immunoreactivity at the injury site was increased in grey and white matter at 48 h. Taken together, our findings indicate that AQP4 provides a major route for excess water entry into the injured spinal cord, which in turn causes spinal cord swelling and elevated spinal cord pressure. Our data suggest AQP4 inhibition or downregulation as novel early neuroprotective manoeuvres in spinal cord injury.	[Saadoun, Samira; Bell, B. Anthony; Papadopoulos, Marios C.] St Georges Univ London, Acad Neurosurg Unit, London SW17 0RE, England; [Marios, A. S. Verkman] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Marios, A. S. Verkman] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	Papadopoulos, MC (corresponding author), St Georges Univ London, Acad Neurosurg Unit, Room 1-122 Jenner Wing,Cranmer Terrace, London SW17 0RE, England.	mpapadop@sgul.ac.uk		Papadopoulos, Marios/0000-0001-9174-4176; Saadoun, Samira/0000-0002-5480-5678	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R37DK035124] Funding Source: NIH RePORTER; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R37 DK35124] Funding Source: Medline; Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Aoki-Yoshino K, 2005, ACTA NEUROPATHOL, V110, P281, DOI 10.1007/s00401-005-1052-2; Auguste KI, 2007, FASEB J, V21, P108, DOI 10.1096/fj.06-6848com; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Binder DK, 2004, J NEUROSCI, V24, P8049, DOI 10.1523/JNEUROSCI.2294-04.2004; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; Bloch O, 2005, J NEUROCHEM, V95, P254, DOI 10.1111/j.1471-4159.2005.03362.x; Bloch O, 2006, J CEREBR BLOOD F MET, V26, P1527, DOI 10.1038/sj.jcbfm.9600306; Boldin C, 2006, SPINE, V31, P554, DOI 10.1097/01.brs.0000201274.59427.a4; Borgens RB, 2000, FASEB J, V14, P27; Brown DA, 2007, J COMP NEUROL, V502, P236, DOI 10.1002/cne.21307; Deo AA, 2006, J NEUROSCI RES, V83, P801, DOI 10.1002/jnr.20783; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fehlings MG, 2006, SPINE, V31, pS28, DOI 10.1097/01.brs.0000217973.11402.7f; Flanders AE, 1999, AM J NEURORADIOL, V20, P926; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; FUJII H, 1993, SPINE, V18, P2030, DOI 10.1097/00007632-199310001-00017; Fujiki M, 2005, BRAIN RES, V1053, P175, DOI 10.1016/j.brainres.2005.06.055; Gaviria M, 2006, NEUROBIOL DIS, V22, P694, DOI 10.1016/j.nbd.2006.01.011; Gomes-Leal W, 2004, EXP NEUROL, V190, P456, DOI 10.1016/j.expneurol.2004.06.028; GUTH L, 1985, EXP NEUROL, V88, P1, DOI 10.1016/0014-4886(85)90109-8; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Joshi M, 2002, J NEUROTRAUM, V19, P191, DOI 10.1089/08977150252806956; Kakulas BA, 1999, SPINAL CORD, V37, P79, DOI 10.1038/sj.sc.3100807; Krzyzak AT, 2005, ACTA NEUROBIOL EXP, V65, P255; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Luo J, 2002, SPINAL CORD, V40, P656, DOI 10.1038/sj.sc.3101363; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mcbride JM, 2007, NEUROSCIENCE, V148, P44, DOI 10.1016/j.neuroscience.2007.05.039; McDonald JW, 2002, LANCET, V359, P417, DOI 10.1016/S0140-6736(02)07603-1; Miyanji F, 2007, RADIOLOGY, V243, P820, DOI 10.1148/radiol.2433060583; Nesic O, 2006, NEUROSCIENCE, V143, P779, DOI 10.1016/j.neuroscience.2006.08.079; Nielsen S, 1997, J NEUROSCI, V17, P171; Nishi RA, 2007, J NEUROTRAUM, V24, P674, DOI 10.1089/neu.2006.0204; Oshio K, 2004, NEUROSCIENCE, V127, P685, DOI 10.1016/j.neuroscience.2004.03.016; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Saadoun S, 2002, J NEUROL NEUROSUR PS, V72, P262, DOI 10.1136/jnnp.72.2.262; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schwartz ED, 2003, EXP NEUROL, V184, P570, DOI 10.1016/S0014-4886(03)00295-4; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Sharma HS, 2005, ANN NY ACAD SCI, V1053, P422, DOI 10.1196/annals.1344.037; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Terayama R, 2007, NEUROSCIENCE, V148, P175, DOI 10.1016/j.neuroscience.2007.05.037; Verdu E, 2003, J NEUROTRAUM, V20, P483, DOI 10.1089/089771503765355559; WAGNER FC, 1981, J NEUROSURG, V54, P802, DOI 10.3171/jns.1981.54.6.0802; WRATHALL JR, 1992, J NEUROTRAUM, V9, pS129; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; Wyndaele M, 2006, SPINAL CORD, V44, P523, DOI 10.1038/sj.sc.3101893; Yam PS, 1998, BRAIN RES PROTOC, V2, P315, DOI 10.1016/S1385-299X(98)00005-1; ZADOR Z, FASEB J, DOI DOI 10.1096/FJ.07-9468C0M	62	147	161	3	15	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	APR	2008	131		4				1087	1098		10.1093/brain/awn014			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	284CH	WOS:000254682300020	18267965	Bronze			2021-06-18	
J	Hall, ED; Bryant, YD; Cho, W; Sullivan, PG				Hall, Edward D.; Bryant, Ying Deng; Cho, Wongil; Sullivan, Patrick G.			Evolution of post-traumatic neurodegeneration after controlled cortical impact traumatic brain injury in mice and rats as assessed by the de Olmos silver and fluorojade staining methods	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; cortex; de Olmos silver staining; hippocampus; neurodegeneration	INDUCED AXONAL INJURY; NEURONAL DEGENERATION; CYCLOSPORINE-A; MOUSE MODEL; HEAD-INJURY; CELL LOSS; JADE; LOCALIZATION; ACTIVATION	This report documents an analysis of post-traumatic neurodegeneration during the first 7 days after controlled cortical impact ( CCI) traumatic brain injury ( TBI) in mice and rats using the de Olmos aminocupric silver staining method, which selectively stains degenerating axons and nerve terminals, compared to the fluorojade method, which stains degenerating neuronal cell bodies. A progressive increase in cortical, hippocampal, and thalamic degeneration was observed over the first 48 h after injury in both species. Approximately 50% of the ipsilateral cortical volume was stained at 48 h. Similarly, the dorsal hippocampus showed widespread degeneration in all of the subfields. This included CA1, CA3, CA4, and dentate cell bodies revealed by fluorojade together with a high degree of axonal degeneration in areas carrying afferent and efferent hippocampal projections that is identified by silver staining. These results show that previous CCI studies which have relied on conventional histological methods that show cell body staining alone have underestimated the degree of axonal damage associated with the CCI-TBI model. In order to capture the full extent of the injury to both axons and cell bodies, the combination of silver staining and fluorojade staining is needed, respectively. Future studies of potential neuroprotective agents should probably not rely on the measure of cortical lesion volume or volume of spared cortical tissue using conventional histological stains alone, since these fail to identify the complete extent of the posttraumatic neuropathology that some agents which reduce cortical lesion volume may not be able to effect.	[Hall, Edward D.; Bryant, Ying Deng; Cho, Wongil; Sullivan, Patrick G.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Room B483,BBSRB,741 S Limestone St, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048191, R01NS046566] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS046566, 1R01NS048191] Funding Source: Medline		Ai JL, 2007, J NEUROTRAUM, V24, P960, DOI 10.1089/neu.2006.0224; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Povlishock JT, 1999, ACT NEUR S, V73, P15; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109	27	147	148	0	8	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2008	25	3					235	247		10.1089/neu.2007.0383			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	282PJ	WOS:000254579400007	18352837				2021-06-18	
J	Candelario-Jalil, E; de Oliveira, ACP; Graf, S; Bhatia, HS; Hull, M; Munoz, E; Fiebich, BL				Candelario-Jalil, Eduardo; de Oliveira, Antonio C. Pinheiro; Graef, Sybille; Bhatia, Harsharan S.; Huell, Michael; Munoz, Eduardo; Fiebich, Bernd L.			Resveratrol potently reduces prostaglandin E-2 production and free radical formation in lipopolysaccharide-activated primary rat microglia	JOURNAL OF NEUROINFLAMMATION			English	Article							FOCAL CEREBRAL-ISCHEMIA; INDUCED OXIDATIVE DAMAGE; TRAUMATIC BRAIN-INJURY; D-ASPARTATE RECEPTORS; IN-VIVO ACTIVATION; NITRIC-OXIDE; PARKINSONS-DISEASE; LIPID-PEROXIDATION; IMMUNOMODULATORY ACTIVITY; ACETYLSALICYLIC-ACID	Background: Neuroinflammatory responses are triggered by diverse ethiologies and can provide either beneficial or harmful results. Microglial cells are the major cell type involved in neuroinflammation, releasing several mediators, which contribute to the neuronal demise in several diseases including cerebral ischemia and neurodegenerative disorders. Attenuation of microglial activation has been shown to confer protection against different types of brain injury. Recent evidence suggests that resveratrol has anti- inflammatory and potent antioxidant properties. It has been also shown that resveratrol is a potent inhibitor of cyclooxygenase (COX)-1 activity. Previous findings have demonstrated that this compound is able to reduce neuronal injury in different models, both in vitro and in vivo. The aim of this study was to examine whether resveratrol is able to reduce prostaglandin E-2 (PGE(2)) and 8-iso-prostaglandin F-2 alpha (8-iso-PGF(2 alpha)) production by lipopolysaccharide (LPS)-activated primary rat microglia. Methods: Primary microglial cell cultures were prepared from cerebral cortices of neonatal rats. Microglial cells were stimulated with 10 ng/ml of LPS in the presence or absence of different concentrations of resveratrol (1-50 mu M). After 24 h incubation, culture media were collected to measure the production of PGE2 and 8- iso- PGF(2 alpha) using enzyme immunoassays. Protein levels of COX-1, COX-2 and microsomal prostaglandin E synthase-1 ( mPGES-1) were studied by Western blotting after 24 h of incubation with LPS. Expression of mPGES- 1 at the mRNA level was investigated using reverse transcription- polymerase chain reaction (RT-PCR) analysis. Results: Our results indicate that resveratrol potently reduced LPS- induced PGE(2) synthesis and the formation of 8-iso-PGF(2 alpha), a measure of free radical production. Interestingly, resveratrol dosedependently reduced the expression (mRNA and protein) of mPGES-1, which is a key enzyme.	Univ Freiburg, Sch Med, Dept Psychiat, Neurochem Res Grp, D-79104 Freiburg, Germany; Univ New Mexico, Hlth Sci Ctr, Dept Neurol, Albuquerque, NM 87131 USA; Univ Freiburg, Sch Med, Ctr Geriatr & Gerontol, D-79106 Freiburg, Germany; Univ Cordoba, Dept Biol Celular Fisiol & Inmunol, Cordoba, Spain; VivaCell Biotechnol GmbH, D-79211 Denzlingen, Germany	Fiebich, BL (corresponding author), Univ Freiburg, Sch Med, Dept Psychiat, Neurochem Res Grp, Hauptstr 5, D-79104 Freiburg, Germany.	ecandelario-jalil@salud.unm.edu; antoniocpo@yahoo.com.br; sybille.graef@mars.uni-freiburg.de; harsharan.bhatia@uniklinik-freiburg.de; michael.huell@uniklinik-freiburg.de; filmuble@uco.es; bernd.fiebich@klinikum.uni-freiburg.de	Candelario-Jalil, Eduardo/A-3528-2008; Candelario-Jalil, Eduardo/I-1139-2019; de Oliveira, Antonio CP/F-1661-2013; Bhatia, Harsharan singh/AAR-4628-2021; Hull, Michael/F-2618-2012; Munoz, Eduardo/I-5225-2012	Candelario-Jalil, Eduardo/0000-0003-3631-1989; de Oliveira, Antonio CP/0000-0003-3217-4294; Munoz, Eduardo/0000-0001-8478-5842; Bhatia, Harsharan Singh/0000-0001-9912-8263			Akundi RS, 2005, GLIA, V51, P199, DOI 10.1002/glia.20198; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Ates O, 2007, J CLIN NEUROSCI, V14, P256, DOI 10.1016/j.jocn.2005.12.010; Ates O, 2006, ACTA PHARMACOL SIN, V27, P1317, DOI 10.1111/j.1745-7254.2006.00416.x; Bastianetto S, 2000, BRIT J PHARMACOL, V131, P711, DOI 10.1038/sj.bjp.0703626; Bauer MKA, 1997, EUR J BIOCHEM, V243, P726, DOI 10.1111/j.1432-1033.1997.00726.x; Beharka AA, 2002, FREE RADICAL BIO MED, V32, P503, DOI 10.1016/S0891-5849(01)00817-6; Bi XL, 2005, INT IMMUNOPHARMACOL, V5, P185, DOI 10.1016/j.intimp.2004.08.008; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Candelario-Jalil E, 2000, EUR J PHARMACOL, V390, P295, DOI 10.1016/S0014-2999(99)00908-5; Candelario-Jalil E, 2004, BRAIN RES, V1007, P98, DOI 10.1016/j.brainres.2004.01.078; Candelario-Jalil E, 2003, NEUROSCI RES, V47, P245, DOI 10.1016/S0168-0102(03)00184-6; Candelario-Jalil E, 2003, J NEUROCHEM, V86, P545, DOI 10.1046/j.1471-4159.2003.01812.x; Candelario-Jalil E, 2002, EUR J PHARMACOL, V453, P189, DOI 10.1016/S0014-2999(02)02422-6; Candelario-Jalil E, 2007, J NEUROCHEM, V100, P1108, DOI 10.1111/j.1471-4159.2006.04280.x; Candelario-Jalil E, 2006, J NEUROIMMUNOL, V174, P39, DOI 10.1016/j.jneuroim.2006.01.003; Candelario-Jalil E, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crofford LJ, 2006, J RHEUMATOL, V33, P1403; Crofford LJ, 2000, CURR PHARM DESIGN, V6, P1725, DOI 10.2174/1381612003398753; Dore S, 2003, ANN NEUROL, V54, P155, DOI 10.1002/ana.10612; Egger T, 2003, BIOCHEM J, V370, P459, DOI 10.1042/BJ20021358; Fiebich BL, 1996, GLIA, V18, P152, DOI 10.1002/(SICI)1098-1136(199610)18:2<152::AID-GLIA7>3.0.CO;2-2; Fiebich BL, 2003, J NEUROCHEM, V86, P173, DOI 10.1046/j.1471-4159.2003.01822.x; Fiebich BL, 2000, NEUROPHARMACOLOGY, V39, P2205, DOI 10.1016/S0028-3908(00)00045-9; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Gao XH, 2003, BIOCHEM PHARMACOL, V66, P2427, DOI 10.1016/j.bcp.2003.08.008; Gao XH, 2001, BIOCHEM PHARMACOL, V62, P1299, DOI 10.1016/S0006-2952(01)00775-4; GEBICKEHAERTER PJ, 1989, J NEUROSCI, V9, P183; Goh SSC, 2007, ANTIOXID REDOX SIGN, V9, P101, DOI 10.1089/ars.2007.9.101; Gusman J, 2001, CARCINOGENESIS, V22, P1111, DOI 10.1093/carcin/22.8.1111; Han YS, 2004, BRIT J PHARMACOL, V141, P997, DOI 10.1038/sj.bjp.0705688; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; Heynekamp JJ, 2006, J MED CHEM, V49, P7182, DOI 10.1021/jm060630x; Hoozemans JJM, 2002, BRAIN RES, V951, P218, DOI 10.1016/S0006-8993(02)03164-5; Hsiao G, 2004, IN VIVO, V18, P351; Huang SS, 2001, LIFE SCI, V69, P1057, DOI 10.1016/S0024-3205(01)01195-X; Hunot S, 2004, P NATL ACAD SCI USA, V101, P665, DOI 10.1073/pnas.0307453101; Ikeda-Matsuo Y, 2005, J NEUROCHEM, V94, P1546, DOI 10.1111/j.1471-4159.2005.03302.x; Ikeda-Matsuo Y, 2006, P NATL ACAD SCI USA, V103, P11790, DOI 10.1073/pnas.0604400103; Kamei D, 2004, J BIOL CHEM, V279, P33684, DOI 10.1074/jbc.M400199200; Kawano T, 2006, NAT MED, V12, P225, DOI 10.1038/nm1362; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Kiziltepe U, 2004, J VASC SURG, V40, P138, DOI 10.1016/j.jvs.2004.03.032; Kudo I, 2005, J BIOCHEM MOL BIOL, V38, P633; Kumar P, 2006, BEHAV PHARMACOL, V17, P485, DOI 10.1097/00008877-200609000-00014; Kummerle AE, 2005, BIOORGAN MED CHEM, V13, P5981, DOI 10.1016/j.bmc.2005.07.028; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YK, 2003, J NEUROSCI, V23, P1605; Li YK, 2001, J NEUROSCI RES, V66, P163, DOI 10.1002/jnr.1208; Lieb K, 2003, NEUROCHEM INT, V42, P131, DOI 10.1016/S0197-0186(02)00076-1; Lu KT, 2006, J AGR FOOD CHEM, V54, P3126, DOI 10.1021/JF053011Q; Marambaud P, 2005, J BIOL CHEM, V280, P37377, DOI 10.1074/jbc.M508246200; Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Miyamoto O, 2003, EUR J PHARMACOL, V459, P179, DOI 10.1016/S0014-2999(02)02876-5; Mokni M, 2007, NEUROCHEM RES, V32, P981, DOI 10.1007/s11064-006-9255-z; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Nogawa S, 1997, J NEUROSCI, V17, P2746; Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180; Pepicelli O, 2005, J NEUROCHEM, V93, P1561, DOI 10.1111/j.1471-4159.2005.03150.x; Pepicelli O, 2002, J NEUROCHEM, V81, P1028, DOI 10.1046/j.1471-4159.2002.00897.x; Phillis JW, 2006, BRAIN RES REV, V52, P201, DOI 10.1016/j.brainresrev.2006.02.002; Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449; Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Szewczuk LM, 2004, J BIOL CHEM, V279, P22727, DOI 10.1074/jbc.M314302200; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Tsai SK, 2007, J VASC SURG, V46, P346, DOI 10.1016/j.jvs.2007.04.044; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; VANDERHOEK JY, 1973, BIOCHIM BIOPHYS ACTA, V296, P382, DOI 10.1016/0005-2760(73)90096-9; Vijitruth R, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-6; Wang Q, 2004, NEUROCHEM RES, V29, P2105, DOI 10.1007/s11064-004-6883-z; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6; Wang TG, 2004, J NEUROCHEM, V88, P939, DOI 10.1046/j.1471-4159.2003.02242.x; Zamin LL, 2006, NEUROBIOL DIS, V24, P170, DOI 10.1016/j.nbd.2006.06.002; Zhuang H, 2003, ANN NY ACAD SCI, V993, P276, DOI 10.1111/j.1749-6632.2003.tb07534.x	81	147	150	0	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	OCT 10	2007	4								25	10.1186/1742-2094-4-25			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	238NA	WOS:000251453300001	17927823	DOAJ Gold, Green Published			2021-06-18	
J	Franko, J; Kish, KJ; O'Connell, BG; Subramanian, S; Yuschak, JV				Franko, Jan; Kish, Karen J.; O'Connell, Brendan G.; Subramanian, Sujata; Yuschak, James V.			Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	19th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 10-14, 2006	Orlando, FL	Eastern Assco Surg Trauma		trauma; coumadin; traumatic intracranial hemorrhage	ATRIAL-FIBRILLATION; INTRACRANIAL HEMORRHAGE; ANTITHROMBOTIC THERAPY; ELDERLY-PATIENTS; INTENSITY; INJURY; IMPACT	Background: A large population of patients on oral anticoagulants is exposed to the risk of traumatic brain injury (TBI). Effects of age and anticoagulation on TBI outcomes need to be assessed separately. Methods: Retrospective analysis of consecutive series of TBI patients (age 18 years and older) in a suburban teaching hospital. Results: A total of 1,493 adult blunt head trauma patients between January 2001 and May 2005 were analyzed. Of these, 159 patients were warfarin-anticoagulated at the time of trauma. The mortality in anticoagulated patients was statistically significantly higher than in the control group (38/159, 23.9% vs. 66/1,334, 4.9%; p < 0.001; odds ratio 6.0). Mortality of patients over 70 years of age was significantly higher than in the younger population (p < 0.001). Both mortality and the occurrence of intracranial hemorrhage (ICH) after head trauma were significantly increased with higher INR (Cochran's linear trend p < 0.001), especially with INR over 4.0 (mortality 50%, risk of ICH 75%). Preinjury warfarin anticoagulation and age were found to be predictive of survival in a binary logistic regression model (92.5% correct prediction, p = 0.027). Addition of Injury Severity Score and initial Glasgow Coma Score to this model only modestly improved its predictive performance (95.4% correct prediction, P < 0.001). Conclusions: Both age and warfarin anticoagulation are independent predictors of mortality after blunt TBI. Warfarin anticoagulation carries a six-fold increase in TBI mortality. Age over 70 years and excessive anticoagulation are associated with higher mortality, as well.	Abington Mem Hosp, Dept Surg, Abington, PA 19001 USA	Franko, J (corresponding author), Abington Mem Hosp, Dept Surg, 1245 Highland Ave,Ste 604, Abington, PA 19001 USA.	jan.franko@gmail.com					Fang MC, 2004, ANN INTERN MED, V141, P745, DOI 10.7326/0003-4819-141-10-200411160-00005; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Gage BF, 2005, AM J MED, V118, P612, DOI 10.1016/j.amjmed.2005.02.022; Gittleman AM, 2005, AM J NEURORADIOL, V26, P603; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Karni A, 2001, AM SURGEON, V67, P1098; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Man-Son-Hing M, 2003, ARCH INTERN MED, V163, P1580, DOI 10.1001/archinte.163.13.1580; Man-Son-Hing M, 1999, ARCH INTERN MED, V159, P677, DOI 10.1001/archinte.159.7.677; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Rosand J, 2004, ARCH INTERN MED, V164, P880, DOI 10.1001/archinte.164.8.880; Singer DE, 2004, CHEST, V126, p429S, DOI 10.1378/chest.126.3_suppl.429S; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	15	147	150	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2006	61	1					107	110		10.1097/01.ta.0000224220.89528.fc			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	065TV	WOS:000239183600023	16832256				2021-06-18	
J	Eyres, S; Carey, A; Gilworth, G; Neumann, V; Tennant, A				Eyres, S; Carey, A; Gilworth, G; Neumann, V; Tennant, A			Construct validity and reliability of the Rivermead Post-Concussion Symptoms Questionnaire	CLINICAL REHABILITATION			English	Article							MINOR HEAD-INJURY; RASCH MODEL; SEQUELAE	Objectives: To provide further evidence of reliability and internal and external construct validity of the Rivermead Post-Concussion Symptoms Questionnaire (RPQ), which measures severity of postconcussion symptoms following head injury. Design and setting: A cross-sectional study of consecutive patients presenting with a head injury in two urban teaching hospitals and a community trust. Patients: Three hundred and sixty-nine patients returned a questionnaire from 1689 consecutive adult patients (18 years and above) referred to radiology for a skull X-ray following a head injury, and those who were currently under the care of a community-based multidisciplinary head injury team. Method: Internal construct validity tested by fit to the Rasch Measurement model-, external construct validity tested by correlations with Rivermead Head Injury Followup Questionnaire (RHFUO); test-retest reliability tested by correlations at two-week intervals. Outcome measures: Rivermead Post-Concussion Symptoms Questionnaire and Rivermead Head Injury Follow-up Questionnaire. Main results: RPQ scores ranged from 0 to 64 (17.3% floor, 0.3% ceiling). Overall fit to the Rasch model was poor (item fit mean - 0.416, SD = 1.989, chi-squared = 172.486, p < 0.01) suggesting a lack of unidimensionality. The items headaches, dizziness and forgetful displayed misfitting residuals and the first two items also displayed significant item trait fit statistics (p < 0.0006). After removing the items headaches, dizziness and subsequently nausea the RPQ demonstrated good fit at overall and individual item levels, both for the remaining 13 items (RPQ-13) and the three items (RPQ-3) which now formed a subsidiary scale. All items functioned consistently across age and gender. The RPQ-13 and RPQ-3 scales showed test-retest reliability coefficients of 0.89 and 0.72 (both p-values < 0.01) and positive correlations with RHFUQ scores (0.83 for RPQ-13, 0.62 for RPQ-3, both p-values < 0.01). Conclusions: As currently used, the RPQ does not meet modern psychometric standards. Its 16 items do not tap into the same underlying construct and should not be summated in a single score. When the RPQ is split into two separate scales, the RPQ-13 and the RPQ-3, each set of items forms a undimensional construct for people with head injury at three months post injury. These scales show good testretest reliability and adequate external construct validity.	Univ Leeds, Acad Unit Musculoskeletal & Rehabil Med, Leeds LS2 9NZ, W Yorkshire, England	Tennant, A (corresponding author), Univ Leeds, Acad Unit Musculoskeletal & Rehabil Med, 36 Clarendon Rd, Leeds LS2 9NZ, W Yorkshire, England.	a.tennant@leeds.ac.uk					ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814; ANDRICH D, 2000, RUMM 2020; Andrich D, 1988, RASCH MODELS MEASURE; Banerji M, 1997, J Outcome Meas, V1, P56; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Linacre J M, 1999, J Outcome Meas, V3, P103; MANDEL S, 1989, POSTGRAD MED, V85, P213; MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Smith R M, 2000, J Appl Meas, V1, P199; SPSS, 2001, SPSS WIND REL 11 0 1; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Swann IJ, 2001, EMERG MED J, V18, P352, DOI 10.1136/emj.18.5.352; Tennant A, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-21; TENNANT A, 1991, J EPIDEMIOL COMMUN H, V45, P312, DOI 10.1136/jech.45.4.312; Tennant A, 2004, MED CARE, V42, P37, DOI 10.1097/01.mlr.0000103529.63132.77; TENNANT A, 1995, TRAUMATIC BRAIN INJU, P12; VANALPHEN A, 1994, J ADV NURS, V20, P196; WHO World Health Organization, 1978, ICD 9 CLASS MENT BEH	29	147	151	1	10	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	DEC	2005	19	8					878	887		10.1191/0269215505cr905oa			10	Rehabilitation	Rehabilitation	988XS	WOS:000233638100008	16323387				2021-06-18	
J	Tian, WM; Hou, SP; Ma, J; Zhang, CL; Xu, QY; Lee, IS; Li, HD; Spector, M; Cui, FZ				Tian, WM; Hou, SP; Ma, J; Zhang, CL; Xu, QY; Lee, IS; Li, HD; Spector, M; Cui, FZ			Hyaluronic acid-poly-D-lysine-based three-dimensional hydrogel for traumatic brain injury	TISSUE ENGINEERING			English	Article							REGENERATION; CULTURE; IMPLANT; MATRIX	Brain tissue engineering in the postinjury brain represents a promising option for cellular replacement and rescue, providing a cell scaffold for either transplanted or resident cells. In this article, a hyaluronic acid ( HA)-poly-D-lysine (PDL) copolymer hydrogel with an open porous structure and viscoelastic properties similar to neural tissue has been developed for brain tissue engineering. The chemicophysical properties of the hydrogel with HA: PDL ratios of 10:1, 5:1, and 4:1 were investigated by scanning electron microscopy (SEM) and X-ray photoelectron spectrometry. Neural cells cultured in the hydrogel were studied by phase-contrast microscope and SEM. The incorporation of PDL peptides into the HA-PDL hydrogel allowed for the modulation of neuronal cell adhesion and neural network formation. Macrophages and multinucleated foreign body giant cells found at the site of implantation of the hydrogel in the rat brain within the first weeks postimplantation decreased in numbers after 6 weeks, consistent with the host response to inert implants in numerous tissues. Of importance was the infiltration of the hydrogel by glial fibrillary acidic protein-positive cells-reactive astrocytes-by immunohistochemistry and the contiguity between the hydrogel and the surrounding tissue demonstrated by SEM. These findings indicated the compatibility of this hydrogel with brain tissue. Collectively, the results demonstrate the promise of an HA-PDL hydrogel as a scaffold material for the repair of defects in the brain.	Tsinghua Univ, Dept Mat Sci & Engn, Biomat Lab, Beijing 100084, Peoples R China; Capital Univ Med Sci, Beijing Inst Neurosci, Beijing, Peoples R China; Yonsei Univ, Atom Scale Surface Sci Res Ctr, Seoul, South Korea; Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA USA; Yonsei Univ, Inst Phys & Appl Phys, Seoul, South Korea; Yonsei Univ, Ctr Nano Technol, Seoul, South Korea	Cui, FZ (corresponding author), Tsinghua Univ, Dept Mat Sci & Engn, Biomat Lab, Beijing 100084, Peoples R China.	cuifz@mail.tsinghua.edu.cn	Ma, Jun/K-2084-2012	Ma, Jun/0000-0001-5167-1750; Spector, Myron/0000-0003-3328-4858; Tian, Weiming/0000-0003-4958-4118			Adanali G, 2003, J RECONSTR MICROSURG, V19, P29, DOI 10.1055/s-2003-37188; ADZICK NS, 1991, PROG CLIN BIOL RES, V365, P177; Bousmina M, 1996, RHEOL ACTA, V35, P369, DOI 10.1007/BF00403538; BRIGHTON CT, 1979, ELECT PROPERTIES BON; CARBONETTO S, 1983, J NEUROSCI, V3, P2324; CHEN W, BIOMATERIALS ENG DEV, V1, P307; CUI FZ, 2003, J BIOACT COMPAT POL, V18, P41; Dillon GP, 1998, J BIOMAT SCI-POLYM E, V9, P1049, DOI 10.1163/156856298X00325; Eagle KS, 1995, J COMP NEUROL, V363, P377, DOI 10.1002/cne.903630304; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; Fournier E, 2003, BIOMATERIALS, V24, P3311, DOI 10.1016/S0142-9612(03)00161-3; HARVEY AR, 1994, RESTOR NEUROL NEUROS, V6, P221, DOI 10.3233/RNN-1994-6306; Hynds DL, 2002, EXP NEUROL, V175, P301, DOI 10.1006/exnr.2002.7862; Iocono JA, 1998, J SURG RES, V76, P111, DOI 10.1006/jsre.1998.5305; LAURENT TC, 1996, IMMUNOL CELL BIOL, V74, P1; LETOURNEAU PC, 1994, J NEUROSCI, V14, P915; LETOURNEAU PC, 1985, MOL BASIS NEURONAL D; MAKOHLISO SA, 1993, J BIOMED MATER RES, V27, P1075, DOI 10.1002/jbm.820270813; MENEI P, 1989, J CONTROL RELEASE, V14, P470; Moriarty Kevin P., 1996, Wound Repair and Regeneration, V4, P346, DOI 10.1046/j.1524-475X.1996.40311.x; Plant GW, 1997, EXP NEUROL, V143, P287, DOI 10.1006/exnr.1997.6407; Rauch U, 1997, CELL TISSUE RES, V290, P349, DOI 10.1007/s004410050940; Rosengren A, 1997, BIOMATERIALS, V18, P979, DOI 10.1016/S0142-9612(97)00012-4; SANES JR, 1983, ANNU REV PHYSIOL, V45, P581, DOI 10.1146/annurev.ph.45.030183.003053; SCHUGENS C, 1995, J BIOMED MATER RES, V29, P1349, DOI 10.1002/jbm.820291106; SECKEL BR, 1995, J NEUROSCI RES, V40, P318, DOI 10.1002/jnr.490400305; TAMARGO RJ, 1989, J BIOMED MATER RES, V23, P253, DOI 10.1002/jbm.820230209; Tomihata K, 1997, J BIOMED MATER RES, V37, P243; Vercruysse KP, 1998, CRIT REV THER DRUG, V15, P513; WINN SR, 1989, J BIOMED MATER RES, V23, P31, DOI 10.1002/jbm.820230104; WOERLY S, 1990, BIOMATERIALS, V11, P97, DOI 10.1016/0142-9612(90)90123-8; WOERY S, 1998, J BIOMAT SCI-POLYM E, V9, P68; YAVIN E, 1974, J CELL BIOL, V62, P540, DOI 10.1083/jcb.62.2.540	33	147	154	4	76	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1076-3279			TISSUE ENG	Tissue Eng.	MAR	2005	11	3-4					513	525		10.1089/ten.2005.11.513			13	Cell & Tissue Engineering	Cell Biology	924SA	WOS:000228999400019	15869430				2021-06-18	
J	Gibson, CL; Murphy, SP				Gibson, CL; Murphy, SP			Progesterone enhances functional recovery after middle cerebral artery occlusion in male mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						progesterone; mouse; middle cerebral artery occlusion; stroke; behavior; recovery	HORMONE REPLACEMENT THERAPY; TRAUMATIC BRAIN-INJURY; CORONARY HEART-DISEASE; NITRIC-OXIDE SYNTHASE; MORRIS WATER MAZE; ADULT FEMALE RAT; DENTATE GYRUS; ESTROGEN-REPLACEMENT; POSTMENOPAUSAL WOMEN; ADRENAL-STEROIDS	Sex differences have been observed in the outcome after ischemia that are believed to be attributable to sex steroid hormones. The present study investigated the possible benefits of progesterone administration after focal cerebral ischemia. Male mice underwent 60-minute middle cerebral artery occlusion (MCAO) and received progesterone (8 mg/kg, intraperitoneally) or vehicle (dimethyl sulfoxide) 1, 6, and 24 hours after MCAO. The lesion volume at 48 hours after MCAO was significantly reduced (P < 0.05) in progesterone-treated mice compared with vehicle-treated mice. All other mice underwent tests of well being (survival rate and body weight recovery), motor ability (grid test and rotarod), and cognitive ability (water maze) for tip to 21 days. MCAO significantly worsened outcome in all of these tests compared with shams. Progesterone treatment was beneficial in that compared with vehicle, it significantly improved survival rate, weight recovery, and motor ability. This improvement was most apparent during water maze testing, where progesterone-treated mice were indistinguishable from shams in terms of acquiring the task. These results indicate beneficial effects of progesterone administration after cerebral ischemia and illustrate the need to further investigate the mechanisms of progesterone action.	Univ Nottingham, Queens Med Ctr, Inst Cell Signalling, Nottingham NG7 2UH, England	Murphy, SP (corresponding author), Univ Nottingham, Queens Med Ctr, Inst Cell Signalling, Nottingham NG7 2UH, England.	sean.murphy@nottingham.ac.uk		Gibson, Claire/0000-0002-3358-7341	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29226] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029226] Funding Source: NIH RePORTER		Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; BARONE FC, 1992, NEUROSCI BIOBEHAV R, V16, P219, DOI 10.1016/S0149-7634(05)80182-4; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Boutin H, 2001, J NEUROSCI, V21, P5528; Bushnell CD, 2001, NEUROLOGY, V56, P1304, DOI 10.1212/WNL.56.10.1304; CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0; Cameron HA, 1998, NEUROSCIENCE, V82, P349; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; FINUCANE FF, 1993, ARCH INTERN MED, V153, P73, DOI 10.1001/archinte.153.1.73; GINSBERG MD, 1988, NEUROCHEM PATHOL, V9, P171; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; Hattori K, 2000, STROKE, V31, P1939, DOI 10.1161/01.STR.31.8.1939; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Jiang W, 2001, STROKE, V32, P1201, DOI 10.1161/01.STR.32.5.1201; KANNEL WB, 1994, HEART, P185; KATAYAMA Y, 1994, ACTA NEUROCHIR, P242; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Loihl AK, 1999, BRAIN RES, V830, P155, DOI 10.1016/S0006-8993(99)01388-8; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; Molinari C, 2001, EXP PHYSIOL, V86, P101, DOI 10.1113/eph8602076; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; Paganini-Hill A, 2001, MATURITAS, V38, P243, DOI 10.1016/S0378-5122(01)00167-0; Pedersen AT, 1997, LANCET, V350, P1277, DOI 10.1016/S0140-6736(97)06005-4; Perez-Martin M, 2003, EUR J NEUROSCI, V18, P923, DOI 10.1046/j.1460-9568.2003.02830.x; Perusquia M, 1996, GEN PHARMACOL, V27, P181, DOI 10.1016/0306-3623(95)00091-7; Petitti DB, 1998, STROKE, V29, P23, DOI 10.1161/01.STR.29.1.23; Powledge TM, 2004, LANCET, V363, P870, DOI 10.1016/S0140-6736(04)15776-0; Reglodi D, 2003, BRAIN RES BULL, V59, P459, DOI 10.1016/S0361-9230(02)00962-0; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; SMITH SS, 1987, BRAIN RES, V400, P353, DOI 10.1016/0006-8993(87)90634-2; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; UPCHURCH M, 1988, BEHAV GENET, V18, P55, DOI 10.1007/BF01067075; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; WAHL F, 1992, STROKE, V23, P267, DOI 10.1161/01.STR.23.2.267; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406	64	147	148	1	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2004	24	7					805	813		10.1097/01.WCB.0000125365.83980.00			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	835RR	WOS:000222503700011	15241189	Bronze			2021-06-18	
J	Saykin, AJ; Wishart, HA; Rabin, LA; Flashman, LA; McHugh, TL; Mamourian, AC; Santulli, RB				Saykin, AJ; Wishart, HA; Rabin, LA; Flashman, LA; McHugh, TL; Mamourian, AC; Santulli, RB			Cholinergic enhancement of frontal lobe activity in mild cognitive impairment	BRAIN			English	Article; Proceedings Paper	15th Annual Meeting of the American-Neuropsychiatric-Association	FEB 21-24, 2004	Bal Harbour, FL	Amer Neuropsychiat Assoc		mild cognitive impairment; Alzheimer's disease; cholinesterase inhibitor; functional MRI; hippocampal volume	CEREBRAL-BLOOD-FLOW; QUALITY STANDARDS SUBCOMMITTEE; ACADEMY-OF-NEUROLOGY; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; WORKING-MEMORY; ACETYLCHOLINESTERASE ACTIVITY; PRACTICE PARAMETER; NICOTINIC RECEPTORS; FOLLOW-UP	Cholinesterase inhibitors positively affect cognition in Alzheimer's disease (AD) and other conditions, but no controlled functional MRI studies have examined where their effects occur in the brain. We examined the effects of donepezil hydrochloride (Aricept(R)) on cognition and brain activity in patients with amnestic mild cognitive impairment (MCI), a diagnosis associated with a high risk of developing AD. Nine older adults with MCI were compared with nine healthy, demographically matched controls. At baseline, patients showed reduced activation of frontoparietal regions relative to controls during a working memory task. After stabilization on donepezil (5.7 +/- 1.7 weeks at 10 mg) patients showed increased frontal activity relative to unmedicated controls, which was positively correlated with improvement in task performance (r = 0.49, P = 0.05) as well as baseline hippocampal volume (r = 0.62, P < 0.05). The patients' overall cognitive function was stable or improved throughout the study. Short-term treatment with a cholinesterase inhibitor appears to enhance the activity of frontal circuitry in patients with MCI, and this increase appears to be related to improved cognition and to baseline integrity of the hippocampus. These relationships have implications for understanding the mechanisms by which cognition-enhancing medications exert their effects on brain function and for the use of functional MRI in early detection and treatment monitoring of AD and MCI.	Dartmouth Coll Sch Med, Brain Imaging Lab, Dept Psychiat, DHMC, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Radiol, Lebanon, NH 03756 USA	Saykin, AJ (corresponding author), Dartmouth Coll Sch Med, Brain Imaging Lab, Dept Psychiat, DHMC, Lebanon, NH 03756 USA.	Andrew.J.Saykin@dartmouth.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG019771] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG19771] Funding Source: Medline		Allain H, 2002, Rev Neurol (Paris), V158, pS35; Baddeley A, 1998, CURR OPIN NEUROBIOL, V8, P234, DOI 10.1016/S0959-4388(98)80145-1; Baddeley Alan, 1995, P755; Barnes CA, 2000, NEUROSCIENCE, V99, P17, DOI 10.1016/S0306-4522(00)00180-9; Belleville S, 1996, NEUROPSYCHOLOGIA, V34, P195, DOI 10.1016/0028-3932(95)00097-6; Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Chetelat G, 2002, NEUROREPORT, V13, P1939; DeKosky ST, 2002, ANN NEUROL, V51, P145, DOI 10.1002/ana.10069; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; Delis DC, 2001, DELISKAPLAN EXECUTIV; Doody RS, 2001, NEUROLOGY, V56, P1154, DOI 10.1212/WNL.56.9.1154; Du AT, 2001, J NEUROL NEUROSUR PS, V71, P441, DOI 10.1136/jnnp.71.4.441; Gauthier S, 2002, CAN MED ASSOC J, V166, P616; Gladsjo JA, 1999, J INT NEUROPSYCH SOC, V5, P247, DOI 10.1017/S1355617799533079; Jack CR, 2000, NEUROLOGY, V55, P484, DOI 10.1212/WNL.55.4.484; Johnson SC, 2000, NEUROIMAGE, V11, P179, DOI 10.1006/nimg.1999.0530; Jonides J, 1997, J COGNITIVE NEUROSCI, V9, P462, DOI 10.1162/jocn.1997.9.4.462; JORM AF, 1989, PSYCHOL MED, V19, P1015, DOI 10.1017/S0033291700005742; Kaasinen V, 2002, J CLIN PSYCHOPHARM, V22, P615, DOI 10.1097/00004714-200212000-00012; Knopman DS, 2003, MAYO CLIN PROC, V78, P1290, DOI 10.4065/78.10.1290; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; Kuhl DE, 2000, ANN NEUROL, V48, P391, DOI 10.1002/1531-8249(200009)48:3<391::AID-ANA17>3.3.CO;2-8; Kuhl DE, 1999, NEUROLOGY, V52, P691, DOI 10.1212/WNL.52.4.691; Lanctot KL, 2003, J PSYCHIATR NEUROSCI, V28, P13; LASHMAN LA, 2003, DEMENTIA PRESENTATIO, P3; Levin ED, 1998, PSYCHOPHARMACOLOGY, V138, P217, DOI 10.1007/s002130050667; Matsuda H, 2001, ANN NUCL MED, V15, P85, DOI 10.1007/BF02988596; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Mega MS, 2001, NEUROPSY NEUROPSY BE, V14, P63; MESULAM M, 2000, CHOLINESTERASES CHOL, P121; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Nakano S, 2001, J NUCL MED, V42, P1441; Nobili F, 2002, J NUCL MED, V43, P983; Nobili F, 2002, CLIN NEUROPHYSIOL, V113, P1241, DOI 10.1016/S1388-2457(02)00110-4; Nordberg A, 1998, ALZ DIS ASSOC DIS, V12, P228, DOI 10.1097/00002093-199809000-00017; Petersen RC, 2000, NEUROL CLIN, V18, P789, DOI 10.1016/S0733-8619(05)70226-7; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; RABIN LA, 2004, P INT NEUROPSCHOL SO, P3; Rombouts SARB, 2002, J NEUROL NEUROSUR PS, V73, P665, DOI 10.1136/jnnp.73.6.665; Rosen AC, 2002, BRAIN COGNITION, V50, P498, DOI 10.1016/S0278-2626(02)00520-1; SAYKIN AJ, 1991, J NEUROPSYCH CLIN N, V3, P286; SAYKIN AJ, 2003, NEUROIMAGE, V19, pS27; SAYKIN AJ, 2003, J INT NEUROPSYCH SOC, V9, P174; Shinotoh H, 2001, NEUROLOGY, V56, P408, DOI 10.1212/WNL.56.3.408; Smith CD, 2002, NEUROLOGY, V58, P1197, DOI 10.1212/WNL.58.8.1197; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Spreen O., 1991, COMPENDIUM NEUROPSYC; SQUIRE LR, 1979, BIOL PSYCHIAT, V14, P791; SVENSSON AL, 2000, CHOLINESTERASES CHOL, P227; Thiel CM, 2003, NEUROBIOL LEARN MEM, V80, P234, DOI 10.1016/S1074-7427(03)00076-5; Tsukada H, 2000, BRAIN RES, V857, P158, DOI 10.1016/S0006-8993(99)02394-X; Venneri A, 2002, NEUROREPORT, V13, P83, DOI 10.1097/00001756-200201210-00020; Wolf H, 2003, ACTA NEUROL SCAND, V107, P52, DOI 10.1034/j.1600-0404.107.s179.10.x; Wolfson D., 1993, HALSTEAD REITAN NEUR; World Health Organization, 2001, WORLD HLTH REP 2001; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; Zakzanis KK, 2003, NEUROPSYCHOL REV, V13, P1, DOI 10.1023/A:1022318921994	62	147	153	0	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUL	2004	127		7				1574	1583		10.1093/brain/awh177			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	830LY	WOS:000222124800012	15140813	Bronze			2021-06-18	
J	Findler, M; Cantor, J; Haddad, L; Gordon, W; Ashman, T				Findler, M; Cantor, J; Haddad, L; Gordon, W; Ashman, T			The reliability and validity of the SF-36 health survey questionnaire for use with individuals with traumatic brain injury	BRAIN INJURY			English	Article							BECK DEPRESSION INVENTORY; QUALITY-OF-LIFE; OUTCOME MEASURE	In order to examine the reliability and validity of the SF-36 for use with individuals with TBI, the SF-36 and three measures of health-related problems in persons with TBI (BDI-II, TIRR Symptom Checklist, Health Problems List) were administered to 271 individuals without a disability, 98 individuals with mild TBI, and 228 individuals with moderate-severe TBI. Internal consistency (reliability) was demonstrated for all SF-36 scales. Significant correlations were found between the SF-36 scales and the other measures, with stronger correlations emerging in the TBI groups. The TBI groups obtained significantly lower SF-36 scores than the comparison group, and the mild TBI group scored lower than the moderate-severe group. For the most part, the differences between the TBI groups disappeared when BDI-II scores were controlled for. These findings suggest that the SF-36 is a reliable and valid measure for use with persons with TBI.	Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Cantor, J (corresponding author), Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave L Levy Pl,Box 1240, New York, NY 10029 USA.	joshua_cantor@mssm.edu	Ashman, Teresa/B-1621-2013; Carneiro D'Albuquerque, Luiz Augusto/A-8812-2013	Ashman, Teresa/0000-0003-2401-7192; Carneiro D'Albuquerque, Luiz Augusto/0000-0001-7607-7168			Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Beck AT., 1996, BECK DEPRESSION INVE, V2; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Coons SJ, 2000, PHARMACOECONOMICS, V17, P13, DOI 10.2165/00019053-200017010-00002; GARRATT AM, 1993, BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; Goller JL, 1997, ADV PERIT D, V13, P128; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; Lin M, 1998, Aust Fam Physician, V27 Suppl 2, pS94; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; *MED OUTC TRUST, 1992, SF 36 HLTH SURV; Nunnaly J., 1978, PSYCHOMETRIC THEORY; Ruta D A, 1994, Qual Health Care, V3, P180, DOI 10.1136/qshc.3.4.180; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; WARE JE, 1993, SF 36 HLTH SURV MAN	19	147	147	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2001	15	8					715	723		10.1080/02699050010013941			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462ZJ	WOS:000170452100005	11485611				2021-06-18	
J	Gunstad, J; Suhr, JA				Gunstad, J; Suhr, JA			"Expectation as etiology" versus "the good old days": Postconcussion syndrome symptom reporting in athletes, headache sufferers, and depressed individuals	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						postconcussion syndrome; expectation as etiology; symptom report; good old days; symptom expectation	PERSONAL-INJURY CLAIMANTS; COMPLAINT BASE RATES; FOOTBALL PLAYERS; CHRONIC PAIN; CONCUSSION; DISORDERS; INDUCTION; SEEKING; HEALTH; NOCEBO	The present study explored the explanatory power of Mittenberg's "expectation as etiology" theory for the persistence of postconcussion syndrome (PCS) complaints. One hundred forty-one participants completed a PCS symptom checklist under 2 conditions. Normal controls, healthy athletes and depressed individuals reported current symptoms and symptoms expected following a hypothetical mild head injury. Head-injured athletes, chronic headache sufferers, and a 2nd sample of normal controls reported current symptoms and retrospective symptoms (prior to their injury/illness or from some point in the past). Depressed individuals reported more current symptoms than normal controls and healthy athletes, demonstrating that "PCS" symptoms are not specific to PCS. All groups expected more symptoms following mild head injury than currently experienced, supporting the idea that individuals expect negative consequences following head injury. However, healthy athletes expected fewer symptoms than normals or depressed individuals, possibly due to preexisting expectations for speedy recovery. Both head-injured athletes and headache sufferers reported more current symptoms than the past, but not at a rate lower than baseline of normal controls. Results suggest that the "expectation as etiology" hypothesis may be too specific, and that, following any negative event, people may attribute all symptoms to that negative event (the "good old days" hypothesis).	Ohio Univ, Dept Psychol, Athens, OH 45719 USA	Suhr, JA (corresponding author), Ohio Univ, Dept Psychol, 200 Porter Hall, Athens, OH 45719 USA.						Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Barth JT., 1989, MILD HEAD INJURY, P257; Bland RC, 1997, CAN J PSYCHIAT, V42, P935, DOI 10.1177/070674379704200904; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BURTON LA, 1988, J NEUROLOGICAL REHAB, V2, P151; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Conway M., 1986, HDB MOTIVATION COGNI, V1, P122; du Fort GG, 1999, J AFFECT DISORDERS, V52, P31, DOI 10.1016/S0165-0327(98)00052-4; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; ERRICO AL, 1990, PSYCHOL ASSESSMENT, V2, P45, DOI DOI 10.1037/1040-3590.2.1.45; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Festinger L., 1957, THEORY COGNITIVE DIS; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GFELLER J, 1996, ASSESSMENT, V3, P393; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRIGSBY J, 1994, ARCH CLIN NEUROPSYCH, V9, P135; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hahn Robert, 1999, EXPECTANCIES SHAPE E, P333, DOI DOI 10.1037/10332-014; HOLM JE, 1983, THESIS OHIO U; HOLM S, 1979, SCAND J STAT, V6, P65; HOLROYD KA, 1995, HDB HLTH REHABILITAT, P3; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kirsch I, 1999, AM PSYCHOL, V54, P504, DOI 10.1037/0003-066X.54.7.504; LANCMAN ME, 1994, ANN NEUROL, V35, P359, DOI 10.1002/ana.410350319; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LIPCHIK G, 1996, THESIS OHIO U ATHENS; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LUPARELLO T, 1968, PSYCHOSOM MED, V30, P819, DOI 10.1097/00006842-196811000-00002; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MAIER W, 1992, PSYCHOPHARMACOLOGY S, V106, P79; McClelland RJ, 1996, J PSYCHOSOM RES, V40, P563, DOI 10.1016/0022-3999(95)00616-8; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; PACKARD RC, 1993, HEADACHE, V33, P365, DOI 10.1111/j.1526-4610.1993.hed3307365.x; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rattan G, 1987, Arch Clin Neuropsychol, V2, P257, DOI 10.1016/0887-6177(87)90013-8; RUSH AJ, 1986, PSYCHIAT RES, V18, P65; Rutherford W. H., 1989, MILD HEAD INJURY, P217; SCHWEIGER A, 1981, PAVLOVIAN J BIOL SCI, V16, P140; SEIDENBERG M, 1994, ARCH CLIN NEUROPSYCH, V9, P353, DOI 10.1016/0887-6177(94)90023-X; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	47	147	147	0	10	CAMBRIDGE UNIV PRESS	PORT CHESTER	110 MIDLAND AVE, PORT CHESTER, NY 10573-4930 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2001	7	3					323	333		10.1017/S1355617701733061			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	427VA	WOS:000168425100006	11311033				2021-06-18	
J	Nashmi, R; Fehlings, MG				Nashmi, R; Fehlings, MG			Changes in axonal physiology and morphology after chronic compressive injury of the rat thoracic spinal cord	NEUROSCIENCE			English	Article						spinal cord injury; rat; axons; demyelination; neurotrauma; pathology	MOTOR EVOKED-POTENTIALS; CENTRAL-NERVOUS-SYSTEM; MONKEY MACACA-MULATTA; IN-VITRO; CONDUCTION VELOCITIES; GLUTAMATE RECEPTORS; CORTICOSPINAL AXONS; SECONDARY INJURY; MYELINATED AXONS; DOUBLE-BLIND	The spinal cord is rarely transected after spinal cord injury. Dysfunction of surviving axons, which traverse the site of spinal cord injury, appears to contribute to post-traumatic neurological deficits, although the underlying mechanisms remain unclear. The subpial rim frequently contains thinly myelinated axons which appear to conduct signals abnormally, although it is uncertain whether this truly reflects maladaptive alterations in conduction properties of injured axons during the chronic phase of spinal cord injury or whether this is merely the result of the selective survival of a subpopulation of axons. In the present study, we examined the changes in axonal conduction properties after chronic clip compression injury of the rat thoracic spinal cord. using the sucrose gap technique and quantitatively examined changes in the morphological and ultrastructural features of injured axonal fibers in order to clarify these issues. Chronically injured dorsal columns had a markedly reduced compound action potential amplitude (8.3% of control) and exhibited significantly reduced excitability. Other dysfunctional conduction properties of injured axons included a slower population conduction velocity, a longer refractory period and a greater degree of high-frequency conduction block at 200 Hz. Light microscopic and ultrastructural analysis showed numerous axons with abnormally thin myelin sheaths as well as unmyelinated axons in the injured spinal cord. The ventral column showed a reduced median axonal diameter and the lateral and dorsal columns showed increased median diameters, with evidence of abnormally large swollen axons. Plots of axonal diameter versus myelination ratio showed that post-injury, dorsal column axone of all diameters had thinner myelin sheaths. Noninjured dorsal column axone had a median myelination ratio (1.56) which was within the optimal range ( 1.43-1.67) for axonal conduction, whereas injured dorsal column axone had a median myelination ratio (1.33) below the optimal value. These data suggest that maladaptive alterations occur postinjury to myelin sheath thickness which reduce the efficiency of axonal signal transmission. In conclusion. chronically injured dorsal column axons show physiological evidence of dysfunction and morphological changes in axonal diameter and reduced myelination ratio. These maladaptive alterations to injured axons. including decrease in myelin thickness and the appearance of axonal swellings. contribute to the decreased excitablity of chronically injured axons. These results further clarify the mechanisms underlying neurological dysfunction after chronic neurotrauma and have significant implications regarding approaches to augment neural repair and regeneration. (C) 2001 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Toronto, Toronto Western Hosp, Inst Res, Div Neurosurg,Inst Med Sci, Toronto, ON M5T 2S8, Canada; Univ Toronto, Toronto Western Hosp, Inst Res, Inst Med Sci,Univ Hlth Network, Toronto, ON M5T 2S8, Canada	Fehlings, MG (corresponding author), Univ Toronto, Toronto Western Hosp, Inst Res, Div Neurosurg,Inst Med Sci, Toronto, ON M5T 2S8, Canada.			Fehlings, Michael/0000-0002-5722-6364; Nashmi, Raad/0000-0001-6596-2620			Agrawal SK, 1998, J NEUROTRAUM, V15, P929, DOI 10.1089/neu.1998.15.929; Agrawal SK, 1996, J NEUROSCI, V16, P545; Agrawal SK, 1997, J NEUROSCI, V17, P1055; ANTHES DL, 1995, BRAIN RES, V702, P1, DOI 10.1016/0006-8993(95)01028-6; BALENTINE JD, 1978, LAB INVEST, V39, P254; BLAKEMORE WF, 1981, J NEUROL SCI, V49, P273, DOI 10.1016/0022-510X(81)90084-8; Blight AR, 1991, J NEUROTRAUM, V8, P103, DOI 10.1089/neu.1991.8.103; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; BLIGHT AR, 1983, NEUROSCIENCE, V10, P1471, DOI 10.1016/0306-4522(83)90128-8; BLIGHT AR, 1989, BRAIN RES BULL, V22, P47, DOI 10.1016/0361-9230(89)90126-3; BLIGHT AR, 1987, J NEUROL SCI, V82, P145, DOI 10.1016/0022-510X(87)90014-1; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; BOSTOCK H, 1985, J PHYSIOL-LONDON, V365, P239, DOI 10.1113/jphysiol.1985.sp015769; BOYD IA, 1979, J PHYSIOL-LONDON, V289, P277, DOI 10.1113/jphysiol.1979.sp012737; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P59, DOI 10.1016/0022-510X(78)90228-9; BRESNAHAN JC, 1976, J NEUROL SCI, V28, P521, DOI 10.1016/0022-510X(76)90122-2; EIDELBERG E, 1977, EXP NEUROL, V56, P312, DOI 10.1016/0014-4886(77)90350-8; FEHLINGS MG, 1995, BRAIN RES, V677, P291, DOI 10.1016/0006-8993(95)00141-C; Fehlings MG, 1997, J NEUROSCI METH, V71, P215, DOI 10.1016/S0165-0270(96)00147-1; Fehlings MG, 1996, BRAIN RES, V736, P135, DOI 10.1016/0006-8993(96)00667-1; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; GLEDHILL RF, 1977, ANN NEUROL, V1, P552, DOI 10.1002/ana.410010607; GRIFFITHS IR, 1983, J NEUROL SCI, V58, P335, DOI 10.1016/0022-510X(83)90093-X; Gruner JA, 1999, BRAIN RES, V816, P446, DOI 10.1016/S0006-8993(98)01184-6; HANSEBOUT RR, 1993, J NEUROTRAUM, V10, P1, DOI 10.1089/neu.1993.10.1; HAYES KC, 1993, PARAPLEGIA, V31, P216, DOI 10.1038/sc.1993.40; Honmou O, 1996, J NEUROSCI, V16, P3199; Imaizumi T, 1998, J NEUROSCI, V18, P6176; KAJI R, 1989, NEUROLOGY, V39, P1364, DOI 10.1212/WNL.39.10.1364; Kalderon N, 1996, P NATL ACAD SCI USA, V93, P11185, DOI 10.1073/pnas.93.20.11185; MCDONALD WI, 1970, BRAIN, V93, P583, DOI 10.1093/brain/93.3.583; MEDIRATTA NK, 1983, J PHYSIOL-LONDON, V336, P545, DOI 10.1113/jphysiol.1983.sp014597; Nashmi R, 2000, EUR J NEUROSCI, V12, P491, DOI 10.1046/j.1460-9568.2000.00926.x; Nashmi R, 1997, J NEUROTRAUM, V14, P151, DOI 10.1089/neu.1997.14.151; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Potter PJ, 1998, J NEUROTRAUM, V15, P837, DOI 10.1089/neu.1998.15.837; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Puckett WR, 1997, EXP NEUROL, V148, P424, DOI 10.1006/exnr.1997.6692; Qiao J, 1997, J NEUROTRAUM, V14, P135, DOI 10.1089/neu.1997.14.135; RITCHIE JM, 1982, PROC R SOC SER B-BIO, V217, P29, DOI 10.1098/rspb.1982.0092; Rivlin A S, 1978, Surg Neurol, V10, P38; Rosenberg LJ, 1999, J NEUROSCI, V19, P6122, DOI 10.1523/JNEUROSCI.19-14-06122.1999; RUSHTON WAH, 1951, J PHYSIOL-LONDON, V115, P101, DOI 10.1113/jphysiol.1951.sp004655; SAKATANI K, 1991, ELECTROEN CLIN NEURO, V81, P108, DOI 10.1016/0168-5597(91)90004-H; Sakatani K, 1987, Cent Nerv Syst Trauma, V4, P161; SANDERS FK, 1948, PROC R SOC SER B-BIO, V135, P323, DOI 10.1098/rspb.1948.0015; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SMITH RS, 1970, AM J PHYSIOL, V219, P1256; SWADLOW HA, 1980, ANNU REV BIOPHYS BIO, V9, P143, DOI 10.1146/annurev.bb.09.060180.001043; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tymianski M, 1996, NEUROSURGERY, V38, P1176; WAXMAN SG, 1972, NATURE-NEW BIOL, V238, P217, DOI 10.1038/newbio238217a0; Wrathall JR, 1998, J NEUROSCI, V18, P8780	54	147	154	1	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2001	104	1					235	251		10.1016/S0306-4522(01)00009-4			17	Neurosciences	Neurosciences & Neurology	426LN	WOS:000168350800021	11311546				2021-06-18	
J	Majdan, M; Plancikova, D; Brazinova, A; Rusnak, M; Nieboer, D; Feigin, V; Maas, A				Majdan, Marek; Plancikova, Dominika; Brazinova, Alexandra; Rusnak, Martin; Nieboer, Daan; Feigin, Valery; Maas, Andrew			Epidemiology of traumatic brain injuries in Europe: a cross-sectional analysis	LANCET PUBLIC HEALTH			English	Article								Introduction Traumatic brain injuries (TBI) are a major medical and socioeconomic problem. We aimed to estimate the hospital-based incidence, population-wide mortality, and the contribution of TBI to injury-related mortalities in European countries, and to provide European summary estimates for these indicators. Methods For this cross-sectional analysis, we obtained population data from Eurostat for hospital discharges and causes of death in European countries in 2012. Outcomes of interest were TBIs that required hospital admission or were fatal. We calculated age-adjusted hospital discharge rates and mortality rates and extrapolated data to 28 European Union countries and all 48 states in Europe. We present between-country comparisons, pooled age-adjusted rates, and comparisons with all-injury rates. Findings In 2012, 1 375 974 hospital discharges (data from 24 countries) and 33 415 deaths (25 countries) related to TBI were identified. The pooled age-adjusted hospital discharge rate was 287.2 per 100 000 (95% CI 232.9-341.5) and the pooled age-adjusted mortality rate was 11 . 7 per 100 000 (9.9-13.6). TBI caused 37% (95% CI 36-38) of all injury-related deaths in the analysed countries. Extrapolating our results, we estimate 56 946 (95% CI 47 286-66 099) TBI-related deaths and 1 445 526 (1 172 996-1 717 039) hospital discharges occurred in 2012 in the European Union (population 508.5 million) and about 82 000 deaths and about 2.1 million hospital discharges in the whole of Europe (population 737 million). We noted substantial between-country differences. Interpretation TBI is an important cause of death and hospital admissions in Europe. The substantial between-country differences observed warrant further study and suggest that the true burden of TBI in Europe has not yet been captured. Rigorous epidemiological studies are needed to fully quantify the effect of TBI on society. Despite a great degree of consistency in data reporting across countries already being achieved, further efforts in this respect could improve the validity of between-country comparisons. Copyright (C) The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.	[Majdan, Marek; Plancikova, Dominika; Brazinova, Alexandra; Rusnak, Martin] Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, 23 Hornopotocna, Trnava 91843, Slovakia; [Nieboer, Daan] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Feigin, Valery] Auckland Univ Technol, Fac Hlth & Environm Sci, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Maas, Andrew] Univ Antwerp, Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium	Majdan, M (corresponding author), Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, 23 Hornopotocna, Trnava 91843, Slovakia.	mmajdan@truni.sk	Brazinova, Alexandra/C-4265-2016; Feigin, Valery/AAF-2313-2019	Brazinova, Alexandra/0000-0003-0625-256X; Feigin, Valery L./0000-0002-6372-1740	European UnionEuropean Commission	European Union, FP7.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Ahmad O.B., 2001, GPE DISCUSSION PAPER; Borenstein M, 2009, INTRO META ANAL, P69; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Brooks JC, 2015, ARCH PHYS MED REHAB, V96, P1000, DOI 10.1016/j.apmr.2015.02.002; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Department of Economic and Social Aff airs PD, 2015, ESAPWP241; Eurostat, 2015, HOSP DISCH DIAGN CAT; Eurostat, 2015, CAUS DEATH HLTH CDEA; Eurostat, 2015, EUR POP DAT; Eurostat, 2013, REV EUR STAND POP RE; Farhad K, 2013, J NEUROTRAUM, V30, P84, DOI 10.1089/neu.2011.2283; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Ma VY, 2014, ARCH PHYS MED REHAB, V95, P986, DOI 10.1016/j.apmr.2013.10.032; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Majdan M, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008672; Murray CJL, 2015, LANCET, V386, P2145, DOI 10.1016/S0140-6736(15)61340-X; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Reilly P, 2007, PROG BRAIN RES, V161, P3, DOI 10.1016/S0079-6123(06)61001-7; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Scholten AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110905; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; WHO, 2015, INT SHORTL HOSP MORB; World Health Organization Statistical Information System, 2015, WHO MORT DAT	33	146	152	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2468-2667			LANCET PUBLIC HEALTH	Lancet Public Health	DEC	2016	1	2					E76	E83		10.1016/S2468-2667(16)30017-2			8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	VE1CA	WOS:000438432700010	29253420	DOAJ Gold	Y	N	2021-06-18	
J	Thurman, DJ				Thurman, David J.			The Epidemiology of Traumatic Brain Injury in Children and Youths: A Review of Research Since 1990	JOURNAL OF CHILD NEUROLOGY			English	Article						traumatic brain injury; epidemiology; incidence; risk factors; systematic review	EMERGENCY-DEPARTMENT VISITS; OPERATIONAL CASE-DEFINITION; ABUSIVE HEAD TRAUMA; UNITED-STATES; POPULATION; TRENDS; HOSPITALIZATION; MILD; SURVEILLANCE; ADOLESCENTS	This report reviews recent research on the epidemiology of traumatic brain injuries among children and youth aged 0 to 20 years. Studies representing populations in North America, Europe, Australia, and New Zealand yield these median estimates of the annual incidence of childhood brain injuries: 691 per 100 000 population treated in emergency departments, 74 per 100 000 treated in hospital, and 9 per 100 000 resulting in death. Males have a higher risk of injury than females: 1.4 times higher among those aged less than 10 years and 2.2 times among those older than 10 years. The leading cause of injury among children aged less than 5 years is falls, whereas the leading cause of injury among youths aged 15 years and older is motor vehicle crashes. The prevalence of disability among all persons who have sustained traumatic brain injury in childhood is unknown, but among those who were hospitalized could approximate 20%.	[Thurman, David J.] Emory Univ, Sch Med, Dept Neurol, Decatur, GA 30030 USA	Thurman, DJ (corresponding author), Emory Univ, Sch Med, Dept Neurol, 468 Pensdale Rd, Decatur, GA 30030 USA.	david.j.thurman@emory.edu		Thurman, David/0000-0002-0533-7062			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; [Anonymous], CENS POP INF; Asemota AO, 2013, J NEUROTRAUM, V30, P67, DOI 10.1089/neu.2012.2605; Baldo V, 2003, EUR J EPIDEMIOL, V18, P1059, DOI 10.1023/A:1026192020963; Barraco RD, 2010, J TRAUMA, V69, P1588, DOI 10.1097/TA.0b013e3181fbc69c; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Berry JG, 2010, INJURY PREV, V16, P198, DOI 10.1136/ip.2009.022442; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; Centers for Disease Control and Prevention National Center for Injury Pre- vention and Control, 2012, NAT ACT PLAN CHILD I; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dahl E, 2006, INJURY, V37, P402, DOI 10.1016/j.injury.2005.09.008; Dellinger AM, 2007, SILENT VICTORIES HIS, P343; Eisele JA, 2006, J HEAD TRAUMA REHAB, V21, P537, DOI 10.1097/00001199-200611000-00008; Engberg A, 1998, EUR J EPIDEMIOL, V14, P165, DOI 10.1023/A:1007492025190; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; Gennarelli TA, 1985, ABBREVIATED INJURY S; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Institute of Medicine and National Research Council, 2013, CONC YOUTH IMPR SCI; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; McCarthy ML, 2002, ACAD EMERG MED, V9, P684; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Murray CJL, 1996, GLOBAL HLTH STAT; Parks SE, 2012, PEDIAT ABUSIVE HEAD; Parks S, 2012, INJURY PREV, V18, P392, DOI 10.1136/injuryprev-2011-040234; Parks SE, 2012, INJURY PREV, V18, P193, DOI 10.1136/injuryprev-2011-040128; Perez K, 2012, ACCIDENT ANAL PREV, V46, P37, DOI 10.1016/j.aap.2011.12.004; Piatt JH, 2012, J NEUROSURG-PEDIATR, V10, P257, DOI 10.3171/2012.7.PEDS11532; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Reid SR, 2001, ARCH PEDIAT ADOL MED, V155, P784, DOI 10.1001/archpedi.155.7.784; Rodriguez SR, 2006, PUBLIC HEALTH REP, V121, P282, DOI 10.1177/003335490612100310; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Sosin DM, 1996, BRAIN INJURY, V10, P47; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Thurman DJ, 1996, WESTERN J MED, V165, P192; Thurman DJ, 1996, STANDARDS SURVEILLAN; Thurman DJ., 1995, GUIDELINES SURVEILLA; Tieves Kelly S, 2005, WMJ, V104, P22; Tieves KS, 2005, WMJ, V104, P54; US Department of Health and Human Services, 2014, INT CLASS DIS 10 REV; US Department of Health and Human Services, 1979, INT CLASS DIS 9 REV; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; World Health Organization, 1992, INT CLASS DIS 10 REV; World Health Organization, 1977, INT CLASS DIS; World Health Organization, 2006, NEUR DIS PUBL HLTH C	59	146	148	2	29	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	JAN	2016	31	1			SI		20	27		10.1177/0883073814544363			8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	CY8HW	WOS:000366650400002	25123531				2021-06-18	
J	Mechoulam, R; Hanus, LO; Pertwee, R; Howlett, AC				Mechoulam, Raphael; Hanus, Lumir O.; Pertwee, Roger; Howlett, Allyn C.			Early phytocannabinoid chemistry to endocannabinoids and beyond	NATURE REVIEWS NEUROSCIENCE			English	Article							CANNABINOID RECEPTOR ANTAGONIST; ARACHIDONOYL-L-SERINE; BLASTOMA CELL-MEMBRANES; TRAUMATIC BRAIN-INJURY; ADENYLATE-CYCLASE; CB2 RECEPTOR; INVERSE AGONIST; SR 141716A; MOLECULAR CHARACTERIZATION; SELECTIVE ANTAGONIST	Isolation and structure elucidation of most of the major cannabinoid constituents-including Delta(9)-tetrahydrocannabinol (Delta(9)-THC), which is the principal psychoactive molecule in Cannabis sativa-was achieved in the 1960s and 1970s. It was followed by the identification of two cannabinoid receptors in the 1980s and the early 1990s and by the identification of the endocannabinoids shortly thereafter. There have since been considerable advances in our understanding of the endocannabinoid system and its function in the brain, which reveal potential therapeutic targets for a wide range of brain disorders.	[Mechoulam, Raphael; Hanus, Lumir O.] Hebrew Univ Jerusalem, Fac Med, Inst Drug Res, IL-91120 Jerusalem, Israel; [Pertwee, Roger] Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland; [Howlett, Allyn C.] Wake Forest Univ Hlth Sci, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA	Mechoulam, R (corresponding author), Hebrew Univ Jerusalem, Fac Med, Inst Drug Res, IL-91120 Jerusalem, Israel.	mechou@cc.huji.ac.il		Pertwee, Roger/0000-0003-3227-2783; Howlett, Allyn/0000-0002-2810-0164	Kessler Family Foundation, Boston, USA; US National Institute on Drug Abuse (NIDA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-3934, DA-9789, DA-3672, DA-3690]; GW Pharmaceuticals; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R37DA003672, R01DA003690, R01DA003934, P01DA009789, R01DA003672] Funding Source: NIH RePORTER	Research in the laboratory of R.M. was supported by the Kessler Family Foundation, Boston, USA, and by a grant from US National Institute on Drug Abuse (NIDA), DA-9789. The research of R.P. was supported by NIDA grants DA-3934, DA-9789 and DA-3672 and GW Pharmaceuticals and the research of A.H. was supported by NIDA grant DA-3690.	ACETO MD, 1995, EUR J PHARMACOL, V282, pR1, DOI 10.1016/0014-2999(95)00447-S; Adams R., 1941, MARIHUANA HARVEY LEC, V37, P168; AGURELL S, 1986, PHARMACOL REV, V38, P21; Alger BE, 2012, J PHYSIOL-LONDON, V590, P2203, DOI 10.1113/jphysiol.2011.220855; Anand P, 2009, BRAIN RES REV, V60, P255, DOI 10.1016/j.brainresrev.2008.12.003; Bandiera T, 2014, PHARMACOL RES, V86, P11, DOI 10.1016/j.phrs.2014.04.011; Bauer M, 2012, J BIOL CHEM, V287, P36944, DOI 10.1074/jbc.M112.382481; Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129; Blankman JL, 2013, PHARMACOL REV, V65, P849, DOI 10.1124/pr.112.006387; BOUABOULA M, 1995, BIOCHEM J, V312, P637, DOI 10.1042/bj3120637; BOUABOULA M, 1995, J BIOL CHEM, V270, P13973, DOI 10.1074/jbc.270.23.13973; Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330; Cahn RS, 1932, J CHEM SOC, P1342, DOI 10.1039/jr9320001342; Cascio MG, 2010, PHARMACOL RES, V61, P349, DOI 10.1016/j.phrs.2009.11.011; Cohen-Yeshurun A, 2013, J CEREBR BLOOD F MET, V33, P1242, DOI 10.1038/jcbfm.2013.75; Cohen-Yeshurun A, 2011, J CEREBR BLOOD F MET, V31, P1768, DOI 10.1038/jcbfm.2011.53; Compton DR, 1996, J PHARMACOL EXP THER, V277, P586; Cosenza M, 2000, SYNAPSE, V38, P477, DOI 10.1002/1098-2396(20001215)38:4<477::AID-SYN13>3.0.CO;2-Y; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; CUNHA JM, 1980, PHARMACOLOGY, V21, P175, DOI 10.1159/000137430; De Petrocellis L, 2011, BRIT J PHARMACOL, V163, P1479, DOI 10.1111/j.1476-5381.2010.01166.x; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEWEY WL, 1986, PHARMACOL REV, V38, P151; Di Marzo V, 2005, HANDB EXP PHARMACOL, V168, P147; Di Marzo V, 2006, TRENDS PHARMACOL SCI, V27, P134, DOI 10.1016/j.tips.2006.01.010; Di Marzo V, 2009, NAT REV ENDOCRINOL, V5, P633, DOI 10.1038/nrendo.2009.197; Felder CC, 1998, J PHARMACOL EXP THER, V284, P291; Fernandez-Ruiz J, 2008, MOL CELL ENDOCRINOL, V286, pS91, DOI 10.1016/j.mce.2008.01.001; Fernandez-Ruiz J, 2007, TRENDS PHARMACOL SCI, V28, P39, DOI 10.1016/j.tips.2006.11.001; Galve-Roperh I, 2013, PROG LIPID RES, V52, P633, DOI 10.1016/j.plipres.2013.05.004; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; GERARD C, 1990, NUCLEIC ACIDS RES, V18, P7142, DOI 10.1093/nar/18.23.7142; Gregg LC, 2012, J NEUROSCI, V32, P9457, DOI 10.1523/JNEUROSCI.0013-12.2012; GUEUDET C, 1995, NEUROREPORT, V6, P1421, DOI 10.1097/00001756-199507100-00015; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; Heimann AS, 2007, P NATL ACAD SCI USA, V104, P20588, DOI 10.1073/pnas.0706980105; HOLLISTER LE, 1986, PHARMACOL REV, V38, P1; Horvath B, 2012, BRIT J PHARMACOL, V165, P2462, DOI 10.1111/j.1476-5381.2011.01381.x; HOWLETT AC, 1984, LIFE SCI, V35, P1803, DOI 10.1016/0024-3205(84)90278-9; HOWLETT AC, 1984, MOL PHARMACOL, V26, P532; HOWLETT AC, 1985, MOL PHARMACOL, V27, P429; HOWLETT AC, 1990, NEUROPHARMACOLOGY, V29, P161, DOI 10.1016/0028-3908(90)90056-W; HOWLETT AC, 1986, MOL PHARMACOL, V29, P307; Howlett AC, 2010, CURR MED CHEM, V17, P1382, DOI 10.2174/092986710790980023; Huffman JW, 1996, J MED CHEM, V39, P3875, DOI 10.1021/jm960394y; Katona I, 2012, ANNU REV NEUROSCI, V35, P529, DOI 10.1146/annurev-neuro-062111-150420; Kirilly E, 2012, ACTA PHYSIOL, V205, P41, DOI 10.1111/j.1748-1716.2012.02402.x; KLEE WA, 1975, LIFE SCI, V16, P1869, DOI 10.1016/0024-3205(75)90293-3; Lan R, 1999, AAPS PharmSci, V1, pE4; Lazary J, 2011, TRENDS PHARMACOL SCI, V32, P270, DOI 10.1016/j.tips.2011.02.013; Leweke FM, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.15; Loewe S, 1950, ARCH EXP PATHOL PH, V211, P175; Lunn CA, 2008, BRIT J PHARMACOL, V153, P226, DOI 10.1038/sj.bjp.0707480; Marriott KSC, 2008, CURR TOP MED CHEM, V8, P187; Mathews WB, 2000, NUCL MED BIOL, V27, P757, DOI 10.1016/S0969-8051(00)00152-9; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; McHugh D, 2012, BRIT J PHARMACOL, V165, P2414, DOI 10.1111/j.1476-5381.2011.01497.x; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MECHOULAM R, 1980, J MED CHEM, V23, P1068, DOI 10.1021/jm00184a002; MECHOULAM R, 1976, CHEM REV, V76, P75, DOI 10.1021/cr60299a002; MECHOULAM R, 1988, EXPERIENTIA, V44, P762, DOI 10.1007/BF01959156; MECHOULAM R, 1963, TETRAHEDRON, V19, P2073, DOI 10.1016/0040-4020(63)85022-X; Mechoulam R., 1986, CANNABINOIDS THERAPE, P1; Melvin L S, 1995, Drug Des Discov, V13, P155; MELVIN LS, 1993, MOL PHARMACOL, V44, P1008; Meschler JP, 2000, BIOCHEM PHARMACOL, V60, P1315, DOI 10.1016/S0006-2952(00)00447-0; Miller AM, 2008, BRIT J PHARMACOL, V153, P299, DOI 10.1038/sj.bjp.0707523; Milman G, 2006, P NATL ACAD SCI USA, V103, P2428, DOI 10.1073/pnas.0510676103; Moreira FA, 2009, BEST PRACT RES CL EN, V23, P133, DOI 10.1016/j.beem.2008.09.003; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Nathan PJ, 2011, CNS NEUROSCI THER, V17, P490, DOI 10.1111/j.1755-5949.2010.00172.x; NATHANSON NM, 1978, P NATL ACAD SCI USA, V75, P1788, DOI 10.1073/pnas.75.4.1788; Nissen SE, 2008, JAMA-J AM MED ASSOC, V299, P1547, DOI 10.1001/jama.299.13.1547; O'Shaugnessy W. B., 1841, THE BENGAL DISPENSAT, P579; Ohno-Shosaku T, 2012, NEUROSCIENTIST, V18, P119, DOI 10.1177/1073858410397377; Pacher P, 2011, PROG LIPID RES, V50, P193, DOI 10.1016/j.plipres.2011.01.001; Pacher P, 2013, FEBS J, V280, P1918, DOI 10.1111/febs.12260; Pamplona FA, 2012, P NATL ACAD SCI USA, V109, P21134, DOI 10.1073/pnas.1202906109; Pasquariello N, 2009, VITAM HORM, V81, P441, DOI 10.1016/S0083-6729(09)81017-0; Perio A, 1996, BEHAV PHARMACOL, V7, P65; PERTWEE R, 1995, LIFE SCI, V56, P1949, DOI 10.1016/0024-3205(95)00175-6; Pertwee R., 2014, HDB OF CANNABIS, P115; Pertwee RG, 2008, BRIT J PHARMACOL, V153, P199, DOI 10.1038/sj.bjp.0707442; Pertwee RG, 2010, PHARMACOL REV, V62, P588, DOI 10.1124/pr.110.003004; Pertwee RG, 2010, CURR MED CHEM, V17, P1360, DOI 10.2174/092986710790980050; Pertwee RG, 2005, AAPS J, V7, pE625, DOI 10.1208/aapsj070364; Pertwee RG, 2006, BRIT J PHARMACOL, V147, pS163, DOI 10.1038/sj.bjp.0706406; PERTWEE RG, 1972, BRIT J PHARMACOL, V46, P753, DOI 10.1111/j.1476-5381.1972.tb06900.x; Pertwee RG, 1999, CURR MED CHEM, V6, P635; PERTWEE RG, 1988, PHARMACOL THERAPEUT, V36, P189, DOI 10.1016/0163-7258(88)90106-4; Pertwee RG, 2014, P NUTR SOC, V73, P96, DOI 10.1017/S0029665113003649; Pertwee RG, 2009, BRIT J PHARMACOL, V156, P397, DOI 10.1111/j.1476-5381.2008.00048.x; Piomelli D, 2014, NAT NEUROSCI, V17, P164, DOI 10.1038/nn.3612; Piomelli D, 2013, TRENDS ENDOCRIN MET, V24, P332, DOI 10.1016/j.tem.2013.03.001; Porter BE, 2013, EPILEPSY BEHAV, V29, P574, DOI 10.1016/j.yebeh.2013.08.037; Pucci M, 2013, BRIT J PHARMACOL, V170, P581, DOI 10.1111/bph.12309; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; RinaldiCarmona M, 1996, LIFE SCI, V58, P1239, DOI 10.1016/0024-3205(96)00085-9; Roitman P, 2014, CLIN DRUG INVEST, V34, P587, DOI 10.1007/s40261-014-0212-3; SABOL SL, 1979, J BIOL CHEM, V254, P1913; Scheen AJ, 2006, LANCET, V368, P1660, DOI 10.1016/S0140-6736(06)69571-8; Schlosburg JE, 2014, J PHARMACOL EXP THER, V350, P196, DOI 10.1124/jpet.114.212753; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Smith TH, 2010, BRIT J PHARMACOL, V160, P454, DOI 10.1111/j.1476-5381.2010.00777.x; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Syed YY, 2014, DRUGS, V74, P563, DOI 10.1007/s40265-014-0197-5; Tam J, 2012, CELL METAB, V16, P167, DOI 10.1016/j.cmet.2012.07.002; Tan B, 2006, AAPS J, V8, pE461, DOI 10.1208/aapsj080354; Tan B, 2010, J LIPID RES, V51, P112, DOI 10.1194/jlr.M900198-JLR200; TODD AR, 1946, EXPERIENTIA, V2, P55, DOI 10.1007/BF02163886; TSOU K, 1995, EUR J PHARMACOL, V280, pR13, DOI 10.1016/0014-2999(95)00360-W; Van Gaal LF, 2005, LANCET, V365, P1389, DOI 10.1016/S0140-6736(05)66374-X; Vaughan CW, 2005, HANDB EXP PHARMACOL, V168, P367; Wilson RI, 2001, NATURE, V410, P588, DOI 10.1038/35069076; Wood TB, 1899, J CHEM SOC T, V75, P20; Wright KL, 2008, BRIT J PHARMACOL, V153, P263, DOI 10.1038/sj.bjp.0707486; Zygmunt PM, 1999, NATURE, V400, P452	119	146	149	1	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-003X	1471-0048		NAT REV NEUROSCI	Nat. Rev. Neurosci.	NOV	2014	15	11					757	764		10.1038/nrn3811			8	Neurosciences	Neurosciences & Neurology	AS2BC	WOS:000344083000011	25315390				2021-06-18	
J	Hughes, C				Hughes, Claire			Changes and Challenges in 20 Years of Research Into the Development of Executive Functions	INFANT AND CHILD DEVELOPMENT			English	Article						executive function; neuroscience; autism; ADHD; social understanding	BEHAVIOR RATING INVENTORY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CONFIRMATORY FACTOR-ANALYSIS; INDIVIDUAL-DIFFERENCES; FUNCTION DEFICITS; SPECTRUM DISORDERS; INHIBITORY CONTROL; SENSITIVE PERIODS; OBJECT PERMANENCE; COGNITIVE CONTROL	This review of 20 years of developmental research on Executive Functions (EF) offers a broad-brushstroke picture that touches on multiple issues including: (i) findings from typical and atypical groups, from infancy to adolescence; (ii) advances in assessment tools and in statistical analysis; (iii) the interplay between EF and other cognitive systems (e.g. those involved in children's developing understanding of mind, and in their processing of reward signals); (iv) integration of cognitive and neuroscience perspectives on EF; and (v) environmental factors that have either a positive influence (e.g. training/intervention programmes; parental scaffolding) or a negative influence (e.g. maltreatment, neglect, traumatic brain injury) on EF. Of the several themes to emerge from this review, two are particularly important; these concern the need to adopt developmental perspectives and the potential importance for intervention work of research on social influences on EF. Specifically, the review highlights both developmental continuities (e.g. in the correlates of EF) and contrasts (e.g. in the nature of EF and its neural substrates) and calls for research that compares developmental trajectories for EF in different groups (e.g. children with autism versus ADHD). In addition, findings from both family-based research and randomized controlled trials of school-based interventions highlight the importance of environmental influences on EF and so support the development of interventions to promote EF and hence improve children's academic and social outcomes. Copyright (C) 2011 John Wiley & Sons, Ltd.	Univ Cambridge, Ctr Family Res, Cambridge CB2 3RF, England	Hughes, C (corresponding author), Univ Cambridge, Ctr Family Res, Free Sch Lane, Cambridge CB2 3RF, England.	ch288@cam.ac.uk		Hughes, Claire/0000-0003-2545-3025			Aksan N, 2004, CHILD DEV, V75, P1477, DOI 10.1111/j.1467-8624.2004.00752.x; Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson P, 2001, CLIN NEUROPSYCHOL, V15, P81, DOI 10.1076/clin.15.1.81.1905; Anderson P, 1996, CLIN NEUROPSYCHOL, V10, P54, DOI 10.1080/13854049608406663; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Anderson V, 2010, NEUROPSYCHOLOGIA, V48, P2041, DOI 10.1016/j.neuropsychologia.2010.03.025; Apperly IA, 2009, DEV PSYCHOL, V45, P190, DOI 10.1037/a0014098; Asbury K, 2005, INTELLIGENCE, V33, P643, DOI 10.1016/j.intell.2005.03.008; Asbury K, 2003, CHILD DEV, V74, P933, DOI 10.1111/1467-8624.00577; Aytaclar S, 1999, J AM ACAD CHILD PSY, V38, P172, DOI 10.1097/00004583-199902000-00016; BAILLARGEON R, 1985, COGNITION, V20, P191, DOI 10.1016/0010-0277(85)90008-3; Barnett WS, 2008, EARLY CHILD RES Q, V23, P299, DOI 10.1016/j.ecresq.2008.03.001; Baron-Cohen S, 2000, NEUROSCI BIOBEHAV R, V24, P355, DOI 10.1016/S0149-7634(00)00011-7; Bernier A, 2010, CHILD DEV, V81, P326, DOI 10.1111/j.1467-8624.2009.01397.x; Best JR, 2009, DEV REV, V29, P180, DOI 10.1016/j.dr.2009.05.002; Bibok MB, 2009, NEW DIR CHILD ADOLES, V123, P17, DOI 10.1002/cd.233; Bierman KL, 2008, DEV PSYCHOPATHOL, V20, P821, DOI 10.1017/S0954579408000394; Bishop DVM, 2001, J CHILD PSYCHOL PSYC, V42, P551, DOI 10.1111/1469-7610.00749; Blair C, 2005, DEV NEUROPSYCHOL, V28, P561, DOI 10.1207/s15326942dn2802_1; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Bodrova E., 1996, TOOLS MIND VYGOTSKIA; Brocki K, 2009, NEUROSCIENCE, V164, P241, DOI 10.1016/j.neuroscience.2009.01.029; Burden V., 2003, BEHAV ASSESSMENT DYS; Carlson SM, 2004, DEV PSYCHOL, V40, P1105, DOI 10.1037/0012-1649.40.6.1105; Carlson SM, 2003, MONOGR SOC RES CHILD, V68, P138, DOI 10.1111/j.0037-976X.2003.00270.x; Carlson SM, 2007, COGNITIVE DEV, V22, P489, DOI 10.1016/j.cogdev.2007.08.002; Chevignard MP, 2010, BRAIN IMPAIR, V11, P125, DOI 10.1375/brim.11.2.125; Cicchetti D, 2002, COGNITIVE DEV, V17, P1407, DOI 10.1016/S0885-2014(02)00121-1; Connor PD, 2000, DEV NEUROPSYCHOL, V18, P331, DOI 10.1207/S1532694204Connor; Cuevas K, 2010, DEV PSYCHOL, V46, P1363, DOI 10.1037/a0020185; Davidson MC, 2006, NEUROPSYCHOLOGIA, V44, P2037, DOI 10.1016/j.neuropsychologia.2006.02.006; De Bellis MD, 2005, CHILD MALTREATMENT, V10, P150, DOI 10.1177/1077559505275116; De Luca CR, 2003, J CLIN EXP NEUROPSYC, V25, P242, DOI 10.1076/jcen.25.2.242.13639; de Vignemont F, 2009, PHILOS STUD, V144, P457, DOI 10.1007/s11098-009-9354-1; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; DIAMOND A, 1988, CHILD DEV, V59, P523, DOI 10.2307/1130330; DIAMOND A, 1989, EXP BRAIN RES, V74, P24; DIAMOND A, 1989, BEHAV NEUROSCI, V103, P526, DOI 10.1037/0735-7044.103.3.526; Diamond A., 2002, PRINCIPLES FRONTAL L, P466, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0029; DIAMOND A, 1997, MONOGRAPHS SOC RES C, V62; Diamond A, 2007, SCIENCE, V318, P1387, DOI 10.1126/science.1151148; Diamond A, 2009, DEV PSYCHOL, V45, P130, DOI 10.1037/a0014025; Dumontheil I, 2010, DEVELOPMENTAL SCI, V13, P331, DOI 10.1111/j.1467-7687.2009.00888.x; Fairchild G, 2009, BIOL PSYCHIAT, V66, P162, DOI 10.1016/j.biopsych.2009.02.024; Flook L, 2010, J APPL SCH PSYCHOL, V26, P70, DOI 10.1080/15377900903379125; Flynn E, 2006, BRIT J DEV PSYCHOL, V24, P631, DOI 10.1348/026151005X57422; Friedman NP, 2008, J EXP PSYCHOL GEN, V137, P201, DOI 10.1037/0096-3445.137.2.201; Garon N, 2008, PSYCHOL BULL, V134, P31, DOI 10.1037/0033-2909.134.1.31; Geurts HM, 2004, J CHILD PSYCHOL PSYC, V45, P836, DOI 10.1111/j.1469-7610.2004.00276.x; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Goldberg MC, 2005, J AUTISM DEV DISORD, V35, P279, DOI 10.1007/s10803-005-3291-4; Golden C. J., 1981, NEUROPSYCHOLOGICAL A, P277; Green CR, 2009, J CHILD PSYCHOL PSYC, V50, P688, DOI 10.1111/j.1469-7610.2008.01990.x; Happe F, 2006, BRAIN COGNITION, V61, P25, DOI 10.1016/j.bandc.2006.03.004; HARRIS PL, 1975, PSYCHOL BULL, V82, P332; Hill EL, 2004, TRENDS COGN SCI, V8, P26, DOI 10.1016/j.tics.2003.11.003; Hooper CJ, 2004, DEV PSYCHOL, V40, P1148, DOI 10.1037/0012-1649.40.6.1148; Hughes C, 2005, DEV NEUROPSYCHOL, V28, P645, DOI 10.1207/s15326942dn2802_5; HUGHES C, 1993, DEV PSYCHOL, V29, P498, DOI 10.1037/0012-1649.29.3.498; Hughes C, 2002, INFANT CHILD DEV, V11, P201, DOI 10.1002/icd.297; HUGHES C, 1994, NEUROPSYCHOLOGIA, V32, P477, DOI 10.1016/0028-3932(94)90092-2; Hughes C, 1998, J CHILD PSYCHOL PSYC, V39, P981, DOI 10.1017/S0021963098003059; Hughes C., 2011, BIENN M SOC RES CHIL; Hughes C., 2002, CHILD ADOL MENT H-UK, V7, P131, DOI DOI 10.1111/1475-3588.00024; Hughes C, 2007, DEV PSYCHOL, V43, P1447, DOI 10.1037/0012-1649.43.6.1447; Hughes C, 2010, DEV NEUROPSYCHOL, V35, P20, DOI 10.1080/87565640903325691; Hughes CH, 2009, NEW DIR CHILD ADOLES, V123, P35, DOI 10.1002/cd.234; Huizinga M, 2006, NEUROPSYCHOLOGIA, V44, P2017, DOI 10.1016/j.neuropsychologia.2006.01.010; Jacobs E, 2010, CHILD PSYCHIAT HUM D, V41, P15, DOI 10.1007/s10578-009-0149-6; Jarrold C, 2010, BRIT J DEV PSYCHOL, V28, P239, DOI 10.1348/026151008X400085; Johnson MH, 2005, DEV PSYCHOBIOL, V46, P287, DOI 10.1002/dev.20057; Karbach J, 2009, DEVELOPMENTAL SCI, V12, P978, DOI 10.1111/j.1467-7687.2009.00846.x; KENDALL PC, 1979, J CONSULT CLIN PSYCH, V47, P1020, DOI 10.1037/0022-006X.47.6.1020; Klimes-Dougan B, 2006, BIOL PSYCHIAT, V60, P957, DOI 10.1016/j.biopsych.2006.03.031; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Klingberg T, 2010, TRENDS COGN SCI, V14, P317, DOI 10.1016/j.tics.2010.05.002; Kloo D, 2003, CHILD DEV, V74, P1823, DOI 10.1046/j.1467-8624.2003.00640.x; Kovas Y., 2007, GENETIC ENV ORIGINS, V72; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; Lackner CL, 2010, NEUROPSYCHOLOGIA, V48, P1767, DOI 10.1016/j.neuropsychologia.2010.02.027; Lehto JE, 2003, BRIT J DEV PSYCHOL, V21, P59, DOI 10.1348/026151003321164627; LeJeune B, 2010, CHILD NEUROPSYCHOL, V16, P182, DOI 10.1080/09297040903352556; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lewis C, 2009, NEW DIR CHILD ADOLES, V123, P1, DOI 10.1002/cd.232; Luciana M, 2005, CHILD DEV, V76, P697, DOI 10.1111/j.1467-8624.2005.00872.x; Luciana M, 2003, J CHILD PSYCHOL PSYC, V44, P649, DOI 10.1111/1469-7610.00152; Luna B, 2004, CHILD DEV, V75, P1357, DOI 10.1111/j.1467-8624.2004.00745.x; Luria A. R., 1966, HIGHER CORTICAL FUNC; Mattson SN, 1999, ALCOHOL CLIN EXP RES, V23, P1808, DOI 10.1097/00000374-199911000-00014; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; Micco JA, 2009, DEPRESS ANXIETY, V26, P780, DOI 10.1002/da.20573; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Montague PR, 2004, NATURE, V431, P760, DOI 10.1038/nature03015; Mosconi MW, 2009, PSYCHOL MED, V39, P1559, DOI 10.1017/S0033291708004984; Mulder H, 2009, DEV NEUROPSYCHOL, V34, P393, DOI 10.1080/87565640902964524; Munakata Y, 2001, TRENDS COGN SCI, V5, P309, DOI 10.1016/S1364-6613(00)01682-X; Noble KG, 2005, DEVELOPMENTAL SCI, V8, P74, DOI 10.1111/j.1467-7687.2005.00394.x; O'Hearn K, 2008, DEV PSYCHOPATHOL, V20, P1103, DOI 10.1017/S0954579408000527; OZONOFF S, 1991, J CHILD PSYCHOL PSYC, V32, P1081, DOI 10.1111/j.1469-7610.1991.tb00351.x; Ozonoff S, 2004, J AUTISM DEV DISORD, V34, P139, DOI 10.1023/B:JADD.0000022605.81989.cc; OZONOFF S, 1995, NEUROPSYCHOLOGY, V9, P491, DOI 10.1037/0894-4105.9.4.491; Paus T, 2010, BRAIN COGNITION, V72, P26, DOI 10.1016/j.bandc.2009.06.002; Pellicano E, 2007, DEV PSYCHOL, V43, P974, DOI 10.1037/0012-1649.43.4.974; Pellicano E, 2010, DEV PSYCHOL, V46, P530, DOI 10.1037/a0018287; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; PERNER J, 1994, CHILD DEV, V65, P1228, DOI 10.1111/j.1467-8624.1994.tb00814.x; Perner J, 2008, TRENDS COGN SCI, V12, P123, DOI 10.1016/j.tics.2008.02.001; Perner J, 2006, SOC NEUROSCI-UK, V1, P245, DOI 10.1080/17470910600989896; Rasmussen C., 2009, CANADIAN J CLIN PHAR, V16, P370; Romer D, 2009, NEUROPSYCHOLOGIA, V47, P2916, DOI 10.1016/j.neuropsychologia.2009.06.019; Rothbart M. K., 2000, TEMPERAMENT PERSONAL, P85; Rothbart MK, 2003, J PERS, V71, P1113, DOI 10.1111/1467-6494.7106009; Rueda MR, 2005, P NATL ACAD SCI USA, V102, P14931, DOI 10.1073/pnas.0506897102; Rutter M, 2004, DEV PSYCHOL, V40, P81, DOI 10.1037/0012-1649.40.1.81; Sabbagh MA, 2009, CHILD DEV, V80, P1147, DOI 10.1111/j.1467-8624.2009.01322.x; Schonfeld AM, 2001, J STUD ALCOHOL, V62, P239, DOI 10.15288/jsa.2001.62.239; Sheese BE, 2008, INFANT BEHAV DEV, V31, P501, DOI 10.1016/j.infbeh.2008.02.001; Solomon M, 2009, NEUROPSYCHOLOGIA, V47, P2515, DOI 10.1016/j.neuropsychologia.2009.04.019; Sonuga-Barke EJS, 2005, BIOL PSYCHIAT, V57, P1231, DOI 10.1016/j.biopsych.2004.09.008; Tager-Flusberg H, 2001, DEVELOPMENT OF AUTISM: PERSPECTIVES FROM THEORY AND RESEARCH, P173; Tau GZ, 2010, NEUROPSYCHOPHARMACOL, V35, P147, DOI 10.1038/npp.2009.115; Thomas MSC, 2008, CURR DIR PSYCHOL SCI, V17, P1, DOI 10.1111/j.1467-8721.2008.00537.x; Thorell LB, 2009, DEVELOPMENTAL SCI, V12, P106, DOI 10.1111/j.1467-7687.2008.00745.x; Vaurio L, 2008, J INT NEUROPSYCH SOC, V14, P119, DOI 10.1017/S1355617708080144; Vygotsky L. S., 1978, MIND SOC DEV HIGHER; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; White SJ, 2009, AUTISM RES, V2, P138, DOI 10.1002/aur.78; WIEBE S, 2010, J EXPT CHILD PSYCHOL, DOI DOI 10.1016/J.JECP2010.1008.1008; Wiebe SA, 2008, DEV PSYCHOL, V44, P575, DOI 10.1037/0012-1649.44.2.575; Wiers RW, 2007, PHARMACOL BIOCHEM BE, V86, P263, DOI 10.1016/j.pbb.2006.09.021; WILLOUGHBY M, 2010, J EXPT CHILD PSYCHOL, DOI DOI 10.1016/J.JECP.2010.1004.1007; Zelazo PD, 2003, MONOGR SOC RES CHILD, V68, P1, DOI 10.1111/j.0037-976X.2003.00261.x	134	146	153	4	128	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA		1522-7219		INFANT CHILD DEV	Infant Child Dev.	MAY-JUN	2011	20	3					251	271		10.1002/icd.736			21	Psychology, Developmental	Psychology	789GE	WOS:000292502300001					2021-06-18	
J	Cripps, RA; Lee, BB; Wing, P; Weerts, E; Mackay, J; Brown, D				Cripps, R. A.; Lee, B. B.; Wing, P.; Weerts, E.; Mackay, J.; Brown, D.			A global map for traumatic spinal cord injury epidemiology: towards a living data repository for injury prevention	SPINAL CORD			English	Article						incidence; prevalence; survival; spinal cord injury; mapping	PREVALENCE; MORTALITY; NEUROTRAUMA; MANAGEMENT; SURVIVAL; NIGERIA; LESIONS; RISK	Study design: Literature review. Objectives: To map traumatic spinal cord injury (TSCI) globally and provide a framework for an ongoing repository of data for prevention. Setting: An initiative of the ISCoS Prevention Committee. Methods: The results obtained from the search of Medline/Embase using search phrases: TSCI incidence, aetiology, prevalence and survival were analysed. Stratification of data into green/yellow/red quality 'zones' allowed comparison between data. Results: Reported global prevalence of TSCI is insufficient (236-1009 per million). Incidence data was comparable only for regions in North America (39 per million), Western Europe (15 per million) and Australia (16 per million). The major cause of TSCI in these regions involves four-wheeled motor vehicles, in contrast to South-east Asia where two-wheeled (and non-standard) road transport predominates. Southern Asia and Oceania have falls from rooftops and trees as the primary cause. High-fall rates are also seen in developed regions with aged populations (Japan/Western Europe). Violence/self-harm (mainly firearm-related) was higher in North America (15%) than either Western Europe (6%) or Australia (2%). Sub-Saharan Africa has the highest reported violence-related TSCI in the world (38%). Rates are also high in north Africa/Middle East (24%) and Latin America (22%). Developed countries have significantly improved TSCI survival compared with developing countries, particularly for tetraplegia. Developing countries have the highest 1-year mortality rates and in some countries in sub-Saharan Africa the occurrence of a spinal injury is likely to be a fatal condition within a year. Conclusion: Missing prevalence and insufficient incidence data is a recurrent feature of this review. The piecemeal approach to epidemiological reporting of TSCI, particularly failing to include sound regional denominators has exhausted its utility. Minimum data collection standards are required. Spinal Cord (2011) 49, 493-501; doi: 10.1038/sc.2010.146; published online 23 November 2010	[Lee, B. B.] Prince Wales Hosp, Spinal Med Dept, Sydney, NSW 2031, Australia; [Cripps, R. A.] Flinders Univ S Australia, Sch Med, Sydney, NSW, Australia; [Lee, B. B.] Univ New S Wales, Sch Publ Hlth, Sydney, NSW, Australia; [Wing, P.] Univ British Columbia, Div Spine, Vancouver, BC V5Z 1M9, Canada; [Weerts, E.] Bach Mai Hosp Spinal Unit, Handicap Int, Hanoi, Vietnam; [Mackay, J.] Univ Hong Kong, Sch Publ Hlth, Pokfulam, Hong Kong, Peoples R China; [Brown, D.] Austin Hosp, Melbourne, Vic 3084, Australia	Lee, BB (corresponding author), Prince Wales Hosp, Spinal Med Dept, High St Entrance Level 2, Sydney, NSW 2031, Australia.	blee@medicalinformatics.net		Lee, Bonne/0000-0002-0433-2913	Prince of Wales Hospital (New South Wales Department of Health, Australia)	We would like to thank Mr Obayd Marial, Mr Adam Rutkowski and Mr Jason Chuang for their generous assistance with translation, and Dr Saaide Alshahari for providing Saudi-Arabian unpublished data. We would also like to thank members of the ISCoS prevention committee and the ISCoS membership for their continuing enthusiasm. Dr Lee and Myriad Mapping were funded by the Prince of Wales Hospital Training, Education and Study Leave fund (New South Wales Department of Health, Australia). Claire Weeks was instrumental in putting together the team for this report.	Ackery A, 2004, J NEUROTRAUM, V21, P1355, DOI 10.1089/neu.2004.21.1355; ACTON PA, 1993, ARCH PHYS MED REHAB, V74, P1035, DOI 10.1016/0003-9993(93)90058-I; ALSHAHRI S, 2010, TRAUMATIC SPIN UNPUB; Augutis M, 2003, SPINAL CORD, V41, P328, DOI 10.1038/sj.sc.3101478; Barnett DJ, 2005, ENVIRON HEALTH PERSP, V113, P561, DOI 10.1289/ehp.7491; Barros F, 1990, REV HOSP CLIN FM SAO, V45, P123; Belanger F, 2008, TRANSPORT RELATED DE; BIERINGSORENSEN F, 1990, PARAPLEGIA, V28, P105, DOI 10.1038/sc.1990.13; BLUMER CE, 1995, NEUROEPIDEMIOLOGY, V14, P258, DOI 10.1159/000109801; Brasil AVB, 1998, SPINAL CORD, V36, P353, DOI 10.1038/sj.sc.3100630; BURNEY RE, 1993, ARCH SURG-CHICAGO, V128, P596; Calancie B, 2005, J SPINAL CORD MED, V28, P92, DOI 10.1080/10790268.2005.11753804; CHEN CF, 1985, PARAPLEGIA, V23, P364, DOI 10.1038/sc.1985.58; Chen HY, 1997, NEUROEPIDEMIOLOGY, V16, P241, DOI 10.1159/000109693; Cripps R, 2008, INJURY RES STAT SERI, V48; Dahlberg A, 2005, SPINAL CORD, V43, P47, DOI 10.1038/sj.sc.3101616; DAPAZ AC, 1992, PARAPLEGIA, V30, P636, DOI 10.1038/sc.1992.126; *DEP EC SOC AFF PD, 2009, WORLD POP AG 2009; Department of Energy & Climatechange, 2009, WORLD POP AG 2009, P1; DeVivo M, 2006, SPINAL CORD, V44, P535, DOI 10.1038/sj.sc.3101958; DEVIVO MJ, 1980, ARCH NEUROL-CHICAGO, V37, P707, DOI 10.1001/archneur.1980.00500600055011; DITUNNO JF, 1994, NEW ENGL J MED, V330, P550, DOI 10.1056/NEJM199402243300808; Divanoglou A, 2009, SPINAL CORD, V47, P796, DOI 10.1038/sc.2009.28; DIXON GS, 1993, NEUROEPIDEMIOLOGY, V12, P88, DOI 10.1159/000110305; Gehrig R, 1988, PARAPLEGIA, V6, P93; Goebert D A, 1991, Hawaii Med J, V50, P47; Gosselin RA, 2005, INT ORTHOP, V29, P330, DOI 10.1007/s00264-005-0665-3; GRIFFIN MR, 1985, J CHRON DIS, V38, P643, DOI 10.1016/0021-9681(85)90018-9; HART C, 1994, PARAPLEGIA, V32, P709, DOI 10.1038/sc.1994.115; *HARV U I HLTH MET, 2009, OP MAN IN PRESS; HARVEY C, 1990, PARAPLEGIA, V28, P537, DOI 10.1038/sc.1990.73; Hoque MF, 1999, SPINAL CORD, V37, P858, DOI 10.1038/sj.sc.3100938; Hu R, 1996, SPINE, V21, P492, DOI 10.1097/00007632-199602150-00016; Ide Makoto, 1993, Journal of UOEH (University of Occupational and Environmental Health), V15, P209; Igun GO, 1999, E AFR MED J, V76, P75; IWEGBU CG, 1983, PARAPLEGIA, V21, P81, DOI 10.1038/sc.1983.11; Jankowski R, 1993, Chir Narzadow Ruchu Ortop Pol, V58, P353; Karacan I, 2000, SPINAL CORD, V38, P697, DOI 10.1038/sj.sc.3101064; KEY AG, 1968, INT MED SOC PAR ANN, P243; KNUTSDOTTIR S, 1993, PARAPLEGIA, V31, P68, DOI 10.1038/sc.1993.10; KNUTSDOTTIR S, 2009, ISCOS C P 48 ISCOS A, P224; Kondakov E N, 2002, Zh Vopr Neirokhir Im N N Burdenko, P50; KOVINDHA A, 1993, CHIANG MAI MED B, V32, P85; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; Krause JS, 2009, ARCH PHYS MED REHAB, V90, P1708, DOI 10.1016/j.apmr.2009.04.020; KURTZKE JF, 1975, EXP NEUROL, V48, P163, DOI 10.1016/0014-4886(75)90175-2; LASFARGUES JE, 1995, PARAPLEGIA, V33, P62, DOI 10.1038/sc.1995.16; Lee BB, 2010, SPINAL CORD, V48, P498, DOI 10.1038/sc.2009.168; Levy LF, 1998, SPINAL CORD, V36, P213, DOI 10.1038/sj.sc.3100574; Mackay J, 2004, ATLAS HEART DIS STRO; Maharaj JC, 1996, SPINAL CORD, V34, P549, DOI 10.1038/sc.1996.99; Mukhida K, 2006, CHILD NERV SYST, V22, P352, DOI 10.1007/s00381-005-1235-0; *NAT SPIN CORD INJ, 2008, SPIN CORD INJ FACTS; New PW, 2008, SPINAL CORD, V46, P406, DOI 10.1038/sj.sc.3102152; Nwadinigwe C U, 2004, Niger J Med, V13, P161; Nwankwo OE, 2003, SPINAL CORD, V41, P129, DOI 10.1038/sj.sc.3101410; O'Connor PJ, 2005, ARCH PHYS MED REHAB, V86, P37, DOI 10.1016/j.apmr.2004.03.018; O'Connor PJ, 2005, SPINAL CORD, V43, P42, DOI 10.1038/sj.sc.3101666; O'Connor RJ, 2006, SPINAL CORD, V44, P445, DOI 10.1038/sj.sc.3101856; Obalum DC, 2009, SPINAL CORD, V47, P134, DOI 10.1038/sc.2008.93; Olasode BJ, 2006, TROP DOCT, V36, P181, DOI 10.1258/004947506777978136; Otom AS, 1997, SPINAL CORD, V35, P253, DOI 10.1038/sj.sc.3100402; Pagliacci MC, 2003, ARCH PHYS MED REHAB, V84, P1266, DOI 10.1016/S0003-9993(03)00234-X; Pajareya K, 1996, SPINAL CORD, V34, P608, DOI 10.1038/sc.1996.108; PEDERSEN V, 1989, PARAPLEGIA, V27, P345, DOI 10.1038/sc.1989.52; PRICE C, 1994, AM J EPIDEMIOL, V139, P37, DOI 10.1093/oxfordjournals.aje.a116933; Raja IA, 2001, WORLD J SURG, V25, P1230; RAZDAN S, 1994, NEUROEPIDEMIOLOGY, V13, P113, DOI 10.1159/000110368; Sabre L, 2009, ISCOS; SHINGU H, 1995, PARAPLEGIA, V33, P183, DOI 10.1038/sc.1995.42; SILBERSTEIN B, 1995, PARAPLEGIA, V33, P322, DOI 10.1038/sc.1995.72; Soden RJ, 2000, SPINAL CORD, V38, P604, DOI 10.1038/sj.sc.3101080; Solagberu Babatunde A, 2002, West Afr J Med, V21, P230; SOOPRAMANIEN A, 1994, PARAPLEGIA, V32, P715, DOI 10.1038/sc.1994.116; STOVER SL, 1987, PARAPLEGIA, V25, P225, DOI 10.1038/sc.1987.40; THURMAN DJ, 1994, PARAPLEGIA, V32, P665, DOI 10.1038/sc.1994.107; VELMAHOS GC, 1995, J TRAUMA, V38, P334, DOI 10.1097/00005373-199503000-00004; WALSH J, 1988, PARAPLEGIA, V26, P380, DOI 10.1038/sc.1988.58; WEERTS E, 2009, FIN REP PROJ OUTC SP; Wyndaele M, 2006, SPINAL CORD, V44, P523, DOI 10.1038/sj.sc.3101893; Yeo JD, 1998, SPINAL CORD, V36, P329, DOI 10.1038/sj.sc.3100628; 2006, R HANSEN SPINAL CORD	82	146	156	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	APR	2011	49	4					493	501		10.1038/sc.2010.146			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	744BZ	WOS:000289069400003	21102572	Bronze			2021-06-18	
J	Taylor, PA; Ford, CC				Taylor, Paul A.; Ford, Corey C.			Simulation of Blast-Induced Early-Time Intracranial Wave Physics leading to Traumatic Brain Injury	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article						biomechanics; brain models; detonation waves; finite volume methods; impact (mechanical); neurophysiology; stress analysis; wounds	DIFFUSE AXONAL INJURY; FINITE-ELEMENT-ANALYSIS; HUMAN HEAD; IMPACT SIMULATIONS; DYNAMIC-RESPONSE; MODEL; DAMAGE; RECOVERY	The objective of this modeling and simulation study was to establish the role of stress wave interactions in the genesis of traumatic brain injury (TBI) from exposure to explosive blast. A high resolution (1 mm(3) voxels) five material model of the human head was created by segmentation of color cryosections from the Visible Human Female data set. Tissue material properties were assigned from literature values. The model was inserted into the shock physics wave code, CTH, and subjected to a simulated blast wave of 1.3 MPa (13 bars) peak pressure from anterior, posterior, and lateral directions. Three-dimensional plots of maximum pressure, volumetric tension, and deviatoric (shear) stress demonstrated significant differences related to the incident blast geometry. In particular, the calculations revealed focal brain regions of elevated pressure and deviatoric stress within the first 2 ms of blast exposure. Calculated maximum levels of 15 KPa deviatoric, 3.3 MPa pressure, and 0.8 MPa volumetric tension were observed before the onset of significant head accelerations. Over a 2 ms time course, the head model moved only 1 mm in response to the blast loading. Doubling the blast strength changed the resulting intracranial stress magnitudes but not their distribution. We conclude that stress localization, due to early-time wave interactions, may contribute to the development of multifocal axonal injury underlying TBI. We propose that a contribution to traumatic brain injury from blast exposure, and most likely blunt impact, can occur on a time scale shorter than previous model predictions and before the onset of linear or rotational accelerations traditionally associated with the development of TBI.	[Taylor, Paul A.] Sandia Natl Labs, Dept Penetrat Syst, Albuquerque, NM 87185 USA; [Ford, Corey C.] Univ New Mexico, Hlth Sci Ctr, Dept Neurol, Albuquerque, NM 87131 USA	Taylor, PA (corresponding author), Sandia Natl Labs, Dept Penetrat Syst, Albuquerque, NM 87185 USA.				United States Department of Energy's National Nuclear Security AdministrationNational Nuclear Security Administration [DE-AC04-94AL85000]	Sandia is a multiprogram laboratory operated by Sandia Corporation, a Lockheed Martin Co., for the United States Department of Energy's National Nuclear Security Administration under Contract No. DE-AC04-94AL85000. The authors would like to express their gratitude to Michael Dwyer, Director of Technical Imaging Development, Buffalo Neuroimaging Analysis Center (BNAC), Jacobs Neurological Institute, University at Buffalo, for segmenting the color cryosections for the head model used in this study. We would also like to thank Dr. M. E. Kipp for his insightful technical review of the manuscript.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Brennen C. E, 2003, 5 INT S CAV CAV2003, P1; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Carter D., 1985, BIOMECHANICS TRAUMA, P135; *CDCP, 2007, TRAUM BRAIN INJ US E; Courant R, 1928, MATH ANN, V100, P32, DOI 10.1007/BF01448839; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; FISCHER H, 2007, RS22452 LIB C; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V2; Gruss E, 2006, J TRAUMA, V60, P1284, DOI 10.1097/01.ta.0000220015.21948.ec; HERTEL ES, 1993, P 19 INT S SHOCK WAV, V1, P377; Hertel ES Jr, 1998, SAND980947 SAND NAT; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; KING AI, 1995, J NEUROTRAUM, V12, P651, DOI 10.1089/neu.1995.12.651; KING AI, 1993, ASME, V115, P582; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lapidus L, 1982, NUMERICAL SOLUTIONS; LUBOCK P, 1980, J BIOMECH, V13, P1041, DOI 10.1016/0021-9290(80)90048-2; Nahum A. M., 1977, P 21 STAPP CAR CRASH, P339; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; *NIH, 2007, VIS HUM PROJ; Nishimoto T, 2000, JSAE REV, V21, P117, DOI 10.1016/S0389-4304(99)00079-X; OMMAYA A K, 1968, Journal of Biomechanics, V1, P127, DOI 10.1016/0021-9290(68)90015-8; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; SHUCK LZ, 1972, ASME, V94, P905; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; STRICH SJ, 1961, LANCET, V2, P443; Suh CM, 2005, KEY ENG MATER, V297-300, P1333, DOI 10.4028/www.scientific.net/KEM.297-300.1333; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; TAYLOR P, 2007, SIMULATION EARLY TIM; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; ZHOU C, 1994, P 38 STAPP CAR CRASH, V38, P133; ZHOU C, 1995, STAPP CAR CRASH J, V39, P121; Zong Z, 2006, J BIOMECH, V39, P284, DOI 10.1016/j.jbiomech.2004.11.015	44	146	148	1	39	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	JUN	2009	131	6							061007	10.1115/1.3118765			11	Biophysics; Engineering, Biomedical	Biophysics; Engineering	445FO	WOS:000266035700007	19449961				2021-06-18	
J	Gioia, GA; Schneider, JC; Vaughan, CG; Isquith, PK				Gioia, G. A.; Schneider, J. C.; Vaughan, C. G.; Isquith, P. K.			Which symptom assessments and approaches are uniquely appropriate for paediatric concussion?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	3rd International Conference on Concussion in Sport	NOV, 2008	Zurich, SWITZERLAND				TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; HIGH-SCHOOL; POSTCONCUSSIVE SYMPTOMS; CLINICAL MEASURES; RECOVERY; PERFORMANCE; CHILDREN; IMPACT	Objective: To (a) identify post-concussion symptom scales appropriate for children and adolescents in sports; (b) review evidence for reliability and validity; and (c) recommend future directions for scale development. Design: Quantitative and qualitative literature review of symptom rating scales appropriate for children and adolescents aged 5 to 22 years. Intervention: Literature identified via search of Medline, Ovid-Medline and PsycInfo databases; review of reference lists in identified articles; querying sports concussion specialists. 29 articles met study inclusion criteria. Results: 5 symptom scales examined in 11 studies for ages 5-12 years and in 25 studies for ages 13-22. 10 of 11 studies for 5-12-year-olds presented validity evidence for three scales; 7 studies provided reliability evidence for two scales; 7 studies used serial administrations but no reliable change metrics. Two scales included parent-reports and one included a teacher report. 24 of 25 studies for 13-22 year-olds presented validity evidence for five measures; seven studies provided reliability evidence for four measures with 18 studies including serial administrations and two examining Reliable Change. Conclusions: Psychometric evidence for symptom scales is stronger for adolescents than for younger children. Most scales provide evidence of concurrent validity, discriminating concussed and non-concussed groups. Few report reliability and evidence for validity is narrow. Two measures include parent/teacher reports. Few scales examine reliable change statistics, limiting interpretability of temporal changes. Future studies are needed to fully define symptom scale psychometric properties with the greatest need in younger student-athletes.	[Gioia, G. A.; Schneider, J. C.; Vaughan, C. G.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Isquith, P. K.] Dartmouth Med Sch, Hanover, NH USA	Gioia, GA (corresponding author), Childrens Natl Med Ctr, 111 Michigan Ave NW, Washington, DC 20010 USA.	ggioia@cnmc.org	Isquith, Peter/AAY-4851-2020		NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [5-M01-RR-020359-02] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P30/HDO40677-07, U17/CCU323352-01] Funding Source: Medline		Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; BRUCE DA, 1984, BRIT MED J, V289, P715, DOI 10.1136/bmj.289.6447.715; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Conners C. K., 2008, CONNERS RATING SCALE; De Los Reyes A, 2005, PSYCHOL BULL, V131, P483, DOI 10.1037/0033-2909.131.4.483; DIVER T, 2007, J INT NEUROPSYCH S1, V13, P63; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Gioia G., 2008, BRAIN INJURY PROFESS, V4, P14; Gioia GA, 2008, J INT NEUROPSYCH SOC, V14, P204; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2004, STUD NEUROPSYCHOL DE, P323; JANUSZ J, BR J SPORTS IN PRESS; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Mailer BJ, 2008, J SPORT REHABIL, V17, P11, DOI 10.1123/jsr.17.1.11; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; *NAT COUNC YOUTH S, 2006, MARK RES; Parsons SK, 1999, INT J CANCER, P46; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schneider J, 2007, DEV NEUROREHABIL, V10, P282; Upton P, 2008, QUAL LIFE RES, V17, P895, DOI 10.1007/s11136-008-9350-5; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Vaughan C, 2008, J INT NEUROPSYCH S1, V14, P207; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	47	146	146	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2009	43			1			I13	I22		10.1136/bjsm.2009.058255			10	Sport Sciences	Sport Sciences	450YO	WOS:000266438100003	19433419				2021-06-18	
J	Gagnon, I; Galli, C; Friedman, D; Grilli, L; Iverson, GL				Gagnon, Isabelle; Galli, Carlo; Friedman, Debbie; Grilli, Lisa; Iverson, Grant L.			Active rehabilitation for children who are slow to recover following sport-related concussion	BRAIN INJURY			English	Article						Concussion; mild traumatic brain injury; paediatric; rehabilitation; sports	TRAUMATIC BRAIN-INJURY; VOLUNTARY EXERCISE; HIGH-SCHOOL; NEUROTROPHIC FACTOR; DEPRESSION; SYMPTOMS; PERSPECTIVE; PERFORMANCE; PLASTICITY; INCREASES	Primary objective: To present an innovative approach to the management of children who are slow to recover after a sport-related concussion. Research design: The article describes the underlying principles and the development of specific interventions for a new rehabilitation programme as well as preliminary data on pre- and post-rehabilitation changes in outcome measures. Methods and procedures: Development of the intervention was done using multiple perspectives including that of the literature, of experts in the field of traumatic brain injury and of experienced clinicians involved with the paediatric and adolescent MTBI clientele. A logic model was developed providing sound theoretical background to the intervention. The intervention was implemented and evaluated with a sample of 16 children and adolescents. Main outcomes and results: The presented cases suggest that involvement in controlled and closely monitored rehabilitation in the post-acute period may promote recovery in children and adolescents who present with atypical recovery following a concussion. All 16 of the children and adolescents who participated in the programme experienced a relatively rapid recovery and returned to their normal lifestyles and sport participation. Conclusions: A gradual, closely-supervised active rehabilitation programme in the post-acute period (i.e. after 1 month post-injury) appears promising to improve the care provided to children who are slow to recover.	[Gagnon, Isabelle] McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Trauma Programs, Montreal, PQ H3H 1P3, Canada; [Gagnon, Isabelle] McGill Univ, Montreal, PQ, Canada; [Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Iverson, Grant L.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada	Gagnon, I (corresponding author), McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Trauma Programs, C-833,2300 Tupper, Montreal, PQ H3H 1P3, Canada.	isabelle.gagnon8@mcgill.ca		Iverson, Grant/0000-0001-7348-9570			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bandura A., 1986, SOCIAL FDN THOUGHT A; Bandura A., 1997, SELF EFFICACY EXERCI; Bauman J, 2005, CLIN J SPORT MED, V15, P432, DOI 10.1097/01.jsm.0000186682.21040.82; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; BRUININKS BD, 2006, BRUININKSOSERETSKY T; *CAN PED SOC, 2006, PEDIAT CHILD HLTH, V11, P420; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Christie BR, 2008, NEUROMOL MED, V10, P47, DOI 10.1007/s12017-008-8033-2; DAVIS G, 2005, BRIT J SPORTS MED, V39; Duman RS, 2005, NEUROBIOL AGING, V26, pS88, DOI 10.1016/j.neurobiolaging.2005.08.018; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Gagnon I, 2004, J HEAD TRAUMA REHAB, V19, P391, DOI 10.1097/00001199-200409000-00004; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guskiewicz KM, 2006, BRIT J SPORT MED, V40, P6, DOI 10.1136/bjsm.2005.021683; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; IVERSON GL, 2006, BRAIN INJ C AM MIAM; Iverson GL, 2006, BRAIN INJURY MED PRI, P373; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Manuel JC, 2002, J ADOLESCENT HEALTH, V31, P391, DOI 10.1016/S1054-139X(02)00400-7; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Mead GE, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub3; Ministere de la sante et des services sociaux du Quebec & Societe d'assurance automobile du Quebec, 2005, OR MIN TRAUM CRAN LE; Nippert AH, 2008, PHYS MED REH CLIN N, V19, P399, DOI 10.1016/j.pmr.2007.12.003; Penninx BWJH, 2002, J GERONTOL B-PSYCHOL, V57, pP124, DOI 10.1093/geronb/57.2.P124; Pietropaolo S, 2008, BEHAV BRAIN RES, V192, P42, DOI 10.1016/j.bbr.2008.03.014; Podlog L, 2007, PSYCHOL SPORT EXERC, V8, P535, DOI 10.1016/j.psychsport.2006.07.008; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Theye Fred, 2004, Clin Med Res, V2, P165; Tracey J, 2003, J APPL SPORT PSYCHOL, V15, P279, DOI 10.1080/714044197; van Praag H, 2008, NEUROMOL MED, V10, P128, DOI 10.1007/s12017-008-8028-z; Vaynman S, 2005, NEUROREHAB NEURAL RE, V19, P283, DOI 10.1177/1545968305280753; Walker N, 2007, J R SOC PROMO HEALTH, V127, P174, DOI 10.1177/1466424007079494; Weinberg R.S., 2007, FDN SPORT EXERCISE P; Wiese-Bjornstal DM, 1998, J APPL SPORT PSYCHOL, V10, P46, DOI 10.1080/10413209808406377; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9	50	146	147	1	42	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	12					956	964		10.3109/02699050903373477			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	529YL	WOS:000272555200003	19831492				2021-06-18	
J	Yi, JH; Park, SW; Brooks, N; Lang, BT; Vemuganti, R				Yi, Jae-Hyuk; Park, Seung-Won; Brooks, Nathaniel; Lang, Bradley T.; Vemuganti, Rahu			PPAR gamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms	BRAIN RESEARCH			English	Article						Rosiglitazone; Brain trauma; Inflammation; Oxidative stress; Neuroprotection	PROLIFERATOR-ACTIVATED-RECEPTORS; TRANSIENT FOCAL ISCHEMIA; GENE-EXPRESSION; NEURONAL DAMAGE; INFLAMMATION; PIOGLITAZONE; STRESS; DYSFUNCTION; RECOVERY; DEATH	Peroxisome proliferator-activated receptor (PPAR)-gamma is a ligand-activated transcription factor of nuclear hormone receptor superfamily. Thiazolidinedione rosiglitazone is a potent agonist of PPAR gamma which was shown to induce neuroprotection in animal models of focal ischemia and spinal cord injury. We currently evaluated the therapeutic potential of rosiglitazone (6 mg/kg at 5 min, 6 h and 24 h; i.p.) following controlled cortical impact (CCI)-induced traumatic brain injury (TBI) in adult mice. CCI injury increased the cortical PPAR gamma mRNA levels which were further elevated by rosiglitazone treatment. In addition, rosiglitazone treatment significantly decreased the cortical lesion volume measured at 7 days compared to vehicle treatment (by 56 +/- 7%; p < 0.05; n=6/group). Following TBI, the spared cortex of the rosiglitazone group showed significantly less numbers of GSI-B4(+) activated microglia/macrophages and ICAM1(+) capillaries, and curtailed induction of pro-inflammatory genes IL6, MCP1 and ICAM1 compared to vehicle group. Rosiglitazone-treated mice also showed significantly less number of TUNEL+ apoptotic neurons and curtailed induction of caspase-3 and Bax, compared to vehicle control. in addition, rosiglitazone significantly enhanced the post-TBI expression of the neuroprotective chaperones HSP27, HSP70 and HSP32/HO1, and the anti-oxidant enzymes catalase, Cu/Zn-SOD and Mn-SOD, compared to vehicle. Treatment with GW9662 (a specific PPAR gamma antagonist) prevented all the above PPAR gamma-mediated actions. Thus, PPAR gamma activation confers neuroprotection after TBI by anti-inflammatory, anti-apoptotic and anti-oxidative mechanisms. (C) 2008 Elsevier B.V. All rights reserved.	[Yi, Jae-Hyuk; Park, Seung-Won; Brooks, Nathaniel; Lang, Bradley T.; Vemuganti, Rahu] Univ Wisconsin, Dept Neurol Surg, Madison, WI 53792 USA; [Park, Seung-Won] Chung Ang Univ, Dept Neurol Surg SP, Seoul 156756, South Korea	Vemuganti, R (corresponding author), Univ Wisconsin, Dept Neurol Surg, K4-8 Mail Code CSC 8660,600 Highland Ave, Madison, WI 53792 USA.	Vemugant@neurosurg.wisc.edu	Won, Park Seung/F-2877-2014	Won, Park Seung/0000-0001-8305-7501	United States National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS044173, RO1 NS049448]; American Heart AssociationAmerican Heart Association [0350164N]; University of Wisconsin; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS044173, R01NS049448] Funding Source: NIH RePORTER	These studies were partially supported by grants from the United States National Institute of Health (RO1 NS044173 and RO1 NS049448), the American Heart Association (Grant-in-Aid 0350164N) and the faculty start-up funds from the University of Wisconsin to R. Vemuganti.	Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0; Breidert T, 2002, J NEUROCHEM, V82, P615, DOI 10.1046/j.1471-4159.2002.00990.x; Collino M, 2006, EUR J PHARMACOL, V530, P70, DOI 10.1016/j.ejphar.2005.11.049; Dempsey RJ, 2003, J NEUROSURG, V98, P867, DOI 10.3171/jns.2003.98.4.0867; Dhodda VK, 2004, J NEUROCHEM, V89, P73, DOI 10.1111/j.1471-4159.2004.02316.x; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; Hyong A, 2008, BRAIN RES, V1215, P218, DOI 10.1016/j.brainres.2008.04.025; Jennings JS, 2008, MINI-REV MED CHEM, V8, P689, DOI 10.2174/138955708784567377; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kapadia R, 2006, J NEUROCHEM, V98, P1718, DOI 10.1111/j.1471-4159.2006.04056.x; Kelty JD, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-01-j0004.2002; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Park SW, 2007, J PHARMACOL EXP THER, V320, P1002, DOI 10.1124/jpet.106.113472; Pedersen WA, 2006, EXP NEUROL, V199, P265, DOI 10.1016/j.expneurol.2006.01.018; Pereira MP, 2006, J CEREBR BLOOD F MET, V26, P218, DOI 10.1038/sj.jcbfm.9600182; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Satriotomo I, 2006, J NEUROCHEM, V98, P1353, DOI 10.1111/j.1471-4159.2006.04051.x; Schutz B, 2005, J NEUROSCI, V25, P7805, DOI 10.1523/JNEUROSCI.2038-05.2005; Sood V, 2000, Diabetes Technol Ther, V2, P429, DOI 10.1089/15209150050194297; Sundararajan S, 2005, NEUROSCIENCE, V130, P685, DOI 10.1016/j.neuroscience.2004.10.021; Tureyen K, 2008, J NEUROCHEM, V105, P1313, DOI 10.1111/j.1471-4159.2008.05233.x; Tureyen K, 2007, J NEUROCHEM, V101, P41, DOI 10.1111/j.1471-4159.2006.04376.x; Vemuganti R, 2006, EUR J NEUROSCI, V23, P1172, DOI 10.1111/j.1460-9568.2006.04651.x; Victor NA, 2006, EUR J NEUROSCI, V24, P1653, DOI 10.1111/j.1460-9568.2006.05037.x; Yi JH, 2007, NEUROCHEM INT, V50, P1014, DOI 10.1016/j.neuint.2007.04.019; Zhao Y, 2005, EUR J NEUROSCI, V22, P278, DOI 10.1111/j.1460-9568.2005.04200.x; Zhao Y, 2006, FASEB J, V20, P1162, DOI 10.1096/fj.05-5007com	33	146	153	2	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 9	2008	1244						164	172		10.1016/j.brainres.2008.09.074			9	Neurosciences	Neurosciences & Neurology	384YH	WOS:000261779600017	18948087	Green Accepted			2021-06-18	
J	Alderfer, MA; Fiese, BH; Gold, JI; Cutuli, JJ; Holmbeck, GN; Goldbeck, L; Chambers, CT; Abad, M; Spetter, D; Patterson, J				Alderfer, Melissa A.; Fiese, Barbara H.; Gold, Jeffrey I.; Cutuli, J. J.; Holmbeck, Grayson N.; Goldbeck, Lutz; Chambers, Christine T.; Abad, Mona; Spetter, Dante; Patterson, Joaen			Evidence-based assessment in pediatric psychology: Family measures	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						assessment; evidence-based; family measurement; pediatric psychology	CHRONICALLY ILL CHILDREN; DYADIC ADJUSTMENT SCALE; SOCIAL ECOLOGICAL MODEL; TRAUMATIC BRAIN-INJURY; CLINICAL RATING-SCALE; OBSERVATIONAL ASSESSMENT; PARENTING STRESS; CYSTIC-FIBROSIS; ENVIRONMENT; PREDICTORS	ObjectiveTo provide a review of the evidence base of family measures relevant to pediatric psychology.MethodTwenty-nine family measures were selected based upon endorsement by Division 54 listserv members, expert judgment, and literature review. Spanning observational and self-report methods, the measures fell into three broad assessment categories: Family functioning, Dyadic family relationships, and Family functioning in the context of childhood chronic health conditions. Measures were categorized as: Well-established, Approaching well-established, or Promising.ResultsNineteen measures met well-established criteria and the remaining ten were approaching well-established. Well-established measures were documented for each of the broad assessment categories named above.ConclusionsMany measures deemed well-established in the general population are proving to be reliable and useful in pediatric samples. More evidence of the validity of family measures is needed in this context. This review should prove helpful to clinicians and researchers as they strive to make evidence-based decisions regarding family measures.	[Alderfer, Melissa A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Alderfer, Melissa A.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Fiese, Barbara H.] Syracuse Univ, Syracuse, NY 13244 USA; [Gold, Jeffrey I.] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA 90089 USA; [Holmbeck, Grayson N.; Abad, Mona] Loyola Univ, Chicago, IL 60611 USA; [Goldbeck, Lutz] Univ Hosp Ulm, Ulm, Germany; [Chambers, Christine T.] Dalhousie Univ, Halifax, NS B3H 3J5, Canada; [Chambers, Christine T.] IWK Hlth Ctr, Halifax, NS, Canada; [Spetter, Dante] Harvard Univ, Cambridge, MA 02138 USA; [Patterson, Joaen] Univ Minnesota, Minneapolis, MN 55455 USA	Alderfer, MA (corresponding author), Childrens Hosp Philadelphia, CHOP N Room 1485,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	alderfer@email.chop.edu	Cutuli, J. J./B-2806-2011; Chambers, Christine T./ABA-9257-2020	Cutuli, J. J./0000-0002-5185-2866; Chambers, Christine T./0000-0002-7138-916X; Holmbeck, Grayson/0000-0002-2216-1927; Fiese, Barbara/0000-0003-2935-8682			ALDERFER MA, 2006, PEDIAT HEMATOLOGY ON, P53; Aniol K, 2004, J DEV PHYS DISABIL, V16, P273, DOI 10.1023/B:JODD.0000032302.61601.99; ARMSDEN GC, 1987, J YOUTH ADOLESCENCE, V16, P427, DOI 10.1007/BF02202939; Atkins DC, 2005, J FAM PSYCHOL, V19, P98, DOI 10.1037/0893-3200.19.1.98; Barney MC, 2005, BRAIN INJURY, V19, P801, DOI 10.1080/02699050400024961; BEAVERS RW, 1990, SUCCESSFUL FAMILIES; Beavers RW, 2003, NORMAL FAMILY PROCES, P549; Berge J.M., 2006, Families, Systems,  Health, V24, P267, DOI [10.1037/1091-7527.24.3.267, DOI 10.1037/1091-7527.24.3.267]; Bingenheimer JB, 2005, J FAM PSYCHOL, V19, P441, DOI 10.1037/0893-3200.19.3.441; BOBROW ES, 1985, DIABETES CARE, V8, P146, DOI 10.2337/diacare.8.2.146; Brown RT, 2003, J TRAUMA STRESS, V16, P309, DOI 10.1023/A:1024465415620; BUSBY DM, 1995, J MARITAL FAM THER, V21, P289, DOI 10.1111/j.1752-0606.1995.tb00163.x; Cahill BM, 1996, AM J MENT RETARD, V101, P149; Chambless DL, 2001, ANNU REV PSYCHOL, V52, P685, DOI 10.1146/annurev.psych.52.1.685; COHEN L, 2008, J PEDIATR PSYCHOL, V33, P2; Cook WL, 2004, J FAM PSYCHOL, V18, P361, DOI 10.1037/0893-3200.18.2.361; Craddock A.E., 2001, J FAM STUD, V7, P29; Cuneo KM, 2002, J ADOLESCENT HEALTH, V31, P363, DOI 10.1016/S1054-139X(01)00324-X; DASHIFF C, 2005, FAMILIES SYSTEMS HLT, V23, P66, DOI DOI 10.1037/1091-7527.23.1.66; DeCato LA, 2002, CLIN PSYCHOL REV, V22, P833, DOI 10.1016/S0272-7358(01)00097-6; Dekovic M, 2005, J FAM ISSUES, V26, P467, DOI 10.1177/0192513X04272617; DeLambo KE, 2004, J PEDIATR PSYCHOL, V29, P343, DOI 10.1093/jpepsy/jsh038; Dickstein S, 1994, PROVIDENCE FAMILY ST; Drotar D, 1997, J PEDIATR PSYCHOL, V22, P149; Fiese B. H., 2006, MULTILEVEL DYNAMICS, P119; Fiese B. H., 1999, MONOGRAPHS SOC RES C, V64, P1, DOI [DOI 10.1111/1540-5834.00017, 10.1111/1540-5834.00017]; FIESE BH, HDB DEV BEH IN PRESS; Foster SL., 1989, NEGOTIATING PARENT A; Franklin C, 2001, RES SOCIAL WORK PRAC, V11, P576, DOI 10.1177/104973150101100503; FURMAN W, 1985, DEV PSYCHOL, V21, P1016, DOI 10.1037/0012-1649.21.6.1016; HAUSER ST, 1984, CHILD DEV, V55, P195, DOI 10.1111/j.1467-8624.1984.tb00284.x; Hofferth S.L., 2007, HDB MEASUREMENT ISSU; HOLAHAN CJ, 1982, AM J COMMUN PSYCHOL, V10, P403, DOI 10.1007/BF00893979; Holmes CS, 2006, J PEDIATR PSYCHOL, V31, P770, DOI 10.1093/jpepsy/jsj083; Hunsley J, 2001, AM J FAM THER, V29, P325, DOI 10.1080/01926180152588734; Janicke DM, 2005, J PEDIATR PSYCHOL, V30, P179, DOI 10.1093/jpepsy/jsi005; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; KAZAK AE, 1989, J CONSULT CLIN PSYCH, V57, P25, DOI 10.1037/0022-006X.57.1.25; Kazak AE, 1988, J FAMILY PSYCHOL, V2, P82, DOI DOI 10.1037/H0080475; Kazak AE, 2003, HDB PEDIAT PSYCHOL, P159; Kerig PK, 2001, FAMILY OBSERVATIONAL CODING SYSTEMS, P1; Krawetz P, 2001, J NERV MENT DIS, V189, P38, DOI 10.1097/00005053-200101000-00007; KRONENBERGER WG, 1990, J CLIN CHILD PSYCHOL, V19, P380, DOI 10.1207/s15374424jccp1904_10; Labay LE, 2004, J PEDIATR PSYCHOL, V29, P309, DOI 10.1093/jpepsy/jsh032; LANDIS JR, 1977, BIOMETRICS, V33, P174; Lindahl KM, 2001, FAMILY OBSERVATIONAL CODING SYSTEMS, P77; LOCKE HJ, 1959, MARRIAGE FAM LIVING, V21, P251, DOI 10.2307/348022; Maharaj S, 2001, J CONSULT CLIN PSYCH, V69, P950, DOI 10.1037//0022-006X.69.6.950; Maharaj SI, 1998, J PSYCHOSOM RES, V44, P479, DOI 10.1016/S0022-3999(97)00273-0; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, BRAIN INJURY, V12, P41; MCCUBBIN HI, 1983, J MARRIAGE FAM, V45, P359, DOI 10.2307/351514; McKernon WL, 2001, J PEDIATR PSYCHOL, V26, P41, DOI 10.1093/jpepsy/26.1.41; Melby JN, 2001, FAMILY OBSERVATIONAL CODING SYSTEMS, P33; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; Mitchell MJ, 2004, J DEV BEHAV PEDIATR, V25, P335, DOI 10.1097/00004703-200410000-00005; MOOS RH, 1990, FAM PROCESS, V29, P199, DOI 10.1111/j.1545-5300.1990.00199.x; Naar-King S, 2006, J CONSULT CLIN PSYCH, V74, P785, DOI 10.1037/0022-006X.74.4.785; Noojin AB, 1996, J PEDIATR PSYCHOL, V21, P483, DOI 10.1093/jpepsy/21.4.483; Nunnally J.C., 1978, PSYCHOMETRIC THEORY; Olson DH, 2003, NORMAL FAMILY PROCES, P514, DOI DOI 10.4324/9780203428436_CHAPTER_19; PATTERSON GR, 1969, MANUAL CODING FAMILY; Phares V, 2005, J PEDIATR PSYCHOL, V30, P631, DOI 10.1093/jpepsy/jsi050; Phipps S, 2005, J PEDIATR PSYCHOL, V30, P139, DOI 10.1093/jpepsy/jsi002; Raiha H, 2002, CHILD CARE HLTH DEV, V28, P419; Repetti RL, 2002, PSYCHOL BULL, V128, P330, DOI 10.1037/0033-2909.128.2.330; ROOSA MW, 1990, FAM PROCESS, V29, P191, DOI 10.1111/j.1545-5300.1990.00191.x; Rousey AM, 2002, RES DEV DISABIL, V23, P17, DOI 10.1016/S0891-4222(01)00089-0; SABOURIN S, 1990, J CONSULT CLIN PSYCH, V2, P333, DOI DOI 10.1037/1040-3590.2.3.333; Sanford K, 1999, PSYCHOL ASSESSMENT, V11, P315, DOI 10.1037/1040-3590.11.3.315; SCHAEFER ES, 1965, CHILD DEV, V36, P413, DOI 10.2307/1126465; SCHLUDER.E, 1970, J PSYCHOL, V76, P239, DOI 10.1080/00223980.1970.9916845; Schludermann S., 1988, QUESTIONNAIRE UNPUB; SHARPLEY CF, 1982, J MARRIAGE FAM, V44, P739, DOI 10.2307/351594; Skinner H, 2000, J FAM THER, V22, P190, DOI 10.1111/1467-6427.00146; Snyder DK, 1997, MANUAL MARITAL SATIS; SPANIER GB, 1976, J MARRIAGE FAM, V38, P15, DOI 10.2307/350547; Spieth LE, 2001, J PEDIATR PSYCHOL, V26, P215, DOI 10.1093/jpepsy/26.4.215; Stein REK, 2003, J DEV BEHAV PEDIATR, V24, P9, DOI 10.1097/00004703-200302000-00004; STEIN REK, 1980, MED CARE, V18, P465, DOI 10.1097/00005650-198004000-00010; Streisand R, 2003, CHILD HEALTH CARE, V32, P245, DOI 10.1207/S15326888CHC3204_1; Streisand R, 2001, J PEDIATR PSYCHOL, V26, P155, DOI 10.1093/jpepsy/26.3.155; Teachman JD, 2000, J MARRIAGE FAM, V62, P1234, DOI 10.1111/j.1741-3737.2000.01234.x; Trute B, 2002, J PEDIATR PSYCHOL, V27, P271, DOI 10.1093/jpepsy/27.3.271; Van Riper M., 2000, J FAM NURS, V6, DOI [https://doi.org/10.1177/107484070000600305, DOI 10.1177/107484070000600305]; Varni JW, 1996, J CHILD PSYCHOL PSYC, V37, P321, DOI 10.1111/j.1469-7610.1996.tb01409.x; Viikinsalo Michele K, 2005, J Spec Pediatr Nurs, V10, P69, DOI 10.1111/j.1744-6155.2005.0015a.x; WALKER JG, 1992, J PEDIATR PSYCHOL, V17, P345, DOI 10.1093/jpepsy/17.3.345; Wallin U, 1996, J FAM THER, V18, P397, DOI 10.1111/j.1467-6427.1996.tb00060.x; Walsh F., 2003, NORMAL FAMILY PROCES; Weiss KA, 2001, CHILD HEALTH CARE, V30, P67, DOI 10.1207/S15326888CHC3001_6	91	146	149	2	31	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	OCT	2008	33	9					1046	1061		10.1093/jpepsy/jsm083			16	Psychology, Developmental	Psychology	350CF	WOS:000259329400013	17905801	Green Published, Bronze			2021-06-18	
J	Levine, B; Kovacevic, N; Nica, EI; Cheung, G; Gao, F; Schwartz, ML; Black, SE				Levine, B.; Kovacevic, N.; Nica, E. I.; Cheung, G.; Gao, F.; Schwartz, M. L.; Black, S. E.			The Toronto traumatic brain injury study - Injury severity and quantified MRI	NEUROLOGY			English	Article							DIFFUSE AXONAL INJURY; PARTIAL LEAST-SQUARES; CLOSED-HEAD-INJURY; AUTOMATED IMAGE REGISTRATION; MAGNETIC-RESONANCE IMAGES; SPATIOTEMPORAL ANALYSIS; CORPUS-CALLOSUM; WHITE-MATTER; VALIDATION; SEGMENTATION	Objective: To assess the relationship between regional brain volume changes and traumatic brain injury (TBI) severity in patients with and without focal lesions. Methods: Sixty-nine chronic-phase TBI patients spanning the full range of severity were recruited from consecutive hospital admissions. Patients received high-resolution structural MRI a minimum of 1 year after injury. Multivariate statistical analyses assessed covariance patterns between volumes of gray matter, white matter, and sulcal/subdural and ventricular CSF across 38 brain regions and TBI severity as assessed by depth of coma at the time of injury. Patients with diffuse and diffuse plus focal injury were analyzed both separately and together. Results: There was a stepwise, dose-response relationship between parenchymal volume loss and TBI severity. Patients with moderate and severe TBI were differentiated from those with mild TBI, who were in turn differentiated from noninjured control subjects. A spatially extensive pattern of volume loss covaried with TBI severity, with particularly widespread effects in white matter volume and sulcal/subdural CSF. The most reliable effects were observed in the frontal, temporal, and cingulate regions, although effects were observed to varying degrees in nearly every brain region. Focal lesions were associated with greater volume loss in frontal and temporal regions, but volume loss remained marked even when analyses were restricted to patients with diffuse injury. Conclusions: Patterns of parenchymal volumetric changes can differentiate among levels of traumatic brain injury (TBI) severity, even in mild TBI. TBI causes a spatially extensive pattern of volume loss that reflects independent but overlapping contributions of focal and diffuse injury.	[Levine, B.; Kovacevic, N.; Nica, E. I.; Black, S. E.] Rotman Res Inst Baycrest, Baycrest Ctr Geriat Care, Toronto, ON M6A 2E1, Canada; [Levine, B.] Univ Toronto, Dept Psychol, Toronto, ON, Canada; [Levine, B.; Black, S. E.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Schwartz, M. L.] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Gao, F.; Black, S. E.] Sunnybrook Hlth Sci Ctr, Dept Diagnost Imaging & Radiol, L C Campbell Cognit Neurol Res Unit, Toronto, ON M4N 3M5, Canada; [Gao, F.; Black, S. E.] Sunnybrook Hlth Sci Ctr, Dept Med Neurol, L C Campbell Cognit Neurol Res Unit, Toronto, ON M4N 3M5, Canada; [Gao, F.; Black, S. E.] Sunnybrook Hlth Sci Ctr, Heart & Stroke Fdn Ctr Stroke Recovery, Toronto, ON M4N 3M5, Canada; [Schwartz, M. L.] Sunnybrook Hlth Sci Ctr, Dept Surg Neurosurg, Toronto, ON M4N 3M5, Canada; [Black, S. E.] Sunnybrook Hlth Sci Ctr, Dept Imaging Res, Toronto, ON M4N 3M5, Canada	Levine, B (corresponding author), Rotman Res Inst Baycrest, Baycrest Ctr Geriat Care, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	blevine@rotman-baycrest.on.ca	Black, Sandra E./C-7294-2011; Levine, Brian/G-4328-2010; Levine, Brian/O-2725-2019	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Black, Sandra/0000-0001-7093-8289	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD42385-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042385] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; AMDT S, 1991, PSYCHIAT RES-NEUROIM, V40, P79; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 1996, J LEARN DISABIL-US, V29, P515, DOI 10.1177/002221949602900507; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Collins DL, 1997, INT J PATTERN RECOGN, V11, P1271, DOI 10.1142/S0218001497000597; Courville C. B., 1937, PATHOLOGY CENTRAL 4; Dade LA, 2004, NEUROIMAGE, V22, P1492, DOI 10.1016/j.neuroimage.2004.03.023; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Edgington E. S., 1980, RANDOMIZATION TESTS; Feinstein A, 2004, NEUROLOGY, V62, P586, DOI 10.1212/01.WNL.0000110316.12086.0C; FUJIWARA E, IN PRESS NEUROPSYCHO; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; Gilboa A, 2005, HIPPOCAMPUS, V15, P535, DOI 10.1002/hipo.20090; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Itier RJ, 2004, PSYCHOPHYSIOLOGY, V41, P643, DOI 10.1111/j.1469-8986.2004.00183.x; Kovacevic N, 2005, CEREB CORTEX, V15, P639, DOI 10.1093/cercor/bhh165; Kovacevic N, 2002, NEUROIMAGE, V17, P1087, DOI 10.1006/nimg.2002.1221; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Lobaugh NJ, 2001, PSYCHOPHYSIOLOGY, V38, P517, DOI 10.1017/S0048577201991681; McIntosh AR, 1996, NEUROIMAGE, V3, P143, DOI 10.1006/nimg.1996.0016; McIntosh AR, 2004, NEUROIMAGE, V23, pS250, DOI 10.1016/j.neuroimage.2004.07.020; Morris R, 1999, J COMP NEUROL, V407, P183, DOI 10.1002/(SICI)1096-9861(19990503)407:2<183::AID-CNE3>3.0.CO;2-N; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; WASSERMAN S, 1989, PSYCHOPHYSIOLOGY, V26, P208, DOI 10.1111/j.1469-8986.1989.tb03159.x; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; WILSON J T L, 1990, Brain Injury, V4, P349; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P153, DOI 10.1097/00004728-199801000-00028; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027	47	146	149	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAR 4	2008	70	10					771	778		10.1212/01.wnl.0000304108.32283.aa			8	Clinical Neurology	Neurosciences & Neurology	271GE	WOS:000253776100006	18316688				2021-06-18	
J	Broglio, SP; Macciocchi, SN; Ferrara, MS				Broglio, Steven P.; Macciocchi, Stephen N.; Ferrara, Michael S.			Neurocognitive performance of concussed athletes when symptom free	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion; symptoms; ImPACT; return to play	SPORT-RELATED CONCUSSION; NEUROPSYCHOLOGICAL TEST PROTOCOL; COLLEGIATE FOOTBALL PLAYERS; COGNITIVE CHANGE; NCAA CONCUSSION; IMPACT; MANAGEMENT; RECOVERY; STABILITY; STATEMENT	Context. Concussed athletes may underreport concussion-related symptoms in order to expedite return to play. Whether neurocognitive impairments persist once concussion-related symptoms resolve has yet to be determined. Reliance on athlete-reported, postconcussion symptoms when making return-to-play decisions may expose athletes to subsequent injury if complete recovery has not occurred. Objective: To evaluate the presence of neurocognitive decrements in concussed athletes no longer reporting concussion-related symptoms. Design: Within-groups design. Setting: University research laboratory. Patients or Other Participants: Twenty-one National Collegiate Athletic Association Division I collegiate athletes (16 men, 5 women). Age = 19.81 +/- 1.25 years, height = 180.95 +/- 10.62 cm, mass = 93.66 +/- 27.60 kg, and previous concussions = 1.76 +/- 2.02. Main Outcome Measure(s): The ImPACT concussion assessment test was administered to concussed athletes at baseline, when symptomatic (within 72 hours of injury), and when asymptomatic. Index scores of verbal memory, visual memory, visual-motor speed, reaction time, and concussion-related symptoms were recorded at each session. The Symptom Assessment Scale was administered daily after injury to establish when the athlete became asymptomatic. Results: When assessed within 72 hours of concussion, 81% of the athletes showed deficits on at least 1 ImPACT variable. At the asymptomatic time point, 38% of the concussed athletes continued to demonstrate neurocognitive impairment on at least 1 ImPACT variable. Conclusions: Neurocognitive decrements may persist when athletes no longer report concussion-related symptoms. The exclusive use of symptom reports in making a return-to-play decision is not advised. A multifaceted approach to concussion assessment that includes evaluation of a myriad of functions is warranted.	[Broglio, Steven P.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Macciocchi, Stephen N.] Shepherd Ctr, Atlanta, GA USA; [Macciocchi, Stephen N.; Ferrara, Michael S.] Univ Georgia, Athens, GA 30602 USA	Broglio, SP (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, 906 S Goodwin Ave, Urbana, IL 61801 USA.	broglio@uiuc.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Collie A, 2003, BRIT J SPORT MED, V37, P370, DOI 10.1136/bjsm.37.4.370-a; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; IVERSON GL, 2003, ANN C INT NEUR SOC F; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Lovell M. R., 2002, Medicine & Science in Sports & Exercise, V34, pS298, DOI 10.1097/00005768-200205001-01680; Lovell MR, 2006, J ATHL TRAINING, V41, P137; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	35	146	146	0	26	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	OCT-DEC	2007	42	4					504	508					5	Sport Sciences	Sport Sciences	251AQ	WOS:000252343100010	18174938				2021-06-18	
J	Clark, ME; Bair, MJ; Buckenmaier, CC; Gironda, RJ; Walker, RL				Clark, Michael E.; Bair, Matthew J.; Buckenmaier, Chester C., III; Gironda, Ronald J.; Walker, Robyn L.			Pain and combat injuries in soldiers returning from Operations Enduring Freedom and Iraqi Freedom: Implications for research and practice	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						acute pain; chronic pain; combat injuries; pain assessment; polytrauma; postacute pain; regional anesthesia; rehabilitation; trauma; traumatic brain injury	PERIPHERAL-NERVE BLOCK; NURSING-HOME RESIDENTS; LOW-BACK-PAIN; RISK-FACTORS; ANESTHESIA; EXPERIENCE; CARE; FEAR; MANAGEMENT; CASUALTIES	Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) have resulted in a growing number of seriously injured soldiers who are evacuated to the United States for comprehensive medical care. Trauma-related pain is an almost universal problem among these war-injured soldiers, and several military and Department of Veterans Affairs initiatives have been implemented to enhance pain care across the continuum of medical services. This article describes several innovative approaches for improving the pain care provided to OEF and OIF military personnel during acute stabilization, transport, medical-surgical treatment, and rehabilitation and presents summary data characterizing the soldiers, pain management services provided, and associated outcomes. We also identify some of the pain assessment, classification, and treatment challenges emerging from work with this population and provide recommendations for future research and practice priorities.	James A Haley Vet Hosp, Chron Pain Rehabil Program, Tampa, FL 33612 USA; Univ S Florida, Tampa, FL USA; Richard L Roudebush Dept Vet Affairs Med Ctr, Ctr Excellence Implementing Evidence Based Practi, Indianapolis, IN USA; Walter Reed Army Med Ctr, Dept Anesthesiol, Washington, DC 20307 USA	Clark, ME (corresponding author), James A Haley Vet Hosp, Chron Pain Rehabil Program, 2CW,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	michael.clark8@va.gov		Buckenmaier III, Chester/0000-0003-3623-5525			Almogy G, 2004, ANN SURG, V239, P295, DOI 10.1097/01.sla.0000114014.63423.55; Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930; Barone F, 2005, REPROD BIOL ENDOCRIN, V3, P1, DOI 10.1186/1477-7827-3-13; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; Bouillon B, 1998, LANGENBECK ARCH SURG, V383, P228, DOI 10.1007/s004230050123; BRAGANZA RJ, 2002, MANUAL PAIN MANAGEME, P231; Branca B, 2004, J HEAD TRAUMA REHAB, V19, P40, DOI 10.1097/00001199-200401000-00005; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Buckenmaier CC, 2005, REGION ANESTH PAIN M, V30, P202, DOI 10.1016/j.rapm.2004.10.005; Buckenmaier CC, 2003, REGION ANESTH PAIN M, V28, P321, DOI 10.1016/S1098-7339(03)00198-6; Clark ME, 2004, PAIN MED, V5, P333, DOI 10.1111/j.1526-4637.2004.04059.x; Clark ME, 2006, WEINERS PAIN MANAGEM, P99; Closs SJ, 2004, J PAIN SYMPTOM MANAG, V27, P196, DOI 10.1016/j.jpainsymman.2003.12.010; Contreras-Diaz HG, 2006, CONSERV GENET, V7, P767, DOI 10.1007/s10592-005-9109-2; Crombez G, 1999, PAIN, V80, P329, DOI 10.1016/S0304-3959(98)00229-2; Davies Elizabeth, 2004, Nurs Stand, V19, P33; Dersh J, 2002, PSYCHOSOM MED, V64, P773, DOI 10.1097/01.PSY.0000024232.11538.54; Doan BK, 2005, AVIAT SPACE ENVIR MD, V76, pC34; EDWARDS W, 2001, BONICAS MANAGEMENT P, P788; Feldt K S, 1998, J Gerontol Nurs, V24, P14; Fritz JM, 2002, PHYS THER, V82, P973, DOI 10.1093/ptj/82.10.973; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Grant SA, 2001, REGION ANESTH PAIN M, V26, P209, DOI 10.1053/rapm.2001.22256; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; GREGORY J, 2004, J ORTHOPAEDIC NURSIN, V8, P91; Grissom Thomas E, 2005, Crit Care Med, V33, pS13, DOI 10.1097/01.CCM.0000151063.85112.5A; Hinsley DE, 2005, BRIT J SURG, V92, P637, DOI 10.1002/bjs.4911; International Association for the Study of Pain (IASP), 1986, PAIN S, V3, pS1, DOI DOI 10.1016/0304-3959(86)90106-5; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Klein SM, 2001, ANESTH ANALG, V93, P601, DOI 10.1097/00000539-200109000-00015; Kotwal RS, 2004, ANN EMERG MED, V44, P121, DOI 10.1016/j.annemergmed.2004.03.025; Machin P, 1998, CLIN J PAIN, V14, P290, DOI 10.1097/00002508-199812000-00004; Manz B D, 2000, Pain Manag Nurs, V1, P106, DOI 10.1053/jpmn.2000.19332; OSGOOD PF, 1990, ACUTE MANAGEMENT BUR, P201; Patel TH, 2004, J TRAUMA, V57, P201, DOI 10.1097/01.TA.0000133638.30269.38; Peoples GE, 2005, MIL MED, V170, P451, DOI 10.7205/MILMED.170.6.451; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; *REH ACCR COMM, 2002, STAND MAN MED REH; Savoia G, 2005, CURR DRUG TARGETS, V6, P755, DOI 10.2174/138945005774574461; Shipton EA, 2005, EUR J ANAESTH, V22, P405, DOI 10.1017/S0265021505000694; Sondenaa K, 2001, EUR J SURG, V167, P125; Stojadinovic A, 2006, PAIN MED, V7, P330, DOI 10.1111/j.1526-4637.2006.00171.x; Stolee P, 2005, J AM GERIATR SOC, V53, P319, DOI 10.1111/j.1532-5415.2005.53121.x; Szycher M, 1986, J Biomater Appl, V1, P274, DOI 10.1177/088532828600100205; THOMPSON GE, 1967, J AMER MED ASSOC, V201, P215; TROUWBORST A, 1987, INJURY, V18, P96, DOI 10.1016/0020-1383(87)90181-1; Tsai Pao-Feng, 2006, J Nurs Manag, V14, P90, DOI 10.1111/j.1365-2934.2006.00560.x; Vadivelu N, 2005, CURR OPIN ANESTHESIO, V18, P540, DOI 10.1097/01.aco.0000183109.27297.75; *VET HLTH ADM, 2005, VHA HDB 3I, P3; Veterans Health Administration, 2005, VHA HDB 2A, P1; Vlaeyen JWS, 2002, CLIN J PAIN, V18, P251, DOI 10.1097/00002508-200207000-00006; Wu N, 2005, MED CARE, V43, P934, DOI 10.1097/01.mlr.0000173595.66356.12; Zieber CG, 2005, INT J PALLIAT NURS, V11, P71, DOI 10.12968/ijpn.2005.11.2.17673	55	146	149	0	13	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2007	44	2					179	193		10.1682/JRRD.2006.05.0057			15	Rehabilitation	Rehabilitation	176NJ	WOS:000247091700006	17551872	Bronze			2021-06-18	
J	Emery, CA; Meeuwisse, WH				Emery, Carolyn A.; Meeuwisse, Willem H.			Injury rates, risk factors, and mechanisms of injury in minor hockey	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	Canadian Conference on Injury Prevention and Control	2005	Halifax, CANADA			child and adolescent; athletic injury; hockey	YOUTH ICE HOCKEY; BODY-CHECKING	Background: Hockey is one of the top sports for participation in youth in Canada. There are limited data on the epidemiology of injury in youth hockey. Purpose: Through implementation and validation of an injury surveillance system, youth ice hockey injury rates, risk factors, and mechanisms of injury will be examined. Study Design: Descriptive epidemiology study. Methods: During the 2004-2005 season in minor hockey in Calgary, Alberta, Canada, 71 hockey teams (N = 986) were studied, including teams from each age group (Atom, 9/10 years; Pee Wee, 11/12 years; Bantam, 13/14 years; Midget, 15/16 years) and division of play (7-10 divisions per age group). A certified athletic therapist or candidate did weekly assessments of any identified hockey injury. Injury definition included any injury occurring during the regular hockey season that required medical attention, removal from a session, or missing a subsequent session. Results: Of the 986 participating players, 216 players sustained a total of 296 injuries in the 2004-2005 season. The overall injury rate was 30.02 injuries per 100 players per season (95% confidence interval, 27.17-32.99) or 4.13 injuries per 1000 player hours (95% confidence interval, 3.67-4.62). Forty-five percent of all injuries occurred during body checking. Compared with the youngest age group, Atom, the risk of injury was greater in Pee Wee (relative risk, 2.97; 95% confidence interval, 1.63-5.8), Bantam (relative risk, 3.72; 95% confidence interval, 2.08-7.14), and Midget (relative risk, 5.43; 95% confidence interval, 3.14-10.17) leagues. The risk of injury in Pee Wee was greatest in the most elite divisions (relative risk, 2.45; 95% confidence interval, 1.15-5.81). Concussion, shoulder sprain/dislocation, and knee sprain were the most common injuries. Conclusion: Significant differences in injury rates were found by age and division of play. The public health significance of body checking injury in minor hockey is great. Future research will include expansion of surveillance to further examine body checking injuries and prevention strategies in minor hockey.	Univ Calgary, Fac Kinesiol, Roger Jackson Ctr Hlth & Wellness Res, Ctr Sports Med, Calgary, AB T2N 1N4, Canada	Emery, CA (corresponding author), Univ Calgary, Fac Kinesiol, Roger Jackson Ctr Hlth & Wellness Res, Ctr Sports Med, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	caemery@ucalgary.ca	Emery, Carolyn/AAI-2761-2020				Benson Brian W, 2005, Med Sport Sci, V49, P86, DOI 10.1159/000085393; BERNARD D, 1993, ASTM STP, V1212, P44; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; *CAN SPIN RES ORG, 2002, SMART HOCK; Emery CA, 2006, CLIN J SPORT MED, V16, P20, DOI 10.1097/01.jsm.0000184638.72075.b7; Emery CA, 2005, AM J SPORT MED, V33, P1882, DOI 10.1177/0363546505279576; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; *HOCK CAN, HOCK CAN ANN REP 200; Macpherson A, 2006, PEDIATRICS, V117, pE143, DOI 10.1542/peds.2005-1163; Marchie A, 2003, CAN MED ASSOC J, V169, P124; Meeuwisse WH, 1997, SPORTS MED, V24, P184, DOI 10.2165/00007256-199724030-00008; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; ROY MA, 1989, PHYSICIAN SPORTSMED, V17, P119, DOI 10.1080/00913847.1989.11709735; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; STUART MJ, 1995, MAYO CLIN PROC, V70, P350, DOI 10.4065/70.4.350; Stuart MJ, 2000, AM SOC TEST MATER, V1341, P19, DOI 10.1520/STP15224S; TATOR CH, 1984, CAN MED ASSOC J, V130, P875; Willer B, 2005, MED SCI SPORT EXER, V37, P1658, DOI 10.1249/01.mss.0000181839.86170.06	18	146	147	0	32	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2006	34	12					1960	1969		10.1177/0363546506290061			10	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	115ES	WOS:000242718200012	16861577				2021-06-18	
J	Biberthaler, P; Linsenmeier, U; Pfeifer, KJ; Kroetz, M; Mussack, T; Kanz, KG; Hoecherl, EFJ; Jonas, F; Marzi, I; Leucht, P; Jochum, M; Mutschler, W				Biberthaler, P; Linsenmeier, U; Pfeifer, KJ; Kroetz, M; Mussack, T; Kanz, KG; Hoecherl, EFJ; Jonas, F; Marzi, I; Leucht, P; Jochum, M; Mutschler, W			Serum S-100B concentration provides additional information for the indication of computed tomography in patients after minor head injury - A prospective multicenter study	SHOCK			English	Article						S-100B proteins; cranial computed tomography; minor head injury; clinical decision rules	TRAUMATIC BRAIN-INJURY; SERUM S-100B PROTEIN; PROGNOSTIC-FACTORS; CLINICAL UTILITY; S100B LEVELS; MARKER; DAMAGE; ALCOHOL; PREDICTORS; MANAGEMENT	Ninety percent of patients with minor head injury (MHI) who have cranial computed tomography (CCT) under the present clinical decision rules have normal scans. Serum concentrations of the astroglial protein S-100B were recently found to provide useful information, but these studies were too small to provide a statistically safe basis for changing the present rule. We have investigated whether S-100B concentrations in patients with MHl can provide additional information to improve indication of the need for an initial CCT scan. One thousand three hundred nine patients with MHI were enrolled in this prospective, multicenter study. All had a CCT scan to confirm diagnosis in accordance with the present clinical decision rules. S-100B was measured in serum samples obtained upon admission. Data were analyzed using contingency table and receiver operating characteristic curve and compared with those for healthy donors (n = 540) and with those for patients with moderate to severe head injury (n = 55). Of the 1309 patients studied, 93 exhibited trauma-relevant intracerebral lesions on the CCT scan (CCT+). With a cutoff limit of 0.10-mu g/L S-100B (95th percentile of values in healthy volunteers), CCT+ patients were identified with a sensitivity level of 99% (95% confidence interval, 96%-100%) and a specificity level of 30% (95% confidence interval, 29%-31%). Adding the measurement of S-100B concentration to the clinical decision rules for a CCT scan in patients with MHl could allow a 30% reduction in scans. A prospective study of the clinical value of S-100B measurement in such patients is now under way.	Univ Munich, Chirurg Klin & Poliklin Innenstadt, D-80336 Munich, Germany; Univ Munich, Inst Klin Radiol Innenstadt, D-80336 Munich, Germany; Stadt Krankenhaus, D-80804 Munich, Germany; Univ Frankfurt, Klinikum Med, D-60590 Frankfurt, Germany; Univ Frankfurt, Fachbereich Med, D-60590 Frankfurt, Germany; Chirurg Klin & Poliklin Innenstadt, Klin Chem & Klin Biochem Abt, D-80336 Munich, Germany	Biberthaler, P (corresponding author), Univ Munich, Chirurg Klin & Poliklin Innenstadt, Nussbaumstr 20, D-80336 Munich, Germany.	Peter.Biberthaler@med.uni-muenchen.de		Leucht, Philipp/0000-0002-8409-8513			*AM COLL SURG, 2004, ATLS ADV TRAUM LIF S, P181; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Biberthaler P, 2002, EUR J MED RES, V7, P164; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; LINSENMAIER U, 2000, EMERG RADIOL, V7, P177; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelinka LE, 2003, SHOCK, V19, P422, DOI 10.1097/01.shk.0000055345.58165.52; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rosengren David, 2004, Emerg Med Australas, V16, P195, DOI 10.1111/j.1742-6723.2004.00563.x; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Stein SC, 2000, NEW ENGL J MED, V343, P1570; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933; Zee CS, 1998, NEUROIMAG CLIN N AM, V8, P525; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	41	146	150	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1073-2322			SHOCK	Shock	MAY	2006	25	5					446	453		10.1097/01.shk.0000209534.61058.35			8	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	041EQ	WOS:000237436700004	16680008				2021-06-18	
J	Max, JE; Lansing, AE; Koele, SL; Castillo, CS; Bokura, H; Schachar, R; Collings, N; Williams, KE				Max, JE; Lansing, AE; Koele, SL; Castillo, CS; Bokura, H; Schachar, R; Collings, N; Williams, KE			Attention deficit hyperactivity disorder in children and adolescents following traumatic brain injury	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD INJURY; PSYCHIATRIC-DISORDERS; ADHD CHILDREN; RELIABILITY; PREVALENCE; INTERVIEW; DIAGNOSES; SCHEDULE; VALIDITY; SCALE	To better characterize pediatric psychopathology after neurological insult, secondary attention deficit hyperactivity disorder (SADHD)-or ADHD that develops after traumatic brain injury (TBI)-and its clinical and neuroimaging correlates were investigated. Outcome data were available for 118 children, ages 5 through 14 at the time of hospitalization following TBI (severe TBI n = 37; mild-moderate TBI n = 57) and orthopedic injury (n = 24). Standardized psychiatric, adaptive functioning, cognitive functioning, family functioning, and family psychiatric history assessments were conducted on all participants. Severity of injury and neuroimaging lesion assessments were conducted on TBI participants only. The diagnosis of SADHD was mutually exclusive with preinjury ADHD, which occurred in 13 of 94 TBI participants and 4 of 24 orthopedic injury participants. SADHD occur-red in 13 of 34 eligible participants with severe TBI but resolved in 4 of 13 of these participants. SADHD also occurred in I of 8 eligible moderate TBI participants, only in the presence of preinjury ADHD traits and 3 of 39 of eligible mild TBI cases. SADHD occurred in I of 20 of eligible participants with orthopedic injury without any brain injury. SADHD was significantly associated with TBI severity recorded by categorical and dimensional measures, intellectual and adaptive functioning deficits, and personality change due to TBI, but not with lesion area or location. These results suggest that SADHD is a clinically important syndrome after severe TBI in children and adolescents.	Childrens Hosp & Hlth Ctr, San Diego, CA 92123 USA; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Vet Hosp, San Diego, CA USA; Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Cedar Ctr, Cedar Rapids, IA USA; Yasugi Daiichi Hosp, Dept Neurol, Shimane, Japan; Hosp Sick Children, Brain & Behav Program, Inst Res, Toronto, ON M5G 1X8, Canada	Max, JE (corresponding author), Childrens Hosp & Hlth Ctr, 3020 Childrens Way,MC 5033, San Diego, CA 92123 USA.	jmax@ucsd.edu		Schachar, Russell/0000-0002-2015-4395	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K 08 MH01800] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; ARMSTRONG K, 2001, J INT NEUROPSYCH SOC, V7, P238; BIEDERMAN J, 1993, J CHILD PSYCHOL PSYC, V34, P1241, DOI 10.1111/j.1469-7610.1993.tb01785.x; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Damasio H., 1989, LESION ANAL NEUROPSY; FARAONE SV, 1995, J AM ACAD CHILD PSY, V34, P1001, DOI 10.1097/00004583-199508000-00009; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; KAUFMAN AS, 1991, J PSYCHOEDUC ASSESS, V9, P4, DOI 10.1177/073428299100900101; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KRAUS JF, 1987, PEDIATRICS, V79, P501; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1998, BRAIN INJURY, V12, P41; MCCUBBIN HI, 1980, FAMILY ASSESSMENT RE, P97; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; PLESS IB, 1995, PEDIATRICS, V95, P219; Sparrow S., 1984, VINELAND ADAPTIVE BE; SZATMARI P, 1989, J CHILD PSYCHOL PSYC, V30, P219, DOI 10.1111/j.1469-7610.1989.tb00236.x; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 1991, WECHSLER INTELLIGENC; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	36	146	146	1	24	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2004	25	1-2					159	177		10.1207/s15326942dn2501&2_9			19	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	774CG	WOS:000188961700009	14984333				2021-06-18	
J	Powell, J; Heslin, J; Greenwood, R				Powell, J; Heslin, J; Greenwood, R			Community based rehabilitation after severe traumatic brain injury: a randomised controlled trial	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							HOSPITAL ANXIETY; DEPRESSION SCALE; INTERRATER RELIABILITY; HEAD-INJURY; OUTCOMES; INDIVIDUALS; SERVICES; FIM+FAM; STROKE; CARE	Objective: Evaluation of multidisciplinary community based outreach rehabilitation after severe traumatic brain injury (TBI). Methods: A randomised controlled trial compared outreach treatment (mean of two sessions a week for 27.3 (SD 19.1) weeks) in community settings such as participants' homes, day centres, or workplaces, with provision of written information detailing alternative resources. Follow up for an average of 24.8 months after initial allocation was by a blinded independent assessor. Participants were aged 16-65, had sustained severe TBI between 3 months and 20 years previously, and had no other neurological conditions. Of 110 initially allocated, 48 outreach and 46 information participants were successfully followed up. Primary outcome measures (Barthel index (BI) and the brain injury community rehabilitation outcome-39 (BICRO-39)) focused on levels of activity and participation. Secondary measures were the functional independence measure and the functional assessment measure (FIM+FAM) and, in a subgroup of 46 participants, the hospital anxiety and depression scale. Analyses were non-parametric. Results: outreach participants were significantly more likely to show gains on the BI and the BICRO-39 total score and self organisation and psychological wellbeing subscales. There were likewise strong trends (p<0.10) for BICRO personal care and mobility, and on the FIM+FAM for personal care and cognitive functions. Differential improvements were not seen for indices of socialising, productive employment, anxiety, or depression. Median changes on individual subscales were small, reflecting the diversity of the clinical population; however, 40% of outreach but only 20% of information participants made a clinically significant improvement of 2+ points on at least one BICRO-39 scale. Time since injury was unrelated to the magnitude of gains. Conclusions: This is the first RCT of multidisciplinary community rehabilitation after severe TBI, and suggests that even years after injury it can yield benefits which outlive the active treatment period.	Univ London Goldsmiths Coll, Dept Psychol, London SE14 6NW, England; Homerton Hosp, Reg neurol Rehabil Unit, London E9 6SR, England	Powell, J (corresponding author), Univ London Goldsmiths Coll, Dept Psychol, Lewisham Way,New Cross, London SE14 6NW, England.						Alcott D, 1997, DISABIL REHABIL, V19, P355, DOI 10.3109/09638289709166551; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; BROOKS N, 1991, Brain Injury, V5, P103, DOI 10.3109/02699059109008082; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; Collin C, 1988, Int Disabil Stud, V10, P61; EDWARDS M, 1995, OCCUP THER J RES, V15, P103, DOI 10.1177/153944929501500203; FLEMINGER S, 1999, EVALUATION OUTCOMES; FREDERICKSON M, 1995, ARCH PHYS MED REHAB, V76, pSC5; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; JOHNSON G, 1995, ACTA PSYCHIAT SCAND, V91, P252, DOI 10.1111/j.1600-0447.1995.tb09778.x; MAHONEY F I, 1965, Md State Med J, V14, P61; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; Powell J, 1999, NEUROPSYCHOL REHABIL, V9, P457, DOI 10.1080/096020199389518; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Semlyen JK, 1996, J NEUROL REHABIL, V10, P251; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; STILWELL J, 1998, NATL TRAUMATIC BRAIN; Stilwell P, 1998, CLIN REHABIL, V12, P521, DOI 10.1191/026921598673761855; Stonnington HH, 1997, BRAIN INJURY, V11, P155, DOI 10.1080/026990597123755; Sutcliffe LM, 1998, CLIN REHABIL, V12, P506, DOI 10.1191/026921598672167702; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wade DT, 1992, MEASUREMENT NEUROLOG; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; Willer B, 1999, ARCH PHYS MED REHAB, V80, P399, DOI 10.1016/S0003-9993(99)90276-9; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	28	146	149	0	28	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2002	72	2					193	202		10.1136/jnnp.72.2.193			10	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	515AA	WOS:000173472200011	11796769	Bronze, Green Accepted, Green Published			2021-06-18	
J	Bramlett, HM; Dietrich, WD				Bramlett, HM; Dietrich, WD			Neuropathological protection after traumatic brain injury in intact female rats versus males or ovariectomized females	JOURNAL OF NEUROTRAUMA			English	Article						female; fluid percussion; histopathology; rats; traumatic brain injury	EXCITATORY AMINO-ACIDS; CEREBRAL BLOOD-FLOW; ESTROGENS ATTENUATE; EXPERIMENTAL STROKE; ESTRADIOL PROTECTS; ALZHEIMERS-DISEASE; CONTUSION INJURY; NMDA RECEPTORS; PROGESTERONE; 17-BETA-ESTRADIOL	An important consideration in traumatic brain injury (TBI) in females is the influence of hormones on recovery. Recent studies in both cerebral ischemia and TBI have demonstrated an attenuation in both damage and neurologic recovery following hormonal treatment. However, the ability of endogenous hormone levels to provide neuropathological protection after fluid percussion (FP) brain injury has not been studied. The purpose of this experiment was to determine whether endogenous circulating hormones in the female rat could provide neuroprotection compared to males and ovariectomized female animals. Sixty-four Sprague-Dawley rats underwent a moderate (1.7-2.2 atm) right parasagittal Fl? injury. Intact females (i.e., nonovariectomized) were subjected to injury either during the proestrous (TBI-FP, n = 18) phase of their cycle or nonproestrous (TBI-FNP, n = 19) phase. A separate group of females were ovariectomized (TBI-OVX, n = 10) 10 days prior to FP injury in order to reduce hormone levels. Male animals were also traumatized (TBI-M, n = 17). Appropriate sham controls (Sham-FP, n = 2; Sham-FNP, n = 2; Sham-OVX, n = 2; Sham-M, n = 2) also underwent all aspects of surgery except for the actual Fl? injury. All groups were sacrificed 3 days following TBI for analysis. Both intact female groups had significantly (p < 0.05) smaller cortical contusions compared to male animals. In addition to this finding, the TBI-FNP group was significantly (p < 0.04) different from the ovariectomized female animals. Ovariectomized rats had larger areas of damage compared to intact females. The TBI-OVX group's cortical contusion volume was similar to male animals. These results provide evidence for endogenous hormonal histopathological protection following parasagittal FP brain injury. The use of hormone therapy after TBI warrants continued exploration.	Univ Miami, Sch Med, Dept Neurol Surg, Neurotrauma Res Ctr, Miami, FL 33101 USA; Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL USA	Bramlett, HM (corresponding author), Univ Miami, Sch Med, Dept Neurol Surg, Neurotrauma Res Ctr, POB 016960,R-48, Miami, FL 33101 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline		Alkayed N. J., 1998, Society for Neuroscience Abstracts, V24, P517; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; COLBURN P, 1978, SCIENCE, V201, P817, DOI 10.1126/science.684408; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; EDWARDS DF, 1975, J PHYSIOL-LONDON, V248, P307; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farhat MY, 1996, BIOCHEM PHARMACOL, V51, P571, DOI 10.1016/S0006-2952(95)02159-0; Freeman ME., 1988, PHYSL REPROD, P1893; Fukuda K, 2000, STROKE, V31, P155, DOI 10.1161/01.STR.31.1.155; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GISCLARD V, 1988, J PHARMACOL EXP THER, V244, P19; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Green PS, 1996, NEUROSCI LETT, V218, P165, DOI 10.1016/S0304-3940(96)13148-7; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HURN PD, 1995, J CEREBR BLOOD F MET, V15, P666, DOI 10.1038/jcbfm.1995.82; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; MARMAROU A, 1985, BRAIN EDEMA, P88; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Pierce JES, 1996, J NEUROSCI, V16, P1083; Regan RF, 1997, BRAIN RES, V764, P133, DOI 10.1016/S0006-8993(97)00437-X; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; SANTAGATI S, 1994, J NEUROCHEM, V63, P2058; Shi J, 1998, BRAIN RES, V810, P87, DOI 10.1016/S0006-8993(98)00888-9; Singer CA, 1996, NEUROSCI LETT, V212, P13, DOI 10.1016/0304-3940(96)12760-9; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; SMITH SS, 1987, BRAIN RES, V400, P353, DOI 10.1016/0006-8993(87)90634-2; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Tannock GW, 1992, LACTIC ACID BACTERIA, P21; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; ZILLES L, 1985, CORTEX RAT STEREOTAX	59	146	150	0	7	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2001	18	9					891	900		10.1089/089771501750451811			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	471TP	WOS:000170945000005	11565601				2021-06-18	
J	Passineau, MJ; Green, EJ; Dietrich, WD				Passineau, MJ; Green, EJ; Dietrich, WD			Therapeutic effects of environmental enrichment on cognitive function and tissue integrity following severe traumatic brain injury in rats	EXPERIMENTAL NEUROLOGY			English	Article						memory; enriched environment; traumatic brain injury; behavior	CLOSED-HEAD-INJURY; FACTOR MESSENGER-RNA; NERVE GROWTH-FACTOR; HIPPOCAMPAL-LESIONS; SPATIAL MEMORY; LOCOMOTOR-ACTIVITY; CEREBRAL-ISCHEMIA; SOCIAL RECOVERY; VISUAL-CORTEX; YOUNG-RATS	Postinjury environmental enrichment (EE) has been shown to alter functional and anatomical outcomes in a number of injury paradigms, including traumatic brain injury (TBI), The question of whether EE alters functional outcome following TBI in a model which produces overt histopathological consequences has not been addressed. We investigated this question using the severe, parasagittal fluid percussion injury (FPI) model. Rats (n = 7 per group, enriched and standard for behavior; n = 15 per group for histology) underwent severe (2.2-2.6 atm) FPI, with sham-operated rats (n = 7 per group, enriched and standard for behavior; n = 6 enriched, n = 3 standard for histology) serving as controls. Animals were allowed to recover for 11 days either in standard single housing or together (injured and sham) in an enriched environment consisting of a 92 x 61 x 77-cm ferret cage filled with various stimulatory objects. Consistent with earlier reports, injured animals recovering in the enriched environment showed significantly (P < 0.05) shorter latencies to find the platform in a Morris Water Maze task versus injured/standard animals on day 12 post-TBI, However, both injured groups showed significant deficits versus sham groups (P < 0,05), There were no differences between the sham/enriched and sham/standard groups. No significant group differences in swim speed were observed. At 14 days post-TBI, enriched animals had approximately twofold smaller lesion areas in regions of the cerebral cortex posterior to the injury epicenter (-4,5, -5,8, -6.8 mm relative to bregma; P < 0.05) compared to injured/standard animals. In addition, overall lesion volume for the entire injured cortical hemisphere was significantly smaller in animals recovering in the enriched environment. These results indicate that noninvasive environmental stimulation is beneficial in attenuating cognitive deficits and preserving tissue integrity in a TBI model which causes cerebral contusion and cell death. <(c)> 2001 Academic Press.	Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Neurol, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Psychol, Miami, FL 33101 USA; Univ Miami, Sch Med, Program Neurosci, Miami, FL 33101 USA; Univ Miami, Sch Med, Neurotrauma Res Ctr, Miami, FL 33101 USA; Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33101 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33101 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER		Bland ST, 2000, STROKE, V31, P1144, DOI 10.1161/01.STR.31.5.1144; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Cassel JC, 1998, NEUROBIOL LEARN MEM, V69, P22, DOI 10.1006/nlme.1997.3807; Czeh B, 1998, HIPPOCAMPUS, V8, P647, DOI 10.1002/(SICI)1098-1063(1998)8:6<647::AID-HIPO7>3.3.CO;2-C; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; FINEMAN I, 1998, NEUROTRAUMA, V15, P868; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; GONZALEZLIMA F, 1994, DEV PSYCHOBIOL, V27, P343, DOI 10.1002/dev.420270603; Good M, 1997, BEHAV NEUROSCI, V111, P487, DOI 10.1037/0735-7044.111.3.487; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; JOHANSEN P, 1995, ARACHNE, V2, P324; Johansson BB, 1999, ACT NEUR S, V73, P51; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MOHAMMED AK, 1990, BRAIN RES, V528, P62, DOI 10.1016/0006-8993(90)90195-H; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MUNDY WR, 1988, NEUROTOXICOLOGY, V9, P511; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PAYLOR R, 1992, BEHAV BRAIN RES, V52, P49, DOI 10.1016/S0166-4328(05)80324-9; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Risedal A, 1999, J CEREBR BLOOD F MET, V19, P997, DOI 10.1097/00004647-199909000-00007; Schallert T, 1997, ADV NEUROL, V73, P229; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; StubleyWeatherly L, 1996, BRAIN RES, V716, P29, DOI 10.1016/0006-8993(95)01589-2; STUMMER W, 1994, STROKE, V25, P1862, DOI 10.1161/01.STR.25.9.1862; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; Torasdotter M, 1996, NEUROSCI LETT, V218, P107, DOI 10.1016/S0304-3940(96)13127-X; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; van Praag H, 1999, NAT NEUROSCI, V2, P266; Warburton EC, 1999, BEHAV BRAIN RES, V98, P27; WHISHAW IQ, 1984, BEHAV BRAIN RES, V11, P123, DOI 10.1016/0166-4328(84)90135-9; Yamaki T, 1997, BRAIN RES, V752, P151, DOI 10.1016/S0006-8993(96)01469-2; Young D, 1999, NAT MED, V5, P448; ZILLES K, 1985, STEREOTAXIC ATLAS	58	146	150	0	11	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	APR	2001	168	2					373	384		10.1006/exnr.2000.7623			12	Neurosciences	Neurosciences & Neurology	418RA	WOS:000167904100018	11259125				2021-06-18	
J	Gerring, JP; Brady, KD; Chen, A; Vasa, R; Grados, M; Bandeen-Roche, KJ; Bryan, RN; Denckla, MB				Gerring, JP; Brady, KD; Chen, A; Vasa, R; Grados, M; Bandeen-Roche, KJ; Bryan, RN; Denckla, MB			Premorbid prevalence of ADHD and development of secondary ADHD after closed head injury	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						closed head injury; attention-deficit hyperactivity disorder; personality change due to closed head injury	DEFICIT HYPERACTIVITY DISORDER; PRACTICAL SCALE; AMNESIA TEST; CHILDREN; ADOLESCENTS; ORIENTATION; TRAUMA; RISK; COMA	Objective: To determine premorbid prevalence of attention-deficit hyperactivity disorder (ADHD) in children with moderate and severe closed head injury (CHI), to determine incidence of ADHD 1 year after injury, and to characterize children who develop ADHD by demographic, neuropsychiatric, and outcome variables. Method: Ninety-nine children who had severe and moderate CHI were followed up for 1 year. Premorbid and 1-year postinjury psychiatric status were ascertained by parent and child structured interviews and questionnaires measuring affective lability, aggression, apathy, and social judgment. Results: Premorbid prevalence of ADHD was 0.20, significantly higher than in a reference population (0.045). Fifteen of the remaining 80 children (0.19) developed full ADHD criteria (except for age of onset) by the end of the first year. Children who developed secondary ADHD (S-ADHD) had significantly greater premorbid psychosocial adversity, posttraumatic affective lability and aggression, posttraumatic psychiatric comorbidity, and overall disability than children who did not develop S-ADHD. Conclusions: There is an excess prevalence of premorbid ADHD among children who present with moderate and severe CHI. Children with high psychosocial adversity are more likely to develop S-ADHD after CHI. S-ADHD has criteria in common with personality change due to CHI, a deficit in behavioral inhibition being the major overlapping feature.	Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA	Gerring, JP (corresponding author), Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.		Bryan, R. Nick/P-1661-2014	Grados, Marco/0000-0002-6189-6264	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR00052] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH-00997] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BARKLEY RA, 1993, PEDIATRICS, V92, P212; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; BENSON DF, 1975, PSYCHIAT ASPECTS NEU; BIEDERMAN J, 1995, ARCH GEN PSYCHIAT, V52, P464; BIEDERMAN J, 1993, J CHILD PSYCHOL PSYC, V34, P1241, DOI 10.1111/j.1469-7610.1993.tb01785.x; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Castellanos FX, 1997, CHILD ADOL PSYCH CL, V6, P383, DOI 10.1016/S1056-4993(18)30310-9; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gerring JP, 1996, PSYCHIAT RES, V63, P205, DOI 10.1016/0165-1781(96)02841-7; Gerson AC, 1996, PSYCHIAT RES, V65, P189, DOI 10.1016/S0165-1781(96)02851-X; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Last CG, 1996, J AM ACAD CHILD PSY, V35, P1502, DOI 10.1097/00004583-199611000-00019; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LISHMAN WA, 1978, ORGANIC PSYCHIAT PSY; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSNER AB, 1995, FUNDAMENTALS BIOSTAT; Rutter M., 1979, PRIMARY PREVENTION P, V3; Shaffer D, 1996, J AM ACAD CHILD PSY, V35, P865, DOI 10.1097/00004583-199607000-00012; Sparrow S., 1984, VINELAND ADAPTIVE BE; SZATMARI P, 1994, INT J METHOD PSYCH, V4, P231; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1989, MANUAL WECHSLER PRES; Wechsler D., 1981, WAIS R MANUAL WECHSL; Wechsler D., 1991, MANUAL WECHSLER INTE; WELNER Z, 1987, J AM ACAD CHILD PSY, V26, P649, DOI 10.1097/00004583-198709000-00007; WILSON J T L, 1990, Brain Injury, V4, P349; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	39	146	147	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0890-8567	1527-5418		J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	JUN	1998	37	6					647	654		10.1097/00004583-199806000-00015			8	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	ZR457	WOS:000073978700016	9628085				2021-06-18	
J	Walker, AE; Kollros, JJ; Case, TJ				Walker, A. Earl; Kollros, Jerry J.; Case, Theodore J.			THE PHYSIOLOGICAL BASIS OF CONCUSSION	JOURNAL OF NEUROSURGERY			English	Article							EXTINCTION		[Walker, A. Earl] Univ Chicago, Div Neurol Surg, Chicago, IL 60637 USA; Univ Chicago, Otho SA Sprague Mem Inst, Chicago, IL 60637 USA	Walker, AE (corresponding author), Univ Chicago, Div Neurol Surg, Chicago, IL 60637 USA.				Committee on Medical Research	The work described in this paper was done under a contract recommended by the Committee on Medical Research, between the Office of Scientific Research and Development and the University of Chicago.	Cannon WB, 1901, AM J PHYSIOL, V6, P91; Courville CB, 1942, ARCH SURG-CHICAGO, V45, P19, DOI 10.1001/archsurg.1942.01220010022002; Cushing H, 1901, B JOHNS HOPKINS HOSP, V12, P290; de Barenne JGD, 1939, J NEUROPHYSIOL, V2, P319; De No RL, 1938, J NEUROPHYSIOL, V1, P207; Denny-Brown D, 1940, J PHYSIOL-LONDON, V99, P153, DOI 10.1113/jphysiol.1940.sp003887; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DIXON KC, 1940, J GERONTOL B-PSYCHOL, V2, P360; Duret H, 1920, REV NEUROL-FRANCE, V36, P888; FELIZET G.-M., 1873, THESIS, P167; GOODWIN CRAIG W., 1941, YALE JOUR BIOL AND MED, V14, P101; GURDJIAN E. S., 1943, RES PUBL AS IN PRESS, P24; HOLBOURN AHS, 1943, J GERONTOL B-PSYCHOL, V2, P438; KOCHER T., 1901, NOTHNAGELS SPECIELLE, V9; Krems KD, 1942, P SOC EXP BIOL MED, V49, P73; Meyers R, 1941, J NEUROPHYSIOL, V4, P250; MILES A, 1892, BRAIN, V15, P153; PUDENZ R, 1943, M ASS RES NERV MENT; Ranson SB, 1930, AM J PHYSIOL, V94, P471; Rosenblueth A, 1942, AM J PHYSIOL, V135, P0690; Scott WW, 1940, ARCH NEURO PSYCHIATR, V43, P270, DOI 10.1001/archneurpsyc.1940.02280020078006; TROTTER W., 1924, J GERONTOL B-PSYCHOL, V1, P933; Webster JE, 1943, J NEUROPHYSIOL, V6, P255; White JC, 1943, ANN SURG, V119, P619, DOI 10.1097/00000658-194310000-00010; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223	25	146	149	1	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	1944	1	2					103	116		10.3171/jns.1944.1.2.0103			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	V25AG	WOS:000208450300003					2021-06-18	
J	Hutchinson, PJ; Jalloh, I; Helmy, A; Carpenter, KLH; Rostami, E; Bellander, BM; Boutelle, MG; Chen, JW; Claassen, J; Dahyot-Fizelier, C; Enblad, P; Gallagher, CN; Helbok, R; Hillered, L; Le Roux, PD; Magnoni, S; Mangat, HS; Menon, DK; Nordstrom, CH; O'Phelan, KH; Oddo, M; Barcena, JP; Robertson, C; Ronne-Engstrom, E; Sahuquillo, J; Smith, M; Stocchetti, N; Belli, A; Carpenter, TA; Coles, JP; Czosnyka, M; Dizdar, N; Goodman, JC; Gupta, AK; Nielsen, TH; Marklund, N; Montcriol, A; O'Connell, MT; Poca, MA; Sarrafzadeh, A; Shannon, RJ; Skjoth-Rasmussen, J; Smielewski, P; Stover, JF; Timofeev, I; Vespa, P; Zavala, E; Ungerstedt, U				Hutchinson, Peter J.; Jalloh, Ibrahim; Helmy, Adel; Carpenter, Keri L. H.; Rostami, Elham; Bellander, Bo-Michael; Boutelle, Martyn G.; Chen, Jeff W.; Claassen, Jan; Dahyot-Fizelier, Claire; Enblad, Per; Gallagher, Clare N.; Helbok, Raimund; Hillered, Lars; Le Roux, Peter D.; Magnoni, Sandra; Mangat, Halinder S.; Menon, David K.; Nordstroem, Carl-Henrik; O'Phelan, Kristine H.; Oddo, Mauro; Barcena, Jon Perez; Robertson, Claudia; Ronne-Engstroem, Elisabeth; Sahuquillo, Juan; Smith, Martin; Stocchetti, Nino; Belli, Antonio; Carpenter, T. Adrian; Coles, Jonathan P.; Czosnyka, Marek; Dizdar, Nil; Goodman, J. Clay; Gupta, Arun K.; Nielsen, Troels H.; Marklund, Niklas; Montcriol, Ambroise; O'Connell, Mark T.; Poca, Maria A.; Sarrafzadeh, Asita; Shannon, Richard J.; Skjoth-Rasmussen, Jane; Smielewski, Peter; Stover, John F.; Timofeev, Ivan; Vespa, Paul; Zavala, Elizabeth; Ungerstedt, Urban			Consensus statement from the 2014 International Microdialysis Forum	INTENSIVE CARE MEDICINE			English	Article						Brain chemistry; Microdialysis; Outcome; Subarachnoid hemorrhage; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; CEREBRAL PERFUSION-PRESSURE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; TIGHT GLYCEMIC CONTROL; SEVERE HEAD-INJURIES; INTRACEREBRAL MICRODIALYSIS; INTRACRANIAL-PRESSURE; METABOLIC DISTRESS; C-13-LABELED MICRODIALYSIS; SPREADING DEPOLARIZATIONS	Microdialysis enables the chemistry of the extracellular interstitial space to be monitored. Use of this technique in patients with acute brain injury has increased our understanding of the pathophysiology of several acute neurological disorders. In 2004, a consensus document on the clinical application of cerebral microdialysis was published. Since then, there have been significant advances in the clinical use of microdialysis in neurocritical care. The objective of this review is to report on the International Microdialysis Forum held in Cambridge, UK, in April 2014 and to produce a revised and updated consensus statement about its clinical use including technique, data interpretation, relationship with outcome, role in guiding therapy in neurocritical care and research applications.	[Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Cambridge CB2 0QQ, England; [Jalloh, Ibrahim; Helmy, Adel; Carpenter, Keri L. H.; Rostami, Elham; Bellander, Bo-Michael; Boutelle, Martyn G.; Chen, Jeff W.; Claassen, Jan; Dahyot-Fizelier, Claire; Enblad, Per; Gallagher, Clare N.; Helbok, Raimund; Hillered, Lars; Le Roux, Peter D.; Magnoni, Sandra; Mangat, Halinder S.; Menon, David K.; Nordstroem, Carl-Henrik; O'Phelan, Kristine H.; Oddo, Mauro; Barcena, Jon Perez; Robertson, Claudia; Ronne-Engstroem, Elisabeth; Sahuquillo, Juan; Smith, Martin; Stocchetti, Nino; Belli, Antonio; Carpenter, T. Adrian; Coles, Jonathan P.; Czosnyka, Marek; Dizdar, Nil; Goodman, J. Clay; Gupta, Arun K.; Nielsen, Troels H.; Marklund, Niklas; Montcriol, Ambroise; O'Connell, Mark T.; Poca, Maria A.; Sarrafzadeh, Asita; Shannon, Richard J.; Skjoth-Rasmussen, Jane; Smielewski, Peter; Stover, John F.; Timofeev, Ivan; Vespa, Paul; Zavala, Elizabeth; Ungerstedt, Urban] Univ Cambridge, Cambridge CB2 0QQ, England	Hutchinson, PJ (corresponding author), Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Box 167,Biomed Campus, Cambridge CB2 0QQ, England.	pjah2@cam.ac.uk; ij232@cam.ac.uk	Mangat, HALINDER/AAN-9153-2020; Helmy, Adel/AAS-3084-2020; Sahuquillo, Juan/B-3577-2008; Stocchetti, Nino/O-7444-2017; Claassen, Jan/AAA-5451-2020; Poca, Maria A./B-8475-2008; Timofeev, Ivan/AAE-7019-2019; Helbok, Raimund/AAA-8361-2021; Belli, Antonio/I-3799-2015; Oddo, Mauro/R-3370-2016; Nielsen, Troels Halfeld/G-3456-2015	Mangat, HALINDER/0000-0003-3426-2001; Helmy, Adel/0000-0002-0531-0556; Sahuquillo, Juan/0000-0003-0713-5875; Stocchetti, Nino/0000-0003-3250-6834; Poca, Maria A./0000-0002-3831-0536; Belli, Antonio/0000-0002-3211-9933; Oddo, Mauro/0000-0002-6155-2525; Hutchinson, Peter/0000-0002-2796-1835; Smielewski, Peter/0000-0001-5096-3938; Nielsen, Troels Halfeld/0000-0002-3943-8128; O'Connell, Mark/0000-0001-6272-8767; Carpenter, Keri/0000-0001-8236-7727; Timofeev, Ivan/0000-0002-1168-0393; Marklund, Niklas/0000-0002-9797-5626; czosnyka, marek/0000-0003-2446-8006	National Institute for Health Research (NIHR)National Institute for Health Research (NIHR); NIHR Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277 ID 98489]; Medical Research Council, Royal College of Surgeons of EnglandUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Wellcome Trust Dept Health Healthcare Innovation Challenge Fund [HICF-0510-080]; Swedish Research Council, VINNOVAVinnovaSwedish Research Council; Uppsala Berzelii Technology Centre for Neurodiagnostics; Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico; NIHRNational Institute for Health Research (NIHR); NIHR Cambridge Biomedical Research Centre (Neuroscience Theme), FP7 Program of the European Union; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; Novartis Foundation for Biomedical Research; Fondo de Investigacion Sanitaria (Instituto de Salud Carlos III) - European Regional Development [PI11/00700]; NIHR University College London Hospitals Biomedical Research Centre; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G1002277, G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, NIHR-RP-R3-12-013] Funding Source: researchfish	We gratefully acknowledge financial support for participants as follows: P.J.H.-National Institute for Health Research (NIHR) Professorship and the NIHR Biomedical Research Centre, Cambridge; I.J. Medical Research Council (G1002277 ID 98489); A. H.-Medical Research Council, Royal College of Surgeons of England; K.L.H.C.-NIHR Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme); M.G.B.-Wellcome Trust Dept Health Healthcare Innovation Challenge Fund (HICF-0510-080); L. H.-The Swedish Research Council, VINNOVA and Uppsala Berzelii Technology Centre for Neurodiagnostics; S. M.-Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico; D.K.M.-NIHR Senior Investigator Award to D.K.M., NIHR Cambridge Biomedical Research Centre (Neuroscience Theme), FP7 Program of the European Union; M. O.-Swiss National Science Foundation and the Novartis Foundation for Biomedical Research; J.S.-Fondo de Investigacion Sanitaria (Instituto de Salud Carlos III) (PI11/00700) co-financed by the European Regional Development; M.S.-NIHR University College London Hospitals Biomedical Research Centre; N. S.-Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico.	Adamides AA, 2009, J AM COLL SURGEONS, V209, P531, DOI 10.1016/j.jamcollsurg.2009.05.028; Agren-Wilsson A, 2003, J NEUROL NEUROSUR PS, V74, P217, DOI 10.1136/jnnp.74.2.217; Antunes AP, 2014, CRIT CARE, V18, DOI 10.1186/cc13916; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Berger C, 2002, STROKE, V33, P519, DOI 10.1161/hs0102.100878; Bhattacharjee R, 2006, Nano-Scale Materials: From Science to Technology, P321; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Carpenter KLH, 2014, EUR J PHARM SCI, V57, P87, DOI 10.1016/j.ejps.2013.12.012; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Charalambides C, 2010, CHILD NERV SYST, V26, P215, DOI 10.1007/s00381-009-1031-3; Chen HI, 2011, NEUROSURGERY, V69, P53, DOI 10.1227/NEU.0b013e3182191451; Chu JT, 2014, ANAL BIOANAL CHEM, V406, P7601, DOI 10.1007/s00216-014-8192-y; Clausen F, 2012, J NEUROTRAUM, V29, P766, DOI 10.1089/neu.2011.1754; Clausen T, 2005, J NEUROSURG, V103, P233, DOI 10.3171/jns.2005.103.2.0233; Dahlin AP, 2014, ANAL CHEM, V86, P8671, DOI 10.1021/ac501880u; Dahlin AP, 2010, ANAL CHEM, V82, P4376, DOI 10.1021/ac1007706; Dahyot-Fizelier C, 2010, ANTIMICROB AGENTS CH, V54, P3502, DOI 10.1128/AAC.01725-09; Dizdarevic K, 2012, CLIN NEUROL NEUROSUR, V114, P142, DOI 10.1016/j.clineuro.2011.10.005; Dohmen C, 2003, STROKE, V34, P2152, DOI 10.1161/01.STR.0000083624.74929.32; DURING MJ, 1993, LANCET, V341, P1607; Eide PK, 2010, J NEUROSURG, V112, P414, DOI [10.3171/2009.5.JNS09122, 10.3171/2009.5.09122]; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Helbok R, 2015, J NEUROL NEUROSUR PS, V86, P79, DOI 10.1136/jnnp-2013-307326; Helbok R, 2012, CRIT CARE, V16, DOI 10.1186/cc11880; Helbok R, 2010, NEUROCRIT CARE, V12, P317, DOI 10.1007/s12028-009-9327-4; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hillered L, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00245; Hillman J, 2006, ACTA NEUROCHIR, V148, P319, DOI 10.1007/s00701-005-0670-8; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; Hutchinson P, 2014, NEUROCRIT CARE, V21, P148, DOI 10.1007/s12028-014-0035-3; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Ibrahim MI, 2007, ASIAN J SURG, V30, P261, DOI 10.1016/S1015-9584(08)60036-6; Jalloh I, 2015, J CEREBR BLOOD F MET, V35, P111, DOI 10.1038/jcbfm.2014.177; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Kett-White R, 2002, J NEUROSURG, V96, P1013, DOI 10.3171/jns.2002.96.6.1013; Kinoshita K, 2010, J SURG RES, V162, P221, DOI 10.1016/j.jss.2009.06.009; Magnoni S, 2012, CRIT CARE MED, V40, P1785, DOI 10.1097/CCM.0b013e318246bd45; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; McNay EC, 2004, J NEUROSCI METH, V132, P35, DOI 10.1016/j.jneumeth.2003.08.014; Nagel A, 2009, NEUROCRIT CARE, V11, P384, DOI 10.1007/s12028-009-9269-x; Nagel A, 2009, J NEUROSURG, V111, P94, DOI 10.3171/2009.1.JNS08587; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P793, DOI 10.1111/aas.12092; Nikaina I, 2012, J CRIT CARE, V27, P83, DOI 10.1016/j.jcrc.2011.04.004; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Notkina N, 2012, BRIT J ANAESTH, V109, P155, DOI 10.1093/bja/aes216; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Oddo M, 2009, STROKE, V40, P1913, DOI 10.1161/STROKEAHA.108.534115; Oddo M, 2009, STROKE, V40, P1275, DOI 10.1161/STROKEAHA.108.527911; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Paraforou Theoniki, 2011, BMC Res Notes, V4, P540, DOI 10.1186/1756-0500-4-540; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Parkin MC, 2003, TRAC-TREND ANAL CHEM, V22, P487, DOI 10.1016/S0165-9936(03)00912-9; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Petzold A, 2011, BRAIN, V134, P464, DOI 10.1093/brain/awq360; Purins K, 2012, NEUROCRIT CARE, V16, P462, DOI 10.1007/s12028-012-9675-3; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Richards DA, 2003, PHARMACOL RES, V48, P101, DOI 10.1016/S1043-6618(03)00081-1; Rogers ML, 2013, ACS CHEM NEUROSCI, V4, P799, DOI 10.1021/cn400047x; RONNEENGSTROM E, 1992, J CEREBR BLOOD F MET, V12, P873, DOI 10.1038/jcbfm.1992.119; Rostami Elham, 2011, J Diabetes Sci Technol, V5, P596; Sakowitz OW, 2013, STROKE, V44, P220, DOI 10.1161/STROKEAHA.112.672352; Samuelsson C, 2009, ACTA NEUROCHIR, V151, P437, DOI 10.1007/s00701-009-0265-x; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Schlenk F, 2008, INTENS CARE MED, V34, P1200, DOI 10.1007/s00134-008-1044-5; Schlenk F, 2008, CRIT CARE, V12, DOI 10.1186/cc6776; Schmidt JM, 2012, CRIT CARE, V16, DOI 10.1186/cc11160; Schmidt JM, 2011, STROKE, V42, P1351, DOI 10.1161/STROKEAHA.110.596874; Schneweis S, 2001, STROKE, V32, P1863, DOI 10.1161/01.STR.32.8.1863; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Sen J, 2005, ACTA NEUROCHIR, V147, P897, DOI 10.1007/s00701-005-0526-2; Skjoth-Rasmussen J, 2004, J NEUROSURG, V100, P8, DOI 10.3171/jns.2004.100.1.0008; Skoglund K, 2014, NEUROCRIT CARE, V20, P413, DOI 10.1007/s12028-013-9876-4; Soukup J, 2002, NEUROL RES, V24, P161, DOI 10.1179/016164102101199710; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Stein NR, 2012, NEUROCRIT CARE, V17, P49, DOI 10.1007/s12028-012-9708-y; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stuart RM, 2010, NEUROCRIT CARE, V12, P188, DOI 10.1007/s12028-010-9330-9; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Tofteng F, 2002, HEPATOLOGY, V36, P1333, DOI 10.1053/jhep.2002.36944; Tolias CM, 2002, CHILD NERV SYST, V18, P368, DOI 10.1007/s00381-002-0623-y; UNGERSTEDT U, 1974, B SCHWEIZ AKAD MED, V30, P44; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Whitmore RG, 2012, J NEUROSURG, V116, P1106, DOI 10.3171/2012.1.JNS11962; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; Zetterling M, 2011, J NEUROSURG, V115, P66, DOI 10.3171/2011.3.JNS10899	112	145	149	2	17	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	SEP	2015	41	9					1517	1528		10.1007/s00134-015-3930-y			12	Critical Care Medicine	General & Internal Medicine	CQ0VD	WOS:000360314900001	26194024	Green Published, Other Gold			2021-06-18	
J	Lucas, S; Hoffman, JM; Bell, KR; Dikmen, S				Lucas, Sylvia; Hoffman, Jeanne M.; Bell, Kathleen R.; Dikmen, Sureyya			A prospective study of prevalence and characterization of headache following mild traumatic brain injury	CEPHALALGIA			English	Article						Posttraumatic headache (PTH); headache; traumatic brain injury (TBI); mild traumatic brain injury; migraine; probable migraine; tension-type headache; cervicogenic headache; secondary headache	POSTTRAUMATIC HEADACHE; CHRONIC PAIN; RATES; EPIDEMIOLOGY; CONCUSSION; SYMPTOMS; SOLDIERS	Background Headache is one of the most common and persistent symptoms following traumatic brain injury (TBI). The current study examines the prevalence and characteristics of headache following mild TBI (mTBI). Methods We prospectively enrolled 212 subjects within one week of mTBI who were hospitalized for observation or other system injuries in a single level 1 US trauma center and followed by telephone at three, six, and 12 months after injury for evaluation of headache. Headaches were classified according to ICHD-2 criteria as migraine, probable migraine, tension-type, cervicogenic, or unclassifiable headache. Results Subjects were 76% male and 75% white, and 58% were injured in vehicle-related crashes. A follow-up rate of 90% (190/212) occurred at 12 months post-injury. Eighteen percent (38/212) of subjects reported having a problem with headaches pre-injury while 54% (114/210) of subjects reported new or worse headaches compared to pre-injury immediately after injury, 62% (126/203) at three months, 69% (139/201) at six months, and 58% (109/189) at one year. Cumulative incidence was 91% (172/189) over one year. Up to 49% of headaches met criteria for migraine and probable migraine, followed by tension-type headaches (up to 40%). Age ( 60) was found to be a risk factor, but no significant difference was found in persistence of new or worse headache compared to pre-injury between males and females. More than one-third of the subjects reported persistent headache across all three follow-up time periods. Conclusions Headache after mTBI is very common and persistent across the first year after injury. Assertive, early treatment may be warranted to avoid chronicity and disability. Further research is needed to determine whether post-traumatic headache (PTH) responds to headache treatment used in the primary headache disorders and whether chronic PTH is preventable.	[Lucas, Sylvia] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Lucas, Sylvia; Hoffman, Jeanne M.; Bell, Kathleen R.; Dikmen, Sureyya] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Med, Seattle, WA 98195 USA; [Lucas, Sylvia; Dikmen, Sureyya] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA	Lucas, S (corresponding author), Univ Washington, Dept Neurol, Box 356097, Seattle, WA 98195 USA.	lucass@uw.edu		Bell, Kathleen/0000-0002-0928-2046	Department of Education, National Institute on Disability and Rehabilitation Research [H133G090022]	This study was funded by the Department of Education, National Institute on Disability and Rehabilitation Research, grant number H133G090022.	Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Castillo J, 1999, HEADACHE, V39, P190, DOI 10.1046/j.1526-4610.1999.3903190.x; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Jensen O K, 2001, Ugeskr Laeger, V163, P5029; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Lerman B, 2011, J NEUROTRAUM, V28, pA16; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lieba-Samal D, 2011, CEPHALALGIA, V31, P1618, DOI 10.1177/0333102411428954; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; Scher AI, 1998, HEADACHE, V38, P497, DOI 10.1046/j.1526-4610.1998.3807497.x; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; SILBERSTEIN SD, 1994, NEUROLOGY, V44, P6; STEWART WF, 1991, AM J EPIDEMIOL, V134, P1111, DOI 10.1093/oxfordjournals.aje.a116014; Stovner LJ, 2009, EUR J NEUROL, V16, P112, DOI 10.1111/j.1468-1331.2008.02363.x; Theeler BJ, 2012, HEADACHE, V52, P732, DOI 10.1111/j.1526-4610.2012.02112.x; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; von Elm E, 2007, EPIDEMIOLOGY, V18, P800, DOI 10.1097/EDE.0b013e3181577654; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x	28	145	145	1	15	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	FEB	2014	34	2					93	102		10.1177/0333102413499645			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	286SU	WOS:000329489800004	23921798				2021-06-18	
J	Silverberg, ND; Iverson, GL				Silverberg, Noah D.; Iverson, Grant L.			Is Rest After Concussion "The Best Medicine?": Recommendations for Activity Resumption Following Concussion in Athletes, Civilians, and Military Service Members	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; concussion; exercise; military; sports	TRAUMATIC BRAIN-INJURY; LOW-BACK-PAIN; BED REST; VESTIBULAR REHABILITATION; EARLY MOBILIZATION; HEAD-INJURY; NEUROCOGNITIVE PERFORMANCE; POSTCONCUSSION SYNDROME; ACTIVITY RESTRICTIONS; PSYCHOLOGICAL-FACTORS	Practice guidelines universally recommend an initial period of rest for people who sustain a sports-related concussion or mild traumatic brain injury (MTBI) in daily life or military service. This practice is difficult to reconcile with the compelling evidence that other health conditions can be worsened by inactivity and improved by early mobilization and exercise. We review the scientific basis for the recommendation to rest after MTBI, the challenges and potential unintended negative consequences of implementing it, and how patient management could be improved by refining it. The best available evidence suggests that complete rest exceeding 3 days is probably not helpful, gradual resumption of preinjury activities should begin as soon as tolerated (with the exception of activities that have a high MTBI exposure risk), and supervised exercise may benefit patients with persistent symptoms.	[Silverberg, Noah D.] Univ British Columbia, GF Strong Rehab Ctr, Vancouver, BC V5Z 1M9, Canada; [Silverberg, Noah D.] Univ British Columbia, Dept Med, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Iverson, Grant L.] Def & Vet Brain Injury Ctr, Washington, DC USA	Silverberg, ND (corresponding author), GF Strong Rehab Ctr, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.	noah.silverberg@vch.ca		Iverson, Grant/0000-0001-7348-9570	Vancouver Coastal Health Research Institute; BC Rehab Foundation; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); Alcohol Beverage Medical Research Council; Rehabilitation Research and Development Service of the US Department of Veterans AffairsUS Department of Veterans Affairs; AstraZeneca CanadaAstraZeneca; Lundbeck CanadaLundbeck Corporation	The Vancouver Coastal Health Research Institute provided salary support for Dr Silverberg but was in no way involved in the in the writing of the manuscript or the decision to submit it for publication.; Dr Silverberg receives funding from the Vancouver Coastal Health Research Institute and the BC Rehab Foundation. Dr Iverson has been reimbursed by the government, professional scientific bodies, and commercial organizations for discussing or presenting research relating to MTBI and sports-related concussion at meetings, scientific conferences, and symposiums. He has a clinical practice in forensic neuropsychology involving individuals who have sustained MTBIs. He has received honorariums for serving on research panels that provide scientific peer review of programs (eg, the Military Operational Medicine Research Program). He is a coinvestigator, collaborator, or consultant on grants funded by several organizations, including, but not limited to, the Canadian Institute of Health Research, Alcohol Beverage Medical Research Council, Rehabilitation Research and Development Service of the US Department of Veterans Affairs, AstraZeneca Canada, and Lundbeck Canada.	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Alla S, 2012, BRIT J SPORT MED, V46, P562, DOI 10.1136/bjsm.2010.081299; Alla S, 2010, J SCI MED SPORT, V13, P24, DOI 10.1016/j.jsams.2008.12.629; Allen C, 1999, LANCET, V354, P1229, DOI 10.1016/S0140-6736(98)10063-6; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; [Anonymous], 1942, Proc R Soc Med, V35, P601; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Battlemind Transition Office Proponency Office for Rehabilitation & Reintegration, 2011, CONC MTBI INF TIM IN, V2011; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bernhardt J, 2008, STROKE, V39, P390, DOI 10.1161/STROKEAHA.107.492363; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Clark LV, 2005, J MENTAL HLTH, V14, P237, DOI DOI 10.1080/09638230500136308; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Craig LE, 2010, STROKE, V41, P2632, DOI 10.1161/STROKEAHA.110.588244; Cumming TB, 2008, J REHABIL MED, V40, P609, DOI 10.2340/16501977-0226; Dahm KT, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007612.pub2; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; Deale A, 1998, J PSYCHOSOM RES, V45, P77, DOI 10.1016/S0022-3999(98)00021-X; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; Echemendia RJ, 2011, ARCH CLIN NEUROPSYCH; EDMONDS M, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003200.PUB2; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Fortney SM, 2011, COMPR PHYSIOL, P889; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gagnon I, 2009, J HEAD TRAUMA REHAB, V24, P355, DOI 10.1097/HTR.0b013e3181b97a4e; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hagen KB, 2005, SPINE, V30, P542, DOI 10.1097/01.brs.0000154625.02586.95; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Indredavik B, 1999, STROKE, V30, P917, DOI 10.1161/01.STR.30.5.917; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, MODIFYING BRIT COLUM; Iverson GL., PTSD MILD TRAUMATIC; Iverson GL, PEDIAT MILD TRAUMATI; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Krogh J, 2011, J CLIN PSYCHIAT, V72, P529, DOI 10.4088/JCP.08r04913blu; Landreville P, 2009, REHABIL PSYCHOL, V54, P315, DOI 10.1037/a0016572; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; LEVINE SA, 1951, AM HEART J, V42, P406, DOI 10.1016/0002-8703(51)90134-2; Lewinsohn PM, 1976, BEHAV MANAGEMENT ANX, P91; Lohnberg JA, 2007, J CLIN PSYCHOL MED S, V14, P113, DOI 10.1007/s10880-007-9062-y; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McDonnell MN, 2011, ARCH PHYS MED REHAB, V92, P1044, DOI 10.1016/j.apmr.2011.01.021; McLean SA, 2004, MED HYPOTHESES, V63, P653, DOI 10.1016/j.mehy.2004.03.022; McLeod TCV, 2010, ATHLET THER TODAY, V15, P1, DOI 10.1123/att.15.2.1; Mead GE, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub3; Menninger K, 1944, J AMER MED ASSOC, V125, P1087, DOI 10.1001/jama.1944.02850340013006; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Motor Accidents Authority New South Wales, 2008, GUID MILD TRAUM BRAI; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; PHILIPS HC, 1987, BEHAV RES THER, V25, P273, DOI 10.1016/0005-7967(87)90005-2; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Riley GA, 2010, NEUROPSYCHOL REHABIL, V20, P869, DOI 10.1080/09602011.2010.503041; Schnabel M, 2004, EMERG MED J, V21, P306, DOI 10.1136/emj.2003.010165; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Smorawinski J, 2001, J APPL PHYSIOL, V91, P249; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Soderlund A, 2000, CLIN REHABIL, V14, P457, DOI 10.1191/0269215500cr348oa; Solomon GS, 2007, J NEUROPSYCH CLIN N, V19, P195, DOI 10.1176/appi.neuropsych.19.2.195; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008; Teasell RW, 2010, PAIN RES MANAG, V15, P295, DOI 10.1155/2010/640164; The Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU, V2010; ThinkFirst Canada, 2011, RET PLAY GUID, V2011; US Department of Health and Human Services Centers for Disease Control and Prevention, 2011, FACTS CONC BRAIN INJ, V2011; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Veale D., 2008, ADV PSYCHIAT TREATME, V14, P29, DOI [10.1192/apt.bp.107.004051, DOI 10.1192/APT.BP.107.004051, DOI 10.1192/apt.bp.107.004051]; Verbunt JA, 2003, EUR J PAIN, V7, P9, DOI 10.1016/S1090-3801(02)00071-X; Vercoulen JHMM, 1998, J PSYCHOSOM RES, V45, P507, DOI 10.1016/S0022-3999(98)00023-3; Waddell G, 1997, BRIT J GEN PRACT, V47, P647; White PD, 2011, LANCET, V377, P823, DOI 10.1016/S0140-6736(11)60096-2; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Williamson GM, 2000, PL S SOC CL, P173; WILLIAMSON GM, 1994, J SOC BEHAV PERS, V9, P249; Winkelman C, 2009, AACN ADV CRIT CARE, V20, P254, DOI 10.1097/NCI.0b013e3181ac838d; Wipfli BM, 2008, J SPORT EXERCISE PSY, V30, P392, DOI 10.1123/jsep.30.4.392; Yardley L, 2001, J ANXIETY DISORD, V15, P107, DOI 10.1016/S0887-6185(00)00045-1; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578	112	145	145	0	45	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					250	259		10.1097/HTR.0b013e31825ad658			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900002	22688215				2021-06-18	
J	McGrath, RE; Mitchell, M; Kim, BH; Hough, L				McGrath, Robert E.; Mitchell, Matthew; Kim, Brian H.; Hough, Leaetta			Evidence for Response Bias as a Source of Error Variance in Applied Assessment	PSYCHOLOGICAL BULLETIN			English	Article						response bias; suppressor variables; moderating variables; employee selection; disability evaluation	TRAUMATIC BRAIN-INJURY; SOCIAL DESIRABILITY SCALES; MMPI-2 VALIDITY SCALES; WORD MEMORY TEST; SELF-DECEPTION; PERSONALITY MEASUREMENT; PERSONNEL-SELECTION; K-CORRECTION; PHYSIOLOGICAL-RESPONSES; IMPRESSION MANAGEMENT	After 100 years of discussion, response bias remains a controversial topic in psychological measurement The use of bias indicators in applied assessment is predicated on the assumptions that (a) response bias suppresses or moderates the criterion-related validity of substantive psychological indicators and (b) bias indicators are capable of detecting the presence of response bias To test these assumptions. we reviewed literature comprising investigations in which bias indicators were evaluated as suppressors or moderators of the validity of other indicators This review yielded only 41 studies across the contexts of personality assessment, workplace variables, emotional disorders, eligibility for disability, and forensic populations In the first two contexts, there were enough studies to conclude that support for the use of bias indicators was weak Evidence suggesting that random or careless responding may represent a biasing influence was noted, but this conclusion was based on a small set of studies Several possible causes for failure to support the overall hypothesis were suggested. including poor validity of bias indicators, the extreme base rate of bias, and the adequacy of the criteria In the other settings, the yield was too small to afford viable conclusions Although the absence of a consensus could be used to justify continued use of bias indicators in such settings, false positives have their costs, including wasted effort and adverse impact Despite many years of research, a sufficient justification for the use of bias indicators in applied settings remains elusive	[McGrath, Robert E.; Mitchell, Matthew] Fairleigh Dickinson Univ, Sch Psychol, Teaneck, NJ 07666 USA; [Kim, Brian H.] Occidental Coll, Dept Psychol, Los Angeles, CA USA; [Hough, Leaetta] Dunnette Grp Ltd, St Paul, MN USA	McGrath, RE (corresponding author), Fairleigh Dickinson Univ, Sch Psychol, T-WH1-01, Teaneck, NJ 07666 USA.						Aguinis H, 2005, J APPL PSYCHOL, V90, P94, DOI 10.1037/0021-9010.90.1.94; Aiken L.S., 1991, MULTIPLE REGRESSION; al'Absi M, 2000, INT J PSYCHOPHYSIOL, V37, P257, DOI 10.1016/S0167-8760(00)00108-2; Allen L.M., 1997, CARB 97 MANUAL COMPU; Alperin JJ, 1996, J PERS ASSESS, V67, P155, DOI 10.1207/s15327752jpa6701_12; Amador XF, 1998, INSIGHT AND PSYCHOSIS, P15; AMELANG M, 2002, PSYCHOL BEITR, V44, P24; ANDERSON CD, 1984, J APPL PSYCHOL, V69, P574, DOI 10.1037/0021-9010.69.4.574; Archer RP, 1998, J PERS ASSESS, V70, P87, DOI 10.1207/s15327752jpa7001_6; ARKES HR, 1981, J CONSULT CLIN PSYCH, V49, P323, DOI 10.1037/0022-006X.49.3.323; ARNOLD HJ, 1985, ACAD MANAGE J, V28, P955, DOI 10.2307/256249; Baer RA, 2002, PSYCHOL ASSESSMENT, V14, P16, DOI 10.1037/1040-3590.14.1.16; Barger SD, 2002, J PERS ASSESS, V79, P286, DOI 10.1207/S15327752JPA7902_11; Barger SD, 1997, J PERS SOC PSYCHOL, V73, P1118, DOI 10.1037/0022-3514.73.5.1118; Barrick MR, 1996, J APPL PSYCHOL, V81, P261, DOI 10.1037/0021-9010.81.3.261; Barthlow DL, 2002, ASSESSMENT, V9, P219, DOI 10.1177/1073191102009003001; Belli RF, 2000, APPL COGNITIVE PSYCH, V14, P295, DOI 10.1002/1099-0720(200007/08)14:4<295::AID-ACP646>3.0.CO;2-1; Ben-Porath Y. S., 1992, PSYCHOL ASSESSMENT, V4, P14, DOI DOI 10.1037/1040-3590.4.1.14; Bender SD, 2004, ARCH CLIN NEUROPSYCH, V19, P49, DOI 10.1016/S0887-6177(02)00165-8; Birkeland SA, 2006, INT J SELECT ASSESS, V14, P317, DOI 10.1111/j.1468-2389.2006.00354.x; Block J., 1965, CHALLENGE RESPONSE S; BORKENAU P, 1992, EUR J PERSONALITY, V6, P199, DOI 10.1002/per.2410060303; BORKENAU P, 1985, J RES PERS, V19, P44, DOI 10.1016/0092-6566(85)90036-4; Bowden SC, 2006, CLIN NEUROPSYCHOL, V20, P858, DOI 10.1080/13854040500246935; Buller D.B., 1994, STRATEGIC INTERPERSO, P191; Burns GN, 2006, RES ORGANIZ ANAL, P115; Butcher JN, 1997, J PERS ASSESS, V68, P385, DOI 10.1207/s15327752jpa6802_9; Butcher JN., 1989, MMPI 2 MINNESOTA MUL; CHAPLIN WF, 1991, J PERS, V59, P143, DOI 10.1111/j.1467-6494.1991.tb00772.x; CHRISTIANSEN ND, 1994, PERS PSYCHOL, V47, P847, DOI 10.1111/j.1744-6570.1994.tb01581.x; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cohen J., 2003, APPL MULTIPLE CORREL; Colby F., 1989, PSYCHOL ASSESSMENT J, V1, P142, DOI 10.1037/1040-3590.1.2.142; COLVIN CR, 1995, J PERS SOC PSYCHOL, V68, P1152, DOI 10.1037/0022-3514.68.6.1152; Cronbach LJ, 1946, EDUC PSYCHOL MEAS, V6, P475, DOI 10.1177/001316444600600405; CROWNE DP, 1960, J CONSULT PSYCHOL, V24, P349, DOI 10.1037/h0047358; Derakshan N, 1998, COGNITION EMOTION, V12, P697; DICKEN C, 1963, EDUC PSYCHOL MEAS, V23, P699, DOI 10.1177/001316446302300406; Dickersin K, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P11; DiStefano C, 2009, PERS INDIV DIFFER, V46, P309, DOI 10.1016/j.paid.2008.10.020; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Dudley NM, 2005, J PERS ASSESS, V85, P50, DOI 10.1207/s15327752jpa8501_05; DUNNETTE MD, 1962, PERS PSYCHOL, V15, P13, DOI 10.1111/j.1744-6570.1962.tb01843.x; DUNNIGAN JF, 1995, VICTORY DECENT DIRTY; Dunning David, 2004, Psychol Sci Public Interest, V5, P69, DOI 10.1111/j.1529-1006.2004.00018.x; Dwight SA, 2003, HUM PERFORM, V16, P1, DOI 10.1207/S15327043HUP1601_1; Dwyer CA, 1996, PSYCHOL ASSESSMENT, V8, P360, DOI 10.1037/1040-3590.8.4.360; Edens JF, 2006, PSYCHOL ASSESSMENT, V18, P220, DOI 10.1037/1040-3590.18.2.220; Edwards A., 1957, SOCIAL DESIRABILITY; Egloff B, 2003, PERS INDIV DIFFER, V35, P1697, DOI 10.1016/S0191-8869(02)00391-4; Ellingson JE, 2001, J APPL PSYCHOL, V86, P122, DOI 10.1037/0021-9010.86.1.122; Ellingson JE, 1999, J APPL PSYCHOL, V84, P155, DOI 10.1037/0021-9010.84.2.155; EVANS MG, 1985, ORGAN BEHAV HUM DEC, V36, P305, DOI 10.1016/0749-5978(85)90002-0; Exner J.E., 2002, RORSCHACH COMPREHENS, V1; Eysenck MW, 1999, ANXIETY STRESS COPIN, V12, P127, DOI 10.1080/10615809908248326; Fan JY, 2008, PERS INDIV DIFFER, V45, P790, DOI 10.1016/j.paid.2008.08.008; Fishbain DA, 2002, PAIN MED, V3, P39, DOI 10.1046/j.1526-4637.2002.02002.x; Fishbain DA, 1999, CLIN J PAIN, V15, P244, DOI 10.1097/00002508-199912000-00002; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; FRANCIS LJ, 1992, J PSYCHOL CHRISTIANI, V11, P255; Franklin CL, 2002, J PERS ASSESS, V79, P274, DOI 10.1207/S15327752JPA7902_10; Frazier PA, 2004, J COUNS PSYCHOL, V51, P115, DOI 10.1037/0022-0167.51.1.115; GEORGE DI, 1990, PUBLIC PERS MANAGE, V19, P175, DOI 10.1177/009102609001900206; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Glenton C, 2003, SOC SCI MED, V57, P2243, DOI 10.1016/S0277-9536(03)00130-8; Goffin RD, 2003, INT J SELECT ASSESS, V11, P340, DOI 10.1111/j.0965-075X.2003.00256.x; Gouvier WD, 2003, NEURO S B C, P405; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, J FORENSIC NEUROPSYC, V2, P97, DOI DOI 10.1300/J151V02N03_05; Green P., 1996, WORD MEMORY TEST USE; Greene, 2000, MMPI 2 INTERPRETIVE; Greiffenstein MF, 2008, ARCH CLIN NEUROPSYCH, V23, P801, DOI 10.1016/j.acn.2008.07.005; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P439, DOI 10.1016/j.acn.2006.06.004; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P534, DOI 10.1080/13854040802232690; Hamamura T, 2008, PERS INDIV DIFFER, V44, P932, DOI 10.1016/j.paid.2007.10.034; HAMILTON DL, 1968, PSYCHOL BULL, V69, P192, DOI 10.1037/h0025606; Handel M.I., 1989, MILITARY DECEPTION P; Hartshorne H., 1928, STUDIES NATURE CHARA, V1; Hathaway Starke, 1967, MINNESOTA MULTIPHASI; HEILBRUN AB, 1963, J CONSULT PSYCHOL, V27, P161, DOI 10.1037/h0042150; Hofmann W, 2005, EUR J PERSONALITY, V19, P25, DOI 10.1002/per.537; Hogan J, 2007, J APPL PSYCHOL, V92, P1270, DOI 10.1037/0021-9010.92.5.1270; Holden RR, 2007, CAN J BEHAV SCI, V39, P184, DOI 10.1037/cjbs2007015; Holden RR, 2008, PERS INDIV DIFFER, V44, P311, DOI 10.1016/j.paid.2007.08.012; HOLDEN RR, 1989, J CONSULT CLIN PSYCH, V57, P500, DOI 10.1037/0022-006X.57.4.500; Hough LM, 1998, HUM PERFORM, V11, P209, DOI 10.1207/s15327043hup1102&3_6; Hough LM, 2005, HUM PERFORM, V18, P373, DOI 10.1207/s15327043hup1804_4; HOUGH LM, 1990, J APPL PSYCHOL, V75, P581, DOI 10.1037/0021-9010.75.5.581; Hough LM, 2001, INT J SELECT ASSESS, V9, P152, DOI 10.1111/1468-2389.00171; JACKSON DN, 1970, CURRENT TOPICS CLIN, V2, P62; JAMNER LD, 1991, PSYCHOSOM MED, V53, P393, DOI 10.1097/00006842-199107000-00005; Johnson JA, 2004, MULTIVAR BEHAV RES, V39, P273, DOI 10.1207/s15327906mbr3902_6; KRIEDT PH, 1961, J APPL PSYCHOL, V45, P175, DOI 10.1037/h0041918; Kurtz JE, 2001, J PERS ASSESS, V76, P315, DOI 10.1207/S15327752JPA7602_12; Kurtz JE, 2008, PERS INDIV DIFFER, V45, P22, DOI 10.1016/j.paid.2008.02.012; La Freniere P., 1988, MACHIAVELLIAN INTELL, P238; Lalwani AK, 2009, J PERS SOC PSYCHOL, V96, P870, DOI 10.1037/a0014622; Lanyon R., 2004, AM J FORENSIC PSYCH, V22, P53; Lee S, 2002, J APPL PSYCHOL, V87, P1175, DOI 10.1037//0021-9010.87.6.1175; Li A, 2006, INT J SELECT ASSESS, V14, P131, DOI 10.1111/j.1468-2389.2006.00339.x; Logan DE, 2008, PAIN, V136, P366, DOI 10.1016/j.pain.2007.07.015; MacCallum RC, 2002, PSYCHOL METHODS, V7, P19, DOI 10.1037//1082-989X.7.1.19; Marshall MB, 2005, PSYCHOL ASSESSMENT, V17, P379, DOI 10.1037/1040-3590.17.3.379; Marston WM, 1917, J EXP PSYCHOL, V2, P117, DOI 10.1037/h0073583; Martocchio JJ, 1997, J APPL PSYCHOL, V82, P764, DOI 10.1037/0021-9010.82.5.764; MCCLELLAND GH, 1993, PSYCHOL BULL, V114, P376, DOI 10.1037/0033-2909.114.2.376; MCCRAE RR, 1986, J GERONTOL, V41, P390, DOI 10.1093/geronj/41.3.390; McCrae RR, 1998, J PERS, V66, P285, DOI 10.1111/1467-6494.00013; MCCRAE RR, 1989, PSYCHOSOM MED, V51, P58, DOI 10.1097/00006842-198901000-00006; MCCRAE RR, 1983, J CONSULT CLIN PSYCH, V51, P882, DOI 10.1037/0022-006X.51.6.882; McFarland LA, 2000, J APPL PSYCHOL, V85, P812, DOI 10.1037/0021-9010.85.5.812; McGrath RE, 2002, J PERS ASSESS, V79, P243, DOI 10.1207/S15327752JPA7902_08; McGrath RE, 1999, J PERS ASSESS, V73, P149, DOI 10.1207/S15327752JPA7302_1; McGrath RE, 2001, J PERS ASSESS, V77, P307, DOI 10.1207/S15327752JPA7702_12; McGrath RE, 2008, PERS INDIV DIFFER, V44, P1819, DOI 10.1016/j.paid.2008.01.015; MCKINLEY JC, 1948, J CONSULT PSYCHOL, V12, P20, DOI 10.1037/h0061377; Medoff D, 1999, BEHAV SCI LAW, V17, P409, DOI 10.1002/(SICI)1099-0798(199910/12)17:4<409::AID-BSL357>3.0.CO;2-N; Melamed S, 1996, PSYCHOSOM MED, V58, P500, DOI 10.1097/00006842-199609000-00012; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Meyer GJ, 1997, J PERS ASSESS, V68, P297, DOI 10.1207/s15327752jpa6802_5; MICHAELIS W, 1971, J GENET PSYCHOL, V118, P223, DOI 10.1080/00221325.1971.10532611; Millon T., 1997, MCMI 3 MANUAL; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Morey L. C., 1991, PERSONALITY ASSESSME; Morey LC, 2002, J PERS ASSESS, V79, P583, DOI 10.1207/S15327752JPA7903_11; Nelson NW, 2006, CLIN NEUROPSYCHOL, V20, P39, DOI 10.1080/13854040500459322; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; O'Connor BP, 2006, ADV PSY RES, V40, P39; Olson MA, 2007, PSYCHOL SCI, V18, P287, DOI 10.1111/j.1467-9280.2007.01890.x; Ones DS, 1996, J APPL PSYCHOL, V81, P660, DOI 10.1037/0021-9010.81.6.660; Ones DS, 1998, HUM PERFORM, V11, P245, DOI 10.1207/s15327043hup1102&3_7; Paulhus D. L., 1998, MANUAL BALANCED INVE; Paulhus DL, 1998, J PERS, V66, P1025, DOI 10.1111/1467-6494.00041; PAULHUS DL, 1984, J PERS SOC PSYCHOL, V46, P598, DOI 10.1037/0022-3514.46.3.598; Pauls CA, 2003, EMOTION, V3, P284, DOI 10.1037/1528-3542.3.3.284; Piedmont RL, 2000, J PERS SOC PSYCHOL, V78, P582, DOI 10.1037//0022-3514.78.3.582; Pinsoneault TB, 2007, PSYCHOL ASSESSMENT, V19, P159, DOI 10.1037/1040-3590.19.1.159; Reid-Seiser HL, 2001, PERS INDIV DIFFER, V31, P639, DOI 10.1016/S0191-8869(00)00168-9; Reynolds CR, 1998, CRIT ISS NE, P261; Robson SM, 2008, HUM PERFORM, V21, P89, DOI 10.1080/08959280701522155; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Rogers R, 1986, CONDUCTING INSANITY; Rogers R, 2008, PSYCHIAT PSYCHOL LAW, V15, P213, DOI 10.1080/13218710802014501; Rohling ML, 2010, CLIN NEUROPSYCHOL, V24, P119, DOI 10.1080/13854040903307243; RORER LG, 1965, PSYCHOL BULL, V63, P129, DOI 10.1037/h0021888; Rosse JG, 1998, J APPL PSYCHOL, V83, P634, DOI 10.1037/0021-9010.83.4.634; Sayer NA, 2004, PSYCHIAT SERV, V55, P589, DOI 10.1176/appi.ps.55.5.589; SCHACTER DL, 1986, BEHAVIORAL SCI LAW, V4, P47, DOI DOI 10.1002/BSL.2370040104; SCHMIT MJ, 1993, J APPL PSYCHOL, V78, P966, DOI 10.1037/0021-9010.78.6.966; Schmitt DP, 2005, J PERS SOC PSYCHOL, V89, P623, DOI 10.1037/0022-3514.89.4.623; Schmitt N, 2006, J APPL PSYCHOL, V91, P613, DOI 10.1037/0021-9010.91.3.613; Schwarz N, 2001, AM J EVAL, V22, P127, DOI 10.1177/109821400102200202; SHAPIRO D, 1995, PSYCHOPHYSIOLOGY, V32, P425, DOI 10.1111/j.1469-8986.1995.tb02093.x; SHEDLER J, 1993, AM PSYCHOL, V48, P1117, DOI 10.1037/0003-066X.48.11.1117; Smith DB, 2002, J APPL PSYCHOL, V87, P211, DOI 10.1037//0021-9010.87.2.211; Snell AF, 1999, HUM RESOUR MANAGE R, V9, P219, DOI 10.1016/S1053-4822(99)00019-4; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; STOKES GS, 1993, PERS PSYCHOL, V46, P739, DOI 10.1111/j.1744-6570.1993.tb01567.x; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; TAYLOR SE, 1994, PSYCHOL BULL, V116, P21, DOI 10.1037/0033-2909.116.1.21; TELLEGEN A, 1988, J PERS, V56, P621, DOI 10.1111/j.1467-6494.1988.tb00905.x; TOMAKA J, 1992, PERS SOC PSYCHOL B, V18, P616, DOI 10.1177/0146167292185012; Tombaugh TN, 1996, TEST MEMORY MALINGER; Viswesvaran C, 1999, EDUC PSYCHOL MEAS, V59, P197, DOI 10.1177/00131649921969802; Vogt DS, 2005, J PERS ASSESS, V84, P239, DOI 10.1207/s15327752jpa8403_03; Weed N, 1990, PSYCHOL ASSESSMENT J, V2, P281, DOI DOI 10.1037/1040-3590.2.3.281; WEINBERGER DA, 1979, J ABNORM PSYCHOL, V88, P369, DOI 10.1037/0021-843X.88.4.369; WOOTEN AJ, 1984, J CONSULT CLIN PSYCH, V52, P468, DOI 10.1037/0022-006X.52.3.468; Zaldivar F, 2009, EUR J PSYCHOL ASSESS, V25, P244, DOI 10.1027/1015-5759.25.4.244; Zickar MJ, 2004, ORGAN RES METHODS, V7, P168, DOI 10.1177/1094428104263674	170	145	148	1	44	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0033-2909	1939-1455		PSYCHOL BULL	Psychol. Bull.	MAY	2010	136	3					450	470		10.1037/a0019216			21	Psychology; Psychology, Multidisciplinary	Psychology	589ET	WOS:000277130000010	20438146				2021-06-18	
J	Lei, P; Li, YH; Chen, X; Yang, SY; Zhang, JN				Lei, Ping; Li, Yaohua; Chen, Xin; Yang, Shuyuan; Zhang, Jianning			Microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury	BRAIN RESEARCH			English	Article						Microarray; MicroRNA; Differential expression; Cerebral cortex; Traumatic brain injury	GENE-EXPRESSION; QUALITY-CONTROL; TARGETS; APOPTOSIS; INVASION; PLATFORM; CANCER; RNA; PCR	MicroRNAs (miRNAs) are very important regulators of biological processes such as development, cellular differentiation, and tumor generation. MiRNA microarray has been found to be a high throughput global analysis tool for detecting miRNA expression profiling, and miRNA expression profiling will facilitate the study of the biological function of miRNAs. In this report, we describe the miRNA expression level in rat cerebral cortex after traumatic brain injury using microarray method. We choose several time points post brain injury: 6 h, 24 h, 48 h and 72 h, respectively, to reveal differential expression of miRNAs in rat brain cortex compared with control groups. Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and S miRNAs were more than 2-fold down-regulated. Furthermore, we revealed global up-regulation of miR-21 expression within all the four time points post injury. Finally, we utilized qRT-PCR methods to verify the microarray results. The qRT-PCR results indicated good consistency with the results of the microarray method. Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course. (c) 2009 Elsevier B.V. All rights reserved.	[Lei, Ping; Li, Yaohua; Chen, Xin; Yang, Shuyuan; Zhang, Jianning] Tianjin Med Univ, Dept Neurosurg, Tianjin Neurol Inst, Gen Hosp,Lab TJIVR, Tianjin 300052, Peoples R China	Zhang, JN (corresponding author), Tianjin Med Univ, Dept Neurosurg, Tianjin Neurol Inst, Gen Hosp,Lab TJIVR, 154 Anshan Rd, Tianjin 300052, Peoples R China.	jianningzhang@hotmail.com			National 973 Projects of ChinaNational Basic Research Program of China [2005CB522604]; Tianjin Science and Technology Development Plan [05YFGDSF02500]; National Science FoundationNational Science Foundation (NSF) [30700865]	This work is supported by a National 973 Projects of China grant (2005CB522604), a Tianjin Science and Technology Development Plan grant (05YFGDSF02500), and a National Science Foundation grant (30700865).	Arikawa E, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-328; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Botling J, 2009, DIAGN MOL PATHOL, V18, P44, DOI 10.1097/PDM.0b013e3181857e92; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; CHENG Y, 2009, J MOL CELL CARDIOL; Chiu K, 2007, J VIS EXP, V269; Davis BN, 2009, J BIOL CHEM, V284, P3728, DOI 10.1074/jbc.M808788200; Ding W, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-32; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisenstein M, 2006, NATURE, V442, P1067, DOI 10.1038/4421067b; El Ouaamari A, 2008, DIABETES, V57, P2708, DOI 10.2337/db07-1614; Enright AJ, 2004, GENOME BIOL, V5; Fleige Simone, 2006, Molecular Aspects of Medicine, V27, P126, DOI 10.1016/j.mam.2005.12.003; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Grun D, 2005, PLOS COMPUT BIOL, V1, P51, DOI 10.1371/journal.pcbi.0010013; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hornstein E, 2005, NATURE, V438, P671, DOI 10.1038/nature04138; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Jeyaseelan K, 2008, STROKE, V39, P959, DOI 10.1161/STROKEAHA.107.500736; John Bino, 2006, V342, P101, DOI 10.1385/1-59745-123-1:101; Kajimoto K, 2006, RNA, V12, P1626, DOI 10.1261/rna.7228806; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Larsson O, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-129; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Mariani TJ, 2002, FASEB J, V16, P321, DOI 10.1096/fj.02-0351fje; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Pekarsky Y, 2006, CANCER RES, V66, P11590, DOI 10.1158/0008-5472.CAN-06-3613; Pickering C, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-97; Pillay NS, 2007, BRAIN RES, V1153, P158, DOI 10.1016/j.brainres.2007.03.056; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Ribaudo R, 2001, Curr Protoc Immunol, VChapter 10, DOI 10.1002/0471142735.im1011s04; Sayed D, 2008, MOL BIOL CELL, V19, P3272, DOI 10.1091/mbc.E08-02-0159; Sethupathy P, 2006, NAT METHODS, V3, P881, DOI 10.1038/NMETH954; Shai RM, 2008, FUTURE ONCOL, V4, P525, DOI 10.2217/14796694.4.4.525; Shi LM, 2008, CURR OPIN BIOTECH, V19, P10, DOI 10.1016/j.copbio.2007.11.003; Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239; Shilo S, 2007, DNA CELL BIOL, V26, P227, DOI 10.1089/dna.2006.0568; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thomson JM, 2004, NAT METHODS, V1, P47, DOI 10.1038/NMETH704; Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106; Wang WX, 2008, BBA-GENE REGUL MECH, V1779, P749, DOI 10.1016/j.bbagrm.2008.01.005; Watanabe T, 2005, FEBS LETT, V579, P318, DOI 10.1016/j.febslet.2004.11.067; Watanabe Y, 2007, METHOD ENZYMOL, V427, P65, DOI 10.1016/S0076-6879(07)27004-1; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhang ZY, 2008, LAB INVEST, V88, P1358, DOI 10.1038/labinvest.2008.94; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	59	145	158	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 11	2009	1284						191	201		10.1016/j.brainres.2009.05.074			11	Neurosciences	Neurosciences & Neurology	488PA	WOS:000269360700017	19501075				2021-06-18	
B	Beaulieu, C		JohansenBerg, H; Behrens, TEJ		Beaulieu, Christian			The Biological Basis of Diffusion Anisotropy	DIFFUSION MRI: FROM QUANTITATIVE MEASUREMENT TO IN VIVO NEUROANATOMY			English	Article; Book Chapter						Diffusion; anisotropy; myelin; DTI; water; diffusion tensor imaging; water; nerve; white matter; FA	SPINAL-CORD-INJURY; SUSCEPTIBILITY-INDUCED GRADIENTS; MULTIPLE-SCLEROSIS BRAIN; TRAUMATIC AXONAL INJURY; WHITE-MATTER PATHOLOGY; TENSOR IMAGING DETECTS; CENTRAL-NERVOUS-SYSTEM; DEVELOPING MOUSE-BRAIN; Q-SPACE DIFFUSION; MAGNETIC-RESONANCE	Anisotropic water diffusion in neural fibers such as nerve, white matter in spinal cord, or white matter in brain forms the basis for the utilization of diffusion tensor imaging (DTI) to track fiber pathways. The fact that water diffusion is sensitive to the underlying tissue microstructure provides a unique method of measuring the orientation and integrity of these neural fibers which may be useful in assessing a number of neurological disorders. The purpose of this chapter is to characterize the relationship of nuclear magnetic resonance measurements of water diffusion and its anisotropy (i.e. directional dependence) with the underlying microstructure of neural fibers. The emphasis will be on model neurological systems both in vitro and in vivo	Univ Alberta, Fac Med & Dent, Dept Biomed Engn, Edmonton, AB T6G 2V2, Canada	Beaulieu, C (corresponding author), Univ Alberta, Fac Med & Dent, Dept Biomed Engn, 1098 Res Transit Facil, Edmonton, AB T6G 2V2, Canada.						Agre P, 2004, NEUROSCIENCE, V129, P849, DOI 10.1016/j.neuroscience.2004.10.001; Andrews TJ, 2006, MAGN RESON MED, V56, P381, DOI 10.1002/mrm.20945; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; BEAULIEU C, 1994, MAGNET RESON MED, V31, P394, DOI 10.1002/mrm.1910310408; Beaulieu C, 1998, MAGN RESON IMAGING, V16, P1201, DOI 10.1016/S0730-725X(98)00151-9; Beaulieu C, 1996, MAGNET RESON MED, V36, P627, DOI 10.1002/mrm.1910360419; BEAULIEU C, 1994, MAGNET RESON MED, V32, P579, DOI 10.1002/mrm.1910320506; Beaulieu C, 1996, MAGNET RESON MED, V36, P39, DOI 10.1002/mrm.1910360108; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Berman JI, 2005, NEUROIMAGE, V27, P862, DOI 10.1016/j.neuroimage.2005.05.018; Biton IE, 2007, MAGN RESON MED, V58, P993, DOI 10.1002/mrm.21389; Biton IE, 2006, MAGN RESON IMAGING, V24, P161, DOI 10.1016/j.mri.2005.10.029; Brown A, 1990, SQUID EXPT ANIMALS, P235; Budde MD, 2008, NMR BIOMED, V21, P589, DOI 10.1002/nbm.1229; Budde MD, 2007, MAGN RESON MED, V57, P688, DOI 10.1002/mrm.21200; CHENEVERT TL, 1990, RADIOLOGY, V177, P401, DOI 10.1148/radiology.177.2.2217776; CHIEN D, 1990, J COMPUT ASSIST TOMO, V14, P514, DOI 10.1097/00004728-199007000-00003; Clark CA, 2001, MAGNET RESON MED, V45, P1126, DOI 10.1002/mrm.1149; Clark CA, 1999, J MAGN RESON, V141, P52, DOI 10.1006/jmre.1999.1872; CLEVELAND GG, 1976, BIOPHYS J, V16, P1043, DOI 10.1016/S0006-3495(76)85754-2; Concha L., 2008, P 16 ANN M INT SOC M, P566; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Conturo TE, 1999, P NATL ACAD SCI USA, V96, P10422, DOI 10.1073/pnas.96.18.10422; Deboy CA, 2007, BRAIN, V130, P2199, DOI 10.1093/brain/awm122; DERBYSHIRE W, 1975, FARADAY DISCUSS, V57, P243; DORAN M, 1990, J COMPUT ASSIST TOMO, V14, P865, DOI 10.1097/00004728-199011000-00001; Drobyshevsky A, 2005, J NEUROSCI, V25, P5988, DOI 10.1523/JNEUROSCI.4983-04.2005; Drobyshevsky A, 2007, J CEREBR BLOOD F MET, V27, P270, DOI 10.1038/sj.jcbfm.9600333; Dubois J, 2006, NEUROIMAGE, V30, P1121, DOI 10.1016/j.neuroimage.2005.11.022; Dubois J, 2008, HUM BRAIN MAPP, V29, P14, DOI 10.1002/hbm.20363; Duong TQ, 1998, MAGN RESON MED, V40, P1, DOI 10.1002/mrm.1910400102; Duong TQ, 2001, MAGN RESON MED, V45, P801, DOI 10.1002/mrm.1108; Ellegood J, 2006, MAGN RESON MED, V55, P1, DOI 10.1002/mrm.20777; Ellegood J, 2005, MAGN RESON MED, V53, P1025, DOI 10.1002/mrm.20427; FORD JC, 1994, MAGNET RESON MED, V31, P488, DOI 10.1002/mrm.1910310504; Ford JC, 1997, MAGNET RESON MED, V37, P387, DOI 10.1002/mrm.1910370315; Ford JC, 1998, JMRI-J MAGN RESON IM, V8, P775, DOI 10.1002/jmri.1880080405; GARRIDO L, 1994, CIRC RES, V74, P789, DOI 10.1161/01.RES.74.5.789; Gaviria M, 2006, NEUROBIOL DIS, V22, P694, DOI 10.1016/j.nbd.2006.01.011; Gilmore JH, 2007, AM J NEURORADIOL, V28, P1789, DOI 10.3174/ajnr.A0751; Guilfoyle DN, 2003, NMR BIOMED, V16, P77, DOI 10.1002/nbm.814; Gulani V, 2001, MAGNET RESON MED, V45, P191, DOI 10.1002/1522-2594(200102)45:2<191::AID-MRM1025>3.0.CO;2-9; Harada M, 2002, NMR BIOMED, V15, P69, DOI 10.1002/nbm.759; Harsan LA, 2006, J NEUROSCI RES, V83, P392, DOI 10.1002/jnr.20742; Harsan LA, 2007, J NEUROSCI RES, V85, P935, DOI 10.1002/jnr.21201; HENKELMAN RM, 1994, MAGNET RESON MED, V32, P592, DOI 10.1002/mrm.1910320508; Huang H, 2006, NEUROIMAGE, V33, P27, DOI 10.1016/j.neuroimage.2006.06.009; Huppi PS, 1998, PEDIATR RES, V44, P584; Hwang SN, 2003, MAGNET RESON MED, V50, P373, DOI 10.1002/mrm.10536; JOLESZ FA, 1987, RADIOLOGY, V164, P89, DOI 10.1148/radiology.164.1.3035608; Jones DK, 1999, MAGN RESON MED, V42, P37, DOI 10.1002/(SICI)1522-2594(199907)42:1<37::AID-MRM7>3.0.CO;2-O; Kim JH, 2006, NEUROBIOL DIS, V21, P626, DOI 10.1016/j.nbd.2005.09.009; Kim JH, 2007, MAGN RESON MED, V58, P253, DOI 10.1002/mrm.21316; Kinoshita Y, 1999, ENVIRON RES, V80, P348, DOI 10.1006/enrs.1998.3935; Kroenke CD, 2004, MAGN RESON MED, V52, P1052, DOI 10.1002/mrm.20260; Kroenke CD, 2004, NEUROCHEM INT, V45, P561, DOI 10.1016/j.neuint.2003.11.020; Larvaron P, 2007, NMR BIOMED, V20, P413, DOI 10.1002/nbm.1082; LATOUR LL, 1994, P NATL ACAD SCI USA, V91, P1229, DOI 10.1073/pnas.91.4.1229; Le Bihan D, 2007, PHYS MED BIOL, V52, pR57, DOI 10.1088/0031-9155/52/7/R02; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; LEBIHAN D, 1993, NEUROREPORT, V4, P887; LIAN J, 1994, J MAGN RESON SER A, V106, P65, DOI 10.1006/jmra.1994.1007; Loy DN, 2007, J NEUROTRAUM, V24, P979, DOI 10.1089/neu.2006.0253; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MACKAY A, 1994, MAGNET RESON MED, V31, P673, DOI 10.1002/mrm.1910310614; Mi S, 2007, NAT MED, V13, P1228, DOI 10.1038/nm1664; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mori S, 2001, MAGN RESON MED, V46, P18, DOI 10.1002/mrm.1155; Moseley M E, 1991, Top Magn Reson Imaging, V3, P50; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; Mottershead JP, 2003, J NEUROL, V250, P1293, DOI 10.1007/s00415-003-0192-3; Nair G, 2005, NEUROIMAGE, V28, P165, DOI 10.1016/j.neuroimage.2005.05.049; Neil JJ, 1998, RADIOLOGY, V209, P57, DOI 10.1148/radiology.209.1.9769812; Nicolay K, 2001, NMR BIOMED, V14, P94, DOI 10.1002/nbm.686; Norris DG, 2001, NMR BIOMED, V14, P77, DOI 10.1002/nbm.682; ONO J, 1995, BRAIN RES, V671, P141, DOI 10.1016/0006-8993(94)01335-F; Partridge SC, 2004, NEUROIMAGE, V22, P1302, DOI 10.1016/j.neuroimage.2004.02.038; Partridge SC, 2005, J MAGN RESON IMAGING, V22, P467, DOI 10.1002/jmri.20410; Pattany PM, 1997, AM J NEURORADIOL, V18, P1049; Peled S, 2007, IEEE T MED IMAGING, V26, P1448, DOI 10.1109/TMI.2007.906787; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; POSSE S, 1993, RADIOLOGY, V188, P719, DOI 10.1148/radiology.188.3.8351339; Prayer D, 1997, NEURORADIOLOGY, V39, P320, DOI 10.1007/s002340050416; Schmierer K, 2008, MAGN RESON MED, V59, P268, DOI 10.1002/mrm.21487; Schmierer K, 2007, NEUROIMAGE, V35, P467, DOI 10.1016/j.neuroimage.2006.12.010; SCHOENIGER JS, 1994, J MAGN RESON SER B, V103, P261, DOI 10.1006/jmrb.1994.1039; Schwartz ED, 2005, NEUROREPORT, V16, P73, DOI 10.1097/00001756-200501190-00017; Sehy JV, 2001, MAGNET RESON MED, V46, P900, DOI 10.1002/mrm.1275.abs; Sen PN, 2005, BIOPHYS J, V89, P2927, DOI 10.1529/biophysj.105.063016; Sen PN, 2005, MAGN RESON IMAGING, V23, P215, DOI 10.1016/j.mri.2004.11.014; Seo Y, 1999, MAGNET RESON MED, V42, P461, DOI 10.1002/(SICI)1522-2594(199909)42:3<461::AID-MRM8>3.0.CO;2-L; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sotak CH, 2004, NEUROCHEM INT, V45, P569, DOI 10.1016/j.neuint.2003.11.010; Stanisz GJ, 2003, ISRAEL J CHEM, V43, P33, DOI 10.1560/E0WU-7FFH-31M6-VLYT; Stanisz GJ, 1997, MAGNET RESON MED, V37, P103, DOI 10.1002/mrm.1910370115; Stanisz GJ, 2001, MAGN RESON MED, V45, P415, DOI 10.1002/1522-2594(200103)45:3<415::AID-MRM1054>3.0.CO;2-M; Sun SW, 2008, NEUROIMAGE, V40, P1, DOI 10.1016/j.neuroimage.2007.11.049; Sun SW, 2006, NEUROIMAGE, V32, P1195, DOI 10.1016/j.neuroimage.2006.04.212; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; Sun SW, 2005, MAGN RESON MED, V53, P1447, DOI 10.1002/mrm.20488; Sun SW, 2003, MAGN RESON MED, V50, P743, DOI 10.1002/mrm.10605; SZAFER A, 1995, MAGNET RESON MED, V33, P697, DOI 10.1002/mrm.1910330516; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; Takahashi M, 2002, P NATL ACAD SCI USA, V99, P16192, DOI 10.1073/pnas.252249999; Thomalla G, 2004, NEUROIMAGE, V22, P1767, DOI 10.1016/j.neuroimage.2004.03.041; THOMSEN C, 1987, ACTA RADIOL, V28, P353; TRUDEAU JD, 1995, J MAGN RESON SER B, V108, P22, DOI 10.1006/jmrb.1995.1098; TURNER R, 1990, RADIOLOGY, V177, P407, DOI 10.1148/radiology.177.2.2217777; Tyszka JM, 2006, NEUROIMAGE, V29, P1058, DOI 10.1016/j.neuroimage.2005.08.037; Upadhyay J, 2007, MAGN RESON MED, V58, P1045, DOI 10.1002/mrm.21372; Upadhyaya J, 2008, NEUROIMAGE, V39, P1, DOI 10.1016/j.neuroimage.2007.08.046; Werring DJ, 2000, J NEUROL NEUROSUR PS, V69, P269, DOI 10.1136/jnnp.69.2.269; WIMBERGER DM, 1995, J COMPUT ASSIST TOMO, V19, P28, DOI 10.1097/00004728-199501000-00005; WOESSNER DE, 1970, J COLLOID INTERF SCI, V34, P283, DOI 10.1016/0021-9797(70)90180-3; Wu QZ, 2007, NEUROIMAGE, V37, P1138, DOI 10.1016/j.neuroimage.2007.06.029; Zhang JY, 2003, NEUROIMAGE, V20, P1639, DOI 10.1016/S1053-8119(03)00410-5	123	145	146	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS			978-0-08-087851-5; 978-0-12-374709-9				2009							105	126		10.1016/B978-0-12-374709-9.00006-7			22	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	BCP49	WOS:000310964900008					2021-06-18	
J	Dutta, A; Gervey, R; Chan, F; Chou, CC; Ditchman, N				Dutta, Alo; Gervey, Robert; Chan, Fong; Chou, Chih-Chin; Ditchman, Nicole			Vocational Rehabilitation Services and Employment Outcomes for People with Disabilities: A United States Study	JOURNAL OF OCCUPATIONAL REHABILITATION			English	Article						Vocational rehabilitation; Employment; Rehabilitation	TRAUMATIC BRAIN-INJURY; FUNCTIONAL LIMITATIONS; MENTAL-ILLNESS; UNEMPLOYMENT; HEALTH; WORK; ACCEPTANCE; PREDICTORS; CLIENTS	Introduction This study examined the effect of vocational rehabilitation services on employment outcomes of people with sensory/communicative, physical, and mental impairments in the United States. Methods The sample frame includes 5,000 clients for each of the three disability groups whose cases were closed as either rehabilitated or not rehabilitated by state vocational rehabilitation agencies in the fiscal year 2005. The dependent variable is employment outcome. The predictor variables include a set of personal history variables and vocational rehabilitation service variables. Results Sixty-two percent of the clients in this study were gainfully employed after receiving vocational rehabilitation services. Individuals with sensory/communicative impairments had the highest success rate (75%) compared to 56% for the physical impairments group and 55% for those with mental impairments. Logistic regression analyses identified job placement, on-the-job support, maintenance, and other services (e.g., medical care for acute conditions) as significant predictors of employment success across all impairment groups. In addition, diagnostic and treatment (D&T) services (odds ratio [OR] = 1.57; 95% CI: 1.35-1.82) and rehabilitation technology services (OR = 1.97, 95% CI: 1.67-2.33) were found to uniquely contribute to employment outcomes for the sensory impairments group as well as the physical impairments group (D&T services: OR = 1.31, 95% CI: 1.15-1.48; RT services: OR = 1.41, 95% CI: 1.13-1.75), but not the mental impairments group. Substantial counseling was associated with employment outcomes for the physical (OR = 1.16, 95% CI: 1.02-1.32) and mental impairments groups (OR = 1.18, 95% CI: 1.03-1.35). Miscellaneous training (OR = 1.31; 95% CI: 1.09-1.49) was specifically associated with employment outcomes of the mental impairments group. Conclusion This study provides some empirical support documenting the association between vocational rehabilitation services and employment outcomes of people with disabilities.	[Dutta, Alo] Southern Univ, Dept Rehabil & Disabil Studies, Baton Rouge, LA 70813 USA; [Gervey, Robert; Chan, Fong; Ditchman, Nicole] Univ Wisconsin, Dept Rehabil Psychol & Special Educ, Madison, WI 53706 USA; [Chan, Fong] Univ Wisconsin, Stout Vocat Rehabil Inst, Stout, WI USA; [Chou, Chih-Chin] Univ Arizona, Dept Special Educ Rehabil & Sch Psychol, Tucson, AZ USA	Dutta, A (corresponding author), Southern Univ, Dept Rehabil & Disabil Studies, 229 AC Blanks Hall, Baton Rouge, LA 70813 USA.	alodutta1992@aol.com			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [#H133A031705] Funding Source: Medline		ATKINS BJ, 1980, J REHABIL, V46, P42; Bellini J, 1998, REHABIL COUNS BULL, V41, P242; Bolton BF, 2000, REHABIL COUNS BULL, V44, P10, DOI 10.1177/003435520004400103; Bruffaerts R, 2004, PSYCHIAT SERV, V55, P685, DOI 10.1176/appi.ps.55.6.685; Capella-McDonnall ME, 2005, J VISUAL IMPAIR BLIN, V99, P303; Chan F, 2006, DISABIL REHABIL, V28, P257, DOI 10.1080/09638280500158307; Chan F., 2005, J APPL REHABILITATIO, V36, P3; Chan F., 1997, PHYS MED REH CLIN N, V8, P311, DOI [10.1016/S1047-9651(18)30328-0, DOI 10.1016/S1047-9651(18)30328-0]; Chan F, 2005, CASE MANAGEMENT REHA, V1; Cardoso EDS, 2007, J HEAD TRAUMA REHAB, V22, P85; DOOLEY D, 1994, AM J COMMUN PSYCHOL, V22, P745, DOI 10.1007/BF02521557; DOOLEY D, 1992, J OCCUP ORGAN PSYCH, V65, P277, DOI 10.1111/j.2044-8325.1992.tb00505.x; Dooley D, 1996, ANNU REV PUBL HEALTH, V17, P449, DOI 10.1146/annurev.pu.17.050196.002313; DZIEKAN KI, 1993, REHABIL COUNS BULL, V36, P183; Fawber HL, 1987, J HEAD TRAUMA REHAB, V2, P27; FEISTPRICE S, 1995, REHABIL COUNS BULL, V39, P119; Gamble D, 2003, J REHABIL, V69, P31; Hennessey JC, 1997, SOC SECUR BULL, V60, P3; Herbert J. T., 1992, J JOB PLACEMENT, V8, P10; Horn W, 2000, DISABIL REHABIL, V22, P358, DOI 10.1080/096382800296601; Kasl SV, 1998, ADVERSITY, STRESS AND PSYCHOPATHOLOGY, P111; Kaye HS, 1998, DIS STAT ABSTR, V20, P1; LENNON MC, 1999, HDB STUDY MENTAL HLT, P287; LINN MW, 1985, AM J PUBLIC HEALTH, V75, P502, DOI 10.2105/AJPH.75.5.502; Main L, 2006, BRIT J OCCUPATIONAL, V69, P288; Marrone J, 1999, PSYCHIATR REHABIL J, V23, P187, DOI 10.1037/h0095171; Rosenthal D., 2006, J REHABILITATION ADM, V29, p229 244; ROSS MG, 1986, EQUAL CHALLENGE PERS, P39; RUBIN SE, 2001, FDN VOCATIONAL REHAB; United States Government Accountability Office, 2005, GAO05865; VanDongen CJ, 1996, COMMUNITY MENT HLT J, V32, P535, DOI 10.1007/BF02251064; Wilson K. B., 2005, J APPL REHABILITATIO, V36, P4; Wilson KB, 2000, REHABIL COUNS BULL, V43, P97, DOI 10.1177/003435520004300205; Wilson KB, 2002, REHABIL COUNS BULL, V45, P168, DOI 10.1177/003435520204500306	34	145	146	2	23	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1053-0487			J OCCUP REHABIL	J. Occup. Rehabil.	DEC	2008	18	4					326	334		10.1007/s10926-008-9154-z			9	Rehabilitation; Social Issues	Rehabilitation; Social Issues	374TD	WOS:000261065700002	18982428				2021-06-18	
S	Van Den Heuvel, C; Thornton, E; Vink, R		Weber, JT; Maas, AIR		Van Den Heuvel, Corinna; Thornton, Emma; Vink, Robert			Traumatic brain injury and Alzheimer's disease: a review	NEUROTRAUMA: NEW INSIGHTS INTO PATHOLOGY AND TREATMENT	PROGRESS IN BRAIN RESEARCH		English	Article; Proceedings Paper	8th International Neurotrauma Symposium	MAY 21-25, 2006	Rotterdam, NETHERLANDS			amyloid precursor protein; traumatic brain injury; apolipoprotein E; Alzheimer's disease	AMYLOID PRECURSOR PROTEIN; SEVERE HEAD-INJURY; A-BETA PEPTIDE; LONG-TERM ACCUMULATION; APOLIPOPROTEIN-E; RISK-FACTOR; CEREBROSPINAL-FLUID; TRANSGENIC MICE; MOUSE MODEL; SECRETASE CLEAVAGE	In an effort to identify the factors that are involved in the pathogenesis of Alzheimer's disease (AD), epidemiological studies have featured prominently in contemporary research. Of those epidemiological factors, accumulating evidence implicates traumatic brain injury (TBI) as a possible predisposing factor in AD development. Exactly how TBI triggers the neurodegenerative cascade of events in AD remains controversial. There has been extensive research directed towards understanding the potential relationship between TBI and AD and the putative influence that apolipoprotein E (APOE) genotype has on this relationship. The aim of the current paper is to provide a critical summary of the experimental and human studies regarding the association between TBI, AD and APOE genotype. It will be shown that despite significant discrepancies in the literature, there still appears to be an increasing trend to support the hypothesis that TBI is a potential risk factor for AD. Furthermore, although it is known that APOE genotype plays an important role in AD, its link to a deleterious outcome following TBI remains inconclusive and ambiguous.	[Van Den Heuvel, Corinna; Thornton, Emma] Univ Adelaide, Discipline Pathol, Adelaide, SA, Australia	Van Den Heuvel, C (corresponding author), Univ Adelaide, Discipline Pathol, Adelaide, SA, Australia.	corinna.vandenheuvel@adelaide.edu.au	AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; , Corinna/0000-0003-0664-8935			Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; AdleBiassette H, 1996, NEUROBIOL AGING, V17, P415, DOI 10.1016/0197-4580(96)00029-2; Andersen OM, 2006, BIOCHEMISTRY-US, V45, P2618, DOI 10.1021/bi052120v; Arbel M, 2005, P NATL ACAD SCI USA, V102, P7718, DOI 10.1073/pnas.0502427102; Awasthi A, 2005, EXP NEUROL, V196, P282, DOI 10.1016/j.expneurol.2005.08.001; BEYREUTHER K, 1993, ANN NY ACAD SCI, V695, P91, DOI 10.1111/j.1749-6632.1993.tb23035.x; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Dewachter I, 2002, LANCET NEUROL, V1, P409, DOI 10.1016/S1474-4422(02)00188-6; Ezra Y, 2003, NEUROSCIENCE, V121, P315, DOI 10.1016/S0306-4522(03)00436-6; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Graham DI, 1996, ACT NEUR S, V66, P96; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Growdon JH, 1998, ARCH NEUROL-CHICAGO, V55, P1053, DOI 10.1001/archneur.55.8.1053; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hartman RE, 2002, J NEUROSCI, V22, P10083; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Kerr M E, 1998, AACN Clin Issues, V9, P524, DOI 10.1097/00044067-199811000-00007; King GD, 2004, J NEUROCHEM, V88, P971, DOI 10.1046/j.1471-4159.2003.02234.x; KRAUS JF, 1993, HEAD INJURY; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lee EB, 2006, J BIOL CHEM, V281, P4292, DOI 10.1074/jbc.M511018200; Lee RKK, 1997, P NATL ACAD SCI USA, V94, P5422, DOI 10.1073/pnas.94.10.5422; Lee RKK, 2000, ANN NY ACAD SCI, V920, P261; LI G, 1992, NEUROLOGY, V42, P1481, DOI 10.1212/WNL.42.8.1481; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Masliah E, 1998, J NEUROPATH EXP NEUR, V57, P1041, DOI 10.1097/00005072-199811000-00007; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mattson MP, 1997, PHYSIOL REV, V77, P1081; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Miguel-Hidalgo JJ, 1998, ACTA NEUROPATHOL, V95, P455, DOI 10.1007/s004010050825; Miller CCJ, 2006, TRENDS NEUROSCI, V29, P280, DOI 10.1016/j.tins.2006.03.001; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; NAKAMURA T, 1994, ANN NEUROL, V36, P903, DOI 10.1002/ana.410360616; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Neve RL, 1998, TRENDS NEUROSCI, V21, P15, DOI 10.1016/S0166-2236(97)01168-5; Nicoll JAR, 1996, NEUROPATH APPL NEURO, V22, P515, DOI 10.1111/j.1365-2990.1996.tb01128.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Raby CA, 1998, J NEUROCHEM, V71, P2505; Racchi M, 1999, J NEUROCHEM, V72, P2464, DOI 10.1046/j.1471-4159.1999.0722464.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; REBECK GW, 1993, NEURON, V11, P575; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; RUDELLI R, 1982, ARCH NEUROL-CHICAGO, V39, P570, DOI 10.1001/archneur.1982.00510210040009; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Szczygielski J, 2005, J NEURAL TRANSM, V112, P1547, DOI 10.1007/s00702-005-0326-0; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2004, NEUROBIOL AGING S1, V25, pP2; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; Wilquet V, 2004, CURR OPIN NEUROBIOL, V14, P582, DOI 10.1016/j.conb.2004.08.001; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134	121	145	145	1	19	ELSEVIER SCIENCE BV	AMSTERDAM	SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0079-6123		978-0-444-53017-2	PROG BRAIN RES			2007	161						303	316		10.1016/S0079-6123(06)61021-2			14	Medicine, General & Internal; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	BGY20	WOS:000251295200021	17618986				2021-06-18	
J	Verma, A; Anand, V; Verma, NP				Verma, Arunima; Anand, Vivek; Verma, Narayan P.			Sleep Disorders in Chronic Traumatic Brain Injury	JOURNAL OF CLINICAL SLEEP MEDICINE			English	Article						CHI; TBI; Daytime somnolence; EDS; OSA; insomnia; parasomnia; Epworth sleepiness scale; Hamilton anxiety scale; Beck Depression Inventory; PSG; MSLT		Study Objective: To examine the spectrum of sleep disorders in patients with chronic traumatic brain injury (TBI) and determine if the severity of sleep disorder is related to severity of chronic TBI. Methods: Patients who underwent evaluation for sleep disorder/s following a TBI were included in this retrospective analysis. Sixty adult patients with TBI (age 20-69 yr; 38 M and 22 F), who presented with sleep-related complaints 3 months to 2 years following TBI, were studied. None had sleep complaints prior to the TBI. Orophrayngeal, chin, and TMJ examinations were considered benign. The severity of injury was assessed by the Global Assessment of Functioning (GAF) scale. Polysomnograms (PSGs) were performed on 54 patients (90%), 28 of whom underwent multiple sleep latency tests (MSLTs) because they scored >11 on the Epworth Sleepiness Scale (ESS). The Beck Depression Inventory (BDI) scale was administered if there was sleep maintenance insomnia, and the Hamilton Anxiety Scale (HAS) was administered if there was sleep onset insomnia. Results: The TBI severity was mild in 40%, moderate in 20%, and severe in 40%. The Epworth Sleepiness Scale (ESS) score was elevated (>11) in 52%. Hypersomnia was the presenting complaint in 50%, mostly due to sleep apnea, narcolepsy, and periodic limb movement disorder (PLMD). Insomnia was the presenting complaint in 25%, half with sleep mainte-nance insomnia and high BDI scores, and the remainder with sleep onset insomnia and high HAS scores. Parasomnia was the presenting complaint in 25%; the most frequent parasomnia was REM behavior disorder (RBD). GAF scores were significantly correlated (p <0.05) with some of the measures of sleep disruption (stage 1, sleep efficiency, and wake during sleep), but not with others (wake before sleep, stage-shifts, PLMI, PLMA and AHI) on the PSG. Fifty-three percent (15/28) had a mean sleep onset latency <5 minutes, and 32% (9/28), also had two or more sleep onset rapid eye movement periods (SOREMPs) on the MSLT. Conclusion: The results of this study demonstrate that a full spectrum of common sleep disorders occurs in patients with chronic TBI. The severity of chronic TBI as measured by GAF scores is correlated with some of the measures of sleep disruption but not others, indicating a complex and multifactorial pathogenesis.	[Verma, Arunima; Anand, Vivek; Verma, Narayan P.] BG Tricounty Neurol & Sleep Clin, Warren, MI USA	Verma, NP (corresponding author), 31150 Hoover,Suite B, Warren, MI 48093 USA.	narayangod@aol.com	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146			American Academy of Sleep Medicine, 2001, INT CLASS SLEEP DIS, P208; Amico G, 1972, RIV SPER FRENIATR ME, V29, P74; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Chesson AL, 1997, SLEEP, V20, P406; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COPES WS, 1990, J TRAUMA, V30, P1200, DOI 10.1097/00005373-199010000-00003; DRAKE ME, 1986, NEUROLOGY, V36, P867, DOI 10.1212/WNL.36.6.867; Frances A., 1994, DIAGNOSTIC STAT MANU; Gill AW, 1941, LANCET, V1, P474; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Hagen C, 1979, REHABILITATION HEAD; Hamilton MC, 1959, HAMILTON ANXIETY SCA; HENDRICKS JC, 1982, BRAIN RES, V239, P81, DOI 10.1016/0006-8993(82)90835-6; Hovda DA, 1997, CRIT CARE MED, V25, P1267, DOI 10.1097/00003246-199708000-00006; iary N, 1994, MOVEMENT DISORD, V9, P98; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; LANKFORD DA, 1994, SLEEP, V17, pS25, DOI 10.1093/sleep/17.suppl_8.S25; MAHOWALD MW, 1989, PRINCIPLES PRACTICE, P389; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; McKeating EG, 1998, BRIT J ANAESTH, V80, P77; MODY I, 1995, TRENDS PHARMACOL SCI, V16, P356, DOI 10.1016/S0165-6147(00)89070-7; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Parker F, 2001, CONTINUUM, V7, P7; PARSONS LC, 1982, NURS RES, V31, P260; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Rechtschaffen A, 1968, MANUAL STANDARDIZED; STRICH SJ, 1961, LANCET, V2, P443; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; THORPY MJ, 1992, SLEEP, V15, P268; Webster JB, 2001, ARCH PHYS MED REHAB, V82, P316, DOI 10.1053/apmr.2001.20840; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249	38	145	146	0	3	AMER ACAD SLEEP MEDICINE	DARIEN	2510 N FRONTAGE RD, DARIEN, IL 60561 USA	1550-9389	1550-9397		J CLIN SLEEP MED	J. Clin. Sleep Med.		2007	3	4					357	362					6	Clinical Neurology	Neurosciences & Neurology	V44VK	WOS:000209776300004	17694723				2021-06-18	
J	Marmarou, A; Signoretti, S; Fatouros, PP; Portella, G; Aygok, GA; Bullock, MR				Marmarou, A; Signoretti, S; Fatouros, PP; Portella, G; Aygok, GA; Bullock, MR			Predominance of cellular edema in traumatic brain swelling in patients with severe head injuries	JOURNAL OF NEUROSURGERY			English	Article						brain edema; trauma; head injury; brain injury; apparent diffusion coefficient	DIFFUSION-WEIGHTED MR; CEREBRAL BLOOD-VOLUME; MAGNETIC-RESONANCE; WATER-CONTENT; T2-WEIGHTED MRI; WHITE-MATTER; NEONATAL-RAT; TIME-COURSE; ISCHEMIA; COEFFICIENT	Object. The edema associated with brain swelling after traumatic brain injury (TBI) has been thought to be vasogenic in origin, but the results of previous laboratory Studies by the authors have shown that a cellular form of edema is mainly responsible for brain swelling after TBI. In this study the authors used magnetic resonance (MR) imaging techniques to identify the type of edema that occurs in patients with TBI. Methods. Diffusion-weighted MR imaging was used to evaluate the apparent diffusion coefficient (ADC) in 44 patients with TBI (Glasgow Coma Scale Score < 8) and in eight healthy volunteers. Higher ADC values have been associated with vasogenic edema, and lower ADC values with a predominantly cellular form of edema. Regional measurements of ADC in patients with focal and diffuse injury were computed. The water content of brain tissue was also assessed in absolute terms by using MR imaging to measure the percentage of water per gram of tissue. Cerebral blood flow (CBF) was measured using stable Xe-computerized tomography (CT) studies to rule out ischemia as a cause of cellular edema. The mean ADC value in the healthy volunteers was 0.82 +/- 0.05 X 10(-3) mm(2)/second. The ADC values in the patients with diffuse brain injury without swelling were close to the mean for the healthy volunteers. In contrast, the patients with brain swelling had increased brain water content and low ADC values (mean 0.74 +/- 0.05 x 10(-3) mm(2)/second). The ADC values correlated with CT classifications. In all patients with low ADC values, the CBF values were outside the range for ischemia. Conclusions. The brain swelling observed in patients with TBI appears to be predominantly cellular, as signaled by low ADC values in brain tissue with high levels of water content.	Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Radiol, Richmond, VA 23298 USA	Marmarou, A (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, Med Coll Virginia Campus,1001 E Broad St,Suite 23, Richmond, VA 23298 USA.	amarmaro@vcu.edu	Signoretti, stefano/AAL-5631-2020	Signoretti, stefano/0000-0002-8086-1622	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, R01NS019235, P01NS012587, R56NS019235] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19235, NS12587] Funding Source: Medline		ADELSON PD, PEDIAT NEUROSURG, V26, P200; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BENVENISTE H, 1992, STROKE, V23, P746, DOI 10.1161/01.STR.23.5.746; Dijkhuizen RM, 1999, J CEREBR BLOOD F MET, V19, P341, DOI 10.1097/00004647-199903000-00012; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EBISU T, 1993, JMRI-J MAGN RESON IM, V3, P863, DOI 10.1002/jmri.1880030612; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122; Fatouros P P, 1990, Adv Neurol, V52, P533; FATOUROS PP, 1990, ACT NEUR S, V51, P37; Fatouros PP, 1999, J NEUROSURG, V90, P109, DOI 10.3171/jns.1999.90.1.0109; FATOUROS PP, 1991, MAGNET RESON MED, V17, P402, DOI 10.1002/mrm.1910170212; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KAWAMATA T, 2000, ACTA NEUROCHIR SUPP, V76, P769; KITA H, 1994, ACTA NEUROCHIR, P452; KLATZO I, 1994, ACTA NEUROCHIR, P3; KRAFT KA, 1987, MAGNET RESON MED, V5, P555, DOI 10.1002/mrm.1910050606; Kuroiwa T, 1998, STROKE, V29, P859, DOI 10.1161/01.STR.29.4.859; Langfitt T W, 1966, W V Med J, V62, P49; LANGFITT THOMAS W., 1964, TRANS AMER NEUROL ASS, V89, P214; LANGFITT TW, 1968, JOHNS HOPKINS MED J, V122, P261; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LANGFITT TW, 1968, SAND J CLIN LAB IN S, V102, pR14; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 1980, Adv Neurol, V28, P345; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Muizelaar JP, 1997, STROKE, V28, P1998, DOI 10.1161/01.STR.28.10.1998; Nakahara M, 2001, ACTA RADIOL, V42, P365, DOI 10.1034/j.1600-0455.2001.420404.x; Portella G, 2000, ACT NEUR S, V76, P273; Rumpel H, 1997, PEDIATR RES, V42, P54, DOI 10.1203/00006450-199707000-00009; Schlaug G, 1997, NEUROLOGY, V49, P113, DOI 10.1212/WNL.49.1.113; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; SEVICK RJ, 1992, RADIOLOGY, V185, P687, DOI 10.1148/radiology.185.3.1438745; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Stroop R, 1998, ACT NEUR S, V71, P303; Tsuura M, 1996, No To Shinkei, V48, P659; Yanaka Kiyoyuki, 1995, Neurologia Medico-Chirurgica, V35, P648, DOI 10.2176/nmc.35.648; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	46	145	153	3	13	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2006	104	5					720	730		10.3171/jns.2006.104.5.720			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	041CD	WOS:000237429800006	16703876				2021-06-18	
J	McGirt, MJ; Woodworth, GF; Coon, AL; Frazier, JM; Amundson, E; Garonzik, I; Olivi, A; Weingart, JD				McGirt, MJ; Woodworth, GF; Coon, AL; Frazier, JM; Amundson, E; Garonzik, I; Olivi, A; Weingart, JD			Independent predictors of morbidity after image-guided stereotactic brain biopsy: a risk assessment of 270 cases	JOURNAL OF NEUROSURGERY			English	Article						stereotactic biopsy; glioma grade; craniotomy; pathology	SPACE-OCCUPYING LESIONS; HEAD-INJURY; HYPERGLYCEMIA; TUMORS; TOMOGRAPHY; EXPERIENCE; GLIOMAS; YIELD	Object. Image-guided stereotactic brain biopsy is associated with transient and permanent incidences of morbidity in 9 and 4.5% of patients, respectively. The goal of this study was to perform a critical analysis of risk factors predictive of an enhanced operative risk in frame-based and frarneless stereotactic brain biopsy. Methods. The authors reviewed the clinical and neuroirriaging records of 270 patients who underwent consecutive frame-based and frameless image-guided stereotactic brain biopsies. The association between preoperative variables and biopsy-related morbidity was assessed by performing a multivariate logistic regression analysis. Transient and permanent stereotactic biopsy-related morbidity was observed in 23 (9%) and 13 (5%) patients, respectively. A hematoma occurred at the biopsy site in 25 patients (9%); 10 patients (4%) were symptomatic. Diabetes mellitus (odds ratio [OR] 3.73, 95% confidence interval [CI] 1.37-10.17, p = 0.01), thalamic lesions (OR 4.06, 95% CI 163-10.11, p = 0.002), and basal ganglia lesions (OR 3.29, 95% CI 1.05-10.25, p = 0.04) were independent risk factors for morbidity. In diabetic patients, a serum level of glucose that was greater than 200 rng/dl on the day of biopsy had a 100% positive predictive value and a glucose level lower than 200 mg/dl on the same day had a 95% negative predictive value for biopsy-related morbidity. Pontine biopsy was not a risk factor for morbidity. Only two (4%) of 45 patients who had epilepsy before the biopsy experienced seizures postoperatively. The creation of more than one needle trajectory increased the incidence of neurological deficits from 17 to 44% when associated with the treatment of deep lesions (those in the basal ganglia or thalamus-, p = 0.05), but was not associated with morbidity when associated with the treatment of cortex lesions. Conclusions.. Basal ganglia lesions, thalamic lesions, and patients with diabetes were independent risk factors for biopsy-associated morbidity. Hyperglycemia oil the day of biopsy predicted morbidity in the diabetic population. Epilepsy did not predispose to biopsy-associated seizure. For deep-seated lesions, increasing the number of biopsy samples along an established track rather than performing a second trajectory may minimize the incidence of morbidity. Close perioperative observation of glucose levels may be warranted.	Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD 21287 USA; Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21287 USA	McGirt, MJ (corresponding author), Johns Hopkins Sch Med, Dept Neurosurg, 600 N Wolfe St,Meyer 8-161, Baltimore, MD 21287 USA.	mmcgirt1@jhmi.edu	Olivi, Alessandro/K-6531-2016	Olivi, Alessandro/0000-0002-4489-7564; Coon, Alexander/0000-0002-1105-4333			APUZZO MLJ, 1983, NEUROSURGERY, V12, P277, DOI 10.1227/00006123-198303000-00005; APUZZO MLJ, 1987, NEUROSURGERY, V20, P930, DOI 10.1227/00006123-198706000-00019; Bernays RL, 2002, J NEUROSURG, V97, P354, DOI 10.3171/jns.2002.97.2.0354; Blaauw G, 1988, Acta Neurochir Suppl (Wien), V42, P161; BOETHIUS J, 1978, ACTA NEUROCHIR, V40, P223, DOI 10.1007/BF01774748; BOUVIER G, 1983, APPL NEUROPHYSIOL, V46, P227; Boviatsis EJ, 2003, NEUROL SCI, V24, P97, DOI 10.1007/s10072-003-0093-3; Bruno A, 2002, NEUROLOGY, V59, P669, DOI 10.1212/WNL.59.5.669; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; Dorward NL, 2002, BRIT J NEUROSURG, V16, P110, DOI 10.1080/02688690220131705; Field P, 2001, J NEUROSURG, V94, P545, DOI 10.3171/jns.2001.94.4.0545; FRIEDMAN WA, 1989, NEUROSURGERY, V25, P180, DOI 10.1227/00006123-198908000-00005; Gralla J, 2003, ZBL NEUROCHIR, V64, P166; GREENE GM, 1989, J NEUROSURG, V71, P494, DOI 10.3171/jns.1989.71.4.0494; Hall WA, 1998, CANCER, V82, P1749, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1756::AID-CNCR23>3.0.CO;2-2; Heilbrun M P, 1983, Clin Neurosurg, V31, P564; Kawai N, 1998, ACT NEUR S, V71, P219; KELLY PJ, 1985, MAYO CLIN PROC, V60, P223, DOI 10.1016/S0025-6196(12)60314-0; Kulkarni AV, 1998, J NEUROSURG, V89, P31, DOI 10.3171/jns.1998.89.1.0031; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LEE T, 1991, British Journal of Neurosurgery, V5, P331, DOI 10.3109/02688699109002859; LOBATO RD, 1982, APPL NEUROPHYSIOL, V45, P426; Mundinger F, 1985, Acta Neurochir Suppl (Wien), V35, P70; Niizuma H, 1988, Acta Neurochir Suppl (Wien), V42, P157; OSTERTAG CB, 1980, SURG NEUROL, V14, P275; Ritter AM, 1996, J NEUROTRAUM, V13, P473, DOI 10.1089/neu.1996.13.473; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Sawin PD, 1998, SURG NEUROL, V49, P640, DOI 10.1016/S0090-3019(97)00435-7; WILD A M, 1990, British Journal of Neurosurgery, V4, P407, DOI 10.3109/02688699008992763; Yamada K, 2004, J CLIN NEUROSCI, V11, P263, DOI 10.1016/j.jocn.2003.03.004; Yu X, 2000, STEREOT FUNCT NEUROS, V75, P103, DOI 10.1159/000048390	31	145	149	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2005	102	5					897	901		10.3171/jns.2005.102.5.0897			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	954KO	WOS:000231154200015	15926716				2021-06-18	
J	Korn, A; Golan, H; Melamed, I; Pascual-Marqui, R; Friedman, A				Korn, A; Golan, H; Melamed, I; Pascual-Marqui, R; Friedman, A			Focal cortical dysfunction and blood-brain barrier disruption in patients with postconcussion syndrome	JOURNAL OF CLINICAL NEUROPHYSIOLOGY			English	Article						blood-brain barrier; LORETA; postconcussion syndrome; QEEG; SPECT	POST-CONCUSSION SYMPTOMS; HEAD-INJURY; ELECTROMAGNETIC TOMOGRAPHY; NEUROPHYSIOLOGICAL ASPECTS; MILD; CORTEX; LOCALIZATION; RAT; NEUROPATHOLOGY; PERMEABILITY	Postconcussion syndrome (PCS) refers to symptoms and signs commonly occurring after mild head injury. The pathogenesis of PCS is unknown. The authors quantitatively analyzed EEG recordings, localized brain sources for abnormal activity, and correlated it with imaging studies. Data from 17 patients with neurologic symptomatology consistent with ICD-10 criteria for PCS was analyzed. Normalized quantitative EEG (QEEG) revealed significantly higher power in the delta band and lower power in the alpha band compared with matched controls. The generators for the abnormal rhythms were focally localized in neocortical regions. Brain computerized tomography and/or MRI did not reveal focal abnormality at the time of diagnosis. Single photon emission computed tomography (SPECT) after Tc-99m-ethylcysteinate dimer administration showed a focal reduction in perfusion in 85% (n = 11) of the patients, and abnormal blood-brain barrier (BBB) after Tc-99m-diethylenetriaminepentaacetic acid administration in 73% (n = 8). In 75% of these patients, low-resolution brain electromagnetic tomography analysis showed that the generators for abnormal rhythms were closely related to the anatomic location of the BBB lesion. These data point to focal cortical dysfunction in conjunction with BBB disruption and hypoperfusion as a possible mechanism of pathogenesis in at least some PCS patients, and offer QEEG and SPECT as important tools in evaluating these patients.	Soroka Univ Hosp, Dept Neurosurg, Lab Funct Neurosurg, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Rabin Med Ctr, Dept Nucl Med, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel; Univ Zurich, Key Inst Brain Mind Res, CH-8006 Zurich, Switzerland; Berlin Med Univ, Inst Physiol, Berlin, Germany	Friedman, A (corresponding author), Soroka Univ Hosp, Dept Neurosurg, Lab Funct Neurosurg, IL-84105 Beer Sheva, Israel.	alonf@bgu.ac.il	Pascual-Marqui, Roberto D./A-2012-2008; Golan, Haim/K-2831-2019	Pascual-Marqui, Roberto D./0000-0002-5029-4065; 			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ANDREW RD, 1991, J NEUROL SCI, V101, P7, DOI 10.1016/0022-510X(91)90013-W; ANDY OJ, 1989, CLIN ELECTROENCEPHAL, V20, P24, DOI 10.1177/155005948902000107; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; COOLEY JW, 1977, STAT METHODS DIGITAL, P377; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dale AM, 2000, NEURON, V26, P55, DOI 10.1016/S0896-6273(00)81138-1; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Frei E, 2001, HUM BRAIN MAPP, V14, P152, DOI 10.1002/hbm.1049; Gaetz M, 2000, BRAIN INJURY, V14, P815; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KUSHI H, 1994, ACTA NEUROCHIR, P472; Kushner D, 2002, AM J NEURORADIOL, V23, P1442; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; Menendez RGD, 2001, BRAIN TOPOGR, V14, P131, DOI 10.1023/A:1012944913650; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Oztas B, 2001, PHARMACOL RES, V44, P209, DOI 10.1006/phrs.2001.0841; Pascual-Marqui RD, 1999, PSYCHIAT RES-NEUROIM, V90, P169, DOI 10.1016/S0925-4927(99)00013-X; PASCUALMARQUI RD, 1994, INT J PSYCHOPHYSIOL, V18, P49, DOI 10.1016/0167-8760(84)90014-X; PASCUALMARQUI RD, 1999, INT J BIOELECTROMAG, V1; PASCUALMARQUI RD, 2002, METHODS FIND EX SC91, V24; Pearl GS, 1998, CLIN LAB MED, V18, P39; Phillips C, 2002, NEUROIMAGE, V16, P678, DOI 10.1006/nimg.2002.1143; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; ROSEN AS, 1990, NEUROSCIENCE, V38, P579, DOI 10.1016/0306-4522(90)90052-6; SALY V, 1993, J NEUROPHYSIOL, V69, P2200; Schwartzkroin PA, 1998, EPILEPSY RES, V32, P275, DOI 10.1016/S0920-1211(98)00058-8; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Sosin DM, 1996, BRAIN INJURY, V10, P47; SOUSTIEL JF, 1995, BRAIN INJURY, V9, P805, DOI 10.3109/02699059509008236; Strik WK, 1998, EVOKED POTENTIAL, V108, P406, DOI 10.1016/S0168-5597(98)00021-5; Sukov W, 1998, J NEUROPHYSIOL, V79, P2875; Talairach J., 1988, COPLANAR STEREOTAXIC; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Tomkins O, 2001, CELL MOL NEUROBIOL, V21, P675, DOI 10.1023/A:1015147920283; TOWLE VL, 1993, ELECTROEN CLIN NEURO, V86, P1, DOI 10.1016/0013-4694(93)90061-Y; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Volkow ND, 1997, P NATL ACAD SCI USA, V94, P2787, DOI 10.1073/pnas.94.7.2787; Walker MC, 2002, BRAIN, V125, P1937, DOI 10.1093/brain/awf203; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; ZAPPULLA RA, 1985, NEUROSURGERY, V16, P630, DOI 10.1227/00006123-198505000-00008	48	145	147	3	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0736-0258	1537-1603		J CLIN NEUROPHYSIOL	J. Clin. Neurophysiol.	JAN-FEB	2005	22	1					1	9		10.1097/01.WNP.0000150973.24324.A7			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	895SM	WOS:000226883600001	15689708				2021-06-18	
J	Iwata, A; Stys, PK; Wolf, JA; Chen, XH; Taylor, AG; Meaney, DF; Smith, DH				Iwata, A; Stys, PK; Wolf, JA; Chen, XH; Taylor, AG; Meaney, DF; Smith, DH			Traumatic axonal injury induces proteolytic cleavage of the voltage-gated sodium channels modulated by tetrodotoxin and protease inhibitors	JOURNAL OF NEUROSCIENCE			English	Article						axon trauma; diffuse axonal injury; sodium channels; calcium; proteolysis; protease inhibitors; noninactivation; tetrodotoxin; traumatic brain injury	SPINAL-CORD-INJURY; EXPERIMENTAL BRAIN INJURY; CNS WHITE-MATTER; HEAD-INJURY; NERVOUS-SYSTEM; ANOXIC INJURY; NA+ CHANNELS; NA+-CA2+ EXCHANGER; CLINICAL-TRIALS; CALCIUM INFLUX	We demonstrated previously that dynamic stretch injury of cultured axons induces structural changes and Ca2+ influx modulated by tetrodotoxin (TTX)-sensitive voltage-gated sodium channels (NaChs). In the present study, we evaluated potential damage to the NaCh alpha-subunit, which can cause noninactivation of NaChs. In addition, we explored the effects of pre-injury and post-injury treatment with TTX and protease inhibition on proteolysis of the NaCh alpha-subunit and intra-axonal calcium levels ([Ca2+]i) over 60 min after trauma. After stretch injury, we found that [Ca2+]i continued to increase in untreated axons for at least 60 min. We also observed that the III-IV intra-axonal loop of the NaCh alpha-subunit was proteolyzed between 5 and 20 min after trauma. Pre-injury treatment of the axons with TTX completely abolished the posttraumatic increase in [Ca2+]i and proteolysis of the NaCh alpha-subunit. In addition, both pre-injury and post-injury inhibition of protease activity attenuated long-term increases in [Ca2+]i as well as mitigating degradation of the NaCh alpha-subunit. These results suggest a unique "feed-forward" deleterious process initiated by mechanical trauma of axons. Na+ influx through NaChs resulting from axonal deformation triggers initial increases in [Ca2+]i and subsequent proteolysis of the NaCh alpha-subunit. In turn, degradation of the alpha-subunit promotes persistent elevations in [Ca2+]i, fueling additional pathologic changes. These observations may have important implications for developing therapeutic strategies for axonal trauma.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Ottawa, Ottawa Hosp, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4K9, Canada	Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	smith, douglas/A-1321-2007; Wolf, John A/A-1034-2007	Wolf, John A/0000-0002-6950-2303; Meaney, David/0000-0002-0954-4122	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG21527, K08 AG021527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS035712, NS41699, NS35712, R01 NS038104, NS38104, F32 NS041699] Funding Source: Medline; CDC HHS [CCR312712] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712, R01NS038104, F32NS041699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG021527] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; BANIK NL, 1987, NEUROCHEM PATHOL, V7, P57, DOI 10.1007/BF02834292; Benz I, 1997, EUR BIOPHYS J BIOPHY, V25, P189, DOI 10.1007/s002490050031; BINDER LI, 1986, ANN NY ACAD SCI, V466, P145, DOI 10.1111/j.1749-6632.1986.tb38392.x; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; DUGANDZIJANOVAKOVIC S, 1995, J NEUROSCI, V15, P492; FERN R, 1995, J NEUROPHYSIOL, V74, P369; GEORGE EB, 1995, J NEUROSCI, V15, P6445; Gitler D, 1998, NEURON, V20, P1123, DOI 10.1016/S0896-6273(00)80494-8; GORDON D, 1987, P NATL ACAD SCI USA, V84, P8682, DOI 10.1073/pnas.84.23.8682; Graham D I, 1988, Prog Clin Biol Res, V264, P159; IIZUKA H, 1986, J NEUROSURG, V65, P92, DOI 10.3171/jns.1986.65.1.0092; Imaizumi T, 1999, BRAIN RES, V817, P84, DOI 10.1016/S0006-8993(98)01214-1; IWASAKI Y, 1987, BRAIN RES, V406, P99, DOI 10.1016/0006-8993(87)90773-6; IWASAKI Y, 1985, BRAIN RES, V347, P124, DOI 10.1016/0006-8993(85)90897-2; Jiang QB, 2000, J NEUROCHEM, V74, P2101, DOI 10.1046/j.1471-4159.2000.0742101.x; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; Meier T, 1997, J NEUROSCI, V17, P6534; MILLER JA, 1983, BIOCHEMISTRY-US, V22, P462, DOI 10.1021/bi00271a032; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Rasband MN, 1999, J NEUROSCI, V19, P7516, DOI 10.1523/JNEUROSCI.19-17-07516.1999; Rosenberg LJ, 1999, J NEUROSCI, V19, P6122, DOI 10.1523/JNEUROSCI.19-14-06122.1999; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; Stys P. K., 2004, MYELIN BIOL DISORDER, P985; STYS PK, 1993, P NATL ACAD SCI USA, V90, P6976, DOI 10.1073/pnas.90.15.6976; STYS PK, 1991, ANN NEUROL, V30, P375, DOI 10.1002/ana.410300309; STYS PK, 1992, J NEUROSCI, V12, P430; Stys PK, 1998, NEUROSCIENCE, V82, P21; Takahashi A, 1999, PHYSIOL REV, V79, P1089; Teng YD, 1997, J NEUROSCI, V17, P4359; Vabnick I, 1996, J NEUROSCI, V16, P4914; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; WESTENBROEK RE, 1989, NEURON, V3, P695, DOI 10.1016/0896-6273(89)90238-9; WITGEN BM, 2001, J NEUROTRAUM, V18, P1171; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	50	145	151	0	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAY 12	2004	24	19					4605	4613		10.1523/JNEUROSCI.0515-03.2004			9	Neurosciences	Neurosciences & Neurology	821QM	WOS:000221477200014	15140932	Bronze, Green Published			2021-06-18	
J	Ross, BD; Ernst, T; Kreis, R; Haseler, LJ; Bayer, S; Danielsen, E; Bluml, S; Shonk, T; Mandigo, JC; Caton, W; Clark, C; Jensen, SW; Lehman, NL; Arcinue, E; Pudenz, R; Shelden, CH				Ross, BD; Ernst, T; Kreis, R; Haseler, LJ; Bayer, S; Danielsen, E; Bluml, S; Shonk, T; Mandigo, JC; Caton, W; Clark, C; Jensen, SW; Lehman, NL; Arcinue, E; Pudenz, R; Shelden, CH			H-1 MRS in acute traumatic brain injury	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						MR spectroscopy; blunt head trauma; diffuse axonal injury; N-acetylaspartate; lactate; prognosis	MAGNETIC-RESONANCE SPECTROSCOPY; ABSOLUTE QUANTITATION; HEAD-INJURY; ENCEPHALOPATHY; METABOLITES; OSMOLYTES; WATER	The objective of this study was to demonstrate H-1 MR spectroscopy (MRS) changes in cerebral metabolites after acute head trauma, Twenty-five patients (12 children, 13 adults) were examined with quantitative H-1 MRS after closed head injury. Clinical grade (Glasgow Coma Scale [GCS]) and outcome (Rancho Los Amigos Medical Center Outcome Score [ROS]) were correlated with quantitative neurochemical findings. N-acetylaspartate (NAA), a neuronal and axonal marker, was reduced (P <.03-.001). In children, a reduced NAA/creatine plus phosphocreatine (Cr) level and the presence of detectable lipid/lactate predicted bad outcome (sensitivity, 89%; specificity, 89%). The first MRS examination of all patients correlated with ROS versus NAA (r =.65, P <.0001). Although most patients showed MRS abnormalities, striking heterogeneity of H-1 MRS characterized the individual patients. IH MRS identifies multiple patterns of diffuse brain injury after blunt head trauma. There was a strong correlation between MRS and outcome. Future prospective studies will be needed to determine the clinical usefulness of MRS in predicting outcome from closed head injury.	Huntington Med Res Inst, Pasadena, CA 91105 USA	Ross, BD (corresponding author), Huntington Med Res Inst, 660 S Fair Oaks Ave, Pasadena, CA 91105 USA.		Kreis, Roland/F-2550-2010; Lehman, Norman L/A-7351-2015	Kreis, Roland/0000-0002-8618-6875; Haseler, Luke/0000-0003-1607-4402; Bluml, Stefan/0000-0003-2124-797X; Lehman, Norman/0000-0001-8394-2607			Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Altman D, 1991, PRACTICAL STAT MED R; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; DANIELSEN ER, 1995, J MAGN RESON SER B, V106, P287, DOI 10.1006/jmrb.1995.1046; DUNCAN P, 1990, REHABILITATION ADULT, P265; ERNST T, 1993, J MAGN RESON SER B, V102, P1, DOI 10.1006/jmrb.1993.1055; Ernst T, 1993, P 12 ANN SCI M SOC M, V1, P323; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; HASELER LJ, 1995, P 3 SOC MAGNETIC RES, V1, P381; HAUSSINGER D, 1994, GASTROENTEROLOGY, V107, P1475; Kreis R, 1996, J CLIN INVEST, V97, P1142, DOI 10.1172/JCI118528; KREIS R, 1993, J MAGN RESON SER B, V102, P9, DOI 10.1006/jmrb.1993.1056; KREIS R, 1993, MAGNET RESON MED, V30, P424, DOI 10.1002/mrm.1910300405; KREIS R, 1992, P SMRM, P237; LEE JH, 1994, NEW ENGL J MED, V331, P439, DOI 10.1056/NEJM199408183310704; ROSS B, 1994, MAGN RESON QUART, V10, P191; Ross Brian D., 1995, V134, P279; STRICH SJ, 1961, LANCET, V2, P443; TEASDALE G, 1974, LANCET, V2, P81; VIDEEN JS, 1995, J CLIN INVEST, V95, P788, DOI 10.1172/JCI117728; YOUNG WB, 1994, SEMIN NEUROL, V14, P46, DOI 10.1055/s-2008-1041058	23	145	154	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	JUL-AUG	1998	8	4					829	840		10.1002/jmri.1880080412			12	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	193NU	WOS:000080143600011	9702884				2021-06-18	
J	GRAHAM, DI; ADAMS, JH; NICOLL, JAR; MAXWELL, WL; GENNARELLI, TA				GRAHAM, DI; ADAMS, JH; NICOLL, JAR; MAXWELL, WL; GENNARELLI, TA			THE NATURE, DISTRIBUTION AND CAUSES OF TRAUMATIC BRAIN INJURY	BRAIN PATHOLOGY			English	Article							DIFFUSE AXONAL INJURY; MISSILE HEAD-INJURY; APOLIPOPROTEIN-E; INTRACRANIAL-PRESSURE; DAMAGE; SECONDARY; TOMOGRAPHY; SHEARING; DISEASE; HUMANS	The identification and interpretation of brain damage resulting from a non-missile head injury is often not easy with the result that the most obvious structural damage identified postmortem may not be the most important in trying to establish clinicopathological correlations. For example patients with a fracture of the skull, quite severe cerebral contusions or a large intracranial haematoma that is successfully treated can make an uneventful and complete recovery if no other types of brain damage are present. However, not infrequently more subtle forms of pathology are present and ones that can only be identified microscopically. A systematic and pragmatic approach through the autopsy is therefore required and one that recognises the need for tissue to be retained in ways that are appropriate for cellular and molecular studies.	UNIV GLASGOW, IBLS, HUMAN ANAT LAB, GLASGOW G61 1BD, LANARK, SCOTLAND; MED COLL PENN, CTR NEUROSCI, DIV NEUROSURG, PHILADELPHIA, PA 19129 USA; HAHNEMANN UNIV, PHILADELPHIA, PA 19102 USA	GRAHAM, DI (corresponding author), UNIV GLASGOW, SO GEN HOSP, INST NEUROL SCI, DEPT NEUROPATHOL, GLASGOW G51 4TF, LANARK, SCOTLAND.		Nicoll, James/I-9253-2017	Nicoll, James/0000-0002-9444-7246			ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1984, LANCET, V2, P1420; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BLUMBERGS P C, 1991, Zentralblatt fuer Neurochirurgie, V52, P89; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BULLOCK R, 1990, HDB CLIN NEUROLOGY, V15, P249; CARRON MJ, 1993, J NEUROTRAUMA S1, V10, pS58; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; Cooper PR, 1993, HEAD INJURY, P275; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; Gean A, 1994, IMAGING HEAD TRAUMA; Gennarelli T.A., 1985, CENTRAL NERVOUS SYST, P391; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1993, HEAD INJURY, P137; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRCEVIC N, 1982, RAD JUGOSL AKAD ZNAN, V402, P265; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HARLAND WA, 1983, J CLIN PATHOL, V36, P1335, DOI 10.1136/jcp.36.12.1335; HARPER CG, 1986, J CLIN PATHOL, V39, P769, DOI 10.1136/jcp.39.7.769; HORSBURGH K, 1995, ALZHEIMER RES S1, V1, P22; IMAJO T, 1987, AM J FOREN MED PATH, V8, P217, DOI 10.1097/00000433-198708030-00004; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KIDA E, 1995, BRAIN RES, V674, P341, DOI 10.1016/0006-8993(94)01467-V; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; MAXWELL WL, 1995, IN PRESS MICROSCOPY; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCKENZIE JE, 1995, J NEUROTRAUMA, V12, P492; McLellan D, 1986, COMA TRAUMATIQUE, P165; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MORTIMER JA, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P3; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nicoll J. A. R., 1995, Journal of Neurotrauma, V12, P434; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PILZ P, 1982, J NEUROL NEUROSUR PS, V45, P422, DOI 10.1136/jnnp.45.5.422; PILZ P, 1983, ACTA NEUROCHIR, V32, P115; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; REILLY PL, 1975, LANCET, V2, P375; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; RYAN GA, 1994, J TRAUMA, V36, P469; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SIMPSON DA, 1989, J TRAUMA, V29, P1519, DOI 10.1097/00005373-198911000-00011; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; WELTE E, 1948, ARCH PSYCHIAT NERVEN, V179, P243; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	85	145	149	2	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	OCT	1995	5	4					397	406		10.1111/j.1750-3639.1995.tb00618.x			10	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	TK374	WOS:A1995TK37400006	8974622				2021-06-18	
J	Sady, MD; Vaughan, CG; Gioia, GA				Sady, Maegan D.; Vaughan, Christopher G.; Gioia, Gerard A.			Psychometric Characteristics of the Postconcussion Symptom Inventory in Children and Adolescents	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; Brain concussion; Symptom checklists	TRAUMATIC BRAIN-INJURY; NEUROCOGNITIVE PERFORMANCE; CONCUSSION SYMPTOMS; INTERNATIONAL-CONFERENCE; SPORT; STATEMENT; VALIDITY	Psychometric characteristics of the Postconcussion Symptom Inventory (PCSI) were examined in both concussed (n=633) and uninjured (n=1,273) 5 to 18 year olds. Parent-and self-report forms were created with developmentally appropriate wording and content. Factor analyses identified physical, cognitive, emotional, and sleep factors; that did not load strongly or discriminate between groups were eliminated. Internal consistency was strong for the total scales (alpha = 0.8-0.9). Test-retest reliability for the self-report forms was moderate to strong (intraclass coeffecients, ICCs = 0.65-0.89). Parent and self-report concordance was moderate (r=.44-. 65), underscoring the importance of both perspectives. Convergent validity with another symptom measure was good (r=.8). Classification analyses indicated greater discriminability from parent report, but caveats to this are presented. With strong psychometric characteristics, the four versions of the PCSI capture important post-concussion symptoms and can be utilized to track recovery from pediatric concussion and guide treatment recommendations.	[Sady, Maegan D.; Vaughan, Christopher G.; Gioia, Gerard A.] Childrens Natl Hlth Syst, Div Pediat Neuropsychol, Rockville, MD 20850 USA	Sady, MD (corresponding author), Childrens Natl Hlth Syst, Div Pediat Neuropsychol, 15245 Shady Grove Rd,Suite 350, Rockville, MD 20850 USA.	msady@childrensnational.org	Meijer, Anna/K-5118-2016		Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17/CCU323352]; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30/HDO40677-07]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD040677] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359] Funding Source: NIH RePORTER	This work was supported in part by the Centers for Disease Control (U17/CCU323352 to GG); the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) (M01RR020359 to GG); and the National Institutes of Health (P30/HDO40677-07 to GG).	ACHENBACH TM, 1987, PSYCHOL BULL, V101, P213, DOI 10.1037/0033-2909.101.2.213; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Chelune GJ, 2010, CLIN NEUROPSYCHOL, V24, P454, DOI 10.1080/13854040802360574; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Iverson GL, 2004, STUD NEUROPSYCHOL DE, P323; Janusz J.A., 2012, MILD TRAUMATIC BRAIN, P241; Kline R.B, 2004, PRINCIPLES PRACTICE; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR., 2000, IMPACT IMMEDIATE POS; Mailer BJ, 2008, J SPORT REHABIL, V17, P11, DOI 10.1123/jsr.17.1.11; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Muthen B., 2007, MPLUS VERSION 4 21; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; SAS Institute, 2008, VERS 9 2; Strauss E, 2006, COMPENDIUM NEUROPSYC, P3; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-1; Vaughan C., 2009, J INT NEUROPSYCH SOC, V15, P189; Wallander JL, 2001, J CLIN PSYCHOL, V57, P571, DOI 10.1002/jclp.1029; Weng LJ, 2004, EDUC PSYCHOL MEAS, V64, P956, DOI 10.1177/0013164404268674; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79	39	144	145	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUN	2014	29	4					348	363		10.1093/arclin/acu014			16	Psychology, Clinical; Psychology	Psychology	AM6BY	WOS:000339947100004	24739735	Bronze, Green Published			2021-06-18	
J	Chrisman, SP; Quitiquit, C; Rivara, FP				Chrisman, Sara P.; Quitiquit, Celeste; Rivara, Frederick P.			Qualitative Study of Barriers to Concussive Symptom Reporting in High School Athletics	JOURNAL OF ADOLESCENT HEALTH			English	Article						Adolescent; Brain concussion; Policy; Qualitative research; Sports	PLAYERS	Purpose: To identify barriers to concussive symptom reporting in high school athletics. Methods: We conducted a qualitative focus group study with varsity high school athletes from three football, two boys' soccer, and four girls' soccer teams in the Seattle, WA, area (50 partici pants). Professional moderators led the groups with a standardized script that discussed concus sion knowledge as well as hypothetical concussion scenarios. Focus groups were recorded and transcribed, and transcripts were analyzed by two investigators using thematic analysis with Atlas.ti. Results: Athletes could describe multiple signs and symptoms of concussion. Athletes also understood the dangers of concussions, and all groups mentioned the possibility of death or long term disability. However, when confronted with scenarios involving concussive symptoms, athletes reported they would not stop playing. They would either continue to play (6/9 groups) or would take a brief break and then return to play (3/9 groups). Several barriers seemed to explain athletes' responses. Athletes wanted to keep playing and knew that reporting symptoms might result in being removed from the game. In addition, concussive symptoms were nonspecific, and thus could be mistaken for another etiology. Finally, athletes were hesitant to report symptoms to coaches if they did not result in significant pain or disability. Conclusions: There are several barriers to concussive symptom reporting in high school athletics. Athlete concussion knowledge does not seem to be a barrier, but coach approachability may be an issue. Interventions that seek to improve coach communication with athletes regarding concussion management might increase symptom reporting. (C) 2013 Society for Adolescent Health and Medicine. All rights reserved.	[Chrisman, Sara P.; Quitiquit, Celeste; Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Chrisman, Sara P.; Quitiquit, Celeste; Rivara, Frederick P.] Seattle Childrens Hosp, Seattle, WA USA	Chrisman, SP (corresponding author), Seattle Childrens Res Ctr, POB 5371,M-S CW8 6, Seattle, WA 98145 USA.	sdow@u.washington.edu		Chrisman, Sara/0000-0001-5373-7223	Ruth L. Kirchstein National Research Service AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	This work was supported in part by a fellowship from the Ruth L. Kirchstein National Research Service Award. Results were presented as a poster at the 2011 annual meeting of the American Medical Society of Sports Medicine (Salt Lake City, Utah).	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; [Anonymous], 2011, MMWR-MORBID MORTAL W, V60, P1337; Bramley HP, 2011, CLIN PEDIAT PHILA; Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Daly J, 2007, J CLIN EPIDEMIOL, V60, P43, DOI 10.1016/j.jclinepi.2006.03.014; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; National Athletic Trainers' Association, 2009, ATHL TRAIN FILL NEC; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	13	144	144	2	54	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1054-139X	1879-1972		J ADOLESCENT HEALTH	J. Adolesc. Health	MAR	2013	52	3					330	+		10.1016/j.jadohealth.2012.10.271			9	Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics	Psychology; Public, Environmental & Occupational Health; Pediatrics	094UP	WOS:000315289900012	23427783				2021-06-18	
J	Luo, CL; Li, BX; Li, QQ; Chen, XP; Sun, YX; Bao, HJ; Dai, DK; Shen, YW; Xu, HF; Ni, H; Wan, L; Qin, ZH; Tao, LY; Zhao, ZQ				Luo, C. -L.; Li, B. -X.; Li, Q. -Q.; Chen, X. -P.; Sun, Y. -X.; Bao, H. -J.; Dai, D. -K.; Shen, Y. -W.; Xu, H. -F.; Ni, H.; Wan, L.; Qin, Z. -H.; Tao, L. -Y.; Zhao, Z. -Q.			AUTOPHAGY IS INVOLVED IN TRAUMATIC BRAIN INJURY-INDUCED CELL DEATH AND CONTRIBUTES TO FUNCTIONAL OUTCOME DEFICITS IN MICE	NEUROSCIENCE			English	Article						traumatic brain injury; autophagy; apoptosis; LC3; p62	CONTROLLED CORTICAL IMPACT; COGNITIVE IMPAIRMENT; SELECTIVE AUTOPHAGY; UP-REGULATION; BECLIN 1; APOPTOSIS; RAT; MECHANISM; P62; MACROAUTOPHAGY	Previous data demonstrate that traumatic brain injury (TBI) activates autophagy, and increases microtubule-associated protein 1 light chain 3 (LC3) immunostaining mainly in neurons. However, the role of autophagy in traumatic brain damage remains elusive. The aim of the present study was to investigate the autophagic mechanisms participating in traumatic brain injury. The autophagy inhibitors 3-methyladenine (3-MA) and bafliomycin A1 (BFA) were administered with a single i.c.v. injection before TBI. We first examined the protein levels of Beclin-1 and LC3 II, which have been found to promote autophagy previously. Immunoblotting analysis showed that 3-MA pretreatment reduced post-TBI Beclin-1 and LC3-II levels, and maintained p62/SQSTM1 (p62) levels. In addition, double immunolabeling showed that the increased punctate LC3-II dots colocalizing with Propidium Iodide (PO-stained nuclei at 24 h after injury, were partially inhibited by 3-MA pretreatment. Furthermore, inhibition of autophagy could reduce TBI-induced cell injury assessed with i.p. injection of PI and lesion volume, and attenuate behavioral outcome evaluated by motor test and Morris water maze. The neuroprotective effects were associated with an inhibition on TBI-induced up-regulation of LC3, Beclin-1, cathepsin B, caspase-3 and the Beclin-1/Bcl-2 ratio. Taken together, these data imply that the autophagy pathway is involved in the pathophysiologic responses after TBI, and inhibition of this pathway may help attenuate traumatic damage and functional outcome deficits. (C) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.	[Li, Q. -Q.; Chen, X. -P.; Sun, Y. -X.; Bao, H. -J.; Dai, D. -K.; Tao, L. -Y.] Soochow Univ, Dept Forens Med, Suzhou 215123, Peoples R China; [Luo, C. -L.; Li, B. -X.; Shen, Y. -W.; Xu, H. -F.; Zhao, Z. -Q.] Fudan Univ, Shanghai Med Coll, Dept Forens Med, Shanghai 200032, Peoples R China; [Ni, H.; Qin, Z. -H.; Tao, L. -Y.] Soochow Univ, Dept Pharmacol, Suzhou 215123, Peoples R China; [Ni, H.; Qin, Z. -H.; Tao, L. -Y.] Soochow Univ, Lab Aging & Nervous Dis, Suzhou 215123, Peoples R China; [Wan, L.; Tao, L. -Y.] Minist Justice, Inst Forens Sci, Shanghai Key Lab Forens Med, Shanghai 200063, Peoples R China	Tao, LY (corresponding author), Soochow Univ, Dept Forens Med, 199 Renai Rd, Suzhou 215123, Peoples R China.	luyang.tao@163.com; zqzhao@shmu.edu.cn			National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30571909, 30872666, 81072512, 30870808]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30930035/C090301]; Shanghai Forensic Key Laboratory Foundation [KF1005]	The work was supported by the National Science Foundation of China (No. 30571909, No. 30872666, No. 81072512, No. 30870808), the Key of Program National Natural Science Foundation of China (No. 30930035/C090301), and the Shanghai Forensic Key Laboratory Foundation (No. KF1005).	Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Chwieralski CE, 2006, APOPTOSIS, V11, P143, DOI 10.1007/s10495-006-3486-y; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Eghwrudjakpor P O, 2010, Niger J Med, V19, P14; Erlich S, 2006, AUTOPHAGY, V2, P49, DOI 10.4161/auto.2156; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Huang QL, 2002, P NATL ACAD SCI USA, V99, P3428, DOI 10.1073/pnas.062525799; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Itakura E, 2011, J CELL BIOL, V192, P17, DOI 10.1083/jcb.201009067; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Komatsu M, 2007, P NATL ACAD SCI USA, V104, P14489, DOI 10.1073/pnas.0701311104; Komatsu M, 2010, FEBS LETT, V584, P1374, DOI 10.1016/j.febslet.2010.02.017; Krysko DV, 2008, METHODS, V44, P205, DOI 10.1016/j.ymeth.2007.12.001; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Lamark T, 2009, CELL CYCLE, V8, P1986, DOI 10.4161/cc.8.13.8892; Lee B, 2010, PROG NEURO-PSYCHOPH, V34, P1085, DOI 10.1016/j.pnpbp.2010.05.031; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu D, 2002, J CEREBR BLOOD F MET, V22, P431, DOI 10.1097/00004647-200204000-00007; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; Maiuri MC, 2010, EMBO J, V29, P515, DOI 10.1038/emboj.2009.377; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Moser EI, 1998, SCIENCE, V281, P2038, DOI 10.1126/science.281.5385.2038; Noh HS, 2010, MOL CELLS, V30, P455, DOI 10.1007/s10059-010-0130-z; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Pozuelo-Rubio M, 2011, AUTOPHAGY, V7, P240, DOI 10.4161/auto.7.2.14286; Puissant A, 2010, AUTOPHAGY, V6, P655, DOI 10.4161/auto.6.5.12126; Qin ZH, 1999, J NEUROSCI, V19, P4023; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9; Uchiyama Y, 2008, AUTOPHAGY, V4, P404, DOI 10.4161/auto.5598; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wang Y, 2008, AUTOPHAGY, V4, P214, DOI 10.4161/auto.5369; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Zhang HL, 2009, J IMMUNOL, V182, P6993, DOI 10.4049/jimmunol.0802502; Zheng YT, 2009, J IMMUNOL, V183, P5909, DOI 10.4049/jimmunol.0900441; Zhou CC, 2010, CHEMOTHERAPY, V56, P393, DOI 10.1159/000317750; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	46	144	151	2	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	JUN 16	2011	184						54	63		10.1016/j.neuroscience.2011.03.021			10	Neurosciences	Neurosciences & Neurology	773SU	WOS:000291331500005	21463664				2021-06-18	
J	Lovell, MR; Pardini, JE; Welling, J; Collins, MW; Bakal, J; Lazar, N; Roush, R; Eddy, WF; Becker, JT				Lovell, Mark R.; Pardini, Jamie E.; Welling, Joel; Collins, Michael W.; Bakal, Jennifer; Lazar, Nicole; Roush, Rebecca; Eddy, William F.; Becker, James T.			Functional brain abnormalities are related to clinical recovery and time to return-to-play in athletes	NEUROSURGERY			English	Article						concussion; functional magnetic resonance imaging; ImPACT; neuropsychological testing; sport injury; traumatic brain injury	SPORTS-RELATED CONCUSSION; COLLEGE FOOTBALL PLAYERS; HIGH-SCHOOL; AGREEMENT STATEMENT; IMPACT; INJURY; MEMORY; VISUALIZATION; PERFORMANCE; SOFTWARE	OBJECTIVE: The relationship between athlete reports of symptoms, neurophysiological activation, and neuropsychological functioning is investigated in a sample of high school athletes. METHODS: All athletes were evaluated using functional magnetic resonance imaging (fMRI), a computer-based battery of neurocognitive tests, and a subjective symptom scale. Athletes were evaluated within approximately 1 week of injury and again after clinical recovery using all assessment modalities. RESULTS: This study found that abnormal fMRI results during the first week of recovery predicted clinical recovery. As a group, athletes who demonstrated hyperactivation on fMRI scans at the time of their first fMRI scan demonstrated a more prolonged clinical recovery than athletes who did not demonstrate hyperactivation at the time of their first fMRI scan. CONCLUSION: These results demonstrate the relationship between neurophysiological, neuropsychological, and subjective symptom data in a relatively large sample composed primarily of concussed high school athletes. WRI represents an important evolving technology for the understanding of brain recovery after concussion and may help shape return-to-play guidelines in the future.	Univ Pittsburgh, Sch Med, Dept Orthoped Surg, Med Ctr Sports Med, Pittsburgh, PA 15203 USA; Carnegie Mellon Univ, Sch Comp Sci, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; Univ Georgia, Dept Stat, Athens, GA 30602 USA; Psychol Software Tools, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15203 USA	Lovell, MR (corresponding author), Univ Pittsburgh, Sch Med, Dept Orthoped Surg, Med Ctr Sports Med, 3200 S Water St, Pittsburgh, PA 15203 USA.	lovellmr@upmc.edu		Becker, James/0000-0003-4425-4726			ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Cox RW, 1997, NMR BIOMED, V10, P171, DOI 10.1002/(SICI)1099-1492(199706/08)10:4/5<171::AID-NBM453>3.0.CO;2-L; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Eddy WF, 1996, MAGNET RESON MED, V36, P923, DOI 10.1002/mrm.1910360615; Ernst T, 2002, NEUROLOGY, V59, P1343, DOI 10.1212/01.WNL.0000031811.45569.B0; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FRISTON KJ, 1993, P ROY SOC B-BIOL SCI, V254, P47, DOI 10.1098/rspb.1993.0125; Herbster AN, 1996, NEUROIMAGE, V4, P67, DOI 10.1006/nimg.1996.0030; Hosmer DW, 1999, APPL SURVIVAL ANAL; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Lazar NA, 2002, NEUROIMAGE, V16, P538, DOI 10.1006/nimg.2002.1107; Lazar NA, 2001, INT STAT REV, V69, P105, DOI 10.2307/1403532; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Shulman RG, 2007, NEUROIMAGE, V36, P277, DOI 10.1016/j.neuroimage.2006.11.035; Talairach J., 1988, COPLANAR STEREOTACTI; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Xu JS, 2006, PSYCHIAT RES-NEUROIM, V148, P103, DOI 10.1016/j.pscychresns.2006.09.005	41	144	145	0	12	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2007	61	2					352	359		10.1227/01.NEU.0000279985.94168.7F			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	197AN	WOS:000248525400030	17762748				2021-06-18	
J	Habgood, MD; Bye, N; Dziegielewska, KM; Ek, CJ; Lane, MA; Potter, A; Morganti-Kossmann, C; Saunders, NR				Habgood, M. D.; Bye, N.; Dziegielewska, K. M.; Ek, C. J.; Lane, M. A.; Potter, A.; Morganti-Kossmann, C.; Saunders, N. R.			Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						blood-brain barrier; brain damage; brain injury	CLOSED-HEAD INJURY; OPOSSUM MONODELPHIS-DOMESTICA; HORSERADISH-PEROXIDASE; EXPERIMENTAL-MODEL; SPINAL-CORD; PROTEIN EXTRAVASATION; FLUID PERCUSSION; CEREBRAL EDEMA; RAT; PLASMA	The entry of therapeutic compounds into the brain and spinal cord is normally restricted by barrier mechanisms in cerebral blood vessels (blood-brain barrier) and choroid plexuses (blood-CSF barrier). In the injured brain, ruptured cerebral blood vessels circumvent these barrier mechanisms by allowing blood contents to escape directly into the brain parenchyma. This process may contribute to the secondary damage that follows the initial primary injury. However, this localized compromise of barrier function in the injured brain may also provide a 'window of opportunity' through which drugs that do not normally cross the blood-brain barriers are able to do so. This paper describes a systematic study of barrier permeability in a mouse model of traumatic brain injury using both small and large inert molecules that can be visualized or quantified. The results show that soon after trauma, both large and small molecules are able to enter the brain in and around the injury site. Barrier restriction to large (protein-sized) molecules is restored by 4-5 h after injury. In contrast, smaller molecules (286-10 000 Da) are still able to enter the brain as long as 4 days postinjury. Thus the period of potential secondary damage from barrier disruption and the period during which therapeutic compounds have direct access to the injured brain may be longer than previously thought.	Univ Melbourne, Dept Pharmacol, Victorian Neurotrauma Res Grp, Parkville, Vic 3010, Australia; Univ Melbourne, CtrNeu, Parkville, Vic 3010, Australia; Alfred Hosp, Natl Trauma Res Inst, Dept Trauma Surg, Melbourne, Vic, Australia	Habgood, MD (corresponding author), Univ Melbourne, Dept Pharmacol, Victorian Neurotrauma Res Grp, Parkville, Vic 3010, Australia.	mhabgood@unimelb.edu.au	Lane, Michael/B-3395-2014; Lane, Michael/A-2824-2013	Lane, Michael/0000-0003-1375-6483; Saunders, Norman/0000-0001-6660-7639; Morganti-Kossmann, Cristina/0000-0002-0807-2063			BRIGHTMA.MW, 1969, J CELL BIOL, V40, P648, DOI 10.1083/jcb.40.3.648; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CLEMENTI F, 1970, J HISTOCHEM CYTOCHEM, V18, P887, DOI 10.1177/18.12.887; COTRAN R, 1968, J CELL BIOL, V37, P123, DOI 10.1083/jcb.37.1.123; COTRAN RS, 1967, P SOC EXP BIOL MED, V126, P557; DALLAL MM, 1994, J APPL PHYSIOL, V77, P1030; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Ek CJ, 2006, J COMP NEUROL, V496, P13, DOI 10.1002/cne.20885; Ek CJ, 2003, J COMP NEUROL, V460, P451, DOI 10.1002/cne.10661; Ek J., 2001, J PHYSL, V536, P841, DOI [10.1111/j.1469-7793.2001.00841.x, DOI 10.1111/J.1469-7793.2001.00841.X]; FREDRIKSSON K, 1985, ACTA NEUROPATHOL, V68, P284, DOI 10.1007/BF00690831; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Hartl R, 1997, ACT NEUR S, V70, P240; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; MAZARIEGOS MR, 1984, J CELL BIOL, V98, P1865, DOI 10.1083/jcb.98.5.1865; Morganti-Kossmann MC, 2005, BLOOD BRAIN BARRIER, V457- 479; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; NORDBORG C, 1991, ACTA NEUROPATHOL, V82, P118, DOI 10.1007/BF00293954; Pardridge WM, 2002, ARCH NEUROL-CHICAGO, V59, P35, DOI 10.1001/archneur.59.1.35; PETITO CK, 1979, J NEUROPATH EXP NEUR, V38, P222, DOI 10.1097/00005072-197905000-00003; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Rawson RA, 1943, AM J PHYSIOL, V138, P0708; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; ROSS MD, 1977, ACTA OTO-LARYNGOL, V84, P187, DOI 10.3109/00016487709123957; Saunders NR, 1999, CLIN EXP PHARMACOL P, V26, P11, DOI 10.1046/j.1440-1681.1999.02986.x; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHINOWARA NL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1771, DOI 10.1001/archopht.1983.01040020773022; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stolp HB, 2005, EUR J NEUROSCI, V22, P2805, DOI 10.1111/j.1460-9568.2005.04483.x; Tannock GW, 1992, LACTIC ACID BACTERIA, P21; Wagner KR, 2002, DEV NEUROSCI-BASEL, V24, P154, DOI 10.1159/000065703	38	144	148	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JAN	2007	25	1					231	238		10.1111/j.1460-9568.2006.05275.x			8	Neurosciences	Neurosciences & Neurology	128TQ	WOS:000243682100023	17241284				2021-06-18	
J	Panikashvili, D; Shein, NA; Mechoulam, R; Trembovler, V; Kohen, R; Alexandrovich, A; Shohami, E				Panikashvili, D; Shein, NA; Mechoulam, R; Trembovler, V; Kohen, R; Alexandrovich, A; Shohami, E			The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines	NEUROBIOLOGY OF DISEASE			English	Article						traumatic brain injury; endocannabinoids; neuroprotection; BBB integrity; inflammation; cytokines; reactive oxygen species	TUMOR-NECROSIS-FACTOR; FACTOR-KAPPA-B; CANNABINOID RECEPTOR-LIGAND; FACTOR-ALPHA; NUCLEAR-FACTOR; RAT-BRAIN; DOWN-REGULATION; CELL-DEATH; CB1; NEUROPROTECTION	Endocannabinoids are involved in neuroprotection through numerous biochemical pathways. We have shown that the endocannabinoid 2-arachidonoyl glycerol (2-AG) is released in mouse brain after closed head injury (CHI), and treatment with exogenous 2-AC. exerts neuroprotection via the central cannabinoid receptor CB1. This process involves inhibition of inflammatory signals that are mediated by activation of the transcription factor NF-kappa B. The present study was designed to examine the effect of 2-AG on the blood-brain barrier (BBB) and the possible inhibition of the early expression of proinflammatory cytokines, which are implicated in BBB disruption. We found that 2-AG decreased BBB permeability and inhibited the acute expression of the main proinflammatory cytokines: TNF-alpha, IL-1 beta and IL-6. It also augmented the levels of endogenous antioxidants. We suggest that 2-AG exerts neuroprotection in part by inhibition of the early (1-4 h) inflammatory response and augmentation of the brain reducing power. (c) 2005 Elsevier Inc. All rights reserved.	Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Dept Pharmacol, IL-91120 Jerusalem, Israel	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-9789] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P01DA009789] Funding Source: NIH RePORTER		BACUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chang YH, 2001, J CELL BIOCHEM, V81, P715, DOI 10.1002/jcb.1103; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chen YQ, 2000, J PHARMACOL EXP THER, V293, P807; Croxford JL, 2003, J CLIN INVEST, V111, P1231, DOI 10.1172/JCI200317652; Di Marzo V, 2000, FASEB J, V14, P1432, DOI 10.1096/fj.14.10.1432; DROUET C, 1991, J IMMUNOL, V147, P1694; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; Gallily R, 2000, EUR J PHARMACOL, V406, pR5, DOI 10.1016/S0014-2999(00)00653-1; Ginis I, 2000, MOL MED, V6, P1028, DOI 10.1007/BF03402054; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Hanus L, 2003, BRAIN RES, V983, P144, DOI 10.1016/S0006-8993(03)03046-4; Herring AC, 1999, J PHARMACOL EXP THER, V291, P1156; Juttler E, 2004, NEUROPHARMACOLOGY, V47, P580, DOI 10.1016/j.neuropharm.2004.05.009; Kirkham TC, 2002, BRIT J PHARMACOL, V136, P550, DOI 10.1038/sj.bjp.0704767; Kohen R, 1999, METHOD ENZYMOL, V300, P428; LIBERMAN R, 1990, DENT MATER, V6, P10, DOI 10.1016/0109-5641(90)90036-E; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Lu J, 2001, J NEUROTRAUM, V18, P399, DOI 10.1089/089771501750170976; LYMAN WD, 1989, J NEUROIMMUNOL, V23, P73, DOI 10.1016/0165-5728(89)90075-1; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; McCarron RM, 2003, ACTA NEUROCHIR SUPPL, V86, P271; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 2002, Sci STKE, V2002, pre5, DOI 10.1126/stke.2002.129.re5; Melis M, 2004, J NEUROSCI, V24, P10707, DOI 10.1523/JNEUROSCI.3502-04.2004; Molina-Holgado F, 2003, J NEUROSCI, V23, P6470; MolinaHolgado F, 1997, NEUROREPORT, V8, P1929, DOI 10.1097/00001756-199705260-00027; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Moro MA, 2003, NEUROSIGNALS, V12, P53, DOI 10.1159/000071814; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; Nagayama T, 1999, J NEUROSCI, V19, P2987; Ouyang YL, 1998, MOL PHARMACOL, V53, P676; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Puffenbarger RA, 2000, GLIA, V29, P58, DOI 10.1002/(SICI)1098-1136(20000101)29:1<58::AID-GLIA6>3.3.CO;2-N; Sancho R, 2003, MOL PHARMACOL, V63, P429, DOI 10.1124/mol.63.2.429; Shen MX, 1996, J NEUROSCI, V16, P4322; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Smith SR, 2000, J PHARMACOL EXP THER, V293, P136; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Sugiura T, 2000, BIOCHEM BIOPH RES CO, V271, P654, DOI 10.1006/bbrc.2000.2686; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Tang JP, 2004, J CEREBR BLOOD F MET, V24, P1133, DOI 10.1097/01.WCB.0000135593.05952.DE; Trembovler V, 1999, J INTERF CYTOK RES, V19, P791, DOI 10.1089/107999099313640; van der Stelt M, 2001, J NEUROSCI, V21, P6475; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; von Gertten C, 2003, J NEUROSCI RES, V73, P803, DOI 10.1002/jnr.10729; Walter L, 2004, BRIT J PHARMACOL, V141, P775, DOI 10.1038/sj.bjp.0705667; Walter L, 2003, J NEUROSCI, V23, P1398; Wang LX, 2003, J IMMUNOL, V171, P3194, DOI 10.4049/jimmunol.171.6.3194; WIRGUIN I, 1994, IMMUNOPHARMACOLOGY, V28, P209, DOI 10.1016/0162-3109(94)90056-6; Witting A, 2004, J NEUROCHEM, V89, P1555, DOI 10.1111/j.1471-4159.2004.02544.x; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	63	144	147	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	MAY	2006	22	2					257	264		10.1016/j.nbd.2005.11.004			8	Neurosciences	Neurosciences & Neurology	040KS	WOS:000237378000005	16364651				2021-06-18	
J	Salmond, CH; Menon, DK; Chatfield, DA; Williams, GB; Pena, A; Sahakian, BJ; Pickard, JD				Salmond, CH; Menon, DK; Chatfield, DA; Williams, GB; Pena, A; Sahakian, BJ; Pickard, JD			Diffusion tensor imaging in chronic head injury survivors: Correlations with learning and memory indices	NEUROIMAGE			English	Article							TRAUMATIC BRAIN-INJURY; COMA SCALE SCORE; ALZHEIMERS-DISEASE; AXONAL INJURY; RISK-FACTOR; WEIGHTED MR; EPISODIC MEMORY; ATTENTION; COEFFICIENT; SEVERITY	Diffusion tensor imaging (DTI) provides a unique insight into the cellular integrity of the brain. While conventional magnetic resonance imaging underestimates the extent of pathology following closed head injury, diffusion-weighted imaging has been shown to more accurately delineate the extent of cerebral damage. There have only been a few case studies of DTI in chronic head injury, survivors. This study used DTI to investigate changes in anisotropy and diffusivity in survivors of head injury at least 6 months after their injury. The relationship between cognition and diffusion abnormality was also investigated. The voxel-based analysis revealed significant bilateral decreases in anisotropy, in major white matter tracts and association fibers in the temporal, frontal, parietal and occipital lobes. Statistically significant increases in diffusivity were also found in widespread areas of the cortex. A significant positive correlation was found between diffusivity, and impairment of learning and memory in the left posterior cingulate, left hippocampal formation and left temporal, frontal and occipital cortex. The common pattern of abnormality despite heterogeneous injury mechanism and lesion location in the group suggests that these cellular changes reflect secondary insults. The importance of diffusion abnormalities in head injury outcome is emphasized by the significant correlation between a learning and memory index and diffusivity in areas known to subserve this cognitive function. (c) 2005 Elsevier Inc. All rights reserved.	Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Anaesthet, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Neurosurg, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Psychiat, Cambridge CB2 2QQ, England	Salmond, CH (corresponding author), Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Box 65, Cambridge CB2 2QQ, England.	chs20@wbic.cam.ac.uk	Sahakian, Barbara/AAW-1198-2020	Sahakian, Barbara/0000-0001-7352-1745	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237, G0001354] Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354B] Funding Source: researchfish		Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Blackwell AD, 2004, DEMENT GERIATR COGN, V17, P42, DOI 10.1159/000074081; Blamire AM, 2002, BRIT J NEUROSURG, V16, P48, DOI 10.1080/02688690120114264; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; Campbell S, 2004, AM J PSYCHIAT, V161, P598, DOI 10.1176/appi.ajp.161.4.598; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Drevets WC, 2000, BIOL PSYCHIAT, V48, P813, DOI 10.1016/S0006-3223(00)01020-9; Eriksson SH, 2001, BRAIN, V124, P617, DOI 10.1093/brain/124.3.617; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; GENTRY LR, 1994, RADIOLOGY, V191, P1; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Gould RL, 2003, NEUROIMAGE, V20, P1006, DOI 10.1016/S1053-8119(03)00365-3; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Habib R, 2003, TRENDS COGN SCI, V7, P241, DOI 10.1016/S1364-6613(03)00110-4; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lepage M, 2000, P NATL ACAD SCI USA, V97, P506, DOI 10.1073/pnas.97.1.506; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Nakahara M, 2001, ACTA RADIOL, V42, P365, DOI 10.1034/j.1600-0455.2001.420404.x; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nyberg L, 1996, P NATL ACAD SCI USA, V93, P11280, DOI 10.1073/pnas.93.20.11280; O'Sullivan M, 2004, J NEUROL NEUROSUR PS, V75, P441, DOI 10.1136/jnnp.2003.014910; OWEN AM, 1995, NEUROPSYCHOLOGIA, V33, P1, DOI 10.1016/0028-3932(94)00098-A; PARK SB, 1994, NEUROPHARMACOLOGY, V33, P575, DOI 10.1016/0028-3908(94)90089-2; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Polo MD, 2002, NEUROPSYCHOLOGIA, V40, P2350, DOI 10.1016/S0028-3932(02)00127-6; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; RUGGGUNN FJ, 2001, J NEUROL, V124, P627; SAHAKIAN B, 1989, BRIT J PSYCHIAT, V154, P797, DOI 10.1192/bjp.154.6.797; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; SHALAT SL, 1987, NEUROLOGY, V37, P1630, DOI 10.1212/WNL.37.10.1630; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; Swainson R, 2001, DEMENT GERIATR COGN, V12, P265, DOI 10.1159/000051269; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; Weiss F, 2002, J NEUROSCI, V22, P3332; Werring DJ, 1998, J NEUROL NEUROSUR PS, V65, P863, DOI 10.1136/jnnp.65.6.863; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Wieshmann UC, 1999, LANCET, V353, P1242, DOI 10.1016/S0140-6736(99)00248-2	75	144	148	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN 1	2006	29	1					117	124		10.1016/j.neuroimage.2005.07.012			8	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	001ZO	WOS:000234581400012	16084738				2021-06-18	
J	Teasdale, GM; Murray, GD; Nicoll, JAR				Teasdale, GM; Murray, GD; Nicoll, JAR			The association between APOE epsilon 4, age and outcome after head injury: a prospective cohort study	BRAIN			English	Article						head injury; traumatic brain injury; genetics; outcome; apolipoprotein E	APOLIPOPROTEIN-E GENOTYPE; TRAUMATIC BRAIN-INJURY; E POLYMORPHISM; SUBARACHNOID HEMORRHAGE; RECOVERY; ALLELE; RISK; DAMAGE; MODEL; E3	Previous preliminary studies have suggested that possession of the APOE epsilon 4 allele is associated with a poor outcome after head injury. This study was designed to confirm and extend those observations in a larger study with examination of additional variables. We prospectively identified admissions to a Neurosurgical Unit for head injury, collected demographic and clinical data, determined APOE genotypes and obtained follow-up information at 6 months. A total of 1094 subjects were enrolled (age range: 0-93 years, mean 37 years). Outcome was assessed using the Glasgow Outcome Scale. There was no overall association between APOE genotype and outcome, with 36% of APOE epsilon 4 carriers having an unfavourable outcome compared with 33% of non-carriers of APOE epsilon 4. However, there was evidence of an interaction between age and APOE genotype on outcome (P = 0.007) such that possession of APOE epsilon 4 reduced the prospect of a favourable outcome in children and young adults. The influence of APOE genotype in younger patients after head injury can be expressed as, at age < 15 years, carriage of APOE epsilon 4 being equivalent to ageing by 25 years. This finding is consistent with experimental data suggesting that the effect of APOE genotype on outcome after head injury may be expressed through the processes of repair and recovery.	Univ Southampton, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England; Univ Glasgow, So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow, Lanark, Scotland; Univ Edinburgh, Sch Med, Div Community Hlth Sci, Edinburgh, Midlothian, Scotland	Nicoll, JAR (corresponding author), Univ Southampton, Southampton Gen Hosp, Level E,Mailpoint 813, Southampton SO16 6YD, Hants, England.	J.Nicoll@soton.ac.uk	Nicoll, James/I-9253-2017	Nicoll, James/0000-0002-9444-7246; Murray, Gordon/0000-0001-9866-4734			Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; CUMMING AM, 1984, CLIN GENET, V25, P310; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Dunn LT, 2001, NEUROSURGERY, V48, P1006, DOI 10.1097/00006123-200105000-00007; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GRADY MS, 1989, J NEUROSURG, V71, P534, DOI 10.3171/jns.1989.71.4.0534; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; JENNETT B, 1975, LANCET, V1, P480; Jorm AF, 2003, PSYCHOSOM MED, V65, P662, DOI 10.1097/01.PSY.0000077506.29218.60; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Kay AD, 2003, J NEUROTRAUM, V20, P243, DOI 10.1089/089771503321532824; Leclercq PD, 2005, J NEUROL NEUROSUR PS, V76, P229, DOI 10.1136/jnnp.2003.025528; Leung CHS, 2002, STROKE, V33, P548, DOI 10.1161/hs0202.102326; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McCarron MO, 2000, ARCH NEUROL-CHICAGO, V57, P1480, DOI 10.1001/archneur.57.10.1480; McCarron MO, 2003, ACTA NEUROL SCAND, V107, P106, DOI 10.1034/j.1600-0404.2003.01365.x; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Niskakangas T, 2001, STROKE, V32, P1181, DOI 10.1161/01.STR.32.5.1181; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Quinn TJ, 2004, NEUROPATH APPL NEURO, V30, P569, DOI 10.1111/j.1365-2990.2004.00581.x; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Tang J, 2003, SURG NEUROL, V60, P391, DOI 10.1016/S0090-3019(03)00323-9; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Turic D, 2001, NEUROSCI LETT, V299, P97, DOI 10.1016/S0304-3940(00)01789-4; White F, 2001, EXP NEUROL, V169, P307, DOI 10.1006/exnr.2001.7655; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	44	144	149	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV	2005	128		11				2556	2561		10.1093/brain/awh595			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	980UV	WOS:000233044600008	16033781	Bronze			2021-06-18	
J	Milman, A; Rosenberg, A; Weizman, R; Pick, CG				Milman, A; Rosenberg, A; Weizman, R; Pick, CG			Mild traumatic brain injury induces persistent cognitive deficits and behavioral disturbances in mice	JOURNAL OF NEUROTRAUMA			English	Article						cognitive deficits; concussive head trauma model; depressive-like behavior; mild traumatic brain injury	RIGHT PARIETAL CORTEX; MINOR HEAD-INJURY; NUCLEUS BASALIS; RAT; IMPAIRMENT; DEPRESSION; TERM; HIPPOCAMPUS; LESIONS; CONSENSUS	Victims of mild traumatic brain injury (mTBI) do not show clear morphological brain defects, but frequently suffer from long-lasting cognitive deficits, emotional difficulties and behavioral disturbances. In the present study, we investigated the effects of experimental mTBI in mice on cognition, spatial and non-spatial tasks, and depressive-like behavior in mice. Experimental brain injury was induced using a concussive head trauma, which creates the TBI by a weight-drop device. Different groups of mice were tested at 7, 30, 60, and 90 days post-injury for cognitive function (the swim T-maze and the passive avoidance test) and for depression-like behavior (the forced swimming test). These tests have been used infrequently in the past in mTBI research. Significant differences were observed between the injured mice compared to the controls in both the swim T-maze (day 30: p < 0.001) and passive avoidance (day 30: p < 0.05) tests. In addition, a significant difference was detected in the forced swimming test between the injured mice and the controls (day 7: p < 0.05; day 90: p < 0.01), which showed a depressive-like state in the injured animals beginning 7 days post-injury. These results demonstrate that persistent deficits in these tests of cognitive learning abilities and emergence of depressive-like behavior in injured mice are similar to those reported in human post-concussion syndrome.	Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Dept Psychiat, IL-69978 Tel Aviv, Israel; Tel Aviv Community Mental Hlth Ctr, Tel Aviv, Israel	Pick, CG (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	pickc@post.tau.ac.il	Pick, Chaim/D-4789-2009	Milman, Anat/0000-0002-8551-4101			BARTUS RT, 1986, PHARMACOL BIOCHEM BE, V24, P1287, DOI 10.1016/0091-3057(86)90186-3; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; GOODLETT CR, 1989, BEHAV BRAIN RES, V32, P63, DOI 10.1016/S0166-4328(89)80072-5; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Heinrichs SC, 1996, NEUROSCIENCE, V74, P303, DOI 10.1016/0306-4522(96)00140-6; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Hogg S, 1998, BEHAV BRAIN RES, V93, P157, DOI 10.1016/S0166-4328(97)00145-9; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; MUNDY WR, 1988, NEUROTOXICOLOGY, V9, P511; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; STRUGAR J, 1993, J TRAUMA, V34, P555, DOI 10.1097/00005373-199304000-00012; TAGHZOUTI K, 1985, BRAIN RES, V344, P9, DOI 10.1016/0006-8993(85)91184-9; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WILLNER P, 1990, PHARMACOL THERAPEUT, V45, P425, DOI 10.1016/0163-7258(90)90076-E; WINOCUR G, 1985, BEHAV BRAIN RES, V16, P135, DOI 10.1016/0166-4328(85)90088-9; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	32	144	145	1	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2005	22	9					1003	1010		10.1089/neu.2005.22.1003			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	967HP	WOS:000232082600007	16156715				2021-06-18	
J	Sullivan, PG; Thompson, M; Scheff, SW				Sullivan, PG; Thompson, M; Scheff, SW			Continuous infusion of cyclosporin A postinjury significantly ameliorates cortical damage following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						trauma; cortical contusion; immunosuppressant	CENTRAL-NERVOUS-SYSTEM; MITOCHONDRIAL PERMEABILITY TRANSITION; TRANSIENT FOREBRAIN ISCHEMIA; RAT HIPPOCAMPAL-NEURONS; EXCITATORY AMINO-ACIDS; REACTIVE OXYGEN; RECEPTOR ACTIVATION; CA2+ HOMEOSTASIS; INNER MEMBRANE; NMDA RECEPTOR	Traumatic brain injury (TBI) results in the rapid necrosis of cortical tissue at the site of injury. In the ensuing hours and days, secondary injury exacerbates the original damage resulting in significant neurological dysfunction. Recent reports from our lab demonstrate that a bolus injection of the immunosuppressant cyclosporin A (CsA) is neuroprotective following TBI. CsA transiently inhibits the opening of the mitochondrial permeability transition pore and maintains calcium homeostasis in isolated mitochondria. The present study utilized a unilateral controlled cortical impact model of TBI to assess whether the neuroprotective effects of CsA could be extended by chronic infusion. Adult rats were subjected to a moderate (2 mm) cortical deformation and the extent of cortical damage was assessed using modern stereological techniques. Animals were administrated a 20 mg/kg intraperitoneal bolus of CsA or vehicle 15 min postinjury and osmotic minipumps were implanted subcutaneously to deliver CsA (4.5 or 10 mg/kg/day) or vehicle. All animals receiving CsA demonstrated a significant reduction in lesion volume, with the highest dose offering the most neuroprotection (74% reduction in lesion volume). These results extend our previous findings and demonstrate that chronic infusion of CsA is neuroprotective following TBI. These findings also suggest that the mechanisms responsible for tissue necrosis following TBI are amenable to manipulation. (C) 2000 Academic Press.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Sullivan, PG (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31220] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220] Funding Source: NIH RePORTER		ALBERS GW, 1992, ARCH NEUROL-CHICAGO, V49, P418, DOI 10.1001/archneur.1992.00530280112031; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BERDEN JHM, 1985, LANCET, V1, P219; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; Braughler J M, 1985, Cent Nerv Syst Trauma, V2, P269; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Camins A, 1997, BRAIN RES, V777, P69, DOI 10.1016/S0006-8993(97)00947-5; Choi D W, 1990, Adv Exp Med Biol, V268, P501; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DEGROEN PC, 1987, NEW ENGL J MED, V317, P861, DOI 10.1056/NEJM198710013171404; Dessi F, 1995, NEUROSCI LETT, V201, P53, DOI 10.1016/0304-3940(95)12128-Q; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; DUGAN LL, 1995, J NEUROSCI, V15, P6377; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAMIGLIO L, 1989, TRANSPLANTATION, V48, P316, DOI 10.1097/00007890-198908000-00025; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313; HUGHES RL, 1990, NEW ENGL J MED, V323, P420; ISAEV NK, 1995, B EXP BIOL MED+, V119, P365, DOI 10.1007/BF02445894; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KRAUS JF, 1996, NEUROTRAUMA, P12; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; NICHOLLS DG, 1985, PROG BRAIN RES, V63, P97; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PATCHELL RA, 1994, ANN NEUROL, V36, P688, DOI 10.1002/ana.410360503; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Prehn JHM, 1998, N-S ARCH PHARMACOL, V357, P316, DOI 10.1007/PL00005173; REECE DE, 1991, BONE MARROW TRANSPL, V8, P393; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Richter C, 1997, BIOSCIENCE REP, V17, P53, DOI 10.1023/A:1027387301845; Scanlon JM, 1998, J NEUROCHEM, V71, P2392; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schinder AF, 1996, J NEUROSCI, V16, P6125; Sengpiel B, 1998, EUR J NEUROSCI, V10, P1903, DOI 10.1046/j.1460-9568.1998.00202.x; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; Sriram K, 1998, J NEUROSCI, V18, P10287; Stout AK, 1998, NAT NEUROSCI, V1, P366; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sureda FX, 1996, N-S ARCH PHARMACOL, V354, P420, DOI 10.1007/BF00168431; SZABO I, 1991, J BIOL CHEM, V266, P3376; TAPPEL AL, 1973, FED PROC, V32, P1870; THAYER SA, 1995, CLIN EXP PHARMACOL P, V22, P303, DOI 10.1111/j.1440-1681.1995.tb02004.x; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; WALKER RW, 1988, NEUROL CLIN, V6, P261, DOI 10.1016/S0733-8619(18)30869-7; Wang GJ, 1996, J NEUROPHYSIOL, V76, P1611; White RJ, 1997, J PHYSIOL-LONDON, V498, P31, DOI 10.1113/jphysiol.1997.sp021839; White RJ, 1996, J NEUROSCI, V16, P5688; WIJDICKS EFM, 1995, NEUROLOGY, V45, P1962, DOI 10.1212/WNL.45.11.1962; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; ZAIDAN E, 1994, J NEUROCHEM, V63, P1812	75	144	147	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2000	161	2					631	637		10.1006/exnr.1999.7282			7	Neurosciences	Neurosciences & Neurology	290FW	WOS:000085666500018	10686082				2021-06-18	
J	Schwartz, MF; Montgomery, MW; Buxbaum, LJ; Lee, SS; Carew, TG; Coslett, HB; Ferraro, M; Fitzpatrick-DeSalme, E; Hart, T; Mayer, N				Schwartz, MF; Montgomery, MW; Buxbaum, LJ; Lee, SS; Carew, TG; Coslett, HB; Ferraro, M; Fitzpatrick-DeSalme, E; Hart, T; Mayer, N			Naturalistic action impairment in closed head injury	NEUROPSYCHOLOGY			English	Article							FRONTAL-LOBE DAMAGE; IDEATIONAL APRAXIA; COMPUTERIZED-TOMOGRAPHY; UTILIZATION BEHAVIOR; CEREBRAL ACTIVATION; WORKING-MEMORY; BRAIN-DAMAGE; DEFICITS	The authors sought to determine whether errors of action committed by patients with closed head injury (CHI) would conform to predictions derived from frontal lobe theories. In Study 1, 30 CHI patients and 18 normal controls performed routine activities, such as wrapping a present, under conditions of graded complexity. CHI patients committed more errors even on the simplest condition; but, except for a higher proportion of omitted actions, their error profile was very similar to that of controls. Study 2 involved a subset of patients whose performance in Study 1 was within normal limits. When these high functioning patients were asked to perform the routine tasks under still more taxing conditions, they, too, committed errors in excess of the control group. Accounts based on frontal mechanisms have a difficult time explaining the overall pattern of findings. An alternative based on limited-capacity resources is suggested.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Temple Univ, Dept Phys Med & Rehabil, Philadelphia, PA 19122 USA; American Univ, Dept Psychol, Washington, DC 20016 USA; Drexel Univ, Dept Psychol, Philadelphia, PA USA; Temple Univ, Ctr Cognit Neurosci, Philadelphia, PA 19122 USA; Temple Univ, Dept Neurol, Philadelphia, PA 19122 USA	Schwartz, MF (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	mschwar@vm.temple.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS31824] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031824] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ARBIB MA, 1981, HDB PHYSL, V3, P1448; Baars BJ., 1992, EXPT SLIPS HUMAN ERR; Baddeley A., 1993, ATTENTION SELECTION, P152; BLACKWELL A, 1995, J COGNITIVE NEUROSCI, V7, P228, DOI 10.1162/jocn.1995.7.2.228; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Buxbaum LJ, 1997, COGNITIVE NEUROPSYCH, V14, P219, DOI 10.1080/026432997381565; Buxbaum LJ, 1995, NEUROCASE, V1, P3, DOI 10.1080/13554799508402342; CANAVAN AGM, 1985, J NEUROL NEUROSUR PS, V48, P1049, DOI 10.1136/jnnp.48.10.1049; Carpenter P.A., 1994, HDB PSYCHOLINGUISTIC, P1075; Cooper R, 1997, PROCEEDINGS OF THE NINETEENTH ANNUAL CONFERENCE OF THE COGNITIVE SCIENCE SOCIETY, P131; COSLETT HB, 1987, NEUROLOGY, V37, P957, DOI 10.1212/WNL.37.6.957; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; DERENZI E, 1988, BRAIN, V111, P1173, DOI 10.1093/brain/111.5.1173; DIAMOND A, 1990, ANN NY ACAD SCI, V608, P637, DOI 10.1111/j.1749-6632.1990.tb48913.x; Fuster J, 1989, PREFRONTAL CORTEX; Goldman-Rakic P. S., 1987, NERVOUS SYSTEM, P373, DOI DOI 10.1002/CPHY.CP010509; Grafman J., 1989, INTEGRATING THEORY P, P93; HART T, 1997, IN PRESS AWARENESS E; HEILMAN KM, 1979, NEUROPSYCHOLOGIA, V17, P315, DOI 10.1016/0028-3932(79)90077-0; HEILMAN KM, 1978, NEUROLOGY, V28, P229, DOI 10.1212/WNL.28.3.229; Kahneman D., 1973, ATTENTION EFFORT; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; LADAVAS E, 1989, NEUROPSYCHOLOGIA, V27, P353, DOI 10.1016/0028-3932(89)90024-9; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LHERMITTE F, 1983, BRAIN, V106, P237, DOI 10.1093/brain/106.2.237; LIEPMANN H, 1980, LEFT HEMISPHERE ACTI; Luria A. R., 1966, HIGHER CORTICAL FUNC; MACKAY DG, 1985, NEUROPSYCHOLOGICAL S, P111; Mayer N., 1990, NEUROPSYCHOLOGY EVER, P259; Neisser U., 1976, COGNITION REALITY; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; NORMAN DA, 1981, PSYCHOL REV, V88, P1, DOI 10.1037/0033-295X.88.1.1; OCHIPA C, 1989, ANN NEUROL, V25, P190, DOI 10.1002/ana.410250214; Penfield W, 1935, BRAIN, V58, P115, DOI 10.1093/brain/58.1.115; Pocock SJ, 1983, CLIN TRIALS PRACTICA; POECK K, 1983, J NEUROL, V230, P1, DOI 10.1007/BF00313591; POSNER MI, 1987, PSYCHOBIOLOGY, V15, P107; Reason J., 1990, HUMAN ERROR; REASON JT, 1982, ABSENT MINDED PSYCHO; ROBERTSON LH, 1993, UNILATERAL NEGLECT C, P257; ROY EA, 1982, NORMALITY PATHOLOGY, P265; SAFFRAN EM, 1992, UNPUB; Schwartz M. F., 1997, APRAXIA NEUROPSYCHOL, P269; Schwartz M. F., 1995, J INT NEUROPSYCH SOC, V1, P149; SCHWARTZ MF, 1991, COGN NEUROPSYCHOL, V8, P381, DOI 10.1080/02643299108253379; Schwartz MF, 1995, COGNITIVE NEUROPSYCH, V12, P863, DOI 10.1080/02643299508251406; Schwartz MF, 1995, ANN NY ACAD SCI, V769, P321, DOI 10.1111/j.1749-6632.1995.tb38148.x; SCHWARTZ MF, 1993, J HEAD TRAUMA REHAB, V8, P59, DOI DOI 10.1097/00001199-199303000-00007; SCHWARTZ MF, 1997, UNPUB NATURALISTIC A; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1989, BRAIN, V112, P1587, DOI 10.1093/brain/112.6.1587; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; Shallice T., 1988, NEUROPSYCHOLOGY MENT; *STAT U NEW YORK B, 1993, GUID US UN DAT SET M; TRENNERY MR, 1989, STROOP NEUROPSYCHOLO; Wickens C.D., 1984, VARIETIES ATTENTION, P63, DOI 10.1038/s41598-020-80452-5	59	144	145	0	3	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JAN	1998	12	1					13	28		10.1037/0894-4105.12.1.13			16	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	YR430	WOS:000071494500002	9460731				2021-06-18	
J	Beetar, JT; Guilmette, TJ; Sparadeo, FR				Beetar, JT; Guilmette, TJ; Sparadeo, FR			Sleep and pain complaints in symptomatic traumatic brain injury and neurologic populations	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEAD-INJURY; POSTCONCUSSION SYNDROME; PREVALENCE	Objective: To compare the incidence of sleep and pain complaints in symptomatic traumatic brain injury (TBI) (mild vs moderate/severe) and neurologic populations. Design: Case-control study. Setting: Outpatient neuropsychology service at a university-affiliated tertiary care center. Patients: A consecutive sample of mild (n=127) and moderate to severe (n=75) patients with TBI and a general neurologic (non-TBI) group (n=123) referred for neuropsychological assessment. Main Outcome Measures: Patient report of sleep and/or pain problems. Results: TBI subjects had significantly more insomnia (56.4% vs 30.9%) and pain complaints (58.9% vs 22%) than non-TBI subjects (p <.0001). For both subject groups, the presence of pain increased insomnia approximately twofold. Poor sleep maintainance was the most common sleep problem. In those subjects without pain, TBI patients reported more sleep complaints that non-TBI patients (p=.05). Mild TBI patients reported significantly (p <.0001) more pain than patients with a moderate to severe injury (70% vs 40%). In TBI subjects without pain, there were significantly more insomnia complaints in mild than in moderate to severe injuries (p <.01). Conclusions: TBI patients with persistent cognitve complaints have more sleep and pain concerns than general neurologic patients. Pain is strongly associated with sleep problems. Aggressive evaluation and treatment of pain and sleep problems in the TBI, especially mild TBI, population appears warranted and may contribute to increased disability. The etiology of greater sleep and pain problems in the mild than in the more severe TBI patients requires further study. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	BROWN UNIV, SCH MED, PROVIDENCE, RI 02912 USA; RHODE ISLAND HOSP, PROVIDENCE, RI USA	Beetar, JT (corresponding author), EMMA PENDLETON BRADLEY HOSP, E PROVIDENCE, RI 02914 USA.		Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604			Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BIXLER EO, 1979, AM J PSYCHIAT, V136, P1257; BONNET MH, 1993, SLEEP, V16, pS65, DOI 10.1093/sleep/16.suppl_8.S65; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROWN SJ, 1994, CLIN NEUROSCI, V6, P15; CARTLIDGE NEF, 1978, SCOT MED J, V23, P103, DOI 10.1177/003693307802300146; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; EVANS RW, 1992, NEUROL CLIN, V10, P815; Glovinsky PB, 1991, CASE STUDIES INSOMNI, P49; GOOD JL, 1989, J NEUROSURG, V71, P765, DOI 10.3171/jns.1989.71.5.0765; GREENBERG GD, 1987, SLEEP, V10, P254, DOI 10.1093/sleep/10.3.254; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Hauri P. J., 1991, CASE STUDIES INSOMNI, P65, DOI DOI 10.1007/978-1-4757-9586-8_5; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; MELLINGER GD, 1985, ARCH GEN PSYCHIAT, V42, P225, DOI 10.1001/archpsyc.1985.01790260019002; PARSONS LC, 1982, NURS RES, V31, P260; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; TSUSHIMA WT, 1993, HEADACHE, V33, P139, DOI 10.1111/j.1526-4610.1993.hed3303139.x; WILKINSON M, 1980, UPSALA J MED SCI, P48; Wooten V, 1994, PRINCIPLES PRACTICE, V2, P509; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13	25	144	145	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1996	77	12					1298	1302		10.1016/S0003-9993(96)90196-3			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	VX898	WOS:A1996VX89800014	8976315				2021-06-18	
J	YOGANANDAN, N; PINTAR, FA; SANCES, A; WALSH, PR; EWING, CL; THOMAS, DJ; SNYDER, RG				YOGANANDAN, N; PINTAR, FA; SANCES, A; WALSH, PR; EWING, CL; THOMAS, DJ; SNYDER, RG			BIOMECHANICS OF SKULL FRACTURE	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, DC	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		BIOMECHANICS; DYNAMIC LOADING; HUMAN TOLERANCE; IMPACT RESPONSE; SKULL FRACTURE; STATIC LOADING	INJURIES	This study was conducted to determine the biomechanics of the human head under quasistatic and dynamic loads. Twelve unembalmed intact human cadaver heads were tested to failure using an electrohydraulic testing device. Quasistatic loading was done at a rate of 2.5 mm/s. Impact loading tests were conducted at a rate of 7.1 to 8.0 mis. Vertex, parietal, temporal, frontal, and occipital regions were selected as the loading sites. Pathological alterations were determined by pretest and posttest radiography, close-up computed tomography (CT) images, macroscopic evaluation, and defleshing techniques. Biomechanical force-deflection response, stiffness, and energy-absorbing characteristics were obtained. Results indicated the skull to have nonlinear structural response. The failure loads, deflections, stiffness, and energies ranged from 4.5 to 14.1 kN, 3.4 to 16.6 mm, 467 to 5867 N/mm, and 14.1 to 68.5 J, respectively. The overall mean values of these parameters for quasistatic and dynamic loads were 6.4 kN (+/-1.1), 12.0 mn (+/-1.6), 812 N/mm (+/-139), 33.5 J (+/-8.5), and 11.9 kN (+/-0.9), 5.8 mm (+/-1.0), 4023 N/mm (+/-541), 28.0 J (+/-5.1), respectively. It should be emphasized that these values do not account for the individual variations in the anatomical locations on the craniun of the specimens. While the X-rays and CT scans identified the fracture, the precise direction and location of the impact on the skull were not apparent in these images. Fracture widths were consistently wider at sites remote from the loading region. Consequently, based on retrospective images, it may not be appropriate to extrapolate the anatomical region that sustained the impact forces. The quantified biomechanical response parameters will assist in the development and validation of finite element models of head injury.	VET AFFAIRS MED CTR,MILWAUKEE,WI; EWING BIODYNAM CORP,NEW ORLEANS,LA; HOECHST CELANESE CORP,SOMERVILLE,NJ; BIODYNAM INT,TUCSON,AZ	YOGANANDAN, N (corresponding author), FMLH MED COLL WISCONSIN,MCW CLIN,DEPT NEUROSURG,9200 W WISCONSIN AVE,MILWAUKEE,WI 53226, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49CCR-507370, R49CCR-703640] Funding Source: Medline		ALLSOP DL, 1993, ACCIDENTAL INJURY BI, P247; BECKER DP, 1985, CENTRAL NERVOUS SYST; Cooper P, 1982, HEAD INJURY; DIMASI F, 1991, AUTO TRAFFIC SAFETY, P20; EWING CL, 1983, IMPACTS INJURY HEAD; GOLDSMITH W, 1972, BIOMECHANICS ITS F O, P585; GOT C, 1978, 22ND STAPP CAR CRASH, P55; GURDJIAN ES, 1958, HEAD INJURIES MECHAN; Gurdjian ES, 1975, IMPACT HEAD INJURY M; GURDJIAN ES, 1961, SURG GYNECOL OBSTET, P185; HARRIS H, 1981, HEAD NECK INJURY CRI, P6; HODGSON VR, 1967, AM J ANAT, V120, P113, DOI 10.1002/aja.1001200109; HODGSON VR, 1970, 14TH STAPP CAR CRASH, P341; HODGSON VR, 1972, 15TH STAPP CAR CRASH, P190; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; McElhaney J., 1972, HUMAN IMPACT TOLERAN, P85; Melvin J.W., 1993, ACCIDENTAL INJURY BI, P268; Nahum A., 1980, 24TH STAPP CAR CRASH, P43; NAHUM A, 1981, 25TH STAPP CAR CRASH, P241; NAKAMURA N, 1986, MECHANISMS HEAD SPIN, P219; Newman JA, 1993, ACCIDENTAL INJURY BI, P292; ODOM GL, 1979, CENTRAL NERVOUS SYST; Ommaya A.K., 1985, BIOMECHANICS TRAUMA, P245; Ono K, 1980, 24TH P STAPP CAR CRA, P101; SANCES A, 1981, CRC CR REV BIOM ENG, V5, P79; SANCES A, 1986, MECH HEAD SPINE TRAU, P189; Schneider DC, 1972, P 16 STAPP CAR CRASH, P186; SNYDER RG, 1970, INT AUTOMOBILE SAFET, P1375; YOGANANDAN N, 1995, NEUROSURGERY, V36, P956, DOI 10.1227/00006123-199505000-00011; YOGANANDAN N, 1991, J TRAUMA, V31, P699, DOI 10.1097/00005373-199105000-00015; Yoganandan N, 1990, SAE T, V98, P1790; YOGANANDAN N, 1989, SAE T, V97, P1104; YOGANANDAN N, 1994, SAE941727 PAP	33	144	149	1	25	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					659	668		10.1089/neu.1995.12.659			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000017	8683617				2021-06-18	
J	Burgess, A; Ayala-Grosso, CA; Ganguly, M; Jordao, JF; Aubert, I; Hynynen, K				Burgess, Alison; Ayala-Grosso, Carlos A.; Ganguly, Milan; Jordao, Jessica F.; Aubert, Isabelle; Hynynen, Kullervo			Targeted Delivery of Neural Stem Cells to the Brain Using MRI-Guided Focused Ultrasound to Disrupt the Blood-Brain Barrier	PLOS ONE			English	Article							LONG-TERM SURVIVAL; DOPAMINERGIC GRAFTS; MOTOR FUNCTION; MIGRATION; PROSPECTS; THERAPY; NEURONS; MODEL	Stem cell therapy is a promising strategy to treat neurodegenerative diseases, traumatic brain injury, and stroke. For stem cells to progress towards clinical use, the risks associated with invasive intracranial surgery used to deliver the cells to the brain, needs to be reduced. Here, we show that MRI-guided focused ultrasound (MRIgFUS) is a novel method for non-invasive delivery of stem cells from the blood to the brain by opening the blood brain barrier (BBB) in specific brain regions. We used MRI guidance to target the ultrasound beam thereby delivering the iron-labeled, green fluorescent protein (GFP)-expressing neural stem cells specifically to the striatum and the hippocampus of the rat brain. Detection of cellular iron using MRI established that the cells crossed the BBB to enter the brain. After sacrifice, 24 hours later, immunohistochemical analysis confirmed the presence of GFP-positive cells in the targeted brain regions. We determined that the neural stem cells expressed common stem cell markers (nestin and polysialic acid) suggesting they survived after transplantation with MRIgFUS. Furthermore, delivered stem cells expressed doublecortin in vivo indicating the stem cells were capable of differentiating into neurons. Together, we demonstrate that transient opening of the BBB with MRIgFUS is sufficient for transplantation of stem cells from the blood to targeted brain structures. These results suggest that MRIgFUS may be an effective alternative to invasive intracranial surgery for stem cell transplantation.	[Burgess, Alison; Ayala-Grosso, Carlos A.; Ganguly, Milan; Jordao, Jessica F.; Aubert, Isabelle; Hynynen, Kullervo] Sunnybrook Res Inst, Toronto, ON, Canada; [Ayala-Grosso, Carlos A.] Inst Venezolano Invest Cient, Ctr Med Expt, Lab Patol Celular & Mol, Caracas, Venezuela; [Jordao, Jessica F.; Aubert, Isabelle; Hynynen, Kullervo] Univ Toronto, Toronto, ON, Canada	Burgess, A (corresponding author), Sunnybrook Res Inst, Toronto, ON, Canada.	aburgess@sri.utoronto.ca	Aubert, Isabelle/AAG-4001-2019; Ayala-Grosso, Carlos/ABD-5221-2020	Aubert, Isabelle/0000-0001-5163-9961; Ayala-Grosso, Carlos/0000-0003-3079-1109	National Institute of Biomedical Imaging And Bioengineering of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB003268, EB009032]; Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Alzheimer's AssociationAlzheimer's Association; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB003268, R01EB009032] Funding Source: NIH RePORTER	Support for this work was provided by the grants EB003268 and EB009032 from the National Institute of Biomedical Imaging And Bioengineering of the National Institutes of Health (Kullervo Hynynen), and grants from the Canadian Institutes for Health Research and the Alzheimer's Association (Isabelle Aubert). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blurton-Jones M, 2009, P NATL ACAD SCI USA, V106, P13594, DOI 10.1073/pnas.0901402106; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141; Bulte JWM, 2004, CURR PHARM BIOTECHNO, V5, P567; Burgess A, 2008, DEV NEUROBIOL, V68, P1580, DOI 10.1002/dneu.20681; Chuang CS, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-9; Danielyan L, 2011, REJUV RES, V14, P3, DOI 10.1089/rej.2010.1130; Gogel S, 2011, GENE THER, V18, P1, DOI 10.1038/gt.2010.130; Hynynen K, 2001, RADIOLOGY, V220, P640, DOI 10.1148/radiol.2202001804; Hynynen K, 2008, ADV DRUG DELIVER REV, V60, P1209, DOI 10.1016/j.addr.2008.03.010; Jordao JF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010549; Kinoshita M, 2006, P NATL ACAD SCI USA, V103, P11719, DOI 10.1073/pnas.0604318103; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; Matsushita T, 2011, NEUROSCI LETT, V502, P41, DOI 10.1016/j.neulet.2011.07.021; McDannold N, 2005, ULTRASOUND MED BIOL, V31, P1527, DOI 10.1016/j.ultrasmedbio.2005.07.010; Nelson PT, 2002, AM J PATHOL, V160, P1201, DOI 10.1016/S0002-9440(10)62546-1; O'Reilly MA, 2011, ULTRASOUND MED BIOL, V37, P587, DOI 10.1016/j.ultrasmedbio.2011.01.008; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; Rossi F, 2002, NAT REV NEUROSCI, V3, P401, DOI 10.1038/nrn809; Seki T, 2007, J COMP NEUROL, V502, P275, DOI 10.1002/cne.21301; SEYFRIED DM, 2008, BRAIN RES, V11, P1224; SINDEN JD, 1992, CURR OPIN NEUROL NEU, V5, P902; Walczak P, 2008, STROKE, V39, P1569, DOI 10.1161/STROKEAHA.107.502047; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115; Yasuhara T, 2006, J NEUROSCI, V26, P12497, DOI 10.1523/JNEUROSCI.3719-06.2006	26	143	145	1	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2011	6	11							e27877	10.1371/journal.pone.0027877			6	Multidisciplinary Sciences	Science & Technology - Other Topics	855HV	WOS:000297555400133	22114718	DOAJ Gold, Green Published			2021-06-18	
J	Mayes, SD; Calhoun, SL; Murray, MJ; Ahuja, M; Smith, LA				Mayes, Susan Dickerson; Calhoun, Susan L.; Murray, Michael J.; Ahuja, Meesha; Smith, Laura A.			Anxiety, depression, and irritability in children with autism relative to other neuropsychiatric disorders and typical development	RESEARCH IN AUTISM SPECTRUM DISORDERS			English	Article						Anxiety; Depression; Irritability; Autism; ADHD; Retardation	TRAUMATIC BRAIN-INJURY; PSYCHIATRIC-DISORDERS; ASPERGER-SYNDROME; SPECTRUM DISORDERS; PROCESSING SPEED; COMORBID ANXIETY; ADHD SUBTYPES; YOUNG-PEOPLE; SYMPTOMS; ADOLESCENTS	Maternal ratings of anxiety, depression, and irritability were analyzed in 1390 children (6-16 years of age), including 233 children with high functioning autism (HFA, IQ >= 80), 117 children with low functioning autism (LFA, IQ < 80), 187 typical children, and 853 children with other disorders. As a group, children with HFA were characterized as irritable and anxious, and children with LFA and ADHD-combined type were irritable only. Children with anxiety disorders were anxious only. Children with major depression or dysthymic disorder were depressed and irritable. Elevated levels of irritability, anxiety, or depression were not found in ADHD-inattentive type, mental retardation, brain injury, or typical development. The frequency of parent reported anxiety symptoms was similar for children with an anxiety disorder and HFA, though some symptoms were more severe in children with anxiety disorders. Children with depression had more frequent and more severe depressive symptoms than children with HFA. Mothers of 54% of children with HFA and 42% with LFA reported depressed mood in their children. Percentages were higher for anxiety (79% and 67%) and irritability (88% and 84%). These remarkably high percentages justify routinely assessing all children with autism for depression, anxiety, and irritability. (C) 2011 Elsevier Ltd. All rights reserved.	[Mayes, Susan Dickerson; Calhoun, Susan L.; Murray, Michael J.; Ahuja, Meesha; Smith, Laura A.] Penn State Coll Med, Dept Psychiat, Hershey, PA USA	Mayes, SD (corresponding author), Milton S Hershey Med Ctr, Dept Psychiat H073, 500 Univ Dr, Hershey, PA 17033 USA.	smayes@psu.edu					Bellini S., 2004, FOCUS AUTISM DEV DIS, V19, P78, DOI DOI 10.1177/10883576040190020201; Bixler EO, 2009, SLEEP, V32, pA66; Bolton PF, 1998, PSYCHOL MED, V28, P385, DOI 10.1017/S0033291797006004; Brereton AV, 2006, J AUTISM DEV DISORD, V36, P863, DOI 10.1007/s10803-006-0125-y; Chalfant AM, 2007, J AUTISM DEV DISORD, V37, P1842, DOI 10.1007/s10803-006-0318-4; Eisenmajer R, 1996, J AM ACAD CHILD PSY, V35, P1523, DOI 10.1097/00004583-199611000-00022; Gadow KD, 2005, AUTISM, V9, P392, DOI 10.1177/1362361305056079; Gadow KD, 2004, J AUTISM DEV DISORD, V34, P379, DOI 10.1023/B:JADD.0000037415.21458.93; Gadow KD, 2008, J AUTISM DEV DISORD, V38, P1710, DOI 10.1007/s10803-008-0556-8; Ghaziuddin M, 1998, J INTELL DISABIL RES, V42, P279; Gillott A, 2001, AUTISM, V5, P277, DOI 10.1177/1362361301005003005; Gordon M., 1983, GORDON DIAGNOSTIC SY; Green J, 2000, J AUTISM DEV DISORD, V30, P279, DOI 10.1023/A:1005523232106; Howlin, 2000, AUTISM, V4, P63, DOI DOI 10.1177/1362361300004001005; Howlin P, 2003, J AUTISM DEV DISORD, V33, P3, DOI 10.1023/A:1022270118899; Hurtig T, 2009, AUTISM, V13, P583, DOI 10.1177/1362361309335719; Kanne SM, 2009, J AUTISM DEV DISORD, V39, P827, DOI 10.1007/s10803-008-0688-x; Kim J.A., 2000, AUTISM INT J RES PRA, V4, P117, DOI DOI 10.1177/1362361300004002002; Krug D. A., 1993, AUTISM BEHAV CHECKLI; Lainhart JE, 1999, INT REV PSYCHIATR, V11, P278, DOI 10.1080/09540269974177; Lecavalier L, 2006, J AUTISM DEV DISORD, V36, P1101, DOI 10.1007/s10803-006-0147-5; Leyfer OT, 2006, J AUTISM DEV DISORD, V36, P849, DOI 10.1007/s10803-006-0123-0; Lindgren S. D., 1987, ADV BEHAV ASSESSMENT, P57; MANJIVIONA J, 1995, J AUTISM DEV DISORD, V25, P23, DOI 10.1007/BF02178165; Matson JL, 2007, RES DEV DISABIL, V28, P341, DOI 10.1016/j.ridd.2005.12.004; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Mayes SD, 2004, J DEV PHYS DISABIL, V16, P257, DOI 10.1023/B:JODD.0000032301.07550.0e; Mayes SD, 2001, J ABNORM CHILD PSYCH, V29, P263, DOI 10.1023/A:1010337916636; Mayes SD, 1999, INFANT YOUNG CHILD, V12, P90, DOI 10.1097/00001163-199910000-00011; Mayes SD, 2008, J DEV BEHAV PEDIATR, V29, P206, DOI 10.1097/DBP.0b013e31816d924f; Mayes SD, 2007, CHILD NEUROPSYCHOL, V13, P469, DOI 10.1080/09297040601112773; Mayes SD, 2009, J ATTEN DISORD, V12, P540, DOI 10.1177/1087054708320402; Mayes SD, 2009, J AUTISM DEV DISORD, V39, P1682, DOI 10.1007/s10803-009-0812-6; Mayes SD, 2009, SLEEP MED CLIN, V4, P19, DOI 10.1016/j.jsmc.2008.12.004; Mayes SD, 2009, RES AUTISM SPECT DIS, V3, P931, DOI 10.1016/j.rasd.2009.04.002; Mayes SD, 2009, J PEDIATR PSYCHOL, V34, P328, DOI 10.1093/jpepsy/jsn083; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142; Miller JN, 2000, J ABNORM PSYCHOL, V109, P227, DOI 10.1037/0021-843X.109.2.227; Miller JN, 1997, J CHILD PSYCHOL PSYC, V38, P247; Muris P, 1998, J ANXIETY DISORD, V12, P387, DOI 10.1016/S0887-6185(98)00022-X; Nichols S, 2000, J PEDIATR PSYCHOL, V25, P545, DOI 10.1093/jpepsy/25.8.545; Ozonoff S., 2000, AUTISM, V4, P29, DOI [DOI 10.1177/1362361300041003, 10.1177/1362361300041003]; Pandina GJ, 2007, J AUTISM DEV DISORD, V37, P367, DOI 10.1007/s10803-006-0234-7; Piven J, 1999, AM J PSYCHIAT, V156, P557; Posey DJ, 2006, J CHILD ADOL PSYCHOP, V16, P181, DOI 10.1089/cap.2006.16.181; Russell E, 2005, AUST NZ J PSYCHIAT, V39, P633, DOI 10.1111/j.1440-1614.2005.01637.x; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; Sofronoff K, 2005, J CHILD PSYCHOL PSYC, V46, P1152, DOI 10.1111/j.1469-7610.2005.00411.x; Stewart ME, 2006, AUTISM, V10, P103, DOI 10.1177/1362361306062013; Sukhodolsky DG, 2008, J ABNORM CHILD PSYCH, V36, P117, DOI 10.1007/s10802-007-9165-9; SZATMARI P, 1995, J AM ACAD CHILD PSY, V34, P1662, DOI 10.1097/00004583-199512000-00017; The Psychological Corporation, 1999, WECHSL ABBR SCAL INT; TRYON P. A., 2006, FOCUS AUTISM OTHER D, V21, P2, DOI DOI 10.1177/10883576060210010101; Vickerstaff S, 2007, J AUTISM DEV DISORD, V37, P1647, DOI 10.1007/s10803-006-0292-x; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 1991, WECHSLER INTELLIGENC; Weisbrot DM, 2005, J CHILD ADOL PSYCHOP, V15, P477, DOI 10.1089/cap.2005.15.477; West L, 2009, J SPEC PEDIATR NURS, V14, P183, DOI 10.1111/j.1744-6155.2009.00196.x; White SW, 2009, J AUTISM DEV DISORD, V39, P1006, DOI 10.1007/s10803-009-0713-8; White SW, 2009, CLIN PSYCHOL REV, V29, P216, DOI 10.1016/j.cpr.2009.01.003; WOLRAICH ML, 1994, NEW ENGL J MED, V330, P301, DOI 10.1056/NEJM199402033300501; Wood JJ, 2009, J CHILD PSYCHOL PSYC, V50, P224, DOI 10.1111/j.1469-7610.2008.01948.x	65	143	146	0	38	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1750-9467	1878-0237		RES AUTISM SPECT DIS	Res. Autism Spectr. Disord.	JAN-MAR	2011	5	1					474	485		10.1016/j.rasd.2010.06.012			12	Education, Special; Psychology, Developmental; Psychiatry; Rehabilitation	Education & Educational Research; Psychology; Psychiatry; Rehabilitation	676XX	WOS:000283953800054					2021-06-18	
J	Whelan-Goodinson, R; Ponsford, J; Schonberger, M				Whelan-Goodinson, Rochelle; Ponsford, Jennie; Schoenberger, Michael			Validity of the Hospital Anxiety and Depression Scale to assess depression and anxiety following traumatic brain injury as compared with the Structured Clinical Interview for DSM-IV	JOURNAL OF AFFECTIVE DISORDERS			English	Article						Brain injury; Assessment; Depression; Anxiety	CLOSED-HEAD INJURY; VALIDATION; POPULATION; ATTENTION; INVENTORY; HADS	Background: Rating scales are often used in the assessment of depression and anxiety in traumatic brain injury (TBI), but few have been validated for use with this population. Overlap of symptoms between such disorders and TBI may lead to under- or over-diagnosis of depression or anxiety. Methods: 100 participants with mild to severe TBI, and 87 informants, were interviewed using the SCID-IV (Axis 1). The HADS was administered at the same time. Results: According to the SCID-TV, 34 participants were diagnosed with major depression and 36 with an anxiety disorder. Higher HADS scores were associated with a greater likelihood of depression and anxiety. However, the "clinical" categories of the HADS did not strongly correspond with the clinical diagnoses of depression and anxiety. Compared with SCID diagnoses, the depression subscale of the HADS had a sensitivity of 62% and a specificity of 92%. The anxiety subscale had a sensitivity of 75% and a specificity of 69%. Positive predictive and negative predictive values were calculated. Limitations: This study included mostly moderate to severe TBI individuals, recruited from a rehabilitation hospital. Therefore, they may not necessarily be representative of the entire TBI population. Conclusions: The HADS was a reliable measure of emotional distress in this TBI sample; however the cut-off scores and categories were not useful in predicting caseness of depression and anxiety. Clinicians should be mindful of the sequelae of TBI that may confound the scores yielded in rating scales and should follow up with a psychiatric interview when diagnosis is unclear. (c) 2008 Elsevier B.V. All rights reserved.	[Whelan-Goodinson, Rochelle; Ponsford, Jennie; Schoenberger, Michael] Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3004, Australia; [Ponsford, Jennie; Schoenberger, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Monash Univ, Dept Psychol, Clayton, Vic 3800, Australia.	rochelle_w@hotmail.com					Aben I, 2002, PSYCHOSOMATICS, V43, P386, DOI 10.1176/appi.psy.43.5.386; Al-Adawi S, 2007, BRAIN INJURY, V21, P385, DOI 10.1080/02699050701311059; *APA, 2000, HDB PSYCH MEAS APA; APA, 2000, DIAGN STAT MAN MENT; Aro P, 2004, SCAND J GASTROENTERO, V39, P1201, DOI 10.1080/00365520410008132; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Brewer T, 2003, AM J NURS, V103, P58, DOI 10.1097/00000446-200307000-00022; Collinson P, 1998, HEART, V80, P215, DOI 10.1136/hrt.80.3.215; Deb S, 1999, AM J PSYCHIAT, V156, P374; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; Eames P. G., 1990, NEUROBEHAVIOURAL SEQ; FIRST MB, 2004, COMPUTER ASSISTED SC; Golden J, 2007, J AFFECT DISORDERS, V100, P265, DOI 10.1016/j.jad.2006.10.020; Herrero MJ, 2003, GEN HOSP PSYCHIAT, V25, P277, DOI 10.1016/S0163-8343(03)00043-4; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kuijpers PMJC, 2003, PSYCHOSOMATICS, V44, P329, DOI 10.1176/appi.psy.44.4.329; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Mamelak M, 2000, NEUROPSY NEUROPSY BE, V13, P125; Marinus J, 2002, CLIN NEUROPHARMACOL, V25, P318, DOI 10.1097/00002826-200211000-00008; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Osborne RH, 2004, QUAL LIFE RES, V13, P191, DOI 10.1023/B:QURE.0000015292.56268.e7; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Snaith RP, 1995, HOSP ANXIETY DEPRESS; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; Vela-Bueno A, 2006, STUD NEUROPSYCH DEV, P163; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; WHELANGOODINSON R, PSYCHIAT DISOR UNPUB; White D, 1999, BRIT J PSYCHIAT, V175, P452, DOI 10.1192/bjp.175.5.452; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	38	143	143	0	21	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0327			J AFFECT DISORDERS	J. Affect. Disord.	APR	2009	114	1-3					94	102		10.1016/j.jad.2008.06.007			9	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	419MO	WOS:000264223900010	18656266				2021-06-18	
J	Shaw, G; Yang, C; Ellis, R; Anderson, K; Mickle, JP; Scheff, S; Pike, B; Anderson, DK; Howland, DR				Shaw, G; Yang, C; Ellis, R; Anderson, K; Mickle, JP; Scheff, S; Pike, B; Anderson, DK; Howland, DR			Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						neurofilaments; NF-H; pNF-H; hyperphosphorylated NF-H; biomarker; traumatic brain injury; spinal cord injury; ELISA; axonal biomarker; asonal injury biomarker; neuronal cytoskeleton; neuronal injury biomarker	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; PHOSPHORYLATION STATE; CEREBROSPINAL-FLUID; CORTICAL CONTUSION; CYCLOSPORINE-A; HEAD-INJURY; PROTEINS; PROTEOLYSIS; CALPAIN	Several lines of reasoning suggest that the phosphorylated axonal form of the neurofilament subunit NF-H is likely to be released from damaged and diseased neurons in significant amounts. Detection of this protein in serum or CSF might therefore provide information about the presence and degree of neuronal loss. We therefore developed a sensitive NF-H ELISA capable of detecting picograrn quantities of phosphorylated NF-H (pNF-H). This assay showed that soluble pNF-H immunoreactivity is readily detectable in the sera of adult rats following various types of experimental spinal cord injury (SCI) and traumatic brain injury (TBI), but is undetectable in the sera of normal animals. Here we describe details of the time course and extent of serum pNF-H expression following experimental SO and TBI. Following SCI, serum pNF-H showed an initial peak of expression at 16 h and a second, usually larger, peak at 3 days. Following TBI, lower levels of serum pNF-H were detected with a peak at 2 days post-injury. We also show that the higher levels of pNF-H released from injured spinal cord as compared to brain are in line with the similar to 20-fold higher levels of pNF-H present in spinal cord. These findings suggest that serum levels of pNF-H immunoreactivity may be used to conveniently monitor neuronal damage and degeneration in experimental and presumably clinical situations. (c) 2005 Elsevier Inc. All rights reserved.	Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32611 USA; Univ Florida, Coll Med, McKnight Brain Inst, Gainesville, FL 32611 USA; Univ Florida, Coll Med, Dept Physiol Sci, Gainesville, FL 32611 USA; Univ Florida, Coll Med, Dept Neurosurg, Gainesville, FL 32611 USA; Malcolm Randall VAMC, Gainesville, FL USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; EnCor Biotechnol Inc, Alachua, FL 32615 USA	Shaw, G (corresponding author), Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32611 USA.	shaw@mbi.ufl.edu	, Gerry/X-2377-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828] Funding Source: Medline		Al-Chalabi A, 2003, BIOESSAYS, V25, P346, DOI 10.1002/bies.10251; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; DELACOURTE A, 1980, BIOCHEM J, V191, P543, DOI 10.1042/bj1910543; Evans J, 2002, J NEUROPHYSIOL, V87, P1076, DOI 10.1152/jn.00088.2001; Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P149, DOI 10.1016/0165-5728(87)90049-X; GREENWOOD JA, 1993, J NEUROCHEM, V61, P191, DOI 10.1111/j.1471-4159.1993.tb03555.x; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Gu YJ, 1996, J NEUROCHEM, V67, P1235; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRIS J, 1991, J NEUROSCI RES, V30, P47, DOI 10.1002/jnr.490300107; Hashimoto R, 1999, PSYCHIAT CLIN NEUROS, V53, P587, DOI 10.1046/j.1440-1819.1999.00610.x; Hu YY, 2002, NEUROSCI LETT, V320, P156, DOI 10.1016/S0304-3940(02)00047-2; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; JOHNSON GVW, 1991, NEUROCHEM RES, V16, P869, DOI 10.1007/BF00965535; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; Lemons ML, 1999, EXP NEUROL, V160, P51, DOI 10.1006/exnr.1999.7184; Liu Q, 2004, CELL MOL LIFE SCI, V61, P3057, DOI 10.1007/s00018-004-4268-8; Loomans EEMG, 2003, ASSAY DRUG DEV TECHN, V1, P445, DOI 10.1089/154065803322163759; Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; Petzold A, 2004, J NEUROL NEUROSUR PS, V75, P1178, DOI 10.1136/jnnp.2003.017236; Petzold A, 2003, J IMMUNOL METHODS, V278, P179, DOI 10.1016/S0022-1759(03)00189-3; POLSON A, 1990, IMMUNOL INVEST, V19, P253; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SCHLAEPFER WW, 1985, J NEUROCHEM, V44, P502, DOI 10.1111/j.1471-4159.1985.tb05442.x; Shaw G, 2004, BIOCHEM BIOPH RES CO, V325, P619, DOI 10.1016/j.bbrc.2004.09.223; SHAW G, 1984, EUR J CELL BIOL, V34, P130; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Strong MJ, 2001, J NEUROCHEM, V76, P1315, DOI 10.1046/j.1471-4159.2001.00094.x; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Togo T, 2002, ACTA NEUROPATHOL, V104, P398, DOI 10.1007/s00401-002-0569-x; Van Geel WJA, 2005, J IMMUNOL METHODS, V296, P179, DOI 10.1016/j.jim.2004.11.015; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7	41	143	156	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X			BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	NOV 4	2005	336	4					1268	1277		10.1016/j.bbrc.2005.08.252			10	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	973IJ	WOS:000232515800039	16176808				2021-06-18	
J	Bibby, H; McDonald, S				Bibby, H; McDonald, S			Theory of mind after traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						mental-state; inference; lesion; brain-damage; cognitive; module	FRONTAL-LOBE DAMAGE; THEORY-OF-MIND; EXECUTIVE FUNCTIONS; SOCIAL COGNITION; HEAD-INJURY; WORKING-MEMORY; IMPAIRMENTS; CHILDREN; PERFORMANCE; DEFICITS	This study investigated whether people with severe traumatic brain injury (TBI) demonstrate a specific impairment on tasks requiring them to make inferences about others' mental states (theory of mind tasks). Participants with severe TBI were compared to a healthy group on verbal first-order and second-order theory of mind (ToM) tasks, non-verbal ToM tasks and on verbal and non-verbal tasks requiring them to make general (non-mental) inferences (NMIs). The clinical group performed more poorly than controls on both ToM and NMI tasks. This performance was not completely accounted for by the working memory or implicit language demands of the tasks. Multiple regression analyses suggested that patients with TBI have a general weakness in inference-making that, combined with linguistic and working memory limitations, impairs their performance on both non-verbal and second-order ToM tasks. However, a specific ToM impairment may underlie their poor performance on verbal first-order tasks. Implications of this finding for the possibility of a separate cognitive module of ToM are discussed, as well as for the rehabilitation of social deficits after TBI. (C) 2004 Published by Elsevier Ltd.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			ADAMS JH, 1989, SCOT MED J, V34, P399, DOI 10.1177/003693308903400106; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Adolphs R, 1999, TRENDS COGN SCI, V3, P469, DOI 10.1016/S1364-6613(99)01399-6; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; ARTUSO M, 2000, DISS ABSTR INT A, V60, P3601; Attwood T, 1998, ASPERGERS SYNDROME G; Bach LJ, 2000, COGN NEUROPSYCHIATRY, V5, P175, DOI DOI 10.1080/13546800050083520; Baron-Cohen S, 1999, EUR J NEUROSCI, V11, P1891, DOI 10.1046/j.1460-9568.1999.00621.x; BARONCOHEN S, 1994, BRIT J PSYCHIAT, V165, P640, DOI 10.1192/bjp.165.5.640; BIHRLE AM, 1986, BRAIN COGNITION, V5, P399, DOI 10.1016/0278-2626(86)90042-4; BISHOP DVM, 1993, J CHILD PSYCHOL PSYC, V34, P279, DOI 10.1111/j.1469-7610.1993.tb00992.x; BOWLER DM, 1992, J CHILD PSYCHOL PSYC, V33, P877, DOI 10.1111/j.1469-7610.1992.tb01962.x; BUTLER ACL, 1997, DISS ABSTR INT A, V57, P3389; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; DAVIS HL, 1995, AUST J PSYCHOL, V47, P25, DOI 10.1080/00049539508258765; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dimitrov M, 1996, CORTEX, V32, P357, DOI 10.1016/S0010-9452(96)80057-8; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Fine C, 2001, BRAIN, V124, P287, DOI 10.1093/brain/124.2.287; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; FODER JA, 1983, MODULARITY MIND; FODOR JA, 1985, BEHAV BRAIN SCI, V8, P1, DOI 10.1017/S0140525X0001921X; FODOR JA, 1992, COGNITION, V44, P283, DOI 10.1016/0010-0277(92)90004-2; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Garfield JL, 2001, MIND LANG, V16, P494, DOI 10.1111/1468-0017.00180; GOEL V, 1995, NEUROREPORT, V6, P1741, DOI 10.1097/00001756-199509000-00009; Gordon ACL, 1998, J EXP CHILD PSYCHOL, V68, P70, DOI 10.1006/jecp.1997.2423; Happe F, 2001, NEUROPSYCHOLOGIA, V39, P83, DOI 10.1016/S0028-3932(00)00093-2; Happe F, 1996, NEUROREPORT, V8, P197, DOI 10.1097/00001756-199612200-00040; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Hughes C, 1998, BRIT J DEV PSYCHOL, V16, P233, DOI 10.1111/j.2044-835X.1998.tb00921.x; Hughes C, 1999, PSYCHOL SCI, V10, P429, DOI 10.1111/1467-9280.00181; Hughes C, 2000, J CHILD PSYCHOL PSYC, V41, P483, DOI 10.1017/S0021963099005533; KAPLAN JA, 1990, BRAIN LANG, V38, P315, DOI 10.1016/0093-934X(90)90117-Y; Keenan T, 1998, NEW ZEAL J PSYCHOL, V27, P36; KEENAN T, 2000, MINDS MAKING ESSAYS, P234; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; Langdon R, 1997, Cogn Neuropsychiatry, V2, P167, DOI 10.1080/135468097396324; LEEKAM SR, 1994, J CHILD PSYCHOL PSYC, V35, P901, DOI 10.1111/j.1469-7610.1994.tb02301.x; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LISHMAN WA, 2001, ORGANIC PSYCHIAT PSY; Lough S, 2001, NEUROCASE, V7, P123, DOI 10.1093/neucas/7.2.123; Mazza M, 2001, SCHIZOPHR RES, V47, P299, DOI 10.1016/S0920-9964(00)00157-2; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; MOSCOVITCH M, 1991, PERSPECTIVES COGNITI, P229; OZONOFF S, 1991, J CHILD PSYCHOL PSYC, V32, P1081, DOI 10.1111/j.1469-7610.1991.tb00351.x; REID F, 1977, J EDUC RES, V70, P335, DOI 10.1080/00220671.1977.10885018; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; Sarfati Y, 2000, PSYCHOPATHOLOGY, V33, P246, DOI 10.1159/000029153; Siegal M, 1996, BRAIN LANG, V53, P40, DOI 10.1006/brln.1996.0035; Spatt J, 1997, ACTA NEUROL SCAND, V95, P173, DOI 10.1111/j.1600-0404.1997.tb00091.x; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; SULLIVAN K, 1995, BRIT J DEV PSYCHOL, V13, P191, DOI 10.1111/j.2044-835X.1995.tb00673.x; Surian L, 2001, BRAIN LANG, V78, P224, DOI 10.1006/brln.2001.2465; TagerFlusberg H, 1997, DEV NEUROPSYCHOL, V13, P487, DOI 10.1080/87565649709540689; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; Varley R, 2001, NEUROCASE, V7, P489, DOI 10.1093/neucas/7.6.489; Wechsler D., 1997, WAIS 3 ADM SCORING M; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; Zelazo PD, 1996, J CHILD PSYCHOL PSYC, V37, P479, DOI 10.1111/j.1469-7610.1996.tb01429.x	66	143	147	0	38	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2005	43	1					99	114		10.1016/j.neuropsychologia.2004.04.027			16	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	874ZB	WOS:000225388100012	15488910				2021-06-18	
J	Lee, JB; Kuroda, S; Shichinohe, H; Ikeda, J; Seki, T; Hida, K; Tada, M; Sawada, K; Iwasaki, Y				Lee, JB; Kuroda, S; Shichinohe, H; Ikeda, J; Seki, T; Hida, K; Tada, M; Sawada, K; Iwasaki, Y			Migration and differentiation of nuclear fluorescence-labeled bone marrow stromal cells after transplantation into cerebral infarct and spinal cord injury in mice	NEUROPATHOLOGY			English	Article						bis-benzimide; bone marrow stromal cells; cerebral infarct; mice; spinal cord injury; transplantation	TRAUMATIC BRAIN INJURY; INTRACEREBRAL TRANSPLANTATION; THERAPEUTIC BENEFIT; ADULT-RAT; MODEL; ISCHEMIA; STROKE; ENGRAFTMENT; EXPRESSION; NEURONS	There is increasing evidence that bone marrow stromal cells (BMSC) have the potential to migrate into the injured neural tissue and to differentiate into the CNS cells, indicating the possibility of autograft transplantation therapy. The present study was aimed to clarify whether the mouse BMSC can migrate into the lesion and differentiate into the CNS cells when transplanted into the mice subjected to focal cerebral infarct or spinal cord injury. The BMSC were harvested from mice and characterized by flow cytometry. Then, the BMSC were labeled by bis-benzimide, a nuclear fluorescence dye, over 24 h, and were stereotactically transplanted into the brain or spinal cord of the mice. The cultured BMSC expressed low levels of CD45 and high levels of CD90 and Sca-1 on flow cytometry. A large number of grafted cells survived in the normal brain 4 weeks after transplantation, many of which were located close to the transplanted sites. They expressed the neuronal marker including NeuN, MAP2, and doublecortin on fluorescent immunohistochemistry. However, when the BMSC were transplanted into the ipsilateral striatum of the mice subjected to middle cerebral artery occlusion, many of the grafted cells migrated into the corpus callosum and injured cortex, and also expressed the neuronal markers 4 weeks after transplantation. In particular, NeuN was very useful to validate the differentiation of the grafted cells, because the marker was expressed in the nuclei and was overlapped with bis-benzimide. Similar results were obtained in the mice subjected to spinal cord injury. However, many of the transplanted BMSC expressed GFAP, an astrocytic protein, in injured spinal cord. The present results indicate that the mouse BMSC can migrate into the CNS lesion and differentiate into the neurons or astrocytes, and that bisbenzimide is a simple and useful marker to label the donor cells and to evaluate their migration and differentiation in the host neural tissues over a long period.	Hokkaido Univ, Dept Neurosurg, Grad Sch Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Div Canc Genes, Inst Med Genet, Sapporo, Hokkaido, Japan; Akita Univ, Sch Med, Dept Internal Med 3, Akita 010, Japan	Kuroda, S (corresponding author), Hokkaido Univ, Dept Neurosurg, Grad Sch Med, Kita Ku, North 15 West 7, Sapporo, Hokkaido 0608638, Japan.	skuroda@med.hokudai.ac.jp	Shichinohe, Hideo/G-5367-2012				Akiyama Y, 2002, J NEUROSCI, V22, P6623; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; CRISSMAN HA, 1987, EXP CELL RES, V173, P256, DOI 10.1016/0014-4827(87)90350-8; Dunnett SB, 2001, NAT REV NEUROSCI, V2, P365, DOI 10.1038/35072572; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Ikeda J, 2001, INT J CANCER, V94, P35, DOI 10.1002/ijc.1431; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Majid A, 2000, STROKE, V31, P2707, DOI 10.1161/01.STR.31.11.2707; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Nakamura M, 2001, EXP NEUROL, V169, P407, DOI 10.1006/exnr.2001.7670; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Schwarz EJ, 1999, HUM GENE THER, V10, P2539, DOI 10.1089/10430349950016870; Seki T, 2002, NEUROSURGERY, V50, P1075, DOI 10.1097/00006123-200205000-00024; SHICHINOHE H, 2003, IN PRESS J CEREB BLO, V23; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C	30	143	175	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-6544	1440-1789		NEUROPATHOLOGY	Neuropathology	SEP	2003	23	3					169	180		10.1046/j.1440-1789.2003.00496.x			12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	719ER	WOS:000185191100003	14570283				2021-06-18	
J	Peterson, CL; Ferrara, MS; Mrazik, M; Piland, T; Elliott, T				Peterson, CL; Ferrara, MS; Mrazik, M; Piland, T; Elliott, T			Evaluation of neuropsychological stability following cerebral domain scores and postural concussion in sports	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						neuropsychology; posturography; self reported symptoms; balance; mild brain injury	MILD HEAD-INJURY; HIGH-SCHOOL; STANDARDIZED ASSESSMENT; FOOTBALL PLAYERS; TEST-PERFORMANCE; SOCCER PLAYERS; COLLEGIATE; RECOVERY; DEFICITS; BALANCE	Context: With increasing knowledge and research about concussion, there have been few objective studies that have used neuropsychological domain scores and postural stability to assess concussion. Objective: To evaluate the recovery curve of athletes who incur sport-related concussion from repeated serial testing of neuropsychological and posturography testing. Design: A prospective epidemiological model was used for the course of the study. Setting: Division I intercollegiate athletics. Participants: Athletes participating in football, soccer, basketball, softball, and cheerleading. Main Outcome Measures: Neuropsychological scores and posturography measures were obtained preseason and serially at day 1, day 2, day 3, and day 10 postconcussion. Control participants were tested at the same intervals. Neuropsychological scores were converted to standards score and then into domains of attention, learning, speed of information processing, concentration, memory, and verbal fluency. Analysis of covariance with the baseline test as the covariate was used to analyze the data with univariate post hoc tests performed. Results: Significant group differences were found for self reported symptoms (P = 0.001), speed of information processing (P = 0.005), mean stability (P = 0.002), and vestibular function (P = 0.003) between injured and control participants. A group, by day, planned comparison found that speed of information processing and composite balance measures demonstrated significant differences through day 10 postinjury, while symptoms and the vestibular ratio remained significant only through day 3. Conclusions: The concussion recovery curve demonstrated short-term neuropsychological and posturography deficits following injury. A comprehensive approach to concussion management should be used to assess the injury and make return-to-play decisions.	James Madison Univ, Harrisonburg, VA 22807 USA; Univ Georgia, Athens, GA 30602 USA; Millard Hlth, Edmonton, AB, Canada	Peterson, CL (corresponding author), James Madison Univ, MSC 4301, Harrisonburg, VA 22807 USA.	peterscl@jmu.edu					Barth JT, 1989, MILD HEAD INJURY; Benton AL, 1978, MULTILINGUAL APHASIA; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Cooper ER, 2001, ATHLET THER TODAY, V6, P6, DOI 10.1123/att.6.1.6; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DIFABIO RP, 1991, ARCH PHYS MED REHAB, V72, P292; DIFABIO RP, 1995, PHYS THER, V75, P290, DOI 10.1093/ptj/75.4.290; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FURMAN JM, 1994, BAILLIERE CLIN NEUR, V3, P501; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 1996, J SPORT REHABIL, V5, P45, DOI 10.1123/jsr.5.1.45; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, ATHLET THER TODAY, V6, P18, DOI 10.1123/att.6.1.18; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Keppel, 1991, DESIGN ANAL RES HDB; Lahat E, 1996, PEDIATR NEUROL, V15, P299, DOI 10.1016/S0887-8994(96)00221-4; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Lepers R, 1997, EUR J APPL PHYSIOL, V76, P55, DOI 10.1007/s004210050212; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Maxwell S.E., 2000, DESIGNING EXPT ANAL; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McKeag DB, 2001, CLIN J SPORT MED, V11, P132, DOI 10.1097/00042752-200107000-00002; NASHNER LM, 1982, J NEUROSCI, V2, P536; PETERSON CL, 1999, J ATHL TRAINING, V34, pS44; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Randolph C, 2001, J ATHL TRAINING, V36, P288; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Riemann BL, 1997, J SPORT REHABIL, V6, P283, DOI 10.1123/jsr.6.3.283; Smith A., 1982, SYMBOL DIGIT MODALIT; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Wechsler D, 1981, WECHSLER MEMORY SCAL	55	143	144	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2003	13	4					230	237		10.1097/00042752-200307000-00006			8	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	705AQ	WOS:000184374400006	12855925				2021-06-18	
J	Mahmood, A; Lu, DY; Wang, L; Chopp, M				Mahmood, A; Lu, DY; Wang, L; Chopp, M			Intracerebral transplantation of marrow stromal cells cultured with neurotrophic factors promotes functional recovery in adult rats subjected to traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						bone marrow stromal cells; neurotrophic factors; stem cells; transplantation; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; BONE-MARROW; STEM-CELLS; OSTEOGENESIS IMPERFECTA; PROGENITOR CELLS; NEURONS; GROWTH; BDNF; HIPPOCAMPUS; EXPRESSION	This study was designed to examine the effects of bone marrow stromal cells (MSCs) cultured in vitro with or without neurotrophic factors transplanted into adult male Wistar rats after traumatic brain injury (TBI). MSCs harvested from donor Wistar rats were cultured with either the culture medium containing brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) or the same culture media without these factors. Control and experimental animals were then traumatized by a controlled cortical impact. One day after the impact, either the placebo or the washed MSCs (1 X 10(6)) cultured with or without NGF and BDNF were transplanted adjacent to the site of injury. In addition, a nontreated group of rats was employed. Motor function of the animals was evaluated by the Rotarod test both before and after the injury. All animals were sacrificed 8 days after TBI, and the brain sections were stained by H&E as well as for immunohistochemistry. MSCs survived and migrated toward the injury site. The group treated with MSCs cultured with BDNF and NGF had a significantly higher number of engrafted cells than the group treated with MSCs cultured without BDNF and NGF (6.3 X 10(4) +/- 4,250 compared to 4.1 X 10(4) +/- 3,684; p < 0.05). In both groups, some transplanted MSCs showed positive staining for astrocytic (GFAP) and neuronal markers (Neu N and MAP-2). The groups treated with MSCs had better motor function than the groups receiving no treatment or receiving the placebo (PBS; p < 0.05); however, the improvement reached statistical significance only in the group treated with MSCs cultured with neurotrophic factors. These data suggest that more robust motor function described in rats subjected to TBI and treated with intracerebral transplantation of MSCs was achieved by the use of MSCs cultured with neurotrophic factors.	Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA	Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu					Andsberg G, 1998, EUR J NEUROSCI, V10, P2026, DOI 10.1046/j.1460-9568.1998.00214.x; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Borlongan CV, 1996, NEUROL RES, V18, P297; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DAVIES AM, 1991, INT REV CYTOL, V128, P109; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EAVES CJ, 1991, BLOOD, V78, P110; FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365-2184.1987.tb01309.x; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Grundy PL, 2000, NEUROREPORT, V11, P3381, DOI 10.1097/00001756-200010200-00023; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Houweling DA, 1998, NEUROSCI LETT, V251, P193, DOI 10.1016/S0304-3940(98)00536-9; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; KORSCHING S, 1986, NEUROSCI LETT, V66, P175, DOI 10.1016/0304-3940(86)90186-2; LAZARUS HM, 1995, BONE MARROW TRANSPL, V16, P557; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; Liu Y, 1999, J NEUROSCI, V19, P4370; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097-4652(199807)176:1<57::AID-JCP7>3.0.CO;2-7; Ostergaard K, 1996, EXP NEUROL, V142, P340, DOI 10.1006/exnr.1996.0203; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; PECHAN PA, 1995, NEUROREPORT, V6, P669, DOI 10.1097/00001756-199503000-00021; Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142; Postmantur R., 1997, NEUROSCIENCE, V77, P765; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RUSSELL RW, 1994, BEHAV NEURAL BIOL, V61, P81, DOI 10.1016/S0163-1047(05)80047-0; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SUTHERLAND DR, 1993, STEM CELLS, V11, P50, DOI 10.1002/stem.5530110914; WALKLEY SU, 1994, P NATL ACAD SCI USA, V91, P2970, DOI 10.1073/pnas.91.8.2970; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; Yurek DM, 1996, EXP NEUROL, V137, P105, DOI 10.1006/exnr.1996.0011	42	143	165	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2002	19	12					1609	1617		10.1089/089771502762300265			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	629UY	WOS:000180070700008	12542861				2021-06-18	
J	Keyser-Marcus, LA; Bricout, JC; Wehman, P; Campbell, LR; Cifu, DX; Englander, J; High, W; Zafonte, RD				Keyser-Marcus, LA; Bricout, JC; Wehman, P; Campbell, LR; Cifu, DX; Englander, J; High, W; Zafonte, RD			Acute predictors of return to employment after traumatic brain injury: A longitudinal follow-up	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; employment; rehabilitation	COMMUNITY INTEGRATION; HEAD-INJURY; VOCATIONAL-REHABILITATION; MULTICENTER ANALYSIS; WORK; PROGRAM; DISABILITIES; OUTCOMES; ADULTS	Objective: To investigate the relation between selected acute injury and patient characteristics and subsequent return to work 1 to 5 years postinjury. Design: Longitudinal design with prospectively collected data. Data were collected on patients at the time of injury and each year postinjury for up to 5 years. Setting: Four medical centers in the federally sponsored Traumatic Brain Injury Model Systems project that provide emergency medical services, intensive and acute medical care, inpatient rehabilitation, and a spectrum of community rehabilitation services. Participants: Patients were selected from a national database of 538 rehabilitation inpatients admitted to acute care within 8 hours of traumatic brain injury (TBI) and seen at I to 5 years follow-up. Interventions: Not applicable. Main Outcome Measures: Employment status (employed vs not employed) at I to 5 years postinjury. Logistic regression analyses were performed to determine the extent to which selected variables predicted employment status at years I to 5 postinjury. Results: At year 1 postinjury, preinjury productivity, age, education, and rehabilitation length of stay were all significantly associated with postinjury employment. Preinjury employment and productivity and age significantly predicted employment at postinjury year 2. At year 3 postinjury, preinjury productivity, age, and FIM(TM) instrument discharge score significantly predicted employment status. Age was significantly associated with employment status at year 4 postinjury. Preinjury employment and productivity and Disability Rating Scale discharge score were found to be significant predictors of postinjury employment at year 5 follow-up. Conclusions: The relationship between certain acute injury and patient variables (eg, age, preinjury productivity, education, discharge FIM) and subsequent return to work may provide rehabilitation professionals with useful information regarding the intensity and types of services needed for individuals in the vocational rehabilitation planning process.	Virginia Commonwealth Univ, Rehabil Res & Training Ctr, Sch Educ, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Rehabil Inst Michigan, Dept Phys Med & Rehabil, Detroit, MI USA	Keyser-Marcus, LA (corresponding author), Virginia Commonwealth Univ, Rehabil Res & Training Ctr, Sch Educ, Box 842011, Richmond, VA 23284 USA.			Keyser-Marcus, Lori/0000-0001-6014-2500; Cifu, David/0000-0003-1600-9387	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H1333A980026, H133B980036] Funding Source: Medline		ADELMAN PB, 1993, LEARN DISABILITY Q, V16, P219, DOI 10.2307/1511328; ADLAF EM, 1992, AM J DRUG ALCOHOL AB, V18, P371, DOI 10.3109/00952999209051036; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Bell KR, 1998, ARCH PHYS MED REHAB, V79, pS21, DOI 10.1016/S0003-9993(98)90116-2; Bogner JA, 1997, J HEAD TRAUMA REHAB, V12, P57, DOI 10.1097/00001199-199710000-00006; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Burton K, 1997, J OCCUP REHABIL, V7, P139, DOI 10.1007/BF02767360; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CRISP R, 1992, J REHABIL, V58, P27; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; EAMES P, 1995, BRAIN INJURY, V10, P631; FABIANO RJ, 1995, J APPL REHABILITATIO, V26, P17; Gates LB, 2000, J OCCUP REHABIL, V10, P85, DOI 10.1023/A:1009445929841; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; Hirsh A, 1996, J VOCAT REHABIL, V7, P217; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JOHNSON VA, 1988, REHABIL COUNS BULL, V32, P50; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; O'Connell MJ, 2000, REHABIL PSYCHOL, V45, P212, DOI 10.1037/0090-5550.45.2.212; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Stokes ME., 1995, CATEGORICAL DATA ANA; STONE D, 1996, J ORGAN BEHAV, V17, P99; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wall JR, 1998, NEUROREHABILITATION, V10, P39, DOI 10.3233/NRE-1998-10105; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; West MD, 1996, J VOCATIONAL REHABIL, V7, P143	41	143	147	0	16	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2002	83	5					635	641		10.1053/apmr.2002.31605			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	550FY	WOS:000175494000008	11994802				2021-06-18	
J	Herrmann, M; Curio, N; Jost, S; Grubich, C; Ebert, AD; Fork, ML; Synowitz, H				Herrmann, M; Curio, N; Jost, S; Grubich, C; Ebert, AD; Fork, ML; Synowitz, H			Release of biochemical markers of damage to neuronal and glial brain tissue is associated with short and long term neuropsychological outcome after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						traumatic brain injury; neuron-specific enolase; protein S-100B; neuropsychology; outcome	PROTEIN S-100; NEUROBIOCHEMICAL MARKERS; COMPUTED-TOMOGRAPHY; HEAD-INJURY; CELL-DEATH; SERUM; ENOLASE; SEVERITY; FAMILY	Objectives-The present study aimed at the analysis of release patterns of neurobiochemical markers of brain damage (neuron specific enolase (NSE) and protein S-100B) in patients with traumatic brain injury and their predictive value with respect to the short and long term neuropsychological outcome. Methods-Serial NSE and S-100B concentrations were analysed in blood samples taken at the first, second, and third day after traumatic brain injury. In 69 patients who fulfilled the inclusion criteria (no history of neurological or psychiatric disorder or alcohol or drug dependency, blood sampling according to the scheduled time scale, aged between 16 and 65 years) standardised neurological examinations and qualitative and quantitative evaluation of CT were performed. Comprehensive neuropsychological assessment was performed in 39 subjects 2 weeks after admission and in 29 subjects at a 6 month follow up examination. Results-Most patients presented with minor head injuries (GCS greater than or equal to 3) at the time of admission. Six months later most patients were fully independent in activities of daily living. Two thirds of the patients, however, still had neuropsychological dysfunction. Patients with short and long term neuropsychological disorders had significantly higher NSE and S-100B serum concentrations and a significantly longer lasting release of both markers. A comparative analysis of the predictive value of clinical, neuroradiological, and biochemical data showed initial S-100B values above 140 ng/l to have the highest predictive power. Conclusions-The analysis of posttraumatic release patterns of neurobiochemical markers of brain damage might help to identify patients with traumatic brain injury who run a risk of long term neuropsychological dysfunction.	Otto von Guericke Univ, Fac Med, Div Neuropsychol & Behav Neurol, D-39120 Magdeburg, Germany; Hanse Inst Adv Study, Dept Neurol 2, Bremen, Germany; Hanse Inst Adv Study, Dept Neurosurg, Bremen, Germany	Herrmann, M (corresponding author), Otto von Guericke Univ, Fac Med, Div Neuropsychol & Behav Neurol, Leipzigerstr 44, D-39120 Magdeburg, Germany.	manfred.herrman@medizin.uni-magdeburg.de	Herrmann, Manfred/H-3931-2011	Herrmann, Manfred/0000-0003-1872-8406			ETTLIN T, 1999, SCI PRACT NEUROPSYCH, P233; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Hu JR, 1996, BBA-MOL CELL RES, V1313, P239, DOI 10.1016/0167-4889(96)00095-X; Hu JR, 1997, J NEUROCHEM, V69, P2294; Huber W., 1983, AACHENER APHASIE TES; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; KESSLER J, 1988, DEMENZTEST MANUAL; KRAMER J, 1977, KRAMER TEST REVISION; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; McKeating EG, 1998, ACT NEUR S, V71, P117; Oswald W. D., 1986, NURNBERGER ALTERS IN; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Spreen O., 1998, COMPENDIUM NEUROPSYC; SULTZER DL, 1992, J AM GERIATR SOC, V40, P549, DOI 10.1111/j.1532-5415.1992.tb02101.x; TEASDALE G, 1974, LANCET, V2, P81; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2; ZIMMERMANN P, 1993, TEST ATTENTIONAL PER	39	143	155	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	2001	70	1					95	100		10.1136/jnnp.70.1.95			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	388KC	WOS:000166178800020	11118255	Green Published, Bronze			2021-06-18	
J	Kutner, KC; Erlanger, DM; Tsai, J; Jordan, B; Relkin, NR				Kutner, KC; Erlanger, DM; Tsai, J; Jordan, B; Relkin, NR			Lower cognitive performance of older football players possessing apolipoprotein E epsilon 4	NEUROSURGERY			English	Article						apolipoprotein E; cognition; concussion; head injury; neuropsychology; sports	AMYLOID PROTEIN DEPOSITION; TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; SOCCER PLAYERS; NEUROPSYCHOLOGICAL SEQUELAE; ALZHEIMERS-DISEASE; UNITED-STATES; CONCUSSION; SPORTS; BOXERS	OBJECTIVE: To determine whether the cognitive status of professional football players varies as a function of age and apolipoprotein E (APOE) genotype. METHODS: Fifty-three active players underwent APOE and neuropsychological assessments. Players were grouped according to age (proxy indicator of high/low exposure to contact) and the presence/absence of at least one copy of the epsilon 4 allele. Outcome measures were overall cognitive performance and scores in cognitive domains. RESULTS: As a group, older players possessing APOE epsilon 4 exhibited significantly lower cognitive test scores than did all other players studied, including non-epsilon 4-possessing players and younger epsilon 4-carriers. Measures of general cognitive functioning, information-processing speed and accuracy, and attention were related to poorer performance among the epsilon 4-carrying players. In an analysis of variance model, the interaction between APOE genotype and age was significant (P = 0.004). As determined using linear regression, age accounted for 34% of the variance in the memory index among APOE epsilon 4-possessing players but did not contribute significantly to variance among the non-epsilon 4-possessing players. Older APOE epsilon 4-carriers were significantly overrepresented among players whose scores indicated possible cognitive impairment, with the criterion of performing two or more standard deviations below the general normal Values in a summary index of general cognitive functioning. CONCLUSION: Older professional football players who possessed the APOE epsilon 4 allele scored lower on cognitive tests than did players without this allele or less experienced players of any genotype. The cognitive status of professional athletes with repeated exposure to head trauma may therefore be influenced by age, inherited factors such as APOE genotype, and cumulative exposure to contact.	Cornell Univ Med Coll, Presbyterian Hosp, Dept Neurol & Neurosci, New York, NY 10021 USA; Columbia Univ, Dept Neurosci, New York, NY USA; Burke Res Inst & Rehabil Hosp, White Plains, NY USA	Relkin, NR (corresponding author), Cornell Univ Med Coll, Presbyterian Hosp, Dept Neurol & Neurosci, 1300 York Ave, New York, NY 10021 USA.						Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Barth JT., 1989, MILD HEAD INJURY, P257; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; BUTLER RJ, 1994, BRIT J SPORT MED, V28, P187, DOI 10.1136/bjsm.28.3.187; CANTU RC, 1996, BR J SPORST MED, V30, P239; CANTU RC, 1991, ADOLESCENT MED STATE, V2, P17; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; COHEN SB, 1998, SPORTS NEUROLOGY, P393; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Friedman J, 1999, PHYS TODAY, V52, P24, DOI 10.1063/1.882550; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GRONWALL D, 1975, LANCET, V2, P995; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; Heaton R.K., 1991, COMPREHENSIVE NORMS; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1993, MED ASPECTS BOXING, P177; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; KANE RL, 1995, B NATL ACAD NEUROPSY, V11, P13; Katzman R, 1996, NEUROLOGY, V46, P889; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; MATLAND HS, 1928, JAMA-J AM MED ASSOC, V19, P1103; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Pitas RE, 1998, BIOCHEM SOC T, V26, P257, DOI 10.1042/bst0260257; POWELL DH, 1993, MICROCOG; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; REY A, 1964, EXAMIN CLIN PSYCHOL; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Sosin DM, 1996, BRAIN INJURY, V10, P47; *SPSS, 1998, STAT PACK SOC SCI; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tsuang D, 1996, J AM GERIATR SOC, V44, P704, DOI 10.1111/j.1532-5415.1996.tb01836.x; TYSVAER A, 1989, ACTA NEUROL SCAND, V80, P51; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	51	143	144	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	SEP	2000	47	3					651	657		10.1097/00006123-200009000-00026			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	349GJ	WOS:000089037100053	10981753				2021-06-18	
J	Brooks, WM; Stidley, CA; Petropoulos, H; Jung, RE; Weers, DC; Friedman, SD; Barlow, MA; Sibbitt, WL; Yeo, RA				Brooks, WM; Stidley, CA; Petropoulos, H; Jung, RE; Weers, DC; Friedman, SD; Barlow, MA; Sibbitt, WL; Yeo, RA			Metabolic and cognitive response to human traumatic brain injury: A quantitative proton magnetic resonance study	JOURNAL OF NEUROTRAUMA			English	Article						inflammation; N-acetylaspartate; neurochemistry; neuropsychological testing; proton magnetic resonance spectroscopy; traumatic brain injury	SEVERE HEAD-INJURY; MR SPECTROSCOPY; IN-VIVO; BIOCHEMICAL MARKERS; AXONAL INJURY; QUANTIFICATION; EXPERIENCE; SPECTRA; DISEASE; WATER	Proton magnetic resonance spectroscopy (H-1-MRS) offers a unique insight into brain cellular metabolism following traumatic brain injury (TBI). The aim of the present study was to assess change in neurometabolite markers of brain injury during the recovery period following TBI. We studied 19 TBI patients at 1.5, 3, and 6 months postinjury and 28 controls. We used H-1-MRS to quantify N-acetylaspartate (NAA), creatine (Cre), choline (Cho), and myoinositol (mIns) in occipitoparietal gray matter (GM) and white matter (WM) remote from the primary injury focus. Neuropsychological testing quantified cognitive impairment and recovery. At 1.5 months, we found cognitive impairment (mean z score = -1.36 vs. 0.18,p < 0.01), lower NAA (GM: 12.42 mM vs. 13.03, p = 0.01; WM: 11.75 vs. 12.81, p < 0.01), and elevated Cho (GM: 1.51 vs. 1.25, p < 0.01; WM: 1.98 vs. 1.79, p < 0.01) in TBI patients compared with controls. GM NAA at 1.5 months predicted cognitive function at outcome (6 months postinjury; r = 0.63, p = 0.04). GM NAA continued to fall by 0.46 mM between 1.5 and 3 months (p = 0.02) indicating continuing neuronal loss, metabolic dysfunction, off both. Between 3 and 6 months, WM NAA increased by 0.55 mM (p = 0.06) suggesting metabolic recovery. Patients with poorer outcomes had elevated mean GM Cho at 3 months postinjury, suggesting active inflammation, as compared to patients with better outcomes (p = 0.002). H-1-MRS offers a noninvasive approach to assessing neuronal injury and inflammation following TBI, and may provide unique data for patient management and assessment of therapeutic efficacy.	Univ New Mexico, Hlth Sci Ctr, Clin & Magnet Resonance Res Ctr, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Neurosci, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Family & Community Med, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Neurol, Albuquerque, NM 87131 USA; Univ Washington, Med Ctr, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Brooks, WM (corresponding author), Univ New Mexico, Hlth Sci Ctr, Clin & Magnet Resonance Res Ctr, 1201 Yale NE, Albuquerque, NM 87131 USA.		Sibbitt, Wilmer/AAI-7746-2020	Sibbitt, Wilmer/0000-0001-5872-160X; brooks, william/0000-0001-6227-7636; friedman, seth/0000-0001-8785-7215	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035708, R01NS039123] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39123, NS35708] Funding Source: Medline		BARKER PB, 1993, NMR BIOMED, V6, P89, DOI 10.1002/nbm.1940060114; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; BRENNER RE, 1993, MAGNET RESON MED, V29, P737, DOI 10.1002/mrm.1910290605; Brooks WM, 1999, MAGNET RESON MED, V41, P193, DOI 10.1002/(SICI)1522-2594(199901)41:1<193::AID-MRM27>3.0.CO;2-P; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHRISTIANSEN P, 1993, MAGN RESON IMAGING, V11, P107, DOI 10.1016/0730-725X(93)90418-D; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; GARNETT MR, 1999, P INT SOC MAGN RESON, V7, P229; GENTLEMAN SM, 1999, J NEUROTRAUM, V16, P994; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; Jung RE, 1999, NEUROREPORT, V10, P3327, DOI 10.1097/00001756-199911080-00014; Jung RE, 1999, P ROY SOC B-BIOL SCI, V266, P1375, DOI 10.1098/rspb.1999.0790; Komoroski RA, 1999, MAGN RESON IMAGING, V17, P427, DOI 10.1016/S0730-725X(98)00186-6; KUGEL H, 1992, RADIOLOGY, V183, P701, DOI 10.1148/radiology.183.3.1584924; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEZAK M, 1995, NEUROPSYCHOLOGIC EVA; LIEN YHH, 1990, J CLIN INVEST, V85, P1427, DOI 10.1172/JCI114587; MACMILLAN CSA, 1999, P INT SOC MAGN RESON, V7, P224; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Petropoulos H, 1999, JMRI-J MAGN RESON IM, V9, P39, DOI 10.1002/(SICI)1522-2586(199901)9:1<39::AID-JMRI5>3.0.CO;2-8; PIJNAPPEL WWF, 1992, J MAGN RESON, V97, P122, DOI 10.1016/0022-2364(92)90241-X; ROSS B, 1994, MAGN RESON QUART, V10, P191; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Saunders DE, 1999, JMRI-J MAGN RESON IM, V9, P711, DOI 10.1002/(SICI)1522-2586(199905)9:5<711::AID-JMRI14>3.0.CO;2-3; Spreen O., 1991, COMPENDIUM NEUROPSYC; Tedeschi G, 1997, J NEUROSURG, V87, P516, DOI 10.3171/jns.1997.87.4.0516; TZIKA AA, 1993, AM J NEURORADIOL, V14, P1267; VANDENBOOGAART A, 1994, MAGNET RESON MED, V31, P347, DOI 10.1002/mrm.1910310402; Yamaki T, 1996, J NUCL MED, V37, P1166	35	143	150	1	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2000	17	8					629	640		10.1089/089771500415382			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	347WF	WOS:000088951600001	10972240				2021-06-18	
J	Garnett, MR; Blamire, AM; Rajagopalan, B; Styles, P; Cadoux-Hudson, TAD				Garnett, MR; Blamire, AM; Rajagopalan, B; Styles, P; Cadoux-Hudson, TAD			Evidence for cellular damage in normal-appearing white matter correlates with injury severity in patients following traumatic brain injury - A magnetic resonance spectroscopy study	BRAIN			English	Article						traumatic brain injury; magnetic resonance spectroscopy; injury severity; N-acetylaspartate; choline	PROTON NMR-SPECTROSCOPY; MODERATE HEAD-INJURY; AXONAL INJURY; H-1 MRS; IN-VIVO; MILD; DYSFUNCTION; INVIVO	Neuropsychological studies in patients who have suffered traumatic brain injury show that the eventual clinical outcome is frequently worse than might be predicted from using conventional (CT or T-1/T-2-weighted MRI) imaging. Furthermore, patients who have sustained an initial mild or moderate injury may show long-term disability. This implies that there may be abnormalities in areas of the brain that actually appear normal on conventional imaging. Proton magnetic resonance spectroscopy studies have shown that N-acetylaspartate and choline-containing compounds can provide measures of cellular injury. We report MRT and proton magnetic resonance spectroscopy studies of 19 head-injured patients performed once the patients were clinically stable (mean 11 days after injury, range 3-38 days), Proton magnetic resonance spectra were acquired from frontal white matter that on conventional MRI appeared normal. that brain matter The on N-acetylaspartate/creatine ratio was reduced [patients (mean +/- standard deviation), 1.28 +/- 0.25; controls, 1.47 +/- 0.24; P = 0.04] and the choline/creatine ratio was increased (patients, 0.85 +/- 0.18; controls, 0.63 +/- 0.10; P < 0.001) compared with controls, when the severity of the injury was assessed using either the Glasgow coma scale or the length of post-traumatic amnesia, the increase in the choline/creatine ratio was significant even in the mildly injured group (P = 0.008 and P = 0.04, respectively). Furthermore, there was a significant correlation (P 0.008) between the severity of head injury and the N-acetylaspartatelcholine ratio. We conclude that there is an early reduction in N-acetylaspartate and an increase in choline compounds in normal-appearing white matter which correlate with head injury severity, and that this may provide a pathological basis for the long-term neurological disability that is seen in these patients.	Univ Oxford, MRC, Biochem & Clin Magnet Resonance Unit, Oxford, England; Univ Oxford, Dept Biochem, Oxford, England; Radcliffe Infirm, Dept Neurosurg, Oxford OX2 6HE, England	Garnett, MR (corresponding author), Oxford Radcliffe Hosp, MRC, Biochem & Clin Magnet Resonance Unit, Oxford OX3 9DU, England.			Blamire, Andrew/0000-0002-8749-1257			Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BROWN TR, 1982, P NATL ACAD SCI-BIOL, V79, P3523, DOI 10.1073/pnas.79.11.3523; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; De Stefano N, 1998, BRAIN, V121, P1469, DOI 10.1093/brain/121.8.1469; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; FRAHM J, 1989, MAGNET RESON MED, V9, P79, DOI 10.1002/mrm.1910090110; FRAHM J, 1989, MAGNET RESON MED, V11, P47, DOI 10.1002/mrm.1910110105; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; HAASE A, 1985, PHYS MED BIOL, V30, P341, DOI 10.1088/0031-9155/30/4/008; JENKINS A, 1986, LANCET, V2, P445; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; McBride DQ, 1995, SURG NEUROL, V44, P137, DOI 10.1016/0090-3019(95)00139-5; Miller BL, 1996, LIFE SCI, V58, P1929, DOI 10.1016/0024-3205(96)00182-8; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Pendlebury ST, 1999, STROKE, V30, P956, DOI 10.1161/01.STR.30.5.956; Pouwels PJW, 1998, MAGN RESON MED, V39, P53, DOI 10.1002/mrm.1910390110; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; TEASDALE G, 1974, LANCET, V2, P81; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007	31	143	158	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUL	2000	123		7				1403	1409		10.1093/brain/123.7.1403			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	334JP	WOS:000088183600009	10869052	Bronze			2021-06-18	
J	Bryant, RA; Harvey, AG				Bryant, RA; Harvey, AG			Postconcussive symptoms and posttraumatic stress disorder after mild traumatic brain injury	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article								Postconcussive symptoms after mild traumatic brain injury (MTBI) may be exacerbated by anxiety associated with posttraumatic stress. The aim of this study waste investigate the relationship between postconcussive symptoms and posttraumatic stress disorder (PTSD) in an MTBI population. Survivors of motor vehicle accidents who either sustained an MTBI (N = 46) or no TBI (N = 59) were assessed 6 months post-trauma for PTSD and postconcussive symptoms. Postconcussive symptoms were more evident in MTBI patients with PTSD than those without PTSD, and in MTBI patients than non-TBI patients. Further, postconcussive symptoms were significantly correlated with PTSD symptoms. These findings indicate that postconcussive symptoms may be mediated by an interaction of neurological and psychological factors after MTBI.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Univ Oxford, Dept Psychiat, Oxford, England	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bohnen N., 1992, J NERV MENT DIS, V180, P183; BRYANT RA, 1995, J ABNORM PSYCHOL, V104, P537, DOI 10.1037/0021-843X.104.3.537; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Levin H. S., 1987, NEUROBEHAVIORAL RECO, P262; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MIDDELBOE T, 1991, Acta Neurologica Scandinavica, V85, P5; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; RUTHERFORD WH, 1989, NEUROBEHAVIORAL RECO, P217; SOLOMON Z, 1988, J ABNORM PSYCHOL, V97, P302, DOI 10.1037/0021-843X.97.3.302	19	143	145	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	MAY	1999	187	5					302	305		10.1097/00005053-199905000-00006			4	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	197BU	WOS:000080345400006	10348085				2021-06-18	
J	Andersson, S; Krogstad, JM; Finset, A				Andersson, S; Krogstad, JM; Finset, A			Apathy and depressed mood in acquired brain damage: relationship to lesion localization and psychophysiological reactivity	PSYCHOLOGICAL MEDICINE			English	Article							FRONTAL-SUBCORTICAL CIRCUITS; STROKE PATIENTS; ALZHEIMERS-DISEASE; NEGATIVE SYMPTOMS; SCHIZOPHRENIA; MOTIVATION; DISORDERS; LOCATION; RELIABILITY; DOPAMINE	Background. Apathy is a frequent neurobehavioural sequel in patients with acquired brain damage and it may seriously affect outcome of rehabilitation. Methods. Patients with traumatic brain injury, cerebrovascular insults and hypoxic brain injury, categorized into four lesion localization groups: left hemisphere damage (LHD); right hemisphere damage (RHD); bilateral hemispheric damage (BHD); and subcortical damage (SCD) were assessed with the Apathy Evaluation Scale (AES) and Montgomery and Asberg Depression Rating Scale (MADRS). Heart rate and electrodermal activity were recorded in an experimental situation that exposed the patients to mental stressors in order to measure psychophysiological reactivity. Results. Significant differences in level of apathy were found between diagnostic groups as well as between localization subgroups. SCD and RHD patients displayed most apathy. Factor analysis of MADRS revealed a three-factor solution; depressed mead, somatic symptoms and negative symptoms. Apathy was significantly correlated with negative symptoms in all localization subgroups, except among the BHD patients. Apathy was not correlated with depressed mood or somatic symptoms. Moreover, apathy was significantly correlated with heart rate reactivity, but not with electrodermal reactivity. Conclusion. Apathy is common, its severity depending on diagnosis and localization of lesion. Apathy and depression in brain damaged patients share common features, but may be differentiated. The significant relationship between apathy and heart rate may provide a psychophysiological correlation of the disengagement, lack of interest and absence of emotional responsivity typically seen in apathy. The results have implications for the theoretical understanding of apathy and related negative symptoms, and for rehabilitation practice.	Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway; Univ Oslo, Inst Behav Sci Med, Oslo, Norway	Andersson, S (corresponding author), Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway.						American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andersson S, 1998, J PSYCHOSOM RES, V44, P645, DOI 10.1016/S0022-3999(97)00305-X; Andersson S., 1992, J NORWEGIAN MED ASS, V112, P2070; Andreasen N. C., 1990, SCHIZOPHRENIA POSITI; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BOGUSSLAVSKY J, 1991, ACTA NEUROL SCAND, V83, P309; BURNS A, 1990, J NERV MENT DIS, V178, P20, DOI 10.1097/00005053-199001000-00004; CHOI DW, 1990, J NEUROSCI, V10, P2493; CHUA SE, 1995, BRIT J PSYCHIAT, V166, P563, DOI 10.1192/bjp.166.5.563; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; DOODY RS, 1995, J NEUROPSYCH CLIN N, V7, P54; FINSET A, 1989, SCAND J REHABIL MED, V21, P1; FINSET A, 1988, CEREBRAL HEMISPHERE, P49; FLAUM M, 1995, J PSYCHIAT RES, V29, P261, DOI 10.1016/0022-3956(94)00046-T; Galynker I, 1997, J NERV MENT DIS, V185, P616, DOI 10.1097/00005053-199710000-00004; GIANOTTI G, 1989, HDB NEUROPSYCHOLOGY, V3, P345; Gray JA, 1987, PSYCHOL FEAR STRESS, P241; GRAY JM, 1994, CLIN REHABIL, V8, P188, DOI DOI 10.1080/09602010902949207; Greenwald M., 1989, J PSYCHOPHYSIOL, V3, P51; Handler J., 1994, HANDB NEUR, P125; HEILMAN KM, 1978, NEUROLOGY, V28, P229, DOI 10.1212/WNL.28.3.229; KALIVAS PW, 1993, LIMBIC MOTOR CIRCUIT; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; Koob GF, 1996, MOL PSYCHIATR, V1, P186; KRISHNAN KRR, 1995, AM J PSYCHIAT, V152, P785; LAPLANE D, 1989, BRAIN, V112, P699, DOI 10.1093/brain/112.3.699; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; MARIN RS, 1993, J AFFECT DISORDERS, V28, P7, DOI 10.1016/0165-0327(93)90072-R; MARIN RS, 1997, REV PSYCHIAT, V15, P205; Masterman DL, 1997, J PSYCHOPHARMACOL, V11, P107, DOI 10.1177/026988119701100203; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Morris PLP, 1996, J NEUROPSYCH CLIN N, V8, P399; MORROW L, 1981, NEUROPSYCHOLOGIA, V19, P65, DOI 10.1016/0028-3932(81)90045-2; Nader K, 1997, ANNU REV PSYCHOL, V48, P85, DOI 10.1146/annurev.psych.48.1.85; Ott BR, 1996, J NEUROPSYCH CLIN N, V8, P41; POWELL WC, 1996, ATTEMPTS UNDERSTAND, V1, P1; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; Robinson RG, 1997, ANNU REV MED, V48, P217; ROINE RO, 1993, STROKE, V24, P1005, DOI 10.1161/01.STR.24.7.1005; ROLLS ET, 1985, SCI BASIS CLIN NEURO, P201; Salamone JD, 1996, J NEUROSCI METH, V64, P137, DOI 10.1016/0165-0270(95)00125-5; SCHNECK SA, 1971, CLIN NEUROLOGY, V2, P1; Seligman M.E.P., 1992, HELPLESSNESS DEV DEP; Smith TW, 1997, PSYCHOPHYSIOLOGY, V34, P65, DOI 10.1111/j.1469-8986.1997.tb02417.x; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; STARKSTEIN SE, 1993, STROKE, V24, P1625, DOI 10.1161/01.STR.24.11.1625; Tandberg E, 1997, ARCH NEUROL-CHICAGO, V54, P625, DOI 10.1001/archneur.1997.00550170097020; TRANEL DT, 1983, PSYCHOPHYSIOLOGY, V20, P652, DOI 10.1111/j.1469-8986.1983.tb00933.x; TURETSKY B, 1995, ARCH GEN PSYCHIAT, V52, P1061; Vincent A, 1996, INT J PSYCHOPHYSIOL, V23, P181, DOI 10.1016/S0167-8760(96)00058-X; WATANABE MD, 1995, J NEUROPSYCH CLIN N, V7, P502; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29; WINTON WM, 1984, J EXP SOC PSYCHOL, V20, P195, DOI 10.1016/0022-1031(84)90047-7; Zemishlany Z, 1996, NEUROPSYCHOBIOLOGY, V33, P127, DOI 10.1159/000119262	62	143	144	0	15	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	0033-2917			PSYCHOL MED	Psychol. Med.	MAR	1999	29	2					447	456		10.1017/S0033291798008046			10	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	181FE	WOS:000079429800021	10218936				2021-06-18	
J	Boden, BP; Kirkendall, DT; Garrett, WE				Boden, BP; Kirkendall, DT; Garrett, WE			Concussion incidence in elite college soccer players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article							FOOTBALL PLAYERS; BRAIN-DAMAGE; INJURIES	A unique aspect of soccer is the use of the head for directing the ball. The potential for resultant head injuries has been the focus of discussions worldwide. Prior work-has attributed neuropsychologic deficits to the cumulative effects of heading, without evaluating concussion rates in soccer players. We prospectively studied the seven men's and eight women's varsity soccer teams in the Atlantic Coast Conference during two seasons to document concussion incidence. The 29 concussions diagnosed over the 2 years in 26 athletes, 17 (59%) concussions in men and 12 (41%) in women, resulted from contact with an opponent's head (8, 28%), elbow (4, 14%), knee (1, 3%), or foot (1, 3%), the ball (7, 24%); the ground (3, 10%); concrete sidelines (1, 3%); goalpost (1, 3%); or a combination of objects (3, 10%). Twenty concussions (69%) occurred in games; none resulted from intentional heading of the ball. The basic incidence was 0.96 concussions per team per season. The overall incidence was 0.6 per 1000 athlete-exposures for men, and 0.4 per 1000 athlete-exposures for women. By concussion grade, there were 21 (72%) grade 1, 8 (28%) grade 2, and no grade 3 concussions. These findings suggest that concussions are more common in soccer than anticipated and that acute head injuries may have potential for long-term neuropsychologic changes.	Duke Univ, Med Ctr, Div Orthopaed Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Sports Med Sect, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Phys & Occupat Therapy, Durham, NC 27710 USA	Boden, BP (corresponding author), 2101 Med Pk Dr,Suite 305, Silver Spring, MD 20902 USA.						BARNES B, 1998, IN PRESS AM J SPORTS; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; GENNARELLI TA, 1982, ATHLETIC INJURIES HE, P65; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; JANDA DH, 1995, AM J SPORT MED, V23, P340, DOI 10.1177/036354659502300316; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Lohnes JH, 1994, SPORTS INJURIES MECH, P603; *NAT COLL ATHL ASS, 1996, 1990 1996 INJ SURV S; Sandelin J, 1985, Br J Sports Med, V19, P30; SANDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538; Schmidt-Olsen S, 1985, Br J Sports Med, V19, P161; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; *US CONS PROD SAF, 1993, NAT EL INJ SURV SYST	17	143	147	0	20	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR-APR	1998	26	2					238	241		10.1177/03635465980260021301			4	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	ZD693	WOS:000072713500013	9548117				2021-06-18	
J	Guskiewicz, KM; Riemann, BL; Perrin, DH; Nashner, LM				Guskiewicz, KM; Riemann, BL; Perrin, DH; Nashner, LM			Alternative approaches to the assessment of mild head injury in athletes	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						concussion; postural stability; cognitive function	SENSORY INTERACTION; POSTURAL CONTROL; CONCUSSION; POSTUROGRAPHY; MANAGEMENT; ADAPTATION; DEFICITS; STANCE	Objectives: Athletic trainers and team physicians are often faced with decisions concerning the severity and timing of an athletes return to play following mild head injury (MHI). These decisions can be the most difficult ones facing clinicians because of the limited amount of quantitative information indicating injury severity. Several authors have published guidelines for return to play following MHI, however these guidelines are based on limited scientific data. The purpose of this paper was to examine the effects of MHI on two objective measures, postural stability and cognitive function, to determine their usefulness in MHI assessment. The data gathered from these two measures has the potential to establish recovery curves based on objective data. Methods: Eleven Division I collegiate athletes who sustained a MHI and eleven matched control subjects were assessed for postural stability and cognitive function at four intervals following injury. Postural stability was assessed using the Sensory Organization Test on the NeuroCom Smart Balance Master. Cognitive functioning was measured through the use of four neuropsychological tests: Stroop Test, Trail Making Test, Digits Span and Hopkins Verbal Learning Test. Separate mixed model repeated measures ANOVAs were calculated for the composite score and three ratio (vestibular, visual and somatosensory) scores from the Sensory Organization Test and the scores from the neuropsychological test to reveal significant differences between groups and across days postinjury. Results: A significant group by day interaction for overall postural stability (composite score) revealed that MHI athletes displayed increased postural instability for the first few days following MHI (p<.05). Analysis of the ratio scores revealed a significant interaction for the visual ratio. No significant group differences were revealed for any of the neuropsychological tests (p>.05), however significant day differences were revealed (p<.05). Conclusions: The results from this study indicate that athletes demonstrate decreased stability until 3 days postinjury. It appears this deficit is related to a sensory interaction problem, whereby the injured athlete fails to use their visual system effectively. These findings suggest that measures of postural stability may provide clinicians with a useful clinical tool for determining when an athlete may safely return to competition, although these findings need to be confirmed in larger groups of athletes.	UNIV VIRGINIA,CURRY SCH EDUC,DEPT HUMAN SERV,CHARLOTTESVILLE,VA; OREGON HLTH SCI UNIV,DEPT PHYSIOL,PORTLAND,OR 97201	Guskiewicz, KM (corresponding author), UNIV N CAROLINA,DEPT PHYS EDUC EXERCISE & SPORT SCI,CHAPEL HILL,NC 27599, USA.			Guskiewicz, Kevin/0000-0002-8682-2130			ADAMS J, 1975, HDB CLIN NEUROLOGY I, P35; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ALVES WM, 1987, CLIN SPORT MED, V6, P211; ARCAN M, 1977, SCAND J REHABIL MED, V9, P165; ASAI M, 1993, ACTA OTOLARYNGOL S S, V504, P120; Barth JT., 1989, MILD HEAD INJURY, P257; BRUCE D, 1982, PRIMARY CARE, V11, P175; CANTU R, 1992, ADOLESC MED, V2, P141; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; CERVETT M, 1995, OTOLARYNGOL HEAD NEC, V122, P676; CHESTER JB, 1991, SPINE, V16, P716, DOI 10.1097/00007632-199107000-00004; *COL MED SOC SPORT, 1994, P MILD BRAIN INJ SPO, P106; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GOEBEL JA, IN PRESS OTOLARYNGOL; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guyton A., 1986, TXB MED PHYSL, P1610; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; HOUGH D, 1994, P MILD BRAIN INJ SPO, P31; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; JORDAN B, 1994, P MILD BRAIN INJ SPO, P43; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LIPP M, 1994, J OTOLARYNGOL, V23, P177; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; MAURITZ KH, 1979, BRAIN, V102, P461, DOI 10.1093/brain/102.3.461; MCINTOSH T, 1989, MILD MODERATE HEAD I, P135; NASHNER L, 1978, BRAIN RES, V150, P403, DOI 10.1016/0006-8993(78)90291-3; NASHNER LM, 1982, J NEUROSCI, V2, P536; NASHNER LM, 1982, TRENDS NEUROSCI, V5, P358, DOI 10.1016/0166-2236(82)90204-1; NASHNER LM, 1976, EXP BRAIN RES, V26, P59; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; NORRE ME, 1993, J LARYNGOL OTOL, V107, P496, DOI 10.1017/S0022215100123564; OLIARO S, 1996, THESIS ESTABLISHMENT; Ommaya A, 1994, P MILD BRAIN INJ SPO, P72; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Weir Mitchell S, 1886, AM J MED SCI, V92, P363	44	143	143	0	13	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0195-9131			MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JUL	1997	29	7		S			S213	S221					9	Sport Sciences	Sport Sciences	XM280	WOS:A1997XM28000002	9247918				2021-06-18	
J	Clark, RSB; Kochanek, PM; Dixon, CE; Chen, MZ; Marion, DW; Heineman, S; DeKosky, ST; Graham, SH				Clark, RSB; Kochanek, PM; Dixon, CE; Chen, MZ; Marion, DW; Heineman, S; DeKosky, ST; Graham, SH			Early neuropathologic effects of mild or moderate hypoxemia after controlled cortical impact injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; brain injury; controlled cortical impact; hypoxemia; neuronal death; rat	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; HUMAN HEAD-INJURY; FLUID PERCUSSION; CELL-DEATH; HIPPOCAMPAL PATHOLOGY; HYPOXIA; MODEL; VULNERABILITY; MECHANISMS	Hypoxemia has detrimental effects after traumatic brain injury (TBI) in both experimental models and humans. The purpose of this study was to determine the effect of mild or moderate hypoxemia on early histologic and motor functional outcome after controlled cortical impact (CCI) in rats. Anesthetized rats under,vent CCI and were randomized to receive mild (FiO(2) = 13%, n = 6), moderate (FiO(2) = 11%, n = 9), or no (FiO(2) = 33%, n 6) hypoxemia for 30 min after trauma. Sham-operated rats without hypoxemia (n = 7) were used as controls. Motor function (beam balance latency) was assessed on days 0-5. Rats were killed 7 days after injury and their brains removed for assessment of survival of hippocampal neurons and contusion volume. Terminal deoxynucleotidyl transferase-mediated biotin-dUTP nick end labeling (TUNEL) was performed on brain sections from rats killed at 6, 24, and 72 h after CCI and moderate hypoxemia to assess DNA fragmentation irt situ. Mild and moderate hypoxemia augmented motor function deficits after CCI in a dose-dependent manner. Moderate hypoxemia after CCI reduced 7-day survival of CA3 neurons but not CA1 neurons vs. sham (55 [46-86] vs. 99 [95-130], p < 0.05, and 79 [63-86] vs. 101 [81-123], NS, respectively; % uninjured hemisphere, median [range]). The addition of mild or moderate hypoxemia did not increase contusion volume. TUNEL-positive neurons were seen in ipsilateral cortex and dentate gyrus at 6, 24, and 72 h after trauma, and in ipsilateral CA3 hippocampal neurons and thalamus at 24 and 72 h. Moderate hypoxemia augments CA3 neuronal death and early motor functional deficits after CCI. The pattern of DNA fragmentation in selectively vulnerable neurons suggests that apoptosis may play a role in the delayed neuronal death seen after TBI.	UNIV PITTSBURGH, DEPT NEUROL, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT ANESTHESIOL & CRIT CARE MED, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT PEDIAT, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT NEUROL SURG, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT PSYCHIAT, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, BRAIN TRAUMA RES CTR, PITTSBURGH, PA 15261 USA			Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33150, 2P50 NS 30318-04A1] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [1KO8 01946-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150, P50NS030318] Funding Source: NIH RePORTER		Amaral David G., 1995, P443; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512000-00014; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; NELSON LR, 1982, SEMINARS NEUROLOGICA, P117; NIDA TY, 1995, J NEUROTRAUM, V12, P77, DOI 10.1089/neu.1995.12.77; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Pearigen P, 1996, BRAIN RES, V725, P184; RINK A, 1995, AM J PATHOL, V147, P1575; Schechter S., 1996, PREPARATION STAINING, P1; SINHA RP, 1973, JAMA-J AM MED ASSOC, V224, P1258, DOI 10.1001/jama.224.9.1258; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUTTON RL, 1995, CENTRAL NERVOUS SYST, P497; Wilberger JE, 1993, HEAD INJURY, P27; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117	43	143	144	1	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	1997	14	4					179	189		10.1089/neu.1997.14.179			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	WY593	WOS:A1997WY59300001	9151767				2021-06-18	
J	RIS, L; DEWAELE, C; SERAFIN, M; VIDAL, PP; GODAUX, E				RIS, L; DEWAELE, C; SERAFIN, M; VIDAL, PP; GODAUX, E			NEURONAL-ACTIVITY IN THE IPSILATERAL VESTIBULAR NUCLEUS FOLLOWING UNILATERAL LABYRINTHECTOMY IN THE ALERT GUINEA-PIG	JOURNAL OF NEUROPHYSIOLOGY			English	Article							HEMILABYRINTHECTOMIZED CATS; CENTRAL COMPENSATION; OCULAR REFLEX; NERVE LESIONS; RECOVERY; DEFICITS; DEAFFERENTATION	1. Neuronal activity was investigated in the left superior vestibular nucleus (SVN), lateral vestibular nucleus (LVN), and rostral part of the medial vestibular nucleus (MVN) in the alert guinea pig after a unilateral (left) labyrinthectomy was performed. Vestibular neurons were recorded either immediately (just-postoperative group, n = 6) or 1 wk after labyrinthectomy (1-wk-postoperative group, n = 6) and compared with the activity recorded in intact animals (control group, n = 6). 2. Animals were prepared for extracellular recording of single-unit activity and for eye movement recording (scleral search coil technique). To enable stimulation of the left vestibular nerve, bipolar silver ball electrodes were chronically implanted either in contact with the bony labyrinth in the control group or close to the stump of the vestibular nerve after labyrinthectomy. Complete labyrinthectomy was performed under halothane anesthesia. 3. The criterion used to select vestibular neurons for analysis was their recruitment by an electric shock on the vestibular nerve. Of the 589 recorded neurons, 424, defined as second-order vestibular neurons, were recruited at monosynaptic latencies (0.85-1.15 ms) and 165 were recruited at polysynaptic latencies. One hundred three second-order vestibular neurons were recorded in the control group, 173 in the just-postoperative group, and 148 in the 1-wk-postoperative group. 4. The activity of the electrically recruited neurons was recorded during sinusoidal horizontal head rotation in the dark (0.3 Hz, 40 degrees/s peak velocity). The behavior of the neurons was analyzed by plotting their firing rate against head velocity. The Y-intercept of the regression line was used to express spontaneous firing rate (resting discharge), and its slope was used to express the sensitivity of the neuron-to-head velocity. 5. In the absence of statistically significant difference between the characteristics of the neuronal discharge of the second-order vestibular neurons recorded in the SVN, LVN, and rostral MVN, the data were pooled. The Resting discharge of these cells amounted to 41.0 +/- 24.7 (SD) spikes/s in the control state, fell to 7.2 +/- 13.9 spikes/s just after labyrinthectomy, and completely returned to normal values 1 wk after surgery (42.5 +/- 21.6 spikes/s). Among the monosynaptically recruited neurons, the percentage of silent units was 0% in the control group, 69% in the just-postoperative group, and 0% in the 1-wk-postoperative group. 6. By contrast, the sensitivity to head velocity of the second-order vestibular neurons, which was 0.69 +/- 0.48 (SD) spikes . s(-1)/deg . s(-1) in the control state and which fell to 0.03 +/- 0.11 spikes . s(-1)/deg . s(-1) just after labyrinthectomy, remained low 1 wk after injury (0.21 +/- 0.26 spikes . s(-1)/deg . s(-1)). Moreover, the slight recovery of sensitivity to head rotation was due only to units behaving as type II neurons. 7. The mean resting discharge of the polysynaptically recruited neurons (pooled from the 3 explored nuclei) was 31.6 +/- 19.3 spikes/s in the control group. It decreased to 11.6 +/- 12.1 spikes/s in the just-postoperative group and recovered to 39.8 +/- 20.2 spikes/s in the l-wk-postoperative group. No neuron was silent at rest either in the control group or in the 1-wk-postoperative group. Just after labyrinthectomy, 35% of the neurons had a null resting activity. The mean sensitivity to head velocity of these neurons was 0.55 +/- 0.42 spikes . s(-1)/deg . s(-1) in the control group. It decreased to 0.05 +/- 0.12 spikes . s(-1)/deg . s(-1) in the just-postoperative group and recovered to 0.22 +/- 0.17 spikes . s(-1)/deg . s(-1) in the 1-wk-postoperative group. 8. We conclude that, at least in the guinea pig, the restoration of the spontaneous activity of the deafferented neurons is complete 1 wk after a unilateral labyrinthectomy and thus probably plays an important role in vestibular compensation. Moreover, the difference seen between the complete recovery of the resting discharge and the absence of recovery of sensitivity to head velocity 1 wk after the lesion is further evidence that compensation of static vestibular symptoms and dynamic symptoms are mediated by two completely distinct mechanisms.	UNIV MONS,NEUROSCI LAB,B-7000 MONS,BELGIUM; CNRS,PHYSIOL PERCEPT & ACT LAB,PARIS,FRANCE							AZZENA GB, 1969, ARCH ITAL BIOL, V107, P43; BAARSMA EA, 1975, ARCH OTO-RHINO-LARYN, V211, P219, DOI 10.1007/BF00456342; COURJON JH, 1977, EXP BRAIN RES, V28, P235; CREMER PD, 1987, NEUROSCI LETT S, V27, P564; CURTHOYS IS, 1975, ACTA OTO-LARYNGOL, V80, P197, DOI 10.3109/00016487509121319; DENISE P, 1988, VESTIBULAR COMPENSAT, P59; DEWAELE C, 1989, EXP BRAIN RES, V77, P166, DOI 10.1007/BF00250579; DEWAELE C, 1990, EXP BRAIN RES, V81, P125, DOI 10.1007/BF00230108; DEWAELE C, 1988, SOC NEUR ABSTR, V14, P331; DIERINGER N, 1982, EXP BRAIN RES, V47, P394; DIERINGER N, 1981, LESION INDUCED NEURO, P184; DUENSING F, 1958, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V198, P225, DOI 10.1007/BF00941383; DUTIA MB, 1985, J PHYSIOL-LONDON, V366, P281, DOI 10.1113/jphysiol.1985.sp015797; ESCUDERO M, 1993, EXP BRAIN RES, V97, P254, DOI 10.1007/BF00228694; FETTER M, 1988, J NEUROPHYSIOL, V59, P370; FETTER M, 1988, J NEUROPHYSIOL, V59, P399; Flohr H., 1981, LESION INDUCED NEURO, P153; FUCHS AF, 1966, J APPL PHYSIOL, V21, P1068; GODAUX E, 1993, J PHYSIOL-LONDON, V469, P549, DOI 10.1113/jphysiol.1993.sp019829; GSTOETTNER W, 1987, J COMP NEUROL, V257, P176, DOI 10.1002/cne.902570205; GSTOETTNER W, 1992, ACTA OTO-LARYNGOL, V112, P486, DOI 10.3109/00016489209137430; HADDAD GM, 1977, BRAIN RES, V135, P192, DOI 10.1016/0006-8993(77)91066-6; JENSEN DW, 1979, NEUROSCIENCE, V4, P1059, DOI 10.1016/0306-4522(79)90187-8; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; LACOUR M, 1981, LESION INDUCED NEURO, P240; LLINAS R, 1975, SCIENCE, V190, P1230, DOI 10.1126/science.128123; Llinas R., 1979, INTEGRATION NERVOUS, P145; MAIOLI C, 1985, EXP BRAIN RES, V59, P267; MAIOLI C, 1983, EXP BRAIN RES, V50, P259; MCCABE BF, 1969, LARYNGOSCOPE, V79, P1728, DOI 10.1288/00005537-196910000-00004; MCCABE BF, 1972, LARYNGOSCOPE, V82, P381, DOI 10.1288/00005537-197203000-00005; NEWLANDS SD, 1990, EXP BRAIN RES, V82, P359, DOI 10.1007/BF00231255; POMPEIANO O, 1984, J NEUROPHYSIOL, V52, P18; PRECHT W, 1965, J NEUROPHYSIOL, V28, P1014; PRECHT W, 1966, J NEUROPHYSIOL, V29, P996; Rapisarda C, 1977, Arch Sci Biol (Bologna), V61, P1; RIED S, 1984, ACTA OTO-LARYNGOL, V98, P1, DOI 10.3109/00016488409107529; RYU JH, 1976, ARCH OTOLARYNGOL, V102, P71; SATO F, 1993, J COMP NEUROL, V333, P554, DOI 10.1002/cne.903330408; Schaefer K. P., 1974, HDB SENSORY PHYSL, P463; SERAFIN M, 1991, EXP BRAIN RES, V84, P417, DOI 10.1007/BF00231464; SHIMAZU H, 1966, J NEUROPHYSIOL, V29, P467; SHIMAZU H, 1965, J NEUROPHYSIOL, V28, P991; SMITH PF, 1986, BRAIN RES, V364, P195, DOI 10.1016/0006-8993(86)91004-8; SMITH PF, 1986, NEUROSCI LETT, V65, P209, DOI 10.1016/0304-3940(86)90306-X; SMITH PF, 1989, BRAIN RES REV, V14, P155, DOI 10.1016/0165-0173(89)90013-1; SMITH PF, 1988, BRAIN RES, V444, P308, DOI 10.1016/0006-8993(88)90939-0; STRAKA H, 1993, NEUROREPORT, V4, P1071; VIBERT N, 1993, EXP BRAIN RES, V97, P263, DOI 10.1007/BF00228695; WILSON VJ, 1972, J NEUROPHYSIOL, V35, P253; XERRI C, 1985, J NEUROPHYSIOL, V54, P1006; Zennou-Azogui Y, 1993, Acta Otolaryngol Suppl, V509, P1	52	143	150	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	NOV	1995	74	5					2087	2099					13	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	TD640	WOS:A1995TD64000024	8592199				2021-06-18	
J	HOLMIN, S; MATHIESEN, T; SHETYE, J; BIBERFELD, P				HOLMIN, S; MATHIESEN, T; SHETYE, J; BIBERFELD, P			INTRACEREBRAL INFLAMMATORY RESPONSE TO EXPERIMENTAL BRAIN CONTUSION	ACTA NEUROCHIRURGICA			English	Article						CNS TRAUMA; EXPERIMENTAL CONTUSION; INFLAMMATION	CENTRAL NERVOUS-SYSTEM; NATURAL-KILLER CELLS; RAT LYMPHOCYTES-T; MONOCLONAL-ANTIBODIES; CLASS-I; HISTOCOMPATIBILITY ANTIGENS; MONONUCLEAR PHAGOCYTES; IMMUNE REACTIVITY; AMINO-ACIDS; INJURY	The inflammatory reaction following experimental brain contusion was studied by immunohistochemistry in 22 rats during the first 16 days after trauma. An inflammatory mononuclear cell response was evident on day 2, with a maximum on days 5-6 and signs remained still 16 days after the trauma. The lime course of the cellular infiltration adjacent to the lesion correlated with blood brain barrier dysfunction in the contralateral side of the traumatized hemisphere. The cellular infiltrate comprised NK cells, T-helper cells and T-cytotoxic suppressor cells as well as monocytes/macrophages. Most of the macrophages appeared to be activated by T-cells. Surprisingly, polymorphonuclear cells appeared less engaged than mononuclear cells in the inflammation. The demonstration of immunocompetent cells and the induction of MHC-1 and MHC-II antigen provides a substrate for inflammatory reactions similar to those that cause neurological damage in inflammatory diseases such as viral infections, multiple sclerosis and experimental allergic encephalitis. Our observations indicate that the role of the inflammatory reactions may have a role, hitherto neglected, in the pathogenesis of secondary traumatic brain injury.	KAROLINSKA INST,KAROLINSKA HOSP,DEPT NEUROSURG,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA INST,KAROLINSKA HOSP,DEPT PATHOL,S-10401 STOCKHOLM,SWEDEN				Holmin, Staffan/0000-0002-1628-1615; Mathiesen, Tiit/0000-0001-9463-1919			ANDERSSON PB, 1991, IMMUNOL LETT, V30, P177, DOI 10.1016/0165-2478(91)90022-3; BARBE E, 1990, IMMUNOBIOLOGY, V182, P88, DOI 10.1016/S0171-2985(11)80586-3; BARCLAY AN, 1981, IMMUNOLOGY, V42, P593; BILSSON B, 1977, J NEUROSURG, V47, P262; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1992, J NEUROTRAUMA, V9, P83; BRIDEAU RJ, 1980, EUR J IMMUNOL, V10, P609, DOI 10.1002/eji.1830100807; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; BULLOCK R, 1989, 7TH P INT S INTR PRE, P637; Cervos-Navarro J., 1991, J NEUROL SCI, V103, P3; CHAMBERS WH, 1989, J EXP MED, V169, P1373, DOI 10.1084/jem.169.4.1373; CUZNER ML, 1988, J NEUROIMMUNOL, V20, P203, DOI 10.1016/0165-5728(88)90161-0; DALLMAN MJ, 1984, EUR J IMMUNOL, V14, P260, DOI 10.1002/eji.1830140311; DALLMAN MJ, 1982, EUR J IMMUNOL, V12, P511, DOI 10.1002/eji.1830120612; DAMOISEAUX JGMC, 1989, J LEUKOCYTE BIOL, V46, P246; DIJKSTRA CD, 1987, SCAND J IMMUNOL, V26, P513, DOI 10.1111/j.1365-3083.1987.tb02285.x; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FUKUMOTO T, 1982, EUR J IMMUNOL, V12, P237, DOI 10.1002/eji.1830120313; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; HAYES GM, 1988, J NEUROIMMUNOL, V19, P177, DOI 10.1016/0165-5728(88)90001-X; HICKEY WF, 1992, J EXP MED, V176, P811, DOI 10.1084/jem.176.3.811; HICKEY WF, 1987, P NATL ACAD SCI USA, V84, P2082, DOI 10.1073/pnas.84.7.2082; JIE Z, 1986, ACTA PATHOL MIC SC, V94, P53; KATAYAMA Y, 1990, ACTA NEUROCHIR WIE S, V54, P308; KAUR C, 1987, J ANAT, V154, P215; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KWO S, 1989, Journal of Neurotrauma, V6, P13, DOI 10.1089/neu.1989.6.13; LAMPSON LA, 1987, TRENDS NEUROSCI, V10, P211, DOI 10.1016/0166-2236(87)90153-6; LAMPSON LA, 1986, J IMMUNOL, V136, P4045; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; LJUNGGREN HG, 1988, J EXP MED, V167, P730, DOI 10.1084/jem.167.2.730; LUZ C, 1990, AM J PATHOL, V137, P1033; MAIN EK, 1988, J IMMUNOL, V141, P2943; MCMASTER WR, 1979, EUR J IMMUNOL, V9, P426, DOI 10.1002/eji.1830090603; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OLSSON T, 1987, J NEUROIMMUNOL, V16, P215, DOI 10.1016/0165-5728(87)90076-2; ORTALDO JR, 1981, J IMMUNOL, V127, P2401; PERRY VH, 1987, J EXP MED, V10, P1138; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; POLMAN CH, 1986, J NEUROIMMUNOL, V11, P215, DOI 10.1016/0165-5728(86)90005-6; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; ROGERS J, 1988, DRUG DEVELOP RES, V15, P227, DOI 10.1002/ddr.430150214; SETHNA MP, 1991, J NEUROIMMUNOL, V34, P121, DOI 10.1016/0165-5728(91)90121-M; SMINIA T, 1987, IMMUNOBIOLOGY, V174, P43, DOI 10.1016/S0171-2985(87)80083-9; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; TODD NV, 1990, ACT NEUR S, V51, P296; TRINCHIERI G, 1984, J EXP MED, V160, P1147, DOI 10.1084/jem.160.4.1147; TURNER WJD, 1990, J NEURO-ONCOL, V8, P121; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; VANDENBRINK MRM, 1990, J EXP MED, V171, P197, DOI 10.1084/jem.171.1.197; WEKERLE H, 1987, J EXP BIOL, V132, P43; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WHITE RAH, 1978, J EXP MED, V901, P664; WILLIAMS AF, 1977, CELL, V12, P633; WILMES F, 1979, ACTA NEUROPATHOL, V45, P47, DOI 10.1007/BF00691804; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; WOOLLETT GR, 1985, EUR J IMMUNOL, V15, P168, DOI 10.1002/eji.1830150211	62	143	144	0	3	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1995	132	1-3					110	119		10.1007/BF01404857			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	QD726	WOS:A1995QD72600018	7754844				2021-06-18	
J	GODFREY, HPD; PARTRIDGE, FM; KNIGHT, RG; BISHARA, S				GODFREY, HPD; PARTRIDGE, FM; KNIGHT, RG; BISHARA, S			COURSE OF INSIGHT DISORDER AND EMOTIONAL DYSFUNCTION FOLLOWING CLOSED-HEAD INJURY - A CONTROLLED CROSS-SECTIONAL FOLLOW-UP-STUDY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article								Closed-head injury (CHI) patients at either 6 months (n = 24), 1 year (n = 19), or 2 to 3 years (n = 23) postinjury, were compared with a group of orthopedic control (OC) patients (n = 27). CHI patients assessed at 6 months postinjury experienced a Post-Traumatic Insight Disorder, in which they underreported the severity of their behavioural impairments. CHI patients in the 1 year and 2 to 3 year follow-up groups evidenced both greater insight about their level of behavioural impairment, and higher levels of emotional dysfunction. These findings suggested that the return of insight is associated with increased risk for emotional dysfunction. Implications of these findings for assessment and treatment of closed-head injury patients are discussed.	UNIV OTAGO,DEPT SURG,DUNEDIN,NEW ZEALAND	GODFREY, HPD (corresponding author), UNIV OTAGO,DEPT PSYCHOL,CTR COMMUNITY COUNSELLING,POB 56,DUNEDIN,NEW ZEALAND.						BOND M, 1984, CLOSED HEAD INJURY P; Brooks N., 1984, CLOSED HEAD INJURY P; ELLEY WB, 1985, NEW ZEAL J EDUC STUD, V20, P115; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GODFREY HPD, 1992, UNPUB MANUAL HED INJ; Grove W. M., 1982, J NERV MENT DIS, V170, P2; HOLM S, 1979, SCAND J STAT, V6, P65; Jennett B, 1981, MANAGEMENT HEAD INJU; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; LWEIN M, 1979, UNDERSTANDING PSYCHO; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Nelson H., 1982, NATIONAL ADULT READI; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; NISBETT RICHARD E., 1980, HUMAN INFERENCE STRA; ODONNELL WE, 1984, J CLIN PSYCHOL, V40, P554; PLATT S, 1980, SOC PSYCHIATR, V15, P43, DOI 10.1007/BF00577960; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	25	143	144	0	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUL	1993	15	4					503	515		10.1080/01688639308402574			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	LJ168	WOS:A1993LJ16800005	8354704				2021-06-18	
J	van der Ploeg, T; Austin, PC; Steyerberg, EW				van der Ploeg, Tjeerd; Austin, Peter C.; Steyerberg, Ewout W.			Modern modelling techniques are data hungry: a simulation study for predicting dichotomous endpoints	BMC MEDICAL RESEARCH METHODOLOGY			English	Article								Background: Modern modelling techniques may potentially provide more accurate predictions of binary outcomes than classical techniques. We aimed to study the predictive performance of different modelling techniques in relation to the effective sample size ("data hungriness"). Methods: We performed simulation studies based on three clinical cohorts: 1282 patients with head and neck cancer (with 46.9% 5 year survival), 1731 patients with traumatic brain injury (22.3% 6 month mortality) and 3181 patients with minor head injury (7.6% with CT scan abnormalities). We compared three relatively modern modelling techniques: support vector machines (SVM), neural nets (NN), and random forests (RF) and two classical techniques: logistic regression (LR) and classification and regression trees (CART). We created three large artificial databases with 20 fold, 10 fold and 6 fold replication of subjects, where we generated dichotomous outcomes according to different underlying models. We applied each modelling technique to increasingly larger development parts (100 repetitions). The area under the ROC-curve (AUC) indicated the performance of each model in the development part and in an independent validation part. Data hungriness was defined by plateauing of AUC and small optimism (difference between the mean apparent AUC and the mean validated AUC <0.01). Results: We found that a stable AUC was reached by LR at approximately 20 to 50 events per variable, followed by CART, SVM, NN and RF models. Optimism decreased with increasing sample sizes and the same ranking of techniques. The RF, SVM and NN models showed instability and a high optimism even with >200 events per variable. Conclusions: Modern modelling techniques such as SVM, NN and RF may need over 10 times as many events per variable to achieve a stable AUC and a small optimism than classical modelling techniques such as LR. This implies that such modern techniques should only be used in medical prediction problems if very large data sets are available.	[van der Ploeg, Tjeerd] Inholland Univ, Dept Sci, Med Ctr Alkmaar, Alkmaar, Netherlands; [Austin, Peter C.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [van der Ploeg, Tjeerd; Steyerberg, Ewout W.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands	van der Ploeg, T (corresponding author), Inholland Univ, Dept Sci, Med Ctr Alkmaar, Alkmaar, Netherlands.	tvdploeg@quicknet.nl		Austin, Peter/0000-0003-3337-233X			Austin PC, 2012, BIOMETRICAL J, V54, P657, DOI 10.1002/bimj.201100251; Breiman L, 1984, CLASSIFICATION REGRE, V19, P368; Datema FR, 2010, HEAD NECK-J SCI SPEC, V32, P728, DOI 10.1002/hed.21245; Ennis M, 1998, STAT MED, V17, P2501; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Harrell Frank E., 2001, REGRESSION MODELING; Harrison RF, 2005, ANN EMERG MED, V46, P431, DOI 10.1016/j.annemergmed.2004.09.012; John G. H., 1996, KDD-96 Proceedings. Second International Conference on Knowledge Discovery and Data Mining, P367; Kurahashi I, 2011, KSPLOT CHECK POWER S; Lee DB, 1975, SIMULETTER, P16; Mangasarian Y-JLOL, 1999, DISCRET MATH PROBL M, V55; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Morgan J, 2003, ACAD INFORM MANAGEME, V6, P71; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Provost F., 1999, P 5 ACM SIGKDD INT C, P23, DOI [10.1145/312129.312188, DOI 10.1145/312129.312188]; R Core Development Team,, 2015, R LANG ENV STAT COMP, DOI [10.1007/978-3-540-74686-7, DOI 10.1007/978-3-540-74686-7]; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2000, STAT MED, V19, P1059, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1059::AID-SIM412>3.0.CO;2-0; Steyerberg EW, 2013, PLOS MED, V10; Steyerberg EW, 2009, VALIDATION UPDATING, V19, P500; Tuffery S., 2011, DATA MINING STAT DEC; Tzoulaki I, 2009, JAMA-J AM MED ASSOC, V302, P2345, DOI 10.1001/jama.2009.1757; van der Ploeg T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100234; van der Ploeg T, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-143; Young NH, 2008, PLOS MED, V5, P1186, DOI 10.1371/journal.pmed.0050168	25	142	143	1	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2288		BMC MED RES METHODOL	BMC Med. Res. Methodol.	DEC 22	2014	14								137	10.1186/1471-2288-14-137			13	Health Care Sciences & Services	Health Care Sciences & Services	AZ1IT	WOS:000347993800001	25532820	DOAJ Gold, Green Published			2021-06-18	
J	Kok, BC; Herrell, RK; Thomas, JL; Hoge, CW				Kok, Brian C.; Herrell, Richard K.; Thomas, Jeffrey L.; Hoge, Charles W.			Posttraumatic Stress Disorder Associated With Combat Service in Iraq or Afghanistan Reconciling Prevalence Differences Between Studies	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article						Posttraumatic stress disorder; PTSD; prevalence; meta-analysis; military; Iraq; Afghanistan	MENTAL-HEALTH PROBLEMS; TRAUMATIC BRAIN-INJURY; US SOLDIERS; MILLENNIUM COHORT; UK MILITARY; DEPLOYMENT; PTSD; SYMPTOMS; IMPACT; WAR	Studies of posttraumatic stress disorder (PTSD) prevalence associated with deployment to Iraq or Afghanistan report wide variability, making interpretation and projection for research and public health purposes difficult. This article placed this literature within a military context. Studies were categorized according to deployment time-frame, screening case definition, and study group (operational infantry units exposed to direct combat versus population samples with a high proportion of support personnel). Precision weighted averages were calculated using a fixed-effects meta-analysis. Using a specific case definition, the weighted postdeployment PTSD prevalence was 5.5% (95% CI, 5.4-5.6) in population samples and 13.2% (12.8-13.7) in operational infantry units. Both population-level and unit-specific studies provided valuable and unique information for public health purposes; understanding the military context is essential for interpreting prevalence studies.	[Kok, Brian C.; Herrell, Richard K.; Thomas, Jeffrey L.; Hoge, Charles W.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA	Kok, BC (corresponding author), Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	brian.kok@us.army.mil					American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bliese PD, 2007, PSYCHOL SERV, V4, P141, DOI DOI 10.1037/1541-1559.4.3.141; Brailey K, 2007, J TRAUMA STRESS, V20, P495, DOI 10.1002/jts.20234; Bray R.M., 2009, 2008 DEP DEFENSE SUR; Bray RM, 2006, 2005 DEP DEFENSE SUR; Cabrera OA, 2007, AM J PREV MED, V33, P77, DOI 10.1016/j.amepre.2007.03.019; Carlson EB, 2001, ASSESSMENT, V8, P431, DOI 10.1177/107319110100800408; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Duma SJ, 2010, J TRAUMA STRESS, V23, P52, DOI 10.1002/jts.20484; Engelhard IM, 2007, BRIT J PSYCHIAT, V191, P140, DOI 10.1192/bjp.bp.106.034884; Fear NT, 2010, LANCET, V375, P1783, DOI 10.1016/S0140-6736(10)60672-1; Ferrier-Auerbach AG, 2010, J PSYCHIATR RES, V44, P470, DOI 10.1016/j.jpsychires.2009.10.010; Garner B, 2009, THESIS; Grieger TA, 2007, MIL MED, V172, P451, DOI 10.7205/MILMED.172.5.451; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2008, INT J EPIDEMIOL, V37, P1158, DOI 10.1093/ije/dyn204; Hoge CW, 2008, AM J EPIDEMIOL, V168, P1095, DOI 10.1093/aje/kwn261; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hotopf M, 2006, LANCET, V367, P1731, DOI 10.1016/S0140-6736(06)68662-5; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Lapierre CB, 2007, J TRAUMA STRESS, V20, P933, DOI 10.1002/jts.20278; Larson GE, 2008, AM J EPIDEMIOL, V167, P1269, DOI 10.1093/aje/kwn084; LeardMann CA, 2009, BMJ-BRIT MED J, V338, P1; Mclay RN, 2008, AM J PSYCHIAT, V165, P775, DOI 10.1176/appi.ajp.2008.07121960; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Ramchand R, 2008, INVISIBLE WAR WOUNDS; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; Riddle JR, 2007, J CLIN EPIDEMIOL, V60, P192, DOI 10.1016/j.jclinepi.2006.04.008; Rona RJ, 2006, BMJ-BRIT MED J, V333, P991, DOI 10.1136/BMJ.38985.610949.55; Rona RJ, 2009, J PSYCHIATR RES, V43, P649, DOI 10.1016/j.jpsychires.2008.09.006; Ryan MAK, 2007, J CLIN EPIDEMIOL, V60, P181, DOI 10.1016/j.jclinepi.2006.05.009; Schell T. L., 2008, INVISIBLE WAR WOUNDS; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shen YC, 2009, MIL MED, V174, P217, DOI 10.7205/MILMED-D-03-4307; Smith TC, 2008, EPIDEMIOLOGY, V19, P505, DOI 10.1097/EDE.0b013e31816a9dff; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Stecker T, 2007, PSYCHIAT SERV, V58, P1358, DOI 10.1176/appi.ps.58.10.1358; Sundin J, 2010, PSYCHOL MED, V40, P367, DOI 10.1017/S0033291709990791; Terhakopian A, 2008, J TRAUMA STRESS, V21, P290, DOI 10.1002/jts.20341; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; US Department of the Army Mental Health Advisory Team (MHAT-I), 2003, OP IR FREED OIF MHAT; US Department of the Army Mental Health Advisory Team (MHAT-II), 2005, OP IR FREED OIF MHAT; US Department of the Army Mental Health Advisory Team (MHAT-III), 2006, OP IR FREED OIF 04 0; US Department of the Army Mental Health Advisory Team (MHAT-IV), 2007, OP IR FREED OIF 05 0; US Department of the Army Mental Health Advisory Team (MHAT-V), 2008, OP IR FREED OIF 06 0; US Department of the Army Mental Health Advisory Team (MHAT-VI), 2009, OP IR FREED OIF 07 0; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Weathers F. W., 1993, ANN M INT SOC TRAUM; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029	56	142	143	0	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-3018	1539-736X		J NERV MENT DIS	J. Nerv. Ment. Dis.	MAY	2012	200	5					444	450		10.1097/NMD.0b013e3182532312			7	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	946ET	WOS:000304335000012	22551799				2021-06-18	
J	Messe, A; Caplain, S; Paradot, G; Garrigue, D; Mineo, JF; Ares, GS; Ducreux, D; Vignaud, F; Rozec, G; Desal, H; Pelegrini-Issac, M; Montreuil, M; Benali, H; Lehericy, S				Messe, Arnaud; Caplain, Sophie; Paradot, Gaelle; Garrigue, Delphine; Mineo, Jean-Francois; Ares, Gustavo Soto; Ducreux, Denis; Vignaud, Frederic; Rozec, Gaelle; Desal, Hubert; Pelegrini-Issac, Melanie; Montreuil, Michele; Benali, Habib; Lehericy, Stephane			Diffusion Tensor Imaging and White Matter Lesions at the Subacute Stage in Mild Traumatic Brain Injury With Persistent Neurobehavioral Impairment	HUMAN BRAIN MAPPING			English	Article						mild traumatic brain injury; diffusion tensor imaging; post-commotional syndrome; outcome; voxel-based morphometry; tract-based spatial statistics	CLOSED-HEAD INJURY; AMYLOID PRECURSOR PROTEIN; VOXEL-BASED MORPHOMETRY; AXONAL INJURY; POSTCONCUSSIVE SYNDROME; FIBER TRACTOGRAPHY; REACTION-TIME; MR-IMAGES; SEQUELAE; CONCUSSION	Mild traumatic brain injury (mTBI) can induce long-term behavioral and cognitive disorders. Although the exact origin of these mTBI-related disorders is not known, they may be the consequence of diffuse axonal injury (DAI). Here, we investigated whether MRI at the subacute stage can detect lesions that are associated with poor functional outcome in mTBI by using anatomical images (T-1) and diffusion tensor imaging (DTI). Twenty-three patients with mTBI were investigated and compared with 23 healthy volunteers. All patients underwent an MRI investigation and clinical tests between 7 and 28 days (D15) and between 3 and 4 months (M3) after injury. Patients were divided in two groups of poor outcome (PO) and good outcome (GO), based on their complaints at M3. Groupwise differences in gray matter partial volume between PO patients, GO patients and controls were analyzed using Voxel-Based Morphometry (VBM) from T-1 data at D15. Differences in microstructural architecture were investigated using Tract-Based Spatial Statistics (TBSS) and the diffusion images obtained from DTI data at D15. Permutation-based non-parametric testing was used to assess cluster significance at p < 0.05, corrected for multiple comparisons. Twelve GO patients and 11 PO patients were identified on the basis of their complaints. In PO patients, gray matter partial volume was significantly lower in several cortical and subcortical regions compared with controls, but did not differ from that of GO patients. No difference in diffusion variables was found between GO and controls. PO patients showed significantly higher mean diffusivity values than both controls and GO patients in the corpus callosum, the right anterior thalamic radiations and the superior longitudinal fasciculus, the inferior longitudinal fasciculus and the fronto-occipital fasciculus bilaterally. In conclusion, PO patients differed from GO patients by the presence of diffusion changes in long association white matter fiber tracts but not by gray matter partial volume. These results suggest that DTI at the subacute stage may be a predictive marker of poor outcome in mTBI. Hum Brain Mapp 32:999-1011, 2011. (C) 2010 Wiley-Liss, Inc.	[Messe, Arnaud] Univ Paris 06, CHU Pitie Salpetriere, INSERM, LIF,UPMC,UMR S 678, F-75634 Paris, France; [Messe, Arnaud] INRIA Sophia Antipolis Mediterranee, Project Team Odysse, F-06902 Sophia Antipolis, France; [Messe, Arnaud; Pelegrini-Issac, Melanie; Benali, Habib; Lehericy, Stephane] Univ Paris 11, IFR49, Bat 145, DSV IBM NeuroSpin, F-91191 Gif Sur Yvette, France; [Caplain, Sophie; Montreuil, Michele] Univ Paris 08, EA 2027, F-93526 St Denis, France; [Paradot, Gaelle; Ducreux, Denis] Bicetre Univ Hosp, Dept Neurosurg, F-94275 Le Kremlin Bicetre, France; [Paradot, Gaelle; Ducreux, Denis] Bicetre Univ Hosp, Dept Neuroradiol, F-94275 Le Kremlin Bicetre, France; [Garrigue, Delphine; Mineo, Jean-Francois; Ares, Gustavo Soto] Roger Salengro Reg Univ Hosp, Dept Neurosurg, F-59037 Lille, France; [Garrigue, Delphine; Mineo, Jean-Francois; Ares, Gustavo Soto] Roger Salengro Reg Univ Hosp, Dept Neuroradiol, F-59037 Lille, France; [Vignaud, Frederic; Rozec, Gaelle; Desal, Hubert] Nantes Univ Hosp, Funct Rehabil Dept, F-44093 Nantes, France; [Vignaud, Frederic; Rozec, Gaelle; Desal, Hubert] Nantes Univ Hosp, Dept Neuroradiol, F-44093 Nantes, France; [Lehericy, Stephane] Univ Paris 06, Ctr Rech Inst Cerveau & Moelle Epiniere, Grp Hosp Pitie Salpetriere, INSERM,CNRS,CRICM,UMR 7225,UMR S 975, F-75013 Paris, France; [Lehericy, Stephane] Univ Paris 06, UPMC, CHU Pitie Salpetriere, Ctr Neuroimaging Res, F-75013 Paris, France	Messe, A (corresponding author), Univ Paris 06, CHU Pitie Salpetriere, INSERM, LIF,UPMC,UMR S 678, 91 Blvd Hop, F-75634 Paris, France.	Arnaud.Messe@imed.jussieu.fr	Desal, Hubert/D-3705-2015; Messe, Arnaud/I-1738-2019; Desal, Hubert/T-2089-2019	Desal, Hubert/0000-0002-4665-1461; Messe, Arnaud/0000-0001-9081-3088; Pelegrini-Issac, Melanie/0000-0003-3260-5795	IRME (Institut pour la Recherche sur la Moelle Epiniere et l'Encephale); GMF (Garantie Mutuelle des Fonctionnaires)	Contract grant sponsors: IRME (Institut pour la Recherche sur la Moelle Epiniere et l'Encephale), GMF (Garantie Mutuelle des Fonctionnaires).	ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Association AP, 1994, DIAGN STAT MAN MENT; Baddeley A. D., 1986, WORKING MEMORY; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Catani M, 2008, CORTEX, V44, P1105, DOI 10.1016/j.cortex.2008.05.004; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Drake RE, 2001, PSYCHIATR SERV, V52, P179, DOI 10.1176/appi.ps.52.2.179; EVANS RW, 1992, NEUROL CLIN, V10, P815; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; Gillum RF, 2002, STROKE, V33, P1717, DOI 10.1161/01.STR.0000016925.58848.EA; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; GOODMAN JC, 1994, SEMIN NEUROL, V14, P19, DOI 10.1055/s-2008-1041054; Harsan LA, 2006, J NEUROSCI RES, V83, P392, DOI 10.1002/jnr.20742; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Lenglet C, 2009, NEUROIMAGE, V45, pS111, DOI 10.1016/j.neuroimage.2008.10.054; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Li XF, 2010, NEURORADIOLOGY, V52, P203, DOI 10.1007/s00234-009-0600-1; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MANGIN JF, 2001, MICCAI 01 UTR LNCS S, P186; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Ragnarsson KT, 2002, RESTOR NEUROL NEUROS, V20, P103; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; RUTHERFORD WH, 1977, LANCET, V1, P1; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; SCOTT J, 1979, ANN RHEUM DIS, V38, P560, DOI 10.1136/ard.38.6.560; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stulemeijer M, 2005, BMJ-BRIT MED J, V330, P14, DOI 10.1136/bmj.38301.587106.63; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tisserand DJ, 2006, BRAIN COGNITION, V60, P216; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	94	142	145	0	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JUN	2011	32	6					999	1011		10.1002/hbm.21092			13	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	762AX	WOS:000290445800014	20669166	Green Published			2021-06-18	
J	Levine, B; Schweizer, TA; O'Connor, C; Turner, G; Gillingham, S; Stuss, DT; Manly, T; Robertson, IH				Levine, Brian; Schweizer, Tom A.; O'Connor, Charlene; Turner, Gary; Gillingham, Susan; Stuss, Donald T.; Manly, Tom; Robertson, Ian H.			Rehabilitation of executive functioning in patients with frontal lobe brain damage with goal management training	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						rehabilitation; executive functioning; frontal lobe; stroke; traumatic brain injury mindfulness	COGNITIVE REHABILITATION; STRATEGY APPLICATION; INJURY; ATTENTION; INTELLIGENCE; FAILURES; BEHAVIOR; DISEASE	Executive functioning deficits due to brain disease affecting frontal lobe functions cause significant real-life disability, yet solid evidence in support of executive functioning interventions is lacking. Goal Management Training (GMT), an executive functioning intervention that draws upon theories concerning goal processing and sustained attention, has received empirical support in studies of patients with traumatic brain injury, normal aging, and case studies. GMT promotes a mindful approach to complex real-life tasks that pose problems for patients with executive functioning deficits, with a main goal of periodically stopping ongoing behavior to monitor and adjust goals. In this controlled trial, an expanded version of GMT was compared to an alternative intervention, Brain Health Workshop that was matched to GMT on non-specific characteristics that can affect intervention outcome. Participants included 19 individuals in the chronic phase of recovery from brain disease (predominantly stroke) affecting frontal lobe function. Outcome data indicated specific effects of GMT on the Sustained Attention to Response Task as well as the Tower Test, a visuospatial problem-solving measure that reflected far transfer of training effects. There were no significant effects on self-report questionnaires, likely owing to the complexity of these measures in this heterogeneous patient sample. Overall, these data support the efficacy of GMT in the rehabilitation of executive functioning deficits.	[Levine, Brian; O'Connor, Charlene; Gillingham, Susan; Stuss, Donald T.] Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada; [Levine, Brian; O'Connor, Charlene; Stuss, Donald T.] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Levine, Brian; Stuss, Donald T.] Univ Toronto, Dept Med Neurol, Toronto, ON M5S 1A1, Canada; [Schweizer, Tom A.] Univ Toronto, Dept Med Neurosurg, Toronto, ON M5S 1A1, Canada; [Schweizer, Tom A.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada; [Turner, Gary] Univ Toronto, Dept Occupat & Rehabil Sci, Toronto, ON M5S 1A1, Canada; [Turner, Gary] Heart & Stroke Fdn, Sunnybrook Hlth Sci Ctr, Ctr Stroke Recovery, Toronto, ON, Canada; [Manly, Tom] MRC, Cognit & Brain Sci Unit, Cambridge, England; [Robertson, Ian H.] Trinity Coll Dublin, Dept Psychol & Neurosci, Dublin, Ireland	Levine, B (corresponding author), Baycrest Ctr Geriatr Care, Rotman Res Inst, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	blevine@rotman-baycrest.on.ca	Levine, Brian/G-4328-2010; Levine, Brian/O-2725-2019	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Robertson, Ian H/0000-0001-8637-561X	JSF McDonnell Foundation [JSMF220020082]; Ontario Heart and Stroke Foundation Centre for Stroke Recovery; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD42385-01]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_U105559837] Funding Source: researchfish; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042385] Funding Source: NIH RePORTER	We thank the patients who participated in this research for volunteering their time and effort. Sam Katerji is thanked for participant testing and coordination. Additional technical assistance was provided by Lisa Strifler, Namita Kumar, and Allison Mackey. This research was supported by grants from the JSF McDonnell Foundation (JSMF220020082), the Ontario Heart and Stroke Foundation Centre for Stroke Recovery, and the National Institute of Child Health and Human Development to Brian Levine (HD42385-01).	BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Delis DC, 2001, DELISKAPLAN EXECUTIV; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Handler J., 1994, HANDB NEUR, P125; Jaeggi SM, 2008, P NATL ACAD SCI USA, V105, P6829, DOI 10.1073/pnas.0801268105; Kabat-Zinn J, 1990, FULL CATASTROPHE LIV; Levine B, 2002, NEUROPSYCHOLOGICAL INTERVENTIONS, P80; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Levine B, 2008, COGNITIVE NEUROREHAB, P464; Levine B, 2007, J INT NEUROPSYCH SOC, V13, P143, DOI 10.1017/S1355617707070178; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; McDonald WI, 1999, PHILOS T R SOC B, V354, P1615, DOI 10.1098/rstb.1999.0506; McIntosh AR, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000106; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; O'Connell RG, 2009, J COGNITIVE NEUROSCI, V21, P93, DOI 10.1162/jocn.2009.21008; OCONNOR C, NEUROPSYCHO IN PRESS; Persson J, 2008, PSYCHOL SCI, V19, P881, DOI 10.1111/j.1467-9280.2008.02172.x; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Raz N, 2000, HDB AGING COGNITION, P1; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Robertson IH, 1996, GOAL MANAGEMENT TRAI; ROBERTSON IH, 2000, NEW COGNITIVE NEUROS, P563; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Schweizer TA, 2008, NEUROREHAB NEURAL RE, V22, P72, DOI 10.1177/1545968307305303; SEGAL ZV, 2002, MINDFULNESS BASED CO, P351; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Stuss DT, 2007, PHILOS T R SOC B, V362, P901, DOI 10.1098/rstb.2007.2096; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Swartz RH, 2008, STROKE, V39, P822, DOI 10.1161/STROKEAHA.107.491936; van Hooren SAH, 2007, PATIENT EDUC COUNS, V65, P205, DOI 10.1016/j.pec.2006.07.010	45	142	145	0	77	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	FEB 17	2011	5								9	10.3389/fnhum.2011.00009			9	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	748VV	WOS:000289421800001	21369362	DOAJ Gold, Green Published			2021-06-18	
J	Emery, CA; Kang, J; Shrier, I; Goulet, C; Hagel, BE; Benson, BW; Nettel-Aguirre, A; McAllister, JR; Hamilton, GM; Meeuwisse, WH				Emery, Carolyn A.; Kang, Jian; Shrier, Ian; Goulet, Claude; Hagel, Brent E.; Benson, Brian W.; Nettel-Aguirre, Alberto; McAllister, Jenelle R.; Hamilton, Gavin M.; Meeuwisse, Willem H.			Risk of Injury Associated With Body Checking Among Youth Ice Hockey Players	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPORT INJURY; CONCUSSION; RATES; PARTICIPATION; STATEMENT; RECOVERY; CALGARY	Context Ice hockey has one of the highest sport participation and injury rates in youth in Canada. Body checking is the predominant mechanism of injury in leagues in which it is permitted. Objective To determine if risk of injury and concussion differ for Pee Wee (ages 11-12 years) ice hockey players in a league in which body checking is permitted (Alberta, Canada) vs a league in which body checking is not permitted (Quebec, Canada). Design, Setting, and Participants Prospective cohort study conducted in Alberta and Quebec during the 2007-2008 Pee Wee ice hockey season. Participants (N=2154) were players from teams in the top 60% of divisions of play. Main Outcome Measures Incidence rate ratios adjusted for cluster based on Poisson regression for game-and practice-related injury and concussion. Results Seventy-four Pee Wee teams from Alberta (n=1108 players) and 76 Pee Wee teams from Quebec (n=1046 players) completed the study. In total, there were 241 injuries (78 concussions) reported in Alberta (85 077 exposure-hours) and 91 injuries (23 concussions) reported in Quebec (82 099 exposure-hours). For game-related injuries, the Alberta vs Quebec incidence rate ratio was 3.26 (95% confidence interval [CI], 2.31-4.60 [n=209 and n=70 for Alberta and Quebec, respectively]) for all injuries, 3.88 (95% CI, 1.91-7.89 [n=73 and n=20]) for concussion, 3.30 (95% CI, 1.77-6.17 [n=51 and n=16]) for severe injury (time loss, >7 days), and 3.61 (95% CI, 1.16-11.23 [n=14 and n=4]) for severe concussion (time loss, >10 days). The estimated absolute risk reduction (injuries per 1000 player-hours) that would be achieved if body checking were not permitted in Alberta was 2.84 (95% CI, 2.18-3.49) for all game-related injuries, 0.72 (95% CI, 0.40-1.04) for severe injuries, 1.08 (95% CI, 0.70-1.46) for concussion, and 0.20 (95% CI, 0.04-0.37) for severe concussion. There was no difference between provinces for practice-related injuries. Conclusion Among 11- to 12-year-old ice hockey players, playing in a league in which body checking is permitted compared with playing in a league in which body checking is not permitted was associated with a 3-fold increased risk of all game-related injuries and the categories of concussion, severe injury, and severe concussion. JAMA. 2010; 303(22): 2265-2272	[Emery, Carolyn A.; Kang, Jian; Benson, Brian W.; McAllister, Jenelle R.; Hamilton, Gavin M.; Meeuwisse, Willem H.] Univ Calgary, Sport Med Ctr, Roger Jackson Ctr Hlth & Wellness Res, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; [Emery, Carolyn A.; Hagel, Brent E.; Nettel-Aguirre, Alberto] Univ Calgary, Alberta Childrens Hosp, Fac Med, Dept Pediat, Calgary, AB T2N 1N4, Canada; [Emery, Carolyn A.; Hagel, Brent E.; Nettel-Aguirre, Alberto; Meeuwisse, Willem H.] Univ Calgary, Fac Med, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada; [Shrier, Ian] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Ctr Clin Epidemiol & Community Studies, Montreal, PQ H3T 1E2, Canada; [Goulet, Claude] Univ Laval, Fac Educ, Dept Phys Educ, Quebec City, PQ, Canada	Emery, CA (corresponding author), Univ Calgary, Sport Med Ctr, Roger Jackson Ctr Hlth & Wellness Res, Fac Kinesiol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	caemery@ucalgary.ca	Hagel, Brent/AAK-3319-2020; Emery, Carolyn/AAI-2761-2020; Shrier, Ian/AAI-6502-2020	Shrier, Ian/0000-0001-9914-3498; Nettel-Aguirre, Alberto/0000-0001-6604-0652	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Max Bell Foundation; Hockey Calgary; Hockey Edmonton; Hockey Quebec; Hockey Alberta; Hockey Canada; Quebec Ministry of Education, Leisure and Sport; Alberta Heritage FoundationAlberta Heritage Foundation for Medical Research; Canadian National Railway Company; Alberta Heritage Foundation for Medical Research Population Health Investigator; Fonds de la Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec	This study was funded by the Canadian Institutes of Health Research and the Max Bell Foundation. This research also received support from Hockey Calgary, Hockey Edmonton, Hockey Quebec, Hockey Alberta, Hockey Canada, and the Quebec Ministry of Education, Leisure and Sport. Dr Emery is supported by a Population Health Investigator Award from the Alberta Heritage Foundation, a New Investigator Award from the Canadian Institutes of Health Research, and a Professorship in Pediatric Rehabilitation in the Faculty of Medicine, University of Calgary (Alberta Children's Hospital Foundation). Dr Hagel holds the Alberta Children's Hospital Foundation Professorship in Child Health and Wellness, funded through the support of an anonymous donor and the Canadian National Railway Company, as well as the Alberta Heritage Foundation for Medical Research Population Health Investigator and Canadian Institutes of Health Research New Investigator Awards. Dr Shrier is supported by the Senior Clinician Scientist program of the Fonds de la Recherche en Sante du Quebec.	Benson B., 2005, CLIN J SPORT MED, V15, P395; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Brunelle JP, 2005, J SCI MED SPORT, V8, P294, DOI 10.1016/S1440-2440(05)80040-4; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Emery CA, 2009, PAED CHILD HEALT-CAN, V14, P439, DOI 10.1093/pch/14.7.439; Emery CA, 2006, CLIN J SPORT MED, V16, P20, DOI 10.1097/01.jsm.0000184638.72075.b7; Emery CA, 2003, CLIN J SPORT MED, V13, P256, DOI 10.1097/00042752-200307000-00011; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, INJURY PREV, V16, P113, DOI 10.1136/ip.2009.022764; Emery CA, 2009, CLIN J SPORT MED, V19, P207, DOI 10.1097/JSM.0b013e31819d658e; Fuller CW, 2006, CLIN J SPORT MED, V16, P97, DOI 10.1097/00042752-200603000-00003; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; *HOCK CAN, BACKGR CHECK; *HOCK CAN, HOCK CAN ANN REP 200; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Makdissi M, 2009, BRIT J SPORT MED, V43, pI23, DOI 10.1136/bjsm.2009.058206; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; ROY MA, 1989, PHYSICIAN SPORTSMED, V17, P119, DOI 10.1080/00913847.1989.11709735; *STATACORP, 2005, STAT STAT SOFTW COMP; *US HOCK, HOCK ANN REP US 2007; *US HOCK, 2007, 2007 09 OFF RUL IC H; Warsh JM, 2009, CLIN J SPORT MED, V19, P134, DOI 10.1097/JSM.0b013e3181987783; Wiggins W., 1999, THESIS LAKEHEAD U TH; Willer B, 2005, MED SCI SPORT EXER, V37, P1658, DOI 10.1249/01.mss.0000181839.86170.06	29	142	143	0	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	2010	303	22					2265	2272		10.1001/jama.2010.755			8	Medicine, General & Internal	General & Internal Medicine	607IY	WOS:000278496800025	20530780	Green Published, Bronze			2021-06-18	
J	Victor, T; Boone, K; Serpa, JG; Buehler, J; Ziegler, E				Victor, Tara L.; Boone, Kyle B.; Serpa, J. Greg; Buehler, Jody; Ziegler, Elizabeth A.			[image omitted]Interpreting the Meaning of Multiple Symptom Validity Test Failure	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	34th Annual Meeting of the International-Neuropsychological-Society	FEB 01-04, 2006	Boston, MA	Int Neuropsychol Soc		Symptom validity; Response bias; Incremental validity; Effort	TRAUMATIC BRAIN-INJURY; PERFORMANCE PATTERNS; INCREMENTAL VALIDITY; RECOGNITION TRIAL; SUSPECT; SENSITIVITY; VALIDATION; SCORES; SPECIFICITY; INDICATORS	While it is recommended that judgments regarding the credibility of test performance be based on the results of more than one effort indicator, and recent efforts have been made to improve interpretation of multiple effort test failure, the field currently lacks adequate guidelines for using multiple measures of effort in concert with one another. A total of 103 patients were referred for outpatient neuropsychological evaluation, which included multiple measures of negative response bias embedded in standard test batteries. Using any pairwise failure combination to predict diagnostic classification was superior (sensitivity = 83.8%, specificity = 93.9%, overall hit rate = 90.3%) to using any one test by itself and to using any three-test failure combination. Further, the results were comparable to the results of logistical regression analyses using the embedded indicators as continuous predictors. Given its parsimony and clinical utility, the pairwise failure model is therefore a recommended criterion for identifying non-credible performance; however, there are of course other important contextual factors and influences to consider, which are also discussed.	[Victor, Tara L.; Serpa, J. Greg] W Angeles Vet Healthcare Syst, Los Angeles, CA USA; [Boone, Kyle B.; Buehler, Jody; Ziegler, Elizabeth A.] Harbor UCLA Med Ctr, Los Angeles, CA USA; [Victor, Tara L.] Calif State Univ Dominguez Hills, Dept Psychol, Carson, CA 90747 USA; [Victor, Tara L.; Boone, Kyle B.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA	Victor, T (corresponding author), Calif State Univ Dominguez Hills, Dept Psychol, 1000 E Victoria St, Carson, CA 90747 USA.	tvictor@csudh.edu	Victor, Tara/K-6581-2019				Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Boone, 2007, ASSESSMENT FEIGNED C; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2000, ARCH CLIN NEUROPSYCH, V15, P227, DOI 10.1016/S0887-6177(99)00014-1; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; DEAN AC, 2007, 26 ANN NAT AC NEUR C; DEAN AD, CLIN NEUROP IN PRESS; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; GREVE KW, 2007, CLIN NEUROPSYCHOL, V22, P769; Haynes SN, 2003, PSYCHOL ASSESSMENT, V15, P456, DOI 10.1037/1040-3590.15.4.456; Hunsley J, 2003, PSYCHOL ASSESSMENT, V15, P446, DOI 10.1037/1040-3590.15.4.446; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Kaufman A. S., 1990, ASSESSING ADOLESCENT; Larrabee G.J., 2007, ASSESSMENT MALINGERE, P334; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Martin RC, 1996, J CLIN EXP NEUROPSYC, V18, P265, DOI 10.1080/01688639608408281; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; MILLIS SR, 2006, 20 ANN M AM AC CLIN; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; Nitch S, 2006, CLIN NEUROPSYCHOL, V20, P873, DOI 10.1080/13854040590967603; Orey SA, 2000, ARCH CLIN NEUROPSYCH, V15, P335, DOI 10.1016/S0887-6177(99)00024-4; Ponton M O, 2000, Appl Neuropsychol, V7, P32, DOI 10.1207/S15324826AN0701_5; Rogers R, 1997, CLIN ASSESSMENT MALI, P1; Rosenfeld B, 2000, ARCH CLIN NEUROPSYCH, V15, P349, DOI 10.1016/S0887-6177(99)00025-6; Salazar X. F., 2007, ASSESSMENT FEIGNED C, P405; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Taylor JS, 1999, STUD NEUROPSYCHOL DE, P419; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vickery CD, 2004, ARCH CLIN NEUROPSYCH, V19, P37, DOI 10.1016/S0887-6177(02)00170-1; Victor T. L., 2007, ASSESSMENT FEIGNED C, P310, DOI 10.1076/jcen.25.7.979.16481; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	49	142	142	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	2					297	313	PII 903042154	10.1080/13854040802232682			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	399LS	WOS:000262802000008	18821138				2021-06-18	
J	Borowski, LA; Yard, EE; Fields, SK; Comstock, RD				Borowski, Laurel A.; Yard, Ellen E.; Fields, Sarah K.; Comstock, R. Dawn			The Epidemiology of US High School Basketball Injuries, 2005-2007	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						high school; basketball; injury; gender; epidemiology; surveillance	ANTERIOR CRUCIATE LIGAMENT; SPORTS-RELATED INJURIES; STATES HIGH-SCHOOL; UNITED-STATES; GENDER-DIFFERENCES; SOCCER PLAYERS; NORTH-CAROLINA; ANKLE INJURIES; KNEE INJURIES; RISK-FACTORS	Background: With more than a million high school athletes playing during the 2006-2007 academic year, basketball is one of the most popular sports in the United States. Hypothesis: Basketball injury rates and patterns differ by gender and type of exposure. Study Design: Descriptive epidemiology study. Methods: Basketball-related injury data were collected during the 2005-2006 and 2006-2007 academic years from 100 nationally representative US high schools via Reporting Information Online. Results: High school basketball players sustained 1518 injuries during 780 651 athlete exposures for an injury rate of 1.94 per 1000 athlete exposures. The injury rate per 1000 athlete exposures was greater during competition (3.27) than during practice (1.40; rate ratio, 2.33; 95% confidence interval, 2.10-2.57) and was greater among girls (2.08) than among boys (1.83; rate ratio, 1.14; 95% confidence interval, 1.03-1.26). The ankle/foot (39.7%), knee (14.7%), head/face/neck (13.6%), arm/hand (9.6%), and hip/thigh/upper leg (8.4%) were most commonly injured. The most frequent injury diagnoses were ligament sprains (44.0%), muscle/tendon strains (17.7%), contusions (8.6%), fractures (8.5%), and concussions (7.0%). Female basketball players sustained a greater proportion of concussions (injury proportion ratio, 2.41; 95% confidence interval, 1.49-3.91) and knee injuries (injury proportion ratio, 1.71; 95% confidence interval, 1.27-2.30), whereas boys more frequently sustained fractures (injury proportion ratio, 1.87; 95% confidence interval, 1.27-2.77) and contusions (injury proportion ratio, 1.52; 95% confidence interval, 1.00-2.31). The most common girls' injury requiring surgery was knee ligament sprains (47.9%). Conclusion: High school basketball injury patterns vary by gender and type of exposure. This study suggests several areas of emphasis for targeted injury prevention interventions.	[Yard, Ellen E.; Comstock, R. Dawn] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Comstock, R. Dawn] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA; [Fields, Sarah K.] Ohio State Univ, Sch Phys Act & Educ Serv, Columbus, OH 43210 USA; [Comstock, R. Dawn] Ohio State Univ, Dept Pediat, Coll Med, Columbus, OH 43210 USA	Yard, EE (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	Ellen.Yard@NationwideChildrens.org			Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000674] Funding Source: NIH RePORTER	This report was funded in part by the Centers for Disease Control and Prevention (CDC) grant No. R49/CE000674-01.	Adachi N, 2008, ARCH ORTHOP TRAUM SU, V128, P473, DOI 10.1007/s00402-007-0461-1; Agel J, 2005, AM J SPORT MED, V33, P524, DOI 10.1177/0363546504269937; Anderson AF, 2001, AM J SPORT MED, V29, P58, DOI 10.1177/03635465010290011501; ARENDT E, 1995, AM J SPORT MED, V23, P694, DOI 10.1177/036354659502300611; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Burt CW, 2001, ANN EMERG MED, V37, P301, DOI 10.1067/mem.2001.111707; Carpenter L. J., 2005, TITLE 9; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Cumps E, 2007, J SPORT SCI MED, V6, P204; Deitch JR, 2006, AM J SPORT MED, V34, P1077, DOI 10.1177/0363546505285383; Emery CA, 2007, CLIN J SPORT MED, V17, P17, DOI 10.1097/JSM.0b013e31802e9c05; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gomez E, 1996, AM J SPORT MED, V24, P684, DOI 10.1177/036354659602400521; Hewett TE, 1999, AM J SPORT MED, V27, P699, DOI 10.1177/03635465990270060301; HUTCHINSON MR, 1995, SPORTS MED, V19, P288, DOI 10.2165/00007256-199519040-00006; Jenkins WL, 2006, J AM PODIAT MED ASSN, V96, P408, DOI 10.7547/0960408; Kelly JP, 2000, SEMIN NEUROL, V20, P165, DOI 10.1055/s-2000-9835; Knowles SB, 2006, AM J EPIDEMIOL, V164, P1209, DOI 10.1093/aje/kwj337; Kocher MS, 2000, SPORTS MED, V30, P117, DOI 10.2165/00007256-200030020-00005; LANESE RR, 1990, AM J PUBLIC HEALTH, V80, P1459, DOI 10.2105/AJPH.80.12.1459; LAPRADE RF, 1994, AM J SPORT MED, V22, P198, DOI 10.1177/036354659402200208; Liu SH, 1997, AM J SPORT MED, V25, P704, DOI 10.1177/036354659702500521; Mansell J, 2005, J ATHL TRAINING, V40, P310; McGuine TA, 2006, AM J SPORT MED, V34, P1103, DOI 10.1177/0363546505284191; McKay G, 2001, J SCI MED SPORT, V4, P196, DOI 10.1016/S1440-2440(01)80030-X; McKay GD, 2001, BRIT J SPORT MED, V35, P103, DOI 10.1136/bjsm.35.2.103; McQuillan R, 2006, PUBLIC HEALTH, V120, P732, DOI 10.1016/j.puhe.2006.02.011; Meeuwisse WH, 2003, AM J SPORT MED, V31, P379, DOI 10.1177/03635465030310030901; Messina DF, 1999, AM J SPORT MED, V27, P294, DOI 10.1177/03635465990270030401; Mountcastle SB, 2007, AM J SPORT MED, V35, P1635, DOI 10.1177/0363546507302917; Myer GD, 2005, J STRENGTH COND RES, V19, P51, DOI 10.1519/13643.1; *NAT FED STAT HIGH, 2004 06 HIGH SCH ATH; Nelson AJ, 2007, J ATHL TRAINING, V42, P381; Powell JW, 1999, J ATHL TRAINING, V34, P277; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Shelbourne KD, 1998, AM J SPORT MED, V26, P402, DOI 10.1177/03635465980260031001; United States Census Bureau, CENS REG DIV US; *US DEP HHS, 1996 SURG GEN REP PH; Yardt EE, 2008, AM J SPORT MED, V36, P57, DOI 10.1177/0363546507307507	42	142	146	0	47	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2008	36	12					2328	2335		10.1177/0363546508322893			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	382PZ	WOS:000261619200007	18765675				2021-06-18	
J	Blackwell, CD; Gorelick, M; Holmes, JF; Bandyopadhyay, S; Kuppermann, N				Blackwell, Charles D.; Gorelick, Marc; Holmes, James F.; Bandyopadhyay, Subhankar; Kuppermann, Nathan			Pediatric head trauma: Changes in use of computed tomography in emergency departments in the United States over time	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Pediatric-Research	MAY   11, 2004	San Francisco, CA	Soc Pediat Res			DECISION RULE; CHILDREN; INJURY	Study objective: Head trauma is common in children. In the absence of evidence-based recommendations, variations exist in the initial emergency department (ED) evaluation and treatment of children with head trauma. We sought to describe the use of computed tomography (CT) over time in the treatment of children with acute closed head trauma in US EDs. Methods: This was a cross-sectional analysis of data from the National Hospital Ambulatory Care Survey database from 1995 to 2003. We identified patients aged 0 to 18 years, with head trauma by chief complaint or discharge diagnosis. We collected the following data: chief complaint, patient demographics, patient disposition, discharge diagnosis, and use of CT. Frequency and characteristics of the use of CT scan for evaluation of children with head trauma. We used descriptive statistics with appropriate weighting to account for the survey methodology. We determined the frequency and the characteristics of the use of CT scans for evaluation of children with head trauma. We used descriptive statistics with appropriate weighting to account for the survey methodology. Results: We identified 2,747 patient encounters, representing 10,536,717 pediatric head trauma visits during the 9-year period. The use of CT increased from 12.8% to 22.4% from 1995 to 2003, with a peak of 28.6% in 2000. CT was used more frequently in the older age groups: 13% (<1 year), 11% (1 to 4 years), 20% (5 to 9 years), and 32% (10 to 18 years). CT was also used more frequently in general EDs (22%) than in pediatric-specific EDs (13%). There were no differences in CT use between teaching and nonteaching facilities (21% in each). Overall, 6.4% of children were either admitted to the hospital or transferred, and this rate remained stable over time. Conclusion: The use of CT has increased substantially in the evaluation of children with head trauma from 1995 to 2003. Further study is needed to identify objective criteria for cranial CT in head-injured children and to evaluate the impact of increased CT use on patient outcomes.	Childrens Hosp & Clin Minnesota, Dept Emergency Med, Minneapolis, MN 55404 USA; Med Coll Wisconsin, Childrens Hosp Wisconsin, Childrens Res Inst, Dept Pediat, Milwaukee, WI 53226 USA; Univ Calif Davis, Sch Med, Dept Emergency Med, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Pediat, Davis, CA 95616 USA; Emory Univ, Sch Med, Div Emergency Med, Dept Pediat, Atlanta, GA USA; Childrens Healthcare Atlanta Egleston, Atlanta, GA USA	Blackwell, CD (corresponding author), Childrens Hosp & Clin Minnesota, Dept Emergency Med, 2525 Chicago Ave S, Minneapolis, MN 55404 USA.	David.Blackwell@childrensmn.org					Bergman DA, 1999, PEDIATRICS, V104, P1407; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; HORNER CJ, 1909, PEDIATRICS, V104, pE78; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; *NAT CTR HLTH STAT, NHAMCS DESCR; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; SHUNK JE, 1996, PEDIATR EMERG CARE, V12, P160; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5	10	142	142	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	MAR	2007	49	3					320	324		10.1016/j.annemergmed.2006.09.025			5	Emergency Medicine	Emergency Medicine	142GI	WOS:000244637000013	17145113				2021-06-18	
J	Marmarou, A; Lu, J; Butcher, I; McHugh, GS; Mushkudiani, NA; Murray, GD; Steyerberg, EW; Maas, AIR				Marmarou, Anthony; Lu, Juan; Butcher, Isabella; McHugh, Gillian S.; Mushkudiani, Nino A.; Murray, Gordon D.; Steyerberg, Ewout W.; Maas, Andrew I. R.			IMPACT database of traumatic brain injury: Design and description	JOURNAL OF NEUROTRAUMA			English	Article						coma; databank; head injury; IMPACT; traumatic brain injury	SEVERE HEAD-INJURY; CONJUGATED SUPEROXIDE-DISMUTASE; PLACEBO-CONTROLLED TRIAL; CLINICAL-TRIALS; MULTICENTER TRIAL; PRACTICAL SCALE; PEG-SOD; CONSORTIUM; EFFICACY; PEGORGOTEIN	The objective of this report is to describe the design and content of the International Mission for Prognosis And Clinical Trial (IMPACT) database of traumatic brain injury which contains the complete dataset from most clinical trials and organized epidemiologic studies conducted over the past 20 years. This effort, funded by the U.S. National Institutes of Health, has led to the accumulation thus far of data from 9205 patients with severe and moderate brain injuries from eight randomized placebo controlled trials and three observational studies. Data relevant to the design and analysis of pragmatic Phase III clinical trials, including pre-hospital, admission, and post-resuscitation assessments, information on the acute management, and short- and long-term outcome were merged into a top priority data set (TPDS). The major emphasis during the first phase of study is on information from time of injury to post-resuscitation and outcome at 6 months thereby providing a unique resource for prognostic analysis and for studies aimed at optimizing the design and analysis of Phase III trials in traumatic brain injury.	Virginia Commonwealth Univ, Sch Med, Dept Neurosurg, Richmond, VA USA; Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland; Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands	Marmarou, A (corresponding author), Virginia Commonwealth Univ Hlth Syst, Dept Neurosurg, 1001 E Broad St,Suite 235, Richmond, VA 23219 USA.	Marmarou@hsc.vcu.edu	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Murray, Gordon/0000-0001-9866-4734; Lu, Juan/0000-0002-5389-7603; Steyerberg, Ewout/0000-0002-7787-0122	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-042691] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER		BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; Beretta I, 2003, Minerva Anestesiol, V69, P223; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Braakman R, 1980, Ned Tijdschr Geneeskd, V124, P548; Citerio G, 2000, ACTA NEUROCHIR, V142, P769, DOI 10.1007/s007010070091; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Edwards P, 2005, LANCET, V365, P1957; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P643, DOI 10.3109/02688699308995093; Foulkes MA, 1991, J NEUROSURG S, V75, P8, DOI 10.3171/sup.1991.75.1s.00s8; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JENNETT B, 1975, LANCET, V1, P480; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2004, ACT NEUR S, V89, P113; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou A, 1996, ACT NEUR S, V66, P118; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Marshall L F, 1988, Clin Neurosurg, V34, P549; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; Muizelaar JP, 2001, HEAD TRAUMA, P417; MUIZELAAR JP, 1995, J NEUROSURG, V83, P942; MUIZELAAR JP, 1994, ADV EXP MED BIOL, V366, P389; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1997, ACTA NEUROCHIR, V139, P797, DOI 10.1007/BF01411397; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	33	142	145	0	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2007	24	2					239	250		10.1089/neu.2006.0036			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	150AL	WOS:000245187900003	17375988				2021-06-18	
J	Bayir, H; Fadeel, B; Palladino, MJ; Witasp, E; Kurnikov, IV; Tyurina, YY; Tyurin, VA; Amoscato, AA; Jiang, J; Kochanek, PM; DeKosky, ST; Greenberger, JS; Shvedova, AA; Kagan, VE				Bayir, H.; Fadeel, B.; Palladino, M. J.; Witasp, E.; Kurnikov, I. V.; Tyurina, Y. Y.; Tyurin, V. A.; Amoscato, A. A.; Jiang, J.; Kochanek, P. M.; DeKosky, S. T.; Greenberger, J. S.; Shvedova, A. A.; Kagan, V. E.			Apoptotic interactions of cyctochrome c: Redox flirting with anionic phospholipids within and outside of mitochondria	BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS			English	Article; Proceedings Paper	14th European Bioenergetic Conference	JUL 22-27, 2006	Moscow, RUSSIA			cytochrome c; phospholipid; mitochondrion	MANGANESE SUPEROXIDE-DISMUTASE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; OXIDATION-SPECIFIC EPITOPES; PROGRAMMED NEURONAL DEATH; TRAUMATIC BRAIN-INJURY; CYTOCHROME-C; REACTIVE OXYGEN; CELL-DEATH; MACROPHAGE CLEARANCE; NATURAL ANTIBODIES	Since the (re)discovery of cytochrome c (cyt c) in the early 1920s and subsequent detailed characterization of its structure and function in mitochondrial electron transport, it took over 70 years to realize that cyt c plays a different, not less universal role in programmed cell death, apoptosis, by interacting with several proteins and forming apoptosomes. Recently, two additional essential functions of cyt c in apoptosis have been discovered that are carried out via its interactions with anionic phospholipids: a mitochondria specific phospholipid, cardiolipin (CL), and plasma membrane phosphatidylserine (PS). Execution of apoptotic program in cells is accompanied by substantial and early mitochondrial production of reactive oxygen species (ROS). Because antioxidant enhancements protect cells against apoptosis, ROS production was viewed not as a meaningless side effect of mitochondrial disintegration but rather playing some - as yet unidentified - role in apoptosis. This conundrum has been resolved by establishing that mitochondria contain a pool of cyt e, which interacts with CL and acts as a CL oxygenase. The oxygenase is activated during apoptosis, utilizes generated ROS and causes selective oxidation of CL. The oxidized CL is required for the release of pro-apoptotic factors from mitochondria into the cytosol. This redox mechanism of cyt c is realized earlier than its other well-recognized functions in the formation of apoptosomes and caspase activation. In the cytosol, released cyt c interacts with another anionic phospholipid, PS, and catalyzes its oxidation in a similar oxygenase reaction. Peroxidized PS facilitates its externalization essential for the recognition and clearance of apoptotic cells by macrophages. Redox catalysis of plasma membrane PS oxidation constitutes an important redox-dependent function of cyt c in apoptosis and phagocytosis. Thus, cyt c acts as an anionic phospholipid specific oxygenase activated and required for the execution of essential stages of apoptosis. This review is focused on newly discovered redox mechanisms of complexes of cyt c with anionic phospholipids and their role in apoptotic pathways in health and disease.	Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Ctr Fee Radical & Antioxidant Hlth, Pittsburgh, PA 15219 USA; Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Radiat Oncol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA 15260 USA; Karolinska Inst, Inst Environm Med, Div Mol Toxicol, S-10401 Stockholm, Sweden; Dept Environm & Occupat Hlth, Pittsburgh, PA 15219 USA; NIOSH, Hlth Effects Lab Div, Physiol Pathol Res Branch, Morgantown, WV 26505 USA	Bayir, H (corresponding author), Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	bayihx@ccm.upmc.edu; vkagan@eoh.pitt.edu		Kagan, Valerian E./0000-0002-7245-1885; Amoscato, Andrew/0000-0002-1340-9150; Tyurina, Yulia/0000-0003-0287-2091; Tyurin, Vladimir/0000-0002-3474-1697; Kochanek, Patrick/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL70755] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U19 AIO68021] Funding Source: Medline; NIOSH CDC HHS [OH008282] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL070755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [R01OH008282] Funding Source: NIH RePORTER		Andoh T, 2002, J BIOL CHEM, V277, P9655, DOI 10.1074/jbc.M110701200; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Arroyo A, 2002, J BIOL CHEM, V277, P49965, DOI 10.1074/jbc.M204513200; Arur S, 2003, DEV CELL, V4, P587, DOI 10.1016/S1534-5807(03)00090-X; BAI J, 1999, J BIOL CHEM, V274, P26124; Bai JX, 2001, BIOL SIGNAL RECEPT, V10, P189; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Belikova NA, 2006, BIOCHEMISTRY-US, V45, P4998, DOI 10.1021/bi0525573; Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218; Binder CJ, 2005, J LIPID RES, V46, P1353, DOI 10.1194/jlr.R500005-JLR200; Binder CJ, 2005, SPRINGER SEMIN IMMUN, V26, P385, DOI 10.1007/s00281-004-0185-z; Bochkov VN, 2002, NATURE, V419, P77, DOI 10.1038/nature01023; Bratton DL, 2005, NAT MED, V11, P26, DOI 10.1038/nm0105-26; Brown JR, 2003, J LEUKOCYTE BIOL, V73, P591, DOI 10.1189/jlb.1202599; Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9; Cande C, 2004, J CELL SCI, V117, P4461, DOI 10.1242/jcs.01356; Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199; Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699; Chang MK, 2004, J EXP MED, V200, P1359, DOI 10.1084/jem.20031763; Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353; Chen Y, 2002, J BIOL CHEM, V277, P33242, DOI 10.1074/jbc.M202026200; Chen YR, 1999, J BIOL CHEM, V274, P3308, DOI 10.1074/jbc.274.6.3308; Chen YR, 2002, J BIOL CHEM, V277, P29781, DOI 10.1074/jbc.M200709200; Cossarizza A, 2002, J INFECT DIS, V185, P299, DOI 10.1086/338564; Cuzzocrea S, 2004, FREE RADICAL RES, V38, P813, DOI 10.1080/10715760410001710829; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dhanasekaran A, 2005, FREE RADICAL BIO MED, V39, P567, DOI 10.1016/j.freeradbiomed.2005.04.016; Dickerson R E., 1971, Journal Molec Evol, V1, P26, DOI 10.1007/BF01659392; Enoksson M, 2005, BIOCHEM BIOPH RES CO, V327, P774, DOI 10.1016/j.bbrc.2004.12.067; Epperly MW, 2003, RADIAT RES, V160, P568, DOI 10.1667/RR3081; Fabisiak JP, 1997, AM J PHYSIOL-CELL PH, V272, pC675; Fadeel B, 2006, CELL DEATH DIFFER, V13, P360, DOI 10.1038/sj.cdd.4401836; Fadeel B, 2003, CELL MOL LIFE SCI, V60, P2575, DOI 10.1007/s00018-003-3145-1; Fadeel B, 2005, J INTERN MED, V258, P479, DOI 10.1111/j.1365-2796.2005.01570.x; Fadeel B, 2003, REDOX REP, V8, P143, DOI 10.1179/135100003225001511; Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fernandez MG, 2002, CELL GROWTH DIFFER, V13, P449; Fleming C, 2005, NAT CHEM BIOL, V1, P270, DOI 10.1038/nchembio730; Flohe L, 1988, Basic Life Sci, V49, P663; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Frostegard J, 2005, ARTHRITIS RHEUM-US, V52, P192, DOI 10.1002/art.20780; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Gohil VM, 2005, ANAL BIOCHEM, V343, P350, DOI 10.1016/j.ab.2005.04.039; Gonzalvez F, 2005, CELL DEATH DIFFER, V12, P659, DOI 10.1038/sj.cdd.4401585; GONZALVEZ F, 2005, CELL DEATH DIFFER, V12, P266; Graham SH, 2001, J CEREBR BLOOD F MET, V21, P99, DOI 10.1097/00004647-200102000-00001; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Greco A, 2004, CURR NEUROVASC RES, V1, P341, DOI 10.2174/1567202043362036; Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; Hampton MB, 1998, BIOCHEM J, V329, P95; Hampton MB, 2002, J LEUKOCYTE BIOL, V71, P775; Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016; HAYERHARTL M, 1992, EUR J BIOCHEM, V209, P423, DOI 10.1111/j.1432-1033.1992.tb17305.x; Henshall DC, 2000, J NEUROCHEM, V74, P1215; Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533; Horkko S, 2001, CIRCULATION, V103, P941; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI11638; Imai H, 2003, BIOCHEM J, V371, P799, DOI 10.1042/BJ20021342; Iverson SL, 2004, ARCH BIOCHEM BIOPHYS, V423, P37, DOI 10.1016/j.abb.2003.12.002; Iwase H, 1996, BIOCHEM BIOPH RES CO, V222, P83, DOI 10.1006/bbrc.1996.0701; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kagan VE, 2005, NANOMED-NANOTECHNOL, V1, P313, DOI 10.1016/j.nano.2005.10.003; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kagan VE, 2003, AM J PHYSIOL-LUNG C, V285, pL1, DOI 10.1152/ajplung.00365.2002; Kagan VE, 2004, FREE RADICAL BIO MED, V37, P1963, DOI 10.1016/j.freeradbiomed.2004.08.016; Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487; Kagan VE, 2000, FEBS LETT, V477, P1, DOI 10.1016/S0014-5793(00)01707-5; Kanai A, 2004, AM J PHYSIOL-HEART C, V286, pH13, DOI 10.1152/ajpheart.00737.2003; Kentner R, 2002, J TRAUMA, V53, P968, DOI 10.1097/00005373-200211000-00025; Kim SJ, 2002, J EXP MED, V196, P655, DOI 10.1084/jem.20020542; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Kinchen JM, 2005, CURR TOP DEV BIOL, V65, P1; Kirkinezos IG, 2005, J NEUROSCI, V25, P164, DOI 10.1523/JNEUROSCI.3829-04.2005; Kirkland RA, 2002, NEUROSCIENCE, V115, P587, DOI 10.1016/S0306-4522(02)00512-2; Kirkland RA, 2001, J NEUROSCI, V21, P1949, DOI 10.1523/JNEUROSCI.21-06-01949.2001; KONDURU NV, 2006, 1 INT C NAN BIOM ASP; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li HQ, 2002, FREE RADICAL BIO MED, V32, P712, DOI 10.1016/S0891-5849(02)00762-1; Liang QH, 2005, BIOCHEM PHARMACOL, V70, P1371, DOI 10.1016/j.bcp.2005.04.011; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; Manfredi AA, 1998, ARTHRITIS RHEUM-US, V41, P205; Mantymaa P, 2000, BRIT J HAEMATOL, V108, P574, DOI 10.1046/j.1365-2141.2000.01852.x; Matsura T, 2005, BBA-MOL CELL BIOL L, V1736, P181, DOI 10.1016/j.bbalip.2005.08.011; Matsura T, 2004, CHEM RES TOXICOL, V17, P685, DOI 10.1021/tx030050s; Mileykovskaya E, 2001, FEBS LETT, V507, P187, DOI 10.1016/S0014-5793(01)02948-9; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; Montine TJ, 2005, ANTIOXID REDOX SIGN, V7, P269, DOI 10.1089/ars.2005.7.269; Moreira PI, 2005, ANN NY ACAD SCI, V1043, P545, DOI 10.1196/annals.1333.062; Nakagawa Y, 2004, ANN NY ACAD SCI, V1011, P177, DOI 10.1196/annals.1293.018; Nantes IL, 2001, J BIOL CHEM, V276, P153, DOI 10.1074/jbc.M006338200; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Oellerich S, 2003, EUR BIOPHYS J BIOPHY, V32, P599, DOI 10.1007/s00249-003-0306-y; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; PANASENKO OM, 2003, FREE RADICAL BIO MED, V34, P362; Patel NSA, 2002, FREE RADICAL BIO MED, V33, P1575, DOI 10.1016/S0891-5849(02)01116-4; Pearce LL, 2005, NITRIC OXIDE-BIOL CH, V13, P254, DOI 10.1016/j.niox.2005.07.010; Pereverzev MO, 2003, BIOCHEM SOC T, V31, P1312; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Petrosillo G, 2004, J BIOL CHEM, V279, P53103, DOI 10.1074/jbc.M407500200; Prasad S, 2002, BBA-PROTEIN STRUCT M, V1596, P63, DOI 10.1016/S0167-4838(02)00205-4; Price BE, 1996, J IMMUNOL, V157, P2201; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P118, DOI 10.1016/0003-9861(91)90172-F; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; Ran QT, 2004, J BIOL CHEM, V279, P55137, DOI 10.1074/jbc.M410387200; Ran QT, 2003, FREE RADICAL BIO MED, V35, P1101, DOI 10.1016/S0891-5849(03)00466-0; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Ricci JE, 2003, CELL DEATH DIFFER, V10, P488, DOI 10.1038/sj.cdd.4401225; ROBINSON NC, 1990, BIOCHEMISTRY-US, V29, P8962, DOI 10.1021/bi00490a012; Roos D, 1996, BLOOD, V87, P1663; Sandra F, 2005, CANCER RES, V65, P8286, DOI 10.1158/0008-5472.CAN-04-1913; Sato K, 2002, J BIOL CHEM, V277, P29568, DOI 10.1074/jbc.M203179200; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Sepodes B, 2004, TRANSPL P, V36, P849, DOI 10.1016/j.transproceed.2004.03.050; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serinkan BF, 2005, CELL DEATH DIFFER, V12, P1141, DOI 10.1038/sj.cdd.4401619; Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472; Shidoji Y, 1999, BIOCHEM BIOPH RES CO, V264, P343, DOI 10.1006/bbrc.1999.1410; Shvedova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL698, DOI 10.1152/ajplung.00084.2005; Sorice M, 2004, CELL DEATH DIFFER, V11, P1133, DOI 10.1038/sj.cdd.4401457; STELLWAGEN E, 1968, BIOCHEMISTRY-US, V7, P2496, DOI 10.1021/bi00847a008; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tarkowski E, 1999, STROKE, V30, P321, DOI 10.1161/01.STR.30.2.321; Theorell H, 1941, J AM CHEM SOC, V63, P1812, DOI 10.1021/ja01852a006; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; TYURIN VA, 2005, SOC NEUR ANN M 12 16; Tyurina YY, 2004, ANTIOXID REDOX SIGN, V6, P209, DOI 10.1089/152308604322899288; Tyurina YY, 2004, J BIOL CHEM, V279, P6056, DOI 10.1074/jbc.M309929200; Vay D, 2006, J HEPATOL, V44, P183, DOI 10.1016/j.jhep.2005.06.010; VLASOVA II, 2006, EPUB J BIOL CHEM; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Warheit DB, 2004, TOXICOL SCI, V77, P117, DOI 10.1093/toxsci/kfg228; Waters KA, 1999, PEDIATR RES, V45, P166, DOI 10.1203/00006450-199902000-00002; Weinberg A, 2004, BRAIN RES, V1012, P13, DOI 10.1016/j.brainres.2004.03.048; Wipf P, 2005, J AM CHEM SOC, V127, P12460, DOI 10.1021/ja053679l; Yao Y, 2003, NEUROLOGY, V61, P475, DOI 10.1212/01.WNL.0000070185.02546.5D; Zhang M, 2005, J BIOL CHEM, V280, P29403, DOI 10.1074/jbc.M504955200; Zucchi MR, 2003, BIOCHEM J, V370, P671, DOI 10.1042/BJ20021521	148	142	148	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0005-2728	1879-2650		BBA-BIOENERGETICS	Biochim. Biophys. Acta-Bioenerg.	MAY-JUN	2006	1757	5-6					648	659		10.1016/j.bbabio.2006.03.002			12	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	069XF	WOS:000239481800046	16740248				2021-06-18	
J	Schneider, HJ; Schneider, M; Saller, B; Petersenn, S; Uhr, M; Husemann, B; von Rosen, F; Stalla, GK				Schneider, HJ; Schneider, M; Saller, B; Petersenn, S; Uhr, M; Husemann, B; von Rosen, F; Stalla, GK			Prevalence of anterior pituitary insufficiency 3 and 12 months after traumatic brain injury	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; HYPOPITUITARISM; DIAGNOSIS; DEFICIENCY; SYSTEM; TESTS	Objective: Cross-sectional Studies report it high prevalence of hypopituitarism after traumatic brain injury (TBI): however, no longitudinal studies oil time of manifestation and reversibility exist. This Study was conducted to assess hypopituitarism 3 and 12 months after TBI. Design: This was it prospective. longitudinal, diagnostic study. Methods: Seventy-eight patients (52 men, 26 women, mean age 36.0 years) with TBI grades I-III and 3 8 healthy subjects (2 5 men. 13 women, mean age 36.4 years) as a control group for the GHRH + arginine test were studied. The prevalence of hypopituitarism was assessed 3 and 12 months after TBI by GHRH + arginine test, short adrenocorticotropic hormone (ACTH) test, and basal hormone measurements in patients. Results: After 3 months. 56%, of all patients had impairment's of at least one pituitary axis with axes being affected its follows: gonadotropic 32%, corticotropic 19%, somatotropic 9% and thyrotropic 8%. After 12 months. fewer patients were affected. but ill some cases new impairments occurred: 36% still had impairments. The axes were affected its follows after 12 months: gonadotropic 21%, somatotropic 10%, corticotropic 9% and thyrotropic 3%. Conclusions: Hypopituitarism occurs often in the post-acute phase after TBI and may normalize later, but may also develop after the post-acute phase of TBI.	Max Planck Inst Psychiat, Clin Neuroendocrinol Grp, D-80804 Munich, Germany; Pfizer GmbH, D-76032 Karlsruhe, Germany; Univ Hosp Essen, Dept Endocrinol, D-45122 Essen, Germany; Neurol Clin Bad Aibling, D-83043 Bad Aibling, Germany	Stalla, GK (corresponding author), Max Planck Inst Psychiat, Clin Neuroendocrinol Grp, Kraepelinstr 10, D-80804 Munich, Germany.	stalla@mpipsykl.mpg.de					Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Brabant G, 2003, HORM RES, V60, P53, DOI 10.1159/000071871; Cernak I, 1999, BRAIN INJURY, V13, P1005; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; Feldman HA, 2002, J CLIN ENDOCR METAB, V87, P589, DOI 10.1210/jc.87.2.589; Ghigo E, 1996, EUR J ENDOCRINOL, V134, P352, DOI 10.1530/eje.0.1340352; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LINDHOLM J, 1987, CLIN ENDOCRINOL, V26, P53, DOI 10.1111/j.1365-2265.1987.tb03638.x; Ruchholtz S, 2002, CHIRURG, V73, P194, DOI 10.1007/s00104-002-0424-6; Schneider HJ, 2004, DTSCH ARZTEBL, V101, pA712; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Springer J, 2001, LANCET, V357, P1848, DOI 10.1016/S0140-6736(00)04953-9; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Van den Berghe G, 2000, EUR J ENDOCRINOL, V143, P1, DOI 10.1530/eje.0.1430001; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x	26	142	150	0	5	BIOSCIENTIFICA LTD	BRISTOL	STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	FEB	2006	154	2					259	265		10.1530/eje.1.02071			7	Endocrinology & Metabolism	Endocrinology & Metabolism	015II	WOS:000235544700011	16452539	Bronze			2021-06-18	
J	Tiersky, LA; Anselmi, V; Johnston, MV; Kurtyka, J; Roosen, E; Schwartz, T; DeLuca, J				Tiersky, LA; Anselmi, V; Johnston, MV; Kurtyka, J; Roosen, E; Schwartz, T; DeLuca, J			A trial of neuropsychologic rehabilitation in mild-spectrum traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; neuropsychology; psychotherapy; rehabilitation	RANDOMIZED CONTROLLED-TRIAL; MINOR HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; ROUTINE FOLLOW-UP; POSTCONCUSSION SYNDROME; ATTENTION; MODERATE; SYMPTOMS; DEFICITS; RECOMMENDATIONS	Objective: To test the effectiveness of a neuropsychologic rehabilitation program consisting of psychotherapy and cognitive remediation in the treatment of the affective and neuropsychologic sequelae of mild-spectrum traumatic brain injury (TBI). Design: Single-blind randomized, wait-listed controlled trial, with repeated measures and multiple baselines. Setting: Outpatient clinic in northern New Jersey. Participants: Twenty persons with persisting complaints after mild and moderate TBI (11 in treatment group, 9 controls). Interventions: The experimental group received both 50 minutes of individual cognitive-behavioral psychotherapy and 50 minutes of individual cognitive remediation, 3 times a week for I I weeks. The control group was wait-listed and received treatment after conclusion of follow-up. Main Outcome Measures: Symptom Check List-90R General Symptom Index, plus scales of depression, anxiety, coping, attention, and neuropsychologic functioning. Results: Compared with the control group, the treatment group showed significantly improved emotional functioning, including lessened anxiety and depression. Most significant improvements in emotional distress were noted at I month and 3 months posttreatment. Performance on a measure of divided auditory attention also improved, but no changes were noted in community integration scores. Conclusions: Cognitive behavioral psychotherapy and cognitive remediation appear to diminish psychologic distress and improve cognitive functioning among community-living persons with mild and moderate TBI.	Fairleigh Dickinson Univ, Sch Psychol, Teaneck, NJ 07666 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosci, Newark, NJ 07103 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA	Tiersky, LA (corresponding author), Fairleigh Dickinson Univ, Sch Psychol, Williams Hall T-WH1-01,1000 River Rd, Teaneck, NJ 07666 USA.	tiersky@fdu.edu					ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT, V4th; ANDRASIK F, 1994, SEMIN NEUROL, V14, P60, DOI 10.1055/s-2008-1041060; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; Beck A.T., 1990, COGNITIVE THERAPY PE; Beck A. T., 1979, COGNITIVE THERAPY DE; Ben-Yishay Y., 1990, REHABILITATION ADULT, P393; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BENYISHAY Y, 1983, REHABILITATION HEAD, P167; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; Chelune GJ, 1986, ADV CLIN NEUROPSYCHO, P95, DOI DOI 10.1007/978-1-4613-2211-5_; Cicerone K. D., 1991, J HEAD TRAUMA REHAB, V6, P30, DOI DOI 10.1097/00001199-199112000-00007; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; DEROGATIS LR, 1994, SCL90R; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dittmar C, 1997, Appl Neuropsychol, V4, P50, DOI 10.1207/s15324826an0401_6; DOHRMANN V, 1994, TREATING MEMORY IMPA; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Ferguson R. J., 1996, SOURCEBOOK PSYCHOL T, P615; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; Hannay HJ, 1996, J HEAD TRAUMA REHAB, V11, P41, DOI 10.1097/00001199-199612000-00007; Hawton K.E., 1989, COGNITIVE BEHAV THER; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; JOHNSTON MV, 1995, AM J PHYS MED REHAB, V74, P383; JOHNSTON MV, 1996, MED REHABILITATION T, P197; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; Keselman HJ, 1999, PSYCHOL METHODS, V4, P58, DOI 10.1037/1082-989X.4.1.58; LAATSCH L, 1996, J COGN REHABIL, V14, P18; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MACCIOCCHI SN, 1993, CURR OPIN NEUROL, V6, P773, DOI 10.1097/00019052-199310000-00016; MATEER CA, 1992, PHYSICAL MED REHABIL, V6, P143; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; MOOS RH, 1993, MANUAL COPING RESPON; *NIH, 1999, NIH CONS DEV C REH P; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Palmese CA, 2000, BRAIN INJURY, V14, P535; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; RASKIN SA, 2000, NEUROPSYCHOLOGICAL M; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Roman DD, 1991, CLIN NEUROPSYCHOL, V5, P33; ROTH A, 1996, CRITICAL REV PSYCHOT; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; SELIGMAN MEP, 1995, AM PSYCHOL, V50, P965, DOI 10.1037/0003-066X.50.12.965; Senn S, 2000, STAT MED, V19, P861, DOI 10.1002/(SICI)1097-0258(20000330)19:6<861::AID-SIM407>3.0.CO;2-F; SMITH LM, 1995, HPD FAMILY SUPPORT P; Sohlberg M M, 1994, ATTENTION PROCESS TR; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WIENS AN, 1988, CLIN NEUROPSYCHOL, V2, P67, DOI DOI 10.1080/13854048808520087; Winer B.J., 1991, STAT PRINCIPLES EXPT; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002	82	142	146	0	25	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2005	86	8					1565	1574		10.1016/j.apmr.2005.03.013			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	953LN	WOS:000231077900010	16084809				2021-06-18	
J	Witgen, BM; Lifshitz, J; Smith, ML; Schwarzbach, E; Liang, SL; Grady, MS; Cohen, AS				Witgen, BM; Lifshitz, J; Smith, ML; Schwarzbach, E; Liang, SL; Grady, MS; Cohen, AS			Regional hippocampal alteration associated with cognitive deficit following experimental brain injury: A systems, network and cellular evaluation	NEUROSCIENCE			English	Article						head injury; hippocampus; conditioned fear response; GABA; mIPSC; stereology	LONG-TERM POTENTIATION; FLUID-PERCUSSION INJURY; TEMPORAL-LOBE EPILEPSY; CONDITIONED FREEZING DEFICIT; RIGHT PARIETAL CORTEX; RAT DENTATE GYRUS; HEAD-INJURY; STEREOLOGICAL ESTIMATION; GABAERGIC INHIBITION; ARBITRARY PARTICLES	Cognitive deficits persist in patients who survive traumatic brain injury (TBI). Lateral fluid percussion brain injury in the mouse, a model of human TBI, results in hippocampal-dependent cognitive impairment, similar to retrograde amnesia often associated with TBI. To identify potential substrates of the cognitive impairment, we evaluated regional neuronal loss, regional hippocampal excitability and inhibitory synaptic transmission. Design-based stereology demonstrated an approximate 40% loss of neurons through all subregions of the hippocampus following injury compared with sham. Input/output curves recorded in slices of injured brain demonstrated increased net synaptic efficacy in the dentate gyrus in concert with decreased net synaptic efficacy and excitatory postsynaptic potential-spike relationship in area CA1 compared with sham slices. Pharmacological agents modulating inhibitory transmission partially restored regional injury-induced alterations in net synaptic efficacy. Both evoked and spontaneous miniature inhibitory postsynaptic currents (mIPSCs) recorded in surviving dentate granule neurons were smaller and less frequent in injured brains than in uninjured brains. Conversely, both evoked and spontaneous mIPSCs recorded in surviving area CA1 pyramidal neurons were larger in injured brains than in uninjured brains. Together, these alterations suggest that regional hippocampal function is altered in the injured brain. This study demonstrates for the first time that brain injury selectively disrupts hippocampal function by causing uniform neuronal loss, inhibitory synaptic dysfunction, and regional, but opposing, shifts in circuit excitability. These changes may contribute to the cognitive impairments that result from brain injury. (c) 2005 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA	Cohen, AS (corresponding author), Abramson Res Ctr, 3516 Civ Ctr Blvd,Room 816H, Philadelphia, PA 19104 USA.	cohena@email.chop.edu		Smith, Michael/0000-0003-3757-2726	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045975] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS045975-01, R01 NS045975-02, NS45975, R01 NS045975-03] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALVAREZ P, 1995, J NEUROSCI, V15, P3796; Anagnostaras SG, 1999, J NEUROSCI, V19, P1106; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bohbot VD, 2000, ANN NY ACAD SCI, V911, P355; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Buhl EH, 1996, SCIENCE, V271, P369, DOI 10.1126/science.271.5247.369; Calhoun ME, 1998, NEUROBIOL AGING, V19, P599, DOI 10.1016/S0197-4580(98)00098-0; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Cave C B, 1991, Hippocampus, V1, P329, DOI 10.1002/hipo.450010323; CHAVEZNORIEGA LE, 1989, NEUROSCI LETT, V104, P58, DOI 10.1016/0304-3940(89)90329-7; Cohen AS, 2000, J NEUROPHYSIOL, V84, P2465; Cohen AS, 2003, EUR J NEUROSCI, V17, P1607, DOI 10.1046/j.1460-9568.2003.02597.x; Cohen AS, 1996, J NEUROPHYSIOL, V76, P953; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Deweer B, 2001, BEHAV BRAIN RES, V127, P209, DOI 10.1016/S0166-4328(01)00366-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Esclapez M, 1997, P NATL ACAD SCI USA, V94, P12151, DOI 10.1073/pnas.94.22.12151; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Gerlai R, 1998, BEHAV BRAIN RES, V95, P191, DOI 10.1016/S0166-4328(97)00144-7; Gibbs JW, 1997, J NEUROPHYSIOL, V77, P1924; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Golarai G, 2001, J NEUROSCI, V21, P8523; GOLARAI G, 1999, SOC NEUR ANN M 23 28; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRONWALL D, 1974, LANCET, V2, P605; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hartman RE, 2002, J NEUROSCI, V22, P10083; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hirsch JC, 1999, NAT NEUROSCI, V2, P499; Hogg S, 1998, BEHAV BRAIN RES, V93, P157, DOI 10.1016/S0166-4328(97)00145-9; Hogg S, 1998, J NEUROTRAUM, V15, P545, DOI 10.1089/neu.1998.15.545; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412; HOVDA DA, 1990, ACT NEUR S, V51, P331; KAIRISS EW, 1987, BRAIN RES, V401, P87, DOI 10.1016/0006-8993(87)91167-X; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; KERR DS, 1994, PSYCHOBIOLOGY, V22, P123; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Lambert JDC, 1996, EPILEPSY RES, V26, P15, DOI 10.1016/S0920-1211(96)00035-6; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; Lin DD, 2001, J NEUROPHYSIOL, V85, P1185; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mathews GC, 2003, J NEUROSCI, V23, P2040; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miller LA, 1998, NEUROPSYCHOLOGIA, V36, P1247, DOI 10.1016/S0028-3932(97)00139-5; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; Paylor R, 2001, PHYSIOL BEHAV, V73, P781, DOI 10.1016/S0031-9384(01)00515-7; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; RAFIQ A, 1993, J NEUROPHYSIOL, V70, P1962; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Seki Y, 1999, STROKE, V30, P433, DOI 10.1161/01.STR.30.2.433; Sepkuty JP, 2002, J NEUROSCI, V22, P6372; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Toth Z, 1997, J NEUROSCI, V17, P8106; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; West MJ, 1999, TRENDS NEUROSCI, V22, P51, DOI 10.1016/S0166-2236(98)01362-9; Westenbroek RE, 1998, J NEUROSCI, V18, P2321; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	87	142	150	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2005	133	1					1	15		10.1016/j.neuroscience.2005.01.052			15	Neurosciences	Neurosciences & Neurology	930MZ	WOS:000229421400001	15893627				2021-06-18	
J	Annegers, JF; Coan, SP				Annegers, JF; Coan, SP			The risks of epilepsy after traumatic brain injury	SEIZURE-EUROPEAN JOURNAL OF EPILEPSY			English	Article; Proceedings Paper	International League Against Epilepsy Millennium Meeting	APR 19-AUG 20, 1999	BIRMINGHAM, ENGLAND			epilepsy; seizure; traumatic brain injury; epidemiology	ROCHESTER; SEIZURES; HISTORY	The aim of this study is to present the incidence of traumatic brain injury (TBI) and identify those characteristics of brain injuries that are associated with the development of seizures. We identified 5984 episodes of TBI (loss of consciousness, post-traumatic amnesia, or skull fracture) in Olmsted County, Minnesota, from 1935 to 1984. Of these, 4541 were followed for seizure. Injuries were classified as mild (loss of consciousness or amnesia less than 30 minutes), moderate (loss of consciousness 30 minutes to 1 day or a skull fracture), or severe (loss of consciousness of more than 1 day, subdural hematoma, or brain contusion). The incidence of TBI in the period from 1975 to 84 peaked at 800 per 100 000 in males aged 15-24. The relative risk of seizures was 1.5 (95 percent confidence interval 1.0-2.2) after mild injuries, but with no increase after 5 years; 2.9 (95 percent confidence interval 1.9-4.1) after moderate injuries; and 17.2 (95 percent confidence interval 12.3-23.6) after severe injuries. Significant risk factors were brain contusion with subdural hematoma, skull fracture, loss of consciousness or amnesia of 1 day or more, and age over 65 years. We conclude that TBI is a major public health problem and contributes to the occurrence of seizures and epilepsy. (C) 2000 BEA Trading Ltd.	Univ Texas, Ctr Hlth Sci, Sch Publ Hlth, Austin, TX 78712 USA	Annegers, JF (corresponding author), Univ Texas, Ctr Hlth Sci, Sch Publ Hlth, Austin, TX 78712 USA.						ANNEGERS JF, 1988, NEUROLOGY, V38, P1407, DOI 10.1212/WNL.38.9.1407; ANNEGERS JF, 1976, EPILEPSIA, V17, P1, DOI 10.1111/j.1528-1157.1976.tb03375.x; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Jennett B, 1975, EPILEPSY NONMISSILE; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; PENFIELD W, 1945, ASS RES NERVOUS MENT, V24, P620; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; *STAT, 1997, STAT STAT SOFTW REL; WALKER AE, 1989, SURG NEUROL, V32, P235, DOI 10.1016/0090-3019(89)90185-7; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006	10	142	148	1	11	W B SAUNDERS CO LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1059-1311			SEIZURE-EUR J EPILEP	Seizure	OCT	2000	9	7					453	457		10.1053/seiz.2000.0458			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	368DU	WOS:000090103100002	11034867				2021-06-18	
J	Guerrero, JL; Thurman, DJ; Sniezek, JE				Guerrero, JL; Thurman, DJ; Sniezek, JE			Emergency department visits associated with traumatic brain injury: United States, 1995-1996	BRAIN INJURY			English	Article							HEAD-INJURY; VIOLENCE	The purposes of this study were to provide a national estimate of the incidence of traumatic brain injuries (TBIs) seen in emergency departments (EDs), but not requiring hospitalization and to determine the causes of these injuries. Using the Centers for Disease Control and Prevention case definition of TBI, ED data was analysed from the National Hospital Ambulatory Medical Care Survey (1995-1996). The average overall incidence rate of TBI-related ED visits for persons who were not hospitalized was 392/100 000 population per year, or 1 027 000 visits to hospital EDs in the US each year. This estimate is nearly twice (392 vs. 216) the previously estimated incidence rate, which was based on data from the 1991 National Health Interview Survey Injury Supplement. It was found that the highest incidence rate occurred among children aged 0-14 years, the rate for males was higher than for females, and the primary reported causes of these injuries were 'falls', motor vehicle-related causes, and 'struck by an object'. Although often considered 'mild' TBIs, these injuries can lead to significant cognitive and emotional impairment. Thus, continued surveillance of TBI-related ED visits is an important part of a comprehensive TBI prevention strategy.	Natl Ctr Injury Prevent & Control, Off Stat & Programming, Atlanta, GA 30341 USA; Natl Ctr Injury Prevent & Control, Div Acute Care Rehabil Res & Disabil Prevent, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Hlth Care & Aging Studies Branch, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA	Guerrero, JL (corresponding author), Natl Ctr Injury Prevent & Control, Off Stat & Programming, MS-K59,4770 Buford Hwy NE, Atlanta, GA 30341 USA.			Thurman, David/0000-0002-0533-7062			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ANDRASIK F, 1994, SEMIN NEUROL, V14, P60, DOI 10.1055/s-2008-1041060; BERSTEIN DM, 1999, BRAIN INJURY, V13, P151; Gronwall D, 1989, MILD HEAD INJURY, P153; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; KRAUS JF, 1984, ANNU REV PUBL HEALTH, V5, P163; KRAUS JF, 1993, EPIDEMIOLOGY HEAD IN, V3, P1; MACCIOCCHI SN, 1993, CURR OPIN NEUROL, V6, P773, DOI 10.1097/00019052-199310000-00016; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; *NAT CTR HLTH STAT, 1992, DAT FIL DOC NAT HOSP; *NAT CTR HLTH STAT, 1995, DAT FIL DOC NAT HOSP; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff R.M., 1989, MILD HEAD INJURY, P176; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; THURMAN DJ, IN PRESS J HEAD TRAU; THURMAN DJ, 1995, SM GUIDELINES SURVEI; *US DHHS, 1996, INT CLASS DIS CLIM M; Zafonte RD, 1997, BRAIN INJURY, V11, P403	19	142	145	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2000	14	2					181	186		10.1080/026990500120827			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	281GW	WOS:000085151000007	10695573				2021-06-18	
J	Sander, AM; Fuchs, KL; High, WM; Hall, KM; Kreutzer, JS; Rosenthal, M				Sander, AM; Fuchs, KL; High, WM; Hall, KM; Kreutzer, JS; Rosenthal, M			The community integration questionnaire revisited: An assessment of factor structure and validity	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; DISABILITY RATING-SCALE; FUNCTIONAL INDEPENDENCE MEASURE; HEAD-INJURY; REHABILITATION OUTCOMES; AGREEMENT; RECOVERY	Objective: To investigate the factor structure and concurrent validity of the Community Integration Questionnaire (CIQ), using a large sample of persons with traumatic brain injury (TBI). Design: Principal components analysis with varimax rotation was performed on CIQ items completed through interview with patients at 1 year after injury. Correlational analyses compared CIQ scores to scores on other widely used outcome measures. Setting: Outpatient clinics affiliated with four TBI Model System rehabilitation centers funded by the National Institute on Disability and Rehabilitation Research. Participants: Three hundred twelve patients with medically documented TBI who were enrolled in the TBI Model Systems Project. The majority of patients were Caucasian males with severe TBI. Main Outcome Measures: CIQ; Functional Independence Measure (FIM); Functional Assessment Measure (FAM); Disability Rating Scale (DRS). Results: Three factors emerged: Home Competency, Social Integration, and Productive Activity. The financial management item was moved from Social Integration to Home Competency, and the travel item was moved from Productive Activity to Social Integration. Each CIQ scale score showed significant correlations in the expected direction with the FIM+FAM and DRS items. Conclusions: The results provide further evidence for the validity of the CIQ and improve the scoring system. The factor structure is clinically and theoretically meaningful. The subscale and total scores show significant relationships with other widely used measures of outcome. Future research should focus on increasing the range of questions, accounting for changes from preinjury functioning, and obtaining normative data on the new factors. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Baylor Coll Med, Dept Phys Med & Rehabil, Brain Injury Res Ctr, Houston, TX 77025 USA; Univ Houston, Inst Rehabil & Res, Brain Injury Res Ctr, Houston, TX USA; Univ Houston, Dept Psychol, Houston, TX USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Wayne State Univ, Rehabil Inst Michigan, Dept Phys Med & Rehabil, Detroit, MI USA	Sander, AM (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, Brain Injury Res Ctr, 4007 Bellaire Blvd,Suite EE, Houston, TX 77025 USA.						CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; ELIASON MR, 1984, PHYS THER, V64, P1357, DOI 10.1093/ptj/64.9.1357; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall K. M., 1992, NEUROREHABILITATION, V2, DOI [10.3233/NRE-1992-2410, DOI 10.3233/NRE-1992-2410]; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; *STAT U NEW YORK B, 1996, UN DAT MED REH VERS; Tabachnick B.G., 1989, USING MULTIVARIATE S; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1993, INT CLASS IMP DIS HA	25	142	142	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1999	80	10					1303	1308		10.1016/S0003-9993(99)90034-5			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	244AW	WOS:000083030500017	10527092				2021-06-18	
J	Kiening, KL; Hartl, R; Unterberg, AW; Schneider, GH; Bardt, T; Lanksch, WR				Kiening, KL; Hartl, R; Unterberg, AW; Schneider, GH; Bardt, T; Lanksch, WR			Brain tissue pO(2)-monitoring in comatose patients: Implications for therapy	NEUROLOGICAL RESEARCH			English	Article						brain tissue pO(2); intracranial pressure; cerebral perfusion pressure; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; VENOUS OXYGEN-SATURATION; INTRACRANIAL-PRESSURE; MANNITOL; DAMAGE	Monitoring of brain tissue partial pressure of O-2 (ti-pO(2)) is a promising new technique that allows early detection of impending cerebral ischemia in brain-injured patients. The purpose of this study was to investigate the effects of standard therapeutic interventions used in the treatment of intracranial hypertension in comatose patients on cerebral oxygenation. In the neurosurgical intensive care unit ti-pO(2), arterial blood pressure, intracranial pressure (ICP), cerebral perfusion pressure (CPP) and jugular bulb oxygen saturation (SjvO(2)) were prospectively studied (0.1 Hz acquisition ratel in 23 comatose patients (21 with severe traumatic brain injury, 2 with intracerebral hematoma) during various treatment modalities: elevation of CPP with dopamine (n = 35), lowering of the head in = 22), induced arterial hypocapnia (n = 13), mannitol infusion (n = 16), and decompressive craniotomy (n = 1). Ischemic episodes ('IE'= ti-pO(2) < 10 mmHg for > 15 min) within the first week after the insult were always associated with unfavorable neurological outcome. Elevation oi CPP from 32 +/- 2 to 67 +/- 4 mmHg significantly improved ti-pO(2) by 62% (13 +/- 2 to 21 +/- 1 mmHg) and reduced ICP indicating intact cerebral autoregulation. Further raising CPP from 68 +/- 2 to 84 +/- 2 mmHg did not alter ti-pO(2). Mannitol-induced ICP reduction from 23 +/- 7 to 16 +/- 2 mmHg did not affect ti-pO(2), nor did lowering of the head from 30 degrees to 0 degrees. Hyperventilation from an endtidal pCO(2) of 29 +/- 3 to 21 +/- 3 mmHg normalized ICP and CPP, but significantly reduced ti-pO(2) from 31 +/- 2 to 14 +/- 13 mmHg. Decompressive craniotomy in a 15-year old patient with refractory intracranial hypertension instantly restored ti-pO(2). Based on the present data, our understanding of many interventions previously believed to improve brain oxygenation might have to be re-evaluated. A CPP > 60 mmHg emerges as the most important factor determining sufficient brain tissue pO(2). Any intervention used to further elevate CPP does not improve ti-pO(2), to the contrary, hyperventilation even bears the risk of inducing brain ischemia.		Kiening, KL (corresponding author), HUMBOLDT UNIV BERLIN, VIRCHOW KLINIKUM, DEPT NEUROSURG, AUGUSTENBURGER PL 1, D-13353 BERLIN, GERMANY.						BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CLARK LC, 1956, T AM SOC ART INT ORG, V2, P41; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; GAAB MR, 1990, ACT NEUR S, V51, P326; GAAB MR, 1990, ACT NEUR S, V51, P320; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; MAAS A, 1993, MONITORING CEREBRAL, P50; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SANTBRINK H, 1996, NEUROSURGERY, V38, P21; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SCHNEIDER GH, 1993, ACTA NEUROCHIR, P107; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; TAKAGI H, 1983, INTRACRANIAL PRESSUR, V5, P729; THEODORSSONNORHEIM E, 1987, COMPUT BIOL MED, V17, P85, DOI 10.1016/0010-4825(87)90003-5; Unterberg A. W., 1995, Journal of Neurotrauma, V12, P405	30	142	157	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	1997	19	3					233	240		10.1080/01616412.1997.11740805			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	XC468	WOS:A1997XC46800004	9192372				2021-06-18	
J	JAFFE, KM; POLISSAR, NL; FAY, GC; LIAO, SQ				JAFFE, KM; POLISSAR, NL; FAY, GC; LIAO, SQ			RECOVERY TRENDS OVER 3 YEARS FOLLOWING PEDIATRIC TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEAD-INJURIES; CHILDREN; SEVERITY; SEQUELAE; COHORT	This cohort study investigated the magnitude of neurobehavioral, academic, and ''real world'' deficits over the course of 3 years in children with mild, moderate, and severe traumatic brain injury (TBI), and their individually matched controls. This series of analyses addresses the history of recovery, tracing changes in performance over time. Data on 72 case-control pairs (mild, n = 40; moderate, n = 17; severe, n = 15) were available for three testing times: 3 weeks, 1 year, and 3 years after the resolution of post-traumatic amnesia. The same standardized battery of tests was used at all testing times. The dependent variables in these analyses included individual test results, a variable summarizing results within each of 10 neurobehavioral domains, and an overall score across all domains. Three statistics were calculated for each variable: (1) the ''grand'' mean across the three testing times; (2) the slope (expressing the linear trend in performance); and (3) the change in slope over time (expressing the change in the rate of recovery). Use of the differences between case and control scores controlled for premorbid factors, maturation, and test-retest effects. Results indicate the chronicity of neurobehavioral deficits across all 3 years for moderately and severely injured children. They show a strong improvement rate during the first year, but a negligible rate of change during the following 2 years postinjury in most domains, All three of the time components-grand mean, slope, and change in slope-have significant Spearman correlations with severity ranging up to rho = -.5. Over time, the recovery rate slows down more for those with greater brain injury severity. The greatest slowing of recovery occurs in Performance IQ, adaptive problem solving, memory, and motor skills, as well as on a summary score of overall performance. Given this ''plateauing'' of recovery, achievement of parity with peers by the moderately and severely injured seems unlikely. Mildly injured children, however, exhibit negligible deficits or change in performance over time. (C) 1995 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195; STAT & EPIDEMIOL RES CORP,SEATTLE,WA; UNIV WASHINGTON,CTR QUANTITAT SCI,SEATTLE,WA	JAFFE, KM (corresponding author), UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,POB 5371,4800 SAND POINT WAY NE,SEATTLE,WA 98105, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR 002299] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; Achenbach TM, 1986, MANUAL TEACHERS REPO; Bruininks R. H., 1984, SCALES INDEPENDENT 4; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1985, DEV MED CHILD NEUROL, V27, P69; Conover W.J., 1980, PRACTICAL NONPARAMET; DRAPER NR, 1981, APPLIED REGRESSION A; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FRIDLUND AJ, 1987, CALIFORNIA VERBAL LE; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Jastak S, 1984, WIDE RANGE ACHIEVEME; JENNETT B, 1979, ADV NEUROL, V22; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1974, WECHSLER ADULT INTEL	18	142	145	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	1995	76	1					17	26		10.1016/S0003-9993(95)80037-9			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	QB197	WOS:A1995QB19700003	7811169				2021-06-18	
J	Grool, AM; Aglipay, M; Momoli, F; Meehan, WP; Freedman, SB; Yeates, KO; Gravel, J; Gagnon, I; Boutis, K; Meeuwisse, W; Barrowman, N; Ledoux, AA; Osmond, MH; Zemek, R				Grool, Anne M.; Aglipay, Mary; Momoli, Franco; Meehan, William P., III; Freedman, Stephen B.; Yeates, Keith Owen; Gravel, Jocelyn; Gagnon, Isabelle; Boutis, Kathy; Meeuwisse, Willem; Barrowman, Nick; Ledoux, Andree-Anne; Osmond, Martin H.; Zemek, Roger		Pediat Emergency Res Canada PERC	Association Between Early Participation in Physical Activity Following Acute Concussion and Persistent Postconcussive Symptoms in Children and Adolescents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPORT-RELATED CONCUSSION; PROPENSITY SCORE; EXERCISE PHYSIOLOGY; AEROBIC FITNESS; BRAIN; REST; COGNITION; SUPPORT; RISK	IMPORTANCE Although concussion treatment guidelines advocate rest in the immediate postinjury period until symptoms resolve, no clear evidence has determined that avoiding physical activity expedites recovery. OBJECTIVE To investigate the association between participation in physical activity within 7 days postinjury and incidence of persistent postconcussive symptoms (PPCS). DESIGN, SETTING, AND PARTICIPANTS Prospective, multicenter cohort study (August 2013-June 2015) of 3063 children and adolescents aged 5.00-17.99 years with acute concussion from 9 Pediatric Emergency Research Canada network emergency departments (EDs). EXPOSURES Early physical activity participation within 7 days postinjury. MAIN OUTCOMES AND MEASURES Physical activity participation and postconcussive symptom severity were rated using standardized questionnaires in the ED and at days 7 and 28 postinjury. PPCS (>= 3 new orworsening symptoms on the Post-Concussion Symptom Inventory) was assessed at 28 days postenrollment. Early physical activity and PPCS relationships were examined by unadjusted analysis, 1: 1 propensity score matching, and inverse probability of treatment weighting (IPTW). Sensitivity analyses examined patients (>= 3 symptoms) at day 7. RESULTS Among 2413 participants who completed the primary outcome and exposure, (mean [SD] age, 11.77 [3.35] years; 1205 [39.3%] females), PPCS at 28 days occurred in 733 (30.4%); 1677 (69.5%) participated in early physical activity including light aerobic exercise (n = 795 [32.9%]), sport-specific exercise (n = 214 [8.9%]), noncontact drills (n = 143 [5.9%]), full-contact practice (n = 106 [4.4%]), or full competition (n = 419 [17.4%]), whereas 736 (30.5%) had no physical activity. On unadjusted analysis, early physical activity participants had lower risk of PPCS than those with no physical activity (24.6% vs 43.5%; Absolute risk difference [ARD], 18.9%[95% CI, 14.7%-23.0%]). Early physical activity was associated with lower PPCS risk on propensity score matching (n = 1108 [28.7% for early physical activity vs 40.1% for no physical activity]; ARD, 11.4%[95% CI, 5.8%-16.9%]) and on inverse probability of treatment weighting analysis (n = 2099; relative risk [RR], 0.74 [95% CI, 0.65-0.84]; ARD, 9.7%[95% CI, 5.7%-13.7%]). Among only patients symptomatic at day 7 (n = 803) compared with those who reported no physical activity (n = 584; PPCS, 52.9%), PPCS rates were lower for participants of light aerobic activity (n = 494 [46.4%]; ARD, 6.5% [95% CI, 5.7%-12.5%]), moderate activity (n = 176 [38.6%]; ARD, 14.3%[95% CI, 5.9%-22.2%]), and full-contact activity (n = 133 [36.1%]; ARD, 16.8%[95% CI, 7.5%-25.5%]). No significant group difference was observed on propensity-matched analysis of this subgroup (n = 776 [47.2% vs 51.5%]; ARD, 4.4%[95% CI, -2.6% to 11.3%]). CONCLUSIONS AND RELEVANCE Among participants aged 5 to 18 years with acute concussion, physical activity within 7 days of acute injury compared with no physical activity was associated with reduced risk of PPCS at 28 days. A well-designed randomized clinical trial is needed to determine the benefits of early physical activity following concussion.	[Grool, Anne M.; Aglipay, Mary; Momoli, Franco; Barrowman, Nick; Ledoux, Andree-Anne] Childrens Hosp Eastern Ontario, Res Inst, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada; [Meehan, William P., III] Boston Childrens Hosp, Sports Concuss Clin, Boston, MA USA; [Freedman, Stephen B.] Univ Calgary, Alberta Childrens Hosp Res Inst, Alberta Childrens Hosp, Dept Pediat, Calgary, AB T2N 1N4, Canada; [Yeates, Keith Owen] Univ Calgary, Dept Psychol, Alberta Childrens Hosp Res Inst, Calgary, AB T2N 1N4, Canada; [Yeates, Keith Owen] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB T2N 1N4, Canada; [Gravel, Jocelyn] Univ Montreal, Hosp Ste Justine, Dept Pediat, Montreal, PQ, Canada; [Gagnon, Isabelle] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ, Canada; [Boutis, Kathy] Hosp Sick Children, Dept Pediat, Toronto, ON, Canada; [Meeuwisse, Willem] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Osmond, Martin H.; Zemek, Roger] Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Pediat, Ottawa, ON, Canada	Zemek, R (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	rzemek@cheo.on.ca	Zemek, Roger/H-1039-2018; Barlow, Karen/I-6492-2019; Yeates, Keith/AAJ-4223-2020; Barrowman, Nick/AAL-3166-2020; Freedman, Stephen/H-9102-2012; Barlow, Karen/C-1323-2014	Barrowman, Nick/0000-0002-4704-9595; Gravel, Jocelyn/0000-0001-5901-4990; Yeates, Keith/0000-0001-7680-2892; Osmond, Martin/0000-0001-8275-8381; Freedman, Stephen/0000-0003-2319-6192; Barlow, Karen/0000-0003-2612-8507	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [MOP 126197]; CIHR-Ontario Neurotrauma Foundation Mild Traumatic Brain Injury [TM1127047]; CIHRCanadian Institutes of Health Research (CIHR) [MRP 119829]	This study was supported by a Canadian Institutes of Health Research (CIHR) operating grant (MOP 126197); a CIHR-Ontario Neurotrauma Foundation Mild Traumatic Brain Injury team grant (TM1127047); and CIHR planning grant (MRP 119829).	Adamo KB, 2009, INT J PEDIATR OBES, V4, P2, DOI 10.1080/17477160802315010; Annest JJ, 2005, PSYCHOL REP, V96, P891, DOI 10.2466/pr0.96.3c.891-898; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786; Brookhart MA, 2006, AM J EPIDEMIOL, V163, P1149, DOI 10.1093/aje/kwj149; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Chaddock-Heyman L, 2014, MONOGR SOC RES CHILD, V79, P25, DOI 10.1111/mono.12129; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; Farquhar WB, 2015, AUTON NEUROSCI-BASIC, V188, P1, DOI 10.1016/j.autneu.2014.11.001; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Haukoos JS, 2015, JAMA-J AM MED ASSOC, V314, P1637, DOI 10.1001/jama.2015.13480; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Howie EK, 2012, J SPORT HEALTH SCI, V1, P160, DOI 10.1016/j.jshs.2012.09.003; Khan NA, 2014, PEDIATR EXERC SCI, V26, P138, DOI 10.1123/pes.2013-0125; Kurth T, 2006, AM J EPIDEMIOL, V163, P262, DOI 10.1093/aje/kwj047; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Longmuir PE, 2014, APPL PHYSIOL NUTR ME, V39, P1271, DOI 10.1139/apnm-2014-0074; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKay HA, 2000, J PEDIATR-US, V136, P156, DOI 10.1016/S0022-3476(00)70095-3; Moor HM, 2015, INT J SPORTS PHYS TH, V10, P225; Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E; Perrey S, 2013, BRAIN SCI, V3, P101, DOI 10.3390/brainsci3010101; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; Rush E, 2014, MED SPORT SCI, V60, P113, DOI 10.1159/000357341; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Scott D.W., 1992, MULTIVARIATE DENSITY; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Steindel SJ, 2010, J AM MED INFORM ASSN, V17, P274, DOI 10.1136/jamia.2009.001230; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Williamson EJ, 2014, RESPIROLOGY, V19, P625, DOI 10.1111/resp.12312; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Zemek R., 2014, GUIDELINES DIAGNOSIN; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003550	42	141	141	1	47	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2016	316	23					2504	2514		10.1001/jama.2016.17396			11	Medicine, General & Internal	General & Internal Medicine	EG3QH	WOS:000390959300018	27997652		Y	N	2021-06-18	
J	Ellis, MJ; Leddy, JJ; Willer, B				Ellis, Michael J.; Leddy, John J.; Willer, Barry			Physiological, vestibulo-ocular and cervicogenic post-concussion disorders: An evidence-based classification system with directions for treatment	BRAIN INJURY			English	Article						Concussion; post-concussion syndrome; physiology; treatment	TRAUMATIC BRAIN-INJURY; VESTIBULAR REHABILITATION; CEREBROVASCULAR RESPONSE; SENSORIMOTOR FUNCTION; UP-REGULATION; NECK PAIN; EXERCISE; DEPRESSION; CHILDREN; RECOVERY	Primary objective: To present a novel pathophysiological approach to acute concussion and post-concussion syndrome (PCS). Research design: Review of the literature Methods and procedures: PubMed searches were performed to identify articles related to the pathophysiology and treatment of concussion and PCS. Relevant articles that contributed to the primary objective of the paper were included. Main outcome and results: This paper presents an evidence-based approach to acute concussion and PCS that focuses on the identification of specific post-concussion disorders (PCDs) caused by impairments in global brain metabolism (Physiologic PCD) or neurological sub-system dysfunction (Vestibulo-ocular PCD and Cervicogenic PCD) that can be distinguished by features of the clinical history, physical examination and treadmill exercise testing. This novel approach also allows for the initiation of evidence-based, multi-disciplinary therapeutic interventions that can improve individual symptoms and promote efficient neurological recovery. Conclusion: Future studies incorporating neuro-imaging and exercise science techniques are underway at the author's institutions to validate this novel pathophysiological approach to acute concussion and PCS.	[Ellis, Michael J.] Univ Manitoba, Pan Clin, Div Neurosurg, Winnipeg, MB, Canada; [Leddy, John J.] SUNY Buffalo, Dept Orthopaed, Buffalo, NY 14214 USA; [Willer, Barry] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14214 USA	Leddy, JJ (corresponding author), Dept Orthopaed, 160 Farber Hall, Buffalo, NY 14214 USA.	leddy@buffalo.edu					Adelson PD, 2011, CHILD NERV SYST, V27, P1465, DOI 10.1007/s00381-011-1476-z; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Armstrong B, 2008, SPORTS MED, V38, P101, DOI 10.2165/00007256-200838020-00002; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/705309; Balaban CD, 2012, BRAIN RES, V1482, P101, DOI 10.1016/j.brainres.2012.08.040; Barker-Collo S, 2013, BRAIN INJURY, V27, P1124, DOI 10.3109/02699052.2013.801513; Bhattacharyya N, 2008, OTOLARYNG HEAD NECK, V139, pS47, DOI 10.1016/j.otohns.2008.08.022; Biondi D M, 2000, J Am Osteopath Assoc, V100, pS7; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Chaibi A, 2012, J HEADACHE PAIN, V13, P351, DOI 10.1007/s10194-012-0436-7; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Cripps A, 2013, J SPORT REHABIL, V22, P67, DOI 10.1123/jsr.22.1.67; Damen L, 2005, PEDIATRICS, V116, pE295, DOI 10.1542/peds.2004-2742; Doering TJ, 1998, AM J PHYS MED REHAB, V77, P490, DOI 10.1097/00002060-199811000-00006; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hamon M, 2013, PROG NEURO-PSYCHOPH, V45, P54, DOI 10.1016/j.pnpbp.2013.04.009; Han Y, 2004, BRAIN RES PROTOC, V14, P1, DOI 10.1016/j.brainresprot.2004.06.002; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Heikkila H, 1996, SCAND J REHABIL MED, V28, P133; Hillier SL, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005397.pub3; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; JURGENS R, 1989, EXP BRAIN RES, V77, P381, DOI 10.1007/BF00274995; Kapoor N, 2004, ARCH PHYS MED REHAB, V85, P1667, DOI 10.1016/j.apmr.2003.12.044; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; King ML, 1997, BRAIN INJURY, V11, P445; Kito S, 2012, BRAIN STIMUL, V5, P547, DOI 10.1016/j.brs.2011.09.004; Koenigs M, 2009, BEHAV BRAIN RES, V201, P239, DOI 10.1016/j.bbr.2009.03.004; Kristjansson E, 2009, J ORTHOP SPORT PHYS, V39, P364, DOI 10.2519/jospt.2009.2834; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Le Pera D, 2001, CLIN NEUROPHYSIOL, V112, P1633, DOI 10.1016/S1388-2457(01)00631-9; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Manzoni GC, 2011, J HEADACHE PAIN, V12, P585, DOI 10.1007/s10194-011-0393-6; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McDonnell MN, 2015, COCHRANE DATABASE SY, V1, DOI [10.1002/14651858, DOI 10.1002/14651858.CD005397.PUB4]; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Miller J, 2010, MANUAL THER, V15, P334, DOI 10.1016/j.math.2010.02.007; Passatore M, 2006, EUR J APPL PHYSIOL, V98, P423, DOI 10.1007/s00421-006-0312-8; PETERSON BW, 1985, J NEUROPHYSIOL, V54, P90; REVEL M, 1994, ARCH PHYS MED REHAB, V75, P895, DOI 10.1016/0003-9993(94)90115-5; Rihn JA, 2009, SPORTS MED, V39, P697, DOI 10.2165/11315190-000000000-00000; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Strakowski SM, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0386-z; Treleaven J, 2003, J REHABIL MED, V35, P36, DOI 10.1080/16501970306109; Treleaven J, 2010, MANUAL THER, V15, P206, DOI 10.1016/j.math.2009.05.001; Tyerman A, 2001, NEUROREHABILITATION, V16, P59; Wenngren BI, 1998, ACTA OTO-LARYNGOL, V118, P609; West SL, 2011, NEUROREHABILITATION, V29, P1, DOI 10.3233/NRE-2011-0671; Whitney SL, 2000, OTOLARYNG CLIN N AM, V33, P659, DOI 10.1016/S0030-6665(05)70232-2; Whitney SL, 2011, NEUROREHABILITATION, V29, P157, DOI 10.3233/NRE-2011-0690; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; WILSON VJ, 1990, J NEUROPHYSIOL, V64, P1695	75	141	142	0	43	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	2					238	248		10.3109/02699052.2014.965207			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AZ4OI	WOS:000348201500013	25314613				2021-06-18	
J	Adamczak, SE; Vaccari, JPD; Dale, G; Brand, FJ; Nonner, D; Bullock, MR; Dahl, GP; Dietrich, WD; Keane, RW				Adamczak, Stephanie E.; Vaccari, Juan Pablo de Rivero; Dale, Gordon; Brand, Frank J., III; Nonner, Doris; Bullock, M. Ross; Dahl, Gerhard P.; Dietrich, W. Dalton; Keane, Robert W.			Pyroptotic neuronal cell death mediated by the AIM2 inflammasome	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; cell death; cerebrospinal fluid; inflammasomes; innate immunity	TRAUMATIC BRAIN-INJURY; CASPASE-1 ACTIVATION; MOLECULAR PLATFORM; CYTOPLASMIC DNA; HEAD-INJURY; PLASMA DNA; APOPTOSIS; ASTROCYTES; ASC; MACROPHAGES	The central nervous system (CNS) is an active participant in the innate immune response to infection and injury. In these studies, we show embryonic cortical neurons express a functional, deoxyribonucleic acid (DNA)-responsive, absent in melanoma 2 (AIM2) inflammasome that activates caspase-1. Neurons undergo pyroptosis, a proinflammatory cell death mechanism characterized by the following: (a) oligomerization of apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC); (b) caspase-1 dependency; (c) formation of discrete pores in the plasma membrane; and (d) release of the inflammatory cytokine interleukin-beta (IL-1 beta). Probenecid and Brilliant Blue FCF, inhibitors of the pannexin1 channel, prevent AIM2 inflammasome-mediated cell death, identifying pannexin1 as a cell death effector during pyroptosis and probenecid as a novel pyroptosis inhibitor. Furthermore, we show activation of the AIM2 inflammasome in neurons by cerebrospinal fluid (CSF) from traumatic brain injury (TBI) patients and oligomerization of ASC. These findings suggest neuronal pyroptosis is an important cell death mechanism during CNS infection and injury that may be attenuated by probenecid.	[Adamczak, Stephanie E.; Dale, Gordon; Brand, Frank J., III; Nonner, Doris; Dahl, Gerhard P.; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; [Vaccari, Juan Pablo de Rivero; Bullock, M. Ross; Dietrich, W. Dalton; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA	Keane, RW (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, 1600 NW 10th Ave,RMSB 5058, Miami, FL 33136 USA.	rkeane@miami.edu	de Rivero Vaccari, Juan Pablo/H-5718-2019; de Rivero Vaccari, Juan Pablo/ABE-3248-2020	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834; Dale, Gordon/0000-0002-4995-6017	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS R01NS05986]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS074583]; Lois Pope LIFE Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS074583] Funding Source: NIH RePORTER	These studies were supported by NIH grant NINDS R01NS05986 to RWK, NINDS grant F31NS074583 to SA, and the Lois Pope LIFE Foundation.	Bergsbaken T, 2011, J IMMUNOL, V187, P2748, DOI 10.4049/jimmunol.1100477; Chekeni FB, 2010, NATURE, V467, P863, DOI 10.1038/nature09413; Chiu RWK, 2005, ACT NEUR S, V95, P471; Clark RSB, 1999, FASEB J, V13, P813; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194; Fernandes-Alnemri T, 2008, METHOD ENZYMOL, V442, P251, DOI [10.1016/S0076-6S79(08)01413-4, 10.1016/S0076-6879(08)01413-4]; Fernandes-Alnemri T, 2010, NAT IMMUNOL, V11, P385, DOI 10.1038/ni.1859; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005; Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x; Franchi L, 2010, CELL HOST MICROBE, V7, P340, DOI 10.1016/j.chom.2010.05.002; Garcia-Olmo DC, 2012, EXPERT OPIN BIOL TH, V12, pS1, DOI 10.1517/14712598.2012.688345; Halle M, 2010, J AM COLL CARDIOL, V55, P1227, DOI 10.1016/j.jacc.2009.10.047; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Jin TC, 2012, IMMUNITY, V36, P561, DOI 10.1016/j.immuni.2012.02.014; KAUFMAN LM, 1983, SCIENCE, V220, P1394, DOI 10.1126/science.6857258; Kaul DR, 2011, AM J TRANSPLANT, V11, P1079, DOI 10.1111/j.1600-6143.2011.03530.x; KAWAMOTO JC, 1986, BRAIN RES, V384, P84, DOI 10.1016/0006-8993(86)91222-9; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; KEANE RW, 1992, TRANSPLANTATION, V54, P520, DOI 10.1097/00007890-199209000-00025; Kerur N, 2011, CELL HOST MICROBE, V9, P363, DOI 10.1016/j.chom.2011.04.008; Krieg AM, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.277pe39; Lam NYL, 2003, CLIN CHEM, V49, P1286, DOI 10.1373/49.8.1286; Lamkanfi M, 2008, MOL CELL PROTEOMICS, V7, P2350, DOI 10.1074/mcp.M800132-MCP200; Locovei S, 2006, FEBS LETT, V580, P239, DOI 10.1016/j.febslet.2005.12.004; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x; Ohayon S, 2012, J NEUROTRAUM, V29, P261, DOI 10.1089/neu.2011.1938; Pierini R, 2012, CELL DEATH DIFFER, V19, P1709, DOI 10.1038/cdd.2012.51; Rathinam VAK, 2010, NAT IMMUNOL, V11, P395, DOI 10.1038/ni.1864; Reinders MK, 2009, ANN RHEUM DIS, V68, P51, DOI 10.1136/ard.2007.083071; Roberts TL, 2009, SCIENCE, V323, P1057, DOI 10.1126/science.1169841; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; TEDESCHI B, 1986, J CELL BIOL, V102, P2244, DOI 10.1083/jcb.102.6.2244; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Wang JJ, 2013, J GEN PHYSIOL, V141, P649, DOI 10.1085/jgp.201310966; Wu JH, 2010, J CLIN IMMUNOL, V30, P693, DOI 10.1007/s10875-010-9425-2; Yurgel VC, 2007, J NEUROTRAUM, V24, P1172, DOI 10.1089/neu.2006.0160	40	141	152	1	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2014	34	4					621	629		10.1038/jcbfm.2013.236			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AE2AE	WOS:000333774900010	24398937	Green Published, Bronze			2021-06-18	
J	Damiani, E; Adrario, E; Girardis, M; Romano, R; Pelaia, P; Singer, M; Donati, A				Damiani, Elisa; Adrario, Erica; Girardis, Massimo; Romano, Rocco; Pelaia, Paolo; Singer, Mervyn; Donati, Abele			Arterial hyperoxia and mortality in critically ill patients: a systematic review and meta-analysis	CRITICAL CARE			English	Article							INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; NORMOBARIC OXYGEN-THERAPY; TRAUMATIC BRAIN-INJURY; CARDIAC-ARREST; ASSOCIATION; STROKE; RESUSCITATION; GUIDELINES; TENSION	Introduction: The safety of arterial hyperoxia is under increasing scrutiny. We performed a systematic review of the literature to determine whether any association exists between arterial hyperoxia and mortality in critically ill patient subsets. Methods: Medline, Thomson Reuters Web of Science and Scopus databases were searched from inception to June 2014. Observational or interventional studies evaluating the relationship between hyperoxia (defined as a supranormal arterial O-2 tension) and mortality in adult intensive care unit (ICU) patients were included. Studies primarily involving patients with exacerbations of chronic pulmonary disease, acute lung injury and perioperative administration were excluded. Adjusted odds ratio (OR) of patients exposed versus those not exposed to hyperoxia were extracted, if available. Alternatively, unadjusted outcome data were recorded. Data on patients, study characteristics and the criteria used for defining hyperoxia exposure were also extracted. Random-effects models were used for quantitative synthesis of the data, with a primary outcome of hospital mortality. Results: In total 17 studies (16 observational, 1 prospective before-after) were identified in different patient categories: mechanically ventilated ICU (number of studies (k) = 4, number of participants (n) = 189,143), post-cardiac arrest (k = 6, n = 19,144), stroke (k = 2, n = 5,537), and traumatic brain injury (k = 5, n = 7,488). Different criteria were used to define hyperoxia in terms of PaO2 value (first, highest, worst, mean), time of assessment and predetermined cutoffs. Data from studies on ICU patients were not pooled because of extreme heterogeneity (inconsistency (I-2) 96.73%). Hyperoxia was associated with increased mortality in post-cardiac arrest patients (OR = 1.42 (1.04 to 1.92) I-2 67.73%) stroke (OR = 1.23 (1.06 to 1.43) I-2 0%) and traumatic brain injury (OR = 1.41 (1.03 to 1.94) I-2 64.54%). However, these results are limited by significant heterogeneity between studies. Conclusions: Hyperoxia may be associated with increased mortality in patients with stroke, traumatic brain injury and those resuscitated from cardiac arrest. However, these results are limited by the high heterogeneity of the included studies.	[Damiani, Elisa; Adrario, Erica; Romano, Rocco; Pelaia, Paolo; Donati, Abele] Univ Politecn Marche, Dept Biomed Sci & Publ Hlth, Anaesthesia & Intens Care Unit, I-60126 Torrette Di Ancona, Italy; [Girardis, Massimo] Univ Hosp Modena, Dept Anaesthesia & Intens Care, I-41124 Modena, Italy; [Singer, Mervyn] UCL, Bloomsbury Inst Intens Care Med, London WC1E 6BT, England	Donati, A (corresponding author), Univ Politecn Marche, Dept Biomed Sci & Publ Hlth, Anaesthesia & Intens Care Unit, Via Tronto 10, I-60126 Torrette Di Ancona, Italy.	a.donati@univpm.it	Damiani, Elisa/AAA-8075-2019; Singer, Mervyn/Q-6142-2019; Girardis, Massimo/K-8974-2016	Singer, Mervyn/0000-0002-1042-6350; Girardis, Massimo/0000-0002-2453-0829; damiani, elisa/0000-0002-3166-1835; Donati, Abele/0000-0001-6792-8741			Altemeier WA, 2007, CURR OPIN CRIT CARE, V13, P73, DOI 10.1097/MCC.0b013e32801162cb; Anderson JL, 2007, J AM COLL CARDIOL, V50, P652, DOI 10.1016/j.jacc.2007.02.028; Asher SR, 2013, J NEUROSURG ANESTH, V25, P168, DOI 10.1097/ANA.0b013e318283d350; Bellomo R, 2011, CRIT CARE, V15, DOI 10.1186/cc10090; Borenstein M., 2009, INTRO METAANALYSIS; BOURASSA MG, 1969, AM J CARDIOL, V24, P172, DOI 10.1016/0002-9149(69)90400-7; Brenner M, 2012, ARCH SURG-CHICAGO, V147, P1042, DOI 10.1001/archsurg.2012.1560; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Cornet AD, 2013, CRIT CARE, V17, DOI 10.1186/cc12554; CRAPO JD, 1994, AM J PHYSIOL-LUNG C, V267, pL797; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; de Graaff AE, 2011, INTENS CARE MED, V37, P46, DOI 10.1007/s00134-010-2025-z; de Jonge E, 2008, CRIT CARE, V12, DOI 10.1186/cc7150; Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309; Diringer MN, 2008, CURR OPIN CRIT CARE, V14, P167, DOI 10.1097/MCC.0b013e3282f57552; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Eastwood G, 2012, INTENS CARE MED, V38, P91, DOI 10.1007/s00134-011-2419-6; Farquhar H, 2009, AM HEART J, V158, P371, DOI 10.1016/j.ahj.2009.05.037; FRACICA PJ, 1991, J APPL PHYSIOL, V71, P2352; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Ihle JF, 2013, CRIT CARE RESUSC, V15, P186; Iscoe S, 2011, CRIT CARE, V15, DOI 10.1186/cc10229; Janz DR, 2012, CRIT CARE MED, V40, P3135, DOI 10.1097/CCM.0b013e3182656976; Kilgannon JH, 2011, CIRCULATION, V123, P2717, DOI 10.1161/CIRCULATIONAHA.110.001016; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Kuisma M, 2006, RESUSCITATION, V69, P199, DOI 10.1016/j.resuscitation.2005.08.010; Kumaria A, 2009, BRIT J NEUROSURG, V23, P576, DOI 10.3109/02688690903050352; Lee BK, 2014, AM J EMERG MED, V32, P55, DOI 10.1016/j.ajem.2013.09.044; Li HG, 2013, CURR OPIN PHARMACOL, V13, P161, DOI 10.1016/j.coph.2013.01.006; Lipsey M.W., 2001, PRACTICAL METAANALYS, V49; LODATO RF, 1989, J APPL PHYSIOL, V67, P1551; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Nelskyla A, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-35; O'Driscoll BR, 2008, THORAX, V63, DOI 10.1136/thx.2008.102947; O'Driscoll BR, 2011, CRIT CARE, V15; Padma MV, 2010, ANN INDIAN ACAD NEUR, V13, P284, DOI 10.4103/0972-2327.74203; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Pilcher J, 2012, RESUSCITATION, V83, P417, DOI 10.1016/j.resuscitation.2011.12.021; Raj R, 2013, CRIT CARE, V17, DOI 10.1186/cc12856; RAWLES JM, 1976, BMJ-BRIT MED J, V1, P1121, DOI 10.1136/bmj.1.6018.1121; Rincon F, 2014, J NEUROL NEUROSUR PS, V85, P799, DOI 10.1136/jnnp-2013-305505; Rincon F, 2014, CRIT CARE MED, V42, P387, DOI 10.1097/CCM.0b013e3182a27732; Ronning OM, 1999, STROKE, V30, P2033, DOI 10.1161/01.STR.30.10.2033; Singhal AB, 2005, STROKE, V36, P797, DOI 10.1161/01.STR.0000158914.66827.2e; Singhal AB, 2006, INT J STROKE, V1, P191, DOI 10.1111/j.1747-4949.2006.00058.x; Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8; Suzuki S, 2014, CRIT CARE MED, V42, P1414, DOI 10.1097/CCM.0000000000000219; Suzuki S, 2013, J CRIT CARE, V28, P647, DOI 10.1016/j.jcrc.2013.03.010; Vaahersalo J, 2014, CRIT CARE MED, V42, P1463, DOI 10.1097/CCM.0000000000000228; Wang CH, 2014, RESUSCITATION, V85, P1142, DOI 10.1016/j.resuscitation.2014.05.021; Young P, 2012, CRIT CARE RESUSC, V14, P14	53	141	148	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1364-8535	1466-609X		CRIT CARE	Crit. Care		2014	18	6							711	10.1186/s13054-014-0711-x			16	Critical Care Medicine	General & Internal Medicine	CI9LV	WOS:000355092500124	25532567	DOAJ Gold, Green Published			2021-06-18	
J	Roozenbeek, B; Lingsma, HF; Lecky, FE; Lu, J; Weir, J; Butcher, I; McHugh, GS; Murray, GD; Perel, P; Maas, AI; Steyerberg, EW				Roozenbeek, Bob; Lingsma, Hester F.; Lecky, Fiona E.; Lu, Juan; Weir, James; Butcher, Isabella; McHugh, Gillian S.; Murray, Gordon D.; Perel, Pablo; Maas, Andrew I.; Steyerberg, Ewout W.		Int Mission Prognosis Anal Clinica; Corticosteroid Randomisation After; Trauma Audit Res Network TARN	Prediction of outcome after moderate and severe traumatic brain injury: External validation of the International Mission on Prognosis and Analysis of Clinical Trials (IMPACT) and Corticoid Randomisation After Significant Head injury (CRASH) prognostic models	CRITICAL CARE MEDICINE			English	Article						external validation; outcome; prediction models; traumatic brain injury	SCALE	Objective: The International Mission on Prognosis and Analysis of Clinical Trials and Corticoid Randomisation After Significant Head injury prognostic models predict outcome after traumatic brain injury but have not been compared in large datasets. The objective of this is study is to validate externally and compare the International Mission on Prognosis and Analysis of Clinical Trials and Corticoid Randomisation after Significant Head injury prognostic models for prediction of outcome after moderate or severe traumatic brain injury. Design: External validation study. Patients: We considered five new datasets with a total of 9,036 patients, comprising three randomized trials and two observational series, containing prospectively collected individual traumatic brain injury patient data. Measurements and Main Results: Outcomes were mortality and unfavorable outcome, based on the Glasgow Outcome Score at 6 months after injury. To assess performance, we studied the discrimination of the models (by area under the receiver operating characteristic curves), and calibration (by comparison of the mean observed to predicted outcomes and calibration slopes). The highest discrimination was found in the Trauma Audit and Research Network trauma registry (area under the receiver operating characteristic curves between 0.83 and 0.87), and the lowest discrimination in the Pharmos trial (area under the receiver operating characteristic curves between 0.65 and 0.71). Although differences in predictor effects between development and validation populations were found (calibration slopes varying between 0.58 and 1.53), the differences in discrimination were largely explained by differences in case mix in the validation studies. Calibration was good, the fraction of observed outcomes generally agreed well with the mean predicted outcome. No meaningful differences were noted in performance between the International Mission on Prognosis and Analysis of Clinical Trials and Corticoid Randomisation After Significant Head injury models. More complex models discriminated slightly better than simpler variants. Conclusions: Since both the International Mission on Prognosis and Analysis of Clinical Trials and the Corticoid Randomisation After Significant Head injury prognostic models show good generalizability to more recent data, they are valid instruments to quantify prognosis in traumatic brain injury. (Crit Care Med 2012; 40: 1609-1617)	[Roozenbeek, Bob; Lingsma, Hester F.; Steyerberg, Ewout W.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; [Roozenbeek, Bob; Maas, Andrew I.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Roozenbeek, Bob; Maas, Andrew I.] Univ Antwerp, Edegem, Belgium; [Lecky, Fiona E.] Trauma Audit & Res Network, Manchester, Lancs, England; [Lecky, Fiona E.] Univ Manchester, Salford Royal Hosp NHS Fdn Trust, Manchester Med Acad Hlth Sci Ctr, Manchester, Lancs, England; [Lu, Juan] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Weir, James; Butcher, Isabella; McHugh, Gillian S.; Murray, Gordon D.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh EH8 9YL, Midlothian, Scotland; [Perel, Pablo] Univ London London Sch Hyg & Trop Med, Nutr & Publ Hlth Intervent Dept, London WC1E 7HT, England	Roozenbeek, B (corresponding author), Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands.	b.roozenbeek@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Gallardo, Angel Jesus Lacerda/AAZ-9478-2020; Abdullah, J/C-2828-2011; Nabil H, khalil/A-9528-2015; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Gallardo, Angel Jesus Lacerda/0000-0001-9171-2000; Abdullah, J/0000-0002-0258-7410; Nabil H, khalil/0000-0001-6293-7972; /0000-0002-2342-301X; Steyerberg, Ewout/0000-0002-7787-0122; Murray, Gordon/0000-0001-9866-4734	U.S. National Institutes of Health (Clinical Trial Design and Analysis in TBI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS-042691]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	Supported, in part, by the U.S. National Institutes of Health (Clinical Trial Design and Analysis in TBI Project: R01 NS-042691).	Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Edwards P, 2005, LANCET, V365, P1957; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Lesko MM, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-72; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Lu J, 2010, J NEUROTRAUM, V27, P843, DOI 10.1089/neu.2010.1293; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; MILLER LP, 2001, HEAD TRAUMA BASIC PR; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Servadei F, 2000, NEUROSURGERY, V46, P70; Steyerberg EW., 2009, CLIN PREDICTION MODE; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; van Leeuwen N, 2011, NEUROSURGERY    0905; Vergouwe Y, 2010, AM J EPIDEMIOL, V172, P971, DOI 10.1093/aje/kwq223; Wilson JTL, 2007, NEUROSURGERY, V61, P123, DOI 10.1227/01.neu.0000279732.21145.9e; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	26	141	141	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAY	2012	40	5					1609	1617		10.1097/CCM.0b013e31824519ce			9	Critical Care Medicine	General & Internal Medicine	930AE	WOS:000303106900027	22511138	Green Accepted			2021-06-18	
J	Zhang, QG; Laird, MD; Han, D; Nguyen, K; Scott, E; Dong, Y; Dhandapani, KM; Brann, DW				Zhang, Quan-Guang; Laird, Melissa D.; Han, Dong; Khoi Nguyen; Scott, Erin; Dong, Yan; Dhandapani, Krishnan M.; Brann, Darrell W.			Critical Role of NADPH Oxidase in Neuronal Oxidative Damage and Microglia Activation following Traumatic Brain Injury	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; AMYLOID PRECURSOR PROTEIN; CENTRAL-NERVOUS-SYSTEM; SUPEROXIDE-PRODUCTION; SYNAPTIC PROTEINS; ISCHEMIA; OXYGEN; EDEMA; NEUROPROTECTION; ATTENUATION	Background: Oxidative stress is known to play an important role in the pathology of traumatic brain injury. Mitochondria are thought to be the major source of the damaging reactive oxygen species (ROS) following TBI. However, recent work has revealed that the membrane, via the enzyme NADPH oxidase can also generate the superoxide radical (O-2(-)), and thereby potentially contribute to the oxidative stress following TBI. The current study thus addressed the potential role of NADPH oxidase in TBI. Methodology/Principal Findings:The results revealed that NADPH oxidase activity in the cerebral cortex and hippocampal CA1 region increases rapidly following controlled cortical impact in male mice, with an early peak at 1 h, followed by a secondary peak from 24-96 h after TBI. In situ localization using oxidized hydroethidine and the neuronal marker, NeuN, revealed that the O-2(-) induction occurred in neurons at 1 h after TBI. Pre- or post-treatment with the NADPH oxidase inhibitor, apocynin markedly inhibited microglial activation and oxidative stress damage. Apocynin also attenuated TBI-induction of the Alzheimer's disease proteins beta-amyloid and amyloid precursor protein. Finally, both pre- and post-treatment of apocynin was also shown to induce significant neuroprotection against TBI. In addition, a NOX2-specific inhibitor, gp91ds-tat was also shown to exert neuroprotection against TBI. Conclusions/Significance: As a whole, the study demonstrates that NADPH oxidase activity and superoxide production exhibit a biphasic elevation in the hippocampus and cortex following TBI, which contributes significantly to the pathology of TBI via mediation of oxidative stress damage, microglial activation, and AD protein induction in the brain following TBI.	[Zhang, Quan-Guang; Han, Dong; Khoi Nguyen; Scott, Erin; Dong, Yan; Brann, Darrell W.] Georgia Hlth Sci Univ, Dept Neurol, Inst Mol Med & Genet, Augusta, GA USA; [Laird, Melissa D.; Dhandapani, Krishnan M.] Georgia Hlth Sci Univ, Dept Neurosurg, Augusta, GA USA	Zhang, QG (corresponding author), Georgia Hlth Sci Univ, Dept Neurol, Inst Mol Med & Genet, Augusta, GA USA.	dbrann@georgiahealth.edu		Dhandapani, Krishnan/0000-0001-7044-1117			Afanas'ev IB, 2007, MOL BIOTECHNOL, V37, P2, DOI 10.1007/s12033-007-0056-7; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Bergamini CM, 2004, CURR PHARM DESIGN, V10, P1611, DOI 10.2174/1381612043384664; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Block ML, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S2-S8; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Chen H, 2009, J CEREB BLOOD FLOW M; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Jackman KA, 2009, BRIT J PHARMACOL, V156, P680, DOI 10.1111/j.1476-5381.2008.00073.x; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; King MD, 2011, J NEUROSURG, V115, P116, DOI 10.3171/2011.2.JNS10784; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lambert AJ, 2009, METHODS MOL BIOL, V554, P165, DOI 10.1007/978-1-59745-521-3_11; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; MOUTON PR, 1994, J CHEM NEUROANAT, V7, P185, DOI 10.1016/0891-0618(94)90028-0; Murotomi K, 2011, MOL CELL NEUROSCI, V46, P681, DOI 10.1016/j.mcn.2011.01.009; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; Raz L, 2010, PLAS ONE; Rey FE, 2001, CIRC RES, V89, P408, DOI 10.1161/hh1701.096037; Serrano F, 2003, BRAIN RES, V988, P193, DOI 10.1016/S0006-8993(03)03364-X; Sorce S, 2009, ANTIOXID REDOX SIGN, V11, P2481, DOI [10.1089/ars.2009.2578, 10.1089/ARS.2009.2578]; Tang LL, 2007, J INT MED RES, V35, P517, DOI 10.1177/147323000703500411; Toklu HZ, 2009, FREE RADICAL RES, V43, P658, DOI 10.1080/10715760902988843; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Wakade C, 2010, J NEUROSURG; Wakade C, 2008, ENDOCRINOLOGY, V149, P367, DOI 10.1210/en.2007-0899; Wang R, 2009, J NEUROSCIE IN PRESS; Zhang QG, 2008, J NEUROSCI, V28, P8430, DOI 10.1523/JNEUROSCI.2752-08.2008; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	44	141	143	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2012	7	4							e34504	10.1371/journal.pone.0034504			10	Multidisciplinary Sciences	Science & Technology - Other Topics	952GU	WOS:000304780500051	22485176	DOAJ Gold, Green Published			2021-06-18	
J	Hoffman, JM; Lucas, S; Dikmen, S; Braden, CA; Brown, AW; Brunner, R; Diaz-Arrastia, R; Walker, WC; Watanabe, TK; Bell, KR				Hoffman, Jeanne M.; Lucas, Sylvia; Dikmen, Sureyya; Braden, Cynthia A.; Brown, Allen W.; Brunner, Robert; Diaz-Arrastia, Ramon; Walker, William C.; Watanabe, Thomas K.; Bell, Kathleen R.			Natural History of Headache after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						headache; natural history; traumatic brain injury	POSTTRAUMATIC HEADACHE; CHRONIC PAIN; PREVALENCE; CONCUSSION; SEVERITY; MODERATE; RATES	Headache is one of the most common persisting symptoms after traumatic brain injury (TBI). Yet there is a paucity of prospective longitudinal studies of the incidence and prevalence of headache in a sample with a range of injury severity. We sought to describe the natural history of headache in the first year after TBI, and to determine the roles of prior history of headache, sex, and severity of TBI as risk factors for post-traumatic headache. A cohort of 452 acute, consecutive patients admitted to inpatient rehabilitation services with TBI were enrolled during their inpatient rehabilitation from February 2008 to June 2009. Subjects were enrolled across 7 acute rehabilitation centers designated as TBI Model Systems centers. They were prospectively assessed by structured interviews prior to inpatient rehabilitation discharge, and at 3, 6, and 12 months after injury. Results of this natural history study suggest that 71% of participants reported headache during the first year after injury. The prevalence of headache remained high over the first year, with more than 41% of participants reporting headache at 3, 6, and 12 months post-injury. Persons with a pre-injury history of headache (p < 0.001) and females (p < 0.01) were significantly more likely to report headache. The incidence of headache had no relation to TBI severity (p=0.67). Overall, headache is common in the first year after TBI, independent of the severity of injury range examined in this study. Use of the International Classification of Headache Disorders criteria requiring onset of headache within 1 week of injury underestimates rates of post-traumatic headache. Better understanding of the natural history of headache including timing, type, and risk factors should aid in the design of treatment studies to prevent or reduce the chronicity of headache and its disruptive effects on quality of life.	[Hoffman, Jeanne M.; Dikmen, Sureyya; Bell, Kathleen R.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Lucas, Sylvia] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Med, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Braden, Cynthia A.] Craig Hosp, Denver, CO USA; [Brown, Allen W.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA; [Brunner, Robert] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Walker, William C.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Watanabe, Thomas K.] Moss Rehab, Dept Phys Med & Rehabil, Philadelphia, PA USA	Hoffman, JM (corresponding author), Univ Washington, Dept Rehabil, Box 356490, Seattle, WA 98195 USA.	jeanneh@uw.edu	Walker, William C/N-3162-2014	Diaz-Arrastia, Ramon/0000-0001-6051-3594; Bell, Kathleen/0000-0002-0928-2046; Brown, Allen W./0000-0001-7228-3351	Department of EducationUS Department of Education; National Institute on Disability and Rehabilitation Research (NIDRR); University of Washington Traumatic Brain Injury Model System [H133A070032]; Rocky Mountain Regional Brain Injury System [H133A070022]; Mayo Clinic Traumatic Brain Injury Model System [H133A070013]; University of Alabama at Birmingham TBI Model System [H133A070039]; North Texas Traumatic Brain Injury Model system [H133A0252604]; Moss Traumatic Brain Injury Model System [H133A070040]; Virginia Commonwealth Traumatic Brain Injury Model System [H133A070036]; MerckMerck & Company; MAP Pharmaceuticals, Inc.; Nupathe; National Headache Foundation; Wadsworth Foundation; National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Department of DefenseUnited States Department of Defense	This study was funded by the Department of Education, the National Institute on Disability and Rehabilitation Research (NIDRR), TBI Model Systems: University of Washington Traumatic Brain Injury Model System H133A070032, the Rocky Mountain Regional Brain Injury System H133A070022, the Mayo Clinic Traumatic Brain Injury Model System H133A070013, the University of Alabama at Birmingham TBI Model System H133A070039, the North Texas Traumatic Brain Injury Model system H133A0252604, the Moss Traumatic Brain Injury Model System H133A070040, and the Virginia Commonwealth Traumatic Brain Injury Model System H133A070036.; Dr. Hoffman, Dr. Lucas, Dr. Dikman, Ms. Braden, Dr. Brown, Dr. Brunner, Dr. Diaz-Arrastia, Dr. Walker, Dr. Watanabe, and Dr. Bell receive research funding from the NIDRR. Dr. Lucas receives funding for other clinical research from Merck, MAP Pharmaceuticals, Inc., Nupathe, the National Headache Foundation, and the Wadsworth Foundation. She also received institutional support for lectures given to Merck, GlaxoSmithKline, and Zogenix. Dr. Dikmen receives research funding from the National Institute of Health (NIH) and the Department of Defense. Dr. Bell receives research funding the Department of Defense. She received payment for travel and lecture to attend the 3rd Croatian Congress on NeuroRehabilitation and Restoration Neurology and for the American Association for the Advancement of Science, Contemporary Forums. She has received funding for travel to attend the American Academy of Physical Medicine and Rehabilitation, INTRuST Clinical Consortium, Alaska Brain Injury Network, Third Trauma Spectrum Conference, Brooke Army Medical Center, and the Kaiser Foundation.	Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Bettucci D, 1998, ITAL J NEUROL SCI, V19, P20, DOI 10.1007/BF03028807; Castillo J, 1999, HEADACHE, V39, P190, DOI 10.1046/j.1526-4610.1999.3903190.x; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jensen O K, 2001, Ugeskr Laeger, V163, P5029; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; MARTINS H, 2009, ARQUIVOS NEUROPSIQUI, P43; Packard Russell C, 2005, Curr Pain Headache Rep, V9, P59, DOI 10.1007/s11916-005-0076-6; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Scher AI, 1998, HEADACHE, V38, P497, DOI 10.1046/j.1526-4610.1998.3807497.x; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; SILBERSTEIN SD, 1994, NEUROLOGY, V44, P6; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x	25	141	142	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1719	1725		10.1089/neu.2011.1914			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000005	21732765	Green Published			2021-06-18	
J	Benicky, J; Sanchez-Lemus, E; Honda, M; Pang, T; Orecna, M; Wang, JA; Leng, Y; Chuang, DM; Saavedra, JM				Benicky, Julius; Sanchez-Lemus, Enrique; Honda, Masaru; Pang, Tao; Orecna, Martina; Wang, Juan; Leng, Yan; Chuang, De-Maw; Saavedra, Juan M.			Angiotensin II AT(1) Receptor Blockade Ameliorates Brain Inflammation	NEUROPSYCHOPHARMACOLOGY			English	Article						innate immune response; lipopolysaccharide; proinflammatory cytokines; microglia activation; sickness behavior	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; INNATE IMMUNE-RESPONSE; ANTAGONIST PREVENTS; LIPOPOLYSACCHARIDE; CANDESARTAN; EXPRESSION; SYSTEM; MECHANISMS; DISEASE	Brain inflammation has a critical role in the pathophysiology of brain diseases of high prevalence and economic impact, such as major depression, schizophrenia, post-traumatic stress disorder, Parkinson's and Alzheimer's disease, and traumatic brain injury. Our results demonstrate that systemic administration of the centrally acting angiotensin II AT(1) receptor blocker (ARB) candesartan to normotensive rats decreases the acute brain inflammatory response to administration of the bacterial endotoxin lipopolysaccharide (LPS), a model of brain inflammation. The broad anti-inflammatory effects of candesartan were seen across the entire inflammatory cascade, including decreased production and release to the circulation of centrally acting proinflammatory cytokines, repression of nuclear transcription factors activation in the brain, reduction of gene expression of brain proinflammatory cytokines, cytokine and prostanoid receptors, adhesion molecules, proinflammatory inducible enzymes, and reduced microglia activation. These effects are widespread, occurring not only in well-known brain target areas for circulating proinflammatory factors and LPS, that is, hypothalamic paraventricular nucleus and the subfornical organ, but also in the prefrontal cortex, hippocampus, and amygdala. Candesartan reduced the associated anorexic effects, and ameliorated associated body weight loss and anxiety. Direct anti-inflammatory effects of candesartan were also documented in cultured rat microglia, cerebellar granule cells, and cerebral microvascular endothelial cells. ARBs are widely used in the treatment of hypertension and stroke, and their anti-inflammatory effects contribute to reduce renal and cardiac failure. Our results indicate that these compounds may offer a novel and safe therapeutic approach for the treatment of brain disorders. Neuropsychopharmacology (2011) 36, 857-870; doi:10.1038/npp.2010.225; published online 8 December 2010	[Benicky, Julius; Sanchez-Lemus, Enrique; Honda, Masaru; Pang, Tao; Orecna, Martina; Wang, Juan; Saavedra, Juan M.] NIMH, Pharmacol Sect, Div Intramural Res Programs, Dept Hlth & Human Serv,NIH, Bethesda, MD 20892 USA; [Leng, Yan; Chuang, De-Maw] NIMH, Mol Neurobiol Sect, Div Intramural Res Programs, Dept Hlth & Human Serv,NIH, Bethesda, MD 20892 USA	Benicky, J (corresponding author), NIMH, Pharmacol Sect, Div Intramural Res Programs, Dept Hlth & Human Serv,NIH, 9000 Rockville Pike,Bldg 10,Room 2D57, Bethesda, MD 20892 USA.	benickyj@mail.nih.gov	Saavedra, Juan/AAO-7149-2020		National Institute of Mental Health, Department of Health and Human Services, USAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); Japan Society for the Promotion of Science Research at NIH; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH002762] Funding Source: NIH RePORTER	This study was supported by the Division of Intramural Research Programs, National Institute of Mental Health, Department of Health and Human Services, USA. Dr Honda was supported by the Japan Society for the Promotion of Science Research Fellowship for Japanese Biomedical and Behavioral Researchers at NIH. We thank Astra-Zeneca, Molndal, Sweden, for the supply of candesartan, and to Andres Negro Vilar MD, PhD, for his helpful comments and suggestions during the preparation of the manuscript.	Anderson C, 2010, J HYPERTENS, V28, P429, DOI 10.1097/HJH.0b013e3283371355; Ando H, 2004, STROKE, V35, P1726, DOI 10.1161/01.STR.0000129788.26346.18; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Benicky J, 2009, CELL MOL NEUROBIOL, V29, P781, DOI 10.1007/s10571-009-9368-4; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Dasu MR, 2009, ATHEROSCLEROSIS, V202, P76, DOI 10.1016/j.atherosclerosis.2008.04.010; Doorduin J, 2009, J NUCL MED, V50, P1801, DOI 10.2967/jnumed.109.066647; Fassbender K, 2004, FASEB J, V18, P203, DOI 10.1096/fj.03-0364fje; Fleegal-DeMotta MA, 2009, J CEREBR BLOOD F MET, V29, P640, DOI 10.1038/jcbfm.2008.158; Gao XM, 1995, BRAIN RES, V703, P63, DOI 10.1016/0006-8993(95)01066-1; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Hope S, 2009, BIPOLAR DISORD, V11, P726, DOI 10.1111/j.1399-5618.2009.00757.x; Hoshino T, 2009, J BIOL CHEM, V284, P18493, DOI 10.1074/jbc.M109.003269; Jenrow KA, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-6; Johren O, 1995, NEUROREPORT, V6, P2549; Kim YS, 2004, MOL BRAIN RES, V128, P95, DOI 10.1016/j.molbrainres.2004.06.009; Konsman JP, 2001, NUTRITION, V17, P664, DOI 10.1016/S0899-9007(01)00602-5; Kulakowska A, 1996, PHARMACOL RES, V34, P109, DOI 10.1006/phrs.1996.0073; KVETNANSKY R, 1979, AM J PHYSIOL, V236, pH457; Larrayoz IM, 2009, J HYPERTENS, V27, P2365, DOI 10.1097/HJH.0b013e3283314bc7; Lenkei Z, 1998, NEUROSCIENCE, V82, P827; Li NC, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5465; Licinio J, 1997, J CLIN INVEST, V100, P2941, DOI 10.1172/JCI119846; LIU Y, 2010, NEUROPHARMA IN PRESS, DOI DOI 10.1016/J.NEUROPHARM; Man SM, 2007, BRAIN PATHOL, V17, P243, DOI 10.1111/j.1750-3639.2007.00067.x; Maynard CL, 2008, IMMUNOL REV, V226, P219, DOI 10.1111/j.1600-065X.2008.00711.x; McEwen BS, 2008, EUR J PHARMACOL, V583, P174, DOI 10.1016/j.ejphar.2007.11.071; Mertens B, 2010, J RENIN-ANGIO-ALDO S, V11, P49, DOI 10.1177/1470320309347789; Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029; MILLIGAN CE, 1991, J COMP NEUROL, V314, P125, DOI 10.1002/cne.903140112; Miyoshi M, 2008, EUR J NEUROSCI, V27, P343, DOI 10.1111/j.1460-9568.2007.06014.x; Nakagawa S, 2009, NEUROCHEM INT, V54, P253, DOI 10.1016/j.neuint.2008.12.002; Nimmo Alan J, 2009, Recent Pat CNS Drug Discov, V4, P86; Nishimura Y, 2000, BRAIN RES, V871, P29, DOI 10.1016/S0006-8993(00)02377-5; Pan WH, 2010, CELL PHYSIOL BIOCHEM, V25, P623, DOI 10.1159/000315081; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Phillips MI, 2008, J MOL MED, V86, P715, DOI 10.1007/s00109-008-0331-5; Platten M, 2009, P NATL ACAD SCI USA, V106, P14948, DOI 10.1073/pnas.0903958106; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Quan N, 2007, BRAIN BEHAV IMMUN, V21, P727, DOI 10.1016/j.bbi.2007.05.005; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Russell VA, 2003, NEUROSCI BIOBEHAV R, V27, P671, DOI 10.1016/j.neubiorev.2003.08.010; SAAVEDRA JM, 1992, ENDOCR REV, V13, P329, DOI 10.1210/er.13.2.329; Saavedra JM, 2006, NEUROPSYCHOPHARMACOL, V31, P1123, DOI 10.1038/sj.npp.1300921; Sanchez-Lemus E, 2008, ENDOCRINOLOGY, V149, P5177, DOI 10.1210/en.2008-0242; Sanchez-Lemus E, 2009, BRAIN BEHAV IMMUN, V23, P945, DOI 10.1016/j.bbi.2009.04.012; Sanchez-Lemus E, 2009, AM J PHYSIOL-REG I, V296, pR1376, DOI 10.1152/ajpregu.90962.2008; Savoia C, 2007, CLIN SCI, V112, P375, DOI 10.1042/CS20060247; Schmerbach K, 2008, BRAIN RES, V1208, P225, DOI 10.1016/j.brainres.2008.02.032; Seeger H, 2001, J RENIN-ANGIO-ALDO S, V2, P141, DOI 10.3317/jraas.2001.016; Seltzer A, 2004, BRAIN RES, V1028, P9, DOI 10.1016/j.brainres.2004.06.079; SIREN AL, 1992, STROKE, V23, P1643, DOI 10.1161/01.STR.23.11.1643; Srinivasan J, 2003, PHYSIOL BEHAV, V78, P585, DOI 10.1016/S0031-9384(03)00036-2; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pR209; Vaisinen J, 2004, CELL MOL NEUROBIOL, V24, P769, DOI 10.1007/s10571-004-6918-7; Watanabe K, 2006, PEPTIDES, V27, P1538, DOI 10.1016/j.peptides.2005.11.005; Weinberg AJ, 2004, AM J NEPHROL, V24, P340, DOI 10.1159/000078950; Yong VW, 2009, NEURON, V64, P55, DOI 10.1016/j.neuron.2009.09.035; Zhou J, 2006, STROKE, V37, P1271, DOI 10.1161/01.STR.0000217404.64352.d7; Zhou J, 2005, J CEREBR BLOOD F MET, V25, P878, DOI 10.1038/sj.jcbfm.9600082	63	141	148	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	MAR	2011	36	4					857	870		10.1038/npp.2010.225			14	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	719FY	WOS:000287188200014	21150913	Green Published, Green Accepted, Bronze			2021-06-18	
J	Frommer, LJ; Gurka, KK; Cross, KM; Ingersoll, CD; Comstock, RD; Saliba, SA				Frommer, Leah J.; Gurka, Kelly K.; Cross, Kevin M.; Ingersoll, Christopher D.; Comstock, R. Dawn; Saliba, Susan A.			Sex Differences in Concussion Symptoms of High School Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						epidemiology; mild traumatic brain injuries; symptom resolution; return to play	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; UNITED-STATES; FOOTBALL PLAYERS; SOCCER PLAYERS; SAFE RETURN; HEAD-INJURY; COLLEGIATE; EPIDEMIOLOGY; PATHOPHYSIOLOGY	Context: More than 1.6 million sport-related concussions occur every year in the United States, affecting greater than 5% of all high school athletes who participate in contact sports. As more females participate in sports, understanding possible differences in concussion symptoms between sexes becomes more important. Objective: To compare symptoms, symptom resolution time, and time to return to sport between males and females with sport-related concussions. Design: Descriptive epidemiology study. Setting: Data were collected from 100 high schools via High School RIO (Reporting Information Online). Patients or Other Participants: Athletes from participating schools who sustained concussions while involved in interscholastic sports practice or competition in 9 sports (boys' football, soccer, basketball, wrestling, and baseball and girls' soccer, volleyball, basketball, and softball) during the 2005-2006 and 2006-2007 school years. A total of 812 sport concussions were reported (610 males, 202 females). Main Outcome Measure(s): Reported symptoms, symptom resolution time, and return-to-play time. Results: No difference was found between the number of symptoms reported (P = .30). However, a difference was seen in the types of symptoms reported. In year 1, males reported amnesia (exact P = .03) and confusion/disorientation (exact P = .04) more frequently than did females. In year 2, males reported more amnesia (exact P = .002) and confusion/disorientation (exact P = .002) than did females, whereas females reported more drowsiness (exact P = .02) and sensitivity to noise (exact P = .002) than did males. No differences were observed for symptom resolution time (P = .40) or return-to-play time (P = .43) between sexes. Conclusions: The types of symptoms reported differed between sexes after sport-related concussion, but symptom resolution time and return-to-play timelines were similar.	[Frommer, Leah J.] Univ Calif Santa Barbara, Santa Barbara, CA 93106 USA; [Gurka, Kelly K.; Cross, Kevin M.; Ingersoll, Christopher D.; Saliba, Susan A.] Univ Virginia, Charlottesville, VA USA; [Comstock, R. Dawn] Ohio State Univ, Columbus, OH 43210 USA; [Comstock, R. Dawn] Nationwide Childrens Hosp, Columbus, OH USA	Saliba, SA (corresponding author), POB 400407, Charlottesville, VA 22904 USA.	saf8u@virginia.edu	Gurka, Kelly K./M-2004-2014; Ingersoll, Christopher/H-6474-2015	Gurka, Kelly K./0000-0003-2779-3234; Ingersoll, Christopher/0000-0001-9157-6846; Saliba, Susan/0000-0001-7179-8310	Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CEOOO674-01]	This research was funded by the Centers for Disease Control and Prevention (CDC), grant no. R49/CEOOO674-01.	Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Comstock D, 2006, SUMMARY REPORT HIGH; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Georgia Institute of Technology, 2002, GEORGIA TECH SPORTS, V11, P3; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Kelly JP, 2001, J ATHL TRAINING, V36, P249; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, pV, DOI 10.1097/00001199-199804000-00001; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leblanc Kim Edward, 1999, Comprehensive Therapy, V25, P39, DOI 10.1007/BF02889833; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; *NAT FED STAT HIGH, 2005 2006 HIGH SCH A; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Piland SG, 2003, J ATHL TRAINING, V38, P104; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Ruchinskas R A, 1997, Appl Neuropsychol, V4, P43, DOI 10.1207/s15324826an0401_5; Santa Maria MP, 2001, ARCH CLIN NEUROPSYCH, V16, P133; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Theye Fred, 2004, Clin Med Res, V2, P165; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Torg JS., 1991, ATHLETIC INJURIES HE; United States Census Bureau, CENS REG US; US Department of Education, 1997, TITL 9 25 YEARS PROG; Yardt EE, 2008, AM J SPORT MED, V36, P57, DOI 10.1177/0363546507307507	53	141	142	2	29	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JAN-FEB	2011	46	1					76	84		10.4085/1062-6050-46.1.76			9	Sport Sciences	Sport Sciences	704SZ	WOS:000286074000010	21214354	Green Published			2021-06-18	
J	Dash, PK; Orsi, SA; Zhang, M; Grill, RJ; Pati, S; Zhao, J; Moore, AN				Dash, Pramod K.; Orsi, Sara A.; Zhang, Min; Grill, Raymond J.; Pati, Shibani; Zhao, Jing; Moore, Anthony N.			Valproate Administered after Traumatic Brain Injury Provides Neuroprotection and Improves Cognitive Function in Rats	PLOS ONE			English	Article							SUBEROYLANILIDE HYDROXAMIC ACID; HISTONE DEACETYLASE INHIBITION; CONTROLLED CORTICAL IMPACT; SPATIAL MEMORY DEFICITS; CLOSED-HEAD INJURY; CELLS IN-VITRO; MOOD STABILIZER; MEDIATED NEUROPROTECTION; GENE-EXPRESSION; H3 ACETYLATION	Background: Traumatic brain injury (TBI) initiates a complex series of neurochemical and signaling changes that lead to pathological events including neuronal hyperactivity, excessive glutamate release, inflammation, increased blood-brain barrier (BBB) permeability and cerebral edema, altered gene expression, and neuronal dysfunction. It is believed that a drug combination, or a single drug acting on multiple targets, may be an effective strategy to treat TBI. Valproate, a widely used antiepileptic drug, has a number of targets including GABA transaminase, voltage-gated sodium channels, glycogen synthase kinase (GSK)-3, and histone deacetylases (HDACs), and therefore may attenuate a number of TBI-associated pathologies. Methodology/Principal Findings: Using a rodent model of TBI, we tested if post-injury administration of valproate can decrease BBB permeability, reduce neural damage and improve cognitive outcome. Dose-response studies revealed that systemic administration of 400 mg/kg (i.p.), but not 15, 30, 60 or 100 mg/kg, increases histone H3 and H4 acetylation, and reduces GSK-3 activity, in the hippocampus. Thirty min post-injury administration of 400 mg/kg valproate improved BBB integrity as indicated by a reduction in Evans Blue dye extravasation. Consistent with its dose response to inhibit GSK-3 and HDACs, valproate at 400 mg/kg, but not 100 mg/kg, reduced TBI-associated hippocampal dendritic damage, lessened cortical contusion volume, and improved motor function and spatial memory. These behavioral improvements were not observed when SAHA (suberoylanilide hydroxamic acid), a selective HDAC inhibitor, was administered. Conclusion/Significance: Our findings indicate that valproate given soon after TBI can be neuroprotective. As clinically proven interventions that can be used to minimize the damage following TBI are not currently available, the findings from this report support the further testing of valproate as an acute therapeutic strategy.	[Dash, Pramod K.; Orsi, Sara A.; Zhang, Min; Zhao, Jing; Moore, Anthony N.] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX USA; [Dash, Pramod K.; Orsi, Sara A.; Zhang, Min; Zhao, Jing; Moore, Anthony N.] Univ Texas Hlth Sci Ctr Houston, Dept Neurosurg, Houston, TX USA; [Grill, Raymond J.] Univ Texas Hlth Sci Ctr Houston, Dept Integrated Biol & Pharmacol, Houston, TX USA; [Pati, Shibani] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Houston, TX USA	Dash, PK (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX USA.	P.Dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	Department of DefenseUnited States Department of Defense [W81XWH-08-2-0134]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32HD049350]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD049350] Funding Source: NIH RePORTER	This research was made possible by funding support from the Department of Defense (W81XWH-08-2-0134) and a training grant from National Institutes of Health (NIH) (5T32HD049350). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam HB, 2009, SURGERY, V146, P325, DOI 10.1016/j.surg.2009.04.007; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Baki SGA, 2009, BRAIN RES, V1280, P98, DOI 10.1016/j.brainres.2009.05.034; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Brandt C, 2006, NEUROPHARMACOLOGY, V51, P789, DOI 10.1016/j.neuropharm.2006.05.021; Butler LM, 2000, CANCER RES, V60, P5165; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1995, J NEUROSCI, V15, P2030; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dash RR, 2009, J HAZARD MATER, V163, P1, DOI 10.1016/j.jhazmat.2008.06.051; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eleuteri S, 2009, NEUROTOX RES, V15, P127, DOI 10.1007/s12640-009-9013-5; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faraco G, 2006, MOL PHARMACOL, V70, P1876, DOI 10.1124/mol.106.027912; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; Gonzales E, 2006, SHOCK, V25, P395, DOI 10.1097/01.shk.0000209522.28120.c8; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hao YL, 2004, J NEUROSCI, V24, P6590, DOI 10.1523/JNEUROSCI.5747-03.2004; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Jallon P, 2001, DRUG SAFETY, V24, P969, DOI 10.2165/00002018-200124130-00004; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Kanai H, 2004, PHARMACOGENOMICS J, V4, P336, DOI 10.1038/sj.tpj.6500269; Li YQ, 2008, SURGERY, V144, P217, DOI 10.1016/j.surg.2008.03.037; Li YQ, 2010, J SURG RES, V159, P474, DOI 10.1016/j.jss.2009.04.011; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002; McDonald HY, 2005, NEUROSCI LETT, V385, P70, DOI 10.1016/j.neulet.2005.05.022; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Miller JS, 2009, NEUROPHARMACOLOGY, V56, P1116, DOI 10.1016/j.neuropharm.2009.03.006; Miller Laura C, 2008, Expert Rev Neurother, V8, P1817, DOI 10.1586/14737175.8.12.1817; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; Ooba S, 2008, NEUROSCI RES, V62, P195, DOI 10.1016/j.neures.2008.08.005; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ren M, 2004, J NEUROCHEM, V89, P1358, DOI 10.1111/j.1471-4159.2004.02406.x; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Roberge MC, 2008, NEUROSCIENCE, V156, P11, DOI 10.1016/j.neuroscience.2008.05.062; Rosenberg G, 2007, CELL MOL LIFE SCI, V64, P2090, DOI 10.1007/s00018-007-7079-x; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Sharma S, 2005, BRAIN RES BULL, V67, P482, DOI 10.1016/j.brainresbull.2005.07.015; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; Wada A, 2009, J PHARMACOL SCI, V110, P14, DOI 10.1254/jphs.09R02CR; Wada A, 2009, FRONT BIOSCI-LANDMRK, V14, P1558, DOI 10.2741/3324; Watterson JM, 2002, BRAIN RES, V934, P69, DOI 10.1016/S0006-8993(02)02362-4; Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047; Yin D, 2007, CLIN CANCER RES, V13, P1045, DOI 10.1158/1078-0432.CCR-06-1261; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang Z, 2008, CELL MOL LIFE SCI, V65, P4055, DOI 10.1007/s00018-008-8521-4; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007	72	141	149	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2010	5	6							e11383	10.1371/journal.pone.0011383			13	Multidisciplinary Sciences	Science & Technology - Other Topics	618QE	WOS:000279370000013	20614021	DOAJ Gold, Green Published			2021-06-18	
J	Brahm, KD; Wilgenburg, HM; Kirby, J; Ingalla, S; Chang, CY; Goodrich, GL				Brahm, Karen D.; Wilgenburg, Heidi M.; Kirby, Jennine; Ingalla, Shanida; Chang, Chea-Yo; Goodrich, Gregory L.			Visual Impairment and Dysfunction in Combat-injured Servicemembers With Traumatic Brain Injury	OPTOMETRY AND VISION SCIENCE			English	Article						traumatic brain injury; binocular vision; vision disorders; blast injuries; vision screening	IRAQ; WAR; AFGHANISTAN; MILITARY	Purpose. The purpose of this study was to determine the frequencies of visual impairment and dysfunction among combat-injured Polytrauma Rehabilitation Center (PRC) inpatient and Polytrauma Network Site (PNS) outpatient military personnel with traumatic brain injury (TBI). Methods. A retrospective analysis of data from vision screenings of 68 PRC-inpatients with moderate to severe levels of TBI and 124 PNS-outpatients with mild TBI at the VA Palo Alto Health Care System was conducted. Results. Eighty-four percent of PRC-inpatients and 90% of PNS-outpatients had TBIs associated with a blast event. The majority of patients in both the PRC and PNS populations had visual acuities of 20/60 or better (77.8% PRC, 98.4% PNS). Visual dysfunctions (e.g., convergence, accommodative, and oculomotor dysfunction) were common in both PRC and PNS populations. In the PRC-inpatient population, acuity loss of 20/100 to no light perception (13%) and visual field defects (32.3%) were found. In the PNS-outpatient population, acuity loss of 20/100 to no light perception (1.6%) and visual field defects (3.2%) were infrequently found. In both the PRC and PNS populations, visual field defects were more often associated with blast than non-blast events. Conclusions. Blast events were the most frequent mechanism of injury associated with TBI in combat-injured service-members. The vision findings suggest that combat troops exposed to blast with a resulting mild TBI are at risk for visual dysfunction, and combat troops with polytrauma injuries are at risk for visual dysfunction and/or visual impairment. The visual consequences of such injuries necessitate further study and support the need for appropriate evaluation and treatment in all severities of TBI. (Optom Vis Sci 2009;86:817-825)	[Brahm, Karen D.; Wilgenburg, Heidi M.; Kirby, Jennine; Ingalla, Shanida; Chang, Chea-Yo; Goodrich, Gregory L.] VA Palo Alto Hlth Care Syst, Western Blind Rehabil Ctr, Palo Alto, CA 94086 USA	Goodrich, GL (corresponding author), VA Palo Alto Hlth Care Syst, Western Blind Rehabil Ctr 124, 3801 Miranda Ave, Palo Alto, CA 94086 USA.	Gregory.Goodrich@va.gov	Goodrich, Gregory L./AAF-7184-2019		VA Quality and Enhancement Research Initiative [RRP 07-339]	This research was supported in part by a grant from VA Quality and Enhancement Research Initiative (QUERI Grant RRP 07-339) to Gregory Goodrich, PhD.	Ari Adrienne B, 2006, Optometry, V77, P329, DOI 10.1016/j.optm.2006.03.015; Bertone A, 2007, J CLIN EXP NEUROPSYC, V29, P467, DOI 10.1080/13803390600770793; Biehl JW, 1999, MIL MED, V164, P780; Bonnier C, 2007, J CHILD NEUROL, V22, P519, DOI 10.1177/0883073807302604; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; *DEP VET AFF VET H, 2005, VHA HDB 2A; *DEP VET AFF VET H, 2004, TRAUM BRAIN INJ; Department of Veteran's Affairs Veterans Health Administration, 2007, SCREEN EV POSS TRAUM; *DVBICE, 2008, HOM DEF VET HEAD INJ; Freeman EE, 2007, INVEST OPHTH VIS SCI, V48, P4445, DOI 10.1167/iovs.07-0326; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Hofstetter HW., 1944, AM J OPTOM ARCH AM A, V21, P345, DOI [10.1097/00006324-194409000-00001, DOI 10.1097/00006324-194409000-00001]; JENNETT B, 1976, LANCET, V1, P1031; La Piana FG., 1999, OPHTHALMOL CLIN, V12, P421; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LEONARD R, 2000, LIGHTHOUSE HDB VISIO, V2, P1201; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; RAND Corporation, 2008, INV WOUNDS MENT HLTH; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Suchoff Irwin B, 2008, Optometry, V79, P259, DOI 10.1016/j.optm.2007.10.012; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Thach AB, 2008, OPHTHALMOLOGY, V115, P377, DOI 10.1016/j.ophtha.2007.04.032; WAISS B, 1996, REMEDIATION MANAGEME, P59; WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010	25	141	141	0	29	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-5488	1538-9235		OPTOMETRY VISION SCI	Optom. Vis. Sci.	JUL	2009	86	7					817	825		10.1097/OPX.0b013e3181adff2d			9	Ophthalmology	Ophthalmology	463CC	WOS:000267405000005	19521270				2021-06-18	
J	Kreutzer, JS; Rapport, LJ; Marwitz, JH; Harrison-Felix, C; Hart, T; Glenn, M; Hammond, F				Kreutzer, Jeffrey S.; Rapport, Lisa J.; Marwitz, Jennifer H.; Harrison-Felix, Cynthia; Hart, Tessa; Glenn, Mel; Hammond, Flora			Caregivers' Well-Being After Traumatic Brain Injury: A Multicenter Prospective Investigation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Caregivers; Family; Rehabilitation; Stress, psychological	FUNCTIONAL INDEPENDENCE MEASURE; SEVERE HEAD-INJURY; DISABILITY RATING-SCALE; PSYCHOLOGICAL DISTRESS; REHABILITATION; DEPRESSION; RELATIVES; RELIABILITY; PREDICTORS; SYMPTOMS	Objective: To describe frequency and magnitude of caregivers' emotional distress and life satisfaction using standardized assessment procedures; compare distress levels among Spouses, parents, and other caregivers; and identify risk factors. Design: Prospective collaborative cohort study. Setting: Six Traumatic Brain Injury Model System Centers providing neurotrauma care, rehabilitation, and outpatient follow-up. Participants: Caregivers (N=273) of patients who were 1, 2, or 5 years postinjury. Interventions: Acute neurotrauma care, inpatient interdisciplinary brain injury rehabilitation, and postacute services. Main Outcome Measure: Brief Symptom Inventory-18 Depression, Anxiety, and Somatic dimensions. Results: Levels of Depression, Anxiety, and Somatic symptoms were equally prevalent, with 1 in 5 caregivers scoring above the cutoff in each area. ne proportion of participants with 1, 2, and 3 elevations was 17.9%, 5.5%, and 10.6%, respectively. Conversely, approximately two thirds (65.9%) had no scores exceeding cutoffs. Distress levels among spouses, parents, and other caregivers were comparable. Higher caregiver distress was associated with caring for survivors who had worse functional status, received more supervision, were less satisfied with life, and used alcohol excessively. Conclusions: Depression, Anxiety, and Somatic symptoms are common among caregivers. Findings substantiate the importance of clinical care systems addressing the needs of caregivers in the long term as well as survivors.	[Kreutzer, Jeffrey S.; Marwitz, Jennifer H.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Rapport, Lisa J.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Harrison-Felix, Cynthia] Craig Hosp, Englewood, CO USA; [Hart, Tessa] Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, Philadelphia, PA 19107 USA; [Hart, Tessa] Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA; [Glenn, Mel] Spaulding Rehabil Hosp, Boston, MA USA; [Hammond, Flora] Carolinas Rehabil, Charlotte, NC USA	Kreutzer, JS (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980542, Richmond, VA 23298 USA.	jskreutz@vcu.edu			National Institute on Disability and Rehabilitation Research, US Department of EducationUS Department of Education [H133A020516, H133A020509, H133A0205 10, H133A020513]	Supported by the National Institute on Disability and Rehabilitation Research, US Department of Education (grant nos. H133A020516, H133A020509, H133A0205 10, H133A020513).	[Anonymous], 1997, GUIDE UNIFORM DATA S; Armstrong Kira, 2002, Pediatr Rehabil, V5, P149, DOI 10.1080/1363849021000039353; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Campbell C H, 1988, Rehabil Nurs, V13, P320; Centers for Disease Control and Prevention, 1998, BEH RISK FACT SURV S; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; *CRAIG HOSP NAT DA, 2006, TRAUM BRAIN INJ MOD; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Derogatis L.R., 2000, BSI 18 BRIEF SYMPTOM; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Derogatis LR, 1983, SCL 90 ADM SCORING P; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Engli M, 1993, J Neurosci Nurs, V25, P78; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hart T, 2007, J HEAD TRAUMA REHAB, V22, P122, DOI 10.1097/01.HTR.0000265100.37059.44; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marks Jean P, 2006, J Neurosci Nurs, V38, P84; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MINTZ MC, 1995, BRAIN INJURY, V9, P173, DOI 10.3109/02699059509008190; Moules S, 1999, BRAIN INJURY, V13, P983; Nelson DE, 2003, AM J PUBLIC HEALTH, V93, P1335, DOI 10.2105/AJPH.93.8.1335; NOVACK TA, 1992, J HEAD TRAUMA REHAB, V6, P69; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Snaith RP, 1976, LEEDS SCALES SELF AS; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	56	141	142	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2009	90	6					939	946		10.1016/j.apmr.2009.01.010			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	455SW	WOS:000266787000007	19480869				2021-06-18	
J	Wang, HC; Lynch, JR; Song, PP; Yang, HJ; Yales, RB; Mace, B; Warner, DS; Guyton, JR; Laskowitz, DT				Wang, Haichen; Lynch, John R.; Song, Pingping; Yang, Hyuk-Jun; Yales, Robert B.; Mace, Brian; Warner, David S.; Guyton, John R.; Laskowitz, Daniel T.			Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; atorvastatin; simvastatin; nitric oxide interleukin 6; TNF alpha; cerebral blood flow	NITRIC-OXIDE SYNTHASE; CONTROLLED CORTICAL IMPACT; HYPERCHOLESTEROLEMIC PATIENTS; SUBARACHNOID HEMORRHAGE; CIRCULATING MONOCYTES; OPTICAL FRACTIONATOR; NEURONAL SURVIVAL; HEAD-INJURY; RATS; STATINS	The treatment of traumatic brain injury (TBI) remains limited, and aside from surgical hematoma evacuation, clinical management is largely Supportive and directed toward management of cerebral edema and intracranial hypertension. Secondary neuronal injury caused by ischemia and the development of cerebral edema may occur in the subacute phase, with intracranial pressures often peaking in the first several days following injury. Because inflammation contributes significantly to the pathophysiology of cerebral ischemia and endothelial dysfunction underlies the development of cerebral edema, therapeutic strategies that target the post-traumatic inflammatory cascade and reduce endothelial dysfunction hold enormous potential to improve clinical outcomes after TBI. Statins inhibit inflammation by suppressing inflammatory cytokine release, and by interfering with multiple steps of leukocyte recruitment and migration into the CNS. In this study, we demonstrate that treatment with atorvastatin and simvastatin markedly reduced functional neurological deficits after traumatic brain injury in mice. These effects were accompanied by histological reduction in degenerating hippocampal neurons and suppression of inflammatory cytokine mRNA expression in brain parenchyma. Furthermore, statin treatment improved cerebral hemodynamics following head injury. Thus, the administration of statins may represent a viable therapeutic strategy in the acute treatment of closed head injury. (C) 2007 Elsevier Inc. All rights reserved.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Div Endocrinol, Durham, NC 27710 USA; Gachon Med Sch, Gil Med Ctr, Dept Emergency Med, Inchon, South Korea	Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 2900, Durham, NC 27710 USA.	danl@neuro.duke.edu		Guyton, John/0000-0003-0224-7923			Amin-Hanjani S, 2001, STROKE, V32, P980, DOI 10.1161/01.STR.32.4.980; Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; Biros M H, 2001, Curr Opin Crit Care, V7, P444, DOI 10.1097/00075198-200112000-00012; BOTTI RE, 1991, CLIN NEUROPHARMACOL, V14, P256, DOI 10.1097/00002826-199106000-00010; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Cucchiara B, 2001, J NEUROL SCI, V187, P81, DOI 10.1016/S0022-510X(01)00529-9; DALKARA T, 1994, NEUROPHARMACOLOGY, V33, P1447, DOI 10.1016/0028-3908(94)90048-5; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Finkelstein EA., 2006, INCIDENCE EC BURDEN; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Lefer AM, 2001, CARDIOVASC RES, V49, P281, DOI 10.1016/S0008-6363(00)00247-9; Lennernas H, 2003, CLIN PHARMACOKINET, V42, P1141, DOI 10.2165/00003088-200342130-00005; Lennernas H, 1997, CLIN PHARMACOKINET, V32, P403, DOI 10.2165/00003088-199732050-00005; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu DY, 2004, J NEUROSURG, V101, P822, DOI 10.3171/jns.2004.101.5.0822; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2005, STROKE, V36, P2024, DOI 10.1161/01.STR.0000177879.11607.10; McGirt MJ, 2002, STROKE, V33, P2950, DOI 10.1161/01.STR.0000038986.68044.39; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Rezaie-Majd A, 2003, ARTERIOSCL THROM VAS, V23, P397, DOI 10.1161/01.ATV.0000059384.34874.F0; Rezaie-Majd A, 2002, ARTERIOSCL THROM VAS, V22, P1194, DOI 10.1161/01.ATV.0000022694.16328.CC; Rikitake Y, 2005, CIRC RES, V97, P1232, DOI 10.1161/01.RES.0000196564.18314.23; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Sironi L, 2003, ARTERIOSCL THROM VAS, V23, P322, DOI 10.1161/01.ATV.0000044458.23905.3B; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; Tsuchiya D, 2003, BRAIN RES, V970, P131, DOI 10.1016/S0006-8993(03)02300-X; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; West MJ, 1996, J COMP NEUROL, V370, P11; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021	41	141	146	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	2007	206	1					59	69		10.1016/j.expneurol.2007.03.031			11	Neurosciences	Neurosciences & Neurology	187CN	WOS:000247825000009	17521631				2021-06-18	
J	Schnebel, B; Gwin, JT; Anderson, S; Gatlin, R				Schnebel, Brock; Gwin, Joseph T.; Anderson, Scott; Gatlin, Ron			In vivo study of head impacts in football: A comparison of national collegiate athletic association division I versus high school impacts	NEUROSURGERY			English	Article						concussion; football; head impact biomechanics; impact tolerance; mild traumatic brain injury; sports injury prevention	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; PLAYERS; ACCELERATION	OBJECTIVE: To compare the frequency and magnitude of head impacts between National Collegiate Athletic Association Division I and American high school football players. The long-term goal is to correlate impact. forces with injury patterns, leading to improvements in protective headgear. METHODS: The helmets of football players at the University of Oklahoma (n = 40) and Casady High School (n = 16) were instrumented with the Head Impact Telemetry System (Simbex, Lebanon, NH). Data were collected for practices and games for the 2005 football season and were analyzed by player position and school. Player positions were separated into two groups (skill and line) for analysis. Two case studies of athletes who sustained a concussion are also presented. RESULTS: A total of 54,154 impacts were recorded at the University of Oklahoma and 8326 at Casady High School. College players sustained high-level impacts greater than 98 g more frequently than high school players. The mean linear accelerations for the top 1, 2, and 5% of all impacts were also higher for college players (P < 0.02). Skill position players received 24.6% of all impacts and sustained an impact greater than 98 g once every 70 impacts. In contrast, linemen sustained the highest number of impacts, but most were relatively low-magnitude (20-30 g). Linemen sustained an impact greater than 98 g once every 125 impacts. CONCLUSION: Differences in the frequency and magnitude of head acceleration after impact exist between a Division I college team and a high school team. Compared with linemen, skill position players typically sustain the highest-level impacts. Additional data collection and analysis are required to correlate concussion diagnosis with acceleration magnitude and impact location.	Univ Oklahoma, Dept Orthoped, Norman, OK 73019 USA; Univ Oklahoma, Dept Athlet, Norman, OK 73019 USA; Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; Univ Oklahoma, Dept Intercollegiate Athlet, Norman, OK 73019 USA; Casady High Sch, Dept Athlet, Oklahoma City, OK USA	Schnebel, B (corresponding author), McBride Clin, 1110 N Lee Ave, Oklahoma City, OK 73103 USA.	bschnebel@mcbrideclinic.com					BANDAK FA, 1994, SAE279; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; CANTU R, 2000, NEUROLOGIC ATHLETIC, P80; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; GUSKIEWICZ KM, 2004, AM J MED SPORTS, V6, P13; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; NUSHOLTZ G, 1993, BIOMECH IMPACT INJUR, P159; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 1999, J ATHL TRAINING, V34, P277	21	141	141	2	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAR	2007	60	3					490	495		10.1227/01.NEU.0000249286.92255.7F			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	144LH	WOS:000244797000014	17327793				2021-06-18	
J	Kleindienst, A; McGinn, MJ; Harvey, HB; Colello, RJ; Hamm, RJ; Bullock, MR				Kleindienst, A; McGinn, MJ; Harvey, HB; Colello, RJ; Hamm, RJ; Bullock, MR			Enhanced hippocampal neurogenesis by intraventricular S100B infusion is associated with improved cognitive recovery after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						differentiation; hippocampus; neurotrophic; proliferation; regeneration; S100B; trauma	TRANSIENT GLOBAL-ISCHEMIA; MARROW STROMAL CELLS; ADULT HIPPOCAMPUS; DENTATE GYRUS; ENVIRONMENTAL ENRICHMENT; PROGENITOR CELLS; S-100 PROTEIN; GRANULE CELLS; RAT; PROLIFERATION	Evidence of injury-induced neurogenesis in the adult hippocampus suggests that an endogenous repair mechanism exists for cognitive dysfunction following traumatic brain injury (TBI). One factor that may be associated with this restoration is S100B, a neurotrophic/mitogenic protein produced by astrocytes, which has been shown to improve memory function. Therefore, we examined whether an intraventricular S100B infusion enhances neurogenesis within the hippocampus following experimental TBI and whether the biological response can be associated with a measurable cognitive improvement. Following lateral fluid percussion or sham injury in male rats (n = 60), we infused S100B (50 ng/h) or vehicle into the lateral ventricle for 7 days using an osmotic micro-pump. Cell proliferation was assessed by injecting the mitotic marker bromodeoxyuridine (BrdU) on day 2 post-injury. Quantification of BrdU-immunoreactive cells in the dentate gyrus revealed an S100B-enhanced proliferation as assessed on day 5 post-injury (p < 0.05), persisting up to 5 weeks (p < 0.05). Using cell-specific markers, we determined the relative numbers of these progenitor cells that became neurons or glia and found that S100B profoundly increased hippocampal neurogenesis 5 weeks after TBI (p < 0.05). Furthermore, spatial learning ability, as assessed by the Morris water maze on day 30-34 post-injury, revealed an improved cognitive performance after S100B infusion (P < 0.05). Collectively, our findings indicate that an intraventricular S100B infusion induces neurogenesis within the hippocampus, which can be associated with an enhanced cognitive function following experimental TBI. These observations provide compelling evidence for the therapeutic potential of S100B in improving functional recovery following TBI.	Univ Gottingen, Dept Neurosurg, D-37075 Gottingen, Germany; Virginia Commonwealth Univ, Ctr Med, Dept Neurosurg, Richmond, VA USA; Virginia Commonwealth Univ, Ctr Med, Dept Anat & Neurobiol, Richmond, VA USA; Virginia Commonwealth Univ, Ctr Med, Dept Psychol, Richmond, VA USA	Kleindienst, A (corresponding author), Univ Gottingen, Dept Neurosurg, Robert Koch Str 40, D-37075 Gottingen, Germany.	andrea.kleindienst@med.uni-goettingen.de	Kleindienst, Andrea/F-1674-2014	Kleindienst, Andrea/0000-0003-4758-0324			Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Brewton LS, 2001, BRAIN RES, V912, P9, DOI 10.1016/S0006-8993(01)02519-7; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fazeli M S, 1990, Adv Exp Med Biol, V268, P369; Goncalves DS, 2000, NEUROREPORT, V11, P807, DOI 10.1097/00001756-200003200-00030; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Gould E, 2002, J NEUROSCI, V22, P619, DOI 10.1523/JNEUROSCI.22-03-00619.2002; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Iwasaki Y, 1997, J NEUROL SCI, V151, P7, DOI 10.1016/S0022-510X(97)00073-7; Kawai T, 2004, J CEREBR BLOOD F MET, V24, P548, DOI 10.1097/00004647-200405000-00009; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; KLEIN JR, 1989, CANCER IMMUNOL IMMUN, V29, P133; Kleindienst A, 2004, J NEUROTRAUM, V21, P541, DOI 10.1089/089771504774129874; Komitova M, 2002, J CEREBR BLOOD F MET, V22, P852, DOI 10.1097/00004647-200207000-00010; Kornack DR, 2001, P NATL ACAD SCI USA, V98, P4752, DOI 10.1073/pnas.081074998; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Landar A, 1996, CELL CALCIUM, V20, P279, DOI 10.1016/S0143-4160(96)90033-0; Li YK, 1998, J NEUROCHEM, V71, P1421; Liu JL, 1998, J NEUROSCI, V18, P7768; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Magavi SS, 2000, NATURE, V405, P951; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Nishi M, 1997, NEUROSCI LETT, V229, P212, DOI 10.1016/S0304-3940(97)00443-6; Nottebohm F, 2002, J NEUROSCI, V22, P624, DOI 10.1523/JNEUROSCI.22-03-00624.2002; ODowd BS, 1997, NEUROBIOL LEARN MEM, V67, P197, DOI 10.1006/nlme.1997.3766; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; RICKMANN M, 1995, BRAIN RES, V688, P8, DOI 10.1016/0006-8993(95)00495-C; Schmidt-Hieber C, 2004, NATURE, V429, P184, DOI 10.1038/nature02553; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; Sharp FR, 2002, DEV BRAIN RES, V134, P23, DOI 10.1016/S0165-3806(01)00286-3; SHASHOUA VE, 1984, J NEUROCHEM, V42, P1536, DOI 10.1111/j.1471-4159.1984.tb12739.x; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Souza TME, 2000, PHYSIOL BEHAV, V71, P29, DOI 10.1016/S0031-9384(00)00299-7; Takasawa K, 2002, J CEREBR BLOOD F MET, V22, P299, DOI 10.1097/00004647-200203000-00007; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; WHITAKERAZMITIA PM, 1990, BRAIN RES, V528, P155, DOI 10.1016/0006-8993(90)90210-3; Wilder PT, 1998, PROTEIN SCI, V7, P794, DOI 10.1002/pro.5560070330; Yagita Y, 2001, STROKE, V32, P1890, DOI 10.1161/01.STR.32.8.1890; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	64	141	146	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2005	22	6					645	655		10.1089/neu.2005.22.645			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	936EN	WOS:000229838400004	15941374				2021-06-18	
J	Yeates, KO; Armstrong, K; Janusz, J; Taylor, HG; Wade, S; Stancin, T; Drotar, D				Yeates, KO; Armstrong, K; Janusz, J; Taylor, HG; Wade, S; Stancin, T; Drotar, D			Long-term attention problems in children with traumatic brain injury	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article; Proceedings Paper	Annual Meeting of the International-Neuropsychological-Society	FEB, 2001	Chicago, IL	Int Neuropsychol Soc		traumatic brain injury; attention; outcomes children	CLOSED-HEAD-INJURY; DEFICIT HYPERACTIVITY DISORDER; DEFICIT/HYPERACTIVITY DISORDER; PSYCHIATRIC-DISORDERS; RESPONSE-INHIBITION; BEHAVIOR; CHILDHOOD; ADHD; IMPAIRMENTS; PREVALENCE	Objective: To examine long-term attention problems and their cognitive correlates after childhood traumatic brain injury (TBI). Method: Data were drawn from a prospective, longitudinal study conducted between 1992 and 2002. Participants included 41 children with severe TBI, 41 with moderate TBI, and 50 with orthopedic injury (OI), who were all between 6 and 12 years of age at the time of injury. Parent ratings of attention problems were obtained at a long-term follow-up on average 4 years post-injury and compared with ratings of premorbid attention problems obtained shortly after injury. At the long-term follow-up, children also completed several cognitive tests of attention and executive functions. Results: Hierarchical linear and logistic regression analyses indicated that the severe TBI group displayed significantly more attention problems than the OI group at 4 years post-injury, both behaviorally and cognitively, after controlling for race, socioeconomic status, and premorbid attention problems. At long-term follow-up, 46% of the severe TBI group displayed significant attention problems on the Child Behavior Checklist, as opposed to 26% of the OI group (odds ratio = 3.38; 95% confidence interval, 1.15-9.94). On the Attention-Deficit/Hyperactivity Disorder Rating Scale, 20% of the severe TBI group displayed clinically significant attention problems compared with 4% in the OI group (odds ratio = 9.59; 95% confidence interval, 1.24-73.99). However, group differences in behavioral symptoms were significantly larger for children with more premorbid symptoms than for children with fewer premorbid problems. Measures of executive functions were significantly related to behavioral attention problems, after controlling for group membership, race, and socioeconomic status. Conclusions: Childhood TBI exacerbates premorbid attention problems. Long-term behavioral symptoms of attention problems are related to the cognitive deficits in attention and executive functions that often occur in association with childhood TBI.	Childrens Hosp, Dept Psychol, Columbus, OH 43220 USA; Ohio State Univ, Dept Pediat, Columbus, OH USA; Columbus Childrens Res Inst, Columbus, OH USA; Case Western Reserve Univ & Rainbow Babies, Dept Pediat, Cleveland, OH 44106 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; Childrens Hosp, Med Ctr, Dept Phys Med & Rehabil, Cincinnati, OH USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH USA; MetroHlth Med Ctr, Cleveland, OH USA	Yeates, KO (corresponding author), Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43220 USA.	yeatesk@chi.osu.edu	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Janusz, Jennifer/0000-0002-6877-0947; Yeates, Keith/0000-0001-7680-2892	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01 NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ 390611] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; *AM PSYCH ASS, 1994, DIATN STAT MAN MENT; Anderson P., 2000, CLIN NEUROPSYCHOL AS, V1, P247, DOI DOI 10.1076/chin.8.4.231.13509; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson VA, 2004, J CLIN EXP NEUROPSYC, V26, P684, DOI 10.1080/13803390490504344; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Barkley R. A., 1994, FRAMES REFERENCE ASS, P69; Barkley RA, 2004, J CHILD PSYCHOL PSYC, V45, P195, DOI 10.1111/j.1469-7610.2004.00214.x; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Berquin PC, 1998, NEUROLOGY, V50, P1087, DOI 10.1212/WNL.50.4.1087; BIEDERMAN J, 1993, J CHILD PSYCHOL PSYC, V34, P1241, DOI 10.1111/j.1469-7610.1993.tb01785.x; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Boyle MH, 1997, ARCH GEN PSYCHIAT, V54, P793; Casey BJ, 1997, J AM ACAD CHILD PSY, V36, P374, DOI 10.1097/00004583-199703000-00016; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P339, DOI 10.1080/01688639408402644; Connor PD, 2000, DEV NEUROPSYCHOL, V18, P331, DOI 10.1207/S1532694204Connor; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; Dennis M, 2000, SCI PRACT NEUROPSYCH, P3; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Doyle AE, 2000, J CONSULT CLIN PSYCH, V68, P477, DOI [10.1037//0022-006X.68.3.477, 10.1037/0022-006X.68.3.477]; DUPAUL GJ, 1991, J CLIN CHILD PSYCHOL, V20, P245, DOI 10.1207/s15374424jccp2003_3; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; Faries DE., 2001, J ATTENTION DISORDER, V5, P107, DOI DOI 10.1177/108705470100500204; Fenwick T, 1999, CHILD NEUROPSYCHOL, V5, P213, DOI 10.1076/0929-7049(199912)05:04;1-R;FT213; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1910, FRAMES REFERENCE ASS; FRANCIS DJ, 1994, NEUROPSYCHOL REV, V4, P199, DOI 10.1007/BF01874892; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Grodzinsky GM, 1999, CLIN NEUROPSYCHOL, V13, P12, DOI 10.1076/clin.13.1.12.1983; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Konrad KN, 2000, BRAIN INJURY, V14, P859; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1997, BRAIN INJURY, V11, P699; MCCLELLAND GH, 1993, PSYCHOL BULL, V114, P376, DOI 10.1037/0033-2909.114.2.376; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Mostofsky SH, 1998, J CHILD NEUROL, V13, P434, DOI 10.1177/088307389801300904; Paniak C, 1997, CLIN NEUROPSYCHOL, V11, P198, DOI 10.1080/13854049708407051; Reid R., 1998, ADHD RATING SCALE 4; ROURKE BP, 1977, J ABNORM CHILD PSYCH, V5, P9, DOI 10.1007/BF00915756; Sattler J.M., 2001, ASSESSMENT CHILDREN, V4th edn; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Vriezen ER, 2000, BRAIN COGNITION, V44, P67; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Wassenberg R, 2004, BRAIN INJURY, V18, P377, DOI 10.1080/02699050310001617325; Wechsler D., 1991, WECHSLER INTELLIGENC; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilens TE, 2002, ANNU REV MED, V53, P113, DOI 10.1146/annurev.med.53.082901.103945; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763	69	141	141	0	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0890-8567	1527-5418		J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	JUN	2005	44	6					574	584		10.1097/01.chi.0000159947.50523.64			11	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	928BH	WOS:000229245600012	15908840				2021-06-18	
J	Rieger, M; Gauggel, S; Burmeister, K				Rieger, M; Gauggel, S; Burmeister, K			Inhibition of ongoing responses following frontal, nonfrontal, and basal ganglia lesions	NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; NO-GO REACTION; CARD SORTING TEST; ATTENTION DEFICIT/HYPERACTIVITY DISORDER; PREFRONTAL UNIT-ACTIVITY; PARKINSONS-DISEASE; HAND MOVEMENT; COLOR DISCRIMINATION; FUNCTIONAL MRI; CORTEX	The authors investigated the role of the frontal lobes and the basal ganglia in the inhibition of ongoing responses. Seventeen patients with frontal lesions (FG), 20 patients with lesions outside the frontal cortex (NFG), 8 patients with lesions to the basal ganglia (BG), and 20 orthopedic controls (OG) performed the stop-signal task that allows the estimation of the time it takes to inhibit an ongoing reaction (stop signal reaction time [SSRT]). The FG and the BG showed significantly longer SSRTs than the OG. Within the FG, patients with right and bilateral lesions showed significantly longer SSRTs than patients with left lesions. Results provide evidence for a role of the frontal lobes and the basal ganglia in the inhibition of ongoing responses.	Univ Marburg, Dept Psychol, D-3550 Marburg, Germany	Rieger, M (corresponding author), Max Planck Inst Psychol Res Cognit & Act, Amalienstr 33, D-80799 Munich, Germany.	rieger@mpipf-muenchen.mpg.de		Gauggel, Siegfried/0000-0002-2742-4917			ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ALIVISATOS B, 1989, NEUROPSYCHOLOGIA, V27, P495, DOI 10.1016/0028-3932(89)90054-7; APICELLA P, 1992, J NEUROPHYSIOL, V68, P945; Band GPH, 1999, ACTA PSYCHOL, V101, P179, DOI 10.1016/S0001-6918(99)00005-0; BAND GPH, 1997, PREPARATION ADJUSTME; BRUNIA CHM, 1993, PSYCHOPHYSIOLOGY, V30, P327, DOI 10.1111/j.1469-8986.1993.tb02054.x; Casey BJ, 1997, J COGNITIVE NEUROSCI, V9, P835, DOI 10.1162/jocn.1997.9.6.835; Casey BJ, 2001, CARN S COGN, P327; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COOPER JA, 1994, BRAIN, V117, P517, DOI 10.1093/brain/117.3.517; Damasio H., 1989, LESION ANAL NEUROPSY; DAUM I, 1995, CORTEX, V31, P413, DOI 10.1016/S0010-9452(13)80057-3; DECARY A, 1995, NEUROPSYCHOLOGIA, V33, P1243, DOI 10.1016/0028-3932(95)00040-A; DELANGEN EG, 1995, REHABILITATION, V34, P9; deZubicaray G, 1996, CLIN NEUROPSYCHOL, V10, P245, DOI 10.1080/13854049608406687; Dimitrov M, 1999, NEUROPSYCHOLOGY, V13, P135, DOI 10.1037/0894-4105.13.1.135; DREWE E A, 1975, Cortex, V11, P8; DREWE EA, 1975, NEUROPSYCHOLOGIA, V13, P421, DOI 10.1016/0028-3932(75)90065-2; ESLINGER PJ, 1993, NEUROPSYCHOLOGIA, V31, P17, DOI 10.1016/0028-3932(93)90077-D; Falkenstein M, 1999, ACTA PSYCHOL, V101, P267, DOI 10.1016/S0001-6918(99)00008-6; FUSTER JM, 1985, HUM NEUROBIOL, V4, P169; Fuster JM, 1999, ACTA PSYCHIAT SCAND, V99, P51, DOI 10.1111/j.1600-0447.1999.tb05983.x; GEMBA DH, 1989, NEUROSCI LETT, V101, P263, DOI 10.1016/0304-3940(89)90543-0; GEMBA H, 1990, BRAIN RES, V537, P340, DOI 10.1016/0006-8993(90)90382-L; GOLDMANRAKIC PS, 1987, COGNITIVE NEUROCHEMI, P90; HEUBROCK D, 1995, EUR J PSYCHOL ASSESS, V11, P21, DOI 10.1027/1015-5759.11.1.21; Heubrock D, 1992, Z DIFFERENTIELLE DIA, V3, P161; Jahanshahi M, 1998, COGN NEUROPSYCHOL, V15, P483, DOI 10.1080/026432998381005; KAERNBACH C, 1991, PERCEPT PSYCHOPHYS, V49, P227, DOI 10.3758/BF03214307; KALASKA JF, 1995, CEREB CORTEX, V5, P410, DOI 10.1093/cercor/5.5.410; Kawashima R, 1996, BRAIN RES, V728, P79, DOI 10.1016/0006-8993(96)00389-7; KEITH RA, 1987, ADV CLIN REHABILITAT, P6; Kiefer M, 1998, NEUROREPORT, V9, P765, DOI 10.1097/00001756-199803090-00037; KOK A, 1986, BIOL PSYCHOL, V23, P21, DOI 10.1016/0301-0511(86)90087-6; Konishi S, 1999, BRAIN, V122, P981, DOI 10.1093/brain/122.5.981; Konishi S, 1998, EUR J NEUROSCI, V10, P1209, DOI 10.1046/j.1460-9568.1998.00167.x; Konrad K, 2000, CHILD NEUROPSYCHOL, V6, P286, DOI 10.1076/chin.6.4.286.3145; Konrad KN, 2000, BRAIN INJURY, V14, P859; Kropotov JD, 1999, INT J PSYCHOPHYSIOL, V31, P197, DOI 10.1016/S0167-8760(98)00051-8; LAPPIN JS, 1966, J EXP PSYCHOL, V72, P805, DOI 10.1037/h0021266; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LHERMITTE F, 1983, BRAIN, V106, P237, DOI 10.1093/brain/106.2.237; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Logan GD., 1981, ATTENTION PERFORMANC, P205; Logan Gordon D., 1994, P189; McGarry T, 1997, J EXP PSYCHOL HUMAN, V23, P1533, DOI 10.1037//0096-1523.23.5.1533; Milner B, 1964, FRONTAL GRANULAR COR, P313; Mink JW, 1996, PROG NEUROBIOL, V50, P381, DOI 10.1016/S0301-0082(96)00042-1; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Partiot A, 1996, NEUROPSYCHOLOGIA, V34, P709, DOI 10.1016/0028-3932(95)00143-3; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; PFEFFERBAUM A, 1985, ELECTROEN CLIN NEURO, V60, P423, DOI 10.1016/0013-4694(85)91017-X; Rieger M, 2002, NEUROPSYCHOLOGIA, V40, P76, DOI 10.1016/S0028-3932(01)00068-9; SASAKI K, 1986, EXP BRAIN RES, V64, P603, DOI 10.1007/BF00340499; SASAKI K, 1989, BRAIN RES, V495, P100, DOI 10.1016/0006-8993(89)91222-5; SCHACHAR R, 1990, DEV PSYCHOL, V26, P710, DOI 10.1037/0012-1649.26.5.710; SCHACHAR RJ, 1993, CLIN PSYCHOL REV, V13, P721, DOI 10.1016/S0272-7358(05)80003-0; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Stefanova ED, 2001, J CLIN EXP NEUROPSYC, V23, P581, DOI 10.1076/jcen.23.5.581.1239; Stewart JAL, 1999, BRAIN COGNITION, V41, P411, DOI 10.1006/brcg.1999.1141; Sturm W., 1993, LEISTUNGSPRUFSYSTEM; Sturm W, 1983, DIAGNOSTICA, V29, P346; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Tabachnick BG, 2013, USING MULTIVARIATE S; Truong MK, 1993, SHORT WISCONSIN CARD; Vallar G, 1999, HDB CLIN EXPT NEUROP, P95; VERFAELLIE M, 1987, ARCH NEUROL-CHICAGO, V44, P1265, DOI 10.1001/archneur.1987.00520240045010; WATANABE M, 1986, BRAIN RES, V382, P1, DOI 10.1016/0006-8993(86)90104-6; WATANABE M, 1986, BRAIN RES, V382, P15, DOI 10.1016/0006-8993(86)90105-8; WECHSLER D, 1987, WMSR WECHSLER MEMORY; Wichmann T, 1996, CURR OPIN NEUROBIOL, V6, P751, DOI 10.1016/S0959-4388(96)80024-9; Williams BR, 1999, DEV PSYCHOL, V35, P205, DOI 10.1037/0012-1649.35.1.205; Zakzanis KK, 1998, J CLIN EXP NEUROPSYC, V20, P419, DOI 10.1076/jcen.20.3.419.821	76	141	142	2	21	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	APR	2003	17	2					272	282		10.1037/0894-4105.17.2.272			11	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	682JX	WOS:000183089400011	12803433				2021-06-18	
J	Yeates, KO; Taylor, HG; Wade, SL; Drotar, D; Stancin, T; Minich, N				Yeates, KO; Taylor, HG; Wade, SL; Drotar, D; Stancin, T; Minich, N			A prospective study of short- and long-term neuropsychological outcomes after traumatic brain injury in children	NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; RECOVERY; FAMILY; SEVERITY; BEHAVIOR; CT; PREVALENCE; PREDICTORS; CHILDHOOD; ATTENTION	Longitudinal neuropsychological outcomes of traumatic brain injury (TBI) were investigated in 53 children with severe TBI, 56 children with moderate TBI, and 80 children with orthopedic injuries only. Neuropsychological functioning was assessed at baseline, at 6- and 12-month follow-ups, and at an extended follow-up (a mean of 4 years postinjury). Mixed model analyses revealed persistent neuropsychological sequelae of TBI that generally did not vary as a function of time postinjury. Some recovery occurred during the first year postinjury, but recovery reached a plateau after that time, and deficits were still apparent at the extended follow-up. Further recovery was uncommon after the first year postinjury. Family factors did not moderate neuropsychological outcomes, despite their demonstrated influence on behavior and academic achievement after childhood TBI.	Childrens Hosp, Dept Psychol, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; Childrens Hosp, Med Ctr, Dept Phys Med & Rehabil, Cincinnati, OH 45229 USA; Metrohlth Med Ctr, Dept Pediat, Cleveland, OH 44109 USA	Yeates, KO (corresponding author), Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43205 USA.	yeates.1@osu.edu	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER		Anderson P., 2000, CLIN NEUROPSYCHOL AS, V1, P247, DOI DOI 10.1076/chin.8.4.231.13509; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BEERY KE, 1989, REVISED ADM SCORING; BURCHINAL MR, 1994, J EARLY INTERVENTION, V18, P403, DOI 10.1177/105381519401800409; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P339, DOI 10.1080/01688639408402644; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; DELIS D, 1986, CALIFORNIA VERBAL LE; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; FRANCIS DJ, 1994, NEUROPSYCHOL REV, V4, P199, DOI 10.1007/BF01874892; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Landry SH, 1997, DEV PSYCHOL, V33, P1040, DOI 10.1037/0012-1649.33.6.1040; LINDGREN S, 1984, PEDIAT ASSESSMENT CO; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MCDERMOTT PA, 1995, J SCHOOL PSYCHOL, V33, P75, DOI 10.1016/0022-4405(94)00025-4; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Moos R, 1994, LIFE STRESSORS SOCIA; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; ROURKE BP, 1977, J ABNORM CHILD PSYCH, V5, P9, DOI 10.1007/BF00915756; *SAS I, 1990, STAT AN SYST VERS 6; SEMEL E, 1987, CELF R CLIN EV LANG; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spreen O., 1991, COMPENDIUM NEUROPSYC; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor HG, 1998, CHILD NEUROPSYCHOL, V4, P21, DOI 10.1076/chin.4.1.21.3188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1992, CLIN NEUROPSYCHOL, V6, P259; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V3, P1; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Wechsler D., 1991, WISC 3 WECHSLER INTE; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; YEATES KO, 1994, CLIN NEUROPSYCHOL, V8, P91, DOI 10.1080/13854049408401546; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215	56	141	143	0	25	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	2002	16	4					514	523		10.1037//0894-4105.16.4.514			10	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	601HR	WOS:000178440800007	12382990				2021-06-18	
J	Zemlan, FP; Jauch, EC; Mulchahey, JJ; Gabbita, SP; Rosenberg, WS; Speciale, SG; Zuccarello, M				Zemlan, FP; Jauch, EC; Mulchahey, JJ; Gabbita, SP; Rosenberg, WS; Speciale, SG; Zuccarello, M			C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome	BRAIN RESEARCH			English	Article						brain trauma; biomarker; MAP-tau	SEVERE HEAD-INJURY; NEUROPROTECTIVE AGENTS; AXONAL INJURY; TRIAL; MULTICENTER; HYPOTHERMIA; NIMODIPINE; EFFICACY	Following traumatic brain injury, the neuronally-localized intracellular protein MAP-tau is proteolytically cleaved (C-tau) and gains access to cerebrospinal fluid (CSF) and serum. The present study compared initial CSF C-tau levels, initial Glasgow Coma Scale (GCS) scores and elevated intracranial pressure (ICP) as predictors of clinical outcome. In this preliminary, prospective study of consecutive severe traumatic brain injured patients (TBI) clinical outcome was quantified with the Glasgow Outcome Scale (GOS) at discharge (n=28). Sensitivity and specificity of initial C-tau levels,and initial GCS scores as predictors of clinical outcome is reported. To assess disease specificity C-tau levels were compared between TBI patients and neurologic (n=87) and non-neurologic control patients (n=67). Initial CSF C-tau levels were elevated 40,000 fold in TBI patients compared to either neurologic or non-neurologic control patients (P<0.001). Initial C-tau levels were correlated with clinical outcome (P=0.006) and were a significant predictor of dichotomized clinical outcome (P=0.011) demonstrating a sensitivity of prediction of 92% and a specificity of 94%. Initial C-tau levels were also a significant predictor of subsequent ICP with higher initial C-tau levels associated with elevated ICP (P=0.014). Initial GCS score were correlated with clinical outcome (P=0.026) and demonstrated a sensitivity of 50% and a specificity of 100% for predicting dichotomized clinical outcome. Statistical analysis indicated that initial C-tau levels and initial GCS scores were independent predictors of clinical outcome. The present preliminary study demonstrates that initial CSF C-tau levels are a significant predictor of ICP and clinical outcome with particular sensitivity for identifying severe TBI patients with good clinical outcome. Future studies employing a larger sample size and clinical outcome assessment at longer periods after hospitalization will be needed to determine the utility of initial C-tau levels as a clinical biomarker in TBI. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Emergency Med, Cincinnati, OH USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX USA; Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA	Zemlan, FP (corresponding author), Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA.			Jauch, Edward/0000-0002-3533-4364			ALVES WM, 1996, NEUROTRAUMA, P947; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHATFIELD DA, IN PRESS BR J NEUROS; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1996, NEUROTRAUMA, P779; DOBBENBERG EM, 1997, ANN NY ACAD SCI, V825, P305; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; GENTRY LR, 1994, RADIOLOGY, V191, P1; GRAHAM DI, 1985, BRIT J ANAESTH, V57, P3, DOI 10.1093/bja/57.1.3; Griner P F, 1981, Ann Intern Med, V94, P557; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Irazuzta JE, 2000, BRAIN RES, V881, P88, DOI 10.1016/S0006-8993(00)02894-8; IRAZUZTA JE, IN PRESS BRAIN RES; KOSIK KS, 1987, J NEUROSCI, V7, P3142; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Maxwell WL, 1999, J NEUROTRAUM, V16, P1225, DOI 10.1089/neu.1999.16.1225; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; PETTUS EH, 1996, BRAIN RES, V772, P1; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; SEGAL MB, 1993, J INHERIT METAB DIS, V16, P617, DOI 10.1007/BF00711896; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; STRAW RN, 1995, P27000017 N AM STUD; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zemlan FP, 1999, J NEUROCHEM, V73, P437; ZEMLAN FP, 1999, J NEUROTRAUM, V16, P960	37	141	147	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 23	2002	947	1					131	139	PII S0006-8993(02)02920-7	10.1016/S0006-8993(02)02920-7			9	Neurosciences	Neurosciences & Neurology	589PR	WOS:000177769400016	12144861				2021-06-18	
J	Pike, BR; Flint, J; Dutta, S; Johnson, E; Wang, KKW; Hayes, RL				Pike, BR; Flint, J; Dutta, S; Johnson, E; Wang, KKW; Hayes, RL			Accumulation of non-erythroid alpha II-spectrin and calpain-cleaved alpha II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats	JOURNAL OF NEUROCHEMISTRY			English	Article						calpain; caspase-3; cell death; cerebrospinal fluid; spectrin; traumatic brain injury	PRIMARY SEPTOHIPPOCAMPAL CULTURES; CORTICAL IMPACT INJURY; SERUM S-100B PROTEIN; SEVERE HEAD-INJURY; CELL-DEATH; NEURONAL APOPTOSIS; CASPASE-3 ACTIVATION; DNA FRAGMENTATION; TEMPORAL PROFILE; AXONAL INJURY	Although a number of increased CSF proteins have been correlated with brain damage and outcome after traumatic brain injury (TBI), a major limitation of currently tested biomarkers is a lack of specificity for defining neuropathological cascades. Identification of surrogate biomarkers that are elevated in CSF in response to brain injury and that offer insight into one or more pathological neurochemical events will provide critical information for appropriate administration of therapeutic compounds for treatment of TBI patients. Nonerythroid all-spectrin is a cytoskeletal protein that is a substrate of both calpain and caspase-3 cysteine proteases. As we have previously demonstrated, cleavage of all-spectrin by calpain and caspase-3 results in accumulation of protease-specific spectrin breakdown products (SBDPs) that can be used to monitor the magnitude and temporal duration of protease activation. However, accumulation of all-spectrin and alpha II-SBDPs in CSF after TBI has never been examined. Following a moderate level (2.0 mm) of controlled cortical impact TBI in rodents, native alpha II-spectrin protein was decreased in brain tissue and increased in CSF from 24 h to 72 h after injury. In addition, calpain-specific SBDPs were observed to increase in both brain and CSF after injury. Increases in the calpain-specific 145 kDa SBDP in CSF were 244%, 530% and 665% of sham-injured control animals at 24 h, 48 h and 72 h after TBI, respectively. The caspase-3-specific SBDP was observed to increase in CSF in some animals but to a lesser degree. Importantly, levels of these proteins were undetectable in CSF of uninjured control rats. These results indicate that detection of alpha II-spectrin and alpha II-SBDPs is a powerful discriminator of outcome and protease activation after TBI. In accord with our previous studies, results also indicate that calpain may be a more important effector of cell death after moderate TBI than caspase-3.	Univ Florida, Dept Neurosci, Evelyn F & William L Mc Knight Brain Inst, Gainesville, FL 32611 USA; Pfizer Inc, Dept Neurosci Therapeut, Ann Arbor, MI USA	Pike, BR (corresponding author), Univ Florida, Dept Neurosci, Evelyn F & William L Mc Knight Brain Inst, 100 S Newell Dr,Box 100244, Gainesville, FL 32611 USA.			Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039091, F32NS010857, R01NS040182] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32-NS10857, R01 NS39091, R01 NS40182] Funding Source: Medline		Allen JW, 1999, FASEB J, V13, P1875; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Buki A, 2000, J NEUROSCI, V20, P2825; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GOODMAN JC, 1996, NEUROTRAUMA, P577; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; Linnik MD, 1996, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1996, P33; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; MARION DW, 1996, NEUROTRAUMA, P767; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Nath R, 2000, NEUROCHEM INT, V36, P119, DOI 10.1016/S0197-0186(99)00112-6; Nath R, 1998, J NEUROCHEM, V71, P186; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NEWCOMB JK, 1998, J NEUROTRAUM, V15, P887; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; PIKE BR, 2000, RESTOR NEUROL NEUROS, V16, P166; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; Shah PT, 1997, NEUROSCIENCE, V79, P999, DOI 10.1016/S0306-4522(97)00013-4; Tapiola T, 2000, NEUROSCI LETT, V280, P119, DOI 10.1016/S0304-3940(00)00767-9; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zhang C, 1999, J NEUROCHEM, V73, P1650, DOI 10.1046/j.1471-4159.1999.0731650.x; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351; Zhao XR, 2000, J CEREBR BLOOD F MET, V20, P550, DOI 10.1097/00004647-200003000-00014	52	141	143	0	2	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	SEP	2001	78	6					1297	1306		10.1046/j.1471-4159.2001.00510.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	474LF	WOS:000171107900011	11579138	Bronze			2021-06-18	
J	Fann, JR; Uomoto, JM; Katon, WJ				Fann, JR; Uomoto, JM; Katon, WJ			Sertraline in the treatment of major depression following mild traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article; Proceedings Paper	152nd Annual Meeting of the American-Psychiatric-Association	MAY 15-20, 1999	WASHINGTON, D.C.	Amer Psychiat Assoc			SICKNESS IMPACT PROFILE; HEALTH-STATUS MEASURE; HEAD-INJURY; MEDICAL OUTCOMES; NORTRIPTYLINE; DISABILITY; SYMPTOMS; DISORDER; DISEASE	An 8-week, nonrandomized, single-blind, placebo run-in trial Of sertraline was conducted on 15 patients diagnosed with major depression between 3 and 24 months after a mild traumatic brain injury. On the Hamilton Rating Scale for Depression, 13 (87%) han a decrease in score of greater than or equal to 50% ("response"), and 10 (67%) achieved ct score of less than or equal to 7 ("remission") by week 8 of sertraline. There was statistically significant improvement in psychological distress, anger and aggression, functioning, ann postconcussive symptoms with treatment.	Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Seattle Pacific Univ, Dept Grad Psychol, Seattle, WA 98119 USA	Fann, JR (corresponding author), Univ Washington, Dept Psychiat & Behav Sci, Box 356560, Seattle, WA 98195 USA.		Uomoto, Jay/AAF-4809-2019				BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BORSON S, 1992, PSYCHOSOMATICS, V33, P190, DOI 10.1016/S0033-3182(92)71995-1; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; CASSIDY JW, 1989, J HEAD TRAUMA REHAB, V4, P67; Chen CPLH, 1996, J NEUROCHEM, V66, P1592, DOI 10.1046/j.1471-4159.1996.66041592.x; Derogatis L.R., 1974, PSYCHOL MEASUREMENTS; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; GUY W, 1976, ADM76338 ECDEU DHEW; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hellings JA, 1996, J CLIN PSYCHIAT, V57, P333; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Knutson B, 1998, AM J PSYCHIAT, V155, P373, DOI 10.1176/ajp.155.3.373; MACKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527; MAIURO RD, 1987, J INTERPERS VIOLENCE, V2, P166, DOI DOI 10.1177/088626087002002003; MAYBERG HS, 1994, J NEUROPSYCH CLIN N, V6, P428; MAYEUX R, 1988, MOVEMENT DISORD, V3, P237, DOI 10.1002/mds.870030308; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MOBAYED M, 1990, J AFFECT DISORDERS, V19, P237, DOI 10.1016/0165-0327(90)90100-M; Ranen NG, 1996, J NEUROPSYCH CLIN N, V8, P338; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; SHEAR MK, 1989, MEASURING MENTAL ILL; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; SULLIVAN M, 1993, ARCH INTERN MED, V153, P2251, DOI 10.1001/archinte.153.19.2251; SWANSON JW, 1990, HOSP COMMUNITY PSYCH, V41, P761; TEASDALE G, 1974, LANCET, V2, P81; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206	36	141	142	0	4	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	2000	12	2					226	232		10.1176/appi.neuropsych.12.2.226			7	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	314UH	WOS:000087075600007	11001601				2021-06-18	
J	Zemlan, FP; Rosenberg, WS; Luebbe, PA; Campbell, TA; Dean, GE; Weiner, NE; Cohen, JA; Rudick, RA; Woo, D				Zemlan, FP; Rosenberg, WS; Luebbe, PA; Campbell, TA; Dean, GE; Weiner, NE; Cohen, JA; Rudick, RA; Woo, D			Quantification of axonal damage in traumatic brain injury: Affinity purification and characterization of cerebrospinal fluid tau proteins	JOURNAL OF NEUROCHEMISTRY			English	Article						tau protein; CSF; traumatic brain injury; neuroprotective agents; CNS tumors; Alzheimer's disease	NEURON-SPECIFIC ENOLASE; MICROTUBULE-ASSOCIATED PROTEIN; PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; HEAD-INJURY; IMMUNOLOGICAL CHARACTERIZATION; NEUROFILAMENT ANTIBODIES; NEUROFIBRILLARY TANGLES; AMINO-ACIDS; PHOSPHORYLATION	Diffuse axonal injury is a primary feature of head trauma and is one of the most frequent causes of mortality and morbidity, Diffuse axonal injury is microscopic in nature and difficult or impossible to detect with imaging techniques. The objective of the present study was to determine whether axonal injury in head trauma patients could be quantified by measuring levels of CSF tau proteins. Tau proteins are structural microtubule binding proteins primarily localized in the axonal compartment of neurons. Monoclonal antibodies recognizing the form of tau found in the CSF of head trauma patients were developed by differential CSF hybridoma screening using CSF from head trauma and control patients. Clones positive for head trauma CSF tau proteins were used to characterize this form of tau and for ELISA development. Using the developed ELISA, CSF tau levels were elevated >1,000-fold in head trauma patients (mean, 1,519 ng/ml of CSF) when compared with patients with multiple sclerosis (mean, 0.014 ng/ml of CSF; p < 0.001), normal pressure hydrocephalus (nondetectable CSF tau), neurologic controls (mean, 0.031 ng/ml of CSF; p < 0.001), or nonneurologic controls (nondetectable CSF tau; p < 0.001), in head trauma, a relationship between clinical improvement and decreased CSF tau levels was observed. These data suggest that CSF tau levels may prove a clinically useful assay for quantifying the axonal injury associated with head trauma and monitoring efficacy of neuroprotective agents. Affinity purification of CSF tau from head trauma patients indicated a uniform cleavage of similar to 18 kDa from all six tau isoforms, reducing their apparent molecular sizes to 30-50 kDa, These cleaved forms of CSF tau consisted of the interior portion of the tau sequence, including the microtubule binding domain, as judged by cyanogen bromide digestion. Consistent with these data, CSF cleaved tau bound taxolpolymerized microtubules, indicating a functionally intact microtubule binding domain. Furthermore, epitope mapping studies suggested that CSF cleaved tau proteins consist of the interior portion of the tau sequence with cleavage at both N and C terminals.	Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; Isolab, Norton, MA USA; Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA	Zemlan, FP (corresponding author), Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U10NS077311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R41AG012572] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 12572] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ANDERTON BH, 1982, NATURE, V298, P84, DOI 10.1038/298084a0; ARAI H, 1995, ANN NEUROL, V38, P649, DOI 10.1002/ana.410380414; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X; BOORSMA DM, 1975, J HISTOCHEM CYTOCHEM, V23, P200, DOI 10.1177/23.3.47869; CAPUTO CB, 1992, NEUROBIOL AGING, V13, P267, DOI 10.1016/0197-4580(92)90039-Z; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; COUCHIE D, 1985, FEBS LETT, V188, P331, DOI 10.1016/0014-5793(85)80397-5; DAUBERSCHMIDT R, 1983, CLIN CHIM ACTA, V131, P165, DOI 10.1016/0009-8981(83)90085-2; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1994, RADIOLOGY, V191, P1; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOTOW T, 1994, J NEUROSCI RES, V37, P691, DOI 10.1002/jnr.490370604; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Johnson GVW, 1997, J NEUROCHEM, V68, P430; KALCHEVA N, 1994, J NEUROCHEM, V63, P2336; KANAI Y, 1995, NEURON, V14, P421, DOI 10.1016/0896-6273(95)90298-8; KANEMARU K, 1992, J NEUROCHEM, V58, P1667, DOI 10.1111/j.1471-4159.1992.tb10039.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOSIK KS, 1987, J NEUROSCI, V7, P3142; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1992, J CELL SCI, V102, P227; Li WP, 1997, J MOL NEUROSCI, V8, P75, DOI 10.1007/BF02736774; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; LITMAN P, 1993, NEURON, V10, P627, DOI 10.1016/0896-6273(93)90165-N; LIU WK, 1993, J NEUROSCI RES, V34, P371, DOI 10.1002/jnr.490340315; MABE H, 1991, SURG NEUROL, V36, P170, DOI 10.1016/0090-3019(91)90108-L; MARANGOS PJ, 1979, BIOL PSYCHIAT, V14, P563; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nishimoto I, 1997, Adv Pharmacol, V41, P337, DOI 10.1016/S1054-3589(08)61064-9; NUKINA N, 1987, P NATL ACAD SCI USA, V84, P3415, DOI 10.1073/pnas.84.10.3415; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; SCARNA H, 1982, NEUROCHEM INT, V4, P405, DOI 10.1016/0197-0186(82)90083-3; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SEGAL MB, 1993, J INHERIT METAB DIS, V16, P617, DOI 10.1007/BF00711896; SHINTAKU M, 1988, NEUROPATH APPL NEURO, V14, P505, DOI 10.1111/j.1365-2990.1988.tb01341.x; SOBEL RA, 1995, NEUROL CLIN, V13, P1; STRICH SJ, 1961, LANCET, V2, P443; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x; VIGOPELFREY C, 1995, NEUROLOGY, V45, P788, DOI 10.1212/WNL.45.4.788; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; WOLOZIN B, 1987, ANN NEUROL, V22, P521, DOI 10.1002/ana.410220412; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509; Zelman FP, 1996, J NEUROSCI RES, V46, P90, DOI 10.1002/(SICI)1097-4547(19961001)46:1<90::AID-JNR11>3.0.CO;2-G	57	141	145	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	FEB	1999	72	2					741	750		10.1046/j.1471-4159.1999.0720741.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	159FR	WOS:000078161800033	9930748	Bronze			2021-06-18	
J	Barnes, BC; Cooper, L; Kirkendall, DT; McDermott, TP; Jordan, BD; Garrett, WE				Barnes, BC; Cooper, L; Kirkendall, DT; McDermott, TP; Jordan, BD; Garrett, WE			Concussion history in elite male and female soccer players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article							FOOTBALL PLAYERS; BRAIN-DAMAGE; INJURIES; HEAD	A unique feature of soccer is the purposeful use of the head for controlling, passing, and shooting a soccer ball. Some concern has been expressed in the literature on the cumulative effects of heading on soccer players. Certain neurophysiologic and neuropsychologic changes have been reported in current or retired players, with heading being blamed. A major factor that could influence some of the findings is a player's history of concussive episodes, which are known to influence brain function. These episodes can occur during aspects of the game other than heading. We interviewed all male and female soccer players (N = 137, average age = 20.5 years) who competed at the U.S. Olympic Sports Festival in 1993. The mechanisms of injuries, frequency, and sequelae were determined. There were 74 concussions in 39 male players (grade 1 = 50) and 28 concussions in 23 female players (grade 1 = 19). For the men, 48 of the 74 episodes were from collisions with another player. For the women, 20 of 28 were from such collisions. Headaches, being "dazed," and dizziness were the most common symptoms reported. Based on concussion history, the odds are 50% that a man, and 22% that a woman, will sustain a concussion within a 10-year period. The data indicate that concussions from player-to-player contact are a frequent hazard in soccer. Head injuries incurred this way may be more of an influence for published findings of physiologic and psychologic deficiencies than routine heading of the soccer ball.	Duke Univ, Med Ctr, Div Orthopaed Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Phys & Occupat Therapy, Durham, NC 27710 USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA	Kirkendall, DT (corresponding author), Duke Univ, Med Ctr, Div Orthopaed Surg, POB 3435, Durham, NC 27710 USA.						ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; Bruce D A, 1982, Clin Sports Med, V1, P495; Carroll EJ, 1936, AM J MED SCI, V191, P706, DOI 10.1097/00000441-193619150-00014; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; IRRGANG, 1994, SPORTS INJURIES MECH, P349; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Lohnes JH, 1994, SPORTS INJURIES MECH, P603; Nilsson S, 1978, Am J Sports Med, V6, P358, DOI 10.1177/036354657800600608; Reilly T., 1976, J HUMAN MOVEMENT STU, V2, P87; Roaas A, 1979, Br J Sports Med, V13, P3; SCHNEIDER PG, 1975, SPORTARZUT SPORTMEDI, V26, P10; Smodlaka VN, 1984, PHYSICIAN SPORTSMED, V12, P127, DOI DOI 10.1080/00913847.1984.11701777; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Watson AWS, 1996, AM J SPORT MED, V24, P323, DOI 10.1177/036354659602400313; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005	20	141	142	0	27	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY-JUN	1998	26	3					433	438		10.1177/03635465980260031601			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	ZQ970	WOS:000073921700016	9617409				2021-06-18	
J	Holmin, S; Almqvist, P; Lendahl, U; Mathiesen, T				Holmin, S; Almqvist, P; Lendahl, U; Mathiesen, T			Adult nestin-expressing subependymal cells differentiate to astrocytes in response to brain injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						nestin; GFAP; neurofilament; stem cell; rat	CENTRAL-NERVOUS-SYSTEM; INTERMEDIATE FILAMENT NESTIN; FIBRILLARY ACIDIC PROTEIN; FOREBRAIN SUBVENTRICULAR ZONE; AP-1 TRANSCRIPTION FACTORS; FIBROBLAST GROWTH-FACTOR; FACTOR MESSENGER-RNA; NEURAL STEM-CELLS; RAT-BRAIN; MAMMALIAN BRAIN	The adult brain contains a small population of central nervous system (CNS) cells in the subependyma which, like embryonic CNS progenitor cells, express the intermediate filament nestin. In this report, the differentiation capacity in vivo of these cells was analysed following a standardized trauma. Before the trauma, the subependymal cells expressed nestin but not the astrocytic and neuronal differentiation markers glial fibrillary acidic protein (GFAP) and neurofilament respectively. In response to injury, the majority of the subependymal cells coexpressed nestin and GFAP, but never nestin and neurofilament. Furthermore, cells coexpressing nestin and GFAP were found progressively further away from the subependyma and closer to the lesion at later time points after the injury, indicating that these cells migrate towards the lesion. Nestin was in addition re-expressed in reactive astrocytes near the lesion and in non-reactive astrocytes very far from the lesion throughout the ipsilateral cortex. In conclusion, our data indicate that the nestin-positive subependymal cells are an in vivo source for the generation of new astrocytes but not neurons after injury, and that nestin re-expression in astrocytes following traumatic stimuli can be used as a sensitive marker for astroglial activation.	KAROLINSKA INST, DEPT CLIN NEUROSCI, NEUROSURG SECT, S-17176 STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT CELL & MOL BIOL, MED NOBEL INST, S-17176 STOCKHOLM, SWEDEN				Lendahl, Urban/0000-0001-9543-8141; Holmin, Staffan/0000-0002-1628-1615; Almqvist, Per/0000-0002-0383-8189; Mathiesen, Tiit/0000-0001-9463-1919			AGUAYO AJ, 1991, PHILOS T R SOC B, V331, P337, DOI 10.1098/rstb.1991.0025; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BONTHIUS DJ, 1993, BRAIN RES, V618, P83, DOI 10.1016/0006-8993(93)90432-M; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; CAVANAGH JB, 1970, J ANAT, V106, P471; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; DAHLSTRAND J, 1995, DEV BRAIN RES, V84, P109, DOI 10.1016/0165-3806(94)00162-S; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; ENG LF, 1992, PROG BRAIN RES, V94, P353; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FISHELL G, 1993, NATURE, V362, P636, DOI 10.1038/362636a0; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; ISHIKAWA R, 1991, NEUROSCI LETT, V127, P70, DOI 10.1016/0304-3940(91)90897-3; JENSEN I, 1976, ACTA NEUROL SCAND, V54, P391, DOI 10.1111/j.1600-0404.1976.tb04372.x; JIE Z, 1986, ACTA PATH MICRO IM A, V94, P353; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KILPATRICK TJ, 1995, MOL CELL NEUROSCI, V6, P2, DOI 10.1006/mcne.1995.1002; KOSHINAGA M, 1993, EXP NEUROL, V120, P32, DOI 10.1006/exnr.1993.1038; KRAIG RP, 1991, J NEUROSCI, V11, P2187; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LEVISON SW, 1993, NEURON, V10, P201, DOI 10.1016/0896-6273(93)90311-E; LEVISON SW, 1993, DEVELOPMENT, V119, P611; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; LIN RCS, 1995, NEUROBIOL DIS, V2, P79, DOI 10.1006/nbdi.1995.0008; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; LUSKIN MB, 1994, GLIA, V11, P211, DOI 10.1002/glia.440110302; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; NORDQVIST ACS, 1996, BRAIN RES MOL BRAIN, V38, P285; OSBORN M, 1982, VIRCHOWS ARCH B, V40, P141, DOI 10.1007/BF02932859; PENNYPACKER KR, 1994, J NEUROSCI, V14, P3998; POLLEN D A, 1970, Science (Washington D C), V167, P1252, DOI 10.1126/science.167.3922.1252; Price Jack, 1994, Current Opinion in Neurobiology, V4, P680, DOI 10.1016/0959-4388(94)90009-4; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; SEJERSEN T, 1993, J CELL SCI, V106, P1291; SMART I, 1961, J COMP NEUROL, V116, P349, DOI 10.1002/cne.901160307; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; TEMPLE S, 1995, NEURON, V15, P249, DOI 10.1016/0896-6273(95)90030-6; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG K, 1993, P SOC NEUROSCI, V13, P1880; ZHENG M, 1988, MOL BRAIN RES, V3, P133, DOI 10.1016/0169-328X(88)90058-7; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	53	141	164	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JAN	1997	9	1					65	75		10.1111/j.1460-9568.1997.tb01354.x			11	Neurosciences	Neurosciences & Neurology	WJ179	WOS:A1997WJ17900009	9042570				2021-06-18	
J	KIMELBERG, HK; RUTLEDGE, E; GODERIE, S; CHARNIGA, C				KIMELBERG, HK; RUTLEDGE, E; GODERIE, S; CHARNIGA, C			ASTROCYTIC SWELLING DUE TO HYPOTONIC OR HIGH K+ MEDIUM CAUSES INHIBITION OF GLUTAMATE AND ASPARTATE UPTAKE AND INCREASES THEIR RELEASE	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						ASTROCYTIC SWELLING; HYPOTONIC MEDIUM; HIGH K+ MEDIUM; GLUTAMATE UPTAKE INHIBITION; ASPARTATE UPTAKE INHIBITION; RELEASE	ANION TRANSPORT INHIBITOR; CEREBRAL-ISCHEMIA; GLIAL-CELLS; AMINO-ACIDS; ELECTRON-MICROSCOPY; CULTURED ASTROCYTES; MILD HYPOTHERMIA; BRAIN EDEMA; MEMBRANE; TAURINE	Astrocytic swelling occurs readily in ischemia and traumatic brain injury (TBI) as part of the cytotoxic or cellular edema response. Ischemia is known to produce large extracellular increases in both [K+] and excitatory amino acids (EAA) in vivo, and astrocytic swelling in vitro leads to marked release of EAA. In this study we compared the effect of swelling due to hypotonic media and high K+ medium on the uptake and release of EAA by rat primary astrocyte cultures in vitro. In both cases, there was a significant inhibition of uptake of [H-3]L-glutamate and [H-3]D-aspartate, and increased release of preloaded [H-3]D-aspartate, The kinetics of the increased efflux was very different in response to hypotonic or high K+ media. In hypotonic medium there was a rapid initial release followed by a decline in the rate of release over time. This release was independent of whether Na+ was present. Upon exposure to high K+ medium there was a slow progressive increase in release of [H-3]D-aspartate, which never showed any subsequent decline until the media was returned to normal [K+]. In high K+ media there was also an initial transient increase in [H-3]D-aspartate release, which we attribute to reversal of the amino acid uptake system. The increased release due to hypotonic medium was not affected by a drop in temperature from 37 to 26 degrees C, while the increased release due to high K+ medium was completely inhibited. The decreased uptake and increased release of EAA when astrocytes swell will short-circuit a presumed important, protective uptake system for EAA and may contribute to the increased levels of extracellular EAA seen during ischemia, TBI, and other pathologic states.	ALBANY MED COLL,DEPT PHARMACOL TOXICOL,ALBANY,NY 12208	KIMELBERG, HK (corresponding author), ALBANY MED COLL,DIV NEUROSURG A60,47 NEW SCOTLAND AVE,ALBANY,NY 12208, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030303, R01NS023750] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 23750, NS 30303] Funding Source: Medline		AMES A, 1968, AM J PATHOL, V52, P437; BARBOUR B, 1993, J PHYSIOL-LONDON, V466, P573; BEDNAR M M, 1992, Neurological Research, V14, P53; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHEN H, 1992, ACTA NEUROPATHOL, V84, P184, DOI 10.1007/BF00311393; CRAGOE EJ, 1986, J MED CHEM, V29, P825, DOI 10.1021/jm00155a038; GARCIA JH, 1977, VIRCHOWS ARCH B, V25, P191; GARCIA JH, 1984, STROKE, V15, P5, DOI 10.1161/01.STR.15.1.5; HANSEN AJ, 1985, PHYSIOL REV, V65, P101; HATASHITA S, 1990, STROKE, V21, P582, DOI 10.1161/01.STR.21.4.582; HOFFMANN EK, 1991, ADV COMP ENV PHYSL, V9, P140; JALONEN T, 1993, GLIA, V9, P227, DOI 10.1002/glia.440090308; JENKINS LW, 1979, ACTA NEUROPATHOL, V48, P113, DOI 10.1007/BF00691152; JENKINS LW, 1982, RECENT PROGR STUDY T, P523; KALIMO H, 1977, VIRCHOWS ARCH B, V25, P207; KATAYAMA Y, 1992, BRAIN RES, V577, P121, DOI 10.1016/0006-8993(92)90544-J; KETTENMANN H, 1990, CHLORIDE CHANNELS AND CARRIERS IN NERVE, MUSCLE, AND GLIAL CELLS, P193; KIMELBERG HK, 1988, GLIA, V1, P219, DOI 10.1002/glia.440010307; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; KIMELBERG HK, 1979, BRAIN RES, V177, P533, DOI 10.1016/0006-8993(79)90470-0; KIMELBERG HK, 1993, BRAIN RES, V622, P237, DOI 10.1016/0006-8993(93)90824-7; KIMELBERG HK, 1991, ANN NY ACAD SCI, V633, P619; KIMELBERG HK, 1986, ASTROCYTES, V3, P129; KOHUT JJ, 1992, STROKE, V23, P93, DOI 10.1161/01.STR.23.1.93; KRAIG RP, 1989, J CEREB BLOOD FLOW S, V9, P58; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; MARTIN DL, 1990, J NEUROSCI, V10, P571; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; OCONNOR ER, 1993, J NEUROSCI, V13, P2638; OCONNOR ER, 1992, AM J PHYSIOL-CELL PH, V264, P471; PASANTESMORALES H, 1989, GLIA, V2, P45, DOI 10.1002/glia.440020105; PHILIBERT RA, 1988, J NEUROCHEM, V51, P122, DOI 10.1111/j.1471-4159.1988.tb04844.x; ROY G, 1993, J MEMBRANE BIOL, V130, P83; SANCHEZOLEA R, 1991, NEUROSCI LETT, V130, P233, DOI 10.1016/0304-3940(91)90404-H; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SYKOVA E, 1994, J CEREBR BLOOD F MET, V14, P301, DOI 10.1038/jcbfm.1994.37; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; WALZ W, 1987, CAN J PHYSIOL PHARM, V65, P1051, DOI 10.1139/y87-166; XUE D, 1992, BRAIN RES, V587, P66, DOI 10.1016/0006-8993(92)91428-H	42	141	147	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	1995	15	3					409	416		10.1038/jcbfm.1995.51			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	QT257	WOS:A1995QT25700008	7713998	Bronze			2021-06-18	
J	SHACKFORD, SR; MACKERSIE, RC; DAVIS, JW; WOLF, PL; HOYT, DB				SHACKFORD, SR; MACKERSIE, RC; DAVIS, JW; WOLF, PL; HOYT, DB			EPIDEMIOLOGY AND PATHOLOGY OF TRAUMATIC DEATHS OCCURRING AT A LEVEL-I TRAUMA CENTER IN A REGIONALIZED SYSTEM - THE IMPORTANCE OF SECONDARY BRAIN INJURY	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article									UNIV CALIF SAN DIEGO,SCH MED,DEPT SURG,DIV TRAUMA,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,LA JOLLA,CA 92093	SHACKFORD, SR (corresponding author), UNIV VERMONT,COLL MED,DEPT SURG,GIVEN BLDG,BURLINGTON,VT 05405, USA.						BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; BAKER CC, 1985, AM J SURG, V149, P453, DOI 10.1016/S0002-9610(85)80039-8; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOWERS SA, 1980, NEUROSURGERY, V6, P237; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; DOVE DB, 1980, J TRAUMA, V20, P760, DOI 10.1097/00005373-198009000-00009; FAIST E, 1983, J TRAUMA, V23, P775, DOI 10.1097/00005373-198309000-00002; GILROY D, 1984, INJURY, V15, P304, DOI 10.1016/0020-1383(84)90051-2; GORIS RJA, 1982, J TRAUMA, V22, P141, DOI 10.1097/00005373-198202000-00011; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HOYT DB, 1989, ARCH SURG-CHICAGO, V124, P906; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KROB MJ, 1984, ANN EMERG MED, V13, P891, DOI 10.1016/S0196-0644(84)80663-0; KULSHRESTHA P, 1988, J TRAUMA, V28, P844, DOI 10.1097/00005373-198806000-00023; LOWE DK, 1983, J TRAUMA, V23, P503, DOI 10.1097/00005373-198306000-00011; MACKERSIE RC, 1983, J TRAUMA, V23, P968, DOI 10.1097/00005373-198311000-00002; MYERS J, 1974, ARCH PATHOL, V98, P33; PEDOWITZ RA, 1989, J TRAUMA, V29, P219, DOI 10.1097/00005373-198902000-00012; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHACKFORD SR, 1987, J TRAUMA, V27, P866, DOI 10.1097/00005373-198708000-00004; SHACKFORD SR, 1986, J TRAUMA, V26, P812, DOI 10.1097/00005373-198609000-00006; SHACKFORD SR, 1987, ARCH SURG-CHICAGO, V122, P523; SIEGEL JH, 1979, SURGERY, V86, P163; SPAIN DM, 1984, AM J PUBLIC HEALTH, V74, P1122, DOI 10.2105/AJPH.74.10.1122; WHIMSTER WF, 1974, AM REV RESPIR DIS, V110, P478	25	141	141	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	1989	29	10					1392	1397		10.1097/00005373-198910000-00018			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AW860	WOS:A1989AW86000018	2810417				2021-06-18	
J	Coronado, VG; Haileyesus, T; Cheng, TA; Bell, JM; Haarbauer-Krupa, J; Lionbarger, MR; Flores-Herrera, J; McGuire, LC; Gilchrist, J				Coronado, Victor G.; Haileyesus, Tadesse; Cheng, Tabitha A.; Bell, Jeneita M.; Haarbauer-Krupa, Juliet; Lionbarger, Michael R.; Flores-Herrera, Javier; McGuire, Lisa C.; Gilchrist, Julie			Trends in Sports- and Recreation-Related Traumatic Brain Injuries Treated in US Emergency Departments: The National Electronic Injury Surveillance System-All Injury Program (NEISS-AIP) 2001-2012	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						emergency department; epidemiology; recreation; sports; traumatic brain injury	STATES HIGH-SCHOOL; OLDER WOMEN; CONCUSSION; PREVENTION; HEAD; EPIDEMIOLOGY; LEGISLATION; SYMPTOMS; COACHES; BALANCE	Importance: Sports-and recreation-related traumatic brain injuries (SRR-TBIs) are a growing public health problem affecting persons of all ages in the United States. Objective: To describe the trends of SRR-TBIs treated in US emergency departments (EDs) from 2001 to 2012 and to identify which sports and recreational activities and demographic groups are at higher risk for these injuries. Design: Data on initial ED visits for an SRR-TBI from the National Electronic Injury Surveillance System-All Injury Program (NEISS-AIP) for 2001-2012 were analyzed. Setting: NEISS-AIP data are drawn from a nationally representative sample of hospital-based EDs. Participants: Cases of TBI were identified from approximately 500 000 annual initial visits for all causes and types of injuries treated in EDs captured by NEISS-AIP. Main Outcome Measure(s): Numbers and rates by age group, sex, and year were estimated. Aggregated numbers and percentages by discharge disposition were produced. Results: Approximately 3.42 million ED visits for an SRR-TBI occurred during 2001-2012. During this period, the rates of SRR-TBIs treated in US EDs significantly increased in both males and females regardless of age (all Ps < .001). For males, significant increases ranged from a low of 45.8% (ages 5-9) to a high of 139.8 % (ages 10-14), and for females, from 25.1% (ages 0-4) to 211.5% (ages 15-19) (all Ps < .001). Every year males had about twice the rates of SRR-TBIs than females. Approximately 70% of all SRR-TBIs were reported among persons aged 0 to 19 years. The largest number of SRR-TBIs among males occurred during bicycling, football, and basketball. Among females, the largest number of SRR-TBIs occurred during bicycling, playground activities, and horseback riding. Approximately 89% of males and 91% of females with an SRR-TBI were treated and released from EDs. Conclusion and Relevance: The rates of ED-treated SRR-TBIs increased during 2001-2012, affecting mainly persons aged 0 to 19 years and males in all age groups. Increases began to appear in 2004 for females and 2006 for males. Activities associated with the largest number of TBIs varied by sex and age. Reasons for the reported increases in ED visits are unknown but may be associated with increased awareness of TBI through increased media exposure and from campaigns, such as the Centers for Disease Control and Prevention's Heads Up. Prevention efforts should be targeted by sports and recreational activity, age, and sex.	[Coronado, Victor G.; Cheng, Tabitha A.; Bell, Jeneita M.; Haarbauer-Krupa, Juliet; Lionbarger, Michael R.; Gilchrist, Julie] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Atlanta, GA 30341 USA; [Haileyesus, Tadesse] Ctr Dis Control & Prevent, Div Anal Res Practice Integrat, Atlanta, GA 30341 USA; [Cheng, Tabitha A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; [Cheng, Tabitha A.] Ctr Dis Control & Prevent, Div Sci Educ & Profess Dev, Atlanta, GA 30341 USA; [McGuire, Lisa C.] Ctr Dis Control & Prevent, Div Nutr Phys Act, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; [Flores-Herrera, Javier] Epidemiol Natl Ctr, Spanish Field Epidemiol Training Program, SUMMA 112, Med Emergency Serv Madrid, Madrid, Spain	Coronado, VG (corresponding author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, 4170 Buford Hwy NE,MS F62, Atlanta, GA 30341 USA.	vgc1@cdc.gov			Intramural CDC HHS [CC999999] Funding Source: Medline		ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Campbell AJ, 1999, AGE AGEING, V28, P513, DOI 10.1093/ageing/28.6.513; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Cantu RC, 2010, SPORTS MED B IN; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; *CDCP, HEADS BRAIN INJ YOUR; Centers for Disease Control and Prevention, 2011, YOUTH RISK BEH SURV; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Coronado VG, 2009, NEUROTRAUMA CRITICAL, P3; Coronado VG, 2013, LIFESTYLE MEDICINE, 2ND EDITION, P1519; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Helmkamp JC, 2012, PUBLIC HEALTH REP, V127, P364, DOI 10.1177/003335491212700404; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Insurance Institute for Highway Safety Highway Loss Data Institute, 2009, HIGHW SAF TOP FAT FA; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Judge J, 1993, PHYS THER, V73, P63; JUDGE JO, 1993, PHYS THER, V73, P254, DOI 10.1093/ptj/73.4.254; Keenan HT, 2004, PEDIATRICS, V113, pE330, DOI 10.1542/peds.113.4.e330; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LORD SR, 1993, ARCH PHYS MED REHAB, V74, P837, DOI 10.1016/0003-9993(93)90010-8; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marshall SWG, 2011, INJURY PREVENTION CH, P261; McBride AS, 2011, PEDIATR EMERG CARE, V27, P97, DOI 10.1097/PEC.0b013e31820942f8; McCrea M., 2008, OXFORD WORKSHOP SERI; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Navarro RR, 2011, CURR SPORT MED REP, V10, P27, DOI 10.1249/JSR.0b013e318205e072; Proctor MR, 2000, CLIN SPORT MED, V19, P693, DOI 10.1016/S0278-5919(05)70233-7; Ray W, 1990, TOPICS GERIATR REHAB, V5, P12; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Runge J W, 1993, Emerg Med Clin North Am, V11, P241; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Sasser H C, 2001, N C Med J, V62, P364; Schroeder T., NEISS SAMPLE DESIGN; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Son BC, 2000, ACT NEUR S, V76, P13; Syed SH, 2013, J CRANIOFAC SURG, V24, P2023, DOI 10.1097/01.scs.0000436699.43090.34; Tellier A, 1999, BRAIN INJURY, V13, P463; Theisen D, 2013, J SCI MED SPORT, V16, P200, DOI 10.1016/j.jsams.2012.07.007; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719; Upperman JS, 2003, J PEDIATR SURG, V38, P1284, DOI 10.1016/S0022-3468(03)00383-X; US Consumer Product Safety Commission, 2001, NEISS DAT HIGHL; US Consumer Product Safety Commission, ATV STAT LEG RES BAN; US Consumer Product Safety Commission, 2010, NEISS DAT HIGHL; US Consumer Product Safety Commission, 2013, NEISS COD MAN; US Consumer Product Safety Commission, 2011, ATV REL DEATHS INJ A; US Consumer Product Safety Commission, 2010, US CONS PROD SAF COM, V325; US Department of Labor Bureau of Labor Statistics. American Time Use Survey, 2010, ATUS TABL TABL 11 TI; US Department of Labor Bureau of Labor Statistics. American Time Use Survey (ATUS), 2003, ATUS TABL TABL A 1 T; US Department of Labor Bureau of Labor Statistics. American Time Use Survey (ATUS), 2003, ATUS TABL 9 AV HOURS; US Department of Transportation National Highway Traffic Safety Administration, 2008, 810886W DOT HS US DE; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Warner M, 2000, Vital Health Stat 10, P1; Winfield RD, 2010, AM SURGEON, V76, P149	68	140	143	1	39	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2015	30	3					185	197		10.1097/HTR.0000000000000156			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CH8PJ	WOS:000354298100131	25955705	Green Accepted			2021-06-18	
J	Payne, ET; Zhao, XY; Frndova, H; McBain, K; Sharma, R; Hutchison, JS; Hahn, CD				Payne, Eric T.; Zhao, Xiu Yan; Frndova, Helena; McBain, Kristin; Sharma, Rohit; Hutchison, James S.; Hahn, Cecil D.			Seizure burden is independently associated with short term outcome in critically ill children	BRAIN			English	Article						seizure burden; continuous video-EEG monitoring; outcome; critical illness; child	INTENSIVE-CARE-UNIT; TRAUMATIC BRAIN-INJURY; STATUS EPILEPTICUS; NONCONVULSIVE SEIZURES; NEONATAL SEIZURES; ELECTROGRAPHIC SEIZURES; COMATOSE CHILDREN; MORTALITY; ELECTROENCEPHALOGRAPHY; PATHOPHYSIOLOGY	Seizures are common among critically ill patients, but their relationship to outcome remains unclear. In a cohort of critically ill children, Payne et al. demonstrate that increasing electrographic seizure burden is independently associated with short-term neurological decline, even after adjusting for seizure aetiology and illness severity.Seizures are common among critically ill children, but their relationship to outcome remains unclear. We sought to quantify the relationship between electrographic seizure burden and short-term neurological outcome, while controlling for diagnosis and illness severity. Furthermore, we sought to determine whether there is a seizure burden threshold above which there is an increased probability of neurological decline. We prospectively evaluated all infants and children admitted to our paediatric and cardiac intensive care units who underwent clinically ordered continuous video-electroencephalography monitoring over a 3-year period. Seizure burden was quantified by calculating the maximum percentage of any hour that was occupied by electrographic seizures. Outcome measures included neurological decline, defined as a worsening Paediatric Cerebral Performance Category score between hospital admission and discharge, and in-hospital mortality. Two hundred and fifty-nine subjects were evaluated (51% male) with a median age of 2.2 years (interquartile range: 0.3 days-9.7 years). The median duration of continuous video-electroencephalography monitoring was 37 h (interquartile range: 21-56 h). Seizures occurred in 93 subjects (36%, 95% confidence interval = 30-42%), with 23 (9%, 95% confidence interval = 5-12%) experiencing status epilepticus. Neurological decline was observed in 174 subjects (67%), who had a mean maximum seizure burden of 15.7% per hour, compared to 1.8% per hour for those without neurological decline (P < 0.0001). Above a maximum seizure burden threshold of 20% per hour (12 min), both the probability and magnitude of neurological decline rose sharply (P < 0.0001) across all diagnostic categories. On multivariable analysis adjusting for diagnosis and illness severity, the odds of neurological decline increased by 1.13 (95% confidence interval = 1.05-1.21, P = 0.0016) for every 1% increase in maximum hourly seizure burden. Seizure burden was not associated with mortality (odds ratio: 1.003, 95% confidence interval: 0.99-1.02, P = 0.613). We conclude that in this cohort of critically ill children, increasing seizure burden was independently associated with a greater probability and magnitude of neurological decline. Our observation that a seizure burden of more than 12 min in a given hour was strongly associated with neurological decline suggests that early antiepileptic drug management is warranted in this population, and identifies this seizure burden threshold as a potential therapeutic target. These findings support the hypothesis that electrographic seizures independently contribute to brain injury and worsen outcome. Our results motivate and inform the design of future studies to determine whether more aggressive seizure treatment can improve outcome.	[Payne, Eric T.; Sharma, Rohit; Hahn, Cecil D.] Hosp Sick Children, Div Neurol, Dept Paediat, Toronto, ON M5G 1X8, Canada; [Zhao, Xiu Yan] Hosp Sick Children, Biostat Design & Anal Unit, Toronto, ON M5G 1X8, Canada; [Frndova, Helena; McBain, Kristin; Hutchison, James S.] Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; [Frndova, Helena; McBain, Kristin; Hutchison, James S.] Univ Toronto, Toronto, ON M5G 1X8, Canada	Hahn, CD (corresponding author), Hosp Sick Children, Div Neurol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	cecil.hahn@sickkids.ca	Hahn, Cecil/J-3372-2016	Hahn, Cecil/0000-0002-0887-8761	Hospital for Sick Children Foundation; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [NI10-021]; Health Research Grant from the Physicians' Services Incorporated Foundation [09-40]; Alberta Innovates Health Solutions; Canadian League Against Epilepsy; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Physicians' Services Incorporated Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Canada Foundation for InnovationCanada Foundation for InnovationCGIAR; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; Ontario Neurotrauma Foundation; Victoria Neurotrauma Initiative	This work was supported by a New Investigator Research Grant from The Hospital for Sick Children Foundation and the Canadian Institutes of Health Research (NI10-021), and a Health Research Grant from the Physicians' Services Incorporated Foundation (09-40). Dr Payne receives fellowship training support from Alberta Innovates Health Solutions and the Canadian League Against Epilepsy. Dr Hahn receives research support from the Canadian Institutes of Health Research, The Hospital for Sick Children Foundation and The Physicians' Services Incorporated Foundation. Dr Hutchison receives research support from the National Institutes of Health, The Hospital for Sick Children Foundation, the Canada Foundation for Innovation, the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada, the Ontario Neurotrauma Foundation, the Physicians' Services Incorporated Foundation, and the Victoria Neurotrauma Initiative.	Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Abend NS, 2013, NEUROLOGY, V81, P383, DOI 10.1212/WNL.0b013e31829c5cfe; Bellinger DC, 2011, CIRCULATION, V124, P1361, DOI 10.1161/CIRCULATIONAHA.111.026963; Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Chen JWY, 2006, LANCET NEUROL, V5, P246, DOI 10.1016/S1474-4422(06)70374-X; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2013, ANN NEUROL, V74, P53, DOI 10.1002/ana.23859; Cornejo BJ, 2007, ANN NEUROL, V61, P411, DOI 10.1002/ana.21071; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Fiser DH, 2000, CRIT CARE MED, V28, P1173, DOI 10.1097/00003246-200004000-00043; Gaynor JW, 2013, J THORAC CARDIOV SUR, V146, P132, DOI 10.1016/j.jtcvs.2013.04.002; Glass HC, 2009, J PEDIATR-US, V155, P318, DOI 10.1016/j.jpeds.2009.03.040; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Holmes GL, 1998, ANN NEUROL, V44, P845, DOI 10.1002/ana.410440602; Holmes GL, 2009, CLIN PERINATOL, V36, P901, DOI 10.1016/j.clp.2009.07.012; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Jiang JX, 2013, P NATL ACAD SCI USA, V110, P3591, DOI 10.1073/pnas.1218498110; Kirkham FJ, 2012, INTENS CARE MED, V38, P853, DOI 10.1007/s00134-012-2529-9; Lambrechtsen FACP, 2008, EPILEPSIA, V49, P615, DOI 10.1111/j.1528-1167.2007.01465.x; Leteurtre S, 2003, LANCET, V362, P192, DOI 10.1016/S0140-6736(03)13908-6; LOTHMAN E, 1990, NEUROLOGY, V40, P13; Ma L, 2012, BRAIN RES, V1469, P103, DOI 10.1016/j.brainres.2012.05.058; McBride MC, 2000, NEUROLOGY, V55, P506, DOI 10.1212/WNL.55.4.506; McCabe BK, 2001, J NEUROSCI, V21, P2094, DOI 10.1523/JNEUROSCI.21-06-02094.2001; McCoy B, 2011, EPILEPSIA, V52, P1973, DOI 10.1111/j.1528-1167.2011.03291.x; MELDRUM BS, 1973, ARCH NEUROL-CHICAGO, V29, P82, DOI 10.1001/archneur.1973.00490260026003; Miller SP, 2002, NEUROLOGY, V58, P542, DOI 10.1212/WNL.58.4.542; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Pisani F, 2008, J CHILD NEUROL, V23, P394, DOI 10.1177/0883073807309253; Pisani F, 2007, NEUROLOGY, V69, P2177, DOI 10.1212/01.wnl.0000295674.34193.9e; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Sanchez SM, 2013, J CLIN NEUROPHYSIOL, V30, P156, DOI 10.1097/WNP.0b013e31827eda27; Sankar R, 2000, ANN NEUROL, V48, P580, DOI 10.1002/1531-8249(200010)48:4<580::AID-ANA4>3.3.CO;2-2; Sankar R, 1998, J NEUROSCI, V18, P8382; Serrano GE, 2011, J NEUROSCI, V31, P14850, DOI 10.1523/JNEUROSCI.3922-11.2011; Shahwan A, 2010, EPILEPSIA, V51, P1198, DOI 10.1111/j.1528-1167.2009.02517.x; Shneker BF, 2003, NEUROLOGY, V61, P1066, DOI 10.1212/01.WNL.0000082653.40257.0B; Topjian AA, 2013, CRIT CARE MED, V41, P215, DOI 10.1097/CCM.0b013e3182668035; Tsuchida TN, 2007, PEDIATR NEUROL, V36, P253, DOI 10.1016/j.pediatrneurol.2006.12.005; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Williams K, 2011, EPILEPSIA, V52, P1130, DOI 10.1111/j.1528-1167.2011.03070.x; Yager JY, 2002, DEV NEUROSCI-BASEL, V24, P367, DOI 10.1159/000069049; Young GB, 1996, NEUROLOGY, V47, P83	45	140	142	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAY	2014	137		5				1429	1438		10.1093/brain/awu042			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AH6PK	WOS:000336252800021	24595203	Bronze, Green Published			2021-06-18	
J	Freund, P; Weiskopf, N; Ashburner, J; Wolf, K; Sutter, R; Altmann, DR; Friston, KJ; Thompson, A; Curt, A				Freund, Patrick; Weiskopf, Nikolaus; Ashburner, John; Wolf, Katharina; Sutter, Reto; Altmann, Daniel R.; Friston, Karl J.; Thompson, Alan; Curt, Armin			MRI investigation of the sensorimotor cortex and the corticospinal tract after acute spinal cord injury: a prospective longitudinal study	LANCET NEUROLOGY			English	Article							VOXEL-BASED MORPHOMETRY; MULTIPLE-SCLEROSIS; ANTI-NOGO; RECOVERY; ATROPHY; MAPS; SEGMENTATION; DISABILITY; OUTCOMES; MYELIN	Background In patients with chronic spinal cord injury, imaging of the spinal cord and brain above the level of the lesion provides evidence of neural degeneration; however, the spatial and temporal patterns of progression and their relation to clinical outcomes are uncertain. New interventions targeting acute spinal cord injury have entered clinical trials but neuroimaging outcomes as responsive markers of treatment have yet to be established. We aimed to use Mill to assess neuronal degeneration above the level of the lesion after acute spinal cord injury. Methods In our prospective longitudinal study, we enrolled patients with acute traumatic spinal cord injury and healthy controls. We assessed patients clinically and by MRI at baseline, 2 months, 6 months, and 12 months, and controls by Mill at the same timepoints. We assessed atrophy in white matter in the cranial corticospinal tracts and grey matter in sensorimotor cortices by tensor-based analyses of T1-weighted MRI data. We used cross-sectional spinal cord area measurements to assess atrophy at cervical level C2/C3. We used myelin-sensitive magnetisation transfer (MT) and longitudinal relaxation rate (R1) maps to assess microstructural changes associated with myelin. We also assessed associations between MRI parameters and clinical improvement. All analyses of brain scans done with statistical parametric mapping were corrected for family-wise error. Findings Between Sept 17,2010, and Dec 31,2012, we recruited 13 patients and 18 controls. In the 12 months from baseline, patients recovered by a mean of 5-27 points per log month (95% CI 1.91-8.63) on the international standards for the neurological classification of spinal cord injury (ISNCSCI) motor score (p=0.002) and by 10-93 points per log month (6-20-15.66) on the spinal cord independence measure (SCIM) score (p<0.0001). Compared with controls, patients showed a rapid decline in cross-sectional spinal cord area (patients declined by 0.46 mm per month compared with a stable cord area in controls; p<0.0001). Patients had faster rates than controls of volume decline of white matter in the cranial corticospinal tracts at the level of the internal capsule (right Z score 5.21, p=0.0081; left Z score 4.12, p=0-0004) and right cerebral peduncle (Z score 3-89, p=0.0302) and of grey matter in the left primary motor cortex (Z score 4.23, p=0.041). Volume changes were paralleled by significant reductions of MT and R1 in the same areas and beyond. Improvements in SCIM scores at 12 months were associated with a reduced loss in cross-sectional spinal cord area over 12 months (Pearson's correlation 0-77, p=0.004) and reduced white matter volume of the corticospinal tracts at the level of the right internal capsule (Z score 4-30, p=0.0021), the left internal capsule (Z score 4.27, p=0.0278), and left cerebral pedunde (Z score 4.05, p=0.0316). Improvements in ISNCSCI motor scores were associated with less white matter volume change encompassing the corticospinal tract at the level of the right internal capsule (Z score 4.01, p<0.0001). Interpretation Extensive upstream atrophic and microstructural changes of corticospinal axons and sensorimotor cortical areas occur in the first months after spinal cord injury, with faster degenerative changes relating to poorer recovery. Structural volumetric and microstructural MRI protocols remote from the site of spinal cord injury could serve as neuroimaging biomarkers in acute spinal cord injury.	[Freund, Patrick; Wolf, Katharina; Curt, Armin] Univ Zurich, Univ Zurich Hosp, Spinal Cord Injury Ctr Balgrist, CH-8008 Zurich, Switzerland; [Sutter, Reto] Univ Zurich, Univ Hosp Balgrist, Dept Radiol, CH-8008 Zurich, Switzerland; [Freund, Patrick; Thompson, Alan] UCL, UCL Inst Neurol, Dept Brain Repair & Rehabil, London, England; [Freund, Patrick; Weiskopf, Nikolaus; Ashburner, John; Friston, Karl J.] UCL, UCL Inst Neurol, Wellcome Trust Ctr Neuroimaging, London, England; [Altmann, Daniel R.] UCL, UCL Inst Neurol, Queen Sq Multiple Sclerosis Ctr, NMR Res Unit, London, England; [Altmann, Daniel R.] London Sch Hyg & Trop Med, Dept Med Stat, London WC1, England; [Thompson, Alan] UCL Hosp Biomed Res Ctr, Natl Inst Hlth Res, London, England	Freund, P (corresponding author), Univ Zurich, Univ Zurich Hosp, Spinal Cord Injury Ctr Balgrist, Forchstr 380, CH-8008 Zurich, Switzerland.	pfreund@paralab.balgrist.ch	Ashburner, John/I-3757-2013; Freund, Patrick/D-4193-2013; Weiskopf, Nikolaus/B-9357-2008; Thompson, Alan J/C-2654-2008; Weiskopf, Nikolaus/ABI-5713-2020; Sutter, Reto/D-6783-2013; Wolf, Katharina/AAN-7729-2020; Friston, Karl/D-9230-2011	Ashburner, John/0000-0001-7605-2518; Freund, Patrick/0000-0002-4851-2246; Weiskopf, Nikolaus/0000-0001-5239-1881; Thompson, Alan J/0000-0002-4333-8496; Weiskopf, Nikolaus/0000-0001-5239-1881; Sutter, Reto/0000-0001-6355-9838; Friston, Karl/0000-0001-7984-8909; Wolf, Katharina/0000-0003-1468-3634	SRH Holding; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; Clinical Research Priority Program "NeuroRehab" University of Zurich; Wellcome TrustWellcome TrustEuropean Commission	Funding SRH Holding, Swiss National Science Foundation, Clinical Research Priority Program "NeuroRehab" University of Zurich, Wellcome Trust.	Anderson K, 2008, J SPINAL CORD MED, V31, P133, DOI 10.1080/10790268.2008.11760704; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Ashburner J, 2013, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00197; Barkhof F, 2009, NAT REV NEUROL, V5, P256, DOI 10.1038/nrneurol.2009.41; Buss A, 2005, BRAIN, V128, P356, DOI 10.1093/brain/awh355; Callaghan M, 2013, 21 SCI M INT SOC MAG; Dick F, 2012, J NEUROSCI, V32, P16095, DOI 10.1523/JNEUROSCI.1712-12.2012; Draganski B, 2011, NEUROIMAGE, V55, P1423, DOI 10.1016/j.neuroimage.2011.01.052; Edgerton VR, 2011, EXPERT REV NEUROTHER, V11, P1351, DOI [10.1586/ERN.11.129, 10.1586/ern.11.129]; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Endo T, 2009, NEUROSCIENTIST, V15, P291, DOI 10.1177/1073858408329508; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Freund P, 2007, J COMP NEUROL, V502, P644, DOI 10.1002/cne.21321; Freund P, 2013, NEUROSCIENTIST, V19, P116, DOI 10.1177/1073858412449192; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Freund PAB, 2010, J MAGN RESON IMAGING, V32, P1242, DOI 10.1002/jmri.22340; Hains BC, 2003, J COMP NEUROL, V462, P328, DOI 10.1002/cne.10733; Helms G, 2009, NEUROIMAGE, V47, P194, DOI 10.1016/j.neuroimage.2009.03.053; Horsfield MA, 2010, NEUROIMAGE, V50, P446, DOI 10.1016/j.neuroimage.2009.12.121; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Jurkiewicz MT, 2006, NEUROLOGY, V66, P762, DOI 10.1212/01.wnl.0000201276.28141.40; KALIL K, 1975, BRAIN RES, V89, P15, DOI 10.1016/0006-8993(75)90130-4; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Kramer JLK, 2012, NEUROREHAB NEURAL RE, V26, P1064, DOI 10.1177/1545968312447306; Losseff NA, 1996, BRAIN, V119, P701, DOI 10.1093/brain/119.3.701; Miyanji F, 2007, RADIOLOGY, V243, P820, DOI 10.1148/radiol.2433060583; NATHAN PW, 1994, BRAIN, V117, P337, DOI 10.1093/brain/117.2.337; Schmierer K, 2004, ANN NEUROL, V56, P407, DOI 10.1002/ana.20202; Sereno MI, 2013, CEREB CORTEX, V23, P2261, DOI 10.1093/cercor/bhs213; Tardif CL, 2009, NEUROIMAGE, V44, P827, DOI 10.1016/j.neuroimage.2008.09.053; van Middendorp JJ, 2011, LANCET, V377, P1004, DOI 10.1016/S0140-6736(10)62276-3; Weiskopf N, 2011, NEUROIMAGE, V54, P2116, DOI 10.1016/j.neuroimage.2010.10.023; Wrigley PJ, 2009, CEREB CORTEX, V19, P224, DOI 10.1093/cercor/bhn072; Zorner B, 2010, ANN NY ACAD SCI, V1198, pE22, DOI 10.1111/j.1749-6632.2010.05566.x	36	140	148	1	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2013	12	9					873	881		10.1016/S1474-4422(13)70146-7			9	Clinical Neurology	Neurosciences & Neurology	210WU	WOS:000323866600016	23827394	Other Gold, Green Published, Green Accepted			2021-06-18	
J	Calkins, DJ				Calkins, David J.			Critical pathogenic events underlying progression of neurodegeneration in glaucoma	PROGRESS IN RETINAL AND EYE RESEARCH			English	Article						Retinal ganglion cell; Optic nerve; Superior colliculus; Optic neuropathy; Intraocular pressure; Axonopathy; Axonal transport; Wallerian degeneration; Dying back; Self-repair	RETINAL GANGLION-CELLS; OPTIC-NERVE HEAD; LATERAL GENICULATE-NUCLEUS; OPEN-ANGLE GLAUCOMA; RETROGRADE AXOPLASMIC-TRANSPORT; INTRAOCULAR-PRESSURE ELEVATION; INDUCED OCULAR HYPERTENSION; DBA/2J MOUSE MODEL; TRAUMATIC BRAIN-INJURY; ALBINO SWISS MICE	Glaucoma is a common optic neuropathy with a complex etiology often linked to sensitivity to intraocular pressure. Though the precise mechanisms that mediate or transduce this sensitivity are not clear, the axon of the retinal ganglion cell appears to be vulnerable to disease-relevant stressors early in progression. One reason may be because the axon is generally thin for both its unmyelinated and myelinated segment and much longer than the thicker unmyelinated axons of other excitatory retinal neurons. This difference may predispose the axon to metabolic and oxidative injury, especially at distal sites where pre-synaptic terminals form connections in the brain. This idea is consistent with observations of early loss of anterograde transport at central targets and other signs of distal axonopathy that accompany physiological indicators of progression. Outright degeneration of the optic projection ensues after a critical period and, at least in animal models, is highly sensitive to cumulative exposure to elevated pressure in the eye. Stress emanating from the optic nerve head can induce not only distal axonopathy with aspects of dying back neuropathy, but also Wallerian degeneration of the optic nerve and tract and a proximal program involving synaptic and dendritic pruning in the retina. Balance between progressive and acute mechanisms likely varies with the level of stress placed on the unmyelinated axon as it traverses the nerve head, with more acute insult pushing the system toward quicker disassembly. A constellation of signaling factors likely contribute to the transduction of stress to the axon, so that degenerative events along the length of the optic projection progress in retinotopic fashion. This pattern leads to well-defined sectors of functional depletion, even at distal-most sites in the pathway. While ganglion cell somatic drop-out is later in progression, some evidence suggests that synaptic and dendritic pruning in the retina may be a more dynamic process. Structural persistence both in the retina and in central projection sites offers the possibility that intrinsic self-repair pathways counter pathogenic mechanisms to delay as long as possible outright loss of tissue. (C) 2012 Elsevier Ltd. All rights reserved.	Vanderbilt Univ, Sch Med, Vanderbilt Eye Inst, Dept Ophthalmol & Visual Sci, Nashville, TN 37232 USA	Calkins, DJ (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Eye Inst, Dept Ophthalmol & Visual Sci, 11435 MRB 4,2215B Garland Ave, Nashville, TN 37232 USA.	david.j.calkins@vanderbilt.edu			Melza M. and Frank Theodore Barr Foundation through the Glaucoma Research Foundation; American Health Assistance FoundationBrightFocus Foundation; Research to Prevent Blindness, Inc.Research to Prevent Blindness (RPB); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EY017427]; NIH P30 core grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EY008126]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY017427, P30EY008126] Funding Source: NIH RePORTER	The author wishes to dedicate this article to Thomas Brunner, for his unwavering and innovative support of biomedical research through the Glaucoma Research Foundation and its Catalyst for a Cure program. The author also expresses his sincerest gratitude to many gifted and dedicated collaborators over the years, in particular Catalyst for a Cure members Rebecca Sappington, Philip Homer, Samuel Crish, Denise Inman, Monica Vetter, Alejandra Bosco, Martin Wax, and Nicholas Marsh-Armstrong. Special thanks are due Wendi Lambert for her expert proof-reading, commentary and critique. This work would not have been possible without the generous financial support of the Melza M. and Frank Theodore Barr Foundation through the Glaucoma Research Foundation, the American Health Assistance Foundation, and Research to Prevent Blindness, Inc. Funding also provided through NIH EY017427 (DJC) and NIH P30 core grant EY008126 to the Vanderbilt Vision Research Center.	Allan VJ, 2011, BIOCHEM SOC T, V39, P1169, DOI 10.1042/BST0391169; Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002; Ames A, 2000, BRAIN RES REV, V34, P42, DOI 10.1016/S0165-0173(00)00038-2; ANDERSON DR, 1974, INVEST OPHTH VISUAL, V13, P771; Anderson MG, 2002, NAT GENET, V30, P81, DOI 10.1038/ng794; Balaratnasingam C, 2007, INVEST OPHTH VIS SCI, V48, P3632, DOI 10.1167/iovs.06-1002; Baltan S, 2010, J NEUROSCI, V30, P5644, DOI 10.1523/JNEUROSCI.5956-09.2010; Band LR, 2009, INVEST OPHTH VIS SCI, V50, P3750, DOI 10.1167/iovs.08-2396; Barron MJ, 2004, BRIT J OPHTHALMOL, V88, P286, DOI 10.1136/bjo.2003.027664; Bayer AU, 2001, INVEST OPHTH VIS SCI, V42, P1258; Bechtold DA, 2005, BRAIN, V128, P18, DOI 10.1093/brain/awh328; Beirowski B, 2008, EUR J NEUROSCI, V28, P1166, DOI 10.1111/j.1460-9568.2008.06426.x; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bernstein SL, 2007, MOL VIS, V13, P1920; Bernstein SL, 2007, INVEST OPHTH VIS SCI, V48, P2304, DOI 10.1167/iovs.06-0486; Bosco A, 2008, INVEST OPHTH VIS SCI, V49, P1437, DOI 10.1167/iovs.07-1337; Bosco A, 2011, J COMP NEUROL, V519, P599, DOI 10.1002/cne.22516; Braak H, 2004, CELL TISSUE RES, V318, P121, DOI 10.1007/s00441-004-0956-9; Bristow EA, 2002, ARCH OPHTHALMOL-CHIC, V120, P791; Buckingham BP, 2008, J NEUROSCI, V28, P2735, DOI 10.1523/JNEUROSCI.4443-07.2008; Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001; Burgoyne CF, 2011, EXP EYE RES, V93, P120, DOI 10.1016/j.exer.2010.09.005; Calkins DJ, 2008, INVEST OPHTH VIS SCI, V49, P5083, DOI 10.1167/iovs.08-2205; Calkins DJ, 2012, INVEST OPHTH VIS SCI, V53, P2482, DOI 10.1167/iovs.12-9483i; Calkins DJ, 1996, NATURE, V381, P613, DOI 10.1038/381613a0; Callaway EM, 2005, J PHYSIOL-LONDON, V566, P13, DOI 10.1113/jphysiol.2005.088047; Carelli V, 2004, BBA-BIOENERGETICS, V1658, P172, DOI 10.1016/j.bbabio.2004.05.009; Carelli V, 2002, NEUROCHEM INT, V40, P573, DOI 10.1016/S0197-0186(01)00129-2; Chang B, 1999, NAT GENET, V21, P405, DOI 10.1038/7741; Chang DTW, 2006, PROG NEUROBIOL, V80, P241, DOI 10.1016/j.pneurobio.2006.09.003; Chang EE, 2012, OPHTHALMOLOGY, V119, P979, DOI 10.1016/j.ophtha.2011.11.003; Chauhan BC, 2002, INVEST OPHTH VIS SCI, V43, P2969; Chen HH, 2011, INVEST OPHTH VIS SCI, V52, P36, DOI 10.1167/iovs.09-5115; Chidlow G, 2011, ACTA NEUROPATHOL, V121, P737, DOI 10.1007/s00401-011-0807-1; Choi SS, 2011, BRIT J OPHTHALMOL, V95, P131, DOI 10.1136/bjo.2010.183756; Chrysostomou V, 2010, OPHTHALMIC RES, V44, P173, DOI 10.1159/000316478; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Cone FE, 2010, EXP EYE RES, V91, P415, DOI 10.1016/j.exer.2010.06.018; Cordeiro MF, 2004, P NATL ACAD SCI USA, V101, P13352, DOI 10.1073/pnas.0405479101; Cowey A, 2011, BRAIN, V134, P2149, DOI 10.1093/brain/awr125; Crish SD, 2011, NEUROSCIENCE, V176, P1, DOI 10.1016/j.neuroscience.2010.12.036; Crish SD, 2010, P NATL ACAD SCI USA, V107, P5196, DOI 10.1073/pnas.0913141107; Cuenca N, 2010, EXP EYE RES, V91, P273, DOI 10.1016/j.exer.2010.05.020; CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103; Dai C, 2012, GLIA, V60, P13, DOI 10.1002/glia.21242; Danias J, 2003, INVEST OPHTH VIS SCI, V44, P5151, DOI 10.1167/iovs.02-1101; De Vos KJ, 2008, ANNU REV NEUROSCI, V31, P151, DOI 10.1146/annurev.neuro.31.061307.090711; Desai D, 2004, BIOCHEM BIOPH RES CO, V318, P642, DOI 10.1016/j.bbrc.2004.04.073; Doh SH, 2010, BRAIN RES, V1308, P158, DOI 10.1016/j.brainres.2009.10.025; DRAGER UC, 1976, J NEUROPHYSIOL, V39, P91; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Fan N, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/264803; Fernandez DC, 2012, AM J PATHOL, V180, P303, DOI 10.1016/j.ajpath.2011.09.018; Filippopoulos T, 2006, INVEST OPHTH VIS SCI, V47, P1968, DOI 10.1167/iovs.05-0955; Franke H, 2006, PFLUG ARCH EUR J PHY, V452, P622, DOI 10.1007/s00424-006-0071-8; Fu CT, 2010, INVEST OPHTH VIS SCI, V51, P980, DOI 10.1167/iovs.09-4324; GARCIAVALENZUELA E, 1995, EXP EYE RES, V61, P33, DOI 10.1016/S0014-4835(95)80056-5; Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200; Gupta N, 2006, BRIT J OPHTHALMOL, V90, P674, DOI 10.1136/bjo.2005.086769; Harazny J, 2009, DOC OPHTHALMOL, V119, P181, DOI 10.1007/s10633-009-9194-5; Harwerth RS, 2002, PROG RETIN EYE RES, V21, P91, DOI 10.1016/S1350-9462(01)00022-2; Hayreh SS, 1999, J GLAUCOMA, V8, P56; Heiduschka P, 2010, EXP EYE RES, V91, P779, DOI 10.1016/j.exer.2010.09.001; Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268; Heijl A, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-31; Hendry SHC, 1998, TRENDS NEUROSCI, V21, P344, DOI 10.1016/S0166-2236(98)01245-4; Hernandez MR, 2000, PROG RETIN EYE RES, V19, P297, DOI 10.1016/S1350-9462(99)00017-8; Hickman SJ, 2002, MULT SCLER J, V8, P339, DOI 10.1191/1352458502ms809oa; Ho Karen W, 2012, Am J Neurodegener Dis, V1, P1; Holcombe DJ, 2008, BRIT J OPHTHALMOL, V92, P683, DOI 10.1136/bjo.2007.133223; HOLLANDER H, 1995, OPHTHALMIC RES, V27, P296, DOI 10.1159/000267739; Hollenbeck Peter J., 1996, Frontiers in Bioscience (online), V1, pD91; Hollenbeck PJ, 2005, J CELL SCI, V118, P5411, DOI 10.1242/jcs.02745; Howell GR, 2007, J CELL BIOL, V179, P1523, DOI 10.1083/jcb.200706181; Howell GR, 2007, BMC GENET, V8, DOI 10.1186/1471-2156-8-45; Howell GR, 2012, J CLIN INVEST, V122, P1246, DOI 10.1172/JCI61135; Howell GR, 2012, EXP NEUROL; Hsu A, 1998, VISION RES, V38, P2539, DOI 10.1016/S0042-6989(97)00370-2; Iester M, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/327326; Inman DM, 2007, GLIA, V55, P942, DOI 10.1002/glia.20516; Inman DM, 2006, INVEST OPHTH VIS SCI, V47, P986, DOI 10.1167/iovs.05-0925; Jakobs TC, 2005, J CELL BIOL, V171, P313, DOI 10.1083/jcb.200506099; Jiang C, 2007, MOL VIS, V13, P1783; Jindahra P, 2009, BRAIN, V132, P628, DOI 10.1093/brain/awp001; JOHANSSON JO, 1988, EXP EYE RES, V46, P223, DOI 10.1016/S0014-4835(88)80079-4; John SWM, 1998, INVEST OPHTH VIS SCI, V39, P951; Johnson EC, 2009, J GLAUCOMA, V18, P341, DOI 10.1097/IJG.0b013e31818c6ef6; Johnson H, 2000, EXP BRAIN RES, V132, P269, DOI 10.1007/s002210000384; Kedar S, 2011, INDIAN J OPHTHALMOL, V59, P103, DOI 10.4103/0301-4738.77013; KENDELL KR, 1995, INVEST OPHTH VIS SCI, V36, P200; Kerrigan LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1031, DOI 10.1001/archopht.1997.01100160201010; Kerrigan-Baumrind LA, 2000, INVEST OPHTH VIS SCI, V41, P741; Kielczewski JL, 2005, INVEST OPHTH VIS SCI, V46, P3188, DOI 10.1167/iovs.05-0321; King WM, 2006, VISUAL NEUROSCI, V23, P137, DOI 10.1017/S0952523806231122; Knox DL, 2007, ARCH OPHTHALMOL-CHIC, V125, P347, DOI 10.1001/archopht.125.3.347; Lambert WS, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-4; Lee S, 2011, EXP EYE RES, V93, P204, DOI 10.1016/j.exer.2010.07.015; Lee S, 2011, J NEUROSCI, V31, P7817, DOI 10.1523/JNEUROSCI.6412-10.2011; Lei Y, 2011, BRIT J OPHTHALMOL, V95, P727, DOI 10.1136/bjo.2010.180869; Lei Y, 2008, INVEST OPHTH VIS SCI, V49, P1940, DOI 10.1167/iovs.07-0735; Leske MC, 2007, OPHTHALMOLOGY, V114, P1965, DOI 10.1016/j.ophtha.2007.03.016; Leske MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P48; Levin LA, 1999, EUR J OPHTHALMOL, V9, pS12, DOI 10.1177/112067219900901S08; Levkovitch-Verbin H, 2004, EYE, V18, P1066, DOI 10.1038/sj.eye.6701576; Levkovitch-Verbin H, 2002, INVEST OPHTH VIS SCI, V43, P402; Levkovitch-Verbin H, 2001, INVEST OPHTH VIS SCI, V42, P975; Li YY, 2012, J NEUROSCI, V32, P746, DOI 10.1523/JNEUROSCI.4926-11.2012; Libby RT, 2005, VISUAL NEUROSCI, V22, P637, DOI 10.1017/S0952523805225130; Libby RT, 2005, PLOS GENET, V1, P17, DOI 10.1371/journal.pgen.0010004; Liu M, 2011, EXP EYE RES, V92, P244, DOI 10.1016/j.exer.2011.01.014; Mabuchi F, 2003, INVEST OPHTH VIS SCI, V44, P4321, DOI 10.1167/iovs.03-0138; Magharious MM, 2011, J VIS EXP; Mallik R, 2004, NATURE, V427, P649, DOI 10.1038/nature02293; Man CYYW, 2005, MED HYPOTHESES, V65, P1038, DOI 10.1016/j.mehy.2004.10.021; McKinnon SJ, 2009, EXP EYE RES, V88, P816, DOI 10.1016/j.exer.2008.12.002; MIHAILOVIC LT, 1971, J COMP NEUROL, V142, P223, DOI 10.1002/cne.901420207; MINCKLER DS, 1976, AM J OPHTHALMOL, V82, P179, DOI 10.1016/0002-9394(76)90416-5; MINCKLER DS, 1977, INVEST OPHTH VIS SCI, V16, P426; Mittag TW, 2000, INVEST OPHTH VIS SCI, V41, P3451; Mojumder DK, 2008, MOL VIS, V14, P1600; Moon JI, 2005, CELL TISSUE RES, V320, P51, DOI 10.1007/s00441-004-1062-8; Moore DL, 2010, J NEURO-OPHTHALMOL, V30, P347, DOI 10.1097/WNO.0b013e3181e755af; Morgan JE, 2004, EYE, V18, P1089, DOI 10.1038/sj.eye.6701574; Morgan JE, 2000, EYE, V14, P437, DOI 10.1038/eye.2000.128; Morquette JB, 2008, J NEURO-OPHTHALMOL, V28, P144, DOI 10.1097/WNO.0b013e318177edf0; Morrison JC, 2005, PROG RETIN EYE RES, V24, P217, DOI 10.1016/j.preteyeres.2004.08.003; Morrison JC, 1997, EXP EYE RES, V64, P85, DOI 10.1006/exer.1996.0184; Morrison JC, 2011, EXP EYE RES, V93, P156, DOI 10.1016/j.exer.2010.08.005; Munemasa Y, 2010, J NEUROCHEM, V115, P1508, DOI 10.1111/j.1471-4159.2010.07057.x; Nagaraju M, 2007, INVEST OPHTH VIS SCI, V48, P4573, DOI 10.1167/iovs.07-0582; Nakazawa T, 2006, J NEUROSCI, V26, P12633, DOI 10.1523/JNEUROSCI.2801-06.2006; Navarro A, 2007, AM J PHYSIOL-CELL PH, V292, pC670, DOI 10.1152/ajpcell.00213.2006; Nguyen D, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.117; Nguyen JV, 2011, P NATL ACAD SCI USA, V108, P1176, DOI 10.1073/pnas.1013965108; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Nickells RW, 2007, CAN J OPHTHALMOL, V42, P278, DOI 10.3129/canjophthalmol.i07-036; Nickells RW, 2012, ANNU REV NEUROSCI, V35, P153, DOI 10.1146/annurev.neuro.051508.135728; NIIDA T, 1990, VISION, MEMORY AND THE TEMPORAL LOBE, P369; Niven JE, 2008, J EXP BIOL, V211, P1792, DOI 10.1242/jeb.017574; Nork TM, 2000, ARCH OPHTHALMOL-CHIC, V118, P235; Oesch NW, 2011, CURR OPIN NEUROBIOL, V21, P238, DOI 10.1016/j.conb.2011.01.008; Osborne NN, 2010, NEUROCHEM RES, V35, P2027, DOI 10.1007/s11064-010-0273-5; Osborne NN, 2010, EXP EYE RES, V90, P750, DOI 10.1016/j.exer.2010.03.008; Osborne NN, 2001, BRIT J OPHTHALMOL, V85, P1252, DOI 10.1136/bjo.85.10.1252; Pang IH, 2007, J GLAUCOMA, V16, P483, DOI 10.1097/IJG.0b013e3181405d4f; Pascale A., 2012, PHARM RES; Pavlidis M, 2003, INVEST OPHTH VIS SCI, V44, P5196, DOI 10.1167/iovs.03-0614; Pease ME, 2000, INVEST OPHTH VIS SCI, V41, P764; Pelzel HR, 2006, MOL VIS, V12, P1272; Perge JA, 2012, J NEUROSCI, V32, P626, DOI 10.1523/JNEUROSCI.4254-11.2012; Perge JA, 2009, J NEUROSCI, V29, P7917, DOI 10.1523/JNEUROSCI.5200-08.2009; Porciatti V, 2010, EXP EYE RES, V90, P452, DOI 10.1016/j.exer.2009.12.005; Quigley HA, 2000, INVEST OPHTH VIS SCI, V41, P3460; QUIGLEY HA, 1980, INVEST OPHTH VIS SCI, V19, P137; QUIGLEY HA, 1987, INVEST OPHTH VIS SCI, V28, P913; Quigley HA, 1999, PROG RETIN EYE RES, V18, P39, DOI 10.1016/S1350-9462(98)00014-7; Quigley HA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1390; QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774; QUIGLEY HA, 1981, ARCH OPHTHALMOL-CHIC, V99, P635, DOI 10.1001/archopht.1981.03930010635009; QUIGLEY HA, 1980, INVEST OPHTH VIS SCI, V19, P505; Raz D, 2003, INVEST OPHTH VIS SCI, V44, P3675, DOI 10.1167/iovs.02-1236; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; Rintoul GL, 2003, J NEUROSCI, V23, P7881; Rintoul GL, 2010, BBA-MOL BASIS DIS, V1802, P143, DOI 10.1016/j.bbadis.2009.09.005; Rosenthal R, 2011, BRIT J PHARMACOL, V162, P806, DOI 10.1111/j.1476-5381.2010.01103.x; Saleh M, 2007, INVEST OPHTH VIS SCI, V48, P4564, DOI 10.1167/iovs.07-0483; Salinas-Navarro M, 2009, MOL VIS, V15, P2578; Salinas-Navarro M, 2010, EXP EYE RES, V90, P168, DOI 10.1016/j.exer.2009.10.003; Sappington RM, 2010, INVEST OPHTH VIS SCI, V51, P207, DOI 10.1167/iovs.09-3947; Sappington RM, 2009, INVEST OPHTH VIS SCI, V50, P717, DOI 10.1167/iovs.08-2321; Saylor M, 2009, ARCH OPHTHALMOL-CHIC, V127, P402, DOI 10.1001/archophthalmol.2009.9; Schlamp CL, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-66; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Scholz M, 2008, INVEST OPHTH VIS SCI, V49, P613, DOI 10.1167/iovs.07-0745; Schuettauf F, 2004, ACTA NEUROPATHOL, V107, P352, DOI 10.1007/s00401-003-0816-9; Sehi M, 2010, OPHTHALMOLOGY, V117, P2329, DOI 10.1016/j.ophtha.2010.08.049; SHELDON WG, 1995, LAB ANIM SCI, V45, P508; Sheng ZH, 2012, NAT REV NEUROSCI, V13, P77, DOI 10.1038/nrn3156; Shields MB, 2008, CURR OPIN OPHTHALMOL, V19, P85, DOI 10.1097/ICU.0b013e3282f3919b; Shou TD, 2003, INVEST OPHTH VIS SCI, V44, P3005, DOI 10.1167/iovs.02-0620; Son JL, 2010, GLIA, V58, P780, DOI 10.1002/glia.20962; Soto I, 2008, J NEUROSCI, V28, P548, DOI 10.1523/JNEUROSCI.3714-07.2008; Soto I, 2011, INVEST OPHTH VIS SCI, V52, P434, DOI 10.1167/iovs.10-5856; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Stokely ME, 2002, INVEST OPHTH VIS SCI, V43, P3223; Stys PK, 2004, CURR MOL MED, V4, P113, DOI 10.2174/1566524043479220; Takahashi Y, 2004, P NATL ACAD SCI USA, V101, P12865, DOI 10.1073/pnas.0403429101; Tao JA, 2011, J NEUROSCI, V31, P5398, DOI 10.1523/JNEUROSCI.3826-10.2011; Tezel G, 2008, PROG BRAIN RES, V173, P409, DOI 10.1016/S0079-6123(08)01128-X; VAEGAN, 1995, EXP EYE RES, V60, P697, DOI 10.1016/S0014-4835(05)80011-9; VANBUREN JM, 1963, ELECTROEN CLIN NEURO, V15, P1, DOI 10.1016/0013-4694(63)90035-X; Velten IM, 2001, BRIT J OPHTHALMOL, V85, P397, DOI 10.1136/bjo.85.4.397; Venkataraman ST, 2010, MICROCIRCULATION, V17, P568, DOI 10.1111/j.1549-8719.2010.00045.x; Vidal-Sanz M, 2001, SURV OPHTHALMOL, V45, pS261, DOI 10.1016/S0039-6257(01)00205-3; Vidal-Sanz M, 2012, PROG RETIN EYE RES, V31, P1, DOI 10.1016/j.preteyeres.2011.08.001; Vrabec JP, 2007, EYE, V21, pS11, DOI 10.1038/sj.eye.6702880; Wagner OI, 2003, J NEUROSCI, V23, P9046; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang L, 2003, INVEST OPHTH VIS SCI, V44, P2, DOI 10.1167/iovs.02-0333; Wang SSH, 2008, J NEUROSCI, V28, P4047, DOI 10.1523/JNEUROSCI.5559-05.2008; Wang X, 2008, INVEST OPHTH VIS SCI, V49, P961, DOI 10.1167/iovs.07-1243; WASSLE H, 1991, PHYSIOL REV, V71, P447; Wax MB, 2008, J NEUROSCI, V28, P12085, DOI 10.1523/JNEUROSCI.3200-08.2008; WAXMAN SG, 1978, NEUROLOGY, V28, P27, DOI 10.1212/WNL.28.9_Part_2.27; Weber AJ, 2005, INVEST OPHTH VIS SCI, V46, P3197, DOI 10.1167/iovs.04-0834; Weber AJ, 1998, INVEST OPHTH VIS SCI, V39, P2304; Weber AJ, 2000, INVEST OPHTH VIS SCI, V41, P1370; Whitmore AV, 2005, PROG RETIN EYE RES, V24, P639, DOI 10.1016/j.preteyeres.2005.04.004; WYGNANSKI T, 1995, AM J OPHTHALMOL, V120, P184, DOI 10.1016/S0002-9394(14)72606-6; Xia JS, 2012, J PHYSIOL-LONDON, V590, P2285, DOI 10.1113/jphysiol.2012.227983; Yucel YH, 2006, ARCH OPHTHALMOL-CHIC, V124, P217, DOI 10.1001/archopht.124.2.217; Yucel YH, 2003, PROG RETIN EYE RES, V22, P465, DOI 10.1016/S1350-9462(03)00026-0; Yucel Y, 2008, PROG BRAIN RES, V173, P465, DOI 10.1016/S0079-6123(08)01132-1; Zhang SD, 2009, BRAIN RES, V1303, P131, DOI 10.1016/j.brainres.2009.09.029; Zhong LC, 2007, INVEST OPHTH VIS SCI, V48, P1212, DOI 10.1167/iovs.06-0757; Zhu Y., 2012, MOL MED	217	140	141	0	43	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1350-9462	1873-1635		PROG RETIN EYE RES	Prog. Retin. Eye Res.	NOV	2012	31	6					702	719		10.1016/j.preteyeres.2012.07.001			18	Ophthalmology	Ophthalmology	035IV	WOS:000310940900008	22871543	Green Accepted			2021-06-18	
